PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bucciol, G; Moens, L; Bosch, B; Bossuyt, X; Casanova, JL; Puel, A; Meyts, I				Bucciol, Giorgia; Moens, Leen; Bosch, Barbara; Bossuyt, Xavier; Casanova, Jean-Laurent; Puel, Anne; Meyts, Isabelle			Lessons learned from the study of human inborn errors of innate immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Infection; inborn error of immunity; immunodeficiency; innate immunity; signaling pathway; Toll-like receptors; nuclear factor kappa light-chain enhancer of activated B cells; interferon; phagocytes	NF-KAPPA-B; ANHIDROTIC ECTODERMAL DYSPLASIA; PYOGENIC BACTERIAL-INFECTIONS; SEVERE CONGENITAL NEUTROPENIA; HERPES-SIMPLEX ENCEPHALITIS; INHERITED CARD9 DEFICIENCY; OF-FUNCTION MUTATIONS; COMBINED IMMUNODEFICIENCY; AUTOSOMAL-DOMINANT; CLINICAL-FEATURES	Innate immunity contributes to host defense through all cell types and relies on their shared germline genetic background, whereas adaptive immunity operates through only 3 main cell types, alpha beta T cells, gamma delta T cells, and B cells, and relies on their somatic genetic diversification of antigen-specific responses. Human inborn errors of innate immunity often underlie infectious diseases. The range and nature of infections depend on the mutated gene, the deleteriousness of the mutation, and other ill-defined factors. Most known inborn errors of innate immunity to infection disrupt the development or function of leukocytes other than T and B cells, but a growing number of inborn errors affect cells other than circulating and tissue leukocytes. Here we review inborn errors of innate immunity that have been recently discovered or clarified. We highlight the immunologic implications of these errors.	[Bucciol, Giorgia; Moens, Leen; Meyts, Isabelle] Katholieke Univ Leuven, Dept Immunol & Microbiol, Lab Childhood Immunol, Leuven, Belgium; [Bossuyt, Xavier] Katholieke Univ Leuven, Expt Lab Immunol, Dept Immunol & Microbiol, Leuven, Belgium; [Bucciol, Giorgia; Bosch, Barbara; Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Herestr 49, B-3000 Leuven, Belgium; [Bossuyt, Xavier] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium; [Bosch, Barbara; Casanova, Jean-Laurent; Puel, Anne] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Casanova, Jean-Laurent; Puel, Anne] Necker Hosp Sick Children, INSERM, U1163, Lab Human Genet Infect Dis,Necker Branch, Paris, France; [Casanova, Jean-Laurent] Necker Hosp Sick Children, INSERM, U1163, Pediat Hematol Immunol Unit, Paris, France; [Casanova, Jean-Laurent; Puel, Anne] Paris Descartes Univ, Imagine Inst, Paris, France	KU Leuven; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Rockefeller University; Howard Hughes Medical Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Meyts, I (corresponding author), Univ Hosp Leuven, Dept Pediat, Herestr 49, B-3000 Leuven, Belgium.	Isabelle.Meyts@uzleuven.be	Bossuyt, Xavier/B-2085-2019; Puel, Anne/H-7305-2017; Meyts, Isabelle/Z-3295-2019	Bossuyt, Xavier/0000-0001-6856-8485; Puel, Anne/0000-0003-2603-0323; Bucciol, Giorgia/0000-0001-5004-0738	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI095983, R01AI127564, U19AI111143, R01AI088364, P01AI061093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS072381] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R37 AI095983, R01 AI127564, U19 AI111143, R01 AI088364, P01 AI061093] Funding Source: Medline; NINDS NIH HHS [R01 NS072381] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen LL, 2015, J EXP MED, V212, P1371, DOI 10.1084/jem.20142274; Arimoto K, 2017, NAT STRUCT MOL BIOL, V24, P279, DOI 10.1038/nsmb.3378; Asgari S, 2017, P NATL ACAD SCI USA, V114, P8342, DOI 10.1073/pnas.1704259114; Baris S, 2015, J CLIN IMMUNOL, V35, P339, DOI 10.1007/s10875-015-0156-2; Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307; Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125; Bigley V, 2018, J ALLERGY CLIN IMMUN, V141, P2234, DOI 10.1016/j.jaci.2017.08.044; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Biswas PS, 2012, J EXP MED, V209, P581, DOI 10.1084/jem.20111195; Bogunovic D, 2012, SCIENCE, V337, P1684, DOI 10.1126/science.1224026; Boisson B, 2017, J CLIN IMMUNOL, V37, P397, DOI 10.1007/s10875-017-0400-z; Boisson B, 2015, J EXP MED, V212, P939, DOI 10.1084/jem.20141130; Boisson B, 2012, NAT IMMUNOL, V13, P1178, DOI 10.1038/ni.2457; Bolze A, 2018, P NATL ACAD SCI US; Bolze A, 2013, SCIENCE, V340, P976, DOI 10.1126/science.1234864; Boztug H, 2016, J CLIN IMMUNOL, V36, P533, DOI 10.1007/s10875-016-0306-1; Boztug K, 2014, NAT GENET, V46, P1021, DOI 10.1038/ng.3069; Buonocore F, 2017, J CLIN INVEST, V127, P1700, DOI 10.1172/JCI91913; Bustamante J, 2014, SEMIN IMMUNOL, V26, P454, DOI 10.1016/j.smim.2014.09.008; Casanova JL, 2015, P NATL ACAD SCI USA, V112, pE7118, DOI 10.1073/pnas.1521644112; Casanova JL, 2015, P NATL ACAD SCI USA, V112, pE7128, DOI 10.1073/pnas.1521651112; Casey JP, 2012, J MED GENET, V49, P242, DOI 10.1136/jmedgenet-2012-100803; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Castro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00847; Charbit-Henrion F, 2017, J PEDIATR GASTR NUTR, V64, P378, DOI 10.1097/MPG.0000000000001262; Chen DH, 2016, AM J HUM GENET, V98, P1146, DOI 10.1016/j.ajhg.2016.04.009; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Ciancanelli MJ, 2015, SCIENCE, V348, P448, DOI 10.1126/science.aaa1578; Coltro G, 2017, AM J HEMATOL, V92, P833, DOI 10.1002/ajh.24775; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; Cottineau J, 2017, J CLIN INVEST, V127, P1991, DOI 10.1172/JCI90727; Davidsson J, 2018, LEUKEMIA, V32, P1106, DOI 10.1038/s41375-018-0074-4; de Diego RP, 2010, IMMUNITY, V33, P400, DOI 10.1016/j.immuni.2010.08.014; Della Mina E, 2017, P NATL ACAD SCI USA, V114, pE514, DOI 10.1073/pnas.1620139114; Dickinson RE, 2014, BLOOD, V123, P863, DOI 10.1182/blood-2013-07-517151; Dickinson RE, 2011, BLOOD, V118, P2656, DOI 10.1182/blood-2011-06-360313; Dinauer MC, 2016, HEMATOL-AM SOC HEMAT, P43, DOI 10.1182/asheducation-2016.1.43; Dittmann M, 2015, CELL, V160, P631, DOI 10.1016/j.cell.2015.01.040; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Donadieu J, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-26; dos Santos PF, 2017, J INTERF CYTOK RES, V37, P246, DOI 10.1089/jir.2016.0103; Drummond RA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005293; Duncan CJA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4227; Eletto D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13992; Eyal O, 2017, AM J HEMATOL, V92, pE74, DOI 10.1002/ajh.24688; Fischer A, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah5861; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Frans G, 2015, J CLIN IMMUNOL, V35, P739, DOI 10.1007/s10875-015-0205-x; Freeley S, 2016, IMMUNOL REV, V274, P16, DOI 10.1111/imr.12472; GALLIN JI, 1978, BLOOD, V51, P919; Garrey SM, 2014, RNA, V20, P1337, DOI 10.1261/rna.044602.114; Gaschignard J, 2014, CLIN INFECT DIS, V59, P244, DOI 10.1093/cid/ciu274; Gineau L, 2012, J CLIN INVEST, V122, P821, DOI 10.1172/JCI61014; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Guerin A, 2018, ELIFE, V7, DOI 10.7554/eLife.32340; Guo YQ, 2011, J EXP MED, V208, P2083, DOI 10.1084/jem.20101568; Hacker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998; Hahn CN, 2011, NAT GENET, V43, P1012, DOI 10.1038/ng.913; Hailfinger S, 2016, FEBS J, V283, P400, DOI 10.1111/febs.13639; Hambleton S, 2013, P NATL ACAD SCI USA, V110, P3053, DOI 10.1073/pnas.1220098110; Hambleton S, 2011, NEW ENGL J MED, V365, P127, DOI 10.1056/NEJMoa1100066; Hanna S, 2012, ANN NY ACAD SCI, V1250, P50, DOI 10.1111/j.1749-6632.2011.06389.x; Hanna S, 2015, J ALLERGY CLIN IMMUN, V136, P1113, DOI 10.1016/j.jaci.2015.04.021; Herman M, 2012, J EXP MED, V209, P1567, DOI 10.1084/jem.20111316; Hernandez N., 2018, J EXP MED; Higgins E, 2015, J ALLERGY CLIN IMMUN, V135, P551, DOI 10.1016/j.jaci.2014.12.1867; Holland SM, 2013, HEMATOL ONCOL CLIN N, V27, P89, DOI 10.1016/j.hoc.2012.11.002; Hoving JC, 2014, CELL MICROBIOL, V16, P185, DOI 10.1111/cmi.12249; Hoyos-Bachiloglu R, 2017, J CLIN INVEST, V127, P4415, DOI 10.1172/JCI93486; Hsu AP, 2011, BLOOD, V118, P2653, DOI 10.1182/blood-2011-05-356352; Hubeau M, 2011, BLOOD, V118, P926, DOI 10.1182/blood-2010-10-315234; Hughes CR, 2012, J CLIN INVEST, V122, P814, DOI 10.1172/JCI60224; Israel L, 2017, CELL, V168, P789, DOI 10.1016/j.cell.2017.01.039; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Jouanguy E, 2013, CURR OPIN ALLERGY CL, V13, P589, DOI 10.1097/ACI.0000000000000011; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kaustio M, 2017, J ALLERGY CLIN IMMUN, V140, P782, DOI 10.1016/j.jaci.2016.10.054; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; KEVY SV, 1968, PEDIATRICS, V42, P752; Kilic SS, 2012, J PEDIATR-US, V160, P1055, DOI 10.1016/j.jpeds.2012.01.056; Klimiankou M, 2016, ANN NY ACAD SCI, V1370, P119, DOI 10.1111/nyas.13097; Klimiankou M, 2015, BLOOD, V126, P1865, DOI 10.1182/blood-2015-07-661264; Kreins AY, 2015, J EXP MED, V212, P1641, DOI 10.1084/jem.20140280; Kuhns DB, 2016, BLOOD, V128, P2135, DOI 10.1182/blood-2016-03-706028; Lamborn IT, 2017, J EXP MED, V214, P1949, DOI 10.1084/jem.20161759; Lanternier F, 2015, J ALLERGY CLIN IMMUN, V135, P1558, DOI 10.1016/j.jaci.2014.12.1930; Lanternier F, 2015, J INFECT DIS, V211, P1241, DOI 10.1093/infdis/jiu412; Lanternier F, 2013, NEW ENGL J MED, V369, P1704, DOI 10.1056/NEJMoa1208487; Leiding JW, 2018, J ALLERGY CLIN IMMUN, V141, P704, DOI 10.1016/j.jaci.2017.03.049; Levy R, 2016, P NATL ACAD SCI USA, V113, pE8277, DOI 10.1073/pnas.1618300114; Lim AI, 2017, CELL, V168, P1086, DOI 10.1016/j.cell.2017.02.021; LIM D, 1976, J PEDIATR-US, V89, P42, DOI 10.1016/S0022-3476(76)80924-9; Lindsley AW, 2014, J CLIN IMMUNOL, V34, P910, DOI 10.1007/s10875-014-0095-3; Liszewski MK, 2017, ANNU REV PATHOL-MECH, V12, P25, DOI 10.1146/annurev-pathol-012615-044145; Liu J, 2015, J VIROL, V89, P1925, DOI 10.1128/JVI.02262-14; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Liu YW, 2014, J CLIN IMMUNOL, V34, P686, DOI 10.1007/s10875-014-0064-x; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Mace EM, 2017, J CLIN INVEST, V127, P306, DOI 10.1172/JCI86276; Mace EM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00545; Mace EM, 2013, BLOOD, V121, P2669, DOI 10.1182/blood-2012-09-453969; Torres JM, 2014, J CLIN INVEST, V124, P5239, DOI 10.1172/JCI77493; Masters SL, 2009, ANNU REV IMMUNOL, V27, P621, DOI 10.1146/annurev.immunol.25.022106.141627; McKinnon ML, 2014, J ALLERGY CLIN IMMUN, V133, P1458, DOI 10.1016/j.jaci.2013.10.045; Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669; Meerschaut I, 2015, AM J MED GENET A, V167, P3214, DOI 10.1002/ajmg.a.37367; Meesilpavikkai K, 2018, J ALLERGY CLIN IMMUN, V142, P328, DOI 10.1016/j.jaci.2018.02.045; Meng XZ, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006884; Meuwissen MEC, 2016, J EXP MED, V213, P1163, DOI 10.1084/jem.20151529; MILLER ME, 1971, LANCET, V1, P665; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Miot C, 2017, BLOOD, V130, P1456, DOI 10.1182/blood-2017-03-771600; Moens L, 2017, J ALLERGY CLIN IMMUN, V139, P1995, DOI 10.1016/j.jaci.2016.10.033; Mossner R, 2016, CLIN INFECT DIS, V62, DOI 10.1093/cid/ciw020; Mork N, 2015, GENES IMMUN, V16, P552, DOI 10.1038/gene.2015.46; Moulding DA, 2013, IMMUNOL REV, V256, P282, DOI 10.1111/imr.12114; Mousallem T, 2014, BLOOD, V124, P2046, DOI 10.1182/blood-2014-04-571265; Narumi S, 2016, NAT GENET, V48, P792, DOI 10.1038/ng.3569; Negishi H, 2005, P NATL ACAD SCI USA, V102, P15989, DOI 10.1073/pnas.0508327102; Nilsson J, 2013, ANN NEUROL, V74, P914, DOI 10.1002/ana.23963; Noad J, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.63; Nounamo B, 2017, VIROLOGY, V503, P94, DOI 10.1016/j.virol.2017.01.004; O'Neill LAJ, 2013, NAT REV IMMUNOL, V13, P453, DOI 10.1038/nri3446; Ogunjimi B, 2017, J CLIN INVEST, V127, P3543, DOI [10.1172/JCI92280, 10.1172/jci92280]; Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282; Ombrello MJ, 2012, NAT IMMUNOL, V13, P1133, DOI 10.1038/ni.2471; Ostergaard P, 2011, NAT GENET, V43, P929, DOI 10.1038/ng.923; Ozen A, 2017, NEW ENGL J MED, V377, P52, DOI 10.1056/NEJMoa1615887; Pannicke U, 2013, NEW ENGL J MED, V369, P2504, DOI 10.1056/NEJMoa1309199; Patin E, 2018, NAT IMMUNOL, V19, P302, DOI 10.1038/s41590-018-0049-7; de Diego RP, 2015, J ALLERGY CLIN IMMUN, V136, P1139, DOI 10.1016/j.jaci.2015.06.031; PETERSEN BH, 1976, J CLIN INVEST, V57, P283, DOI 10.1172/JCI108279; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Picard C, 2010, MEDICINE, V89, P403, DOI 10.1097/MD.0b013e3181fd8ec3; Pilli M, 2012, IMMUNITY, V37, P223, DOI 10.1016/j.immuni.2012.04.015; Priam P, 2017, NAT GENET, V49, P753, DOI 10.1038/ng.3812; Puel A, 2012, CURR OPIN ALLERGY CL, V12, P616, DOI 10.1097/ACI.0b013e328358cc0b; Punwani D, 2015, J CLIN IMMUNOL, V35, P135, DOI 10.1007/s10875-014-0125-1; Ram S, 2010, CLIN MICROBIOL REV, V23, P740, DOI 10.1128/CMR.00048-09; Rice GI, 2014, NAT GENET, V46, P503, DOI 10.1038/ng.2933; Richardson JP, 2015, VIRULENCE, V6, P327, DOI 10.1080/21505594.2015.1004977; Rieber N, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89890; Rodero MP, 2016, J EXP MED, V213, P2527, DOI 10.1084/jem.20161596; Ronald PC, 2010, SCIENCE, V330, P1061, DOI 10.1126/science.1189468; Roos D, 2016, BRIT MED BULL, V118, P53, DOI 10.1093/bmb/ldw009; Rozmus J, 2016, CLIN IMMUNOL, V168, P1, DOI 10.1016/j.clim.2016.04.011; Salem S, 2014, BLOOD, V124, P1894, DOI 10.1182/blood-2014-04-570879; Sancho-Shimizu V, 2011, CURR OPIN VIROL, V1, P487, DOI 10.1016/j.coviro.2011.10.016; Sancho-Shimizu V, 2011, J CLIN INVEST, V121, P4889, DOI 10.1172/JCI59259; Schwartz JR, 2017, LEUKEMIA, V31, P1827, DOI 10.1038/leu.2017.142; Schwerd T, 2017, J EXP MED, V214, P2547, DOI 10.1084/jem.20161810; Serafini N, 2015, NAT REV IMMUNOL, V15, P415, DOI 10.1038/nri3855; Shah RK, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26571; Shahni R, 2015, BRAIN, V138, P2834, DOI 10.1093/brain/awv182; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sivan G, 2015, MBIO, V6, DOI 10.1128/mBio.01122-15; Skokowa J, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.32; Speer SD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11496; Spinner MA, 2014, BLOOD, V123, P809, DOI 10.1182/blood-2013-07-515528; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Standing ASI, 2017, J EXP MED, V214, P59, DOI 10.1084/jem.20161228; Starokadomskyy P, 2016, NAT IMMUNOL, V17, P495, DOI 10.1038/ni.3409; Stepensky P, 2013, PEDIATR TRANSPLANT, V17, P820, DOI 10.1111/petr.12169; Stepensky P, 2013, BLOOD, V121, P5078, DOI 10.1182/blood-2012-12-475566; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Tesi B, 2017, BLOOD, V129, P2266, DOI 10.1182/blood-2016-10-743302; Tholouli E, 2018, BLOOD, V131, P1383, DOI 10.1182/blood-2017-10-811489; Tosi MF, 2005, J ALLERGY CLIN IMMUN, V116, P241, DOI 10.1016/j.jaci.2005.05.036; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Triot A, 2014, BLOOD, V123, P3811, DOI 10.1182/blood-2013-11-535419; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Vargas-Hernandez A, 2018, J ALLERGY CLIN IMMUN, V141, P2142, DOI 10.1016/j.jaci.2017.08.040; Vely F, 2016, NAT IMMUNOL, V17, P1291, DOI 10.1038/ni.3553; Vilboux T, 2013, NEW ENGL J MED, V369, P54, DOI 10.1056/NEJMoa1301296; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; Wang J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149859; Wang XW, 2014, J ALLERGY CLIN IMMUN, V133, P905, DOI 10.1016/j.jaci.2013.09.033; Weinacht KG, 2017, J ALLERGY CLIN IMMUN, V139, P1629, DOI 10.1016/j.jaci.2016.11.022; Whitley Richard J, 2005, Semin Pediatr Infect Dis, V16, P17, DOI 10.1053/j.spid.2004.09.007; Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405; Willmann K, 2014, NAT COMMUN, V5, P1; Witzel M, 2017, NAT GENET, V49, P742, DOI 10.1038/ng.3833; Yan N, 2012, NAT IMMUNOL, V13, P214, DOI 10.1038/ni.2229; Zaki M, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00130; Zerbe CS, 2016, CLIN INFECT DIS, V62, P986, DOI 10.1093/cid/civ1220; Zhang LK, 2013, J PROTEOME RES, V12, P2666, DOI 10.1021/pr400011k; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522; Zhang SY, 2018, CELL, V172, P952, DOI 10.1016/j.cell.2018.02.019; Zhang XQ, 2015, NATURE, V517, P89, DOI 10.1038/nature13801; Zimmerman O, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx202	193	32	32	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					507	527		10.1016/j.jaci.2018.07.013	http://dx.doi.org/10.1016/j.jaci.2018.07.013			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30075154	Bronze, Green Accepted			2022-12-18	WOS:000457718700006
J	Leyva-Castillo, JM; Yoon, J; Geha, RS				Leyva-Castillo, Juan Manuel; Yoon, Juhan; Geha, Raif S.			IL-22 promotes allergic airway inflammation in epicutaneously sensitized mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-22; atopic dermatitis; asthma; neutrophils	ARYL-HYDROCARBON RECEPTOR; TH17 CELLS; IFN-GAMMA; TNF-ALPHA; T-CELLS; INTERLEUKIN (IL)-22; ATOPIC-DERMATITIS; TH22 CELLS; EXPRESSION; CYTOKINE	Background: Serum IL-22 levels are increased in patients with atopic dermatitis, which commonly precedes asthma in the atopic march. Epicutaneous sensitization in mice results in T(H)2-dominated skin inflammation that mimics atopic dermatitis and sensitizes the airways for antigen challenge-induced allergic inflammation characterized by the presence of both eosinophils and neutrophils. Epicutaneous sensitization results in increased serum levels of IL-22. Objective: We sought to determine the role of IL-22 in antigen-driven airway allergic inflammation after inhalation challenge in epicutaneously sensitized mice. Methods: Wild-type (WT) and Il22(-/-) mice were sensitized epicutaneously or immunized intraperitoneally with ovalbumin (OVA) and challenged intranasally with antigen. OVA T-cell receptor-specific T cells were T(H)22 polarized in vitro. Airway inflammation, mRNA levels in the lungs, and airway hyperresponsiveness (AHR) were examined. Results: Epicutaneous sensitization preferentially elicited an IL-22 response compared with intraperitoneal immunization. Intranasal challenge of mice epicutaneously sensitized with OVA elicited in the lungs Il22 mRNA expression, IL-22 production, and accumulation of CD3(+)CD4(+)IL-22(+) T cells that coexpressed IL-17A and TNF-alpha. Epicutaneously sensitized Il22(-/-) mice exhibited diminished eosinophil and neutrophil airway infiltration and decreased AHR after intranasal OVA challenge. Production of IL-13, IL-17A, and TNF-alpha was normal, but IFN-gamma production was increased in lung cells from airway-challenged and epicutaneously sensitized Il22(-/-) mice. Intranasal instillation of IFN-gamma-neutralizing antibody partially reversed the defect in eosinophil recruitment. WT recipients of T(H)22-polarized WT, but not IL-22-deficient, T-cell receptor OVA-specific T cells, which secrete both IL-17A and TNF-alpha, had neutrophil-dominated airway inflammation and AHR on intranasal OVA challenge. Intranasal instillation of IL-22 with TNF-alpha, but not IL-17A, elicited neutrophil-dominated airway inflammation and AHR in WT mice, suggesting that loss of IL-22 synergy with TNF-alpha contributed to defective recruitment of neutrophils into the airways of Il22(-/-) mice. TNF-alpha, but not IL-22, blockade at the time of antigen inhalation challenge inhibited airway inflammation in epicutaneously sensitized mice. Conclusion: Epicutaneous sensitization promotes generation of antigen-specific IL-22-producing T cells that promote airway inflammation and AHR after antigen challenge, suggesting that IL-22 plays an important role in the atopic march.	Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA; Harvard Med Sch, Dept Pediat, Boston, MA USA; [Yoon, Juhan] Sungkyunkwan Univ, DRC, C&C Res Labs, Seoul, Gyeonggi Do, South Korea	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Sungkyunkwan University (SKKU)	Geha, RS (corresponding author), Childrens Hosp, Boston, MA 02115 USA.	Raif.geha@childrens.harvard.edu		Leyva Castillo, Juan Manuel/0000-0001-7394-4457	National Institutes of Health [HHSN272201000020C, AI113294]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673, R01AI113294] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants HHSN272201000020C and AI113294.	Basu R, 2012, IMMUNITY, V37, P1061, DOI 10.1016/j.immuni.2012.08.024; Bernink J, 2013, IMMUNOL REV, V252, P133, DOI 10.1111/imr.12034; Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Brembilla NC, 2016, ANN RHEUM DIS, V75, P1697, DOI 10.1136/annrheumdis-2015-207477; Chang Y, 2012, FASEB J, V26, P5152, DOI 10.1096/fj.12-208033; Chang Y, 2011, J ALLERGY CLIN IMMUN, V127, P1046, DOI 10.1016/j.jaci.2010.12.1117; Di Cesare A, 2008, J INVEST DERMATOL, V128, P2569, DOI 10.1038/jid.2008.283; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Eyerich S, 2011, EUR J IMMUNOL, V41, P1894, DOI 10.1002/eji.201041197; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; He R, 2009, J ALLERGY CLIN IMMUN, V124, P761, DOI 10.1016/j.jaci.2009.07.040; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; Jin HL, 2009, J CLIN INVEST, V119, P47, DOI 10.1172/JCI32310; Justa S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093279; Kreymborg K, 2007, J IMMUNOL, V179, P8098, DOI 10.4049/jimmunol.179.12.8098; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; Liang SC, 2007, J IMMUNOL, V179, P7791, DOI 10.4049/jimmunol.179.11.7791; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Mielke LA, 2013, J EXP MED, V210, P1117, DOI 10.1084/jem.20121588; Mitchell C, 2011, J IMMUNOL, V187, P3815, DOI 10.4049/jimmunol.1100436; Nakahama T, 2011, P NATL ACAD SCI USA, V108, P14222, DOI 10.1073/pnas.1111786108; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Pennino D, 2013, J ALLERGY CLIN IMMUN, V131, P562, DOI 10.1016/j.jaci.2012.09.036; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; Savinko T, 2013, J INVEST DERMATOL, V133, P2522, DOI 10.1038/jid.2013.195; Schnyder B, 2010, CYTOKINE, V50, P220, DOI 10.1016/j.cyto.2010.02.003; Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Sugita S, 2013, J IMMUNOL, V190, P5799, DOI 10.4049/jimmunol.1202677; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takahashi K, 2011, J ALLERGY CLIN IMMUN, V128, P1067, DOI 10.1016/j.jaci.2011.06.018; Taube C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021799; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Yeste A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4753; Yoon J, 2016, J EXP MED, V213, P2147, DOI 10.1084/jem.20150376; Yu JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039032; Zhao XM, 2015, CYTOKINE, V73, P66, DOI 10.1016/j.cyto.2015.01.027; Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhu J, 2011, ASIAN PAC J ALLERGY, V29, P266; Zindl CL, 2013, P NATL ACAD SCI USA, V110, P12768, DOI 10.1073/pnas.1300318110	49	32	37	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					619	+		10.1016/j.jaci.2018.05.032	http://dx.doi.org/10.1016/j.jaci.2018.05.032			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29920352	Bronze, Green Accepted			2022-12-18	WOS:000457718700021
J	Okano, T; Imai, K; Tsujita, Y; Mitsuiki, N; Yoshida, K; Kamae, C; Honma, K; Mitsui-Sekinaka, K; Sekinaka, Y; Kato, T; Hanabusa, K; Endo, E; Takashima, T; Hiroki, H; Yeh, TW; Tanaka, K; Nagahori, M; Tsuge, I; Bando, Y; Iwasaki, F; Shikama, Y; Inoue, M; Kimoto, T; Moriguchi, N; Yuza, Y; Kaneko, T; Suzuki, K; Matsubara, T; Maruo, Y; Kunitsu, T; Waragai, T; Sano, H; Hashimoto, Y; Tasaki, K; Suzuki, O; Shirakawa, T; Kato, M; Uchiyama, T; Ishimura, M; Tauchi, T; Yagasaki, H; Jou, ST; Yu, HH; Kanegane, H; Kracker, S; Durandy, A; Kojima, D; Muramatsu, H; Wada, T; Inoue, Y; Takada, H; Kojima, S; Ogawa, S; Ohara, O; Nonoyama, S; Morio, T				Okano, Tsubasa; Imai, Kohsuke; Tsujita, Yuki; Mitsuiki, Noriko; Yoshida, Kenichi; Kamae, Chikako; Honma, Kenichi; Mitsui-Sekinaka, Kanako; Sekinaka, Yujin; Kato, Tamaki; Hanabusa, Katsuyuki; Endo, Eri; Takashima, Takehiro; Hiroki, Haruka; Yeh, Tzu-Wen; Tanaka, Keisuke; Nagahori, Masakazu; Tsuge, Ikuya; Bando, Yuki; Iwasaki, Fuminori; Shikama, Yoshiaki; Inoue, Masami; Kimoto, Tomiko; Moriguchi, Naohiko; Yuza, Yuki; Kaneko, Takashi; Suzuki, Kyoko; Matsubara, Tomoyo; Maruo, Yoshihiro; Kunitsu, Tomoaki; Waragai, Tomoko; Sano, Hideki; Hashimoto, Yuko; Tasaki, Kazuhiro; Suzuki, Osamu; Shirakawa, Toshihiko; Kato, Motohiro; Uchiyama, Toru; Ishimura, Masataka; Tauchi, Tetsuzo; Yagasaki, Hiroshi; Jou, Shiann-Tarng; Yu, Hsin-Hui; Kanegane, Hirokazu; Kracker, Sven; Durandy, Anne; Kojima, Daiei; Muramatsu, Hideki; Wada, Taizo; Inoue, Yuzaburo; Takada, Hidetoshi; Kojima, Seiji; Ogawa, Seishi; Ohara, Osamu; Nonoyama, Shigeaki; Morio, Tomohiro			Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase delta syndrome type 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Activated phosphatidylinositol-3-OH kinase delta syndrome type 1; PIK3CD; hematopoietic stem cell transplantation; combined immunodeficiency; T-cell receptor excision circle; kappa-deleting recombination excision circle; IgG(2)	EXCISION CIRCLES; IDENTIFICATION; QUANTIFICATION; MUTATION; FEATURES; GENE	Background: Activated phosphatidylinositol-3-OH kinase delta syndrome type 1 (APDS1) is a recently described primary immunodeficiency syndrome characterized by recurrent respiratory tract infections, lymphoid hyperplasia, and Herpesviridae infections caused by germline gain-of-function mutations of PIK3CD. Hematopoietic stem cell transplantation (HSCT) can be considered to ameliorate progressive immunodeficiency and associated malignancy, but appropriate indications, methods, and outcomes of HSCT for APDS1 remain undefined. Objective: Our objective was to analyze the clinical manifestations, laboratory findings, prognosis, and treatment of APDS1 and explore appropriate indications and methods of HSCT. Methods: We reviewed retrospectively the medical records of cohorts undergoing HSCT at collaborating facilities. Results: Thirty-year overall survival was 86.1%, but event-free survival was 39.6%. Life-threatening events, such as severe infections or lymphoproliferation, were frequent in childhood and adolescence and were common indications for HSCT. Nine patients underwent HSCT with fludarabine-based reduced-intensity conditioning. Seven patients survived after frequent adverse complications and engraftment failure. Most symptoms improved after HSCT. Conclusion: Patients with APDS1 showed variable clinical manifestations. Life-threatening progressive combined immunodeficiency and massive lymphoproliferation were common indications for HSCT. Fludarabine-based reduced-intensity conditioning-HSCT ameliorated clinical symptoms, but transplantation-related complications were frequent, including graft failure.	[Okano, Tsubasa; Imai, Kohsuke; Mitsuiki, Noriko; Hanabusa, Katsuyuki; Endo, Eri; Takashima, Takehiro; Hiroki, Haruka; Yeh, Tzu-Wen; Tanaka, Keisuke; Kanegane, Hirokazu; Morio, Tomohiro] Tokyo Med & Dent Univ, Dept Pediat, Tokyo, Japan; [Nagahori, Masakazu] Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan; [Tsujita, Yuki; Kamae, Chikako; Honma, Kenichi; Mitsui-Sekinaka, Kanako; Sekinaka, Yujin; Kato, Tamaki; Nonoyama, Shigeaki] Natl Def Med Coll, Dept Pediat, Saitama, Japan; [Yoshida, Kenichi; Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan; [Tsuge, Ikuya] Fujita Hlth Univ, Sch Med, Dept Pediat, Toyoake, Aichi, Japan; [Bando, Yuki] Kitasato Univ, Sch Med, Dept Pediat, Sagamihara, Kanagawa, Japan; [Iwasaki, Fuminori] Kanagawa Childrens Med Ctr, Div Hematooncol Regenerat Med, Yokohama, Kanagawa, Japan; [Shikama, Yoshiaki] Kanagawa Childrens Med Ctr, Div Infect Dis & Immunol, Yokohama, Kanagawa, Japan; [Inoue, Masami; Kimoto, Tomiko] Osaka Womens & Childrens Hosp, Dept Hematol Oncol, Osaka, Japan; [Moriguchi, Naohiko] Kindai Univ Sakai Hosp, Dept Pediat, Sakai, Osaka, Japan; [Yuza, Yuki; Kaneko, Takashi] Tokyo Metropolitan Childrens Med Ctr, Dept Hematol Oncol, Tokyo, Japan; [Suzuki, Kyoko; Matsubara, Tomoyo] Juntendo Univ, Urayasu Hosp, Dept Pediat, Chiba, Japan; [Maruo, Yoshihiro; Kunitsu, Tomoaki] Shiga Univ Med Sci, Dept Pediat, Shiga, Japan; [Waragai, Tomoko] Fukushima Med Univ, Dept Pediat, Fukushima, Japan; [Sano, Hideki] Fukushima Med Univ, Dept Pediat Oncol, Fukushima, Japan; [Hashimoto, Yuko; Tasaki, Kazuhiro; Suzuki, Osamu] Fukushima Med Univ, Sch Med, Dept Diagnost Pathol, Fukushima, Japan; [Shirakawa, Toshihiko] Nagasaki Univ Hosp, Dept Pediat, Nagasaki, Japan; [Kato, Motohiro] Natl Ctr Child Hlth & Dev, Childrens Canc Ctr, Div Transplantat & Cell Therapy, Tokyo, Japan; [Uchiyama, Toru] Natl Ctr Child Hlth & Dev, Dept Human Genet, Tokyo, Japan; [Ishimura, Masataka] Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Fukuoka, Fukuoka, Japan; [Tauchi, Tetsuzo] Tokyo Med Univ, Dept Hematol, Tokyo, Japan; [Yagasaki, Hiroshi] Nihon Univ, Itabashi Hosp, Dept Pediat, Tokyo, Japan; [Jou, Shiann-Tarng; Yu, Hsin-Hui] Natl Taiwan Univ, Coll Med, Childrens Hosp, Dept Pediat, Taipei, Taiwan; [Kracker, Sven; Durandy, Anne] Univ Paris 05, Sorbonne Paris Cite, Human Lymphohematopoiesis Lab, Imagine Inst,INSERM,UMR 1163, Paris, France; [Kojima, Daiei; Muramatsu, Hideki; Kojima, Seiji] Nagoya Univ, Grad Sch Med, Dept Pediat, Nagoya, Aichi, Japan; [Wada, Taizo] Kanazawa Univ, Grad Sch Med Sci, Dept Pediat, Kanazawa, Ishikawa, Japan; [Inoue, Yuzaburo] Eastern Chiba Med Ctr, Dept Pediat, Togane, Chiba, Japan; [Takada, Hidetoshi] Kyushu Univ, Grad Sch Med Sci, Dept Perinatal & Pediat Med, Fukuoka, Fukuoka, Japan; [Ohara, Osamu] Kazusa DNA Res Inst, Dept Technol Dev, Kisarazu, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); National Defense Medical College - Japan; Kyoto University; Fujita Health University; Kitasato University; Tokyo Metropolitan Children's Medical Center; Juntendo University; Shiga University of Medical Science; Fukushima Medical University; Fukushima Medical University; Fukushima Medical University; Nagasaki University; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; Kyushu University; Tokyo Medical University; Nihon University; National Taiwan University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Nagoya University; Kanazawa University; Kyushu University; Kazusa DNA Research Institute	Imai, K (corresponding author), Tokyo Med & Dent Univ, Dept Community Pediat Perinatal & Maternal Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	kimai.ped@tmd.ac.jp	Imai, Kohsuke/Q-2602-2015; Inoue, Yuzaburo/E-3262-2019; Ogawa, Seishi/AAE-7088-2019; 岡野, 翼/AAU-8246-2021; Ohara, Osamu/G-5448-2015; Yu, Hsin-Hui/AAV-2068-2020; Muramatsu, Hideki/ABA-3376-2021	Imai, Kohsuke/0000-0003-2132-8403; Inoue, Yuzaburo/0000-0001-5904-687X; Ohara, Osamu/0000-0002-3328-9571; Yu, Hsin-Hui/0000-0003-2611-5175; Muramatsu, Hideki/0000-0002-8801-0021; Kato, Motohiro/0000-0001-5145-1774; Morio, Tomohiro/0000-0002-9259-1025; JOU, SHIANN-TANG/0000-0003-1483-0403; UCHIYAMA, TORU/0000-0001-9610-0900	Japan Ministry of Defense; Japan Ministry of Health, Labor, and Welfare, JSPS KAKENHI [15K09640]; Ministry of Health, Labour and Welfare, Japan [17933299]; Japan Intractable Diseases Research Foundation; Japan Foundation for Pediatric Research; Jeffery Modell Foundation; Japan Society for the Promotion of Science [17H04233]; French National Research Agency (ANR) as part of the program "Investissements d'Avenir" [ANR-10-IAHU-01]; Kawano Masanori Foundation for Promotion of Pediatrics; Grants-in-Aid for Scientific Research [15K09640] Funding Source: KAKEN	Japan Ministry of Defense; Japan Ministry of Health, Labor, and Welfare, JSPS KAKENHI; Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Japan Intractable Diseases Research Foundation; Japan Foundation for Pediatric Research; Jeffery Modell Foundation; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); French National Research Agency (ANR) as part of the program "Investissements d'Avenir"(French National Research Agency (ANR)); Kawano Masanori Foundation for Promotion of Pediatrics; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by grants from the Japan Ministry of Defense; the Japan Ministry of Health, Labor, and Welfare, JSPS KAKENHI Grant no. 15K09640; a grant from the Ministry of Health, Labour and Welfare, Japan (17933299); the Japan Intractable Diseases Research Foundation; the Japan Foundation for Pediatric Research; the Kawano Masanori Foundation for Promotion of Pediatrics; the Jeffery Modell Foundation; a grant from the Japan Society for the Promotion of Science (17H04233); and a public grant overseen by the French National Research Agency (ANR) as part of the program "Investissements d'Avenir" (reference: ANR-10-IAHU-01).	Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Coulter TI, 2017, J ALLERGY CLIN IMMUN, V139, P597, DOI 10.1016/j.jaci.2016.06.021; Goto F, 2017, J CLIN IMMUNOL, V37, P347, DOI 10.1007/s10875-017-0393-7; Jou ST, 2006, INT J IMMUNOGENET, V33, P361, DOI 10.1111/j.1744-313X.2006.00627.x; Kracker S, 2014, J ALLERGY CLIN IMMUN, V134, P233, DOI 10.1016/j.jaci.2014.02.020; Lucas CL, 2016, NAT REV IMMUNOL, V16, P702, DOI 10.1038/nri.2016.93; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Morinishi Y, 2009, J PEDIATR-US, V155, P829, DOI 10.1016/j.jpeds.2009.05.026; Morishima Y, 2013, BIOL BLOOD MARROW TR, V19, P1197, DOI 10.1016/j.bbmt.2013.05.020; Nademi Z, 2017, J ALLERGY CLIN IMMUN, V139, P1046, DOI 10.1016/j.jaci.2016.09.040; Nakagawa N, 2011, J ALLERGY CLIN IMMUN, V128, P223, DOI 10.1016/j.jaci.2011.01.052; Nakatani K, 2014, BONE MARROW TRANSPL, V49, P1155, DOI 10.1038/bmt.2014.123; Poire X, 2011, EXPERT OPIN BIOL TH, V11, P1099, DOI 10.1517/14712598.2011.592824; Takashima T, 2014, J CLIN IMMUNOL, V34, pS431; Teranishi Hideto, 2017, Rinsho Ketsueki, V58, P20, DOI 10.11406/rinketsu.58.20; Tsujita Y, 2016, J ALLERGY CLIN IMMUN, V138, P1672, DOI 10.1016/j.jaci.2016.03.055	16	32	35	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					266	275		10.1016/j.jaci.2018.04.032	http://dx.doi.org/10.1016/j.jaci.2018.04.032			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29778502	Bronze			2022-12-18	WOS:000454918300031
J	Dykewicz, MS; Rodrigues, JM; Slavin, RG				Dykewicz, Mark S.; Rodrigues, Jonathan M.; Slavin, Raymond G.			Allergic fungal rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Rhinosinusitis; fungal allergy; chronic rhinosinusitis with nasal polyps	INNATE LYMPHOID-CELLS; EOSINOPHILIC MUCIN RHINOSINUSITIS; NASAL POLYPS; ASPERGILLUS SINUSITIS; BRONCHOPULMONARY ASPERGILLOSIS; GENE-EXPRESSION; BONY EROSION; IMMUNOTHERAPY; DIAGNOSIS; ENDOTYPES	Allergic fungal rhinosinusitis (AFRS) is a subset of chronic rhinosinusitis with nasal polyps (CRSwNP) characterized by antifungal IgE sensitivity, eosinophil-rich mucus (ie, allergic mucin), and characteristic computed tomographic and magnetic resonance imaging findings in paranasal sinuses. AFRS develops in immunocompetent patients, with occurrence influenced by climate, geography, and several identified host factors. Molecular pathways and immune responses driving AFRS are still being delineated, but prominent adaptive and more recently recognized innate type 2 immune responses are important, many similar to those established in patients with other forms of CRSwNP. It is unclear whether AFRS represents merely a more extreme expression of pathways important in patients with CRSwNP or whether there are other disordered immune responses that would define a distinct endotype or endotypes. Although AFRS and allergic bronchopulmonary aspergillosis share some analogous immune mechanisms, the 2 conditions do not occur commonly in the same patient. Treatment of AFRS almost always requires surgical debridement of the involved sinuses. Oral corticosteroids decrease recurrence after surgery, but other adjunctive pharmacologic agents, including topical and oral antifungal agents, do not have a firm evidence basis for use. There is good rationale for use of biologic agents that target eosinophilic inflammation or other type 2 responses, but studies in patients with AFRS are required.	[Dykewicz, Mark S.; Slavin, Raymond G.] St Louis Univ, Sch Med, Dept Internal Med, Sect Allergy & Immunol,Div Infect Dis Allergy & I, St Louis, MO USA; [Rodrigues, Jonathan M.] Sanford Hlth, Allergy & Immunol, Sioux Falls, SD USA; [Rodrigues, Jonathan M.] Univ North Dakota, Sch Med & Hlth Sci, Dept Internal Med, Grand Forks, ND USA	Saint Louis University; Sanford Health; University of North Dakota Grand Forks	Dykewicz, MS (corresponding author), St Louis Univ, Allergy & Immunol, 1402 S Grand Blvd,M157, St Louis, MO 63104 USA.	Mark.dykewicz@health.slu.edu						Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Al-Radadi AM, 2011, J PAK MED ASSOC, V61, P704; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; ALLPHIN AL, 1991, LARYNGOSCOPE, V101, P815, DOI 10.1288/00005537-199108000-00003; Andes D, 2000, CLIN INFECT DIS, V31, P202, DOI 10.1086/313938; Aribandi M, 2007, RADIOGRAPHICS, V27, DOI 10.1148/rg.275065189; Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P621, DOI 10.1016/j.jaip.2016.05.004; Bassichis BA, 2001, OTOLARYNG HEAD NECK, V125, P487, DOI 10.1067/mhn.2001.119585; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; Bohman A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185244; Callejas CA, 2013, CLIN EXP ALLERGY, V43, P835, DOI 10.1111/cea.12118; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chakrabarti A, 2016, J FUNGI BASEL, V2, P1; Chakrabarti A, 2015, MYCOSES, V58, P294, DOI 10.1111/myc.12314; Chakrabarti A, 2009, LARYNGOSCOPE, V119, P1809, DOI 10.1002/lary.20520; Cleland EJ, 2014, INT FORUM ALLERGY RH, V4, P259, DOI 10.1002/alr.21297; CODY DT, 1994, LARYNGOSCOPE, V104, P1074, DOI 10.1288/00005537-199409000-00005; Collins M, 2004, LARYNGOSCOPE, V114, P1242, DOI 10.1097/00005537-200407000-00019; Derycke L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097581; Deshazo RD, 2009, MED MYCOL, V47, pS309, DOI 10.1080/13693780802213399; Dietz CP, 2016, ADV OTO-RHINO-LARYNG, V79, P58, DOI 10.1159/000445130; Dutre T, 2013, J ALLERGY CLIN IMMUN, V132, P487, DOI 10.1016/j.jaci.2013.02.040; Evans MO, 2014, ALLERGY RHINOL, V5, pE172, DOI 10.2500/ar.2014.5.0098; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; Ferguson BJ, 2000, OTOLARYNG CLIN N AM, V33, P441, DOI 10.1016/S0030-6665(00)80018-3; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Folker RJ, 1998, LARYNGOSCOPE, V108, P1623, DOI 10.1097/00005537-199811000-00007; Gan EC, 2015, AM J OTOLARYNG, V36, P672, DOI 10.1016/j.amjoto.2015.05.008; Gan EC, 2014, INT FORUM ALLERGY RH, V4, P702, DOI 10.1002/alr.21352; Ghegan MD, 2006, OTOLARYNG HEAD NECK, V134, P592, DOI 10.1016/j.otohns.2005.11.025; Greenhaw B, 2011, ANN ALLERG ASTHMA IM, V107, P432, DOI 10.1016/j.anai.2011.05.021; Gurrola J, 2017, J ALLERGY CLIN IMMUN, V140, P1499, DOI 10.1016/j.jaci.2017.10.006; Hamilos DL, 2015, J ALLERGY CLIN IMMUN, V136, P1454, DOI 10.1016/j.jaci.2015.10.011; Hamilos Daniel L, 2010, Proc Am Thorac Soc, V7, P245, DOI 10.1513/pats.200909-098AL; Ho J, 2015, CLIN EXP ALLERGY, V45, P394, DOI 10.1111/cea.12462; Holbrook JF, 2014, J NEUROIMAGING, V24, P95, DOI 10.1111/j.1552-6569.2011.00670.x; Hutcheson PS, 2010, AM J RHINOL ALLERGY, V24, P405, DOI 10.2500/ajra.2010.24.3533; Ikram Mubasher, 2009, Ear Nose Throat J, V88, pE8; Illing EA, 2015, OTOLARYNG HEAD NECK, V152, P541, DOI 10.1177/0194599814567302; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; Kim JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077177; Kupferberg SB, 1997, OTOLARYNG HEAD NECK, V117, P35, DOI 10.1016/S0194-5998(97)70203-1; Lackner A, 2005, AM J RHINOL, V19, P125, DOI 10.1177/194589240501900203; Liu JK, 2004, J NEUROSURG, V100, P883, DOI 10.3171/jns.2004.100.5.0883; Lu-Myers Y, 2015, OTOLARYNG HEAD NECK, V153, P137, DOI 10.1177/0194599815580978; Luong A, 2009, AM J RHINOL ALLERGY, V23, P281, DOI 10.2500/ajra.2009.23.3311; Mabry RL, 2000, OTOLARYNG HEAD NECK, V122, P104, DOI 10.1016/S0194-5998(00)70153-7; Mabry RL, 1998, OTOLARYNG HEAD NECK, V119, P648, DOI 10.1016/S0194-5998(98)70027-0; Mabry RL, 2000, OTOLARYNG CLIN N AM, V33, P433, DOI 10.1016/S0030-6665(00)80017-1; Manning SC, 1997, LARYNGOSCOPE, V107, P170, DOI 10.1097/00005537-199702000-00007; Marple BF, 1999, AM J RHINOL, V13, P191, DOI 10.2500/105065899781389740; Marple BF, 2000, AM J RHINOL, V14, P223, DOI 10.2500/105065800779954482; Meltzer EO, 2006, J ALLERGY CLIN IMMUN, V118, pS17, DOI 10.1016/j.jaci.2006.09.005; Melzer JM, 2015, ANN OTO RHINOL LARYN, V124, P782, DOI 10.1177/0003489415583686; Michael RC, 2008, INDIAN J PATHOL MICR, V51, P493; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; MILLAR JW, 1981, THORAX, V36, P710; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Nussenbaum B, 2001, OTOLARYNG HEAD NECK, V124, P150, DOI 10.1067/mhn.2001.112573; Orlandi RR, 2007, OTOLARYNG HEAD NECK, V136, P707, DOI 10.1016/j.otohns.2006.11.033; Pant H, 2014, ALLERGY RHINOL, V5, pE146, DOI 10.2500/ar.2014.5.0103; Patro SK, 2015, AM J RHINOL ALLERGY, V29, P299, DOI 10.2500/ajra.2015.29.4187; Peters AT, 2014, ANN ALLERG ASTHMA IM, V113, P347, DOI 10.1016/j.anai.2014.07.025; Porter PC, 2014, J ALLERGY CLIN IMMUN, V134, P325, DOI 10.1016/j.jaci.2014.04.028; Rai G, 2018, INT IMMUNOPHARMACOL, V57, P55, DOI 10.1016/j.intimp.2018.02.009; ROBSON JMB, 1989, AUST NZ J MED, V19, P351, DOI 10.1111/j.1445-5994.1989.tb00278.x; Rodrigues J, 2016, EXPERT REV CLIN IMMU, V12, P531, DOI 10.1586/1744666X.2016.1142874; Rupa V, 2010, EUR ARCH OTO-RHINO-L, V267, P233, DOI 10.1007/s00405-009-1075-8; Sacks PL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008263.pub2; SAFIRSTEIN BH, 1976, CHEST, V70, P788, DOI 10.1378/chest.70.6.788; Schlosser RJ, 2010, AM J RHINOL ALLERGY, V24, P21, DOI 10.2500/ajra.2010.24.3399; Schubert MS, 2004, J ALLERGY CLIN IMMUN, V114, P1376, DOI 10.1016/j.jaci.2004.08.029; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; Schubert MS, 2001, J ALLERGY CLIN IMMUN, V108, P466, DOI 10.1067/mai.2001.117592; Seiberling K, 2009, AM J RHINOL ALLERGY, V23, P303, DOI 10.2500/ajra.2009.23.3315; Shah A, 2001, CLIN EXP ALLERGY, V31, P1896, DOI 10.1046/j.1365-2222.2001.01159.x; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shaw JL, 2012, INT FORUM ALLERGY RH, V2, P233, DOI 10.1002/alr.21021; Slavin RG, 2006, ALLERGY ASTHMA PROC, V27, P447, DOI 10.2500/aap.2006.27.2890; Stewart AE, 2002, OTOLARYNG HEAD NECK, V127, P324, DOI 10.1067/mhn.2002.126801; Tan BK, 2018, J ALLERGY CLIN IMMUN, V141, P1553, DOI 10.1016/j.jaci.2018.03.002; Tyler MA, 2017, J ALLERGY CLIN IMMUN, V139, P1061, DOI 10.1016/j.jaci.2016.09.048; Uri N, 2013, J LARYNGOL OTOL, V127, P867, DOI 10.1017/S0022215113001680; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Venarske DL, 2002, CHEST, V121, P1670, DOI 10.1378/chest.121.5.1670; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; WAXMAN JE, 1987, LARYNGOSCOPE, V97, P261; White LC, 2015, AM J RHINOL ALLERGY, V29, P243, DOI 10.2500/ajra.2015.29.4186; Wise SK, 2008, OTOLARYNG HEAD NECK, V138, P38, DOI 10.1016/j.otohns.2007.10.020; Wise SK, 2009, OTOLARYNG HEAD NECK, V140, P735, DOI 10.1016/j.otohns.2008.12.053; ZINREICH SJ, 1988, RADIOLOGY, V169, P439, DOI 10.1148/radiology.169.2.3174990	94	32	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					341	352		10.1016/j.jaci.2018.06.023	http://dx.doi.org/10.1016/j.jaci.2018.06.023			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	30080526				2022-12-18	WOS:000440664400001
J	Komlosi, ZI; Kovacs, N; van de Veen, W; Kirsch, AI; Fahrner, HB; Wawrzyniak, M; Rebane, A; Stanic, B; Palomares, O; Ruckert, B; Menz, G; Akdis, M; Losonczy, G; Akdis, CA				Komlosi, Zsolt I.; Kovacs, Nora; van de Veen, Willem; Kirsch, Anna Isabella; Fahrner, Heinz Benedikt; Wawrzyniak, Marcin; Rebane, Ana; Stanic, Barbara; Palomares, Oscar; Ruckert, Beate; Menz, Gunter; Akdis, Mubeccel; Losonczy, Gyorgy; Akdis, Cezmi A.			Human CD40 ligand-expressing type 3 innate lymphoid cells induce IL-10-producing immature transitional regulatory B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type 3 innate lymphoid cells; immature transitional regulatory B cells; regulatory B cells; tonsils; allergy; asthma; IL-10; immunoregulation; immune tolerance	ACTIVATING FACTOR; INTESTINAL INFLAMMATION; ALLERGIC RHINITIS; MARGINAL ZONE; HUMAN TONSILS; T-CELLS; IL-15; IDENTIFICATION; ANTIGEN; PHENOTYPE	Background: Type 3 innate lymphoid cells (ILC3s) are involved in maintenance of mucosal homeostasis; however, their role in immunoregulation has been unknown. Immature transitional regulatory B (itBreg) cells are innate-like B cells with immunosuppressive properties, and the in vivo mechanisms by which they are induced have not been fully clarified. Objective: We aimed to investigate the ILC3-B-cell interaction that probably takes place in human tonsils. Methods: ILC3s were isolated from peripheral blood and palatine tonsils, expanded, and cocultured with naive B cells. Tonsillar ILC3s and regulatory B cells were visualized with immunofluorescence histology. ILC3 frequencies were measured in tonsil tissue of allergic and nonallergic patients and in peripheral blood of allergic asthmatic patients and healthy control subjects. Results: A mutually beneficial relationship was revealed between ILC3s and B cells: ILC3s induced IL-15 production in B cells through B cell-activating factor receptor, whereas IL-15, a potent growth factor for ILC3s, induced CD40 ligand (CD40L) expression on circulating and tonsillar ILC3s. IL-15-activated CD40L(+) ILC3s helped B-cell survival, proliferation, and differentiation of IL-10-secreting, PD-L1-expressing functional itBreg cells in a CD40L-and B cell-activating factor receptor-dependent manner. ILC3s and regulatory B cells were in close connection with each other in palatine tonsils. ILC3 frequency was reduced in tonsil tissue of allergic patients and in peripheral blood of allergic asthmatic patients. Conclusion: Human CD40L(+) ILC3s provide innate B-cell help and are involved in an innate immunoregulatory mechanism through induction of itBreg cell differentiation, which takes place in palatine tonsils in vivo. This mechanism, which can contribute to maintenance of immune tolerance, becomes insufficient in allergic diseases.	[Komlosi, Zsolt I.; Kovacs, Nora; van de Veen, Willem; Wawrzyniak, Marcin; Rebane, Ana; Stanic, Barbara; Palomares, Oscar; Ruckert, Beate; Akdis, Mubeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Komlosi, Zsolt I.; Kovacs, Nora; van de Veen, Willem; Wawrzyniak, Marcin; Rebane, Ana; Stanic, Barbara; Palomares, Oscar; Ruckert, Beate; Akdis, Mubeccel; Akdis, Cezmi A.] CK CARE Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Komlosi, Zsolt I.; Losonczy, Gyorgy] Semmelweis Univ, Dept Pulmonol, 1-C Diosarok, H-1125 Budapest, Hungary; [Kovacs, Nora] Lung Hlth Hosp, Torokbalint, Hungary; [Kirsch, Anna Isabella; Menz, Gunter] Hochgebirgsklinik, Davos, Switzerland; [Fahrner, Heinz Benedikt] Kantonsspital Graubunden, Dept ENT, Chur, Switzerland; [Rebane, Ana] Univ Tartu, Inst Biomed & Translat Med, Tartu, Estonia; [Stanic, Barbara] AO Res Inst, Davos, Switzerland; [Palomares, Oscar] Univ Complutense Madrid, Sch Chem, Dept Biochem & Mol Biol, Madrid, Spain	Swiss Institute of Allergy & Asthma Research; University of Zurich; Semmelweis University; Kantonsspital Graubunden; University of Tartu; Complutense University of Madrid	Komlosi, ZI (corresponding author), Semmelweis Univ, Dept Pulmonol, 1-C Diosarok, H-1125 Budapest, Hungary.; Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22,Davos Pl, CH-7270 Davos, Switzerland.	drkomlo@yahoo.com; akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; Wawrzyniak, Marcin/AAT-9094-2021; Wawrzyniak, Marcin/E-5878-2017; Palomares, Oscar/ABG-5229-2020; Rebane, Ana/D-4279-2013	Akdis, Cezmi/0000-0001-8020-019X; Wawrzyniak, Marcin/0000-0002-6911-8010; Rebane, Ana/0000-0001-6051-1361; van de Veen, Willem/0000-0001-9951-6688; Komlosi, Zsolt Istvan/0000-0002-4149-1497	European Respiratory Society Fellowship [LTRF55-2010]; Swiss National Science Foundation grants [310030-156823, 320030-140772]; Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland	European Respiratory Society Fellowship; Swiss National Science Foundation grants(Swiss National Science Foundation (SNSF)); Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland	Z.I.K. is the recipient of a European Respiratory Society Fellowship (LTRF55-2010). This work was supported by Swiss National Science Foundation grants 310030-156823 and 320030-140772 and the Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.	Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Aoi N, 2006, J ALLERGY CLIN IMMUN, V117, P1359, DOI 10.1016/j.jaci.2006.02.018; Aparicio-Domingo P, 2015, J EXP MED, V212, P1783, DOI 10.1084/jem.20150318; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Braza F, 2015, ALLERGY, V70, P1421, DOI 10.1111/all.12697; Carter NA, 2011, J IMMUNOL, V186, P5569, DOI 10.4049/jimmunol.1100284; Cella M, 2010, P NATL ACAD SCI USA, V107, P10961, DOI 10.1073/pnas.1005641107; Crellin NK, 2010, J EXP MED, V207, P281, DOI 10.1084/jem.20091509; Das A, 2012, J IMMUNOL, V189, P3925, DOI 10.4049/jimmunol.1103139; Flores-Borja F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005407; Fukuoka A, 2013, INT IMMUNOL, V25, P373, DOI 10.1093/intimm/dxs160; Gil-Cruz C, 2016, NAT IMMUNOL, V17, P1388, DOI 10.1038/ni.3566; Guo XH, 2014, IMMUNITY, V40, P25, DOI 10.1016/j.immuni.2013.10.021; Hepworth MR, 2015, SCIENCE, V348, P1031, DOI 10.1126/science.aaa4812; Huggins J, 2007, BLOOD, V109, P1611, DOI 10.1182/blood-2006-03-008441; Ishimitsu R, 2001, J IMMUNOL, V166, P1991, DOI 10.4049/jimmunol.166.3.1991; Karnekura R, 2015, CLIN IMMUNOL, V158, P204, DOI 10.1016/j.clim.2015.02.016; Khan AR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6997; Kim AS, 2016, J ALLERGY CLIN IMMUN, V138, P1192, DOI 10.1016/j.jaci.2016.03.017; Kim S, 2011, EUR J IMMUNOL, V41, P1563, DOI 10.1002/eji.201040915; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Lemoine S, 2011, J AUTOIMMUN, V36, P228, DOI 10.1016/j.jaut.2011.01.005; Li Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11394; Liu CC, 2000, IMMUNOL TODAY, V21, P113, DOI 10.1016/S0167-5699(99)01581-9; Lombardi V, 2016, J ALLERGY CLIN IMMUN, V138, P305, DOI 10.1016/j.jaci.2015.12.1325; Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572; Magri G, 2014, NAT IMMUNOL, V15, P354, DOI 10.1038/ni.2830; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Moingeon P, 2013, J ALLER CL IMM-PRACT, V1, P228, DOI 10.1016/j.jaip.2013.03.013; Newell KA, 2010, J CLIN INVEST, V120, P1836, DOI 10.1172/JCI39933; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Pietravalle F, 1996, J BIOL CHEM, V271, P5965, DOI 10.1074/jbc.271.11.5965; Qiu J, 2013, IMMUNITY, V39, P386, DOI 10.1016/j.immuni.2013.08.002; QUIDING M, 1993, CLIN EXP IMMUNOL, V91, P157; Romera-Hernandez M, 2013, CURR OPIN IMMUNOL, V25, P156, DOI 10.1016/j.coi.2013.01.007; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Rosser EC, 2014, NAT MED, V20, P1334, DOI 10.1038/nm.3680; Sanos SL, 2011, IMMUNOLOGY, V132, P453, DOI 10.1111/j.1365-2567.2011.03410.x; Sasaki Y, 2004, J IMMUNOL, V173, P2245, DOI 10.4049/jimmunol.173.4.2245; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Scandella E, 2008, NAT IMMUNOL, V9, P667, DOI 10.1038/ni.1605; Schneider P, 2001, J EXP MED, V194, P1691, DOI 10.1084/jem.194.11.1691; Schneider R, 2011, J IMMUNOL, V187, P4119, DOI 10.4049/jimmunol.1100885; Simon Q, 2016, J ALLERGY CLIN IMMUN, V137, P1577, DOI 10.1016/j.jaci.2015.09.014; Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Tsuji M, 2008, IMMUNITY, V29, P261, DOI 10.1016/j.immuni.2008.05.014; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Vollmer J, 2004, J ENDOTOXIN RES, V10, P431, DOI 10.1179/096805104225006534; Yang M, 2010, J IMMUNOL, V184, P3321, DOI 10.4049/jimmunol.0902551; Zhang XM, 2013, CELL MOL IMMUNOL, V10, P113, DOI 10.1038/cmi.2012.63	54	32	34	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					178	+		10.1016/j.jaci.2017.07.046	http://dx.doi.org/10.1016/j.jaci.2017.07.046			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	28939410	Bronze, Green Accepted			2022-12-18	WOS:000437837500022
J	Song, J; Wang, H; Zhang, YN; Cao, PP; Liao, B; Wang, ZZ; Shi, LL; Yao, Y; Zhai, GT; Wang, ZC; Liu, LM; Zeng, M; Lu, X; Wang, H; Yang, XP; Yu, D; Bachert, C; Liu, Z				Song, Jia; Wang, Hai; Zhang, Ya-Na; Cao, Ping-Ping; Liao, Bo; Wang, Zhe-Zheng; Shi, Li-Li; Yao, Yin; Zhai, Guan-Ting; Wang, Zhi-Chao; Liu, Li-Meng; Zeng, Ming; Lu, Xiang; Wang, Heng; Yang, Xiang-Ping; Yu, Di; Bachert, Claus; Liu, Zheng			Ectopic lymphoid tissues support local immunoglobulin production in patients with chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ectopic lymphoid tissue; immunoglobulin; lymphoid aggregate; lymphorganogenesis	B-CELLS; T-CELLS; IGE; ALLERGEN; MUCOSA; INFLAMMATION; PATHOGENESIS; EXPRESSION; NEOGENESIS; ENTEROTOXINS	Background: The contribution of ectopic lymphoid tissues (eLTs) to local immunoglobulin hyperproduction in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is unclear. Objective: We sought to explore the cellular basis, formation mechanisms, and function of eLTs in patients with CRSwNP. Methods: We graded lymphoid aggregations in sinonasal mucosa and histologically studied their structures. The expression of lymphorganogenic factors and molecules required for immunoglobulin production was measured by using real-time PCR, and their localization was analyzed by means of immunohistochemistry and immunofluorescence. The phenotype of follicular helper T cells was analyzed by performing flow cytometry. Immunoglobulin levels were quantified by using the Bio-Plex assay or ImmunoCAP system. Nasal tissue explants were challenged ex vivo with Dermatophagoides pteronyssinus group 1 (Der p 1), and the expression of I epsilon-C mu and I epsilon-C gamma circle transcripts was detected by using seminested PCR. Results: Increased formation of eLTs with germinal center-like structures was discovered in patients with eosinophilic (20.69%) and noneosinophilic (17.31%) CRSwNP compared with that in patients with chronic rhinosinusitis without nasal polyps (5.66%) and control subjects (3.70%). The presence of eLTs was associated with increased expression of lymphorganogenic and inflammatory chemokines and cytokines, as well as their receptors. The expression of molecules required for immunoglobulin production, generation of follicular helper T cells, and production of IgE in eosinophilic polyps and IgG and IgA in both eosinophilic and noneosinophilic polyps were predominantly upregulated in patients with eLTs. After Der p 1 challenge ex vivo, I epsilon-C mu transcript was detected only in eosinophilic polyps with eLTs but not in polyps without eLTs and noneosinophilic polyps. Conclusion: eLTs might support local immunoglobulin production and therefore significantly contribute to the development of CRSwNP.	[Song, Jia; Wang, Hai; Cao, Ping-Ping; Liao, Bo; Wang, Zhe-Zheng; Shi, Li-Li; Yao, Yin; Zhai, Guan-Ting; Wang, Zhi-Chao; Zeng, Ming; Lu, Xiang; Wang, Heng; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China; [Yang, Xiang-Ping] Huazhong Univ Sci & Technol, Tongji Hosp, Sch Basic Med, Dept Immunol, Wuhan, Hubei, Peoples R China; [Zhang, Ya-Na; Yang, Xiang-Ping] Cent China Normal Univ, Guangzhou Women & Childrens Med Ctr, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China; [Liu, Li-Meng] Cent China Normal Univ, Middle Sch 1, Wuhan, Hubei, Peoples R China; [Yu, Di] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, ACT, Australia; [Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Central China Normal University; Central China Normal University; Australian National University; John Curtin School of Medical Research; Ghent University	Liu, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.	zhengliuent@hotmail.com	Yu, Di/C-2163-2009; Bachert, Claus/J-8825-2012	Yu, Di/0000-0003-1721-8922; Yin, Yao/0000-0002-5833-5263	National Natural Science Foundation of China (NSFC) [81630024, 81570899, 81325006, 81500777, 81400449, 81670911]; 12th Five Year Science and Technology Support Program [2014BAI07B04]; Australian National Health and Medical Research Council Fellowship	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); 12th Five Year Science and Technology Support Program; Australian National Health and Medical Research Council Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	Supported by National Natural Science Foundation of China (NSFC) grants 81630024, 81570899 and 81325006 (to Z.L.), 81500777 (to L.-L.S.), 81400449 (to P.-P.C.), and 81670911 (to X.L.); the 12th Five Year Science and Technology Support Program (2014BAI07B04); and an Australian National Health and Medical Research Council Fellowship (to D.Y.).	Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Canete JD, 2007, ANN RHEUM DIS, V66, P720, DOI 10.1136/ard.2006.062042; Cao PP, 2014, CLIN EXP ALLERGY, V44, P690, DOI 10.1111/cea.12304; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; De Schryver E, 2016, J ALLERGY CLIN IMMUN, V138, P893, DOI 10.1016/j.jaci.2016.03.040; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; Drayton DL, 2004, J IMMUNOL, V173, P6161, DOI 10.4049/jimmunol.173.10.6161; Eweiss A, 2009, EUR ARCH OTO-RHINO-L, V266, P377, DOI 10.1007/s00405-008-0762-1; Feldman S, 2017, CLIN EXP ALLERGY, V47, P457, DOI 10.1111/cea.12878; Fleige H, 2014, J EXP MED, V211, P643, DOI 10.1084/jem.20131737; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Frija-Masson J, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01873-2016; GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Lau A, 2017, J ALLERGY CLIN IMMUN, V139, P1371, DOI 10.1016/j.jaci.2016.08.052; Litsiou E, 2013, AM J RESP CRIT CARE, V187, P1194, DOI 10.1164/rccm.201208-1543OC; Ma J, 2016, CLIN EXP ALLERGY, V46, P1162, DOI 10.1111/cea.12758; Manzo A, 2005, EUR J IMMUNOL, V35, P1347, DOI 10.1002/eji.200425830; Mechtcheriakova D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025611; Min JY, 2016, ADV OTO-RHINO-LARYNG, V79, P48, DOI 10.1159/000445129; Nayar S, 2016, J IMMUNOL, V197, P1957, DOI 10.4049/jimmunol.1500686; Patadia M, 2010, AM J RHINOL ALLERGY, V24, P11, DOI 10.2500/ajra.2010.24.3386; Peters A, 2011, IMMUNITY, V35, P986, DOI 10.1016/j.immuni.2011.10.015; Pikor NB, 2015, IMMUNITY, V43, P1160, DOI 10.1016/j.immuni.2015.11.010; Pitzalis C, 2014, NAT REV IMMUNOL, V14, P447, DOI 10.1038/nri3700; Rangel-Moreno J, 2011, NAT IMMUNOL, V12, P639, DOI 10.1038/ni.2053; Schlosser RJ, 2016, JAMA OTOLARYNGOL, V142, P731, DOI 10.1001/jamaoto.2016.0927; Shi LL, 2014, AM J RESP CRIT CARE, V190, P628, DOI 10.1164/rccm.201402-0234OC; Shinoda K, 2016, P NATL ACAD SCI USA, V113, pE2842, DOI 10.1073/pnas.1512600113; Stevens WW, 2015, J ALLERGY CLIN IMMUN, V136, P1442, DOI 10.1016/j.jaci.2015.10.009; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Tan BK, 2017, J ALLERGY CLIN IMMUN, V139, P699, DOI 10.1016/j.jaci.2016.06.063; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Upadhyay V, 2013, NAT REV IMMUNOL, V13, P270, DOI 10.1038/nri3406; Van Roey GA, 2017, J ALLERGY CLIN IMMUN, V140, P89, DOI 10.1016/j.jaci.2016.11.015; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Wu XF, 2012, ARCH OTOLARYNGOL, V138, P389, DOI 10.1001/archoto.2012.155; Xin JW, 2015, MOL MED REP, V11, P3391, DOI 10.3892/mmr.2015.3174; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x; Zhang YN, 2016, J ALLERGY CLIN IMMUN, V137, P462, DOI 10.1016/j.jaci.2015.07.025	47	32	35	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					927	937		10.1016/j.jaci.2017.10.014	http://dx.doi.org/10.1016/j.jaci.2017.10.014			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29103995	Bronze			2022-12-18	WOS:000426974800013
J	Mouraux, S; Bernasconi, E; Pattaroni, C; Koutsokera, A; Aubert, JD; Claustre, J; Pison, C; Royer, PJ; Magnan, A; Kessler, R; Benden, C; Soccal, PM; Marsland, BJ; Nicod, LP				Mouraux, Stephane; Bernasconi, Eric; Pattaroni, Celine; Koutsokera, Angela; Aubert, John-David; Claustre, Johanna; Pison, Christophe; Royer, Pierre-Joseph; Magnan, Antoine; Kessler, Romain; Benden, Christian; Soccal, Paola M.; Marsland, Benjamin J.; Nicod, Laurent P.		SysCLAD Consortium	Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway remodeling; fibroblasts; macrophages; matrix; microbiota	IDIOPATHIC PULMONARY-FIBROSIS; ALLOGRAFT DYSFUNCTION; ACUTE EXACERBATIONS; SERUM-LEVELS; PDGF-D; EXPRESSION; MACROPHAGES; DISEASE; COPD; INFLAMMATION	Background: Homeostatic turnover of the extracellular matrix conditions the structure and function of the healthy lung. In lung transplantation, long-term management remains limited by chronic lung allograft dysfunction, an umbrella term used for a heterogeneous entity ultimately associated with pathological airway and/or parenchyma remodeling. Objective: This study assessed whether the local cross-talk between the pulmonary microbiota and host cells is a key determinant in the control of lower airway remodeling posttransplantation. Methods: Microbiota DNA and host total RNA were isolated from 189 bronchoalveolar lavages obtained from 116 patients post lung transplantation. Expression of a set of 11 genes encoding either matrix components or factors involved in matrix synthesis or degradation (anabolic and catabolic remodeling, respectively) was quantified by real-time quantitative PCR. Microbiota composition was characterized using 16S ribosomal RNA gene sequencing and culture. Results: We identified 4 host gene expression profiles, among which catabolic remodeling, associated with high expression of metallopeptidase-7, -9, and -12, diverged from anabolic remodeling linked to maximal thrombospondin and platelet-derived growth factor D expression. While catabolic remodeling aligned with a microbiota dominated by proinflammatory bacteria (eg, Staphylococcus, Pseudomonas, and Corynebacterium), anabolic remodeling was linked to typical members of the healthy steady state (eg, Prevotella, Streptococcus, and Veillonella). Mechanistic assays provided direct evidence that these bacteria can impact host macrophage-fibroblast activation and matrix deposition. Conclusions: Host-microbes interplay potentially determines remodeling activities in the transplanted lung, highlighting new therapeutic opportunities to ultimately improve long-term lung transplant outcome.	[Mouraux, Stephane; Bernasconi, Eric; Pattaroni, Celine; Koutsokera, Angela; Aubert, John-David; Marsland, Benjamin J.; Nicod, Laurent P.] CHU Vaudois, Serv Pneumol, Lausanne, Switzerland; [Claustre, Johanna; Pison, Christophe] Ctr Hosp Univ Grenoble Alpes, Clin Univ Pneumol, Pole Thorax & Vaisseaux, Grenoble, France; [Claustre, Johanna; Pison, Christophe] Univ Grenoble Alpes, Grenoble, France; [Claustre, Johanna; Pison, Christophe] Inst Natl Sante & Rech Med 1055, St Martin Dheres, France; [Royer, Pierre-Joseph; Magnan, Antoine] Univ Nantes, CHU Nantes, Inst Thorax, Serv Pneumol,INSERM,CNRS, Nantes, France; [Kessler, Romain] Ctr Hosp Univ, Nouvel Hop Civil, Serv Pneumol, Strasbourg, France; [Benden, Christian] Univ Hosp Zurich, Div Pulmonol, Zurich, Switzerland; [Soccal, Paola M.] Geneva Univ Hosp, Div Pulm Med, Geneva, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; CHU Strasbourg; University of Zurich; University Zurich Hospital; University of Geneva	Bernasconi, E (corresponding author), Serv Pneumol, CLE D02-207,Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	Eric.Bernasconi@chuv.ch	Nicod, Laurent/ABD-3360-2020; MAGNAN, ANTOINE/GVT-4308-2022; /AFN-8948-2022; Benden, Christian/E-9774-2012; CHAVANON, Olivier/AAC-8171-2019; kessler, romain/B-9149-2018; Schuepbach, Reto/J-9737-2012	/0000-0002-9920-1181; Thomas, Pascal/0000-0002-3305-6989; Inci, Ilhan/0000-0003-3937-7705; Dorfmuller, Peter/0000-0003-2499-6829; Mercier, Olaf/0000-0002-4760-6267; Falcoz, Pierre-Emmanuel/0000-0002-5915-5512; Claustre, Johanna/0000-0003-3788-0892; CHAVANON, Olivier/0000-0001-8625-691X; Koutsokera, Angela/0000-0003-1227-1679; maury, jean-michel/0000-0002-3494-3678; kessler, romain/0000-0002-5798-5715; gonzalez, michel/0000-0001-8705-4279; Massard, Gilbert/0000-0003-0609-9710; Schuepbach, Reto/0000-0002-7058-4377; Bernasconi, Eric/0000-0002-4641-1409; Holzmann, David/0000-0002-8176-8358; Bourgoin-Voillard, Sandrine/0000-0001-6511-0612; Aubert, John-David/0000-0001-8856-4000	European Commission FP7 [305457]; Swiss National Science Foundation [156897]; Fondation de la Banque Cantonale Vaudoise; Fondation Juchum; Fondation Professeur Placide Nicod; Association Vaincre La Mucoviscidose; Association Gregory Lemarchal; Region Pays de La Loire; Agence de Biomedecine; Institut Hospitalo-Universitaire CESTI; French government [ANR-10-IBHU-005]; Nantes Metropole	European Commission FP7(European CommissionEuropean Commission Joint Research Centre); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Fondation de la Banque Cantonale Vaudoise; Fondation Juchum; Fondation Professeur Placide Nicod; Association Vaincre La Mucoviscidose; Association Gregory Lemarchal; Region Pays de La Loire(Region Pays de la Loire); Agence de Biomedecine; Institut Hospitalo-Universitaire CESTI; French government; Nantes Metropole(Region Pays de la Loire)	This work was supported by European Commission FP7 (grant no. 305457, SysCLAD Consortium), Swiss National Science Foundation (grant no. 156897, L.P.N.), Fondation de la Banque Cantonale Vaudoise (J.-D.A., E.B.), Fondation Juchum (S.M., A.K.), and Fondation Professeur Placide Nicod (C.Pa.). The Cohort of Lung Transplantation was financially supported by the Association Vaincre La Mucoviscidose, the Association Gregory Lemarchal, the Region Pays de La Loire, the Agence de Biomedecine, and the Institut Hospitalo-Universitaire CESTI. This work was realized in the context of the IHU-Cesti project thanks to French government financial support managed by the National Research Agency via the Investment into the Future program (ANR-10-IBHU-005). The IHU-Cesti project was also supported by Nantes Metropole and Region Pays de la Loire.	Bernasconi E, 2016, AM J RESP CRIT CARE, V194, P1252, DOI 10.1164/rccm.201512-2424OC; Buhl EM, 2016, KIDNEY INT, V89, P848, DOI 10.1016/j.kint.2015.12.037; Cao B, 2000, CHINESE MED J-PEKING, V113, P776; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Charlson ES, 2012, AM J RESP CRIT CARE, V186, P536, DOI 10.1164/rccm.201204-0693OC; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Dela Cruz CS, 2012, CELL HOST MICROBE, V12, P34, DOI 10.1016/j.chom.2012.05.017; Dickson RP, 2014, LANCET, V384, P691, DOI 10.1016/S0140-6736(14)61136-3; Gela A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146192; Gratchev A, 2001, SCAND J IMMUNOL, V53, P386, DOI 10.1046/j.1365-3083.2001.00885.x; Guiot J, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0249-6; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2014, J CLIN MICROBIOL, V52, P2813, DOI 10.1128/JCM.00035-14; Ide M, 2008, RESP MED, V102, P1625, DOI 10.1016/j.rmed.2008.05.009; Ishii T, 2006, EUR RESPIR J, V27, P300, DOI 10.1183/09031936.06.00090405; Jenkins RG, 2015, LANCET RESP MED, V3, P462, DOI 10.1016/S2213-2600(15)00048-X; Jonigk D, 2015, AM J PATHOL, V185, P3178, DOI 10.1016/j.ajpath.2015.08.016; Kristensen JH, 2015, CLIN BIOCHEM, V48, P1083, DOI 10.1016/j.clinbiochem.2015.07.009; Kumar P, 2015, SCI REP-UK, V5, DOI 10.1038/srep08729; Lai TW, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0338-3; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Larsen JM, 2015, IMMUNOLOGY, V144, P333, DOI 10.1111/imm.12376; Molyneaux PL, 2014, AM J RESP CRIT CARE, V190, P906, DOI 10.1164/rccm.201403-0541OC; Murphy-Ullrich JE, 2014, MATRIX BIOL, V37, P1, DOI 10.1016/j.matbio.2014.07.005; Pain M, 2017, AM J TRANSPLANT, V17, P1502, DOI 10.1111/ajt.14166; Papakonstantinou E, 2016, CHEST, V149, P685, DOI 10.1378/chest.14-2868; Pardo A, 2005, PLOS MED, V2, P891, DOI 10.1371/journal.pmed.0020251; Pison C, 2014, EUR RESPIR J, V43, P689, DOI 10.1183/09031936.00161313; Schnoor M, 2008, J IMMUNOL, V180, P5707, DOI 10.4049/jimmunol.180.8.5707; Stewart S, 2007, J HEART LUNG TRANSPL, V26, P1229, DOI 10.1016/j.healun.2007.10.017; Stolz D, 2017, CHEST, V151, P47, DOI 10.1016/j.chest.2016.08.1440; Suwara MI, 2014, TRANSPL INT, V27, P857, DOI 10.1111/tri.12341; Sweetwyne MT, 2012, MATRIX BIOL, V31, P178, DOI 10.1016/j.matbio.2012.01.006; Taylor SL, 2015, ANN AM THORAC SOC, V12, P701, DOI 10.1513/AnnalsATS.201411-513OC; Team RDC, 2011, R LANG ENV STAT COMP; Uh ST, 1998, AM J RESP CRIT CARE, V158, P1626, DOI 10.1164/ajrccm.158.5.9804025; Vandermeulen E, 2016, TRANSPL IMMUNOL, V38, P27, DOI 10.1016/j.trim.2016.08.004; Wang KX, 2008, CYTOKINE GROWTH F R, V19, P333, DOI 10.1016/j.cytogfr.2008.08.001; Yadava K, 2016, AM J RESP CRIT CARE, V193, P975, DOI 10.1164/rccm.201504-0779OC; Yusen RD, 2015, J HEART LUNG TRANSPL, V34, P1264, DOI 10.1016/j.healun.2015.08.014; Zhao TQ, 2013, AM J PHYSIOL-HEART C, V304, pH1719, DOI 10.1152/ajpheart.00130.2013; Zhou Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007096; Zhuo Y, 2004, AM J PHYSIOL-LUNG C, V286, pL182, DOI 10.1152/ajplung.00083.2003	43	32	32	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					718	+		10.1016/j.jaci.2017.06.022	http://dx.doi.org/10.1016/j.jaci.2017.06.022			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28729000	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000424410800028
J	Pitt, TJ; Becker, AB; Chan-Yeung, M; Chan, ES; Watson, WTA; Chooniedass, R; Azad, MB				Pitt, Tracy J.; Becker, Allan B.; Chan-Yeung, Moira; Chan, Edmond S.; Watson, Wade T. A.; Chooniedass, Rishma; Azad, Meghan B.			Reduced risk of peanut sensitization following exposure through breast-feeding and early peanut introduction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Breast-feeding; lactation; maternal peanut consumption; peanut allergy; peanut sensitization; timing of peanut introduction	PROSPECTIVE BIRTH COHORT; SOLID FOOD INTRODUCTION; PRIMARY PREVENTION; ALLERGY; CONSUMPTION; PREVALENCE; MILK; CHILDREN; INFANTS; ASTHMA	Background: Recent trials have shown that avoiding peanuts during infancy increases the risk of peanut allergy; however, these studies did not address maternal peanut consumption. Objective: We sought to investigate the relationship between maternal peanut consumption while breast-feeding, timing of direct peanut introduction, and peanut sensitization at age 7 years. Methods: Secondary analysis of a nested cohort within the 1995 Canadian Asthma Primary Prevention Study intervention study was performed. Breast-feeding and maternal and infant peanut consumption were captured by repeated questionnaires during infancy. Skin prick testing for peanut sensitization was performed at age 7 years. Results: Overall, 58.2% of mothers consumed peanuts while breast-feeding and 22.5% directly introduced peanuts to their infant by 12 months. At 7 years, 9.4% of children were sensitized to peanuts. The lowest incidence (1.7%) was observed among children whose mothers consumed peanuts while breast-feeding and directly introduced peanuts before 12 months. Incidence was significantly higher (P<.05) if mothers consumed peanuts while breast-feeding but delayed introducing peanuts to their infant beyond 12 months (15.1%), or if mothers avoided peanuts themselves but directly introduced peanuts by 12 months (17.6%). Interaction analyses controlling for study group and maternal atopy confirmed that maternal peanut consumption while breast-feeding and infant peanut consumption by 12 months were protective in combination, whereas either exposure in isolation was associated with an increased risk of sensitization (P interaction =.003). Conclusions: In this secondary analysis, maternal peanut consumption while breast-feeding paired with direct introduction of peanuts in the first year of life was associated with the lowest risk of peanut sensitization, compared with all other combinations of maternal and infant peanut consumption.	[Pitt, Tracy J.] Humber River Hosp, Toronto, ON, Canada; [Becker, Allan B.; Chooniedass, Rishma; Azad, Meghan B.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada; [Becker, Allan B.; Chooniedass, Rishma; Azad, Meghan B.] Childrens Hosp, Res Inst Manitoba, Dev Origins Chron Dis Children Network DEVOTION, Winnipeg, MB, Canada; [Chan-Yeung, Moira] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Chan, Edmond S.] Univ British Columbia, Dept Pediat, Div Allergy & Immunol, Vancouver, BC, Canada; [Watson, Wade T. A.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of British Columbia; University of British Columbia; Dalhousie University	Azad, MB (corresponding author), Childrens Hosp, Res Inst Manitoba, 501G-715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	meghan.azad@umanitoba.ca	Azad, Meghan/H-7226-2019	Azad, Meghan/0000-0002-5942-4444	Canadian Institutes of Health Research; Allergy, Genes and Environment (AllerGen) Network of Centres of Excellence	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Allergy, Genes and Environment (AllerGen) Network of Centres of Excellence	The study was funded by the Canadian Institutes of Health Research and the Allergy, Genes and Environment (AllerGen) Network of Centres of Excellence. These entities had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Baker SS, 2000, PEDIATRICS, V106, P346; Ballard O, 2013, PEDIATR CLIN N AM, V60, P49, DOI 10.1016/j.pcl.2012.10.002; Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Bernard H, 2014, ALLERGY, V69, P888, DOI 10.1111/all.12411; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; DesRoches A, 2010, J INVEST ALLERG CLIN, V20, P289; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fleischer DM, 2015, PEDIATRICS, V33, P103; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Joseph CLM, 2011, J ALLERGY CLIN IMMUN, V127, P1203, DOI 10.1016/j.jaci.2011.02.018; Kemp AS, 2011, CLIN EXP ALLERGY, V41, P224, DOI 10.1111/j.1365-2222.2010.03668.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Rinaldi M, 2012, J ALLERGY CLIN IMMUN, V130, P945, DOI 10.1016/j.jaci.2012.07.042; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Soller L, 2012, J ALLERGY CLIN IMMUN, V130, P986, DOI 10.1016/j.jaci.2012.06.029; Tran MM, 2017, PEDIAT ALLERG IMM-UK, V28, P471, DOI 10.1111/pai.12739; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521; Zutavern A, 2008, PEDIATRICS, V121, pE44, DOI 10.1542/peds.2006-3553	30	32	33	11	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					620	+		10.1016/j.jaci.2017.06.024	http://dx.doi.org/10.1016/j.jaci.2017.06.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28916221	Bronze			2022-12-18	WOS:000424410800018
J	Takada, S; Kambe, N; Kawasaki, Y; Niwa, A; Honda-Ozaki, F; Kobayashi, K; Osawa, M; Nagahashi, A; Semi, K; Hotta, A; Asaka, I; Yamada, Y; Nishikomori, R; Heike, T; Matsue, H; Nakahata, T; Saito, MK				Takada, Sanami; Kambe, Naotomo; Kawasaki, Yuri; Niwa, Akira; Honda-Ozaki, Fumiko; Kobayashi, Kazuki; Osawa, Mitsujiro; Nagahashi, Ayako; Semi, Katsunori; Hotta, Akitsu; Asaka, Isao; Yamada, Yasuhiro; Nishikomori, Ryuta; Heike, Toshio; Matsue, Hiroyuki; Nakahata, Tatsutoshi; Saito, Megumu K.			Pluripotent stem cell models of Blau syndrome reveal an IFN-gamma-dependent inflammatory response in macrophages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Blau syndrome; nucleotide-binding oligomerization domain 2; nuclear factor kappa B; IFN-gamma; disease-specific induced pluripotent stem cells	EARLY-ONSET SARCOIDOSIS; NUCLEOTIDE OLIGOMERIZATION DOMAIN-2; KAPPA-B ACTIVATION; MURAMYL DIPEPTIDE; CARD15 MUTATIONS; BCG VACCINATION; TNF-ALPHA; RNA-SEQ; NOD2; DISEASE	Background: Blau syndrome, or early-onset sarcoidosis, is a juvenile-onset systemic granulomatosis associated with a mutation in nucleotide-binding oligomerization domain 2 (NOD2). The underlying mechanisms of Blau syndrome leading to autoinflammation are still unclear, and there is currently no effective specific treatment for Blau syndrome. Objectives: To elucidate the mechanisms of autoinflammation in patients with Blau syndrome, we sought to clarify the relation between disease-associated mutant NOD2 and the inflammatory response in human samples. Methods: Blau syndrome specific induced pluripotent stem cell (iPSC) lines were established. The disease-associated NOD2 mutation of iPSCs was corrected by using a CRISPR-Cas9 system to precisely evaluate the in vitro phenotype of iPSC-derived cells. We also introduced the same NOD2 mutation into a control iPSC line. These isogenic iPSCs were then differentiated into monocytic cell lineages, and the statuses of nuclear factor kappa B pathway and proinflammatory cytokine secretion were investigated. Results: IFN-gamma acted as a priming signal through upregulation of NOD2. In iPSC-derived macrophages with mutant NOD2, IFN-gamma treatment induced ligand-independent nuclear factor kappa B activation and proinflammatory cytokine production. RNA sequencing analysis revealed distinct transcriptional profiles of mutant macrophages both before and after IFN-gamma treatment. Patient-derived macrophages demonstrated a similar IFN-gamma dependent inflammatory response. Conclusions: Our data support the significance of ligand-independent autoinflammation in the pathophysiology of Blau syndrome. Our comprehensive isogenic disease-specific iPSC panel provides a useful platform for probing therapeutic and diagnostic clues for the treatment of patients with Blau syndrome.	[Takada, Sanami; Kawasaki, Yuri; Niwa, Akira; Honda-Ozaki, Fumiko; Kobayashi, Kazuki; Osawa, Mitsujiro; Nakahata, Tatsutoshi; Saito, Megumu K.] Kyoto Univ, Dept Clin Applicat, Kyoto, Japan; [Nagahashi, Ayako; Asaka, Isao] Kyoto Univ, Dept Fundamental Cell Technol, Kyoto, Japan; [Semi, Katsunori; Hotta, Akitsu; Yamada, Yasuhiro] Kyoto Univ, Dept Life Sci Frontiers, Ctr iPS Cell Res & Applicat, Kyoto, Japan; [Hotta, Akitsu; Yamada, Yasuhiro] Kyoto Univ, Inst Integrated Cell Mat Sci, Kyoto, Japan; [Takada, Sanami; Matsue, Hiroyuki] Chiba Univ, Grad Sch Med, Dept Dermatol, Chiba, Japan; [Kambe, Naotomo] Kansai Med Univ, Dept Dermatol, Hirakata, Osaka, Japan; [Nishikomori, Ryuta; Heike, Toshio] Kyoto Univ, Dept Pediat, Grad Sch Med, Kyoto, Japan; [Matsue, Hiroyuki] Chiba Univ, Div Mol Immunol, Med Mycol Res Ctr, Chiba, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University; Chiba University; Kansai Medical University; Kyoto University; Chiba University	Saito, MK (corresponding author), Kyoto Univ, Dept Clin Applicat, Ctr iPS Cell Res & Applicat, Kyoto 6068507, Japan.	msaito@cira.kyoto-u.ac.jp	Kambe, Naotomo/H-3987-2017; Nishikomori, Ryuta/AAM-5771-2020; Nishikomori, Ryuta/N-4039-2018	Kambe, Naotomo/0000-0001-9610-4952; Nishikomori, Ryuta/0000-0002-9407-6158; Nishikomori, Ryuta/0000-0002-9407-6158; Hotta, Akitsu/0000-0002-2619-7441	grant for the Core Center for iPS Cell Research of Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development; Program for Intractable Diseases Research utilizing Disease-specific iPS cells of AMED [15652070]; Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) of AMED [14525046]; Practical Research Project for Rare/Intractable Diseases of AMED [15634527, 16668375, 17929899, 17930095]; Research Project for Practical Applications of Regenerative Medicine from AMED; Japan Society for the Promotion of Science (JSPS) KAKENHI [13389802, 14431432]	grant for the Core Center for iPS Cell Research of Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Program for Intractable Diseases Research utilizing Disease-specific iPS cells of AMED; Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) of AMED; Practical Research Project for Rare/Intractable Diseases of AMED; Research Project for Practical Applications of Regenerative Medicine from AMED; Japan Society for the Promotion of Science (JSPS) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by the grant for the Core Center for iPS Cell Research of Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (to A.H., T.N., and M.K.S.); the Program for Intractable Diseases Research utilizing Disease-specific iPS cells of AMED (15652070; to I.A., T.N., and M.K.S.); the Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) of AMED (14525046; to M.K.S.); the Practical Research Project for Rare/Intractable Diseases of AMED (15634527; to N.K., R.N., T.H., T.N., and M.K.S.); the Practical Research Project for Rare/Intractable Diseases of AMED (16668375, 17929899 and 17930095; to M.K.S.); the Research Project for Practical Applications of Regenerative Medicine from AMED (to M.K.S.). and the Japan Society for the Promotion of Science (JSPS) KAKENHI (grant nos. 13389802 [to M.K.S.] and 14431432 [to R.N., T.H., and M.K.S.]).	Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8; BLAU EB, 1985, J PEDIATR-US, V107, P689, DOI 10.1016/S0022-3476(85)80394-2; Bustamante J, 2014, SEMIN IMMUNOL, V26, P454, DOI 10.1016/j.smim.2014.09.008; Ding QR, 2013, CELL STEM CELL, V12, P393, DOI 10.1016/j.stem.2013.03.006; Dugan J, 2015, J IMMUNOL, V194, P349, DOI 10.4049/jimmunol.1402330; Fink CW, 1997, J RHEUMATOL, V24, P174; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Haruta M, 2013, GENE THER, V20, P504, DOI 10.1038/gt.2012.59; HETHERINGTON S, 1982, AM J DIS CHILD, V136, P13, DOI 10.1001/archpedi.1982.03970370015002; Ikeda K, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4533; Ikeda K, 2013, J PEDIATR-US, V163, P1525, DOI 10.1016/j.jpeds.2013.05.059; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Janssen CEI, 2012, J ALLERGY CLIN IMMUN, V129, P1076, DOI 10.1016/j.jaci.2012.02.004; Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood-2004-07-2972; Lee KH, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.410027; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Martin TM, 2009, ARTHRITIS RHEUM, V60, P611, DOI 10.1002/art.24222; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Milman N, 2006, APMIS, V114, P912, DOI 10.1111/j.1600-0463.2006.apm_522.x; Nakagawa M, 2014, SCI REP-UK, V4, DOI 10.1038/srep03594; Niwa A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022261; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Okafuji I, 2009, ARTHRITIS RHEUM-US, V60, P242, DOI 10.1002/art.24134; Okita K, 2013, STEM CELLS, V31, P458, DOI 10.1002/stem.1293; Osborne GEN, 2003, J AM ACAD DERMATOL, V48, pS99, DOI 10.1067/mjd.2003.158; Otsubo Y, 2017, MOD RHEUMATOL, V27, P169, DOI 10.3109/14397595.2014.964388; Peixoto L, 2015, NUCLEIC ACIDS RES, V43, P7664, DOI 10.1093/nar/gkv736; Risso D, 2014, NAT BIOTECHNOL, V32, P896, DOI 10.1038/nbt.2931; Rose CD, 2015, RHEUMATOLOGY, V54, P1008, DOI 10.1093/rheumatology/keu437; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Rosenzweig HL, 2009, INVEST OPHTH VIS SCI, V50, P1739, DOI 10.1167/iovs.08-2756; Son S, 2010, RHEUMATOL INT, V30, P1121, DOI 10.1007/s00296-009-1342-4; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tanaka S, 2014, J EXP MED, V211, P1857, DOI 10.1084/jem.20130791; Totemeyer S, 2006, J IMMUNOL, V176, P4804, DOI 10.4049/jimmunol.176.8.4804; Vinay Kumar AK, 2014, ROBBINS COTRAN PATHO, P352; Wouters CH, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-33; Yanagimachi MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059243	42	32	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					339	+		10.1016/j.jaci.2017.04.013	http://dx.doi.org/10.1016/j.jaci.2017.04.013			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28587749	Bronze			2022-12-18	WOS:000419312200039
J	Zhu, YN; Underwood, J; Macmillan, D; Shariff, L; O'Shaughnessy, R; Harper, JI; Pickard, C; Friedmann, PS; Healy, E; Di, WL				Zhu, Yanan; Underwood, Joanne; Macmillan, Derek; Shariff, Leila; O'Shaughnessy, Ryan; Harper, John I.; Pickard, Chris; Friedmann, Peter S.; Healy, Eugene; Di, Wei-Li			Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Kallikrein 5; atopic dermatitis; skin barrier; serine protease inhibitor; SFTI	TRYPSIN-INHIBITOR SFTI-1; NETHERTON-SYNDROME; STRATUM-CORNEUM; SIGNAL-TRANSDUCTION; HUMAN KERATINOCYTES; PROTEASE ACTIVITY; RECEPTORS PARS; MOUSE MODEL; BARRIER; EXPRESSION	Background: Upregulation of kallikreins (KLKs) including KLK5 has been reported in atopic dermatitis (AD). KLK5 has biological functions that include degrading desmosomal proteins and inducing proinflammatory cytokine secretion through protease-activated receptor 2 (PAR2). However, due to the complex interactions between various cells in AD inflamed skin, it is difficult to dissect the precise and multiple roles of upregulated KLK5 in AD skin. Objective: We investigated the effect of upregulated KLK5 on the expression of epidermal-related proteins and cytokines in keratinocytes and on skin architecture. Methods: Lesional and nonlesional AD skin biopsies were collected for analysis of morphology and protein expression. The relationship between KLK5 and barrier-related molecules was investigated using an ex vivo dermatitis skin model with transient KLK5 expression and a cell model with persistent KLK5 expression. The influence of upregulated KLK5 on epidermal morphology was investigated using an in vivo skin graft model. Results: Upregulation of KLK5 and abnormal expression of desmoglein 1 (DSG1) and filaggrin, but not PAR2 were identified in AD skin. PAR2 was increased in response to transient upregulation of KLK5, whereas persistently upregulated KLK5 did not show this effect. Persistently upregulated KLK5 degraded DSG1 and stimulated secretion of IL-8, IL-10, and thymic stromal lymphopoietin independent of PAR2 activity. With control of higher KLK5 activity by the inhibitor sunflower trypsin inhibitor G, restoration of DSG1 expression and a reduction in AD-related cytokine IL-8, thymic stromal lymphopoietin, and IL-10 secretion were observed. Furthermore, persistently elevated KLK5 could induce AD-like skin architecture in an in vivo skin graft model. Conclusions: Persistently upregulated KLK5 resulted in AD-like skin architecture and secretion of AD-related cytokines from keratinocytes in a PAR2 independent manner. Inhibition of KLK5-mediated effects may offer potential as a therapeutic approach in AD.	[Zhu, Yanan; O'Shaughnessy, Ryan; Harper, John I.; Di, Wei-Li] UCL, Inst Child Hlth, Immunobiol Sect, Infect Immun Inflammat & Physiol Med Programme, London, England; [Macmillan, Derek; Shariff, Leila] UCL, Dept Chem, London, England; [Underwood, Joanne; Pickard, Chris; Friedmann, Peter S.; Healy, Eugene] Univ Southampton, Fac Med, Sir Henry Wellcome Labs, Southampton Gen Hosp,Dermatopharmacol, Southampton, Hants, England; [Healy, Eugene] Univ Hosp Southampton, Natl Hlth Serv Fdn Trust, Dermatol, Southampton, Hants, England	University of London; University College London; University of London; University College London; University of Southampton	Di, WL (corresponding author), UCL, Inst Child Hlth, Immunobiol Sect, 30 Guildford St, London WC1N 1EH, England.	w.di@ucl.ac.uk		Healy, Eugene/0000-0001-5591-6970; O'Shaughnessy, Ryan/0000-0002-3701-0267	Sparks; Livingstone Fund (Great Ormond Street Hospital Children's Charity); Biotechnology and Biological Sciences Research Council; Sparks Charity [13ICH03] Funding Source: researchfish	Sparks; Livingstone Fund (Great Ormond Street Hospital Children's Charity); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Sparks Charity	Supported by Sparks and the Livingstone Fund (Great Ormond Street Hospital Children's Charity) and Biotechnology and Biological Sciences Research Council.	Angelova-Fischer I, 2016, CURR PROBL DERMATOL, V49, P80, DOI 10.1159/000441547; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bonnart C, 2010, J CLIN INVEST, V120, P871, DOI 10.1172/JCI41440; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; Briot A, 2010, J INVEST DERMATOL, V130, P2736, DOI 10.1038/jid.2010.233; Buddenkotte J, 2005, J INVEST DERMATOL, V124, P38, DOI 10.1111/j.0022-202X.2004.23539.x; Caubet C, 2004, J INVEST DERMATOL, V122, P1235, DOI 10.1111/j.0022-202X.2004.22512.x; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; de Veer SJ, 2015, BIOCHEM J, V469, P243, DOI 10.1042/BJ20150412; de Veer SJ, 2013, BIOPOLYMERS, V100, P510, DOI [10.1002/bip.22231, 10.1002/peps.22231]; Debela M, 2008, BIOL CHEM, V389, P623, DOI 10.1515/BC.2008.075; Descargues P, 2006, J INVEST DERMATOL, V126, P1622, DOI 10.1038/sj.jid.5700284; Di WL, 2009, BRIT J DERMATOL, V161, P404, DOI 10.1111/j.1365-2133.2009.09231.x; Di WL, 2012, HUM GENE THER, V23, P83, DOI 10.1089/hum.2011.091; Di WL, 2011, MOL THER, V19, P408, DOI 10.1038/mt.2010.201; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Elias PM, 2009, CURR ALLERGY ASTHM R, V9, P265, DOI [10.1007/s11882-009-0037-y, 10.1097/ACI.0b013e32832e7d36]; Fortugno P, 2012, HUM MOL GENET, V21, P4187, DOI 10.1093/hmg/dds243; Furio L, 2014, J EXP MED, V211, P499, DOI 10.1084/jem.20131797; Gratio V, 2011, AM J PATHOL, V179, P2625, DOI 10.1016/j.ajpath.2011.07.016; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Komatsu N, 2005, BRIT J DERMATOL, V153, P274, DOI 10.1111/j.1365-2133.2005.06754.x; Komatsu N, 2007, EXP DERMATOL, V16, P513, DOI 10.1111/j.1600-0625.2007.00562.x; Lundwall A, 2008, CELL MOL LIFE SCI, V65, P2019, DOI 10.1007/s00018-008-8024-3; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Oikonomopoulou K, 2006, BIOL CHEM, V387, P817, DOI 10.1515/BC.2006.104; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rallabhandi P, 2008, J BIOL CHEM, V283, P24314, DOI 10.1074/jbc.M804800200; Ramsay AJ, 2008, J BIOL CHEM, V283, P12293, DOI 10.1074/jbc.M709493200; Sales KU, 2010, NAT GENET, V42, P676, DOI 10.1038/ng.629; Shariff L, 2014, TETRAHEDRON, V70, P7675, DOI 10.1016/j.tet.2014.06.059; Soh UJK, 2010, BRIT J PHARMACOL, V160, P191, DOI 10.1111/j.1476-5381.2010.00705.x; Stefansson K, 2008, J INVEST DERMATOL, V128, P18, DOI 10.1038/sj.jid.5700965; Stefansson K, 2006, BIOL CHEM, V387, P761, DOI 10.1515/BC.2006.095; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Swedberg JE, 2009, CHEM BIOL, V16, P633, DOI 10.1016/j.chembiol.2009.05.008; Tan X, 2015, J MED CHEM, V58, P598, DOI 10.1021/jm500988d; Tan X, 2013, BIOORG MED CHEM LETT, V23, P4547, DOI 10.1016/j.bmcl.2013.06.039; Teixeira TSP, 2011, BIOORG MED CHEM LETT, V21, P6112, DOI 10.1016/j.bmcl.2011.08.044; Torma H, 2008, J INVEST DERMATOL, V128, P1212, DOI 10.1038/sj.jid.5701170; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; Voegeli R, 2009, BRIT J DERMATOL, V161, P70, DOI 10.1111/j.1365-2133.2009.09142.x; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Walley AJ, 2001, GENOMICS, V72, P15, DOI 10.1006/geno.2000.6435; Yamasaki K, 2006, FASEB J, V20, P2068, DOI 10.1096/fj.06-6075com	46	32	36	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1310	+		10.1016/j.jaci.2017.01.025	http://dx.doi.org/10.1016/j.jaci.2017.01.025			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28238749	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000414304300011
J	Broekman, HCHP; Knulst, AC; Jager, CFD; van Bilsen, JHM; Raymakers, FML; Kruizinga, AG; Gaspari, M; Gabriele, C; Bruijnzeel-Koomen, CAFM; Houben, GF; Verhoeckx, KCM				Broekman, Henrike C. H. P.; Knulst, Andre C.; Jager, Constance F. den Hartog; van Bilsen, Jolanda H. M.; Raymakers, Florine M. L.; Kruizinga, Astrid G.; Gaspari, Marco; Gabriele, Caterine; Bruijnzeel-Koomen, Carla A. F. M.; Houben, Geert F.; Verhoeckx, Kitty C. M.			Primary respiratory and food allergy to mealworm	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OCCUPATIONAL ASTHMA; PROTEINS		[Broekman, Henrike C. H. P.; Knulst, Andre C.; Jager, Constance F. den Hartog; Raymakers, Florine M. L.; Bruijnzeel-Koomen, Carla A. F. M.; Houben, Geert F.; Verhoeckx, Kitty C. M.] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands; [van Bilsen, Jolanda H. M.; Kruizinga, Astrid G.; Houben, Geert F.; Verhoeckx, Kitty C. M.] TNO, Zeist, Netherlands; [Gaspari, Marco; Gabriele, Caterine] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; [Broekman, Henrike C. H. P.; Knulst, Andre C.; Jager, Constance F. den Hartog; van Bilsen, Jolanda H. M.; Kruizinga, Astrid G.; Bruijnzeel-Koomen, Carla A. F. M.; Houben, Geert F.; Verhoeckx, Kitty C. M.] Utrecht Ctr Food Allergy, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Netherlands Organization Applied Science Research; Magna Graecia University of Catanzaro	Broekman, HCHP (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands.; Broekman, HCHP (corresponding author), Utrecht Ctr Food Allergy, Utrecht, Netherlands.	h.c.h.broekman-4@umcutrecht.nl	Gaspari, Marco/C-2756-2009; Gaspari, Marco/HGB-2399-2022; Gaspari, Marco/ABE-1539-2020	Gaspari, Marco/0000-0002-5411-8800; Gaspari, Marco/0000-0002-5411-8800; Knulst, Andre/0000-0002-1056-3179; van Bilsen, Jolanda/0000-0003-3439-5445; Houben, Geert/0000-0001-7261-3912; Verhoeckx, Kitty/0000-0002-6557-3198	TNO; Dutch Food and Consumer Product Safety Authority	TNO; Dutch Food and Consumer Product Safety Authority	Supported by grants from TNO and the Dutch Food and Consumer Product Safety Authority.	ANDERSEN SO, 1995, INSECT BIOCHEM MOLEC, V25, P177, DOI 10.1016/0965-1748(94)00048-M; [Anonymous], 2015, MOL NUTR FOOD RES; BERNSTEIN DI, 1983, J ALLERGY CLIN IMMUN, V72, P475, DOI 10.1016/0091-6749(83)90584-5; Bowman CC, 2008, TOXICOL SCI, V102, P100, DOI 10.1093/toxsci/kfm288; Broekman H, 2016, J ALLERGY CLIN IMMUN, V137, P1261, DOI 10.1016/j.jaci.2016.01.005; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; Jeebhay MF, 2001, OCCUP ENVIRON MED, V58, P553, DOI 10.1136/oem.58.9.553; LYBARGER JA, 1982, J ALLERGY CLIN IMMUN, V69, P448, DOI 10.1016/0091-6749(82)90120-8; Nakamura S, 1974, Allerg Immunol (Leipz), V20-21, P449; SIRACUSA A, 1994, J ALLERGY CLIN IMMUN, V93, P424, DOI 10.1016/0091-6749(94)90350-6; Verhoeckx KCM, 2014, FOOD CHEM TOXICOL, V65, P364, DOI 10.1016/j.fct.2013.12.049	11	32	32	2	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					600	+		10.1016/j.jaci.2017.01.035	http://dx.doi.org/10.1016/j.jaci.2017.01.035			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28274747				2022-12-18	WOS:000406855500038
J	Pouessel, G; Claverie, C; Labreuche, J; Dorkenoo, A; Renaudin, JM; Eb, M; Lejeune, S; Deschildre, A; Leteurtre, S				Pouessel, Guillaume; Claverie, Claire; Labreuche, Julien; Dorkenoo, Aimee; Renaudin, Jean-Marie; Eb, Mireille; Lejeune, Stephanie; Deschildre, Antoine; Leteurtre, Stephane			Fatal anaphylaxis in France: Analysis of national anaphylaxis data, 1979-2011	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							UNITED-STATES; POPULATION		[Pouessel, Guillaume] Childrens Hosp, Dept Pediat, Roubaix, France; [Pouessel, Guillaume; Lejeune, Stephanie; Deschildre, Antoine] CHRU Lille, Pediat Pulmonol & Allergy Dept, Pole Enfant, Hop Jeanne de Flandre, Lille, France; [Pouessel, Guillaume; Lejeune, Stephanie; Deschildre, Antoine] Univ Nord France, Lille, France; [Pouessel, Guillaume; Renaudin, Jean-Marie; Deschildre, Antoine] Allergy Vigilance Network, Vandoeuvre Les Nancy, France; [Claverie, Claire; Dorkenoo, Aimee; Leteurtre, Stephane] CHU Lille, Pediat Intens Care Unit, Lille, France; [Labreuche, Julien] CHU Lille, Dept Biostat, Lille, France; [Labreuche, Julien; Leteurtre, Stephane] Univ Lille, Sante Publ Epidemiol & Qualite Soins, Lille, France; [Renaudin, Jean-Marie] Emile Durkheim Hosp, Dept Allergol, Epinal, France; [Eb, Mireille] Natl Mortal Ctr, Dept Epidemiol CepiDC, Le Kremlin Bicetre, France	Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS)	Pouessel, G (corresponding author), Childrens Hosp, Dept Pediat, Roubaix, France.; Pouessel, G (corresponding author), CHRU Lille, Pediat Pulmonol & Allergy Dept, Pole Enfant, Hop Jeanne de Flandre, Lille, France.; Pouessel, G (corresponding author), Univ Nord France, Lille, France.; Pouessel, G (corresponding author), Allergy Vigilance Network, Vandoeuvre Les Nancy, France.	guillaume.pouessel@gmail.com	Lejeune, Stephanie/AIB-7115-2022	Lejeune, Stephanie/0000-0001-7009-2113				Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Kivisto JE, 2016, J ALLERGY CLIN IMMUN, V138, P630, DOI 10.1016/j.jaci.2016.05.015; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Ma L, 2014, J ALLERGY CLIN IMMUN, V133, P1075, DOI 10.1016/j.jaci.2013.10.029; Mullins RJ, 2016, CLIN EXP ALLERGY, V46, P1099, DOI 10.1111/cea.12748; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021	6	32	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					610	+		10.1016/j.jaci.2017.02.014	http://dx.doi.org/10.1016/j.jaci.2017.02.014			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28283420	Bronze			2022-12-18	WOS:000406855500042
J	Tabellini, G; Vairo, D; Scomodon, O; Tamassia, N; Ferraro, RM; Patrizi, O; Gasperini, S; Soresina, A; Giardino, G; Pignata, C; Lougaris, V; Plebani, A; Dotta, L; Cassatella, MA; Parolini, S; Badolato, R				Tabellini, Giovanna; Vairo, Donatella; Scomodon, Omar; Tamassia, Nicola; Ferraro, Rosalba Monica; Patrizi, Ornella; Gasperini, Sara; Soresina, Annarosa; Giardino, Giuliana; Pignata, Claudio; Lougaris, Vassilios; Plebani, Alessandro; Dotta, Laura; Cassatella, Marco A.; Parolini, Silvia; Badolato, Raffaele			Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer cells; cytotoxic activity; IL-15; signal transducer and activator of transcription 1; signal transducer and activator of transcription 5; candidiasis	CHRONIC MUCOCUTANEOUS CANDIDIASIS; PRIMARY IMMUNODEFICIENCY; IL-17 IMMUNITY; UNDERLIE; CYTOTOXICITY; RECEPTORS; RESPONSES; ACTIN	Background: Gain-of-function (GOF) mutations affecting the coiled-coil domain or the DNA-binding domain of signal transducer and activator of transcription 1 (STAT1) cause chronic mucocutaneous candidiasis disease. This condition is characterized by fungal and bacterial infections caused by impaired generation of TH17 cells; meanwhile, some patients with chronic mucocutaneous candidiasis disease might also have viral or intracellular pathogen infections. Objective: We sought to investigate the effect of STAT1 GOF mutations on the functioning of natural killer (NK) cells. Methods: Because STAT1 is involved in the signaling response to several cytokines, we studied NK cell functional activities and STAT1 signaling in 8 patients with STAT1 GOF mutations. Results: Functional analysis of NK cells shows a significant impairment of cytolytic and degranulation activities in patients with STAT1 GOF mutations. Moreover, NK cells from these patients display lower production of IFN-gamma in response to IL-15 and reduced proliferation after stimulation with IL-2 or IL-15, suggesting that STAT5 signaling is affected. In addition, signaling studies demonstrate that the increased phosphorylation of STAT1 in response to IFN-alpha is associated with detectable activation of STAT1 and increased STAT1 binding to the interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) promoter in response to IL-15, whereas STAT5 phosphorylation and DNA binding to IL-2 receptor a (IL2RA) are reduced or not affected in response to the same cytokine. Conclusion: These observations suggest that persistent activation of STAT1 might affect NK cell proliferation and functional activities.	[Tabellini, Giovanna; Vairo, Donatella; Ferraro, Rosalba Monica; Patrizi, Ornella; Parolini, Silvia] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Vairo, Donatella; Scomodon, Omar; Ferraro, Rosalba Monica; Lougaris, Vassilios; Plebani, Alessandro; Dotta, Laura; Badolato, Raffaele] Univ Brescia, Inst Mol Med Angelo Nocivelli, Brescia, Italy; [Scomodon, Omar; Lougaris, Vassilios; Plebani, Alessandro; Dotta, Laura; Badolato, Raffaele] Univ Brescia, Dept Expt & Clin Sci, Brescia, Italy; [Tamassia, Nicola; Gasperini, Sara; Cassatella, Marco A.] Univ Verona, Sch Med, Sect Gen Pathol, Dept Med, Verona, Italy; [Soresina, Annarosa] Spedali Civili Brescia, Unit Paediat, Brescia, Italy; [Giardino, Giuliana; Pignata, Claudio] Federico II Univ Naples, Dept Translat Med Sci, Naples, Italy	University of Brescia; University of Brescia; University of Brescia; University of Verona; Hospital Spedali Civili Brescia; University of Naples Federico II	Badolato, R (corresponding author), Univ Brescia, Ist Med Mol Angelo Nocivelli, Spedali Civili, I-25123 Brescia, Italy.	raffaele.badolato@unibs.it	Badolato, Raffaele/A-8081-2010; Pignata, Claudio/O-2466-2013; Cassatella, M A/B-8037-2013; Giardino, Giuliana/AAC-2008-2019; Giardino, Giuliana/AAF-9841-2021; Patrizi, Ornella/ABC-5102-2020; Tamassia, Nicola/J-8621-2016	Badolato, Raffaele/0000-0001-7375-5410; Pignata, Claudio/0000-0003-1568-9843; Cassatella, M A/0000-0001-7824-1806; Tamassia, Nicola/0000-0003-2990-3003; PAROLINI, Silvia/0000-0003-1968-7765	Italian Ministry of Health	Italian Ministry of Health(Ministry of Health, Italy)	R. Badolato receives grant support from the Italian Ministry of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Agaugue S, 2008, BLOOD, V112, P1776, DOI 10.1182/blood-2008-02-135871; [Anonymous], 2016, CLIN IMMUNOL; [Anonymous], 2015, J CLIN IMMUNOL; [Anonymous], 2015, SCIENCE; Bernasconi A, 2006, PEDIATRICS, V118, pE1584, DOI 10.1542/peds.2005-2882; Bucher P, 1997, IMMUNOBIOLOGY, V198, P136, DOI 10.1016/S0171-2985(97)80034-4; Dotta L, 2016, DATA BRIEF, V7, P311, DOI 10.1016/j.dib.2016.02.040; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fontana S, 2006, BLOOD, V107, P4857, DOI 10.1182/blood-2005-11-4398; Forbes LR, 2014, J CLIN IMMUNOL S, pS139; Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676; Gismondi A, 2004, BLOOD, V104, P436, DOI 10.1182/blood-2003-07-2621; Hirahara K, 2015, IMMUNITY, V42, P877, DOI 10.1016/j.immuni.2015.04.014; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Kisand K, 2013, CURR OPIN PEDIATR, V25, P715, DOI 10.1097/MOP.0000000000000028; Kumar N, 2014, J ALLERGY CLIN IMMUN, V134, P236, DOI 10.1016/j.jaci.2014.02.037; Lanternier F, 2013, CURR OPIN PEDIATR, V25, P736, DOI 10.1097/MOP.0000000000000031; Lee CK, 2000, J IMMUNOL, V165, P3571, DOI 10.4049/jimmunol.165.7.3571; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Marcenaro E, 2011, IMMUNOTHERAPY-UK, V3, P1075, DOI [10.2217/IMT.11.99, 10.2217/imt.11.99]; Minegishi Y, 2011, ANN NY ACAD SCI, V1246, P34, DOI 10.1111/j.1749-6632.2011.06280.x; Mizesko MC, 2013, J ALLERGY CLIN IMMUN, V131, P840, DOI 10.1016/j.jaci.2012.12.1568; Mizoguchi Y, 2014, J LEUKOCYTE BIOL, V95, P667, DOI 10.1189/jlb.0513250; Montaldo E, 2013, CYTOM PART A, V83A, P702, DOI 10.1002/cyto.a.22302; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Nguyen KB, 2002, J IMMUNOL, V169, P4279, DOI 10.4049/jimmunol.169.8.4279; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Pillet AH, 2011, HUM IMMUNOL, V72, P1013, DOI 10.1016/j.humimm.2011.07.311; Puel A, 2012, CURR OPIN ALLERGY CL, V12, P616, DOI 10.1097/ACI.0b013e328358cc0b; Pugliese-Pires PN, 2010, EUR J ENDOCRINOL, V163, P349, DOI 10.1530/EJE-10-0272; Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939; Sampaio EP, 2012, J CLIN IMMUNOL, V32, P681, DOI 10.1007/s10875-012-9659-2; Sharfe N, 2014, J ALLERGY CLIN IMMUN, V133, P807, DOI 10.1016/j.jaci.2013.09.032; Smeekens SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029248; Soltesz B, 2013, J MED GENET, V50, P567, DOI 10.1136/jmedgenet-2013-101570; Tamassia N, 2010, FASEB J, V24, P1365, DOI 10.1096/fj.09-145573; Toth B, 2012, LANCET, V379, P2500, DOI 10.1016/S0140-6736(12)60365-1; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Vairo D, 2011, BLOOD, V118, P1806, DOI 10.1182/blood-2011-01-330571; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Yamazaki Y, 2014, J IMMUNOL, V193, P4880, DOI 10.4049/jimmunol.1401467	43	32	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					553	+		10.1016/j.jaci.2016.10.051	http://dx.doi.org/10.1016/j.jaci.2016.10.051			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28069426	Green Published, Bronze			2022-12-18	WOS:000406855500027
J	Trivedi, A; Hall, C; Hoffman, EA; Woods, JC; Gierada, DS; Castro, M				Trivedi, Abhaya; Hall, Chase; Hoffman, Eric A.; Woods, Jason C.; Gierada, David S.; Castro, Mario			Using imaging as a biomarker for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Imaging; chest CT; MRI; PET; biomarker	RESOLUTION COMPUTED-TOMOGRAPHY; REGIONAL LUNG-FUNCTION; AIRWAY WALL THICKNESS; POSITRON-EMISSION-TOMOGRAPHY; DISEASE PROBABILITY MEASURE; HYPERPOLARIZED HE-3; BRONCHIAL THERMOPLASTY; ITERATIVE RECONSTRUCTION; QUANTITATIVE-ANALYSIS; VENTILATION CHANGES	There have been significant advancements in the various imaging techniques being used for the evaluation of asthmatic patients, both from a clinical and research perspective. Imaging characteristics can be used to identify specific asthmatic phenotypes and provide a more detailed understanding of endotypes contributing to the pathophysiology of the disease. Computed tomography, magnetic resonance imaging, and positron emission tomography can be used to assess pulmonary structure and function. It has been shown that specific airway and lung density measurements using computed tomography correlate with clinical parameters, including severity of disease and pathology, but also provide unique phenotypes. Hyperpolarized Xe-129 and He-3 are gases used as contrast media for magnetic resonance imaging that provide measurement of distal lung ventilation reflecting small-airway disease. Positron emission tomography can be useful to identify and target lung inflammation in asthmatic patients. Furthermore, imaging techniques can serve as a potential biomarker and be used to assess response to therapies, including newer biological treatments and bronchial thermoplasty.	[Trivedi, Abhaya; Hall, Chase; Gierada, David S.; Castro, Mario] Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, 660 S Euclid Ave,Campus Box 8052, St Louis, MO 63110 USA; [Hoffman, Eric A.] Univ Iowa, Coll Med, Dept Radiol, Dept Biomed Engn, Iowa City, IA 52242 USA; [Woods, Jason C.] Cincinnati Childrens Hosp Med Ctr, Ctr Pulm Imaging Res, Cincinnati, OH 45229 USA	Washington University (WUSTL); University of Iowa; Cincinnati Children's Hospital Medical Center	Castro, M (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, 660 S Euclid Ave,Campus Box 8052, St Louis, MO 63110 USA.	castrom@wustl.edu		Hoffman, Eric/0000-0001-8456-9437; Castro, Mario/0000-0001-6328-8994	NHLBI NIH HHS [R01 HL091762, R01 HL069149, T32 HL007317, R01 HL130883, U10 HL109257] Funding Source: Medline; NIAID NIH HHS [T32 AI106688] Funding Source: Medline; NIEHS NIH HHS [P30 ES005605] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109257, R01HL130883, T32HL007317, R01HL069149, R01HL091762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI106688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aliverti A, 2013, EUR RESPIR J, V41, P1179, DOI 10.1183/09031936.00050112; Altes TA, 2016, J ALLERGY CLIN IMMUN, V137, P789, DOI 10.1016/j.jaci.2015.08.045; Aysola R, 2010, J MAGN RESON IMAGING, V32, P1379, DOI 10.1002/jmri.22388; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; Brillet PY, 2013, EUR RADIOL, V23, P1594, DOI 10.1007/s00330-012-2743-4; BRUDIN LH, 1994, EUR J NUCL MED, V21, P297, DOI 10.1007/BF00947964; Bullone M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136284; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Castro M, 2011, J ALLERGY CLIN IMMUN, V128, P467, DOI 10.1016/j.jaci.2011.04.051; Chen DL, 2006, MOL PHARMACEUT, V3, P488, DOI 10.1021/mp060050w; Chen DL, 2006, AM J RESP CRIT CARE, V173, P1363, DOI 10.1164/rccm.200506-934OC; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Choi S, 2015, J APPL PHYSIOL, V118, P1286, DOI 10.1152/japplphysiol.01094.2014; Choi S, 2014, J APPL PHYSIOL, V117, P593, DOI 10.1152/japplphysiol.00280.2014; Coxson HO, 2008, AM J RESP CRIT CARE, V177, P1201, DOI 10.1164/rccm.200712-1776OC; Coxson HO, 2009, AM J RESP CRIT CARE, V180, P588, DOI 10.1164/rccm.200901-0159PP; De Backer JW, 2008, J BIOMECH, V41, P106, DOI 10.1016/j.jbiomech.2007.07.009; de Gonzalez AB, 2009, ARCH INTERN MED, V169, P2071, DOI 10.1001/archinternmed.2009.440; de Jong PA, 2006, AM J RESP CRIT CARE, V173, P199, DOI 10.1164/rccm.200505-810OC; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; Diaz S, 2009, EUR J RADIOL, V71, P257, DOI 10.1016/j.ejrad.2008.04.013; Dougherty L, 2006, ACAD RADIOL, V13, P14, DOI 10.1016/j.acra.2005.09.081; Einstein AJ, 2007, JAMA-J AM MED ASSOC, V298, P317, DOI 10.1001/jama.298.3.317; Fain S, 2010, J MAGN RESON IMAGING, V32, P1398, DOI 10.1002/jmri.22375; Fain SB, 2008, ACAD RADIOL, V15, P753, DOI 10.1016/j.acra.2007.10.019; FINDLEY LJ, 1981, CHEST, V80, P535, DOI 10.1378/chest.80.5.535; Galban CJ, 2012, NAT MED, V18, P1711, DOI 10.1038/nm.2971; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Gorska K, 2016, RESP MED, V117, P131, DOI 10.1016/j.rmed.2016.06.011; Grimm R, 2015, MED IMAGE ANAL, V19, P110, DOI 10.1016/j.media.2014.08.003; Gupta S, 2014, J ALLERGY CLIN IMMUN, V133, P729, DOI 10.1016/j.jaci.2013.09.039; Gupta S, 2010, THORAX, V65, P775, DOI 10.1136/thx.2010.136374; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Harmanci E, 2002, RESPIRATION, V69, P420, DOI 10.1159/000064018; Hartley R, 2015, EXPERT REV CLIN IMMU, V11, P1147, DOI 10.1586/1744666X.2015.1072049; Haubenreisser H, 2015, EUR J RADIOL, V84, P1608, DOI 10.1016/j.ejrad.2015.04.018; Higano NS, 2016, MAGN RESON MED; Hoffman EA, 2016, J MAGN RESON IMAGING, V43, P544, DOI 10.1002/jmri.25010; IMV, 2006, IMV 2006 CT MARK SUM; Jones HA, 1997, EUR RESPIR J, V10, P795; Kirby M, 2014, AM J RESP CRIT CARE, V189; Kirby M, 2015, AM J RESP CRIT CARE, V191; Kirby M, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12068; Kirby M, 2015, EUR RESPIR J, V46, P859, DOI 10.1183/09031936.00016815; Longest PW, 2012, ADV DRUG DELIVER REV, V64, P296, DOI 10.1016/j.addr.2011.05.009; LYNCH DA, 1993, RADIOLOGY, V188, P829, DOI 10.1148/radiology.188.3.8351357; MacDougall RD, 2016, J APPL CLIN MED PHYS, V17, P328, DOI 10.1120/jacmp.v17i1.5756; Madsen PH, 2013, HELL J NUCL MED, V16, P121; Minard KR, 2012, J MAGN RESON, V221, P129, DOI 10.1016/j.jmr.2012.05.007; Mistry NN, 2010, MAGN RESON MED, V63, P658, DOI 10.1002/mrm.22311; Newell JD, 2015, INVEST RADIOL, V50, P40, DOI 10.1097/RLI.0000000000000093; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; Pennati F, 2014, RADIOLOGY, V273, P580, DOI 10.1148/radiol.14132470; Qing K, 2014, J MAGN RESON IMAGING, V39, P346, DOI 10.1002/jmri.24181; Quirk JD, 2011, RADIOLOGY, V260, P866, DOI 10.1148/radiol.11102226; Richards JC, 2016, IMMUNOL ALLERGY CLIN, V36, P529, DOI 10.1016/j.iac.2016.03.005; Rompel O, 2016, PEDIATR RADIOL, V46, P462, DOI 10.1007/s00247-015-3510-x; Sarikonda K, 2014, AM J RESP CRIT CARE, V189; SCHUSTER DP, 1989, AM REV RESPIR DIS, V139, P818, DOI 10.1164/ajrccm/139.3.818; Sieren JP, 2016, AM J RESP CRIT CARE, V194, P794, DOI 10.1164/rccm.201506-1208PP; Simon BA, 2000, J CLIN MONITOR COMP, V16, P433, DOI 10.1023/A:1011444826908; Sodickson A, 2009, RADIOLOGY, V251, P175, DOI 10.1148/radiol.2511081296; Soja J, 2009, CHEST, V136, P797, DOI 10.1378/chest.08-2759; Solomon J, 2015, MED PHYS, V42, P4941, DOI 10.1118/1.4923172; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Tgavalekos NT, 2005, J APPL PHYSIOL, V99, P2388, DOI 10.1152/japplphysiol.00391.2005; The Organisation for Economic Co-operation and Development (OECD), HLTH GLANC 2013 OECD; Thomen RP, 2015, RADIOLOGY, V274, P250, DOI 10.1148/radiol.14140080; Tunon-de-Lara JM, 2007, J ALLERGY CLIN IMMUN, V119, P583, DOI 10.1016/j.jaci.2006.11.005; Venegas JG, 2005, RESP PHYSIOL NEUROBI, V148, P57, DOI 10.1016/j.resp.2005.05.023; Walenga RL, 2016, J PHARM SCI-US, V105, P147, DOI 10.1016/j.xphs.2015.11.027; Walkup LL, 2014, NMR BIOMED, V27, P1429, DOI 10.1002/nbm.3151; Wang CB, 2008, J MAGN RESON IMAGING, V28, P80, DOI 10.1002/jmri.21408; WHITE CS, 1991, CHEST, V100, P14, DOI 10.1378/chest.100.1.14; Williamson JP, 2011, AM J RESP CRIT CARE, V183, P612, DOI 10.1164/rccm.201002-0178OC; Yablonskiy DA, 2002, P NATL ACAD SCI USA, V99, P3111, DOI 10.1073/pnas.052594699; Yablonskiy DA, 2009, J APPL PHYSIOL, V107, P1258, DOI 10.1152/japplphysiol.00386.2009; Zha NX, 2016, ACAD RADIOL, V23, P176, DOI 10.1016/j.acra.2015.10.010; ZIEVERINK SE, 1982, RADIOLOGY, V145, P27, DOI 10.1148/radiology.145.1.7122890	82	32	35	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					1	10		10.1016/j.jaci.2016.11.009	http://dx.doi.org/10.1016/j.jaci.2016.11.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	28065276	Green Accepted, Bronze			2022-12-18	WOS:000393996800001
J	Han, MY; Chung, Y; Hong, JY; Rajput, C; Lei, J; Hinde, JL; Chen, Q; Weng, SP; Bentley, JK; Hershenson, MB				Han, Mingyuan; Chung, Yutein; Hong, Jun Young; Rajput, Charu; Lei, Jing; Hinde, Joanna L.; Chen, Qiang; Weng, Steven P.; Bentley, J. Kelley; Hershenson, Marc B.			Toll-like receptor 2-expressing macrophages are required and sufficient for rhinovirus-induced airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alternative activation; asthma; CD11b; exacerbation; M2 macrophage	INFECTION; EXPRESSION; CELLS; MODEL; GENE; VP4	Background: We have shown that rhinovirus, a cause of asthma exacerbation, colocalizes with CD68(+) and CD11b(+) airway macrophages after experimental infection in human subjects. We have also shown that rhinovirus-induced cytokine expression is abolished in Toll-like receptor (TLR2)(-/-) bone marrow-derived macrophages. Objective: We hypothesize that TLR2 1 macrophages are required and sufficient for rhinovirus-induced airway inflammation in vivo. Methods: Naive and ovalbumin (OVA)-sensitized and challenged C57BL/6 wild-type and TLR2(-/-) mice were infected with RV1B, followed by IgG or anti-TLR2, to determine the requirement and sufficiency of TLR2 for rhinovirus-induced airway responses. Bone marrow chimera experiments using OVA-treated C57BL/6 and TLR2(-/-) mice were also performed. Finally, naive TLR2(-/-) mice underwent intranasal transfer of bone marrow-derived wild-type macrophages. Results: RV1B infection of naive wild-type mice induced an influx of airway neutrophils and CD11b(+) exudative macrophages, which was reduced in TLR2(-/-) mice. After allergen exposure, rhinovirus-induced neutrophilic and eosinophilic airway inflammation and hyperresponsiveness were reduced in TLR2(-/-) and anti-TLR2-treated mice. Transfer of TLR2(-/-) bone marrow into wild-type, OVA-treated C57BL/6 mice blocked rhinovirus-induced airway responses, whereas transfer of wild-type marrow to TLR2(-/-) mice restored them. Finally, transfer of wild-type macrophages to naive TLR2(-/-) mice was sufficient for neutrophilic inflammation after rhinovirus infection, whereas macrophages treated with IL-4 (to induce M2 polarization) were sufficient for eosinophilic inflammation, mucous metaplasia, and airways hyperresponsiveness. Conclusions: TLR2 is required for early inflammatory responses induced by rhinovirus, and TLR2(+) macrophages are sufficient to confer airway inflammation to TLR2(-/-) mice, with the pattern of inflammation depending on the macrophage activation state.	[Han, Mingyuan; Chung, Yutein; Rajput, Charu; Lei, Jing; Hinde, Joanna L.; Chen, Qiang; Weng, Steven P.; Bentley, J. Kelley; Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; [Hong, Jun Young; Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hershenson, MB (corresponding author), Med Sci Res Bldg 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	mhershen@umich.edu	Han, Mingyuan/O-5065-2019	Han, Mingyuan/0000-0002-2970-6715; Bentley, John Kelley/0000-0001-8865-7979; Hong, Jun Young/0000-0002-4963-7147	National Institutes of Health [HL081420]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081420, R01HL134369] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant HL081420 (to M.B.H.).	Bentley JK, 2013, J ALLERGY CLIN IMMUN, V132, P758, DOI 10.1016/j.jaci.2013.04.020; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; Chung Y, 2015, AM J RESP CELL MOL, V52, P205, DOI 10.1165/rcmb.2014-0068OC; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, pe1, DOI DOI 10.1016/HACI.2010.10.050; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P390, DOI 10.1016/j.jaci.2010.10.050; Davis MP, 2008, J VIROL, V82, P4169, DOI 10.1128/JVI.01070-07; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Ford AQ, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-6; Han HW, 2013, J IMMUNOL, V190, P904, DOI 10.4049/jimmunol.1201808; Hubbard LLN, 2008, EXP LUNG RES, V34, P263, DOI 10.1080/01902140802022518; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lewis JK, 1998, P NATL ACAD SCI USA, V95, P6774, DOI 10.1073/pnas.95.12.6774; Melgert BN, 2011, J ALLERGY CLIN IMMUN, V127, P831, DOI 10.1016/j.jaci.2010.10.045; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Nagarkar DR, 2010, J IMMUNOL, V185, P2525, DOI 10.4049/jimmunol.1000286; Naik PK, 2012, AM J PHYSIOL-LUNG C, V303, pL1046, DOI 10.1152/ajplung.00139.2012; Newcomb DC, 2008, AM J RESP CRIT CARE, V177, P1111, DOI 10.1164/rccm.200708-1243OC; Newcomb DC, 2005, J BIOL CHEM, V280, P36952, DOI 10.1074/jbc.M502449200; Panjwani A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004294; Proud D, 2008, AM J RESP CRIT CARE, V178, P962, DOI 10.1164/rccm.200805-670OC; Saba TG, 2014, AM J RESP CELL MOL, V50, P974, DOI 10.1165/rcmb.2013-0354OC; Staples KJ, 2012, J ALLERGY CLIN IMMUN, V130, P1404, DOI 10.1016/j.jaci.2012.07.023; Triantafilou K, 2011, VIRULENCE, V2, P22, DOI 10.4161/viru.2.1.13807; Tuthill TJ, 2003, J GEN VIROL, V84, P2829, DOI 10.1099/vir.0.19109-0; Unger BL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002969; van Bergenhenegouwen J, 2013, J LEUKOCYTE BIOL, V94, P885, DOI 10.1189/jlb.0113003; Wang Q, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002070; Wang Q, 2009, J IMMUNOL, V183, P6989, DOI 10.4049/jimmunol.0901386; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; Zhong B, 2014, J LEUKOCYTE BIOL, V96, P1065, DOI 10.1189/jlb.3A0313-136RRR	33	32	34	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1619	1630		10.1016/j.jaci.2016.01.037	http://dx.doi.org/10.1016/j.jaci.2016.01.037			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27084403	Green Accepted, Bronze			2022-12-18	WOS:000390019300018
J	Malhotra, N; Yoon, J; Leyva-Castillo, JM; Galand, C; Archer, N; Miller, LS; Geha, RS				Malhotra, Nidhi; Yoon, Juhan; Leyva-Castillo, Juan Manuel; Galand, Claire; Archer, Nathan; Miller, Lloyd S.; Geha, Raif S.			IL-22 derived from gamma delta T cells restricts Staphylococcus aureus infection of mechanically injured skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-22; S aureus; neutrophils; AD	ATOPIC-DERMATITIS; DISEASE; SENSITIZATION; COLONIZATION; INFLAMMATION; IMMUNITY	Background: Staphylococcus aureus is an opportunistic pathogen that colonizes the skin of patients with atopic dermatitis (AD) and aggravates their disease. Neutrophils and the cytokines IL-17A and IL-17F, which drive the expression of the neutrophil-attracting chemokines, are important for the clearance of S aureus infection. The cytokine IL-22 is often coproduced by IL-17-secreting cells. The levels of IL-22 are elevated in AD skin lesions. Objective: We sought to determine the role of IL-22 in the clearance of S aureus infection of mouse skin subjected to tape stripping, a surrogate for scratching, a cardinal feature of AD. Methods: S aureus was applied to the tape-stripped skin of wild-type and Il22(-/-) mice. Bacterial burden was evaluated by enumerating colony-forming units. Quantitative PCR and ELISA were performed to quantify Il22 mRNA and IL-22 protein in mouse and human skin. Flow cytometry was used to enumerate neutrophils in the skin. Results: Scratching the skin of healthy adults and tape stripping of mouse skin induced local expression of Il22 mRNA and IL-22 protein. Induction of Il22 expression by tape stripping was dependent on IL-23 and gamma delta T cells. Clearance of Saureus from tape stripped skin was significantly impaired in Il22(-/-) mice. Neutrophil infiltration and upregulation of expression of genes encoding the antimicrobial peptides antigen-6/urokinase-type plasminogen activator receptor related protein-1 and beta-DEFENSIN 14 and the chemokine (C-X-C motif) ligand following tape stripping were significantly impaired in Il22(-/-) mice. Conclusions: These findings show that IL-22 is important for limiting the growth of S aureus on mechanically injured skin and caution that IL-23 and IL-22 blockade in patients with AD may enhance susceptibility to staphylococcal skin infection.	[Malhotra, Nidhi; Yoon, Juhan; Leyva-Castillo, Juan Manuel; Galand, Claire; Geha, Raif S.] Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA; [Malhotra, Nidhi; Yoon, Juhan; Leyva-Castillo, Juan Manuel; Galand, Claire; Geha, Raif S.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Archer, Nathan; Miller, Lloyd S.] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University	Geha, RS (corresponding author), Childrens Hosp, Boston, MA 02115 USA.	Raif.geha@childrens.harvard.edu		Archer, Nathan/0000-0002-8212-8985; Leyva Castillo, Juan Manuel/0000-0001-7394-4457	National Institutes of Health [HHSN272201000020C]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR069502, P30AR069625] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by the National Institutes of Health (grant no. HHSN272201000020C).	Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gray EE, 2011, J IMMUNOL, V186, P6091, DOI 10.4049/jimmunol.1100427; Huang JT, 2009, PEDIATRICS, V123, pE808, DOI 10.1542/peds.2008-2217; Huvenne W, 2010, CLIN EXP ALLERGY, V40, P1079, DOI 10.1111/j.1365-2222.2010.03464.x; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Laouini D, 2003, J ALLERGY CLIN IMMUN, V112, P981, DOI 10.1016/j.jaci.2003.07.007; Masaki K, 2014, ALLERGOL INT, V63, P13, DOI 10.2332/allergolint.13-OA-0632; Mashiko S, 2015, J ALLERGY CLIN IMMUN, V136, P351, DOI 10.1016/j.jaci.2015.01.033; Matsui K, 2002, CLIN EXP ALLERGY, V32, P783, DOI 10.1046/j.1365-2222.2002.01357.x; Miller LS, 2011, NAT REV IMMUNOL, V11, P505, DOI 10.1038/nri3010; Molne L, 2000, INFECT IMMUN, V68, P6162, DOI 10.1128/IAI.68.11.6162-6167.2000; Moriwaki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140750; Myles IA, 2013, NAT IMMUNOL, V14, P804, DOI 10.1038/ni.2637; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; Rutz S, 2013, IMMUNOL REV, V252, P116, DOI 10.1111/imr.12027; Savinko T, 2005, J IMMUNOL, V175, P8320, DOI 10.4049/jimmunol.175.12.8320; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Tauber M, 2016, J ALLERGY CLIN IMMUN, V134; Van Belle AB, 2012, J IMMUNOL, V188, P462, DOI 10.4049/jimmunol.1102224; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Yeaman MR, 2014, P NATL ACAD SCI USA, V111, pE5555, DOI 10.1073/pnas.1415610111; Zanger P, 2010, INFECT IMMUN, V78, P3112, DOI 10.1128/IAI.00078-10; Zhang LJ, 2015, SCIENCE, V347, P67, DOI 10.1126/science.1260972; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	34	32	34	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1098	+		10.1016/j.jaci.2016.07.001	http://dx.doi.org/10.1016/j.jaci.2016.07.001			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27543072	Bronze, Green Accepted			2022-12-18	WOS:000385499400015
J	Yan, Y; Tan, KS; Li, CW; Tran, T; Chao, SS; Sugrue, RJ; Shi, L; Chow, VT; Wang, DY				Yan, Yan; Tan, Kai Sen; Li, Chunwei; Thai Tran; Chao, Siew Shuen; Sugrue, Richard J.; Shi, Li; Chow, Vincent T.; Wang, De-Yun			Human nasal epithelial cells derived from multiple subjects exhibit differential responses to H3N2 influenza virus infection in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POLYPS; CILIA		[Yan, Yan; Li, Chunwei; Chao, Siew Shuen; Wang, De-Yun] Natl Univ Singapore, Dept Otolaryngol, Singapore, Singapore; [Tan, Kai Sen; Chow, Vincent T.] Natl Univ Singapore, Dept Microbiol & Immunol, Singapore, Singapore; [Thai Tran] Natl Univ Singapore, Dept Physiol, Singapore, Singapore; [Tan, Kai Sen] Singapore Massachusetts Inst Technol Alliance Res, Infect Dis Interdisciplinary Res Grp, Singapore, Singapore; [Sugrue, Richard J.] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore; [Shi, Li] Shandong Univ, Qilu Hosp, Dept Otolaryngol, Shandong, Peoples R China	National University of Singapore; National University of Singapore; National University of Singapore; Massachusetts Institute of Technology (MIT); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Shandong University	Chow, VT (corresponding author), Natl Univ Singapore, Dept Microbiol & Immunol, Singapore, Singapore.	vincent_chow@nuhs.edu.sg; entwdy@nus.edu.sg	Sugrue, Richard J/A-2214-2011; Tran, Thai/D-9087-2012	TRAN, Thai/0000-0002-8662-3676; Tan, Kai Sen/0000-0002-8611-1611; Chow, Vincent/0000-0003-2634-6213				Braciale TJ, 2012, NAT REV IMMUNOL, V12, P295, DOI 10.1038/nri3166; Brandenburg B, 2007, NAT REV MICROBIOL, V5, P197, DOI 10.1038/nrmicro1615; Conrad C, 2007, NAT MED, V13, P836, DOI 10.1038/nm1605; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676; Jumat MR, 2015, VIROLOGY, V484, P395, DOI 10.1016/j.virol.2015.05.014; Li YY, 2014, J ALLERGY CLIN IMMUN, V134, P1282, DOI 10.1016/j.jaci.2014.07.038; Wang DY, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-014-0490-0; Wang W, 2014, LAB CHIP, V14, P677, DOI 10.1039/c3lc51208h; Yan Y, 2013, CURR OPIN OTOLARYNGO, V21, P263, DOI 10.1097/MOO.0b013e32835f80a0; Yu XM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04619	11	32	35	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					276	281		10.1016/j.jaci.2015.11.016	http://dx.doi.org/10.1016/j.jaci.2015.11.016			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26806046	Bronze			2022-12-18	WOS:000379659100030
J	Kim, J; Kim, BE; Lee, J; Han, Y; Jun, HY; Kim, H; Choi, J; Leung, DYM; Ahn, K				Kim, Jihyun; Kim, Byung Eui; Lee, Jeongok; Han, Youngshin; Jun, Hyun-Young; Kim, Hyunmi; Choi, Jaehee; Leung, Donald Y. M.; Ahn, Kangmo			Epidermal thymic stromal lymphopoietin predicts the development of atopic dermatitis during infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DOWN-REGULATES FILAGGRIN; OF-FUNCTION MUTATIONS; CIS-UROCANIC ACID; STRATUM-CORNEUM; SKIN BARRIER; EXPRESSION; KERATINOCYTES; MONOCHROMATOR; INTERVALS		[Kim, Jihyun; Choi, Jaehee; Ahn, Kangmo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea; [Kim, Jihyun; Lee, Jeongok; Han, Youngshin; Jun, Hyun-Young; Kim, Hyunmi; Choi, Jaehee; Ahn, Kangmo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Environm Hlth Ctr Atop Dis, Seoul, South Korea; [Kim, Byung Eui; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; National Jewish Health	Ahn, K (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea.; Ahn, K (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Environm Hlth Ctr Atop Dis, Seoul, South Korea.; Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, Denver, CO USA.	leungd@njhealth.org; kmaped@skku.edu	Ahn, Kangmo/F-4609-2014	Ahn, Kangmo/0000-0001-7751-9829; Kim, Byung Eui/0000-0003-4923-1814				Broccardo CJ, 2009, J ALLERGY CLIN IMMUN, V124, P1113, DOI 10.1016/j.jaci.2009.07.057; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; CAMPBELL MJ, 1988, BRIT MED J, V296, P1454, DOI 10.1136/bmj.296.6634.1454; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; Eckhart L, 2008, J DERMATOL SCI, V50, P209, DOI 10.1016/j.jdermsci.2007.12.009; Elias PM, 2005, EXP DERMATOL, V14, P719, DOI 10.1111/j.1600-0625.2005.00363.x; Finlay-Jones JJ, 1998, MUTAT RES-FUND MOL M, V422, P155, DOI 10.1016/S0027-5107(98)00187-0; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; Fornasa G, 2015, J ALLERGY CLIN IMMUN, V136, P413, DOI 10.1016/j.jaci.2015.04.011; GILMOUR JW, 1993, J INVEST DERMATOL, V101, P169, DOI 10.1111/1523-1747.ep12363652; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kim BE, 2011, J INVEST DERMATOL, V131, P1272, DOI 10.1038/jid.2011.24; Kim JH, 2015, J ALLERGY CLIN IMMUN, V136, P205, DOI 10.1016/j.jaci.2015.04.026; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; LYNLEY AM, 1983, BIOCHIM BIOPHYS ACTA, V744, P28, DOI 10.1016/0167-4838(83)90336-9; MACKENZIE LA, 1973, BRIT J DERMATOL, V89, P251, DOI 10.1111/j.1365-2133.1973.tb02972.x; McLoone P, 2005, J INVEST DERMATOL, V124, P1071, DOI 10.1111/j.0022-202X.2005.23731.x; Moseley H, 2009, PHOTODERMATOL PHOTO, V25, P8, DOI 10.1111/j.1600-0781.2009.00391.x; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; NOONAN FP, 1992, IMMUNOL TODAY, V13, P250, DOI 10.1016/0167-5699(92)90005-R; Sano Y, 2013, CLIN EXP IMMUNOL, V171, P330, DOI 10.1111/cei.12021; Seltmann J, 2015, J ALLERGY CLIN IMMUN, V135, P1659, DOI 10.1016/j.jaci.2015.01.048; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Walterscheid JP, 2006, P NATL ACAD SCI USA, V103, P17420, DOI 10.1073/pnas.0603119103	30	32	35	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1282	+		10.1016/j.jaci.2015.12.1306	http://dx.doi.org/10.1016/j.jaci.2015.12.1306			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26879860	Bronze			2022-12-18	WOS:000373351200048
J	Morbach, H; Schickel, JN; Cunningham-Rundles, C; Conley, ME; Reisli, I; Franco, JL; Meffre, E				Morbach, Henner; Schickel, Jean-Nicolas; Cunningham-Rundles, Charlotte; Conley, Mary Ellen; Reisli, Ismail; Luis Franco, Jose; Meffre, Eric			CD19 controls Toll-like receptor 9 responses in human B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cells; Toll-like receptor 9; CD19; phosphoinositide 3-kinase; Bruton tyrosine kinase; AKT; common variable immunodeficiency	TYROSINE KINASE; LYMPHOCYTE DEVELOPMENT; ANTIBODY-DEFICIENCY; ACTIVATION; ADAPTER; PI3K; BCAP; DNA; DIFFERENTIATION; MUTATIONS	Background: CD19 is a B cell-specific molecule that serves as a major costimulatory molecule for amplifying B-cell receptor (BCR) responses. Biallelic CD19 gene mutations cause common variable immunodeficiency in human subjects. BCR- and Toll-like receptor (TLR) 9-induced B-cell responses are impaired in most patients with common variable immunodeficiency. Objective: We sought to analyze whether CD19 is required for TLR9 function in human B cells. Methods: Expression of surface activation markers was assessed after anti-IgM or CpG stimulation by using flow cytometry on B cells from patients with 1 or 2 defective CD19 alleles, which decrease or abrogate CD19 expression, respectively. The phosphorylation or interaction of signaling molecules was analyzed by using phospho flow cytometry, immunoblotting, or co-immunoprecipitation in CD19-deficient or control B cells and in a B-cell line in which CD19 has been knocked down with lentivirus-transduced short hairpin RNA. Results: B cells from subjects with 1 or 2 defective CD19 alleles showed defective upregulation in vitro of CD86, transmembrane activator and CAML interactor (TACI), and CD23 activation markers after TLR9 stimulation. TLR9 ligands normally induce phosphorylation of CD19 through myeloid differentiation primary response gene-88 (MYD88)/proline-rich tyrosine kinase 2 (PYK2)/LYN complexes, which allows recruitment of phosphoinositide 3-kinase (PI3K) and phosphorylation of Bruton tyrosine kinase (BTK) and AKT in human B cells with a different kinetic than that of BCRs. In addition, inhibition of PI3K, AKT, or BTK, as well as BTK deficiency, also resulted in TLR9 activation defects in B cells similar to those in patients with CD19 deficiency. Conclusion: CD19 is required for TLR9-induced B-cell activation. Hence CD19/PI3K/AKT/BTK is an essential axis integrating BCRs and TLR9 signaling in human B cells.	[Morbach, Henner; Schickel, Jean-Nicolas; Meffre, Eric] Yale Univ, Sch Med, Dept Immunobiol, 300 George St, New Haven, CT 06511 USA; [Cunningham-Rundles, Charlotte] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA; [Conley, Mary Ellen] Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN USA; [Reisli, Ismail] Selcuk Univ, Meram Med Fac, Dept Immunol & Allergy, Konya, Turkey; [Luis Franco, Jose] Univ Antioquia, Grp Primary Immunodeficiencies, Medellin, Colombia	Yale University; Icahn School of Medicine at Mount Sinai; University of Tennessee System; University of Tennessee Health Science Center; Selcuk University; Universidad de Antioquia	Meffre, E (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, 300 George St, New Haven, CT 06511 USA.	eric.meffre@yale.edu	FRANCO, JOSE/AAK-1590-2020	FRANCO, JOSE/0000-0001-5664-6415	National Institute of Health (NIH) [AI061093, AI071087, AI082713, AI095848]; German Research Foundation [MO 2160/2-1]; NATIONAL CANCER INSTITUTE [P30CA016359] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071087, R18AI048693, U24AI086037, R21AI095848, P01AI061093, U19AI082713] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Foundation(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institute of Health (NIH) grants AI061093, AI071087, AI082713, and AI095848 (to E.M.) and German Research Foundation grant MO 2160/2-1 (to H.M.).	Aiba Y, 2008, BLOOD, V111, P1497, DOI 10.1182/blood-2007-08-109769; Anzelon AN, 2003, NAT IMMUNOL, V4, P287, DOI 10.1038/ni892; Artac H, 2010, GENES IMMUN, V11, P523, DOI 10.1038/gene.2010.22; Baumann CL, 2010, J EXP MED, V207, P2689, DOI 10.1084/jem.20101111; Buhl AM, 1999, J IMMUNOL, V162, P4438; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Castello A, 2013, NAT IMMUNOL, V14, P966, DOI 10.1038/ni.2685; Christensen SR, 2006, IMMUNITY, V25, P417, DOI 10.1016/j.immuni.2006.07.013; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Conley ME, 2005, IMMUNOL REV, V203, P216, DOI 10.1111/j.0105-2896.2005.00233.x; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; Denz A, 2000, EUR J IMMUNOL, V30, P1069, DOI 10.1002/(SICI)1521-4141(200004)30:4<1069::AID-IMMU1069>3.0.CO;2-M; Doyle SL, 2007, J BIOL CHEM, V282, P36953, DOI 10.1074/jbc.M707682200; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Fujimoto M, 2002, J IMMUNOL, V168, P5465, DOI 10.4049/jimmunol.168.11.5465; Fujimoto M, 1998, SEMIN IMMUNOL, V10, P267, DOI 10.1006/smim.1998.9999; Han CF, 2010, NAT IMMUNOL, V11, P734, DOI 10.1038/ni.1908; Hasegawa M, 2001, J IMMUNOL, V167, P2469, DOI 10.4049/jimmunol.167.5.2469; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Huggins J, 2007, BLOOD, V109, P1611, DOI 10.1182/blood-2006-03-008441; Isnardi I, 2008, IMMUNITY, V29, P746, DOI 10.1016/j.immuni.2008.09.015; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Janssen E, 2014, J ALLERGY CLIN IMMUN, V134, P1365, DOI 10.1016/j.jaci.2014.07.042; Kubo T, 2009, J EXP MED, V206, P1971, DOI 10.1084/jem.20082392; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Ni MJ, 2012, P NATL ACAD SCI USA, V109, P267, DOI 10.1073/pnas.1111957108; Nickerson KM, 2013, J IMMUNOL, V190, P1447, DOI 10.4049/jimmunol.1202115; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Rawlings DJ, 2012, NAT REV IMMUNOL, V12, P282, DOI 10.1038/nri3190; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Romberg N, 2013, J CLIN INVEST, V123, P4283, DOI 10.1172/JCI69854; Sauer AV, 2012, J CLIN INVEST, V122, P2141, DOI 10.1172/JCI61788; Schickel JN, 2012, EMBO MOL MED, V4, P1261, DOI 10.1002/emmm.201201595; Suzuki H, 2003, NAT IMMUNOL, V4, P280, DOI 10.1038/ni890; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; Troutman TD, 2012, P NATL ACAD SCI USA, V109, P273, DOI 10.1073/pnas.1118579109; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2011, HUM MOL GENET, V20, P1854, DOI 10.1093/hmg/ddr068; Vince N, 2011, J ALLERGY CLIN IMMUN, V127, P538, DOI 10.1016/j.jaci.2010.10.019; Weller S, 2012, BLOOD, V120, P4992, DOI 10.1182/blood-2012-07-440776; Yang G, 2013, BLOOD, V122, P1222, DOI 10.1182/blood-2012-12-475111; Yazawa N, 2003, BLOOD, V102, P1374, DOI 10.1182/blood-2002-11-3573; Yu JE, 2009, J ALLERGY CLIN IMMUN, V124, P349, DOI 10.1016/j.jaci.2009.05.019; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	48	32	32	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					889	+		10.1016/j.jaci.2015.08.040	http://dx.doi.org/10.1016/j.jaci.2015.08.040			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26478008	Bronze, Green Accepted			2022-12-18	WOS:000371897500033
J	Shim, JU; Lee, SE; Hwang, W; Lee, C; Park, JW; Sohn, JH; Nam, JH; Kim, Y; Rhee, JH; Im, SH; Koh, YI				Shim, Jae-Uoong; Lee, Shee Eun; Hwang, Won; Lee, Changhon; Park, Jung-Won; Sohn, Jung-Ho; Nam, Jong Hee; Kim, Young; Rhee, Joon Haeng; Im, Sin-Hyeog; Koh, Young-Il			Flagellin suppresses experimental asthma by generating regulatory dendritic cells and T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; Toll-like receptor 5; flagellin; dendritic cells; regulatory T cells	ADJUVANT ACTIVITY; FUSION PROTEIN; EXPRESSION; TOLERANCE; FOXP3; RESPONSES; HYPERREACTIVITY; DIFFERENTIATION; IMMUNOTHERAPY; INFLAMMATION	Background: Although the hygiene hypothesis suggests that microbial infections could subvert asthma and thus a microbial product might serve as a therapeutic adjuvant for asthma, the relationship between bacterial components and asthma is complex. Recently, low levels of flagellin, the Toll-like receptor (TLR) 5 ligand, have been reported to promote asthma. Objective: We show that a therapeutic dose of flagellin suppresses asthma and that the effect occurs through generating regulatory dendritic cells (rDCs) and regulatory T (Treg) cells. Methods: Ovalbumin (OVA)-induced wild-type and TLR5 knockout asthmatic mice were treated intranasally with a mixture of OVA and 10 mu g of a flagellin B (FlaB; of Vibrio vulnificus). OVA/FlaB-treated rDCs were adoptively transferred to mice with OVA-induced asthma. Anti-CD25 mAb was used to deplete Treg cells. A mixture of house dust mite (HDM) and FlaB was used to treat mice with HDM-induced asthma. Blood CD14(+) monocyte-derived dendritic cells from HDM-sensitive asthmatic patients were treated with FlaB and incubated with autologous CD14(+) T cells. Results: An OVA/FlaB mixture ameliorated OVA-induced asthma by inhibiting T(H)1/T(H)2/T(H)17 responses in a TLR5-dependent manner through generating rDCs and Treg cells. The adoptive transfer of OVA/FlaB-treated dendritic cells inhibited OVA-induced asthma, whereas the depletion of CD25(+) cells eliminated the inhibitory effect. A similar effect of FlaB was observed in mice with HDM-induced asthma. In patients with HDM-sensitive asthma, FlaB-treated rDCs inhibited HDM-stimulated T(H)1/T(H)2 responses while enhancing Treg cells in an IL-10-dependent manner. Conclusion: These findings collectively suggest that flagellin could be used as a tolerogenic adjuvant to treat allergic asthma.	[Shim, Jae-Uoong; Koh, Young-Il] Chonnam Natl Univ, Sch Med, Dept Internal Med, Div Allergy Asthma & Clin Immunol, Gwangju 501757, South Korea; [Lee, Shee Eun] Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Gwangju, South Korea; [Hwang, Won] Gwangju Inst Sci & Technol, Sch Life Sci, Gwangju, South Korea; [Park, Jung-Won; Sohn, Jung-Ho] Yonsei Univ, Coll Med, Dept Internal Med, Div Allergy & Immunol, Seoul, South Korea; [Park, Jung-Won; Sohn, Jung-Ho] Yonsei Univ, Coll Med, Inst Allergy, Seoul, South Korea; [Nam, Jong Hee; Kim, Young] Chonnam Natl Univ, Sch Med, Dept Pathol, Gwangju, South Korea; [Rhee, Joon Haeng] Chonnam Natl Univ, Sch Med, Natl Res Lab Mol Microbial Pathogenesis, Clin Vaccine R&D Ctr,Res Inst Vibrio Infect,Dept, Gwangju 501190, South Korea; [Hwang, Won; Lee, Changhon; Im, Sin-Hyeog] AIM, IBS, Pohang 790784, South Korea; [Lee, Changhon; Im, Sin-Hyeog] Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol IBB, 77 Cheongam Ro, Pohang 790784, South Korea	Chonnam National University; Chonnam National University; Gwangju Institute of Science & Technology (GIST); Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Chonnam National University; Chonnam National University; Institute for Basic Science - Korea (IBS); Pohang University of Science & Technology (POSTECH)	Rhee, JH (corresponding author), Chonnam Natl Univ, Sch Med, Natl Res Lab Mol Microbial Pathogenesis, Clin Vaccine R&D Ctr,Res Inst Vibrio Infect,Dept, Gwangju 501190, South Korea.; Im, SH (corresponding author), AIM, IBS, Pohang 790784, South Korea.; Im, SH (corresponding author), Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol IBB, 77 Cheongam Ro, Pohang 790784, South Korea.; Rhee, JH (corresponding author), Chonnam Natl Univ, Sch Med, Dept Microbiol, 5 Hak Dong, Gwangju 501190, South Korea.; Koh, YI (corresponding author), Chonnam Natl Univ, Sch Med, Dept Internal Med, 42 Jebong Ro, Gwangju 501757, South Korea.	jhrhee@chonnam.ac.kr; iimsh@postech.ac.kr; yikoh@jnu.ac.kr	Im, Sin-Hyeog/AAM-9586-2021; Im, Sin-Hyeog/E-6811-2013	Im, Sin-Hyeog/0000-0002-3173-1856; Im, Sin-Hyeog/0000-0002-3173-1856; Hwang, Won/0000-0001-5428-4158; Lee, Changhon/0000-0002-2810-400X; Park, Jung-Won/0000-0003-0249-8749	Korean Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI14C0187];  [IBS-R005-G1-2015-a00]	Korean Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea; 	Supported by a grant of the Korean Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), which is funded by the Ministry of Health and Welfare, Republic of Korea (HI14C0187). S.-H. I. was supported by grants from a research program by IBS-R005-G1-2015-a00.	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Amodio G, 2012, TRANSPLANT RES, V1, DOI 10.1186/2047-1440-1-14; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Bates JT, 2009, J IMMUNOL, V182, P7539, DOI 10.4049/jimmunol.0804225; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Cao XF, 2007, IMMUNITY, V27, P635, DOI 10.1016/j.immuni.2007.08.014; Codispoti CD, 2010, J ALLERGY CLIN IMMUN, V125, P1054, DOI 10.1016/j.jaci.2010.02.004; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; Cong YZ, 2009, P NATL ACAD SCI USA, V106, P19256, DOI 10.1073/pnas.0812681106; Cosmi L, 2011, ALLERGY, V66, P989, DOI 10.1111/j.1398-9995.2011.02576.x; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Dalpke AH, 2005, IMMUNOLOGY, V116, P203, DOI 10.1111/j.1365-2567.2005.02211.x; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Hammad H, 2015, 2015 KEYST S DENDR C; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Hedl M, 2013, MUCOSAL IMMUNOL, V6, P205, DOI 10.1038/mi.2012.139; Hilkens CMU, 2013, CLIN EXP IMMUNOL, V172, P148, DOI 10.1111/cei.12038; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Huang H, 2010, J IMMUNOL, V185, P5003, DOI 10.4049/jimmunol.0903446; Johnson DJ, 2013, ANN NY ACAD SCI, V1284, P46, DOI 10.1111/nyas.12114; Karman J, 2012, J BIOL CHEM, V287, P11098, DOI 10.1074/jbc.M111.283705; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Lankford S, 2008, VET IMMUNOL IMMUNOP, V122, P159, DOI 10.1016/j.vetimm.2007.11.007; Lee SE, 2006, INFECT IMMUN, V74, P694, DOI 10.1128/IAI.74.1.694-702.2006; Lee SE, 2008, J CLIN IMMUNOL, V28, P157, DOI 10.1007/s10875-007-9138-3; Li XL, 2010, AM J RESP CELL MOL, V42, P190, DOI 10.1165/rcmb.2009-0023OC; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lun SWM, 2009, J CLIN IMMUNOL, V29, P330, DOI 10.1007/s10875-008-9269-1; Maneachotesuwan K, 2009, J ALLERGY CLIN IMMUN, V123, P239, DOI 10.1016/j.jaci.2008.10.018; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Provoost S, 2009, ALLERGY, V64, P1539, DOI 10.1111/j.1398-9995.2009.02056.x; Qiu HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022004; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Schulke S, 2011, J ALLERGY CLIN IMMUN, V128, P1340, DOI 10.1016/j.jaci.2011.07.036; Schulke S, 2010, MOL IMMUNOL, V48, P341, DOI 10.1016/j.molimm.2010.07.006; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Sharma S, 2005, CANCER RES, V65, P5211, DOI 10.1158/0008-5472.CAN-05-0141; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Le TA, 2011, INT ARCH ALLERGY IMM, V155, P31, DOI 10.1159/000318679; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wilson RH, 2012, NAT MED, V18, P1705, DOI 10.1038/nm.2920	47	32	38	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					426	435		10.1016/j.jaci.2015.07.010	http://dx.doi.org/10.1016/j.jaci.2015.07.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26303344				2022-12-18	WOS:000369235500011
J	Cowan, MJ; Gennery, AR				Cowan, Morton J.; Gennery, Andrew R.			Radiation-sensitive severe combined immunodeficiency: The arguments for and against conditioning before hematopoietic cell transplantation-what to do?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; radiation sensitivity; hematopoietic cell transplantation; nonhomologous end joining; DNA repair	BONE-MARROW-TRANSPLANTATION; LIGASE-IV DEFICIENCY; DNA-REPAIR; ARTEMIS; MUTATIONS; RECONSTITUTION; CERNUNNOS; DISEASE; CHEMOTHERAPY; CLEARANCE	Defects in DNA cross-link repair 1C (DCLRE1C), protein kinase DNA activated catalytic polypeptide (PRKDC), ligase 4 (LIG4), NHEJ1, and NBS1 involving the nonhomologous end-joining (NHEJ) DNA repair pathway result in radiation-sensitive severe combined immunodeficiency (SCID). Results of hematopoietic cell transplantation for radiation-sensitive SCID suggest that minimizing exposure to alkylating agents and ionizing radiation is important for optimizing survival and minimizing late effects. However, use of preconditioning with alkylating agents is associated with a greater likelihood of full T-and B-cell reconstitution compared with no conditioning or immunosuppression alone. A reduced-intensity regimen using fludarabine and low-dose cyclophosphamide might be effective for patients with LIG4, NHEJ1, and NBS1 defects, although more data are needed to confirm these findings and characterize late effects. For patients with mutations in DCLRE1C (Artemis-deficient SCID), there is no optimal approach that uses standard dose-alkylating agents without significant late effects. Until nonchemotherapy agents, such as anti-CD45 or anti-CD117, become available, options include minimizing exposure to alkylators, such as single-agent low-dose targeted busulfan, or achieving T-cell reconstitution, followed several years later with a conditioning regimen to restore B-cell immunity. Gene therapy for these disorders will eventually remove the issues of rejection and graft-versus-host disease. Prospective multicenter studies are needed to evaluate these approaches in this rare but highly vulnerable patient population.	[Cowan, Morton J.] Univ Calif San Francisco, Benioff Childrens Hosp, Allergy Immunol & Blood & Marrow Transplant Div, San Francisco, CA 94143 USA; [Gennery, Andrew R.] Great North Childrens Hosp, Paediat Immunol Dept, Newcastle Upon Tyne, Tyne & Wear, England	University of California System; University of California San Francisco	Cowan, MJ (corresponding author), UCSF Benioff Childrens Hosp, 505 Parnassus Ave, San Francisco, CA 94143 USA.	mcowan@peds.ucsf.edu			National Institute of Allergy and Infectious Disease (NIAID); National Center for Advancing Translational Sciences (NCATS) Office of Rare Disease Research (ORDR); Rare Disease Clinical Research Network (RDCRN) [U54-AI 082973, R13 AI 094943]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R13AI094943, U54AI082973] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Disease (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Advancing Translational Sciences (NCATS) Office of Rare Disease Research (ORDR); Rare Disease Clinical Research Network (RDCRN); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by grants from the National Institute of Allergy and Infectious Disease (NIAID), the National Center for Advancing Translational Sciences (NCATS) Office of Rare Disease Research (ORDR), and the Rare Disease Clinical Research Network (RDCRN), U54-AI 082973 and R13 AI 094943. The views expressed in written materials or publications do not necessarily reflect the official policies of the Department of Health and Human Services, nor does mention by trade names, commercial practices, or organizations imply endorsement by the US Government.	Albert MH, 2010, BONE MARROW TRANSPL, V45, P622, DOI 10.1038/bmt.2009.207; Benjelloun F, 2008, MOL THER, V16, P1490, DOI 10.1038/mt.2008.118; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Buckley RH, 2013, J CLIN IMMUNOL, V33, P96, DOI 10.1007/s10875-012-9797-6; Burroughs LM, 2014, BIOL BLOOD MARROW TR, V20, P1996, DOI 10.1016/j.bbmt.2014.08.020; Cagdas D, 2012, PEDIATR TRANSPLANT, V16, pE167, DOI 10.1111/j.1399-3046.2011.01491.x; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; Deriano L, 2013, ANNU REV GENET, V47, P433, DOI 10.1146/annurev-genet-110711-155540; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Dvorak CC, 2014, J ALLERGY CLIN IMMUN, V134, P935, DOI 10.1016/j.jaci.2014.06.021; Dvorak CC, 2014, PEDIATR TRANSPLANT, V18, P609, DOI 10.1111/petr.12310; Enders A, 2006, J IMMUNOL, V176, P5060, DOI 10.4049/jimmunol.176.8.5060; Evans PM, 2006, HUM MOL GENET, V15, P1303, DOI 10.1093/hmg/ddl050; Faraci M, 2009, PEDIATR TRANSPLANT, V13, P785, DOI 10.1111/j.1399-3046.2008.01028.x; Felgentreff K, 2014, P NATL ACAD SCI USA, V111, P8889, DOI 10.1073/pnas.1323649111; Gruhn B, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-5; Grunebaum E, 2008, J ALLERGY CLIN IMMUN, V122, P1219, DOI 10.1016/j.jaci.2008.08.031; Haddad E, 2013, J ALLERGY CLIN IMMUN, V131, P994, DOI 10.1016/j.jaci.2013.01.047; Ivovic V, 2013, J CLIN MICROBIOL, V51, P2686; Iyama T, 2013, DNA REPAIR, V12, P620, DOI 10.1016/j.dnarep.2013.04.015; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Mostoslavsky G, 2006, P NATL ACAD SCI USA, V103, P16406, DOI 10.1073/pnas.0608130103; Musio A, 2005, EUR J IMMUNOL, V35, P1250, DOI 10.1002/eji.200425555; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; O'Marcaigh AS, 2001, BONE MARROW TRANSPL, V27, P703, DOI 10.1038/sj.bmt.1702831; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Pietzner J, 2013, HUM MOL GENET, V22, P493, DOI 10.1093/hmg/dds448; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Robertson LE, 1996, CANCER CHEMOTH PHARM, V37, P445, DOI 10.1007/s002800050410; Savic RM, 2013, BIOL BLOOD MARROW TR, V19, P1608, DOI 10.1016/j.bbmt.2013.08.014; Schuetz C, 2014, BLOOD, V123, P281, DOI 10.1182/blood-2013-01-476432; Slatter MA, 2005, BONE MARROW TRANSPL, V35, P683, DOI 10.1038/sj.bmt.1704872; Straathof KC, 2009, LANCET, V374, P912, DOI 10.1016/S0140-6736(09)60945-4; Unal S, 2009, PEDIATR BLOOD CANCER, V53, P482, DOI 10.1002/pbc.22031; Ussowicz M, 2013, BONE MARROW TRANSPL, V48, P740, DOI 10.1038/bmt.2012.207; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; van Der Burg M, 2006, HAEMATOLOGICA, V91, P1705; van der Burg M, 2009, J CLIN INVEST, V119, P91, DOI 10.1172/JCI37141; Woodbine L, 2013, J CLIN INVEST, V123, P2969, DOI 10.1172/JCI67349; Wozniak M, 2015, PEDIATR TRANSPLANT, V19, pE51, DOI 10.1111/petr.12420	49	32	33	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1178	1185		10.1016/j.jaci.2015.04.027	http://dx.doi.org/10.1016/j.jaci.2015.04.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26055221	Green Accepted			2022-12-18	WOS:000364787200005
J	Lemoine, S; Jaron, B; Tabka, S; Ettreiki, C; Deriaud, E; Zhivaki, D; Le Ray, C; Launay, O; Majlessi, L; Tissieres, P; Leclerc, C; Lo-Man, R				Lemoine, Sebastien; Jaron, Barbara; Tabka, Sabrine; Ettreiki, Chourouk; Deriaud, Edith; Zhivaki, Dania; Le Ray, Camille; Launay, Odile; Majlessi, Laleh; Tissieres, Pierre; Leclerc, Claude; Lo-Man, Richard			Dectin-1 activation unlocks IL12A expression and reveals the T(H)1 potency of neonatal dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Newborn; dendritic cells; T(H)1; adjuvant; C-type lectin receptor; Toll-like receptor; innate immunity	CD4(+) T-CELLS; CYTOKINE RESPONSES; GAMMA PRODUCTION; RECEPTOR; IMMUNITY; INNATE; RECOGNITION; AGONISTS; LIPOPOLYSACCHARIDE; ENGAGEMENT	Background: Early life is characterized by a high susceptibility to infection and a T(H)2-biased CD4 T-cell response to vaccines. Toll-like receptor (TLR) agonists are currently being implemented as new vaccine adjuvants for T(H)1 activation, but their translation to the field of pediatric vaccines is facing the impairment of neonatal innate TLR responses. Objective: We sought to analyze C-type lectin receptor pathways as an alternative or a coactivator to TLRs for neonatal dendritic cell activation for T(H)1 polarization. Methods: Neonatal monocyte-derived dendritic cells (moDCs) were exposed to various combinations of TLR agonists with or without Dectin-1 agonist. IL-12 and IL-23 responses were analyzed at the transcriptional and protein levels after stimulation. The intracellular pathways triggered by combined TLR plus Dectin-1 stimulation was determined by using pharmacologic inhibitors. The capacity of neonatal moDCs to differentiate naive CD4 T-H cells was evaluated in cocultures with heterologous neonatal naive T cells. Curdlan was finally tested as an adjuvant within a subunit tuberculosis vaccine in neonatal mice. Results: Simultaneous coactivation through Dectin-1 and TLRs induced robust secretion of IL-12p70 by neonatal moDCs by unlocking transcriptional control on the p35 subunit of IL-12. Both the spleen tyrosine kinase and Raf-1 pathways were involved in this process, allowing differentiation of neonatal naive T cells toward IFN-gamma-producing T(H)1 cells. In vivo a Dectin-1 agonist as adjuvant was sufficient to induce T(H)1 responses after vaccination of neonatal mice. Conclusion: Coactivation of neonatal moDCs through Dectin-1 allows TLR-mediated IL-12p70 secretion and T(H)1 polarization of neonatal T cells. Dectin-1 agonists represent a promising T(H)1 adjuvant for pediatric vaccination.	[Lemoine, Sebastien; Jaron, Barbara; Tabka, Sabrine; Deriaud, Edith; Zhivaki, Dania; Leclerc, Claude; Lo-Man, Richard] Inst Pasteur, Unite Regulat Immunitaire & Vaccinol, Paris, France; [Lemoine, Sebastien; Jaron, Barbara; Tabka, Sabrine; Deriaud, Edith; Zhivaki, Dania; Leclerc, Claude; Lo-Man, Richard] INSERM U1041, Paris, France; [Ettreiki, Chourouk; Tissieres, Pierre] Hop Univ Paris Sud, AP HP, Unite Reanimat Pediat & Med Neonatale, Le Kremlin Bicetre, France; [Zhivaki, Dania] Univ Paris Diderot, Paris, France; [Le Ray, Camille] Maternite Port Royal, AP HP, Dept Obstet & Gynecol, Paris, France; [Le Ray, Camille; Launay, Odile] Univ Paris 05, Fac Med, Paris, France; [Launay, Odile] INSERM CIC1417, Paris, France; [Majlessi, Laleh] Inst Pasteur, Unite Pathogenom Mycobacterienne Integree, Paris, France; [Ettreiki, Chourouk; Tissieres, Pierre] Univ Paris 11, Inst Genet & Microbiol, UMR 8621, Grp Equipe Endotoxine Struct & Activite, F-91405 Orsay, France; [Tissieres, Pierre] Univ Paris 11, Fac Med, Le Kremlin Bicetre, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Lo-Man, R (corresponding author), Inst Pasteur, Regulat Immunitaire & Vaccinol, 25 Rue Docteur Roux, Paris, France.	richard.lo-man@pasteur.fr		Le Ray, Camille/0000-0003-0891-1063	ANR grant [ANR 09-MIEN-017]; Fondation pour la Recherche Medicale [DEQ20120323719]; French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases'' [ANR-10-LABX-62-IBEID]; European Commission FP7 ADITEC program [HEALTH-F4-2011-280873]; DIM Malinf; Region Ile de France; ANR	ANR grant(French National Research Agency (ANR)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases''(French National Research Agency (ANR)); European Commission FP7 ADITEC program; DIM Malinf; Region Ile de France(Region Ile-de-France); ANR(French National Research Agency (ANR))	Supported by an ANR grant (ANR 09-MIEN-017) and Fondation pour la Recherche Medicale (grant no. DEQ20120323719). This study also received funding from the French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases'' (grant no. ANR-10-LABX-62-IBEID). S.L. was supported by ANR and the European Commission FP7 ADITEC program (HEALTH-F4-2011-280873). D.Z. was supported by DIM Malinf and Region Ile de France.	Aksoy E, 2007, BLOOD, V109, P2887, DOI 10.1182/blood-2006-06-027862; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Bekeredjian-Ding I, 2006, J IMMUNOL, V176, P7438, DOI 10.4049/jimmunol.176.12.7438; Collin M, 2013, IMMUNOLOGY, V140, P22, DOI 10.1111/imm.12117; Elahi S, 2013, NATURE, V504, P158, DOI 10.1038/nature12675; Goriely S, 2006, BLOOD, V107, P1078, DOI 10.1182/blood-2005-06-2416; Goriely S, 2004, J EXP MED, V199, P1011, DOI 10.1084/jem.20031272; Gringhuis SI, 2009, NAT IMMUNOL, V10, P203, DOI 10.1038/ni.1692; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Hebel K, 2014, J IMMUNOL, V192, P5160, DOI 10.4049/jimmunol.1302539; Hervas-Stubbs S, 2006, INFECT IMMUN, V74, P3396, DOI 10.1128/IAI.02086-05; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; Ifrim DC, 2013, J IMMUNOL, V190, P4129, DOI 10.4049/jimmunol.1202611; Ishikawa E, 2009, J EXP MED, V206, P2879, DOI 10.1084/jem.20091750; Jiao XN, 2002, J IMMUNOL, V168, P1294, DOI 10.4049/jimmunol.168.3.1294; Kamath AT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005771; Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481; Krumbiegel D, 2007, HUM IMMUNOL, V68, P813, DOI 10.1016/j.humimm.2007.08.001; Levy O, 2004, J IMMUNOL, V173, P4627, DOI 10.4049/jimmunol.173.7.4627; Levy O, 2006, BLOOD, V108, P1284, DOI 10.1182/blood-2005-12-4821; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394; Mintz-Cole RA, 2012, J IMMUNOL, V189, P3609, DOI 10.4049/jimmunol.1200589; Miyake Y, 2013, IMMUNITY, V38, P1050, DOI 10.1016/j.immuni.2013.03.010; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Ota MOC, 2002, J IMMUNOL, V168, P919, DOI 10.4049/jimmunol.168.2.919; Philbin VJ, 2012, J ALLERGY CLIN IMMUN, V130, P195, DOI 10.1016/j.jaci.2012.02.042; PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189; Reikie BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044763; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Rose S, 2007, J IMMUNOL, V178, P2667, DOI 10.4049/jimmunol.178.5.2667; Rothfuchs AG, 2007, J IMMUNOL, V179, P3463, DOI 10.4049/jimmunol.179.6.3463; Sancho D, 2012, ANNU REV IMMUNOL, V30, P491, DOI 10.1146/annurev-immunol-031210-101352; Schreibelt G, 2010, CANCER IMMUNOL IMMUN, V59, P1573, DOI 10.1007/s00262-010-0833-1; Segura E, 2013, IMMUNITY, V38, P336, DOI 10.1016/j.immuni.2012.10.018; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Smolen KK, 2014, J ALLERGY CLIN IMMUN, V133, P818, DOI 10.1016/j.jaci.2013.09.038; Sun CM, 2005, IMMUNITY, V22, P467, DOI 10.1016/j.immuni.2005.02.008; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002; van den Biggelaar AHJ, 2009, J ALLERGY CLIN IMMUN, V124, P544, DOI 10.1016/j.jaci.2009.03.040; Vanden Eijnden S, 2006, EUR J IMMUNOL, V36, P21, DOI 10.1002/eji.200535467; Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1; Wevers BA, 2014, CELL HOST MICROBE, V15, P494, DOI 10.1016/j.chom.2014.03.008; Yadav M, 2006, BLOOD, V108, P3168, DOI 10.1182/blood-2006-05-024406; Yoshimoto M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051587; Zhang XM, 2014, J INFECT DIS, V210, P424, DOI 10.1093/infdis/jiu103; Zhang X, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008748; Zhang X, 2009, IMMUNITY, V31, P761, DOI 10.1016/j.immuni.2009.09.016	51	32	36	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1355	+		10.1016/j.jaci.2015.02.030	http://dx.doi.org/10.1016/j.jaci.2015.02.030			29	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	25865351				2022-12-18	WOS:000364787200026
J	Castiello, MC; Scaramuzza, S; Pala, F; Ferrua, F; Uva, P; Brigida, I; Sereni, L; van der Burg, M; Ottaviano, G; Albert, MH; Roncarolo, MG; Naldini, L; Aiuti, A; Villa, A; Bosticardo, M				Castiello, Maria Carmina; Scaramuzza, Samantha; Pala, Francesca; Ferrua, Francesca; Uva, Paolo; Brigida, Immacolata; Sereni, Lucia; van der Burg, Mirjam; Ottaviano, Giorgio; Albert, Michael H.; Roncarolo, Maria Grazia; Naldini, Luigi; Aiuti, Alessandro; Villa, Anna; Bosticardo, Marita			B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wiskott-Aldrich syndrome; gene therapy; B cell; primary immunodeficiency; lentiviral vector	SYSTEMIC-LUPUS-ERYTHEMATOSUS; SYNDROME PROTEIN; RHEUMATOID-ARTHRITIS; ACTIVATING FACTOR; ADHERENCE TEST; LYMPHOCYTES; COMPLEMENT; TRANSPLANTATION; EXPRESSION; OVEREXPRESSION	Background: Wiskott-Aldrich syndrome (WAS) is a severe X-linked immunodeficiency characterized by microthrombocytopenia, eczema, recurrent infections, and susceptibility to autoimmunity and lymphomas. Hematopoietic stem cell transplantation is the treatment of choice; however, administration of WAS gene-corrected autologous hematopoietic stem cells has been demonstrated as a feasible alternative therapeutic approach. Objective: Because B-cell homeostasis is perturbed in patients with WAS and restoration of immune competence is one of the main therapeutic goals, we have evaluated reconstitution of the B-cell compartment in 4 patients who received autologous hematopoietic stem cells transduced with lentiviral vector after a reduced-intensity conditioning regimen combined with anti-CD20 administration. Methods: We evaluated B-cell counts, B-cell subset distribution, B cell-activating factor and immunoglobulin levels, and autoantibody production before and after gene therapy (GT). WAS gene transfer in B cells was assessed by measuring vector copy numbers and expression of Wiskott-Aldrich syndrome protein. Results: After lentiviral vector-mediated GT, the number of transducedBcells progressively increased in the peripheral blood of all patients. Lentiviral vector-transduced progenitor cells were able to repopulate the B-cell compartment with a normal distribution of B-cell subsets both in bone marrow and the periphery, showing a WAS protein expression profile similar to that of healthy donors. In addition, after GT, we observed a normalized frequency of autoimmune-associated CD19(+)CD21(-)CD35(-) and CD21(low) B cells and a reduction in B cell-activating factor levels. Immunoglobulin serum levels and autoantibody production improved in all treated patients. Conclusions: We provide evidence that lentiviral vector-mediated GT induces transgene expression in the B-cell compartment, resulting in ameliorated B-cell development and functionality and contributing to immunologic improvement in patients with WAS.	[Castiello, Maria Carmina; Scaramuzza, Samantha; Pala, Francesca; Brigida, Immacolata; Sereni, Lucia; Roncarolo, Maria Grazia; Naldini, Luigi; Aiuti, Alessandro; Villa, Anna; Bosticardo, Marita] IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy TIGET, I-20132 Milan, Italy; [Ferrua, Francesca; Ottaviano, Giorgio] IRCCS San Raffaele Sci Inst, Pediat Immunohematol & Bone Marrow Transplantat U, I-20132 Milan, Italy; [Uva, Paolo] Sci & Technol Pk Polaris, CRS4, Cagliari, Italy; [van der Burg, Mirjam] Univ Med Ctr, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Albert, Michael H.] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; [Roncarolo, Maria Grazia; Naldini, Luigi] Univ Vita Salute San Raffaele, Milan, Italy; [Aiuti, Alessandro] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy; [Villa, Anna] IRGB CNR, Milan Unit, Milan, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Erasmus University Rotterdam; Erasmus MC; University of Munich; Vita-Salute San Raffaele University; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR)	Villa, A (corresponding author), IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy TIGET, Via Olgettina 58, I-20132 Milan, Italy.	villa.anna@hsr.it	Bosticardo, Marita/ABA-2688-2021; Ferrua, Francesca/K-4340-2016; AIUTI, ALESSANDRO/K-3918-2016; Scaramuzza, Samantha/AAN-2204-2020; Uva, Paolo/A-2877-2011; Pala, Francesca/AAE-8664-2019; Castiello, Maria Carmina/K-9767-2016; Ottaviano, Giorgio/GPT-0120-2022	Bosticardo, Marita/0000-0002-1771-4523; Ferrua, Francesca/0000-0002-5695-4490; AIUTI, ALESSANDRO/0000-0002-5398-1717; Scaramuzza, Samantha/0000-0003-2903-3650; Uva, Paolo/0000-0002-9524-8492; Castiello, Maria Carmina/0000-0003-2581-9648; Ottaviano, Giorgio/0000-0003-3777-0394; Brigida, Immacolata/0000-0002-0338-2230; Pala, Francesca/0000-0003-4537-9061; NALDINI, Luigi/0000-0002-7835-527X; SERENI, LUCIA/0000-0002-8234-3490; Villa, Anna/0000-0003-4428-9013	Telethon [A2]; Ministero della Salute; EU [261387]; Dutch Scientific organization [016.126.323]	Telethon(Fondazione Telethon); Ministero della Salute(Ministry of Health, Italy); EU(European Commission); Dutch Scientific organization(Netherlands Organization for Scientific Research (NWO))	Supported by Telethon (TIGET Core grant A2 to A. V.), Ministero della Salute (RF 2009 Giovani Ricercatori Grant, to M.v.d.B.), EU project CELL PID (FP7 no. 261387 to A. A. and A. V.). M.v.d.B. is supported by the Dutch Scientific organization (ZonMW Vidi grant no. 016.126.323). L.S. conducted this study as partial fulfillment of her PhD in Molecular Medicine, Program in Basic and Applied Immunology, San Raffaele University, Milan, Italy. Since January 2014, GlaxoSmithKline has in-licensed the WAS gene therapy program and has become the financial sponsor of the clinical trial conducted at TIGET.	Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Becker-Merok A, 2006, LUPUS, V15, P570, DOI 10.1177/0961203306071871; Bosticardo M, 2011, J ALLERGY CLIN IMMUN, V127, P1376, DOI 10.1016/j.jaci.2011.03.030; Bosticardo M, 2009, BLOOD, V113, P6288, DOI 10.1182/blood-2008-12-115253; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Brigida I, 2014, J ALLERGY CLIN IMMUN, V133, P799, DOI 10.1016/j.jaci.2013.12.1043; Cancro MP, 2009, NAT REV IMMUNOL, V9, P657, DOI 10.1038/nri2621; Candotti F, 2014, INT J HEMATOL, V99, P383, DOI 10.1007/s12185-014-1524-z; Castiello MC, 2014, J AUTOIMMUN, V50, P42, DOI 10.1016/j.jaut.2013.10.006; Catucci M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00209; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Dupre L, 2004, MOL THER, V10, P903, DOI 10.1016/j.ymthe.2004.08.008; Groom J, 2002, J CLIN INVEST, V109, P59, DOI 10.1172/JCI200214121; Haddad E, 2013, J ALLERGY CLIN IMMUN, V131, P994, DOI 10.1016/j.jaci.2013.01.047; Huang W, 2005, J IMMUNOL, V174, P2602, DOI 10.4049/jimmunol.174.5.2602; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Jacobson CA, 2014, BIOL BLOOD MARROW TR, V20, P668, DOI 10.1016/j.bbmt.2014.01.021; JONES CD, 1990, AM J CLIN PATHOL, V93, P552, DOI 10.1093/ajcp/93.4.552; Kremlitzka M, 2013, INT IMMUNOL, V25, P25, DOI 10.1093/intimm/dxs090; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; Li QZ, 2007, CLIN EXP IMMUNOL, V147, P60, DOI 10.1111/j.1365-2249.2006.03251.x; Mahlaoui N, 2013, BLOOD, V121, P1510, DOI 10.1182/blood-2012-08-448118; Meffre E, 2011, ANN NY ACAD SCI, V1246, P1, DOI 10.1111/j.1749-6632.2011.06347.x; Meyer-Bahlburg A, 2008, J EXP MED, V205, P155, DOI 10.1084/jem.20071088; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; OCHS HD, 1980, BLOOD, V55, P243; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Park JY, 2005, CLIN EXP IMMUNOL, V139, P297, DOI 10.1111/j.1365-2249.2005.02693.x; Prodeus AP, 1998, IMMUNITY, V9, P721, DOI 10.1016/S1074-7613(00)80669-X; RACHEL JM, 1985, MED LAB SCI, V42, P194; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Saadoun D, 2013, ARTHRITIS RHEUM-US, V65, P1085, DOI 10.1002/art.37828; Scaramuzza S, 2013, MOL THER, V21, P175, DOI 10.1038/mt.2012.23; SHIBATA Y, 1981, VOX SANG, V41, P25, DOI 10.1111/j.1423-0410.1981.tb01007.x; Silvin C, 2001, J BIOL CHEM, V276, P21450, DOI 10.1074/jbc.M010729200; Simon KL, 2014, J ALLERGY CLIN IMMUN, V133, P896, DOI 10.1016/j.jaci.2013.08.050; Small TN, 2009, BIOL BLOOD MARROW TR, V15, P104, DOI 10.1016/j.bbmt.2008.10.016; Stepensky P, 2013, J PEDIAT HEMATOL ONC, V35, pE234, DOI 10.1097/MPH.0b013e318279cbfc; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; Stohl W, 2003, ARTHRITIS RHEUM-US, V48, P3475, DOI 10.1002/art.11354; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Taylor MD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000813; Tussiwand R, 2012, EUR J IMMUNOL, V42, P206, DOI 10.1002/eji.201141957; TUVESON DA, 1991, J EXP MED, V173, P1083, DOI 10.1084/jem.173.5.1083; Warnatz K, 2002, IMMUNOBIOLOGY, V206, P502, DOI 10.1078/0171-2985-00198; Westerberg LS, 2008, BLOOD, V112, P4139, DOI 10.1182/blood-2008-02-140715; Westerberg LS, 2012, BLOOD, V119, P3966, DOI 10.1182/blood-2010-09-308197; Zhu XJ, 2009, BLOOD, V114, P5362, DOI 10.1182/blood-2009-05-217513	49	32	33	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					692	+		10.1016/j.jaci.2015.01.035	http://dx.doi.org/10.1016/j.jaci.2015.01.035			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25792466	Green Published, hybrid			2022-12-18	WOS:000360913300022
J	Mountjoy, M; Fitch, K; Boulet, LP; Bougault, V; van Mechelen, W; Verhagen, E				Mountjoy, Margo; Fitch, Ken; Boulet, Louis-Philippe; Bougault, Valerie; van Mechelen, Willem; Verhagen, Evert			Prevalence and characteristics of asthma in the aquatic disciplines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; exercise-induced bronchoconstriction; airway hyperresponsiveness; swimming; diving; synchronized swimming; water polo; Olympic Games; endurance training	EXERCISE-INDUCED ASTHMA; INHALED BETA(2)-AGONISTS; AIRWAY INFLAMMATION; SWIMMERS; PERFORMANCE; DYSFUNCTION; RESPONSES; SYMPTOMS; CRITERIA; ATHLETE	Background: Despite the health benefits of swimming as a form of exercise, evidence exists that both the swimming pool environment and endurance exercise are etiologic factors in the development of asthma. The prevalence of asthma in swimmers is high compared with that in participants in other Olympic sport disciplines. There are no publications comparing the prevalence of asthma in the 5 aquatic disciplines. Objective: The purpose of this study is to examine and compare the prevalence of asthma in the aquatic disciplines and in contrast with other Olympic sports. Methods: Therapeutic Use Exemptions containing objective evidence of athlete asthma/airway hyperresponsiveness (AHR) were collected for all aquatic athletes participating in swimming, diving, synchronized swimming, water polo, and open water swimming for major events during the time period from 2004-2009. The prevalence of asthma/AHR in the aquatic disciplines was analyzed for statistical significance (with 95% CIs) and also compared with that in other Olympic sports. Results: Swimming had the highest prevalence of asthma/AHR in comparison with the other aquatic disciplines. The endurance aquatic disciplines have a higher prevalence of asthma/AHR than the aquatic nonendurance disciplines. Asthma/AHR is more common in Oceania, Europe, and North America than in Asia, Africa, and South America. In comparison with other Olympic sports, swimming, synchronized swimming, and open water swimmingwereamong the top 5 sports for asthma/AHRprevalence. Conclusion: Asthma/AHR in the endurance aquatic disciplines is common at the elite level and has a varied geographic distribution. Findings from this study demonstrate the need for development of aquatic discipline-specific prevention, screening, and treatment regimens.	[Mountjoy, Margo] McMaster Univ, Michael G DeGroote Sch Med, Dept Family Med, Hamilton, ON, Canada; [Mountjoy, Margo] Int Olymp Comm IOC, Lausanne, Switzerland; [Mountjoy, Margo] Federat Int Natat FINA, Lausanne, Switzerland; [Fitch, Ken] Univ Western Australia, Fac Life Sci, Sch Sports Sci Exercise & Hlth, Crawley, Australia; [Boulet, Louis-Philippe] Univ Laval, Quebec Heart & Lung Inst, Quebec City, PQ, Canada; [Bougault, Valerie] Univ Lille, Fac Sport Sci, Lille, France; [van Mechelen, Willem; Verhagen, Evert] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [Verhagen, Evert] Federat Univ Australia, Australian Ctr Res Injury Sport & Its Prevent ACR, Ballarat, Vic, Australia	McMaster University; University of Western Australia; Laval University; Quebec Heart & Lung Institute; Universite de Lille - ISITE; Universite de Lille; Vrije Universiteit Amsterdam; Federation University Australia	Mountjoy, M (corresponding author), McMaster Univ, Michael G DeGroote Sch Med, FINA, Waterloo Reg Campus,10-B Victoria St South, Kitchener, ON N2G 1C5, Canada.	mmsportdoc@mcmaster.ca	Verhagen, Evert/A-1502-2013; Bougault, Valerie/G-9904-2018	Verhagen, Evert/0000-0001-9227-8234; van Mechelen, Willem/0000-0001-7136-6382; Bougault, Valerie/0000-0002-2258-6562	Serie Cientifica Latinoamerican; Australasian College of Sports Physicians; AstraZeneca; GlaxoSmithKline; Merck; Schering; AllerGen; Altair; Amgen; Asmacure; Boehringer Ingelheim; Genentech; Novartis; Ono Pharma; Pharmaxis; Wyeth	Serie Cientifica Latinoamerican; Australasian College of Sports Physicians; AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Schering; AllerGen; Altair; Amgen(Amgen); Asmacure; Boehringer Ingelheim(Boehringer Ingelheim); Genentech(Roche HoldingGenentech); Novartis(Novartis); Ono Pharma; Pharmaxis; Wyeth(Wyeth)	M. Mountjoy is employed by the McMaster Medical School and the University of Guelph, has received payment for delivering lectures from Serie Cientifica Latinoamerican, and has received compensation for travel and other meeting-related expenses from the International Olympic Committee, FINA, and the World Anti-Doping Agency. K. Fitch has received payment for the development of educational presentations from the Australasian College of Sports Physicians. L.-P. Boulet has received compensation for board membership from GlaxoSmithKline, Novartis, AstraZeneca, Merck, and Schering; has received or has grants pending from AstraZeneca, GlaxoSmithKline, Merck, Schering, AllerGen, Altair, Amgen, Asmacure, Boehringer Ingelheim, Genentech, Novartis, Ono Pharma, Pharmaxis, and Wyeth; has received payment for delivering lectures from AstraZeneca, GlaxoSmithKline, Merck, and Novartis; has received payment for the development of educational presentations from AstraZeneca, GlaxoSmithKline, Merck, Boehringer Ingelheim, Novartis; and has received payment as a governmental advisor for INNESS, the Quebec National Health Institute, and as a member of the Quebec Workmen Compensation Board Respiratory Committee. The rest of the authors declare that they have no relevant conflicts of interest.	Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; BAROR O, 1992, SPORTS MED, V14, P397, DOI 10.2165/00007256-199214060-00006; Bernard A, 2007, CURR MED CHEM, V14, P1771; Bernard A, 2007, PEDIATRICS, V119, P1095, DOI 10.1542/peds.2006-3333; Bougault V, 2009, EUR RESPIR J, V33, P740, DOI 10.1183/09031936.00117708; Bougault V, 2012, BRIT J SPORT MED, V46, P402, DOI 10.1136/bjsports-2011-090821; Bougault V, 2012, J ALLERGY CLIN IMMUN, V129, P351, DOI 10.1016/j.jaci.2011.11.010; Bougault V, 2011, J ALLERGY CLIN IMMUN, V127, P892, DOI 10.1016/j.jaci.2010.11.003; Bougault V, 2010, CHEST, V138, p31S, DOI 10.1378/chest.09-1689; Bougault V, 2009, SPORTS MED, V39, P295, DOI 10.2165/00007256-200939040-00003; Brunekreef B, 2009, ENVIRON HEALTH PERSP, V117, P1791, DOI 10.1289/ehp.0800467; Carbonnelle S, 2002, BIOMARKERS, V7, P464, DOI 10.1080/13547500210166612; Castricum A, 2010, BRIT J SPORT MED, V44, P736, DOI 10.1136/bjsm.2008.051169; Couto M, 2013, CLIN J SPORT MED, V23, P74, DOI 10.1097/JSM.0b013e31826869ef; Dickinson JW, 2005, THORAX, V60, P629, DOI 10.1136/thx.2004.037499; DONNELLY PM, 1991, LANCET, V337, P179, DOI 10.1016/0140-6736(91)90848-J; Fiks IN, 2012, J BRAS PNEUMOL, V38, P24, DOI 10.1590/S1806-37132012000100005; FITCH KD, 1976, ARCH DIS CHILD, V51, P190, DOI 10.1136/adc.51.3.190; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; Fitch KD, 2008, J ALLERGY CLIN IMMUN, V122, P254, DOI 10.1016/j.jaci.2008.07.003; Fitch KD, 2013, BRIT J SPORT MED, V47, P815, DOI 10.1136/bjsports-2013-092460; Haahtela T, 2008, ALLERGY, V63, P685, DOI 10.1111/j.1398-9995.2008.01686.x; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; INBAR O, 1980, EUR J APPL PHYSIOL O, V44, P43, DOI 10.1007/BF00421762; Jacobs JH, 2007, EUR RESPIR J, V29, P690, DOI 10.1183/09031936.00024706; Kindermann W, 2007, SPORTS MED, V37, P95, DOI 10.2165/00007256-200737020-00001; Kippelen P, 2013, IMMUNOL ALLERGY CLIN, V33, P299, DOI 10.1016/j.iac.2013.02.002; Kippelen P, 2012, BRIT J SPORT MED, V46, P385, DOI 10.1136/bjsports-2011-090819; Kuipers H, 2008, BRIT J SPORT MED, V42, P868, DOI 10.1136/bjsm.2007.042572; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; McKenzie DC, 2011, CLIN J SPORT MED, V21, P46, DOI 10.1097/IAE.0b013e318203c0ef; Moreira A, 2011, RESP MED, V105, P1761, DOI 10.1016/j.rmed.2011.05.011; Nordberg GF, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000973; Parsons JP, 2013, AM J RESP CRIT CARE, V187, P1016, DOI 10.1164/rccm.201303-0437ST; Pearce N, 2000, EUR RESPIR J, V16, P420, DOI 10.1183/9031936.00.16337700; Pedersen L, 2008, MED SCI SPORT EXER, V40, P1567, DOI 10.1249/MSS.0b013e31875719a; Pluim BM, 2011, SPORTS MED, V41, P39, DOI 10.2165/11537540-000000000-00000; Romberg K, 2012, SCAND J MED SCI SPOR, V22, P362, DOI 10.1111/j.1600-0838.2010.01177.x; Romberg K, 2012, RESP MED, V106, P15, DOI 10.1016/j.rmed.2011.09.011; Sidiropoulou MP, 2012, J STRENGTH COND RES, V26, P1644, DOI 10.1519/JSC.0b013e318234eb0c; Stadelmann K, 2011, MED SCI SPORT EXER, V43, P375, DOI 10.1249/MSS.0b013e3181f1c0b1; Turmel J, 2012, PHYSICIAN SPORTSMED, V40, P55, DOI 10.3810/psm.2012.09.1982; Weiler JM, 2007, J ALLERGY CLIN IMMUN, V119, P1349, DOI 10.1016/j.jaci.2007.02.041; World Health Organization (WHO), 2006, GUID SAF RECR WAT EN, V2, P60	44	32	35	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					588	594		10.1016/j.jaci.2015.01.041	http://dx.doi.org/10.1016/j.jaci.2015.01.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25819982	Bronze			2022-12-18	WOS:000360913300008
J	Sicherer, SH; Leung, DYM				Sicherer, Scott H.; Leung, Donald Y. M.			Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dermatology; skin disease; urticaria; atopic dermatitis; eczema; anaphylaxis; allergy; peanut; hypersensitivity disorders; food; drug; insect venom	SEVERE ATOPIC-DERMATITIS; OF-FUNCTION MUTATIONS; VITAMIN-D; EOSINOPHILIC ESOPHAGITIS; PENICILLIN ALLERGY; ORAL IMMUNOTHERAPY; NATURAL-HISTORY; EMERGENCY-DEPARTMENT; PEANUT SENSITIZATION; CHRONIC URTICARIA	This review highlights some of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects; and allergic skin diseases that were reported in the Journal in 2014. Studies on food allergy suggest worrisomely high rates of peanut allergy and food-induced anaphylaxis-related hospitalizations. Evidence is mounting to support the theory that environmental exposure to peanut, such as in house dust, especially with an impaired skin barrier attributed to atopic dermatitis (AD) and loss of function mutations in the filaggrin gene, is a risk factor for sensitization and allergy. Diagnostic tests are improving, with early studies suggesting the possibility of developing novel cellular tests with increased diagnostic utility. Treatment trials continue to show the promise and limitations of oral immunotherapy, and mechanistic studies are elucidating pathways that might define the degree of efficacy of this treatment. Studies have also provided insights into the prevalence and characteristics of anaphylaxis and insect venom allergy, such as suggesting that baseline platelet-activating factor acetylhydrolase activity levels are related to the severity of reactions. Advances in drug allergy include identification of HLA associations for penicillin allergy and a microRNA biomarker/mechanism for toxic epidermal necrolysis. Research identifying critical events leading to skin barrier dysfunction and the polarized immune pathways that drive AD have led to new therapeutic approaches in the prevention and management of AD.	[Sicherer, Scott H.] Icahn Sch Med Mt Sinai, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Div Pediat Allergy Immunol, Denver, CO USA	Icahn School of Medicine at Mount Sinai; National Jewish Health	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			Food Allergy Research and Education (FARE); Novartis; National Institute of Allergy and Infectious Diseases; FARE; Biomarin; Alopexx	Food Allergy Research and Education (FARE); Novartis(Novartis); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FARE; Biomarin; Alopexx	S. H. Sicherer is a member of the American Board of Allergy and Immunology, has received consultancy fees from Food Allergy Research and Education (FARE) and Novartis, has received research support from the National Institute of Allergy and Infectious Diseases and FARE, and has received royalties from UpToDate. D. Y. M. Leung is an advisory board member for Celgene, Novartis, and Regeneron and has received consultancy fees from Biomarin and Alopexx.	Ahn K, 2014, J ALLERGY CLIN IMMUN, V134, P993, DOI 10.1016/j.jaci.2014.09.023; Alexander ES, 2014, J ALLERGY CLIN IMMUN, V134, P1084, DOI 10.1016/j.jaci.2014.07.021; Allen KJ, 2014, J ALLERGY CLIN IMMUN, V133, P156, DOI 10.1016/j.jaci.2013.06.042; Alvarez-Twose I, 2014, J ALLERGY CLIN IMMUN, V133, P520, DOI 10.1016/j.jaci.2013.06.020; Annunziato RA, 2014, J ALLER CL IMM-PRACT, V2, P639, DOI 10.1016/j.jaip.2014.05.001; Arshad SH, 2014, J ALLERGY CLIN IMMUN, V134, P1462, DOI 10.1016/j.jaci.2014.09.026; Baar A, 2014, J ALLERGY CLIN IMMUN, V133, P585, DOI 10.1016/j.jaci.2013.10.044; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Banerji A, 2014, J ALLER CL IMM-PRACT, V2, P428, DOI 10.1016/j.jaip.2014.04.010; Banerji A, 2014, J ALLER CL IMM-PRACT, V2, P46, DOI 10.1016/j.jaip.2013.08.012; Beppu LY, 2014, J ALLERGY CLIN IMMUN, V134, P1100, DOI 10.1016/j.jaci.2014.04.004; Bernstein JA, 2014, J ALLERGY CLIN IMMUN, V133, P1270, DOI 10.1016/j.jaci.2014.02.036; Bertelsen RJ, 2014, J ALLERGY CLIN IMMUN, V133, P165, DOI 10.1016/j.jaci.2013.07.032; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Blumchen K, 2014, J ALLERGY CLIN IMMUN, V134, P390, DOI 10.1016/j.jaci.2014.03.035; Blumenthal KG, 2014, J ALLER CL IMM-PRACT, V2, P407, DOI 10.1016/j.jaip.2014.02.003; Boguniewicz M, 2013, J ALLERGY CLIN IMMUN, V132, P511, DOI 10.1016/j.jaci.2013.06.030; Borzutzky A, 2014, J ALLERGY CLIN IMMUN, V134, P981, DOI 10.1016/j.jaci.2014.05.032; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P1329, DOI 10.1016/j.jaci.2014.06.032; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Bunyavanich S, 2014, J ALLERGY CLIN IMMUN, V134, P753, DOI 10.1016/j.jaci.2014.05.050; Bunyavanich S, 2014, J ALLERGY CLIN IMMUN, V133, P1373, DOI 10.1016/j.jaci.2013.11.040; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Caldwell JM, 2014, J ALLERGY CLIN IMMUN, V134, P1114, DOI 10.1016/j.jaci.2014.07.026; Camargo CA, 2014, J ALLERGY CLIN IMMUN, V134, P831, DOI 10.1016/j.jaci.2014.08.002; Cardet JC, 2014, J ALLER CL IMM-PRACT, V2, P208, DOI 10.1016/j.jaip.2013.12.003; Caubet JC, 2014, J ALLERGY CLIN IMMUN, V134, P382, DOI 10.1016/j.jaci.2014.04.008; Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; Cheng HM, 2014, J ALLERGY CLIN IMMUN, V133, P1048, DOI 10.1016/j.jaci.2013.10.055; Cifuentes L, 2014, J ALLERGY CLIN IMMUN, V133, P909, DOI 10.1016/j.jaci.2013.09.047; Clark S, 2014, J ALLERGY CLIN IMMUN, V134, P1125, DOI 10.1016/j.jaci.2014.05.018; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Colson D, 2014, J ALLER CL IMM-PRACT, V2, P587, DOI 10.1016/j.jaip.2014.05.012; Commins SP, 2014, J ALLERGY CLIN IMMUN, V134, P108, DOI 10.1016/j.jaci.2014.01.024; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Fischer J, 2014, J ALLERGY CLIN IMMUN, V134, P755, DOI 10.1016/j.jaci.2014.05.051; Flohr C, 2013, J ALLERGY CLIN IMMUN, V132, P774, DOI 10.1016/j.jaci.2013.03.016; Fox SJ, 2014, J ALLER CL IMM-PRACT, V2, P439, DOI 10.1016/j.jaip.2014.04.013; Fujisawa D, 2014, J ALLERGY CLIN IMMUN, V134, P622, DOI 10.1016/j.jaci.2014.05.004; Fung IN, 2014, J ALLER CL IMM-PRACT, V2, P114, DOI 10.1016/j.jaip.2013.09.011; Fyhrquist N, 2014, J ALLERGY CLIN IMMUN, V134, P1301, DOI 10.1016/j.jaci.2014.07.059; Ghosh D, 2014, J ALLERGY CLIN IMMUN, V134, P969, DOI 10.1016/j.jaci.2014.05.016; Gill RK, 2014, J ALLERGY CLIN IMMUN, V133, P576, DOI 10.1016/j.jaci.2013.10.042; Greenberger PA, 2014, J ALLER CL IMM-PRACT, V2, P243, DOI 10.1016/j.jaip.2014.02.012; Grimshaw KEC, 2014, J ALLERGY CLIN IMMUN, V133, P511, DOI 10.1016/j.jaci.2013.05.035; Gueant JL, 2015, J ALLERGY CLIN IMMUN, V135, P253, DOI 10.1016/j.jaci.2014.07.047; Gupta RS, 2014, J ALLER CL IMM-PRACT, V2, P300, DOI 10.1016/j.jaip.2013.12.006; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hong DI, 2014, J ALLER CL IMM-PRACT, V2, P13, DOI 10.1016/j.jaip.2013.11.007; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Iammatteo M, 2014, J ALLER CL IMM-PRACT, V2, P768, DOI 10.1016/j.jaip.2014.08.001; Ichihara A, 2014, J ALLERGY CLIN IMMUN, V133, P1065, DOI 10.1016/j.jaci.2013.09.019; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Johns CB, 2014, J ALLERGY CLIN IMMUN, V133, P582, DOI 10.1016/j.jaci.2013.12.006; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Kaesler S, 2014, J ALLERGY CLIN IMMUN, V134, P92, DOI 10.1016/j.jaci.2014.02.017; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Kelso JM, 2014, J ALLERGY CLIN IMMUN, V133, P1509, DOI 10.1016/j.jaci.2014.03.011; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kohler J, 2014, J ALLERGY CLIN IMMUN, V133, P1383, DOI 10.1016/j.jaci.2013.10.060; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Le TM, 2014, J ALLER CL IMM-PRACT, V2, P480, DOI 10.1016/j.jaip.2014.02.019; Lee SG, 2014, J ALLER CL IMM-PRACT, V2, P281, DOI 10.1016/j.jaip.2014.01.012; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Levy Y, 2014, J ALLER CL IMM-PRACT, V2, P471, DOI 10.1016/j.jaip.2014.03.002; Ma L, 2014, J ALLERGY CLIN IMMUN, V133, P1075, DOI 10.1016/j.jaci.2013.10.029; Macy E, 2014, J ALLERGY CLIN IMMUN, V133, P790, DOI 10.1016/j.jaci.2013.09.021; Maggadottir SM, 2014, J ALLERGY CLIN IMMUN, V133, P1487, DOI 10.1016/j.jaci.2014.02.004; Manivannan V, 2014, J ALLER CL IMM-PRACT, V2, P294, DOI 10.1016/j.jaip.2013.11.009; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Moghaddam AE, 2014, J ALLERGY CLIN IMMUN, V134, P1453, DOI 10.1016/j.jaci.2014.07.032; Molina-Infante J, 2014, J ALLERGY CLIN IMMUN, V134, P1093, DOI 10.1016/j.jaci.2014.07.023; Mozzicato SM, 2014, J ALLER CL IMM-PRACT, V2, P637, DOI 10.1016/j.jaip.2014.04.016; Muehleisen B, 2013, J ALLERGY CLIN IMMUN, V131, P324, DOI 10.1016/j.jaci.2012.12.1562; Muraro A, 2014, J ALLERGY CLIN IMMUN, V134, P749, DOI 10.1016/j.jaci.2014.05.043; Nachshon L, 2014, J ALLERGY CLIN IMMUN, V134, P1108, DOI 10.1016/j.jaci.2014.06.026; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Nwaru BI, 2014, J ALLERGY CLIN IMMUN, V133, P1084, DOI 10.1016/j.jaci.2013.12.1069; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027; Oyoshi MK, 2014, J ALLERGY CLIN IMMUN, V133, P309, DOI 10.1016/j.jaci.2013.12.1045; Pavlos R, 2014, J ALLER CL IMM-PRACT, V2, P21, DOI 10.1016/j.jaip.2013.11.005; Pellerin L, 2014, J ALLERGY CLIN IMMUN, V134, P1459, DOI 10.1016/j.jaci.2014.07.056; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Pravettoni V, 2014, J ALLERGY CLIN IMMUN, V133, P1218, DOI 10.1016/j.jaci.2013.10.033; Pyle RC, 2014, J ALLER CL IMM-PRACT, V2, P52, DOI 10.1016/j.jaip.2013.11.002; Radano MC, 2014, J ALLER CL IMM-PRACT, V2, P475, DOI 10.1016/j.jaip.2014.02.018; Rebane A, 2014, J ALLERGY CLIN IMMUN, V134, P836, DOI 10.1016/j.jaci.2014.05.022; Robbins KA, 2014, J ALLERGY CLIN IMMUN, V134, P1463, DOI 10.1016/j.jaci.2014.08.053; Robbins KA, 2014, J ALLERGY CLIN IMMUN, V134, P1466, DOI 10.1016/j.jaci.2014.08.037; Roduit C, 2014, J ALLERGY CLIN IMMUN, V133, P1056, DOI 10.1016/j.jaci.2013.12.1044; Roekevisch E, 2014, J ALLERGY CLIN IMMUN, V133, P429, DOI 10.1016/j.jaci.2013.07.049; Romano A, 2014, J ALLER CL IMM-PRACT, V2, P3, DOI 10.1016/j.jaip.2013.11.006; Rozenblit M, 2014, J ALLERGY CLIN IMMUN, V134, P955, DOI 10.1016/j.jaci.2014.05.024; Rudders SA, 2014, J ALLERGY CLIN IMMUN, V134, P960, DOI 10.1016/j.jaci.2014.06.018; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Samuelov L, 2014, J ALLERGY CLIN IMMUN, V134, P808, DOI 10.1016/j.jaci.2014.07.061; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Schmitt J, 2014, J ALLERGY CLIN IMMUN, V134, P800, DOI 10.1016/j.jaci.2014.07.043; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Shah SS, 2014, J ALLER CL IMM-PRACT, V2, P288, DOI 10.1016/j.jaip.2013.09.016; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P324, DOI 10.1016/j.jaci.2013.11.013; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P492, DOI 10.1016/j.jaci.2013.12.1041; Silverberg JI, 2014, J ALLERGY CLIN IMMUN, V133, P1041, DOI 10.1016/j.jaci.2013.08.012; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Sirvent S, 2014, J ALLERGY CLIN IMMUN, V133, P1765, DOI 10.1016/j.jaci.2014.01.035; Slifka MK, 2014, J ALLERGY CLIN IMMUN, V133, P439, DOI 10.1016/j.jaci.2013.10.037; Song Y, 2014, J ALLERGY CLIN IMMUN, V134, P1339, DOI 10.1016/j.jaci.2014.08.034; Sturm GJ, 2014, J ALLERGY CLIN IMMUN, V133, P1635, DOI 10.1016/j.jaci.2013.10.046; Sturm JM, 2014, J ALLER CL IMM-PRACT, V2, P461, DOI 10.1016/j.jaip.2014.02.004; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tan JA, 2014, J ALLER CL IMM-PRACT, V2, P355, DOI 10.1016/j.jaip.2014.02.002; Tang TS, 2014, J ALLERGY CLIN IMMUN, V133, P1615, DOI 10.1016/j.jaci.2013.12.1079; Teraki Y, 2013, J ALLERGY CLIN IMMUN, V132, P971, DOI 10.1016/j.jaci.2013.07.029; Tey D, 2014, J ALLERGY CLIN IMMUN, V133, P476, DOI 10.1016/j.jaci.2013.11.019; Thawer-Esmail F, 2014, J ALLERGY CLIN IMMUN, V133, P280, DOI 10.1016/j.jaci.2013.09.053; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Tripathi A, 2014, J ALLER CL IMM-PRACT, V2, P259, DOI 10.1016/j.jaip.2014.02.017; Turner PJ, 2014, J ALLERGY CLIN IMMUN, V134, P751, DOI 10.1016/j.jaci.2014.06.016; Uysal P, 2014, J ALLERGY CLIN IMMUN, V133, P914, DOI 10.1016/j.jaci.2013.10.015; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Voskamp AL, 2014, J ALLER CL IMM-PRACT, V2, P629, DOI 10.1016/j.jaip.2014.04.012; Wasserman RL, 2014, J ALLER CL IMM-PRACT, V2, P91, DOI 10.1016/j.jaip.2013.10.001; Weiler T, 2014, J ALLER CL IMM-PRACT, V2, P320, DOI 10.1016/j.jaip.2014.01.011; Weller K, 2014, J ALLERGY CLIN IMMUN, V133, P1365, DOI 10.1016/j.jaci.2013.12.1076; Wong JT, 2014, J ALLER CL IMM-PRACT, V2, P40, DOI 10.1016/j.jaip.2013.08.011; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P461, DOI 10.1016/j.jaci.2013.08.016; Yoshida K, 2014, J ALLERGY CLIN IMMUN, V134, P856, DOI 10.1016/j.jaci.2014.08.001; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133, P1744, DOI 10.1016/j.jaci.2013.12.004	134	32	36	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					357	367		10.1016/j.jaci.2014.12.1906	http://dx.doi.org/10.1016/j.jaci.2014.12.1906			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25662305				2022-12-18	WOS:000349372300007
J	Wu, JF; Liu, DW; Tu, WW; Song, WX; Zhao, XD				Wu, Junfeng; Liu, Dawei; Tu, Wenwei; Song, Wenxia; Zhao, Xiaodong			T-cell receptor diversity is selectively skewed in T-cell populations of patients with Wiskott-Aldrich syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wiskott-Aldrich syndrome; T-cell receptor repertoire diversity; high-throughput sequencing	SYNDROME PROTEIN; WASP; LYMPHOCYTES; THROMBOCYTOPENIA; IMMUNOGLOBULIN; REPERTOIRE; MUTATIONS; APOPTOSIS; CD4(+); ALPHA	Background: Wiskott-Aldrich syndrome (WAS) is a severe disorder characterized by thrombocytopenia, eczema, immunodeficiency, and increased risk of autoimmune disease and lymphoid malignancies. The immunodeficiency caused by a lack of WAS protein expression has been mainly attributed to defective T-cell functions. Whether WAS mutations differentially influence the T-cell receptor (TCR) diversity of different T-cell subsets is unknown. Objective: We aimed to identify the degree and pattern of skewing in the variable region of the TCR b-chain (Vb) in different T-cell subsets from patients with WAS. Methods: The TCR repertoire diversity in total peripheral T cells, sorted CD4 1 and CD8 1 T cells, and CD45RA 1 (CD45RA 1 CD45RO 2 cells) and CD45RO 1 (CD45RA 2 CD45RO 1 cells) CD4 1 and CD8 1 T cells from patients with WAS and age-matched healthy control subjects was analyzed and compared by using spectratyping of complementarity-determining region 3. The complementaritydetermining region 3 of TCRb transcripts in CD45RA 1 CD4 1 and CD45RA 1 CD8 1 T cells, CD45RO 1 CD4 1 T cells, CD8 1 terminally differentiated effector memory T (Temra) cells, and naive CD8 1 T cells (CD8 1 CD45RO 2 CCR7 1 cells) from patients and control subjects were analyzed and compared by using high-throughput sequencing. Results: The TCR repertoire diversity in CD45RO 1 CD4 1 T cells and CD8 1 Temra cells of patients with WAS was significantly skewed in comparison with that seen in agematched control subjects. Conclusion: Our results indicate that WAS gene mutations selectively influence TCR repertoire development or expansion in CD45RO 1 (memory) CD4 1 T cells.	[Wu, Junfeng; Liu, Dawei; Song, Wenxia; Zhao, Xiaodong] Chongqing Med Univ, Childrens Hosp, Key Lab Child Dev & Disorders, Minist Educ, Chongqing 400014, Peoples R China; [Tu, Wenwei] Univ Hong Kong, LKS Fac Med, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China; [Song, Wenxia] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA	Chongqing Medical University; University of Hong Kong; University System of Maryland; University of Maryland College Park	Zhao, XD (corresponding author), Chongqing Med Univ, Childrens Hosp, Div Immunol, Chongqing 400014, Peoples R China.	zhaoxd530@aliyun.com			National Natural Science Foundation of China [81172878]; Public Welfare Scientific Research Project of China [201402012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Public Welfare Scientific Research Project of China	Supported by the National Natural Science Foundation of China (81172878) and the Public Welfare Scientific Research Project of China (201402012).	Advisory Committee on Immunization Practices, 2006, MMWR Recomm Rep, V55, P1; Albert MH, 2010, BLOOD, V115, P3231, DOI 10.1182/blood-2009-09-239087; Aspinall R, 2003, NAT IMMUNOL, V4, P203, DOI 10.1038/ni0303-203; Badour K, 2007, P NATL ACAD SCI USA, V104, P1593, DOI 10.1073/pnas.0610543104; Batliwalla F, 1996, HUM IMMUNOL, V48, P68, DOI 10.1016/0198-8859(96)00077-8; Bomberger C, 1998, BLOOD, V91, P2588, DOI 10.1182/blood.V91.7.2588.2588_2588_2600; Bosticardo M, 2009, BLOOD, V113, P6288, DOI 10.1182/blood-2008-12-115253; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Bristeau-Leprince A, 2008, J IMMUNOL, V181, P440, DOI 10.4049/jimmunol.181.1.440; Calvez R, 2011, HAEMATOL-HEMATOL J, V96, P1415, DOI 10.3324/haematol.2011.040204; Currier JR, 1996, HUM IMMUNOL, V48, P39, DOI 10.1016/0198-8859(96)00076-6; De Meester J, 2011, ROLE WISKOTT ALDRICH; Gallego MD, 2006, INT IMMUNOL, V18, P221, DOI 10.1093/intimm/dxh310; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; Han J, 2012, Patent No. [US20120183969, 20120183969]; Imai K, 2004, BLOOD, V103, P456, DOI 10.1182/blood-2003-05-1480; Johnson PLF, 2012, P NATL ACAD SCI USA, V109, P21432, DOI 10.1073/pnas.1209283110; Jost L, 2007, ECOLOGY, V88, P2427, DOI 10.1890/06-1736.1; Keylock CJ, 2005, OIKOS, V109, P203, DOI 10.1111/j.0030-1299.2005.13735.x; Langerak AW, 2001, BLOOD, V98, P165, DOI 10.1182/blood.V98.1.165; Magurran A.E., 2004, MEASURING BIOL DIVER; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; Monod MY, 2004, BIOINFORMATICS, V20, P379, DOI 10.1093/bioinformatics/bth945; Morales-Tirado V, 2010, BLOOD, V115, P3498, DOI 10.1182/blood-2009-07-235754; Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Ochs HD, 2002, ISR MED ASSOC J, V4, P379; Okajima M, 2009, CLIN EXP IMMUNOL, V155, P166, DOI 10.1111/j.1365-2249.2008.03842.x; Park JY, 2004, CLIN EXP IMMUNOL, V136, P104, DOI 10.1111/j.1365-2249.2004.02409.x; Puck JM, 2006, NEW ENGL J MED, V355, P1759, DOI 10.1056/NEJMp068209; Rawlings SL, 1999, BLOOD, V94, P3872, DOI 10.1182/blood.V94.11.3872.423k37_3872_3882; Rengan R, 2000, BLOOD, V95, P1283, DOI 10.1182/blood.V95.4.1283.004k44_1283_1292; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Schurman SH, 2003, CURR OPIN RHEUMATOL, V15, P446, DOI 10.1097/00002281-200307000-00012; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; Stewart JJ, 1997, MOL IMMUNOL, V34, P1067, DOI 10.1016/S0161-5890(97)00130-2; Trifari S, 2006, J IMMUNOL, V177, P7451, DOI 10.4049/jimmunol.177.10.7451; Venturi V, 2007, J IMMUNOL METHODS, V321, P182, DOI 10.1016/j.jim.2007.01.019; Wada T, 2005, BLOOD, V106, P3895, DOI 10.1182/blood-2005-06-2336; Wada T, 2001, P NATL ACAD SCI USA, V98, P8697, DOI 10.1073/pnas.151260498; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329; ZHU QL, 1995, BLOOD, V86, P3797, DOI 10.1182/blood.V86.10.3797.bloodjournal86103797	44	32	39	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					209	U316		10.1016/j.jaci.2014.06.025	http://dx.doi.org/10.1016/j.jaci.2014.06.025			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25091438	Bronze			2022-12-18	WOS:000347298200025
J	Sabato, V; Van de Vijver, E; Hagendorens, M; Vrelust, I; Reyniers, E; Fransen, E; Bridts, C; De Clerck, L; Mortier, G; Valent, P; Ebo, D				Sabato, Vito; Van de Vijver, Els; Hagendorens, Margo; Vrelust, Inge; Reyniers, Edwin; Fransen, Erik; Bridts, Chris; De Clerck, Luc; Mortier, Geert; Valent, Peter; Ebo, Didier			Familial hypertryptasemia with associated mast cell activation syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INDUCED SPUTUM; INFLAMMATION; DISEASE		[Sabato, Vito; Hagendorens, Margo; Bridts, Chris; De Clerck, Luc; Ebo, Didier] Univ Antwerp, Dept Immunol Allergol & Rheumatol, B-2020 Antwerp, Belgium; [Sabato, Vito; Hagendorens, Margo; Bridts, Chris; De Clerck, Luc; Ebo, Didier] Univ Antwerp Hosp, Antwerp, Belgium; [Van de Vijver, Els; Hagendorens, Margo] Univ Antwerp Hosp, Dept Paediat, Antwerp, Belgium; [Vrelust, Inge] Univ Antwerp Hosp, Dept Hematol, Antwerp, Belgium; [Mortier, Geert] Univ Antwerp Hosp, Ctr Med Genet, Antwerp, Belgium; [Reyniers, Edwin; Fransen, Erik; Mortier, Geert] Univ Antwerp, Ctr Med Genet, B-2020 Antwerp, Belgium; [Reyniers, Edwin; Fransen, Erik; Mortier, Geert] Univ Antwerp, StatUa Ctr Stat, B-2020 Antwerp, Belgium; [Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria; [Valent, Peter] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, Vienna, Austria	University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp; Medical University of Vienna; Ludwig Boltzmann Institute; Medical University of Vienna	Sabato, V (corresponding author), Univ Antwerp, Dept Immunol Allergol & Rheumatol, B-2020 Antwerp, Belgium.	immuno@uantwerpen.be	Test, PV/U-9451-2019; Gamperl, Susi/V-2715-2019; BRIDTS, Chris HM/M-7933-2016; EBO, Didier/H-4894-2016; Valent, Peter/B-8533-2016; van de vijver, els/ABB-5840-2020; Test, Test/Y-7921-2019; Mortier, Geert/D-2542-2012; Sabato, Vito/B-6479-2017	Gamperl, Susi/0000-0003-0456-5095; BRIDTS, Chris HM/0000-0002-3324-7320; EBO, Didier/0000-0003-0672-7529; Valent, Peter/0000-0003-0456-5095; Mortier, Geert/0000-0001-9871-4578; Sabato, Vito/0000-0002-1321-314X; Hagendorens, Margo/0000-0001-6361-9503				Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Carlsten C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057166; CHANYEUNG M, 1982, J ALLERGY CLIN IMMUN, V70, P32, DOI 10.1016/0091-6749(82)90198-1; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Haenisch B, 2012, IMMUNOLOGY, V137, P197, DOI 10.1111/j.1365-2567.2012.03627.x; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; Lyons JJ, 2014, J ALLERGY CLIN IMMUN, V133, P1471, DOI 10.1016/j.jaci.2013.11.039; Molderings GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076241; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Valent P, 2013, ALLERGY, V68, P417, DOI 10.1111/all.12126; Valent P, 2001, WHO CLASSIFICATION T, P291; Valent P, 2013, AM J CANCER RES, V3, P159; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760	17	32	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1448	+		10.1016/j.jaci.2014.06.007	http://dx.doi.org/10.1016/j.jaci.2014.06.007			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25086867				2022-12-18	WOS:000346075400030
J	Carlsen, KCL; Mowinckel, P; Hovland, V; Haland, G; Riiser, A; Carlsen, KH				Carlsen, Karin C. Lodrup; Mowinckel, Petter; Hovland, Vegard; Haland, Geir; Riiser, Amund; Carlsen, Kai-Hakon			Lung function trajectories from birth through puberty reflect asthma phenotypes with allergic comorbidity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lung function trajectory; asthma; allergic disease; child; birth cohort	1ST 6 YEARS; AIRWAY RESPONSIVENESS; RESPIRATORY-FUNCTION; PULMONARY-FUNCTION; CHILDHOOD ASTHMA; MATERNAL SMOKING; FLOW LIMITATION; LIFE; POPULATION; CHILDREN	Background: Childhood asthma phenotypes reflecting underlying developmental mechanisms are sought, with little information on asthma phenotypes based on allergic comorbidities. Objective: We asked whether lung function trajectories from birth to 16 years were associated with asthma phenotypes with comorbid allergic rhinitis and atopic dermatitis. Methods: Lung function (given as z scores) was measured at birth in 329 subjects in the "Environment and Childhood Asthma'' birth cohort study in Oslo by using tidal flow volume loops, and at 10 and 16 years by using spirometry. Asthma phenotypes were classified on the basis of recurrent bronchial obstruction at 0 to 2 years, and asthma from the 2- to 10-year and 10- to 16-year intervals, and by combining asthma, atopic dermatitis, and/or allergic rhinitis from 10 to 16 years, stratifying for allergic sensitization. The reference group included 231 subjects without recurrent bronchial obstruction or asthma. Results: Lung function trajectories differed significantly for asthma comorbidity phenotypes for FEV1, forced expiratory flow at 25% to 75% of forced vital capacity, and FEV1/forced vital capacity (all P < .0001). Significant lung function impairment was observed from birth through 16 years among subjects with asthma, atopic dermatitis, and allergic rhinitis. Lung function trajectories in subjects with asthma at 10 to 16 years or asthma in remission differed significantly for all 3 spirometric values compared with the trajectories in those who never had asthma (P < .0001), but not between asthma groups. Allergic sensitization was not significantly associated with asthma phenotype lung function trajectories. Conclusions: The trajectory consisting of impaired lung function from birth throughout childhood in children with asthma, atopic dermatitis, and allergic rhinitis appears less likely to be driven by allergic sensitization, and may imply disease onset in utero, with clinical presentation later in childhood.	[Carlsen, Karin C. Lodrup; Mowinckel, Petter; Hovland, Vegard; Haland, Geir; Riiser, Amund; Carlsen, Kai-Hakon] Oslo Univ Hosp, Dept Paediat, NO-0407 Oslo, Norway; [Carlsen, Karin C. Lodrup; Mowinckel, Petter; Hovland, Vegard; Haland, Geir; Riiser, Amund; Carlsen, Kai-Hakon] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway	University of Oslo; University of Oslo	Carlsen, KCL (corresponding author), Oslo Univ Hosp, Dept Paediat, NO-0407 Oslo, Norway.	k.c.l.carlsen@medisin.uio.no		Riiser, Amund/0000-0003-1921-6912	European Union under the Health Cooperation Work Programme of the 7th Framework programme [261357]; Norwegian Research Council; Regional Health Board South East, Health and Rehabilitation; European Union (Global Asthma and Allergy European Network) [FOOD-CT-2004-506378]; European Union (Mechanisms of the Development of ALLergy projects) [261357]; Norwegian Association of Asthma and Allergy; Kloster Foundation; AstraZeneca	European Union under the Health Cooperation Work Programme of the 7th Framework programme; Norwegian Research Council(Research Council of NorwayEuropean Commission); Regional Health Board South East, Health and Rehabilitation; European Union (Global Asthma and Allergy European Network); European Union (Mechanisms of the Development of ALLergy projects); Norwegian Association of Asthma and Allergy; Kloster Foundation; AstraZeneca(AstraZeneca)	This study was performed within the Oslo Research Group of Asthma and Allergy in Childhood; the Lung and Environment (ORAACLE), a member of the Global Asthma and Allergy European Network (GA<SUP>2</SUP>LEN) and Mechanisms of the Development of ALLergy (MeDALL), a collaborative project conducted within the European Union under the Health Cooperation Work Programme of the 7th Framework programme (grant agreement no. 261357). The Environment and Childhood Asthma study has been funded through the 16 years by the following public funding bodies: The Norwegian Research Council, The Regional Health Board South East, Health and Rehabilitation, the European Union (Global Asthma and Allergy European Network and Mechanisms of the Development of ALLergy projects; MeDALL: grant no. 261357, GA<SUP>2</SUP>LEN: FOOD-CT-2004-506378), by unrestricted grants from the Norwegian Association of Asthma and Allergy, Rimi as well as by financing PhD students by the Kloster Foundation and AstraZeneca, and by providing IgE analyses by Thermo-Fisher, Uppsala, Sweden, in collaboration with Furst Medical Laboratory, Oslo, Norway.	Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Carlsen KCL, 2010, CLIN EXP ALLERGY, V40, P1767, DOI 10.1111/j.1365-2222.2010.03620.x; Carlsen KCL, 2010, PEDIAT ALLERG IMM-UK, V21, P814, DOI 10.1111/j.1399-3038.2009.00973.x; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774, DOI 10.1183/09031936.97.10081774; CARLSEN KCL, 1994, EUR RESPIR J, V7, P1660, DOI 10.1183/09031936.94.07091660; Guerra S, 2008, RESP MED, V102, P1473, DOI 10.1016/j.rmed.2008.04.011; Haland G, 2007, PEDIAT ALLERG IMM-UK, V18, P528, DOI 10.1111/j.1399-3038.2007.00555.x; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129, DOI 10.1164/ajrccm/145.5.1129; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Hoo AF, 1998, AM J RESP CRIT CARE, V158, P700, DOI 10.1164/ajrccm.158.3.9711057; Hovland V, 2014, PEDIAT ALLERG IMM-UK, V25, P351, DOI 10.1111/pai.12241; Hovland V, 2013, EUR RESPIR J, V41, P838, DOI 10.1183/09031936.00071512; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; Martinez Fernando D, 2009, Proc Am Thorac Soc, V6, P272, DOI 10.1513/pats.200808-092RM; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Mullane D, 2013, JAMA PEDIATR, V167, P368, DOI 10.1001/jamapediatrics.2013.633; Pinart M, 2014, LANCET RESP MED, V2, P131, DOI 10.1016/S2213-2600(13)70277-7; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Stanojevic S, 2009, AM J RESP CRIT CARE, V180, P547, DOI 10.1164/rccm.200903-0323OC; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Stick S, 2000, THORAX, V55, P587, DOI 10.1136/thorax.55.7.587; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; Turner S, 2008, THORAX, V63, P234, DOI 10.1136/thx.2006.064642; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Turner SW, 2002, AM J RESP CRIT CARE, V165, P1294, DOI 10.1164/rccm.200110-018OC; YOUNG S, 1995, ARCH DIS CHILD, V72, P16, DOI 10.1136/adc.72.1.16; Yuksel B, 1996, THORAX, V51, P815, DOI 10.1136/thx.51.8.815; Ziyab AH, 2010, CLIN EXP ALLERGY, V40, P1776, DOI 10.1111/j.1365-2222.2010.03633.x	38	32	32	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					917	U537		10.1016/j.jaci.2014.05.020	http://dx.doi.org/10.1016/j.jaci.2014.05.020			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	24997636				2022-12-18	WOS:000343155700020
J	von Moos, S; Johansen, P; Tay, F; Graf, N; Kundig, TM; Senti, G				von Moos, Seraina; Johansen, Pal; Tay, Fabian; Graf, Nicole; Kuendig, Thomas M.; Senti, Gabriela			Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STRATUM-CORNEUM; DENDRITIC CELLS; IMMUNIZATION; PRETREATMENT; DISRUPTION; PATCH		[von Moos, Seraina; Senti, Gabriela] Univ Zurich, Univ Zurich Hosp, Dept Internal Med, Zurich, Switzerland; [Johansen, Pal; Kuendig, Thomas M.] Univ Zurich, Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland; [Tay, Fabian] Univ Zurich, Univ Zurich Hosp, Clin Trials Ctr, Zurich, Switzerland; [Graf, Nicole] Graf Biostat, Winterthur, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	von Moos, S (corresponding author), Univ Zurich, Univ Zurich Hosp, Dept Internal Med, Zurich, Switzerland.	gabriela.senti@usz.ch	Senti, Gabriela/Y-1019-2019; Johansen, Pål/A-1403-2013	Senti, Gabriela/0000-0002-9066-8383; Johansen, Pål/0000-0002-5055-6299				Chen XY, 2012, J CONTROL RELEASE, V159, P43, DOI 10.1016/j.jconrel.2012.01.002; De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Frerichs DM, 2008, VACCINE, V26, P2782, DOI 10.1016/j.vaccine.2008.02.070; Glenn GM, 2007, INFECT IMMUN, V75, P2163, DOI 10.1128/IAI.01740-06; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P128, DOI 10.1016/j.jaci.2011.08.036; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019	9	32	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					965	967		10.1016/j.jaci.2014.07.037	http://dx.doi.org/10.1016/j.jaci.2014.07.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25282570	Green Accepted, hybrid			2022-12-18	WOS:000343155700029
J	Iwasaki, J; Smith, WA; Khoo, SK; Bizzintino, J; Zhang, GC; Cox, DW; Laing, IA; Le Souef, PN; Thomas, WR; Hales, BJ				Iwasaki, Jua; Smith, Wendy-Anne; Khoo, Siew-Kim; Bizzintino, Joelene; Zhang, Guicheng; Cox, Des W.; Laing, Ingrid A.; Le Souef, Peter N.; Thomas, Wayne R.; Hales, Belinda J.			Comparison of rhinovirus antibody titers in children with asthma exacerbations and species-specific rhinovirus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human rhinovirus; VP1; IgG(1) antibody; asthma exacerbation; children	VIRAL-INFECTIONS; YOUNG-CHILDREN; T-CELLS; RESPONSES; VIRUSES; IMMUNOPATHOLOGY; ASSOCIATION; CHILDHOOD; RELEVANCE; COMMUNITY	Background: Asthma exacerbations are associated with human rhinovirus (HRV) infections, and more severe exacerbations are associated with HRV-C. We have previously shown that the HRV-C-specific antibody response is low in healthy adult sera and that most of the antibody to HRV-C is cross-reactive with HRV-A. Objectives: To compare the antibody response to each HRV species in asthmatic and nonasthmatic children in whom the type of HRV infection was known. Methods: Total and specific IgG(1) binding to HRV viral capsid protein antigens of HRV-A, -B, and -C were tested in the plasma from nonasthmatic children (n=47) and children presenting to the emergency department with asthma exacerbations (n=96). HRV, found in most of the children at the time of their exacerbation (72%), was analyzed using molecular typing. Results: Asthmatic children had higher antibody responses to HRV. The titers specific to HRV-A, and to a lesser extent HRV-B, were higher than in nonasthmatic controls. The species-specific responses to HRV-C were markedly lower than titers to HRV-A and HRV-B in both asthmatic and nonasthmatic children (P<.001). The titers both at presentation and after convalescence were not associated with the HRV genotype detected during the exacerbation. Conclusions: The higher total anti-HRV antibody titers of asthmatic children and their higher anti-HRV-A and -B titers show their development of a heightened antiviral immune response. The low species-specific HRV-C titers found in all groups, even when the virus was found, point to a different and possibly less efficacious immune response to this species.	[Iwasaki, Jua; Smith, Wendy-Anne; Thomas, Wayne R.; Hales, Belinda J.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Khoo, Siew-Kim; Bizzintino, Joelene; Zhang, Guicheng; Cox, Des W.; Laing, Ingrid A.; Le Souef, Peter N.; Hales, Belinda J.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Zhang, Guicheng] Curtin Univ, Sch Publ Hlth, Perth, WA 6845, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; Curtin University	Hales, BJ (corresponding author), Univ Western Australia, Telethon Inst Child Hlth Res, 100 Roberts Rd, Subiaco, WA 6008, Australia.	belinda@ichr.uwa.edu.au	Bizzintino, Joelene/C-8665-2016; Cox, Des/AAC-5933-2021; Le Souef, Peter N/H-5256-2014; Laing, Ingrid/I-7092-2013; Zhang, Brad/AAF-8719-2021; Khoo, Siew-Kim/D-7655-2016; Bizzintino, Joelene A/H-8840-2014; Cox, Des W/Z-2054-2018	Cox, Des/0000-0002-2127-7178; Laing, Ingrid/0000-0002-1641-9899; Cox, Des W/0000-0002-2127-7178; Iwasaki, Jua/0000-0002-5833-7146; Zhang, Guicheng/0000-0001-9888-5385; Le Souef, Peter/0000-0003-0930-1654	National Health and Medical Research Council of Australia; Australian Postgraduate Award; University of Western Australia Scholarship; Stan and Jean Perron Scholarship; Asthma Foundation of Western Australia Scholarship	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); University of Western Australia Scholarship; Stan and Jean Perron Scholarship; Asthma Foundation of Western Australia Scholarship	This work was supported by the National Health and Medical Research Council of Australia. J.I. was supported by an Australian Postgraduate Award, a University of Western Australia Scholarship, a Stan and Jean Perron Scholarship, and an Asthma Foundation of Western Australia Scholarship.	Aarntzen EHJG, 2012, CANCER IMMUNOL IMMUN, V61, P2003, DOI 10.1007/s00262-012-1263-z; Avery DT, 2008, J IMMUNOL, V181, P1767, DOI 10.4049/jimmunol.181.3.1767; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Brooks GD, 2003, AM J RESP CRIT CARE, V168, P1091, DOI 10.1164/rccm.200306-737OC; Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828; Cox DW, 2013, AM J RESP CRIT CARE, V188, P1358, DOI 10.1164/rccm.201303-0498OC; Gern JE, 1997, J INFECT DIS, V175, P1108, DOI 10.1086/516449; Hales BJ, 2008, THORAX, V63, P221, DOI 10.1136/thx.2006.069492; Hales BJ, 2009, CLIN EXP ALLERGY, V39, P1170, DOI 10.1111/j.1365-2222.2009.03252.x; Hales BJ, 2012, THORAX, V67, P321, DOI 10.1136/thoraxjnl-2011-200650; Heymann PW, 2012, J ALLERGY CLIN IMMUN, V130, P1315, DOI 10.1016/j.jaci.2012.10.024; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hofmeister Y, 2011, J VIROL, V85, P1896, DOI 10.1128/JVI.02155-10; Honkinen M, 2012, CLIN MICROBIOL INFEC, V18, P300, DOI 10.1111/j.1469-0691.2011.03603.x; Iwasaki J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070552; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lau SKP, 2009, J INFECT DIS, V200, P1096, DOI 10.1086/605697; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Mak RKY, 2011, PEDIATR INFECT DIS J, V30, P749, DOI 10.1097/INF.0b013e31821b8c71; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Nabors GS, 2000, VACCINE, V18, P1743, DOI 10.1016/S0264-410X(99)00530-7; Niespodziana K, 2012, FASEB J, V26, P1001, DOI 10.1096/fj.11-193557; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Parry DE, 2000, J ALLERGY CLIN IMMUN, V105, P692, DOI 10.1067/mai.2000.104785; Pritchard AL, 2012, J IMMUNOL, V188, P5898, DOI 10.4049/jimmunol.1103507; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Weinfurter JT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002381; Wimalasundera SS, 1997, J INFECT DIS, V176, P755, DOI 10.1086/514101; Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352	35	32	34	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					25	+		10.1016/j.jaci.2014.03.014	http://dx.doi.org/10.1016/j.jaci.2014.03.014			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24767874	Bronze, Green Submitted			2022-12-18	WOS:000338930300004
J	Romeo, MJ; Agrawal, R; Pomes, A; Woodfolk, JA				Romeo, Martin J.; Agrawal, Rachana; Pomes, Anna; Woodfolk, Judith A.			A molecular perspective on T(H)2-promoting cytokine receptors in patients with allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; IL-4; IL-13; receptors; cytokines; T(H)2; allergy; asthma treatment	THYMIC STROMAL LYMPHOPOIETIN; B-CELL DEVELOPMENT; INTERLEUKIN-4 RECEPTOR; IL-4 RECEPTOR; DENDRITIC CELLS; GAMMA-CHAIN; IL-4/IL-13 ANTAGONIST; SIGNAL-TRANSDUCTION; HUMAN KERATINOCYTES; ASTHMATIC-PATIENTS	The cytokines IL-4, IL-13, and thymic stromal lymphopoietin play a key role in allergic disease by virtue of their ability to initiate, maintain, and augment T(H)2 responses. These molecules mediate their effects through type 1 cytokine receptors, which bind cytokines with a characteristic structure. Receptors are expressed on a broad array of immune cell types and are integral to complex cytokine networks operating in health and disease. T(H)2-promoting cytokines bind different configurations of receptors. Receptor subunits can exist in surface-bound or soluble forms, as well as in isolation or in partnership with other subunits. Sharing of receptor subunits among different cytokine receptor complexes adds to the intricate landscape. This article describes the characteristics of receptors for IL-4, IL-13, and thymic stromal lymphopoietin and their respective ligands from a structure-function perspective. We detail the mechanisms of receptor complex assembly, the interrelated nature of these receptors, and the effect on allergic inflammation. The ability for novel and atypical types of receptors to modulate inflammatory processes is also discussed. We highlight current and emerging treatments that target T(H)2-promoting receptor complexes. Understanding the molecular features of these receptors provides insight into different disease phenotypes and the variable clinical outcomes arising from targeted therapies. These considerations can be used to inform future directions for research and creative strategies for treating individual patients.	[Romeo, Martin J.; Agrawal, Rachana; Woodfolk, Judith A.] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Pomes, Anna] Indoor Biotechnol Inc, Charlottesville, VA USA	University of Virginia; INDOOR Biotechnologies	Woodfolk, JA (corresponding author), Univ Virginia Hlth Syst, Div Allergy, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu	Pomés, Anna/H-7010-2019	Pomés, Anna/0000-0002-8729-1829; Romeo, Martin/0000-0001-7941-1862	National Institutes of Health/National Institute of Allergy and Infectious Diseases [R01 AI-052196]; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR-059058]; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases; NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases; Danisco/DuPont; American Academy of Allergy, Asthma Immunology; ITN; NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059058] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Danisco/DuPont; American Academy of Allergy, Asthma Immunology; ITN; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (R01 AI-052196) and the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR-059058).; J.A. Woodfolk has been supported by one or more grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases and the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases; is employed by the University of Virginia; has received one or more grants from or has one or more grants pending with Danisco/DuPont; has received one or more payments for lecturing from or is on the speakers' bureau for and has received one or more payments for travel/accommodations/meeting expenses from the American Academy of Allergy, Asthma & Immunology; and has received one or more payments for grant review from ITN and the NIH. The rest of the authors declare that they have no relevant conflicts of interest.	Alms WJ, 1996, MOL IMMUNOL, V33, P361, DOI 10.1016/0161-5890(95)00154-9; Andrews AL, 2006, J ALLERGY CLIN IMMUN, V118, P858, DOI 10.1016/j.jaci.2006.06.041; Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Arima K, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000567; Arinobu Y, 1999, CELL IMMUNOL, V191, P161, DOI 10.1006/cimm.1998.1431; ARMITAGE RJ, 1991, ADV EXP MED BIOL, V292, P121; Bartfai T, 2012, TRENDS PHARMACOL SCI, V33, P9, DOI 10.1016/j.tips.2011.09.006; Bhattacharjee A, 2013, FREE RADICAL BIO MED, V54, P1, DOI 10.1016/j.freeradbiomed.2012.10.553; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Campbell-Harding G, 2013, J ALLERGY CLIN IMMUN, V131, P849, DOI 10.1016/j.jaci.2012.08.030; Carpino N, 2004, MOL CELL BIOL, V24, P2584, DOI 10.1128/MCB.24.6.2584-2592.2004; Chen W, 2013, J ALLERGY CLIN IMMUN; Chen WG, 2008, J ALLERGY CLIN IMMUN, V122, P625, DOI 10.1016/j.jaci.2008.06.022; Chen WG, 2009, J IMMUNOL, V183, P7870, DOI 10.4049/jimmunol.0901028; Cole AR, 1999, J BIOL CHEM, V274, P7207, DOI 10.1074/jbc.274.11.7207; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Dagil R, 2012, STRUCTURE, V20, P270, DOI 10.1016/j.str.2011.12.010; Daines MO, 2007, J ALLERGY CLIN IMMUN, V119, P375, DOI 10.1016/j.jaci.2006.09.039; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; Evsyukova I, 2013, RNA, V19, P103, DOI 10.1261/rna.035410.112; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Getz EB, 2009, J CLIN PHARMACOL, V49, P1025, DOI 10.1177/0091270009341183; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; Harper JI, 2010, BRIT J DERMATOL, V162, P397, DOI 10.1111/j.1365-2133.2009.09467.x; Hart TK, 2002, CLIN EXP IMMUNOL, V130, P93, DOI 10.1046/j.1365-2249.2002.01973.x; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; Heller NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039673; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Hulse KE, 2008, J ALLERGY CLIN IMMUN, V121, P756, DOI 10.1016/j.jaci.2007.10.016; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Ito T, 2009, J BIOL CHEM, V284, P24289, DOI 10.1074/jbc.M109.007286; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Jung T, 1999, EUR J IMMUNOL, V29, P864, DOI 10.1002/(SICI)1521-4141(199903)29:03<864::AID-IMMU864>3.0.CO;2-T; Jung T, 1999, INT ARCH ALLERGY IMM, V119, P23, DOI 10.1159/000024171; Junttila IS, 2008, J EXP MED, V205, P2595, DOI 10.1084/jem.20080452; Junttila IS, 2012, NAT CHEM BIOL, V8, P990, DOI [10.1038/NCHEMBIO.1096, 10.1038/nchembio.1096]; Kakkar T, 2011, PHARM RES-DORDR, V28, P2530, DOI 10.1007/s11095-011-0481-y; Kammer W, 1996, J BIOL CHEM, V271, P23634, DOI 10.1074/jbc.271.39.23634; Kaur D, 2006, ALLERGY, V61, P1047, DOI 10.1111/j.1398-9995.2006.01139.x; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kruse S, 1999, INT IMMUNOL, V11, P1965, DOI 10.1093/intimm/11.12.1965; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Lee HC, 2012, J ALLERGY CLIN IMMUN, V130, P1187, DOI 10.1016/j.jaci.2012.07.031; Lupardus PJ, 2010, STRUCTURE, V18, P332, DOI 10.1016/j.str.2010.01.003; Luzina IG, 2012, CYTOKINE, V58, P20, DOI 10.1016/j.cyto.2011.12.017; Madhankumar AB, 2004, NEOPLASIA, V6, P15, DOI 10.1016/S1476-5586(04)80049-6; Maes T, 2012, AM J RESP CELL MOL, V47, P261, DOI 10.1165/rcmb.2012-0080TR; Malka Y, 2008, J BIOL CHEM, V283, P33569, DOI 10.1074/jbc.M803125200; McElroy CA, 2012, P NATL ACAD SCI USA, V109, P2503, DOI 10.1073/pnas.1116582109; Miazgowicz MM, 2013, J INFLAMM RES, V6, P53, DOI 10.2147/JIR.S42381; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Moynihan BJ, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-84; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; O'Toole M, 2008, CLIN EXP ALLERGY, V38, P594, DOI 10.1111/j.1365-2222.2007.02921.x; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; Pillet AH, 2008, EUR CYTOKINE NETW, V19, P49, DOI 10.1684/ecn.2008.0120; Prikk K, 2002, LAB INVEST, V82, P1535, DOI 10.1097/01.LAB.0000035023.53893.B6; Ray RJ, 1996, EUR J IMMUNOL, V26, P10, DOI 10.1002/eji.1830260103; Reardon C, 2011, IMMUNITY, V35, P223, DOI 10.1016/j.immuni.2011.05.015; Reefer AJ, 2010, J ALLERGY CLIN IMMUN, V126, P1049, DOI 10.1016/j.jaci.2010.07.023; Rickert M, 2005, SCIENCE, V308, P1477, DOI 10.1126/science.1109745; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Romeo MJ, 2013, J ALLERGY CLIN IMMUN, V131, pAB102, DOI 10.1016/j.jaci.2012.12.1034; Rose T, 2010, J BIOL CHEM, V285, P14898, DOI 10.1074/jbc.M110.104232; Scheeren FA, 2010, EUR J IMMUNOL, V40, P955, DOI 10.1002/eji.200939419; Slager RE, 2012, J ALLERGY CLIN IMMUN, V130, P516, DOI 10.1016/j.jaci.2012.03.030; Slager RE, 2010, J ALLERGY CLIN IMMUN, V126, P875, DOI 10.1016/j.jaci.2010.08.001; Spadoni I, 2012, MUCOSAL IMMUNOL, V5, P184, DOI 10.1038/mi.2011.64; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Tabata Y, 2006, J IMMUNOL, V177, P7905, DOI 10.4049/jimmunol.177.11.7905; Taylor BC, 2009, J EXP MED, V206, P655, DOI 10.1084/jem.20081499; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Tomkinson A, 2010, ALLERGY, V65, P69, DOI 10.1111/j.1398-9995.2009.02156.x; Ultsch M, 2013, J MOL BIOL, V425, P1330, DOI 10.1016/j.jmb.2013.01.024; Walsh STR, 2012, IMMUNOL REV, V250, P303, DOI 10.1111/j.1600-065X.2012.01160.x; Wang XQ, 2009, ANNU REV IMMUNOL, V27, P29, DOI 10.1146/annurev.immunol.24.021605.090616; Wang XQ, 2005, SCIENCE, V310, P1159, DOI 10.1126/science.1117893; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1.51.pe55; Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC; Xie Y, 2012, J DERMATOL SCI, V66, P233, DOI 10.1016/j.jdermsci.2012.03.007; Yoshikawa M, 2003, BIOCHEM BIOPH RES CO, V312, P1248, DOI 10.1016/j.bbrc.2003.11.077; Zhang WP, 2001, BIOCHEM BIOPH RES CO, V281, P878, DOI 10.1006/bbrc.2001.4432; Zhong J, 2010, MOL IMMUNOL, V47, P1207, DOI 10.1016/j.molimm.2009.12.017; Zhong J, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-5; Zhu LY, 2012, J IMMUNOL, V188, P5571, DOI 10.4049/jimmunol.1102259; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	97	32	37	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					952	+		10.1016/j.jaci.2013.08.006	http://dx.doi.org/10.1016/j.jaci.2013.08.006			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24084078	Green Accepted			2022-12-18	WOS:000333531700002
J	Sabry, A; Hauk, PJ; Jing, H; Su, HC; Stence, NV; Mirsky, DM; Nagel, MA; Abbott, JK; Dragone, LL; Armstrong-Wells, J; Curtis, DJ; Cohrs, R; Schmid, DS; Gilden, D; Gelfand, EW				Sabry, Angela; Hauk, Pia J.; Jing, Huie; Su, Helen C.; Stence, Nicholas V.; Mirsky, David M.; Nagel, Maria A.; Abbott, Jordan K.; Dragone, Leonard L.; Armstrong-Wells, Jennifer; Curtis, Donna J.; Cohrs, Randall; Schmid, D. Scott; Gilden, Don; Gelfand, Erwin W.			Vaccine strain varicella- zoster virus- induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CLINICAL-MANIFESTATIONS		[Sabry, Angela; Hauk, Pia J.; Abbott, Jordan K.; Dragone, Leonard L.; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA; [Sabry, Angela; Hauk, Pia J.; Abbott, Jordan K.; Dragone, Leonard L.; Gelfand, Erwin W.] Natl Jewish Hlth, Div Cell Biol, Denver, CO USA; [Jing, Huie; Su, Helen C.] NIAID, NIH, Bethesda, MD 20892 USA; [Stence, Nicholas V.; Mirsky, David M.; Armstrong-Wells, Jennifer; Curtis, Donna J.; Cohrs, Randall; Gilden, Don] Univ Colorado, Sch Med, Aurora, CO USA; [Stence, Nicholas V.; Mirsky, David M.; Nagel, Maria A.; Armstrong-Wells, Jennifer; Curtis, Donna J.] Childrens Hosp Colorado, Aurora, CO USA; [Schmid, D. Scott] Ctr Dis Control & Prevent, Div Viral Dis, Herpesvirus Team, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA	National Jewish Health; National Jewish Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; Centers for Disease Control & Prevention - USA	Sabry, A (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA.	gelfande@njhealth.org	Abbott, Jordan K/P-2509-2016; Su, Helen C/H-9541-2015; Armstrong, Jennifer/AAG-7279-2019	Abbott, Jordan K/0000-0001-6334-5266; Su, Helen C/0000-0002-5582-9110; Armstrong, Jennifer/0000-0003-3797-3562	NIAID NIH HHS [R01 AI077609] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077609, ZIAAI001193] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alsum Z, 2013, J CLIN IMMUNOL, V33, P55, DOI 10.1007/s10875-012-9769-x; Banning C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009344; Freeman AF, 2010, DIS MARKERS, V29, P123, DOI [10.1155/2010/580197, 10.3233/DMA-2010-0734]; Gilden D, 2009, LANCET NEUROL, V8, P731, DOI 10.1016/S1474-4422(09)70134-6; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Lambe T, 2011, EUR J IMMUNOL, V41, P3423, DOI 10.1002/eji.201141759; Quinlivan ML, 2012, J CLIN MICROBIOL, V50, P1533, DOI 10.1128/JCM.06630-11; Randall KL, 2010, DIS MARKERS, V29, P141, DOI [10.1155/2010/143612, 10.3233/DMA-2010-0739]; Swamy M., 2006, SCI STKE, V2006, pl4, DOI DOI 10.1126/STKE.3452006PL4.PMID:16868305; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Zhang QA, 2010, DIS MARKERS, V29, P131, DOI 10.3233/DMA-2010-0737; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	12	32	33	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1225	1227		10.1016/j.jaci.2013.11.031	http://dx.doi.org/10.1016/j.jaci.2013.11.031			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24418481	Green Accepted			2022-12-18	WOS:000333531700040
J	Farhadi, N; Lambert, L; Triulzi, C; Openshaw, PJM; Guerra, N; Culley, FJ				Farhadi, Nazanin; Lambert, Laura; Triulzi, Chiara; Openshaw, Peter J. M.; Guerra, Nadia; Culley, Fiona J.			Natural killer cell NKG2D and granzyme B are critical for allergic pulmonary inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate immunity; lung; natural killer cell; house dust mite; allergic inflammation; asthma	HOUSE-DUST MITE; NK CELLS; T-CELLS; AIRWAY INFLAMMATION; DENDRITIC CELLS; LYMPH-NODES; GM-CSF; RECEPTOR; ACTIVATION; INFECTION	Background: The diverse roles of innate immune cells in the pathogenesis of asthma remain to be fully defined. Natural killer (NK) cells are innate lymphocytes that can regulate adaptive immune responses. NK cells are activated in asthma; however, their role in allergic airway inflammation is not fully understood. Objective: We investigated the importance of NK cells in house dust mite (HDM)-triggered allergic pulmonary inflammation. Specifically, we aimed to determine the role of the major NK-cell activating receptor NKG2D and NK-cell effector functions mediated by granzyme B. Methods: Allergic airway inflammation was induced in the airways of mice by repeated intranasal HDM extract administration and responses in wild-type and NKG2D-deficient mice were compared. Adoptive transfer studies were used to identify the cells and mechanisms involved. Results: Mice that lacked NKG2D were resistant to the induction of allergic inflammation and showed little pulmonary eosinophilia, few airway T(H)2 cells, and no rise in serum IgE after multiple HDM-allergen exposures. However, NKG2D was not required for pulmonary inflammation after a single inoculation of allergen. NKG2D-deficient mice showed no alteration in responses to respiratory virus infection. Transfer of wild-type NK cells (but not CD3(+) cells) into NKG2D-deficient mice restored allergic inflammatory responses only if the NK cells expressed granzyme B. Conclusions: These studies established a pivotal role for NK-cell NKG2D and granzyme B in the pathogenesis of HDM-induced allergic lung disease, and identified novel therapeutic targets for the prevention and treatment of asthma.	[Farhadi, Nazanin; Lambert, Laura; Openshaw, Peter J. M.; Culley, Fiona J.] Univ London Imperial Coll Sci Technol & Med, Ctr Resp Infect, London W2 1PG, England; [Farhadi, Nazanin; Lambert, Laura; Openshaw, Peter J. M.; Culley, Fiona J.] Univ London Imperial Coll Sci Technol & Med, MRC Asthma UK Ctr Allerg Mech Asthma, Dept Resp Infect, Natl Heart & Lung Inst,Fac Med, London W2 1PG, England; [Triulzi, Chiara; Guerra, Nadia] Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Div Cell & Mol Biol, London W2 1PG, England	Imperial College London; Imperial College London; University of London; King's College London; Imperial College London	Culley, FJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Resp Med, Norfolk Pl, London W2 1PG, England.	f.culley@imperial.ac.uk	Openshaw, Peter/AAL-9442-2020	Openshaw, Peter/0000-0002-7220-2555; Culley, Fiona/0000-0001-5208-4259	MRC [G1001763]; MRC-Asthma UK Centre for Allergic Mechanisms in Asthma [G0400503]; Wellcome Trust [087805/Z/08/Z, 088381/Z/09/Z]; Wellcome Trust (Centre for Respiratory Infection) [083567/Z/07/Z]; MRC [G0400503] Funding Source: UKRI; Medical Research Council [G1001763, G0400503, G1000758] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC-Asthma UK Centre for Allergic Mechanisms in Asthma(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Wellcome Trust (Centre for Respiratory Infection)(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	This work was funded by the MRC (F. Culley, New Investigator Award G1001763) the MRC-Asthma UK Centre for Allergic Mechanisms in Asthma (N. Farhadi, PhD studentship G0400503) and the Wellcome Trust (P. Openshaw, Programme grant 087805/Z/08/Z; Centre for Respiratory Infection 083567/Z/07/Z; and N. Guerra, Research Career Development Fellowship 088381/Z/09/Z).	Afonina IS, 2011, MOL CELL, V44, P265, DOI 10.1016/j.molcel.2011.07.037; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Borchers MT, 2009, J CLIN INVEST, V119, P636, DOI 10.1172/JCI34462; Borchers MT, 2006, INFECT IMMUN, V74, P2578, DOI 10.1128/IAI.74.5.2578-2586.2006; Bousquet J, 2007, GLOBAL SURVEILLANCE; Bratke K, 2004, CLIN EXP IMMUNOL, V136, P542, DOI 10.1111/j.1365-2249.2004.02468.x; Cates EC, 2004, J IMMUNOL, V173, P6384, DOI 10.4049/jimmunol.173.10.6384; Colonna M, 2001, NAT IMMUNOL, V2, P899, DOI 10.1038/ni1001-899; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Culley FJ, 2009, IMMUNOLOGY, V128, P151, DOI 10.1111/j.1365-2567.2009.03167.x; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Di Lorenzo G, 2001, ALLERGY, V56, P323, DOI 10.1034/j.1398-9995.2001.00879.x; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Gregoire C, 2007, IMMUNOL REV, V220, P169, DOI 10.1111/j.1600-065X.2007.00563.x; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hiebert PR, 2012, TRENDS MOL MED, V18, P732, DOI 10.1016/j.molmed.2012.09.009; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Holgate ST, 2011, IMMUNOL REV, V242, P205, DOI 10.1111/j.1600-065X.2011.01030.x; Huntington ND, 2007, NAT REV IMMUNOL, V7, P703, DOI 10.1038/nri2154; JIRA M, 1988, ALLERGY, V43, P294, DOI 10.1111/j.1398-9995.1988.tb00903.x; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Kaiko GE, 2010, J IMMUNOL, V185, P4681, DOI 10.4049/jimmunol.1001758; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lu LR, 2007, IMMUNITY, V26, P593, DOI 10.1016/j.immuni.2007.03.017; Malarkannan S, 1998, J IMMUNOL, V161, P3501; Marcenaro E, 2005, J IMMUNOL, V174, P3992, DOI 10.4049/jimmunol.174.7.3992; Maroof A, 2008, IMMUNITY, V29, P295, DOI 10.1016/j.immuni.2008.06.012; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Matangkasombut P, 2009, MUCOSAL IMMUNOL, V2, P383, DOI 10.1038/mi.2009.96; Matusali G, 2012, J ALLERGY CLIN IMMUN, V130, P1003, DOI 10.1016/j.jaci.2012.07.004; McDermott JR, 2005, J IMMUNOL, V175, P3207, DOI 10.4049/jimmunol.175.5.3207; Moretta L, 2006, IMMUNOL REV, V214, P219, DOI 10.1111/j.1600-065X.2006.00450.x; Nedvetzki S, 2007, BLOOD, V109, P3776, DOI 10.1182/blood-2006-10-052977; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nishikado H, 2011, J IMMUNOL, V186, P5766, DOI 10.4049/jimmunol.1100370; Ogasawara K, 2005, NAT IMMUNOL, V6, P938, DOI 10.1038/ni1236; Openshaw PJM, 2005, CLIN MICROBIOL REV, V18, P541, DOI 10.1128/CMR.18.3.541-555.2005; Ple C, 2010, SCAND J IMMUNOL, V72, P118, DOI 10.1111/j.1365-3083.2010.02419.x; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Roy S, 2008, J IMMUNOL, V180, P1729, DOI 10.4049/jimmunol.180.3.1729; Saglani S, 2009, AM J RESP CELL MOL, V41, P281, DOI 10.1165/rcmb.2008-0396OC; Scordamaglia F, 2008, J ALLERGY CLIN IMMUN, V121, P479, DOI 10.1016/j.jaci.2007.09.047; Sheppard S, 2013, BLOOD, V121, P5025, DOI 10.1182/blood-2012-12-471607; Slifka MK, 2000, J IMMUNOL, V164, P2009, DOI 10.4049/jimmunol.164.4.2009; Strid J, 2011, SCIENCE, V334, P1293, DOI 10.1126/science.1211250; Sykes A, J ALLERGY CLIN IMMUN; TIMONEN T, 1985, CLIN EXP IMMUNOL, V59, P85; Trambley J, 1999, J CLIN INVEST, V104, P1715, DOI 10.1172/JCI8082; Tremblay GM, 2000, J IMMUNOL, V165, P3966, DOI 10.4049/jimmunol.165.7.3966; Tschopp CM, 2006, BLOOD, V108, P2290, DOI 10.1182/blood-2006-03-010348; Waggoner SN, 2012, NATURE, V481, P394, DOI 10.1038/nature10624; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Wills-Karp M, 2010, CURR OPIN IMMUNOL, V22, P777, DOI 10.1016/j.coi.2010.10.011; WILTROUT RH, 1985, J LEUKOCYTE BIOL, V37, P597, DOI 10.1002/jlb.37.5.597; Wortham BW, 2012, J IMMUNOL, V188, P4468, DOI 10.4049/jimmunol.1102643; Xia MC, 2011, CIRCULATION, V124, P2933, DOI 10.1161/CIRCULATIONAHA.111.034850; Zafirova B, 2009, IMMUNITY, V31, P270, DOI 10.1016/j.immuni.2009.06.017; Zingoni A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00408	65	32	32	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					827	+		10.1016/j.jaci.2013.09.048	http://dx.doi.org/10.1016/j.jaci.2013.09.048			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24290277	hybrid, Green Published			2022-12-18	WOS:000332397600027
J	Rabinovitch, N; Mauger, DT; Reisdorph, N; Covar, R; Malka, J; Lemanske, RF; Morgan, WJ; Guilbert, TW; Zeiger, RS; Bacharier, LB; Szefler, SJ				Rabinovitch, Nathan; Mauger, David T.; Reisdorph, Nichole; Covar, Ronina; Malka, Jonathan; Lemanske, Robert F., Jr.; Morgan, Wayne J.; Guilbert, Theresa W.; Zeiger, Robert S.; Bacharier, Leonard B.; Szefler, Stanley J.			Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; Best Add-On Giving Effective Response; children; fraction of exhaled nitric oxide; inhaled corticosteroids; impulse oscillometry; long-acting beta(2)-agonist; leukotriene E-4; leukotriene receptor antagonist	RANDOMIZED CONTROLLED-TRIAL; EXHALED NITRIC-OXIDE; CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; LEUKOTRIENE E-4; SMALL AIRWAYS; MONTELUKAST; INFLAMMATION; FLUTICASONE; PROTEIN	Background: Predictors of improvement in asthma control and lung function to step 3 therapy in children with persistent asthma have not been identified despite reported heterogeneity in responsiveness. Objective: We sought to evaluate potential predictors of asthma control and lung function responsiveness to step 3 therapy. Methods: A post hoc analysis from the Best Add-On Giving Effective Response (BADGER) study tested the association between baseline biological, asthma control, pulmonary function, and demographic markers and responsiveness to step-up to a higher dose of inhaled corticosteroid (ICS step-up therapy) or addition of leukotriene receptor antagonist (LTRA step-up therapy) or long-acting beta(2)-agonist (LABA step-up therapy). Results: In multivariate analyses higher impulse oscillometry reactance area was associated (P=.048) with a differential FEV1 response favoring LABA over ICS step-up therapy, whereas higher urinary leukotriene E-4 levels were marginally (P=.053) related to a differential FEV1 response favoring LTRA over LABA step-up therapy. Predictors of differential responses comparing ICS with LTRA step-up therapy were not apparent, probably because of suppression of allergic markers with low-dose ICS treatment. Minimal overlap was seen across FEV1 and asthma control day predictors, suggesting distinct mechanisms related to lung function and asthma control day responses. Conclusion: Levels of impulse oscillometry reactance area indicating peripheral airway obstruction and urinary leukotriene E-4 levels indicating cysteinyl leukotriene inflammation can differentiate LABA step-up responses from responses to LTRA or ICS step-up therapy. Further studies with physiologic, genetic, and biological markers related to these phenotypes will be needed to predict individual responses to LABA step-up therapy.	[Rabinovitch, Nathan; Reisdorph, Nichole; Covar, Ronina; Malka, Jonathan; Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Rabinovitch, Nathan; Reisdorph, Nichole; Covar, Ronina; Malka, Jonathan; Szefler, Stanley J.] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA; [Mauger, David T.] Penn State Univ, Dept Hlth Evaluat Sci, Hershey, PA USA; [Lemanske, Robert F., Jr.; Guilbert, Theresa W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Morgan, Wayne J.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Zeiger, Robert S.] Kaiser Permanente, Dept Allergy, San Diego, CA USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Bacharier, Leonard B.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Wisconsin System; University of Wisconsin Madison; University of Arizona; Kaiser Permanente; University of California System; University of California San Diego; Washington University (WUSTL)	Rabinovitch, N (corresponding author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.	rabinovitchn@njhealth.org	Reisdorph, Nichole/AAX-8774-2020	Reisdorph, Nichole/0000-0002-0425-8012; Guilbert, Theresa/0000-0002-6932-712X; Bacharier, Leonard/0000-0003-0432-2704; Szefler, Stanley/0000-0002-6911-3199; Zeiger, Robert/0000-0001-5788-5063	National Heart, Lung, and Blood Institute [HL064307, HL064288, HL064295, HL064287, HL064305, HL064313]; National Institute of Allergy and Infectious Diseases [T32AI007635]; Clinical Translational Science Award program of the National Center for Research Resources [UL1-RR025011, UL1-RR024992]; Colorado CTSA from NCRR/NIH [UL1 RR025780]; NIH/NCATS [UL1 TR000154]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, UL1TR000448, UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, M01RR000036, M01RR003186, UL1RR024992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064288, U10HL064307, U10HL064287, U10HL064305, U10HL064313, U10HL064295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES015510] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Clinical Translational Science Award program of the National Center for Research Resources; Colorado CTSA from NCRR/NIH; NIH/NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants from the National Heart, Lung, and Blood Institute (HL064307, HL064288, HL064295, HL064287, HL064305, and HL064313); the National Institute of Allergy and Infectious Diseases (T32AI007635); and the Clinical Translational Science Award program of the National Center for Research Resources (UL1-RR025011 [Wisconsin] and UL1-RR024992 [St Louis]). This study was performed in part by the General Clinical Research Centers at Washington University School of Medicine (M01-RR00036) and the University of Wisconsin (M01-RR03186). This study was also supported by Colorado CTSA Grant UL1 RR025780 from NCRR/NIH and UL1 TR000154 from NIH/NCATS.	Armstrong M, 2009, J CHROMATOGR B, V877, P3169, DOI 10.1016/j.jchromb.2009.08.011; Bartoli ML, 2010, EUR J CLIN INVEST, V40, P566, DOI 10.1111/j.1365-2362.2010.02297.x; Calhoun WJ, 2012, JAMA-J AM MED ASSOC, V308, P987, DOI 10.1001/2012.jama.10893; Duroudier NP, 2009, ALLERGY, V64, P823, DOI 10.1111/j.1398-9995.2009.02015.x; Fritscher LG, 2009, RESP MED, V103, P296, DOI 10.1016/j.rmed.2008.08.007; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; In KH, 1999, CLIN REV ALLERG IMMU, V17, P59, DOI 10.1007/BF02737597; Kaczka David W., 2011, Critical Reviews in Biomedical Engineering, V39, P337, DOI 10.1615/CritRevBiomedEng.v39.i4.60; Kelly HW, 2011, J ALLERGY CLIN IMMUN, V128, P278, DOI 10.1016/j.jaci.2011.05.002; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1454; Knuffman JE, 2009, J ALLERGY CLIN IMMUN, V123, P411, DOI 10.1016/j.jaci.2008.11.016; Larsen GL, 2009, J ALLERGY CLIN IMMUN, V123, P861, DOI 10.1016/j.jaci.2008.10.036; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054; Nakaji H, 2013, ANN ALLERG ASTHMA IM, V110, P198, DOI 10.1016/j.anai.2012.12.016; Niimi A, 1998, CLIN EXP ALLERGY, V28, P233; Rabinovitch N, 2010, J ALLERGY CLIN IMMUN, V126, P545, DOI 10.1016/j.jaci.2010.07.008; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; Scichilone N, 2009, ALLERGY, V64, P1563, DOI 10.1111/j.1398-9995.2009.02139.x; Severien C, 2000, EUR RESPIR J, V16, P588, DOI 10.1034/j.1399-3003.2000.16d03.x; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; von Mutius E, 2010, NEW ENGL J MED, V362, P1042, DOI 10.1056/NEJMe1002058; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	26	32	32	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					350	356		10.1016/j.jaci.2013.07.039	http://dx.doi.org/10.1016/j.jaci.2013.07.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24084071	Bronze, Green Accepted			2022-12-18	WOS:000332397100006
J	Landheer, J; Giovannone, B; Mattson, JD; Tjabringa, S; Bruijnzeel-Koomen, CAFM; McClanahan, T; Malefyt, RD; Knol, E; Hijnen, D				Landheer, Janneke; Giovannone, Barbara; Mattson, Jeanine D.; Tjabringa, Sandra; Bruijnzeel-Koomen, Carla A. F. M.; McClanahan, Terrill; Malefyt, Rene de Waal; Knol, Edward; Hijnen, DirkJan			Epicutaneous application of house dust mite induces thymic stromal lymphopoietin in non-lesional skin of patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ACTIVATION-REGULATED CHEMOKINE; HISTAMINE-RELEASE; EPITHELIAL-CELLS; CLINICAL-TRIALS; SERUM THYMUS; IMMUNOTHERAPY; ALLERGY		[Landheer, Janneke; Giovannone, Barbara; Tjabringa, Sandra; Bruijnzeel-Koomen, Carla A. F. M.; Knol, Edward; Hijnen, DirkJan] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands; [Mattson, Jeanine D.; McClanahan, Terrill; Malefyt, Rene de Waal] Merck Res Labs, Palo Alto, CA USA	Utrecht University; Utrecht University Medical Center; Merck & Company	Landheer, J (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands.	D.J.Hijnen@umcutrecht.nl	Hijnen, DirkJan/L-1387-2015	Hijnen, DirkJan/0000-0003-3379-3425; Knol, Edward/0000-0001-7368-9820; Giovannone, Barbara/0000-0003-3143-1922; de Waal Malefyt, Rene/0000-0002-2663-383X				Al-Ghouleh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033929; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Blom L, 2012, J IMMUNOL, V189, P4331, DOI 10.4049/jimmunol.1103685; Blom L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021695; Bousquet J, 2011, ALLERGY, V66, P765, DOI 10.1111/j.1398-9995.2011.02590.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Godicke V, 2010, ALLERGY, V65, P1499, DOI 10.1111/j.1398-9995.2010.02436.x; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; ICH Harmonised Tripartite Guideline, 2001, J POSTGRAD MED, V47, P45; Ivers NM, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-120; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Parish Christopher R, 2009, Curr Protoc Immunol, VChapter 4, DOI 10.1002/0471142735.im0409s84; Reche PA, 2001, J IMMUNOL, V167, P336, DOI 10.4049/jimmunol.167.1.336; Saeki H, 2006, J DERMATOL SCI, V43, P75, DOI 10.1016/j.jdermsci.2006.06.002; Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI [10.1016/j.jclinepi.2010.02.005, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18, 10.4103/0976-500X.72352]; SKOV PS, 1985, ALLERGY, V40, P213; SKOV PS, 1977, ACTA ALLERGOL, V32, P170, DOI 10.1111/j.1398-9995.1977.tb01347.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Takai T, 2012, ALLERGOL INT, V61, P3, DOI 10.2332/allergolint.11-RAI-0395	22	32	32	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1252	1254		10.1016/j.jaci.2013.07.051	http://dx.doi.org/10.1016/j.jaci.2013.07.051			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24112829				2022-12-18	WOS:000326235600040
J	Teraki, Y; Sakurai, A; Izaki, S				Teraki, Yuichi; Sakurai, Aika; Izaki, Seiichi			IL-13/IL-22-coproducing T cells, a novel subset, are increased in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERLEUKIN 22; IL-22		[Teraki, Yuichi; Sakurai, Aika; Izaki, Seiichi] Saitama Med Univ, Dept Dermatol, Saitama Med Ctr, Kawagoe, Saitama, Japan	Saitama Medical University	Teraki, Y (corresponding author), Saitama Med Univ, Dept Dermatol, Saitama Med Ctr, Kawagoe, Saitama, Japan.	teraki@saitama-med.ac.jp						Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Nakayamada S, 2012, CURR OPIN IMMUNOL, V24, P297, DOI 10.1016/j.coi.2012.01.014; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Teraki Y, 2000, BRIT J DERMATOL, V143, P373, DOI 10.1046/j.1365-2133.2000.03665.x; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001	10	32	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					971	+		10.1016/j.jaci.2013.07.029	http://dx.doi.org/10.1016/j.jaci.2013.07.029			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	24001799	Bronze			2022-12-18	WOS:000325096500026
J	Hsu, AP; Sowerwine, KJ; Lawrence, MG; Davis, J; Henderson, CJ; Zarember, KA; Garofalo, M; Gallin, JI; Kuhns, DB; Heller, T; Milner, JD; Puck, JM; Freeman, AF; Holland, SM				Hsu, Amy P.; Sowerwine, Kathryn J.; Lawrence, Monica G.; Davis, Joie; Henderson, Carolyn J.; Zarember, Kol A.; Garofalo, Mary; Gallin, John I.; Kuhns, Douglas B.; Heller, Theo; Milner, Joshua D.; Puck, Jennifer M.; Freeman, Alexandra F.; Holland, Steven M.			Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Somatic mosaicism; autosomal dominant hyper-IgE syndrome; Job syndrome; signal transducer and activator of transcription 3	STAT3 MUTATIONS; JOBS SYNDROME; INFECTION; CANDIDIASIS; DEFICIENCY; IMMUNITY; TISSUES; HUMANS; CELLS	Background: Autosomal dominant hyper-IgE syndrome (AD-HIES) is caused by mutations in signal transducer and activator of transcription 3 (STAT3). We describe 2 subjects in whom somatic mosaicism was associated with intermediate phenotypes. Objective: Somatic mosaics might shed light on the pathogenesis of dominant STAT3 mutations and the mechanisms behind the immunologic and nonimmunologic features of the disease. Methods: Clinical evaluations were conducted. Mutant STAT3 was amplified from different tissues and sequenced, and the percentage of mosaicism in various cell types was calculated. Flow cytometry was performed to determine percentages of IL-17(+) cells, IL-22(+) cells, or both. Suction blisters were induced in 1 subject, and exudate fluid was analyzed for whether emigrating neutrophils were STAT3 mutant or wild-type; neutrophils from peripheral blood were simultaneously examined. Results: The 2 subjects with STAT3 somatic mosaicism had intermediate phenotypes and were found to have preserved T(H)17 cell compartments and apparently normal CD8 cells. However, they still had infections, including mucocutaneous candidiasis. The percentage of STAT3 mutant neutrophils migrating into blisters at 16 hours was the same as in peripheral blood, suggesting normal chemotaxis. Conclusion: STAT3 mosaicism accounts for a milder phenotype and allows for further investigation into the pathogenesis of AD-HIES. Despite having a preserved T(H)17 cell compartment, both subjects with mosaicism had chronic mucocutaneous candidiasis, suggesting that candidiasis in subjects with AD-HIES is not driven solely by low T(H)17 cell numbers. The percentage of STAT3 mutant neutrophils emigrating into a suction blister at 16 hours was the same as the percentage in peripheral blood, suggesting that early chemotaxis of STAT3 neutrophils is normal in vivo.	[Hsu, Amy P.; Sowerwine, Kathryn J.; Davis, Joie; Henderson, Carolyn J.; Freeman, Alexandra F.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Lawrence, Monica G.; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Zarember, Kol A.; Garofalo, Mary; Gallin, John I.] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; [Kuhns, Douglas B.] SAIC Frederick, Appl Dev Res Directorate, Neutrophil Monitoring Lab, Frederick, MD USA; [Heller, Theo] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA; [Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco	Sowerwine, KJ (corresponding author), 10 Ctr Dr,Rm B3-4233, Bethesda, MD 20892 USA.	kathryn.sowerwine@nih.gov; smh@nih.gov		Zarember, Kol/0000-0002-9624-7096; Heller, Theo/0000-0002-2643-6289; Hsu, Amy/0000-0001-6841-2122	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health; Neutrophil Monitoring Laboratory, Applied/Developmental Research Directorate, SAIC-Frederick, Frederick, Maryland; National Center for Research Resources NCRR UCSF CTSI [UL1 RR024131]; UCSF Jeffrey Modell Foundation Diagnostic Center for Primary Immunodeficiencies; National Institutes of Health; Jeffrey Modell Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001183, ZIAAI000521, ZIAAI000155, ZIAAI001151, ZIAAI000647, ZIAAI001098, Z01AI000646, ZIAAI000646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075008] Funding Source: NIH RePORTER	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Neutrophil Monitoring Laboratory, Applied/Developmental Research Directorate, SAIC-Frederick, Frederick, Maryland; National Center for Research Resources NCRR UCSF CTSI; UCSF Jeffrey Modell Foundation Diagnostic Center for Primary Immunodeficiencies; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jeffrey Modell Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and the Neutrophil Monitoring Laboratory, Applied/Developmental Research Directorate, SAIC-Frederick, Frederick, Maryland. J.M.P. acknowledges support from the National Center for Research Resources NCRR UCSF CTSI (UL1 RR024131) and the UCSF Jeffrey Modell Foundation Diagnostic Center for Primary Immunodeficiencies. The views expressed in this article are those of the authors and do not reflect the official policy of the US Government.; Disclosure of potential conflict of interest: J. M. Puck has been supported by one or more grants from the National Institutes of Health and the Jeffrey Modell Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	BUCKLEY RH, 1972, PEDIATRICS, V49, P59; Chandesris MO, 2012, MEDICINE, V91, pE1, DOI 10.1097/MD.0b013e31825f95b9; Conti HR, 2011, MUCOSAL IMMUNOL, V4, P448, DOI 10.1038/mi.2011.5; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; DAVIS SD, 1966, LANCET, V1, P1013; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; DONABEDIAN H, 1983, MEDICINE, V62, P195, DOI 10.1097/00005792-198307000-00001; Foster Barbara, 2007, Curr Protoc Immunol, VChapter 6, DOI 10.1002/0471142735.im0624s78; Freeman AF, 2011, J ALLERGY CLIN IMMUN, V128, P1124, DOI 10.1016/j.jaci.2011.07.046; Goussetis E, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.005; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Heimall J, 2010, CLIN IMM SOC CIS ANN; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Johnson KD, 2012, J CLIN INVEST, V122, P3692, DOI 10.1172/JCI61623; Kolls JK, 2008, NAT REV IMMUNOL, V8, P829, DOI 10.1038/nri2433; KUHNS DB, 1992, J CLIN INVEST, V89, P1734, DOI 10.1172/JCI115775; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2011, ANN NY ACAD SCI, V1246, P34, DOI 10.1111/j.1749-6632.2011.06280.x; Minegishi Y, 2009, J EXP MED, V206, P1291, DOI 10.1084/jem.20082767; Nieminen P, 2011, AM J HUM GENET, V89, P67, DOI 10.1016/j.ajhg.2011.05.024; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Siegel AM, 2011, IMMUNITY, V35, P806, DOI 10.1016/j.immuni.2011.09.016; Spielberger BD, 2012, J ALLERGY CLIN IMMUN, V130, P1426, DOI 10.1016/j.jaci.2012.07.030; van de Veerdonk FL, 2010, CLIN EXP IMMUNOL, V159, P57, DOI 10.1111/j.1365-2249.2009.04043.x; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; WRIGHT DG, 1986, BLOOD, V67, P1023	30	32	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1586	1593		10.1016/j.jaci.2013.02.038	http://dx.doi.org/10.1016/j.jaci.2013.02.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23623265	Green Accepted			2022-12-18	WOS:000320532800019
J	Kienzler, AK; Rizzi, M; Reith, M; Nutt, SL; Eibel, H				Kienzler, Anne-Kathrin; Rizzi, Marta; Reith, Maike; Nutt, Stephen L.; Eibel, Hermann			Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DIFFERENTIATION; IMMUNOGLOBULINS		[Kienzler, Anne-Kathrin; Rizzi, Marta; Reith, Maike; Eibel, Hermann] Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Kienzler, Anne-Kathrin] Univ Freiburg, Fac Biol, Freiburg, Germany; [Nutt, Stephen L.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	University of Freiburg; University of Freiburg; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Kienzler, AK (corresponding author), Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany.	hermann.eibel@uniklinik-freiburg.de	Nutt, Stephen L/C-9256-2013; Rizzi, Marta/ABE-7264-2020	Nutt, Stephen L/0000-0002-0020-6637; Kienzler, Anne-Kathrin/0000-0002-3082-9210; Rizzi, Marta/0000-0002-5153-6089				Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Callenbach PMC, 2003, CLIN EXP IMMUNOL, V132, P144, DOI 10.1046/j.1365-2249.2003.02097.x; Cambridge G, 2006, ARTHRITIS RHEUM-US, V54, P3612, DOI 10.1002/art.22211; Eom TH, 2012, NEUROL SCI; GARZON P, 1985, GEN PHARMACOL, V16, P411, DOI 10.1016/0306-3623(85)90207-1; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Kaiser M, 2006, HAEMATOL-HEMATOL J, V91, P248; Nencioni A, 2007, CLIN CANCER RES, V13, P3933, DOI 10.1158/1078-0432.CCR-06-2903; Vojinovic J, 2011, ARTHRITIS RHEUM-US, V63, P1452, DOI 10.1002/art.30238; Yamaguchi T, 2010, GENE DEV, V24, P455, DOI 10.1101/gad.552310	10	32	33	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1695	1699		10.1016/j.jaci.2013.01.018	http://dx.doi.org/10.1016/j.jaci.2013.01.018			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23465661				2022-12-18	WOS:000320532800032
J	van der Heijden, J; Geissler, J; van Mirre, E; van Deuren, M; van der Meer, JWM; Salama, A; van den Berg, TK; Roos, D; Kuijpers, TW				van der Heijden, Joris; Geissler, Judy; van Mirre, Edwin; van Deuren, Marcel; van der Meer, Jos W. M.; Salama, Abdulgabar; van den Berg, Timo K.; Roos, Dirk; Kuijpers, Taco W.			A novel splice variant of Fc gamma RIIa: A risk factor for anaphylaxis in patients with hypogammaglobulinemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; common variable immunodeficiency; idiopathic thrombocytopenia; intravenous immunoglobulin; Fc gamma receptors; Kawasaki disease; splice variant; neutrophils; elastase	COPY NUMBER VARIATION; ANTI-IGA ANTIBODIES; IMMUNODEFICIENT PATIENTS; ADVERSE-REACTIONS; MANAGEMENT; RECEPTORS; AFFINITY; THERAPY; FCGR2C; ACTIVATION	Background: Our index case was a patient with common variable immunodeficiency (CVID). She had anaphylactoid reactions on administration of intravenous immunoglobulin (IVIg) associated with the presence of IgG antibodies against IgA. Objective: We sought to determine the role of Fc gamma receptor (Fc gamma R) IIa in IVIg-induced anaphylactoid reactions. Methods: Neutrophils and PBMCs were isolated from healthy subjects and IVIg-treated patients. Fc gamma RIIa mRNA and DNA were analyzed by using real-time PCR and sequencing. IgG-mediated elastase release and intracellular Ca2+ mobilization were determined in neutrophils and transfected cell lines, respectively. Results: A novel splice variant of Fc gamma RIIa containing an expressed cryptic exon 6* (Fc gamma RIIa(exon6*)) was identified in our index patient. This exon is normally spliced out of all Fc gamma RII isoforms, except the inhibitory Fc gamma RIIb1. Compared with healthy control subjects, the heterozygous FCRR2A(c.742+871A>G) mutation was more frequent in patients with CVID (n = 53, P <.013). Expression in patients with CVID was associated with anaphylaxis on IVIg infusion (P =.002). On screening of additional IVIg-treated patient cohorts, we identified 6 FCGR2A(c.7421871A>G) allele-positive patients with Kawasaki disease (n = 208) and 1 patient with idiopathic thrombocytopenia (n = 93). None had adverse reactions to IVIg. Moreover, Fc gamma RIIa(exon6*) was also demonstrated in asymptomatic family members. Functional studies in primary cells and transfected murine cells demonstrated enhanced cellular activation by Fc gamma RIIaexon6* compared with its native form, as shown by increased elastase release and intracellular calcium mobilization. Conclusion: A novel splice variant, FcgRII(aexon6*), was characterized as a low-frequency allele, coding for a gain-of-function receptor for IgG. In the presence of immune complexes, FcgRII(aexon6*) can contribute to anaphylaxis in patients with CVID.	[van der Heijden, Joris; Geissler, Judy; van Mirre, Edwin; van den Berg, Timo K.; Roos, Dirk; Kuijpers, Taco W.] Univ Amsterdam, Acad Med Ctr, Dept Blood Cell Res, Sanquin Res CLB, NL-1105 AZ Amsterdam, Netherlands; [van der Heijden, Joris; Geissler, Judy; van Mirre, Edwin; van den Berg, Timo K.; Roos, Dirk; Kuijpers, Taco W.] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; [Geissler, Judy; Kuijpers, Taco W.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; [van Deuren, Marcel; van der Meer, Jos W. M.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Salama, Abdulgabar] Univ Klinikum Charite, Inst Transfus Med, Campus Virchow Klinikum, Berlin, Germany	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Radboud University Nijmegen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kuijpers, TW (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pediat Hematol Immunol & Infect Dis, H7-230,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	t.w.kuijpers@amc.nl	van den Berg, Timo K/AAC-2479-2022; Deuren, Marcel/O-1846-2013; van der Meer, Jos W.M./C-8521-2013	van der Meer, Jos W.M./0000-0001-5120-3690	Netherlands Organization for Scientific Research (NWO) [HORIZON 050-71-034]	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	Supported in part by a grant from the Netherlands Organization for Scientific Research (NWO; HORIZON 050-71-034). Also supported by Sanquin.	Ahrens N, 2008, CLIN EXP IMMUNOL, V151, P455, DOI 10.1111/j.1365-2249.2007.03483.x; Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Breunis WB, 2009, HUM MUTAT, V30, pE640, DOI 10.1002/humu.20997; Breunis WB, 2008, BLOOD, V111, P1029, DOI 10.1182/blood-2007-03-079913; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; Burns JC, 2004, LANCET, V364, P533, DOI 10.1016/S0140-6736(04)16814-1; Campos RD, 2000, J CLIN IMMUNOL, V20, P77; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; EDEN OB, 1992, ARCH DIS CHILD, V67, P1056, DOI 10.1136/adc.67.8.1056; Eijkhout HW, 2003, NETH J MED, V61, P213; Furukawa T, 2008, ARCH DIS CHILD, V93, P142, DOI 10.1136/adc.2007.126144; George JN, 1998, ANN MED, V30, P38, DOI 10.3109/07853899808999383; Gilstad CW, 2003, CURR OPIN HEMATOL, V10, P419, DOI 10.1097/00062752-200311000-00004; HACK CE, 1988, J IMMUNOL, V141, P1602; Han RK, 2000, ARCH PEDIAT ADOL MED, V154, P694, DOI 10.1001/archpedi.154.7.694; Hornung M, 1998, EUR J IMMUNOL, V28, P3812, DOI 10.1002/(SICI)1521-4141(199811)28:11<3812::AID-IMMU3812>3.3.CO;2-E; Ibarrola I, 1997, BBA-MOL CELL RES, V1357, P348, DOI 10.1016/S0167-4889(97)00034-7; Jonsson F, 2012, BLOOD, V119, P2533, DOI 10.1182/blood-2011-07-367334; McKenzie SE, 1999, J IMMUNOL, V162, P4311; Newburger JW, 2004, CIRCULATION, V110, P2747, DOI 10.1161/01.CIR.0000145143.19711.78; Nimmerjahn F, 2006, IMMUNITY, V24, P19, DOI 10.1016/j.immuni.2005.11.010; Pricop L, 2001, J IMMUNOL, V166, P531, DOI 10.4049/jimmunol.166.1.531; Rachid R, 2012, J ALLERGY CLIN IMMUN, V129, P628, DOI 10.1016/j.jaci.2011.06.047; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Salama A, 2004, TRANSFUSION, V44, P509, DOI 10.1111/j.1537-2995.2004.03316.x; Salama A, 2001, VOX SANG, V81, P45, DOI 10.1046/j.1423-0410.2001.00047.x; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Su K, 2002, GENES IMMUN, V3, pS51, DOI 10.1038/sj.gene.6363879; Sundin U, 1998, CLIN EXP IMMUNOL, V112, P341; Teeling JL, 1998, CLIN EXP IMMUNOL, V114, P264; van der Heijden J, 2012, J IMMUNOL, V188, P1318, DOI 10.4049/jimmunol.1003945; van Mirre E, 2004, J IMMUNOL, V173, P332, DOI 10.4049/jimmunol.173.1.332; van Mirre E, 2006, BLOOD, V108, P584, DOI 10.1182/blood-2005-12-4997; van Sorge NM, 2003, TISSUE ANTIGENS, V61, P189, DOI 10.1034/j.1399-0039.2003.00037.x; VANDENHERIKOUDIJK IE, 1995, BLOOD, V85, P2202, DOI 10.1182/blood.V85.8.2202.bloodjournal8582202; VANDENHERIKOUDIJK IE, 1994, J IMMUNOL, V152, P574; VYAS GN, 1968, LANCET, V2, P312; Wallace CA, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e78; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; WARMERDAM PAM, 1993, J BIOL CHEM, V268, P7346; WOLBINK GJ, 1993, J IMMUNOL METHODS, V163, P67, DOI 10.1016/0022-1759(93)90240-8; Wouters D, 2005, J IMMUNOL METHODS, V298, P35, DOI 10.1016/j.jim.2004.12.018	43	32	34	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1408	U254		10.1016/j.jaci.2013.02.009	http://dx.doi.org/10.1016/j.jaci.2013.02.009			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23545275				2022-12-18	WOS:000318912200019
J	Magerus-Chatinet, A; Stolzenberg, MC; Lanzarotti, N; Neven, B; Daussy, C; Picard, C; Neveux, N; Desai, M; Rao, M; Ghosh, K; Madkaikar, M; Fischer, A; Rieux-Laucat, F				Magerus-Chatinet, Aude; Stolzenberg, Marie-Claude; Lanzarotti, Nina; Neven, Benedicte; Daussy, Cecile; Picard, Capucine; Neveux, Nathalie; Desai, Mukesh; Rao, Meghana; Ghosh, Kanjaksha; Madkaikar, Manisha; Fischer, Alain; Rieux-Laucat, Frederic			Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoimmune lymphoproliferative syndrome; Fas ligand; diagnosis	SYNDROME ALPS; LYMPHOCYTE APOPTOSIS; DISEASE; EXPRESSION; PATIENT; CELLS	Background: Autoimmune lymphoproliferative syndrome (ALPS) is characterized by chronic nonmalignant lymphoproliferation, accumulation of double-negative T cells, hypergammaglobulinemia G and A, and autoimmune cytopenia. Objectives: Although mostly associated with FAS mutations, different genetic defects leading to impaired apoptosis have been described in patients with ALPS, including the FAS ligand gene (FASLG) in rare cases. Here we report on the first case of complete FAS ligand deficiency caused by a homozygous null mutant. Methods: Double-negative T-cell counts and plasma IL-10 and FAS ligand concentrations were determined as ALPS markers. The FASLG gene was sequenced, and its expression was analyzed by means of Western blotting. FAS ligand function was assessed based on reactivation-induced cell death. Results: We describe a patient born to consanguineous parents who presented with a severe form of ALPS caused by FASLG deficiency. Although the clinical presentation was compatible with a homozygous FAS mutation, FAS-induced apoptosis was normal, and plasma FAS ligand levels were not detectable. This patient carries a homozygous, germline, single-base-pair deletion in FASLG exon 1, leading to a premature stop codon (F87fs x95) and a complete defect in FASLG expression. The healthy parents were each heterozygous for the mutation, confirming its recessive trait. Conclusion: FAS ligand deficiency should be screened in patients presenting with ALPS features but lacking the usual markers, including plasma soluble FAS ligand and an in vitro apoptotic defect. An activation-induced cell death test could help in discrimination. (J Allergy Clin Immunol 2013;131:486-90.)	[Magerus-Chatinet, Aude; Stolzenberg, Marie-Claude; Lanzarotti, Nina; Neven, Benedicte; Daussy, Cecile; Fischer, Alain; Rieux-Laucat, Frederic] Hop Necker Enfants Malad, INSERM, U768, F-75015 Paris, France; [Magerus-Chatinet, Aude; Stolzenberg, Marie-Claude; Lanzarotti, Nina; Neven, Benedicte; Daussy, Cecile; Picard, Capucine; Fischer, Alain; Rieux-Laucat, Frederic] Univ Paris 05, Inst Imagine, Paris, France; [Neven, Benedicte; Picard, Capucine; Fischer, Alain; Rieux-Laucat, Frederic] AP HP, Unite Immunol & Hematol Pediat, Paris, France; [Picard, Capucine] AP HP, Ctr Etud Deficits Immunitaires, Paris, France; [Picard, Capucine] Fac Necker, INSERM, U980, Lab Genet Humaine Malad Infect, Paris, France; [Neveux, Nathalie] Univ Paris 05, Fac Pharm, EA 4466, Lab Biol Nutr, Paris, France; [Neveux, Nathalie] APHP, Serv Biochim Interhosp Cochin Hotel Dieu, Paris, France; [Desai, Mukesh] Bai Jerbai Wadia Hosp Children, Bombay, Maharashtra, India; [Rao, Meghana; Ghosh, Kanjaksha; Madkaikar, Manisha] KEM Hosp Campus, Natl Inst Immunohaematol, Bombay, Maharashtra, India	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Indian Council of Medical Research (ICMR); ICMR - National Institute of Immunohaemotology (NIIH)	Magerus-Chatinet, A (corresponding author), Hop Necker Enfants Malad, INSERM, U768, 149 Rue Sevres, F-75015 Paris, France.	aude.magerus@inserm.fr	Rieux-Laucat, Frédéric/A-7916-2017; Picard, Capucine/H-3914-2017; Magerus-Chatinet, Aude/I-6245-2017; Stolzenberg, Marie-Claude/I-6281-2017; Madkaikar, Mnaisha/K-8502-2015; Ghosh, Kanjaksha/D-7621-2015	Rieux-Laucat, Frédéric/0000-0001-7858-7866; Picard, Capucine/0000-0001-8788-5056; Magerus-Chatinet, Aude/0000-0001-7365-699X; Stolzenberg, Marie-Claude/0000-0001-8026-0360; Ghosh, Kanjaksha/0000-0002-0645-6565; Madkaikar, Manisha/0000-0001-6380-3116	INSERM, Agence Nationale de la Recherche (ANR) [08-GENO-015-01]; E-Rare programme (EPINOSTICS); Ligue National Contre le Cancer; European STREP (AUTOROME); European Research Council (ERC); European STREP; Centre de Reference des Deficits Immunitaires Hereditaires (CEREDIH); ERC; INSERM	INSERM, Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); E-Rare programme (EPINOSTICS); Ligue National Contre le Cancer(Ligue nationale contre le cancer); European STREP (AUTOROME); European Research Council (ERC)(European Research Council (ERC)European Commission); European STREP(European Commission); Centre de Reference des Deficits Immunitaires Hereditaires (CEREDIH); ERC(European Research Council (ERC)European Commission); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	Supported by grants from INSERM, Agence Nationale de la Recherche (ANR; grant no. 08-GENO-015-01), the E-Rare 2007 programme (EPINOSTICS), the Ligue National Contre le Cancer, the European STREP (AUTOROME), and an advanced grant from the European Research Council (ERC). A. M.-C. was funded by the European STREP, the Centre de Reference des Deficits Immunitaires Hereditaires (CEREDIH) and the ERC. N.L. was awarded a doctoral fellowship by INSERM.	Bi LL, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-41; Bleesing JJH, 2001, SEMIN HEMATOL, V38, P100, DOI 10.1053/shem.2001.21922; Caminha I, 2010, J ALLERGY CLIN IMMUN, V125, P946, DOI 10.1016/j.jaci.2009.12.983; CANALE VC, 1967, J PEDIATR-US, V70, P891, DOI 10.1016/S0022-3476(67)80262-2; Del-Rey M, 2006, BLOOD, V108, P1306, DOI 10.1182/blood-2006-04-015776; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Hao ZY, 2008, IMMUNITY, V29, P615, DOI 10.1016/j.immuni.2008.07.016; Holzelova E, 2004, NEW ENGL J MED, V351, P1409, DOI 10.1056/NEJMoa040036; Jackson CE, 1999, AM J HUM GENET, V64, P1002, DOI 10.1086/302333; Kasahara Y, 1998, INT IMMUNOL, V10, P195, DOI 10.1093/intimm/10.2.195; Lopatin U, 2001, BLOOD, V97, P3161, DOI 10.1182/blood.V97.10.3161; Magerus-Chatinet A, 2011, J CLIN INVEST, V121, P106, DOI 10.1172/JCI43752; Magerus-Chatinet A, 2009, BLOOD, V113, P3027, DOI 10.1182/blood-2008-09-179630; Mateo V, 2007, BLOOD, V110, P4285, DOI 10.1182/blood-2007-05-088286; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Rieux-Laucat F, 2003, CELL DEATH DIFFER, V10, P124, DOI 10.1038/sj.cdd.4401190; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Worth A, 2006, BRIT J HAEMATOL, V133, P124, DOI 10.1111/j.1365-2141.2006.05993.x; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892	22	32	33	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					486	490		10.1016/j.jaci.2012.06.011	http://dx.doi.org/10.1016/j.jaci.2012.06.011			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22857792	Green Accepted, Bronze			2022-12-18	WOS:000314661500028
J	Lupinek, C; Marth, K; Niederberger, V; Valenta, R				Lupinek, Christian; Marth, Katharina; Niederberger, Verena; Valenta, Rudolf			Analysis of serum IgE reactivity profiles with microarrayed allergens indicates absence of de novo IgE sensitizations in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIBODY-RESPONSES; IMMUNOTHERAPY; COMPONENTS; WORKERS		[Lupinek, Christian; Marth, Katharina; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Vienna, Austria; [Marth, Katharina; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol,Dept Pathophysiol & Allergy Res, Vienna, Austria; [Niederberger, Verena] Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Lupinek, C (corresponding author), Med Univ Vienna, Div Immunopathol, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Lupinek, Christian/I-3311-2019	Lupinek, Christian/0000-0002-8612-8245; Valenta, Rudolf/0000-0001-5944-3365	Austrian Science Fund FWF [F 4605, F 4613] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Eich-Wanger C, 1998, CLIN EXP ALLERGY, V28, P1292, DOI 10.1046/j.1365-2222.1998.00411.x; Fasce L, 2004, IMMUNOL LETT, V93, P45, DOI 10.1016/j.imlet.2004.01.016; Green BJ, 2011, CLIN EXP ALLERGY, V41, P1022, DOI 10.1111/j.1365-2222.2011.03756.x; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Niederberger V, 2002, EUR J IMMUNOL, V32, P576, DOI 10.1002/1521-4141(200202)32:2<576::AID-IMMU576>3.0.CO;2-U; Renstrom A, 2011, ALLERGY, V66, P1081, DOI 10.1111/j.1398-9995.2011.02591.x	9	32	32	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1418	1420		10.1016/j.jaci.2012.06.028	http://dx.doi.org/10.1016/j.jaci.2012.06.028			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22867692	Green Accepted			2022-12-18	WOS:000311641100026
J	Rinaldi, M; Harnack, L; Oberg, C; Schreiner, P; Sauver, JS; Travis, LL				Rinaldi, Maria; Harnack, Lisa; Oberg, Charles; Schreiner, Pamela; Sauver, Jennifer St.; Travis, Lori L.			Peanut allergy diagnoses among children residing in Olmsted County, Minnesota	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; children; incidence; prevalence; Olmsted County; Rochester Epidemiology Project	TREE NUT ALLERGY; FOOD ALLERGY; PREVALENCE; POPULATION; HEALTH; TIME; AGE	Background: Peanut allergy is a major health concern, particularly in developed countries. Research indicates that as many as 2% of children are allergic to peanuts, which represents a 3-fold increase in diagnoses over the past 2 decades. Objective: This population-based descriptive study used the Rochester Epidemiology Project to estimate the prevalence in 2007 and annual incidence rates of peanut allergy diagnoses from 1999 to 2007 among children residing in Olmsted County, Minnesota. Methods: Residents of Olmsted County from January 1, 1999, through December 31, 2007, who received medical care at a Rochester Epidemiology Project facility and provided research authorization were eligible for the study. A medical chart review of 547 potential diagnoses resulted in 244 prevalent and 170 incident cases. Annual rates, crude and adjusted for age and sex, were standardized with the use of the indirect method to the Olmsted County population data in 1999. Incidence rate ratios were estimated with Poisson regression. Results: The prevalence in 2007 was 0.65%. Female children were less likely to be diagnosed than male children (incidence rate ratio = 0.18; 95% CI, 0.07-0.48). Children aged birth to 2 years were significantly more likely to be diagnosed than older children aged 3-17 years (incidence rate ratio = 0.001; 95% CI, 0.0004-0.004). A significant 3-fold increasing trend was observed in diagnoses over time from 2.05 cases per 10,000 children in 1999 to 6.88 cases per 10,000 in 2007. Conclusions: Peanut allergies are an increasing concern in Olmsted County, Minnesota, as indicated by a 3-fold increase in diagnoses from 2.05 per 10,000 children in 1999 to 6.88 per 10,000 children in 2007. (J Allergy Clin Immunol 2012; 130:945-50.)	[Rinaldi, Maria; Harnack, Lisa; Oberg, Charles; Schreiner, Pamela] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA; [Rinaldi, Maria; Sauver, Jennifer St.] Mayo Clin, Div Epidemiol, Rochester, MN USA; [Travis, Lori L.] Ctr Outcomes Res Evaluat, Maine Med Res Inst, Portland, ME USA	University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic	Rinaldi, M (corresponding author), Univ Minnesota, Div Epidemiol & Community Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.	rinal002@umn.edu		St Sauver, Jennifer/0000-0002-9789-8544; Schreiner, Pamela/0000-0002-9920-6257; Harnack, Lisa/0000-0003-1963-5316	National Institute on Aging of the National Institutes of Health (NIH) [R01AG034676]; National Institute of Aging; NATIONAL INSTITUTE ON AGING [R01AG034676] Funding Source: NIH RePORTER	National Institute on Aging of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Study data were obtained from the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health (NIH) under Award Number R01AG034676. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.; J. St. Sauver has received grants from the National Institute of Aging. L.L. Travis was hired by M. Rinaldi to teach statistical methods and software code for data analysis. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; Branum Amy M, 2008, NCHS Data Brief, P1; Chapman JA, 2006, ANN ALLERG ASTHMA IM, V96, pS1, DOI 10.1016/S1081-1206(10)60926-X; DunnGalvin A, 2006, ALLERGY, V61, P1336, DOI 10.1111/j.1398-9995.2006.01181.x; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Kotz D, 2011, J ALLERGY CLIN IMMUN, V127, P623, DOI 10.1016/j.jaci.2010.11.021; Luccioli S, 2008, PEDIATRICS, V122, pS105, DOI 10.1542/peds.2008-1315n; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Mullins RJ, 2009, ANN ALLERG ASTHMA IM, V103, P488, DOI 10.1016/S1081-1206(10)60265-7; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; St Sauver JL, 2011, AM J EPIDEMIOL, V173, P1059, DOI 10.1093/aje/kwq482; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x	28	32	32	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					945	950		10.1016/j.jaci.2012.07.042	http://dx.doi.org/10.1016/j.jaci.2012.07.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22944484	Green Accepted			2022-12-18	WOS:000309594800016
J	Cliffe, ST; Bloch, DB; Suryani, S; Kamsteeg, EJ; Avery, DT; Palendira, U; Church, JA; Wainstein, BK; Trizzino, A; Lefranc, G; Akatcherian, C; Megarbane, A; Gilissen, C; Moshous, D; Reichenbach, J; Misbah, S; Salzer, U; Abinun, M; Ong, PY; Stepensky, P; Ruga, E; Ziegler, JB; Wong, M; Tangye, SG; Lindeman, R; Buckley, MF; Roscioli, T				Cliffe, Simon T.; Bloch, Donald B.; Suryani, Santi; Kamsteeg, Erik-Jan; Avery, Danielle T.; Palendira, Umaimainthan; Church, Joseph A.; Wainstein, Brynn K.; Trizzino, Antonino; Lefranc, Gerard; Akatcherian, Carlo; Megarbane, Andre; Gilissen, Christian; Moshous, Despina; Reichenbach, Janine; Misbah, Siraj; Salzer, Uli; Abinun, Mario; Ong, Peck Y.; Stepensky, Polina; Ruga, Ezia; Ziegler, John B.; Wong, Melanie; Tangye, Stuart G.; Lindeman, Robert; Buckley, Michael F.; Roscioli, Tony			Clinical, molecular, and cellular immunologic findings in patients with SP110-associated veno-occlusive disease with immunodeficiency syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Veno-occlusive disease with immunodeficiency; hypogammaglobulinemia; SP110; B-cell development	MEMORY B-CELLS; IMPAIRED HUMORAL IMMUNITY; DIFFERENTIAL EXPRESSION; NUCLEAR-BODY; SECRETING CELLS; GENUS MUS; RECEPTOR; GENERATION; EVOLUTION; CLUSTER	Background: Mutations in the SP110 gene result in infantile onset of the autosomal recessive primary immunodeficiency disease veno-occlusive disease with immunodeficiency syndrome (VODI), which is characterized by hypogammaglobulinemia, T-cell dysfunction, and a high frequency of hepatic veno-occlusive disease. Objectives: We sought to further characterize the clinical features, B-lineage cellular immunologic findings, and molecular pathogenesis of this disorder in 9 patients with new diagnoses, including 4 novel mutations from families of Italian, Hispanic, and Arabic ethnic origin. Methods: Methods used include clinical review; Sanger DNA sequencing of the SP110 gene; determination of transfected mutant protein function by using immunofluorescent studies in Hep-2 cells; quantitation of B-cell subsets by means of flow cytometry; assessments of B-cell function after stimulation with CD40 ligand, IL-21, or both; and differential gene expression array studies of EBV-transformed B cells. Results: We confirm the major diagnostic criteria and the clinical utility of SP110 mutation testing for the diagnosis of VODI. Analysis of 4 new alleles confirms that VODI is caused by reduced functional SP110 protein levels. Detailed B-cell immunophenotyping demonstrated that Sp110 deficiency compromises the ability of human B cells to respond to T cell-dependent stimuli and differentiate into immunoglobulin-secreting cells in vitro. Expression microarray studies have identified pathways involved in B-lymphocyte differentiation and macrophage function. Conclusion: These studies show that a range of mutations in SP110 that cause decreased SP110 protein levels and impaired late B-cell differentiation cause VODI and that the condition is not restricted to the Lebanese population. (J Allergy Clin Immunol 2012;130:735-42.)	[Cliffe, Simon T.; Lindeman, Robert; Buckley, Michael F.; Roscioli, Tony] Prince Wales Hosp, Dept Haematol & Genet, Sydney, NSW 2031, Australia; [Bloch, Donald B.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; [Bloch, Donald B.] Harvard Univ, Sch Med, Boston, MA USA; [Suryani, Santi; Avery, Danielle T.; Palendira, Umaimainthan; Tangye, Stuart G.] Univ New S Wales, Program Immunol, Garvan Inst Med Res, Sydney, NSW, Australia; [Suryani, Santi; Avery, Danielle T.; Palendira, Umaimainthan] Univ New S Wales, St Vincents Clin Sch, Sydney, NSW, Australia; [Kamsteeg, Erik-Jan; Gilissen, Christian] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [Church, Joseph A.; Ong, Peck Y.] Childrens Hosp Los Angeles, Div Clin Immunol & Allergy, Los Angeles, CA USA; [Wainstein, Brynn K.; Ziegler, John B.] Sydney Childrens Hosp, Dept Immunol & Infect Dis, Sydney, NSW, Australia; [Trizzino, Antonino] Osped Bambini G Di Cristina, ARNAS Civico, Palermo, Italy; [Lefranc, Gerard] Univ Montpellier 2, Montpellier, France; [Lefranc, Gerard] CNRS, Inst Human Genet, UPR 1142, Montpellier, France; [Akatcherian, Carlo] St Joseph Univ, Hosp Hotel Dieu France, Dept Pediat, Beirut, Lebanon; [Megarbane, Andre] St Joseph Univ, Fac Med, Med Genet Unit, Beirut, Lebanon; [Moshous, Despina] Univ Paris 05, Fac Med Rene Descartes, IFR94, Paris, France; [Moshous, Despina] Hop Necker Enfants Malad, AP HP, Unite Immunol & Hematol Pediat, Paris, France; [Reichenbach, Janine] Univ Childrens Hosp Zurich, Div Immunol Haematol BMT, Zurich, Switzerland; [Reichenbach, Janine] Univ Childrens Hosp Zurich, Childrens Res Ctr, Zurich, Switzerland; [Reichenbach, Janine] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, CH-8006 Zurich, Switzerland; [Misbah, Siraj] John Radcliffe Hosp, Oxford Ctr Clin Immunol, Dept Clin Immunol, Oxford, England; [Salzer, Uli] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency CCI, Freiburg, Germany; [Salzer, Uli] Univ Freiburg, Freiburg, Germany; [Abinun, Mario] Newcastle Gen Hosp, Dept Paediat Immunol, Newcastle, England; [Stepensky, Polina] Hadassah Univ Hosp, IL-91120 Jerusalem, Israel; [Ruga, Ezia] Univ Padua, Dept Pediat, Padua, Italy; [Wong, Melanie] Childrens Hosp, Dept Allergy Immunol & Infect Dis, Westmead, NSW, Australia; [Roscioli, Tony] Sydney Childrens Hosp, Sch Women & Childrens Hlth, Sydney, NSW, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney; Radboud University Nijmegen; Children's Hospital Los Angeles; University of Sydney; A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; American University of Beirut; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University Children's Hospital Zurich; University Children's Hospital Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Oxford; University of Freiburg; University of Freiburg; Newcastle General Hospital; Hebrew University of Jerusalem; University of Padua; University of Sydney; University of Sydney	Buckley, MF (corresponding author), Prince Wales Hosp, Dept Haematol & Genet, Barker St, Sydney, NSW 2031, Australia.	michael.buckley@sesiahs.health.nsw.gov.au	Moshous, Despina/B-7507-2017; Kamsteeg, Erik-Jan/L-4421-2015; Tangye, Stuart G/H-4023-2014; Reichenbach, Janine/U-2171-2018; Palendira, Umaimainthan/AAA-6447-2022; Ong, Peck Y/AAE-2944-2021; Megarbane, Andre/ABD-5574-2021; Gilissen, Christian/E-5246-2012	Moshous, Despina/0000-0001-6719-3693; Tangye, Stuart G/0000-0002-5360-5180; Reichenbach, Janine/0000-0002-9008-1312; Ong, Peck Y/0000-0002-6664-463X; Gilissen, Christian/0000-0003-1693-9699; Bloch, Donald/0000-0002-6828-4754; buckley, michael/0000-0002-8298-8758; Wainstein, Brynn/0000-0001-5704-650X	Massachusetts General Hospital; Research Council of the Saint Joseph University, Beirut; Robert A Good/Jeffrey Modell Fellowship in Transplantation and Immunodeficiency; Gebert Ruf Stiftung, Program Rare Diseases-New Approaches [GRS-046/10]; NHMRC [427620]; EU Science Directorate [PIIF-GA-2008-221048]; Australian NHMRC postdoctoral research fellowship; Jeffrey Modell Foundation; Chronic Granulomatous Disorder Research Trust; Gebert Ruf Stiftung; European Union Directorate of Science	Massachusetts General Hospital(General Electric); Research Council of the Saint Joseph University, Beirut; Robert A Good/Jeffrey Modell Fellowship in Transplantation and Immunodeficiency; Gebert Ruf Stiftung, Program Rare Diseases-New Approaches; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); EU Science Directorate; Australian NHMRC postdoctoral research fellowship(National Health and Medical Research Council (NHMRC) of Australia); Jeffrey Modell Foundation; Chronic Granulomatous Disorder Research Trust; Gebert Ruf Stiftung; European Union Directorate of Science	Infrastructure support was provided by the Department of Haematology and Genetics, South Eastern Area Laboratory Services, Sydney, and the Department of Human Genetics, Radboud University, Nijmegen Medical Centre. D. B. B. is supported by a grant from the Massachusetts General Hospital. C. A. and A. M. were supported in part by the Research Council of the Saint Joseph University, Beirut. D. M. was supported by the Robert A Good/Jeffrey Modell Fellowship in Transplantation and Immunodeficiency. J.R. was supported by the Gebert Ruf Stiftung, Program Rare Diseases-New Approaches, grant no. GRS-046/10. S. G. T. is an NHMRC Senior Research Fellow with research funding provided by NHMRC Program Grant no. 427620. M. F. B. is the recipient of a Marie Curie Fellowship (PIIF-GA-2008-221048) from the EU Science Directorate. T. R. is supported by an Australian NHMRC postdoctoral research fellowship.; D. Moshous has received research support from the Jeffrey Modell Foundation. J. Reichenbach has received research support from the Chronic Granulomatous Disorder Research Trust and Gebert Ruf Stiftung. M. F. Buckley has received research support from the European Union Directorate of Science. The rest of the authors declare they have no relevant conflicts of interest.	Agematsu K, 1998, BLOOD, V91, P173, DOI 10.1182/blood.V91.1.173; AGULNIK S, 1993, MAMM GENOME, V4, P704, DOI 10.1007/BF00357793; Al-Muhsen S, 2008, J ALLERGY CLIN IMMUN, V122, P1043, DOI 10.1016/j.jaci.2008.10.037; Alnemri ES, 2010, J CLIN IMMUNOL, V30, P512, DOI 10.1007/s10875-010-9419-0; Avery DT, 2008, BLOOD, V112, P1784, DOI 10.1182/blood-2008-02-142745; Bloch DB, 2000, MOL CELL BIOL, V20, P6138, DOI 10.1128/MCB.20.16.6138-6146.2000; Bloch DB, 2005, J RHEUMATOL, V32, P477; Breloer M, 2007, EUR J IMMUNOL, V37, P634, DOI 10.1002/eji.200636852; Cuss AK, 2006, J IMMUNOL, V176, P1506, DOI 10.4049/jimmunol.176.3.1506; Dallaporta B, 2000, CELL DEATH DIFFER, V7, P368, DOI 10.1038/sj.cdd.4400661; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Ellyard JI, 2004, BLOOD, V103, P3805, DOI 10.1182/blood-2003-09-3109; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jacquot S, 1997, J IMMUNOL, V159, P2652; Keerthikumar S, 2009, NUCLEIC ACIDS RES, V37, pD863, DOI 10.1093/nar/gkn682; Leon C, 2006, J IMMUNOL, V176, P5934, DOI 10.4049/jimmunol.176.10.5934; Ma CS, 2005, J CLIN INVEST, V115, P1049, DOI 10.1172/JCI23139; Madani N, 2002, J VIROL, V76, P11133, DOI 10.1128/JVI.76.21.11133-11138.2002; Mihalci SA, 2010, J IMMUNOL, V185, P1045, DOI 10.4049/jimmunol.1001120; Nicewonger J, 2004, J VIROL, V78, P9412, DOI 10.1128/JVI.78.17.9412-9422.2004; Pathak SK, 2005, J BIOL CHEM, V280, P42794, DOI 10.1074/jbc.M506471200; Romero X, 2004, TISSUE ANTIGENS, V64, P132, DOI 10.1111/j.1399-0039.2004.00247.x; Roscioli T, 2006, NAT GENET, V38, P620, DOI 10.1038/ng1780; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Suryani S, 2010, BLOOD, V115, P519, DOI 10.1182/blood-2009-07-234799; Tangye SG, 2003, J IMMUNOL, V170, P261, DOI 10.4049/jimmunol.170.1.261; Tangye SG, 2007, J IMMUNOL, V179, P13, DOI 10.4049/jimmunol.179.1.13; Traut W, 2001, CHROMOSOMA, V110, P247, DOI 10.1007/s004120100152; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Weichenhan D, 2001, MAMM GENOME, V12, P590, DOI 10.1007/s00335-001-3015-9	32	32	32	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					735	+		10.1016/j.jaci.2012.02.054	http://dx.doi.org/10.1016/j.jaci.2012.02.054			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22621957				2022-12-18	WOS:000308463500024
J	Tang, YF; Guan, SP; Chua, BYL; Zhou, Q; Ho, AWS; Wong, KHS; Wong, KL; Wong, WSF; Kemeny, DM				Tang, Yafang; Guan, Shou Ping; Chua, Benson Y. L.; Zhou, Qian; Ho, Adrian W. S.; Wong, Kenneth H. S.; Wong, Kok Loon; Wong, W. S. Fred; Kemeny, David M.			Antigen-specific effector CD8 T cells regulate allergic responses via IFN-gamma and dendritic cell function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; OT-I; IFN-gamma(-/-) OT-I; CD8 T cells; effector; IFN-gamma; eosinophils; CD11b(+)CD103(-)DC; T(H)1	STIMULATORY FACTOR INTERLEUKIN-12; BRONCHOALVEOLAR LAVAGE FLUID; BLOOD MONONUCLEAR-CELLS; AIRWAY SMOOTH-MUSCLE; BROWN-NORWAY RATS; IGE RESPONSES; MURINE MODEL; BRONCHIAL HYPERRESPONSIVENESS; EOSINOPHILIC BRONCHITIS; INDUCED SENSITIZATION	Background: Previous studies have shown that CD8 T cells can both prevent and cause allergic responses. However, the underlying mechanisms remain to be elucidated. Objective: We aim to investigate the potential of CD8 T cells with different IFN-gamma expressions to modulate the elicitation of allergic inflammation following ovalbumin (OVA) challenge and investigate the underlying mechanisms. Methods: To study the role of IFN-gamma in the effect of CD8 T cells, effector CD8 T cells from CD8 OVA transgenic (OT-I) mice and IFN-gamma(-/-) OT-I mice were transferred to OVA-sensitized mice the day before 3 challenges with OVA. The effect on lung dendritic cells (DCs) exerted by CD8 T cells was studied with ex vivo culture of sorted DCs from treatment mice with CD4 T cells. Results: Effector OT-I, but not IFN-gamma(-/-) OT-I CD8 T cells, attenuated eosinophilia and mucus secretion in the lungs of sensitized mice in an antigen-specific manner. Effector IFN-gamma(-/-) OT-I CD8 T cells displayed a Tc2-/Tc17-biased phenotype with weaker cytotoxicity and were able to both induce and exacerbate eosinophilia as well as neutrophilia. OT-I CD8 T cells increased the ability of lung CD11b(+)CD103(-) DCs to both prime the differentiation of naive OVA-specific CD4 T cells toward a T(H)1 phenotype and enhance IFN-gamma production by antigen-experienced lung CD4 T cells. Conclusion: Effector CD8 T cells attenuate pulmonary inflammation and alter the ability of DCs within the allergic lung to polarize T cells to a T(H)1 phenotype during a T(H)2 response. In the absence of IFN-gamma, CD8 T cells assume a Tc2-/Tc17-biased phenotype and potentiate inflammation. (J Allergy Clin Immunol 2012; 129: 1611-20.)	[Tang, Yafang; Guan, Shou Ping; Chua, Benson Y. L.; Zhou, Qian; Ho, Adrian W. S.; Wong, Kenneth H. S.; Wong, W. S. Fred; Kemeny, David M.] Natl Univ Singapore, Ctr Life Sci, Immunol Programme, Singapore 117456, Singapore; [Tang, Yafang; Chua, Benson Y. L.; Zhou, Qian; Ho, Adrian W. S.; Wong, Kenneth H. S.; Kemeny, David M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117456, Singapore; [Tang, Yafang; Kemeny, David M.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn NGS, Singapore 117456, Singapore; [Guan, Shou Ping; Wong, W. S. Fred] Natl Univ Singapore, Dept Pharmacol, Yong Loo Lin Sch Med, Natl Univ Hlth Syst, Singapore 117456, Singapore; [Wong, Kok Loon] Biopolis, Agcy Sci Technol & Res, Singapore Immunol Network, Singapore, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN)	Kemeny, DM (corresponding author), Natl Univ Singapore, Ctr Life Sci, Immunol Programme, 03-05,28 Med Dr, Singapore 117456, Singapore.	mickdm@nus.edu.sg	Wong, Wai Shui Fred/D-8205-2013	Ho, Adrian/0000-0002-6501-5196; Wong, Wai Shiu Fred/0000-0001-7010-3759	Biomedical Research Council [BMRC 05/1/21/19/41]; National University of Singapore; National Research Foundation HUJ-CREATE	Biomedical Research Council(Agency for Science Technology & Research (A*STAR)); National University of Singapore(National University of Singapore); National Research Foundation HUJ-CREATE	This work was supported by the Biomedical Research Council (grant no. BMRC 05/1/21/19/41). Y.T. was supported by an National University of Singapore scholarship. D. M. K. is supported by the National Research Foundation HUJ-CREATE programme on Cellular and Molecular Mechanisms of Inflammation.	Aguilar-Pimentel JA, 2010, AM J RESP CRIT CARE, V181, P7, DOI 10.1164/rccm.200902-0190OC; Berend N, 2008, RESPIROLOGY, V13, P624, DOI 10.1111/j.1440-1843.2008.01330.x; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Busse WW, 2010, CHEST, V138, p4S, DOI 10.1378/chest.10-0100; BUSSE WW, 1995, AM J RESP CRIT CARE, V152, P388, DOI 10.1164/ajrccm.152.1.7599853; Castilow EM, 2008, J IMMUNOL, V180, P2376, DOI 10.4049/jimmunol.180.4.2376; Cheung PFY, 2008, J IMMUNOL, V180, P5625, DOI 10.4049/jimmunol.180.8.5625; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; del Rio ML, 2007, J IMMUNOL, V178, P6861, DOI 10.4049/jimmunol.178.11.6861; Desch AN, 2011, J EXP MED, V208, P1789, DOI 10.1084/jem.20110538; DIAZSANCHEZ D, 1993, IMMUNOLOGY, V78, P226; Dragon S, 2007, AM J PHYSIOL-LUNG C, V292, pL1023, DOI 10.1152/ajplung.00306.2006; Finkelman FD, 2010, J IMMUNOL, V184, P1663, DOI 10.4049/jimmunol.0902185; GIBSON PG, 1989, LANCET, V1, P1346; Gibson PG, 2000, J ALLERGY CLIN IMMUN, V105, P752, DOI 10.1067/mai.2000.105319; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Heidema J, 2007, J IMMUNOL, V179, P8410, DOI 10.4049/jimmunol.179.12.8410; Holmes BJ, 1996, IMMUNOLOGY, V88, P252, DOI 10.1111/j.1365-2567.1996.tb00012.x; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Huang TJ, 1999, IMMUNOLOGY, V96, P416; Intlekofer AM, 2008, SCIENCE, V321, P408, DOI 10.1126/science.1159806; Ishimitsu R, 2001, J IMMUNOL, V166, P1991, DOI 10.4049/jimmunol.166.3.1991; Joetham A, 2011, J IMMUNOL, V186, P113, DOI 10.4049/jimmunol.1001663; Kawaguchi Mio, 2009, Inflammation & Allergy Drug Targets, V8, P383; Lewis Christina C, 2009, J Allergy Clin Immunol, V123, P795, DOI 10.1016/j.jaci.2009.01.003; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; Meissner N, 1997, CLIN EXP ALLERGY, V27, P1402, DOI 10.1111/j.1365-2222.1997.tb02984.x; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Miyahara N, 2004, J IMMUNOL, V172, P2549, DOI 10.4049/jimmunol.172.4.2549; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; NOBLE A, 1995, J IMMUNOL, V155, P2928; OKUMURA K, 1977, J EXP MED, V146, P1234, DOI 10.1084/jem.146.5.1234; Peterson KE, 2002, J VIROL, V76, P7942, DOI 10.1128/JVI.76.16.7942-7948.2002; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; RENZ H, 1994, J IMMUNOL, V152, P351; Robinson DS, 2010, J ALLERGY CLIN IMMUN, V126, P1081, DOI 10.1016/j.jaci.2010.06.025; Sawicka E, 2004, EUR J IMMUNOL, V34, P2599, DOI 10.1002/eji.200425018; Schaller MA, 2005, EUR J IMMUNOL, V35, P2061, DOI 10.1002/eji.200425715; SEDER RA, 1992, J IMMUNOL, V148, P1652; SEDGWICK JD, 1984, EUR J IMMUNOL, V14, P893, DOI 10.1002/eji.1830141006; Stock P, 2004, EUR J IMMUNOL, V34, P1817, DOI 10.1002/eji.200324623; Sud D, 2006, J IMMUNOL, V176, P4296, DOI 10.4049/jimmunol.176.7.4296; Sung SSJ, 2006, J IMMUNOL, V176, P2161, DOI 10.4049/jimmunol.176.4.2161; Suzuki M, 2002, J ALLERGY CLIN IMMUN, V109, P803, DOI 10.1067/mai.2002.123233; Suzuki M, 1999, J IMMUNOL, V163, P5574; TADA T, 1972, J IMMUNOL, V108, P1535; Takeda K, 2009, J IMMUNOL, V183, P181, DOI 10.4049/jimmunol.0803967; Taube C, 2006, J IMMUNOL, V176, P3157, DOI 10.4049/jimmunol.176.5.3157; Thomas MJ, 2002, J IMMUNOL, V168, P216, DOI 10.4049/jimmunol.168.1.216; Uzonna JE, 2004, J EXP MED, V199, P1559, DOI 10.1084/jem.20040172; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wells JW, 2007, J ALLERGY CLIN IMMUN, V119, P226, DOI 10.1016/j.jaci.2006.09.004; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Wong KL, 2008, EUR J IMMUNOL, V38, P2251, DOI 10.1002/eji.200838199; Yen HR, 2009, J IMMUNOL, V183, P7161, DOI 10.4049/jimmunol.0900368; Ying S, 1997, J IMMUNOL, V158, P3539	64	32	33	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1611	+		10.1016/j.jaci.2011.12.976	http://dx.doi.org/10.1016/j.jaci.2011.12.976			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22385629				2022-12-18	WOS:000304764600023
J	Fukutomi, Y; Sjolander, S; Nakazawa, T; Borres, MP; Ishii, T; Nakayama, S; Tanaka, A; Taniguchi, M; Saito, A; Yasueda, H; Nakamura, H; Akiyama, K				Fukutomi, Yuma; Sjolander, Sigrid; Nakazawa, Takuya; Borres, Magnus P.; Ishii, Toyota; Nakayama, Satoshi; Tanaka, Akira; Taniguchi, Masami; Saito, Akemi; Yasueda, Hiroshi; Nakamura, Hiroyuki; Akiyama, Kazuo			Clinical relevance of IgE to recombinant Gly m 4 in the diagnosis of adult soybean allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BIRCH POLLEN; SOY; CHILDREN		[Fukutomi, Yuma; Nakazawa, Takuya; Ishii, Toyota; Taniguchi, Masami; Saito, Akemi; Yasueda, Hiroshi; Akiyama, Kazuo] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Fukutomi, Yuma; Nakamura, Hiroyuki] Kanazawa Univ, Dept Environm & Prevent Med, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan; [Sjolander, Sigrid; Borres, Magnus P.] Thermo Fisher Sci, ImmunoDiagnost, Uppsala, Sweden; [Borres, Magnus P.] Univ Gothenburg, Dept Pediat, Sahlgrenska Acad, Gothenburg, Sweden; [Nakayama, Satoshi; Tanaka, Akira] Thermo Fisher Sci, ImmunoDiagnost, Tokyo, Japan	Kanazawa University; Thermo Fisher Scientific; University of Gothenburg; Thermo Fisher Scientific	Fukutomi, Y (corresponding author), Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan.	y-fukutomi@sagamihara-hosp.gr.jp	Fukutomi, Yuma/AFQ-4306-2022	Fukutomi, Yuma/0000-0001-9913-4524	Grants-in-Aid for Scientific Research [21500629, 24791017] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Ebisawa Motohiro, 2006, Arerugi, V55, P107; Holzhauser T, 2009, J ALLERGY CLIN IMMUN, V123, P452, DOI 10.1016/j.jaci.2008.09.034; Ito K, 2011, J ALLERGY CLIN IMMUN, V128, P673, DOI 10.1016/j.jaci.2011.04.025; Kosma P, 2011, ACTA PAEDIATR, V100, P305, DOI 10.1111/j.1651-2227.2010.02049.x; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Skypala IJ, 2011, CLIN EXP ALLERGY, V41, P1001, DOI 10.1111/j.1365-2222.2011.03759.x; van Zuuren EJ, 2010, ALLERGY, V65, P1348, DOI 10.1111/j.1398-9995.2010.02357.x; Yagami A, 2009, J DERMATOL, V36, P50, DOI 10.1111/j.1346-8138.2008.00585.x	8	32	32	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					860	863		10.1016/j.jaci.2012.01.031	http://dx.doi.org/10.1016/j.jaci.2012.01.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22285279	Green Submitted			2022-12-18	WOS:000301189300040
J	Micol, R; Kayal, S; Mahlaoui, N; Beaute, J; Brosselin, P; Dudoit, Y; Obenga, G; Barlogis, V; Aladjidi, N; Kebaili, K; Thomas, C; Dulieu, F; Monpoux, F; Nove-Josserand, R; Pellier, I; Lambotte, O; Salmon, A; Masseau, A; Galanaud, P; Oksenhendler, E; Tabone, MD; Teira, P; Coignard-Biehler, H; Lanternier, F; Join-Lambert, O; Mouillot, G; Theodorou, I; Lecron, JC; Alyanakian, MA; Picard, C; Blanche, S; Hermine, O; Suarez, F; Debre, M; Lecuit, M; Lortholary, O; Durandy, A; Fischer, A				Micol, Romain; Kayal, Samer; Mahlaoui, Nizar; Beaute, Julien; Brosselin, Pauline; Dudoit, Yasmine; Obenga, Gaelle; Barlogis, Vincent; Aladjidi, Nathalie; Kebaili, Kamila; Thomas, Caroline; Dulieu, Fabienne; Monpoux, Fabrice; Nove-Josserand, Raphaele; Pellier, Isabelle; Lambotte, Olivier; Salmon, Alexandra; Masseau, Agathe; Galanaud, Pierre; Oksenhendler, Eric; Tabone, Marie-Dominique; Teira, Pierre; Coignard-Biehler, Helene; Lanternier, Fanny; Join-Lambert, Olivier; Mouillot, Gael; Theodorou, Ioannis; Lecron, Jean-Claude; Alyanakian, Marie-Alexandra; Picard, Capucine; Blanche, Stephane; Hermine, Olivier; Suarez, Felipe; Debre, Marianne; Lecuit, Marc; Lortholary, Olivier; Durandy, Anne; Fischer, Alain			Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Haemophilus influenzae; infections; immunoglobulins; IgM; immunodeficiency	X-LINKED AGAMMAGLOBULINEMIA; COMMON VARIABLE IMMUNODEFICIENCY; INDUCED CYTIDINE DEAMINASE; OUTER-MEMBRANE PROTEIN; REPLACEMENT THERAPY; MOLECULAR ANALYSIS; IMMUNIZATION; DISEASE; BRONCHIECTASIS; INFECTION	Background: Primary immunoglobulin deficiencies lead to recurrent bacterial infections of the respiratory tract and bronchiectasis, even with adequate immunoglobulin replacement therapy. It is not known whether patients able to secrete IgM (eg, those with hyper-IgM [HIgM] syndrome) are as susceptible to these infections as patients who lack IgM production (eg, those with panhypogammaglobulinemia [PHG]). Objective: This study is aimed at identifying specific microbiological and clinical (infections) characteristics that distinguish immunoglobulin-substituted patients with PHG from patients with HIgM syndrome. Methods: A cohort of patients with HIgM syndrome (n = 25) and a cohort of patients with PHG (n = 86) were monitored prospectively for 2 years while receiving similar polyvalent immunoglobulin replacement therapies. Regular bacterial analyses of nasal swabs and sputum were performed, and clinical events were recorded. In parallel, serum and saliva IgM antibody concentrations were measured. Results: When compared with patients with PHG, patients with HIgM syndrome were found to have a significantly lower risk of nontypeable Haemophilus influenzae carriage in particular (relative risk, 0.39; 95% CI, 0.21-0.63). Moreover, patients with HIgM syndrome (including those unable to generate somatic hypermutations of immunoglobulin genes) displayed anti-nontypeable H influenzae IgM antibodies in their serum and saliva. Also, patients with HIgM syndrome had a lower incidence of acute respiratory tract infections. Conclusions: IgM antibodies appear to be microbiologically and clinically protective and might thus attenuate the infectious consequences of a lack of production of other immunoglobulin isotypes in patients with HIgM syndrome. Polyvalent IgG replacement therapy might not fully compensate for IgM deficiency. It might thus be worth adapting long-term antimicrobial prophylactic regimens according to the underlying B-cell immunodeficiency phenotype. (J Allergy Clin Immunol 2012; 129: 770-7.)	[Fischer, Alain] Hop Necker Enfants Malad, Pediat Immunol Hematol Dept, INSERM, U768, Paris, France; [Micol, Romain; Mahlaoui, Nizar; Beaute, Julien; Brosselin, Pauline; Dudoit, Yasmine; Obenga, Gaelle; Barlogis, Vincent; Aladjidi, Nathalie; Kebaili, Kamila; Thomas, Caroline; Dulieu, Fabienne; Monpoux, Fabrice; Nove-Josserand, Raphaele; Pellier, Isabelle; Lambotte, Olivier; Salmon, Alexandra; Masseau, Agathe; Galanaud, Pierre; Oksenhendler, Eric; Tabone, Marie-Dominique; Teira, Pierre; Picard, Capucine; Blanche, Stephane; Hermine, Olivier; Suarez, Felipe; Debre, Marianne; Lecuit, Marc; Lortholary, Olivier; Fischer, Alain] Hop Necker Enfants Malad, AP HP, CEREDIH Network, French Natl Reference Ctr Primary Immunodeficienc, Paris, France; [Kayal, Samer; Join-Lambert, Olivier] Hop Necker Enfants Malad, AP HP, Serv Bacteriol Virol Parasitol & Hyg, Paris, France; [Micol, Romain; Kayal, Samer; Join-Lambert, Olivier; Alyanakian, Marie-Alexandra; Picard, Capucine; Blanche, Stephane; Hermine, Olivier; Suarez, Felipe; Lecuit, Marc; Lortholary, Olivier; Fischer, Alain] Univ Paris 05, Paris, France; [Micol, Romain; Mahlaoui, Nizar; Picard, Capucine; Blanche, Stephane; Debre, Marianne; Durandy, Anne; Fischer, Alain] Hop Necker Enfants Malad, AP HP, Unite Immunol & Hematol Pediat, Paris, France; [Barlogis, Vincent] Hop Enfants La Timone, AP HM, Serv Hematol Pediat, Marseille, France; [Aladjidi, Nathalie] Ctr Hosp Pellegrin, Serv Hematol Pediat, Bordeaux, France; [Kebaili, Kamila] Inst Hematol & Oncol Pediat, Lyon, France; [Thomas, Caroline] Hop Mere Enfants, Serv Hematol Oncol, Nantes, France; [Dulieu, Fabienne] Fdn Lenval, Serv Pediat, Nice, France; [Monpoux, Fabrice] Hop Archet II, Serv Pediat Hematol, Nice, France; [Nove-Josserand, Raphaele] Hop Lyon Sud, Serv Med Interne, Lyon, France; [Pellier, Isabelle] Ctr R Debre, Unite Immunohematol Oncol Pediat, Angers, France; [Lambotte, Olivier] Hop Bicetre, Serv Med Interne & Malad Infect, Le Kremlin Bicetre, France; [Salmon, Alexandra] Hop Enfants, Serv Hemato Oncol Pediat & Transplantat Medullair, Nancy, France; [Masseau, Agathe] Hop Hotel Dieu, Serv Med Interne, Nantes, France; [Galanaud, Pierre] Hop Antoine Beclere, Serv Med Interne Immunol Clin, Clamart, France; [Oksenhendler, Eric] Hop St Louis, Serv Immunol Clin, Paris, France; [Tabone, Marie-Dominique] Hop Armand Trousseau, Serv Hematol Immunol Oncol Pediat, Paris, France; [Teira, Pierre] Hop Purpan, Serv Pediat Hematol Oncol, Toulouse, France; [Coignard-Biehler, Helene; Lanternier, Fanny; Lecuit, Marc; Lortholary, Olivier] Hop Necker Enfants Malad, AP HP, Serv Malad Infect & Trop, Ctr Infectiol Necker Pasteur, Paris, France; [Mouillot, Gael; Theodorou, Ioannis] Hop La Pitie Salpetriere, Serv Immunol Biol, Paris, France; [Lecron, Jean-Claude] Univ Poitiers, Lab Inflammat Tissus Epitheliaux & Cytokines, EA 4331, CHU Poitiers, Poitiers, France; [Alyanakian, Marie-Alexandra] Univ Paris 05, Immunol Lab, Hop Necker Enfants Malad, AP HP, Paris, France; [Picard, Capucine] Hop Necker Enfants Malad, AP HP, Ctr Etude Deficits Immunitaires, Paris, France; [Picard, Capucine] Fac Med Necker Enfants Malad, Lab Genet Humain Malad Infect, INSERM, U980, Paris, France; [Hermine, Olivier; Suarez, Felipe] Hop Necker Enfants Malad, AP HP, Serv Hematol Adulte, Paris, France; [Lecuit, Marc] Inst Pasteur, INSERM Avenir U604, Grp Microorganismes & Barrieres Hote, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Bordeaux; Nantes Universite; CHU de Nantes; CHU Nice; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; CHU de Nancy; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Poitiers; Universite de Poitiers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Fischer, A (corresponding author), Hop Necker Enfants Malad, Pediat Immunol Hematol Dept, INSERM, U768, Paris, France.	alain.fischer@inserm.fr	Picard, Capucine/H-3914-2017; Lambotte, Olivier/GRT-0160-2022; isabelle, pellier/L-5683-2015; Hermine, Olivier/Q-7072-2018; Lanternier, Fanny/AAQ-2815-2021; MAHLAOUI, Nizar/AAH-6103-2020; Join-Lambert, Olivier/AAE-5205-2019; Lecuit, Marc/M-4126-2019; Mahlaoui, Nizar/J-7928-2017; Lecuit, Marc/J-4073-2013; Durandy, Anne/H-7475-2017	Picard, Capucine/0000-0001-8788-5056; MAHLAOUI, Nizar/0000-0002-0030-8094; Lecuit, Marc/0000-0002-4491-1063; Mahlaoui, Nizar/0000-0002-0030-8094; Lecuit, Marc/0000-0002-4491-1063; Durandy, Anne/0000-0001-7706-8466; LECRON, Jean-Claude/0000-0003-3990-5213; Hermine, Olivier/0000-0003-2574-3874	French Ministry of Health; INSERM, Assistance Publique-Hopitaux de Paris [P060308]; European Community [201549]; ARC (Association pour la Recherche sur le Cancer)	French Ministry of Health; INSERM, Assistance Publique-Hopitaux de Paris(Institut National de la Sante et de la Recherche Medicale (Inserm)); European Community(European Commission); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer)	Supported by an institutional grant from the French Ministry of Health to the Rare Diseases National Reference Centre for Primary Immune Deficiencies (CEREDIH), by INSERM, Assistance Publique-Hopitaux de Paris [grant no. P060308], a senior ERC grant "PIDIMMUN" [grant no. 249816], by the European Community 7th Framework Programme: Euro PADnet (grant no. 201549), and by ARC (Association pour la Recherche sur le Cancer).	Akkoyunlu M, 1996, APMIS, V104, P709, DOI 10.1111/j.1699-0463.1996.tb04933.x; Bandi V, 2001, AM J RESP CRIT CARE, V164, P2114, DOI 10.1164/ajrccm.164.11.2104093; Basile N, 2009, J CLIN IMMUNOL, V29, P123, DOI 10.1007/s10875-008-9227-y; Brandtzaeg P, 2005, IMMUNOL REV, V206, P32, DOI 10.1111/j.0105-2896.2005.00283.x; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Cutter D, 2002, J INFECT DIS, V186, P1115, DOI 10.1086/344233; DeMaria TF, 1996, INFECT IMMUN, V64, P5187, DOI 10.1128/IAI.64.12.5187-5192.1996; Durandy Anne, 2007, Adv Immunol, V94, P275, DOI 10.1016/S0065-2776(06)94009-7; Ehrenstein MR, 2010, NAT REV IMMUNOL, V10, P778, DOI 10.1038/nri2849; Eldika N, 2006, CURR OPIN PULM MED, V12, P118, DOI 10.1097/01.mcp.0000208451.50231.8f; Erwin AL, 2007, TRENDS MICROBIOL, V15, P355, DOI 10.1016/j.tim.2007.06.004; Fagarasan S, 2002, SCIENCE, V298, P1424, DOI 10.1126/science.1077336; Ferry BL, 2005, CLIN EXP IMMUNOL, V140, P532, DOI 10.1111/j.1365-2249.2005.02793.x; GREEN BA, 1991, INFECT IMMUN, V59, P3191, DOI 10.1128/IAI.59.9.3191-3198.1991; Gross J, 2008, J BIOL CHEM, V283, P26010, DOI 10.1074/jbc.M801819200; Harada Y, 2003, J EXP MED, V197, P1779, DOI 10.1084/jem.20021457; Hendrixson DR, 1998, MOL CELL, V2, P841, DOI 10.1016/S1097-2765(00)80298-1; Howard V, 2006, CLIN IMMUNOL, V118, P201, DOI 10.1016/j.clim.2005.11.002; Kainulainen L, 1999, AM J RESP CRIT CARE, V159, P1199, DOI 10.1164/ajrccm.159.4.9807067; Kainulainen L, 2007, ARCH OTOLARYNGOL, V133, P597, DOI 10.1001/archotol.133.6.597; King PT, 2008, CLIN EXP IMMUNOL, V153, P376, DOI 10.1111/j.1365-2249.2008.03697.x; King PT, 2007, RESP MED, V101, P1633, DOI 10.1016/j.rmed.2007.03.009; Lindberg K, 2001, SCAND J INFECT DIS, V33, P904, DOI 10.1080/00365540110076769; Murphy TF, 2009, PEDIATR INFECT DIS J, V28, P43, DOI 10.1097/INF.0b013e318184dba2; Oksenhendler E, 2008, CLIN INFECT DIS, V46, P1547, DOI 10.1086/587669; PATERSON AJ, 1987, EPIDEMIOL INFECT, V99, P179, DOI 10.1017/S0950268800067017; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Plebani A, 2002, CLIN IMMUNOL, V104, P221, DOI 10.1006/clim.2002.5241; Quartier P, 1999, J PEDIATR-US, V134, P589, DOI 10.1016/S0022-3476(99)70246-5; Rao VK, 1999, FEMS MICROBIOL REV, V23, P99, DOI 10.1016/S0168-6445(98)00039-4; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; STGEME JW, 1994, MOL MICROBIOL, V14, P217, DOI 10.1111/j.1365-2958.1994.tb01283.x; Tsang RSW, 2007, CLIN INFECT DIS, V44, P1611, DOI 10.1086/518283; TURK DC, 1984, J MED MICROBIOL, V18, P1, DOI 10.1099/00222615-18-1-1; Twiss J, 2006, THORAX, V61, P414, DOI 10.1136/thx.2005.047332; Winter LE, 2006, CLIN VACCINE IMMUNOL, V13, P1333, DOI 10.1128/CVI.00221-06	37	32	32	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					770	777		10.1016/j.jaci.2011.09.047	http://dx.doi.org/10.1016/j.jaci.2011.09.047			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22153772				2022-12-18	WOS:000301189300024
J	Caubet, JC; Nowak-Wegrzyn, A				Caubet, Jean-Christoph; Nowak-Wegrzyn, Anna			Food protein-induced enterocolitis to hen's egg	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							MANAGEMENT; CHALLENGE		[Caubet, Jean-Christoph; Nowak-Wegrzyn, Anna] Mt Sinai Sch Med, Jaffe Food Allergy Inst, Dept Pediat, Div Allergy & Immunol, New York, NY 10028 USA; [Caubet, Jean-Christoph] Univ Hosp Geneva, Dept Child & Adolescent, Geneva, Switzerland; [Caubet, Jean-Christoph] Univ Geneva, Sch Med, CH-1211 Geneva 4, Switzerland	Icahn School of Medicine at Mount Sinai; University of Geneva; University of Geneva	Caubet, JC (corresponding author), Mt Sinai Sch Med, Pediat Allergy & Immunol Div, 1245 Pk Ave, New York, NY 10028 USA.	jeanchristoph.caubet@gmail.com		Nowak-Wegrzyn, Anna/0000-0002-0960-9854				[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Benhamou AH, 2010, ALLERGY, V65, P283, DOI 10.1111/j.1398-9995.2009.02251.x; Hwang JB, 2009, ARCH DIS CHILD, V94, P425, DOI 10.1136/adc.2008.143289; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, P647, DOI 10.1016/j.jaci.2010.12.1105; Lake AM, 2000, J PEDIATR GASTR NUTR, V30, pS58, DOI 10.1097/00005176-200001001-00009; MCDONALD PJ, 1984, PEDIATR RES, V18, P751, DOI 10.1203/00006450-198408000-00016; Monti G, 2011, J ALLERGY CLIN IMMUN, V127, P679, DOI 10.1016/j.jaci.2010.10.017; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033	11	32	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1386	1388		10.1016/j.jaci.2011.07.011	http://dx.doi.org/10.1016/j.jaci.2011.07.011			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21851972				2022-12-18	WOS:000298342700044
J	Wang, B; Jia, J; Zhang, X; Zcharia, E; Vlodavsky, I; Pejler, G; Li, JP				Wang, Bo; Jia, Juan; Zhang, Xiao; Zcharia, Eyal; Vlodavsky, Israel; Pejler, Gunnar; Li, Jin-Ping			Heparanase affects secretory granule homeostasis of murine mast cells through degrading heparin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; heparin; heparanase; protease; allergy	MACROMOLECULAR HEPARIN; MAMMALIAN HEPARANASE; SERGLYCIN PROTEOGLYCAN; MOUSE MASTOCYTOMA; EXPRESSION; INFLAMMATION; PROTEASES; SULFATE; CLONING; ENZYME	Background: Heparanase degradation of heparan sulfate plays important roles in a number of pathological processes, including inflammation. In vitro experiments show that heparanase is capable of degrading heparin, a polysaccharide present in mast cells (MCs), in which it has a key role in promoting the storage of secretory granule compounds. Objective: We sought to investigate the functions of heparanase in MCs. Methods: Primarily cultured fetal skin-derived mast cells (FSMCs) isolated from embryos and adult peritoneal MCs were analyzed for storage and release of granule molecules in response to MC activation. Results: FSMCs from heparanase-overexpressing mice contained substantially shorter heparin chains and significantly less proteases than control cells. Conversely, FSMCs lacking heparanase contained heparin of larger size and more proteases than control cells. Correspondingly, heparanase-overexpressing adult MCs exhibited reduced release of heparin-bound proteases, a finding that could be attributed to spontaneous release of granular compounds. Heparanase was found to be upregulated in MCs on activation. Conclusion: These findings reveal a novel function of heparanase in maintaining MC homeostasis through controlled degradation of heparin present in the MC secretory granules. (J Allergy Clin Immunol 2011;128:1310-7.)	[Wang, Bo; Jia, Juan; Li, Jin-Ping] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Zhang, Xiao] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden; [Zcharia, Eyal; Vlodavsky, Israel] Technion Israel Inst Technol, Canc & Vasc Biol Res Ctr, Haifa, Israel; [Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden	Uppsala University; Uppsala University; Technion Israel Institute of Technology; Swedish University of Agricultural Sciences	Li, JP (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.	Jin-Ping.Li@imbim.uu.se			Swedish Medical Research Council [K2009 67X 21128 01 3]; Swedish Cancer Research Foundation [09 0717]; Polysackaridforskning Foundation (Uppsala, Sweden); National Institutes of Health [CA106456]; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Cancer Research Foundation; Polysackaridforskning Foundation (Uppsala, Sweden); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by the Swedish Medical Research Council (K2009 67X 21128 01 3), the Swedish Cancer Research Foundation (09 0717), the Polysackaridforskning Foundation (Uppsala, Sweden), and National Institutes of Health grant CA106456 (I.V.).	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; Feyerabend TB, 2006, NAT CHEM BIOL, V2, P195, DOI 10.1038/nchembio777; Feyerabend TB, 2005, MOL CELL BIOL, V25, P6199, DOI 10.1128/MCB.25.14.6199-6210.2005; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Galvis MLE, 2007, NAT CHEM BIOL, V3, P773, DOI 10.1038/nchembio.2007.41; Gong F, 2003, J BIOL CHEM, V278, P35152, DOI 10.1074/jbc.M300925200; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; Henningsson F, 2006, FEBS J, V273, P4901, DOI 10.1111/j.1742-4658.2006.05489.x; HORNER AA, 1971, J BIOL CHEM, V246, P231; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Lindahl U., 1989, HEPARIN, P159; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lundequist A, 2011, CELL MOL LIFE SCI, V68, P965, DOI 10.1007/s00018-010-0587-0; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Massena S, 2010, BLOOD, V116, P1924, DOI 10.1182/blood-2010-01-266072; McKenzie EA, 2007, BRIT J PHARMACOL, V151, P1, DOI 10.1038/sj.bjp.0707182; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; OGREN S, 1975, J BIOL CHEM, V250, P2690; PEJLER G, 1994, J BIOL CHEM, V269, P14451; Pejler G, 2007, ADV IMMUNOL, V95, P167, DOI 10.1016/S0065-2776(07)95006-3; Pejler G, 2010, BLOOD, V115, P4981, DOI 10.1182/blood-2010-01-257287; Peterson SB, 2010, J BIOL CHEM, V285, P14504, DOI 10.1074/jbc.M110.104166; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Ringvall M, 2008, J ALLERGY CLIN IMMUN, V121, P1020, DOI 10.1016/j.jaci.2007.11.031; SALI A, 1993, J BIOL CHEM, V268, P9023; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; Spiegel A, 2008, BLOOD, V111, P4934, DOI 10.1182/blood-2007-10-116145; Stevens R L, 1989, Prog Clin Biol Res, V297, P131; Stevens RL, 2007, IMMUNOL REV, V217, P155, DOI 10.1111/j.1600-065X.2007.00525.x; THUNBERG L, 1982, J BIOL CHEM, V257, P278; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Waern I, 2010, MOL IMMUNOL, V47, P1467, DOI 10.1016/j.molimm.2010.02.004; Welle M, 1997, J LEUKOCYTE BIOL, V61, P233, DOI 10.1002/jlb.61.3.233; Zcharia E, 2005, FASEB J, V19, P211, DOI 10.1096/fj.04-1970com; Zcharia E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005181	41	32	34	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1310	U680		10.1016/j.jaci.2011.04.011	http://dx.doi.org/10.1016/j.jaci.2011.04.011			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21575986	Green Accepted			2022-12-18	WOS:000298342700022
J	Bosticardo, M; Draghici, E; Schena, F; Sauer, AV; Fontana, E; Castiello, MC; Catucci, M; Locci, M; Naldini, L; Aiuti, A; Roncarolo, MG; Poliani, PL; Traggiai, E; Villa, A				Bosticardo, Marita; Draghici, Elena; Schena, Francesca; Sauer, Aisha Vanessa; Fontana, Elena; Castiello, Maria Carmina; Catucci, Marco; Locci, Michela; Naldini, Luigi; Aiuti, Alessandro; Roncarolo, Maria Grazia; Poliani, Pietro Luigi; Traggiai, Elisabetta; Villa, Anna			Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gene therapy; lentiviral vectors; primary immunodeficiency; Wiskott-Aldrich syndrome; B cells; autoimmunity	BONE-MARROW-TRANSPLANTATION; SYNDROME PROTEIN-DEFICIENCY; HEMATOPOIETIC-CELLS; WASP; HOMEOSTASIS; IMMUNODEFICIENCIES; LYMPHOCYTES; ACTIVATION; EXPRESSION; EFFICACY	Background: Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency characterized by thrombocytopenia, eczema, infections, autoimmunity, and lymphomas. Transplantation of hematopoietic stem cells from HLA-identical donors is curative, but it is not available to all patients. We have developed a gene therapy (GT) approach for WAS by using a lentiviral vector encoding for human WAS promoter/cDNA (w1.6W) and demonstrated its preclinical efficacy and safety. Objective: To evaluate B-cell reconstitution and correction of B-cell phenotype in GT-treated mice. Methods: We transplanted Was(-/-) mice sublethally irradiated (700 rads) with lineage marker-depleted bone marrow wild-type cells, Was(-/-) cells untransduced or transduced with the w1.6W lentiviral vector and analyzed B-cell reconstitution in bone marrow, spleen, and peritoneum. Results: Here we show that WAS protein(+) B cells were present in central and peripheral B-cell compartments from GT-treated mice and displayed the strongest selective advantage in the splenic marginal zone and peritoneal B1 cell subsets. After GT, splenic architecture was improved and B-cell functions were restored, as demonstrated by the improved antibody response to pneumococcal antigens and the reduction of serum IgG autoantibodies. Conclusion: WAS GT leads to improvement of B-cell functions, even in the presence of a mixed chimerism, further validating the clinical application of the w1.6W lentiviral vector. (J Allergy Clin Immunol 2011;127:1376-84.)	[Bosticardo, Marita; Draghici, Elena; Sauer, Aisha Vanessa; Castiello, Maria Carmina; Catucci, Marco; Locci, Michela; Naldini, Luigi; Aiuti, Alessandro; Roncarolo, Maria Grazia; Villa, Anna] San Raffaele Telethon Inst Gene Therapy HSR TIG, Milan, Italy; [Schena, Francesca; Traggiai, Elisabetta] IGG, Lab Immunol & Rheumat Dis, Genoa, Italy; [Fontana, Elena; Poliani, Pietro Luigi] Univ Brescia, Dept Pathol, Brescia, Italy; [Naldini, Luigi; Roncarolo, Maria Grazia] Univ Vita Salute San Raffaele, Milan, Italy; [Aiuti, Alessandro] Univ Roma Tor Vergata, Rome, Italy; [Villa, Anna] CNR IRGB, Milan, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); University of Brescia; Vita-Salute San Raffaele University; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR)	Villa, A (corresponding author), HSR TIGET, Via Olgettina 58, I-20132 Milan, Italy.	anna.villa@itb.cnr.it	Castiello, Maria Carmina/K-9767-2016; Poliani, Pietro Luigi/E-8145-2010; Schena, Francesca/AAA-9214-2020; Fontana, Elena/K-3845-2016; Naldini, Luigi/E-9083-2012; Catucci, Marco/AAC-3491-2019; Bosticardo, Marita/ABA-2688-2021; AIUTI, ALESSANDRO/K-3918-2016	Castiello, Maria Carmina/0000-0003-2581-9648; Poliani, Pietro Luigi/0000-0002-5662-8978; Schena, Francesca/0000-0002-5868-7699; Fontana, Elena/0000-0001-8853-3335; Catucci, Marco/0000-0002-1037-5741; Bosticardo, Marita/0000-0002-1771-4523; AIUTI, ALESSANDRO/0000-0002-5398-1717; Villa, Anna/0000-0003-4428-9013; NALDINI, Luigi/0000-0002-7835-527X; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Italian Telethon Foundation; Ministero della Salute [RF 2007-RF 2008]; Giovani Ricercatori	Italian Telethon Foundation(Fondazione Telethon); Ministero della Salute(Ministry of Health, Italy); Giovani Ricercatori	Supported by grants from the Italian Telethon Foundation (M.G.R., A.V.), and Ministero della Salute RF 2007-RF 2008 Giovani Ricercatori Grants (M.B.).	Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Berland R, 2002, ANNU REV IMMUNOL, V20, P253, DOI 10.1146/annurev.immunol.20.100301.064833; Bosticardo M, 2009, BLOOD, V113, P6288, DOI 10.1182/blood-2008-12-115253; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Charrier S, 2007, GENE THER, V14, P415, DOI 10.1038/sj.gt.3302863; Dupre L, 2006, HUM GENE THER, V17, P303, DOI 10.1089/hum.2006.17.303; Dupre L, 2004, MOL THER, V10, P903, DOI 10.1016/j.ymthe.2004.08.008; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; Galy A, 2008, EXPERT OPIN BIOL TH, V8, P181, DOI 10.1517/14712598.8.2.181 ; Humblet-Baron S, 2007, J CLIN INVEST, V117, P407, DOI 10.1172/JCI29539; Kobayashi R, 2006, BRIT J HAEMATOL, V135, P362, DOI 10.1111/j.1365-2141.2006.06297.x; Marangoni F, 2009, MOL THER, V17, P1073, DOI 10.1038/mt.2009.31; Martin F, 2002, NAT REV IMMUNOL, V2, P323, DOI 10.1038/nri799; Martin F, 2001, CURR OPIN IMMUNOL, V13, P195, DOI 10.1016/S0952-7915(00)00204-1; Meyer-Bahlburg A, 2008, BLOOD, V112, P4158, DOI 10.1182/blood-2008-02-140814; Nikolov NP, 2010, BLOOD, V116, P740, DOI 10.1182/blood-2009-08-237560; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Ozsahin H, 1996, J PEDIATR-US, V129, P238, DOI 10.1016/S0022-3476(96)70248-2; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Park JY, 2005, CLIN EXP IMMUNOL, V139, P297, DOI 10.1111/j.1365-2249.2005.02693.x; Petrella A, 1998, BLOOD, V91, P4554, DOI 10.1182/blood.V91.12.4554.412k26_4554_4560; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Vermi W, 1999, AM J SURG PATHOL, V23, P182, DOI 10.1097/00000478-199902000-00007; Westerberg L, 2005, BLOOD, V105, P1144, DOI 10.1182/blood-2004-03-1003; Westerberg L, 2003, IMMUNOLOGY, V109, P384, DOI 10.1046/j.1365-2567.2003.01668.x; Westerberg L, 2001, BLOOD, V98, P1086, DOI 10.1182/blood.V98.4.1086; Westerberg LS, 2008, BLOOD, V112, P4139, DOI 10.1182/blood-2008-02-140715; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329	28	32	33	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1376	U109		10.1016/j.jaci.2011.03.030	http://dx.doi.org/10.1016/j.jaci.2011.03.030			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21531013				2022-12-18	WOS:000291048500008
J	Baumann, LM; Robinson, CL; Combe, JM; Gomez, A; Romero, K; Gilman, RH; Cabrera, L; Hansel, NN; Wise, RA; Breysse, PN; Barnes, K; Hernandez, JE; Checkley, W				Baumann, Lauren M.; Robinson, Colin L.; Combe, Juan M.; Gomez, Alfonso; Romero, Karina; Gilman, Robert H.; Cabrera, Lilia; Hansel, Nadia N.; Wise, Robert A.; Breysse, Patrick N.; Barnes, Kathleen; Hernandez, Juan E.; Checkley, William			Effects of distance from a heavily transited avenue on asthma and atopy in a periurban shantytown in Lima, Peru	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma symptoms; atopy; distance; traffic; particulate matter; spirometry	CHRONIC RESPIRATORY SYMPTOMS; AIR-POLLUTION; ALLERGIC SENSITIZATION; CHILDHOOD ASTHMA; PARTICULATE MATTER; MAJOR HIGHWAY; MAIN ROAD; CHILDREN; EXPOSURE; PREVALENCE	Background: Proximity to roadways increases the risk of asthma in developed countries; however, relatively little is known about this relationship in developing countries, where rapid and uncontrolled growth of cities has resulted in urban sprawl and heavy traffic volumes. Objective: We sought to determine the effect of distance from a heavily transited avenue on asthma symptoms and quantitative respiratory outcome measures in a periurban shantytown in Lima, Peru. Methods: We enrolled 725 adolescents aged 13 to 15 years who were administered a survey on asthma symptoms and measured spirometry, response to allergy skin testing, and exhaled nitric oxide (eNO). We calculated distances from the main avenue for all households and measured indoor particulate matter in 100 households. We used multivariable regression to model the risk of asthma symptoms, risk of atopy, eNO levels, and FEV1/forced vital capacity ratio as a function of distance. Results: Compared against 384 meters, the odds of current asthma symptoms in households living within 100 meters increased by a factor of 2 (P < .05). The odds of atopy increased by a factor of 1.07 for every 100-meter difference in the distance from the avenue (P = .03). We found an inverse relationship in prebronchodilator FEV1/forced vital capacity and distance to the avenue in female subjects (P = .01) but not in male subjects. We did not find an association between eNO or household particulate matter levels and distance. Conclusion: Living in close proximity to a high-traffic-density avenue in a periurban community in Peru was associated with a greater risk of asthma symptoms and atopy. Regulation of mobile-source pollutants in periurban areas of developing countries might help reduce the burden of asthma symptoms and atopy. (J Allergy Clin Immunol 2011;127:875-82.)	[Baumann, Lauren M.; Robinson, Colin L.; Hansel, Nadia N.; Wise, Robert A.; Barnes, Kathleen; Checkley, William] Johns Hopkins Univ, Div Pulm & Crit Care, Baltimore, MD 21205 USA; [Baumann, Lauren M.; Robinson, Colin L.; Combe, Juan M.; Gomez, Alfonso; Romero, Karina; Gilman, Robert H.; Cabrera, Lilia; Checkley, William] AB PRISMA, Lima, Peru; [Gilman, Robert H.] Johns Hopkins Univ, Program Global Dis Epidemiol & Control, Dept Int Hlth, Baltimore, MD 21205 USA; [Gilman, Robert H.; Checkley, William] Univ Peruana Cayetano Heredia, Dept Microbiol, Fac Ciencias & Filosofia, Lima, Peru; [Gilman, Robert H.; Checkley, William] Univ Peruana Cayetano Heredia, CRONICAS Ctr Excellence Chron Dis, Lima, Peru; [Hansel, Nadia N.; Barnes, Kathleen] Johns Hopkins Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Hansel, Nadia N.; Wise, Robert A.; Breysse, Patrick N.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; [Hernandez, Juan E.] Inst Nacl Salud Publ, Ctr Informac Decis Salud Publ, Cuernavaca, Morelos, Mexico	Johns Hopkins University; Johns Hopkins University; Universidad Peruana Cayetano Heredia; Universidad Peruana Cayetano Heredia; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Instituto Nacional de Salud Publica	Checkley, W (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care, 1830 Monument St,5th Floor, Baltimore, MD 21205 USA.	wcheckl1@jhmi.edu		Hernandez-Avila, Juan Eugenio/0000-0001-9638-6718; Checkley, William/0000-0003-1106-8812; /0000-0002-5604-725X; Wise, Robert/0000-0002-8353-2349	Johns Hopkins Center; Fogarty International Center [R24 TW007988]; Johns Hopkins University [K99/R00]; National Heart, Lung, and Blood Institute [K99HL096955]; National Institutes of Health [HHSN268200900033C]; Mary Beryl Patch Turnbull Scholar Program; Tufts University School of Medicine; NIH [T35AI065385]; National Institute for Environmental Health Sciences [ES015903, ES03819]; National Institutes of Health; Sanofi-Aventis; FOGARTY INTERNATIONAL CENTER [R24TW007988] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL096955, R00HL096955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T35AI065385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES015903, R01ES018845, P30ES003819] Funding Source: NIH RePORTER	Johns Hopkins Center; Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Johns Hopkins University(Johns Hopkins University); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary Beryl Patch Turnbull Scholar Program; Tufts University School of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute for Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sanofi-Aventis(Sanofi-Aventis); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by a Johns Hopkins Center for Global Health Award (PI: Hansel) and the Fogarty International Center Training Grant (Grant R24 TW007988). W. C. was supported by a Clinician Scientist Award from the Johns Hopkins University, a K99/R00 Pathway to Independence Award (K99HL096955) from the National Heart, Lung, and Blood Institute, National Institutes of Health, and by a contract (HHSN268200900033C) with the National Heart, Lung, and Blood Institute, National Institutes of Health. K. B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program. C. L. R. was a Fogarty International Clinical Research Scholar during the time of this work and was further supported by Tufts University School of Medicine. L. M. B. was supported by a predoctoral NIH T35 Training Grant (T35AI065385). Support for exposure measurements were provided by National Institute for Environmental Health Sciences grants ES015903 and ES03819. Additional support came from A. B. PRISMA and collaborators at JHU. Lincoln Diagnostics (Decatur, Ill) and ALK-Abello (Round Rock, Tex) generously donated all skin prick atopy kits and antigens, respectively, used in this in this study. Aerocrine (New Providence, NJ) provided us, at discount, materials for eNO testing.; Disclosure of potential conflict of interest: K. Barnes has received research support from the National Institutes of Health and Sanofi-Aventis. The rest of the authors have declared that they have no conflict of interest.	Baumann L, 2010, AM J RESP CRIT CARE, V181; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Chakrabarti B, 2004, ATMOS ENVIRON, V38, P3329, DOI 10.1016/j.atmosenv.2004.03.007; CORBO GM, 1993, J ALLERGY CLIN IMMUN, V92, P616, DOI 10.1016/0091-6749(93)90086-U; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Efron B., 1994, MONOGR STAT APPL PRO, DOI DOI 10.1007/978-1-4899-4541-9; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; FERNANDEZCONCHA D, 1991, T ROY SOC TROP MED H, V85, P809, DOI 10.1016/0035-9203(91)90465-B; Gilbert NL, 2003, SCI TOTAL ENVIRON, V312, P43, DOI 10.1016/S0048-9697(03)00228-6; GILMAN RH, 1988, LANCET, V1, P343, DOI 10.1016/S0140-6736(88)91131-2; Gilmour MI, 1996, FUND APPL TOXICOL, V31, P65, DOI 10.1006/faat.1996.0076; Hastie T.J., 1990, GEN ADDITIVE MODELS, V43; Holguin F, 2007, AM J RESP CRIT CARE, V176, P1236, DOI 10.1164/rccm.200611-1616OC; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Kim JJ, 2008, ENVIRON HEALTH PERSP, V116, P1274, DOI 10.1289/ehp.10735; Koutrakis P, 2005, J AIR WASTE MANAGE, V55, P342, DOI 10.1080/10473289.2005.10464627; Leonardi GS, 2000, INHAL TOXICOL, V12, P1; Lewis SA, 2005, AM J EPIDEMIOL, V161, P406, DOI 10.1093/aje/kwi059; Mallol J, 2000, PEDIATR PULM, V30, P439, DOI 10.1002/1099-0496(200012)30:6<439::AID-PPUL1>3.0.CO;2-E; Mar TF, 2005, ENVIRON HEALTH PERSP, V113, P1791, DOI 10.1289/ehp.7883; MATA FC, 2005, J INVESTIG ALLERGOL, V15, P201; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241, DOI 10.1136/oem.53.4.241; Pujades-Rodriguez M, 2009, OCCUP ENVIRON MED, V66, P679, DOI 10.1136/oem.2008.043885; RIEDEL F, 1988, J ALLERGY CLIN IMMUN, V82, P527, DOI 10.1016/0091-6749(88)90961-X; Roorda-Knape MC, 1999, SCI TOTAL ENVIRON, V235, P339, DOI 10.1016/S0048-9697(99)00217-X; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.05.014; Samuelsen M, 2008, TOXICOLOGY, V246, P124, DOI 10.1016/j.tox.2008.01.001; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stone V, 2000, AM J RESP CRIT CARE, V162, pS44, DOI 10.1164/ajrccm.162.supplement_1.maic-12; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn A, 2005, OCCUP ENVIRON MED, V62, P376, DOI 10.1136/oem.2004.017228; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/ajrccm.164.12.2106126; Viera L, 2009, CURR ALLERGY ASTHM R, V9, P327, DOI 10.1007/s11882-009-0046-x; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032, DOI 10.1080/10473289.2002.10470842; 1998, INDIAN PEDIAT, V35, P812	40	32	34	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					875	882		10.1016/j.jaci.2010.11.031	http://dx.doi.org/10.1016/j.jaci.2010.11.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21237505	Bronze, Green Accepted			2022-12-18	WOS:000289055800007
J	Kaufman, EH; Fryer, AD; Jacoby, DB				Kaufman, Elad H.; Fryer, Allison D.; Jacoby, David B.			Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor 7; asthma; virus; bronchodilator; large-conductance; calcium-activated potassium channel; prostaglandins; adenosine; nitric oxide; imiquimod; IRS661; guinea pig	IMMUNE-RESPONSE; VIRAL-INFECTIONS; ALLERGIC-ASTHMA; TLR7 LIGAND; TOLL-LIKE-RECEPTOR-7; RECOGNITION; ACTIVATION; CHANNEL; CELLS; STIMULATION	Background: Respiratory tract viral infections result in asthma exacerbations. Toll-like receptor (TLR) 7 is a receptor for viral single-stranded RNA and is expressed at high levels in the lungs. Objective: Because TLR7 polymorphisms are associated with asthma, we examined the effects of TLR7 agonists in guinea pig airways. Methods: We induced bronchoconstriction in guinea pigs in vivo by means of electrical stimulation of the vagus nerve or intravenous administration of acetylcholine and measured the effect of a TLR7 agonist administered intravenously. We induced contraction of airway smooth muscle in segments of isolated guinea pig tracheas in vitro and measured the effect of TLR7 agonists, antagonists, and pharmacologic inhibitors of associated signaling pathways administered directly to the bath. Results: TLR7 agonists acutely inhibited bronchoconstriction in vivo and relaxed contraction of airway smooth muscle in vitro within minutes of administration. Airway relaxation induced by the TLR7 agonist R837 (imiquimod) was partially blocked with a TLR7 antagonist and was also blocked by inhibitors of large-conductance, calcium-activated potassium channels; prostaglandin synthesis; and nitric oxide generation. Another TLR7 agonist, 21-mer single-stranded phosphorothioated polyuridylic acid (PolyUs), mediated relaxation that was completely blocked by a TLR7 antagonist. Conclusions: These data demonstrate a novel protective mechanism to limit bronchoconstriction and maintain airflow during respiratory tract viral infections. The fast time frame is inconsistent with canonical TLR7 signaling. R837 mediates bronchodilation by means of TLR7-dependent and TLR7-independent mechanisms, whereas PolyUs does so through only the TLR7-dependent mechanism. TLR7-independent mechanisms involve prostaglandins and large-conductance, calcium-activated potassium channels, whereas TLR7-dependent mechanisms involve nitric oxide. TLR7 is an attractive therapeutic target for its ability to reverse bronchoconstriction within minutes. (J Allergy Clin Immunol 2011;127:462-9.)	[Kaufman, Elad H.; Fryer, Allison D.; Jacoby, David B.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA; [Fryer, Allison D.; Jacoby, David B.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Kaufman, EH (corresponding author), Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, 3181 SW Sam Jackson Pk Rd,Mailcode UHN67, Portland, OR 97239 USA.	kaufmane@ohsu.edu	Fryer, Allison/F-2420-2014	Fryer, Allison/0000-0003-1712-9831; Jacoby, David/0000-0003-2195-9512	US National Institutes of Health [5T32AI007472, NIH HL61013, HL71795, AI75064, HL55543, ES14601]; Oregon Health and Science University Tartar Trust; Achievement Awards for College Scientists Foundation scholarship; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113023, T32HL083808, R01HL061013, R01HL054659, R01HL055543, R01HL071795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI075064, T32AI007472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES017592, R01ES014601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM071338] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Oregon Health and Science University Tartar Trust; Achievement Awards for College Scientists Foundation scholarship; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the US National Institutes of Health (5T32AI007472, NIH HL61013 [D.B.J.], HL71795 [D.B.J.], AI75064 [D.B.J.], HL55543 [A.D.F.], and ES14601 [A.D.F.]), an Oregon Health and Science University Tartar Trust Research Fellowship (E.H.K.), and an Achievement Awards for College Scientists Foundation scholarship (E.H.K.).; The authors have received research support from the National Institutes of Health. In addition, E. H. Kaufman has received support from the Oregon Health and Science University Tartar Trust and Achievement Awards for College Scientists Foundation.	Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; Balzary RW, 2006, J PHARMACOL EXP THER, V317, P806, DOI 10.1124/jpet.105.097634; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Camateros P, 2007, AM J RESP CRIT CARE, V175, P1241, DOI 10.1164/rccm.200701-054OC; Camateros P, 2009, PHYSIOL GENOMICS, V38, P303, DOI 10.1152/physiolgenomics.00057.2009; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Demedts IK, 2006, AM J RESP CELL MOL, V35, P387, DOI 10.1165/rcmb.2005-0382OC; Diebold SS, 2006, EUR J IMMUNOL, V36, P3256, DOI 10.1002/eji.200636617; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Fogel M, 2002, J LEUKOCYTE BIOL, V72, P932; FREED AN, 1987, J APPL PHYSIOL, V62, P574, DOI 10.1152/jappl.1987.62.2.574; Gorden KKB, 2006, J IMMUNOL, V177, P6584, DOI 10.4049/jimmunol.177.10.6584; Hammadi A, 2008, NITRIC OXIDE-BIOL CH, V19, P138, DOI 10.1016/j.niox.2008.04.017; Hattermann K, 2007, FASEB J, V21, P1575, DOI 10.1096/fj.06-7457com; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; Lan T, 2007, P NATL ACAD SCI USA, V104, P13750, DOI 10.1073/pnas.0706059104; Lee SW, 1999, INT J IMPOT RES, V11, P189, DOI 10.1038/sj.ijir.3900399; Moisan J, 2006, AM J PHYSIOL-LUNG C, V290, pL987, DOI 10.1152/ajplung.00440.2005; Moller-Larsen S, 2008, THORAX, V63, P1064, DOI 10.1136/thx.2007.094128; MURRAY TC, 1992, J APPL PHYSIOL, V72, P608, DOI 10.1152/jappl.1992.72.2.608; NAKAJIMA S, 1966, J GEN PHYSIOL, V49, P629, DOI 10.1085/jgp.49.4.629; Roponen M, 2010, EUR RESPIR J, V35, P64, DOI 10.1183/09031936.00172008; Scheel O, 2006, INFECT IMMUN, V74, P4354, DOI 10.1128/IAI.01783-05; Schon MP, 2006, J INVEST DERMATOL, V126, P1338, DOI 10.1038/sj.jid.5700286; Spaner DE, 2005, LEUKEMIA LYMPHOMA, V46, P935, DOI 10.1080/10428190500054426; Stokes JR, 1998, EUR RESPIR J, V11, P324, DOI 10.1183/09031936.98.11020324; Sukkar MB, 2006, J ALLERGY CLIN IMMUN, V118, P641, DOI 10.1016/j.jaci.2006.05.013; TOMAI MA, 1995, ANTIVIR RES, V28, P253, DOI 10.1016/0166-3542(95)00054-P; Tumurkhuu G, 2010, CELL IMMUNOL, V261, P122, DOI 10.1016/j.cellimm.2009.11.009; Uehara A, 2007, MOL IMMUNOL, V44, P3100, DOI 10.1016/j.molimm.2007.02.007; Verhein KC, 2008, AM J RESP CELL MOL, V39, P730, DOI 10.1165/rcmb.2008-0045OC; Xirakia C, 2010, AM J RESP CRIT CARE, V181, P1207, DOI 10.1164/rccm.200908-1255OC; Yamaki F, 2001, N-S ARCH PHARMACOL, V364, P538, DOI 10.1007/s002100100485; Zhu JZ, 2008, MOL IMMUNOL, V45, P3238, DOI 10.1016/j.molimm.2008.02.028	40	32	34	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					462	469		10.1016/j.jaci.2010.10.029	http://dx.doi.org/10.1016/j.jaci.2010.10.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21167577	Green Accepted			2022-12-18	WOS:000286808000021
J	Lopez-Lera, A; Favier, B; de la Cruz, RM; Garrido, S; Drouet, C; Lopez-Trascasa, M				Lopez-Lera, Alberto; Favier, Bertrand; Mena de la Cruz, Rocio; Garrido, Sofia; Drouet, Christian; Lopez-Trascasa, Margarita			A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							C1 INHIBITOR		[Lopez-Lera, Alberto; Mena de la Cruz, Rocio; Garrido, Sofia; Lopez-Trascasa, Margarita] Hosp Univ La Paz, Immunol Unit, Madrid, Spain; [Lopez-Lera, Alberto; Mena de la Cruz, Rocio; Lopez-Trascasa, Margarita] Ctr Invest Biomed Red CIBERER, Madrid, Spain; [Lopez-Lera, Alberto; Mena de la Cruz, Rocio; Garrido, Sofia; Lopez-Trascasa, Margarita] Hosp La Paz, Hlth Res Inst, IdiPAZ, Madrid, Spain; [Favier, Bertrand; Drouet, Christian] Univ J Fourier, GREPI TIMC IMAG, CNRS, UMR 5525, Grenoble, France; [Favier, Bertrand; Drouet, Christian] CHU Grenoble, Unite Explorat Angioedeme, Grenoble, France	Hospital Universitario La Paz; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital Universitario La Paz; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Lopez-Lera, A (corresponding author), Hosp Univ La Paz, Immunol Unit, Madrid, Spain.	a_lopezlera@yahoo.es	Lera, Alberto López/V-4181-2019; López-Trascasa, Margarita/L-2699-2014; del Rocío Mena, María/Q-6059-2019; DROUET, Christian/AAE-5682-2020; Favier, Bertrand/B-7258-2013; DROUET, Christian/J-8775-2019	López-Trascasa, Margarita/0000-0001-8594-282X; del Rocío Mena, María/0000-0002-8887-7100; DROUET, Christian/0000-0003-1318-4278; DROUET, Christian/0000-0003-1318-4278; Lopez Lera, Alberto/0000-0002-9596-6910				Blanch A, 2006, J ALLERGY CLIN IMMUN, V118, P1330, DOI 10.1016/j.jaci.2006.07.035; Cugno M, 2009, TRENDS MOL MED, V15, P69, DOI 10.1016/j.molmed.2008.12.001; Cugno M, 2008, AUTOIMMUN REV, V8, P156, DOI 10.1016/j.autrev.2008.05.003; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Grigoriadou S, 2009, CLIN EXP IMMUNOL, V155, P367, DOI 10.1111/j.1365-2249.2008.03845.x; NUIJENS JH, 1987, IMMUNOLOGY, V61, P387; Vinci G, 2002, J IMMUNOL, V169, P5948, DOI 10.4049/jimmunol.169.10.5948	7	32	33	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1307	1310		10.1016/j.jaci.2010.07.037	http://dx.doi.org/10.1016/j.jaci.2010.07.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20864152				2022-12-18	WOS:000284947800034
J	Roifman, CM; Dadi, H; Somech, R; Nahum, A; Sharfe, N				Roifman, Chaim M.; Dadi, Harjit; Somech, Raz; Nahum, Amit; Sharfe, Nigel			Characterization of zeta-associated protein, 70 kd (ZAP70)-deficient human lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell development; T(H)2 response; T cells; thymopoiesis; T-cell receptor exclusion circle; T-cell rearrangement; ZAP70	SEVERE COMBINED IMMUNODEFICIENCY; STEM-CELL TRANSPLANTATION; CD4(+) T-CELLS; TYROSINE KINASE; TGF-BETA; ANTIGEN RECEPTOR; GENE-EXPRESSION; ZAP-70; GATA-3; MICE	Background: zeta-associated protein, 70 kd (ZAP70), deficiency in human subjects results in a combined immunodeficiency characterized by normal numbers of circulating CD4 T cells and CD8 lymphocytopenia. Patients who live beyond infancy can also experience autoimmune manifestations. Objectives: We sought to further characterize the nature of the T-cell populations found in ZAP70-deficient patients and explored the mechanisms that might predispose them to autoimmunity. Methods: T-cell development was assessed by examining T-cell receptor (TCR) gene rearrangements and thymopoiesis by measuring TCR exclusion circle levels. TCR repertoire on CD4 and CD8 T-cell populations was assessed by means of flow cytometry. T-cell gene expression patterns were examined by means of exonic microarray analysis and apoptotic responses by means of Annexin V binding and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling. Results: Cells displaying recombination events from all stages of TCR gene rearrangement were present in the peripheral blood of ZAP70-deficient patients; however, the late TCRD-deleting rearrangement was significantly reduced. TCR exclusion circle levels were also found to be low. Surprisingly, all V beta families were detected in both CD4 1 and CD8 1 circulating T cells. Several Vb families were significantly overrepresented, which is reminiscent of autoimmune disorders. Levels of mRNA for cytotoxic T lymphocyte-associated antigen 4, TGF-beta, and IL-10 were found to be low, a signature of autoimmunity. Finally, Fas-mediated CD4 T-cell apoptosis was found to be reduced in vitro, and staining of thymus biopsy specimens revealed reduced thymocyte apoptosis. Conclusion: We show that in the absence of ZAP70, thymopoiesis is altered and differentiation to double-positive cells is hampered. Circulating T cells appear poorly regulated, do not differentiate into T(H)2 T cells, lack a number of inhibitory growth controls, and display reduced apoptosis, all predisposing patients to exaggerated inflammation and autoimmunity. (J Allergy Clin Immunol 2010;126:1226-33.)	Hosp Sick Children, Div Immunol & Allergy, Canadian Ctr Primary Immunodeficiency, Jeffrey Modell Res Lab Diag Primary Immunodeficie, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Roifman, CM (corresponding author), Hosp Sick Children, Div Allergy Immunol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca			Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation	Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation	Supported by the Canadian Centre for Primary Immunodeficiency and the Jeffrey Modell Foundation. C.M.R. is the holder of the Donald and Audrey Campbell Chair of Immunology.	ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chu DH, 1999, J IMMUNOL, V163, P2610; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Dik WA, 2005, J EXP MED, V201, P1715, DOI 10.1084/jem.20042524; Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5; Elder ME, 2001, J IMMUNOL, V166, P656, DOI 10.4049/jimmunol.166.1.656; FLORENTINO DF, 1989, J EXP MED, V170, P2081; Goodnow CC, 2005, NATURE, V435, P590, DOI 10.1038/nature03724; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; JIN YJ, 1990, J IMMUNOL, V144, P647; Katamura K, 1999, CLIN EXP IMMUNOL, V115, P124; Krammer P H, 1999, Adv Immunol, V71, P163; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; LAW CL, 1994, J BIOL CHEM, V269, P12310; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Parry DE, 1996, J ALLERGY CLIN IMMUN, V97, P830; Roifman CM, 2010, IMMUNOL ALLERGY CLIN, V30, pXI, DOI 10.1016/j.iac.2010.03.002; ROIFMAN CM, 1989, J EXP MED, V170, P2177, DOI 10.1084/jem.170.6.2177; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; Sharfe N, 2007, LYMPHOCYTE ACTIVATIO; Smith K, 2001, J EXP MED, V194, P1253, DOI 10.1084/jem.194.9.1253; Somech R, 2009, J ALLERGY CLIN IMMUN, V124, P793, DOI 10.1016/j.jaci.2009.06.048; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Stumhofer JS, 2007, NAT IMMUNOL, V8, P1363, DOI 10.1038/ni1537; Turul T, 2009, EUR J PEDIATR, V168, P87, DOI 10.1007/s00431-008-0718-x; Verrecchia F, 2006, AUTOIMMUN REV, V5, P563, DOI 10.1016/j.autrev.2006.06.001; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wong P, 2001, J EXP MED, V193, P1179, DOI 10.1084/jem.193.10.1179; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304; Zhang JY, 2005, PEDIATRICS, V116, pE445, DOI 10.1542/peds.2005-0369	45	32	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1226	U243		10.1016/j.jaci.2010.07.029	http://dx.doi.org/10.1016/j.jaci.2010.07.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20864151				2022-12-18	WOS:000284947800022
J	Brasholt, M; Baty, F; Bisgaard, H				Brasholt, Martin; Baty, Florent; Bisgaard, Hans			Physical activity in young children is reduced with increasing bronchial responsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Accelerometer; physical activity; exercise; bronchial responsiveness; young children	ASTHMA; CHILDHOOD; CALIBRATION; FITNESS; ACCELEROMETER; VALIDATION; INFANTS; AIRWAY; LEVEL	Background: Physical activity is essential for young children to develop adequately and for quality of life. It can be lower in children with subclinical asthma, and therefore methods to reveal subclinical reduction in physical activity in young children are warranted. Objective: We sought to study an association between physical activity in preschool children and objectively assessed intermediary asthma phenotypes. Methods: We studied 253 five-year-old children (127 girls) participating in the Copenhagen Prospective Studies on Asthma in Childhood. The main outcome measure was level of physical activity assessed objectively with accelerometers worn on an ankle for 4 weeks. Objective assessment of asthma intermediary phenotypes included prebronchodilator and postbronchodilator specific airway resistance, bronchial responsiveness to cold dry-air hyperventilation, and exhaled nitric oxide levels. Analyses were performed with generalized linear model and principal component analysis. Results: Physical activity was inversely associated with bronchial responsiveness (relative rate, 0.89; 95% CI, 0.83-0.95; P = .007) and significantly increased in the months of spring and summer (P <.001) and in boys (relative rate, 1.16; 95% CI, 1.09-1.25; P <.001). Physical activity was independent of asthma diagnosis, age, body mass index, baseline specific airway resistance, reversibility to beta(2)-agonist, sensitization, and exhaled nitric oxide level. Conclusion: Physical activity in preschool children was reduced with increasing bronchial responsiveness. The reduced physical activity was subclinical and not realized by parents or doctors despite daily diary cards and close clinical follow-up since birth. This observation warrants awareness of even very mild asthma symptoms in clinical practice. (J Allergy Clin Immunol 2010;125:1007-12.)	[Bisgaard, Hans] Univ Copenhagen, Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark	University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Copenhagen Prospect Studies Asthma Childhood, Gentofte Ledreborg 34 2900, Copenhagen, Denmark.	Bisgaard@copsac.com	Kronow, Joern/B-1054-2011; Schmoelz, Camilie/D-1707-2012; Bisgaard, Hans/N-4761-2016	Schmoelz, Camilie/0000-0003-2221-9954; Bisgaard, Hans/0000-0003-4131-7592	Lundbeck Foundation; Pharmacy Foundation of 1991; Augustinus Foundation; Danish Medical Research Council; Danish Pediatric Asthma Center; Aerocrine; AstraZeneca; Altana; GlaxoSmithKline; Merck; MedImmune; NeoLab; Pfizer	Lundbeck Foundation(Lundbeckfonden); Pharmacy Foundation of 1991; Augustinus Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Pediatric Asthma Center; Aerocrine; AstraZeneca(AstraZeneca); Altana; GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); MedImmune(AstraZenecaMedimmune); NeoLab; Pfizer(Pfizer)	Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) is supported by private and public research funds, all of which are listed at www.copsac.com. The Lundbeck Foundation, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Center provide core support for COPSAC.; Disclosure of potential conflict of interest: H. Bisgaard has been a consultant to, a paid lecturer for, and holds sponsored grants from Aerocrine, AstraZeneca, Altana, GlaxoSmithKline, Merck, MedImmune, NeoLab, and Pfizer; has received research support from Aerocrine, AstraZeneca, GlaxoSmithKline, Merck, and Med Immune; and has served as an expert witness for NeoLab. The rest of the authors have declared that they have no conflict of interest.	Andersen LB, 2006, LANCET, V368, P299, DOI 10.1016/S0140-6736(06)69075-2; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Bisgaard H, 2005, CHEST, V128, P355, DOI 10.1378/chest.128.1.355; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Chadwick S, 1996, CHILD CARE HLTH DEV, V22, P175, DOI 10.1046/j.1365-2214.1996.786786.x; Finn K, 2002, J PEDIATR-US, V140, P81, DOI 10.1067/mpd.2002.120693; Fogelholm M, 2008, INT J PEDIATR OBES, V3, P10, DOI 10.1080/17477160801896481; Freedson P, 2005, MED SCI SPORT EXER, V37, pS523, DOI 10.1249/01.mss.0000185658.28284.ba; Gammelgaard A, 2006, ARCH DIS CHILD, V91, P977, DOI 10.1136/adc.2006.096073; GINA Executive Committee, GLOB STRAT ASTHM MAN; Glazebrook C, 2006, PEDIATRICS, V118, P2443, DOI 10.1542/peds.2006-1846; Huovinen E, 2001, THORAX, V56, P234, DOI 10.1136/thorax.56.3.234; JIMENEZPAVON D, 2009, INT J PEDIAT OBES; Joliffe I. T., 2002, PRINCIPAL COMPONENT, V2nd; Lang DM, 2004, PEDIATRICS, V113, pE341, DOI 10.1542/peds.113.4.e341; Milgrom H, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.3.e38; Moreira A, 2008, EUR RESPIR J, V32, P1570, DOI 10.1183/09031936.00171707; Nielsen Kim Gjerum, 2005, Paediatr Respir Rev, V6, P255, DOI 10.1016/j.prrv.2005.09.013; Nystad W, 2001, RESP MED, V95, P806, DOI 10.1053/rmed.2001.1149; Nystad W, 1997, SCAND J MED SCI SPOR, V7, P331; Pate RR, 2004, PEDIATRICS, V114, P1258, DOI 10.1542/peds.2003-1088-L; Pate RR, 2006, OBESITY, V14, P2000, DOI 10.1038/oby.2006.234; Peat JK, 2001, THORAX, V56, P406, DOI 10.1136/thorax.56.5.406; Pianosi PT, 2004, PEDIATRICS, V113, pE225, DOI 10.1542/peds.113.3.e225; Puyau MR, 2002, OBES RES, V10, P150, DOI 10.1038/oby.2002.24; Puyau MR, 2004, MED SCI SPORT EXER, V36, P1625, DOI 10.1249/01.MSS.0000139898.30804.60; Ram FSF, 2000, BRIT J SPORT MED, V34, P162, DOI 10.1136/bjsm.34.3.162; Rasmussen F, 2000, EUR RESPIR J, V16, P866, DOI 10.1183/09031936.00.16586600; RCore Team, 2022, R LANG ENV STAT COMP; Riddoch CJ, 2007, ARCH DIS CHILD, V92, P963, DOI 10.1136/adc.2006.112136; Shaaban R, 2007, THORAX, V62, P403, DOI 10.1136/thx.2006.068205; Shoup JA, 2008, QUAL LIFE RES, V17, P407, DOI 10.1007/s11136-008-9312-y; Toelle BG, 2004, EUR RESPIR J, V23, P66, DOI 10.1183/09031936.03.00046903; Toschke JA, 2007, CLIN NUTR, V26, P416, DOI 10.1016/j.clnu.2007.03.009; Vahlkvist S, 2009, ALLERGY, V64, P1649, DOI 10.1111/j.1398-9995.2009.02081.x; Weisgerber M, 2008, PEDIATR PULM, V43, P1175, DOI 10.1002/ppul.20895; Westerterp KR, 1999, INT J OBESITY, V23, pS45, DOI 10.1038/sj.ijo.0800883; Worsnop CJ, 2003, CHEST, V124, P421, DOI 10.1378/chest.124.2.421	41	32	32	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1007	1012		10.1016/j.jaci.2010.02.002	http://dx.doi.org/10.1016/j.jaci.2010.02.002			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392480				2022-12-18	WOS:000277686700008
J	Reynolds, C; Barkans, J; Clark, P; Kariyawasam, H; Altmann, D; Kay, B; Boyton, R				Reynolds, Catherine; Barkans, Julia; Clark, Peter; Kariyawasam, Harsha; Altmann, Daniel; Kay, Barry; Boyton, Rosemary			Natural killer T cells in bronchial biopsies from human allergen challenge model of allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY; HYPERREACTIVITY; INFLAMMATION		[Reynolds, Catherine; Barkans, Julia; Boyton, Rosemary] MRC, Lung Immunol Grp Allergy & Clin Immunol, London W1N 4AL, England; [Clark, Peter; Kariyawasam, Harsha; Kay, Barry] MRC, Natl Heart & Lung Inst, London W1N 4AL, England; [Altmann, Daniel] Univ London Imperial Coll Sci Technol & Med, Dept Infect & Immun, Human Dis Immunogenet Grp, London SW7 2AZ, England	Imperial College London; Imperial College London	Reynolds, C (corresponding author), MRC, Lung Immunol Grp Allergy & Clin Immunol, London W1N 4AL, England.	r.boyton@imperial.ac.uk		Altmann, Daniel/0000-0002-2436-6192	Medical Research Council [G108/495] Funding Source: Medline; Medical Research Council [G0400503B] Funding Source: researchfish; MRC [G108/495] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Boyton R, 2008, J PATHOL, V214, P276, DOI 10.1002/path.2290; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Matangkasombut P, 2009, J ALLERGY CLIN IMMUN, V123, P1181, DOI 10.1016/j.jaci.2009.02.013; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507	6	32	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					860	862		10.1016/j.jaci.2009.07.022	http://dx.doi.org/10.1016/j.jaci.2009.07.022			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767076	Bronze			2022-12-18	WOS:000270802800042
J	Smith, AD; Cowan, JO; Taylor, DR				Smith, Andrew D.; Cowan, Jan O.; Taylor, D. Robin			Exhaled nitric oxide levels in asthma: Personal best versus reference values	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; exhaled nitric oxide; inhaled corticosteroid; prednisone; reference values	AIRWAY INFLAMMATION; CLINICAL REMISSION; ATOPIC ASTHMA; CHILDREN; ADULTS; HEALTHY	Background: Factors affecting the fraction of nitric oxide in exhaled air (FENO) are multiple. Interpreting values when assessing airways disease may be problematic. Clinically optimum levels have not been defined. Objectives: We aimed to establish the relationship between predicted values for FENO obtained from equations by Olin et al, Travers et al, and Dressel et al, and normalized levels after oral prednisone. We also compared postprednisone FENO levels with those obtained during optimized treatment with inhaled fluticasone. Methods: Data were obtained before and after a trial of oral prednisone (30mg/d for 14 days), and also from a previously published study in which patients had their dose of inhaled corticosteroid adjusted using either FENO or symptoms/lung function to optimize treatment. Results: Seventy-three patients completed the study. The geometric mean FENO after prednisone (17.7 parts per billion [ppb]; 95% CI, 15.5-20.2) was significantly lower than mean FENO at the optimized fluticasone dose (20.2 ppb; 95% CI, 17.1-23.8; P=.04) and at loss of control (27.6 ppb; 95% CI, 22.8-33.4; P<.001). FENO levels after prednisone did not differ significantly from the predicted values of Olin et al (16.8 ppb, 95% CI, 16.0-17.5; P=.44), but were significantly lower than values of Travers et al (predicted, 21.5 ppb; 95% CI, 20.9-22.2; P=.005) and Dressel et al (predicted, 27.8 ppb; 95% CI, 26.7-28.9; P<.001). Conclusions: Optimum FENO levels are best established by using oral rather than inhaled steroid treatment, and these approximate to predicted values from the reference equation by Olin et al. However, at optimized doses of inhaled corticosteroid, although FENO levels were higher than predicted, asthma was well controlled. Targeting FENO on reference values is not justified. (J Allergy Clin Immunol 2009;124:714-8.)	[Smith, Andrew D.; Cowan, Jan O.; Taylor, D. Robin] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand	University of Otago	Taylor, DR (corresponding author), Univ Otago, Dunedin Sch Med, POB 913, Dunedin, New Zealand.	robin.taylor@stonebow.otago.ac.nz			Otago Medical Research Foundation; Dunedin School of Medicine; University of Otago; GlaxoSmithKiine (New Zealand); Aerocrine AB, Solna, Sweden	Otago Medical Research Foundation; Dunedin School of Medicine; University of Otago; GlaxoSmithKiine (New Zealand)(GlaxoSmithKline); Aerocrine AB, Solna, Sweden	Supported by the Otago Medical Research Foundation, the Dean's Fund of the Dunedin School of Medicine, and the University of Otago (research grant). Supplies of fluticasone were provided by GlaxoSmithKline (New Zealand). A.D.S. received an educational fellowship from GlaxoSmithKiine (New Zealand) for the duration of the study.; D. R. Taylor has received honoraria and research support from Aerocrine AB, Solna, Sweden. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P912; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Dressel H, 2008, RESP MED, V102, P962, DOI 10.1016/j.rmed.2008.02.012; Gelb AF, 2004, AM J RESP CRIT CARE, V170, P737, DOI 10.1164/rccm.200403-408OC; Global Initiative for Asthma, 2006, GLOB STRAT ASTHM MAN; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; Kharitonov SA, 2000, EUR RESPIR J, V16, P781, DOI 10.1183/09031936.00.16478100; Lund MB, 2007, EUR RESPIR J, V29, P292, DOI 10.1183/09031936.00044805; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; Olin AC, 2007, CHEST, V131, P1852, DOI 10.1378/chest.06-2928; Olivieri M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-94; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Pijnenburg MWH, 2005, CLIN EXP ALLERGY, V35, P920, DOI 10.1111/j.1365-2222.2005.02279.x; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Taylor DR, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-82; Taylor SL, 2006, ARCH ENVIRON OCCUP H, V61, P27, DOI 10.3200/AEOH.61.1.27-32; Travers J, 2007, AM J RESP CRIT CARE, V176, P238, DOI 10.1164/rccm.200609-1346OC; van den Toorn LM, 2005, RESP MED, V99, P779, DOI 10.1016/j.rmed.2004.11.011; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953, DOI 10.1164/ajrccm.162.3.9909033; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC	23	32	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					714	718		10.1016/j.jaci.2009.07.020	http://dx.doi.org/10.1016/j.jaci.2009.07.020			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767074				2022-12-18	WOS:000270802800014
J	Cochard, MM; Eigenmann, PA				Cochard, Marie M.; Eigenmann, Philippe A.			Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GRASS-POLLEN; EFFICACY; CHILDREN		[Cochard, Marie M.; Eigenmann, Philippe A.] Univ Hosp Geneva, Dept Pediat, Geneva, Switzerland	University of Geneva	Cochard, MM (corresponding author), Univ Hosp Geneva, Dept Pediat, Geneva, Switzerland.	Philippe.Eigenmann@hcuge.ch	Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826				Agostinis F, 2008, ALLERGY, V63, P1637, DOI 10.1111/j.1398-9995.2008.01742.x; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; DI RV, 2003, CLIN EXP ALLERGY, V33, P206; NICHANI JR, 2008, J LARYNGOL OTOL, V23, P1; Passalacqua G, 2007, CURR DRUG SAF, V2, P117, DOI 10.2174/157488607780598340; Stelmach I, 2009, CLIN EXP ALLERGY, V39, P401, DOI 10.1111/j.1365-2222.2008.03159.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	7	32	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					378	379		10.1016/j.jaci.2009.04.040	http://dx.doi.org/10.1016/j.jaci.2009.04.040			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19541352				2022-12-18	WOS:000268860400029
J	Jerath, MR; Kwan, M; Kannarkat, M; Mirakhur, B; Carey, L; Valgus, J; Platts-Mills, TAE; Tarrant, PK				Jerath, Maya R.; Kwan, Mildred; Kannarkat, Mily; Mirakhur, Beloo; Carey, Lisa; Valgus, John; Platts-Mills, Thomas A. E.; Tarrant, Presa K.			A desensitization protocol for the mAb cetuximab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFUSION REACTIONS		[Jerath, Maya R.; Kwan, Mildred; Tarrant, Presa K.] Univ N Carolina, Sch Med, Div Rheumatol Allergy & Immunol, Chapel Hill, NC 27515 USA; [Jerath, Maya R.; Kwan, Mildred; Kannarkat, Mily; Carey, Lisa; Valgus, John; Tarrant, Presa K.] Univ N Carolina Hosp, Chapel Hill, NC USA; [Mirakhur, Beloo] Bristol Myers Squibb Co, Plainsboro, NJ USA; [Carey, Lisa] Univ N Carolina, Sch Med, Div Oncol, Chapel Hill, NC USA; [Platts-Mills, Thomas A. E.] Univ Virginia, Sch Med, Asthma & Allerg Dis Res Ctr, Charlottesville, VA 22908 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University North Carolina Hospital; Bristol-Myers Squibb; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Virginia	Jerath, MR (corresponding author), Univ N Carolina, Sch Med, Div Rheumatol Allergy & Immunol, Chapel Hill, NC 27515 USA.	tarra002@med.unc.edu		Tarrant, Teresa/0000-0003-4067-5363; Platts-Mills, Thomas/0000-0002-1263-329X				Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cheifetz A, 2005, MT SINAI J MED, V72, P250; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; *IMCLONE SYST INC, 2007, ERB CET DRUG PROD LA, P24702; *NAT CANC I, 2006, CANC THER EV PROGR C, P24702; Nielsen DL, 2006, ACTA ONCOL, V45, P1137, DOI 10.1080/02841860600871764; O'Neil BH, 2007, J CLIN ONCOL, V25, P3644, DOI 10.1200/JCO.2007.11.7812; Patel DD, 2006, ONCOLOGY-NY, V20, P1373	9	32	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					260	262		10.1016/j.jaci.2008.09.046	http://dx.doi.org/10.1016/j.jaci.2008.09.046			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19022494				2022-12-18	WOS:000262793900041
J	Maneachotesuwan, K; Wamanuttajinda, V; Kasetsinsombat, K; Huabprasert, S; Yaikwawong, M; Barnes, PJ; Wongkajornsilp, A				Maneachotesuwan, Kittipong; Wamanuttajinda, Valla; Kasetsinsombat, Kanda; Huabprasert, Sukit; Yaikwawong, Metha; Barnes, Peter J.; Wongkajornsilp, Adisak			Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Der p 1; IDO; dendritic cells; T(H)2 cells; asthma	REGULATORY T-CELLS; DERMATOPHAGOIDES-PTERONYSSINUS; TRANSPLANT TOLERANCE; 2,3-DIOXYGENASE GENE; TH2 RESPONSES; IN-VITRO; EXPRESSION; GAMMA; IDO; ALLERGEN	Background: Indoleamine 2, 3-dioxygenase (IDO), a tryptophan-degrading enzyme in dendritic cells (DCs), mediates an immunosuppressive effect on activated T lymphocytes. However, little is known about the effect of Der p 1 on IDO in human DCs. Objective: The aim was to investigate the effect of Der p 1 on the expression and activity of IDO in monocyte-derived DCs from house dust mite (HDM)-sensitive patients with asthma. Methods: Using real-time RT-PCR and HPLC, the expression and activity of IDO were assessed in TNF-alpha-induced mature DCs from HDM-sensitive and nonatopic patients with asthma in response to Der p 1 exposure ex vivo. We also monitored the alteration of IDO activity in Der p 1-pulsed DCs after the coincubation with autologous T cells. Results: With a reliance on its protease activity, Der p 1 suppressed functional IDO in DCs from HDM-sensitive patients with asthma but enhanced IDO activity in DCs from nonatopic patients with asthma. This suppression was maintained by the reciprocally induced IL-4 from the coculturing autologous HDM-sensitive T cells. Conversely, the upregulation of IDO activity in Der p 1-pulsed DCs was maintained by IFN-gamma released from autologous nonatopic T cells and the regulatory T-cell subset. Der p 1. pulsation to sensitive DCs failed to raise regulatory T cells but raised progenitor fractions from cloned HDM-sensitive CD4(+) cells through direct contact and soluble mediators. Conclusion: House dust mite-sensitive DCs exposed to Der p 1 downregulated IDO activity and tipped the T(H)1/T(H)2 cytokine balance toward IL-4, resulting in sustainable IDO suppression. (J Allergy Clin Immunol 2009;123:239-48.)	[Maneachotesuwan, Kittipong] Mahidol Univ, Fac Med, Siriraj Hosp, Div Resp Dis & TB,Dept Med, Bangkok 10700, Thailand; [Maneachotesuwan, Kittipong; Wamanuttajinda, Valla; Kasetsinsombat, Kanda; Huabprasert, Sukit; Yaikwawong, Metha; Wongkajornsilp, Adisak] Mahidol Univ, Fac Med, Siriraj Hosp, Dept Pharmacol, Bangkok 10700, Thailand; [Barnes, Peter J.] Imperial Coll, Natl Heart & Lung Inst, London, England	Mahidol University; Mahidol University; Imperial College London	Maneachotesuwan, K (corresponding author), Mahidol Univ, Fac Med, Siriraj Hosp, Div Resp Dis & TB,Dept Med, 2 Prannok Rd, Bangkok 10700, Thailand.	sikmn@mahidol.ac.th	Wongkajornsilp, Adisak/AAH-7668-2019	Wongkajornsilp, Adisak/0000-0002-3965-0997; Barnes, Peter/0000-0002-5122-4018	Faculty of Medicine Siriraj Hospital	Faculty of Medicine Siriraj Hospital	Supported by the Siriraj Grant for Research Development and Medical Education of the Faculty of Medicine Siriraj Hospital (K.M.. A.W.).	Bresson D, 2006, J CLIN INVEST, V116, P1371, DOI 10.1172/JCI27191; Bullens DMA, 2005, CLIN EXP ALLERGY, V35, P1535, DOI 10.1111/j.1365-2222.2005.02352.x; Chon SY, 1996, J BIOL CHEM, V271, P17247, DOI 10.1074/jbc.271.29.17247; Comoy EE, 1998, J IMMUNOL, V160, P2456; Gordon JR, 2005, J IMMUNOL, V175, P1516, DOI 10.4049/jimmunol.175.3.1516; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Hilchey Shannon P, 2007, Immunol Invest, V36, P629, DOI 10.1080/08820130701674463; Kikuchi Y, 2006, J IMMUNOL, V177, P1609, DOI 10.4049/jimmunol.177.3.1609; KOIDE Y, 1994, INFECT IMMUN, V62, P948, DOI 10.1128/IAI.62.3.948-955.1994; Li M, 2008, INT IMMUNOL, V20, P285, DOI 10.1093/intimm/dxm142; LIOTTA F, 2008, J ALLERGY CLIN IMMUN, V121; Lyons AB, 2000, J IMMUNOL METHODS, V243, P147, DOI 10.1016/S0022-1759(00)00231-3; MacKenzie CR, 1999, ADV EXP MED BIOL, V467, P533; Mahnke K, 2007, CELL IMMUNOL, V250, P1, DOI 10.1016/j.cellimm.2008.01.004; Maneechotesuwan K, 2008, J ALLERGY CLIN IMMUN, V121, P43, DOI 10.1016/j.jaci.2007.10.011; Mellor AL, 2004, INT IMMUNOL, V16, P1391, DOI 10.1093/intimm/dxh140; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Min WP, 2003, J IMMUNOL, V170, P1304, DOI 10.4049/jimmunol.170.3.1304; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; MUSSO T, 1994, BLOOD, V83, P1408; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909, DOI 10.4049/jimmunol.173.10.5909; Orabona C, 2006, BLOOD, V107, P2846, DOI 10.1182/blood-2005-10-4077; PARRONCHI P, 1992, EUR J IMMUNOL, V22, P1615, DOI 10.1002/eji.1830220640; Swanson KA, 2004, AM J RESP CELL MOL, V30, P311, DOI 10.1165/rcmb.2003-0268OC; Takahama H, 2002, HUM IMMUNOL, V63, P558, DOI 10.1016/S0198-8859(02)00406-8; WONGKAJORNSILP A, 2008, CANC INVEST IN PRESS; Xu H, 2008, P NATL ACAD SCI USA, V105, P6690, DOI 10.1073/pnas.0708809105; Yu G, 2008, J GENE MED, V10, P754, DOI 10.1002/jgm.1201; Yu G, 2008, TRANSPL IMMUNOL, V18, P208, DOI 10.1016/j.trim.2007.08.006; Zheng Y, 2008, J IMMUNOL, V181, P1683, DOI 10.4049/jimmunol.181.3.1683	32	32	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					239	248		10.1016/j.jaci.2008.10.018	http://dx.doi.org/10.1016/j.jaci.2008.10.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19058839				2022-12-18	WOS:000262793900038
J	Patino, CM; Okelo, SO; Rand, CS; Riekert, KA; Krishnan, JA; Thompson, K; Quartey, RI; Perez-Williams, D; Bilderback, A; Merriman, B; Paulin, L; Hansel, N; Diette, GB				Patino, Cecilia M.; Okelo, Sande O.; Rand, Cynthia S.; Riekert, Kristin A.; Krishnan, Jerry A.; Thompson, Kathy; Quartey, Ruth I.; Perez-Williams, Deanna; Bilderback, Andrew; Merriman, Barry; Paulin, Laura; Hansel, Nadia; Diette, Gregory B.			The Asthma Control and Communication Instrument: A clinical tool developed for ethnically diverse populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma control; asthma treatment assignment; validation; racial disparities; quality of asthma care	QUALITY-OF-LIFE; HEALTH-CARE UTILIZATION; UNITED-STATES; PATIENT FACTORS; SEVERITY; RACE; ASSOCIATION; MORTALITY; CHILDREN; DISEASE	Background: Lower levels of quality asthma care among racially diverse populations might be due to inaccurate disease status assessments. The Asthma Control and Communication Instrument (ACCI) is a new tool that captures patient report of disease status during routine care. Objective: We sought to test the ACCI's psychometric properties in a racially diverse population. Methods: We performed a cross-sectional study. Subjects were recruited from specialist and generalist urban outpatient clinics. The ACCI and measures of asthma control, quality of life, lung function, and specialist rating of asthma status were collected. Four ACCI domains were separately validated: Acute Care, Bother, Control, and Direction. Principal component analysis, internal consistency, concurrent, discriminative, known-groups validity, and accuracy were evaluated. Results: Two hundred seventy asthmatic patients (77% female subjects, 55% black) participated. ACCI Control domain internal consistency was 0.80. ACCI Bother, Control, and Direction domains showed strong concurrent validity with asthma control and quality-of-life measures (all P<.001). ACCI Acute Care and Direction domains showed strong concurrent validity with individual validation items (all P<.001). The ACCI Control domain discriminated clinically important levels of disease status measured by asthma control, quality of life (both P<.001), and percent predicted peak expiratory flow rate (P = .005) and was associated with specialist rating of disease status (P<.001), confirming known-groups validity. The accuracy of the ACCI Control domain in classifying patients with uncontrolled asthma was very good (area under the curve, 0.851; 95% CI, 0.742-0.95870). Results were similar for both black and white subjects. Conclusion: The ACCI is a promising clinical tool that measures asthma disease status during routine health care and is valid for use in both black and white populations. (J Allergy Clin Immunol 2008;122:936-43.)	[Patino, Cecilia M.; Rand, Cynthia S.; Riekert, Kristin A.; Thompson, Kathy; Bilderback, Andrew; Hansel, Nadia; Diette, Gregory B.] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; [Merriman, Barry; Diette, Gregory B.] Johns Hopkins Univ, Bloomberg Sch Publ Health, Dept Epidemiol, Baltimore, MD 21205 USA; [Krishnan, Jerry A.] Univ Chicago, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; [Okelo, Sande O.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Paulin, Laura] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21205 USA; [Quartey, Ruth I.; Perez-Williams, Deanna] Howard Univ, Dept Microbiol, Washington, DC 20059 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Chicago; University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; Howard University	Diette, GB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, 1830 E Monument St,5th Floor, Baltimore, MD 21205 USA.	gdiette@jhmi.edu		Patino, Cecilia M./0000-0001-5742-2157; Paulin, Laura/0000-0003-0265-6858	National Heart, Lung, and Blood Institute [5UO1HL072455]; National Institutes of Health (NIH); Bowman Lingle Trust; Pfizer; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072455] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bowman Lingle Trust; Pfizer(Pfizer); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the National Heart, Lung, and Blood Institute (5UO1HL072455).; Disclosure of potential conflict of interest: C. S. Rand is on the advisory boards for Schering-Plough, Merck. and Novartis. K. A. Rickert receives grant support from the National Institutes of Health (NIH). J.A. Krishnan received grant support from the Bowman Lingle Trust. B. Merriman received grant support from the NIH. N. Hansel receives grant support from Pfizer. G. B. Diette receives grant support from the NIH. The rest of the authors have declared that they have no conflict of interest.	Aday LA, 1996, DESIGNING CONDUCTING; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 2002, UNEQUAL TREATMENT CO; Boudreaux ED, 2003, CHEST, V124, P803, DOI 10.1378/chest.124.3.803; *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P145; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Diette GB, 2007, CHEST, V132, p802S, DOI 10.1378/chest.07-1909; Diette GB, 2007, ARCH INTERN MED, V167, P1360, DOI 10.1001/archinte.167.13.1360; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; *GINA, 2007, GLOB STRAT ASTHM MAN; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Hair J.F., 1998, NJ PRENTICE HALL, V3, P98; Halterman JS, 2002, ARCH PEDIAT ADOL MED, V156, P141, DOI 10.1001/archpedi.156.2.141; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hardie GE, 2000, CHEST, V117, P935, DOI 10.1378/chest.117.4.935; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kerlinger FN, 1973, FDN BEHAV RES, V2nd; Krishnan JA, 2001, ARCH INTERN MED, V161, P1660, DOI 10.1001/archinte.161.13.1660; Lang T., 1997, REPORT STAT MED ANNO, DOI 10.1097/00006205-199705000-00022; LEVY DR, 1985, PEDIATRICS, V75, P639; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; McCoy L, 2005, J ASTHMA, V42, P757, DOI 10.1080/02770900500308189; McDowell I, 1987, MEASURING HLTH GUIDE; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; MULL JD, 1993, WESTERN J MED, V159, P609; *NAT HEART LUNG BL, 1997, NIH PUBL; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Okelo SO, 2008, PEDIATRICS, V122, pE195, DOI 10.1542/peds.2007-2271; Okelo SO, 2007, J GEN INTERN MED, V22, P976, DOI 10.1007/s11606-007-0209-1; Ortega AN, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e1; PATINO CM, 2004, AM J RESP CRIT CARE, V169, pA365; Patino CM, 2005, AM J RESP CRIT CARE, V2, pA254; QUILL TE, 1989, ANN INTERN MED, V111, P51, DOI 10.7326/0003-4819-111-1-51; Santanello NC, 1999, EUR RESPIR J, V14, P23, DOI 10.1034/j.1399-3003.1999.14a06.x; Skinner Elizabeth A, 2004, Dis Manag, V7, P305, DOI 10.1089/dis.2004.7.305; Stoloff SW, 2006, J ALLERGY CLIN IMMUN, V117, P544, DOI 10.1016/j.jaci.2006.01.005; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wolfenden LL, 2003, ARCH INTERN MED, V163, P231, DOI 10.1001/archinte.163.2.231; Wyrwich KW, 2005, HEALTH SERV RES, V40, P577, DOI 10.1111/j.1475-6773.2005.0l374.x; Wyrwich KW, 1999, MED CARE, V37, P469, DOI 10.1097/00005650-199905000-00006; REDUCING ASTHMA DISP; 2003, ASTHMA PREVALENCE HL	53	32	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					936	943		10.1016/j.jaci.2008.08.027	http://dx.doi.org/10.1016/j.jaci.2008.08.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18848721	Green Accepted			2022-12-18	WOS:000260940100012
J	Cox, L				Cox, Linda			Advantages and disadvantages of accelerated immunotherapy schedules	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						rush immunotherapy; cluster immunotherapy; systemic; reaction; premedication; allergic rhinitis; asthma	RUSH IMMUNOTHERAPY; SYSTEMIC REACTIONS; ALLERGEN IMMUNOTHERAPY; DERMATOPHAGOIDES-PTERONYSSINUS; VENOM IMMUNOTHERAPY; DOUBLE-BLIND; SAFETY; PREMEDICATION; EFFICACY; EXTRACT				Cox, L (corresponding author), 5333 N Dixie Highway, Ft Lauderdale, FL 33334 USA.	lindaswolfcox@msn.com	Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870				Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Cox L, 2006, ANN ALLERG ASTHMA IM, V97, P126, DOI 10.1016/S1081-1206(10)60003-8; Goldberg A, 2003, ANN ALLERG ASTHMA IM, V91, P405, DOI 10.1016/S1081-1206(10)61689-4; Harvey SM, 2004, ANN ALLERG ASTHMA IM, V92, P414, DOI 10.1016/S1081-1206(10)61776-0; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; Michils A, 2000, ALLERGY, V55, P455, DOI 10.1034/j.1398-9995.2000.00412.x; More DR, 2002, ANN ALLERG ASTHMA IM, V88, P391, DOI 10.1016/S1081-1206(10)62370-8; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Parmiani S, 2002, Allergol Immunopathol (Madr), V30, P283; PORTNOY J, 1992, ANN ALLERGY, V68, P493; PORTNOY J, 1994, ANN ALLERGY, V73, P409; Schiavino D, 2004, ANN ALLERG ASTHMA IM, V92, P409, DOI 10.1016/S1081-1206(10)61775-9; Sharkey P, 1996, ANN ALLERG ASTHMA IM, V76, P175, DOI 10.1016/S1081-1206(10)63419-9; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956	17	32	34	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					432	434		10.1016/j.jaci.2008.06.007	http://dx.doi.org/10.1016/j.jaci.2008.06.007			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18619664				2022-12-18	WOS:000258426300044
J	Busse, WW; Shah, SR; Somerville, L; Parasuraman, B; Martin, P; Goldman, M				Busse, William W.; Shah, Shailen R.; Somerville, Laura; Parasuraman, Bhash; Martin, Paula; Goldman, Mitchell			Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						budesonide; formoterol; fluticasone propionate; salmeterol; adjustable dosing; asthma	SINGLE INHALER; SALMETEROL/FLUTICASONE PROPIONATE; MAINTENANCE; ADULTS; FORMOTEROL/BUDESONIDE; REGIMEN; TRIAL	Background: The adjustable-dose budesonide/formoterol dry powder inhaler (DPI) has demonstrated similar or greater asthma control with less inhaled corticosteroid compared with the fixed-dose budesonide/formoterol DPI. Objective: We sought to evaluate the efficacy, tolerability, and resource use of maintenance therapy with the adjustable-dose budesonide/formoterol pressurized metered-dose inhaler versus the fixed-dose budesonide/formoterol pressurized metered-dose inhaler and the fixed-dose fluticasone propionate/salmeterol DPI. Methods: This was a randomized, open-label, multicenter study of patients (N = 1225) 12 years and older with moderate-to-severe persistent asthma. After 10 to 14 days of current therapy, patients were randomized 2:1 to fixed-dose budesonide/formoterol (160/4.5 mu g X 2 inhalations [320/9 mu g] twice daily) or fixed-dose fluticasone propionate/salmeterol (250/50 mu g x 1 inhalation twice daily) for 1 month (treatment period 1), after which, the fixed-dose fluticasone propionate/salmeterol group continued therapy and the fixed-dose budesonide/formoterol group was randomized 1:1 to fixed-dose budesonide/formoterol or adjustable-dose budesonide/formoterol (adjustable from 2 inhalations [320/9 mu g] twice daily to 2 inhalations [320/9 mu g] once daily or 4 inhalations [640/18 mu g] twice daily) for 6 months (treatment period 2). Results: There were no significant between-group differences in asthma exacerbations (primary variable), asthma symptoms, or lung function during the 7-month treatment period. Less study drug (inhalations per day, P<.001) was used with adjustable-dose versus fixed-dose budesonide/formoterol. All treatments were well tolerated. Conclusions: Adjustable-dose and fixed-dose budesonide/formoterol showed no differences in asthma control or tolerability versus fixed-dose fluticasone propionate/salmeterol.	[Busse, William W.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA; [Shah, Shailen R.] Allergy & Asthma Consultants, Collegeville, PA USA; [Somerville, Laura] Houston Allergy & Asthma Associates, Houston, TX USA; [Parasuraman, Bhash; Martin, Paula; Goldman, Mitchell] AstraZeneca, Wilmington, NC USA	University of Wisconsin System; University of Wisconsin Madison; AstraZeneca	Busse, WW (corresponding author), Univ Wisconsin Hosp & Clin, 600 Highland Ave,K-4950 Clin Sci Ctr, Madison, WI 53792 USA.	wwb@medicine.wisc.edu						Aalbers R, 2004, CURR MED RES OPIN, V20, P225, DOI 10.1185/030079903125002928; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; BERGER WE, 2007, AM J RESP CRIT CARE, V175, pA188; Bruggenjurgen B, 2005, PHARMACOECONOMICS, V23, P723; Buhl R, 2004, CURR MED RES OPIN, V20, P1209, DOI 10.1185/030079903125004303; Dahl R, 2006, RESP MED, V100, P1152, DOI 10.1016/j.rmed.2006.03.001; FitzGerald J Mark, 2003, Can Respir J, V10, P427; FitzGerald JM, 2005, CLIN THER, V27, P393, DOI 10.1016/j.clinthera.2005.03.006; Ind PW, 2004, RESP MED, V98, P464, DOI 10.1016/j.rmed.2003.07.010; Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x; Leuppi JD, 2003, SWISS MED WKLY, V133, P302; Morice AH, 2008, PULM PHARMACOL THER, V21, P32, DOI 10.1016/j.pupt.2006.10.006; National Asthma Education and Prevention Program National Heart Lung and Blood Institute, 2007, NIH PUBL; Stallberg B, 2003, INT J CLIN PRACT, V57, P656; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; 2007, SYMBICORT PRODUCT IN; 2007, ADVAIR DISKUS PRODUC	18	32	34	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1407	1414		10.1016/j.jaci.2008.03.019	http://dx.doi.org/10.1016/j.jaci.2008.03.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18455221				2022-12-18	WOS:000256771700016
J	Hard, D; Lehmann, N; Hoffmann, F; Jansson, A; Hector, A; Notheis, G; Roos, D; Belohradsky, BH; Wintergerst, U				Hard, Dominik; Lehmann, Natalie; Hoffmann, Florian; Jansson, Annette; Hector, Andreas; Notheis, Gundula; Roos, Dirk; Belohradsky, Bernd H.; Wintergerst, Uwe			Dysregulation of innate immune receptors on neutrophils in chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic granulomatous disease; neutrophils; innate immune system; nicotinamide adenine dinucleotide phosphate oxidase; Toll-like receptors; complement; receptors; Toll-like receptor 5; Toll-like receptor 9; CXCR1	GENE-THERAPY; C3B RECEPTORS; ACTIVATION; EXPRESSION; LEUKOCYTES; ASSAY	Background: Chronic granulomatous; disease (CGD) is the most common inherited disorder of neutrophil function, is caused by mutations in the reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, and results in recurrent bacterial infections. Objective: We sought to investigate the expression and function of innate immune receptors on neutrophils in patients with CGD. Methods: We quantified mRNA and protein expression of Toll-like receptors (TLRs), complement receptors, and chemokine receptors on neutrophils from 15 patients with CGD compared with that seen in healthy control subjects (n = 15) and control patients with bacterial pneumonia (n = 15). Phagocytosis, chemotaxis, and TLR function of isolated neutrophils were analyzed. The effect of NADPH oxidase inhibition on receptor expression and function was analyzed in control neutrophils. Results: Neutrophils from patients with CGD had lower expression levels of TLR5, TLR9, CD11b, CD18, CD35, and CXCR1 compared with those from healthy control subjects, whereas similar or increased receptor expressions were found in patients without CGD but with bacterial pneumonia. Reduced TLR5 expression resulted in impaired neutrophil activation by bacterial flagella, reduced CD11b/CD18 expression was associated with impaired phagocytosis of Staphylococcus aureus, and reduced CXCR1 expression was associated with decreased chemotaxis. TLR5 and CD18 expression levels correlated with disease severity in patients with CGD. TLR5 and TLR9 expression were greater in patients with residual NADPH oxidase activity. Inhibition of the NADPH oxidase in control neutrophils in vitro decreased TLR5 and TLR9 expression and impaired TLR5 function. Conclusion: These results provide the first evidence that innate immune receptors are dysregulated in patients with CGD.	[Hard, Dominik; Lehmann, Natalie; Hoffmann, Florian; Jansson, Annette; Hector, Andreas; Notheis, Gundula; Belohradsky, Bernd H.; Wintergerst, Uwe] Univ Munich, Childrens Hosp, Res Ctr, D-80337 Munich, Germany; [Roos, Dirk] Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, NL-1012 WX Amsterdam, Netherlands	University of Munich; University of Amsterdam; Academic Medical Center Amsterdam	Hard, D (corresponding author), Univ Munich, Childrens Hosp, Res Ctr, Lindwurmstr 2A, D-80337 Munich, Germany.	dominic.hartl@med.uni-muenchen.de		Wintergerst, Uwe/0000-0002-0785-0337; Hector, Andreas/0000-0002-5745-4746				Akira S, 2006, CURR TOP MICROBIOL, V311, P1; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; Alvarez ME, 2006, J IMMUNOL, V177, P4037, DOI 10.4049/jimmunol.177.6.4037; Assari Tracy, 2006, Med Immunol, V5, P4, DOI 10.1186/1476-9433-5-4; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BERGER M, 1984, J CLIN INVEST, V74, P1566, DOI 10.1172/JCI111572; Burg ND, 2001, CLIN IMMUNOL, V99, P7, DOI 10.1006/clim.2001.5007; Bylund J, 2007, EUR J IMMUNOL, V37, P1087, DOI 10.1002/eji.200636651; COOK J, 1983, NOUV REV FR HEMATOL, V25, P297; DeGendt CM, 1996, CLIN CHIM ACTA, V249, P189, DOI 10.1016/0009-8981(96)06279-1; DINAUER MC, 1992, ANNU REV MED, V43, P117, DOI 10.1146/annurev.med.43.1.117; FALLMAN M, 1993, J IMMUNOL, V151, P330; GAITHER TA, 1984, INFLAMMATION, V8, P429, DOI 10.1007/BF00918218; Grumach A S, 1993, Rev Paul Med, V111, P472; HASUI M, 1991, J LAB CLIN MED, V117, P291; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Johnston RB, 2001, CURR OPIN HEMATOL, V8, P17, DOI 10.1097/00062752-200101000-00004; Jozsef L, 2006, J IMMUNOL, V176, P1195, DOI 10.4049/jimmunol.176.2.1195; Jozsef L, 2004, FASEB J, V18, P1776, DOI 10.1096/fj.04-2048fje; Kobayashi SD, 2005, ARCH IMMUNOL THER EX, V53, P505; Kobayashi SD, 2004, J IMMUNOL, V172, P636, DOI 10.4049/jimmunol.172.1.636; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; Lekstrom-Himes JA, 2005, J IMMUNOL, V174, P411, DOI 10.4049/jimmunol.174.1.411; Malech HL, 2004, JPN J INFECT DIS, V57, pS27; Motulsky H., 1995, INTUITIVE BIOSTATIST; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Prince A, 2006, AM J RESP CELL MOL, V34, P548, DOI 10.1165/rcmb.2006-0022SF; QUIE PG, 1986, J ALLERGY CLIN IMMUN, V77, P387, DOI 10.1016/0091-6749(86)90169-7; Roos D, 2003, MICROBES INFECT, V5, P1307, DOI 10.1016/j.micinf.2003.09.009; Roos D, 2002, SCIENCE, V296, P669, DOI 10.1126/science.1071271; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; SENGELOV H, 1995, CRIT REV IMMUNOL, V15, P107, DOI 10.1615/CritRevImmunol.v15.i2.10; Stein S, 2006, CURR OPIN MOL THER, V8, P415; Stossel T P, 1977, Prog Clin Biol Res, V13, P87; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	37	32	35	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					375	382		10.1016/j.jaci.2007.10.037	http://dx.doi.org/10.1016/j.jaci.2007.10.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18155283				2022-12-18	WOS:000253337800015
J	Fujita, S; Yamashita, N; Ishii, Y; Sato, Y; Sato, K; Eizumia, K; Fukaya, T; Nozawa, R; Takamoto, Y; Yamashita, N; Taniguchi, M; Sato, K				Fujita, Shigeharu; Yamashita, Naomi; Ishii, Yasuyuki; Sato, Yumiko; Sato, Kaori; Eizumia, Kawori; Fukaya, Tomohiro; Nozawa, Risa; Takamoto, Yukiko; Yamashita, Naohide; Taniguchi, Masaru; Sato, Katsuaki			Regulatory dendritic cells protect against allergic airway inflammation in a murine asthmatic model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; T(H)2 cells; T regulatory cells; tolerance; IgE; airway hyperreactivity	T-CELLS; CORD BLOOD; RESPONSES; ACTIVATION; SUPPRESSION; INDUCTION; DISEASE; FOXP3; IL-21; LINES	Background: Dendritic cells (DCs) are crucial for the induction of immunity and tolerance. Despite an improved understanding of the DC-mediated control of T(H)1-biased immunity, little is known about how DCs regulate T(H)2-mediated immunity. Objective: The effects of immunostimulatory mature DCs (maDCs) and regulatory DCs (DCregs) on T(H)2-driven allergic immunity involving IgE production were examined. Methods: A murine model of airway hyperresponsiveness; the adoptive transfer of maDCs, DCregs, and T cells; and T-cell function were studied. Results: Antigen-pulsed maDCs inhibited antigen-specific IgE production but enhanced the production of antigen-specific IgG1 and IgG2a. Analysis of Ifng(-/-) mice and Il21r(-/-) mice revealed that the inhibitory effect of antigen-pulsed maDCs on antigen-specific IgE production involved IL-21-producing T follicular helper cells but not IFN-gamma-producing T(H)1 cells. In contrast, antigen-pulsed DCregs impaired the production of antigen-specific IgE, IgG1, and IgG2a. In vivo blockade experiments showed that antigen-specific CD4(+)CD25(+)Foxp3(+) regulatory T cells mainly mediated the suppressive effect of antigen-pulsed DCregs on the production of antigen-specific IgE. Antigen-pulsed maDCs promoted airway inflammation, whereas antigen-pulsed DCregs markedly suppressed the pathogenesis. Conclusion: DCregs abolish T(H)2-mediated IgE production and allergic inflammation based on antigen-specific dominant tolerance, whereas maDCs exacerbate the pathogenesis despite inhibiting the IgE response through the activation of diverse types of T-H cell responses.	[Fujita, Shigeharu; Sato, Kaori; Eizumia, Kawori; Fukaya, Tomohiro; Sato, Katsuaki] RIKEN Yokohama Inst, Res Ctr Allergy & Immunol, Lab Dendrit Cell Immunobiol, Kanagawa 2300045, Japan; [Fujita, Shigeharu; Yamashita, Naohide] RIKEN Yokohama Inst, Res Ctr Allergy & Immunol, Lab Vaccine Design, Kanagawa 2300045, Japan; [Yamashita, Naomi] RIKEN Yokohama Inst, Res Ctr Allergy & Immunol, Lab Immune Regulat, Kanagawa 2300045, Japan; [Fujita, Shigeharu; Yamashita, Naohide] Univ Tokyo, Inst Med Sci, Dept Adv Med Sci, Tokyo, Japan; [Yamashita, Naomi] Musashino Univ, Res Inst Pharmaceut Sci, Dept Pharm, Tokyo, Japan	RIKEN; RIKEN; RIKEN; University of Tokyo	Sato, K (corresponding author), RIKEN Yokohama Inst, Res Ctr Allergy & Immunol, Lab Dendrit Cell Immunobiol, Suehirocho 1-7-22, Kanagawa 2300045, Japan.	katsuaki@rcai.riken.jp	Yamashita, Naomi/F-5045-2011; Taniguchi, Masaru/N-7932-2015	Taniguchi, Masaru/0000-0001-7821-7179				Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akiba H, 2005, J IMMUNOL, V175, P2340, DOI 10.4049/jimmunol.175.4.2340; Brandt K, 2003, BLOOD, V102, P4090, DOI 10.1182/blood-2003-03-0669; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Fujita S, 2006, BLOOD, V107, P3656, DOI 10.1182/blood-2005-10-4190; Godfrey WR, 2005, BLOOD, V105, P750, DOI 10.1182/blood-2004-06-2467; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Harada M, 2006, J EXP MED, V203, P2929, DOI 10.1084/jem.20062206; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Li LQ, 2005, BLOOD, V106, P3068, DOI 10.1182/blood-2005-04-1531; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Morelli AE, 2003, IMMUNOL REV, V196, P125, DOI 10.1046/j.1600-065X.2003.00079.x; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Pesce J, 2006, J CLIN INVEST, V116, P2044, DOI 10.1172/JCI27727; Rutella S, 2006, BLOOD, V108, P1435, DOI 10.1182/blood-2006-03-006403; Sato K, 2003, IMMUNITY, V18, P367, DOI 10.1016/S1074-7613(03)00055-4; Sato K, 2003, BLOOD, V101, P3581, DOI 10.1182/blood-2002-09-2712; Sato Katsuaki, 2007, Allergol Int, V56, P183, DOI 10.2332/allergolint.R-06-139; Tomura T, 1999, J IMMUNOL, V162, P195; Vinuesa CG, 2005, NAT REV IMMUNOL, V5, P853, DOI 10.1038/nri1714; Yamashita N, 2006, J ALLERGY CLIN IMMUN, V117, P1040, DOI 10.1016/j.jaci.2006.01.009	25	32	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					95	104		10.1016/j.jaci.2007.08.038	http://dx.doi.org/10.1016/j.jaci.2007.08.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17920666	Bronze			2022-12-18	WOS:000252372000014
J	Rauter, I; Krauth, MT; Westritschnig, K; Horak, F; Flicker, S; Gieras, A; Repa, A; Balice, N; Spitzauer, S; Huss-Marp, J; Brockow, K; Darsow, U; Behrendt, H; Ring, J; Kricek, F; Valent, P; Valenta, R				Rauter, Ingrid; Krauth, Maria-Theresa; Westritschnig, Kerstin; Horak, Friedrich; Flicker, Sabine; Gieras, Anna; Repa, Andreas; Balice, Nadja; Spitzauer, Susanne; Huss-Marp, Johannes; Brockow, Knut; Darsow, Ulf; Behrendt, Heidrun; Ring, Johannes; Kricek, Franz; Valent, Peter; Valenta, Rudolf			Mast cell-derived proteases control allergic inflammation through cleavage of IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; mast cells/basophils; allergic inflammation; proteases	BIRCH POLLEN ALLERGEN; GRASS PHLEUM-PRATENSE; MONOCLONAL-ANTIBODIES; SECRETORY GRANULES; COMPLEMENTARY-DNA; MAJOR ALLERGEN; RECEPTOR; RELEASE; CLONING; IMMUNOTHERAPY	Background: Cross-linking of mast cell-bound IgE releases proinflammatory mediators, cytokines, and proteolytic enzymes and is a key event in allergic inflammation. Objective: We sought to study the effect of proteases released on effector cell activation on receptor-bound IgE and their possible role in the regulation of allergic inflammation. Methods: Using molar ratios of purified recombinant tryptase and human IgE, we studied whether tryptase can cleave IgE. Similar experiments were performed with mast cell lysates in the presence or absence of protease inhibitors. IgE cleavage products were detected in supernatants of allergen cross-linked, cultivated mast cells and in tissue fluids collected from patients' skin after IgE-mediated degranulation. The effects of prolamine, an inhibitor of heparin-dependent proteases on IgE-mediated allergic in vivo skin inflammation in human subjects were studied. Results: We show that P-tryptase, a major protease released during mast cell activation, cleaves IgE. IgE degradation products were detected in tryptase-containing tissue fluids collected from sites of allergic inflammation. The biologic significance of this mechanism is demonstrated by in vivo experiments showing that protease inhibition enhances allergic skin inflammation. Conclusion: We suggest that IgE cleavage by effector cell proteases is a natural mechanism for controlling allergic inflammation.	[Rauter, Ingrid; Westritschnig, Kerstin; Flicker, Sabine; Gieras, Anna; Valenta, Rudolf] Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Div Immunopathol, A-1090 Vienna, Austria; [Krauth, Maria-Theresa; Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria; [Horak, Friedrich] Med Univ Vienna, Dept ENT, Vienna, Austria; [Repa, Andreas] Med Univ Vienna, Dept Pediat, Div Neonatol, Vienna, Austria; [Balice, Nadja; Spitzauer, Susanne] Med Univ Vienna, Med & Chem Lab Diagnost, Vienna, Austria; [Huss-Marp, Johannes; Brockow, Knut; Darsow, Ulf; Behrendt, Heidrun; Ring, Johannes] TUM, ZAUM Ctr Allergy & Environm, Div Environm Dermatol & Allergy GSF, Munich, Germany; [Huss-Marp, Johannes; Brockow, Knut; Darsow, Ulf; Behrendt, Heidrun; Ring, Johannes] TUM, Dept Dermatol & Allergy Biederstein, Munich, Germany; [Kricek, Franz] Novartis Inst Biomed Res, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Technical University of Munich; Technical University of Munich; Novartis	Valenta, R (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Gamperl, Susi/V-2715-2019; Ring, Johannes/GLN-4341-2022; Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Gieras, Anna/S-8345-2019	Gamperl, Susi/0000-0003-0456-5095; Ring, Johannes/0000-0001-8236-3152; Valent, Peter/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365; Flicker, Sabine/0000-0003-4768-8693; Gieras, Anna/0000-0002-5147-2281				Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Brockow K, 2002, J ALLERGY CLIN IMMUN, V109, P82, DOI 10.1067/mai.2002.120524; DVORAK AM, 1986, LAB INVEST, V54, P663; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Hogan AD, 1997, METHODS, V13, P43, DOI 10.1006/meth.1997.0494; IRANI AMA, 1992, BLOOD, V80, P3009; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; KNUTTIMULLER JM, 1986, ALLERGY, V41, P457, DOI 10.1111/j.1398-9995.1986.tb00327.x; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Laffer S, 2001, J ALLERGY CLIN IMMUN, V108, P409, DOI 10.1067/mai.2001.117593; MCGLASHAM DW, 2002, IGE ANTI IGE THERAPY; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Nechansky A, 1997, HYBRIDOMA, V16, P441, DOI 10.1089/hyb.1997.16.441; Rauter I, 2006, FASEB J, V20, P967, DOI 10.1096/fj.05-3999fje; Saito H, 1996, J IMMUNOL, V157, P343; SCHWARTZ LB, 1987, AM REV RESPIR DIS, V135, P1186; Sheen CH, 2007, ALLERGY, V62, P532, DOI 10.1111/j.1398-9995.2007.01345.x; Tkaczyk C, 2004, INT ARCH ALLERGY IMM, V133, P305, DOI 10.1159/000077213; TOBIN MC, 1986, MOL IMMUNOL, V23, P245, DOI 10.1016/0161-5890(86)90050-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valenta R, 2004, ADV IMMUNOL, V82, P105, DOI 10.1016/S0065-2776(04)82003-0; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Vrtala S, 2000, J IMMUNOL, V165, P6653, DOI 10.4049/jimmunol.165.11.6653; VRTALA S, 1993, J IMMUNOL, V151, P4773; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836; Xu K, 1998, J CELL SCI, V111, P2385; Zhao W, 2006, J IMMUNOL, V177, P694, DOI 10.4049/jimmunol.177.1.694	30	32	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					197	202		10.1016/j.jaci.2007.08.015	http://dx.doi.org/10.1016/j.jaci.2007.08.015			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17904627				2022-12-18	WOS:000252372000030
J	Wisnivesky, JP; Sampson, H; Berns, S; Kattan, M; Halm, EA				Wisnivesky, Juan P.; Sampson, Hugh; Berns, Stephen; Kattan, Meyer; Halm, Ethan A.			Lack of association between indoor allergen sensitization and asthma morbidity in inner-city adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; sensitization; inner-city; morbidity; allergy; IgE	HOME DAMPNESS; LUNG-FUNCTION; ENVIRONMENTAL INTERVENTION; IGE ANTIBODIES; PUERTO-RICAN; EXPOSURE; CHILDREN; HEALTH; MITE; SENSITIVITY	Background: Sensitivity and exposure to indoor allergens is associated with increased asthma morbidity in inner-city children. However, it is unknown whether sensitization is associated with worse asthma in adults. Objective: To evaluate the relationship between sensitization and asthma morbidity in urban adults. Methods: We prospectively studied 245 adults with persistent asthma recruited from an inner-city clinic. Sensitization to indoor allergens was evaluated by specific IgE antibodies measured at enrollment. Data on asthma control, asthma-related emergency department visits, hospitalizations, and oral steroid use were collected at baseline and at 1-month and 3-month follow-up contacts. Univariate, stratified, and multiple regression analyses were used to compare asthma morbidity in sensitized and nonsensitized patients after controlling for self-reported exposure and other potential confounders. Results: The study cohort consisted predominantly of low income, minority patients with high rates of resource utilization. The prevalences of sensitization to cockroach, dust mite, cat, mold, and mouse were 60%, 43%, 41%, 21%, and 14%. On univariate analyses, patients sensitized to each allergen did not have worse asthma control or higher resource utilization compared with nonsensitized individuals. Stratified and multivariate analyses also showed no association between sensitization and several measures of asthma morbidity even after controlling for self-reported exposure to indoor allergens and other potential confounders. Conclusion: Sensitization to indoor allergens does not appear to he associated with increased asthma morbidity in inner-city adults. Clinical implications: These findings suggest that efforts to improve asthma control among urban populations should focus on other modifiable risk factors for morbidity.	Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA; Mt Sinai Sch Med, Div Pulm Crit Care & Sleep Med, Dept Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Wisnivesky, JP (corresponding author), Mt Sinai Sch Med, Div Gen Internal Med, 1 Gustave L Levy Pl,Box 1087, New York, NY 10029 USA.	juan.wisnvesky@mssm.edu			AHRQ HHS [R01 HS09973, K08 HS013312] Funding Source: Medline; NCRR NIH HHS [M01 RR00071] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS013312, R01HS009973] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*AM LUNG ASS EP ST, 2007, TRENDS ASTHM MORB MO; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Busse PJ, 2005, J ALLERGY CLIN IMMUN, V116, P146, DOI 10.1016/j.jaci.2005.03.031; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; DALES RE, 1994, INDOOR AIR, V4, P2, DOI 10.1111/j.1600-0668.1994.t01-3-00002.x; DALES RE, 1991, AM REV RESPIR DIS, V143, P505, DOI 10.1164/ajrccm/143.3.505; DALES RE, 1991, AM J EPIDEMIOL, V134, P196, DOI 10.1093/oxfordjournals.aje.a116072; De Vries MP, 2005, J ASTHMA, V42, P659, DOI 10.1080/02770900500264903; DELOVINFOSSE S, 1994, ALLERGY, V49, P64, DOI 10.1111/j.1398-9995.1994.tb00776.x; DEPALO VA, 1994, CHEST, V106, P447, DOI 10.1378/chest.106.2.447; Diette GB, 2002, ARCH INTERN MED, V162, P1123, DOI 10.1001/archinte.162.10.1123; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Eisner MD, 2001, RESP RES, V2, P53, DOI 10.1186/rr37; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Findley S, 2003, J ASTHMA, V40, P557, DOI 10.1081/JAS-120019028; Ford JG, 2001, CHEST, V120, P1129, DOI 10.1378/chest.120.4.1129; Graham LM, 2006, CHEST, V130, p13S, DOI 10.1378/chest.130.1_suppl.13S; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Halm EA, 2006, CHEST, V129, P573, DOI 10.1378/chest.129.3.573; Halm EA, 2005, CHEST, V128, P1943, DOI 10.1378/chest.128.4.1943; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hunninghake GM, 2006, AM J RESP CRIT CARE, V173, P143, DOI 10.1164/rccm.200508-1232SO; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Ledogar RJ, 2000, AM J PUBLIC HEALTH, V90, P929, DOI 10.2105/AJPH.90.6.929; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/ajrccm.165.7.2103044; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; Maestrelli P, 2001, CLIN EXP ALLERGY, V31, P715, DOI 10.1046/j.1365-2222.2001.01020.x; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Murray Clare S, 2004, Proc Am Thorac Soc, V1, P99, DOI 10.1513/pats.2306027; *NAT ASTHM ED PREV, 2003, EXP PAN REP GUID DIA; *NAT HEART LUNG BL, 1999, GUID DIAGN MAN ASTHM; *NAT HEART LUNG BL, 1997, EXP PAN REP 2 GUID D; Neter J., 1990, APPL LINEAR STAT MOD; NIEMEIJER NR, 1992, ALLERGY, V47, P431, DOI 10.1111/j.1398-9995.1992.tb02084.x; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Pesola GR, 2004, ACAD EMERG MED, V11, P944, DOI 10.1197/j.aem.2004.03.020; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Rogers L, 2002, CHEST, V122, P1580, DOI 10.1378/chest.122.5.1580; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rosias PPR, 2004, PEDIATR PULM, V38, P107, DOI 10.1002/ppul.20056; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; Thorn J, 2001, ALLERGY, V56, P287, DOI 10.1034/j.1398-9995.2001.00805.x; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; Ungar WJ, 1998, J CLIN EPIDEMIOL, V51, P1335, DOI 10.1016/S0895-4356(98)00117-6; Wisnivesky JP, 2005, J ALLERGY CLIN IMMUN, V116, P636, DOI 10.1016/j.jaci.2005.05.031; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7	57	32	33	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					113	120		10.1016/j.jaci.2007.03.044	http://dx.doi.org/10.1016/j.jaci.2007.03.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17531297				2022-12-18	WOS:000248066400016
J	Jarvis, D; Zock, JP; Heinrich, J; Svanes, C; Verlato, G; Olivieri, M; Villani, S; Ponzio, M; Leynaert, B; Sunyer, J; Dahlman-Hoglund, A; Chinn, S; Luczynska, C; Norback, D; Burney, P				Jarvis, Deborah; Zock, Jan-Paul; Heinrich, Joachim; Svanes, Cecilie; Verlato, Giuseppe; Olivieri, Mario; Villani, Simona; Ponzio, Michela; Leynaert, Benedicte; Sunyer, Jordi; Dahlman-Hoglund, Anna; Chinn, Susan; Luczynska, Christina; Norbaeck, Dan; Burney, Peter			Cat and dust mite allergen levels, specific IgG and IgG(4), and respiratory symptoms in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ECRHS; IgG; cat; house dust mite	HEALTH SURVEY-II; NATURAL EXPOSURE; HUMAN FILARIASIS; ANTIBODY; SENSITIZATION; CHILDREN; SUBCLASS; ASTHMA; ASSOCIATION; TOLERANCE	Background: Exposure to allergen may induce a modified T(H)2 response characterized by high IgG(4) levels, absence of IgE sensitization, and a decreased risk of allergic respiratory symptoms. Objective: To assess the association of IgG(4) level with allergic respiratory symptoms in a community-based sample of adults. Methods: Information on exposure to cats, respiratory symptoms, and mattress allergen levels was obtained from 2780 adults. Levels of cat and house dust mite (HDM) specific IgE, IgG, and IgG(4) were measured. The association of exposure to allergen with IgG(4) and of IgG(4) with symptoms was assessed. Results: Geometric mean (GM) cat specific IgG and IgG(4) was higher in subjects who had a cat that was allowed in the bedroom than in subjects without a cat (adjusted ratio of GM IgG(4), 1.41; 95% CI, 1.25-1.57). Levels of HDM specific IgG and IgG(4) were similar in subjects with undetectable and high (> 20.22 mu g/g) mattress Der 1 levels (adjusted ratio of GM IgG(4), 1.02; 95% CI, 0.89-1.17). There was no evidence that high cat or HDM specific IgG(4) levels were associated with less IgE sensitization or with fewer symptoms. Conclusion: In this community-based sample of adults, high IgG(4) levels to cat or HDM were not associated with a lower risk of allergic respiratory symptoms. Clinical implications: In adults, high cat allergen exposure does not protect against respiratory symptoms.	Natl Heart & Lung Inst, Resp Epidemiol & Publ Hlth Grp, London SW3 6LR, England; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England; Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, I-37100 Verona, Italy; Univ Verona, Dept Med & Publ Hlth, Unit Occupat Med, I-37100 Verona, Italy; GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Municipal Inst Med Res, Ctr Res Environm Epidemiol, Barcelona, Spain; Univ Pavia, Dept Hlth Sci, Sect Med Stat & Epidemiol, I-27100 Pavia, Italy; Haukeland Hosp, Dept Thorac Med, Dept Med, N-5021 Bergen, Norway; Uppsala Univ, Dept Med Sci Occupat & Environm Med, S-75105 Uppsala, Sweden; Gothenburg Univ, Sahlgrenska Hosp, Sahlgrenska Acad, Dept Occupat & Environm Med, S-41124 Gothenburg, Sweden; Univ Paris 07, INSERM U700, Paris, France; Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain	Imperial College London; University of London; King's College London; University of Verona; University of Verona; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Pavia; University of Bergen; Haukeland University Hospital; Uppsala University; Sahlgrenska University Hospital; University of Gothenburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Pompeu Fabra University	Jarvis, D (corresponding author), Natl Heart & Lung Inst, Resp Epidemiol & Publ Hlth Grp, Emmanuel Kaye Bldg,Manresa Rd, London SW3 6LR, England.	djarvis@imperial.ac.uk	Svanes, Cecilie/N-7556-2017; Leynaert, Benedicte/N-5251-2018; Heinrich, Joachim/N-1720-2013; SESM, SESM/C-1440-2008; Zock, Jan-Paul/P-5034-2018; Sunyer, Jordi/G-6909-2014; Jarvis, Deborah/E-6494-2011	Svanes, Cecilie/0000-0001-8512-5192; Heinrich, Joachim/0000-0002-9620-1629; Zock, Jan-Paul/0000-0002-2941-6259; Sunyer, Jordi/0000-0002-2602-4110; Leynaert, Benedicte/0000-0001-5045-2492; Norback, Dan/0000-0002-5174-6668; /0000-0003-2517-6515; Jarvis, Deborah/0000-0002-1753-3896; Burney, Peter/0000-0001-8635-5678				AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; AALBERSE RC, 1983, J IMMUNOL, V130, P722; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chinn S, 2004, THORAX, V59, P646, DOI 10.1136/thx.2004.021642; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Hesselmar B, 2003, CLIN EXP ALLERGY, V33, P1681, DOI 10.1111/j.1365-2222.2003.01821.x; HUSSAIN R, 1987, J IMMUNOL, V139, P2794; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; *INT LAB OFF G, 1990, INT STAND CLAS OCC I; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jenmalm MC, 1999, PEDIATR ALLERGY IMMU, V10, P112, DOI 10.1034/j.1399-3038.1999.00015.x; KEMENY DM, 1989, CLIN EXP ALLERGY, V19, P545, DOI 10.1111/j.1365-2222.1989.tb02431.x; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MCSHARRY C, 1994, CLIN EXP IMMUNOL, V97, P499, DOI 10.1111/j.1365-2249.1994.tb06116.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Portengen L, 2004, CLIN EXP ALLERGY, V34, P1243, DOI 10.1111/j.1365-2222.2004.02025.x; *STAT, 2005, STATA STAT SOFTW REL; Uitti J, 2005, INT ARCH OCC ENV HEA, V78, P71, DOI 10.1007/s00420-004-0556-8; *UN MED DENT SCH G, 1993, EUR COMM RESP HLTH S; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; Witteman AM, 1996, INT ARCH ALLERGY IMM, V109, P369, DOI 10.1159/000237265; Zock JP, 2006, J ALLERGY CLIN IMMUN, V118, P682, DOI 10.1016/j.jaci.2006.04.060	28	32	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					697	704		10.1016/j.jaci.2006.10.042	http://dx.doi.org/10.1016/j.jaci.2006.10.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17270260				2022-12-18	WOS:000244925000024
J	Martel, MJ; Rey, E; Beauchesne, MF; Perreault, S; Forget, A; Maghni, K; Lefebvre, GE; Blais, L				Martel, Marie-Josee; Rey, Evelyne; Beauchesne, Marie-France; Perreault, Sylvie; Forget, Amelie; Maghni, Karim; Lefebvre, Genevieve; Blais, Lucie			Use of short-acting beta(2)-agonists during pregnancy and the risk of pregnancy-induced hypertension	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pregnancy; short-acting beta(2)-agonists; pregnancy-induced hypertension; preeclampsia; gestational hypertension; asthma medications; pharmacoepidemiology; administrative databases	PERINATAL OUTCOMES; INHALED SALBUTAMOL; ASTHMA; DATABASE; WOMEN; INFORMATION; ALBUTEROL; FENOTEROL; SELECTION; ACCURACY	Background: The effect of inhaled short-acting beta(2)-agonists (SABAs) on pregnancy outcome, especially hypertensive complications, is not well documented. After the finding of a possible protective association of inhaled SABAs with pregnancy-induced hypertension (PIH) in a previous study, we decided to further investigate their effect on this condition. Objective: We sought to determine the effect of inhaled SABA use during pregnancy on the risk of PIH (gestational. hypertension, preeclampsia, or eclampsia) in asthmatic women. Methods: Three of Quebec's administrative databases were linked to constitute a cohort of asthmatic women who had at least 1 delivery between 1990 and 2000. A nested case-control study was performed using up to 10 control subjects matched to each case patient for the year of conception and gestational age. Statistical analyses considered 22 confounders. Results: The cohort was composed of 3505 asthmatic women who had a total of 4593 pregnancies. Three hundred two patients with PIH and 3013 control subjects were identified. Compared with nonuse, inhaled SABA use during pregnancy was significantly associated with a reduced risk of PIH (adjusted rate ratios: > 0-3 doses/week, 0.62 (95% CI, 0.44-0.87); > 3-10 doses/week, 0.51 (95% CI, 0.34-0.79); and > 10 doses/week, 0.48 (95% C1, 0.30-0.75)). Conclusions: To our knowledge, this is the first study reporting that inhaled SABA use during pregnancy is associated with a reduced risk of PIH. Potential explanations include pharmacologic and physiological effects or residual confounding. Clinical implications: These results increase the evidence about the safety of inhaled SABAs in this population, although they should not undervalue the importance of maintaining good control of asthma symptoms.	Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Math, Montreal, PQ H3C 3J7, Canada; Hop St Justine, Dept Obstet & Gynecol, Montreal, PQ H3T 1C5, Canada; Hop Sacre Coeur, Dept Pharm, Montreal, PQ H4J 1C5, Canada; Hop Sacre Coeur, Res Ctr, Montreal, PQ H4J 1C5, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Blais, L (corresponding author), Univ Montreal, Fac Pharm, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	lucie.blais@umontreal.ca	Perreault, Sylvie/AAM-8009-2020	Perreault, Sylvie/0000-0002-0066-0127				Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; [Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, P34; BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; BENNETT JA, 1994, THORAX, V49, P771, DOI 10.1136/thx.49.8.771; Blais L, 2006, PHARMACOEPIDEM DR S, V15, P245, DOI 10.1002/pds.1202; BLAIS L, 2004, PHARMACOEPIDEMIOL S, V13, pS125; Blais Lucie, 2006, J Adolesc Health, V38, DOI 10.1016/j.jadohealth.2005.02.010; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; BREMNER P, 1993, EUR RESPIR J, V6, P204; Brown J.H., 2001, GOODMAN GILMANS PHAR, V10th ed., P10; Burggraaf J, 2001, THORAX, V56, P567, DOI 10.1136/thorax.56.7.567; Clark DJ, 1997, CLIN PHARMACOKINET, V32, P58, DOI 10.2165/00003088-199732010-00003; CRANE J, 1989, THORAX, V44, P136, DOI 10.1136/thx.44.2.136; Cunningham FG, 2005, WILLIAMS OBSTET; Dombrowski MP, 1997, OBSTET GYN CLIN N AM, V24, P559, DOI 10.1016/S0889-8545(05)70322-3; Helewa ME, 1997, CAN MED ASSOC J, V157, P715; KUNG M, 1987, CHEST, V91, P382, DOI 10.1378/chest.91.3.382; Liccardi G, 1998, Monaldi Arch Chest Dis, V53, P151; Lipworth BJ, 2001, THORAX, V56, P506, DOI 10.1136/thorax.56.7.506; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; MARCOUX S, 1989, AM J EPIDEMIOL, V130, P950, DOI 10.1093/oxfordjournals.aje.a115427; Martel MJ, 2005, BMJ-BRIT MED J, V330, P230, DOI 10.1136/bmj.38313.624352.8F; *NIH, 1997, 974051 NIH; *NIH, 2000, 003029 NIH; RAYBURN WF, 1994, AM J OBSTET GYNECOL, V171, P770, DOI 10.1016/0002-9378(94)90095-7; Schatz M, 2004, J ALLERGY CLIN IMMUN, V113, P1040, DOI 10.1016/j.jaci.2004.03.017; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; SCHATZ M, 1988, J ALLERGY CLIN IMMUN, V82, P686, DOI 10.1016/0091-6749(88)90984-0; SCHATZ M, 1998, ASTHMA IMMUNOLGICAL; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; VANDENBRANDT PA, 1991, PHARM WEEKBLAD, V13, P91, DOI 10.1007/BF01974987; WEST SL, 1995, AM J EPIDEMIOL, V142, P1103, DOI 10.1093/oxfordjournals.aje.a117563; Zhang J, 1999, AM J OBSTET GYNECOL, V181, P1407, DOI 10.1016/S0002-9378(99)70384-4	34	32	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					576	582		10.1016/j.jaci.2006.10.034	http://dx.doi.org/10.1016/j.jaci.2006.10.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17166573	Bronze			2022-12-18	WOS:000244925000008
J	Daines, MO; Chen, WG; Tabata, Y; Walker, BA; Gibson, AM; Masino, JA; Warrier, MR; Daines, CL; Wenzel, SE; Hershey, GKK				Daines, Michael O.; Chen, Weiguo; Tabata, Yasuhiro; Walker, Bradley A.; Gibson, Aaron M.; Masino, J. Alexander; Warrier, Manoj R.; Daines, Cori L.; Wenzel, Sally E.; Hershey, Gurjit K. Khurana			Allergen-dependent solubilization of IL-13 receptor alpha 2 reveals a novel mechanism to regulate allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13R alpha 2; allergen; house dust mite; asthma; cytokine receptor	INTERLEUKIN (IL)-13 RESPONSES; CYSTEINE PROTEASE ACTIVITY; HOUSE-DUST MITE; INTERFERON-GAMMA; SEVERE ASTHMA; CLONING; EXPRESSION; DER-P-1; CHAIN; INFLAMMATION	Background: Allergic sensitization affects half of western populations and often precedes the development of allergic disorders including asthma. Despite the critical role of allergens in the pathogenesis of these disorders, little is known about how allergens modulate the immune response. IL-13 receptor alpha 2 (IL-13R alpha 2) is a decoy receptor for IL-13. Objective: Although the existence of soluble IL-13R alpha 2 has been documented, the mechanisms underlying its generation are unknown. Many allergens possess protease activity; we investigated whether IL-13R alpha 2 is solubilized in response to allergen treatment. Methods: We evaluated the ability of allergens to solubilize IL-13R alpha 2 in vitro and in vivo and examined the effect on IL-13 signaling and responses. Results: We determined that treatment of cells with house dust mite (HDM) allergen or purified Dermatophagoides pteronyssinus or Dermatophagoides farinae, but not other allergens, resulted in release of soluble IL-13R alpha 2 that was biologically active and inhibited IL-13 signaling. Prolonged exposure to HDM or treatment with mold allergens resulted in IL-13R alpha 2 degradation. This was associated with increased IL-13 signaling. A single treatment of HDM in vivo resulted in release of IL-13R alpha 2 into the bronchoalveolar lavage (BAL) fluid. BAL fluid from humans also contained IL-13R alpha 2; BAL fluid from individuals with asthma contained less IL-13R alpha 2 than that from controls. Conclusion: Allergen exposure can directly affect the level of soluble IL-13R alpha 2 in a way that affects IL-13 signaling and responses. Clinical implications: Soluble IL-13R alpha 2 may be an important biomarker of environmental allergen exposure and asthma.	Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pediat, Coll Med, Cincinnati, OH 45221 USA; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Boulder, CO 80309 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org		Daines, Michael/0000-0003-2464-9034	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI053150, R01AI058157] Funding Source: NIH RePORTER; NIAID NIH HHS [K08 AI053150-04, K08 AI053150-03, K08 AI053150, K08 AI053150-01A1, R01 AI058157, K08 AI053150-05, K08 AI053150-02, K08 AI053150-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Daines MO, 2006, J IMMUNOL, V176, P7495, DOI 10.4049/jimmunol.176.12.7495; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HUANG SK, 1995, J IMMUNOL, V155, P2688; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Nakamura Y, 1996, AM J RESP CELL MOL, V15, P680, DOI 10.1165/ajrcmb.15.5.8918375; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; TABATA Y, 2006, IN PRESS J IMMUNOLOG; TANG MLK, 1995, CLIN EXP ALLERGY, V25, P515, DOI 10.1111/j.1365-2222.1995.tb01088.x; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	36	32	33	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					375	383		10.1016/j.jaci.2006.09.039	http://dx.doi.org/10.1016/j.jaci.2006.09.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17140645	Green Accepted			2022-12-18	WOS:000244327900015
J	Grinnan, D; Sung, SS; Dougherty, JA; Knowles, AR; Allen, MB; Rose, CE; Nakano, H; Gunn, MD; Fu, SM; Rose, CE				Grinnan, Dan; Sung, Sun-Sang; Dougherty, Joseph A.; Knowles, Amy Ryce; Allen, Matthew B.; Rose, Charles E., III; Nakano, Hideki; Gunn, Michael D.; Fu, Shu Man; Rose, C. Edward, Jr.			Enhanced allergen-induced airway inflammation in paucity of lymph node T cell (plt) mutant mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; chemokines; CCR7; dendritic cells; EBV-induced lymphoid chemokine/CCL19; eosinophils; lymphocytes; mice; monocyte-derived chemoattractant/CCL22; secondary lymphoid chemokine/CCL21	MONOCYTE CHEMOTACTIC PROTEIN-2; CC-CHEMOKINE RECEPTOR; DENDRITIC CELLS; LACKING EXPRESSION; ORGAN CHEMOKINE; ATOPIC ASTHMA; MCP-2; MOUSE; DELETION; GENE	Background: Dendritic cells and lymphocytes play a central role in allergic asthma. Chemokines for these cells include the CCR7 agonists secondary lymphoid chemokine/CCL21 and EBV-induced lymphoid chemokine/CCL19, but their role in allergic asthma is poorly understood. Objective: We sought to determine the effects of abrogation of lymphoid tissue expression of CCR7 agonists on allergic airway responses. Methods: Paucity of lymphocyte T cell (plt) mutant mice, deficient in EBV-induced lymphoid chemokine/CCL19 and the lymphoid form of secondary lymphoid chemokine/CCL21, were evaluated in an established ovalbumin (OVA)-induced asthma model (plt-OVA group) and compared with similarly immunized +/+ BALB/c mice (+/+OVA group). Results: APTI responses to methacholine increased similarly in OVA-challenged plt and +/+ mice. However, airway inflammation was strikingly enhanced in plt-OVA mutants over +/+OVA mice and included increased numbers of eosinophils, CD4 and B cells, neutrophils, and total leukocytes in bronchoalveolar lavage fluid and inflammatory cell cuffing around pulmonary arterioles. Enhanced airway inflammation was accompanied by an increase in lung T(H)2 activity, with increased levels of IL-4 and monocyte-derived chemoattractant/CCL22. Conclusions: Induction of allergic asthma in mutant mice with impaired CCR7 responses results in characteristics that resemble severe asthma in human subjects, including severe bronchial lymphocytosis, eosinophilia, and neutrophilia, but not in enhancement in airway hyperreactivity. Clinical implications: Disruption of chemokines responsible for trafficking of antigen-processing cells and lymphocytes to the draining lymph nodes might lead to enhanced allergic airway responses.	Univ Virginia, Sch Med, Div Pulm & Crit Care Med, Hlth Syst, Charlottesville, VA 22901 USA; Univ Virginia, Sch Med, Div Rheumatol & Immunol, Charlottesville, VA 22901 USA; Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA	University of Virginia; University of Virginia; Duke University	Rose, CE (corresponding author), Univ Virginia, Sch Med, Div Pulm & Crit Care Med, Hlth Syst, POB 800546, Charlottesville, VA 22901 USA.	cer@virginia.edu		Fu, Shu Man/0000-0001-5158-3494; Gunn, Michael/0000-0003-4602-0667	NHLBI NIH HHS [HL070656, R01 HL065344, HL065344] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065344] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; Conroy DM, 2003, J LEUKOCYTE BIOL, V74, P558, DOI 10.1189/jlb.0103030; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1, DOI 10.1152/ajpregu.2000.279.1.R1; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Haley KJ, 1998, AM J RESP CRIT CARE, V157, P1; *I LAB AN RES NRC, 1996, GUID CAR US LAB AN; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kim Y, 2001, J IMMUNOL, V166, P5183, DOI 10.4049/jimmunol.166.8.5183; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; LEVITT RC, 1995, AM J RESP CRIT CARE, V151, P1537, DOI 10.1164/ajrccm.151.5.7735612; Lira SA, 2005, NAT IMMUNOL, V6, P866, DOI 10.1038/ni0905-866; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Luther SA, 2000, P NATL ACAD SCI USA, V97, P12694, DOI 10.1073/pnas.97.23.12694; Mori S, 2001, J EXP MED, V193, P207, DOI 10.1084/jem.193.2.207; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nakano H, 1997, EUR J IMMUNOL, V27, P215, DOI 10.1002/eji.1830270132; Nakano H, 1998, BLOOD, V91, P2886, DOI 10.1182/blood.V91.8.2886.2886_2886_2895; Nakano H, 2001, J IMMUNOL, V166, P361, DOI 10.4049/jimmunol.166.1.361; NOSO N, 1994, BIOCHEM BIOPH RES CO, V200, P1470, DOI 10.1006/bbrc.1994.1616; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; *SAS I, 1987, SAS STAT GUID PERS C; SOZZANI S, 1994, J IMMUNOL, V152, P3615; Sung SSJ, 2001, J IMMUNOL, V166, P1261, DOI 10.4049/jimmunol.166.2.1261; Sung SSJ, 2006, J IMMUNOL, V176, P2161, DOI 10.4049/jimmunol.176.4.2161; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; Vassileva G, 1999, J EXP MED, V190, P1183, DOI 10.1084/jem.190.8.1183; WEBER M, 1995, J IMMUNOL, V154, P4166	40	32	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1234	1241		10.1016/j.jaci.2006.07.036	http://dx.doi.org/10.1016/j.jaci.2006.07.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157652				2022-12-18	WOS:000242880300005
J	Lee, SY; Cho, JY; Miller, M; McElwain, K; McElwain, S; Sriramarao, P; Raz, E; Broide, DH				Lee, SY; Cho, JY; Miller, M; McElwain, K; McElwain, S; Sriramarao, P; Raz, E; Broide, DH			Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; remodeling; angiogenesis; VEGF; ISS; TLR-9	ENDOTHELIAL GROWTH-FACTOR; UP-REGULATION; EXPRESSION; ASTHMA; CELLS; IMMUNOREACTIVITY; INFLAMMATION; LUNG	Background: Airway remodeling in asthma is associated with angiogenesis. Objective: We have examined whether immunostimulatory sequences of DNA (ISSs) inhibit allergen-induced airway angiogenesis and expression of angiogenic cytokines in a mouse model of airway remodeling. Methods: Mice sensitized to ovalbumin were challenged repetitively with ovalbumin for three months to develop airway remodeling and angiogenesis. Levels of angiogenesis were compared in ISS-treated and control mice. Results: Mice challenged with ovalbumin developed significantly increased levels of peribronchial angiogenesis (increase in the number of CD31(+) peribronchial small blood vessels) and an increase in the peribronchial vascular area as assessed by image analysis. Ovalbumin-induced peribronchial angiogenesis was associated with increased bronchoalveolar lavage levels or vascular endothelial growth factor (VEGF) and an increase in the number of peribronchial cells expressing VEGF. Treatment of mice with ISS before repetitive ovalbumin challenge significantly reduced the levels or peribronchial angiogenesis as well as the levels of bronchoalveolar lavage VEGF and the number of peribronchial cells expressing VEGF. ISS is unlikely to act directly oil endothelial cells to inhibit angiogenesis because lung endothelial cells did not express Toll receptor 9, the receptor for ISS as assessed by RT-PCR. In vitro studies demonstrated that ISS inhibited macrophage expression of VEGF. Conclusion: The ability of ISS to inhibit angiogenesis in vivo is likely to be mediated by several mechanisms, including ISS reducing the number of peribronchial inflammatory cells that express VEGF, ISS inhibiting expression of T(H)2 cytokines such as IL-13 that promote VEGF expression, and direct effects of ISS oil macrophages to inhibit VEGF expression.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Kangnam St Marys Hosp, Seoul, South Korea; La Jolla Inst Mol Med, La Jolla, CA USA	University of California System; University of California San Diego; Catholic University of Korea; Catholic University Korea Hospital	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, Basic Sci Bldg,Room 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.	dbroide@ucsd.edu		Rao, Srirama/0000-0001-9082-1029; Broide, David/0000-0001-8405-9090	NIAID NIH HHS [AI 40682, AI 38425] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038425, P01AI040682, R37AI038425] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; Boesiger J, 1998, J EXP MED, V188, P1135, DOI 10.1084/jem.188.6.1135; Boussat S, 2000, AM J PHYSIOL-LUNG C, V279, pL371, DOI 10.1152/ajplung.2000.279.2.L371; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Cho JY, 2004, AM J RESP CELL MOL, V30, P651, DOI 10.1165/rcmb.2003-0066OC; CHO JY, 2004, J IMMUNOL, V173, P7556; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horiuchi T, 1997, AM J RESP CELL MOL, V17, P70, DOI 10.1165/ajrcmb.17.1.2796; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2003, EUR RESPIR J, V21, P804, DOI 10.1183/09031936.03.00082002; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Khaldoyanidi S, 2001, BLOOD, V98, P303, DOI 10.1182/blood.V98.2.303; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39, DOI 10.1164/ajrccm.164.supplement_2.2106065; Newman PJ, 1997, J CLIN INVEST, V100, pS25; Redington AE, 2001, J ALLERGY CLIN IMMUN, V107, P384, DOI 10.1067/mai.2001.112268; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Wen FQ, 2003, J ALLERGY CLIN IMMUN, V111, P1307, DOI 10.1067/mai.2003.1455; Zhao Q, 2005, J BIOL CHEM, V280, P8101, DOI 10.1074/jbc.M411760200; Zheng M, 2002, P NATL ACAD SCI USA, V99, P8944, DOI 10.1073/pnas.132605599	25	32	37	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					597	603		10.1016/j.jaci.2005.11.008	http://dx.doi.org/10.1016/j.jaci.2005.11.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522459				2022-12-18	WOS:000236263100015
J	Plager, DA; Weiss, EA; Kephart, GM; Mocharla, RM; Matsumoto, R; Checkel, JL; Schwartz, LB; Gleich, GJ; Leiferman, KM				Plager, DA; Weiss, EA; Kephart, GM; Mocharla, RM; Matsumoto, R; Checkel, JL; Schwartz, LB; Gleich, GJ; Leiferman, KM			Identification of basophils by a mAb directed against pro-major basic protein 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; immunofluorescence; immunohistochemistry; monoclonal antibody; pro-major basic protein	MESSENGER-RIBONUCLEIC-ACID; UNIQUE SECRETORY PRODUCT; LEYDEN CRYSTAL PROTEIN; HUMAN IGE SYNTHESIS; BASIC-PROTEIN; MAST-CELLS; IMMUNOHISTOCHEMICAL DETECTION; INFLAMMATORY CELLS; ATOPIC-DERMATITIS; ANTIBODY 97A6	Background: Basophils possess characteristics of both mast cells and eosinophils, and all 3 cell types often are found together, particularly during allergic reactions. A mAb (J175-7D4) generated against the recombinant pro-form of human eosinophil granule major basic protein 1 (rproMBP1) appeared to stain only basophils in tissue specimens. Objective: We investigated J175-7D4 to characterize its specificity for basophils. Methods: Fluid-phase immunoprecipitation, Western blotting, and immunocytochemistry and immunohistochemistry were used to establish the specificity of J175-7D4. Results: First, J175-7D4 binds to various glycosylated and proteolytically processed forms of rproMBP1, but not to major basic protein. Second, cells transfected with the rproMBP1 gene and human placental tissue (known to express the pro-form of major basic protein 1 [proMBP1]) stain specifically with J175-7D4. In contrast, although mature eosinophils contain substantial major basic protein, they lack proMBP1 and do not stain. Neutrophils, lymphocytes, monocytes, and skin mast cells also are not stained. However, blood basophils are stained by J175-7D4, anti-IgE, Wright-Giemsa (metachromatically), and a previously characterized basophil-specific mAb, 2D7. Finally, formaldehyde-fixed, paraffin-embedded basophils are identically detected by J175-7D4 and 2D7, and J175-7D4 also recognizes putative basophils in formaldehyde-fixed., paraffin-embedded tissue specimens from inflammatory dermatoses, such as atopic dermatitis and delayed pressure urticaria. Conclusion: The J175-7D4 mAb recognizes proMBP1 as a novel marker for human basophils.J175-7D4 should prove useful for characterizing basophil involvement in human health and disease.	Univ Utah, Hlth Sci Ctr, Dept Dermatol, Sch Med 4B454, Salt Lake City, UT 84132 USA; Mayo Clin Rochester, Dept Dermatol, Rochester, MN USA; Mayo Clin Rochester, Dept Immunol, Rochester, MN USA; Mayo Clin Rochester, Dept Med, Rochester, MN USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23284 USA	Utah System of Higher Education; University of Utah; Mayo Clinic; Mayo Clinic; Mayo Clinic; Virginia Commonwealth University	Leiferman, KM (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Dermatol, Sch Med 4B454, 30 North 1900 East, Salt Lake City, UT 84132 USA.	kristin.leiferman@hsc.utah.eclu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050494, U01AI034577, R37AI009728, P50AI011483, U19AI034577, R01AI027517, R01AI009728] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 50494, AI 34577, AI 27517, AI 11483, AI 09728, AI 07047] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; ACKERMAN SJ, 1983, J EXP MED, V158, P946, DOI 10.1084/jem.158.3.946; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; BODGER MP, 1987, BLOOD, V69, P1414; BONNO M, 1994, LAB INVEST, V70, P234; BROWN SJ, 1982, J IMMUNOL, V129, P790; Buhring HJ, 2001, BLOOD, V97, P3303, DOI 10.1182/blood.V97.10.3303; Buhring HJ, 1999, BLOOD, V94, P2343; BUTTERFIELD JH, 1990, LAB INVEST, V62, P77; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; DENBURG JA, 1985, BLOOD, V66, P312; Denburg JA, 1998, J ALLERGY CLIN IMMUN, V102, pS74, DOI 10.1016/S0091-6749(98)70034-X; Dorman SC, 2004, AM J RESP CRIT CARE, V169, P573, DOI 10.1164/rccm.200307-1004OC; DVORAK HF, 1972, J EXP MED, V135, P235, DOI 10.1084/jem.135.2.235; Falcone FH, 2000, BLOOD, V96, P4028; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; ISHIZAKA T, 1989, INT ARCH ALLER A IMM, V88, P46, DOI 10.1159/000234746; JOHNSTON NW, 1974, J IMMUNOL METHODS, V4, P189, DOI 10.1016/0022-1759(74)90060-X; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025; KRENIK KD, 1989, J IMMUNOL METHODS, V117, P91, DOI 10.1016/0022-1759(89)90122-1; LARSEN FS, 2000, ALLERGIC SKIN DIS MU, P1; LEIFERMAN KM, 1986, J IMMUNOL, V136, P852; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Lozano P, 1999, J ALLERGY CLIN IMMUN, V104, P957, DOI 10.1016/S0091-6749(99)70075-8; MacGlashan Donald Jr, 2002, Curr Allergy Asthma Rep, V2, P126, DOI 10.1007/s11882-002-0007-0; MADDOX DE, 1984, J EXP MED, V160, P29, DOI 10.1084/jem.160.1.29; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; McEuen AR, 1999, LAB INVEST, V79, P27; McEuen AR, 2001, J ALLERGY CLIN IMMUN, V107, P842, DOI 10.1067/mai.2001.114650; MITCHELL EB, 1982, LANCET, V1, P127; Nakajima T, 2001, BLOOD, V98, P1127, DOI 10.1182/blood.V98.4.1127; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; OXVIG C, 1994, FEBS LETT, V341, P213, DOI 10.1016/0014-5793(94)80459-1; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; Plager DA, 1999, J BIOL CHEM, V274, P14464, DOI 10.1074/jbc.274.20.14464; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; POPKENHARRIS P, 1995, J IMMUNOL, V155, P1472; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Schroeder J. T., 2003, MIDDLETONS ALLERGY P, P347; STEEVES EBT, 1990, INT J PARASITOL, V20, P655, DOI 10.1016/0020-7519(90)90124-6; Tang EA, 2003, MIDDLETONS ALLERGY P, V1, P1127; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Yanagihara Y, 1998, CLIN EXP IMMUNOL, V111, P136; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236; Ying S, 1999, J IMMUNOL, V163, P3976	51	32	33	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					626	634		10.1016/j.jaci.2005.10.023	http://dx.doi.org/10.1016/j.jaci.2005.10.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522463	Bronze			2022-12-18	WOS:000236263100019
J	Aaronson, DW				Aaronson, DW			The "black box" warning and allergy drugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						"black box" warning; long-acting beta-agonists; topical immunosuppressive agents; informed consent; Food and Drug Administration		In the past years, several drugs commonly used by allergy specialists have received a "black box" warning added to their package insert at the direction of the Food and Drug Administration (FDA). A "black box" warning is the highest level of 5 possible warning categories found in the package insert. The FDA has never articulated the basis for "black box" warnings. They generally appear to be based on clinical data, but occasionally can be based on serious animal toxicity. In the last several years, several drugs commonly used by allergists have received recommendations for "black box" warnings. Long-acting beta-agonists (salmeterol and formoterol) received "black box" warnings because of reports of the occurrences of severe asthma exacerbations in some patients with asthma, with some associated death. Topical calcineurin inhibitors (tacrolimus and pimecrolimus) received a recommendation for application of a "black box" warnings because of a possible increase of cancer developing in patients taking these drugs. Although the addition of a "black box" warning was recommended by the FDA Pediatric Advisory Committee for these 2 topical agents, the FDA has not yet implemented this warning. Informed consent principles require that a patient be adequately informed of the risks (among other components) of any recommended treatment. The risks, as described, of the long-acting beta-agonists and topical immunosuppressants should be presented to the patients to aid them in deciding whether they are willing to take these drugs when recommended by their physician.	Finch Univ, Sch Hlth Sci, Chicago Med Sch, N Chicago, IL USA	Chicago Medical School	Aaronson, DW (corresponding author), 3500 N Lake Shore Dr, Chicago, IL 60657 USA.	doclaw@post.harvard.edu						Beach JE, 1998, FOOD DRUG LAW J, V53, P403; BIANCO ED, 1995, CONSENT REFUSAL MED, P274; BIANO ED, 1998, CONSENT REFUSAL MED, P257; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CHOWDHURY BA, DIV DIR MEM; Fonacier L, 2005, J ALLERGY CLIN IMMUN, V115, P1249, DOI 10.1016/j.jaci.2005.04.006; FRIEDMAN MA, 1999, JAMA-J AM MED ASSOC, V281, P1718; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LESSER KE, 2002, JAMA-J AM MED ASSOC, V287, P2215; Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70; MURPHY D, 2004, PED ADV COMM M POSS; PITTSMR, ODS POST MARK SAF RE	12	32	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					40	44		10.1016/j.jaci.2005.08.060	http://dx.doi.org/10.1016/j.jaci.2005.08.060			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387582				2022-12-18	WOS:000235687100007
J	Rosenblatt, HM; Song, LY; Nachman, SA; Stanley, KE; Krogstad, PA; Johnson, GM; Wiznia, AA				Rosenblatt, HM; Song, LY; Nachman, SA; Stanley, KE; Krogstad, PA; Johnson, GM; Wiznia, AA		Pediat AIDS Clinical Trials Grp	Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antiretroviral therapy; highly active; child; diphtheria-tetanus-acellular; pertussis vaccines; HIV infections; immune response	IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; IMMUNOLOGICAL RESPONSE; PLUS NEVIRAPINE; RITONAVIR; QUANTITATION; NELFINAVIR; PROGRAM; PLASMA	Background: HIV infection often impairs the immune response to childhood vaccines. Objective: We sought to study the ability of HIV-infected children receiving highly active antiretroviral therapy (HAART) to generate a booster response to immunization with a recall antigen to which they had lost Immoral immunity. Methods: Diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccination was given at either 16 or 36 weeks after initiation of HAART to 37 HIV-infected children 2 to 9 years of age with a history of DTaP or diphtheria-tetanus-pertussis receipt who had negative tetanus antibody titers (<= 1:243) at baseline. Results: There was a clear increase in tetanus titers after vaccination, with an increase of 27-fold over the baseline values at weeks 4 and 8. The effect on tetanus titers faded to a 9-fuld and 3-fold increase over baseline values at weeks 18 and 32, respectively. DTaP vaccination did not affect HIV-1 RNA viral load or CD4 percentage or cell count. There was no increase in either acute or long-term adverse events associated with the DTaP vaccination. Conclusion: Although children with stable HIV infection receiving HAART can mount antigen-specific responses to tetanus immunization, the durability of these responses might be limited. Long-term monitoring of specific immune function in such children is indicated.	Baylor Coll Med, Dept Pediat, Houston, TX USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; SUNY Stony Brook, Dept Pediat, Stony Brook, NY USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA USA; Med Univ S Carolina, Dept Pediat, Charleston, SC USA; Jacobi Med Ctr, Dept Pediat, Bronx, NY USA; Albert Einstein Coll Med, Bronx, NY USA	Baylor College of Medicine; Harvard University; Harvard T.H. Chan School of Public Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Medical University of South Carolina; Jacobi Medical Center; Yeshiva University; Albert Einstein College of Medicine	Rosenblatt, HM (corresponding author), Texas Childrens Hosp, Allergy & Immunol Sect, 6621 Fannin St, Houston, TX 77030 USA.	hmrosenb@TexasChildrensHospital.org	Krogstad, Paul/AAQ-8495-2020		NIAID NIH HHS [AI-41110] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041110] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Borkowsky W, 2000, J INFECT DIS, V182, P96, DOI 10.1086/315672; GELMAN R, 1993, CLIN IMMUNOL IMMUNOP, V66, P150, DOI 10.1006/clin.1993.1019; Hollander M, 1973, NONPARAMETRIC STAT M; Krogstad P, 2002, CLIN INFECT DIS, V34, P991, DOI 10.1086/338814; Melvin AJ, 2003, PEDIATRICS, V111, pE641, DOI 10.1542/peds.111.6.e641; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Nachman SA, 2000, JAMA-J AM MED ASSOC, V283, P492, DOI 10.1001/jama.283.4.492; RIGAUD M, 2004, 11 CROI FEB 8 11 SAN; Rosenblatt HM, 2005, J INFECT DIS, V192, P445, DOI 10.1086/431597; VOLK VK, 1962, PUBLIC HEALTH REP, V77, P185, DOI 10.2307/4591451; Wiznia A, 2000, AIDS RES HUM RETROV, V16, P1113, DOI 10.1089/088922200414956; *WORK GROUP ANT TH, 2004, GUID US ANT AG PED H; YenLieberman B, 1996, J CLIN MICROBIOL, V34, P2695, DOI 10.1128/JCM.34.11.2695-2701.1996	14	32	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					698	703		10.1016/j.jaci.2005.05.016	http://dx.doi.org/10.1016/j.jaci.2005.05.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159645				2022-12-18	WOS:000235686500035
J	Hong, SJ; Lee, SY; Kim, HB; Kim, JH; Kim, BS; Choi, SO; Lee, SG; Shin, ES; Hong, TJ				Hong, SJ; Lee, SY; Kim, HB; Kim, JH; Kim, BS; Choi, SO; Lee, SG; Shin, ES; Hong, TJ			IL-5 and thromboxane A2 receptor gene polymorphisms are associated with decreased pulmonary function in Korean children with atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pulmonary function; IL-5; thromboxane A2 receptor; polymorphism	MESSENGER-RNA; A(2) ANTAGONIST; INTERLEUKIN-5; EXPRESSION; ALPHA; HYPERRESPONSIVENESS; INFLAMMATION; EOSINOPHILIA; POPULATION; MECHANISMS	Background: Asthmatic airways undergo chronic inflammatory cell infiltration by T cells and eosinophils, which results in sustained airway hyperresponsiveness. IL-5 is important for eosinophil-induced airway inflammation and airway hyperresponsiveness. Thromboxane A2 and its receptor, TBXA2R, are involved in constriction of respiratory smooth muscles and may play a role in thickening and remodeling of airways, which contributes to the severity of asthma. The relationship between IL-5 and TBXA2R gene polymorphisms and pulmonary function in children with asthma has rarely been examined. Objective: To determine whether IL-5 (T-746C) and TBXA2R (T924C) gene polymorphisms are associated with asthma phenotype and pulmonary function in Korean children with atopic and nonatopic asthma. Methods: We conducted an association study between known polymorphisms of IL-5 (T-746C) and TBXA2R (T924C) and asthma phenotype and the parameters of atopy and pulmonary function in atopic and nonatopic Korean children with asthma. The subjects were 240 atopic children with asthma, 70 nonatopic children with asthma, and 106 nonatopic healthy children. Asthma phenotypes and bronchial responsiveness to methacholine were determined by a physician. IL-5 and TBXA2R gene polymorphisms were determined by genotyping by using PCR-RFLP assays. Results: The genotype frequencies of IL-5 and TBXA2R polymorphisms did not differ between healthy controls and atopic or nonatopic children with asthma. A significant association was observed between the IL-5 polymorphism and forced expiratory How at 25% to 75% of forced vital capacity (FEF25-75%; %; P =.002), and between the TBXA2R polymorphism and FEV1 (%; P =.035) and FEF25-75% (%; P =.042) in children with atopic asthma, whereas no such association between the polymorphisms and lung function was observed in nonatopic or control children. In atopic children with asthma, we identified a significant gene-gene interaction in that the combination of the IL-5 (T-746C) and TBXA2R (T924C) mutant alleles was shown to be associated with reduced pulmonary function as determined by FEF25-75% measurement. Conclusion: The current study indicates that IL-5 (T-746C) and TBXA2R (T924C) polymorphisms alone are associated with spirometric markers of asthma severity, whereas they are not associated with presence of asthma per se. In addition, the data suggest that an interaction between IL-5 and TBXA2R genes may contribute to the severity of asthma, especially atopic asthma. These results suggest that IL-5 and TBXA2R genes may be disease-modifying genes in Korean children with atopic asthma.	Pusan Natl Univ, Coll Med, Dept Internal Med, Pusan 602739, South Korea; Univ Ulsan, Coll Med, Dept Pediat, Seoul, South Korea; Dongguk Univ, Stat Res Inst, Pusan, South Korea	Pusan National University; University of Ulsan; Dongguk University	Hong, TJ (corresponding author), Pusan Natl Univ, Coll Med, Dept Internal Med, 1-10 Ami Dong Seo Gu, Pusan 602739, South Korea.	sjhong@amc.seoul.kr	Hong, Soo-Jong/AAR-1788-2020	Hong, Soo-Jong/0000-0003-1409-2113				Aizawa H, 1998, PROSTAG LEUKOTR ESS, V59, P185, DOI 10.1016/S0952-3278(98)90061-8; Aizawa H, 1996, CHEST, V109, P338, DOI 10.1378/chest.109.2.338; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARANGER L, 1994, BRIT J HAEMATOL, V88, P343, DOI 10.1111/j.1365-2141.1994.tb05029.x; Borger P, 1999, CLIN EXP ALLERGY, V29, P772; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044; DANIELS SE, 1996, AM J RESP CRIT CARE, V155, pA257; Devillier P, 1997, FUNDAM CLIN PHARM, V11, P2, DOI 10.1111/j.1472-8206.1997.tb00163.x; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V103, P1054, DOI 10.1016/S0091-6749(99)70179-X; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; Keatings VM, 1997, J ALLERGY CLIN IMMUN, V99, P693, DOI 10.1016/S0091-6749(97)70032-0; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee SG, 2004, CLIN EXP ALLERGY, V34, P1202, DOI 10.1111/j.1365-2222.2004.02015.x; Leung TF, 2002, PEDIAT ALLERG IMM-UK, V13, P10, DOI 10.1034/j.1399-3038.2002.01033.x; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; Nagase T, 1997, AM J RESP CRIT CARE, V156, P1621, DOI 10.1164/ajrccm.156.5.9703016; OByrne PM, 1997, ANN INTERN MED, V127, P472, DOI 10.7326/0003-4819-127-6-199709150-00009; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Shi H, 1998, EUR RESPIR J, V11, P624; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Unoki M, 2000, HUM GENET, V106, P440, DOI 10.1007/s004390000267; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Weller PF, 1997, J ALLERGY CLIN IMMUN, V100, P283, DOI 10.1016/S0091-6749(97)70237-9; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413, DOI 10.1164/ajrccm.155.4.9105087	32	32	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					758	763		10.1016/j.jaci.2004.10.047	http://dx.doi.org/10.1016/j.jaci.2004.10.047			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805995	Bronze			2022-12-18	WOS:000228373400014
J	Bodtger, U; Linneberg, A				Bodtger, U; Linneberg, A			Remission of allergic rhinitis: An 8-year observational study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; allergy; IgE; longitudinal; remission	8 YEARS APART; SKIN-TEST; SENSITIZATION; POPULATION; ADULTS; AEROALLERGENS; PREVALENCE; HISTORY; ASTHMA	Background: Allergic rhinitis (AR) and sensitization are considered chronic conditions. However, few studies have reported remission rates in adults. Objective: We sought to estimate the incidence of remission of AR during an 8-year period. Methods: Participants in a population-based study of 15- to 69-year-old patients in 1990 were invited to a follow-up in 1998. Questionnaires on respiratory symptoms and serum for specific IgE (s-IgE) analyses were collected at both visits in 734 subjects (69% of those invited). Pollen AR was defined as rhinitis symptoms on pollen exposure within the last 12 months and s-IgE levels of class 2 or greater against pollen (birch, grass, or mugwort). This was similar for AR to animals (cat or dog) or house dust mites (HDMs). Remission of AR was defined as AR at baseline but no rhinitis symptoms at follow-up and sensitization (s-IgE level class greater than or equal to2 at baseline and class <2 at follow-up). Results: Remission of AR occurred in 12% (pollen AR), 19% (animal AR), and 38% (HDM AR; overall, 17%) and was predicted by low s-IgE levels. Age, sex, asthma, atopic predisposition, age at AR onset, and AR duration had no predictive value. A decrease in s-IgE level was observed in only 22% of remitting subjects yet was seen significantly more often than in nonremitting subjects (7.4%). Remission of sensitization occurred in 6% (HDM) to 11% (pollen-furry animal) and was predicted on the basis of low s-IgE levels (class 2) at baseline. Conclusion: Remission of AR symptoms was relatively infrequent, and remission of both symptoms and IgE sensitization was rare. The results underline the chronic nature of AR in adulthood.	Copenhagen Univ Hosp, Allergy Clin Ta 7551, Copenhagen, Denmark; Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark	University of Copenhagen; University of Copenhagen	Bodtger, U (corresponding author), Natl Univ Hosp, Allergy Clin 4222, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	ub-all@rh.dk		Bodtger, Uffe/0000-0002-1231-9209; Linneberg, Allan/0000-0002-0994-0184				BJORKSTEN B, 1998, ALLERGY PRINCIPLES P, P816; Bodtger U, 2003, ALLERGY, V58, P1180, DOI 10.1046/j.1398-9995.2003.00323.x; Bodtger U, 2003, CLIN EXP ALLERGY, V33, P496, DOI 10.1046/j.1365-2222.2003.01611.x; Bodtger U, 2003, J ALLERGY CLIN IMMUN, V111, P149, DOI 10.1067/mai.2003.37; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bodtger U, 2004, CURR OPIN ALLERGY CL, V4, P5, DOI 10.1097/01.all.0000113671.13639.1f; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Kaiser HB, 2004, ALLERGY ASTHMA PROC, V25, P7; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; Linneberg A, 2003, ALLERGY, V58, P21, DOI 10.1034/j.1398-9995.2003.23639.x; Linneberg A, 2000, ALLERGY, V55, P767, DOI 10.1034/j.1398-9995.2000.00672.x; Linneberg A, 2001, ALLERGY, V56, P328, DOI 10.1034/j.1398-9995.2000.00509.x-i1; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; NIELSEN NH, 1993, ALLERGY, V48, P319, DOI 10.1111/j.1398-9995.1993.tb02400.x; Okawa T, 2003, INT ARCH ALLERGY IMM, V131, P39, DOI 10.1159/000070433; Pastorello E A, 1988, Boll Ist Sieroter Milan, V67, P377; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920, DOI 10.1164/ajrccm.162.3.9912030; Ring J, 2001, ANN ALLERG ASTHMA IM, V87, P2, DOI 10.1016/S1081-1206(10)62332-0; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; SOLOMON WR, 1998, ALLERGY PRINCIPLES P, P367; ZWICK H, 1991, ALLERGY, V46, P362, DOI 10.1111/j.1398-9995.1991.tb00599.x	21	32	35	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1384	1388		10.1016/j.jaci.2004.08.039	http://dx.doi.org/10.1016/j.jaci.2004.08.039			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577841				2022-12-18	WOS:000225577400020
J	Wynne, SM; Kwon-Chung, KJ; Shea, YR; Filie, AC; Varma, A; Lupo, P; Holland, SM				Wynne, SM; Kwon-Chung, KJ; Shea, YR; Filie, AC; Varma, A; Lupo, P; Holland, SM			Invasive infection with Trichosporon inkin in 2 siblings with chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						neutrophil dysfunction; posaconazole; voriconazole; caspofungin; amphotericin	AMBULATORY PERITONEAL-DIALYSIS; ENDOCARDITIS; PATIENT	A 9-year-old girl with autosomal recessive chronic granulomatous disease (CGD) presented with asymptomatic bilateral pulmonary infiltrates on routine computed tomography. Fine-needle aspirate of the infiltrates was obtained and showed fungal cells resembling Trichosporon inkin. The specimen grew in culture, and testing by means of both API 20C and PCR amplification confirmed the diagnosis of T inkin. The infiltrates increased in size, despite sequential therapy with voriconazole, liposomal amphotericin B, caspofungin, and posaconazole. The patient required resection of the infected lung tissue, after which she recovered completely. While she was undergoing therapy, her 13-year-old brother, also with CGD, was given a diagnosis of bilateral T inkin-induced pulmonary infection. He also required bilateral pulmonary resection for cure. These cases demonstrate the predisposition of patients with CGD to have invasive infections with unusual fungal organisms, such as T inkin. They also illustrate the difficulty of treating invasive T inkin infections with antifungal agents alone. There are 9 previously reported cases of invasive infections caused by T inkin, 3 of which are in patients with CGD. All patients required removal of infected prosthetic devices or surgical resection of infected tissue for cure.	NIAID, Immunoregulat Lab, Bethesda, MD 20892 USA; NIAID, Lab clin Infect Dis, Bethesda, MD 20892 USA; NCI, Ctr Clin, Dept Lab Med, Bethesda, MD 20892 USA; NCI, Pathol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Holland, SM (corresponding author), Bldg 10,Room 11N103,10 Ctr Dr,MSC 1886, Bethesda, MD 20892 USA.	smh@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646, Z01AI000646] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chaumentin G, 1996, CLIN INFECT DIS, V23, P396, DOI 10.1093/clinids/23.2.396; Crowther KS, 2003, CLIN NEPHROL, V59, P69; GUEHO E, 1994, MYCOSES, V37, P3, DOI 10.1111/j.1439-0507.1994.tb00277.x; KENNEY RT, 1990, AM J CLIN PATHOL, V94, P344, DOI 10.1093/ajcp/94.3.344; Kurtzman CP, 1997, J CLIN MICROBIOL, V35, P1216, DOI 10.1128/JCM.35.5.1216-1223.1997; Kwon-Chung K.J., 1992, MED MYCOL, P183; Lacy SH, 2003, COMPARATIVE MED, V53, P303; Lopes JO, 1997, MYCOPATHOLOGIA, V139, P15, DOI 10.1023/A:1006870017725; LYMAN CA, 1994, J INFECT DIS, V170, P1557, DOI 10.1093/infdis/170.6.1557; Madariaga MG, 2003, J CLIN MICROBIOL, V41, P5827, DOI 10.1128/JCM.41.12.5827-5829.2003; Moretti-Branchini ML, 2001, DIAGN MICR INFEC DIS, V39, P161, DOI 10.1016/S0732-8893(01)00215-2; Mussa AY, 1998, J MYCOL MED, V8, P196; Piwoz JA, 2000, PEDIATR INFECT DIS J, V19, P1025, DOI 10.1097/00006454-200010000-00023; Ramos JM, 2004, J CLIN MICROBIOL, V42, P2341, DOI 10.1128/JCM.42.5.2341-2344.2004; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Sugita T, 1998, J CLIN MICROBIOL, V36, P1458, DOI 10.1128/JCM.36.5.1458-1460.1998; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	17	32	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1418	1424		10.1016/j.jaci.2004.07.066	http://dx.doi.org/10.1016/j.jaci.2004.07.066			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577847				2022-12-18	WOS:000225577400026
J	Gray, HC; Hutcheson, PS; Slavin, RG				Gray, HC; Hutcheson, PS; Slavin, RG			Is glucosamine safe in patients with seafood allergy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OSTEOARTHRITIS; SULFATE; CHONDROITIN; PROGRESSION		St Louis Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63104 USA	Saint Louis University	Gray, HC (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, 1402 S Grand Blvd,Rm 209, St Louis, MO 63104 USA.	slavinrg@slu.edu						Deal CL, 1999, RHEUM DIS CLIN N AM, V25, P379, DOI 10.1016/S0889-857X(05)70074-0; Lee DY, 2002, J VET MED SCI, V64, P645, DOI 10.1292/jvms.64.645; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; MOSKOWITZ R, ARTHRITIS GLUCOSAMIN; Pavelka K, 2002, ARCH INTERN MED, V162, P2113, DOI 10.1001/archinte.162.18.2113; REFGINSTER JY, 2003, CURR OPIN RHEUMATOL, V15, P651; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2	7	32	33	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					459	460		10.1016/j.jaci.2004.05.050	http://dx.doi.org/10.1016/j.jaci.2004.05.050			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15341031	Bronze			2022-12-18	WOS:000223405600043
J	Nelson, HS				Nelson, HS			Advances in upper airway diseases and allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinitis; sinusitis; upper airway; immunotherapy; one airway	QUALITY-OF-LIFE; POLLEN; INFLAMMATION; RESPONSES; RHINITIS; CELLS; ANTIHISTAMINES; DESLORATADINE; SENSITIZATION; LORATADINE	Evidence for one airway continues to accumulate. Nasal allergen challenges increase lower airway inflammation, and nasal corticosteroid treatment reduces lower airway inflammation. Allergic respiratory inflammation might even spread systemically to involve nonrespiratory organs. Eosinophilic enteritis and eosinophilic esophagitis are reported during pollen seasons in patients with seasonal allergic rhinitis. Chronic hypertrophic sinusitis (CHS) is found in the majority of patients with asthma. Like asthma, the histology of CHS is characterized by epithelial damage, basement membrane thickening, and eosinophilic inflammation. The damaged epithelium might explain the acute bacterial exacerbations seen in patients with CHS. Studies have extended evidence of the safety and efficacy of the second- and third-generation antihistamines to younger children and to patients with perennial rhinitis but continue to show improvement of symptom scores over that seen with placebo of less than 20%. Studies on antihistamine use in the first trimester in nearly 500 women (65% taking loratadine) revealed no increase in the complications of pregnancy or congenital anomalies. Positive skin prick test responses to birch in asymptomatic young adults predicted later development of clinical allergic rhinitis. A dose response was demonstrated for immunotherapy with cat dander extract. The best results were in subjects receiving a dose containing 15 mug of the major cat allergen Fel d 1 (equivalent to approximately 2500 bioequivalent allergen units). Both topical intranasal immunotherapy and high-dose sublingual immunotherapy have been repeatedly proved to be safe and effective in double-blind, placebo-controlled studies. CD4(+)CD25(+) regulatory T cells secreting IL-10, TGF-beta, or both appear important in normal individuals and in patients treated with allergen immunotherapy in maintaining or restoring normal T(H)1/T(H)2 balance and overall suppression of both phenotypes.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P770, DOI 10.1067/mai.2003.1408; Bodtger U, 2003, J ALLERGY CLIN IMMUN, V111, P149, DOI 10.1067/mai.2003.37; Bryce PJ, 2003, J ALLERGY CLIN IMMUN, V112, P149, DOI 10.1067/mai.2003.1616; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Cates EC, 2003, J ALLERGY CLIN IMMUN, V111, P1076, DOI 10.1067/mai.2003.1460; Diav-Citrin O, 2003, J ALLERGY CLIN IMMUN, V111, P1239, DOI 10.1067/mai.2003.1499; Eddleston J, 2003, J ALLERGY CLIN IMMUN, V111, P106, DOI 10.1067/mai.2003.19; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Feuchtinger T, 2003, J ALLERGY CLIN IMMUN, V111, P428, DOI 10.1067/mai.2003.56; Fiset PO, 2003, J ALLERGY CLIN IMMUN, V111, P580, DOI 10.1067/mai.2003.179; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gijzen M, 2003, J ALLERGY CLIN IMMUN, V112, P803, DOI 10.1016/S0091-6749(03)01884-0; Iwasaki M, 2003, J ALLERGY CLIN IMMUN, V112, P134, DOI 10.1067/mai.2003.1554; Juniper EF, 2003, J ALLERGY CLIN IMMUN, V111, P484, DOI 10.1067/mai.2003.137; Kopp MV, 2002, J ALLERGY CLIN IMMUN, V110, P728, DOI 10.1067/mai.2002.128804; Law AW, 2003, J ALLERGY CLIN IMMUN, V111, P296, DOI 10.1067/mai.2003.68; Liccardi G, 2003, J ALLERGY CLIN IMMUN, V111, P1410, DOI 10.1067/mai.2003.1521; Liu YH, 2003, J ALLERGY CLIN IMMUN, V112, P301, DOI 10.1067/mai.2003.1619; Magnusson J, 2003, J ALLERGY CLIN IMMUN, V112, P45, DOI 10.1067/mai.2003.1604; Mastruzzo C, 2003, J ALLERGY CLIN IMMUN, V112, P37, DOI 10.1067/mai.2003.1586; McCusker C, 2002, J ALLERGY CLIN IMMUN, V110, P891, DOI 10.1067/mai.2002.130048; Moretti ME, 2003, J ALLERGY CLIN IMMUN, V111, P479, DOI 10.1067/mai.2003.130; Ponikau JU, 2003, J ALLERGY CLIN IMMUN, V112, P877, DOI 10.1016/j.jaci.2003.08.009; Ponikau JU, 2002, J ALLERGY CLIN IMMUN, V110, P862, DOI 10.1067/mai.2002.130051; Roberts G, 2003, J ALLERGY CLIN IMMUN, V111, P491, DOI 10.1067/mai.2003.138; Sandrini A, 2003, J ALLERGY CLIN IMMUN, V111, P313, DOI 10.1067/mai.2003.64; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P1244, DOI 10.1067/mai.2003.1496; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P617, DOI 10.1067/mai.2003.168; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338; Victor JR, 2003, J ALLERGY CLIN IMMUN, V111, P269, DOI 10.1067/mai.2003.39; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wahn U, 2003, J ALLERGY CLIN IMMUN, V111, P763, DOI 10.1067/mai.2003.1384; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683; Zemann B, 2003, J ALLERGY CLIN IMMUN, V111, P1069, DOI [10.1067/mai.2003.1411, 10.1067/mai.2003/1411]	37	32	37	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					635	642		10.1016/j.jaci.2004.01.741	http://dx.doi.org/10.1016/j.jaci.2004.01.741			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100666				2022-12-18	WOS:000220956600008
J	Khoo, SK; Hayden, CM; Roberts, M; Horak, E; de Klerk, N; Zhang, GC; Robertson, CF; Goldblatt, J; Le Souef, P				Khoo, SK; Hayden, CM; Roberts, M; Horak, E; de Klerk, N; Zhang, GC; Robertson, CF; Goldblatt, J; Le Souef, P			Associations of the IL12B promoter polymorphism in longitudinal data from asthmatic patients 7 to 42 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IL12B; promoter; polymorphism; longitudinal study; association	GENOME-WIDE SEARCH; INHERITED INTERLEUKIN-12 DEFICIENCY; INDUCED AIRWAY HYPERRESPONSIVENESS; SERUM IGE LEVELS; WHEEZY BRONCHITIS; CHILDHOOD ASTHMA; GENE; SUSCEPTIBILITY; CHILDREN; GENOTYPE	Background: The IL12B gene encodes the p40 chain of IL-12, a proinflammatory cytokine that antagonizes T(H)2 expression and hence may play a critical role in the pathogenesis of airway inflammation observed in asthma. A promoter polymorphism of the gene was recently shown to be associated with asthma severity in children but only in heterozygotes. Objective: The aim of the present study was to test the hypothesis that the IL12B promoter polymorphism is associated with asthma susceptibility, severity, and related phenotypes in a cohort with longitudinal phenotypic data, from childhood to adulthood. Methods: Four hundred one 7-year-old children (106 control children, 295 asthmatic children) and 83 10-year-old children with severe asthma were recruited from a 1957 birth cohort. Atopic status and respiratory functions were determined at ages 7, 10, 14, 21, 28, 35, and 42 years. At age 42 years, blood samples were taken from 244 individuals for genotyping and the determination of plasma IgE levels and PHA- and house dust mite-induced IFN-gamma responses. Genotyping was done by the PCR restriction fragment length polymorphism method, using Alu I, and confirmed in 10% of the samples by direct sequencing. Results: The IL12B genotypes were not associated with asthma susceptibility, severity, or atopy at ages 7 and 42 years. Total serum IgE levels at age 42 of men with at least one CTCTAA allele were higher than those homozygous for the GC allele (P = .042), whereas no difference was observed for women. At all ages, female subjects with at least 1 copy of the CTCTAA allele had lower mean percent predicted levels of FEV1 and FVC compared with those without this allele; these differences were significant at ages 10 and 14 years (P < .05) and in the asthmatic subgroup at age 7 years (P = .001). Conclusions: In this long-term study of asthmatic subjects with comprehensive data on asthma severity, we found no evidence to support the presence of a heterozygote effect of the IL12B promoter polymorphism on the level of asthma in early childhood or adulthood. The polymorphism was also not associated with asthma susceptibility, but the CTCTAA allele may have been associated with elevated serum IgE levels in male subjects and reduced pulmonary function in female subjects in early childhood.	Univ Western Australia, Sch Pediat & Child Hlth, Perth, WA 6009, Australia; Murdoch Childrens Res Inst, Royal Childrens Hosp, Dept Resp Med, Melbourne, Vic, Australia; Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; Curtin Univ Technol, Sch Publ Hlth, Perth, WA 6001, Australia	University of Western Australia; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Telethon Kids Institute; University of Western Australia; Curtin University	Le Souef, P (corresponding author), Princess Margaret Hosp Children, Sch Paediat & Child Hlth, GPO Box D184, Perth, WA 6001, Australia.		Khoo, Siew-Kim/B-6493-2012; Khoo, Siew-Kim/D-7655-2016; Le Souef, Peter N/H-5256-2014; de Klerk, Nicholas H/D-8388-2016; Zhang, Brad/AAF-8719-2021	de Klerk, Nicholas H/0000-0001-9223-0767; Zhang, Guicheng/0000-0001-9888-5385; Le Souef, Peter/0000-0003-0930-1654				Aidoo M, 2002, LANCET, V359, P1311, DOI 10.1016/S0140-6736(02)08273-9; Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Ellsworth DL, 2002, INT J OBESITY, V26, P928, DOI 10.1038/sj.ijo.0802020; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; Garces C, 2002, ACTA PAEDIATR, V91, P1039, DOI 10.1080/080352502760311511; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Haraguchi S, 1998, P NATL ACAD SCI USA, V95, P13125, DOI 10.1073/pnas.95.22.13125; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; Huang D, 2000, GENES IMMUN, V1, P515, DOI 10.1038/sj.gene.6363720; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Morahan G, 2002, GENES IMMUN, V3, P414, DOI 10.1038/sj.gene.6363909; Morahan G, 2002, LANCET, V360, P455, DOI 10.1016/S0140-6736(02)09676-9; Morahan G, 2001, NAT GENET, V27, P218, DOI 10.1038/84872; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; Noguchi E, 2001, GENES IMMUN, V2, P401, DOI 10.1038/sj.gene.6363790; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; OSWALD H, 1994, BRIT MED J, V309, P95, DOI 10.1136/bmj.309.6947.95; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Picard C, 2002, AM J HUM GENET, V70, P336, DOI 10.1086/338625; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Pravica V, 2000, EUR J IMMUNOGENET, V27, P35, DOI 10.1046/j.1365-2370.2000.00190.x; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Robertson CF, 2002, MED J AUSTRALIA, V177, pS42; Robertson CF, 1998, MED J AUSTRALIA, V168, P434, DOI 10.5694/j.1326-5377.1998.tb139022.x; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Sandford A, 2002, LANCET, V360, P422, DOI 10.1016/S0140-6736(02)09693-9; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIEBURTH D, 1992, GENOMICS, V14, P59, DOI 10.1016/S0888-7543(05)80283-6; Smart JM, 2002, J ALLERGY CLIN IMMUN, V110, P450, DOI 10.1067/mai.2002.127283; Tekkanat KK, 2001, AM J PATHOL, V159, P631, DOI 10.1016/S0002-9440(10)61734-8; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; van Veen T, 2001, ANN NEUROL, V50, P275, DOI 10.1002/ana.1107; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; Weatherall DJ, 1997, ANN TROP MED PARASIT, V91, P885, DOI 10.1080/00034989760653; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; Wolfe R, 2000, AM J RESP CRIT CARE, V162, P2177, DOI 10.1164/ajrccm.162.6.9812019; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201	48	32	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					475	481		10.1016/j.jaci.2003.10.043	http://dx.doi.org/10.1016/j.jaci.2003.10.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007350				2022-12-18	WOS:000220144200020
J	Chen, YH; Bieneman, AP; Creticos, PS; Chichester, KL; Schroeder, JT				Chen, YH; Bieneman, AP; Creticos, PS; Chichester, KL; Schroeder, JT			IFN-alpha inhibits IL-3 priming of human basophil cytokine secretion but not leukotriene C4 and histamine release	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; innate immunity; hypersensitivity; cytokine priming; histamine; leukotriene	COLONY-STIMULATING FACTOR; NERVE GROWTH-FACTOR; INTERFERON-ALPHA; MEDIATOR RELEASE; IMMUNOHISTOCHEMICAL DETECTION; RECEPTOR; TYPE-1; EXPRESSION; GENERATION; HEPATITIS	Background: Innate immune responses play a critical role in determining the course of acquired immunity, including that associated with allergic disease. Type I interferons, which are generated early in these reactions, are important soluble factors that prime for T(H)1-like activity. Objective: Because human basophils secrete IL-4 and IL-13 in response to both IgE-dependent and IgE-independent stimuli, we tested whether IFN-alpha, a major type I IFN, affects the production of these T(H)2 cytokines and/or mediator release from these cells. Methods: Basophils isolated from blood were treated with IFN-alpha in the presence and absence of IL-3 priming before stimulating through the IgE receptor to release histamine, leukotriene C-4, and IL-4. Effects of IFN-alpha on IL-3-mediated IL-13 secretion and basophil survival were also tested. IFN-a receptor expression was determined by RT-PCR. Results: IFN-alpha specifically inhibited the effects IL-3 has on basophil cytokine secretion. Enhanced secretion of IL-4 resulting from IL-3 priming was significantly inhibited in cells concurrently cultured with IFN-alpha. This effect was specific for cytokine generation, because histamine and leukotriene C4 were unaffected. Furthermore, IFN-alpha blocked IL-13 secretion directly induced by IL-3. Although IFN-beta also possessed some inhibitory activity, IFN-gamma (a type II IFN) had no effect on basophil cytokine secretion. Basophils constitutively expressed mRNA for the type I IFN receptor, and IFN-alpha did not affect basophil viability with regard to inhibition of cytokine secretion. Conclusions: These results support the belief that early innate immune responses resulting in IFN-alpha production negatively regulate allergic responses by also inhibiting priming of basophil cytokine release.	Johns Hopkins Univ, Div Clin Immunol, Dept Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Schroeder, JT (corresponding author), Johns Hopkins Univ, Div Clin Immunol, Dept Med, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI22241] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkinson NF, 1980, MEASUREMENT TOTAL SE; ALAM R, 1989, J IMMUNOL, V142, P3431; Aldebert D, 1996, BLOOD, V87, P2354, DOI 10.1182/blood.V87.6.2354.bloodjournal8762354; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; BISSONNETTE EY, 1995, IMMUNOLOGY, V86, P12; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; BUTTERFIELD JH, 1994, J ALLERGY CLIN IMMUN, V94, P1318, DOI 10.1016/0091-6749(94)90348-4; Butterfield JH, 1998, BRIT J DERMATOL, V138, P489; Chang SE, 2002, CLIN EXP DERMATOL, V27, P135, DOI 10.1046/j.1365-2230.2002.00989.x; CONLON KC, 1990, CANCER, V65, P2237, DOI 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5; Corssmit EPM, 1997, CLIN EXP IMMUNOL, V107, P359, DOI 10.1111/j.1365-2249.1997.269-ce1161.x; DOLEN J, 1996, J INTERF CYTOK RES, V16, P973; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; Foster GR, 1998, J VIRAL HEPATITIS, V5, P143, DOI 10.1046/j.1365-2893.1998.00103.x; FUNK J, 1991, BRIT J DERMATOL, V125, P463, DOI 10.1111/j.1365-2133.1991.tb14774.x; GILBERT HS, 1975, BLOOD, V46, P279; Gratzl S, 2000, J ALLERGY CLIN IMMUN, V105, P1035, DOI 10.1067/mai.2000.105317; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; Hober D, 1998, SCAND J IMMUNOL, V48, P436, DOI 10.1046/j.1365-3083.1998.00417.x; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025; Kirkwood J, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.33078; Krishnaswamy G, 2002, J INTERF CYTOK RES, V22, P379, DOI 10.1089/107999002753675811; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; Lie WJ, 1999, J ALLERGY CLIN IMMUN, V104, P1000, DOI 10.1016/S0091-6749(99)70081-3; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; Mazzella G, 1999, AM J GASTROENTEROL, V94, P2246, DOI 10.1111/j.1572-0241.1999.01300.x; Miura K, 2000, J IMMUNOL, V164, P3026, DOI 10.4049/jimmunol.164.6.3026; Miura K, 2001, J IMMUNOL, V167, P2282, DOI 10.4049/jimmunol.167.4.2282; Mizukoshi E, 1999, J INTERF CYTOK RES, V19, P1019, DOI 10.1089/107999099313235; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Ochensberger B, 1996, BLOOD, V88, P3028, DOI 10.1182/blood.V88.8.3028.bloodjournal8883028; Pianko S, 2000, J GASTROEN HEPATOL, V15, P581, DOI 10.1046/j.1440-1746.2000.02082.x; Redrup AC, 1998, J IMMUNOL, V160, P1957; SARMIENTO EU, 1995, J IMMUNOL, V155, P2211; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; Schroeder JT, 2001, CLIN EXP ALLERGY, V31, P1369, DOI 10.1046/j.1365-2222.2001.01130.x; Schroeder JT, 1998, J LEUKOCYTE BIOL, V63, P692, DOI 10.1002/jlb.63.6.692; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Sin AZ, 2001, J ALLERGY CLIN IMMUN, V108, P387; TOGIAS A, 2002, J ALLERGY CLIN IMMUN, V9, pA799; Yamaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1279, DOI 10.1016/S0091-6749(96)70196-3	49	32	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					944	950		10.1016/j.jaci.2003.08.027	http://dx.doi.org/10.1016/j.jaci.2003.08.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610485				2022-12-18	WOS:000186553300018
J	Makela, MJ; Tripp, R; Dakhama, A; Park, JW; Ikemura, T; Joetham, A; Waris, M; Anderson, LJ; Gelfand, EW				Makela, MJ; Tripp, R; Dakhama, A; Park, JW; Ikemura, T; Joetham, A; Waris, M; Anderson, LJ; Gelfand, EW			Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway hyperresponsiveness; asthma; allergen; viral infection; T lymphocytes; cytokines	RESPIRATORY SYNCYTIAL VIRUS; NASOPHARYNGEAL SECRETIONS; SENSITIZED MICE; INFECTION; INFLAMMATION; RESPONSES; BRONCHIOLITIS; SEVERITY; INFANTS; CELLS	Background: Respiratory syncytial virus (RSV) bronchiolitis in early life can lead to changes in airway function, but there are likely additional predisposing factors, such as prior allergen exposure, determining which children develop wheezing and asthma. Objective: To define the effects of prior airway exposure to sensitizing allergen on the development of airway inflammation and hyperresponsiveness (AHR) to subsequent RSV infection. Methods: BALB/c mice were exposed to ovalbumin or PBS exclusively through the airways and subsequently infected with RSV or sham-inoculated. AHR, lung inflammation, and the frequency of cytokine-producing T lymphocytes in the lung were determined. Results: In PBS-exposed mice, RSV infection induced AHR and an increased proportion of T(H)1-type (IFN-gamma and IL-12) cytokine-producing cells in the lungs. However, in mice previously exposed to ovalbumin through the airways and subsequently infected with RSV, the degree of AHR was significantly increased and was associated with an increased proportion of T(H)2 (IL-4, IL-5) cytokine-producing T lymphocytes. This response was also associated with an increased accumulation of eosinophils, neutrophils, and CD8(+) T cells in the lungs. Conclusions: These data suggest that prior airway exposure to allergen may predispose sensitized hosts to a greater degree of altered airway function upon subsequent respiratory viral infection.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Ctr Dis Control & Prevent, Atlanta, GA USA; Univ Turku, Dept Pulm Dis & Clin Allergol, Turku, Finland	National Jewish Health; Centers for Disease Control & Prevention - USA; University of Turku	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.		Tripp, Ralph/F-5218-2011; Waris, Matti E/A-6418-2008	Tripp, Ralph/0000-0002-2924-9956; Waris, Matti/0000-0002-6747-0889; Park, Jung-Won/0000-0003-0249-8749	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL061005] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36577, HL-61005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Betts MR, 2001, IMMUNOL LETT, V79, P117, DOI 10.1016/S0165-2478(01)00273-5; Bont L, 1999, EUR RESPIR J, V14, P144, DOI 10.1034/j.1399-3003.1999.14a24.x; Ehlenfield DR, 2000, PEDIATRICS, V105, P79, DOI 10.1542/peds.105.1.79; Garofalo R, 1994, Pediatr Allergy Immunol, V5, P111, DOI 10.1111/j.1399-3038.1994.tb00227.x; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934, DOI 10.1164/ajrccm.160.3.9806029; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hornsleth A, 1998, PEDIATR INFECT DIS J, V17, P1114, DOI 10.1097/00006454-199812000-00003; Maecker HT, 2001, J IMMUNOL METHODS, V255, P27, DOI 10.1016/S0022-1759(01)00416-1; MATSUDA K, 1995, CLIN DIAGN LAB IMMUN, V2, P322, DOI 10.1128/CDLI.2.3.322-324.1995; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; O'Donnell DR, 1998, CLIN EXP ALLERGY, V28, P1501; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; PARK JW, 2002, AM J RESP CRIT CARE, V165, pB43; Peebles RS, 1999, J MED VIROL, V57, P186, DOI 10.1002/(SICI)1096-9071(199902)57:2<186::AID-JMV17>3.0.CO;2-Q; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Robinson PJ, 1997, J ALLERGY CLIN IMMUN, V100, P492, DOI 10.1016/S0091-6749(97)70141-6; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; Schwarze J, 1999, J IMMUNOL, V163, P5729; Schwarze J, 2000, AM J RESP CRIT CARE, V162, P380, DOI 10.1164/ajrccm.162.2.9903057; Schwarze J, 1999, J IMMUNOL, V162, P4207; Schwarze J, 1999, J IMMUNOL, V162, P2997; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Sigurs N, 2001, AM J RESP CRIT CARE, V163, pS2, DOI 10.1164/ajrccm.163.supplement_1.2011109; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Tripp RA, 2000, J IMMUNOL, V164, P5913, DOI 10.4049/jimmunol.164.11.5913; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255	28	32	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					861	869		10.1067/mai.2003.1768	http://dx.doi.org/10.1067/mai.2003.1768			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610471				2022-12-18	WOS:000186553300006
J	Bernstein, JA				Bernstein, JA			Material safety data sheets: Are they reliable in identifying human hazards?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INFORMATION; ASTHMA; SURVEILLANCE	The material safety data sheet (MSDS) is an integral part of a worker's evaluation for suspected occupational asthma and dermatitis, However, established US federal guidelines for creating an MSDS do not require that certain key information relevant to the diagnosis of these disorders be included. This rostrum is intended to highlight the limitations of MSDSs as they pertain to the diagnosis of occupational asthma and occupational dermatitis so that future consideration can be given to modification of the existing MSDS guidelines. This article summarizes the origins of MSDS documents, provides an overview of their format, and discusses some of their inherent limitations, which at times impede proper medical evaluation by, physicians and other health care professionals. MSDSs are an essential part of making the workplace a safer environment. More complete disclosure about both irritation and sensitization risks in these documents would facilitate the evaluation of workers for OA and OD. Their current ambiguity often delays the diagnosis of these occupational diseases and places the worker at further risk for development of occupational-related long-term disorders. Health care professionals have an obligation to better educate themselves regarding the interpretation of MSDSs and to recognize that they sometimes provide incomplete data.	Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Bernstein, JA (corresponding author), Univ Cincinnati, Coll Med, 231 Albert Sabin Way,ML 563, Cincinnati, OH 45267 USA.			Bernstein, Jonathan/0000-0002-3476-1196				BELSITO DV, 1993, DERMATOLOGY GEN MED; BERNSTEIN JA, 1995, ALLERGY CLIN IMMUNOL, P529; BERNSTEIN JL, 1999, ASTHMA WORKPLACE, P501; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Chan-Yeung M., 1999, ASTHMA WORKPLACE; Cote R, 1998, REGUL TOXICOL PHARM, V27, P61, DOI 10.1006/rtph.1997.1179; Dedhia HV, 2000, OCCUP MED-STATE ART, V15, P399; DYKEWICZ M, 1998, COMPR THER, V23, P142; Fluke C, 1993, J Healthc Mater Manage, V11, P64; Frazier LM, 2001, J GEN INTERN MED, V16, P89, DOI 10.1046/j.1525-1497.2001.91108.x; HADDEN SG, 1989, J OCCUP ENVIRON MED, V31, P528, DOI 10.1097/00043764-198906000-00009; HenriksEckerman ML, 1997, CONTACT DERMATITIS, V36, P164, DOI 10.1111/j.1600-0536.1997.tb00405.x; KOLP P, 1993, AM J IND MED, V23, P135, DOI 10.1002/ajim.4700230119; LERMAN SE, 1990, ARCH INTERN MED, V150, P981, DOI 10.1001/archinte.150.5.981; MATTE TD, 1990, CHEST, V98, pS173, DOI 10.1378/chest.98.5_Supplement.173S; MEREDITH SK, 1989, BR J IND MED, V48, P292; Nixon R L, 1997, Australas J Dermatol, V38, P165, DOI 10.1111/j.1440-0960.1997.tb01139.x; PEPYS J, 1999, ASTHMA WORKPLACE, P5; SALLIE BA, 1994, OCCUP MED-OXFORD, V44, P177, DOI 10.1093/occmed/44.4.177; Solomon C J, 1988, AAOHN J, V36, P376; *US DHEW, 1979, REC STAND OCC EXP DI; *US DHHS, 1997, NIOSH POCK GUID CHEM; Welsh M S, 2000, Appl Occup Environ Hyg, V15, P409; ZEISS CR, 1999, ASTHMA WORKPLACE, P479	24	32	34	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					35	38		10.1067/mai.2002.124891	http://dx.doi.org/10.1067/mai.2002.124891			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110815				2022-12-18	WOS:000176870300007
J	Untersmayr, E; Focke, M; Kinaciyan, T; Poulsen, LK; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E				Untersmayr, E; Focke, M; Kinaciyan, T; Poulsen, LK; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E			Anaphylaxis to Russian Beluga caviar	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IGE		Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Dermatol, Div Allergy Immunol & Infect Dis, A-1090 Vienna, Austria; Rigshosp, Lab Med & Allergol, DK-2100 Copenhagen, Denmark	University of Vienna; University of Vienna; Rigshospitalet; University of Copenhagen	Untersmayr, E (corresponding author), Univ Vienna, Dept Pathophysiol, Waehringer Guertel 18, A-1090 Vienna, Austria.		Jensen-Jarolim, Erika/C-5120-2018; Poulsen, Lars K/J-3065-2019	Jensen-Jarolim, Erika/0000-0003-4019-5765; Poulsen, Lars K/0000-0002-1730-847X; Kinaciyan, Tamar/0000-0002-8238-2561				Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Hiramatsu N, 2002, COMP BIOCHEM PHYS A, V131, P429, DOI 10.1016/S1095-6433(01)00497-4; ISAAC P, 1977, LANCET, V2, P816; Jeebhay MF, 2001, OCCUP ENVIRON MED, V58, P553, DOI 10.1136/oem.58.9.553; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; Taylor AV, 2000, J ALLERGY CLIN IMMUN, V105, P166, DOI 10.1016/S0091-6749(00)90192-1	6	32	32	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					1034	1035		10.1067/mai.2002.124893	http://dx.doi.org/10.1067/mai.2002.124893			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063537				2022-12-18	WOS:000176442700023
J	Holberg, CJ; Halonen, M; Solomon, S; Graves, PE; Baldini, M; Erickson, RP; Martinez, FD				Holberg, CJ; Halonen, M; Solomon, S; Graves, PE; Baldini, M; Erickson, RP; Martinez, FD			Factor analysis of asthma and atopy traits shows 2 major components, one of which is linked to markers on chromosome 5q	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; genetics; factor analysis; linkage; chromosome 5q	SERUM IGE LEVELS; IMMUNOGLOBULIN-E; LINKAGE ANALYSIS; QUANTITATIVE TRAIT; GENETIC-ANALYSIS; ASSOCIATION; POLYMORPHISMS; CHILDHOOD; CHILDREN; 5Q31-Q33	Background: A variety of definitions of asthma and atopy traits have been used in genetic studies. The variables used may be correlated, increasing the likelihood of type I error. Objective: We sought to clarify and quantify phenotypes that may be characterized by related traits. Principal components and factor analysis were applied to the correlation matrix of asthma and atopy traits before linkage analysis. Methods: Factor analysis was performed on 468 Hispanic and non-Hispanic white children enrolled in the Tucson Children's Respiratory Study, with complete information on 24 items, including skin test response to 7 allergens, total serum IgE levels, presence or absence of asthma attacks, wheezing episodes, hay fever, and cough. Factor score coefficients were then applied to all siblings (n = 877), and quantitative factor scores were derived. Single-point and multipoint nonparametric sib-pair analyses were performed to assess linkage to markers on chromosome 5q31-33. Analyses were also performed for individual items. Results: Two main factors were identified: Factor I had high loadings on atopic items, including skin test responses, IgE, and hay fever, and Factor II had high loadings that included asthma diagnosis, wheezing, cough, and Alternaria species skin test response. Factors I and II were correlated at an r value of 0.19. For the quantitative factor scores, significant single-point linkage (P <.0001) was demonstrated only for atopic Factor I, and a peak multipoint LOD score of 2.7 was seen for marker D5S479. Multipoint LOD scores for individual items were 1.1 or less. Conclusion: These analyses suggest evidence for a locus or loci mapping to chromosome 5q31-33 associated with this composite atopic phenotype.	Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA; Univ Arizona, Hlth Sci Ctr, Dept Pediat, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	Holberg, CJ (corresponding author), Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, POB 245030, Tucson, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056177] Funding Source: NIH RePORTER; NCRR NIH HHS [1 P41 RR03655] Funding Source: Medline; NHLBI NIH HHS [HL-03154-01, R01 HL-56177] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; BLUMENTHAL MN, 1981, AM J MED GENET, V10, P219, DOI 10.1002/ajmg.1320100304; BOUSHEY HA, 1995, ENVIRON HEALTH PERSP, V103, P229, DOI 10.2307/3432378; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Bowden SC, 1997, J CLIN EXP NEUROPSYC, V19, P755, DOI 10.1080/01688639708403757; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; *CAS W RES U RAMM, 1997, SAGE STAT AN GEN EP; COOKSON WOCM, 1989, LANCET, V1, P1292; COYLE AJ, 1995, J CLIN INVEST, V95, P1735, DOI 10.1172/JCI117850; DEMENAIS FM, 1989, PROG CLIN BIOL RES, V329, P201; DODGE R, 1983, CHEST, V84, P587, DOI 10.1378/chest.84.5.587; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; ELSTON RC, 1993, GENETICS ASTHMA, P143; Falconer D.S., 1996, INTRO QUANTITATIVE G; Garcia A, 1998, AM J TROP MED HYG, V58, P705, DOI 10.4269/ajtmh.1998.58.705; GERRARD JW, 1978, AM J HUM GENET, V30, P46; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; GREGG I, 1983, EPIDEMIOLOGIC ASPECT; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P449, DOI 10.1016/S0091-6749(98)70134-4; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Husby S, 1996, CLIN GENET, V50, P332; Kim J.O., 1975, STAT PACKAGE SOCIAL; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; Laitinen T, 1997, HUM MOL GENET, V6, P2069, DOI 10.1093/hmg/6.12.2069; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; LEVITT RC, 1990, AM J PHYSIOL, V258, pL157, DOI 10.1152/ajplung.1990.258.4.L157; Liggett SB, 1997, AM J RESP CRIT CARE, V156, pS156, DOI 10.1164/ajrccm.156.4.12tac-15; Mansur AH, 1998, CLIN EXP ALLERGY, V28, P141; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSH DG, 1993, GENETICS ASTHMA, P321; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MARTINEZ FD, 1994, AM J HUM GENET, V55, P555; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Martinez FD, 1997, AM J RESP CRIT CARE, V156, pS117, DOI 10.1164/ajrccm.156.4.12tac-8; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Morton NE, 1998, CLIN EXP ALLERGY, V28, P95; *NAT ASTHM ED PREV, 1997, NIH PUBL; *NIH, 1993, NHLBI WHO WORKSH REP; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Punnonen J, 1997, J ALLERGY CLIN IMMUN, V100, P792, DOI 10.1016/S0091-6749(97)70276-8; Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857; SAMET JM, 1982, AM REV RESPIR DIS, V125, P152; SAMET JM, 1987, CHEST, V91, pS74, DOI 10.1378/chest.91.6.74S; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Wright AL, 1996, AM J RESP CRIT CARE, V153, P1259, DOI 10.1164/ajrccm.153.4.8616551	64	32	33	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					772	780		10.1067/mai.2001.119158	http://dx.doi.org/10.1067/mai.2001.119158			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692103				2022-12-18	WOS:000172523800018
J	Haselden, BM; Syrigou, E; Jones, M; Huston, D; Ichikawa, K; Chapman, MD; Kay, AB; Larche, M				Haselden, BM; Syrigou, E; Jones, M; Huston, D; Ichikawa, K; Chapman, MD; Kay, AB; Larche, M			Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; peptide; T lymphocyte; cytokine	HUMAN T-CELL; BIRCH POLLEN ALLERGEN; HUMAN INTERLEUKIN-5; MAJOR ALLERGEN; MESSENGER-RNA; HUMAN TH1; EPITOPES; SECRETION; RESPONSES; EOSINOPHILS	Background: In general, T cells from normal, nonatopic individuals respond to aeroallergens with synthesis and release of IFN-gamma. In contrast, release of T(H)2-type cytokines by activated lymphocytes is a feature of allergic rhinitis and atopic asthma. Objective: The purpose of this study was to determine differences in T-cell recognition of epitopes within allergenic sequences, in terms of proliferation and cytokine production, in subjects with atopic asthma compared with subjects with allergic rhinitis and normal controls. Methods: Proliferative responses and IL-5/IFN-gamma release patterns from PBMCs from cat-allergic asthmatic, cat-allergic rhinitic, and non-cat-allergic asthmatic subjects and nonatopic normal controls were determined in primary cultures. Cells were challenged with 7 overlapping peptides spanning chain 1 of the major cat allergen, Fel d 1. Results: The 4 groups did not differ with respect to the ability to mount proliferative responses to Fel d 1 peptides. In all groups, the IFN-gamma responses were predominantly to the amino terminus peptides. Cat-allergic and non-cat-allergic asthmatic subjects (and not cat-allergic rhinitic subjects and normal controls) made IL-5 responses to most of the Fel d 1 peptides, the result being a mixed (T(H)0) cytokine response at the N-terminus and a restricted (T(H)2) response at the C-terminus. Conclusion: Proliferative and IL-5/IFN-gamma responses of T cells from asthmatic and atopic rhinitic subjects and normal controls to allergen peptides can be dissociated. Furthermore, differing cytokine responses to peptides derived from a single antigen suggest that certain domains of the molecule might preferentially induce IL-5 rather than IFN-gamma and as a result could be more important in disease pathogenesis.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sch Med, Dept Allergy & Clin Immunol, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sch Med, Dept Occupat & Environm Med, London SW3 6LY, England; Baylor Coll Med, Dept Med, Immunol Sect, Houston, TX 77030 USA; Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	Imperial College London; Imperial College London; Baylor College of Medicine; University of Virginia	Larche, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sch Med, Dept Allergy & Clin Immunol, Dovehouse St, London SW3 6LY, England.		Larche, Mark/B-4326-2010	Larche, Mark/0000-0002-1439-7593; Huston, David/0000-0002-2332-0010; Chapman, Martin/0000-0002-0845-3632				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; Cardaba B, 1998, CLIN EXP ALLERGY, V28, P413; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CORRIGAN CJ, 1992, BRIT MED BULL, V48, P72, DOI 10.1093/oxfordjournals.bmb.a072543; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; DICKASON R, 1998, CYTOKINE, V6, P647; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; KUMAR V, 1995, P NATL ACAD SCI USA, V92, P9510, DOI 10.1073/pnas.92.21.9510; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MAGGI E, 1992, J IMMUNOL, V148, P2142; Mark PG, 1996, CLIN EXP ALLERGY, V26, P1316, DOI 10.1111/j.1365-2222.1996.tb00529.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURRAY JS, 1992, EUR J IMMUNOL, V22, P559, DOI 10.1002/eji.1830220239; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; PALFRAMAN RT, 1998, J EXP MED, V118, P1; Parronchi P, 1998, EUR J IMMUNOL, V28, P37, DOI 10.1002/(SICI)1521-4141(199801)28:01<37::AID-IMMU37>3.0.CO;2-C; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; Texier C, 2000, J IMMUNOL, V164, P3177, DOI 10.4049/jimmunol.164.6.3177; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; Till SJ, 1998, AM J RESP CRIT CARE, V158, P404, DOI 10.1164/ajrccm.158.2.9705007; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; WIERENGA EA, 1991, J IMMUNOL, V147, P2942	37	32	35	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					349	356		10.1067/mai.2001.117461	http://dx.doi.org/10.1067/mai.2001.117461			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544452				2022-12-18	WOS:000171215400004
J	Noguchi, E; Shibasaki, M; Inudou, M; Kamioka, M; Yokouchi, Y; Yamakawa-Kobayashi, K; Hamaguchi, H; Matsui, A; Arinami, T				Noguchi, E; Shibasaki, M; Inudou, M; Kamioka, M; Yokouchi, Y; Yamakawa-Kobayashi, K; Hamaguchi, H; Matsui, A; Arinami, T			Association between a new polymorphism in the activation-induced cytidine deaminase gene and atopic asthma and the regulation of total serum IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; AICDA; total serum IgE; TDT; splice variants	B MESSENGER-RNA; MOLECULAR-CLONING; CHILDHOOD ASTHMA; AID; FAMILIES; PROTEIN; SWITCH; MITE	Background: Activation-induced cytidine deaminase (AICDA) is a recently identified RNA-editing deaminase that plays an important role in class-switching. Defects in AICDA result in a hyper-IgM phenotype and lack of IgG, IgA, and IgE in both human beings and mice. Objective: The aim of this study was to determine whether the AICDA gene is related to regulation of total serum IgE and development of atopic asthma. Methods: We screened for polymorphisms in the 5 ' -flanking and coding regions of the AICDA gene in subjects with atopic asthma and analyzed the effect of these polymorphisms on the development of atopic asthma and on total serum IgE levels in Japanese asthmatic families. Results: We identified 3 novel polymorphisms (5923A/G, 7888C/T, and 8578A/C) and 1 rare variant (Arg25Cys) in the AICDA gene. Transmission disequilibrium testing showed that the 7888C allele was transmitted preferentially to asthma-affected children (P = .007). Mean log [total serum IgE] levels of parents with the 7888C/7888C, 7888C/7888T, and 7888T/7888T genotypes were 2.12, 1.99, and 1.77, respectively, and a significant association was observed between the genotypes (P = .02). In RT-PCR experiments, we found 2 novel splice variants of AICDA, one lacking all of exon 4 (variant 1; 367 base pairs) and the other lacking the first 30 base pairs of exon 4 (variant 2; 453 base pairs). These variants were not associated with the 7888C/T polymorphism. Conclusion: The 7888C/T polymorphism might be associated with the pathogenesis of atopic asthma and the regulation of total serum IgE levels.	Univ Tsukuba, Inst Basic Med Sci, Dept Med Genet, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Pediat, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba	Noguchi, E (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Med Genet, Tsukuba, Ibaraki 3058575, Japan.		Yamakawa-Kobayashi, Kimiko/C-1698-2013	Yokouchi, Yukako/0000-0003-2108-7515				Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698; Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Cunningham S.J., 1997, EMERG PEDIAT, V10, P33; DUFFY DL, 2000, SIB PAIR V 0 93; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823, DOI 10.1164/ajrccm/146.4.823; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muto T, 2000, GENOMICS, V68, P85, DOI 10.1006/geno.2000.6268; Nagumo H, 1998, J IMMUNOL, V161, P6496; Nanavaty U, 2001, AM J MED SCI, V321, P11, DOI 10.1097/00000441-200101000-00003; Oettgen HC, 2000, CURR OPIN IMMUNOL, V12, P618, DOI 10.1016/S0952-7915(00)00153-9; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Sandford AJ, 2000, AM J RESP CRIT CARE, V161, pS202, DOI 10.1164/ajrccm.161.supplement_2.a1q4-11; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHIBASAKI M, 1988, J ALLERGY CLIN IMMUN, V82, P86, DOI 10.1016/0091-6749(88)90056-5; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201	22	32	36	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					382	386		10.1067/mai.2001.117456	http://dx.doi.org/10.1067/mai.2001.117456			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544457				2022-12-18	WOS:000171215400009
J	Zhuang, QL; Mazer, B				Zhuang, QL; Mazer, B			Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intravenous immunoglobulin; B lymphocytes; IgE; cell cycle	FC-GAMMA-RIIB; IN-VITRO; GLOBULIN THERAPY; IMMUNE GLOBULIN; B-LYMPHOCYTES; CROSS-LINKING; MESSENGER-RNA; CELLS; PROLIFERATION; SUPPRESSION	Background: Intravenous immunoglobulin (IVIG) has been shown to suppress Ig production both in vivo and in Nitro. We have previously found that IVIG inhibits IgE synthesis in human tonsillar B cells stimulated with IL-4 and anti-CD40 antibody. Objective: The purpose of this study was to further clarify the mechanism behind the inhibition of IgE production by MG through comparing the effects of intact whole molecular IVIG and the F(ab')(2) or Fc fragments of IVIG. Methods: Human B lymphocytes were purified from tonsils. Cell proliferation was measured by means of tritiated thymidine incorporation. IgE was determined by means of ELISA. Cell-cycle analysis was performed by using flow cytometry. Results: Both intact and fractionated IVIG inhibited anti-CD40- and IL-4-stimulated IgE production in a dose-dependent manner. The maximal inhibition was achieved at 67 mu mol/L (eg, 10, 6, and 4 mg/mL for intact IVIG, F[ab'](2), and Fc, respectively). The effect of F(ab)(2) was more pronounced than that of Fe at equimolar concentrations. Similarly, both intact and fragmented IVIG dose-dependently decreased tritiated thymidine incorporation. F(ab')(2) was also more potent than Fc in this effect. Heat-aggregated IVIG exhibited similar potency to regular IVIG in inhibiting B-cell proliferation. The inhibitory effects of IVIG were unlikely to have been caused by the induction of apoptosis because neither intact nor fractionated IVIG had a significant effect on cell-cycle parameters at the concentrations used. Conclusion: These data suggest that both F(ab)(2) and Fe portions contribute to the inhibition of in Nitro IgE production by MG. The role of the F(ab)(2) portion is more important than that of the Fc portion.	McGill Univ, Meakins Christie Labs, Montreal Childrens Hosp, Div Allergy & Immunol, Montreal, PQ H2X 2P2, Canada	McGill University	Mazer, B (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; AMRAN D, 1994, CLIN IMMUNOL IMMUNOP, V73, P180, DOI 10.1006/clin.1994.1186; Ballow M, 1999, CLIN IMMUNOL, V91, P123, DOI 10.1006/clim.1999.4722; BICHTHUY LT, 1979, J IMMUNOL, V122, P1842; BUSSEL JB, 1989, CLIN IMMUNOL IMMUNOP, V53, P147; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; FRANK MM, 1992, CLIN IMMUNOL IMMUNOP, V62, pS82, DOI 10.1016/0090-1229(92)90045-P; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; HAAS H, 1995, J CLIN IMMUNOL, V15, P172, DOI 10.1007/BF01541086; HENRY C, 1968, J EXP MED, V128, P133, DOI 10.1084/jem.128.1.133; Klaesson S, 1996, SCAND J IMMUNOL, V43, P574, DOI 10.1046/j.1365-3083.1996.d01-72.x; KLAESSON S, 1993, SCAND J IMMUNOL, V38, P477, DOI 10.1111/j.1365-3083.1993.tb02591.x; KONDO N, 1991, J CLIN IMMUNOL, V11, P152, DOI 10.1007/BF00918683; KONDO N, 1994, SCAND J IMMUNOL, V40, P37, DOI 10.1111/j.1365-3083.1994.tb03430.x; LUO HY, 1991, J IMMUNOL, V146, P2122; Malbec O, 1999, CURR TOP MICROBIOL, V244, P13; MAZER B, 1994, PRACT ALLERGY IMMUNO, V9, P104; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; MORETTA L, 1977, J EXP MED, V146, P184, DOI 10.1084/jem.146.1.184; Pearse RN, 1999, IMMUNITY, V10, P753, DOI 10.1016/S1074-7613(00)80074-6; Prasad NKA, 1998, J IMMUNOL, V161, P3781; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; SARMAY G, 1995, EUR J IMMUNOL, V25, P262, DOI 10.1002/eji.1830250143; Sigman K, 1998, J ALLERGY CLIN IMMUN, V102, P421, DOI 10.1016/S0091-6749(98)70130-7; Sooryanarayana, 1999, BIOCHEM BIOPH RES CO, V264, P896, DOI 10.1006/bbrc.1999.1592; Spellberg B, 1999, NEW ENGL J MED, V341, P57; Stangel M, 1999, ARCH NEUROL-CHICAGO, V56, P661, DOI 10.1001/archneur.56.6.661; TODD AAM, 1992, BLOOD REV, V6, P105, DOI 10.1016/0268-960X(92)90012-F; TOYODA M, 1994, J CLIN IMMUNOL, V14, P178, DOI 10.1007/BF01533367; TSUBAKIO T, 1983, CLIN EXP IMMUNOL, V53, P697; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Yu ZY, 1999, NEW ENGL J MED, V340, P227, DOI 10.1056/NEJM199901213400311	33	32	33	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					229	234		10.1067/mai.2001.116291	http://dx.doi.org/10.1067/mai.2001.116291			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496239				2022-12-18	WOS:000170584600011
J	Holloway, JA; Holgate, ST; Semper, AE				Holloway, JA; Holgate, ST; Semper, AE			Expression of the high-affinity IgE receptor on peripheral blood dendritic cells: Differential binding of IgE in atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; Fc epsilon RI; dendritic cell; asthma; atopy; peripheral blood; flow cytometry	FC-EPSILON-RI; MEDIATED ALLERGEN PRESENTATION; CLASS-II PRESENTATION; S-DEPENDENT PATHWAY; RELEASE; ANTIGEN; CORTICOSTEROIDS; CHALLENGE; MONOCYTES; INHIBIT	Background: Dendritic cells can express the high-affinity IgE receptor (Fc epsilon RI), which, in the presence of specific IgE, facilitates the uptake of allergen, leading to increased activation of allergen-specific T tells. FceRI expression by dendritic cells is higher in the airways of atopic asthmatic subjects than in those of healthy, nonatopic control subjects. Objective: The aims of this study were to determine whether a similar difference in Fc epsilon RI expression occurs between dendritic cells in the peripheral blood of atopic asthmatic subjects and healthy individuals and also whether an altered ability of Fc epsilon RI+ peripheral blood dendritic cells to bind IgE accompanies the atopic asthmatic state. Methods: Flow cytometry was used to analyze the surface expression of Fc epsilon RI and exogenously bound IgE on dendritic tells identified as lineage negative (CD3, CD14, CD16, CD19, and CD56) and HLA-DR bright. Results: The total expression of Fc epsilon RI on the surface of dendritic cells from healthy and asthmatic subjects was not significantly different. However, in vivo, dendritic cells from atopic asthmatic subjects had higher levels of receptor occupancy by IgE and bound exogenous IgE in vitro more efficiently than dendritic cells from healthy subjects. Conclusion: The similar levels of expression of Fc epsilon RI on peripheral blood dendritic cells from healthy and asthmatic subjects suggest that the local environment in the airway is responsible for the upregulation of surface FceRI on airway dendritic cells in asthma, The results also suggest that the functional ability of FceRI to bind IgE is differentially controlled in the atopic state.	Univ Southampton, Sch Med, Allergy & Inflammat Sci Div, Southampton, Hants, England; Univ Southampton, Sch Med, Resp Cell & Mol Biol Div, Southampton, Hants, England	University of Southampton; University of Southampton	Semper, AE (corresponding author), Southampton Gen Hosp, Allergy & Inflammat Sci Div, Dermatopharmacol Unit, Mailstop 825,Level F S Block, Southampton SO16 6YD, Hants, England.		Holloway, Judith A/A-1757-2010	Holloway, Judith A/0000-0002-2268-3071				de Jong EC, 1999, J LEUKOCYTE BIOL, V66, P201, DOI 10.1002/jlb.66.2.201; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Holt PG, 1997, IMMUNOLOGY, V91, P145, DOI 10.1046/j.1365-2567.1997.00321.x; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; Kon O. M., 1996, Journal of Allergy and Clinical Immunology, V97, P358, DOI 10.1016/S0091-6749(96)80919-5; LIU FT, 1995, AM J PATHOL, V147, P1016; Matyszak MK, 2000, EUR J IMMUNOL, V30, P1233, DOI 10.1002/(SICI)1521-4141(200004)30:4<1233::AID-IMMU1233>3.0.CO;2-F; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1997, J INVEST DERMATOL, V109, P404; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Maurer D, 1998, J IMMUNOL, V161, P2731; MYGIND N, 1986, ESSENTIAL ALLERGY, P120; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Reischl IG, 1996, CLIN EXP ALLERGY, V26, P630, DOI 10.1046/j.1365-2222.1996.1047408.x; Semper AE, 1995, ADV EXP MED BIOL, V378, P135; Semper Amanda, 1998, Immunology, V95, P67; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; TAYLOR GW, 1989, LANCET, V1, P584; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; WOLLENBERG A, 1993, J EXP MED, V178, P777, DOI 10.1084/jem.178.3.777; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; 1983, B EUR PHYSIOPATHOL R, V19, P495	26	32	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1009	1018		10.1067/mai.2001.115039	http://dx.doi.org/10.1067/mai.2001.115039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398078				2022-12-18	WOS:000169454800012
J	Kita, H; Jorgensen, RK; Reed, CE; Dunnette, SL; Swanson, MC; Bartemes, KR; Squillace, D; Blomgren, J; Bachman, K; Gleich, GJ				Kita, H; Jorgensen, RK; Reed, CE; Dunnette, SL; Swanson, MC; Bartemes, KR; Squillace, D; Blomgren, J; Bachman, K; Gleich, GJ			Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; topical budesonide; cytokines; eosinophils; adhesion molecules; IgE; secretory IgA	MAJOR BASIC-PROTEIN; MESSENGER-RNA EXPRESSION; NASAL-LAVAGE FLUID; BECLOMETHASONE DIPROPIONATE; IMMUNOGLOBULIN-E; ANTIGEN CHALLENGE; HUMAN-LYMPHOCYTES; CATIONIC PROTEIN; INDUCED RHINITIS; GENE-EXPRESSION	Background: Allergic rhinitis is traditionally defined as an IgE- and mast cell-mediated hypersensitivity reaction. Allergen challenge models suggest that cytokines and eosinophil mediators may also play roles. However, the causal relationship among inflammatory cells, their products, and patients' symptoms during natural allergen exposure has not been established. Objective: We sought to elucidate the mechanisms of seasonal allergic rhinitis and the beneficial effects of topical glucocorticoids. Methods: Thirty patients with ragweed-induced hay fever and a strongly positive serologic test response for ragweed IgE antibody received budesonide nasal spray or placebo in a randomized, parallel, double-blind study. Nasal wash Fluids and sera were collected before and during the hay fever season. The levels of inflammatory mediators and allergen-specific immunoglobulins were measured by immunoassay. The activation markers on blood eosinophils were quantitated by flow cytometry. Results: Compared with placebo-treated patients, budesonide-treated patients had strikingly reduced symptoms. In the placebo group, nasal symptoms correlated with nasal lavage fluid eosinophil-derived neurotoxin and IL-5 levels. At the season peak, the budesonide-treated group had significantly lower nasal fluid eosinophil-derived neurotoxin, IL-5, and soluble intracellular adhesion molecule-1 levels. In the treated group eosinophil expression of CD11b was suppressed at the season peak. In contrast, levels of IL-4 and IL-6 in nasal fluid and the seasonal increases in serum ragweed-specific IgE and nasal fluid IgA antibodies did not differ between groups. Conclusion: Eosinophilic inflammation plays a critical role in seasonal allergic rhinitis symptoms. One of the therapeutic effects of glucocorticoids is to suppress this inflammation.	Mayo Clin & Mayo Fdn, Dept Immunol, Div Allergy, Mayo Grad Sch Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Div Allergy, Mayo Grad Sch Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Kita, H (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, Div Allergy, Mayo Grad Sch Med, Rochester, MN 55905 USA.			Bartemes, Kathleen/0000-0003-4561-3233	NIAID NIH HHS [AI 34577, AI 34486] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034486, R29AI034486, U01AI034577, U19AI034577, R56AI034486] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; AYARS GH, 1989, AM REV RESPIR DIS, V140, P125; BAROODY FM, 1996, CLIN IMMUNOLOGY PRIN, V1, P889; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Druce HM, 1998, ALLERGY PRINCIPLES P, P1005; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FISCHER A, 1991, IMMUNOLOGY, V74, P228; FRIGAS E, 1980, LAB INVEST, V42, P35; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; HASTIE AT, 1987, AM REV RESPIR DIS, V135, P848, DOI 10.1164/arrd.1987.135.4.848; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; Jorgensen R. K., 1996, Journal of Allergy and Clinical Immunology, V97, P371, DOI 10.1016/S0091-6749(96)80973-0; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; KAY AB, 1995, INT ARCH ALLERGY IMM, V107, P208, DOI 10.1159/000236979; Kita H, 1999, J IMMUNOL, V162, P6901; KUPFER A, 1991, P NATL ACAD SCI USA, V88, P775, DOI 10.1073/pnas.88.3.775; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Masuyama K, 1998, J ALLERGY CLIN IMMUN, V102, P610, DOI 10.1016/S0091-6749(98)70277-5; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Nakajima H, 1996, J IMMUNOL, V156, P4859; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; POSEY WC, 1978, J ALLERGY CLIN IMMUN, V62, P340, DOI 10.1016/0091-6749(78)90134-3; RATNER PH, 1992, J ALLERGY CLIN IMMUN, V90, P285, DOI 10.1016/S0091-6749(05)80005-3; REED CE, 1991, INT ARCH ALLER A IMM, V94, P275, DOI 10.1159/000235382; Reed CE, 1998, J ALLERGY CLIN IMMUN, V101, P14, DOI 10.1016/S0091-6749(98)70187-3; ROLFE FG, 1992, IMMUNOLOGY, V77, P494; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SIM TC, 1994, AM J RESP CRIT CARE, V149, P339, DOI 10.1164/ajrccm.149.2.8306027; SULAKVELIDZE I, 1995, ASTHMA RHINITS, P231; TOBLER A, 1992, BLOOD, V79, P45; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WANG D, 1995, ALLERGY, V50, P147; WANG DY, 1994, ACTA OTO-LARYNGOL, V114, P552, DOI 10.3109/00016489409126103; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053; Ying S, 1997, J IMMUNOL, V158, P3539; Yunginger JW, 1992, MANUAL CLIN LAB IMMU, V4th, P678	52	32	37	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					521	529						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984373	Bronze			2022-12-18	WOS:000089471900016
J	Gordon, JR				Gordon, JR			Monocyte chemoattractant peptide-1 expression during cutaneous allergic reactions in mice is mast cell dependent and largely mediates the monocyte recruitment response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monocyte chemotactic peptide-1; chemokine; allergy; mast cells; monocytes/macrophages	NECROSIS-FACTOR-ALPHA; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; TNF-ALPHA; ALVEOLAR MACROPHAGES; BLOOD MONOCYTES; GM-CSF; ASTHMA; MOUSE; IGE; CHEMOKINES	Background: Macrophages and infiltrating monocytes comprise the largest population of cells within the airways of patients with allergic asthma, Both become activated and thus contribute to the pathologic features of allergic reactions, but the mechanism by which they are recruited has not been well documented, Objective: Our purpose was to assess the role of the CC chemokine monocyte chemotactic peptide-1 (MCP-1) in monocyte recruitment during allergic reactions in mice. Method: We used immunohistochemistry and Northern blotting to assess MCP-1 expression, selective mast cell reconstitution of mast cell-deficient W/W-v mice to demonstrate the mast cell dependence of MCP-I expression and monocyte recruitment and neutralizing anti-MCP-l antibodies to block monocyte recruitment during cutaneous allergic reactions. Results: MCP-I was expressed largely by resident dermal cells within the allergic lesions at 4 hours after challenge, followed within several hours by an influx of monocytes; at 10 hours after challenge monocytes comprised a substantial proportion of the infiltrating cells at the nidus of the response. Mast cell-reconstituted, but not mast cell-deficient W/W-v mice expressed MCP-I transcripts and developed monocyte infiltrates after allergen challenge. Finally, anti-MCP-l antibody treatments reduced by similar to 63% the influx of monocytes into the reaction sites. Conclusions: These data clearly demonstrate the mast cell dependence of the MCP-I expression and the monocyte influx and establish a substantial, but not exclusive, causal relationship between these 2 events.	Univ Saskatchewan, Dept Vet Microbiol, Saskatoon, SK, Canada	University of Saskatchewan	Gordon, JR (corresponding author), Univ Saskatchewan, Dept Vet Microbiol, 52 Campus Dr, Saskatoon, SK, Canada.		Gordon, John/D-7621-2013	Gordon, John/0000-0003-3830-8070				Ajuebor MN, 1999, BIOCHEM BIOPH RES CO, V255, P279, DOI 10.1006/bbrc.1999.0196; ALAM R, 1994, J IMMUNOL, V152, P1298; Albanesi C, 1998, CLIN EXP ALLERGY, V28, P101; ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BURKE LA, 1991, J ALLERGY CLIN IMMUN, V88, P226, DOI 10.1016/0091-6749(91)90333-J; Caswell JL, 1998, VET PATHOL, V35, P124, DOI 10.1177/030098589803500206; Christodoulopoulos P, 1999, J ALLERGY CLIN IMMUN, V103, P1036, DOI 10.1016/S0091-6749(99)70176-4; EVANOFF HL, 1992, IMMUNOL INVEST, V21, P39, DOI 10.3109/08820139209069361; FOWLER AA, 1984, J ALLERGY CLIN IMMUN, V74, P777, DOI 10.1016/0091-6749(84)90177-5; GALLI SJ, 1992, ANN NY ACAD SCI, V664, P69, DOI 10.1111/j.1749-6632.1992.tb39750.x; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; GORDON JR, 1992, FASEB J, V6, pA1147; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GORDON JR, 1997, IGE RECEPTOR FCERI F, P209; GORDON JR, 2000, IN PRESS CELL IMMUNO; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; HALLSWORTH MP, 1994, EUR RESPIR J, V7, P1096; Kendall JC, 1997, J ALLERGY CLIN IMMUN, V99, P113; Krombach F, 1996, EUR RESPIR J, V9, P984, DOI 10.1183/09031936.96.09050984; Kuna P, 1996, J ALLERGY CLIN IMMUN, V97, P104, DOI 10.1016/S0091-6749(96)70288-9; LITCHFIELD TM, 1992, J ASTHMA, V29, P181, DOI 10.3109/02770909209099026; LIU FT, 1980, J IMMUNOL, V124, P2728; OCONNELL KA, 1990, J IMMUNOL, V144, P521; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; Viksman MY, 1997, AM J RESP CRIT CARE, V155, P858, DOI 10.1164/ajrccm.155.3.9117017; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WILKINSON JRW, 1989, INT ARCH ALLER A IMM, V90, P64, DOI 10.1159/000235078; Yamashiro S, 1998, INT ARCH ALLERGY IMM, V115, P15, DOI 10.1159/000023825	36	32	32	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				110	116						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887313				2022-12-18	WOS:000088393300015
J	Zimmerman, B; Silverman, FS; Tarlo, SM; Chapman, KR; Kubay, JM; Urch, B				Zimmerman, B; Silverman, FS; Tarlo, SM; Chapman, KR; Kubay, JM; Urch, B			Induced sputum: Comparison of postinfectious cough with allergic asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic cough; eosinophils; induced sputum; eosinophil cationic protein; IL-8; methacholine challenge; postviral	CHRONIC PERSISTENT COUGH; AIRWAY INFLAMMATION; BRONCHIAL-ASTHMA; HEALTHY-SUBJECTS; HYPERRESPONSIVENESS; EOSINOPHILS; MECHANISMS; CHALLENGE; CHILDHOOD; RESPONSES	Background: Cough persisting after a respiratory infection Is common in children and is often managed as asthma, However, little is known about the pathophysiologic: mechanisms of such cough and how it compares with asthma, Objective: We used the technique of induced sputum to examine the inflammatory index values associated with persistent cough or allergic asthma in children. We hypothesized that the sputum from children with persistent postinfectious cough would differ from that of children with allergic asthma in that the former would lack eosinophils compared with the latter. Study design: Sputum production was induced with hypertonic saline solution in 34 children: 12 with cough persisting for 1 month or more after an apparent respiratory tract infection, not treated with corticosteroid; 11 with untreated atopic asthma, not using inhaled corticosteroid; and 11 with treated atopic asthma using inhaled corticosteroid, Results: The percentage of eosinophils in the sputum of children with cough was significantly lower than in the sputum of children with untreated allergic asthma (median 0.5% vs 14.5%, F < .0001), Similarly, the percentage of eosinophils in the sputum of children with asthma treated with inhaled steroids was significantly lower compared with untreated asthmatic children (1.5% vs 14.5%, P < .0001). The peripheral blood eosinophils, serum eosinophil cationic protein, and nasal percent eosinophils of the patients with cough were also significantly lower than those from patients with untreated asthma, Methacholine challenge in 6 of the 11 cough patients tested showed mild-to-moderate hyperresponsiveness, whereas the other 5 had a negative methacholine challenge, Conclusions: Children with persistent postinfectious cough do not have airway eosinophilia typical of untreated asthma, Despite the absence of eosinophilic inflammation, some of the patients with chronic cough had reactive airways. These results suggest that postinfectious cough in children has different pathophysiologic features than allergic asthma and probably represents a different disease.	St Michaels Hosp, Gage Occupat & Environm Hlth Unit, Toronto, ON M5B 1W8, Canada; Univ Toronto, Toronto Western Hosp, Asthma Ctr, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Zimmerman, B (corresponding author), 45A Alvin Ave, Toronto, ON M4T 2A7, Canada.		Urch, R. Bruce/C-9162-2014	Tarlo, Susan/0000-0002-4746-5310				American Thoracic Society, 1998, PULM FUNCT LAB MAN P; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BECKLAKE M, 1991, AM REV RESPIR DIS, V144, P1202; Cai Y, 1998, EUR RESPIR J, V11, P848, DOI 10.1183/09031936.98.11040848; Carney IK, 1997, AM J RESP CRIT CARE, V156, P211, DOI 10.1164/ajrccm.156.1.9605044; CLOUGH JB, 1994, AM J RESP CRIT CARE, V150, P48, DOI 10.1164/ajrccm.150.1.8025771; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; Corrao WM, 1996, PEDIATR ANN, V25, P162, DOI 10.3928/0090-4481-19960301-09; DEBENEDICTIS FM, 1986, J ASTHMA, V23, P303, DOI 10.3109/02770908609073177; ELLULMICALLEF R, 1983, BRIT MED J, V287, P940, DOI 10.1136/bmj.287.6397.940; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; Fujimura M, 1997, J ASTHMA, V34, P119, DOI 10.3109/02770909709075656; GALVEZ RA, 1987, J ALLERGY CLIN IMMUN, V79, P331, DOI 10.1016/0091-6749(87)90150-3; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; GIBSON PG, 1989, LANCET, V1, P1346; Gibson PG, 1998, AM J RESP CRIT CARE, V158, P36, DOI 10.1164/ajrccm.158.1.9705031; HANNAWAY PJ, 1982, JAMA-J AM MED ASSOC, V247, P206, DOI 10.1001/jama.247.2.206; HARGREAVE FE, 1989, J ALLERGY CLIN IMMUN, V83, P525, DOI 10.1016/0091-6749(89)90033-X; HOLGATE ST, 1990, J ROY COLL PHYS LOND, V24, P304; HYNES B, 1988, ARCH ENVIRON HEALTH, V43, P357, DOI 10.1080/00039896.1988.9934949; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; Juniper EF, 1991, HISTAMINE METHACHOLI; KIRSHNER B, 1990, J CLIN EPIDEMIOL, V43, P765, DOI 10.1016/0895-4356(90)90236-I; KOREN HS, 1990, TOXICOLOGY, V60, P15, DOI 10.1016/0300-483X(90)90159-E; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533, DOI 10.1164/ajrccm.159.5.9805028; MCFADDEN ER, 1975, NEW ENGL J MED, V292, P555, DOI 10.1056/NEJM197503132921103; Piacentini GL, 1998, CLIN EXP ALLERGY, V28, P561, DOI 10.1046/j.1365-2222.1998.00260.x; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; PIN I, 1993, EUR RESPIR J, V6, P1249; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Pizzichini M M, 1999, Can Respir J, V6, P323; Sorva R, 1997, PEDIAT ALLERG IMM-UK, V8, P45, DOI 10.1111/j.1399-3038.1997.tb00142.x; Teran LM, 1997, AM J RESP CRIT CARE, V155, P1362, DOI 10.1164/ajrccm.155.4.9105080; Twaddell SH, 1996, EUR RESPIR J, V9, P2104, DOI 10.1183/09031936.96.09102104; Wright AL, 1996, AM J RESP CRIT CARE, V153, P1259, DOI 10.1164/ajrccm.153.4.8616551; ZIMMERMAN B, 1998, CAN J ALLERGY CLIN I, V4, P16	40	32	35	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					495	499		10.1067/mai.2000.104933	http://dx.doi.org/10.1067/mai.2000.104933			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719299				2022-12-18	WOS:000088946700015
J	Blaylock, MG; Sexton, DW; Walsh, GM				Blaylock, MG; Sexton, DW; Walsh, GM			Ligation of CD45 and the isoforms CD45RA and CD45RB accelerates the rate of constitutive apoptosis in human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; apoptosis; CD45; allergy asthma; cell surface molecules	COLONY-STIMULATING FACTOR; PROGRAMMED CELL-DEATH; CROSS-LINKING; TYROSINE PHOSPHATASE; REGULATES APOPTOSIS; IL-5; HEMATOPOIETINS; PHAGOCYTOSIS; MACROPHAGES; NEUTROPHILS	Background: Eosinophils are important effector cells in asthma pathogenesis, and an understanding of the mechanisms involved in eosinophil apoptosis induction might thus be relevant to the resolution of asthmatic inflammation. Objective: Our aim was to determine the role of the common leukocyte antigen CD45 and the isoforms CD45RA, CD45RB, and CD45RO in human eosinophil apoptosis induction. Methods: Immmunostaining and flow cytometry were used to assess CD45 and CD45 isoform expression by cosinophils purified with use of density gradients and immunomagnetic negative selection. Apoptosis induction was measured by binding of fluorescein isothiocyanate-labeled annexin V to eosinophils cultured for 20 hours alone or with saturating quantities of m-lb against CD45. CD45RA, CD45RB, CD45RO, CD9, CD11b, and isotype-matched controls in the presence or absence of GM-CSF. Results: Freshly isolated eosinophils had high expression of CD45 and CD45RO, modest expression of CD45RB, and low expression of CD45RA. Eosinophils cultured alone for 20 hours were found to be approximately 20% to 25% apoptotic, Incubation with mAb against CD45, CD45RA, and CD45RB resulted in significant (P < .005) enhancement (>100%) of their constitutive rate of apoptosis. Incubation with CD45RO, CD11b CD9 mAb, or isotype controls had no significant effect on the rate of eosinophil constitutive apoptosis, The addition of GM-CSF inhibited eosinophil apoptosis but did not prevent CD15, CD45RA or CD45RB mAb-dependent apoptosis induction. Conclusion: These data indicate that ligation of CD45. CD45RA, or CD45RB represents a novel pathway for the induction of apoptosis in human eosinophils.	Univ Aberdeen, Dept Med & Therapeut, Sch Med, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Walsh, GM (corresponding author), Univ Aberdeen, Dept Med & Therapeut, Sch Med, IMS Bldg,Forsterhill, Aberdeen AB25 2ZD, Scotland.		Walsh, Garry/D-4869-2013; Sexton, Darren/AAF-3171-2020	Walsh, Garry/0000-0002-7138-4078; Sexton, Darren/0000-0003-3344-3150	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALAM R, 1994, J EXP MED, V179, P1041, DOI 10.1084/jem.179.3.1041; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; Dewson G, 1999, AM J RESP CELL MOL, V20, P720, DOI 10.1165/ajrcmb.20.4.3453; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; Druilhe A, 1996, BLOOD, V87, P2822, DOI 10.1182/blood.V87.7.2822.bloodjournal8772822; Druilhe A, 1998, AM J RESP CELL MOL, V18, P315, DOI 10.1165/ajrcmb.18.3.3019; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; Klaus SJ, 1996, J IMMUNOL, V156, P2743; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; Lesage S, 1997, J IMMUNOL, V159, P4762; LILES WC, 1995, J IMMUNOL, V155, P2175; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Matsumoto K, 1998, INT ARCH ALLERGY IMM, V117, P34, DOI 10.1159/000053568; Meagher LC, 1996, J IMMUNOL, V156, P4422; Ochiai K, 1997, CLIN EXP IMMUNOL, V107, P198, DOI 10.1046/j.1365-2249.1997.d01-884.x; ONG CJ, 1994, J IMMUNOL, V152, P3793; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; PULIDO R, 1990, EUR J IMMUNOL, V20, P2667, DOI 10.1002/eji.1830201221; Stern M, 1996, AM J PATHOL, V149, P911; STERN M, 1992, J IMMUNOL, V148, P3543; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TROWBRIDGE JS, 1992, ADV EXP MED BIOL, V323, P29; Walsh GM, 1996, BLOOD, V87, P2815, DOI 10.1182/blood.V87.7.2815.bloodjournal8772815; Walsh GM, 1997, BRIT J HAEMATOL, V97, P701, DOI 10.1046/j.1365-2141.1997.00125.x; Walsh GM, 1997, J ALLERGY CLIN IMMUN, V100, P208, DOI 10.1016/S0091-6749(97)70226-4; Walsh GM, 1998, J IMMUNOL METHODS, V217, P153, DOI 10.1016/S0022-1759(98)00103-3; Walsh GM, 1997, CLIN EXP ALLERGY, V27, P482, DOI 10.1111/j.1365-2222.1997.tb00735.x; WALSH GM, 1997, ADHESION MOL ALLERGI, P187; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; Wedi B, 1998, J ALLERGY CLIN IMMUN, V102, P1013, DOI 10.1016/S0091-6749(98)70340-9; WELLER PF, 1994, CURR OPIN IMMUNOL, V6, P85, DOI 10.1016/0952-7915(94)90038-8; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Ying S, 1997, P ASSOC AM PHYSICIAN, V109, P42; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	40	32	36	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1244	1250		10.1016/S0091-6749(99)70020-5	http://dx.doi.org/10.1016/S0091-6749(99)70020-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589008				2022-12-18	WOS:000084289200020
J	Kohama, Y; Akizuki, O; Hagihara, K; Yamada, E; Yamamoto, H				Kohama, Y; Akizuki, O; Hagihara, K; Yamada, E; Yamamoto, H			Immunostimulatory oligodeoxynucleotide induces T-H1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cedar pollen allergen; immunostimulatory DNA sequence; oligodeoxynucleotide; IFN-gamma; IL-4; IgE; IgG2a; IgG1; T-H1 response; T-H2 response	INTRADERMAL GENE IMMUNIZATION; STIMULATORY FACTOR-I; DNA-SEQUENCES; PREFERENTIAL INDUCTION; MONOCLONAL-ANTIBODY; T-LYMPHOCYTES; PLASMID DNA; POLLINOSIS; RECEPTOR; CRY-J-1	Background: Immunotherapy for cedar pollinosis makes use of multiple injections of allergens, but its effectiveness remains controversial. Recent studies indicate that immunization with certain protein antigens and immunostimulatory DNA sequence (ISS) oligodeoxynucleotides (ODNs) represent a potential approach to allergen-specific immunotherapy, Objective: We determined whether the coadministration of 2 major protein allergens, Cry j 1 and Cry j 2, of Japanese cedar pollen and ISS-ODN (5' TGACTCTGAACGTTCGAGATGA-3) improves the immune responses induced by protein allergens in BALB/c mice. Methods: Mice were primed intradermally with allergens or ISS-ODN in saline solution and boosted with allergens in alum, and other mice were primed with allergens in alum and boosted with allergens/ISS-ODN. Allergen-specific IgG2a and IgG1 antibody responses were measured by means of ELISA in sera after ODN injection, and allergen-specific IgE antibody production was measured by the passive cutaneous anaphylaxis reaction. IFN-gamma and IL-4 releases were also measured by ELISA in the supernatants of allergen-stimulated spleen cells, Results: The coadministration of allergens/ISS-ODN increased IgG2a titers and IFN-gamma release in both groups of mice, whereas it decreased IgG1 titers and IL-4 release in comparison with control mice injected with allergens/mutant ODN, The coadministration additionally inhibited IgE antibody production. Conclusion: The data demonstrate that the coadministration of cedar pollen allergens and ISS-ODNs before secondary T-H2 and IgE responses or during ongoing primary T-H2 and IgE responses brings about a T-H1-shifted immune response and inhibition of IgE antibody production, suggesting that this coadministration strategy may provide a novel type of immunotherapy for cedar pollinosis.	Osaka Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Suita, Osaka 5650871, Japan	Osaka University	Kohama, Y (corresponding author), Osaka Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Yamadaoka 1-6, Suita, Osaka 5650871, Japan.			Hagihara, Katsunobu/0000-0003-0094-2543				Broide D, 1998, J IMMUNOL, V161, P7054; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1991, INT IMMUNOL, V3, P599, DOI 10.1093/intimm/3.6.599; FINKELMAN FD, 1989, J IMMUNOL, V142, P403; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Goodman JS, 1998, INT ARCH ALLERGY IMM, V116, P177, DOI 10.1159/000023943; Hartl A, 1999, J ALLERGY CLIN IMMUN, V103, P107, DOI 10.1016/S0091-6749(99)70533-6; HASHIMOTO M, 1995, CLIN EXP ALLERGY, V25, P848, DOI 10.1111/j.1365-2222.1995.tb00027.x; Hirahara K, 1998, J ALLERGY CLIN IMMUN, V102, P961, DOI 10.1016/S0091-6749(98)70334-3; Ikagawa S, 1996, J ALLERGY CLIN IMMUN, V97, P53, DOI 10.1016/S0091-6749(96)70283-X; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; KOHAMA Y, 1995, BIOL PHARM BULL, V18, P1315; KOHAMA Y, 1997, ALLERGOLOGIE, V3, P268; Kohno K, 1996, CELL IMMUNOL, V168, P211, DOI 10.1006/cimm.1996.0068; LEBRUN P, 1987, J IMMUNOL, V139, P1459; Leclerc C, 1997, CELL IMMUNOL, V179, P97, DOI 10.1006/cimm.1997.1161; MANICKAN E, 1995, J IMMUNOL, V155, P259; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OVARY Z, 1975, INT ARCH ALLER A IMM, V48, P16, DOI 10.1159/000231289; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Ryan JJ, 1997, J ALLERGY CLIN IMMUN, V99, P1; Sakaguchi M, 1997, IMMUNOLOGY, V91, P161, DOI 10.1046/j.1365-2567.1997.00255.x; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Sone T, 1998, J IMMUNOL, V161, P448; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Sugimura K, 1996, ALLERGY, V51, P732; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; Wheeler AW, 1997, ALLERGY, V52, P602, DOI 10.1111/j.1398-9995.1997.tb01038.x	31	32	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1231	1238		10.1016/S0091-6749(99)70018-7	http://dx.doi.org/10.1016/S0091-6749(99)70018-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589006				2022-12-18	WOS:000084289200018
J	Bili, A; Condemi, JJ; Bottone, SM; Ryan, CK				Bili, A; Condemi, JJ; Bottone, SM; Ryan, CK			Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Churg-Strauss syndrome; leukotriene receptor antagonists; asthma; eosinophilia; vasculitis; corticosteroids; case series	ALLERGIC GRANULOMATOSIS; SYSTEMIC VASCULITIS; CLASSIFICATION; ZAFIRLUKAST; EOSINOPHILIA; ANGIITIS; CRITERIA; ASTHMA	Background: Various forms of Churg-Strauss syndrome have been reported in association with the use of leukotriene receptor antagonists in asthmatic patients. Objective: Our purpose was to increase awareness that different forms of the Churg-Strauss syndrome occur in patients not receiving leukotriene modifiers. Methods: We searched for all the casts of Churg-Strauss syndrome that were seen in the University of Rochester Medical Center, New York, in the past 4 years. Results: We identified 7 patients, 6 of whom fulfilled the American College of Rheumatology criteria for the classification of Churg-Strauss syndrome, None of them used leukotriene receptor antagonists, All had asthma and sinus disease, The duration and severity of their asthma varied considerably; In the majority of the patients the features of Churg-Strauss syndrome became obvious as the systemic corticosteroid dose was being tapered or discontinued, although 3 patients had not been receiving maintenance oral corticosteroids at disease onset, Three patients had positive antineutrophil cytoplasmic antibodies test result (perinuclear pattern). There was histologic documentation of vasculitis in 4 patients, Five of 7 patients responded to high-dose corticosteroid treatment. Conclusion: Our 7 cases are similar to the various forms of Churg-Strauss syndrome that have been reported in association with the leukotriene receptor antagonists. Complete or incomplete forms of this syndrome ran become apparent in asthmatic patients as systemic corticosteroids are being tapered but ran also occur in patients with mild asthma of short duration who use only inhaled corticosteroids.	Univ Rochester, Allergy Immunol Rheumatol Unit, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Genesee Hosp, Allergy Immunol Rheumatol Unit, Rochester, NY USA	University of Rochester; University of Rochester	Bili, A (corresponding author), Univ Rochester, Strong Mem Hosp, 601 Elmwood Ave,Box 695, Rochester, NY 14642 USA.							Churg A, 1998, LANCET, V352, P32, DOI 10.1016/S0140-6736(05)79511-8; CHURG A, 1995, CHEST, V108, P320, DOI 10.1378/chest.108.2.320; CHURG J, 1951, AM J PATHOL, V27, P277; Green RL, 1999, LANCET, V353, P725, DOI 10.1016/S0140-6736(99)00565-6; GUILLEVIN L, 1993, J RHEUMATOL, V20, P1354; Katz RS, 1998, JAMA-J AM MED ASSOC, V279, P1949, DOI 10.1001/jama.279.24.1949; Kinoshita M, 1999, J ALLERGY CLIN IMMUN, V103, P534, DOI 10.1016/S0091-6749(99)70483-5; Knoell DL, 1998, CHEST, V114, P332, DOI 10.1378/chest.114.1.332; LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001; LIE JT, 1993, PATHOL ANNU, V28, P199; LIE JT, 1986, MT SINAI J MED, V53, P429; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; Rao JK, 1998, ANN INTERN MED, V129, P345, DOI 10.7326/0003-4819-129-5-199809010-00001; WATTS RA, 1995, SEMIN ARTHRITIS RHEU, V25, P28, DOI 10.1016/S0049-0172(95)80015-8; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455	15	32	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1060	1065		10.1016/S0091-6749(99)70089-8	http://dx.doi.org/10.1016/S0091-6749(99)70089-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550753				2022-12-18	WOS:000083778400031
J	Sutherland, MF; O'Hehir, RE; Czarny, D; Suphioglu, C				Sutherland, MF; O'Hehir, RE; Czarny, D; Suphioglu, C			Macadamia nut anaphylaxis: Demonstration of specific IgE reactivity and partial cross-reactivity with hazelnut	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Monash Univ, Alfred Hosp, Sch Med, Dept Allergy Asthma & Clin Immunol, Prahran, Vic 3181, Australia	Florey Institute of Neuroscience & Mental Health; Monash University	Sutherland, MF (corresponding author), Monash Univ, Alfred Hosp, Sch Med, Dept Allergy Asthma & Clin Immunol, Commercial Rd, Prahran, Vic 3181, Australia.		O'Hehir, Robyn E/H-3627-2011	O'Hehir, Robyn E/0000-0002-3489-7595				SUPHIOGLU C, 1993, ALLERGY, V48, P273, DOI 10.1111/j.1398-9995.1993.tb00728.x; Teuber SS, 1997, J ALLERGY CLIN IMMUN, V99, P502, DOI 10.1016/S0091-6749(97)70077-0; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	3	32	38	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				889	890		10.1016/S0091-6749(99)70304-0	http://dx.doi.org/10.1016/S0091-6749(99)70304-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518838				2022-12-18	WOS:000083281200025
J	Yun, YY; Ko, SH; Park, JW; Hong, CS				Yun, YY; Ko, SH; Park, JW; Hong, CS			Anaphylaxis to venom of the Pachycondyla species ant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pachycondyla species ant; anaphylaxis; cross-reactivity; imported fire ants		Background: In the southeastern United States, imported fire ants have caused systemic reactions with a high incidence. On the contrary, in Korea Pachycondyla species ants (P chinensis and P solitaria), and the family Formicidae, which are in the genus Pachycondyla and the subfamily Ponerinae, have only occasionally caused systemic reactions, Objective: We sought to assess whether commercially available imported fire ant extract would be useful in treating patients with anaphylaxis induced by venom from a Pachycondyla species ant, Methods: Serum samples were collected from 2 women who had anaphylaxis induced by Pachycondyla species ant venom and from 6 volunteers with no history of having been stung. Specific IgE to Pachycondyla species ant extracts was measured by means of ELISA and possible allergenic components by immunoblot, Cross-reactivity between Pachycondyla chinensis, P solitaria, and imported fire ant extracts was also measured by inhibitory ELISA, Results: Skin prick test responses were strongly positive to the extract of P chinensis (1:20 wt/vol) in the patient. Ten healthy volunteers exhibited negative responses, The 2 patients' sera exhibited high ELISA values, with absorbencies of 0.78 and 0.61 for P chinensis and 0.83 and 0.68 for P solitaria, respectively, and negative ELISA values for the extract of imported fire ants (absorbency <0.01). Imported fire ants showed no inhibition of the IgE binding to P chinensis or P solitaria, Possible allergenic components of Pachycondyla species ant extracts are 29- and 27-kd proteins and, less frequently, 16 kd proteins. Conclusion: Our data suggest that patients who have had an anaphylactic reaction to a Pachycondyla species ant might not benefit from immunotherapy with an imported fire ant extract. Immunotherapy with the extract of Pachycondyla species ants is expected to be highly effective.	Yonsei Univ, Coll Med, Dept Internal Med, Inst Allergy, CPO Box 8044, Seoul, South Korea	Yonsei University; Yonsei University Health System	Hong, CS (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Inst Allergy, CPO Box 8044, Seoul, South Korea.			Park, Jung-Won/0000-0003-0249-8749				Choi BM, 1985, CHEONG JU TEA COLL, V22, P439; Holldobler B., 1990, pi; KANG SY, 1985, KOREAN J ALLERGY, V5, P183; Kim Byung-Jin, 1998, Korean Journal of Entomology, V28, P145; Kim Si-Chan, 1992, Yonsei Medical Journal, V33, P281; PARKER KD, 1996, GREAT PLAINS QUART, V16, P83	6	32	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				879	882		10.1016/S0091-6749(99)70302-7	http://dx.doi.org/10.1016/S0091-6749(99)70302-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518836				2022-12-18	WOS:000083281200023
J	Aul, DJ; Bhaumik, A; Kennedy, AL; Brown, WE; Lesage, J; Malo, JL				Aul, DJ; Bhaumik, A; Kennedy, AL; Brown, WE; Lesage, J; Malo, JL			Specific IgG response to monomeric and polymeric diphenylmethane diisocyanate conjugates in subjects with respiratory reactions to isocyanates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; iscyanates; specific IgE; specific IgG	INHALATION CHALLENGE TESTS; OCCUPATIONAL ASTHMA; HYPERSENSITIVITY PNEUMONITIS; HEXAMETHYLENE DIISOCYANATE; ANTIBODIES; WORKERS; MDI; ALVEOLITIS; EXPOSURE; SERUM	Background: Isocyanates are a frequent cause of occupational asthma and can also induce hypersensitivity pneumonitis. Objectives: It is still unclear whether antibodies to diphenylmethane diisocyanate (MDI), which are elicited in some subjects with these conditions, are specific for this type of isocyanate, Moreover, preparation of conjugates to human serum albumin (HSA) with the polymeric formulation rather than monomeric MDI might result in improved detection of antibodies. Methods: We addressed these issues by testing the sera of 13 subjects with asthma (n = 12) and hypersensitivity pneumonitis (n = 1) induced by MDI (n = 4 or 5, see below) by comparing them with sera obtained from subjects with occupational asthma caused by toluene diisocyanate (TDI; n = 5) and hexamethylene diisocyanate (HDI; n = 2), Conjugate preparations were compared by using SDS-PAGE, absorbance spectral analysis, and isolectric focusing. Immunologic screening was done by ELISA. Results: Specific IgG antibodies that recognize MDI-HSA conjugates mere detected in all but 1 of the MDI-exposed workers and could not be found in TDI-exposed and HDI-exposed workers, The levels of specific IgG antibodies were more elevated when tested against the HSA conjugates formed with polymeric MDI compared with the HSA conjugates formed with monomeric MDI, Conclusion: This study shows that specific IgG antibodies to MDI appear to be specific for MDI without cross-reactivity with TDI and HDI and higher by use of polymeric rather than monomeric MDI-HSA test antigens.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15260 USA; Inst Rech Sante & Secut Travail, Montreal, PQ, Canada	Universite de Montreal; Carnegie Mellon University	Malo, JL (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 West Gouin, Montreal, PQ H4J 1C5, Canada.							BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BAUR X, 1995, J ALLERGY CLIN IMMUN, V95, P1004, DOI 10.1016/S0091-6749(95)70101-X; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; Bernstein David I., 1993, P93; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; Engrall E, 1971, IMMUNOCHEMISTRY, V8, P871; FUCHS S, 1951, Arch Mal Prof, V12, P191; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V86, P94, DOI 10.1016/S0091-6749(05)80128-9; KAROL MH, 1994, AM J RESP CRIT CARE, V149, P611, DOI 10.1164/ajrccm.149.3.8118626; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESAGE J, 1992, AM IND HYG ASSOC J, V53, P146, DOI 10.1202/0002-8894(1992)053<0146:WETI>2.0.CO;2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; MALO JL, 1982, AM REV RESPIR DIS, V125, P113; MALO JL, 1996, OCCUPATIONAL ENV RES, P55; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; OBRIEN IM, 1979, CLIN ALLERGY, V9, P7, DOI 10.1111/j.1365-2222.1979.tb01517.x; PATTERSON R, 1987, INT ARCH ALLER A IMM, V84, P93, DOI 10.1159/000234404; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; VANDENPLAS O, 1993, AM REV RESPIR DIS, V147, P338, DOI 10.1164/ajrccm/147.2.338; VANDENPLAS O, 1993, J ALLERGY CLIN IMMUN, V91, P850, DOI 10.1016/0091-6749(93)90342-D; VANDENPLAS O, 1993, BRIT J IND MED, V50, P213; VANDENPLAS O, 1992, AM REV RESPIR DIS, V145, P582, DOI 10.1164/ajrccm/145.3.582; VANDENPLAS O, 1992, J ALLERGY CLIN IMMUN, V89, P1183, DOI 10.1016/0091-6749(92)90303-J; WALKER CL, 1989, J OCCUP ENVIRON MED, V31, P315; WELINDER H, 1988, CLIN ALLERGY, V18, P85, DOI 10.1111/j.1365-2222.1988.tb02847.x; WOODS G, 1990, ICI URETHANES BOOK, P10	30	32	33	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				749	755		10.1016/S0091-6749(99)70415-X	http://dx.doi.org/10.1016/S0091-6749(99)70415-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329805				2022-12-18	WOS:000080470200005
J	Vliagoftis, H; Hutson, AM; Mahmudi-Azer, S; Kim, H; Rumsaeng, V; Oh, CK; Moqbel, R; Metcalfe, DD				Vliagoftis, H; Hutson, AM; Mahmudi-Azer, S; Kim, H; Rumsaeng, V; Oh, CK; Moqbel, R; Metcalfe, DD			Mast cells express connexins on their cytoplasmic membrane	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; connexins; gap junctions; fibroblasts; cell communication	GAP JUNCTIONAL COMMUNICATION; EPITHELIAL-CELLS; MESSENGER-RNA; FIBROBLASTS; RAT; LIVER; BETA; GROWTH; IL-3; MICE	Background: Because of the close association between mast cells and fibroblasts in the microenvironment and the importance of connexins (Cxs) in fibroblast communication with other cells, we hypothesized that mast cells also express Cxs, allowing them to similarly communicate with other cells through gap junctions. Objectives: We sought to identify the expression of Cxs (particularly Cx43, Cx32, and Cx26) by murine mast cells. Methods: The expression of Cxs was studied by RT-PCR, Northern blot analysis, Western blot analysis, flow cytometry, and confocal laser scanning microscopy. Results: In this report we demonstrate that murine bone marrow cultured mast cells and the growth factor-independent murine mast cell line C57, express Cx43 and Cx32 as assessed by RT-PCR, Northern blot analysis, Western blot analysis, and flow cytometry, but do not express Cx26, We also show, by confocal laser scanning microscopy, that Cx43 localizes to the cytoplasmic membrane of mast cells in a pattern similar to that seen in fibroblasts, Conclusions: Mast cells express Cx43 and Cx32, and Cx43 is associated with the cytoplasmic membrane, suggesting that mast cells have the potential to communicate with other cells in their microenvironment in part through gap junctions.	Univ Alberta, Dept Med, Pulm Res Grp, Edmonton, AB T6G 2S2, Canada; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA	University of Alberta; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Vliagoftis, H (corresponding author), Univ Alberta, Dept Med, Pulm Res Grp, 574 HMRC, Edmonton, AB T6G 2S2, Canada.		Vliagoftis, Harissis/C-6480-2013	Vliagoftis, Harissis/0000-0002-5029-855X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000513, Z01AI000513] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI S, 1992, BLOOD, V79, P650; ALVES LA, 1995, EUR J IMMUNOL, V25, P431, DOI 10.1002/eji.1830250219; BEYER EC, 1991, J BIOL CHEM, V266, P7971; Cho JJ, 1998, BIOCHEM BIOPH RES CO, V242, P226, DOI 10.1006/bbrc.1997.7644; DASTYCH J, 1994, J IMMUNOL, V152, P213; GINSBURG H, 1982, IMMUNOLOGY, V45, P371; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; Gruber BL, 1997, J IMMUNOL, V158, P2310; JARA PI, 1995, P NATL ACAD SCI USA, V92, P7011, DOI 10.1073/pnas.92.15.7011; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KURAOKA A, 1993, J HISTOCHEM CYTOCHEM, V41, P971, DOI 10.1177/41.7.8390496; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; Nelles E, 1996, P NATL ACAD SCI USA, V93, P9565, DOI 10.1073/pnas.93.18.9565; Oliani SM, 1995, ACTA ANAT, V154, P267; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; POLACEK D, 1993, AM J PATHOL, V142, P593; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; RAZIN E, 1991, J IMMUNOL, V146, P981; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; ROTTEM M, 1993, J IMMUNOL, V151, P4950; RUCH RJ, 1994, CARCINOGENESIS, V15, P301, DOI 10.1093/carcin/15.2.301; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; SULLIVAN R, 1995, J CELL BIOL, V130, P419, DOI 10.1083/jcb.130.2.419; TSAI M, 1996, FASEB J, V10, pA1218	25	32	34	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					656	662		10.1016/S0091-6749(99)70239-3	http://dx.doi.org/10.1016/S0091-6749(99)70239-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200016				2022-12-18	WOS:000079723900020
J	Kohno, Y; Minoguchi, K; Oda, N; Yokoe, T; Yamashita, N; Sakane, T; Adachi, M				Kohno, Y; Minoguchi, K; Oda, N; Yokoe, T; Yamashita, N; Sakane, T; Adachi, M			Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; rush immunotherapy; T-H2 cell; mast cell; IL-5; eosinophil; airway inflammation; airway hyperresponsiveness; late asthmatic response	GRASS-POLLEN IMMUNOTHERAPY; DUST MITE IMMUNOTHERAPY; DERMATOPHAGOIDES-PTERONYSSINUS; CONTROLLED TRIAL; INDUCED SPUTUM; T-LYMPHOCYTES; MESSENGER-RNA; ATOPIC ASTHMA; IFN-GAMMA; CELLS	Background: Rush immunotherapy (RIT) has been shown to be effective in allergic asthma. Objective: We investigated the mechanisms of RIT on the basis of cytokine production by T-cell lines and airway inflammation and responsiveness. Methods: Subjects were 8 patients with house dust mite-allergic asthma treated with dust mite extract RIT for 6 months and 6 RIT-untreated control patients. IL-5 production by Dermatophagoides farinae-specific T-cell lines, eosinophil percentages, and eosinophil cationic protein (ECP) in induced sputum and airway responsiveness to allergen and histamine were evaluated before and after treatment. Changes in eosinophil percentages and ECP in induced sputum and responsiveness to histamine 24 hours after allergen inhalation were also studied. Results: After 6 months of RIT, percentages of total eosinophils (43.0% +/- 6.90% to 16.8% +/- 2.48%; P < .01), percentages of EG(2+) eosinophils (32.6% +/- 6.39% to 19.7% +/- 4.68%; P < .01) and ECP (362.7 +/- 125.3 ng/mL to 26.2 +/- 5.15 ng/mL; P < .05) decreased in induced sputum, and IL-5 production by T-cell lines decreased (617 +/- 93.2 pg/mL to 200.0 +/- 34.1 pg/mL; P < .01). RIT decreased both early- and late-phase bronchoconstriction (early phase: 33.2% +/- 3.46% to 25.4% +/- 1.42%; P < .03; late phase: 16.2% +/- 3.52% to 6.2% +/- 1.96%; P < .03) and suppressed increases in the percentages of total (61.8% +/- 4.89% to 42.0% +/- 4.67%; P < .01) and EG2-positive eosinophils (55.54% +/- 7.21% to 36.5% +/- 6.43%; P < .01) and ECP (685.6 +/- 217.0 ng/mL to 85.4 +/- 23.4 ng/mL; P < .05) in induced sputum after allergen inhalation. RIT also decreased airway responsiveness to dust mite (1:303.7 +/- 123.7 wt/vol to 1:65.0 +/- 13.2 wt/vol; P < .03) and to histamine before (397.1 +/- 206.9 mu g/mL to 1391.3 +/- 283.3 mu g/mL; P < .03) and after allergen inhalation (139.2 +/- 36.5 mu g/mL to 629.1 +/- 196.3 pg/mL; P < .03). Conclusion: RIT decreases airway inflammation and airway hyperresponsiveness before and after bronchial provocation with allergen, possibly by inhibiting both allergen-specific T-cell- and mast cell-dependent pathways. RIT is an effective antiinflammatory treatment in allergic asthma.	Showa Univ, Sch Med, Dept Internal Med, Shinagawa Ku, Tokyo 142, Japan; St Marianna Univ, Dept Immunol & Med, Kanagawa, Japan	Showa University; Saint Marianna University	Minoguchi, K (corresponding author), Showa Univ, Sch Med, Dept Internal Med, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.							ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; Charlesworth EN, 1996, J ALLERGY CLIN IMMUN, V98, pS291, DOI 10.1016/S0091-6749(96)80114-X; Costa JCT, 1996, ALLERGY, V51, P238, DOI 10.1111/j.1398-9995.1996.tb04599.x; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JUTEL M, 1995, J IMMUNOL, V154, P4187; Keatings VM, 1997, J ALLERGY CLIN IMMUN, V99, P693, DOI 10.1016/S0091-6749(97)70032-0; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAGATA M, 1994, J ALLERGY CLIN IMMUN, V94, P160, DOI 10.1016/0091-6749(94)90035-3; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; PERONI DG, 1995, ALLERGY, V50, P925, DOI 10.1111/j.1398-9995.1995.tb02500.x; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SHALIT M, 1995, CLIN EXP ALLERGY, V25, P896, DOI 10.1111/j.1365-2222.1995.tb00033.x; SMITH H, 1992, CLIN EXP ALLERGY, V22, P187, DOI 10.1111/j.1365-2222.1992.tb03072.x; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399, DOI 10.1111/j.1365-2222.1989.tb02405.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; YASUEDA H, 1991, Japanese Journal of Allergology, V40, P1218	33	32	35	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				927	934		10.1016/S0091-6749(98)70330-6	http://dx.doi.org/10.1016/S0091-6749(98)70330-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847433	Bronze			2022-12-18	WOS:000077690700010
J	Slater, JE; Paupore, EJ; Elwell, MR; Truscott, W				Slater, JE; Paupore, EJ; Elwell, MR; Truscott, W			Lipopolysaccharide augments IgG and IgE responses of mice to the latex allergen Hev b 5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; endotoxin; lipopolysaccharide; mouse; IgE; IgG1; T-H1; T-H2	INHALED ENDOTOXIN; MACROPHAGES; INDUCTION; ANTIGENS; IL-4	Background: LPS is a common contaminant in the health care environment and in latex examination gloves. Objective: We sought to investigate the role of LPS in enhancing the immune responses of mice to inhaled latex allergen. Methods: As our model allergen, we used a fusion protein containing the potent latex allergen Hev b 5. BALB/c mice were lightly anesthetized and given repeated intranasal doses of saline, LPS, and/or Hev b 5. The doses were given in 2 courses separated by a 6-week period, with the first course consisting of 6 doses and the second consisting of 3 doses. Results: After the first set of immunizations, mice given Hev b 5 alone had no detectable IgG1 or IgE responses to Hev b 5, whereas mice given the antigen along with LPS had significant responses (IgG1, 0.73 U +/- 0.05; IgE, 0.88 U +/- 0.2). No enhancement of specific IgG2a was observed. A stimulatory effect of LPS on all 3 immunoglobulin types was apparent after the second course. Lymphocytes from mice immunized with LPS and Hev b 5 had increased proliferation to Hev b 5 and its fusion partner. Conclusions: LPS may be an important immunoadjuvant for the development of allergic reactions to latex protein allergens.	Childrens Natl Med Ctr, Childrens Res Inst, Ctr Mol Mech Dis Res, Washington, DC USA; Expt Pathol Labs Inc, Herndon, VA USA; Safeskin Corp, San Diego, CA USA	Children's National Health System	Slater, JE (corresponding author), US FDA, Ctr Biol Evaluat & Res, Lab Immunobiochem, 1401 Rockville Rd, Rockville, MD 20852 USA.							Bellezzo JM, 1996, AM J PHYSIOL-GASTR L, V270, pG956, DOI 10.1152/ajpgi.1996.270.6.G956; DANNEMAN PJ, 1976, CELL IMMUNOL, V22, P128, DOI 10.1016/0008-8749(76)90014-9; DeKruyff RH, 1997, J IMMUNOL, V158, P359; FREUDENBERG MA, 1989, INFECTION, V17, P322, DOI 10.1007/BF01650719; HERBEIN G, 1995, CLIN EXP IMMUNOL, V102, P430; MANDLER R, 1993, J IMMUNOL, V150, P407; MCINTYRE TM, 1995, J IMMUNOL, V154, P3156; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; MICHEL O, 1995, CLIN EXP ALLERGY, V25, P73, DOI 10.1111/j.1365-2222.1995.tb01005.x; MILTON DK, 1995, AM J IND MED, V28, P469, DOI 10.1002/ajim.4700280404; MORENO E, 1984, INFECT IMMUN, V46, P74, DOI 10.1128/IAI.46.1.74-80.1984; Salkowski CA, 1997, INFECT IMMUN, V65, P3239, DOI 10.1128/IAI.65.8.3239-3247.1997; Simpson AECM, 1997, INFLAMM RES, V46, P65, DOI 10.1007/s000110050078; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V93, P825, DOI 10.1016/0091-6749(94)90372-7; SNAPPER CM, 1991, J IMMUNOL, V147, P1163; VIJAY HM, 1984, INT ARCH ALLER A IMM, V74, P232, DOI 10.1159/000233549; Wesselius LJ, 1997, J LAB CLIN MED, V129, P106, DOI 10.1016/S0022-2143(97)90167-0; Williams PB, 1997, ANN ALLERG ASTHMA IM, V79, P303, DOI 10.1016/S1081-1206(10)63019-0; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X; Zimmer S., 1996, Journal of Burn Care and Rehabilitation, V17, P491, DOI 10.1097/00004630-199611000-00004	23	32	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				977	983		10.1016/S0091-6749(98)70336-7	http://dx.doi.org/10.1016/S0091-6749(98)70336-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847439	Bronze			2022-12-18	WOS:000077690700016
J	Helbling, A; Gayer, F; Pichler, WJ; Brander, KA				Helbling, A; Gayer, F; Pichler, WJ; Brander, KA			Mushroom (basidiomycete) allergy: Diagnosis established by skin test and nasal challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basidiomycetes; Pleurotus pulmonalis; Coprinus comatus; respiratory allergy; allergens; sensitization; diagnosis; nasal provocation test; immunoblot	CROSS-REACTIVE IGE; RESPIRATORY ALLERGY; MOLD ALLERGY; ASTHMA; DETERMINANTS; SYMPTOMS; EXTRACTS; POLLEN; ANTIBODIES; PREVALENCE	Background: Fungal spores are universal components in the air and established as important causes of respiratory allergies. Whereas fungi imperfecti are accepted sources of allergic asthma and rhinitis, the significance of basidiomycetes as respiratory allergens is not established. Objectives: The aims of the present study were to investigate the rate of sensitization in subjects referred to an allergy clinic to 3 basidiomycetes commonly found in Europe. We demonstrate the clinical relevance of basidiomycete sensitization by active anterior rhinomanometry and identified basidiomycete allergens by immunoblotting. Methods and Results: Consecutive outpatient clinic attendees (n = 1207, >12 years of age) were given the skin prick test with a panel of common inhalant allergens and extracts of Boletus, Coprinus, and Pleurotus. To evaluate a cause-and-effect relation between basidiomycete allergens and respiratory allergies, 12 Pleurotus pulmonalis spore-sensitized subjects with respiratory symptoms and 6 control subjects were challenged by anterior rhinomanometry. SDS-PAGE immunoblots were used to identify basidiomycete-specific IgE antibodies in sera from subjects with positive skin prick test results. Of 1207 subjects tested, 48 (4%) reacted to at least 1 of the basidiomycete extracts. Whereas all of the 12 subjects with Pleurotus pulmonalis-positive skin test results showed a significant decrease in nasal air flow (mean 73%), none of the control subjects reacted, Immunoblots revealed several different IgE-binding proteins in Pleurotus and Coprinus extracts. Conclusions: Our results demonstrate that sensitization to basidiomycetes in subjects with respiratory allergies is frequent. Furthermore, Pleurotus pulmonalis spore extracts can definitely induce respiratory allergy in sensitized subjects, Immunoblot assays disclosed different IgE-reactive hands indicating the existence of basidiomycete allergens.	Univ Hosp Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Helbling, A (corresponding author), Univ Hosp Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland.			Pichler, Werner J./0000-0002-8117-359X				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Baldo B.A., 1989, PROTEIN BLOTTING MET; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BUTCHER BT, 1987, J ALLERGY CLIN IMMUN, V80, P803, DOI 10.1016/S0091-6749(87)80269-5; Clement P A, 1984, Rhinology, V22, P151; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; DEZUBIRIA A, 1990, J ALLERGY CLIN IMMUN, V86, P26, DOI 10.1016/S0091-6749(05)80119-8; Epton MJ, 1997, THORAX, V52, P528, DOI 10.1136/thx.52.6.528; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P342; HELBLING A, 1993, INT ARCH ALLERGY IMM, V100, P263, DOI 10.1159/000236422; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LOPEZ M, 1989, J ALLERGY CLIN IMMUN, V84, P242, DOI 10.1016/0091-6749(89)90331-X; MALLING HJ, 1986, ALLERGY, V41, P342, DOI 10.1111/j.1398-9995.1986.tb00311.x; Malling HJ., 2003, ALLERGY, V48, P55; ONEIL CE, 1988, INT ARCH ALLER A IMM, V85, P161, DOI 10.1159/000234496; ONEIL CE, 1990, CLIN EXP ALLERGY, V20, P533, DOI 10.1111/j.1365-2222.1990.tb03146.x; SANTILLI J, 1985, ANN ALLERGY, V55, P469; SASTRE J, 1990, CLIN EXP ALLERGY, V20, P13, DOI 10.1111/j.1365-2222.1990.tb02769.x; SINGH AB, 1995, CLIN EXP ALLERGY, V25, P440, DOI 10.1111/j.1365-2222.1995.tb01075.x; TORICELLI R, 1997, ALLERGY, V52, P747; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; WILKENJENSN K, 1984, ATLAS MOULDS EUROPE	27	32	32	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					853	858		10.1016/S0091-6749(98)70028-4	http://dx.doi.org/10.1016/S0091-6749(98)70028-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819305	Bronze			2022-12-18	WOS:000077033400022
J	Frew, A; Chang, JH; Chan, H; Quirce, S; Noertjojo, K; Keown, P; Chan-Yeung, M				Frew, A; Chang, JH; Chan, H; Quirce, S; Noertjojo, K; Keown, P; Chan-Yeung, M			T-lymphocyte responses to plicatic acid human serum albumin conjugate in occupational asthma caused by western red cedar	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; T-lymphocytes; cell-mediated immunity; occupational asthma; immediate hypersensitivity; cytokines; flow cytometry	TOLUENE DIISOCYANATE TDI; TRIMELLITIC ANHYDRIDE; ATOPIC ASTHMA; LUNG INJURY; CELLS; INTERLEUKIN-5; MECHANISMS; REACTIVITY; GAMMA	Background: T cells are known to play a major role in the pathogenesis of atopic allergic asthma, but it is less clear whether they are involved in occupational asthma caused by low molecular weight chemicals such as plicatic acid. Objectives: We sought to determine whether peripheral blood T cells from patients with western red cedar asthma (WRCA) recognize plicatic acid (PA) conjugated to human serum albumin (HSA) as judged by proliferation or cytokine production and to analyze the response to PA inhalation with flow cytometry. Results: Significant proliferative responses to PA-HSA were observed in eight of 33 patients with WRCA, none of 10 exposed nonasthmatic cedar workers, and one of 18 nonasthmatic control subjects. Two of 25 patients with WRCA also showed proliferative responses to unconjugated PA. All the WRCA responders were either currently exposed to cedar or had ceased exposure within the preceding 2 years. None of the four patients receiving oral steroids responded, but inhaled steroids did not seem to influence responsiveness. No correlations were found between the maximum stimulation response and any of the current FEV1 values, the current PC20 methacholine values, or the magnitude of the late asthmatic response to PA. Peripheral blood T-cell subset proportions and their degree of activation were similar in patients with WRCA and exposed control subjects. There was no change in T-cell phenotypes or their activation markers after PA inhalation challenge. In vitro, PA-HSA stimulation did not affect subset ratios but led to release of small amounts of IL-5 and IFN-gamma, with no detectable increase in IL-4. Conclusions: PA-HSA-specific T lymphocytes seem to be present in small numbers in the peripheral blood of patients with WRCA and may respond to antigenic exposure by producing IFN-gamma and IL-5, However, the proportion of responding cells would appear to be lower than in comparable studies of atopic asthma.	Univ Southampton, Southampton, Hants, England; Univ British Columbia, Dept Med, Div Resp, Vancouver, BC, Canada; Univ British Columbia, Vancouver Gen Hosp, Dept Med, Vancouver, BC V5Z 1M9, Canada	University of Southampton; University of British Columbia; University of British Columbia	Frew, A (corresponding author), Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.		Kelly, Frank J/C-6125-2009; s, q/AAD-7171-2020; Noertjojo, Kukuh/H-6806-2019	Kelly, Frank J/0000-0003-2558-8392; 				AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; Borish L, 1997, J ALLERGY CLIN IMMUN, V99, P161, DOI 10.1016/S0091-6749(97)70090-3; Chang JH, 1996, J ALLERGY CLIN IMMUN, V98, P922, DOI 10.1016/S0091-6749(96)80008-X; CHANYEUNG M, 1971, CAN MED ASSOC J, V105, P56; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1103; CORRIGAN CJ, 1988, LANCET, V1, P1129; CORRIGAN CJ, 1995, ASTHMA RHINITIS, P450; DOLOVICH J, 1984, BRIT J IND MED, V41, P51; FREW A, 1993, J ALLERGY CLIN IMMUN, V92, P466, DOI 10.1016/0091-6749(93)90126-Z; FREW AJ, 1992, J ALLERGY CLIN IMMUN, V89, P783, DOI 10.1016/0091-6749(92)90431-Z; FREW AJ, 1995, AM J RESP CRIT CARE, V151, P340, DOI 10.1164/ajrccm.151.2.7842189; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; Holtzman MJ, 1996, AM J RESP CELL MOL, V14, P316, DOI 10.1165/ajrcmb.14.4.8600934; JUNG T, 1995, EUR J IMMUNOL, V25, P2413, DOI 10.1002/eji.1830250843; KAY AB, 1991, CLIN EXP ALLERGY, V21, P23, DOI 10.1111/j.1365-2222.1991.tb01760.x; KIPS JC, 1997, CLIN ASTHMA REV, V1, P45; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; KUSAKA Y, 1989, IND HEALTH, V27, P155, DOI 10.2486/indhealth.27.155; LEACH CL, 1988, AM REV RESPIR DIS, V137, P186, DOI 10.1164/ajrccm/137.1.186; MAESTRELLI P, 1993, J ALLERGY CLIN IMMUN, V91, P220; MAPP CE, 1994, EUR RESPIR J, V7, P544, DOI 10.1183/09031936.94.07030544; MOIRA CY, 1989, J ALLERGY CLIN IMMUN, V84, P762, DOI 10.1016/0091-6749(89)90306-0; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; PAGANO M, 1993, PRINCIPLES BIOSTATIS; PAULY JL, 1973, J LAB CLIN MED, V82, P500; PIEN LC, 1988, J ALLERGY CLIN IMMUN, V82, P1098; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; VICKERS MR, 1974, IMMUNOLOGY, V26, P425; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1	39	32	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				841	847		10.1016/S0091-6749(98)70313-6	http://dx.doi.org/10.1016/S0091-6749(98)70313-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648713				2022-12-18	WOS:000074414200020
J	Smith, AM; Chapman, MD; Taketomi, EA; Platts-Mills, TAE; Sung, SSJ				Smith, AM; Chapman, MD; Taketomi, EA; Platts-Mills, TAE; Sung, SSJ			Recombinant allergens for immunotherapy: A Der p 2 variant with reduced IgE reactivity retains T-cell epitopes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Univ Virginia, Sch Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Med, Div Rheumatol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Smith, AM (corresponding author), Univ Virginia, Sch Med, Asthma & Allerg Dis Ctr, Box 225, Charlottesville, VA 22908 USA.		Taketomi, Ernesto A/M-5717-2013	Taketomi, Ernesto A/0000-0003-4854-6822; Platts-Mills, Thomas/0000-0002-1263-329X; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032557, R01AI020565, R37AI020565, U19AI034607, U01AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-32557, AI-34607, AI-20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; Smith AM, 1997, CLIN EXP ALLERGY, V27, P593, DOI 10.1111/j.1365-2222.1997.tb00750.x; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SMITH AM, IN PRESS IMMUNOTHERA; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754	5	32	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					423	425		10.1016/S0091-6749(98)70259-3	http://dx.doi.org/10.1016/S0091-6749(98)70259-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525463				2022-12-18	WOS:000072593900024
J	Hoffman, DR				Hoffman, DR			Reactions to less common species of fire ants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; amino acid sequence; anaphylaxis; cross-reaction; fire ant; Sol r 2; Sol r 3; venom	AMINO-ACID-SEQUENCES; HYMENOPTERA VENOM; SOLENOPSIS-INVICTA; ALLERGENS; FORMICIDAE; HYBRIDIZATION; POPULATIONS; RICHTERI	Background: There are four species of fire ants found in the United States in addition to the most common, Solenopsis invicta. Reactions have been reported from stings of each of these species, but large numbers of insects and adequate amounts of venom for study are very difficult to obtain. Methods: Venom was obtained, the purified allergens were isolated, and the complete amino acid sequences were determined for two of the three allergens from S. richteri. Skin testing and RAST studies were performed on patients with reactions to native fire ant stings and analyzed in comparison with clinical history. Results: The structures of S. richteri allergens have a high degree of similarity to S. invicta allergens. The Sol 2 allergens are less related to each other than either the Sol 1 (phospholipase AB) or Sol 3 (antigen 5) allergens. Patients sensitized to native species of fire ants react primarily to the Sol 1 and Sol 3 allergens, whereas those originally sensitized to S. invicta also react significantly to the Sol 2 and Sol 4 allergens. Some patients are initially sensitized to S. invicta and have life-threatening reactions to stings of native species. The tropical fire ant, S. geminata, has become a serious problem in some areas of the Pacific and South Asia, especially Okinawa and Guam. Conclusions: The venoms from all of the species of fire ants examined appear to be highly cross-reactive. S. invicta imported fire ant venom extracts are probably sufficient for diagnosis and may warrant a clinical trial for immunotherapy of allergic reactions to venoms of any of the other four species.			Hoffman, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL & LAB MED,GREENVILLE,NC 27858, USA.							DIFFIE S, 1988, J ENTOMOL SCI, V23, P187, DOI 10.18474/0749-8004-23.2.187; ELLIS MH, 1992, J ALLERGY CLIN IMMUN, V89, P293; ETTERSHANK G., 1966, AUSTRALIAN J ZOOL, V14, P73, DOI 10.1071/ZO9660073; Helmly R B, 1970, Hawaii Med J, V29, P368; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1995, ALLERGY, V50, P535, DOI 10.1111/j.1398-9995.1995.tb01196.x; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1990, J ALLERGY CLIN IMMUN, V85, P988, DOI 10.1016/0091-6749(90)90042-3; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; Lofgren C.S., 1986, FIRE ANTS LEAF CUTTI, V1st; Perfecto I, 1996, OECOLOGIA, V108, P577, DOI 10.1007/BF00333736; ROSS KG, 1987, EVOLUTION, V41, P280, DOI 10.1111/j.1558-5646.1987.tb05797.x; TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7; VANDERMEER RK, 1988, FLA ENTOMOL, V71, P323, DOI 10.2307/3495440; VANDERMEER RK, 1989, J CHEM ECOL, V15, P1757, DOI 10.1007/BF01012263; VANDERMEER RK, 1985, FLA ENTOMOL, V68, P501, DOI 10.2307/3495147; WEISS S J, 1990, Journal of Allergy and Clinical Immunology, V85, P212; [No title captured]	20	32	40	1	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					679	683		10.1016/S0091-6749(97)70173-8	http://dx.doi.org/10.1016/S0091-6749(97)70173-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389299				2022-12-18	WOS:A1997YG20200016
J	Rolla, G; Colagrande, P; Scappaticci, E; Bottomicca, F; Magnano, M; Brussino, L; Dutto, L; Bucca, C				Rolla, G; Colagrande, P; Scappaticci, E; Bottomicca, F; Magnano, M; Brussino, L; Dutto, L; Bucca, C			Damage of the pharyngeal mucosa and hyperresponsiveness of airway in sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; airway hyperresponsiveness; pharyngeal pathology; pharyngeal innervation; pharyngobronchial reflexes	BRONCHIAL-ASTHMA; RESPIRATORY-TRACT; MILD ASTHMA; INFLAMMATION; EOSINOPHIL; DISEASE; CELLS	Background: In sinusitis bronchoconstriction is supposed to originate from pharyngobronchial reflexes triggered bg seeding of the inflammatory process into the pharynx. Objective: Our aim was to evaluate whether in sinusitis bronchial and extrathoracic airway (EA) dysfunction correlate with morphologic abnormalities of the pharyngeal mucosa. Methods: We performed histamine inhalation challenge, nasal lavage, and nasophanyngeal biopsies in 24 nonasthmatic patients with exacerbation of chronic sinusitis. The histamine PC20 was the threshold of bronchial responsiveness, and that causing 25% fall in maximal midinspiratory flow was the threshold of EA responsiveness (PC25MIF50). Thresholds of 8 mg/ml or less were assumed to indicate bronchial hyperresponsiveness (BHR) or EA hyperresponsiveness (EAHR). PC20 and PC25MIF50 values were related to clinical data. nasal lavage fluid eosinophils, pharyngeal epithelium and basement membrane thickness, and density of submucosal vessels and nervous fibers. Results: The PC20 was closely related to PC25MIF50 (p = 0.0004). Ten patients had EAHR, 9 had combined EAHR and BHR, and 5 had neither EAHR nor BHR. EAHR was strongly associated with epithelial thinning, and BHR with long-standing sinusitis, a lower PC25MIF50, increased submucosal nerve density and increased nasal lavage fluid eosinophils. Conclusions: Our findings suggest that in nonasthmatic patients with sinusitis, pharyngeal damage may contribute to airway dysfunction by favoring the access of irritants to submucosal nerve endings, with activation of constrictive reflexes to the EA. Proliferation of sensory neurons, consequent to long-lasting pharyngeal inflammation, may cause more severe EA narrowing and activate pharyngobronchial reflexes.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,I-10126 TURIN,ITALY; OSPED MAGGIORE S GIOVANNI BATTISTA,TURIN,ITALY	University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette			Rolla, Giovanni/C-9901-2009; Bucca, Caterina/C-9886-2009; brussino, luisa/J-2486-2012	Rolla, Giovanni/0000-0001-5997-7172; Bucca, Caterina/0000-0002-9941-9236; brussino, luisa/0000-0001-7249-7616				ADINOFF AD, 1987, SEMIN RESPIR MED, V8, P308, DOI 10.1055/s-2007-1012669; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BORSON DB, 1989, J APPL PHYSIOL, V66, P2653, DOI 10.1152/jappl.1989.66.6.2653; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; BUCCA C, 1995, LANCET, V346, P791, DOI 10.1016/S0140-6736(95)91617-2; BURROWS B, 1989, NEW ENGL J MED, V320, P171; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FILLEY WV, 1982, LANCET, V2, P11; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HARGREAVE FE, 1985, AIRWAY RESPONSIVENES, P122; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; IRVIN CG, 1992, J ALLERGY CLIN IMMUN, V90, P521, DOI 10.1016/0091-6749(92)90179-6; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V8, P1; OGURA JH, 1971, ACTA OTO-LARYNGOL, V71, P123, DOI 10.3109/00016487109125340; OGURA JH, 1964, ANN OTO RHINOL LARYN, V73, P381, DOI 10.1177/000348946407300211; OLLERENSHAW SL, 1991, EUR RESPIR J, V4, P673; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; VANHOUTTE PM, 1989, J ALLERGY CLIN IMMUN, V83, P885; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	28	32	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					52	57		10.1016/S0091-6749(97)70194-5	http://dx.doi.org/10.1016/S0091-6749(97)70194-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257787				2022-12-18	WOS:A1997XP42800009
J	Tamaoki, J; Nakata, J; Takeyama, K; Chiyotani, A; Konno, K				Tamaoki, J; Nakata, J; Takeyama, K; Chiyotani, A; Konno, K			Histamine H-2 receptor-mediated airway goblet cell secretion and its modulation by histamine-degrading enzymes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mucus secretion; histamine receptor; histamine N-methyltransferase; diamine oxidase; asthma	GUINEA-PIG AIRWAYS; NASAL-MUCOSA; TRACHEA; DEGRADATION; EPITHELIUM; ASTHMA	Background: Airway goblet cell hypersecretion may contribute to the pathophysiology of asthma. However, it is unknown whether histamine affects goblet cell secretion and, if so, which subtype of histamine receptor is involved and whether endogenous histamine-degrading enzymes modulate these actions. Methods: We morphometrically assessed goblet cell secretion in the guinea pig trachea stained with alcian blue and periodic acid Schiff stains by measuring the mucus score, which wash inversely related to the degree of mucus glycoprotein discharge. Results: Inhalation of histamine caused a dose-dependent decrease in mucus score, an affect that was inhibited by pretreatment with the H-2-receptor antagonist cimetidine but not with the H-1-receptor antagonist mepyramine or the H-3-receptor antagonist thioperamide. Inhaled Dimaprit, a selective H-2-receptor agonist, likewise decreased mucus score; whereas stimulation of H-1- and H-3-receptors with 2-methylhistamine and (R)-alpha-methylhistamine, respectively, had no effect. Pretreatment with the histamine N-methyltransferase inhibitor SKF 91488, but not the diamine oxidase inhibitor aminoguanidine, potentiated the dose-dependent effect of histamine on goblet cell secretion, causing a decrease in the concentration of inhaled histamine required to produce a half-maximal effect from 0.80 +/- 0.12 to 0.48 +/- 0.09 mg/ml (p < 0.01). The histamine methyltransferase activity in the tracheal mucosa was 29 times higher than diamine oxidase activity. Conclusion: These findings suggest that histamine stimulates airway goblet cell secretion through H-2-receptors and that this effect may be modulate principally by endogenous histamine methyltransferase through a degradation of histamine.			Tamaoki, J (corresponding author), TOKYO WOMENS MED COLL,DEPT MED 1,SHINJUKU KU,8-1 KAWADA CHO,TOKYO 162,JAPAN.							ABE Y, 1993, CLIN EXP ALLERGY, V23, P512, DOI 10.1111/j.1365-2222.1993.tb03239.x; ABE Y, 1993, CLIN EXP ALLERGY, V23, P132, DOI 10.1111/j.1365-2222.1993.tb00308.x; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; Beaven M A, 1978, Monogr Allergy, V13, P1; BEAVEN MA, 1979, AGENTS ACTIONS, V9, P455, DOI 10.1007/BF01968110; BERTACCINI G, 1979, BRIT J PHARMACOL, V66, P13, DOI 10.1111/j.1476-5381.1979.tb16091.x; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BURGAUD JL, 1993, J PHARM PHARMACOL, V45, P955, DOI 10.1111/j.2042-7158.1993.tb05634.x; FUKUDA H, 1991, J CHROMATOGR-BIOMED, V567, P459, DOI 10.1016/0378-4347(91)80152-3; ICHINOSE M, 1989, BRIT J PHARMACOL, V97, P13, DOI 10.1111/j.1476-5381.1989.tb11917.x; LINDSTROM EG, 1991, AGENTS ACTIONS, V33, P170, DOI 10.1007/BF01993158; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDERMOTT RP, 1974, J CLIN INVEST, V54, P545; MCDONALD DM, 1988, J NEUROCYTOL, V17, P583, DOI 10.1007/BF01260988; OHRUI T, 1992, J PHARMACOL EXP THER, V261, P1268; SCHULER W, 1952, EXPERIENTIA, V8, P230, DOI 10.1007/BF02170726; Sekizawa K, 1995, J ALLERGY CLIN IMMUN, V96, P910, DOI 10.1016/S0091-6749(95)70228-8; SEKIZAWA K, 1993, AM REV RESPIR DIS, V147, P92, DOI 10.1164/ajrccm/147.1.92; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; THURLBECK WM, 1975, AM REV RESPIR DIS, V112, P65; TOKUYAMA K, 1990, AM J PHYSIOL, V259, pL108, DOI 10.1152/ajplung.1990.259.2.L108; VERDUGO P, 1990, ANNU REV PHYSIOL, V52, P157, DOI 10.1146/annurev.ph.52.030190.001105; WHITE MV, 1987, AM REV RESPIR DIS, V135, P1165; YAMADA K, 1994, RESP PHYSIOL, V97, P105, DOI 10.1016/0034-5687(94)90015-9; ZEINGER RS, 1976, J ALLERGY CLIN IMMUN, V58, P172	26	32	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					233	238		10.1016/S0091-6749(97)70102-7	http://dx.doi.org/10.1016/S0091-6749(97)70102-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042051				2022-12-18	WOS:A1997WH83100014
J	Harada, Y; Watanabe, S; Yssel, H; Arai, KI				Harada, Y; Watanabe, S; Yssel, H; Arai, KI			Factors affecting the cytokine production of human T cells stimulated by different modes of activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell clone; T-cell receptor signal; T-H1; T-H2; prostaglandin E(2); cyclic adenosine monophosphate nuclear factor of activated T cells; nuclear factor kappa B	NF-KAPPA-B; PROTEIN-KINASE-C; HUMAN LYMPHOCYTES-T; GROWTH FACTOR-BETA; TRANSCRIPTION FACTOR; ANTIGEN RECEPTOR; PHENOTYPE DEVELOPMENT; TYROSINE KINASE; PHORBOL ESTER; HUMAN TH1	According to the widely accepted classification, human T-H cell clones can be divided into two mutually exclusive subsets, T-H1 and T-H2, based on their profile of cytokine production. The intracellular difference between these clones is not clear. To characterize the biochemical nature of T-cell receptor (TCR)/CD3 complex-mediated signal transduction pathways, we introduced several human T-H cell clones of T-H0- or T-H1-like phenotype and analyzed the effects of various drugs and antibodies on cytokine production or proliferation of these clones. The tyrosine kinase inhibitor herbimycin inhibited the production of interferon-gamma (IFN-gamma) by T-H0-like clone, after stimulation with anti-CD3 monoclonal antibody alpha CD3-mAb) or with phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore A23187. However, whereas herbimycin strongly inhibited the production of IL-4 and IL-5 by alpha CD3 mAb stimulated T cells, it did not affect the production of these cytokines after PMA/A23187 stimulation. Cyclosporin A inhibited the proliferation as well as the production of the cytokines, including that of IL-2, IL-4, IL-5, and IFN-gamma, irrespective of the mode of stimulation. A23187, which synergizes with PMA in the induction of IL-4 and IFN-gamma, inhibited PMA-induced IL-10 production in a dose-dependent manner. Transforming growth factor-beta and anti-IL-2 receptor monoclonal antibody partially inhibited alpha CD3 mAb-mediated T-cell proliferation, but has no effect on the proliferation induced by PMA and A23187. Cyclic adenosine monophosphate (cAMP)-elevating drugs, like prostaglandin E(2) and dibutyryl cAMP, inhibited the TCR-mediated cytokine production but shifted the cytokine production profile from a T-H0 to a T-H2 type after stimulation with PMA and A23187. Finally, we analyzed the induction of activity of two transcription factors, nuclear factor-kappa B (NF-kappa B) and nuclear factor of activated T cells, involved in the regulation of cytokine gene expression, after a different mode of activation. The induction of NF-kappa B (p50/p65 heterodimer) by using alpha CD3-mAb stimulation but not by using PMA/A23187 stimulation was found to be inhibited by using cAMP-elevating drugs.	UNIV TOKYO,INST MED SCI,DEPT MOL & DEV BIOL,MINATO KU,TOKYO 108,JAPAN; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT HUMAN IMMUNOL,PALO ALTO,CA 94304	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yssel, Hans/AFV-2907-2022; Yssel, Hans/C-6406-2009	Yssel, Hans/0000-0001-7454-1836; Yssel, Hans/0000-0001-7454-1836				ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BETZ M, 1991, J IMMUNOL, V146, P108; Bours V, 1992, Curr Top Microbiol Immunol, V182, P411; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1993, INT IMMUNOL, V5, P371; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JUNE CH, 1989, J IMMUNOL, V143, P153; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mossmann TR, 1986, J IMMUNOL, V136, P2348; NEL AE, 1990, J IMMUNOL, V144, P2683; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; PALIARD X, 1988, J IMMUNOL, V141, P849; PARK DJ, 1992, J BIOL CHEM, V267, P1496; PHIPPS RP, 1990, IMMUNOL REV, V117, P135, DOI 10.1111/j.1600-065X.1990.tb00571.x; RIEGEL JS, 1990, J IMMUNOL, V144, P3611; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; RONCAROLO MG, 1988, J EXP MED, V168, P2139, DOI 10.1084/jem.168.6.2139; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIMKIN NJ, 1987, J IMMUNOL, V138, P1074; STREET NE, 1990, J IMMUNOL, V144, P1629; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; TADA T, 1991, J IMMUNOL, V146, P1077; TAMIR A, 1994, J IMMUNOL, V152, P3391; WATANABE S, 1994, INT IMMUNOL, V6, P523, DOI 10.1093/intimm/6.4.523; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; YAN MH, 1994, NATURE, V372, P798; YSSEL H, 1992, J IMMUNOL, V149, P2378	48	32	33	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S161	S173		10.1016/S0091-6749(96)70063-5	http://dx.doi.org/10.1016/S0091-6749(96)70063-5			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977524				2022-12-18	WOS:A1996WC44700001
J	DSouza, W; Burgess, C; Ayson, M; Crane, J; Pearce, N; Beasley, R				DSouza, W; Burgess, C; Ayson, M; Crane, J; Pearce, N; Beasley, R			Trial of a ''credit card'' asthma self-management plan in a high-risk group of patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; self-management plan; asthma education	GENERAL-PRACTICE; PEAK FLOW; EDUCATION; PROGRAM; EMERGENCY; SYMPTOMS; RATES	Background: The ''credit card'' asthma self-management plan provides the adult asthmatic patient with sample guidelines for the self-management of asthma, which are based on the self-assessment of peak expiratory flow rate recordings and symptoms. Objective: The study was a trial of the clinical efficacy of the credit card plan in a high-risk group of asthmatic patients. Methods: In this ''before-and-after'' trial, patients discharged from the emergency department of Wellington Hospital, after treatment for severe asthma with invited to attend a series of hospital outpatient clinics at which the credit card plan was introduced. Questionnaires were used to compare markers of asthma morbidity, requirement for emergency medical care, and medication use during the 6-month period before and after intervention with the credit card plant. Results: Of the 30 patients with asthma who attended the first outpatient clinic, 26 (17 women and 9 men) completed the program. In these 26 participants, there was a reduction in both morbidity and requirement for acute medical services: specifically, the proportion waking with asthma more than once a week decreased from 65% to 23% (p = 0.005) and the proportion visiting the emergency department for treatment of severe asthma decreased from 58% to 15% (p = 0.004). The patients attending the clinics commented favorably on the plan, in particular on its usefulness as an educational tool for monitoring and treating their asthma. Conclusions: Although the interpretation of this study is limited by lack of a randomized control groups, the findings are consistent with other evidence that the credit card asthma self-management plant can be an effect and acceptable system for improving asthma care in a high-risk group of adult patients with asthma.	WELLINGTON SCH MED,DEPT MED,WELLINGTON,NEW ZEALAND	University of Otago				D'Souza, Wendyl/0000-0002-1750-5131; Pearce, Neil/0000-0002-9938-7852; Beasley, Richard/0000-0003-0337-406X				BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; Campbell M. J., 1990, MED STAT COMMON SENS; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CHARLTON I, 1994, ARCH DIS CHILD, V70, P313, DOI 10.1136/adc.70.4.313; CLARK NM, 1992, AM REV RESPIR DIS, V145, P722, DOI 10.1164/ajrccm/145.3.722; CRANE J, 1991, 211 DEP HLTH; DALES RE, 1992, ARCH INTERN MED, V152, P2041, DOI 10.1001/archinte.152.10.2041; DSOUZA W, 1994, EUR RESPIR J, V7, P1260, DOI 10.1183/09031936.94.07071260; GARRETT JE, 1989, NEW ZEAL MED J, V102, P121; GARRETT JE, 1988, NEW ZEAL MED J, V101, P359; GARRETT JE, 1988, N Z MED J, V101, P235; HILTON S, 1982, J ROY SOC MED, V75, P625; HILTON S, 1986, LANCET, V1, P26; KOTSES H, 1991, J ASTHMA, V28, P287, DOI 10.3109/02770909109073386; KWONG T, 1989, NEW ZEAL MED J, V102, P547; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P702, DOI 10.1016/0091-6749(93)90189-M; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; MAZZUKA SA, 1982, J CHRON DIS, V35, P226; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MUHLHAUSER I, 1991, J INTERN MED, V230, P157; PESSANO SRW, 1987, J ALLERGY CLIN IMMUN, V80, P487; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; RUBINFIELD AR, 1976, LANCET, V2, P822; *US DEP HHS, 1992, INT CONS REP DIAGN M; YOON R, 1991, THORAX, V46, P886, DOI 10.1136/thx.46.12.886	25	32	32	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1085	1092		10.1016/S0091-6749(96)70262-2	http://dx.doi.org/10.1016/S0091-6749(96)70262-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626986				2022-12-18	WOS:A1996UL26100009
J	Steinberg, P; McNutt, BE; Marshall, P; Schenck, C; Lurie, N; Pheley, A; Peterson, PK				Steinberg, P; McNutt, BE; Marshall, P; Schenck, C; Lurie, N; Pheley, A; Peterson, PK			Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic fatigue syndrome atopy; antihistamines; terfenadine; immediate skin tests; delayed skin tests	EPSTEIN-BARR VIRUS; CONTROLLED TRIAL; ACTIVATION; POPULATION; REACTIVITY; ANTIBODIES; INFECTION; RHINITIS; HEALTH; ADULTS	Background: There is no established treatment for chronic fatigue syndrome (CFS), an illness characterized by disabling fatigue exacerbated by physical activity. A variety of immunologic abnormalities have been reported, including a high incidence of atopy and hypoergy or anergy. Objective: Because of anecdotal reports and uncontrolled trials showing antihistamine efficacy in CFS, we evaluated the clinical efficacy of the antihistamine terfenadine (60 mg twice daily) in a placebo-controlled study. Methods: Thirty patients with CFS were enrolled in a 2-month, double-blind, placebo-controlled trial of terfenadine. Participants underwent a battery of both immediate- and delayed-type hypersensitivity skin tests and completed a self-assessment questionnaire used to measure severity of symptoms, physical and social functioning health perceptions, and mental health before each of six biweekly visits. Results: Twenty-eight patients completed the trial History of atopy and positive immediate skin test results were prevalent, 73% and 53%, respectively. No evidence for hypoergy or anergy after. delayed-type hypersensitivity skin testing was found. No therapeutic benefit from terfenadine could be detected in terms of symptom amelioration, improved physical or social functioning, health perceptions, or mental health. A high incidence of atopy in patients with CFS was confirmed. Conclusion: Although this trial involved a small number of patients, the results suggest that terfenadine is unlikely to be of clinical benefit in treating CFS symptoms.	HENNEPIN CTY MED CTR,DEPT MED,MINNEAPOLIS,MN 55415; HENNEPIN CTY MED CTR,DEPT PSYCHIAT,MINNEAPOLIS,MN 55415; HENNEPIN CTY MED CTR,PROGRAM CLIN EPIDEMIOL EFFECTIVENESS & POLICY,MINNEAPOLIS,MN 55415; MARION MERRELL DOW INC,KANSAS CITY,MO	Hennepin County Medical Center; Hennepin County Medical Center; Hennepin County Medical Center; Dow Chemical Company								BAKHEIT AMO, 1993, ACTA NEUROL SCAND, V87, P234; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; CHANYEUNG M, 1985, ARCH ENVIRON HEALTH, V40, P53, DOI 10.1080/00039896.1985.10545889; CLARK S, 1984, ARTHRITIS RHEUM S, V27, pS76; DAVIS W, 1991, Journal of Allergy and Clinical Immunology, V87, P266, DOI 10.1016/0091-6749(91)91790-Z; DEMITRACK M, 1992, BIOL PSYCHIAT, V32, P1067; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GUPTA S, 1991, SCAND J IMMUNOL, V33, P319, DOI 10.1111/j.1365-3083.1991.tb01777.x; HIRATADULAS CAI, 1994, CHRONIC FATIGUE SYND, P387; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JONES JF, 1987, ANNU REV MED, V38, P195, DOI 10.1146/annurev.med.38.1.195; KEMP JP, 1985, ANN ALLERGY, V54, P502; KNIKER WT, 1984, ANN ALLERGY, V52, P75; KOMAROFF AL, 1991, REV INFECT DIS S1, V13, P8; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; Lipman RS., 1977, SCL 90 MANUAL I SCOR; LLOYD A, 1990, AM J MED, V89, P561, DOI 10.1016/0002-9343(90)90173-B; LLOYD A, 1991, J INFECT DIS, V164, P1023, DOI 10.1093/infdis/164.5.1023; LLOYD AR, 1989, MED J AUSTRALIA, V151, P122, DOI 10.5694/j.1326-5377.1989.tb139594.x; MENI I, 1992, CLIN SCI BASIS MYALG, P432; NORMAN PS, 1992, MANUAL CLIN LABORATO, P685; PETERSON PK, 1991, MINN MED, V74, P21; PETERSON PK, 1990, AM J MED, V89, P554, DOI 10.1016/0002-9343(90)90172-A; RICHELSON E, 1983, MAYO CLIN PROC, V58, P40; RYSTEDT I, 1984, INT ARCH ALLER A IMM, V75, P179, DOI 10.1159/000233610; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V81, P975, DOI 10.1016/0091-6749(88)90164-9; SMITH DL, 1992, MANUAL CLIN LABORATO, P202; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STRANNEGARD IL, 1981, INT ARCH ALLER A IMM, V64, P314, DOI 10.1159/000232709; STRAUS SE, 1988, J ALLERGY CLIN IMMUN, V81, P791, DOI 10.1016/0091-6749(88)90933-5; STRAUS SE, 1988, J INFECT DIS, V157, P405, DOI 10.1093/infdis/157.3.405; STRAUS SE, 1984, ANN INTERN MED, V102, P7; SUHADOLNIK RJ, 1991, 31ST INT C ANT AG CH, pS74; TOBI M, 1982, LANCET, V1, P61; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	38	32	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				119	126		10.1016/S0091-6749(96)70290-7	http://dx.doi.org/10.1016/S0091-6749(96)70290-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568124				2022-12-18	WOS:A1996TR94700015
J	BAUR, X; CZUPPON, A				BAUR, X; CZUPPON, A			DIAGNOSTIC VALIDATION OF SPECIFIC IGE ANTIBODY CONCENTRATIONS, SKIN PRICK TESTING, AND CHALLENGE TESTS IN CHEMICAL WORKERS WITH SYMPTOMS OF SENSITIVITY TO DIFFERENT ANHYDRIDES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACID ANHYDRIDES; IGE ANTIBODY; SKIN PRICK TEST; NASAL CHALLENGE TEST; BRONCHIAL CHALLENGE TEST; OCCUPATIONAL ASTHMA	TRIMELLITIC-ANHYDRIDE; ACID ANHYDRIDES	Background: The diagnostic possibilities of sensitization to various acid anhydrides are limited because of the lack of standardized allergens for the different test systems. This makes the diagnosis of IgE-mediated sensitization caused by occupational exposure difficult. Methods: We prepared conjugates of human serum albumin with phthalic, maleic, trimellitic, and pyromellitic anhydrides to be used for IgE estimation by enzyme-allergosorbent test, skin prick tests, and nasal and bronchial challenge tests. Nine anhydride workers, who complained of various respiratory symptoms, were studied. Results: Of the nine workers, four had immediate-type skin test responses to one or more conjugates. All four subjects had elevated IgE concentrations in addition to two other workers . Three of six nasal challenges and four of nine branchial challenges resulted in positive responses. All but one of the positive nasal or bronchial test responses were associated with elevated IgE levels. The seven positive challenge test results included five positive skin test responses. On the other hand in all but two of the subjects with negative challenge test results, no specific IgE could be detected In these two subjects the negative results were associated with low levels of IgE, and in one, with the absence of asthma. None of the results of tests with unconjugated anhydrides were positive. Conclusions: Anhydrides investigated in this study can induce IgE-mediated hypersensitivity, which can be diagnosed by using the respective human serum albumin in estimation of specific IgE and in skin, nasal, and bronchial challenge tests. Estimation of IgE was demonstrated to be move sensitive than skin prick testing.			BAUR, X (corresponding author), RUHR UNIV BOCHUM,INST OCCUPAT MED,BUERKLE CAMP PL 1,D-44789 BOCHUM,GERMANY.							AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; BAUR X, IN PRESS INT ARCH OC; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; CHEN Z, 1994, J ALLERGY CLIN IMMUN, V93, P264; CZUPPON AB, 1994, ALLERGY, V49, P337, DOI 10.1111/j.1398-9995.1994.tb02278.x; GRAMMER LC, 1993, AM REV RESPIR DIS, V148, P54, DOI 10.1164/ajrccm/148.1.54; LISS GM, 1993, J ALLERGY CLIN IMMUN, V92, P237, DOI 10.1016/0091-6749(93)90167-E; MCGRATH KG, 1984, J OCCUP ENVIRON MED, V26, P671; MEADWAY J, 1980, BRIT J DIS CHEST, V74, P149, DOI 10.1016/0007-0971(80)90026-1; NIELSEN J, 1994, CLIN EXP ALLERGY, V24, P440, DOI 10.1111/j.1365-2222.1994.tb00932.x; TOPPING MD, 1986, J ALLERGY CLIN IMMUN, V77, P834, DOI 10.1016/0091-6749(86)90381-7; VENABLES KM, 1989, BRIT J IND MED, V46, P222; ZEISS CR, 1991, J ALLERGY CLIN IMMUN, V87, P755, DOI 10.1016/0091-6749(91)90118-8; ZEISS CR, 1983, ANN INTERN MED, V98, P8, DOI 10.7326/0003-4819-98-1-8	14	32	32	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					489	494		10.1016/S0091-6749(95)70292-X	http://dx.doi.org/10.1016/S0091-6749(95)70292-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560660				2022-12-18	WOS:A1995TA09500009
J	ELLINGSON, AR; LEDOUX, RA; VEDANTHAN, PK; WEBER, RW				ELLINGSON, AR; LEDOUX, RA; VEDANTHAN, PK; WEBER, RW			THE PREVALENCE OF DERMATOPHAGOIDES MITE ALLERGEN IN COLORADO HOMES UTILIZING CENTRAL EVAPORATIVE COOLERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DERMATOPHAGOIDES; DUST MITE; COLORADO; EVAPORATIVE COOLERS; HUMIDITY	HOUSE-DUST MITES; SEASONAL-VARIATION; ASTHMA; EXPOSURE; SENSITIZATION; ANTIBODIES; CHILDREN; RISK; HUMIDITY; ALTITUDE	Objective: The prevalence of mite allergen was studied in homes in which the indoor relative humidity may be increased by use of an evaporative cooler. Methods: Colorado homes in which central evaporative coolers are used and control homes were evaluated. ELISAs with monoclonal antibodies specific for Der p 1 and Der f 1 were performed on dust samples from each home in May and August. Indoor relative humidity and temperatures were recorded daily. Results: May samples did not show significant levels of mite allergen (<2 mu g/gm dust). Of the August samples, 48 of 95 samples from homes with evaporative coolers (50.5%) had levels of Der p 1 and Der f 1 of 2 mu g/gm dust or greater, but only 5 of 95 control samples (5.2%) had levels of 2 mu g/gm dust or greater (p < 0.00001). Twelve of 19 homes with evaporative coolers (63%) were positive for mite allergen. Five of 19 (26%) control homes were positive (p < 0.05). The homes with evaporative coolers had average indoor relative humidity of 51% or greater: control homes had average relative humidity of less than 45%. Conclusion: Altering the indoor environment by raising indoor relative humidity through use of evaporative coolers lends to conditions that may facilitate Dermatophagoides survival.	FITZSIMONS ARMY MED CTR,AURORA,CO 80045; ALLERGY & SKIN CLIN PC,LAKEWOOD,CO									ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; CHAPMAN MD, 1985, INT ARCH ALLER A IMM, V77, P168; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; HALLAS TE, 1991, ALLERGY, V46, P6, DOI 10.1111/j.1398-9995.1991.tb00641.x; KALRA S, 1992, THORAX, V47, P928, DOI 10.1136/thx.47.11.928; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MOYER DB, 1985, ANN ALLERGY, V55, P680; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TUFT L, 1949, J INVEST DERMATOL, V12, P211, DOI 10.1038/jid.1949.33; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7	26	32	33	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					473	479		10.1016/S0091-6749(95)70289-X	http://dx.doi.org/10.1016/S0091-6749(95)70289-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560657				2022-12-18	WOS:A1995TA09500006
J	OTSUKA, H; INABA, M; FUJIKURA, T; KUNITOMO, M				OTSUKA, H; INABA, M; FUJIKURA, T; KUNITOMO, M			HISTOCHEMICAL AND FUNCTIONAL-CHARACTERISTICS OF METACHROMATIC CELLS IN THE NASAL EPITHELIUM IN ALLERGIC RHINITIS - STUDIES OF NASAL SCRAPINGS AND THEIR DISPERSED CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; TRYPTASE-POSITIVE MASH CELL; TRYPTASE-CHYMASE POSITIVE CELL; HISTAMINE RELEASE; RAST; SODIUM CROMOGLYCATE	MUCOSAL MAST-CELLS; HISTAMINE-SECRETION; MEDIATOR RELEASE; IGE; HETEROGENEITY; PATHOGENESIS; PURIFICATION; PROGENITORS; ACTIVATION; ANTIBODIES	Background: In allergic rhinitis, metachromatic cells in the nasal epithelium increase in number and are thought to play an important role in nasal allergic manifestation. Methods: To determine immunohistochemical and functional characteristics of the metachromatic cells, nasal scrapings and their dispersed cells from patients with perennial allergic rhinitis were studied. Results: Eighty-three percent of all metachromatic cells in dispersed cell preparations were tryptase-positive mast cells (MC(T)), 10% were tryptase-chymase-positive cells (MC(TC)), and 7% were negative (n = 10), The mean histamine content per metachromatic cell was 1.9 +/- 0.2 pg. The histamine content and histamine release from nasal surface scrapings of patients sensitized with mire antigen were strongly correlated with the level of serum IgE antibody for mite antigen. The net histamine release from nasal scrapings was antigen-dose-dependent (1:2 x 10(7) to 1:2 x 10(3) dilution), and the antigen stimulated release of Icp to 17% of cell-associated histamine within 5 to 7 minutes. Histamine release from nasal scrapings induced by calcium ionophore A23187 was lip to 21% of cell-associated histamine within 2 to 4 minutes, but no histamine release was stimulated by compound 48/80 substance P, ol poly-L-lysine. Histamine release fi on? nasal scrapings was inhibited 46% (10(-5) mol/L) to 96% (10(-4) mol/L) by quercetin and 58% (10(-4) mol/L) to 72% (10(-3) mol/L) by sodium cromoglycate. Conclusions: These findings show the predominant characteristics of mast cells in the nasal epithelium in allergic rhinitis, and this information may be useful in relation to a therapeutic approach.			OTSUKA, H (corresponding author), NIPPON MED COLL,DAI HOSP 2,DEPT OTORHINOLARYNGOL,ALLERGY IMMUNOL LAB,NAKAHARA KU,KAWASAKI,KANAGAWA 211,JAPAN.							BEFUS AD, 1987, J IMMUNOL, V138, P2604; BEFUS D, 1985, INT ARCH ALLER A IMM, V76, P232, DOI 10.1159/000233697; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BENYON RC, 1987, J IMMUNOL, V138, P861; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; CHURCH MK, 1982, J IMMUNOL, V129, P2116; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; ENERBACK L, 1987, INT ARCH ALLER A IMM, V82, P249, DOI 10.1159/000234199; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; FOREMAN JC, 1980, BIOCHIM BIOPHYS ACTA, V629, P587, DOI 10.1016/0304-4165(80)90164-6; HASTIE R, 1979, LAB INVEST, V40, P554; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; KAWABORI S, 1985, CLIN ALLERGY, V15, P509, DOI 10.1111/j.1365-2222.1985.tb02303.x; Kawabori Shinichi, 1993, Japanese Journal of Allergology, V42, P894; Lagerwall S.T., 1984, FERROELECTRICS, V59, P25, DOI [10.1080/00150198408240737, DOI 10.1080/00150198408240737]; MARTIN TR, 1993, J CLIN INVEST, V91, P1176, DOI 10.1172/JCI116277; MIDDLETON E, 1981, J IMMUNOL, V127, P546; NORMAN P, 1975, ADV DIAGNOSIS ALLERG, P45; OHTSUKA H, 1981, ARCH OTO-RHINO-LARYN, V233, P227, DOI 10.1007/BF00454387; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OKUDA M, 1977, ORL DIGEST, V39, P26; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; OTSUKA H, 1987, AM REV RESPIR DIS, V136, P710, DOI 10.1164/ajrccm/136.3.710; PATTERSON R, 1978, J CLIN INVEST, V62, P519, DOI 10.1172/JCI109155; PEARCE FL, 1984, J ALLERGY CLIN IMMUN, V73, P819, DOI 10.1016/0091-6749(84)90453-6; REES PH, 1988, IMMUNOLOGY, V65, P437; RUITENBERG EJ, 1982, INT ARCH ALLER A IMM, V67, P233, DOI 10.1159/000233024; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; YAMATODANI A, 1985, J CHROMATOGR, V344, P115, DOI 10.1016/S0378-4347(00)82012-5; ZWEIMAN B, 1983, CLIN REV ALLERG, V1, P417	38	32	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					528	536		10.1016/S0091-6749(95)70297-0	http://dx.doi.org/10.1016/S0091-6749(95)70297-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560665				2022-12-18	WOS:A1995TA09500014
J	MOSCATO, G; GODNICCVAR, J; MAESTRELLI, P				MOSCATO, G; GODNICCVAR, J; MAESTRELLI, P			STATEMENT ON SELF-MONITORING OF PEAK EXPIRATORY FLOWS IN THE INVESTIGATION OF OCCUPATIONAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RATE RECORDS; DIAGNOSIS; TESTS											BERNSTEIN DI, 1993, ASTHMA WORKPLACE, P1; BERUBE D, 1991, CHEST, V99, P831, DOI 10.1378/chest.99.4.831; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; BURGE PS, 1989, CLIN EXP ALLERGY, V19, P649, DOI 10.1111/j.1365-2222.1989.tb02762.x; BURGE PS, 1979, THORAX, V34, P308, DOI 10.1136/thx.34.3.308; BURGE PS, 1979, THORAX, V34, P317, DOI 10.1136/thx.34.3.317; CARTIER A, 1994, EUR RESPIR J, V7, P153, DOI 10.1183/09031936.94.07010153; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CARTIER A, 1984, CLIN ALLERGY, V14, P193, DOI 10.1111/j.1365-2222.1984.tb02652.x; COTE J, 1993, THORAX, V48, P48, DOI 10.1136/thx.48.1.48; COTE J, 1990, J ALLERGY CLIN IMMUN, V85, P592, DOI 10.1016/0091-6749(90)90098-O; GODNICCVAR J, 1993, MARC EAACI SUBC OCC; LISS GM, 1991, CHEST, V100, P63, DOI 10.1378/chest.100.1.63; LUCAS JM, 1990, TECHNOMETRICS, V32, P1, DOI 10.2307/1269835; MALO JL, 1993, THORAX, V48, P1211, DOI 10.1136/thx.48.12.1211; MILLER MR, 1994, BMJ-BRIT MED J, V308, P548, DOI 10.1136/bmj.308.6928.548; Moscato G, 1993, Monaldi Arch Chest Dis, V48, P23; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PERRIN B, 1992, EUR RESPIR J, V5, P40; QUANJER PH, 1992, AUG ERS ANN C WIEN; SLY PD, 1994, BRIT MED J, V308, P572, DOI 10.1136/bmj.308.6928.572; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; VENABLES KM, 1984, THORAX, V39, P828, DOI 10.1136/thx.39.11.828; YEUNG MC, 1986, AM REV RESPIR DIS, V133, P686; [No title captured]; 1987, AM REV RESPIR DIS, V136, P225; 1992, CLIN EXP ALLERGY, V22, P103	27	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					295	301						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560631				2022-12-18	WOS:A1995RU66000001
J	PFISTER, R; LUTOLF, M; SCHAPOWAL, A; GLATTE, B; SCHMITZ, M; MENZ, G				PFISTER, R; LUTOLF, M; SCHAPOWAL, A; GLATTE, B; SCHMITZ, M; MENZ, G			SCREENING FOR SINUS DISEASE IN PATIENTS WITH ASTHMA - A COMPUTED TOMOGRAPHY-CONTROLLED COMPARISON OF A-MODE ULTRASONOGRAPHY AND STANDARD RADIOGRAPHY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SINUSITIS; ASTHMA; A-MODE ULTRASONOGRAPHY; COMPUTED TOMOGRAPHY; WATERS VIEW RADIOGRAPH	PARANASAL SINUSES; ALLERGIC RHINITIS; ULTRASOUND; DIAGNOSIS; NASAL; CT	Background: Paranasal sinus disease and bronchial asthma are frequently associated. Patients with asthma often have chronic inflammatory changes of the paranasal mucosa rather than acute bacterial sinusitis. Our aim was to compare the rankings of A-mode ultrasonography and standard radiography as routine screening procedures in the diagnostic workup of these patients. Methods: We compared the evaluation of the maxillary sinuses by A-mode ultrasonography and standard radiographs. Computed tomography served as a gold standard in 19 patients with asthma who had no history of sinus surgery. Results: Computed tomography showed at least some minimal mucosal thickening and any of the paranasal sinuses in 74% and of the maxillary sinuses in 61% of the patients. Compared with the results of computed tomography, plain-view radiography gave a specificity of 86.7% for the maxillary sinuses. Although all cases of severe muscosal thickening were detected, sensitivity for minimal mucosal hyperplasia was low, at 52.2%. In contrast, A-mode ultrasonography demonstrated a sensitivity of 70% but a specificity of only 22%. Conclusions: Even symptom-free patients with asthma show a high prevalence of at least limited muscosal thickening in the paranasal sinuses. Acute sinusitis is not a common finding. A-mode ultrasonography does nor allow sufficient evaluation of this mucosal hyperplasia and is therefore not suitable for initial screening in these patients. It may prove helpful as a follow-up in selected patients with known anatomic characteristics, however especially when antral fluid is involved. For routine screening in patients with asthma, a conventional Waters' view radiograph should be used in conjunction with direct visualization of the ostial-meatal area by fiberoptic or rigid rhinoscopy. This combination provides information about the degree of mucosal hyperplasia as well as mrtcosal inflammation and secretion.	ZURCHER HOCHGEBIRGSKLIN,CH-7265 DAVOS,SWITZERLAND; KANTONSSPITAL CHUR,DEPT RADIOL,CHUR,SWITZERLAND									AUBIER M, 1992, AM REV RESPIR DIS, V146, P122, DOI 10.1164/ajrccm/146.1.122; COOKE LD, 1991, J LARYNGOL OTOL, V105, P278, DOI 10.1017/S0022215100115609; DRUCE HM, 1991, ANN ALLERGY, V66, P132; DRUCE HM, 1993, IMMUNOL ALLERGY CLIN, V13, P119; DRUCE HM, 1991, J ALLERGY CLIN IMMUN, V88, P675, DOI 10.1016/0091-6749(91)90161-G; FRIDAY GA, 1988, CLIN CHEST MED, V9, P557; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; JENSEN C, 1987, ACTA RADIOL, V28, P31; LANDMAN MD, 1986, OTOLARYNG HEAD NECK, V94, P157, DOI 10.1177/019459988609400205; LLOYD GAS, 1990, J LARYNGOL OTOL, V104, P477, DOI 10.1017/S0022215100112927; PFLEIDERER AG, 1984, CLIN OTOLARYNGOL, V9, P335, DOI 10.1111/j.1365-2273.1984.tb01517.x; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RAK KM, 1991, AM J ROENTGENOL, V156, P381, DOI 10.2214/ajr.156.2.1898819; Revonta M, 1980, Acta Otolaryngol Suppl, V370, P1; ROHR AS, 1986, J ALLERGY CLIN IMMUN, V78, P58, DOI 10.1016/0091-6749(86)90115-6; SCHAPOWAL A, 1993, ALLERGOLOGIE, V16, P187; SHAPIRO GG, 1986, J ALLERGY CLIN IMMUN, V77, P59, DOI 10.1016/0091-6749(86)90324-6; SILK HT, 1990, J ASTHMA, V27, P1; SLAVIN GS, 1992, J ALLERGY CLIN IMMUN, V90, P531; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; VANDUIJN NP, 1992, BRIT MED J, V305, P6684; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WHITE PS, 1991, J LARYNGOL OTOL, V105, P20, DOI 10.1017/S0022215100114720; WILSON PS, 1990, J LARYNGOL OTOL, V104, P694, DOI 10.1017/S0022215100113647; ZINREICH SJ, 1990, OTOLARYNG HEAD NECK, V103, P863, DOI 10.1177/01945998901030S505	26	32	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					804	809		10.1016/0091-6749(94)90146-5	http://dx.doi.org/10.1016/0091-6749(94)90146-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963148				2022-12-18	WOS:A1994PR24000003
J	GARCIA, DP; CORBETT, ML; EBERLY, SM; JOYCE, MR; LE, HT; KARIBO, JM; PENCE, HL; NGUYEN, KL				GARCIA, DP; CORBETT, ML; EBERLY, SM; JOYCE, MR; LE, HT; KARIBO, JM; PENCE, HL; NGUYEN, KL			RADIOGRAPHIC IMAGING STUDIES IN PEDIATRIC CHRONIC SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SINUS CT SCANS; PEDIATRIC CHRONIC SINUSITIS; SINUS RADIOGRAPHS; LIMITED SINUS CT SCANS	PARA-NASAL SINUSES; LOW-DOSE CT; PARANASAL SINUSES; CHILDREN; SURGERY; DISEASE; ABNORMALITIES; DIAGNOSIS; SEDATION	Background: The diagnosis of chronic sinusitis is dependent an the radiographic evidence of sinus disease. Methods: We evaluated the performance of radiographs and computed tomographic (CT) scans for the examination of the paranasal sinuses of 91 patients of both sexes, ranging in age from 2 to 17 years, who had chronic upper respiratory tract symptoms for at least 3 months. The CT scan findings were categorized as no disease; minimal disease, and mild, moderate, and severe sinusitis. Results: Fifty-eight patients (63%) had chronic sinusitis: CT scan abnormalities were minimal in 17%, mild in 19%, moderate in 21%, and severe in 43%. There was a statistically significant correlation between rhinorrhea (r = 0.25, p = 0.01), cough (r = 0.27, p = 0.009), and the severity of sinus abnormality as determined by CT scan. Clinical presentation in the mild, moderate, and severe sinusitis groups (p < 0.05) was significantly different from that of the no disease group, whereas the minimal disease group had subclinical presentation (p = 0.11). Clinically significant chronic sinusitis often occurred at multiple sites: 44% of patients had pansinusitis, 50% had disease involvement of at least two sinuses, and 6% had disease in a single sinus. When sinus radiographs were compared with CT scans (n = 70 cases), radiographs could not identify minimal disease. For clinically significant sinusitis, sinus radiographs detected disease in 1 of 5 (20%) frontal sinuses, 0 of 12 (0%) sphenoidal sinuses, and 17 of 31 (54%) ethmoidal sinuses. With the minimal criteria of 40% to 50% opacification or fluid level filling of the maxillary antrum, radiographs detected disease in 37 of 49 (75%) cases. The sensitivity and specificity for a Waters view to confirm clinically significant chronic sinusitis without specifying the sites and severity were acceptable at 76% and 81%, respectively. When limited sinus CT scans were compared with full CT evaluation (n = 49 cases), limited studies detected 5 of 5 (100%) frontal, 9 of 11 (82%) sphenoidal, 14 of 19 (73%) ethmoidal, and 39 of 40 (97%) cases of maxillary sinusitis. The overall agreement was 88%. Conclusions: A single Waters view is art acceptable part of the initial evaluation of pediatric chronic sinusitis; however, a limited CT scan is a better alternative.	UNIV LOUISVILLE,SCH MED,DEPT PEDIAT,LOUISVILLE,KY 40292; UNIV LOUISVILLE,SCH MED,DEPT INTERNAL MED,LOUISVILLE,KY 40292; UNIV LOUISVILLE,SCH MED,DEPT RADIOL,LOUISVILLE,KY 40292; UNIV LOUISVILLE,SCH MED,ALLERGY & IMMUNOL SECT,LOUISVILLE,KY 40292	University of Louisville; University of Louisville; University of Louisville; University of Louisville								BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; BROOK I, 1981, JAMA-J AM MED ASSOC, V246, P967, DOI 10.1001/jama.246.9.967; CASTELLANOS J, 1989, J ALLERGY CLIN IMMUN, V83, P91, DOI 10.1016/0091-6749(89)90481-8; DIAMENT MJ, 1987, J COMPUT ASSIST TOMO, V11, P426, DOI 10.1097/00004728-198705000-00011; DUVOISIN B, 1991, NEURORADIOLOGY, V33, P403, DOI 10.1007/BF00598612; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GLASIER CM, 1986, AM J NEURORADIOL, V7, P861; GREENBERG SB, 1991, J COMPUT ASSIST TOMO, V15, P467, DOI 10.1097/00004728-199105000-00023; GROSS GW, 1991, AM J ROENTGENOL, V156, P367, DOI 10.2214/ajr.156.2.1898816; HUBBARD AM, 1992, J COMPUT ASSIST TOMO, V16, P3, DOI 10.1097/00004728-199201000-00002; JENSEN C, 1987, ACTA RADIOL, V28, P31; KALINER MA, 1992, J ALLERGY CLIN IMMUN, V90, P424, DOI 10.1016/0091-6749(92)90162-U; KENNEDY DW, 1990, OTOLARYNG HEAD NECK, V103, P884, DOI 10.1177/01945998901030S509; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; LEW D, 1983, NEW ENGL J MED, V309, P1149, DOI 10.1056/NEJM198311103091904; LUSK RP, 1990, LARYNGOSCOPE, V100, P654; MARMOLYA G, 1991, RADIOLOGY, V181, P689, DOI 10.1148/radiology.181.3.1947083; MCALISTER WH, 1989, AM J ROENTGENOL, V153, P1259, DOI 10.2214/ajr.153.6.1259; MCCROHAN JL, 1987, RADIOLOGY, V163, P263, DOI 10.1148/radiology.163.1.3823446; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P900, DOI 10.1016/0091-6749(88)90032-2; NGUYEN KL, 1993, J ALLERGY CLIN IMMUN, V92, P824, DOI 10.1016/0091-6749(93)90059-O; OHASHI Y, 1983, ACTA OTOLARYNGOL S S, V397, P11; OTT NL, 1991, MAYO CLIN PROC, V66, P1238, DOI 10.1016/S0025-6196(12)62475-6; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RICHARDSON M, 1990, Journal of Allergy and Clinical Immunology, V85, P286; SHAPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417, DOI 10.1016/0091-6749(92)90160-4; SOM PM, 1984, HEAD NECK IMAGING EX, P5; Swischuk L. E., 1982, RADIOGRAPHICS, V2, P241; Towbin R, 1982, RADIOGRAPHICS, V2, P253; WAGENMANN M, 1992, J ALLERGY CLIN IMMUN, V90, P419, DOI 10.1016/0091-6749(92)90161-T; WALD ER, 1981, PEDIATR CLIN N AM, V28, P777; WALD ER, 1988, PEDIATR INFECT DIS J, V7, pS150, DOI 10.1097/00006454-198811001-00006; WHITE PS, 1990, AUST NZ J SURG, V60, P25, DOI 10.1111/j.1445-2197.1990.tb07348.x; ZINREICH SJ, 1987, RADIOLOGY, V163, P769, DOI 10.1148/radiology.163.3.3575731	36	32	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				523	530		10.1016/0091-6749(94)90209-7	http://dx.doi.org/10.1016/0091-6749(94)90209-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083458				2022-12-18	WOS:A1994PG90700012
J	SAMPSON, HA				SAMPSON, HA			FOOD ALLERGY AND THE ROLE OF IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							1ST 3 YEARS; NATURAL-HISTORY; HYPERSENSITIVITY; CHILDREN; LIFE		JOHNS HOPKINS UNIV,SCH MED,DIV ALLERGY IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24439] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1992, J ALLERGY CLIN IMMUN, V89, P192; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P41, DOI 10.1016/S0091-6749(05)80121-6; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, IN PRESS N ENGL J ME; Walzer Matthew, 1942, JOUR ALLERGY, V13, P554, DOI 10.1016/S0021-8707(42)90068-6; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	12	32	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					151	152		10.1016/0091-6749(92)90065-A	http://dx.doi.org/10.1016/0091-6749(92)90065-A			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500621				2022-12-18	WOS:A1992JJ42300002
J	SILVENNOINENKASSINEN, S; IKAHEIMO, I; KARVONEN, J; KAUPPINEN, M; KALLIOINEN, M				SILVENNOINENKASSINEN, S; IKAHEIMO, I; KARVONEN, J; KAUPPINEN, M; KALLIOINEN, M			MONONUCLEAR CELL SUBSETS IN THE NICKEL-ALLERGIC REACTION INVITRO AND INVIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NICKEL SENSITIVITY; LYMPHOCYTE PHENOTYPES; INVITRO STIMULATION; SKIN REACTION	NORMAL HUMAN-SKIN; MEMORY T-CELLS; CONTACT-DERMATITIS; LYMPHOCYTE-TRANSFORMATION; PREDOMINANTLY BELONG; HELPER-INDUCER; RECEPTOR; SENSITIVITY; EXPRESSION; CLONES	Nickel is the major cause of metal-induced contact allergy. To understand the mechanism of its immune reaction, we studied changes in lymphocyte surface markers during nickel challenge in both allergic and healthy subjects using an in vitro nickel reaction in which the lymphocytes of allergic subjects divide when they are stimulated with nickel sulfate. The lymphocytes were labeled with monoclonal antibodies (MAbs) to cell-surface antigens and studied by flow cytometry. Mononuclear cells from the nickel reaction in vivo were studied from skin biopsy specimens using MAbs and avidin-biotin immunohistochemistry. Nickel-induced lymphoblast transformation occurred in vitro only in cells from nickel-allergic subjects. CD4+ cells and CD45RO+ cells were overrepresented among the lymphoblasts of nickel-sensitive subjects, whereas CD8+ and CD8+CD11b+ and CD4+CD45R+ cells were underrepresented. The lymphoblasts contained T cells with the following activation markers: CD25, HLA-DR, CD26, CD71, Ki-67, and activation-associated antigen detected by the MAb, M21C5, but they were CD30-. CD16+ cells were overrepresented among the lymphoblasts. Nickel-reacting T cells used predominantly the T cell receptor, alpha-beta-heterodimer, but no preferential selection of either V-beta-5, V-beta-6, or V-beta-8 was observed. The phenotypes of nickel-reacting cells from cutaneous biopsy specimens were in agreement with the in vitro results.	UNIV OULU,DEPT DERMATOL,SF-90220 OULU,FINLAND; UNIV OULU,DEPT PATHOL,SF-90220 OULU,FINLAND	University of Oulu; University of Oulu	SILVENNOINENKASSINEN, S (corresponding author), UNIV OULU,DEPT MED MICROBIOL,KAJAANINTIE 46E,SF-90220 OULU,FINLAND.							BOS JD, 1990, J INVEST DERMATOL, V94, P37, DOI 10.1111/1523-1747.ep12873333; BOS JD, 1989, ARCH DERMATOL RES, V281, P24, DOI 10.1007/BF00424268; BOS JD, 1987, J INVEST DERMATOL, V88, P569, DOI 10.1111/1523-1747.ep12470172; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DUPUY P, 1990, J INVEST DERMATOL, V94, P764, DOI 10.1111/1523-1747.ep12874626; EMTESTAM L, 1989, TISSUE ANTIGENS, V33, P531, DOI 10.1111/j.1399-0039.1989.tb01704.x; EVERNESS KM, 1990, BRIT J DERMATOL, V122, P293, DOI 10.1111/j.1365-2133.1990.tb08276.x; FOSTER CA, 1990, J EXP MED, V171, P997, DOI 10.1084/jem.171.4.997; GOTTLIEB AB, 1986, J EXP MED, V164, P1013, DOI 10.1084/jem.164.4.1013; HAFLER DA, 1989, J IMMUNOL, V142, P2590; HORN TD, 1990, J CUTAN PATHOL, V17, P165, DOI 10.1111/j.1600-0560.1990.tb00076.x; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAPSENBERG ML, 1988, EUR J IMMUNOL, V18, P977, DOI 10.1002/eji.1830180702; KAPSENBERG ML, 1987, EUR J IMMUNOL, V17, P861, DOI 10.1002/eji.1830170620; KARTTUNEN R, 1988, CLIN EXP IMMUNOL, V74, P387; MARKEY AC, 1990, BRIT J DERMATOL, V122, P325, DOI 10.1111/j.1365-2133.1990.tb08280.x; MOLLER DR, 1988, J CLIN INVEST, V82, P1183, DOI 10.1172/JCI113715; NETHERCOTT JR, 1990, J AM ACAD DERMATOL, V22, P756, DOI 10.1016/0190-9622(90)70104-P; OMARY MB, 1988, J IMMUNOL, V141, P3492; PELTONEN L, 1979, CONTACT DERMATITIS, V5, P27, DOI 10.1111/j.1600-0536.1979.tb05531.x; Pirila V, 1975, Contact Dermatitis, V1, P48, DOI 10.1111/j.1600-0536.1975.tb05311.x; POSNETT DN, 1990, J CLIN INVEST, V85, P1770, DOI 10.1172/JCI114634; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SCHWARTING R, 1989, BLOOD, V74, P1678; SILVENNOINENKASSINEN S, 1986, J INVEST DERMATOL, V86, P18, DOI 10.1111/1523-1747.ep12283725; SILVENNOINENKASSINEN S, 1980, SCAND J IMMUNOL, V12, P61, DOI 10.1111/j.1365-3083.1980.tb00041.x; SILVENNOINENKASSINEN S, 1991, SCAND J IMMUNOL, V33, P429, DOI 10.1111/j.1365-3083.1991.tb01791.x; SINIGAGLIA F, 1985, J IMMUNOL, V135, P3929; STERRY W, 1989, J AM ACAD DERMATOL, V21, P98, DOI 10.1016/S0190-9622(89)70155-9; STERRY W, 1990, BRIT J DERMATOL, V123, P59, DOI 10.1111/j.1365-2133.1990.tb01824.x; VANDEBRIEL RJ, 1989, 7TH INT C IMM; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0	32	32	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					794	800		10.1016/0091-6749(92)90433-3	http://dx.doi.org/10.1016/0091-6749(92)90433-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1532806	Bronze			2022-12-18	WOS:A1992HN86000003
J	OHEHIR, RE; BUSCH, R; ROTHBARD, JB; LAMB, JR				OHEHIR, RE; BUSCH, R; ROTHBARD, JB; LAMB, JR			AN INVITRO MODEL OF PEPTIDE-MEDIATED IMMUNOMODULATION OF THE HUMAN T-CELL RESPONSE TO DERMATOPHAGOIDES SPP (HOUSE DUST MITE)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MHC CLASS-II; LYMPHOCYTES-T; GENE-PRODUCTS; ALLERGIC DISEASE; IMMUNE-RESPONSE; ANTIGEN; RECOGNITION; BINDING; HLA; MOLECULES	Allergic sensitivity of Dermatophagoides spp (house dust mites) is mediated by specific IgE antibody, the production of which requires the presence of CD4+ helper T cells. Attempts to hyposensitize this response in allergic individuals have depended on the administration of extracts of specific allergen. However, the ability of peptides derived from unrelated antigens to inhibit specific immune responses offers an alternative approach to therapy. We have addressed this question by examining the ability of a nonstimulatory peptide analogue derived from influenza virus hemagglutinin to modulate T cell recognition of house dust mite. The peptide inhibited the response of mite-specific CD4+ T cell clones restricted by either the HLA-DRAB1 or DRAB3 gene products. Furthermore, mite-induced polyclonal T cell responses were negatively modulated by the peptide, whereas recognition of common recall antigens remained intact. The inhibitory effects were mediated at the level of the antigen-presenting cell, since no inhibition of mitogen or anti-CD3 antibody-driven T cell proliferation was observed. In direct binding assays, the peptide analogue bound to selected HLA-DR molecules expressed on the membrane of antigen-presenting cells, with specificity predominantly for those class II proteins capable of restricting house dust mite-allergen T cell recognition.	IMMULOG PHARMACEUT CORP,PALO ALTO,CA		OHEHIR, RE (corresponding author), ST MARYS HOSP,SCH MED,WRIGHT FLEMING INST,DEPT IMMUNOL,NORFOLK PL,LONDON W2 1PG,ENGLAND.		O'Hehir, Robyn E/H-3627-2011	O'Hehir, Robyn E/0000-0002-3489-7595; Busch, Robert/0000-0002-4132-0751	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; BARANY G, 1979, PEPTIDES ANAL SYNTHE, P1; BLUMENTHAL MN, 1986, J ALLERGY CLIN IMMUN, V78, P962, DOI 10.1016/0091-6749(86)90286-1; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; BUSCH R, IN PRESS J IMMUNOL M; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CHAPMAN MD, 1988, ALLERGY, V43, P7, DOI 10.1111/j.1398-9995.1988.tb05042.x; COOKSON WOCM, 1989, LANCET, V1, P1292; CROMWELL O, 1988, ALLERGIC BASIS ASTHM, P197; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; GORSKI J, 1985, J EXP MED, V162, P105, DOI 10.1084/jem.162.1.105; HUNT KJ, 1978, NEW ENGL J MED, V299, P257; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; KAY AB, 1988, ALLERGIC BASIS ASTHM, P1; LAMPSON LA, 1980, J IMMUNOL, V125, P293; Lett-Brown M A, 1989, Year Immunol, V5, P195; LITWIN A, 1988, INT ARCH ALLER A IMM, V87, P361, DOI 10.1159/000234701; Moller G., 1987, IMMUNOL REV, V98, P1; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; OHEHIR RE, 1990, INT IMMUNOL, V2, P885, DOI 10.1093/intimm/2.9.885; OHEHIR RE, 1987, IMMUNOLOGY, V62, P634; OKUMURA K, 1971, J IMMUNOL, V106, P1019; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; RABOURDINCOMBE C, 1983, NATURE, V303, P670, DOI 10.1038/303670a0; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; RONCHESE F, 1987, J IMMUNOL, V139, P629; ROSENTHAL AS, 1978, IMMUNOL REV, V40, P136, DOI 10.1111/j.1600-065X.1978.tb00404.x; Rothbard J B, 1989, Int Immunol, V1, P487, DOI 10.1093/intimm/1.5.487; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SETTE A, 1989, J IMMUNOL, V142, P35; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; URBAN JL, 1989, CELL, V59, P257, DOI 10.1016/0092-8674(89)90288-2; WERDELIN O, 1982, J IMMUNOL, V129, P1883; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	40	32	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1120	1127		10.1016/0091-6749(91)92158-W	http://dx.doi.org/10.1016/0091-6749(91)92158-W			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045616				2022-12-18	WOS:A1991FR06600012
J	KOENDERMAN, L; KUIJPERS, TW; BLOM, M; TOOL, ATJ; ROOS, D; VERHOEVEN, AJ				KOENDERMAN, L; KUIJPERS, TW; BLOM, M; TOOL, ATJ; ROOS, D; VERHOEVEN, AJ			CHARACTERISTICS OF CR3-MEDIATED AGGREGATION IN HUMAN EOSINOPHILS - EFFECT OF PRIMING BY PLATELET-ACTIVATING-FACTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PROTEIN KINASE-C; HUMAN-NEUTROPHILS; NORMAL INDIVIDUALS; RESPIRATORY BURST; COMPLEMENT; ADHESION; LFA-1; SCHISTOSOMULA; GRANULOCYTES; CHEMOTAXIS	We have used double-color fluorescence-activated cell sorter analysis to characterize the homotypic aggregation response of human eosinophils (EOs). With this method, we demonstrate for the first time that EOs are able to form stable aggregates. The aggregation response induced by the phorbol ester, phorbol myristate acetate (PMA), was low and was not primed by platelet-activating factor (PAF). In contrast, the aggregation response induced by opsonized particles was markedly enhanced after priming with PAF. Additional experiments with several blocking monoclonal antibodies indicate that the CR3 receptor present on human EOs mediates the homotypic aggregation induced by PMA and by small opsonized particles through a putative "cell-adhesion" site on CR3, which binds to its counter structure on the opposing cell. The signal that initiates this binding event is generated after PMA addition or activation of the iC3b-binding site and is not sensitive for priming by PAF. The priming by PAF of the aggregation response induced by opsonized particles is restricted to an action on the iC3b-binding site, possibly by enhancing the affinity for its ligand.	NETHERLANDS RED CROSS BLOOD TRANSFUS SERV,CENT LAB,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Amsterdam				Koenderman, Leo/0000-0002-5636-6453				ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; BRUIJNZEEL PLB, 1990, BRIT J PHARMACOL, V99, P798, DOI 10.1111/j.1476-5381.1990.tb13009.x; BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; FUKUDA T, 1989, J ALLERGY CLIN IMMUN, V83, P369, DOI 10.1016/0091-6749(89)90120-6; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GOLDSTEIN IM, 1975, J CLIN INVEST, V56, P1155, DOI 10.1172/JCI108191; GRAZIANO RF, 1989, J IMMUNOL, V142, P230; HARLAN JM, 1985, BLOOD, V65, P513; HOOGERWERF M, 1990, MOL IMMUNOL, V27, P159, DOI 10.1016/0161-5890(90)90111-C; KLOPROGGE E, 1989, J ALLERGY CLIN IMMUN, V83, P393, DOI 10.1016/0091-6749(89)90124-3; KOENDERMAN L, 1990, J IMMUNOL, V145, P3883; KOENDERMAN L, 1988, J LEUKOCYTE BIOL, V44, P79, DOI 10.1002/jlb.44.2.79; KUYPERS TW, 1989, RES IMMUNOL, V140, P461, DOI 10.1016/0923-2494(89)90114-4; KUYPERS TW, 1990, EUR J IMMUNOL, V20, P501, DOI 10.1002/eji.1830200307; LEE TC, 1984, J BIOL CHEM, V259, P5526; LUCE G G, 1985, Biotechniques, V3, P270; MIEDEMA F, 1984, EUR J IMMUNOL, V14, P518, DOI 10.1002/eji.1830140607; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SMITH CD, 1988, BIOCHEM BIOPH RES CO, V156, P1250, DOI 10.1016/S0006-291X(88)80767-8; TEVELDE AA, 1987, IMMUNOLOGY, V61, P261; VANDERREIJDEN HJ, 1983, BLOOD, V61, P443; VANNOESEL C, 1988, NATURE, V333, P850, DOI 10.1038/333850a0; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; VERHAGEN J, 1984, FEBS LETT, V168, P23, DOI 10.1016/0014-5793(84)80199-4; WALLIS WJ, 1986, BLOOD, V67, P1007; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; YAZDANBAKHSH M, 1987, J IMMUNOL, V138, P3443; YAZDANBAKHSH M, 1987, IMMUNOLOGY, V60, P123	31	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					947	954		10.1016/0091-6749(91)90416-L	http://dx.doi.org/10.1016/0091-6749(91)90416-L			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	1673978				2022-12-18	WOS:A1991FM09500006
J	SWANSON, MC; LI, JTC; WENTZMURTHA, PE; TRUDEAU, WL; FERNANDEZCALDAS, E; GREIFE, A; RODRIGO, MAJ; MORELL, F; REED, CE				SWANSON, MC; LI, JTC; WENTZMURTHA, PE; TRUDEAU, WL; FERNANDEZCALDAS, E; GREIFE, A; RODRIGO, MAJ; MORELL, F; REED, CE			SOURCE OF THE AEROALLERGEN OF SOYBEAN DUST - A LOW-MOLECULAR MASS GLYCOPEPTIDE FROM THE SOYBEAN TELA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ASTHMA	Airborne soybean allergens in the dust generated during the unloading of soybeans in the harbor caused asthma epidemics in Barcelona, Spain. The major allergen causing the epidemics was a glycopeptide < 14 kd molecular mass abundant in soybean dust. This allergen occurs in all parts of the soybean plant at all stages of growth, but the telae (hulls) and pods are by far the richest source. Small amounts of a similar cross-reacting allergen are found in some other grain dusts. The botanical function and significance of this soybean plant component is not known nor is the potential for airborne dispersion of this allergen at other grain-handling sites.	MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV ALLERG DIS,ALLERG DIS RES LAB,ROCHESTER,MN 55905; HOSP VALL DHEBRON,SERV PNEUMOL,BARCELONA,SPAIN; HOSP VALL DHEBRON,SERV BIOQUIM,BARCELONA,SPAIN; UNIV S FLORIDA,DIV ALLERGY & IMMUNOL,TAMPA,FL 33620; NIOSH,CINCINNATI,OH 45226	Mayo Clinic; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; State University System of Florida; University of South Florida; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)				Morell Brotad, Ferran/0000-0002-7206-4543	NIAID NIH HHS [AI 21255] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021255] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTO JM, 1986, LANCET, V1, P900, DOI 10.1016/S0140-6736(86)90999-2; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; CODINA R, 1990, STUDY POSSIBLE ETIOL, P8; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7	5	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					783	788		10.1016/0091-6749(91)90123-6	http://dx.doi.org/10.1016/0091-6749(91)90123-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013673				2022-12-18	WOS:A1991FG05900006
J	MORGAN, JE; DAUL, CB; LEHRER, SB				MORGAN, JE; DAUL, CB; LEHRER, SB			THE RELATIONSHIPS AMONG SHRIMP-SPECIFIC IGG SUBCLASS ANTIBODIES AND IMMEDIATE ADVERSE REACTIONS TO SHRIMP CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112; ALTON OCHSNER MED FDN & OCHSNER CLIN,ALLERGY SECT,NEW ORLEANS,LA 70121	Tulane University; Ochsner Health System					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019266] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19266] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1983, J IMMUNOL, V130, P722; AMBROSINO DM, 1986, J CLIN INVEST, V78, P361, DOI 10.1172/JCI112585; BARNES RMR, 1986, INT ARCH ALLER A IMM, V81, P141, DOI 10.1159/000234123; DAUL CB, 1987, J ALLERGY CLIN IMMUN, V80, P716, DOI 10.1016/0091-6749(87)90293-4; DAUL CB, 1988, J ALLERGY CLIN IMMUN, V81, P1180, DOI 10.1016/0091-6749(88)90888-3; DAUL CB, IN PRESS J ALLERGY C; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; HAMMARSTROM L, 1985, IMMUNOLOGY, V54, P821; HOMBURGER HA, 1986, J ALLERGY CLIN IMMUN, V77, P427, DOI 10.1016/0091-6749(86)90176-4; KEMENY DM, 1986, CLIN ALLERGY, V16, P571, DOI 10.1111/j.1365-2222.1986.tb01996.x; MORGAN JE, 1989, J ALLERGY CLIN IMMUN, V83, P1112, DOI 10.1016/0091-6749(89)90454-5; NAKAGAWA T, 1986, MONOGR ALLERGY, V19, P253; PARISH WE, 1970, LANCET, V2, P591; SHAKIB F, 1986, CLIN ALLERGY, V16, P451, DOI 10.1111/j.1365-2222.1986.tb01980.x; STANWORTH DR, 1986, MONOGR ALLERGY, V19, P227; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9; WEISS JB, 1983, J CLIN INVEST, V72, P96, DOI 10.1172/JCI110988	18	32	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				387	392		10.1016/S0091-6749(05)80102-2	http://dx.doi.org/10.1016/S0091-6749(05)80102-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2212410				2022-12-18	WOS:A1990EA85900013
J	LEHRER, SB; IBANEZ, MD; MCCANTS, ML; DAUL, CB; MORGAN, JE				LEHRER, SB; IBANEZ, MD; MCCANTS, ML; DAUL, CB; MORGAN, JE			CHARACTERIZATION OF WATER-SOLUBLE SHRIMP ALLERGENS RELEASED DURING BOILING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LEHRER, SB (corresponding author), TULANE UNIV,SCH MED,DEPT MED,CLIN IMMUNOL SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019266] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19266] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; AUKRUST L, 1978, INT ARCH ALLER A IMM, V57, P253, DOI 10.1159/000232110; BUSH RF, UNPUB SNOW CRAB ASTH; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P344, DOI 10.1016/S0091-6749(86)80087-2; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DAUL CB, 1987, J ALLERGY CLIN IMMUN, V80, P716, DOI 10.1016/0091-6749(87)90293-4; GOLDSTEIN GB, 1970, J ALLERGY, V46, P270, DOI 10.1016/0021-8707(70)90068-7; HALMEPURO L, 1987, INT ARCH ALLER A IMM, V84, P165, DOI 10.1159/000234418; HOFFMAN DR, 1975, IMMUNOCHEMISTRY, V12, P535, DOI 10.1016/0019-2791(75)90080-4; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; LEHRER SB, 1986, ANN ALLERGY, V57, P267; MAY CD, 1978, ALLERGY PRINCIPLES P, P1159; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; NAGPAL S, 1989, J ALLERGY CLIN IMMUN, V83, P26, DOI 10.1016/0091-6749(89)90474-0; NAGPAL S, 1987, J IMMUNOL, V138, P4169; NORMAN PS, 1986, J ALLERGY CLIN IMMUN, V77, P405, DOI 10.1016/0091-6749(86)90173-9; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V69, P1, DOI 10.1016/0091-6749(82)90079-3; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9	21	32	32	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					1005	1013		10.1016/0091-6749(90)90044-5	http://dx.doi.org/10.1016/0091-6749(90)90044-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2355151	Bronze			2022-12-18	WOS:A1990DK50900005
J	REBUCK, AS; KESTEN, S; BOULET, LP; CARTIER, A; COCKCROFT, D; GRUBER, J; LABERGE, F; LEECHUY, E; KESHMIRI, M; MACDONALD, GF; MALO, JL; MAZZA, J; MOOTE, DW; SANDHAM, JD; THOMAS, P; YEUNG, M				REBUCK, AS; KESTEN, S; BOULET, LP; CARTIER, A; COCKCROFT, D; GRUBER, J; LABERGE, F; LEECHUY, E; KESHMIRI, M; MACDONALD, GF; MALO, JL; MAZZA, J; MOOTE, DW; SANDHAM, JD; THOMAS, P; YEUNG, M			A 3-MONTH EVALUATION OF THE EFFICACY OF NEDOCROMIL SODIUM IN ASTHMA - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NEDOCROMIL SODIUM CONDUCTED BY A CANADIAN MULTICENTER STUDY-GROUP	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SASKATCHEWAN HOSP, SASKATOON S7N 0W8, SASKATCHEWAN, CANADA; VANCOUVER GEN HOSP, VANCOUVER V5Z 1M9, BC, CANADA; VICTORIA HOSP, LONDON N6A 4G5, ONTARIO, CANADA; EDMONTON GEN HOSP, EDMONTON, ALBERTA, CANADA; FOOTHILLS PROV GEN HOSP, CALGARY, ALBERTA, CANADA; HOP LAVAL, ST FOY, QUEBEC, CANADA; HOP SACRE COEUR, MONTREAL H4J 1C5, QUEBEC, CANADA; ST MICHAELS HOSP, TORONTO M5B 1W8, ONTARIO, CANADA; MONTREAL CHEST HOSP, MONTREAL, QUEBEC, CANADA	University of Saskatchewan; University of British Columbia; University of Victoria; Western University (University of Western Ontario); University of Calgary; Laval University; Universite de Montreal; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McGill University	REBUCK, AS (corresponding author), TORONTO WESTERN HOSP, 399 BATHURST ST, SUITE 4-009, EDITH CAVELL WING, TORONTO M5T 2S8, ONTARIO, CANADA.			Kesten, Steven/0000-0002-5522-7910				ALTOUNYAN REC, 1985, ANN ALLERGY, V55, P689; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; BIANCO S, 1986, EUR J RESPIR DI S147, V69, P286; CARRASCO E, 1988, J INT MED RES, V16, P394, DOI 10.1177/030006058801600509; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; COTT GR, 1988, NEW ENGL J MED, V318, P634, DOI 10.1056/NEJM198803103181010; CRAPS LP, 1985, BRONCHIAL ASTHMA MEC, P734; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EADY RP, 1986, EUR J RESPIR DIS, V69, P112; FAIRFAX AJ, 1988, J INT MED RES, V16, P216, DOI 10.1177/030006058801600309; FANTA CH, 1982, AM REV RESPIR DIS, V125, P61; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; HARGREAVE FE, 1986, EUR J RESPIR DIS, V69, P16; KAY AB, 1986, EUR J RESPIR DIS, V69, P38; LEUNG KBP, 1986, EUR J RESPIR DIS, V69, P223; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; OBYRNE PM, 1987, AM REV RESPIR DIS S, V136, P535; PAANANEN M, 1986, EUR J RESPIR DIS, V69, P330; PATEL KR, 1981, BRIT MED J, V282, P932, DOI 10.1136/bmj.282.6268.932; PATTRIDGE MR, 1979, THORAX, V34, P771; REED CE, 1986, J ALLERGY CLIN IMMUN, V77, P537, DOI 10.1016/0091-6749(86)90342-8; RUFFIN RE, 1987, AUST NZ J MED, V17, P557, DOI 10.1111/j.1445-5994.1987.tb01255.x; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; 1987, AM REV RESPIR DIS, V136, P225	25	32	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					612	617		10.1016/0091-6749(90)90101-9	http://dx.doi.org/10.1016/0091-6749(90)90101-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2155958				2022-12-18	WOS:A1990CU66800012
J	BOUSQUET, J; KNANI, J; VELASQUEZ, G; MENARDO, JL; GUILLOUX, L; MICHEL, FB				BOUSQUET, J; KNANI, J; VELASQUEZ, G; MENARDO, JL; GUILLOUX, L; MICHEL, FB			EVOLUTION OF SENSITIVITY TO HYMENOPTERA VENOM IN 200 ALLERGIC PATIENTS FOLLOWED FOR UP TO 3 YEARS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INST PASTEUR, CTR RADIOANAL, LYON, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BOUSQUET, J (corresponding author), CHU MONTPELLIER, MALAD RESP CLIN, AVE MAJOR FLANDRE, F-34059 MONTPELLIER, FRANCE.		Bousquet, Jean/O-4221-2019					BOUSQUET J, 1984, J ALLERGY CLIN IMMUN, V73, P332, DOI 10.1016/0091-6749(84)90405-6; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V79, P947, DOI 10.1016/0091-6749(87)90245-4; BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; BOUSQUET J, 1986, 12 P INT C ALL CLIN, P326; DAY JH, 1986, J ALLERGY CLIN IMMUN, V77, P142; ENGLER RJM, 1986, J ALLERGY CLIN IMMUN, V77, P179; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDEN DBK, 1988, J ALLERGY CLIN IMMUN, V81, P201, DOI 10.1016/0091-6749(88)90366-1; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GRAFT DF, 1987, J ALLERGY CLIN IMMUN, V80, P162, DOI 10.1016/0091-6749(87)90125-4; GRAFT DF, 1984, J ALLERGY CLIN IMMUN, V73, P61, DOI 10.1016/0091-6749(84)90485-8; GUILLOUX L, 1984, PATHOL BIOL, V32, P785; GUILLOUX L, 1987, REV F ALLERGOL, V27, P216; LANTNER R, 1988, J ALLERGY CLIN IMMUN, V81, P200; LAWRENCE ID, 1986, J ALLERGY CLIN IMMUN, V77, P178; MUELLER HL, 1959, PEDIATR CLIN N AM, V6, P917; MULLER UR, 1986, J ALLERGY CLIN IMMUN, V78, P115, DOI 10.1016/0091-6749(86)90123-5; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1988, ALLERGY PRINCIPLES P, P1345; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SCHUBERTH K C, 1982, Journal of Allergy and Clinical Immunology, V69, P124; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4; ZELEZNICK LD, 1977, J ALLERGY CLIN IMMUN, V59, P2, DOI 10.1016/0091-6749(77)90169-5; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	26	32	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				944	950		10.1016/0091-6749(89)90393-X	http://dx.doi.org/10.1016/0091-6749(89)90393-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2600326				2022-12-18	WOS:A1989CG29300014
J	LOPEZ, M; VOIGTLANDER, JR; LEHRER, SB; SALVAGGIO, JE				LOPEZ, M; VOIGTLANDER, JR; LEHRER, SB; SALVAGGIO, JE			BRONCHOPROVOCATION STUDIES IN BASIDIOSPORE-SENSITIVE ALLERGIC SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LOPEZ, M (corresponding author), TULANE UNIV,SCH MED,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,1430 TULANE AVE,ROOM 7209,NEW ORLEANS,LA 70112, USA.							ADAMS KF, 1968, ACTA ALLERGOL, V23, P265, DOI 10.1111/j.1398-9995.1968.tb04059.x; BRUCE RA, 1963, INT ARCH ALLER A IMM, V22, P294, DOI 10.1159/000229372; BUTCHER BT, 1987, J ALLERGY CLIN IMMUN, V80, P803, DOI 10.1016/S0091-6749(87)80269-5; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CUTTEN AEC, 1988, NEW ZEAL MED J, V101, P361; DAVIES RR, 1963, ACTA ALLERGOL, V18, P131, DOI 10.1111/j.1398-9995.1963.tb03156.x; GIANNINI EH, 1975, ANN ALLERGY, V35, P372; GREGORY PH, 1952, NATURE, V170, P414, DOI 10.1038/170414a0; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; HASHAIN SM, 1985, NZ MED J SCI, V98, P393; HERXHEIMER M, 1969, LANCET, V2, P313; HYDE H. A., 1960, ACTA ALLERGOL, V15, P159; KRAMER C. L., 1959, TRANS KANSAS A CAD SCI, V62, P184, DOI 10.2307/3626975; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P82, DOI 10.1016/0091-6749(71)90090-X; SANTILLI J, 1985, ANN ALLERGY, V55, P469; SPRENGER JD, 1986, J ALLERGY CLIN IMMUN, V77, P200	19	32	34	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					242	246		10.1016/0091-6749(89)90331-X	http://dx.doi.org/10.1016/0091-6749(89)90331-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2668382				2022-12-18	WOS:A1989AL83600016
J	SAXON, A; GIORGI, JV; SHERR, EH; KAGAN, JM				SAXON, A; GIORGI, JV; SHERR, EH; KAGAN, JM			FAILURE OF B-CELLS IN COMMON VARIABLE IMMUNODEFICIENCY TO TRANSIT FROM PROLIFERATION TO DIFFERENTIATION IS ASSOCIATED WITH ALTERED B-CELL SURFACE-MOLECULE DISPLAY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SAXON, A (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [P01CA012800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015251, P50AI015332, R21AI015251] Funding Source: NIH RePORTER; NCI NIH HHS [CA 12800] Funding Source: Medline; NIAID NIH HHS [AI 15332, AI 15251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHMAN RF, 1980, J ALLERGY CLIN IMMUN, V65, P242, DOI 10.1016/0091-6749(80)90151-7; AULT KA, 1985, J EXP MED, V161, P1483, DOI 10.1084/jem.161.6.1483; CALIGARISCAPPIO F, 1982, J EXP MED, V155, P623, DOI 10.1084/jem.155.2.623; CHIEN MM, 1986, J IMMUNOL, V136, P2844; CICCIMARRA F, 1976, J CLIN INVEST, V57, P1386, DOI 10.1172/JCI108407; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELACONCHA EG, 1977, CLIN EXP IMMUNOL, V27, P308; FALKOFF RJM, 1982, J IMMUNOL, V129, P97; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FRADE R, 1986, MOL IMMUNOL, V23, P1249, DOI 10.1016/0161-5890(86)90159-8; FROLAND S S, 1972, Scandinavian Journal of Immunology, V1, P1, DOI 10.1111/j.1365-3083.1972.tb03730.x; GEHA RS, 1974, NEW ENGL J MED, V291, P1, DOI 10.1056/NEJM197407042910101; GIORGI JV, 1987, J CLIN IMMUNOL, V7, P140, DOI 10.1007/BF00916008; GOLAY JT, 1986, CLIN EXP IMMUNOL, V65, P100; GORDON J, 1986, EUR J IMMUNOL, V16, P1627, DOI 10.1002/eji.1830161225; GUPTA S, 1985, J CLIN LAB IMMUNOL, V16, P59; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; HOKLAND P, 1985, J IMMUNOL, V135, P1746; HOKLAND P, 1983, J EXP MED, V157, P114, DOI 10.1084/jem.157.1.114; JEONG G, 1985, J CLIN IMMUNOL, V5, P122, DOI 10.1007/BF00915010; KANSAS GS, 1985, J IMMUNOL, V134, P3003; KEHRL JH, 1984, EUR J IMMUNOL, V14, P115, DOI 10.1002/eji.1830140203; KEHRL JH, 1984, J IMMUNOL, V132, P2857; KEHRL JH, 1984, IMMUNOL REV, V78, P75, DOI 10.1111/j.1600-065X.1984.tb00477.x; KIKUTANI H, 1986, J EXP MED, V164, P1455, DOI 10.1084/jem.164.5.1455; KIMATA H, 1987, CELL IMMUNOL, V107, P74, DOI 10.1016/0008-8749(87)90267-X; KURITANI T, 1983, J IMMUNOL, V131, P1306; KURITANI T, 1982, J EXP MED, V155, P839, DOI 10.1084/jem.155.3.839; MATSUMOTO M, 1987, J IMMUNOL, V138, P1826; MAYER L, 1984, J CLIN INVEST, V74, P2115, DOI 10.1172/JCI111636; MURAGUCHI A, 1984, J IMMUNOL, V132, P76; NADLER LM, 1986, LEUKOCYTE TYPING 2, V2, P509; PEREIRA S, 1982, EUR J IMMUNOL, V12, P540, DOI 10.1002/eji.1830120703; PLATERZYBERK C, 1985, ARTHRITIS RHEUM, V28, P971, DOI 10.1002/art.1780280903; PREUDHOM.JL, 1973, CLIN IMMUNOL IMMUNOP, V1, P241, DOI 10.1016/0090-1229(73)90025-1; REINHERZ EL, 1981, NEW ENGL J MED, V304, P811, DOI 10.1056/NEJM198104023041403; REINHERZ EL, 1981, J CLIN INVEST, V68, P699, DOI 10.1172/JCI110305; RODRIGUEZ MA, 1983, CLIN IMMUNOL IMMUNOP, V29, P35, DOI 10.1016/0090-1229(83)90005-3; ROSEN F S, 1983, Clinical Immunology and Immunopathology, V28, P450, DOI 10.1016/0090-1229(83)90112-5; ROSEN FS, 1984, NEW ENGL J MED, V311, P300, DOI 10.1056/NEJM198408023110506; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; SAIKI O, 1982, P NATL ACAD SCI-BIOL, V79, P6008, DOI 10.1073/pnas.79.19.6008; SAXON A, 1977, CANCER RES, V37, P1154; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SCHWARTZ SA, 1977, J CLIN INVEST, V59, P1176, DOI 10.1172/JCI108742; SHERR E, 1988, J EXP MED, V168, P55, DOI 10.1084/jem.168.1.55; SHERR EH, 1987, J IMMUNOL, V138, P3836; SHERR EH, 1988, INT ARCH ALLER A IMM, V85, P154, DOI 10.1159/000234495; SIEGAL FP, 1978, NEW ENGL J MED, V299, P172, DOI 10.1056/NEJM197807272990404; SIEGAL FP, 1976, J CLIN INVEST, V58, P109, DOI 10.1172/JCI108439; STEVENS RH, 1988, CLIN IMMUNOL IMMUNOP, V16, P336; TEDDER TF, 1985, J IMMUNOL, V135, P1786; WALDMANN TA, 1974, LANCET, V2, P609; WANG CY, 1988, EXP MED, V151, P1539; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; WU LYE, 1973, J CLIN INVEST, V52, P3180, DOI 10.1172/JCI107518; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YASHIZAKE K, 1982, J IMMUNOL, V128, P1296; YUKAWA K, 1987, J IMMUNOL, V138, P2576	59	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					44	55		10.1016/0091-6749(89)90177-2	http://dx.doi.org/10.1016/0091-6749(89)90177-2			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2787815				2022-12-18	WOS:A1989AG12000008
J	BUSSE, W				BUSSE, W			NEW DIRECTIONS AND DIMENSIONS IN THE TREATMENT OF ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BUSSE, W (corresponding author), UNIV WISCONSIN,SCH MED,DEPT MED,DIV ALLERGY CLIN IMMUNOL,MADISON,WI 53706, USA.							CLAYTON DE, 1981, J ALLERGY CLIN IMMUN, V67, P2, DOI 10.1016/0091-6749(81)90037-3; DICKSON DJ, 1986, MONOGRAPH, P9; DOCKHORN RJ, 1987, IMMUNOL ALLERGY PRAC, V9, P124; GRAFT DF, 1985, ALLERGY, P679; HANDELMAN NI, 1977, J ALLERGY CLIN IMMUN, V59, P237, DOI 10.1016/0091-6749(77)90156-7; MYGIND N, 1985, NEW ENGL REG ALLERGY, V6, P245; NORMAN PS, 1983, J ALLERGY CLIN IMMUN, V72, P421, DOI 10.1016/0091-6749(83)90577-8; NORMAN PS, 1985, J ALLERGY CLIN IMMUN, V75, P531, DOI 10.1016/0091-6749(85)90024-7; SIEGEL SC, 1986, MONOGRAPH, P14; SPECTOR SL, 1987, J RESPIR DIS, V7, P24; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5	11	32	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	2	S			890	900		10.1016/0091-6749(88)90031-0	http://dx.doi.org/10.1016/0091-6749(88)90031-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2353	2903877				2022-12-18	WOS:A1988R235300002
J	GREENBERG, MA; KAUFMAN, CR; GONZALEZ, GE; TRUSEWYCH, ZP; ROSENBLATT, CD; SUMMERS, RJ				GREENBERG, MA; KAUFMAN, CR; GONZALEZ, GE; TRUSEWYCH, ZP; ROSENBLATT, CD; SUMMERS, RJ			LATE SYSTEMIC-ALLERGIC REACTIONS TO INHALANT ALLERGEN IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USA,WOMACK ARMY COMMUNITY HOSP,ALLERGY & IMMUNIZAT CLIN,FT BRAGG,NC; USA,MARTIN ARMY HOSP,FT BENNING,GA; WALTER REED ARMY MED CTR,ALLERGY IMMUNOL SERV,WASHINGTON,DC 20307; NATL NAVAL MED CTR,ALLERGY IMMUNOL SERV,BETHESDA,MD 20814	United States Department of Defense; United States Army; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Walter Reed National Military Medical Center								Committee on the Safety of Medicines (CSM) in Great Britain, 1986, BR MED J, V293, P948; Cooke RA, 1922, J IMMUNOL, V7, P119; FIGLEY KD, 1931, J ALLERGY, V2, P39; Furstenberg FF, 1937, B JOHNS HOPKINS HOSP, V60, P412; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; KAUFMAN CR, 1984, ANN ALLERGY, V52, P220; LEVINE MI, 1979, J ALLERGY CLIN IMMUN, V63, P209; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; RANSOM JH, 1971, ANN ALLERGY, V29, P635; VANARSDEL PP, 1957, J ALLERGY, V28, P251, DOI 10.1016/0021-8707(57)90130-2; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x	12	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					287	290		10.1016/0091-6749(88)91013-5	http://dx.doi.org/10.1016/0091-6749(88)91013-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3403869				2022-12-18	WOS:A1988P874100023
J	SAVLIWALA, MN; REISMAN, RE				SAVLIWALA, MN; REISMAN, RE			STUDIES OF THE NATURAL-HISTORY OF STINGING-INSECT ALLERGY - LONG-TERM FOLLOW-UP OF PATIENTS WITHOUT IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,BUFFALO GEN HOSP,DEPT MED,ALLERGY RES LAB,BUFFALO,NY 14203	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [5R01 AI-1450109] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014501] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V68, P254, DOI 10.1016/0091-6749(81)90148-2; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P735; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; WYPYCH JI, 1984, INT ARCH ALLER A IMM, V73, P14, DOI 10.1159/000233430; WYPYCH JI, 1979, J ALLERGY CLIN IMMUN, V63, P267, DOI 10.1016/0091-6749(79)90111-8	12	32	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					741	745		10.1016/0091-6749(87)90296-X	http://dx.doi.org/10.1016/0091-6749(87)90296-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	3680818				2022-12-18	WOS:A1987K993000016
J	OLSON, GB; KANAAN, MN; GERSUK, GM; KELLEY, LM; JONES, JF				OLSON, GB; KANAAN, MN; GERSUK, GM; KELLEY, LM; JONES, JF			CORRELATION BETWEEN ALLERGY AND PERSISTENT EPSTEIN-BARR VIRUS-INFECTIONS IN CHRONIC-ACTIVE EPSTEIN-BARR VIRUS-INFECTED PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO	National Jewish Health	OLSON, GB (corresponding author), UNIV ARIZONA,DEPT MICROBIOL & IMMUNOL,TUCSON,AZ 85721, USA.							BAHNA SL, 1978, J ALLERGY CLIN IMMUN, V62, P167, DOI 10.1016/0091-6749(78)90102-1; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; HENLE W, 1974, HUM PATHOL, V5, P551, DOI 10.1016/S0046-8177(74)80006-7; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; KERNS DL, 1973, AM J DIS CHILD, V125, P187, DOI 10.1001/archpedi.1973.04160020023004; KIBLER R, 1985, J CLIN IMMUNOL, V5, P46, DOI 10.1007/BF00915168; RANDOLPH TG, 1945, AM J MED SCI, V209, P306; RAY CG, 1982, JAMA-J AM MED ASSOC, V248, P2990, DOI 10.1001/jama.248.22.2990; RYSTEDT I, 1984, INT ARCH ALLER A IMM, V75, P179, DOI 10.1159/000233610; Sokal R.R., 1969, INTRO BIOSTATISTICS; STRANNEGARD IL, 1981, INT ARCH ALLER A IMM, V64, P314, DOI 10.1159/000232709; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; TOBI M, 1982, LANCET, V1, P62; Veldman DJ, 1967, FORTRAN PROGRAMMING; WANDS JR, 1984, INT ARCH ALLERGY APP, V74, P1; ZANG Y, 1982, INTERVIROLOGY, V18, P33	18	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					308	314		10.1016/S0091-6749(86)80081-1	http://dx.doi.org/10.1016/S0091-6749(86)80081-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3016066				2022-12-18	WOS:A1986D726100011
J	SHULT, PA; GRAZIANO, FM; BUSSE, WW				SHULT, PA; GRAZIANO, FM; BUSSE, WW			ENHANCED EOSINOPHIL LUMINOL-DEPENDENT CHEMILUMINESCENCE IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015685, P50AI010404] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 00343, AI 10404, AI 15685] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1976, BIOCHEM BIOPH RES CO, V69, P245, DOI 10.1016/S0006-291X(76)80299-9; ANWAR ARE, 1980, J IMMUNOL, V124, P1122; ANWAR ARE, 1978, J IMMUNOL, V121, P1245; BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; BEESON PB, 1977, EOSINOPHIL, P1; BESWICK PH, 1981, CLIN EXP IMMUNOL, V43, P399; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRUCHELT G, 1984, J CLIN CHEM CLIN BIO, V22, P1; Cohen SG, 1983, ALLERGY PRINCIPLES P, P701; DAVID JR, 1980, NEW ENGL J MED, V303, P1147, DOI 10.1056/NEJM198011133032004; DECHATELET LR, 1978, J RETICULOENDOTH SOC, V24, P73; DESIMONE C, 1982, CLIN EXP IMMUNOL, V48, P249; DESSEIN AJ, 1982, J EXP MED, V156, P90, DOI 10.1084/jem.156.1.90; DESSEIN AJ, 1984, CELL IMMUNOL, V85, P100, DOI 10.1016/0008-8749(84)90282-X; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; GOETZL EJ, 1975, ARCH PATHOL, V99, P1; Kazura J. W., 1980, The eosinophil in health and disease. (Proc. eosinophil centennial, Brook Lodge, Augusta, Michigan, Sep. 24-28 1979)., P231; MOQBEL R, 1983, CLIN EXP IMMUNOL, V52, P519; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; PILOT ML, 1950, AM J CLIN PATHOL, V20, P870, DOI 10.1093/ajcp/20.9_ts.870; PINCUS SH, 1981, BLOOD, V58, P1175; PRENDERGAST E, 1981, J CLIN MICROBIOL, V13, P390, DOI 10.1128/JCM.13.2.390-392.1981; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; SHER R, 1983, CLIN EXP IMMUNOL, V51, P525; SHULT PA, 1985, J LAB CLIN MED, V106, P638; VADAS MA, 1983, BLOOD, V66, P1231; VADAS MA, 1983, IMMUNOBIOLOGY EOSINO, P77; VEITH MC, 1983, J EXP MED, V157, P1828, DOI 10.1084/jem.157.6.1828	29	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					702	708		10.1016/0091-6749(86)90414-8	http://dx.doi.org/10.1016/0091-6749(86)90414-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3700895	Bronze			2022-12-18	WOS:A1986C390300012
J	ANDERSON, JA; CHAI, H; CLAMAN, HN; ELLIS, EF; FINK, JN; KAPLAN, AP; LIEBERMAN, PL; PIERSON, WE; SALVAGGIO, JE; SHEFFER, AL; SLAVIN, RG				ANDERSON, JA; CHAI, H; CLAMAN, HN; ELLIS, EF; FINK, JN; KAPLAN, AP; LIEBERMAN, PL; PIERSON, WE; SALVAGGIO, JE; SHEFFER, AL; SLAVIN, RG			PERSONNEL AND EQUIPMENT TO TREAT SYSTEMIC REACTIONS CAUSED BY IMMUNOTHERAPY WITH ALLERGENIC EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																			0	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					271	273		10.1016/S0091-6749(86)80103-8	http://dx.doi.org/10.1016/S0091-6749(86)80103-8			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899					2022-12-18	WOS:A1986A089900001
J	WARDLAW, AJ; KAY, AB				WARDLAW, AJ; KAY, AB			PAF-ACETHER IS A POTENT CHEMOTACTIC FACTOR FOR HUMAN EOSINOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									BROMPTON HOSP,INST CARDIOTHORAC,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital									0	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	2	S			236	236						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD38					2022-12-18	WOS:A1986AZD3800460
J	GEORGITIS, JW; NICKELSEN, JA; WYPYCH, JI; KANE, JH; REISMAN, RE				GEORGITIS, JW; NICKELSEN, JA; WYPYCH, JI; KANE, JH; REISMAN, RE			LOCAL NASAL IMMUNOTHERAPY - EFFICACY OF LOW-DOSE AQUEOUS RAGWEED EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,BUFFALO GEN HOSP,DEPT MED,DIV ALLERGY,ALLERGY RES LAB,BUFFALO,NY 14260	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [5R01-AI 013026] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		HAMILTON RG, 1979, J IMMUNOL, V122, P1073; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; NICKELSEN JA, 1983, CLIN ALLERGY, V13, P509, DOI 10.1111/j.1365-2222.1983.tb02632.x; NICKELSEN JA, 1983, J ALLERGY CLIN IMMUN, V71, P118, DOI 10.1016/0091-6749(83)90244-0; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P241, DOI 10.1007/BF00458318; SIEGEL S, 1946, NONPARAMETRIC STATIS, P116; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1; WELSH PW, 1983, J ALLERGY CLIN IMMUN, V71, P454, DOI 10.1016/0091-6749(83)90461-X	10	32	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	4					496	500		10.1016/S0091-6749(85)80023-3	http://dx.doi.org/10.1016/S0091-6749(85)80023-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AFY44	3980884				2022-12-18	WOS:A1985AFY4400010
J	HOWARTH, PH; HOLGATE, ST				HOWARTH, PH; HOLGATE, ST			ASTEMIZOLE, A H-ANTAGONIST, IN ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					166	166		10.1016/0091-6749(85)90383-5	http://dx.doi.org/10.1016/0091-6749(85)90383-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ACF22					2022-12-18	WOS:A1985ACF2200248
J	SIEGEL, SC; RACHELEFSKY, GS				SIEGEL, SC; RACHELEFSKY, GS			ASTHMA IN INFANTS AND CHILDREN .1.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles								ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; ANDERSON HR, 1980, BMJ-BRIT MED J, V281, P491; BARR LW, 1966, AM J DIS CHILD, V112, P214; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BERKOVICH S, 1970, ANN ALLERGY, V28, P43; BERQUIST WE, 1981, PEDIATRICS, V68, P29; BERQUIST WE, 1984, J ALLERGY CLIN IMMUN, V73, P253, DOI 10.1016/S0091-6749(84)80016-0; BIERMAN CW, 1984, J ALLERGY CLIN IMMUN, V73, P654, DOI 10.1016/0091-6749(84)90300-2; BIERMAN CW, 1967, AM J DIS CHILD, V114, P42, DOI 10.1001/archpedi.1967.02090220048008; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BLAIR H, 1974, Clinical Allergy, V4, P389, DOI 10.1111/j.1365-2222.1974.tb01400.x; BLUMBERG MZ, 1976, J ALLERGY CLIN IMMUN, V57, P493, DOI 10.1016/0091-6749(76)90066-X; BLUMENTHAL MN, 1983, ALLERGY PRINCIPLES P, P11; BOCK J, 1942, Z KINDERHEILKD, V63, P579; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BRYAN AC, 1977, DEV LUNG, P445; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214, DOI 10.1001/archpedi.1966.02090120082007; BURR ML, 1983, ARCH DIS CHILD, V58, P561, DOI 10.1136/adc.58.7.561; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; CUNNINGHAM AS, 1975, J PEDIATR-US, V87, P426, DOI 10.1016/S0022-3476(75)80650-0; DEES SC, 1957, AMA J DIS CHILD, V93, P228, DOI 10.1001/archpedi.1957.02060040230004; DODGE R, 1982, ARCH ENVIRON HEALTH, V37, P151, DOI 10.1080/00039896.1982.10667555; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; EATON KK, 1982, CLIN ALLERGY, V12, P107, DOI 10.1111/j.1365-2222.1982.tb03132.x; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; EGGLESTON PA, 1974, PEDIATRICS, V54, P442; ELLIS EF, 1983, J ALLERGY CLIN IMMUN, V72, P526, DOI 10.1016/0091-6749(83)90479-7; ERIIKSSONLIHR Z, 1955, ACTA ALLERGOL, V8, P289; EULER AR, 1979, PEDIATRICS, V63, P47; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; FIELD WINIFRED E. H., 1968, BRIT J PIS CHEST, V62, P11, DOI 10.1016/S0007-0971(68)80025-7; FREEMAN GL, 1962, AM J DIS CHILD, V104, P330, DOI 10.1001/archpedi.1962.02080030332002; FREUDENBERG N, 1980, J SCHOOL HEALTH, V50, P522, DOI 10.1111/j.1746-1561.1980.tb02079.x; GALANT SP, 1978, PEDIATRICS, V61, P46; GRANT IWB, 1983, BRIT MED J, V286, P374, DOI 10.1136/bmj.286.6362.374; GURWITZ D, 1980, AM REV RESPIR DIS, V122, P95; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; HIDE DW, 1981, ARCH DIS CHILD, V56, P172, DOI 10.1136/adc.56.3.172; HODGKIN JE, 1984, CHEST, V86, P830, DOI 10.1378/chest.86.6.830; HOGG JC, 1970, NEW ENGL J MED, V282, P1283, DOI 10.1056/NEJM197006042822302; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23; HOSHAW TC, 1974, ARCH OTOLARYNGOL, V100, P194; HOZOURI K, 1982, Journal of Allergy and Clinical Immunology, V69, P121; JACKSON RT, 1983, NEW ZEAL MED J, V96, P728; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JOHNSTON.DE, 1968, AM J DIS CHILD, V115, P213, DOI 10.1001/archpedi.1968.02100010215010; KAJOSAARI M, 1983, ACTA PAEDIATR SCAND, V72, P411, DOI 10.1111/j.1651-2227.1983.tb09738.x; KARETZKY MS, 1977, J ALLERGY CLIN IMMUN, V60, P383, DOI 10.1016/0091-6749(77)90070-7; KAUFMAN HS, 1981, CLIN ALLERGY, V11, P549, DOI 10.1111/j.1365-2222.1981.tb02173.x; KEENS TG, 1978, J APPL PHYSIOL, V44, P909, DOI 10.1152/jappl.1978.44.6.909; KILBURN K, COMMUNICATION; KOENIG JQ, 1983, AM REV RESPIR DIS, V128, P221; KRAEPELEIN S, 1954, ACTA PAEDIATR SC   S, V43, P100; KUZEMKO JA, 1980, J PEDIATR-US, V97, P886, DOI 10.1016/S0022-3476(80)80415-X; LEBOWITZ MD, 1984, J ALLERGY CLIN IMMUN, V73, P259, DOI 10.1016/S0091-6749(84)80017-2; LOREN ML, 1978, CHEST, V74, P126, DOI 10.1378/chest.74.2.126; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; Macklin CC, 1936, ARCH PATHOL, V21, P202; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARTIN AJ, 1981, MED J AUSTRALIA, V2, P470, DOI 10.5694/j.1326-5377.1981.tb112942.x; MARTIN AJ, 1982, AUST PAEDIATR J, V18, P84; MARTIN AJ, 1981, ACTA PAEDIATR SCAND, V70, P683, DOI 10.1111/j.1651-2227.1981.tb05768.x; MARTIN ME, 1982, ANN ALLERGY, V49, P318; MATSUBA K, 1972, AM REV RESPIR DIS, V105, P908; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; Miettinen's modification, 1974, NIH PUBLICATION, V79-1649; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; MULLALLY DI, 1984, ANN ALLERGY, V53, P15; MULLER NL, 1979, PEDIATR CLIN N AM, V26, P503; ORGEL HA, 1975, PEDIATR CLIN N AM, V22, P17; PALM CR, 1970, J ALLERGY, V46, P257, DOI 10.1016/0021-8707(70)90067-5; PARCEL GS, 1979, PEDIATRICS, V64, P878; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; POLMAR SH, 1972, PEDIATRICS, V50, P279; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; RACHELEFSKY GS, 1974, AM J DIS CHILD, V128, P355, DOI 10.1001/archpedi.1974.02110280085010; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RACHELEFSKY GS, 1975, PEDIATRICS, V56, P443; RACHELEFSKY GS, 1980, ALLERGIC DISORDERS I, P526; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; RACKEMANN FM, 1944, J ALLERGY, V15, P249; ROONEY JC, 1967, J PEDIATR, V70, P533; RUPP GH, 1982, PEDIATRICS, V70, P437; RYSSING E, 1959, Acta Paediatr, V48, P255; SCHIFFER CG, 1963, US DHEW CHILDRENS BU, V405; SCHWARTZ M, 1952, ACTA ALLERG KBH S2, V5, P3; SHAPIRO GG, 1979, PEDIATRICS, V63, P207; SHAPIRO GG, 1983, J ASTHMA, V20, P383, DOI 10.3109/02770908309077381; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SIEGEL SC, 1983, ALLERGY PRINCIPLES P, P863; SIMS DG, 1978, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.6104.11; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SLY RM, 1984, ANN ALLERGY, V53, P20; SMERLER A, 1974, NY STATE J MED, V74, P2166; Smith J M, 1975, Allergol Immunopathol (Madr), V3, P127; SMITH JM, 1976, BRIT J DIS CHEST, V70, P73; SNAITH AH, 1977, LANCET, V2, P500; SPEIZER FE, 1968, BRIT MED J, V3, P245, DOI 10.1136/bmj.3.5612.245; STANHOPE JM, 1979, NEW ZEAL MED J, V90, P279; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; TAUSSIG LM, 1982, J APPL PHYSIOL, V53, P1220, DOI 10.1152/jappl.1982.53.5.1220; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; UNGER L, 1936, J ALLERGY, V7, P364; UTELL MJ, 1983, AM REV RESPIR DIS, V128, P444, DOI 10.1164/arrd.1983.128.3.444; VANASPEREN PP, 1984, CLIN ALLERGY, V14, P525; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; WEISS ST, 1980, AM REV RESPIR DIS, V122, P697, DOI 10.1164/arrd.1980.122.5.697; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WELLIVER RC, 1983, PEDIATR CLIN N AM, V30, P819; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WILSON JD, 1981, LANCET, V1, P1235; 1982, ATS NEWS, P5; 1962, AM REV RESPIR DIS, V875, P761	124	32	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					1	14		10.1016/0091-6749(85)90795-X	http://dx.doi.org/10.1016/0091-6749(85)90795-X			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	3891825				2022-12-18	WOS:A1985AMV8400001
J	BJORKSTEN, F; HAAHTELA, T; BACKMAN, A; SUONIEMI, I				BJORKSTEN, F; HAAHTELA, T; BACKMAN, A; SUONIEMI, I			ASSAY OF THE BIOLOGIC ACTIVITY OF ALLERGEN SKIN-TEST PREPARATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TIURU HOSP,DEPT PULM DIS,TIURUNIEMI,FINLAND		BJORKSTEN, F (corresponding author), UNIV HELSINKI,CENT HOSP,HOSP ALLERG DIS,SF-00250 HELSINKI 25,FINLAND.							AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BECKER EL, 1948, J ALLERGY, V19, P108, DOI 10.1016/0021-8707(48)90097-5; BJORKSTEN F, 1980, ALLERGY, V35, P233, DOI 10.1111/j.1398-9995.1980.tb01757.x; BRIGHTON WD, 1979, CLIN ALLERGY, V9, P591, DOI 10.1111/j.1365-2222.1979.tb00484.x; GRIMMER O, 1980, ALLERGY, V35, P220, DOI 10.1111/j.1398-9995.1980.tb01753.x; HAAHTELA T, 1980, ALLERGY, V35, P15, DOI 10.1111/j.1398-9995.1980.tb01712.x; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; SWAIN HH, 1952, J ALLERGY, V23, P441, DOI 10.1016/0021-8707(52)90008-7; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VOORHORST R, 1979, ANN ALLERGY, V43, P100; 1982, NLN PUBLICATION NORD, V7, P1	13	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					324	331		10.1016/0091-6749(84)90404-4	http://dx.doi.org/10.1016/0091-6749(84)90404-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6699313	Bronze			2022-12-18	WOS:A1984SK15500005
J	GOLDMAN, DW; GOETZL, EJ				GOLDMAN, DW; GOETZL, EJ			SELECTIVE TRANSDUCTION OF HUMAN POLYMORPHONUCLEAR LEUKOCYTE FUNCTIONS BY SUBSETS OF RECEPTORS FOR LEUKOTRIENE-B4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	GOLDMAN, DW (corresponding author), UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,HOWARD HUGHES MED INST LABS,SAN FRANCISCO,CA 94143, USA.		Goldman, David/F-9772-2010	Goldman, David/0000-0002-1724-5405	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019784] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31809] Funding Source: Medline; NIAID NIH HHS [AI 19784] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASS D A, 1981, Progress in Lipid Research, V20, P735; BRAY MA, 1981, BRIT J PHARMACOL, V72, P483, DOI 10.1111/j.1476-5381.1981.tb11000.x; FEINMARK SJ, 1981, FEBS LETT, V136, P141, DOI 10.1016/0014-5793(81)81233-1; FORDHUTCHINSON AW, 1981, J ROY SOC MED, V74, P831, DOI 10.1177/014107688107401111; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GOETZL EJ, 1983, IMMUNOLOGY, V50, P35; GOETZL EJ, 1981, PROSTAGLANDINS, V22, P279, DOI 10.1016/0090-6980(81)90042-3; GOETZL EJ, 1981, J EXP MED, V153, P482, DOI 10.1084/jem.153.2.482; GOETZL EJ, 1980, J IMMUNOL, V125, P1789; GOETZL EJ, 1982, IMMUNOLOGY, V45, P249; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; GOLDMAN DW, 1984, FED PROC, V43, P845; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; KREISLE RA, 1983, J EXP MED, V157, P628, DOI 10.1084/jem.157.2.628; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; LOHR KM, 1982, J IMMUNOL, V129, P1594; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; OFLAHERTY JT, 1981, BIOCHEM BIOPH RES CO, V103, P552, DOI 10.1016/0006-291X(81)90487-3; OFLAHERTY JT, 1981, AM J PATHOL, V105, P264; PALMER RMJ, 1980, PROSTAGLANDINS, V20, P411, DOI 10.1016/S0090-6980(80)80058-X; RAE SA, 1981, J PHARM PHARMACOL, V33, P616, DOI 10.1111/j.2042-7158.1981.tb13884.x; SAMUELSSON B, 1981, BIOCH ACUTE ALLERGIC, P1; SHAAFI RI, 1981, J CELL PHYSIOL, V108, P401, DOI 10.1002/jcp.1041080314; SHOWELL HJ, 1976, J EXP MED, V143, P1154, DOI 10.1084/jem.143.5.1154; SNYDERMAN R, 1983, FED PROC, V42, P2855; VITKAUSKAS G, 1980, MOL IMMUNOL, V17, P171, DOI 10.1016/0161-5890(80)90069-3; WARD PA, 1968, J EXP MED, V127, P693, DOI 10.1084/jem.127.4.693; YULI I, 1982, P NATL ACAD SCI-BIOL, V79, P5906, DOI 10.1073/pnas.79.19.5906	29	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					373	377		10.1016/0091-6749(84)90133-7	http://dx.doi.org/10.1016/0091-6749(84)90133-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6088613				2022-12-18	WOS:A1984TQ63300013
J	KERN, EB				KERN, EB			SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO MED SCH,ROCHESTER,MN 55901	Mayo Clinic								COSTRINI NV, 1977, MANUAL MED THERAPEUT; VANCAUWENBERGE P, 1982, ADV SINUSITIS MICROB	2	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					25	31		10.1016/0091-6749(84)90480-9	http://dx.doi.org/10.1016/0091-6749(84)90480-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6693664				2022-12-18	WOS:A1984SB99000004
J	LEMIRE, I; CARTIER, A; MALO, JL; PINEAU, L; GHEZZO, H; MARTIN, RR				LEMIRE, I; CARTIER, A; MALO, JL; PINEAU, L; GHEZZO, H; MARTIN, RR			EFFECT OF SODIUM CROMOGLYCATE ON HISTAMINE INHALATION TESTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP SACRE COEUR, SERV PNEUMOL, MONTREAL H4J 1C5, QUEBEC, CANADA	Universite de Montreal								ALTOUNYAN REC, 1979, MAST CELL ITS ROLE H, P199; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; COLE M, 1982, MOD PROBL PAEDIATR, V21, P104; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; JUNIPER EF, 1979, J ALLERGY CLIN IMMUN, V63, P161; KANG B, 1976, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6014.867; KERSHNER RP, 1981, J AM STAT ASSOC, V76, P612, DOI 10.2307/2287519; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LENNEY W, 1978, ARCH DIS CHILD, V33, P474; PEGELOW KO, 1974, ACTA ALLERGOL, V29, P365, DOI 10.1111/j.1398-9995.1974.tb01472.x; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927; 1962, AM REV RESPIR DIS, V85, P762; 1979, AM REV RESPIR DIS, V112, P831	19	32	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					234	239		10.1016/S0091-6749(84)80013-5	http://dx.doi.org/10.1016/S0091-6749(84)80013-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6421918				2022-12-18	WOS:A1984SF02000003
J	LEVINE, L; WORTH, N				LEVINE, L; WORTH, N			EICOSAPENTAENOIC ACID - ITS EFFECTS ON ARACHIDONIC-ACID METABOLISM BY CELLS IN CULTURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LEVINE, L (corresponding author), BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027256] Funding Source: NIH RePORTER; NCI NIH HHS [CA 17309] Funding Source: Medline; NIGMS NIH HHS [GM 27256] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAM I, 1979, ANAL BIOCHEM, V93, P339; BERGSTROM S, 1968, PHARMACOL REV, V20, P1; BLACK KL, 1979, PROSTAG LEUKOTR ESS, V3, P257, DOI 10.1016/0161-4630(79)90067-3; COUGHLIN SR, 1981, P NATL ACAD SCI-BIOL, V78, P7134, DOI 10.1073/pnas.78.11.7134; CULP BR, 1979, PROSTAG LEUKOTR ESS, V3, P269, DOI 10.1016/0161-4630(79)90068-5; DYERBERG J, 1975, AM J CLIN NUTR, V28, P958, DOI 10.1093/ajcn/28.9.958; DYERBERG J, 1978, LANCET, V2, P117, DOI 10.1016/s0140-6736(78)91505-2; DYERBERG J, 1978, LANCET, V1, P152; HAYES EC, 1983, J IMMUNOL, V131, P429; HONG SCL, 1976, J BIOL CHEM, V251, P776; KOBAYASHI T, 1983, J BIOL CHEM, V258, P9116; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LEVINE L, 1977, NATURE, V268, P447, DOI 10.1038/268447a0; LEVINE L, 1981, P NATL ACAD SCI-BIOL, V78, P7692, DOI 10.1073/pnas.78.12.7692; LEVINE L, 1981, ADV CANCER RES, V35, P49, DOI 10.1016/S0065-230X(08)60908-2; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; PRICKETT JD, 1981, J CLIN INVEST, V68, P556, DOI 10.1172/JCI110288; SNOEK GT, 1983, CANCER RES, V43, P4743	18	32	32	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					430	436		10.1016/0091-6749(84)90143-X	http://dx.doi.org/10.1016/0091-6749(84)90143-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6088616				2022-12-18	WOS:A1984TQ63300023
J	MATHEWS, KP				MATHEWS, KP			CLINICAL SPECTRUM OF ALLERGIC AND PSEUDOALLERGIC DRUG-REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MATHEWS, KP (corresponding author), UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV ALLERGY, ANN ARBOR, MI 48109 USA.							APPEL GB, 1983, AM J MED, V74, P337, DOI 10.1016/0002-9343(83)90642-3; DUKOR P, 1980, PSEUDOALLERGIC REACT, V2; DUKOR P, 1980, PSEUDOALLERGIC REACT, V1, P1; Ellis EF., 1983, ALLERGY PRINCIPLES P, P1389; FENOGLIO JJ, 1981, HUM PATHOL, V12, P900, DOI 10.1016/S0046-8177(81)80195-5; FISHER AA, 1982, ANN ALLERGY, V49, P97; HASAN T, 1983, J AM ACAD DERMATOL, V8, P836, DOI 10.1016/S0190-9622(83)80013-9; HERMAN JJ, 1983, J ALLERGY CLIN IMMUN, V71, P339, DOI 10.1016/0091-6749(83)90089-1; HOLMBERG L, 1980, AM J MED, V69, P733, DOI 10.1016/0002-9343(80)90443-X; Kleinknecht D, 1983, Adv Nephrol Necker Hosp, V12, P277; KUOKKANEN K, 1972, ACTA ALLERGOL, V27, P407, DOI 10.1111/j.1398-9995.1972.tb01440.x; MILLS PR, 1983, J ROY SOC MED, V76, P393, DOI 10.1177/014107688307600513; NELSON AM, 1980, JAMA-J AM MED ASSOC, V243, P329, DOI 10.1001/jama.1980.03300300011004; PARKER CW, 1982, PHARMACOL REV, V34, P85; PATTERSON R, 1982, JAMA-J AM MED ASSOC, V248, P2637, DOI 10.1001/jama.248.20.2637; SPEED BR, 1982, AUST NZ J MED, V12, P261, DOI 10.1111/j.1445-5994.1982.tb02473.x; TEPPO AM, 1976, SCAND J IMMUNOL, V5, P247; WEBB PK, 1979, JAMA-J AM MED ASSOC, V241, P2061, DOI 10.1001/jama.241.19.2061; WEEDON D, 1982, INT J DERMATOL, V21, P203, DOI 10.1111/j.1365-4362.1982.tb02072.x	19	32	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					558	566		10.1016/0091-6749(84)90107-6	http://dx.doi.org/10.1016/0091-6749(84)90107-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6208232				2022-12-18	WOS:A1984TQ16300004
J	WASSERMAN, SI; GINSBERG, MH				WASSERMAN, SI; GINSBERG, MH			RELEASE OF PLATELET FACTOR-4 INTO THE BLOOD AFTER COLD CHALLENGE OF PATIENTS WITH COLD URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037	Scripps Research Institute	WASSERMAN, SI (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,LA JOLLA,CA 92093, USA.				NHLBI NIH HHS [HL-30312] Funding Source: Medline; NIADDK NIH HHS [AM-27214] Funding Source: Medline; NIAID NIH HHS [AI-17268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017268] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; BASRAN G S, 1983, European Journal of Pharmacology, V86, P143; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRINDLEY LL, 1983, J CLIN INVEST, V72, P1218, DOI 10.1172/JCI111077; CENTER DM, 1977, CLIN RES, V25, P355; DAWES J, 1978, THROMB RES, V12, P851, DOI 10.1016/0049-3848(78)90279-7; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; EADY RAJ, 1981, CLIN EXP DERMATOL, V6, P355, DOI 10.1111/j.1365-2230.1981.tb02318.x; GINSBERG MH, 1980, IMMUNOASSAYS CLIN LA, P351; HANDIN RI, 1978, J LAB CLIN MED, V91, P340; HENSON PM, 1980, PLATELETS BIOL PATHO, P265; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; LEVINE SP, 1977, THROMB RES, V11, P673, DOI 10.1016/0049-3848(77)90025-1; MCMANUS LM, 1981, J CLIN INVEST, V67, P903, DOI 10.1172/JCI110108; PINCKARD RN, 1980, J RETICULOENDOTH SOC, V28, pS95; SIEGEL S, 1956, NONPARAMETRIC STATIS, P237; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; WALTZ D, 1977, THROMB RES, V11, P893; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V57, P570	22	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					275	279		10.1016/0091-6749(84)90258-6	http://dx.doi.org/10.1016/0091-6749(84)90258-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6470362				2022-12-18	WOS:A1984TJ80800010
J	VERVLOET, D; SENFT, M; DUGUE, P; ARNAUD, A; CHARPIN, J				VERVLOET, D; SENFT, M; DUGUE, P; ARNAUD, A; CHARPIN, J			ANAPHYLACTIC REACTIONS TO MODIFIED FLUID GELATINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP ST MARGUERITE,INSERM U174,F-13277 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VERVLOET, D (corresponding author), HOP ST MARGUERITE,DEPT CHEST DIS,F-13277 MARSEILLE 9,FRANCE.							ARNON R, 1960, BIOCHEM J, V75, P103, DOI 10.1042/bj0750103; BENBUNAN M, 1976, ANESTH ANALG REANIM, V33, P709; FREEMAN MK, 1979, ANAESTHESIA, V34, P341, DOI 10.1111/j.1365-2044.1979.tb04933.x; GILLEPSIE E, 1979, BR J CLIN INVEST, V51, P2941; LORENZ W, 1978, AGENTS ACTIONS, V8, P397, DOI 10.1007/BF01968642; LUND N, 1973, BRIT J ANAESTH, V45, P929, DOI 10.1093/bja/45.8.929; MAURER PH, 1956, J IMMUNOL, V76, P335; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; PICCININO F, 1963, Minerva Anestesiol, V29, P340; RING J, 1977, LANCET, V1, P466; SAISSY JM, 1980, ANN ANESTH FRANCE, V2, P148; SHORE PA, 1959, J PHARM, V127, P192; VERVLOET D, 1979, J ALLERGY CLIN IMMUN, V63, P348, DOI 10.1016/0091-6749(79)90130-1; WISBORG K, 1973, BR J ANAESTH, V47, P116; 1979, VOX SANG, V36, P39	15	32	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					535	540		10.1016/0091-6749(83)90433-5	http://dx.doi.org/10.1016/0091-6749(83)90433-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6189875	Bronze			2022-12-18	WOS:A1983QV13900003
J	HUSSAIN, R; NORMAN, PS; MARSH, DG				HUSSAIN, R; NORMAN, PS; MARSH, DG			RAPIDLY RELEASED ALLERGENS FROM SHORT RAGWEED POLLEN .2. IDENTIFICATION AND PARTIAL-PURIFICATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GOOD SAMARITAN HOSP,BALTIMORE,MD 21239; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST LAB,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University			Hussain, Rabia/E-9982-2015		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI004866, R37AI004866] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-04866, AI-09565, AI-13370] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; GOLDFARB AR, 1968, J IMMUNOL, V100, P902; GRIFFITHS BW, 1971, CAN J BIOCHEM CELL B, V49, P396, DOI 10.1139/o71-058; HUSSAIN R, 1980, J ALLERGY CLIN IMMUN, V65, P230; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; LOWENSTEIN H, 1978, J ALLERGY CLIN IMMUN, V61, P180, DOI 10.1016/0091-6749(78)90411-6; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MARSH DG, 1975, IMMUNOCHEMISTRY, V12, P539, DOI 10.1016/0019-2791(75)90081-6; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V67, P206, DOI 10.1016/0091-6749(81)90063-4; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MARSH DG, 1974, ALLERGOLOGIE, P381; MCKABA DG, 1962, J ALLERGY, V33, P18, DOI 10.1016/0021-8707(62)90059-X; ROEBBER MG, 1975, THESIS MCGILL U MONT; SANTILLI J, 1980, J ALLERGY CLIN IMMUN, V65, P406, DOI 10.1016/0091-6749(80)90232-8; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x	20	32	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					217	222		10.1016/0091-6749(81)90064-6	http://dx.doi.org/10.1016/0091-6749(81)90064-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	7462538				2022-12-18	WOS:A1981LG77800009
J	SUMMERS, R; SIGLER, R; SHELHAMER, JH; KALINER, M				SUMMERS, R; SIGLER, R; SHELHAMER, JH; KALINER, M			EFFECTS OF INFUSED HISTAMINE ON ASTHMATIC AND NORMAL SUBJECTS - COMPARISON OF SKIN-TEST RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	SUMMERS, R (corresponding author), WALTER REED ARMY MED CTR,DEPT ALLERGY,WASHINGTON,DC 20012, USA.							ALBERS D, 1942, BEITR KLIN TUBERK, V98, P382; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BEAVEN MA, 1976, NEW ENGL J MED, V294, P320, DOI 10.1056/NEJM197602052940608; BEAVEN MA, 1976, NEW ENGL J MED, V294, P30, DOI 10.1056/NEJM197601012940108; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BOURNE HR, 1971, SCIENCE, V173, P743, DOI 10.1126/science.173.3998.743; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BROWN R, 1977, J APPL PHYSIOL, V42, P221, DOI 10.1152/jappl.1977.42.2.221; BURKA JF, 1976, INT ARCH ALLER A IMM, V50, P664, DOI 10.1159/000231545; CARUSI R, 1930, POLICLINICO SEZ MED, V37, P289; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAKRIN LW, 1974, AGENTS ACTIONS, V4, P297, DOI 10.1007/BF01964930; CHAND N, 1975, AGENTS ACTIONS, V5, P277, DOI 10.1007/BF02205232; CORNELL BS, 1928, J LAB CLIN MED, V14, P290; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; Dale HH, 1919, J PHYSIOL-LONDON, V52, P355; DRAZEN JM, 1978, AM REV RESPIR DIS, V117, P479; DUTTA NK, 1949, BRIT J PHARM CHEMOTH, V4, P281, DOI 10.1111/j.1476-5381.1949.tb00549.x; Gordon W, 1935, J CLIN INVEST, V14, P367, DOI 10.1172/JCI100686; GRODZINSKA L, 1975, J PHARM PHARMACOL, V27, P88, DOI 10.1111/j.2042-7158.1975.tb09414.x; HAGERMARK O, 1979, ACTA DERM-VENEREOL, V59, P297; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HOLROYDE MC, 1978, J PHARMACOL EXP THER, V204, P183; HUTCHCROFT BJ, 1979, J ALLERGY CLIN IMMUN, V63, P376, DOI 10.1016/0091-6749(79)90209-4; KALINER M, 1978, AM REV RESPIR DIS, V118, P1015; KALINER M, 1974, BIOCHEM PHARMACOL, V23, P763, DOI 10.1016/0006-2952(74)90206-8; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; LECOMTE J, 1951, ARCH INT PHYS BIOCH, V59, P395, DOI 10.3109/13813455109145027; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; MACKAY ME, 1977, AM J PHYSL, V82, P546; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; OKPAKO D T, 1974, European Journal of Pharmacology, V29, P10, DOI 10.1016/0014-2999(74)90163-0; Peters GA, 1944, AM HEART J, V27, P845, DOI 10.1016/S0002-8703(44)90315-7; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; PLAUT M, 1979, J ALLERGY CLIN IMMUN, V63, P371, DOI 10.1016/0091-6749(79)90208-2; REDING P, 1977, LANCET, V2, P1227; ROBERTSON I, 1978, BRIT J CLIN PHARMACO, V5, P319, DOI 10.1111/j.1365-2125.1978.tb01714.x; ROCHA, 1961, CHEMOTHERAPIE, V3, P544; SMITH JA, 1979, ANN ALLERGY, V42, P353; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; Stead EA, 1944, J CLIN INVEST, V23, P279, DOI 10.1172/JCI101491; Weiss S, 1932, ARCH INTERN MED, V49, P360, DOI 10.1001/archinte.1932.00150100017002; Windaus A, 1907, BER DTSCH CHEM GES, V40, P3691, DOI 10.1002/cber.190704003164; WOLFE JD, 1979, J ALLERGY CLIN IMMUN, V63, P208; YEN SS, 1976, PROSTAGLANDINS, V11, P227, DOI 10.1016/0090-6980(76)90146-5	45	32	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	6					456	464		10.1016/0091-6749(81)90099-3	http://dx.doi.org/10.1016/0091-6749(81)90099-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LU068	7346529				2022-12-18	WOS:A1981LU06800007
J	ZEISS, CR; GRAMMER, LC; LEVITZ, D				ZEISS, CR; GRAMMER, LC; LEVITZ, D			COMPARISON OF THE RADIOALLERGOSORBENT TEST AND A QUANTITATIVE SOLID-PHASE RADIOIMMUNOASSAY FOR THE DETECTION OF RAGWEED-SPECIFIC IMMUNOGLOBULIN-E ANTIBODY IN PATIENTS UNDERGOING IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ZEISS, CR (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1980, J ALLERGY CLIN IMMUN, V65, P1, DOI 10.1016/0091-6749(80)90169-4; EVANS R, 1975, ADV DIAGNOSIS ALLERG, P3; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HENDRIX S, 1980, J ALLERGY CLIN IMMUN, V65, P164; ISHIZAKA K, 1966, J ALLERGY, V37, P169, DOI 10.1016/0021-8707(66)90091-8; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; LYNCH NR, 1975, CLIN EXP IMMUNOL, V22, P35; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0; ZEISS CR, 1978, J ALLERGY CLIN IMMUN, V62, P83, DOI 10.1016/0091-6749(78)90083-0; ZEISS CR, 1973, J IMMUNOL, V110, P414; ZIMMERMAN BS, 1980, J ALLERGY CLIN IMMUN, V65, P232	15	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					105	110		10.1016/0091-6749(81)90004-X	http://dx.doi.org/10.1016/0091-6749(81)90004-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	7451776				2022-12-18	WOS:A1981LB94700004
J	BIERMAN, CW; SPIRO, SG; PETHERAM, I				BIERMAN, CW; SPIRO, SG; PETHERAM, I			LATE RESPONSE IN EXERCISE-INDUCED ASTHMA (EIA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	3					206	206						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ620					2022-12-18	WOS:A1980JJ62000139
J	SOLLEY, GO; HYATT, RE				SOLLEY, GO; HYATT, RE			HYPERSENSITIVITY PNEUMONITIS INDUCED BY PENICILLIUM SPECIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SOLLEY, GO (corresponding author), MAYO CLIN & MAYO FDN, DEPT MED, ROCHESTER, MN 55901 USA.							ANTHONISEN NR, 1969, RESP PHYSIOL, V8, P58, DOI 10.1016/0034-5687(69)90044-9; AVILA R, 1974, CLIN ALLERGY, V4, P109, DOI 10.1111/j.1365-2222.1974.tb01368.x; BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BATES DV, 1955, J PHYSIOL-LONDON, V129, P237, DOI 10.1113/jphysiol.1955.sp005350; BURKE GW, 1977, JAMA-J AM MED ASSOC, V238, P2705, DOI 10.1001/jama.238.25.2705; COHEN HI, 1967, AM J MED, V43, P785, DOI 10.1016/0002-9343(67)90121-0; DEWECK AL, 1969, SCHWEIZ MED WSCHR, V99, P872; EDWARDS JH, 1976, NATURE, V264, P438, DOI 10.1038/264438a0; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; HARGREAV.FE, 1966, LANCET, V1, P445; PEPYS J, 1963, LANCET, V2, P607; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; RIDDLE HFV, 1968, THORAX, V23, P271, DOI 10.1136/thx.23.3.271; SALVAGGIO J, 1969, AM J MED, V46, P538, DOI 10.1016/0002-9343(69)90073-4; WARHURST DC, 1977, THORAX, V32, P658; 1977, THORAX, V32, P2653	16	32	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					65	70		10.1016/0091-6749(80)90179-7	http://dx.doi.org/10.1016/0091-6749(80)90179-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	7350206				2022-12-18	WOS:A1980JB45900011
J	YACHNIN, S; SOLTANI, K; LESTER, EP				YACHNIN, S; SOLTANI, K; LESTER, EP			FURTHER-STUDIES ON THE MECHANISM OF SUPPRESSION OF HUMAN-LYMPHOCYTE TRANSFORMATION BY HUMAN ALPHA FETOPROTEIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FRANKLIN MCLEAN MEM RES INST,CHICAGO,IL 60637		YACHNIN, S (corresponding author), UNIV CHICAGO,SCH MED,DEPT MED,HEMATOL ONCOL SECT,CHICAGO,IL 60637, USA.							AUER IO, 1977, CELL IMMUNOL, V30, P173, DOI 10.1016/0008-8749(77)90058-2; CHARPENTIER B, 1977, J IMMUNOL, V119, P897; DATTWYLER RJ, 1975, NATURE, V256, P656, DOI 10.1038/256656a0; EARDLEY DD, 1978, J EXP MED, V147, P1106, DOI 10.1084/jem.147.4.1106; GOEKEN NE, 1977, J IMMUNOL, V119, P139; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GUPTA S, 1977, J IMMUNOL, V118, P405; JEGASOTHY BV, 1976, SCIENCE, V193, P1260, DOI 10.1126/science.183266; JOHNSON GD, 1973, HDB EXPT IMMUNOLOGY, pCH18; LESTER EP, 1976, P NATL ACAD SCI USA, V73, P4645, DOI 10.1073/pnas.73.12.4645; LESTER EP, 1978, BIOCHIM BIOPHYS ACTA, V536, P165, DOI 10.1016/0005-2795(78)90062-4; LESTER EP, 1978, IMMUNOLOGY, V34, P189; LESTER EP, 1978, IMMUNOL COMMUN, V7, P137, DOI 10.3109/08820137809033881; LESTER EP, 1977, P NATL ACAD SCI USA, V74, P3988, DOI 10.1073/pnas.74.9.3988; LITTMAN BH, 1977, CELL IMMUNOL, V30, P35, DOI 10.1016/0008-8749(77)90045-4; MURGITA RA, 1975, J EXP MED, V141, P269, DOI 10.1084/jem.141.2.269; MURGITA RA, 1977, NATURE, V267, P257, DOI 10.1038/267257a0; MURGITA RA, 1975, J EXP MED, V141, P440; NAMBA Y, 1977, J IMMUNOL, V118, P1379; NOVOGRODSKY A, 1977, J IMMUNOL, V118, P852; PARKER CW, 1976, NEW ENGL J MED, V295, P1180, DOI 10.1056/NEJM197611182952110; PECK AB, 1978, J EXP MED, V147, P667, DOI 10.1084/jem.147.3.667; RAZ A, 1972, BIOCHEM J, V130, P631, DOI 10.1042/bj1300631; RAZ A, 1972, BIOCHIM BIOPHYS ACTA, V280, P602, DOI 10.1016/0005-2760(72)90140-3; RUOSLAHTI E, 1976, NATURE, V260, P804, DOI 10.1038/260804a0; RUOSLAHTI E, 1976, P NATL ACAD SCI USA, V73, P4641, DOI 10.1073/pnas.73.12.4641; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SETARO F, 1976, ANAL BIOCHEM, V71, P313, DOI 10.1016/0003-2697(76)90043-9; SMITH JW, 1971, J CLIN INVEST, V50, P442, DOI 10.1172/JCI106511; SMITH JW, 1971, J CLIN INVEST, V50, P432, DOI 10.1172/JCI106510; SOLTANI K, 1978, J INVEST DERMATOL, V70, P204, DOI 10.1111/1523-1747.ep12541327; STANWORTH DR, 1973, HDB EXPT IMMUNOLOGY, pCH10; YACHNIN S, 1976, CLIN EXP IMMUNOL, V26, P484; YACHNIN S, 1977, J IMMUNOL, V119, P555; YACHNIN S, 1976, P NATL ACAD SCI USA, V73, P2857, DOI 10.1073/pnas.73.8.2857; YACHNIN S, 1977, BIOCHIM BIOPHYS ACTA, V493, P418, DOI 10.1016/0005-2795(77)90198-2; YACHNIN S, 1975, J EXP MED, V141, P242, DOI 10.1084/jem.141.1.242	37	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					127	135		10.1016/0091-6749(80)90197-9	http://dx.doi.org/10.1016/0091-6749(80)90197-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	6153188	Bronze			2022-12-18	WOS:A1980JF19900008
J	COCKCROFT, DW; TARLO, SM; DOLOVICH, J; HARGREAVE, FE				COCKCROFT, DW; TARLO, SM; DOLOVICH, J; HARGREAVE, FE			ALLERGEN INJECTION THERAPY WITH GLUTARALDEHYDE-MODIFIED-RAGWEED POLLEN-TYROSINE ADSORBATE - DOUBLE-BLIND TRIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA; ST JOSEPHS HOSP,DEPT PEDIAT,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON 16,ONTARIO,CANADA	McGill University; McMaster University; McGill University; McMaster University; McMaster University				Tarlo, Susan/0000-0002-4746-5310				ARBESMAN CE, 1963, J ALLERGY, V34, P39, DOI 10.1016/0021-8707(63)90084-4; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHATTERJEE J, 1974, CAN MED ASSOC J, V110, P659; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FRANKLAND AW, 1954, LANCET, V1, P1055; JOHANSSO.SG, 1974, CLIN ALLERGY, V4, P57, DOI 10.1111/j.1365-2222.1974.tb01363.x; JOHANSSON SG, 1974, CLIN ALLERGY, V4, P255, DOI 10.1111/j.1365-2222.1974.tb01383.x; LAZAR H, 1970, ANN ALLERGY, V28, P214; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; MILLER ACML, 1974, CLIN ALLERGY, V4, P49, DOI 10.1111/j.1365-2222.1974.tb01362.x; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1974, MED CLIN N AM, V58, P111, DOI 10.1016/S0025-7125(16)32181-2; NORMAN PS, 1967, J ALLERGY, V39, P82, DOI 10.1016/0021-8707(67)90114-1; NORMAN PS, 1966, J ALLERGY, V38, P93, DOI 10.1016/0021-8707(66)90048-7; PATTERSON R, 1973, J IMMUNOL, V110, P1402; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	22	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	1					56	62		10.1016/0091-6749(77)90083-5	http://dx.doi.org/10.1016/0091-6749(77)90083-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DN224	406299	Bronze			2022-12-18	WOS:A1977DN22400008
J	KARETZKY, MS				KARETZKY, MS			ASTHMA IN SOUTH BRONX - CLINICAL AND EPIDEMIOLOGIC CHARACTERISTICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MORRISANIA CITY HOSP,BRONX,NY									BOOTH S, 1965, ARCH ENVIRON HEALTH, V10, P152, DOI 10.1080/00039896.1965.10663974; BRODER I, 1962, J ALLERGY, V33, P513, DOI 10.1016/0021-8707(62)90019-9; BROWN EB, 1968, J ALLERGY, V41, P254, DOI 10.1016/0021-8707(68)90031-2; BURCH GE, 1967, ARCH INTERN MED, V120, P389, DOI 10.1001/archinte.120.4.389; DAWSON B, 1969, LANCET, V1, P827; DERRICK E H, 1969, International Journal of Biometeorology, V13, P295, DOI 10.1007/BF01553037; DERRICK E. H., 1960, AUSTRALASIAN ANN MED, V9, P180; DERRICK E. H., 1965, INT J BIOMETEOROL, V9, P239, DOI 10.1007/BF02219956; DERRICK EH, 1971, MED J AUSTRALIA, V1, P1317, DOI 10.5694/j.1326-5377.1971.tb88132.x; DERRICK EH, 1970, MED J AUSTRALIA, V2, P670, DOI 10.5694/j.1326-5377.1970.tb63108.x; EARNEST M, 1966, PUBLIC HEALTH REP, V81, P911, DOI 10.2307/4592867; ERIKSSONLIHR Z, 1963, ACTA PAEDIATR   S140, V52, P80; FAGERBERG ERIK, 1957, ACTA ALLERGOL, V11, P327, DOI 10.1111/j.1398-9995.1957.tb03042.x; Flensborg E. Winge, 1945, ACTA PEDIATRICA [UPPSALA], V33, P4, DOI 10.1111/j.1651-2227.1945.tb16776.x; FORD RM, 1969, MED J AUSTRALIA, V1, P628, DOI 10.5694/j.1326-5377.1969.tb92346.x; GIRSH LS, 1967, J ALLERGY, V39, P347, DOI 10.1016/0021-8707(67)90047-0; GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005; GRAHAM PJ, 1967, BRIT J PREV SOC MED, V21, P78; GREENBUR.L, 1966, ARCH ENVIRON HEALTH, V12, P561, DOI 10.1080/00039896.1966.10664433; GREENBURG L, 1962, JAMA-J AM MED ASSOC, V182, P161, DOI 10.1001/jama.1962.03050410057012; GREENBURG L, 1964, ARCH ENVIRON HEALTH, V8, P642, DOI 10.1080/00039896.1964.10663734; GREENBURG L, 1965, ARCH ENVIRON HEALTH, V10, P351, DOI 10.1080/00039896.1965.10664008; GREENBURG L, 1965, J Asthma Res, V2, P195, DOI 10.3109/02770906509107707; HANRIEDER BD, 1970, CHARACTERISTICS POPU, P25; HERXHEIMER H, 1969, LANCET, V2, P131; HOBDAY JD, 1973, AUST NZ J MED, V3, P552, DOI 10.1111/j.1445-5994.1973.tb04294.x; HORN MEC, 1973, CHEST              S, V63, P44; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; KLEIN A, 1971, NEW ENGL J MED, V285, P179; LEE HY, 1972, BRIT MED J, V2, P93; MARCHAND A M, 1968, Journal of Asthma Research, V6, P93, DOI 10.3109/02770906809100267; MAUNSELL K, 1968, LANCET, V1, P1267; MCINTOSH E, 1973, J PEDIATR, V82, P587; MCKERROW CB, 1968, THORAX, V23, P340, DOI 10.1136/thx.23.4.340; MCNICHOL KN, 1973, BRIT MED J, V4, P16, DOI 10.1136/bmj.4.5883.16; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MITHOEFER JC, 1968, SURGERY AGED DEBILIT, P138; NEWELL RN, 1963, PEDIATRICS, V31, P134; OGILVIE A. G., 1962, THORAX, V17, P183, DOI 10.1136/thx.17.3.183; PEPYS J, 1968, LANCET, V1, P1270; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SALVAGGIO J, 1973, CHEST              S, V63, P14; SMITH JM, 1961, BRIT MED J, V1, P711, DOI 10.1136/bmj.1.5227.711; SPODNIK MJ, 1966, ARCH ENVIRON HEALTH, V13, P243, DOI 10.1080/00039896.1966.10664542; TROMP SW, 1963, 2ND P INT BIOCL C, P477; TROMP SW, 1966, 3 BIOM RES CTR, P1; TULLIS DCH, 1970, NEW ENGL J MED, V282, P370, DOI 10.1056/NEJM197002122820706; VANDELLEN RG, 1971, NEW ENGL J MED, V285, P146, DOI 10.1056/NEJM197107152850304; WELLS RE, 1960, NEW ENGL J MED, V263, P268, DOI 10.1056/NEJM196008112630602; WILLIAMS EO, 1949, BMJ-BRIT MED J, V2, P897, DOI 10.1136/bmj.2.4633.897; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; 1968, LANCET, V1, P1295; 1973, MAR US DEP COMM; 1972, PHC1145 US BUR CE P1	56	32	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	6					383	390		10.1016/0091-6749(77)90070-7	http://dx.doi.org/10.1016/0091-6749(77)90070-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ED834	925262				2022-12-18	WOS:A1977ED83400008
J	WELSH, PW; YUNGINGER, JW; KERN, EB; GLEICH, GJ				WELSH, PW; YUNGINGER, JW; KERN, EB; GLEICH, GJ			PRESEASONAL IGE RAGWEED ANTIBODY LEVEL AS A PREDICTOR OF RESPONSE TO THERAPY OF RAGWEED HAY-FEVER WITH INTRANASAL CROMOLYN SODIUM SOLUTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT OTORHINOLARYNGOL,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								ANDERSON WV, 1972, PRACTITIONER, V208, P676; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V50, P235, DOI 10.1016/0091-6749(72)90017-6; BLAIR H, 1973, Clinical Allergy, V3, P283, DOI 10.1111/j.1365-2222.1973.tb01335.x; BLAIR H, 1972, PRACTITIONER, V208, P671; BLUMENTHAL MN, 1973, J ALLERGY CLIN IMMUN, V52, P105, DOI 10.1016/0091-6749(73)90082-1; CAPEL LH, 1971, LANCET, V1, P575; CHAMPION RH, 1971, LANCET, V1, P187; DIXON WJ, 1969, INTRO STATISTICAL AN, P341; ENGSTROM L, 1971, ANN ALLERGY, V29, P505; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P346, DOI 10.1016/0091-6749(75)90006-8; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P83; HETHERINGTON HD, 1973, MED J AUSTRALIA, V1, P493, DOI 10.5694/j.1326-5377.1973.tb110515.x; HOLOPAIN.E, 1971, LANCET, V1, P55; ILLUM P, 1973, ACTA ALLERGOL, V28, P416, DOI 10.1111/j.1398-9995.1973.tb01455.x; IRANI FA, 1972, AM REV RESPIR DIS, V106, P179, DOI 10.1164/arrd.1972.106.2.179; KNIGHT A, 1976, J ALLERGY CLIN IMMUN, V58, P278, DOI 10.1016/0091-6749(76)90132-9; LEIFERMAN KM, 1975, J ALLERGY CLIN IMMUN, V56, P481, DOI 10.1016/0091-6749(75)90066-4; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOFKVIST T, 1975, ACTA ALLERGOL, V30, P227, DOI 10.1111/j.1398-9995.1975.tb01345.x; LOPEZ M, 1969, J ALLERGY, V44, P118, DOI 10.1016/0021-8707(69)90008-2; MANNERS B, 1973, Clinical Allergy, V3, P311, DOI 10.1111/j.1365-2222.1973.tb01339.x; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; SMITH JM, 1968, BRIT MED J, V2, P340, DOI 10.1136/bmj.2.5601.340; SMITH JM, 1971, LANCET, V1, P295; TAYLOR G, 1971, Clinical Allergy, V1, P189, DOI 10.1111/j.1365-2222.1971.tb03018.x; TOOGOOD JH, 1971, AM REV RESPIR DIS, V104, P323, DOI 10.1164/arrd.1971.104.3.323; TUFFIASH WA, 1975, J ALLERGY CLIN IMMUN, V55, P116; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1975, PEDIATR CLIN N AM, V22, P3; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	32	32	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	2					104	109		10.1016/0091-6749(77)90034-3	http://dx.doi.org/10.1016/0091-6749(77)90034-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR448	406300				2022-12-18	WOS:A1977DR44800003
J	KERN, F; SOBOTKA, AK; VALENTINE, MD; BENTON, AW; LICHTENSTEIN, LM				KERN, F; SOBOTKA, AK; VALENTINE, MD; BENTON, AW; LICHTENSTEIN, LM			ALLERGY TO INSECT STING .3. ALLERGENIC CROSS-REACTIVITY AMONG VESPID VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PENN STATE UNIV,UNIVERSITY PK,PA 16802; JOHNS HOPKINS UNIV GOOD SAMARITAN HOSP,SCH MED,BALTIMORE,MD 21239	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Johns Hopkins University; Johns Hopkins Medicine								BERNTON HS, 1966, J ALLERGY, V36, P284; HUNT KJ, 1975, J ALLERGY CLIN IMMUN, V55, P74; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; LICHTENSTEIN L, 1973, J ALLERGY CLIN IMMUN, V51, P285, DOI 10.1016/0091-6749(73)90130-9; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; MACDONALD J F, 1974, Melanderia, V18, P1; MARSH DG, 1972, IMMUNOLOGY, V22, P1013; MILLER CEF, 1961, CAN ENT            S, V22, P52; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0	10	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					554	559		10.1016/0091-6749(76)90006-3	http://dx.doi.org/10.1016/0091-6749(76)90006-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	58880				2022-12-18	WOS:A1976BV05400006
J	LAMKIN, N; LIEBERMAN, P; HASHIMOTO, K; MOROHASHI, M; SULLIVAN, P				LAMKIN, N; LIEBERMAN, P; HASHIMOTO, K; MOROHASHI, M; SULLIVAN, P			ALLERGIC REACTIONS TO INSULIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TENNESSEE,CTR HLTH SCI,DEPT MED,ALLERGY IMMUNOL SECT,MEMPHIS,TN 38163; VET ADM HOSP,DERMATOL SECT,ELECTRON MICROSCOPY SECT,MEMPHIS,TN 38104	University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center								CONSTAM GR, 1956, DIABETES, V5, P121, DOI 10.2337/diab.5.2.121; DAVIDSON JA, 1974, 34TH ANN M AM DIAB A; DESWARTE RD, 1972, ALLERGIC DIS, P479; DOLOVICH J, 1970, J ALLERGY, V46, P127, DOI 10.1016/0021-8707(70)90091-2; FEDERLIN K, 1971, IMMUNOPATHOLOGY INSU, P19; GAYELIN HR, 1922, J METAB RES, V2, P767; GORDON BE, 1974, ESSENTIALS IMMUNOLOG, P46; HANAUER L, 1961, DIABETES, V10, P105, DOI 10.2337/diab.10.2.105; Kern RA, 1939, J AMER MED ASSOC, V113, P198, DOI 10.1001/jama.1939.02800280010003; KROLL LP, 1971, JOSLINS DIABETES MEL, P659; Lawrence RD, 1925, LANCET, V1, P1125; LIEBERMAN P, 1971, J AMER MED ASSOC, V215, P1106; MATTSON JR, 1975, ARCH INTERN MED, V135, P818, DOI 10.1001/archinte.135.6.818; OBNEDA A, 1974, DIABETES, V23, P41; PATTERSON R, 1969, J IMMUNOL, V103, P1061; PATTERSON R, 1973, Journal of Immunology, V110, P1135; PORTER RD, 1970, J AMER MED ASSOC, V214, P1884, DOI 10.1001/jama.214.10.1884; Poulsen J E, 1967, Acta Med Scand Suppl, V476, P91; SOLLEY GO, 1975, J ALLERGY CLIN IMMUN, V55, P112; TOMSOVIC EJ, 1971, ACTA PAEDIATR SCAND, V60, P647, DOI 10.1111/j.1651-2227.1971.tb07005.x; Williams JR., 1922, J METAB RES, V2, P729; WILLIAMS RH, 1974, TXB ENDOCRINOLOGY, P504; YALOW RS, 1961, AM J MED, V31, P882, DOI 10.1016/0002-9343(61)90030-4	23	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					213	223		10.1016/0091-6749(76)90157-3	http://dx.doi.org/10.1016/0091-6749(76)90157-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	956558				2022-12-18	WOS:A1976BX74400011
J	MATSUMURA, Y; TAN, EM; VAUGHAN, JH				MATSUMURA, Y; TAN, EM; VAUGHAN, JH			HYPERSENSITIVITY TO HISTAMINE AND SYSTEMIC-ANAPHYLAXIS IN MICE WITH PHARMACOLOGIC BETA-ADRENERGIC BLOCKADE - PROTECTION BY NUCLEOTIDES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,DIV ALLERGY & IMMUNOL,LA JOLLA,CA 92037	Scripps Research Institute								BERGMAN RK, 1965, NATURE, V205, P910, DOI 10.1038/205910a0; CRONHOLM LS, 1968, P SOC EXP BIOL MED, V127, P1178; FISHEL CW, 1962, J IMMUNOL, V89, P8; FISHER RA, 1936, STATISTICAL METHODS, P100; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; MATSUMURA Y, 1974, J ALLERGY CLIN IMMUN, V54, P191, DOI 10.1016/0091-6749(74)90061-X; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P395, DOI 10.1016/0091-6749(76)90120-2; MATSUMURA Y, IN PRESS; MUNOZ J, 1968, BACTERIOL REV, V32, P103, DOI 10.1128/MMBR.32.2.103-126.1968; ROBISON GA, 1967, ANN NY ACAD SCI, V139, P703, DOI 10.1111/j.1749-6632.1967.tb41239.x; TOWNLEY RG, 1970, J ALLERGY, V45, P71; TOWNLEY RG, 1967, J ALLERGY, V39, P177, DOI 10.1016/0021-8707(67)90036-6; ZURIER RB, 1974, J CLIN INVEST, V53, P297, DOI 10.1172/JCI107550	13	32	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					387	394		10.1016/0091-6749(76)90119-6	http://dx.doi.org/10.1016/0091-6749(76)90119-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	184134	Bronze			2022-12-18	WOS:A1976CD45400005
J	MCLEAN, JA; CIARKOWSKI, AA; SOLOMON, WR; MATHEWS, KP				MCLEAN, JA; CIARKOWSKI, AA; SOLOMON, WR; MATHEWS, KP			IMPROVED TECHNIQUE FOR NASAL INHALATION CHALLENGE TESTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,MED SCH,DEPT INTERN MED,SECT ALLERGY,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan								BERNSTEI.IL, 1973, J ALLERGY CLIN IMMUN, V51, P22, DOI 10.1016/0091-6749(73)90004-3; BRIDGER GP, 1969, ANN OTOL, V78, P481; COHEN BM, 1969, RESPIRATION, V26, P35, DOI 10.1159/000192591; CONNELL JT, 1968, J ALLERGY, V41, P101; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; DIXON FW, 1949, ANN OTO RHINOL LARYN, V58, P535; FLISBERG K, 1962, Acta Otolaryngol, V55, P457, DOI 10.3109/00016486209127380; GROBLER NJ, 1966, REACTIVITY NASAL MUC; JENSSEN A O, 1973, Clinical Allergy, V3, P277, DOI 10.1111/j.1365-2222.1973.tb01334.x; LIPPMANN M, 1970, ANN OTO RHINOL LARYN, V79, P519, DOI 10.1177/000348947007900314; LOWELL FC, 1967, J ALLERGY, V39, P110; MEAD J, 1961, PHYSIOL REV, V41, P315; PELIKAN Z, 1970, ANN ALLERGY, V28, P548; PETERSON OS, 1974, ARCH ENVIRON HLTH, V28, P31; RALSTON HJ, 1945, AM J PHYSIOL, V144, P305, DOI 10.1152/ajplegacy.1945.144.2.305; ROBINSON C C, 1971, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V75, P402; Rohrer F, 1915, ARCH GES PHYSL, V162, P225; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; SOLOMON WR, 1965, ANN OTO RHINOL LARYN, V74, P978, DOI 10.1177/000348946507400406; SOLOMON WR, 1966, J ALLERGY, V37, P216, DOI 10.1016/0021-8707(66)90116-X; SOLOMON WR, 1969, J ALLERGY, V44, P25, DOI 10.1016/0021-8707(69)90045-8; SOLOMON WR, 1967, J ALLERGY, V39, P108; SOLOMON WR, UNPUBLISHED OBSERVAT; TAKAGI Y, 1969, ANN OTO RHINOL LARYN, V78, P40, DOI 10.1177/000348946907800104; TAYLOR G, 1971, Clinical Allergy, V1, P189, DOI 10.1111/j.1365-2222.1971.tb03018.x; TAYLOR G, 1971, Clinical Allergy, V1, P63, DOI 10.1111/j.1365-2222.1971.tb02448.x; TUFT L, 1950, J ALLERGY, V21, P326, DOI 10.1016/0021-8707(50)90066-9	27	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	2					153	163		10.1016/0091-6749(76)90034-8	http://dx.doi.org/10.1016/0091-6749(76)90034-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BE952	1249349				2022-12-18	WOS:A1976BE95200007
J	SCHUMACHER, MJ; JEFFERY, SE				SCHUMACHER, MJ; JEFFERY, SE			VARIABILITY OF ALTERNARIA-ALTERNATA - BIOCHEMICAL AND IMMUNOLOGICAL CHARACTERISTICS OF CULTURE FILTRATES FROM 7 ISOLATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROY ALEXANDRA HOSP CHILDREN,CAMPERDOWN 2050,NEW S WALES,AUSTRALIA									AAS K, 1970, ARCH DIS CHILD, V45, P221, DOI 10.1136/adc.45.240.221; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BAILEY PJ, 1969, BIOCHIM BIOPHYS ACTA, V185, P381, DOI 10.1016/0005-2744(69)90431-8; BALLOU CE, 1974, SCIENCE, V184, P127, DOI 10.1126/science.184.4133.127; BHATTI T, 1968, CLIN CHIM ACTA, V22, P563, DOI 10.1016/0009-8981(68)90104-6; BRONSKY EA, 1969, PEDIATR CLIN N AM, V16, P85; BUCHT B, 1968, ARCH BIOCHEM BIOPHYS, V124, P135, DOI 10.1016/0003-9861(68)90312-3; CINO PM, 1972, MYCOPATH MYCOL APPL, V47, P285, DOI 10.1007/BF02051666; DUCKWORTH M, 1969, BIOCHEM J, V113, P687, DOI 10.1042/bj1130687; EBNER E, 1973, J BIOL CHEM, V248, P5360; ELLIS MB, 1971, DEMATIACEOUS HYPHOMY, P465; ENDRESEN C, 1973, ACTA PATH MICRO IM B, VB 81, P571; FRANKE RG, 1972, MYCOLOGIA, V64, P830, DOI 10.2307/3757938; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; JOHNSON MC, 1957, J ALLERGY, V28, P170, DOI 10.1016/0021-8707(57)90022-9; KOTHARI GC, 1971, J GEN MICROBIOL, V68, P77, DOI 10.1099/00221287-68-1-77; KRISH.CR, 1961, BIOCHEM J, V78, P715; KULIK MM, 1973, MYCOPATH MYCOL APPL, V51, P1, DOI 10.1007/BF02141281; MARQUARDT H, 1972, HUMANGENETIK, V16, P7, DOI 10.1007/BF00393979; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MINDEN P, 1969, J EXP MED, V130, P931, DOI 10.1084/jem.130.5.931; MINDEN P, 1973, HDB EPXT IMMUNOLOGY, pCH15; Nakayama Y, 1971, Acta Paediatr Jpn, V13, P36; PETTERSSON G, 1968, ARCH BIOCHEM BIOPHYS, V123, P307, DOI 10.1016/0003-9861(68)90139-2; PRINCE HOMER E., 1956, ANN ALLERGY, V14, P15; ROSENFEL.L, 1974, J BIOL CHEM, V249, P2319; SCHLUETER DP, 1972, ANN INTERN MED, V77, P907, DOI 10.7326/0003-4819-77-6-907; SCHMIDT G, 1974, EUR J BIOCHEM, V42, P303, DOI 10.1111/j.1432-1033.1974.tb03340.x; SCHUMACHER MJ, 1975, J ALLERGY CLIN IMMUN, V56, P54, DOI 10.1016/0091-6749(75)90034-2; SCHUMACHER MJ, 1975, J ALLERGY CLIN IMMUN, V56, P39, DOI 10.1016/0091-6749(75)90033-0; SELBY K, 1967, BIOCHEM J, V104, P716, DOI 10.1042/bj1040716; SELBY K, 1965, BIOCHEM J, V94, P578, DOI 10.1042/bj0940578; SIMMONS EG, 1967, MYCOLOGIA, V59, P67, DOI 10.2307/3756943; SNIDER RD, 1974, MYCOLOGIA, V66, P743, DOI 10.2307/3758195; SVENNERHOLM L, 1956, J NEUROCHEM, V1, P42, DOI 10.1111/j.1471-4159.1956.tb12053.x; Tompkins ER, 1942, J BIOL CHEM, V142, P477; TSUCHIYA HM, 1952, J BACTERIOL, V64, P513, DOI 10.1128/JB.64.4.513-519.1952; VARGA JM, 1972, J ALLERGY CLIN IMMUN, V49, P274, DOI 10.1016/0091-6749(72)90095-4; VINCENT PG, 1973, MYCOPATH MYCOL APPL, V51, P251, DOI 10.1007/BF02057797; WELLS WW, 1964, CLIN CHIM ACTA, V10, P352, DOI 10.1016/0009-8981(64)90066-X; WRIGHT GL, 1971, CLIN CHIM ACTA, V32, P285, DOI 10.1016/0009-8981(71)90345-7; WU TCM, 1971, J BACTERIOL, V108, P874, DOI 10.1128/JB.108.2.874-884.1971	42	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	2					263	277		10.1016/0091-6749(76)90131-7	http://dx.doi.org/10.1016/0091-6749(76)90131-7			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA661	985835				2022-12-18	WOS:A1976CA66100003
J	GROSSMAN, J; PUTNAM, JS				GROSSMAN, J; PUTNAM, JS			SMALL AIRWAY-OBSTRUCTION IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM BEAUMONT ARMY MED CTR,DEPT MED,PULM DIV,POB 70465,EL PASO,TX 79920; WILLIAM BEAUMONT ARMY MED CTR,DEPT MED,ALLERGY DIV,POB 70465,EL PASO,TX 79920	William Beaumont Army Medical Center; William Beaumont Army Medical Center								BASS H, 1973, CHEST, V63, P171, DOI 10.1378/chest.63.2.171; Canter H G, 1967, Med Ann Dist Columbia, V36, P584; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; HYATT RE, 1958, J APPL PHYSIOL, V13, P331, DOI 10.1152/jappl.1958.13.3.331; KORY RC, 1961, AM J MED, V30, P243, DOI 10.1016/0002-9343(61)90096-1; LEBLANC P, 1970, J APPL PHYSIOL, V28, P448, DOI 10.1152/jappl.1970.28.4.448; LIM TPK, 1973, AM REV RESPIR DIS, V108, P985; MACKLEM PT, 1971, J APPL PHYSIOL, V22, P167; MATHISON DA, 1973, J ALLERGY CLIN IMMUN, V51, P94, DOI 10.1016/S0091-6749(73)80037-5; MCFADDEN ER, 1972, AM J MED, V52, P725, DOI 10.1016/0002-9343(72)90078-2; OLIVE JT, 1972, AM REV RESPIR DIS, V106, P366, DOI 10.1164/arrd.1972.106.3.366; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2; TOWNLEY RG, 1971, J ALLERGY, V47, P91; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; WOOLCOCK AJ, 1969, J CLIN INVEST, V48, P1097, DOI 10.1172/JCI106066	16	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	1					49	55		10.1016/S0091-6749(75)80007-8	http://dx.doi.org/10.1016/S0091-6749(75)80007-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V2344	1110292				2022-12-18	WOS:A1975V234400006
J	ROSENBERG, TF; MEDSGER, TA; DECICCO, FA; FIREMAN, P				ROSENBERG, TF; MEDSGER, TA; DECICCO, FA; FIREMAN, P			ALLERGIC GRANULOMATOUS ANGIITIS (CHURG-STRAUSS SYNDROME)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion									UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BOURONCLE BA, 1967, AM J MED, V42, P314, DOI 10.1016/0002-9343(67)90030-7; CHURG J, 1951, AM J PATHOL, V27, P277; CITRON BP, 1970, NEW ENGL J MED, V283, P1003, DOI 10.1056/NEJM197011052831901; GOCKE DJ, 1970, LANCET, V2, P1149; KNOWLES HC, 1953, ARCH INTERN MED, V92, P789, DOI 10.1001/archinte.1953.00240240025002; NOVACK SN, 1971, NEW ENGL J MED, V284, P938, DOI 10.1056/NEJM197104292841703; PARONETTO F, 1969, TEXTBOOK IMMUNOPATH, V2, P722; SIEGEL M, 1968, 3RD P INT S NEW YORK, P245; TAWES RL, 1970, ANN SURG, V171, P409, DOI 10.1097/00000658-197003000-00014	9	32	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	1					56	67		10.1016/S0091-6749(75)80008-X	http://dx.doi.org/10.1016/S0091-6749(75)80008-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V2344	1110293	Bronze			2022-12-18	WOS:A1975V234400007
J	SALVAGGIO, J; SEABURY, J				SALVAGGIO, J; SEABURY, J			NEW-ORLEANS ASTHMA .4. SEMIQUANTITATIVE AIRBORNE SPORE SAMPLING, 1967 AND 1968	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		CHAFEE FH, 1964, J ALLERGY, V35, P193, DOI 10.1016/0021-8707(64)90001-2; CORSO ARTURO, 1966, HARVARD UNIV BOT MUS LEAFL, V21, P213; DUPONT EM, 1967, J ALLERGY, V39, P238, DOI 10.1016/0021-8707(67)90017-2; Feinberg S. M., 1936, J ALLERGY, V7, P149; FEINBERG SM, 1935, WISC MED J, V34, P254; FISCHER GW, 1957, BIOLOGY CONTROL SMUT, P6; Gregory PH., 1961, MICROBIOLOGY ATMOSPH, P251; HAMILTON ELIZABETH D., 1959, ACTA ALLERGOL, V13, P143, DOI 10.1111/j.1398-9995.1959.tb02761.x; HIRST J. M., 1953, TRANS BRIT MYCOL SOC, V36, P375; HOLMES R. M., 1963, INTERNATL JOUR BIOMETEOROLOGY, V7, P27, DOI 10.1007/BF02189179; Ingold C. T., 1965, SPORE LIBERATION; KRAMER C. L., 1959, TRANS KANSAS A CAD SCI, V62, P184, DOI 10.2307/3626975; MIQUEL MP, 1885, ANNUAIRE OBSERVATOIR; MORROW MB, 1964, ANN ALLERGY, V22, P575; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; OGDEN EC, 1963, 5 NEW YORK STAT MUS; PADY SM, 1967, J ALLERGY, V39, P302, DOI 10.1016/0021-8707(67)90094-9; PRINCE HE, 1934, TEXAS J MED, V30, P340; Raper KB, 1965, GENUS ASPERGILLUS, P129; RAYNOR GS, 1970, J ALLERGY, V45, P329, DOI 10.1016/0021-8707(70)90041-9; ROOKS R, 1960, J ALLERGY, V31, P97, DOI 10.1016/0021-8707(60)90033-2; SAAD SI, 1959, J BOT, V2, P17; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SALVAGGIO J, IN PRESS; SALVAGGIO JE, 1967, J ALLERGY, V39, P227, DOI 10.1016/0021-8707(67)90015-9; SHAPIRO RS, 1965, J ALLERGY, V36, P472, DOI 10.1016/0021-8707(65)90141-3; SOLOMON WR, 1968, J ALLERGY, V41, P290, DOI 10.1016/0021-8707(68)90034-8; SOLOMON WR, 1967, MANUAL CLINICAL ALLE, P427; SOLOMON WR, 1967, MANUAL CLINICAL ALLE, P402; SOLOMON WR, 1967, MANUAL CLINICAL ALLE, P332; VANDERWERFF J, 1958, MOLD FUNGI BRONCHIAL; 1968, LOCAL CLIMATOLOGIC D	32	32	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	2					82	+		10.1016/0091-6749(71)90090-X	http://dx.doi.org/10.1016/0091-6749(71)90090-X			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K0446	5283606	Bronze			2022-12-18	WOS:A1971K044600003
J	Mobus, L; Rodriguez, E; Harder, I; Stolzl, D; Boraczynski, N; Gerdes, S; Kleinheinz, A; Abraham, S; Heratizadeh, A; Handrick, C; Haufe, E; Werfel, T; Schmitt, J; Weidinger, S				Mobus, Lena; Rodriguez, Elke; Harder, Inken; Stolzl, Dora; Boraczynski, Nicole; Gerdes, Sascha; Kleinheinz, Andreas; Abraham, Susanne; Heratizadeh, Annice; Handrick, Christiane; Haufe, Eva; Werfel, Thomas; Schmitt, Jochen; Weidinger, Stephan		TREATgermany Study Grp	Atopic dermatitis displays stable and dynamic skin transcriptome signatures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; transcriptome; RNA-sequencing; gene expression; dupilumab; cyclosporine; type 2 inflammation; residual signatures	GENE-EXPRESSION; READ ALIGNMENT; RNA-SEQ; ACTIVATION; PROTEINS; TOOL	Background: Skin transcriptome studies in atopic dermatitis (AD) showed broad dysregulation as well as "improvement"under therapy. These observations were mainly made in trials and based on microarray data. Objectives: Our aim was to explore the skin transcriptome and the impact of systemic treatment in patients of the TREATgermany registry. Methods: Biopsy specimens from 59 patients with moderate-tosevere AD before and 30 patients 12 weeks after start of systemic treatment (dupilumab [n = 22] or cyclosporine [n = 8]) and from 31 healthy controls were subjected to mRNA sequencing. Differential expression, pathway enrichment, correlation, and coexpression network analysis were conducted. Results: Both lesional and nonlesional skin showed a stable "core"signature characterized by disturbed epidermal differentiation and activation of IL-31/IL-1 signaling. A second dynamic signature showed progressive enrichment for type 2 inflammation, T(H)17 signaling, and natural killer cell function. Markers correlated with disease activity have functions in epidermal barrier properties and immune modulation. IL4RA was among the top 3 central dysregulated genes. Cyclosporine led to a more pronounced global transcriptome reversion and normalized T(H)17 cell/IL23 signaling, whereas dupilumab led to a stronger increase in level of epidermal differentiation markers. Both treatments strongly decreased levels of type 2 markers, but overall the residual profile was still profoundly different from that of healthy skin. Lower levels of IL4RA and IL13 and high IL36A expression were related to a stronger clinical response to dupilumab. Conclusion: The AD core signature is characterized by dysregulation of genes related to keratinocyte differentiation and itch signaling. A dynamic signature reflects progressive immune responses dominated by type 2 cytokines with an additional role of T(H)17 and natural killer cell signaling.	[Mobus, Lena; Rodriguez, Elke; Harder, Inken; Stolzl, Dora; Boraczynski, Nicole; Gerdes, Sascha; Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol & Allergy, Campus Kiel,Amold Heller Str 3, Kiel, Germany; [Kleinheinz, Andreas] Elbe Med Ctr, Dept Dermatol, Buxtehude, Germany; [Abraham, Susanne] Tech Univ Dresden, Carl Gustav Carus Univ, Univ Allergy Ctr, Med Ctr, Dresden, Germany; [Heratizadeh, Annice; Werfel, Thomas] Hannover Med Sch, Dept Dermatol Allergy & Venereol, Div Immunodermatol & Allergy Res, Hannover, Germany; [Handrick, Christiane] Christiane Handrick, Practice Dermatol & Venereol, Berlin, Germany; [Haufe, Eva; Schmitt, Jochen] Tech Univ Dresden, Ctr Evidence Based Hlth Care, Med Fac Carl Gustav Carus, Dresden, Germany	University of Kiel; Schleswig Holstein University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Hannover Medical School; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Weidinger, S (corresponding author), Univ Hosp Schleswig Holstein, Dept Dermatol & Allergy, Campus Kiel,Amold Heller Str 3, Kiel, Germany.	sweidinger@dermatology.uni-kiel.de	Gerdes, Sascha/J-4308-2017	Gerdes, Sascha/0000-0002-6667-7757; Schmitt, Jochen/0000-0003-0264-0960; Rodriguez, Elke/0000-0003-3692-3950; Mobus, Lena/0000-0003-0685-0893; Sander, Nicole/0000-0001-9084-7069	Sanofi-Aventis Deutschland GmbH; BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) - Innovative Medicines Initiative 2 Joint Undertaking [821511]; European Union's Horizon 2020 research and innovation programme; European Federation of Pharmaceutical Industries and Associations (EFPIA); German Research Council (DFG) cluster of excellence Precision Medicine in Inflammation [EXC2167]	Sanofi-Aventis Deutschland GmbH(Sanofi-Aventis); BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) - Innovative Medicines Initiative 2 Joint Undertaking; European Union's Horizon 2020 research and innovation programme; European Federation of Pharmaceutical Industries and Associations (EFPIA); German Research Council (DFG) cluster of excellence Precision Medicine in Inflammation(German Research Foundation (DFG))	TREATgermany is financially supported by Sanofi-Aventis Deutschland GmbH. This work also received support through BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis), a project funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 821511. The joint undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Infrastructure support was provided through the German Research Council (DFG) cluster of excellence Precision Medicine in Inflammation (grant EXC2167).	Abrahamsen G, 2018, SCI REP-UK, V8, P1; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Berdyshev E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98006; Brandner JM, 2016, CURR PROBL DERMATOL, V49, P27, DOI 10.1159/000441541; Brunner PM, 2019, J ALLERGY CLIN IMMUN, V143, P142, DOI 10.1016/j.jaci.2018.07.028; Brunner PM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09207-z; Castellano F, 2017, MOLECULES, V22, DOI 10.3390/molecules22122151; Chaitidis P, 2005, CYTOKINE, V30, P366, DOI 10.1016/j.cyto.2005.02.004; Choudhary V, 2015, J INVEST DERMATOL, V135, P499, DOI 10.1038/jid.2014.412; Crinier A, 2018, IMMUNITY, V49, P971, DOI 10.1016/j.immuni.2018.09.009; Edfors F, 2016, MOL SYST BIOL, V12, DOI 10.15252/msb.20167144; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Foster AM, 2014, J IMMUNOL, V192, P6053, DOI 10.4049/jimmunol.1301481; Garber M, 2011, NAT METHODS, V8, P469, DOI [10.1038/NMETH.1613, 10.1038/nmeth.1613]; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V144, P482, DOI 10.1016/j.jaci.2018.11.053; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Han HY, 2017, FASEB J, V31, P491, DOI 10.1096/fj.201600679RR; Heratizadeh A, 2020, J EUR ACAD DERMATOL, V34, P1263, DOI 10.1111/jdv.16078; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Koussounadis A, 2015, SCI REP-UK, V5, DOI 10.1038/srep10775; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li S, 2018, IMMUNITY, V49; Liu S, 2011, NUCLEIC ACIDS RES, V39, P578, DOI 10.1093/nar/gkq817; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mack MR, 2020, SCI TRANSL MED, P12; Manetti M, 2012, ANN RHEUM DIS, V71, P1064, DOI 10.1136/annrheumdis-2011-200837; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Marwah VS, 2018, BIOINFORMATICS, V34, P2136, DOI 10.1093/bioinformatics/bty063; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; Nattkemper LA, 2016, ACTA DERM-VENEREOL, V96, P894, DOI 10.2340/00015555-2417; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Reynolds MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015800; Roy NC, 2011, BRIEF FUNCT GENOMICS, V10, P135, DOI 10.1093/bfgp/elr005; Scala G, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2639-2; Smits J, 2017, J INVEST DERMATOL, V137, pS212, DOI 10.1016/j.jid.2017.06.003; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Tsoi LC, 2020, J ALLERGY CLIN IMMUN, V145, P1406, DOI 10.1016/j.jaci.2019.11.047; Tsoi LC, 2019, J INVEST DERMATOL, V139, P1480, DOI 10.1016/j.jid.2018.12.018; USUKI K, 1992, BIOCHEM BIOPH RES CO, V184, P1311, DOI 10.1016/S0006-291X(05)80025-7; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Zeeuwen PLJM, 2004, HUM MOL GENET, V13, P1069, DOI 10.1093/hmg/ddh115; Zhu AQ, 2019, BIOINFORMATICS, V35, P2084, DOI 10.1093/bioinformatics/bty895	52	31	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					213	223		10.1016/j.jaci.2020.06.012	http://dx.doi.org/10.1016/j.jaci.2020.06.012		JAN 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32615169	Green Published			2022-12-18	WOS:000613645900025
J	Qi, CC; Jiang, Y; Yang, IV; Forno, E; Wang, T; Vonk, JM; Gehring, U; Smit, HA; Milanzi, EB; Carpaij, OA; Berg, M; Hesse, L; Brouwer, S; Cardwell, J; Vermeulen, CJ; Acosta-Perez, E; Canino, G; Boutaoui, N; van den Berge, M; Teichmann, SA; Nawijn, MC; Chen, W; Celedon, JC; Xu, CJ; Koppelman, GH				Qi, Cancan; Jiang, Yale; Yang, Ivana, V; Forno, Erick; Wang, Ting; Vonk, Judith M.; Gehring, Ulrike; Smit, Henriette A.; Milanzi, Edith B.; Carpaij, Orestes A.; Berg, Marijn; Hesse, Laura; Brouwer, Sharon; Cardwell, Jonathan; Vermeulen, Cornelis J.; Acosta-Perez, Edna; Canino, Glorisa; Boutaoui, Nadia; van den Berge, Maarten; Teichmann, Sarah A.; Nawijn, Martijn C.; Chen, Wei; Celedon, Juan C.; Xu, Cheng-Jian; Koppelman, Gerard H.			Nasal DNA methylation profiling of asthma and rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; rhinitis; united airways; epigenetics; environmental exposure	EPIGENOME-WIDE ASSOCIATION; EPITHELIAL-CELLS; CHILDREN; BIRTH; RISK; IGE; METAANALYSIS; EOSINOPHILS; EXPOSURE; ECZEMA	Background: Epigenetic signatures in the nasal epithelium, which is a primary interface with the environment and an accessible proxy for the bronchial epithelium, might provide insights into mechanisms of allergic disease. Objective: We aimed to identify and interpret methylation signatures in nasal epithelial brushes associated with rhinitis and asthma. Methods: Nasal epithelial brushes were obtained from 455 children at the 16-year follow-up of the Dutch Prevention and Incidence of Asthma and Mite Allergy birth cohort study. Epigenome-wide association studies were performed on children with asthma, rhinitis, and asthma and/or rhinitis (AsRh) by using logistic regression, and the top results were replicated in 2 independent cohorts of African American and Puerto Rican children. Significant CpG sites were related to environmental exposures (pets, active and passive smoking, and molds) during secondary school and were correlated with gene expression by RNA-sequencing (n = 244). Results: The epigenome-wide association studies identified CpG sites significantly associated with rhinitis (n = 81) and AsRh (n = 75), but not with asthma. We significantly replicated 62 of 81 CpG sites with rhinitis and 60 of 75 with AsRh, as well as 1 CpG site with asthma. Methylation of cg03565274 was negatively associated with AsRh and positively associated with exposure to pets during secondary school. DNA methylation signals associated with AsRh were mainly driven by specific IgE positive subjects. DNA methylation related to gene transcripts that were enriched for immune pathways and expressed in immune and epithelial cells. Nasal CpG sites performed well in predicting AsRh. Conclusions: We identified replicable DNA methylation profiles of asthma and rhinitis in nasal brushes. Exposure to pets may affect nasal epithelial methylation in relation to asthma and rhinitis.	[Qi, Cancan; Xu, Cheng-Jian; Koppelman, Gerard H.] Univ Groningen, Dept Pediat Pulmonol & Pediat Allergy, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen, Netherlands; [Vonk, Judith M.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Carpaij, Orestes A.; Vermeulen, Cornelis J.; van den Berge, Maarten] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands; [Berg, Marijn; Hesse, Laura; Brouwer, Sharon; Nawijn, Martijn C.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands; [Qi, Cancan; Vonk, Judith M.; Carpaij, Orestes A.; Berg, Marijn; Hesse, Laura; Brouwer, Sharon; Vermeulen, Cornelis J.; van den Berge, Maarten; Nawijn, Martijn C.; Xu, Cheng-Jian; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Gronigen Res Inst Asthma & COPD, Groningen, Netherlands; [Jiang, Yale; Forno, Erick; Wang, Ting; Boutaoui, Nadia; Chen, Wei; Celedon, Juan C.] UPMC Childrens Hosp Pittsburgh, Div Pulm Med, Pittsburgh, PA USA; [Jiang, Yale; Forno, Erick; Wang, Ting; Boutaoui, Nadia; Chen, Wei; Celedon, Juan C.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Jiang, Yale] Tsinghua Univ, Sch Med, Beijing, Peoples R China; [Yang, Ivana, V; Cardwell, Jonathan] Univ Colorado, Dept Med, Aurora, CO USA; [Gehring, Ulrike; Milanzi, Edith B.] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Smit, Henriette A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Acosta-Perez, Edna; Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA; [Teichmann, Sarah A.] Wellcome Sanger Inst, Wellcome Genome Campus, Cambridge, England; [Teichmann, Sarah A.] Univ Cambridge, Cavendish Lab, Theory Condensed Matter Grp, Dept Phys, Cambridge, England; [Xu, Cheng-Jian] Ctr Individualised Infect Med, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany; [Xu, Cheng-Jian] TWINCORE, Ctr Expt & Clin Infect Res, Hannover, Germany	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tsinghua University; University of Colorado System; University of Colorado Anschutz Medical Campus; Utrecht University; Utrecht University; Utrecht University Medical Center; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Wellcome Trust Sanger Institute; University of Cambridge; Helmholtz Association; Helmholtz-Center for Infection Research	Koppelman, GH (corresponding author), Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp, POB 30-001, NL-9700 RB Groningen, Netherlands.	g.h.koppelman@umcg.nl	Milanzi, Edith/AAH-3566-2021; Chen, Wei/AAX-5994-2020; Xu, Cheng-Jian/G-9144-2018; Qi, Cancan/ABG-5425-2020; Xu, Cheng/GXH-4815-2022; Forno, Erick/I-1476-2019	Milanzi, Edith/0000-0002-7305-6035; Chen, Wei/0000-0001-7196-8703; Xu, Cheng-Jian/0000-0003-1586-4672; Xu, Cheng/0000-0003-1000-733X; Forno, Erick/0000-0001-6497-9885; Hesse, Laura/0000-0002-0009-4903; Koppelman, Gerard/0000-0001-8567-3252; Berg, Marijn/0000-0002-9870-1571; Gehring, Ulrike/0000-0003-3612-5780; van den Berge, Maarten/0000-0002-9336-7340; Qi, Cancan/0000-0003-3825-5802; Nawijn, Martijn/0000-0003-3372-6521; acosta, edna/0000-0001-7101-3157	Netherlands Organization for Health Research and Development; Netherlands Organization for Scientific Research; Lung Foundation of the Netherlands [AF 4.1.14.001]; Netherlands Ministry of Spatial Planning, Housing, and the Environment; Netherlands Ministry of Health, Welfare, and Sport; China Scholarship Council; US National Institutes of Health (NIH) [HL079966, HL117191]; NIH [MD011764, U54MD007587, N01-AI90052]; Department of Pediatrics of UPMC Children's Hospital of Pittsburgh	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Lung Foundation of the Netherlands; Netherlands Ministry of Spatial Planning, Housing, and the Environment; Netherlands Ministry of Health, Welfare, and Sport; China Scholarship Council(China Scholarship Council); US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Pediatrics of UPMC Children's Hospital of Pittsburgh	The PIAMA study was supported by The Netherlands Organization for Health Research and Development; The Netherlands Organization for Scientific Research; the Lung Foundation of the Netherlands (with methylation studies supported by AF 4.1.14.001); The Netherlands Ministry of Spatial Planning, Housing, and the Environment; and The Netherlands Ministry of Health, Welfare, and Sport. C.Q. was supported by a grant from the China Scholarship Council. The Epigenetic Variation and Childhood Asthma in Puerto Ricans Study was supported by grants HL079966 and HL117191 from the US National Institutes of Health (NIH). The contributions of J.C.C. and W.C. were additionally supported by grant MD011764 from the NIH, and RNA Sequencing was funded by the Department of Pediatrics of UPMC Children's Hospital of Pittsburgh. Research infrastructure for the Epigenetic Variation and Childhood Asthma in Puerto Ricans Study was additionally supported by grant U54MD007587 from the NIH. The Inner City Asthma Consortium was supported by contract N01-AI90052 from the NIH.	Bergougnoux A, 2015, EPIGENOMICS-UK, V7, P119, DOI [10.2217/EPI.14.65, 10.2217/epi.14.65]; Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5; Burnham ME, 2013, J IMMUNOL, V191, P2900, DOI 10.4049/jimmunol.1300297; Cardenas A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11058-3; Chen W, 2017, J ALLERGY CLIN IMMUN, V140, P571, DOI 10.1016/j.jaci.2016.11.030; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Forno E, 2019, LANCET RESP MED, V7, P336, DOI 10.1016/S2213-2600(18)30466-1; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gur Michal, 2017, F1000Res, V6, P2152, DOI 10.12688/f1000research.11601.1; HARTIGAN JA, 1985, ANN STAT, V13, P70, DOI 10.1214/aos/1176346577; Herwig R, 2016, NAT PROTOC, V11, P1889, DOI 10.1038/nprot.2016.117; Imkamp K, 2018, J ALLERGY CLIN IMMUN, V142, P314, DOI 10.1016/j.jaci.2018.01.047; Jang Y, 2014, CELL CALCIUM, V55, P355, DOI 10.1016/j.ceca.2014.02.006; Jiang HY, 2017, MOL MED REP, V16, P8477, DOI 10.3892/mmr.2017.7595; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Lopez-Guisa JM, 2012, J ALLERGY CLIN IMMUN, V129, P990, DOI 10.1016/j.jaci.2011.11.035; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Nicodemus-Johnson J, 2016, AM J RESP CRIT CARE, V193, P376, DOI 10.1164/rccm.201506-1243OC; O'Connor GT, 2018, J ALLERGY CLIN IMMUN, V141, P1468, DOI 10.1016/j.jaci.2017.06.040; Ordovas-Montanes J, 2018, NATURE, V560, P649, DOI 10.1038/s41586-018-0449-8; Park HW, 2014, J ALLERGY CLIN IMMUN, V133, P664, DOI 10.1016/j.jaci.2013.12.1042; Park SJ, 2007, EXP MOL MED, V39, P629, DOI 10.1038/emm.2007.69; Pedersen BS, 2012, BIOINFORMATICS, V28, P2986, DOI 10.1093/bioinformatics/bts545; Pelucchi C, 2013, J ALLERGY CLIN IMMUN, V132, P616, DOI 10.1016/j.jaci.2013.04.009; Peters TJ, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-6; Pinart M, 2014, LANCET RESP MED, V2, P131, DOI 10.1016/S2213-2600(13)70277-7; Raedler D, 2015, J ALLERGY CLIN IMMUN, V135, P81, DOI 10.1016/j.jaci.2014.07.046; Rochman M, 2015, MUCOSAL IMMUNOL, V8, P785, DOI 10.1038/mi.2014.109; Saulyte J, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001611; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Thacher JD, 2017, ALLERGY, V72, P967, DOI 10.1111/all.13102; Tost J, 2018, LANCET RESP MED, V6, P322, DOI 10.1016/S2213-2600(18)30051-1; van Iterson M, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1131-9; van Strien RT, 2002, ENVIRON HEALTH PERSP, V110, pA693, DOI 10.1289/ehp.021100693; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x; Wijga AH, 2014, INT J EPIDEMIOL, V43, P527, DOI 10.1093/ije/dys231; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Wu DW, 2018, AM J RHINOL ALLERGY, V32, P359, DOI 10.1177/1945892418782233; Xu CJ, 2018, LANCET RESP MED, V6, P379, DOI 10.1016/S2213-2600(18)30052-3; Yang IV, 2017, J ALLERGY CLIN IMMUN, V139, P1478, DOI 10.1016/j.jaci.2016.07.036; Yip KH, 2014, J ALLERGY CLIN IMMUN, V133, P1356, DOI 10.1016/j.jaci.2013.11.030; Zariwala MA, 2013, AM J HUM GENET, V93, P336, DOI 10.1016/j.ajhg.2013.06.007; Zhang X, 2018, EPIGENOMICS-UK, V10, P629, DOI 10.2217/epi-2017-0127; Zhu ZZ, 2018, NAT GENET, V50, P857, DOI 10.1038/s41588-018-0121-0	46	31	32	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1655	1663		10.1016/j.jaci.2020.12.911	http://dx.doi.org/10.1016/j.jaci.2020.12.911			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	31953105				2022-12-18	WOS:000539157800020
J	Mansbach, JM; Luna, PN; Shaw, CA; Hasegawa, K; Petrosino, JF; Piedra, PA; Sullivan, AF; Espinola, JA; Stewart, CJ; Camargo, CA				Mansbach, Jonathan M.; Luna, Pamela N.; Shaw, Chad A.; Hasegawa, Kohei; Petrosino, Joseph F.; Piedra, Pedro A.; Sullivan, Ashley F.; Espinola, Janice A.; Stewart, Christopher J.; Camargo, Carlos A., Jr.			Increased Moraxella and Streptococcus species abundance after severe bronchiolitis is associated with recurrent wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchiolitis; recurrent wheezing; Moraxella species; Streptococcus species; Haemophilus species; respiratory syncytial virus; rhinovirus; longitudinal studies; microbiome	RESPIRATORY SYNCYTIAL VIRUS; NASOPHARYNGEAL MICROBIOTA; PATHOGENIC BACTERIA; CHILDHOOD ASTHMA; AIRWAY; INFECTION; CHILDREN; INFANTS; RISK	Background: The role of the airway microbiome in the development of recurrent wheezing and asthma remains uncertain, particularly in the high-risk group of infants hospitalized for bronchiolitis. Objective: We sought to examine the relation of the nasal microbiota at bronchiolitis-related hospitalization and 3 later points to the risk of recurrent wheezing by age 3 years. Methods: In 17 US centers researchers collected clinical data and nasal swabs from infants hospitalized for bronchiolitis. Trained parents collected nasal swabs 3 weeks after hospitalization and, when healthy, during the summer and 1 year after hospitalization. We applied 16S rRNA gene sequencing to all nasal swabs. We used joint modeling to examine the relation of longitudinal nasal microbiota abundances to the risk of recurrent wheezing. Results: Among 842 infants hospitalized for bronchiolitis, there was 88% follow-up at 3 years, and 31% had recurrent wheezing. The median age at enrollment was 3.2 months (interquartile range, 1.7-5.8 months). In joint modeling analyses adjusting for 16 covariates, including viral cause, a 10% increase in relative abundance of Moraxella or Streptococcus species 3 weeks after day 1 of hospitalization was associated with an increased risk of recurrent wheezing (hazard ratio [HR] of 1.38 and 95% highdensity interval [HDI] of 1.11-1.85 and HR of 1.76 and 95% HDI of 1.13-3.19, respectively). Increased Streptococcus species abundance the summer after hospitalization was also associated with a greater risk of recurrent wheezing (HR, 1.76; 95% HDI, 1.15-3.27). Conclusions: Enrichment of Moraxella or Streptococcus species after bronchiolitis hospitalization was associated with recurrent wheezing by age 3 years, possibly providing new avenues to ameliorate the long-term respiratory outcomes of infants with severe bronchiolitis.	[Mansbach, Jonathan M.] Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; [Luna, Pamela N.; Shaw, Chad A.] Rice Univ, Dept Stat, Houston, TX 77251 USA; [Shaw, Chad A.] Baylor Univ, Dept Mol & Human Genet, Houston, TX 77030 USA; [Hasegawa, Kohei; Sullivan, Ashley F.; Espinola, Janice A.; Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Petrosino, Joseph F.; Stewart, Christopher J.] Baylor Coll Med, Alkek Ctr Metagen & Microbiome Res, Houston, TX 77030 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Stewart, Christopher J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England	Harvard University; Boston Children's Hospital; Harvard Medical School; Rice University; Baylor University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Newcastle University - UK	Mansbach, JM (corresponding author), Boston Childrens Hosp, Main Clin Bldg,9157,300 Longwood Ave, Boston, MA 02115 USA.	jonathan.mansbach@childrens.harvard.edu	Stewart, Christopher/M-4615-2017; Camargo, Carlos A./C-2145-2008	Stewart, Christopher/0000-0002-6033-338X; Camargo, Carlos A./0000-0002-5071-7654	National Institute of Allergy and Infectious Diseases [U01 AI-087881, R01 AI-114552, R01 AI-108588, R01 AI-137091, R01 AI-134940]; Office of the Director at the National Institutes of Health (Bethesda, Md) [UG3/UH3 OD-023253]	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of the Director at the National Institutes of Health (Bethesda, Md)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants U01 AI-087881, R01 AI-114552, R01 AI-108588, R01 AI-137091, and R01 AI-134940 from the National Institute of Allergy and Infectious Diseases and UG3/UH3 OD-023253 from the Office of the Director at the National Institutes of Health (Bethesda, Md). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Beigelman A, 2015, J ALLERGY CLIN IMMUN, V135, P1171, DOI 10.1016/j.jaci.2014.10.001; Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P1283, DOI 10.1164/rccm.201407-1240OC; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Depner M, 2017, J ALLERGY CLIN IMMUN, V139, P826, DOI 10.1016/j.jaci.2016.05.050; Dharmage SC, 2009, EUR RESPIR J, V33, P237, DOI 10.1183/09031936.00062907; Dickson RP, 2014, LANCET RESP MED, V2, P238, DOI 10.1016/S2213-2600(14)70028-1; Fazlollahi M, 2018, J ALLERGY CLIN IMMUN, V142, P834, DOI 10.1016/j.jaci.2018.02.020; Folsgaard NV, 2013, AM J RESP CRIT CARE, V187, P589, DOI 10.1164/rccm.201207-1297OC; Gelman A, 2012, J RES EDUC EFF, V5, P189, DOI 10.1080/19345747.2011.618213; Hasegawa K, 2016, EUR RESPIR J, V48, P1329, DOI 10.1183/13993003.00152-2016; Hasegawa K, 2014, EXPERT REV ANTI-INFE, V12, P817, DOI 10.1586/14787210.2014.906901; Hasegawa K, 2013, PEDIATRICS, V132, P28, DOI 10.1542/peds.2012-3877; Hickey GL, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0212-5; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2010, J ALLERGY CLIN IMMUN, V127, pe1; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Lemon KP, 2010, MBIO, V1, DOI 10.1128/mBio.00129-10; Luna PN, 2018, MICROBIOME, V6, DOI 10.1186/s40168-017-0385-0; Mansbach JM, 2019, J INFECT DIS, V219, P1804, DOI 10.1093/infdis/jiy741; Mansbach JM, 2016, J ALLERGY CLIN IMMUN, V137, P1909, DOI 10.1016/j.jaci.2016.01.036; Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669; Marri PR, 2012, J ALLERGY CLIN IMMUN, V131, pe1; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McDougall CM, 2008, AM J RESP CELL MOL, V39, P560, DOI 10.1165/rcmb.2007-0325OC; Meissner HC, 2016, NEW ENGL J MED, V374, P62, DOI 10.1056/NEJMra1413456; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Piters WAAD, 2016, AM J RESP CRIT CARE, V194, P1104, DOI 10.1164/rccm.201602-0220OC; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Rosas-Salazar C, 2016, AM J RESP CRIT CARE, V193, P1180, DOI 10.1164/rccm.201512-2350LE; Sande CJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10222-z; Spacova I, 2019, ALLERGY, V74, P100, DOI 10.1111/all.13502; Teo SM, 2018, CELL HOST MICROBE, V24, P341, DOI 10.1016/j.chom.2018.08.005; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Zhou YJ, 2016, J ALLERGY CLIN IMMUN, V138, P1215, DOI 10.1016/j.jaci.2016.03.054	36	31	32	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					518	+		10.1016/j.jaci.2019.10.034	http://dx.doi.org/10.1016/j.jaci.2019.10.034			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31738994	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000512887400015
J	Schoettler, N; Rodriguez, E; Weidinger, S; Ober, C				Schoettler, Nathan; Rodriguez, Elke; Weidinger, Stephan; Ober, Carole			Advances in asthma and allergic disease genetics: Is bigger always better?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic disease; genetics	GENOME-WIDE ASSOCIATION; IMMUNOGLOBULIN-E LEVEL; BRONCHODILATOR RESPONSE; CHILDHOOD-ONSET; HAY-FEVER; HLA ANTIGENS; RISK LOCI; VARIANTS; CHILDREN; EXACERBATIONS	This review focuses on genome-wide association studies (GWASs) of asthma and allergic diseases published between January 1, 2018, and June 30, 2019. During this time period, there were 38 GWASs reported in 19 articles, including the largest performed to date for many of these conditions. Overall, we learned that childhood-onset asthma is associated with the most independent loci compared with other defined groups of asthma and allergic disease cases; adult-onset asthma and moderate-to-severe asthma are associated with fewer genes, which are largely a subset of those associated with childhood-onset asthma. There is significant genetic overlap between asthma and allergic diseases, particularly with respect to childhood-onset asthma, which involves genes that reflect the importance of barrier function biology, and to HLA region genes, which are the most frequently associated genes overall in both groups of diseases. Although the largest GWASs in African American and Latino/Hispanic populations were reported during this period, they are still significantly underpowered compared with studies reported in populations of European ancestry, highlighting the need for larger studies, particularly in patients with childhood-onset asthma and allergic diseases, in these important populations that carry the greatest burden of disease.	[Schoettler, Nathan] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA; [Schoettler, Nathan; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Rodriguez, Elke; Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol Allergol & Venereol, Campus Kiel, Kiel, Germany	University of Chicago; University of Chicago; University of Kiel; Schleswig Holstein University Hospital	Schoettler, N (corresponding author), 5841 S Maryland Ave,MC6026, Chicago, IL 60637 USA.	Nathan.Schoettler@uchospitals.edu	Rodríguez, Elke/C-4259-2013	Rodríguez, Elke/0000-0003-3692-3950	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122712, R01HL129735] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P1513, DOI 10.1016/j.jaci.2017.10.047; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P991, DOI 10.1016/j.jaci.2017.09.015; Bhattacharjee S, 2012, AM J HUM GENET, V90, P821, DOI 10.1016/j.ajhg.2012.03.015; Blake K, 2008, CHEST, V134, P981, DOI 10.1378/chest.07-2991; BLUMENTHAL M, 1985, J ALLERGY CLIN IMMUN, V75, P155, DOI 10.1016/0091-6749(85)90338-0; BLUMENTHAL M, 1992, J IMMUNOL, V148, P411; BLUMENTHAL MN, 1974, SCIENCE, V184, P1301, DOI 10.1126/science.184.4143.1301; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; Bush Andrew, 2009, Proc Am Thorac Soc, V6, P712, DOI 10.1513/pats.200906-046DP; BUSSE W, 1995, AM J RESP CRIT CARE, V151, P1635, DOI 10.1164/ajrccm.151.5.7735626; Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Dahl A, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008009; Dahlin A, 2019, J ALLERGY CLIN IMMUN, V143, P1633, DOI 10.1016/j.jaci.2018.11.037; Dahlin A, 2015, IMMUN INFLAMM DIS, V3, P350, DOI 10.1002/iid3.73; Daya M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08469-7; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; Drake KA, 2014, J ALLERGY CLIN IMMUN, V133, P370, DOI 10.1016/j.jaci.2013.06.043; Duan QL, 2014, PHARMACOGENOMICS J, V14, P41, DOI 10.1038/tpj.2013.5; Ernst P, 2002, AM J MED, V112, P44, DOI 10.1016/S0002-9343(01)01033-6; Fagnani C, 2008, TWIN RES HUM GENET, V11, P121, DOI 10.1375/twin.11.2.121; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Ferreira MAR, 2019, AM J HUM GENET, V104, P665, DOI 10.1016/j.ajhg.2019.02.022; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Fujii R, 2018, NAGOYA J MED SCI, V80, P109, DOI 10.18999/nagjms.80.1.109; Gignoux CR, 2019, J ALLERGY CLIN IMMUN, V143, P957, DOI 10.1016/j.jaci.2016.08.057; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Hernandez-Pacheco N, 2019, CLIN EXP ALLERGY, V49, P789, DOI 10.1111/cea.13354; Himes BE, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002824; Israel E, 2015, AM J RESP CRIT CARE, V191, P530, DOI 10.1164/rccm.201408-1426OC; Keet CA, 2015, J ALLERGY CLIN IMMUN, V135, P655, DOI 10.1016/j.jaci.2014.11.022; Khor SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18241-w; Kreiner E, 2017, J ALLERGY CLIN IMMUN, V140, P771, DOI 10.1016/j.jaci.2016.10.055; Levin AM, 2019, J ALLERGY CLIN IMMUN, V143, P1791, DOI 10.1016/j.jaci.2018.09.034; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Liu X, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000010043, 10.1097/md.0000000000010043]; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Mak ACY, 2018, AM J RESP CRIT CARE, V197, P1552, DOI 10.1164/rccm.201712-2529OC; Marenholz I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01220-0; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Mills MC, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-018-0261-x; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; Mosteller M, 2017, J ALLERGY CLIN IMMUN, V139, P797, DOI 10.1016/j.jaci.2016.05.032; Noguchi E, 2019, J ALLERGY CLIN IMMUN, V144, P1354, DOI 10.1016/j.jaci.2019.06.034; Park TJ, 2014, CLIN CHIM ACTA, V436, P20, DOI 10.1016/j.cca.2014.04.023; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pickrell JK, 2016, NAT GENET, V48, P709, DOI 10.1038/ng.3570; Pividori M, 2019, LANCET RESP MED, V7, P509, DOI 10.1016/S2213-2600(19)30055-4; Shrine N, 2019, LANCET RESP MED, V7, P20, DOI 10.1016/S2213-2600(18)30389-8; Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539; Spear ML, 2019, PHARMACOGENOMICS J, V19, P249, DOI 10.1038/s41397-018-0042-4; Tantisira KG, 2012, AM J RESP CRIT CARE, V185, P1286, DOI 10.1164/rccm.201111-2061OC; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Urquhart A, 2020, J ASTHMA, V57, P510, DOI 10.1080/02770903.2019.1590588; Vercelli D, 2006, J ALLERGY CLIN IMMUN, V117, P1303, DOI 10.1016/j.jaci.2006.03.030; Vicente CT, 2015, AM J HUM GENET, V97, P329, DOI 10.1016/j.ajhg.2015.06.010; Vijverberg SJH, 2015, CLIN EXP ALLERGY, V45, P1051, DOI 10.1111/cea.12492; Vonk JM, 2018, CLIN EXP ALLERGY, V48, P1286, DOI 10.1111/cea.13181; Waage J, 2018, NAT GENET, V50, P1072, DOI 10.1038/s41588-018-0157-1; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Wang Y, 2015, PHARMACOGENOMICS J, V15, P422, DOI 10.1038/tpj.2014.83; Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132; Wu AC, 2014, J ALLERGY CLIN IMMUN, V133, P723, DOI 10.1016/j.jaci.2013.09.037; Zahran HS, 2018, MMWR-MORBID MORTAL W, V67, P149, DOI 10.15585/mmwr.mm6705e1; Zhu ZZ, 2018, NAT GENET, V50, P857, DOI 10.1038/s41588-018-0121-0	77	31	31	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1495	1506		10.1016/j.jaci.2019.10.023	http://dx.doi.org/10.1016/j.jaci.2019.10.023			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31677964	Green Accepted, hybrid			2022-12-18	WOS:000500694900005
J	Karvonen, AM; Kirjavainen, PV; Taubel, M; Jayaprakash, B; Adams, RI; Sordillo, JE; Gold, DR; Hyvarinen, A; Remes, S; von Mutius, E; Pekkanen, J				Karvonen, Anne M.; Kirjavainen, Pirkka V.; Taubel, Martin; Jayaprakash, Balamuralikrishna; Adams, Rachel I.; Sordillo, Joanne E.; Gold, Diane R.; Hyvarinen, Anne; Remes, Sami; von Mutius, Erika; Pekkanen, Juha			Indoor bacterial microbiota and development of asthma by 10.5 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma development; children; diversity; environment; Lactococcus species	IN-HOUSE DUST; CHILDHOOD ASTHMA; EARLY-LIFE; EXPOSURE; ALLERGY; ATOPY; DIVERSITY; ENDOTOXIN; PROTECT; RISK	Background: Early-life indoor bacterial exposure is associated with the risk of asthma, but the roles of specific bacterial genera are poorly understood. Objective: We sought to determine whether individual bacterial genera in indoor microbiota predict the development of asthma. Methods: Dust samples from living rooms were collected at 2 months of age. The dust microbiota was characterized by using Illumina MiSeq sequencing amplicons of the bacterial 16S ribosomal RNA gene. Children (n = 373) were followed up for ever asthma until the age of 10.5 years. Results: Richness was inversely associated with asthma after adjustments (P = .03). The phylogenetic microbiota composition in asthmatics patients' homes was characteristically different from that in nonasthmatic subjects' homes (P = .02, weighted UniFrac, adjusted association, permutational multivariate analysis of variance, PERMANOVA-S). The first 2 axis scores of principal coordinate analysis of the weighted UniFrac distance matrix were inversely associated with asthma. Of 658 genera detected in the dust samples, the relative abundances of 41 genera correlated (r > vertical bar 0.4 vertical bar) with one of these axes. Lactococcus genus was a risk factor for asthma (adjusted odds ratio, 1.36 [95% CI, 1.13-1.63] per interquartile range change). The abundance of 12 bacterial genera (mostly from the Actinomycetales order) was associated with lower asthma risk (P < .10), although not independently of each other. The sum relative abundance of these 12 intercorrelated genera was significantly protective and explained the majority of the association of richness with less asthma. Conclusion: Our data confirm that phylogenetic differences in the microbiota of infants' homes are associated with subsequent asthma risk and suggest that communities of selected bacteria are more strongly linked to asthma protection than individual bacterial taxa or mere richness.	[Karvonen, Anne M.; Kirjavainen, Pirkka V.; Taubel, Martin; Jayaprakash, Balamuralikrishna; Hyvarinen, Anne; Pekkanen, Juha] Finnish Inst Hlth & Welf, Dept Hlth Secur, POB 95, FIN-70701 Kuopio, Finland; [Karvonen, Anne M.; Sordillo, Joanne E.; Gold, Diane R.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Karvonen, Anne M.; Sordillo, Joanne E.; Gold, Diane R.] Harvard Med Sch, Boston, MA 02115 USA; [Kirjavainen, Pirkka V.] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland; [Adams, Rachel I.] Univ Calif Berkeley, Plant & Microbial Biol, Berkeley, CA 94720 USA; [Adams, Rachel I.] Calif Dept Publ Hlth, Environm Hlth Lab Branch, Richmond, CA USA; [Sordillo, Joanne E.] Harvard Med Sch, Dept Populat Med, Boston, MA 02115 USA; [Sordillo, Joanne E.] Harvard Pilgrim Hlth Care, Boston, MA USA; [Remes, Sami] Kuopio Univ Hosp, Dept Pediat, Kuopio, Finland; [von Mutius, Erika] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Munich, Germany; [von Mutius, Erika] German Ctr Lung Res, Giessen, Germany; [von Mutius, Erika] Helmholtz Zentrum Munchen, Inst Asthma & Allergy Prevent IAP, Munich, Germany; [Pekkanen, Juha] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Eastern Finland; University of California System; University of California Berkeley; California Department of Public Health; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Kuopio University Hospital; University of Eastern Finland; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Helsinki	Karvonen, AM (corresponding author), Finnish Inst Hlth & Welf, Dept Hlth Secur, POB 95, FIN-70701 Kuopio, Finland.	anne.karvonen@thl.fi	Kirjavainen, Pirkka/AAX-8069-2020; Kirjavainen, Pirkka/AAW-6833-2021; Täubel, Martin/P-7059-2019	Kirjavainen, Pirkka/0000-0001-6119-8768; Täubel, Martin/0000-0001-8082-1041; Hyvarinen, Anne/0000-0002-2823-0866	Academy of Finland [139021, 287675, 296814, 296817, 308254]; Juho Vainio Foundation; Yrjo Jahnsson Foundation; Foundation for Pediatric Research; EVO/VTR-funding; Paivikki and Sakari Sohlberg Foundation; Finnish Cultural Foundation; European Union [QLK4-CT-2001-00250]; Finnish Institute for Health and Welfare, Finland	Academy of Finland(Academy of Finland); Juho Vainio Foundation; Yrjo Jahnsson Foundation; Foundation for Pediatric Research; EVO/VTR-funding; Paivikki and Sakari Sohlberg Foundation; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); European Union(European Commission); Finnish Institute for Health and Welfare, Finland	Supported by research grants from the Academy of Finland (grants 139021, 287675, 296814, 296817, and 308254), the Juho Vainio Foundation, the Yrjo Jahnsson Foundation, the Foundation for Pediatric Research, EVO/VTR-funding, the Paivikki and Sakari Sohlberg Foundation, the Finnish Cultural Foundation, the European Union (QLK4-CT-2001-00250), and the Finnish Institute for Health and Welfare, Finland.	Birzele LT, 2017, ALLERGY, V72, P109, DOI 10.1111/all.13002; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Dannemiller KC, 2014, INDOOR AIR, V24, P236, DOI 10.1111/ina.12072; Dannemiller KC, 2016, J ALLERGY CLIN IMMUN, V138, P76, DOI 10.1016/j.jaci.2015.11.027; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Depner M, 2017, J ALLERGY CLIN IMMUN, V139, P826, DOI 10.1016/j.jaci.2016.05.050; Doreswamy V, 2011, CLIN EXP ALLERGY, V41, P9, DOI 10.1111/j.1365-2222.2010.03628.x; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Eren AM, 2013, METHODS ECOL EVOL, V4, P1111, DOI 10.1111/2041-210X.12114; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Haahtela T, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00470-2017; Holt PG, 2015, J ALLERGY CLIN IMMUN, V136, P15, DOI 10.1016/j.jaci.2015.05.011; Hyytiainen HK, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0405-8; Kanchongkittiphon W, 2015, ENVIRON HEALTH PERSP, V123, P6, DOI [10.1289/ehp.1307922, 10.1289/ehp.123-A6]; Karvonen AM, 2014, ALLERGY, V69, P1092, DOI 10.1111/all.12439; Karvonen AM, 2012, CLIN EXP ALLERGY, V42, P1246, DOI 10.1111/j.1365-2222.2012.04002.x; Karvonen AM, 2009, PEDIATRICS, V124, pE329, DOI 10.1542/peds.2008-1590; Kirjavainen P., 2019, ENV MICROBIOTA ASTHM, P216; Kirjavainen PV, 2019, NAT MED, V25, P1089, DOI 10.1038/s41591-019-0469-4; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Leppanen HK, 2018, J EXPO SCI ENV EPID, V28, P231, DOI 10.1038/jes.2017.24; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; O'Connor GT, 2018, J ALLERGY CLIN IMMUN, V141, P1468, DOI 10.1016/j.jaci.2017.06.040; Ottman N, 2019, J ALLERGY CLIN IMMUN, V143, P1198, DOI 10.1016/j.jaci.2018.06.024; Quigley L, 2013, J DAIRY SCI, V96, P4928, DOI 10.3168/jds.2013-6688; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Sordillo JE, 2010, CLIN EXP ALLERGY, V40, P902, DOI 10.1111/j.1365-2222.2010.03509.x; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Tang ZZ, 2016, BIOINFORMATICS, V32, P2618, DOI 10.1093/bioinformatics/btw311; Taubel M, 2009, J ALLERGY CLIN IMMUN, V124, P834, DOI 10.1016/j.jaci.2009.07.045; Tischer C, 2016, ENVIRON HEALTH PERSP, V124, P1919, DOI 10.1289/EHP158; Tischer C, 2015, EUR RESPIR J, V45, P328, DOI 10.1183/09031936.00060214; Tun HM, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0254-x; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871	38	31	31	2	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1402	1410		10.1016/j.jaci.2019.07.035	http://dx.doi.org/10.1016/j.jaci.2019.07.035			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31415782	Green Published, Bronze			2022-12-18	WOS:000495004700030
J	Huber, M; Cato, ACB; Ainooson, GK; Freichel, M; Tsvilovskyy, V; Jessberger, R; Riedlinger, E; Sommerhoff, CP; Bischoff, SC				Huber, Michael; Cato, Andrew C. B.; Ainooson, George K.; Freichel, Marc; Tsvilovskyy, Volodymyr; Jessberger, Rolf; Riedlinger, Eva; Sommerhoff, Christian P.; Bischoff, Stephan C.			Regulation of the pleiotropic effects of tissue-resident mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fc epsilon RI; stem cell factor; IL-4; calcium signaling; phosphatases; chemotaxis; tryptase; chymase; integrins; Toll-like receptors; ion channels	FC-EPSILON-RI; AFFINITY IGE RECEPTOR; ENRICHED TYROSINE PHOSPHATASE; ALLERGIC INFLAMMATION; TRANSCRIPTION FACTOR; NEGATIVE REGULATION; CONNECTIVE-TISSUE; INTESTINAL NEMATODE; CYTOKINE PRODUCTION; PROTEASE PHENOTYPE	Mast cells (MCs), which are best known for their detrimental role in patients with allergic diseases, act in a diverse array of physiologic and pathologic functions made possible by the plurality of MC types. Their various developmental avenues and distinct sensitivity to (micro-) environmental conditions convey extensive heterogeneity, resulting in diverse functions. We briefly summarize this heterogeneity, elaborate on molecular determinants that allow MCs to communicate with their environment to fulfill their tasks, discuss the protease repertoire stored in secretory lysosomes, and consider different aspects of MC signaling. Furthermore, we describe key MC governance mechanisms (ie, the high-affinity receptor for IgE [Fc epsilon RI]), the stem cell factor receptor KIT, the IL-4 system, and both Ca2+- and phosphatase-dependent mechanisms. Finally, we focus on distinct physiologic functions, such as chemotaxis, phagocytosis, host defense, and the regulation of MC functions at the mucosal barriers of the lung, gastrointestinal tract, and skin. A deeper knowledge of the pleiotropic functions of MC mediators, as well as the molecular processes of MC regulation and communication, should enable us to promote beneficial MC traits in physiology and suppress detrimental MC functions in patients with disease.	[Huber, Michael] Rhein Westfal TH Aachen, Med Fac, Inst Biochem & Mol Immunol, Aachen, Germany; [Cato, Andrew C. B.; Ainooson, George K.] Karlsruhe Inst Technol, Inst Toxicol & Genet, Eggenstein Leopoldshafen, Germany; [Freichel, Marc; Tsvilovskyy, Volodymyr] Heidelberg Univ, Inst Pharmacol, Med Fac, Heidelberg, Germany; [Jessberger, Rolf] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Physiol Chem, Dresden, Germany; [Riedlinger, Eva; Sommerhoff, Christian P.] Ludwig Maximilians Univ Munchen, Univ Hosp, Inst Lab Med, Munich, Germany; [Bischoff, Stephan C.] Univ Hohenheim, Inst Nutr Med, Fruwirthstr 12, D-70599 Stuttgart, Germany	RWTH Aachen University; Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Munich; University Hohenheim	Bischoff, SC (corresponding author), Univ Hohenheim, Inst Nutr Med, Fruwirthstr 12, D-70599 Stuttgart, Germany.; Huber, M (corresponding author), Rhein Westfal TH Aachen, Inst Biochem & Mol Immunol, Pauwelsstr 30, D-52074 Aachen, Germany.	mhuber@ukaachen.de; bischoff.stephan@uni-hohenheim.de	Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834; Ainooson, George/0000-0003-1231-785X	Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease; Deutsche Forschungsgemeinschaft Priority Programme 1394 ("Mast cells-promoters of health and modulators of disease'');  [TR-SFB 152]	Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft Priority Programme 1394 ("Mast cells-promoters of health and modulators of disease''); 	This article was published as part of a supplement sponsored by the members of the Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease.; Supported in part by the Deutsche Forschungsgemeinschaft Priority Programme 1394 ("Mast cells-promoters of health and modulators of disease''; to M.H., A.C. B.C., M.F., R.J., C.P.S., and S.C.B.). Further support was granted by TR-SFB 152 (to M.F.). A.C.B.C. acknowledges the help of V. Gourain, NGS Facility of the Institute of Toxicology and Genetics (KIT; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc5GSE108972).	Abel J, 2011, J INNATE IMMUN, V3, P495, DOI 10.1159/000327714; Abonia JP, 2006, BLOOD, V108, P1588, DOI 10.1182/blood-2005-12-012781; Abonia JP, 2005, BLOOD, V105, P4308, DOI 10.1182/blood-2004-09-3578; Ahmad J, 2014, BIOL CHEM, V395, P1253, DOI 10.1515/hsz-2014-0174; Ainooson GK, 2018, DATA BRIEF, V20, P1177, DOI 10.1016/j.dib.2018.08.188; Akimoto M, 2009, SCAND J IMMUNOL, V69, P401, DOI 10.1111/j.1365-3083.2009.02235.x; Alcaide P, 2007, J EXP MED, V204, P431, DOI 10.1084/jem.20060626; Andersson CK, 2009, THORAX, V64, P297, DOI 10.1136/thx.2008.101683; Andrade MV, 2011, EUR J IMMUNOL, V41, P760, DOI 10.1002/eji.201040718; Arock M, 1998, INFECT IMMUN, V66, P6030, DOI 10.1128/IAI.66.12.6030-6034.1998; Ashmole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074895; Babina M, 2004, J LEUKOCYTE BIOL, V75, P244, DOI 10.1189/jlb.0403157; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Bischoff SC, 2016, EUR J PHARMACOL, V778, P139, DOI 10.1016/j.ejphar.2016.02.018; Bischoff SC, 2009, SEMIN IMMUNOPATHOL, V31, P185, DOI 10.1007/s00281-009-0165-4; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Brenner SA, 2014, IMMUNOLOGY, V143, P174, DOI 10.1111/imm.12299; Brown JK, 2003, J HELMINTHOL, V77, P155, DOI 10.1079/JOH2002160; Brown MA, 2012, IMMUNITY, V36, P891, DOI 10.1016/j.immuni.2012.05.004; Buttgereit F, 2004, ARTHRITIS RHEUM-US, V50, P3408, DOI 10.1002/art.20583; Caughey GH, 2006, CURR RESPIR MED REV, V2, P263, DOI 10.2174/157339806778019024; Caughey GH, 2016, EUR J PHARMACOL, V778, P44, DOI 10.1016/j.ejphar.2015.04.045; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Cohen R, 2009, J IMMUNOL, V183, P6478, DOI 10.4049/jimmunol.0901615; Collington SJ, 2011, TRENDS IMMUNOL, V32, P478, DOI 10.1016/j.it.2011.08.002; Collington SJ, 2010, J IMMUNOL, V184, P6114, DOI 10.4049/jimmunol.0904177; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Dahdah A, 2014, J CLIN INVEST, V124, P4577, DOI 10.1172/JCI75212; Dahlin JS, 2016, BLOOD, V127, P383, DOI 10.1182/blood-2015-06-650648; Dahlin JS, 2015, STEM CELLS DEV, V24, P1703, DOI 10.1089/scd.2014.0553; Dahlin JS, 2015, MOL IMMUNOL, V63, P9, DOI 10.1016/j.molimm.2014.01.018; de Castro RO, 2012, J BIOL CHEM, V287, P8194, DOI 10.1074/jbc.M111.326850; Dietrich N, 2010, P NATL ACAD SCI USA, V107, P8748, DOI 10.1073/pnas.0912551107; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Draber P, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00130; Draber P, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00095; Drube S, 2010, BLOOD, V115, P3899, DOI 10.1182/blood-2009-10-247411; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Dvorak AM, 1997, J ALLERGY CLIN IMMUN, V99, P812, DOI 10.1016/S0091-6749(97)80016-4; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; EADY RAJ, 1979, BRIT J DERMATOL, V100, P623, DOI 10.1111/j.1365-2133.1979.tb08065.x; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Fajt Merritt L, 2013, Ann Am Thorac Soc, V10 Suppl, pS158, DOI 10.1513/AnnalsATS.201303-064AW; Fang Y, 2012, ALLERGY, V67, P1233, DOI [10.1111/j.1398-9995.2012.02878.x, 10.1111/j.1398-9995.2012.02878.x.]; Feger F, 2002, TRENDS IMMUNOL, V23, P151, DOI 10.1016/S1471-4906(01)02156-1; Fehrenbach K, 2009, J IMMUNOL, V182, P7897, DOI 10.4049/jimmunol.0801773; Feuser K, 2012, CYTOKINE, V58, P178, DOI 10.1016/j.cyto.2012.01.001; Feuser K, 2011, MOL IMMUNOL, V48, P546, DOI 10.1016/j.molimm.2010.10.010; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Fischer M, 2006, J CLIN INVEST, V116, P2748, DOI 10.1172/JCI24274; Freichel M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00150; Frossi B, 2018, IMMUNOL REV, V282, P35, DOI 10.1111/imr.12636; Furumoto Y, 2011, BLOOD, V118, P5466, DOI 10.1182/blood-2010-09-309955; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Gebhardt T, 2005, GUT, V54, P928, DOI 10.1136/gut.2004.054650; Gentek R, 2018, IMMUNITY, V48, P1160, DOI 10.1016/j.immuni.2018.04.025; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Goldmann O, 2016, CELL MICROBIOL, V18, P807, DOI 10.1111/cmi.12550; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; Grochowy G, 2009, CELL SIGNAL, V21, P1277, DOI 10.1016/j.cellsig.2009.03.018; Gurish MF, 2001, J EXP MED, V194, P1243, DOI 10.1084/jem.194.9.1243; Haddon DJ, 2009, J IMMUNOL, V183, P228, DOI 10.4049/jimmunol.0900427; Hallgren J, 2001, J BIOL CHEM, V276, P42774, DOI 10.1074/jbc.M105531200; Hallgren J, 2007, IMMUNOL REV, V217, P8, DOI 10.1111/j.1600-065X.2007.00502.x; Hallgren J, 2011, ADV EXP MED BIOL, V716, P14, DOI 10.1007/978-1-4419-9533-9_2; Halova I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00119; He YT, 2013, J MED CHEM, V56, P4990, DOI 10.1021/jm400248c; Holowka D, 2016, BIOCHEM SOC T, V44, P505, DOI 10.1042/BST20150273; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hua XY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024947; Huber M, 2006, EUR J IMMUNOL, V36, P701, DOI 10.1002/eji.200535593; Huber M, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-7; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; Iida M, 2001, BLOOD, V97, P1016, DOI 10.1182/blood.V97.4.1016; Iikura M, 2007, LAB INVEST, V87, P971, DOI 10.1038/labinvest.3700663; Ito T, 2012, J IMMUNOL, V188, P5428, DOI 10.4049/jimmunol.1103366; Jackson NE, 2008, J BIOL CHEM, V283, P34178, DOI 10.1074/jbc.M807553200; Jacob C, 2005, J BIOL CHEM, V280, P31936, DOI 10.1074/jbc.M506338200; Jeffrey KL, 2006, NAT IMMUNOL, V7, P274, DOI 10.1038/ni1310; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Jones TG, 2009, J IMMUNOL, V183, P5251, DOI 10.4049/jimmunol.0901471; Jung MY, 2013, J IMMUNOL, V190, P531, DOI 10.4049/jimmunol.1201576; Juremalm M, 2005, CHEM IMMUNOL ALLERGY, V87, P130, DOI 10.1159/000087640; Kamata T, 2003, J CLIN INVEST, V111, P109, DOI 10.1172/JCI200315719; Karlson U, 2003, J BIOL CHEM, V278, P39625, DOI 10.1074/jbc.M301512200; Kasakura K, 2014, BIOSCI BIOTECH BIOCH, V78, P1669, DOI 10.1080/09168451.2014.930327; Kashiwakura JI, 2011, ADV EXP MED BIOL, V716, P29, DOI 10.1007/978-1-4419-9533-9_3; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Katz HR, 2002, CURR OPIN IMMUNOL, V14, P698, DOI 10.1016/S0952-7915(02)00400-4; Keck S, 2011, J IMMUNOL, V186, P5478, DOI 10.4049/jimmunol.1000458; Kennelly R, 2011, CURR PHARM DESIGN, V17, P3772, DOI 10.2174/138161211798357854; Kuehn HS, 2010, J CELL SCI, V123, P2576, DOI 10.1242/jcs.071043; Kuhny M, 2014, CURR TOP MICROBIOL, V382, P111, DOI 10.1007/978-3-319-07911-0_6; Kulka A, 2006, MOL IMMUNOL, V43, P1579, DOI 10.1016/j.molimm.2005.09.019; Kunii J, 2011, IMMUNOBIOLOGY, V216, P692, DOI 10.1016/j.imbio.2010.10.007; Kunori Y, 2002, EUR J BIOCHEM, V269, P5921, DOI 10.1046/j.1432-1033.2002.03316.x; Lee SH, 2010, EXP MOL MED, V42, P366, DOI 10.3858/emm.2010.42.5.038; Leung WH, 2007, J IMMUNOL, V179, P95, DOI 10.4049/jimmunol.179.1.95; Lin DA, 2005, J IMMUNOL, V175, P5430, DOI 10.4049/jimmunol.175.8.5430; Lorentz A, 2000, J IMMUNOL, V164, P43, DOI 10.4049/jimmunol.164.1.43; Lu-Kuo JM, 1999, J BIOL CHEM, V274, P5791, DOI 10.1074/jbc.274.9.5791; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; Ma HT, 2008, J IMMUNOL, V180, P2233, DOI 10.4049/jimmunol.180.4.2233; Ma HT, 2009, CRIT REV IMMUNOL, V29, P155, DOI 10.1615/CritRevImmunol.v29.i2.40; Maier JV, 2007, MOL ENDOCRINOL, V21, P2663, DOI 10.1210/me.2007-0067; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marquardt U, 2002, J MOL BIOL, V321, P491, DOI 10.1016/S0022-2836(02)00625-3; Maruyama H, 2000, J IMMUNOL, V164, P3749, DOI 10.4049/jimmunol.164.7.3749; Matsushima H, 2004, J IMMUNOL, V173, P531, DOI 10.4049/jimmunol.173.1.531; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; McPherson VA, 2009, J IMMUNOL, V183, P4940, DOI 10.4049/jimmunol.0900702; Medic N, 2013, CELL CALCIUM, V53, P315, DOI 10.1016/j.ceca.2013.02.001; Medic N, 2011, CELL CALCIUM, V50, P473, DOI 10.1016/j.ceca.2011.08.003; Mierke CT, 2000, J EXP MED, V192, P801, DOI 10.1084/jem.192.6.801; Migalovich-Sheikhet H, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00238; Miyake K, 2004, TRENDS MICROBIOL, V12, P186, DOI 10.1016/j.tim.2004.02.009; Mollerherm H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00265; Molfetta R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00449; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Nakata K, 2008, J IMMUNOL, V181, P5414, DOI 10.4049/jimmunol.181.8.5414; Nakata K, 2011, MOL IMMUNOL, V48, P472, DOI 10.1016/j.molimm.2010.10.001; NILSSON G, 1994, J IMMUNOL, V153, P3717; Nomura I, 2001, CLIN EXP ALLERGY, V31, P1424, DOI 10.1046/j.1365-2222.2001.01181.x; Obiri DD, 2012, ALLERGY, V67, P175, DOI 10.1111/j.1398-9995.2011.02731.x; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Oda S, 2013, PFLUG ARCH EUR J PHY, V465, P1023, DOI 10.1007/s00424-013-1219-y; Okayama Y, 2009, EUR RESPIR J, V34, P425, DOI 10.1183/09031936.00121008; Olynych TJ, 2006, J ALLERGY CLIN IMMUN, V118, P837, DOI 10.1016/j.jaci.2006.06.008; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Oppong E, 2013, MOL CELL ENDOCRINOL, V380, P119, DOI 10.1016/j.mce.2013.05.014; Papadopoulos EJ, 2000, EUR J IMMUNOL, V30, P2355, DOI 10.1002/1521-4141(2000)30:8<2355::AID-IMMU2355>3.0.CO;2-#; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Pejler G, 2007, ADV IMMUNOL, V95, P167, DOI 10.1016/S0065-2776(07)95006-3; Peng Q, 2003, EUR J BIOCHEM, V270, P270, DOI 10.1046/j.1432-1033.2003.03385.x; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Perez-Silva JG, 2016, NUCLEIC ACIDS RES, V44, pD351, DOI 10.1093/nar/gkv1201; Petra AI, 2018, ALLERGY ASTHMA PROC, V39, P153, DOI 10.2500/aap.2018.38.4105; Pietrzak A, 2009, IMMUNOL LETT, V123, P46, DOI 10.1016/j.imlet.2009.02.003; Piliponsky AM, 2010, AM J PATHOL, V176, P926, DOI 10.2353/ajpath.2010.090342; Pinke KH, 2016, IMMUNOBIOLOGY, V221, P220, DOI 10.1016/j.imbio.2015.09.004; Poplutz M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04890-4; Raymond WW, 2009, J IMMUNOL, V182, P5770, DOI 10.4049/jimmunol.0900127; Ribbing C, 2011, ALLERGY, V66, P110, DOI 10.1111/j.1398-9995.2010.02437.x; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Rixecker T, 2016, SCI REP-UK, V6, DOI 10.1038/srep32981; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; Ruschmann J, 2012, J IMMUNOL, V188, P3839, DOI 10.4049/jimmunol.1003875; Saluja R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043547; Samayawardhena LA, 2010, J IMMUNOL, V185, P5993, DOI 10.4049/jimmunol.1001261; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; Sharma N, 2014, J IMMUNOL, V192, P4859, DOI 10.4049/jimmunol.1301155; SHEFFER AL, 1995, INT ARCH ALLERGY IMM, V107, P11, DOI 10.1159/000236917; Shin J, 2013, EUR J IMMUNOL, V43, P240, DOI 10.1002/eji.201242571; Sibilano R, 2014, EUR J IMMUNOL, V44, P2558, DOI 10.1002/eji.201444546; Siebenhaar F, 2018, TRENDS IMMUNOL, V39, P151, DOI 10.1016/j.it.2017.10.005; Solis-Lopez A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171366; Sommerhoff CP, 2007, CURR PHARM DESIGN, V13, P313, DOI 10.2174/138161207779313579; Sommerhoff CP, 1999, P NATL ACAD SCI USA, V96, P10984, DOI 10.1073/pnas.96.20.10984; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; Supajatura V, 2001, J IMMUNOL, V167, P2250, DOI 10.4049/jimmunol.167.4.2250; Suzuki R, 2017, BIOL PHARM BULL, V40, P1828, DOI 10.1248/bpb.b17-00465; Suzuki R, 2010, J LEUKOCYTE BIOL, V88, P863, DOI 10.1189/jlb.0510253; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Trevisan E, 2014, INFLAMMATION, V37, P2174, DOI 10.1007/s10753-014-9951-9; Trivedi NN, 2009, J ALLERGY CLIN IMMUN, V124, P1099, DOI 10.1016/j.jaci.2009.07.026; Tsutsui H, 2017, J BIOL CHEM, V292, P1061, DOI 10.1074/jbc.M116.754648; Tsvilovskyy V, 2018, CELL CALCIUM, V71, P24, DOI 10.1016/j.ceca.2017.11.004; Tumova M, 2010, EUR J IMMUNOL, V40, P3235, DOI 10.1002/eji.201040403; Ugajin T, 2009, J LEUKOCYTE BIOL, V86, P1417, DOI 10.1189/jlb.0609400; Vaeth M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14714; Valent P, 2002, INT J HEMATOL, V75, P357, DOI 10.1007/BF02982124; Vang T, 2008, ANNU REV IMMUNOL, V26, P29, DOI 10.1146/annurev.immunol.26.021607.090418; Vanuytsel T, 2014, GUT, V63, P1293, DOI 10.1136/gutjnl-2013-305690; Varadaradjalou S, 2003, EUR J IMMUNOL, V33, P899, DOI 10.1002/eji.200323830; Varshney P, 2016, IMMUNOLOGY, V149, P13, DOI 10.1111/imm.12617; Vennekens R, 2007, NAT IMMUNOL, V8, P312, DOI 10.1038/ni1441; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Vukman KV, 2013, J LEUKOCYTE BIOL, V94, P439, DOI 10.1189/jlb.0313130; Wang HW, 2002, J IMMUNOL, V169, P5145, DOI 10.4049/jimmunol.169.9.5145; WEIDNER N, 1993, PATHOL RES PRACT, V189, P156, DOI 10.1016/S0344-0338(11)80086-5; Welle M, 1997, J LEUKOCYTE BIOL, V61, P233, DOI 10.1002/jlb.61.3.233; Weller CL, 2007, P NATL ACAD SCI USA, V104, P11712, DOI 10.1073/pnas.0701700104; Weller CL, 2005, J EXP MED, V201, P1961, DOI 10.1084/jem.20042407; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; Wong GW, 2002, J BIOL CHEM, V277, P41906, DOI 10.1074/jbc.M205868200; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0; Xiao WB, 2005, J IMMUNOL, V175, P6885, DOI 10.4049/jimmunol.175.10.6885; Xing W, 2011, P NATL ACAD SCI USA, V108, P14210, DOI 10.1073/pnas.1111048108; Yang Z, 2009, IMMUNOBIOLOGY, V214, P321, DOI 10.1016/j.imbio.2008.09.002; Young RM, 2005, J BIOL CHEM, V280, P1230, DOI 10.1074/jbc.M408339200; Yu YX, 2016, EUR J PHARMACOL, V778, P33, DOI 10.1016/j.ejphar.2015.07.017; Zarnegar B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00310; Zhang D, 2012, PHYSIOL RES, V61, P113, DOI 10.33549/physiolres.932053; Zhang L, 2010, J IMMUNOL, V184, P1180, DOI 10.4049/jimmunol.0901972; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518; Zierler S, 2016, J PHYSIOL-LONDON, V594, P2957, DOI 10.1113/JP271564	201	31	32	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4		S	SI		S31	S45		10.1016/j.jaci.2019.02.004	http://dx.doi.org/10.1016/j.jaci.2019.02.004			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8GI	30772496	hybrid, Green Published			2022-12-18	WOS:000488805000004
J	Nowak-Wegrzyn, A; Warren, CM; Brown-Whitehorn, T; Cianferoni, A; Schultz-Matney, F; Gupta, RS				Nowak-Wegrzyn, Anna; Warren, Christopher M.; Brown-Whitehorn, Terri; Cianferoni, Antonella; Schultz-Matney, Fallon; Gupta, Ruchi S.			Food protein-induced enterocolitis syndrome in the US population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PREVALENCE; ALLERGY		[Nowak-Wegrzyn, Anna] NYU Langone Hlth, Dept Pediat, New York, NY 10016 USA; [Nowak-Wegrzyn, Anna] Univ Warmia & Mazury, Coll Med, Dept Pediat Gastroenterol & Nutr, Olsztyn, Poland; [Warren, Christopher M.; Gupta, Ruchi S.] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Chicago, IL 60611 USA; [Brown-Whitehorn, Terri; Cianferoni, Antonella] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat,Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Schultz-Matney, Fallon] Int FPIES Assoc, Point Pleasant Beach, NJ USA	NYU Langone Medical Center; University of Warmia & Mazury; Northwestern University; Feinberg School of Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Nowak-Wegrzyn, A (corresponding author), NYU Langone Hlth, Dept Pediat, New York, NY 10016 USA.; Nowak-Wegrzyn, A (corresponding author), Univ Warmia & Mazury, Coll Med, Dept Pediat Gastroenterol & Nutr, Olsztyn, Poland.	anna.nowak-wegrzyn@nyulangone.org		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	National Institute of Allergy and Infectious Disease	National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institute of Allergy and Infectious Disease (grant no. R21AI135702-PI: R.S.G.).	Alonso SB, 2019, J ALLERGY CLIN IMMUN, V143, P430, DOI 10.1016/j.jaci.2018.08.045; Gonzalez-Delgado P, 2019, J ALLER CL IMM-PRACT, V7, P670, DOI 10.1016/j.jaip.2018.07.028; Greenhawt M, 2016, J ALLERGY CLIN IMMUN, V137, P1251, DOI 10.1016/j.jaci.2015.09.056; Gupta RS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.5630; Gupta RS, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-1235; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, P647, DOI 10.1016/j.jaci.2010.12.1105; Mehr S, 2017, J ALLERGY CLIN IMMUN, V140, P1323, DOI 10.1016/j.jaci.2017.03.027; Nowak-Wegrzyn A, 2017, J ALLERGY CLIN IMMUN, V139, P1111, DOI 10.1016/j.jaci.2016.12.966	9	31	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					1128	1130		10.1016/j.jaci.2019.06.032	http://dx.doi.org/10.1016/j.jaci.2019.06.032			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31288044	Bronze, Green Accepted			2022-12-18	WOS:000488803900030
J	Bier, J; Rao, G; Payne, K; Brigden, H; French, E; Pelham, SJ; Lau, A; Lenthall, H; Edwards, ESJ; Smart, JM; Cole, TS; Choo, S; Joshi, AY; Abraham, RS; O'Sullivan, M; Boztug, K; Meyts, I; Gray, PE; Berglund, LJ; Hsu, P; Wong, M; Holland, SM; Notarangelo, LD; Uzel, G; Ma, CS; Brink, R; Tangye, SG; Deenick, EK				Bier, Julia; Rao, Geetha; Payne, Kathryn; Brigden, Henry; French, Elise; Pelham, Simon J.; Lau, Anthony; Lenthall, Helen; Edwards, Emily S. J.; Smart, Joanne M.; Cole, Theresa S.; Choo, Sharon; Joshi, Avni Y.; Abraham, Roshini S.; O'Sullivan, Michael; Boztug, Kaan; Meyts, Isabelle; Gray, Paul E.; Berglund, Lucinda J.; Hsu, Peter; Wong, Melanie; Holland, Steven M.; Notarangelo, Luigi D.; Uzel, Gulbu; Ma, Cindy S.; Brink, Robert; Tangye, Stuart G.; Deenick, Elissa K.			Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Phosphoinositide 3-kinase; PIK3CD; activated PI3K delta syndrome; CD4(+) T-cell function; follicular helper T cells; humoral immunity; immune class regulation; humans; mouse models	FOLLICULAR HELPER-CELL; PHOSPHOINOSITIDE 3-KINASE P110-DELTA; CYTOKINE PRODUCTION; B-CELLS; ICOS; RESPONSES; MICE; EXPRESSION; INFECTION; DEFICIENT	Background: Gain-of-function (GOF) mutations in PIK3CD cause a primary immunodeficiency characterized by recurrent respiratory tract infections, susceptibility to herpesvirus infections, and impaired antibody responses. Previous work revealed defects in CD8(+) T and B cells that contribute to this clinical phenotype, but less is understood about the role of CD4(+) T cells in disease pathogenesis. Objective: We sought to dissect the effects of increased phosphoinositide 3-kinase (PI3K) signaling on CD4(+) T-cell function. Methods: We performed detailed ex vivo, in vivo, and in vitro phenotypic and functional analyses of patients' CD4(+) T cells and a novel murine disease model caused by overactive PI3K signaling. Results: PI3K overactivation caused substantial increases in numbers of memory and follicular helper T (T-FH) cells and dramatic changes in cytokine production in both patients and mice. Furthermore, PIK3CD GOF human T-FH cells had dysregulated phenotype and function characterized by increased programmed cell death protein 1, CXCR3, and IFN-gamma expression, the phenotype of a T-FH cell subset with impaired B-helper function. This was confirmed in vivo in which Pik3cd GOF CD4(+) T cells also acquired an aberrant T-FH phenotype and provided poor help to support germinal center reactions and humoral immune responses by antigen-specific wild-type B cells. The increase in numbers of both memory and T-FH cells was largely CD4(+) T-cell extrinsic, whereas changes in cytokine production and T-FH cell function were cell intrinsic. Conclusion: Our studies reveal that CD4(+) T cells with overactive PI3K have aberrant activation and differentiation, thereby providing mechanistic insight into dysfunctional antibody responses in patients with PIK3CD GOF mutations.	[Bier, Julia; Rao, Geetha; Payne, Kathryn; Brigden, Henry; French, Elise; Pelham, Simon J.; Lau, Anthony; Lenthall, Helen; Edwards, Emily S. J.; Ma, Cindy S.; Brink, Robert; Tangye, Stuart G.; Deenick, Elissa K.] Garvan Inst Med Res, Div Immunol, 384 Victoria St, Darlinghurst, NSW 2010, Australia; [Bier, Julia; Pelham, Simon J.; Lau, Anthony; Edwards, Emily S. J.; Ma, Cindy S.; Brink, Robert; Tangye, Stuart G.; Deenick, Elissa K.] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia; [Brigden, Henry; French, Elise] Univ Bath, Bath, Avon, England; [Smart, Joanne M.; Cole, Theresa S.; Choo, Sharon] Royal Childrens Hosp Melbourne, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Joshi, Avni Y.; Abraham, Roshini S.] Mayo Clin, Childrens Ctr, Dept Lab Med & Pathol, Div Allergy & Immunol, Rochester, MN USA; [Abraham, Roshini S.] Nationwide Childrens Hosp, Dept Pathol & Lab Med, Columbus, OH USA; [O'Sullivan, Michael] Princess Margaret Hosp, Dept Immunol & Allergy, Subiaco, WA, Australia; [Boztug, Kaan] Ludwig Boltzmann Inst Rare & Undiagnosed Dis, Vienna, Austria; [Boztug, Kaan] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Boztug, Kaan] Med Univ Vienna, St Anna Childrens Hosp, Vienna, Austria; [Boztug, Kaan] Med Univ Vienna, Childrens Canc Res Inst, Dept Pediat & Adolescent Med, Vienna, Austria; [Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Dept Immunol & Microbiol, Childhood Immunol, Leuven, Belgium; [Meyts, Isabelle] Katholieke Univ Leuven, Leuven, Belgium; [Gray, Paul E.] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Gray, Paul E.; Berglund, Lucinda J.; Hsu, Peter; Wong, Melanie; Ma, Cindy S.; Brink, Robert; Tangye, Stuart G.; Deenick, Elissa K.] Clin Immunogen Res Consortia Australia, Sydney, NSW, Australia; [Berglund, Lucinda J.] Westmead Hosp, Immunopathol Dept, Westmead, NSW, Australia; [Berglund, Lucinda J.; Hsu, Peter; Wong, Melanie] Univ Sydney, Fac Med, Sydney, NSW, Australia; [Hsu, Peter; Wong, Melanie] Childrens Hosp Westmead, Westmead, NSW, Australia; [Holland, Steven M.; Notarangelo, Luigi D.; Uzel, Gulbu] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Edwards, Emily S. J.] Monash Univ, Dept Pathol & Immunol, Cent Clin Sch, Melbourne, Vic, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; University of Bath; Royal Children's Hospital Melbourne; Mayo Clinic; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna; Saint Anna Children's Hospital; Medical University of Vienna; Saint Anna Children's Hospital; KU Leuven; University Hospital Leuven; KU Leuven; University of New South Wales Sydney; University of Sydney; University of Sydney; University of Sydney; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Monash University	Tangye, SG; Deenick, EK (corresponding author), Garvan Inst Med Res, Div Immunol, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	s.tangye@garvan.org.au; e.deenick@garvan.org.au	Deenick, Elissa/AAY-8998-2020; Brigden, Henry/GXG-7349-2022; Boztug, Kaan/AAM-4161-2021; O'Sullivan, Michael/AAZ-5853-2021; Meyts, Isabelle/Z-3295-2019; Cole, Theresa/AAX-7893-2021; S, Cindy/B-2340-2012; Edwards, Emily S.J./AAI-6037-2020	Deenick, Elissa/0000-0002-9271-0004; Boztug, Kaan/0000-0001-8387-9185; O'Sullivan, Michael/0000-0001-7896-2697; Cole, Theresa/0000-0002-8272-4074; S, Cindy/0000-0001-5387-8413; Edwards, Emily S.J./0000-0002-0240-4370; Berglund, Lucinda/0000-0002-6595-9947; Bier, Julia/0000-0001-7727-1149; Gray, Paul/0000-0003-2057-3968; Lau, Anthony/0000-0002-7338-7176; Brink, Robert/0000-0002-9586-3655	National Health and Medical Research Council of Australia [1088215, 1127157, 1016953, 1113904, 1042925, 1105877]; Susan and John Freeman Cancer Research Grant from Cancer Council NSW (Australia); Office of Health and Medical Research of the NSW Government; Jeffrey Modell Foundation; John Cook Brown Foundation; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); Early-Mid Career Research Fellowship from the New South Wales State Government; Postgraduate Research Scholarship - Fundacao Estudar (Brazil); Tuition Fee Scholarship from UNSW Sydney; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646, ZIAAI000647, ZIAAI001222] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Susan and John Freeman Cancer Research Grant from Cancer Council NSW (Australia); Office of Health and Medical Research of the NSW Government; Jeffrey Modell Foundation; John Cook Brown Foundation; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Early-Mid Career Research Fellowship from the New South Wales State Government; Postgraduate Research Scholarship - Fundacao Estudar (Brazil); Tuition Fee Scholarship from UNSW Sydney; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by project grants 1088215 (to E.K.D. and C.S.M.) and 1127157 (to S.G.T., E.K.D., and C.S.M.), program grants (1016953 and 1113904 to S.G.T. and R.B.), and Principal Research Fellowships (1042925 to S.G.T. and 1105877 to R. B.) from the National Health and Medical Research Council of Australia, the Susan and John Freeman Cancer Research Grant from Cancer Council NSW (Australia to S.G.T.), the Office of Health and Medical Research of the NSW Government, the Jeffrey Modell Foundation, the John Cook Brown Foundation, and a Bench to Bedside grant from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH; to S.G.T., G.U., and L.D.N.). C.S.M. is supported by an Early-Mid Career Research Fellowship from the New South Wales State Government. J.B. is supported by the Postgraduate Research Scholarship awarded by Fundacao Estudar (Brazil). A. L. is supported by a Tuition Fee Scholarship from UNSW Sydney. S.M.H., L.D.N., and G.U. are supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH.	Akiba H, 2005, J IMMUNOL, V175, P2340, DOI 10.4049/jimmunol.175.4.2340; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Attridge K, 2014, J IMMUNOL, V192, P2195, DOI 10.4049/jimmunol.1302082; Avery DT, 2018, J EXP MED, V215, P2073, DOI 10.1084/jem.20180010; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020; Bentebibel SE, 2011, P NATL ACAD SCI USA, V108, pE488, DOI 10.1073/pnas.1100898108; Bossaller L, 2006, J IMMUNOL, V177, P4927, DOI 10.4049/jimmunol.177.7.4927; Boswell KL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003853; Cannons JL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01758; Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Coulter TI, 2017, J ALLERGY CLIN IMMUN, V139, P597, DOI 10.1016/j.jaci.2016.06.021; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Cubas RA, 2013, NAT MED, V19, P494, DOI 10.1038/nm.3109; Cunill V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00174; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; de Valle E, 2016, J EXP MED, V213, P621, DOI 10.1084/jem.20151182; Deenick EK, 2005, EUR J IMMUNOL, V35, P2949, DOI 10.1002/eji.200425719; Dil N, 2009, MOL IMMUNOL, V46, P1970, DOI 10.1016/j.molimm.2009.03.010; Doi T, 2008, INT IMMUNOL, V20, P499, DOI 10.1093/intimm/dxn009; Edwards ESJ, 2019, J ALLERGY CLIN IMMUN, V143, P276, DOI 10.1016/j.jaci.2018.04.030; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Gigoux M, 2009, P NATL ACAD SCI USA, V106, P20371, DOI 10.1073/pnas.0911573106; Han JM, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00245; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Hedrick SM, 2012, NAT REV IMMUNOL, V12, P649, DOI 10.1038/nri3278; Karnowski A, 2012, J EXP MED, V209, P2049, DOI 10.1084/jem.20111504; Kim JR, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-3; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KING CL, 1993, J IMMUNOL, V150, P1873; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; Ma CS, 2009, IMMUNOL CELL BIOL, V87, P590, DOI 10.1038/icb.2009.64; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Okkenhaug K, 2006, J IMMUNOL, V177, P5122, DOI 10.4049/jimmunol.177.8.5122; Okkenhaug K, 2013, ANNU REV IMMUNOL, V31, P675, DOI 10.1146/annurev-immunol-032712-095946; Patton DT, 2006, J IMMUNOL, V177, P6598, DOI 10.4049/jimmunol.177.10.6598; Phan TG, 2003, J EXP MED, V197, P845, DOI 10.1084/jem.20022144; Preite S, 2018, NAT IMMUNOL, V19, P986, DOI 10.1038/s41590-018-0182-3; Rolf J, 2010, J IMMUNOL, V185, P4042, DOI 10.4049/jimmunol.1001730; Salek-Ardakani S, 2011, J IMMUNOL, V186, P5294, DOI 10.4049/jimmunol.1100406; Sallusto F, 2016, ANNU REV IMMUNOL, V34, P317, DOI 10.1146/annurev-immunol-032414-112056; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Schatorje EJH, 2012, SCAND J IMMUNOL, V75, P436, DOI 10.1111/j.1365-3083.2012.02671.x; Schmitt N, 2009, IMMUNITY, V31, P158, DOI 10.1016/j.immuni.2009.04.016; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Spergel J, 2018, J ALLERGY CLIN IMMUN, V142, P1, DOI 10.1016/j.jaci.2018.05.001; Stark AK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05674-8; Stone EL, 2015, IMMUNITY, V42, P239, DOI 10.1016/j.immuni.2015.01.017; Tangye SG, 2013, NAT REV IMMUNOL, V13, P412, DOI 10.1038/nri3447; Tsantikos E, 2010, J IMMUNOL, V184, P1348, DOI 10.4049/jimmunol.0901878; Unger S, 2018, J ALLERGY CLIN IMMUN, V141, P730, DOI 10.1016/j.jaci.2017.04.041; Wentink MWJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00446; Wray-Dutra MN, 2018, J EXP MED, V215, P2485, DOI 10.1084/jem.20180617; Xu HP, 2013, NATURE, V496, P523, DOI 10.1038/nature12058; Yang H, 2014, NAT PROTOC, V9, P1956, DOI 10.1038/nprot.2014.134; Zhang TT, 2008, J ALLERGY CLIN IMMUN, V122, P811, DOI 10.1016/j.jaci.2008.08.008; Zhu JF, 2010, IMMUNITY, V32, P11, DOI 10.1016/j.immuni.2010.01.001	63	31	32	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					236	253		10.1016/j.jaci.2019.01.033	http://dx.doi.org/10.1016/j.jaci.2019.01.033			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30738173	Green Accepted, Bronze			2022-12-18	WOS:000473432800026
J	Thoms, F; Jennings, GT; Maudrich, M; Vogel, M; Haas, S; Zeltins, A; Hofmann-Lehmann, R; Riond, B; Grossmann, J; Hunziker, P; Fettelschoss-Gabriel, A; Senti, G; Kundig, TM; Bachmann, MF				Thoms, Franziska; Jennings, Gary T.; Maudrich, Melanie; Vogel, Monique; Haas, Stefanie; Zeltins, Andris; Hofmann-Lehmann, Regina; Riond, Barbara; Grossmann, Jonas; Hunziker, Peter; Fettelschoss-Gabriel, Antonia; Senti, Gabriela; Kundig, Thomas M.; Bachmann, Martin F.			Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fel d 1; cat allergy; vaccine; antibody; virus-like particle	VIRUS-LIKE PARTICLES; IMMUNOTHERAPY; EXPRESSION; VACCINE; MECHANISMS; TOLERANCE; FEL-D-1	Background: Cat allergy in human subjects is usually caused by the major cat allergen Fel d 1 and is found in approximately 10% of the Western population. Currently, there is no efficient and safe therapy for cat allergy available. Allergic patients usually try to avoid cats or treat their allergy symptoms. Objective: We developed a new strategy to treat Fel d 1-induced allergy in human subjects by immunizing cats against their own major allergen, Fel d 1. Methods: A conjugate vaccine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic virus containing the tetanus toxin-derived universal T-cell epitope tt830-843 (CuMVTT) was used to immunize cats. A first tolerability and immunogenicity study, including a boost injection, was conducted by using the Fel-CuMVTT vaccine alone or in combination with an adjuvant. Results: The vaccine was well tolerated and had no overt toxic effect. All cats induced a strong and sustained specific IgG antibody response. The induced anti-Fel d 1 antibodies were of high affinity and exhibited a strong neutralization ability tested both in vitro and in vivo. A reduction in the endogenous allergen level and a reduced allergenicity of tear samples, were observed. Conclusion: Vaccination of cats with Fel-CuMVTT induces neutralizing antibodies and might result in reduced symptoms of allergic cat owners. Both human subjects and animals could profit from this treatment because allergic cat owners would reduce their risk of developing chronic diseases, such as asthma, and become more tolerant of their cats, which therefore could stay in the households and not need to be relinquished to animal shelters.	[Thoms, Franziska; Jennings, Gary T.; Maudrich, Melanie; Haas, Stefanie; Fettelschoss-Gabriel, Antonia] Zurich Univ Hosp, Dept Dermatol, Schlieren, Switzerland; [Thoms, Franziska; Jennings, Gary T.; Haas, Stefanie; Fettelschoss-Gabriel, Antonia; Kundig, Thomas M.] Univ Zurich, Fac Med, Zurich, Switzerland; [Thoms, Franziska; Jennings, Gary T.; Haas, Stefanie; Bachmann, Martin F.] HypoPet AG, Zurich, Switzerland; [Vogel, Monique; Bachmann, Martin F.] Univ Bern, Inselspital, Dept Immunol, Bern, Switzerland; [Zeltins, Andris] Latvian Biomed Res & Study Ctr, Riga, Latvia; [Hofmann-Lehmann, Regina; Riond, Barbara] Univ Zurich, Vetsuisse Fac, Dept Clin Diagnost & Serv, Clin Lab, Zurich, Switzerland; [Grossmann, Jonas; Hunziker, Peter] Univ Zurich, Funct Genom Ctr Zurich, ETH Zurich, Zurich, Switzerland; [Senti, Gabriela] Univ Hosp Zurich, Clin Trials Ctr, Zurich, Switzerland; [Kundig, Thomas M.] Univ Hosp, Dept Dermatol, Zurich, Switzerland; [Bachmann, Martin F.] Univ Oxford, Jenner Inst, Oxford, England	University of Zurich; University Zurich Hospital; University of Geneva; University of Zurich; University of Bern; University Hospital of Bern; Latvian Biomedical Research & Study Centre; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Oxford; Jenner Institute	Thoms, F (corresponding author), Wagistr 12, CH-8952 Schlieren, Switzerland.; Bachmann, MF (corresponding author), Inselspital Bern, Sahlihaus 2, Bern, Switzerland.	franziska.thoms@usz.ch; martin.bachmann@me.com	Gabriel, Antonia/AAD-2355-2019; Zeltins, Andris/AAI-1017-2021; Hofmann-Lehmann, Regina/C-6528-2009	Gabriel, Antonia/0000-0002-6189-172X; Hofmann-Lehmann, Regina/0000-0001-9750-4296; Grossmann, Jonas/0000-0002-6899-9020	Commission for Technology and Innovation (CTI) [16015.2 PFLS-LS]; Benchmark Vaccines Limited, United Kingdom	Commission for Technology and Innovation (CTI); Benchmark Vaccines Limited, United Kingdom	Supported by funding of the Commission for Technology and Innovation (CTI project 16015.2 PFLS-LS to T.M.K. and G.S.) and Benchmark Vaccines Limited, United Kingdom, through a licensing agreement with HypoPet AG.	ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P563, DOI 10.1016/0091-6749(85)90776-6; Bachmann MF, 2017, ALLERGY, V72, P13, DOI 10.1111/all.12890; Bachmann MF, 2018, J ALLERGY CLIN IMMUN, V142, P279, DOI 10.1016/j.jaci.2017.12.994; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Beerli RR, 2008, P NATL ACAD SCI USA, V105, P14336, DOI 10.1073/pnas.0805942105; Bessa J, 2009, J IMMUNOL, V183, P3788, DOI 10.4049/jimmunol.0804004; Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381; CHARPIN C, 1994, CLIN EXP ALLERGY, V24, P1174, DOI 10.1111/j.1365-2222.1994.tb03325.x; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; Day MJ, 2016, J SMALL ANIM PRACT, V57, pE1, DOI 10.1111/jsap.2_12431; DeAndrade AD, 1996, CLIN EXP ALLERGY, V26, P178, DOI 10.1111/j.1365-2222.1996.tb00077.x; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; Engeroff P, 2018, ALLERGY, V73, P341, DOI 10.1111/all.13268; Fettelschoss-Gabriel A, 2018, J ALLERGY CLIN IMMUN, V142, P1194, DOI 10.1016/j.jaci.2018.01.041; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; Ichikawa K, 2001, CLIN EXP ALLERGY, V31, P1279, DOI 10.1046/j.1365-2222.2001.01169.x; Jegerlehner A, 2007, J IMMUNOL, V178, P2415, DOI 10.4049/jimmunol.178.4.2415; Jennings GT, 2009, ANNU REV PHARMACOL, V49, P303, DOI 10.1146/annurev-pharmtox-061008-103129; Kall L, 2008, J PROTEOME RES, V7, P29, DOI 10.1021/pr700600n; Kaiser L, 2003, INT ARCH ALLERGY IMM, V132, P25, DOI 10.1159/000073261; Kaiser L, 2007, J MOL BIOL, V370, P714, DOI 10.1016/j.jmb.2007.04.074; Kristensen AK, 1997, BIOL CHEM, V378, P899; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Linneberg A, 2003, ALLERGY, V58, P21, DOI 10.1034/j.1398-9995.2003.23639.x; Morales M, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0193-0; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Platts-Mills TAE, 2004, SPRINGER SEMIN IMMUN, V25, P271, DOI 10.1007/s00281-003-0149-8; Sanz ML, 2002, J INVEST ALLERG CLIN, V12, P143; Scarlett J M, 1999, J Appl Anim Welf Sci, V2, P41, DOI 10.1207/s15327604jaws0201_4; Schmitz N, 2009, J EXP MED, V206, P1941, DOI 10.1084/jem.20090199; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Smith W, 2004, CLIN EXP ALLERGY, V34, P1732, DOI 10.1111/j.1365-2222.2004.02090.x; Smith W, 2011, INT ARCH ALLERGY IMM, V156, P159, DOI 10.1159/000322879; Uermosi C, 2010, J ALLERGY CLIN IMMUN, V126, P375, DOI 10.1016/j.jaci.2010.05.040; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; VANMILLIGEN FJ, 1990, INT ARCH ALLER A IMM, V92, P375, DOI 10.1159/000235168; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029; Zabel F, 2013, CURR OPIN VIROL, V3, P357, DOI 10.1016/j.coviro.2013.05.004; Zeltins A, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0030-8; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zha LS, 2018, J ALLERGY CLIN IMMUN, V142, P1529, DOI 10.1016/j.jaci.2017.09.054	45	31	32	3	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					193	203		10.1016/j.jaci.2019.01.050	http://dx.doi.org/10.1016/j.jaci.2019.01.050			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	31056187	hybrid, Green Accepted, Green Published			2022-12-18	WOS:000473432800022
J	Hanania, NA; Chipps, BE; Griffin, NM; Yoo, B; Iqbal, A; Casale, TB				Hanania, Nicola A.; Chipps, Bradley E.; Griffin, Noelle M.; Yoo, Bongin; Iqbal, Ahmar; Casale, Thomas B.			Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HEALTH; LUNG; US		[Hanania, Nicola A.] Baylor Coll Med, Airways Clin Res Ctr, Houston, TX 77030 USA; [Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA; [Griffin, Noelle M.] Aimmune Therapeut, Brisbane, CA USA; [Yoo, Bongin; Iqbal, Ahmar] Genentech Inc, San Francisco, CA 94080 USA; [Casale, Thomas B.] Univ S Florida, Tampa, FL USA	Baylor College of Medicine; Roche Holding; Genentech; State University System of Florida; University of South Florida	Iqbal, A (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.	iqbal.ahmar@gene.com	Hanania, Nicola A/C-5875-2016	Hanania, Nicola A/0000-0003-3087-9530	Genentech, Inc, a member of the Roche Group; Novartis Pharma AG; No-vartis Pharmaceuticals Corporation	Genentech, Inc, a member of the Roche Group; Novartis Pharma AG; No-vartis Pharmaceuticals Corporation	This study (clinicaltrials.gov identifier: NCT01922037) was funded by Genentech, Inc, a member of the Roche Group, and Novartis Pharma AG. Benjamin L. Trzaskoma, MS, of Genentech, Inc, provided statistical analysis support. Third-party writing assistance was provided by Nicole Tom, PhD, and Mark Snape, MB BS, CMPP, of Envision Pharma Ltd, and funded by Genentech, Inc, a member of the Roche Group, and No-vartis Pharmaceuticals Corporation.	Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; Casale TB, 2019, J ALLER CL IMM-PRACT, V7, P156, DOI 10.1016/j.jaip.2018.04.043; Fragoso CAV, 2017, INT J CHRONIC OBSTR, V12, P517, DOI 10.2147/COPD.S121223; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Tat TS, 2016, J ASTHMA, V53, P1048, DOI 10.1080/02770903.2016.1178281; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5; Woodruff PG, 2017, AM J RESP CRIT CARE, V196, P375, DOI 10.1164/rccm.201705-0973WS; Wurst KE, 2017, COPD, V14, P200, DOI 10.1080/15412555.2016.1257598; Yalcin AD, 2016, IMMUNOPHARM IMMUNOT, V38, P253, DOI 10.3109/08923973.2016.1173057	9	31	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1629	+		10.1016/j.jaci.2018.11.032	http://dx.doi.org/10.1016/j.jaci.2018.11.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30576755	hybrid			2022-12-18	WOS:000463348900040
J	Mensa-Vilaro, A; Garcia-Morato, MB; de la Calle-Martin, O; Franco-Jarava, C; Martinez-Saavedra, MT; Gonzalez-Granado, LI; Gonzalez-Roca, E; Fuster, JL; Alsina, L; Mutchinick, OM; Balderrama-Rodriguez, A; Ramos, E; Modesto, C; Mesa-del-Castillo, P; Ortego-Centeno, N; Clemente, D; Souto, A; Palmou, N; Remesal, A; Leslie, KS; de la Fuente, EG; Gallego, LYB; Campistol, JM; Dhouib, NG; Bejaoui, M; Dutra, LA; Terreri, MT; Mosquera, C; Gonzalez, T; Canellas, J; de Morales, JMGR; Wouters, CH; Bosque, MT; Cham, WT; Jimenez-Trevino, S; de Inocencio, J; Bloomfield, M; de Diego, RP; Martinez-Pomar, N; Rodriguez-Pena, R; Gonzalez-Santesteban, C; Soler-Palacin, P; Casals, F; Yague, J; Allende, LM; Rodriguez-Gallego, JC; Colobran, R; Martinez-Martinez, L; Lopez-Granados, E; Arostegui, JI				Mensa-Vilaro, Anna; Bravo Garcia-Morato, Maria; de la Calle-Martin, Oscar; Franco-Jarava, Clara; Teresa Martinez-Saavedra, Maria; Gonzalez-Granado, Luis I.; Gonzalez-Roca, Eva; Luis Fuster, Jose; Alsina, Laia; Mutchinick, Osvaldo M.; Balderrama-Rodriguez, Angelica; Ramos, Eduardo; Modesto, Consuelo; Mesa-del-Castillo, Pablo; Ortego-Centeno, Norberto; Clemente, Daniel; Souto, Alejandro; Palmou, Natalia; Remesal, Agustin; Leslie, Kieron S.; Gomez de la Fuente, Enrique; Bravo Gallego, Luz Yadira; Maria Campistol, Josep; Guirat Dhouib, Naouel; Bejaoui, Mohamed; Almeida Dutra, Livia; Teresa Terreri, Maria; Mosquera, Catalina; Gonzalez, Tatiana; Canellas, Jeronima; Maria Garcia-Ruiz de Morales, Jose; Wouters, Carine H.; Teresa Bosque, Maria; Cham, Weng Tarng; Jimenez-Trevino, Santiago; de Inocencio, Jaime; Bloomfield, Marketa; Perez de Diego, Rebeca; Martinez-Pomar, Natalia; Rodriguez-Pena, Rebeca; Gonzalez-Santesteban, Cecilia; Soler-Palacin, Pere; Casals, Ferran; Yague, Jordi; Allende, Luis M.; Carlos Rodriguez-Gallego, Jose; Colobran, Roger; Martinez-Martinez, Laura; Lopez-Granados, Eduardo; Arostegui, Juan I.			Unexpected relevant role of gene mosaicism in patients with primary immunodeficiency diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Postzygotic variants; gene mosaicism; primary immunodeficiency diseases; next-generation sequencing; amplicon-based deep sequencing; autoinflammatory diseases	CHRONIC GRANULOMATOUS-DISEASE; SOMATIC NLRP3 MUTATION; PARENTAL MOSAICISM; INBORN-ERRORS; IDENTIFICATION; TRANSMISSION; FEMALE; EXOME	Background: Postzygotic de novo mutations lead to the phenomenon of gene mosaicism. The 3 main types are called somatic, gonadal, and gonosomal mosaicism, which differ in terms of the body distribution of postzygotic mutations. Mosaicism has been reported occasionally in patients with primary immunodeficiency diseases (PIDs) since the early 1990s, but its real involvement has not been systematically addressed. Objective: We sought to investigate the incidence of gene mosaicism in patients with PIDs. Methods: The amplicon-based deep sequencing method was used in the 3 parts of the study that establish (1) the allele frequency of germline variants (n = 100), (2) the incidence of parental gonosomal mosaicism in families with PIDs with de novo mutations (n = 92), and (3) the incidence of mosaicism in families with PIDs with moderate-to-high suspicion of gene mosaicism (n = 36). Additional investigations evaluated body distribution of postzygotic mutations, their stability over time, and their characteristics. Results: The range of allele frequency (44.1% to 55.6%) was established for germline variants. Those with minor allele frequencies of less than 44.1% were assumed to be postzygotic. Mosaicism was detected in 30 (23.4%) of 128 families with PIDs, with a variable minor allele frequency (0.8% to 40.5%). Parental gonosomal mosaicism was detected in 6 (6.5%) of 92 families with de novo mutations, and a high incidence of mosaicism (63.9%) was detected among families with moderateto- high suspicion of gene mosaicism. In most analyzed cases mosaicism was found to be both uniformly distributed and stable over time. Conclusion: This study represents the largest performed to date to investigate mosaicism in patients with PIDs, revealing that it affects approximately 25% of enrolled families. Our results might have serious consequences regarding treatment and genetic counseling and reinforce the use of next-generation sequencing-based methods in the routine analyses of PIDs.	[Mensa-Vilaro, Anna; Gonzalez-Roca, Eva; Yague, Jordi; Arostegui, Juan I.] Hosp Clin IDIBAPS, Dept Immunol CDB, Barcelona, Spain; [Bravo Garcia-Morato, Maria; Bravo Gallego, Luz Yadira; Rodriguez-Pena, Rebeca; Lopez-Granados, Eduardo] Hosp Univ La Paz, Dept Immunol, Madrid, Spain; [Remesal, Agustin] Hosp Univ La Paz, Dept Pediat Rheumatol, Madrid, Spain; [Perez de Diego, Rebeca] Hosp Univ La Paz, Lab Immunogenet Dis, Madrid, Spain; [Perez de Diego, Rebeca] Hosp Univ La Paz, IdiPAZ Inst Hlth Res, Innate Immun Grp, Madrid, Spain; [de la Calle-Martin, Oscar; Gonzalez-Santesteban, Cecilia; Martinez-Martinez, Laura] Hosp Santa Creu & Sant Pau, Dept Immunol, Barcelona, Spain; [Franco-Jarava, Clara] Hosp Univ Vall dHebron, Vall dHebron Res Inst, Dept Immunol, Barcelona, Spain; [Franco-Jarava, Clara; Soler-Palacin, Pere; Colobran, Roger] Jeffrey Modell Diagnost & Res Ctr Primary Immunod, Barcelona, Spain; [Teresa Martinez-Saavedra, Maria; Carlos Rodriguez-Gallego, Jose] Hosp Univ Gran Canaria Doctor Negrin, Dept Immunol, Las Palmas Gran Canaria, Spain; [Gonzalez-Granado, Luis I.] Hosp Univ 12 Octubre, Primary Immunodeficiencies Unit, Dept Pediat, Madrid, Spain; [Gonzalez-Granado, Luis I.; de Inocencio, Jaime; Allende, Luis M.] Hosp Univ 12 Octubre, Inst Invest I 12, Madrid, Spain; [de Inocencio, Jaime] Hosp Univ 12 Octubre, Dept Pediat Rheumatol, Madrid, Spain; [Allende, Luis M.] Hosp Univ 12 Octubre, Dept Immunol, Madrid, Spain; [Gonzalez-Granado, Luis I.; Allende, Luis M.] Univ Complutense, Madrid, Spain; [Luis Fuster, Jose] Hosp Clin Univ Virgen de la Arrixaca, Dept Hematol, Murcia, Spain; [Mesa-del-Castillo, Pablo] Hosp Clin Univ Virgen de la Arrixaca, Dept Pediat Rheumatol, Murcia, Spain; [Alsina, Laia] Hosp St Joan de Deu, Dept Allergy & Clin Immunol, Esplugues, Spain; [Alsina, Laia] Hosp St Joan de Deu, Inst Recerca Pediat, Esplugues, Spain; [Mutchinick, Osvaldo M.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Genet, Mexico City, DF, Mexico; [Balderrama-Rodriguez, Angelica] Serv Salud Publ Dist Fed, Jurisdicc Sanitaria Cuajimalpa, Mexico City, DF, Mexico; [Ramos, Eduardo; Jimenez-Trevino, Santiago] Hosp Univ Cent Asturias, Dept Pediat, Oviedo, Spain; [Modesto, Consuelo] Hosp Univ Vall dHebron, Dept Pediat Rheumatol, Barcelona, Spain; [Ortego-Centeno, Norberto] Hosp Univ San Cecilio, Dept Internal Med, Granada, Spain; [Clemente, Daniel] Hosp Univ Nino Jesus, Dept Pediat Rheumatol, Madrid, Spain; [Souto, Alejandro] Hosp Clin Univ Santiago, Dept Rheumatol, Santiago De Compostela, Spain; [Palmou, Natalia] Hosp Univ Marques de Valdecilla, Dept Rheumatol, Santander, Spain; [Leslie, Kieron S.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Gomez de la Fuente, Enrique] Hosp Univ Fdn Alcorcon, Dept Dermatol, Alcorcon, Spain; [Maria Campistol, Josep] Hosp Clin IDIBAPS, Dept Nephrol, Barcelona, Spain; [Guirat Dhouib, Naouel; Bejaoui, Mohamed] Bone Marrow Transplantat Ctr, Pediat Immunohematol Unit, Tunis, Tunisia; [Almeida Dutra, Livia] Univ Fed Sao Paulo, Div Gen Neurol, Sao Paulo, Brazil; [Teresa Terreri, Maria] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pediat, Sao Paulo, Brazil; [Mosquera, Catalina] Univ El Bosque, Dept Pediat Rheumatol, Bogota, Colombia; [Gonzalez, Tatiana] Univ Cartagena, Dept Pediat Rheumatol, Cartagena, Colombia; [Canellas, Jeronima] Hosp Badalona Germans Trias & Pujol, Dept Rheumatol, Badalona, Spain; [Maria Garcia-Ruiz de Morales, Jose] Complejo Asistencial Univ Leon, Dept Immunol, Leon, Spain; [Wouters, Carine H.] KU Univ Leuven, Univ Hosp Leuven, Dept Pediat Rheumatol, Leuven, Belgium; [Wouters, Carine H.] KU Univ Leuven, Univ Hosp Leuven, Dept Microbiol, Leuven, Belgium; [Wouters, Carine H.] KU Univ Leuven, Univ Hosp Leuven, Dept Immunol, Leuven, Belgium; [Teresa Bosque, Maria] Hosp Clin Univ Lozano Blesa, Dept Rheumatol, Zaragoza, Spain; [Cham, Weng Tarng] Sunway Med Ctr, Dept Pediat Rheumatol, Kuala Lumpur, Malaysia; [Bloomfield, Marketa] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague, Czech Republic; [Bloomfield, Marketa] Univ Hosp Motol, Prague, Czech Republic; [Martinez-Pomar, Natalia] Hosp Univ Son Espases, Dept Immunol, Palma De Mallorca, Spain; [Soler-Palacin, Pere] Hosp Univ Vall dHebron, Pediat Infect Dis & Immunodeficiencies Unit, Vall dHebron Inst Recerca, Barcelona, Spain; [Colobran, Roger] Hosp Univ Vall dHebron, Dept Clin & Mol Genet, Div Immunol, Vall dHebron Inst Recerca, Barcelona, Spain; [Casals, Ferran] Univ Pompeu Fabra, Dept Genom, Barcelona, Spain; [Colobran, Roger] Autonomous Univ Barcelona, Dept Cell Biol Physiol & Immunol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital of Santa Creu i Sant Pau; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Complutense University of Madrid; Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico Universitario Virgen de la Arrixaca; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Central University Hospital Asturias; Hospital Universitari Vall d'Hebron; Hospital Universitario San Cecilio; Complexo Hospitalario Universitario de Santiago de Compostela; Hospital Universitario Marques de Valdecilla (HUMV); University of California System; University of California San Francisco; Alcorcon Foundation University Hospital; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universite de Tunis-El-Manar; Centre Nationale de Greffe de la Moelle Osseuse; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Universidad El Bosque; Universidad de Cartagena; Hospital Germans Trias i Pujol; Universidad de Leon; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Lozano Blesa University Clinical Hospital; Charles University Prague; Motol University Hospital; Hospital Universitari Son Espases; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Pompeu Fabra University; Autonomous University of Barcelona	Mensa-Vilaro, A; Arostegui, JI (corresponding author), Hosp Clin Barcelona, Dept Immunol Esc 4 Pl 0, Villarroel 170, Barcelona 08036, Spain.	amensa@clinic.ub.es; jiaroste@clinic.ub.es	Clemente, Daniel/AAS-7600-2021; Bloomfield, Marketa/ABC-8118-2020; Casals, Ferran/H-4347-2015; Gonzalez-Granado, Luis Ignacio/ABG-4515-2020; Colobran, Roger/HGB-6371-2022; RODRIGUEZ-GALLEGO, CARLOS/AAB-7516-2022; de la Calle-Martin, Oscar/Q-3353-2016; De Inocencio, Jaime/AAI-8881-2020; Alsina, Laia/AID-4372-2022; Bloomfield, Marketa/ABH-3275-2021; Gonzalez-Granado, Luis Ignacio/B-9257-2009; Soler-Palacin, Pere/N-2373-2014; Ortego-Centeno, Norberto/C-4793-2019; Dutra, Livia Almeida/J-6583-2014; Alsina, Laia/GQI-3516-2022	Clemente, Daniel/0000-0002-1605-7488; Bloomfield, Marketa/0000-0001-5330-9341; Casals, Ferran/0000-0002-8941-0369; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; de la Calle-Martin, Oscar/0000-0001-9717-053X; Bloomfield, Marketa/0000-0001-5330-9341; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; Soler-Palacin, Pere/0000-0002-0346-5570; Rodriguez-Gallego, Carlos/0000-0002-4344-8644; YAGUE, JORDI/0000-0001-8210-1929; De Inocencio, Jaime/0000-0002-0438-0245; Palmou Fontana, Natalia/0000-0002-8609-0283; Gonzalez-Roca, Eva/0000-0002-1126-0321; Wouters, Carine/0000-0002-6426-8845; Ortego-Centeno, Norberto/0000-0003-2325-0937; Dutra, Livia Almeida/0000-0001-6309-9077; Mesa-del-Castillo, Pablo/0000-0002-4408-8169; Franco-Jarava, Clara/0000-0002-9788-189X; Colobran, Roger/0000-0002-5964-536X; Bravo Gallego, Luz Yadira/0000-0002-4919-5166; Mensa-Vilaro, Anna/0000-0001-7541-9672; Arostegui, Juan Ignacio/0000-0003-4757-504X; Martinez de Saavedra Alvarez, Maria Teresa/0000-0001-8579-226X; Perez de Diego, Rebeca/0000-0001-8426-8765; Alsina, Laia/0000-0002-3559-0018; /0000-0001-9586-8539	CERCA Programme/Generalitat de Catalunya; Spanish Ministry of Economy and Competitiveness - European Regional Development Fund (ERDF) [SAF2015-68472-C2-1-R]; Instituto de Salud Carlos III/Transnational Research Projects on Rare Diseases [AC15/00027]; Instituto de Salud Carlos III - ERDF [PI14/00405]; Fondo de Investigaciones Sanitarias (FIS) - ERDF [PI 2016/2053]; FIS - ERDF [PI 2016/0044, PI 2009/0310, PI 13/01456, PI16/00759]; Spanish Ministry of Economy and Competitiveness - ERDF [SAF2015-68472-C2-2-R]	CERCA Programme/Generalitat de Catalunya; Spanish Ministry of Economy and Competitiveness - European Regional Development Fund (ERDF); Instituto de Salud Carlos III/Transnational Research Projects on Rare Diseases; Instituto de Salud Carlos III - ERDF(Instituto de Salud Carlos III); Fondo de Investigaciones Sanitarias (FIS) - ERDF; FIS - ERDF; Spanish Ministry of Economy and Competitiveness - ERDF	Supported in part by CERCA Programme/Generalitat de Catalunya (JIA), grant SAF2015-68472-C2-1-R from the Spanish Ministry of Economy and Competitiveness co-financed by European Regional Development Fund (ERDF; JIA), grant AC15/00027 from the Instituto de Salud Carlos III/Transnational Research Projects on Rare Diseases (JIA), grant PI14/00405 from the Instituto de Salud Carlos III cofinanced by ERDF (to R.C.), grant PI 2016/2053 from Fondo de Investigaciones Sanitarias (FIS) cofinanced by ERDF (to L.I.G.-G. and L.M.A.), grant PI 2016/0044 from FIS cofinanced by ERDF (to L.I.G.-G.), grant PI 2009/0310 from FIS cofinanced by ERDF (to O.d.l.C.-M.), grants PI 13/01456 and PI16/00759 from FIS cofinanced by ERDF (to J.C.R.-G.), and grant SAF2015-68472-C2-2-R from the Spanish Ministry of Economy and Competitiveness co-financed by ERDF (to F.C.).	Acuna-Hidalgo R, 2015, AM J HUM GENET, V97, P67, DOI 10.1016/j.ajhg.2015.05.008; Alsina L, 2013, J ALLERGY CLIN IMMUN, V132, P741, DOI 10.1016/j.jaci.2013.03.038; Anazi S, 2014, CLIN GENET, V85, P278, DOI 10.1111/cge.12156; [Anonymous], 2015, J ALLERGY CLIN IMMUN, V136, P484, DOI 10.1016/j.jaci.2014.12.1941; Arostegui JI, 2010, ARTHRITIS RHEUM-US, V62, P1158, DOI 10.1002/art.27342; Biesecker LG, 2013, NAT REV GENET, V14, P307, DOI 10.1038/nrg3424; Campbell IM, 2015, TRENDS GENET, V31, P382, DOI 10.1016/j.tig.2015.03.013; Cohen ASA, 2015, CLIN GENET, V87, P554, DOI 10.1111/cge.12502; Manu-Perira MD, 2015, AM J HEMATOL, V90, pE217, DOI 10.1002/ajh.24178; Forsberg LA, 2017, NAT REV GENET, V18, P128, DOI 10.1038/nrg.2016.145; Galante PAF, 2011, NUCLEIC ACIDS RES, V39, P6056, DOI 10.1093/nar/gkr221; Helderman-van den Enden ATJM, 2009, CLIN GENET, V75, P465, DOI 10.1111/j.1399-0004.2009.01173.x; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Holzelova E, 2004, NEW ENGL J MED, V351, P1409, DOI 10.1056/NEJMoa040036; Hsu AP, 2013, J ALLERGY CLIN IMMUN, V131, P1586, DOI 10.1016/j.jaci.2013.02.038; Itan Y, 2016, NAT METHODS, V13, P109, DOI 10.1038/nmeth.3739; Jimenez-Trevino S, 2013, ANN RHEUM DIS, V72, P1109, DOI 10.1136/annrheumdis-2012-202913; Kadowaki T, 2018, J ALLERGY CLIN IMMUN, V141, P1485, DOI 10.1016/j.jaci.2017.10.039; Kawasaki Y, 2017, ARTHRITIS RHEUMATOL, V69, P447, DOI 10.1002/art.39960; Kennedy SR, 2012, MECH AGEING DEV, V133, P118, DOI 10.1016/j.mad.2011.10.009; Leuer M, 2001, AM J HUM GENET, V69, P75, DOI 10.1086/321285; Lindhurst MJ, 2011, NEW ENGL J MED, V365, P611, DOI 10.1056/NEJMoa1104017; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Manthiram K, 2017, NAT IMMUNOL, V18, P832, DOI 10.1038/ni.3777; Mensa-Vilaro A, 2016, ARTHRITIS RHEUMATOL, V68, P3035, DOI 10.1002/art.39770; Mensa-Vilaro A, 2016, ARTHRITIS RHEUMATOL, V68, P1039, DOI 10.1002/art.39519; Meyts I, 2016, J ALLERGY CLIN IMMUN, V138, P957, DOI 10.1016/j.jaci.2016.08.003; Myers CT, 2018, NEW ENGL J MED, V378, P1646, DOI 10.1056/NEJMc1714579; Nakagawa K, 2015, ANN RHEUM DIS, V74, P603, DOI 10.1136/annrheumdis-2013-204361; Nijman IJ, 2014, J ALLERGY CLIN IMMUN, V133, P529, DOI 10.1016/j.jaci.2013.08.032; OMarcaigh AS, 1997, J CLIN IMMUNOL, V17, P29, DOI 10.1023/A:1027332327827; Petrovski S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003709; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; PUCK JM, 1995, J CLIN INVEST, V95, P895, DOI 10.1172/JCI117740; Raj A, 2010, NATURE, V463, P913, DOI 10.1038/nature08781; Rowczenio DM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01410; Saito M, 2005, ARTHRITIS RHEUM-US, V52, P3579, DOI 10.1002/art.21404; Sakamoto M, 2001, AM J MED GENET, V99, P234, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1159>3.0.CO;2-M; Shipman AR, 2014, JAMA DERMATOL, V150, P1025, DOI 10.1001/jamadermatol.2014.281; Stray-Pedersen A, 2017, J ALLERGY CLIN IMMUN, V139, P232, DOI 10.1016/j.jaci.2016.05.042; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wolach B, 2005, BLOOD, V105, P61, DOI 10.1182/blood-2004-02-0675; Xu XJ, 2015, HUM MUTAT, V36, P861, DOI 10.1002/humu.22819; Yamada M, 2012, GENE, V497, P110, DOI 10.1016/j.gene.2012.01.019; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601	46	31	31	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					359	368		10.1016/j.jaci.2018.09.009	http://dx.doi.org/10.1016/j.jaci.2018.09.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30273710	Bronze			2022-12-18	WOS:000454918300039
J	Howard, R; Belgrave, D; Papastamoulis, P; Simpson, A; Rattray, M; Custovic, A				Howard, Rebecca; Belgrave, Danielle; Papastamoulis, Panagiotis; Simpson, Angela; Rattray, Magnus; Custovic, Adnan			Evolution of IgE responses to multiple allergen components throughout childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergens; asthma; childhood; component-resolved diagnostics; IgE; machine learning; rhinitis	LABEL SWITCHING PROBLEM; CHAIN MONTE-CARLO; CLINICAL SYMPTOMS; MANCHESTER ASTHMA; PREDICTIVE-VALUE; BIRTH COHORT; RISK-FACTORS; R PACKAGE; CHILDREN; ATOPY	Background: There is a paucity of information about longitudinal patterns of IgE responses to allergenic proteins (components) from multiple sources. Objectives: This study sought to investigate temporal patterns of component-specific IgE responses from infancy to adolescence, and their relationship with allergic diseases. Methods: In a population-based birth cohort, we measured IgE to 112 components at 6 follow-ups during childhood. We used a Bayesian method to discover cross-sectional sensitization patterns and their longitudinal trajectories, and we related these patterns to asthma and rhinitis in adolescence. Results: We identified 1 sensitization cluster at age 1, 3 at age 3, 4 at ages 5 and 8, 5 at age 11, and 6 at age 16 years. "Broad'' cluster was the only cluster present at every follow-up, comprising components from multiple sources. "Dust mite'' cluster formed at age 3 years and remained unchanged to adolescence. At age 3 years, a single-component "Grass'' cluster emerged, which at age 5 years absorbed additional grass components and Fel d 1 to form the "Grass/cat'' cluster. Two new clusters formed at age 11 years: "Cat'' cluster and "PR-10/profilin'' (which divided at age 16 years into "PR-10'' and "Profilin''). The strongest contemporaneous associate of asthma at age 16 years was sensitization to dust mite cluster (odds ratio: 2.6; 95% CI: 1.2-6.1; P < .05), but the strongest early life predictor of subsequent asthma was sensitization to grass/cat cluster (odds ratio: 3.5; 95% CI: 1.6-7.4; P < .01). Conclusions: We describe the architecture of the evolution of IgE responses to multiple allergen components throughout childhood, which may facilitate development of better diagnostic and prognostic biomarkers for allergic diseases.	[Howard, Rebecca; Papastamoulis, Panagiotis; Rattray, Magnus] Univ Manchester, Fac Biol Med & Hlth, Div Informat Imaging & Data Sci, Manchester, Lancs, England; [Belgrave, Danielle; Custovic, Adnan] Imperial Coll London, Dept Med, Paediat Sect, London, England; [Simpson, Angela] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Simpson, Angela] Univ Hosp South Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England	University of Manchester; Imperial College London; University of Manchester; University of Manchester; Wythenshawe Hospital NHS Foundation Trust	Custovic, A (corresponding author), Imperial Coll London, Dept Paediat, Sch Med, St Marys Campus,Room 244,Norfolk Pl, London W2 1PG, England.	a.custovic@imperial.ac.uk	Custovic, Adnan/A-2435-2012; Rattray, Magnus/AAE-3297-2021; Papastamoulis, Panagiotis/ABB-1040-2020; Rattray, Magnus/B-4393-2009	Custovic, Adnan/0000-0001-5218-7071; Rattray, Magnus/0000-0001-8196-5565; Papastamoulis, Panagiotis/0000-0001-9468-7613; Rattray, Magnus/0000-0001-8196-5565; Simpson, Angela/0000-0003-2733-6666; Howard, Rebecca/0000-0003-3283-4184	UK Medical Research Council (MRC) [MR/K002449/1, MR/LO12693/1]; MRC Health eResearch Centre [MR/K006665/1]; MRC Career Development grant [MRC MR/M015181/1]; MRC [MR/K002449/1, MR/K002449/2, MR/M015181/1, MR/L012693/1, G0601361] Funding Source: UKRI	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Health eResearch Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Career Development grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the UK Medical Research Council (MRC) grants MR/K002449/1 and MR/LO12693/1, and the MRC Health eResearch Centre grant MR/K006665/1; D.B. is supported by the MRC Career Development grant MRC MR/M015181/1.	Altekar G, 2004, BIOINFORMATICS, V20, P407, DOI 10.1093/bioinformatics/btg427; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Belgrave D, 2017, J ALLERGY CLIN IMMUN, V139, P400, DOI 10.1016/j.jaci.2016.11.003; Belgrave DCM, 2013, J ALLERGY CLIN IMMUN, V132, P575, DOI 10.1016/j.jaci.2013.05.041; Bishop CM, 2013, PHILOS T R SOC A, V371, DOI 10.1098/rsta.2012.0222; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Carroll WD, 2006, ARCH DIS CHILD, V91, P405, DOI 10.1136/adc.2005.088278; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2015, J ALLERGY CLIN IMMUN; Custovic A, 2013, CURR OPIN ALLERGY CL, V13, P173, DOI 10.1097/ACI.0b013e32835e82b6; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Geyer C., 1991, COMP SCI STAT, P156, DOI DOI 10.1080/01621459.1995.10476590; GEYER CJ, 1995, J AM STAT ASSOC, V90, P909, DOI 10.1080/01621459.1995.10476590; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Holt PG, 2016, J ALLERGY CLIN IMMUN, V137, P379, DOI 10.1016/j.jaci.2015.08.044; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Melioli G, 2011, CLIN BIOCHEM, V44, P1005, DOI 10.1016/j.clinbiochem.2011.05.007; Nicolaou N, 2010, J ALLERGY CLIN IMMUN; Nicolaou N, 2011, CURR OPIN ALLERGY CL, V11, P222, DOI 10.1097/ACI.0b013e32834656c2; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Papastamoulis P, 2017, R J, V9, P403; Papastamoulis P, 2016, J STAT SOFTW, V69, P1; Papastamoulis P, 2014, COMMUN STAT-SIMUL C, V43, P913, DOI 10.1080/03610918.2012.718840; Papastamoulis P, 2013, METHODOL COMPUT APPL, V15, P293, DOI 10.1007/s11009-011-9238-7; Papastamoulis P, 2010, J COMPUT GRAPH STAT, V19, P313, DOI 10.1198/jcgs.2010.09008; Patelis A, 2016, CLIN EXP ALLERGY, V46, P1022, DOI 10.1111/cea.12761; Posa D, 2017, J ALLERGY CLIN IMMUN, V139, P541, DOI 10.1016/j.jaci.2016.08.014; Prosperi MCF, 2014, PEDIAT ALLERG IMM-UK, V25, P71, DOI 10.1111/pai.12139; Prosperi MCF, 2013, AM J RESP CRIT CARE, V188, P1303, DOI 10.1164/rccm.201304-0694OC; REDNER RA, 1984, SIAM REV, V26, P195, DOI 10.1137/1026034; Schwarz A, 2016, J ALLERGY CLIN IMMUN, V138, P1426, DOI 10.1016/j.jaci.2016.01.057; Simpson A, 2015, J ALLERGY CLIN IMMUN, V136, P1224, DOI 10.1016/j.jaci.2015.03.027; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Treudler R, 2013, CURR ALLERGY ASTHM R, V13, P110, DOI 10.1007/s11882-012-0318-8; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC	40	31	31	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1322	1330		10.1016/j.jaci.2017.11.064	http://dx.doi.org/10.1016/j.jaci.2017.11.064			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29428391	Green Submitted, Green Accepted, hybrid, Green Published			2022-12-18	WOS:000446327300029
J	Zhou, GX; Wu, W; Yu, L; Yu, TM; Yang, WJ; Wang, P; Zhang, XP; Cong, YZ; Liu, ZJ				Zhou, Guangxi; Wu, Wei; Yu, Lin; Yu, Tianming; Yang, Wenjing; Wang, Ping; Zhang, Xiaoping; Cong, Yingzi; Liu, Zhanju			Tripartite motif-containing (TRIM) 21 negatively regulates intestinal mucosal inflammation through inhibiting T(H)1/T(H)17 cell differentiation in patients with inflammatory bowel diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tripartite motif-containing 21; inflammatory bowel disease; CD4(+) T cells; mucosal inflammation; T(H)1; T(H)17	CYTOKINE EXPRESSION; ULCERATIVE-COLITIS; AUTOANTIGEN RO52; GUT MICROBIOTA; EMERGING ROLES; T-CELLS; GAMMA; PROLIFERATION; AUTOIMMUNITY; PATHOGENESIS	Background: Tripartite motif-containing (TRIM) 21 has been implicated in the pathogenesis of several types of autoimmune diseases. Objective: We sought to elucidate TRIM21 expression in patients with inflammatory bowel diseases (IBDs) and its role in regulating intestinal mucosal inflammation. Methods: TRIM21 expression was analyzed in the inflamed mucosa of patients with IBDs by means of quantitative RT-PCR and immunohistochemistry. Peripheral blood CD4(+) T cells were transfected with lentivirus-expressing TRIM21 (LV-TRIM21) or LV-sh-TRIM21, and cytokine expression was determined by using quantitative RT-PCR and ELISA. TRIM21(-/-) mice were generated, and trinitrobenzene sulfonic acid- and CD45RB(high) CD4(+) T cell-induced colitis models were established to determine its role in induction of intestinal inflammation. Results: TRIM21 was expressed predominantly in CD4(+) T cells and decreased markedly in the inflamed mucosa of patients with IBDs compared with healthy control subjects. Ectopic expression of TRIM21 inhibited IBD CD4(+) T cells to differentiate into T(H)1 and T(H)17 cells, whereas downregulation of TRIM21 had the opposite effects. TRIM21(-/-) mice had more severe colitis after administration of trinitrobenzene sulfonic acid compared with wild-type mice, which was characterized by increased expression of IFN-gamma, TNF-alpha, and IL-17A in the colon. TRIM21(-/-) CD45RB(high) CD4(+) T cells reconstituted into recombination-activating gene (Rag1)(-/-) mice induced more severe colitis than in wild-type control mice. Mechanistically, interferon regulatory factor 3 was identified as a functional downstream target of TRIM21 in that silencing of interferon regulatory factor 3 suppressed TRIM21(-/-) CD4(+) T-cell differentiation into T(H)1 and T(H)17 cells. Conclusions: TRIM21 plays a protective role in mucosal inflammation through inhibiting T(H)1 and T(H)17 cell differentiation. Thus TRIM21 might serve as a potential therapeutic target for the treatment of IBDs.	[Zhou, Guangxi; Wu, Wei; Yu, Lin; Yu, Tianming; Yang, Wenjing; Liu, Zhanju] Tongji Univ, Shanghai Peoples Hosp 10, Dept Gastroenterol, Shanghai 200072, Peoples R China; [Wang, Ping] Tongji Univ, Shanghai Peoples Hosp 10, Cent Lab, Shanghai, Peoples R China; [Zhang, Xiaoping] Tongji Univ, Sch Med, Inst Intervent Vessel, Shanghai 200092, Peoples R China; [Cong, Yingzi] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	Tongji University; Tongji University; Tongji University; University of Texas System; University of Texas Medical Branch Galveston	Liu, ZJ (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Gastroenterol, Shanghai 200072, Peoples R China.; Zhang, XP (corresponding author), Tongji Univ, Sch Med, Inst Intervent Vessel, Shanghai 200092, Peoples R China.; Cong, YZ (corresponding author), Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.	zxpkxy@126.com; yicong@utmb.edu; liuzhanju88@126.com	Yang, Wenjing/AAE-5924-2021	Yang, Wenjing/0000-0003-1541-1892; Cong, Yingzi/0000-0003-4167-7395	National Natural Science Foundation of China [81770546, 81630017, 81470822]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Supported by grants from the National Natural Science Foundation of China (81770546, 81630017, and 81470822).	Bertin S, 2017, GUT, V66, P1584, DOI 10.1136/gutjnl-2015-310710; Bolland S, 2009, J EXP MED, V206, P1647, DOI 10.1084/jem.20091507; Brandl C, 2015, FEBS OPEN BIO, V5, P26, DOI 10.1016/j.fob.2014.11.009; Brauner S, 2015, J INTERN MED, V278, P323, DOI 10.1111/joim.12375; Chapuy L, 2014, J ALLERGY CLIN IMMUN, V134, P978, DOI 10.1016/j.jaci.2014.05.025; Chen FD, 2016, J IMMUNOL, V196, P4390, DOI 10.4049/jimmunol.1501541; Eeckhaut V, 2014, GUT, V63, P367, DOI 10.1136/gutjnl-2013-305293; Espinosa A, 2006, J IMMUNOL, V176, P6277, DOI 10.4049/jimmunol.176.10.6277; Espinosa A, 2009, J EXP MED, V206, P1661, DOI 10.1084/jem.20090585; Feng T, 2011, GASTROENTEROLOGY, V140, P2031, DOI 10.1053/j.gastro.2011.03.009; Feng T, 2010, J EXP MED, V207, P1321, DOI 10.1084/jem.20092253; Habtezion A, 2016, GASTROENTEROLOGY, V150, P340, DOI 10.1053/j.gastro.2015.10.046; He C, 2016, GUT, V65, P1938, DOI 10.1136/gutjnl-2015-309389; Her M, 2016, J ALLERGY CLIN IMMUN, V137, P19, DOI 10.1016/j.jaci.2015.10.023; Higgs R, 2008, J IMMUNOL, V181, P1780, DOI 10.4049/jimmunol.181.3.1780; Ishii T, 2003, J IMMUNOL, V170, P3653, DOI 10.4049/jimmunol.170.7.3653; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Kong HJ, 2007, J IMMUNOL, V179, P26, DOI 10.4049/jimmunol.179.1.26; Krausgruber T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11627; Li Q, 2016, GASTROENTEROLOGY, V150, P1196, DOI 10.1053/j.gastro.2016.01.031; Liu C, 2013, CLIN EXP IMMUNOL, V173, P102, DOI 10.1111/cei.12084; Liu JL, 2014, REV ADHES ADHES, V2, P1, DOI 10.7569/RAA.2013.097316; Liu TC, 2016, ANNU REV PATHOL-MECH, V11, P127, DOI 10.1146/annurev-pathol-012615-044152; Liu ZJ, 2000, J IMMUNOL, V164, P6005, DOI 10.4049/jimmunol.164.11.6005; Marchesi JR, 2016, GUT, V65, P330, DOI 10.1136/gutjnl-2015-309990; McDaniel DK, 2016, INFLAMM BOWEL DIS, V22, P2265, DOI 10.1097/MIB.0000000000000858; Monteleone G, 2010, CLIN SCI, V118, P707, DOI 10.1042/CS20100027; Murugaiyan G, 2015, J CLIN INVEST, V125, P1069, DOI 10.1172/JCI74347; Ng SC, 2015, GUT, V64, P1063, DOI 10.1136/gutjnl-2014-307410; Noguchi K, 2011, CARCINOGENESIS, V32, P995, DOI 10.1093/carcin/bgr068; Oke V, 2012, J AUTOIMMUN, V39, P77, DOI 10.1016/j.jaut.2012.01.014; Ozato K, 2008, NAT REV IMMUNOL, V8, P849, DOI 10.1038/nri2413; Pan W, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8096; Qiu ZW, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt258; Rajsbaum R, 2008, EUR J IMMUNOL, V38, P619, DOI 10.1002/eji.200737916; Sartor RB, 2017, GASTROENTEROLOGY, V152, P327, DOI 10.1053/j.gastro.2016.10.012; Sato T, 2015, ONCOGENE, V34, P1280, DOI 10.1038/onc.2014.68; Scheibe K, 2017, GUT, V66, P823, DOI 10.1136/gutjnl-2015-310374; Schulte-Pelkum J, 2009, AUTOIMMUN REV, V8, P632, DOI 10.1016/j.autrev.2009.02.010; Schwerd T, 2017, GUT, V66, P1060, DOI 10.1136/gutjnl-2015-310382; Sun M, 2015, MUCOSAL IMMUNOL, V8, P969, DOI 10.1038/mi.2015.49; Suzuki M, 2016, CELL MOL LIFE SCI, V73, P1085, DOI 10.1007/s00018-015-2040-x; Tahara T, 2015, CLIN EXP MED, V15, P327, DOI 10.1007/s10238-014-0295-4; Tosiek MJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10888; Troncone E, 2013, INT REV IMMUNOL, V32, P526, DOI 10.3109/08830185.2013.823421; West CE, 2015, J ALLERGY CLIN IMMUN, V135, P3, DOI 10.1016/j.jaci.2014.11.012; Wu W, 2016, INFLAMM BOWEL DIS, V22, P1473, DOI 10.1097/MIB.0000000000000775; Wu W, 2015, SCI REP-UK, V5, DOI 10.1038/srep10501; Yoshimi R, 2009, J IMMUNOL, V182, P7527, DOI 10.4049/jimmunol.0804121	49	31	35	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1218	+		10.1016/j.jaci.2017.09.038	http://dx.doi.org/10.1016/j.jaci.2017.09.038			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29113905				2022-12-18	WOS:000446327300021
J	Nagatake, T; Shiogama, Y; Inoue, A; Kikuta, J; Honda, T; Tiwari, P; Kishi, T; Yanagisawa, A; Isobe, Y; Matsumoto, N; Shimojou, M; Morimoto, S; Suzuki, H; Hirata, S; Steneberg, P; Edlund, H; Aoki, J; Arita, M; Kiyono, H; Yasutomi, Y; Ishii, M; Kabashima, K; Kunisawa, J				Nagatake, Takahiro; Shiogama, Yumiko; Inoue, Asuka; Kikuta, Junichi; Honda, Tetsuya; Tiwari, Prabha; Kishi, Takayuki; Yanagisawa, Atsushi; Isobe, Yosuke; Matsumoto, Naomi; Shimojou, Michiko; Morimoto, Sakiko; Suzuki, Hidehiko; Hirata, So-ichiro; Steneberg, Par; Edlund, Helena; Aoki, Junken; Arita, Makoto; Kiyono, Hiroshi; Yasutomi, Yasuhiro; Ishii, Masaru; Kabashima, Kenji; Kunisawa, Jun			The 17,18-epoxyeicosatetraenoic acid-G protein-coupled receptor 40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						17,18-Epoxyeicosatetraenoic acid; G protein-coupled receptor 40; omega 3 fatty acid; contact hypersensitivity; dermatitis; neutrophil	POLYUNSATURATED FATTY-ACIDS; ATOPIC-DERMATITIS; RESOLVIN E1; IN-VIVO; CYTOCHROME-P450 ENZYMES; EICOSAPENTAENOIC ACID; DENDRITIC CELLS; INFLAMMATION; SKIN; OMEGA-3-FATTY-ACIDS	Background: Metabolites of eicosapentaenoic acid exert various physiologic actions. 17,18-Epoxyeicosatetraenoic acid (17,18-EpETE) is a recently identified new class of antiallergic and anti-inflammatory lipid metabolite of eicosapentaenoic acid, but its effects on skin inflammation and the underlying mechanisms remain to be investigated. Objective: We evaluated the effectiveness of 17,18-EpETE for control of contact hypersensitivity in mice and cynomolgus macaques. We further sought to reveal underlying mechanisms by identifying the responsible receptor and cellular target of 17,18-EpETE. Methods: Contact hypersensitivity was induced by topical application of 2,4-dinitrofluorobenzene. Skin inflammation and immune cell populations were analyzed by using flow cytometric, immunohistologic, and quantitative RT-PCR analyses. Neutrophil mobility was examined by means of imaging analysis in vivo and neutrophil culture in vitro. The receptor for 17,18-EpETE was identified by using the TGF-alpha shedding assay, and the receptor's involvement in the anti-inflammatory effects of 17,18-EpETE was examined by using KO mice and specific inhibitor treatment. Results: We found that preventive or therapeutic treatment with 17,18-EpETE ameliorated contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques. 17,18-EpETE was recognized by G protein-coupled receptor (GPR) 40 (also known as free fatty acid receptor 1) and inhibited chemoattractant-induced Rac activation and pseudopod formation in neutrophils. Indeed, the antiallergic inflammatory effect of 17,18-EpETE was abolished in the absence or inhibition of GPR40. Conclusion: 17,18-EpETE inhibits neutrophil mobility through GPR40 activation, which is a potential therapeutic target to control allergic inflammatory diseases.	[Nagatake, Takahiro; Tiwari, Prabha; Matsumoto, Naomi; Shimojou, Michiko; Morimoto, Sakiko; Suzuki, Hidehiko; Hirata, So-ichiro; Kunisawa, Jun] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Ctr Vaccine & Adjuvant Res, Lab Vaccine Mat, Ibaraki, Japan; [Nagatake, Takahiro; Tiwari, Prabha; Matsumoto, Naomi; Shimojou, Michiko; Morimoto, Sakiko; Suzuki, Hidehiko; Hirata, So-ichiro; Kunisawa, Jun] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Lab Gut Environm Syst, Ibaraki, Japan; [Shiogama, Yumiko; Yasutomi, Yasuhiro] NIBIOHN, Lab Immunoregulat & Vaccine Res, Tsukuba, Ibaraki, Japan; [Shiogama, Yumiko; Yasutomi, Yasuhiro] NIBIOHN, Tsukuba Primate Res Ctr, Tsukuba, Ibaraki, Japan; [Inoue, Asuka; Kishi, Takayuki; Aoki, Junken] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Mol & Cellular Biochem, Sendai, Miyagi, Japan; [Kikuta, Junichi; Yanagisawa, Atsushi; Ishii, Masaru] Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Suita, Osaka, Japan; [Kunisawa, Jun] Osaka Univ, Grad Sch Dent, Grad Sch Pharmaceut Sci, Grad Sch Med, Suita, Osaka, Japan; [Honda, Tetsuya; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Isobe, Yosuke; Arita, Makoto] RIKEN Ctr Integrat Med Sci, Lab Metabol, Yokohama, Kanagawa, Japan; [Hirata, So-ichiro; Kunisawa, Jun] Kobe Univ, Grad Sch Med, Dept Microbiol & Immunol, Kobe, Hyogo, Japan; [Steneberg, Par; Edlund, Helena] Umea Univ, Umea Ctr Mol Med, Umea, Sweden; [Arita, Makoto] Yokohama City Univ, Grad Sch Med Life Sci, Tsurumi Ku, Yokohama, Kanagawa, Japan; [Arita, Makoto] Keio Univ, Grad Sch Pharmaceut Sci, Div Physiol Chem & Metab, Minato Ku, Tokyo, Japan; [Kiyono, Hiroshi; Kunisawa, Jun] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Mucosal Immunol, Tokyo, Japan; [Kiyono, Hiroshi; Kunisawa, Jun] Univ Tokyo, Inst Med Sci, Int Res & Dev Ctr Mucosal Vaccines, Tokyo, Japan; [Kiyono, Hiroshi] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan; [Yasutomi, Yasuhiro] Mie Univ, Grad Sch Med, Dept Mol & Expt Med, Div Immunoregulat, Tsu, Mie, Japan	Tohoku University; Osaka University; Osaka University; Kyoto University; RIKEN; Kobe University; Umea University; Yokohama City University; Keio University; University of Tokyo; University of Tokyo; Chiba University; Mie University	Kunisawa, J (corresponding author), NIBIOHN, Ctr Vaccine & Adjuvant Res, Lab Vaccine Mat, 7-6-8 Asagi Saito, Ibaraki, Osaka 5670085, Japan.; Kunisawa, J (corresponding author), NIBIOHN, Lab Gut Environm Syst, 7-6-8 Asagi Saito, Ibaraki, Osaka 5670085, Japan.	kunisawa@nibiohn.go.jp	Kiyono, Hiroshi/AAC-6735-2022; Tiwari, Prabha/GPF-6552-2022; Tiwari, Prabha/GQR-2661-2022; Nagatake, Takahiro/AAL-1995-2020	Tiwari, Prabha/0000-0002-7143-7504; Edlund, Helena/0000-0002-3553-7348; Arita, Makoto/0000-0001-9902-0463	Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT); Japan Society for the Promotion of Science (JSPS; KAKENHI) [JP15K19142, JP17K08264, JP15K09766, JP17K08301, JP15H05897, JP15H04648, JP15K15417, JP15H02551, JP15H05790, JP26670241, JP26293111]; Japan Science and Technology Agency (JST), PRESTO [JPMJPR1331]; Japan Agency for Medical Research and Development (AMED) [JP17ek0410032h0002, JP17gm5910013, JP17gm0710001, JP17ek0410032s0102, JP17ek0210078h0002, JP17ak0101068h0001, JP17gm1010006s0101]; Ministry of Health and Welfare of Japan; Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries, and Food Industry; MEXT [JP15H05897, JP15H05906, JP3701, JP15K21738, JP15H05898, JP15H01155, JP23116506, JP16H01373, JP25116706]; Strategic Research Program in Diabetes at Umea University; Grant for Joint Research Project of the Institute of Medical Science; University of Tokyo; Astellas Foundation for Research on Metabolic Disorders; Terumo Foundation for Life Sciences and Arts; Nipponham Foundation for the Future of Food; Suzuken Memorial Foundation; Canon Foundation; RIKEN Special Postdoctoral Researcher Program; Tokyo Biochemical Research Foundation; Takeda Science Foundation; JSPS Research Fellowship; Grants-in-Aid for Scientific Research [15H04648, 15H05897, 15H05898] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS; KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Science and Technology Agency (JST), PRESTO(Japan Science & Technology Agency (JST)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Ministry of Health and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries, and Food Industry; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Strategic Research Program in Diabetes at Umea University; Grant for Joint Research Project of the Institute of Medical Science; University of Tokyo; Astellas Foundation for Research on Metabolic Disorders; Terumo Foundation for Life Sciences and Arts; Nipponham Foundation for the Future of Food; Suzuken Memorial Foundation; Canon Foundation(Canon Foundation); RIKEN Special Postdoctoral Researcher Program; Tokyo Biochemical Research Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); JSPS Research Fellowship(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT) and the Japan Society for the Promotion of Science (JSPS; KAKENHI [JP15K19142 to T.N., JP17K08264 to A.I., JP15K09766 to T.H., JP17K08301 to H.S., JP15H05897 to J.A., JP15H04648 to M.A., JP15K15417 and JP15H02551 to K.K., JP15H05790 to K.K. and J.K., and JP26670241 and JP26293111 to J.K.]); the Japan Science and Technology Agency (JST), PRESTO (to A.I.; JPMJPR1331); the Japan Agency for Medical Research and Development (AMED; [JP17ek0410032h0002 to H.K., JP17gm5910013 to A.I., JP17gm0710001 to J.A. and JP17ek0410032s0102, JP17ek0210078h0002, JP17ak0101068h0001 and JP17gm1010006s0101 to J.K.]); the Ministry of Health and Welfare of Japan (to J.K.); the Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries, and Food Industry (to M.A. and J.K.); a grant-in-aid for Scientific Research on Innovative Areas from MEXT (JP15H05906 to T.H.; JP3701, JP15K21738, JP15H05898, and JP15H05897 to M.A.; JP15H01155 to K.K.; JP23116506 to H.K. and J.K.; and JP16H01373 and JP25116706 to J.K.); the Strategic Research Program in Diabetes at Umea University (to H.E. and P.S.); the Grant for Joint Research Project of the Institute of Medical Science, the University of Tokyo (to J.K.); the Astellas Foundation for Research on Metabolic Disorders (to J.K.); Terumo Foundation for Life Sciences and Arts (to J.K.); the Nipponham Foundation for the Future of Food; and the Suzuken Memorial Foundation (to J.K.); the Canon Foundation (to J.K.). Y.I. was supported by a RIKEN Special Postdoctoral Researcher Program. P.T. was supported by a fellowship from the Tokyo Biochemical Research Foundation and Takeda Science Foundation. T.K. was supported by a JSPS Research Fellowship.	Abdel-Latif D, 2004, BLOOD, V104, P832, DOI 10.1182/blood-2003-07-2624; Arita M, 2007, J IMMUNOL, V178, P3912, DOI 10.4049/jimmunol.178.6.3912; Arnold C, 2010, J BIOL CHEM, V285, P32720, DOI 10.1074/jbc.M110.118406; Barbara G, 2012, J CLIN GASTROENTEROL, V46, pS52, DOI 10.1097/MCG.0b013e318264e918; Brick T, 2016, J ALLERGY CLIN IMMUN, V137, P1699, DOI 10.1016/j.jaci.2015.10.042; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Cassimeris L, 1990, Semin Cell Biol, V1, P125; Cattani F, 2006, EUR CYTOKINE NETW, V17, P42; Chang HH, 2008, LIPIDS, V43, P499, DOI 10.1007/s11745-008-3171-8; Cheng DT, 2013, J ALLERGY CLIN IMMUN, V132, P455, DOI 10.1016/j.jaci.2013.05.011; Christensen AD, 2014, IMMUN INFLAMM DIS, V2, P21, DOI 10.1002/iid3.16; Fujita T, 2011, J INVEST DERMATOL, V131, P1660, DOI 10.1038/jid.2011.123; Gross S, 2009, NAT MED, V15, P455, DOI 10.1038/nm.1886; Hansen S, 2017, J ALLERGY CLIN IMMUN, V139, P104, DOI 10.1016/j.jaci.2016.02.042; Hauge M, 2015, MOL METAB, V4, P3, DOI 10.1016/j.molmet.2014.10.002; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; HONJO S, 1985, J MED PRIMATOL, V14, P75; Ingraham RH, 2011, CURR MED CHEM, V18, P587; Inoue A, 2012, NAT METHODS, V9, P1021, DOI [10.1038/NMETH.2172, 10.1038/nmeth.2172]; Jangale Nivedita M, 2013, Food Chem, V141, P187, DOI 10.1016/j.foodchem.2013.03.001; Kaku K, 2016, DIABETES OBES METAB, V18, P925, DOI 10.1111/dom.12693; Keijsers RRMC, 2014, J INVEST DERMATOL, V134, P1276, DOI 10.1038/jid.2013.526; Kim TH, 2012, INT IMMUNOPHARMACOL, V14, P384, DOI 10.1016/j.intimp.2012.08.005; Kish DD, 2012, J IMMUNOL, V189, P2191, DOI 10.4049/jimmunol.1102729; Kubota T, 2014, FASEB J, V28, P586, DOI 10.1096/fj.13-236224; Kunisawa J, 2015, SCI REP-UK, V5, DOI 10.1038/srep09750; Kunisawa J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2718; Lucas D, 2010, J LIPID RES, V51, P1125, DOI 10.1194/jlr.M003061; Magnusson J, 2015, J ALLERGY CLIN IMMUN, V136, P1247, DOI 10.1016/j.jaci.2015.05.030; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; Mashimo H, 2008, INVEST OPHTH VIS SCI, V49, P5450, DOI 10.1167/iovs.08-1878; Miyamoto J, 2015, J BIOL CHEM, V290, P2902, DOI 10.1074/jbc.M114.610733; Miyata J, 2015, ALLERGOL INT, V64, P27, DOI 10.1016/j.alit.2014.08.003; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; Mizuno K, 2015, J DERMATOL SCI, V80, P45, DOI 10.1016/j.jdermsci.2015.06.016; Molesworth-Kenyon SJ, 2005, J LEUKOCYTE BIOL, V77, P552, DOI 10.1189/jlb.0904485; Moniaga CS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15319; Mori T, 2008, J INVEST DERMATOL, V128, P1719, DOI 10.1038/jid.2008.5; Morin C, 2010, AM J RESP CELL MOL, V43, P564, DOI 10.1165/rcmb.2009-0155OC; Morrison AR, 2014, J EXP MED, V211, P1957, DOI 10.1084/jem.20132130; Nagatake T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127460; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Natsuaki Y, 2014, NAT IMMUNOL, V15, P1064, DOI 10.1038/ni.2992; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oyoshi MK, 2012, IMMUNITY, V37, P747, DOI 10.1016/j.immuni.2012.06.018; Park DK, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/879696; Peiser M, 2012, CELL MOL LIFE SCI, V69, P763, DOI 10.1007/s00018-011-0846-8; Ridley AJ, 2015, CURR OPIN CELL BIOL, V36, P103, DOI 10.1016/j.ceb.2015.08.005; Sawada Y, 2015, J EXP MED, V212, P1921, DOI 10.1084/jem.20150381; Schwarz D, 2004, BIOCHEM PHARMACOL, V67, P1445, DOI 10.1016/j.bcp.2003.12.023; Scimone ML, 2005, IMMUNOLOGY, V114, P375, DOI 10.1111/j.1365-2567.2005.02104.x; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Shi GX, 2007, J EXP MED, V204, P2705, DOI 10.1084/jem.20071267; Steneberg R, 2005, CELL METAB, V1, P245, DOI 10.1016/j.cmet.2005.03.007; Tajima Y, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-68; Tsuji RF, 2002, J EXP MED, V196, P1277, DOI 10.1084/jem.20020649; van der Hoeven D, 2010, BIOCHEM PHARMACOL, V79, P1667, DOI 10.1016/j.bcp.2010.02.002; Wang JH, 2006, J BIOL CHEM, V281, P34457, DOI 10.1074/jbc.M608019200; Weber FC, 2015, J EXP MED, V212, P15, DOI 10.1084/jem.20130062; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Welch Heidi C E, 2015, Small GTPases, V6, P49, DOI 10.4161/21541248.2014.973770; Yan YQ, 2013, IMMUNITY, V38, P1154, DOI 10.1016/j.immuni.2013.05.015; Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111; Zachariah MA, 2010, SCIENCE, V328, P1129, DOI 10.1126/science.1188222; Zhang MJ, 2012, ANNU REV NUTR, V32, P203, DOI 10.1146/annurev-nutr-071811-150726; Zhou SF, 2009, DRUG METAB REV, V41, P89, DOI 10.1080/03602530902843483	67	31	31	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					470	+		10.1016/j.jaci.2017.09.053	http://dx.doi.org/10.1016/j.jaci.2017.09.053			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29288079	Green Published, hybrid			2022-12-18	WOS:000440664400016
J	Aceves, SS; King, E; Collins, MH; Yang, GY; Capocelli, KE; Abonia, JP; Atkins, D; Bonis, PA; Carpenter, CL; Dellon, ES; Eby, MD; Falk, GW; Gonsalves, N; Gupta, SK; Hirano, I; Kocher, K; Krischer, JP; Leung, J; Lipscomb, J; Menard-Katcher, P; Mukkada, VA; Pan, ZX; Spergel, JM; Sun, Q; Wershil, BK; Rothenberg, ME; Furuta, GT				Aceves, Seema S.; King, Eileen; Collins, Margaret H.; Yang, Guang-Yu; Capocelli, Kelley E.; Abonia, J. Pablo; Atkins, Dan; Bonis, Peter A.; Carpenter, Christina L.; Dellon, Evan S.; Eby, Michael D.; Falk, Gary W.; Gonsalves, Nirmala; Gupta, Sandeep K.; Hirano, Ikuo; Kocher, Kendra; Krischer, Jeffrey P.; Leung, John; Lipscomb, Jessi; Menard-Katcher, Paul; Mukkada, Vincent A.; Pan, Zhaoxing; Spergel, Jonathan M.; Sun, Qin; Wershil, Barry K.; Rothenberg, Marc E.; Furuta, Glenn T.		Consortium Eosinophilic	Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; eosinophilic esophagitis; eosinophilic oesophagitis; Consortium of Eosinophilic Gastrointestinal Disease Researchers; patient-reported outcomes; pediatric eosinophilic esophagitis symptom score; version 2; pediatric QOL EoE module; symptoms; quality of life	SYMPTOMS; DISEASE; LONG	Background: Patient-reported outcome metrics for eosinophilic esophagitis (EoE) have been developed and validated but not used in a multicenter pediatric population or systematically aligned with histology. Objective: We sought to understand (1) the potential of caregiver report to predict patient self-reported symptoms and (2) the correlation of patient-reported outcome domains with histology. Methods: Patients with EoE (n = 310) and their parents participating in the Consortium of Gastrointestinal Eosinophilic Disease Researchers (CEGIR) observational clinical trial were queried for baseline patient symptoms and quality of life (QOL) by using the Pediatric Eosinophilic Esophagitis Symptom Score, version 2 (PEESSv2.0), and the Pediatric QOL EoE module (PedsQL-EoE), and biopsy specimens were analyzed by using the EoE Histology Scoring System. Results: PEESSv2.0 parental and child reports aligned across all domains (r = 0.68-0.73, P<.001). PedsQL-EoE reports correlated between parents and children across ages and multiple domains (r 5 0.48-0.79, P<.001). There was a tight correlation between symptoms on PEESSv2.0 and their effects on QOL both on self-report and parental report (P<.001). Self-reported symptoms on PEESSv2.0 (positively) and PedsQL-EoE (inversely) showed a weak correlation with proximal, but not distal, peak eosinophil counts and features and architectural tissue changes on the EoE Histology Scoring System (P<.05). Conclusions: Parents of children with EoE aged 3 to 18 years accurately reflected their children's disease symptoms and QOL. Self- and parent-reported symptoms correlate with proximal esophageal histology. Our data suggest that parental report in young children can function as an adequate marker for self-reported symptoms and that self-reported symptoms can reflect changes in tissue histology in the proximal esophagus. These findings should be considered during clinical trials for drug development.	[Aceves, Seema S.] Univ Calif San Diego, Div Allergy Immunol, Rady Childrens Hosp, San Diego, CA 92103 USA; [King, Eileen; Lipscomb, Jessi; Sun, Qin] Univ Cincinnati, Coll Med, Dept Pediat,Div Biostat & Epidemiol, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Collins, Margaret H.] Univ Cincinnati, Coll Med, Dept Pediat, Div Pathol, Cincinnati, OH USA; [Yang, Guang-Yu] Northwestern Univ, Feinberg Sch Med, Div Pathol, Chicago, IL 60611 USA; [Gonsalves, Nirmala; Hirano, Ikuo] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA; [Capocelli, Kelley E.] Childrens Hosp Colorado, Div Pathol, Aurora, CO USA; [Atkins, Dan] Childrens Hosp Colorado, Sect Allergy, Immunol, Aurora, CO USA; [Abonia, J. Pablo; Eby, Michael D.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Bonis, Peter A.; Leung, John] Tufts Med Ctr, Div Gastroenterol, Boston, MA USA; [Carpenter, Christina L.; Krischer, Jeffrey P.] Univ S Florida, Morsani Coll Med, Hlth Informat Inst, Dept Pediat, Tampa, FL USA; [Carpenter, Christina L.; Krischer, Jeffrey P.] Univ S Florida, Morsani Coll Med, Hlth Informat Inst, Dept Med, Tampa, FL USA; [Dellon, Evan S.] Univ N Carolina, Dept Gastroenterol & Hepatol, Sch Med, Chapel Hill, NC 27515 USA; [Falk, Gary W.] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA; [Gupta, Sandeep K.] Univ Illinois, Coll Med, Dept Pediat Gastroenterol Hepatol & Nutr, Chicago, IL USA; [Kocher, Kendra; Menard-Katcher, Paul; Furuta, Glenn T.] Univ Colorado, Childrens Hosp Colorado, Gastrointestinal Eosinophil Dis Program, Sect Pediat Gastroenterol Hepatol & Nutr,Sch Med, Aurora, CO USA; [Mukkada, Vincent A.] Univ Cincinnati, Coll Med, Dept Pediat,Div Gastroenterol Hepatol & Nutr, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Pan, Zhaoxing] Childrens Hosp Colorado, Pediat Gastroenterol Pediat Allergy & Immunol, Aurora, CO USA; [Spergel, Jonathan M.] Univ Penn, Childrens Hosp Philadelphia, Dept Allergy & Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Wershil, Barry K.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Gastroenterol Hepatol & Nutr, Chicago, IL 60611 USA	Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Children's Hospital Colorado; Children's Hospital Colorado; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Tufts Medical Center; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Children's Hospital Colorado; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Ann & Robert H. Lurie Children's Hospital of Chicago	Rothenberg, ME (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Marc.Rothenberg@cchmc.org	Mukkada, Vincent/AAF-6995-2019	Mukkada, Vincent/0000-0003-4225-5506	CEGIR [U54 AI117804]; Rare Diseases Clinical Research Network (RDCRN); NIAID; NIDDK; NCATS; American Partnership for Eosinophilic Disorders (APFED); Campaign Urging Research for Eosinophilic Disease (CURED); Eosinophilic Family Coalition (EFC).; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [U01TR001263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI117804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER	CEGIR; Rare Diseases Clinical Research Network (RDCRN); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); American Partnership for Eosinophilic Disorders (APFED); Campaign Urging Research for Eosinophilic Disease (CURED); Eosinophilic Family Coalition (EFC).; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Amanda Rudman-Spergel for guidance and input, Shawna Hottinger for editorial assistance, colleagues and clinical support staff in CEGIR for procuring biopsy specimens and clinical data, and families for participating in the trial. This study was supported by CEGIR (U54 AI117804), which is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS, and is co-funded by the NIAID, NIDDK, and NCATS. CEGIR is also supported by patient advocacy groups including the American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC).	Aceves SS, 2014, DIGEST DIS, V32, P143, DOI 10.1159/000357131; Aceves SS, 2009, ANN ALLERG ASTHMA IM, V103, P401, DOI 10.1016/S1081-1206(10)60359-6; Cheng Katherine, 2017, Transl Sci Rare Dis, V2, P141, DOI 10.3233/TRD-170016; Collins MH, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12470; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Dellon ES, 2012, CLIN GASTROENTEROL H, V10, P1066, DOI 10.1016/j.cgh.2012.06.003; Franciosi JP, 2013, J PEDIATR GASTR NUTR, V57, P57, DOI 10.1097/MPG.0b013e31828f1fd2; Franciosi JP, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-135; Franciosi JP, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-126; Greuter T, 2017, AM J GASTROENTEROL, V112, P1527, DOI 10.1038/ajg.2017.202; Huang IC, 2014, QUAL LIFE RES, V23, P747, DOI 10.1007/s11136-013-0607-2; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lynch MK, 2018, J PEDIATR PSYCHOL, V43, P464, DOI 10.1093/jpepsy/jsx128; Martin LJ, 2015, J ALLERGY CLIN IMMUN, V135, P1519, DOI 10.1016/j.jaci.2015.03.004; Mukkada V, 2018, CLIN GASTROENTEROL H, V16, P495, DOI 10.1016/j.cgh.2017.06.036; Pentiuk S, 2009, J PEDIATR GASTR NUTR, V48, P152, DOI 10.1097/MPG.0b013e31817f0197; Santos MFO, 2017, J PEDIAT RIO J; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Shoda T, 2018, LANCET GASTROENTEROL, V3, P477, DOI 10.1016/S2468-1253(18)30096-7	19	31	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					130	+		10.1016/j.jaci.2018.05.014	http://dx.doi.org/10.1016/j.jaci.2018.05.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29852258	Bronze, Green Accepted			2022-12-18	WOS:000437837500017
J	Garzorz-Stark, N; Lauffer, F; Krause, L; Thomas, J; Atenhan, A; Franz, R; Roenneberg, S; Boehner, A; Jargosch, M; Batra, R; Mueller, NS; Haak, S; Gross, C; Gross, O; Traidl-Hoffmann, C; Theis, FJ; Schmidt-Weber, CB; Biedermann, T; Eyerich, S; Eyerich, K				Garzorz-Stark, Natalie; Lauffer, Felix; Krause, Linda; Thomas, Jenny; Atenhan, Anne; Franz, Regina; Roenneberg, Sophie; Boehner, Alexander; Jargosch, Manja; Batra, Richa; Mueller, Nikola S.; Haak, Stefan; Gross, Christina; Gross, Olaf; Traidl-Hoffmann, Claudia; Theis, Fabian J.; Schmidt-Weber, Carsten B.; Biedermann, Tilo; Eyerich, Stefanie; Eyerich, Kilian			Toll-like receptor 7/8 agonists stimulate plasmacytoid dendritic cells to initiate T(H)17-deviated acute contact dermatitis in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; contact dermatitis; imiquimod; Aldara; plasmacytoid dendritic cell; IL-23; T(H)17; cytotoxicity; Toll-dlike receptor; innate immunity	PSORIASIFORM SKIN INFLAMMATION; LANGERHANS CELLS; ATOPIC ECZEMA; PATCH TEST; T-CELLS; IMIQUIMOD; NICKEL; MICE; INDUCTION; SIGNATURE	Background: A standardized human model to study early pathogenic events in patients with psoriasis is missing. Activation of Toll-like receptor 7/8 by means of topical application of imiquimod is the most commonly used mouse model of psoriasis. Objective: We sought to investigate the potential of a human imiquimod patch test model to resemble human psoriasis. Methods: Imiquimod (Aldara 5% cream; 3M Pharmaceuticals, St Paul, Minn) was applied twice a week to the backs of volunteers (n = 18), and development of skin lesions was monitored over a period of 4 weeks. Consecutive biopsy specimens were taken for whole-genome expression analysis, histology, and T-cell isolation. Plasmacytoid dendritic cells (pDCs) were isolated from whole blood, stimulated with Toll-like receptor 7 agonist, and analyzed by means of extracellular flux analysis and real-time PCR. Results: We demonstrate that imiquimod induces a monomorphic and self-limited inflammatory response in healthy subjects, as well as patients with psoriasis or eczema. The clinical and histologic phenotype, as well as the transcriptome, of imiquimod-induced inflammation in human skin resembles acute contact dermatitis rather than psoriasis. Nevertheless, the imiquimod model mimics the hallmarks of psoriasis. In contrast to classical contact dermatitis, in which myeloid dendritic cells sense haptens, pDCs are primary sensors of imiquimod. They respond with production of proinflammatory and TH17-skewing cytokines, resulting in a TH17 immune response with IL-23 as a key driver. In a proof-of-concept setting systemic treatment with ustekinumab diminished imiquimod-induced inflammation. Conclusion: In human subjects imiquimod induces contact dermatitis with the distinctive feature that pDCs are the primary sensors, leading to an IL-23/TH17 deviation. Despite these shortcomings, the human imiquimod model might be useful to investigate early pathogenic events and prove molecular concepts in patients with psoriasis.	[Garzorz-Stark, Natalie; Lauffer, Felix; Franz, Regina; Roenneberg, Sophie; Boehner, Alexander; Biedermann, Tilo; Eyerich, Kilian] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Krause, Linda; Batra, Richa; Mueller, Nikola S.; Theis, Fabian J.] German Ctr Lung Res DZL, Helmholtz Ctr Munich, Inst Computat Biol, Neuherberg, Germany; [Thomas, Jenny; Atenhan, Anne; Jargosch, Manja; Haak, Stefan; Schmidt-Weber, Carsten B.; Eyerich, Stefanie] Tech Univ, ZAUM Ctr Allergy & Environm, Munich, Germany; [Thomas, Jenny; Atenhan, Anne; Jargosch, Manja; Haak, Stefan; Schmidt-Weber, Carsten B.; Eyerich, Stefanie] German Ctr Lung Res DZL, Helmholtz Ctr Munich, Munich, Germany; [Gross, Christina; Gross, Olaf] Tech Univ Munich, Inst Clin Chem & Pathobiochem, Munich, Germany; [Traidl-Hoffmann, Claudia] Tech Univ, Inst Environm Med UNIKAT, Augsburg, Germany; [Traidl-Hoffmann, Claudia] Helmholtz Ctr Munich, Augsburg, Germany; [Theis, Fabian J.] Tech Univ Munich, Dept Math, Garching, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Garzorz-Stark, N (corresponding author), Dept Dermatol & Allergy, Biedersteiner Str 29, D-80802 Munich, Germany.	natalie.garzorz@tum.de	Krause, Linda/ACQ-7999-2022; Thomas, Jenny/AGH-3046-2022; Batra, Richa/ABF-1240-2021; Schmidt-Weber, Carsten B./AAU-1621-2021; Theis, Fabian J/ABD-5212-2021; Gross, Olaf/E-4570-2010	Batra, Richa/0000-0003-3708-0086; Schmidt-Weber, Carsten B./0000-0002-3203-8084; Theis, Fabian J/0000-0002-2419-1943; Krause, Linda/0000-0002-8490-5717; Gross, Olaf/0000-0001-8660-3619; Gross, Christina/0000-0002-5982-6881; Biedermann, Tilo/0000-0002-5352-5105	European Research Council [IMCIS 676858, FLAMMASEC 337689]; German Research Foundation [EY97/3-1]; Bavarian Molecular Biosystems Research Network (BioSysNet); Helmholtz Association ("Impuls- und Vernetzungsfonds''); German Research Foundation (DFG) through the Graduate School of Quantitative Biosciences Munich	European Research Council(European Research Council (ERC)European Commission); German Research Foundation(German Research Foundation (DFG)); Bavarian Molecular Biosystems Research Network (BioSysNet); Helmholtz Association ("Impuls- und Vernetzungsfonds''); German Research Foundation (DFG) through the Graduate School of Quantitative Biosciences Munich(German Research Foundation (DFG))	Supported by the European Research Council (IMCIS 676858 and FLAMMASEC 337689), German Research Foundation (EY97/3-1), Bavarian Molecular Biosystems Research Network (BioSysNet), and Helmholtz Association ("Impuls- und Vernetzungsfonds''). L.K. is supported by the German Research Foundation (DFG) through the Graduate School of Quantitative Biosciences Munich.	Boehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7; Chyou S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032828; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Di Domizio J, 2017, METHODS MOL BIOL, V1559, P83, DOI 10.1007/978-1-4939-6786-5_7; Dickson MC, 2015, INFLAMM RES, V64, P171, DOI 10.1007/s00011-015-0795-z; Dombrowski Y, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002001; El Malki K, 2013, J INVEST DERMATOL, V133, P441, DOI 10.1038/jid.2012.318; Eyerich K, 2015, TRENDS IMMUNOL, V36, P788, DOI 10.1016/j.it.2015.10.006; Eyerich K, 2010, EXP DERMATOL, V19, P511, DOI 10.1111/j.1600-0625.2009.00980.x; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Garzorz-Stark N, 2016, EXP DERMATOL, V25, P767, DOI 10.1111/exd.13077; Gilliet M, 2004, ARCH DERMATOL, V140, P1490, DOI 10.1001/archderm.140.12.1490; Gordon KB, 2015, NEW ENGL J MED, V373, P136, DOI 10.1056/NEJMoa1501646; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Grine L, 2015, J IMMUNOL, V194, P5094, DOI 10.4049/jimmunol.1403015; Gross CJ, 2016, IMMUNITY, V45, P761, DOI 10.1016/j.immuni.2016.08.010; Hawkes JE, 2017, J INVEST DERMATOL, V137, P546, DOI 10.1016/j.jid.2016.10.024; Kaplan DH, 2012, NAT REV IMMUNOL, V12, P114, DOI 10.1038/nri3150; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Lebwohl MG, 2016, AM J CLIN DERMATOL, V17, P87, DOI 10.1007/s40257-015-0169-x; Lin ZX, 2016, P NATL ACAD SCI USA, V113, P14662, DOI 10.1073/pnas.1617317113; Martin SF, 2012, CURR OPIN IMMUNOL, V24, P720, DOI 10.1016/j.coi.2012.08.003; Patel U, 2011, BRIT J DERMATOL, V164, P670, DOI 10.1111/j.1365-2133.2010.10124.x; Puig L, 2017, EXPERT REV CLIN IMMU, V13, P525, DOI 10.1080/1744666X.2017.1292137; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Riol-Blanco L, 2014, NATURE, V510, P157, DOI 10.1038/nature13199; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Singh TP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13581; Suarez-Farinas M, 2012, J INVEST DERMATOL, V132, P2552, DOI 10.1038/jid.2012.184; Swindell WR, 2016, J INVEST DERMATOL, V136, P1820, DOI 10.1016/j.jid.2016.04.035; Swindell WR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034594; Swindell WR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018266; Traidl C, 2000, J IMMUNOL, V165, P3058, DOI 10.4049/jimmunol.165.6.3058; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Vinter H, 2015, BRIT J DERMATOL, V172, P345, DOI 10.1111/bjd.13236; Walter A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2566; Yoshiki R, 2014, J INVEST DERMATOL, V134, P1912, DOI 10.1038/jid.2014.98	37	31	31	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1320	+		10.1016/j.jaci.2017.07.045	http://dx.doi.org/10.1016/j.jaci.2017.07.045			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28935206	Green Published, hybrid, Green Submitted			2022-12-18	WOS:000429197800018
J	Thijs, JL; Strickland, I; Bruijnzeel-Koomen, CAFM; Nierkens, S; Giovannone, B; Knol, EF; Csomor, E; Sellman, BR; Mustelin, T; Sleeman, MA; de Bruin-Weller, MS; Herath, A; Drylewicz, J; May, RD; Hijnen, D				Thijs, Judith L.; Strickland, Ian; Bruijnzeel-Koomen, Carla A. F. M.; Nierkens, Stefan; Giovannone, Barbara; Knol, Edward F.; Csomor, Eszter; Sellman, Bret R.; Mustelin, Tomas; Sleeman, Matthew A.; de Bruin-Weller, Marjolein S.; Herath, Athula; Drylewicz, Julia; May, Richard D.; Hijnen, DirkJan			Serum biomarker profiles suggest that atopic dermatitis is a systemic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RISK; COMORBIDITIES; ASSOCIATION		[Thijs, Judith L.; Bruijnzeel-Koomen, Carla A. F. M.; Giovannone, Barbara; Knol, Edward F.; de Bruin-Weller, Marjolein S.; Hijnen, DirkJan] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands; [Thijs, Judith L.; Nierkens, Stefan; Giovannone, Barbara; Knol, Edward F.; Drylewicz, Julia; Hijnen, DirkJan] Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [Strickland, Ian; Csomor, Eszter; Sleeman, Matthew A.; Herath, Athula; May, Richard D.] MedImmune, Granta Pk, Cambridge, England; [Sellman, Bret R.; Mustelin, Tomas] MedImmune, Gaithersburg, MD USA	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; AstraZeneca; Medimmune; AstraZeneca; Medimmune	Hijnen, D (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands.; Hijnen, D (corresponding author), Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands.	dirkjanhijnen@gmail.com	Nierkens, Stefan/AAQ-5564-2021; Hijnen, DirkJan/L-1387-2015	Nierkens, Stefan/0000-0003-3406-817X; Knol, Edward/0000-0001-7368-9820; Drylewicz, Julia/0000-0002-9434-8459; Giovannone, Barbara/0000-0003-3143-1922; Hijnen, DirkJan/0000-0003-3379-3425; Mustelin, Tomas/0000-0001-5912-8840; May, Richard/0000-0001-7825-2716	MedImmune [CW435174]	MedImmune(AstraZenecaMedimmune)	The study was supported by MedImmune (CW435174).	Andersen YMF, 2016, J ALLERGY CLIN IMMUN, V138, P310, DOI 10.1016/j.jaci.2016.01.015; Boehncke WH, 2011, EXP DERMATOL, V20, P303, DOI 10.1111/j.1600-0625.2011.01261.x; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Standl M, 2017, J INVEST DERMATOL, V137, P1074, DOI 10.1016/j.jid.2016.11.031; Thyssen JP, 2017, J AM ACAD DERMATOL, V76, P1088, DOI 10.1016/j.jaad.2017.01.030; UEHIRA M, 1993, INT IMMUNOL, V5, P1619, DOI 10.1093/intimm/5.12.1619; Yamanaka K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104479	9	31	31	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1523	+		10.1016/j.jaci.2017.12.991	http://dx.doi.org/10.1016/j.jaci.2017.12.991			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29410314	Bronze			2022-12-18	WOS:000429197800048
J	Schulten, V; Tripple, V; Seumois, G; Qian, Y; Scheuermann, RH; Fu, Z; Locci, M; Rosales, S; Vijayanand, P; Sette, A; Alam, R; Crotty, S; Peters, B				Schulten, Veronique; Tripple, Victoria; Seumois, Gregory; Qian, Yu; Scheuermann, Richard H.; Fu, Zheng; Locci, Michela; Rosales, Sandy; Vijayanand, Pandurangan; Sette, Alessandro; Alam, Rafeul; Crotty, Shane; Peters, Bjoern			Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Schulten, Veronique; Tripple, Victoria; Seumois, Gregory; Fu, Zheng; Locci, Michela; Rosales, Sandy; Vijayanand, Pandurangan; Sette, Alessandro; Crotty, Shane; Peters, Bjoern] La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA; [Qian, Yu; Scheuermann, Richard H.] J Craig Venter Inst, La Jolla, CA USA; [Scheuermann, Richard H.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; [Alam, Rafeul] Natl Jewish Hlth, Denver, CO USA	La Jolla Institute for Immunology; J. Craig Venter Institute; University of California System; University of California San Diego; National Jewish Health	Schulten, V (corresponding author), La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA.	Veronique@lji.org	Sette, Alessandro/AFO-8916-2022; Crotty, Shane/AAE-8446-2019; Crotty, Shane/AAC-6703-2019	Crotty, Shane/0000-0002-6484-6262; Seumois, Gregory/0000-0002-8164-6852	US National Institute of Health [HHSN272200700048C, 1U19AI100275-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR027366] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102943, U19AI118626, U19AI100275] Funding Source: NIH RePORTER	US National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by US National Institute of Health (contract nos. HHSN272200700048C and 1U19AI100275-01).	Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kemeny DM, 2012, CELL MOL IMMUNOL, V9, P386, DOI 10.1038/cmi.2012.31; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Kobayashi T, 2017, J ALLERGY CLIN IMMUN, V139, P300, DOI 10.1016/j.jaci.2016.04.021; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Seumois G, 2016, J IMMUNOL, V197, P655, DOI 10.4049/jimmunol.1600397; Varricchi G, 2016, ALLERGY, V71, P1086, DOI 10.1111/all.12878	10	31	31	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					775	+		10.1016/j.jaci.2017.04.032	http://dx.doi.org/10.1016/j.jaci.2017.04.032			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28506846	Bronze, Green Accepted			2022-12-18	WOS:000424410800035
J	Frei, R; Ferstl, R; Roduit, C; Ziegler, M; Schiavi, E; Barcik, W; Rodriguez-Perez, N; Wirz, OF; Wawrzyniak, M; Pugin, B; Nehrbass, D; Jutel, M; Smolinska, S; Konieczna, P; Bieli, C; Loeliger, S; Waser, M; Pershagen, G; Riedler, J; Depner, M; Schaub, B; Genuneit, J; Renz, H; Pekkanen, J; Karvonen, AM; Dalphin, JC; van Hage, M; Doekes, G; Akdis, M; Braun-Fahrlander, C; Akdis, CA; von Mutius, E; O'Mahony, L; Lauener, RP				Frei, Remo; Ferstl, Ruth; Roduit, Caroline; Ziegler, Mario; Schiavi, Elisa; Barcik, Weronika; Rodriguez-Perez, Noelia; Wirz, Oliver F.; Wawrzyniak, Marcin; Pugin, Benoit; Nehrbass, Dirk; Jutel, Marek; Smolinska, Sylwia; Konieczna, Patrycja; Bieli, Christian; Loeliger, Susanne; Waser, Marco; Pershagen, Goeran; Riedler, Josef; Depner, Martin; Schaub, Bianca; Genuneit, Jon; Renz, Harald; Pekkanen, Juha; Karvonen, Anne M.; Dalphin, Jean-Charles; van Hage, Marianne; Doekes, Gert; Akdis, Mubeccel; Braun-Fahrlander, Charlotte; Akdis, Cezmi A.; von Mutius, Erika; O'Mahony, Liam; Lauener, Roger P.		Prevention Allergy Risk Factors Se; Protection Against Allergy Study R	Exposure to nonmicrobial N-glycolylneuraminic acid protects farmers' children against airway inflammation and colitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Farmers' children; nonmicrobial; N-glycolylneuraminic acid; airway inflammation; colitis; anti-inflammatory	NONHUMAN SIALIC-ACID; SCHOOL-AGE-CHILDREN; ALLERGIC DISEASES; EARLY-LIFE; HAY-FEVER; ATOPIC SENSITIZATION; INNATE IMMUNITY; ASTHMA; RISK; MICE	Background: Childhood exposure to a farm environment has been shown to protect against the development of inflammatory diseases, such as allergy, asthma, and inflammatory bowel disease. Objective: We sought to investigate whether both exposure to microbes and exposure to structures of nonmicrobial origin, such as the sialic acid N-glycolylneuraminic acid (Neu5Gc), might play a significant role. Methods: Exposure to Neu5Gc was evaluated by quantifying anti-Neu5Gc antibody levels in sera of children enrolled in 2 farm studies: the Prevention of Allergy Risk factors for Sensitization in Children Related to Farming and Anthroposophic Lifestyle (PARSIFAL) study (n = 299) and the Protection Against Allergy Study in Rural Environments (PASTURE) birth cohort (cord blood [n = 836], 1 year [n = 734], 4.5 years [n = 700], and 6 years [n = 728]), and we associated them with asthma and wheeze. The effect of Neu5Gc was examined in murine airway inflammation and colitis models, and the role of Neu5Gc in regulating immune activation was assessed based on helper T-cell and regulatory T-cell activation in mice. Results: In children anti-Neu5Gc IgG levels correlated positively with living on a farm and increased peripheral blood forkhead box protein 3 expression and correlated inversely with wheezing and asthma in nonatopic subjects. Exposure to Neu5Gc in mice resulted in reduced airway hyperresponsiveness and inflammatory cell recruitment to the lung. Furthermore, Neu5Gc administration to mice reduced the severity of a colitis model. Mechanistically, we found that Neu5Gc exposure reduced IL-17(+) T-cell numbers and supported differentiation of regulatory T cells. Conclusions: In addition to microbial exposure, increased exposure to non microbial-derived Neu5Gc might contribute to the protective effects associated with the farm environment.	[Frei, Remo; Ferstl, Ruth; Roduit, Caroline; Ziegler, Mario; Schiavi, Elisa; Barcik, Weronika; Rodriguez-Perez, Noelia; Wirz, Oliver F.; Wawrzyniak, Marcin; Pugin, Benoit; Konieczna, Patrycja; Bieli, Christian; Loeliger, Susanne; Akdis, Mubeccel; Akdis, Cezmi A.; O'Mahony, Liam; Lauener, Roger P.] CK CARE, Davos, Switzerland; [Frei, Remo; Ferstl, Ruth; Ziegler, Mario; Schiavi, Elisa; Barcik, Weronika; Rodriguez-Perez, Noelia; Wirz, Oliver F.; Wawrzyniak, Marcin; Pugin, Benoit; Konieczna, Patrycja; Akdis, Mubeccel; Akdis, Cezmi A.; O'Mahony, Liam] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Roduit, Caroline; Bieli, Christian; Loeliger, Susanne] Univ Zurich, Childrens Hosp, Davos, Switzerland; [Nehrbass, Dirk] AO Res Inst Davos, Davos, Switzerland; [Jutel, Marek; Smolinska, Sylwia] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland; [Jutel, Marek; Smolinska, Sylwia] ALL MED Med Res Inst, Wroclaw, Poland; [Waser, Marco; Braun-Fahrlander, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Waser, Marco; Braun-Fahrlander, Charlotte] Univ Basel, Basel, Switzerland; [Pershagen, Goeran] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Riedler, Josef] Childrens Hosp Schwarzach, Salzburg, Austria; [Depner, Martin; Schaub, Bianca; von Mutius, Erika] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Munich, Germany; [Genuneit, Jon] Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, Germany; [Renz, Harald] Philipps Univ Marburg, Inst Lab Med Pathobiochem & Mol Diagnost, Marburg, Germany; [Pekkanen, Juha; Karvonen, Anne M.] Natl Inst Hlth & Welf, Dept Environm Hlth, Kuopio, Finland; [Pekkanen, Juha] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; [Dalphin, Jean-Charles] Univ Hosp Besancon, UMR CNRS Chronoenvironm 6249, Dept Resp Dis, Besancon, France; [van Hage, Marianne] Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, Stockholm, Sweden; [van Hage, Marianne] Karolinska Univ Hosp, Stockholm, Sweden; [Doekes, Gert] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [von Mutius, Erika] German Ctr Lung Res, CPC M, Munich, Germany; [Lauener, Roger P.] Childrens Hosp Eastern Switzerland, Claudiusstr 6, CH-9000 St Gallen, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Zurich; Wroclaw Medical University; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Karolinska Institutet; University of Munich; Ulm University; Philipps University Marburg; Finland National Institute for Health & Welfare; University of Helsinki; Universite de Franche-Comte; CHU Besancon; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Utrecht University	Lauener, RP (corresponding author), Childrens Hosp Eastern Switzerland, Claudiusstr 6, CH-9000 St Gallen, Switzerland.; Frei, R (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	remo.frei@siaf.uzh.ch; roger.lauener@kispisg.ch	Wawrzyniak, Marcin/AAT-9094-2021; riedler, josef/AAQ-4666-2020; Akdis, Cezmi/AAV-4844-2020; Smolinska, Sylwia/ABH-7971-2020; van Hage, Marianne/A-9678-2017; Schaub, Bianca/B-9935-2019; Pugin, Benoit/X-2984-2018; Wirz, Oliver/U-7914-2019; Frei, Remo/AAI-9180-2020; Ege, Markus/C-1962-2012; O'Mahony, Liam/AAG-5838-2019; Barcik, Weronika/L-5094-2019; Ferstl, Ruth/ABB-9679-2021; Wawrzyniak, Marcin/E-5878-2017; Roduit, Caroline/S-4928-2017; Genuneit, Jon/I-9323-2012; Roponen, Marjut/C-2086-2017; Bieli, Christian/F-7209-2014	Wawrzyniak, Marcin/0000-0002-6911-8010; Akdis, Cezmi/0000-0001-8020-019X; Smolinska, Sylwia/0000-0001-6736-2696; van Hage, Marianne/0000-0003-3091-1596; Schaub, Bianca/0000-0003-1652-8873; Pugin, Benoit/0000-0001-7132-9477; Wirz, Oliver/0000-0003-0377-6464; Ege, Markus/0000-0001-6643-3923; O'Mahony, Liam/0000-0003-4705-3583; Genuneit, Jon/0000-0001-5764-1528; Roponen, Marjut/0000-0002-4442-9090; Roduit, Caroline/0000-0002-5988-0570; Loss, Georg/0000-0003-1090-812X; Hyvarinen, Anne/0000-0002-2823-0866; Barcik, Weronika/0000-0001-8580-9690; Bieli, Christian/0000-0002-2128-6082; JUTEL, MAREK/0000-0003-1555-9379	European Union [QLRT 1999-01391]; Swedish Foundation for Health Care Science and Allergy Research; Swiss National Foundation [32-100324]; National Heart, Lung, and Blood Institute [HL66800, HL66806, HL67672]; European Union research grants PASTURE/EFRAIM [QRLT4-CT 2001-00250, KBBE-2-2-06]	European Union(European Commission); Swedish Foundation for Health Care Science and Allergy Research; Swiss National Foundation(Swiss National Science Foundation (SNSF)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); European Union research grants PASTURE/EFRAIM	The Prevention of Allergy Risk factors for Sensitization in Children Related to Farming and Anthroposophic Lifestyle (PARSIFAL) study was supported by a research grant from the European Union (QLRT 1999-01391), the Swedish Foundation for Health Care Science and Allergy Research, the Swiss National Foundation (32-100324), and the National Heart, Lung, and Blood Institute (HL66800, HL66806, and HL67672). The PASTURE birth cohort was supported by European Union research grants PASTURE/EFRAIM (QRLT4-CT 2001-00250, KBBE-2-2-06).	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Amon R, 2014, CARBOHYD RES, V389, P115, DOI 10.1016/j.carres.2014.02.004; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cocco P, 2013, INT J CANCER, V132, P2613, DOI 10.1002/ijc.27908; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Eleftheriou P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/963230; Felliet H, 2004, CURR OPIN GASTROEN, V20, P560; Frei R, 2012, ALLERGY, V67, P451, DOI 10.1111/j.1398-9995.2011.02783.x; Frei R, 2015, CURR OPIN GASTROEN, V31, P153, DOI 10.1097/MOG.0000000000000151; Frei R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091097; Frei R, 2013, J ALLERGY CLIN IMMUN, V132, P194, DOI 10.1016/j.jaci.2013.01.013; Hedlund M, 2007, MOL CELL BIOL, V27, P4340, DOI 10.1128/MCB.00379-07; Kjellev S, 2006, INT IMMUNOPHARMACOL, V6, P1341, DOI 10.1016/j.intimp.2006.04.017; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Le Leu R, 2013, DIGEST DIS SCI, V58, P3475, DOI 10.1007/s10620-013-2844-1; Liston A, 2014, NAT REV IMMUNOL, V14, P154, DOI 10.1038/nri3605; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Munster-Kuhnel AK, 2004, GLYCOBIOLOGY, V14, p43R, DOI 10.1093/glycob/cwh113; Nguyen DH, 2005, J IMMUNOL, V175, P228, DOI 10.4049/jimmunol.175.1.228; Park BV, 2015, CELL MOL IMMUNOL, V12, P533, DOI 10.1038/cmi.2015.21; Pearce OMT, 2014, P NATL ACAD SCI USA, V111, P5998, DOI 10.1073/pnas.1209067111; PUENTE R, 1993, BIOL CHEM H-S, V374, P475, DOI 10.1515/bchm3.1993.374.7-12.475; Radon K, 2007, PEDIATRICS, V120, P354, DOI 10.1542/peds.2006-3624; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roduit C, 2014, J ALLERGY CLIN IMMUN, V133, P1056, DOI 10.1016/j.jaci.2013.12.1044; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Samraj AN, 2015, P NATL ACAD SCI USA, V112, P542, DOI 10.1073/pnas.1417508112; Samraj AN, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00033; Schmidt SV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00274; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tangvoranuntakul P, 2003, P NATL ACAD SCI USA, V100, P12045, DOI 10.1073/pnas.2131556100; Taylor RE, 2010, J EXP MED, V207, P1637, DOI 10.1084/jem.20100575; Uh HW, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-59; Varki A, 2001, YEARB PHYS ANTHROPOL, V44, P54, DOI 10.1002/ajpa.10018; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301	47	31	30	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					382	+		10.1016/j.jaci.2017.04.051	http://dx.doi.org/10.1016/j.jaci.2017.04.051			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28629745	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000419312200043
J	Waldram, J; Walters, K; Simon, R; Woessner, K; Waalen, J; White, A				Waldram, Jeremy; Walters, Kristen; Simon, Ronald; Woessner, Katherine; Waalen, Jill; White, Andrew			Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratoly disease; asthma; chronic rhinosinusitis; aspirin desensitization	LEUKOTRIENE-MODIFIER DRUGS; ASTHMA; SENSITIVITY; CHALLENGES; OMALIZUMAB	Background: Aspirin desensitization is an effective treatment option for aspirin-exacerbated respiratory disease. Aspirin desensitization protocol modifications have improved the safety and efficiency of this procedure, yet some providers remain reluctant to perform it. Objective: The primary objective of this study was to evaluate the safety and outcomes of outpatient aspirin desensitization procedures. A secondary objective was to assess clinical characteristics that might predict reaction severity during aspirin desensitization. Methods: Two hundred seventy-five patients underwent aspirin desensitization at Scripps Clinic between January 2009 and August 2015. Baseline patient characteristics and reaction results were analyzed in the 167 patients who reacted during desensitization. Results: All of the 167 reactors, including 23 who were classified as severe reactors, were successfully desensitized in the outpatient setting. The average desensitization duration among reactors was 1.67 days, and the average duration for gastrointestinal reactors was 2.29 days. The mean baseline Sino-Nasal Outcome Test score was higher in severe reactors compared with nonsevere reactors (P=.05). Overall, patients receiving omalizumab had a similar reaction profile to those not receiving omalizumab. Conclusions: Most patients undergoing aspirin desensitization will have symptoms. It remains difficult to predict the severity of these symptoms. However, desensitization can be done safely and efficiently in an appropriately equipped outpatient setting. This treatment option should be made available to all patients with aspirin-exacerbated respiratory disease. The Sino-Nasal Outcome Test score might be able to predict more severe reactions and merits further study. Eight of the 9 patients receiving omalizumab reacted during desensitization, suggesting that it does not block reactions during aspirin desensitization.	[Waldram, Jeremy; Walters, Kristen; Simon, Ronald; Woessner, Katherine; White, Andrew] Scripps Clin, Dept Allergy & Immunol, San Diego, CA USA; [Waalen, Jill] Scripps Translat Sci Inst, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute	Waldram, J (corresponding author), 3811 Valley Ctr Dr, San Diego, CA 92130 USA.	jdwaldram@gmail.com			Scripps Translational Science Institute's Clinical Translational Science Award from the National Institutes of Health [UL54 AI108353]	Scripps Translational Science Institute's Clinical Translational Science Award from the National Institutes of Health	J.W.'s work is supported by the Scripps Translational Science Institute's Clinical Translational Science Award UL54 AI108353 from the National Institutes of Health.	Aksu K, 2013, ALLERGOL IMMUNOPATH, V41, P208, DOI 10.1016/j.aller.2012.02.005; Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; Bergmann KC, 2015, J ALLER CL IMM-PRACT, V3, P459, DOI 10.1016/j.jaip.2015.01.012; Bobolea I, 2010, J INVEST ALLERG CLIN, V20, P448; Chen JR, 2015, J ALLER CL IMM-PRACT, V3, P926, DOI 10.1016/j.jaip.2015.06.013; Choi JH, 2015, CURR OPIN ALLERGY CL, V15, P21, DOI 10.1097/ACI.0000000000000122; Dahlen B, 2000, AM J RESP CRIT CARE, V161, pS137, DOI 10.1164/ajrccm.161.supplement_1.ltta-27; Dursun AB, 2008, ANN ALLERG ASTHMA IM, V100, P420, DOI 10.1016/S1081-1206(10)60465-6; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Hope AP, 2009, J ALLERGY CLIN IMMUN, V123, P406, DOI 10.1016/j.jaci.2008.09.048; Lang DM, 2016, J ALLERGY CLIN IMMUN, V137, pAB91, DOI 10.1016/j.jaci.2015.12.424; Lee RU, 2010, ANN ALLERG ASTHMA IM, V105, P130, DOI 10.1016/j.anai.2010.05.020; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Stevenson DD, 2004, IMMUNOL ALLERGY CLIN, V24, P491, DOI 10.1016/j.iac.2004.03.001; Szczeklik A, 2014, MIDDLETONS ALLERGY P, P1227; Waldram JD, 2016, J ALLER CL IMM-PRACT, V4, P1253, DOI 10.1016/j.jaip.2016.06.016; White A, 2006, ANN ALLERG ASTHMA IM, V97, P688, DOI 10.1016/S1081-1206(10)61101-5	19	31	31	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					250	256		10.1016/j.jaci.2017.05.006	http://dx.doi.org/10.1016/j.jaci.2017.05.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28550988				2022-12-18	WOS:000419312200030
J	Chen, E; Shalowitz, MU; Story, RE; Ehrlich, KB; Manczak, EM; Ham, PJ; Van Le; Miller, GE				Chen, Edith; Shalowitz, Madeleine U.; Story, Rachel E.; Ehrlich, Katherine B.; Manczak, Erika M.; Ham, Paula J.; Van Le; Miller, Gregory E.			Parents' childhood socioeconomic circumstances are associated with their children's asthma outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Socioeconomic status; family stress; asthma; childhood	PSYCHOLOGICAL STRESS; CARDIOVASCULAR RISK; INNATE IMMUNITY; BIRTH-WEIGHT; SOCIAL-CLASS; HEALTH; LIFE; DISEASE; GENERATION; MECHANISMS	Background: Previous literature documents associations between low socioeconomic status (SES) and poor health outcomes, including asthma. However, this literature has largely focused on the effects of current family circumstances. Objective: We sought to test an intergenerational hypothesis, that the childhood SES that parents experience will be associated with asthma outcomes in their children, independent of effects of current family SES. Second, we aimed to test whether this association is in part due to difficulties in current parent-child relationships. Methods: This was an observational study, whereby 150 parents were interviewed about their childhood SES and their children (physician-diagnosed asthma, ages 9-17 years) were interviewed about current family stress. Asthma control was assessed by parent report and child report (primary outcome), and blood was collected from children to measure cytokine production relevant to asthma (secondary outcomes). Results: To the degree that parents had lower childhood SES, their offspring showed worse asthma outcomes across multiple indicators. This included lower asthma control scores (parent and child report, Ps < .05), and greater stimulated production of T(H)2 and T(H)1 cytokines by PBMCs (Ps < .05). These associations were independent of current family SES. Mediation analyses were consistent with a scenario wherein parents with low childhood SES had current family relationships that were more stressful, and these difficulties, in turn, related to worse asthma control and greater cytokine production in children. Conclusions: These results suggest the potential "long reach'' of low SES across generations, and the importance of expanding theories of how the social environment can affect childhood asthma to include characteristics of earlier generations.	[Chen, Edith; Ehrlich, Katherine B.; Manczak, Erika M.; Ham, Paula J.; Van Le; Miller, Gregory E.] Northwestern Univ, Dept Psychol, Evanston, IL 60208 USA; [Shalowitz, Madeleine U.; Story, Rachel E.] NorthShore Univ Hlth Syst, Evanston, IL USA	Northwestern University; NorthShore University Health System	Chen, E (corresponding author), Northwestern Univ, 2029 Sheridan Rd, Evanston, IL 60208 USA.	edith.chen@northwestern.edu	Ehrlich, Katherine B/AAF-4687-2020		National Institutes of Health [R01 HL108723]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108723] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Institutes of Health (grant no. R01 HL108723).	Adler NE, 2008, ANNU REV PUBL HEALTH, V29, P235, DOI 10.1146/annurev.publhealth.29.020907.090852; ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ADRIAN C, 1993, J CONSULT CLIN PSYCH, V61, P354, DOI 10.1037/0022-006X.61.2.354; Aiken CE, 2014, HUM REPROD UPDATE, V20, P63, DOI 10.1093/humupd/dmt043; Amre DK, 2002, J ASTHMA, V39, P625, DOI 10.1081/JAS-120014927; Astone NM, 2007, PAEDIATR PERINAT EP, V21, P310, DOI 10.1111/j.1365-3016.2007.00821.x; Behrman JR, 2009, AM J CLIN NUTR, V90, P1372, DOI 10.3945/ajcn.2009.27524; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; Bower JE, 2011, J CLIN ONCOL, V29, P3517, DOI 10.1200/JCO.2011.36.1154; Bradley RH, 2001, CHILD DEV, V72, P1844, DOI 10.1111/1467-8624.t01-1-00382; Burton T, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0311; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Chen E, 2002, PSYCHOL BULL, V128, P295, DOI 10.1037/0033-2909.128.2.295; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Chen E, 2016, PSYCHOSOM MED, V78, P1043, DOI 10.1097/PSY.0000000000000392; Chen E, 2011, J ALLERGY CLIN IMMUN, V128, P970, DOI 10.1016/j.jaci.2011.06.040; Chen E, 2010, PSYCHOL SCI, V21, P31, DOI 10.1177/0956797609355566; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Cohen S, 2004, PSYCHOSOM MED, V66, P553, DOI 10.1097/01.psy.0000126200.05189.d3; Conger RD, 1994, FAMILIES TROUBLED TI; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; Curley JP, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.025.2009; Drake AJ, 2004, J ENDOCRINOL, V180, P1, DOI 10.1677/joe.0.1800001; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570, DOI 10.1164/ajrccm.152.2.7633709; Evans GW, 2004, AM PSYCHOL, V59, P77, DOI 10.1037/0003-066X.59.2.77; Finn Patricia W, 2009, Proc Am Thorac Soc, V6, P260, DOI 10.1513/pats.200807-064RM; Franklin TB, 2010, BIOL PSYCHIAT, V68, P408, DOI 10.1016/j.biopsych.2010.05.036; Galobardes B, 2006, ANN EPIDEMIOL, V16, P91, DOI 10.1016/j.annepidem.2005.06.053; Galobardes B, 2004, EPIDEMIOL REV, V26, P7, DOI 10.1093/epirev/mxh008; Gemou-Engesaeth V, 1994, Pediatr Allergy Immunol, V5, P170, DOI 10.1111/j.1399-3038.1994.tb00234.x; Gustafsson PA, 2002, PEDIAT ALLERG IMM-UK, V13, P51, DOI 10.1034/j.1399-3038.2002.00086.x; HAMMEN C, 1991, J ABNORM PSYCHOL, V100, P555, DOI 10.1037/0021-843X.100.4.555; Holtzman MJ, 2002, PHYSIOL REV, V82, P19, DOI 10.1152/physrev.00020.2001; Kittleson MM, 2006, ARCH INTERN MED, V166, P2356, DOI 10.1001/archinte.166.21.2356; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Krieger N, 1998, AM J EPIDEMIOL, V147, P704; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Lichtenstein JHR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126926; Lu YX, 2015, J ALLERGY CLIN IMMUN, V135, P1061, DOI 10.1016/j.jaci.2014.10.036; Lynch J, 2005, ANNU REV PUBL HEALTH, V26, P1, DOI 10.1146/annurev.publhealth.26.021304.144505; Marmot M, 2015, HLTH GAP CHALLENGE U; Marmot M, 2000, SOCIAL DETERMINANTS; Maziak W, 2004, PEDIAT ALLERG IMM-UK, V15, P166, DOI 10.1046/j.1399-3038.2003.00105.x; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; Miller G, 2007, PSYCHOSOM MED, V69, P402, DOI 10.1097/PSY.0b013e318068fcf9; Miller GE, 2011, PSYCHOL BULL, V137, P959, DOI 10.1037/a0024768; Miller GE, 2009, P NATL ACAD SCI USA, V106, P14716, DOI 10.1073/pnas.0902971106; Miller GE, 2009, J ALLERGY CLIN IMMUN, V123, P824, DOI 10.1016/j.jaci.2008.12.019; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Painter RC, 2008, BJOG-INT J OBSTET GY, V115, P1243, DOI 10.1111/j.1471-0528.2008.01822.x; Patti ME, 2013, CELL MOL LIFE SCI, V70, P1597, DOI 10.1007/s00018-013-1298-0; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Repetti RL, 2002, PSYCHOL BULL, V128, P330, DOI 10.1037/0033-2909.128.2.330; Rudolph KD, 1999, CHILD DEV, V70, P660, DOI 10.1111/1467-8624.00048; Saavedra-Rodriguez L, 2013, BIOL PSYCHIAT, V73, P44, DOI 10.1016/j.biopsych.2012.06.035; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schreier HMC, 2013, PSYCHOL BULL, V139, P606, DOI 10.1037/a0029416; Schreier HMC, 2010, BRAIN BEHAV IMMUN, V24, P1324, DOI 10.1016/j.bbi.2010.06.007; Simon PA, 2003, J ASTHMA, V40, P535, DOI 10.1081/JAS-120018788; Simpson JL, 2008, PAEDIATR RESPIR REV, V9, P263, DOI 10.1016/j.prrv.2008.05.007; Stein AD, 2003, AM J CLIN NUTR, V78, P162, DOI 10.1093/ajcn/78.1.162; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; Susser E, 2012, ANNU REV ANTHROPOL, V41, P577, DOI 10.1146/annurev-anthro-081309-145645; WAHLER RG, 1990, J SOC CLIN PSYCHOL, V9, P43, DOI 10.1521/jscp.1990.9.1.43; Ward MM, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-147; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC	70	31	31	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					828	+		10.1016/j.jaci.2016.11.040	http://dx.doi.org/10.1016/j.jaci.2016.11.040			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	FF8CA	28089871	Bronze, Green Accepted			2022-12-18	WOS:000409241500021
J	Strzepa, A; Majewska-Szczepanik, M; Lobo, FM; Wen, L; Szczepanik, M				Strzepa, Anna; Majewska-Szczepanik, Monika; Lobo, Francis M.; Wen, Li; Szczepanik, Marian			Broad spectrum antibiotic enrofloxacin modulates contact sensitivity through gut microbiota in a murine model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Contact sensitivity; gut microbiota; immunoregulation; dysbiosis; regulatory cells	INTESTINAL MICROBIOTA; INCREASED RISK; T-CELLS; BACTERIA; MICE; PRIMERS; LIFE; HYPERSENSITIVITY; SUSCEPTIBILITY; INFLAMMATION	Background: Medical advances in the field of infection therapy have led to an increasing use of antibiotics, which, apart from eliminating pathogens, also partially eliminate naturally existing commensal bacteria. It has become increasingly clear that less exposure to microbiota early in life may contribute to the observed rise in "immune-mediated'' diseases, including autoimmunity and allergy. Objective: We sought to test whether the change of gut microbiota with the broad spectrum antibiotic enrofloxacin will modulate contact sensitivity (CS) in mice. Methods: Natural gut microbiota were modified by oral treatment with enrofloxacin prior to sensitization with trinitrophenyl chloride followed by CS testing. Finally, adoptive cell transfers were performed to characterize the regulatory cells that are induced by microbiota modification. Results: Oral treatment with enrofloxacin suppresses CS and production of anti-trinitrophenyl chloride IgG1 antibodies. Adoptive transfer experiments show that antibiotic administration favors induction of regulatory cells that suppress CS. Flow cytometry and adoptive transfer of purified cells show that antibiotic-induced suppression of CS is mediated by TCR alpha beta(+) CD4(+) CD25(+) FoxP3(+) Treg, CD19(+) B220(+) CD5(+) IL-10(+), IL10(+) Tr1, and IL-10(+) TCR gamma delta(+) cells. Treatment with the antibiotic induces dysbiosis characterized by increased proportion of Clostridium coccoides (cluster XIVa), C coccoides-Eubacterium rectale (cluster XIVab), Bacteroidetes, and Bifidobacterium spp, but decreased segmented filamentous bacteria. Transfer of antibiotic-modified gut microbiota inhibits CS, but this response can be restored through oral transfer of control gut bacteria to antibiotic-treated animals. Conclusions: Oral treatment with a broad spectrum antibiotic modifies gut microbiota composition and promotes anti-inflammatory response, suggesting that manipulation of gut microbiota can be a powerful tool to modulate the course of CS.	[Strzepa, Anna; Majewska-Szczepanik, Monika; Szczepanik, Marian] Jagiellonian Univ, Coll Med, Fac Hlth Sci, Dept Med Biol, Krakow, Poland; [Lobo, Francis M.] Yale Univ, Sch Med, Dept Internal Med, Sect Allergy & Clin Immunol, New Haven, CT 06510 USA; [Wen, Li] Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, 333 Cedar St, New Haven, CT 06520 USA	Jagiellonian University; Collegium Medicum Jagiellonian University; Yale University; Yale University	Wen, L (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, 333 Cedar St, New Haven, CT 06520 USA.; Szczepanik, M (corresponding author), Jagiellonian Univ, Coll Med, Dept Med Biol, Ul Kopemika 7a, PL-31034 Krakow, Poland.	li.wen@yale.edu; mmszczep@cyf-kr.edu.pl	Szczepanik, Marian/ABA-7001-2021	Wen, Li/0000-0002-8805-2934	National Science Center in Poland [2011/01/B/NZ6/00300, K/ZDS/004650]; National Institutes of Health [DK088181, DK092882, K/DSC/002879]	National Science Center in Poland(National Science Centre, Poland); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by grants from National Science Center in Poland (2011/01/B/NZ6/00300 and K/ZDS/004650 to M.S.) and National Institutes of Health (DK088181 and DK092882 to L.W., and K/DSC/002879 to A.S.).	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Alexander KL, 2014, IMMUNOL REV, V260, P206, DOI 10.1111/imr.12180; Antonopoulos DA, 2009, INFECT IMMUN, V77, P2367, DOI 10.1128/IAI.01520-08; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Buffie CG, 2012, INFECT IMMUN, V80, P62, DOI 10.1128/IAI.05496-11; Candela M, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-95; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Diepgen TL, 2007, J EUR ACAD DERMATOL, V21, P9, DOI 10.1111/j.1468-3083.2007.02381.x; Ebringer A, 2010, NAT REV RHEUMATOL, V6, P622, DOI 10.1038/nrrheum.2010.163; Fujiwara R, 2010, J NUTR SCI VITAMINOL, V56, P260, DOI 10.3177/jnsv.56.260; Fujiwara R, 2010, BRIT J NUTR, V103, P530, DOI 10.1017/S000711450999198X; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; Hacini-Rachinel F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004903; Hill DA, 2010, ANNU REV IMMUNOL, V28, P623, DOI 10.1146/annurev-immunol-030409-101330; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Jakobsson HE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009836; Karimi K, 2009, AM J RESP CRIT CARE, V179, P186, DOI 10.1164/rccm.200806-951OC; Kosiewicz MM, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00180; Kozyrskyj AL, 2007, CHEST, V131, P1753, DOI 10.1378/chest.06-3008; Lee YK, 2011, P NATL ACAD SCI USA, V108, P4615, DOI 10.1073/pnas.1000082107; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majewska-Szczepanik M, 2014, INT ARCH ALLERGY IMM, V164, P122, DOI 10.1159/000363446; Mariat D, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-123; Marra F, 2009, PEDIATRICS, V123, P1003, DOI 10.1542/peds.2008-1146; Matsuki T, 2002, APPL ENVIRON MICROB, V68, P5445, DOI 10.1128/AEM.68.11.5445-5451.2002; Metsala J, 2013, EPIDEMIOLOGY, V24, P303, DOI 10.1097/EDE.0b013e31827f520f; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; Ochoa-Reparaz J, 2010, MUCOSAL IMMUNOL, V3, P487, DOI 10.1038/mi.2010.29; Ochoa-Reparaz J, 2010, GUT MICROBES, V1, P103, DOI 10.4161/gmic.1.2.11515; Ochoa-Reparaz J, 2009, J IMMUNOL, V183, P6041, DOI 10.4049/jimmunol.0900747; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Pot C, 2011, SEMIN IMMUNOL, V23, P202, DOI 10.1016/j.smim.2011.07.005; Rinttila T, 2004, J APPL MICROBIOL, V97, P1166, DOI 10.1111/j.1365-2672.2004.02409.x; Simpson CR, 2002, CLIN EXP ALLERGY, V32, P37, DOI 10.1046/j.0022-0477.2001.01250.x; Song H, 2016, J ALLERGY CLIN IMMUN, V137, P852, DOI 10.1016/j.jaci.2015.08.021; Strzepa A, 2016, PHARMACOL REP, V68, P44, DOI 10.1016/j.pharep.2015.07.002; Szczepanik M, 1996, J EXP MED, V184, P2129, DOI 10.1084/jem.184.6.2129; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Ubeda C, 2010, J CLIN INVEST, V120, P4332, DOI 10.1172/JCI43918; Ubeda C, 2012, TRENDS IMMUNOL, V33, P459, DOI 10.1016/j.it.2012.05.003; Watanabe J, 2008, BRIT J NUTR, V100, P339, DOI 10.1017/S0007114507901221; Watanabe R, 2007, AM J PATHOL, V171, P560, DOI 10.2353/ajpath.2007.061279; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001; Zanvit P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9424; Zeissig S, 2014, NAT IMMUNOL, V15, P307, DOI 10.1038/ni.2847; Zhang LL, 2010, J GASTROEN HEPATOL, V25, P928, DOI 10.1111/j.1440-1746.2009.06193.x	47	31	31	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					121	+		10.1016/j.jaci.2016.11.052	http://dx.doi.org/10.1016/j.jaci.2016.11.052			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28130148	Green Published, Bronze			2022-12-18	WOS:000404542000012
J	Busse, PJ; Birmingham, JM; Calatroni, A; Manzi, J; Goryachokovsky, A; Fontela, G; Federman, AD; Wisnivesky, JP				Busse, Paula J.; Birmingham, Janette M.; Calatroni, Agustin; Manzi, Joseph; Goryachokovsky, Anna; Fontela, Giselle; Federman, Alex D.; Wisnivesky, Juan P.			Effect of aging on sputum inflammation and asthma control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; sputum; inflammation; sensitization; inner city	REGULATORY T-CELLS; INNER-CITY ASTHMA; OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; AIRWAY NEUTROPHILIA; UNITED-STATES; RISK-FACTORS; HUMAN LUNG; IN-VIVO; AGE	Background: Aged asthmatic patients experience increased morbidity and mortality. Knowledge of the aging effect on airway inflammation and asthma control is limited. Objective: We sought to compare airway inflammation and its relationship to asthma control in aged versus younger patients and determine whether differences are asthma specific or caused by "inflamm-aging." Methods: We performed a prospective study of aged (>60 years) and younger (21-40 years) inner-city patients with asthma. After a run-in period to control for inhaled corticosteroid use, induced sputum was collected. Age-matched nonasthmatic control subjects were included to measure age-related inflammatory changes. Results: Aged (mean age, 67.9 +/- 5.1 years; n = 35) compared with younger (mean age, 30.8 +/- 5.9 years; n = 37) asthmatic patients had significantly worse asthma control and lower FEV1. Aged asthmatic patients had higher sputum neutrophil (30.5 x 10(4)/mL and 23.1%) and eosinophil (7.0 x 10(4)/mL and 3.8%) numbers and percentages compared with younger patients (neutrophils, 13.0 x 10(4)/mL [P < .01] and 6.9% [P < .01]; eosinophils, 2.0 x 10(4)/mL [P < .01] and 1.2% [P < .01]). Aged asthmatic patients had higher sputum IL-6 (P < .01) and IL-8 (P = .01) levels. No significant inflammatory differences between aged and younger control subjects were observed. In aged asthmatic patients increased sputum IL-6 and macrophage inflammatory protein 3 alpha/CCL20 levels were significantly associated with decreased asthma control and increased sputum neutrophil numbers and IL-1 beta, IL-6, and macrophage inflammatory protein 3 alpha/CCL20 levels were associated with hospitalization. Conclusions: The inflammatory patterns of aged versus younger asthmatic patients are associated with increased sputum neutrophil and eosinophil values and cytokine levels related to neutrophil recruitment. Differences in airway inflammation can contribute to diminished asthma control in the aged. Further understanding of asthma pathophysiology in aged patients is needed to improve management of this vulnerable population.	[Busse, Paula J.; Birmingham, Janette M.; Manzi, Joseph; Goryachokovsky, Anna; Fontela, Giselle] Icahn Sch Med Mt Sinai, Div Clin Immunol, 1425 Madision Ave,Rm 11-20, New York, NY 10029 USA; [Federman, Alex D.; Wisnivesky, Juan P.] Icahn Sch Med Mt Sinai, Div Gen Internal Med, New York, NY 10029 USA; [Wisnivesky, Juan P.] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA; [Calatroni, Agustin] Fed Syst Div, Rho, Chapel Hill, NC USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rho	Busse, PJ (corresponding author), Icahn Sch Med Mt Sinai, Div Clin Immunol, 1425 Madision Ave,Rm 11-20, New York, NY 10029 USA.	paula.busse@mssm.edu		Manzi, Joseph/0000-0002-8825-0105	National Institutes of Health [5R21 AI101425]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI101425] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant 5R21 AI101425.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Aparicio-Siegmund S, 2015, CYTOKINE GROWTH F R, V26, P579, DOI 10.1016/j.cytogfr.2015.07.008; Arbes SJ, 2013, CLIN EXP ALLERGY, V43, P544, DOI 10.1111/cea.12069; Askenasy N, 2008, AUTOIMMUN REV, V7, P370, DOI 10.1016/j.autrev.2008.03.001; Bellia V, 2007, CHEST, V132, P1175, DOI 10.1378/chest.06-2824; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Brooks CR, 2013, RESPIROLOGY, V18, P857, DOI 10.1111/resp.12079; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; Busse PJ, 2007, CLIN EXP ALLERGY, V37, P1392, DOI 10.1111/j.1365-2222.2007.02775.x; Chen XJ, 2014, CLIN INTERV AGING, V9, P433, DOI 10.2147/CIA.S45300; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; Compte N, 2015, EXP GERONTOL, V61, P105, DOI 10.1016/j.exger.2014.11.016; Cosmi L, 2011, ALLERGY, V66, P989, DOI 10.1111/j.1398-9995.2011.02576.x; Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722; Diette GB, 2002, ARCH INTERN MED, V162, P1123, DOI 10.1001/archinte.162.10.1123; Diette GB, 2000, 96 INT C TOR MAY 5; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Dragon S, 2008, MOL IMMUNOL, V45, P160, DOI 10.1016/j.molimm.2007.04.027; Ducharme ME, 2011, RESP MED, V105, P1284, DOI 10.1016/j.rmed.2011.04.006; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; Farah CS, 2015, RESPIROLOGY, V20, P975, DOI 10.1111/resp.12550; Findley S, 2003, J ASTHMA, V40, P557, DOI 10.1081/JAS-120019028; Finotto S, 2007, INT IMMUNOL, V19, P685, DOI 10.1093/intimm/dxm037; Fogal B, 2011, J IMMUNOL, V187, P6268, DOI 10.4049/jimmunol.1003774; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Fu JJ, 2013, OMICS, V17, P187, DOI 10.1089/omi.2012.0104; Garg R., 2003, ASTHMA FACTS, VSecond; Gergen PJ, 2016, J ALLER CL IMM-PRACT, V4, P22, DOI 10.1016/j.jaip.2015.07.024; Gergen PJ, 2015, IMMUNOL ALLERGY CLIN, V35, P101, DOI 10.1016/j.iac.2014.09.006; Gershman NH, 1996, EUR RESPIR J, V9, P2448, DOI 10.1183/09031936.96.09122448; Gershman NH, 1999, J ALLERGY CLIN IMMUN, V104, P322, DOI 10.1016/S0091-6749(99)70374-X; Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hadjicharalambous C, 2004, J ALLERGY CLIN IMMUN, V113, P657, DOI 10.1016/j.jaci.2004.01.757; Hardie JA, 2005, RESP MED, V99, P186, DOI 10.1016/j.rmed.2004.06.006; Hartert TV, 2002, ANN ALLERG ASTHMA IM, V89, P467, DOI 10.1016/S1081-1206(10)62083-2; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hawkins GA, 2012, J ALLERGY CLIN IMMUN, V130, P510, DOI 10.1016/j.jaci.2012.03.018; Hewett P, 2007, ANN OCCUP HYG, V51, P611, DOI 10.1093/annhyg/mem045; Hwang KA, 2009, MECH AGEING DEV, V130, P509, DOI 10.1016/j.mad.2009.06.003; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kawayama T, 2013, ALLERGOL INT, V62, P203, DOI 10.2332/allergolint.12-OA-0492; Kim YK, 2002, CLIN EXP ALLERGY, V32, P1706, DOI 10.1046/j.1365-2222.2002.01524.x; Kinoshita T, 2014, J ALLERGY CLIN IMMUN, V133, P696, DOI 10.1016/j.jaci.2013.08.025; Kryczek I, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002949; Kurtulus S, 2010, IMMUNOL REV, V236, P54, DOI 10.1111/j.1600-065X.2010.00920.x; Lay JC, 2011, INHAL TOXICOL, V23, P392, DOI 10.3109/08958378.2011.575568; Lexberg MH, 2008, EUR J IMMUNOL, V38, P2654, DOI 10.1002/eji.200838541; Li FW, 2015, INT J CLIN EXP MED, V8, P12601; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; Linden A, 2014, EUR RESPIR J, V44, P1319, DOI 10.1183/09031936.00002314; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu CK, 2016, AGE, V38, DOI 10.1007/s11357-015-9864-z; Louis R, 1999, EUR RESPIR J, V13, P660, DOI 10.1183/09031936.99.13366099; Maes T, 2016, J ALLERGY CLIN IMMUN, V137, P1433, DOI 10.1016/j.jaci.2016.02.018; Malik A, 2004, ALLERGY ASTHMA PROC, V25, P169; Mathur SK, 2008, CHEST, V133, P412, DOI 10.1378/chest.07-2114; McHugh MK, 2009, J ASTHMA, V46, P759, DOI 10.3109/02770900903067895; Meka RR, 2015, AUTOIMMUN REV, V14, P1131, DOI 10.1016/j.autrev.2015.08.001; Meyer KC, 1999, THORAX, V54, P697, DOI 10.1136/thx.54.8.697; Meyer KC, 1998, MECH AGEING DEV, V104, P169, DOI 10.1016/S0047-6374(98)00065-7; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mohammadnia-Afrouzi M, 2015, AUTOIMMUNITY, V48, P556, DOI 10.3109/08916934.2015.1070835; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Murray MA, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/692546; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Heart Lung and Blood Institute, 2007, 3 NATL HEART LUNG BL; Nyenhuis Sharmilee M, 2010, Immun Ageing, V7, P8, DOI 10.1186/1742-4933-7-8; Nyenhuis SM, 2010, J ALLERGY CLIN IMMUN, V125, P1163, DOI 10.1016/j.jaci.2010.02.015; O'Connor RA, 2015, IMMUNOLOGY, V146, P194, DOI 10.1111/imm.12507; Older Americans, 2012, KEY IND WELL BEING; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Parameswaran K, 1998, RESP MED, V92, P573, DOI 10.1016/S0954-6111(98)90311-0; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Provoost S, 2009, ALLERGY, V64, P1539, DOI 10.1111/j.1398-9995.2009.02056.x; Raynor J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00161; Raynor J, 2012, CURR OPIN IMMUNOL, V24, P482, DOI 10.1016/j.coi.2012.04.005; Rincon M, 2012, INT J BIOL SCI, V8, P1281, DOI 10.7150/ijbs.4874; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Roussel L, 2010, J IMMUNOL, V184, P4531, DOI 10.4049/jimmunol.0903162; Samson M, 2012, ARTHRITIS RHEUM-US, V64, P2499, DOI 10.1002/art.34477; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Toungoussova O, 2007, RESP MED, V101, P1543, DOI 10.1016/j.rmed.2006.12.009; Tsaknaridis L, 2003, J NEUROSCI RES, V74, P296, DOI 10.1002/jnr.10766; Vale-Pereira S, 2011, CLIN EXP ALLERGY, V41, P490, DOI 10.1111/j.1365-2222.2010.03640.x; Wood LG, 2012, CHEST, V142, P86, DOI 10.1378/chest.11-1838; Yanez A, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-8; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Zhao L, 2007, J LEUKOCYTE BIOL, V81, P1386, DOI 10.1189/jlb.0506364	94	31	32	2	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1808	+		10.1016/j.jaci.2016.09.015	http://dx.doi.org/10.1016/j.jaci.2016.09.015			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27725186	Green Accepted, Bronze			2022-12-18	WOS:000402724600012
J	Arshad, SH; Karmaus, W; Zhang, H; Holloway, JW				Arshad, S. Hasan; Karmaus, Wilfried; Zhang, Hongmei; Holloway, John W.			Multigenerational cohorts in patients with asthma and allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cohort; multigenerational; epigenetics; asthma; allergy; DNA methylation	PERSISTENT ORGANIC POLLUTANTS; DNA METHYLATION; TRANSGENERATIONAL INHERITANCE; BIRTH-WEIGHT; EPIGENETIC INHERITANCE; GENETIC-VARIANTS; SMOKING; NUTRITION; RISK; GRANDPARENTS	Recent observations that disease risk can be transmitted across generations without the need for direct exposure of the child to the index environmental insult has sparked interest in transgenerational inheritance. Epigenetics describes processes that modify gene expression without a change in the nucleotide sequence. Epigenetic processes can be induced in response to environmental exposures, can influence disease risk, and might explain these multigenerational effects. In experimental models a number of epigenetic mechanisms have been identified that could mediate vertical transmission of epigenetic inheritance. However, relevance of these findings to human disease is not yet clear. An alternative model is one in which transgenerational inheritance of disease risk requires the presence of exposurerelated diseases in the mother during pregnancy (termed induced epigenetic transmission model). A number of crosssectional studies have investigated multigenerational effects in allergy and asthma. However, given the early-life origins of asthma and allergy, birth cohort studies are ideal to investigate the effect of genetic predisposition, epigenetics, and environmental exposures, avoiding pitfalls, such as recall bias and confounding by ongoing exposures, disease, and treatment. The well-characterized 3 generations of the Isle of Wight cohort include 2 consecutive birth cohorts, providing longitudinal data that can be studied for epigenetic transfer of information, such as the effect of grand parental smoking or exposure to other toxic compounds. Further large multigenerational birth cohorts are needed to establish the clinical relevance of this phenomenon and differentiate between vertical and induced transmission models, which might influence future preventive strategies.	[Arshad, S. Hasan] David Hide Asthma & Allergy Res Ctr, Newport, Isle Of Wight, England; [Arshad, S. Hasan; Holloway, John W.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England; [Karmaus, Wilfried; Zhang, Hongmei] Univ Memphis, Sch Publ Hlth, Div Epidemiol Biostat & Environm Hlth, Memphis, TN 38152 USA; [Holloway, John W.] Univ Southampton, Southampton Gen Hosp, Fac Med, Human Dev & Hlth, Southampton, Hants, England	University of Southampton; University of Memphis; University of Southampton	Arshad, SH (corresponding author), Southampton Gen Hosp, MP-810,South Block,Tremona Rd, Southampton, Hants, England.	sha@soton.ac.uk	Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464	National Institutes of Health USA [R01 HL082925, R01 AI091905, R01 AI121226, R01 HL132321, R01AI121226, R01AI091905, 1R01HL132321]; Asthma UK [364]; Ageing Lungs in European Cohorts Study; European Union's Horizon 2020 Research and Innovation programme [633212.]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082925, R01HL132321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091905, R01AI121226] Funding Source: NIH RePORTER	National Institutes of Health USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asthma UK; Ageing Lungs in European Cohorts Study; European Union's Horizon 2020 Research and Innovation programme; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Isle of Wight birth cohort assessments have been supported by the National Institutes of Health USA (grant nos. R01 HL082925, R01 AI091905, R01 AI121226, and R01 HL132321) and Asthma UK (grant no. 364). S.H.A., W.K., H.Z., and J.W.H. and ongoing studies in the Isle of Wight cohorts are currently supported by the National Institutes of Health (R01AI121226, and R01AI091905, and 1R01HL132321). J.W.H. acknowledges support from the Ageing Lungs in European Cohorts Study (www.alecstudy.org), which has been funded by the European Union's Horizon 2020 Research and Innovation programme under grant agreement no. 633212.	Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Arshad SH, 2012, J ALLERGY CLIN IMMUN, V130, P427, DOI 10.1016/j.jaci.2012.03.042; Balcazar AJ, 2015, PUBLIC HEALTH, V129, P691, DOI 10.1016/j.puhe.2015.04.007; Bock C, 2006, PLOS GENET, V2, P243, DOI 10.1371/journal.pgen.0020026; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chakrabortee S, 2016, CELL, V167, P369, DOI 10.1016/j.cell.2016.09.017; Chen Q, 2016, SCIENCE, V351, P397, DOI 10.1126/science.aad7977; Chinnery PF, 2012, INT J EPIDEMIOL, V41, P177, DOI 10.1093/ije/dyr232; Clavel-Chapelon F, 2015, INT J EPIDEMIOL, V44, P801, DOI 10.1093/ije/dyu184; Everson TM, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0213-8; Gapp K, 2014, NAT NEUROSCI, V17, P667, DOI 10.1038/nn.3695; Gertz J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002228; Golding J, 2014, AM J HUM BIOL, V26, P731, DOI 10.1002/ajhb.22594; Guthikonda K, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-17; Hackett JA, 2013, SCIENCE, V339, P448, DOI 10.1126/science.1229277; Halfmann R, 2012, NATURE, V482, P363, DOI 10.1038/nature10875; Han ST, 2015, ANN APPL STAT, V9, P2052, DOI 10.1214/15-AOAS865; Heard E, 2014, CELL, V157, P95, DOI 10.1016/j.cell.2014.02.045; Hsu WW, 2014, ENVIRON RES, V132, P384, DOI 10.1016/j.envres.2014.03.009; Kaati G, 2007, EUR J HUM GENET, V15, P784, DOI 10.1038/sj.ejhg.5201832; Kanda J, 2012, BIOL BLOOD MARROW TR, V18, P1664, DOI 10.1016/j.bbmt.2012.06.005; Kelleher CC, 2014, P NUTR SOC, V73, P118, DOI 10.1017/S002966511300373X; Li LX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062526; Manikkam M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102091; Manor O, 2010, INT J EPIDEMIOL, V39, P1264, DOI 10.1093/ije/dyq046; Marczylo EL, 2012, EPIGENETICS-US, V7, P432, DOI 10.4161/epi.19794; McCarron P, 2004, J EPIDEMIOL COMMUN H, V58, P517, DOI 10.1136/jech.2003.007989; Miska EA, 2016, SCIENCE, V354, P59, DOI 10.1126/science.aaf4945; Monick MM, 2012, AM J MED GENET B, V159B, P141, DOI 10.1002/ajmg.b.32021; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Niedzwiecki M, 2012, ALLERGY, V67, P904, DOI 10.1111/j.1398-9995.2012.02841.x; Northstone K, 2014, EUR J HUM GENET, V22, P1382, DOI 10.1038/ejhg.2014.31; Osada T, 2012, CANCER IMMUNOL IMMUN, V61, P1941, DOI 10.1007/s00262-012-1248-y; Ost A, 2014, CELL, V159, P1352, DOI 10.1016/j.cell.2014.11.005; Padmanabhan N, 2013, CELL, V155, P81, DOI 10.1016/j.cell.2013.09.002; Patil VK, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-22; Philibert RA, 2012, J LEUKOCYTE BIOL, V92, P621, DOI 10.1189/jlb.1211632; Porpora MG, 2013, INT J ENV RES PUB HE, V10, P699, DOI 10.3390/ijerph10020699; Rechavi O, 2014, CELL, V158, P277, DOI 10.1016/j.cell.2014.06.020; Rehan VK, 2013, AM J PHYSIOL-LUNG C, V305, pL501, DOI 10.1152/ajplung.00078.2013; Rehan VK, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-129; Relton CL, 2012, INT J EPIDEMIOL, V41, P5, DOI 10.1093/ije/dys006; Shenker NS, 2013, HUM MOL GENET, V22, P843, DOI 10.1093/hmg/dds488; Skinner MK, 2014, MOL CELL ENDOCRINOL, V398, P4, DOI 10.1016/j.mce.2014.07.019; Smith GCS, 2010, AM J EPIDEMIOL, V171, P736, DOI 10.1093/aje/kwp448; Soto-Ramirez N, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-1; Svanes C, 2016, INT J EPIDEMIOL; Toren K, 2004, EUR RESPIR J, V24, P942, DOI 10.1183/09031936.04.00044804; Tycko B, 2010, HUM MOL GENET, V19, pR210, DOI 10.1093/hmg/ddq376; Veerish VKHJ, 2014, ALLERGY, V69, P326; Vizcaino E, 2014, ENVIRON INT, V65, P107, DOI 10.1016/j.envint.2014.01.004; Waterland RA, 2008, INT J OBESITY, V32, P1373, DOI 10.1038/ijo.2008.100; Weinmann T, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2555-y; Yousefi M, 2013, INT J MOL EPIDEMIOL, V4, P86; Zhang HM, 2016, STAT METHODS MED RES, V25, P1736, DOI 10.1177/0962280213499679; Zhang HM, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-8; Ziyab AH, 2013, J EUR ACAD DERMATOL, V27, pe420, DOI 10.1111/jdv.12000	59	31	34	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					415	421		10.1016/j.jaci.2016.12.002	http://dx.doi.org/10.1016/j.jaci.2016.12.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	28183434	Green Accepted, Bronze			2022-12-18	WOS:000397002400005
J	Faber, MA; Van Gasse, AL; Decuyper, II; Uyttebroek, A; Sabato, V; Hagendorens, MM; Bridts, CH; De Clerck, LS; Fernandez-Rivas, M; Pascal, M; Diaz-Perales, A; Ebo, DG				Faber, Margaretha A.; Van Gasse, Athina L.; Decuyper, Ine I.; Uyttebroek, Astrid; Sabato, Vito; Hagendorens, Margo M.; Bridts, Chris H.; De Clerck, Luc S.; Fernandez-Rivas, Montserrat; Pascal, Mariona; Diaz-Perales, Araceli; Ebo, Didier G.			IgE-reactivity profiles to nonspecific lipid transfer proteins in a northwestern European country	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SENSITIZATION; POLLENS; ALLERGY		[Faber, Margaretha A.; Van Gasse, Athina L.; Decuyper, Ine I.; Uyttebroek, Astrid; Sabato, Vito; Hagendorens, Margo M.; Bridts, Chris H.; De Clerck, Luc S.; Ebo, Didier G.] Univ Antwerp, Dept Immunol Allergol & Rheumatol, Antwerp, Belgium; [Faber, Margaretha A.; Van Gasse, Athina L.; Decuyper, Ine I.; Uyttebroek, Astrid; Sabato, Vito; Hagendorens, Margo M.; Bridts, Chris H.; De Clerck, Luc S.; Ebo, Didier G.] Univ Antwerp Hosp, Antwerp, Belgium; [Van Gasse, Athina L.; Decuyper, Ine I.; Hagendorens, Margo M.] Univ Antwerp, Dept Paediat, Antwerp, Belgium; [Fernandez-Rivas, Montserrat] IdISSC, Hosp Clin San Carlos, Dept Allergy, Madrid, Spain; [Pascal, Mariona] Univ Barcelona, Hosp Clin, Ctr Diagnost Biomed, Dept Immunol, Barcelona, Spain; [Pascal, Mariona] Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain; [Diaz-Perales, Araceli] UPM, Ctr Plant Biotechnol & Genom, Pozuelo De Alarcon, Spain	University of Antwerp; University of Antwerp; University of Antwerp; Hospital Clinico San Carlos; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universidad Politecnica de Madrid	Faber, MA (corresponding author), Univ Antwerp, Dept Immunol Allergol & Rheumatol, Antwerp, Belgium.	immuno@uantwerpen.be	Pascal, Mariona/HCG-9380-2022; Sabato, Vito/B-6479-2017; Faber, Margaretha/L-2903-2017; BRIDTS, Chris HM/M-7933-2016; EBO, Didier/H-4894-2016; Díaz-Perales, Araceli/D-8433-2016	Sabato, Vito/0000-0002-1321-314X; Faber, Margaretha/0000-0002-1277-5052; BRIDTS, Chris HM/0000-0002-3324-7320; EBO, Didier/0000-0003-0672-7529; Díaz-Perales, Araceli/0000-0002-1093-3627	Innovation by Science and Technology organization [IWT-TBM 140185]	Innovation by Science and Technology organization	We thank Mrs Christel Mertens for her technical skills and Karin Van Cotthem for her contribution to the sIgE determination. We thank Thermoscientific-Phadia (Uppsala, Sweden) for kindly providing ImmunoCAP allergen components. Didier Ebo is a Senior Clinical Researcher of the Research Foundation Flanders (FWO: 1800614N). A funding was obtained by the Innovation by Science and Technology organization (grant no. IWT-TBM 140185).	Andersen MBS, 2011, CLIN REV ALLERG IMMU, V41, P4, DOI 10.1007/s12016-009-8177-3; Asero R, 2009, CLIN EXP ALLERGY, V39, P547, DOI 10.1111/j.1365-2222.2008.03167.x; Barber D, 2008, ALLERGY, V63, P1550, DOI 10.1111/j.1398-9995.2008.01807.x; Cabrera-Freitag P, 2011, J INVEST ALLERG CLIN, V21, P414; Gonzalez-Mancebo E, 2011, J INVEST ALLERG CLIN, V21, P278; Ma SK, 2013, J ALLERGY CLIN IMMUN, V132, P764, DOI 10.1016/j.jaci.2013.04.017; Pascal M, 2012, CLIN EXP ALLERGY, V42, P1529, DOI 10.1111/j.1365-2222.2012.04071.x; Scala E, 2015, ALLERGY, V70, P933, DOI 10.1111/all.12635; Schulten V, 2011, ALLERGY, V66, P1005, DOI 10.1111/j.1398-9995.2011.02567.x	9	31	31	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					679	682		10.1016/j.jaci.2016.06.016	http://dx.doi.org/10.1016/j.jaci.2016.06.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27522157	Green Accepted, Bronze			2022-12-18	WOS:000397002400033
J	Tse, SM; Rifas-Shiman, SL; Coull, BA; Litonjua, AA; Oken, E; Gold, DR				Tse, Sze Man; Rifas-Shiman, Sheryl L.; Coull, Brent A.; Litonjua, Augusto A.; Oken, Emily; Gold, Diane R.			Sex-specific risk factors for childhood wheeze and longitudinal phenotypes of wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; sex differences; parental asthma; bronchiolitis	RESPIRATORY SYNCYTIAL VIRUS; EARLY-LIFE; GENDER-DIFFERENCES; ALLERGIC DISEASES; AFRICAN ANCESTRY; LUNG-FUNCTION; ASTHMA; AGE; BRONCHIOLITIS; BIRTH	Background: Although sexual dimorphism in wheeze and asthma prevalence are well documented, sex-specific risk factors for wheeze and longitudinal wheeze phenotypes have not been well elucidated. Objective: By using a large prebirth cohort, this study aimed to identify sex-specific risk factors for wheeze from birth through midchildhood and identifydistinct longitudinal wheeze phenotypes and the sex-specific risk factors associated with these phenotypes. Methods: Mothers reported child wheeze symptoms over the past year approximately yearly on 9 occasions starting at age 1 year. We identified sex-specific predictors of wheeze, wheeze phenotypes, and sex-specific predictors of these phenotypes by using generalized estimating equations, latent class mixed models, and multinomial logistic analysis, respectively. Results: A total of 1623 children had information on wheeze at 1 or more time points. Paternal asthma was a stronger predictor of ever wheezing in boys (odds ratio [OR], 2.15; 95% CI, 1.74-2.66) than in girls (OR, 1.53; 95% CI, 1.19-1.96; P for sex by paternal asthma interaction 5.03), whereas being black or Hispanic, birth weight for gestational age z score, and breast feeding duration had stronger associations among girls. We identified 3 longitudinal wheeze phenotypes: never/infrequent wheeze (74.1%), early transient wheeze (12.7%), and persistent wheeze (13.1%). Compared with never/infrequent wheeze, maternal asthma, infant bronchiolitis, and atopic dermatitis were associated with persistent wheeze in both sexes, but paternal asthma was associated with persistent wheeze in boys only (OR, 4.27; 95% CI, 2.33-7.83; P for sex by paternal asthma interaction 5.02), whereas being black or Hispanic was a predictor for girls only. Conclusion: We identified sex-specific predictors of wheeze and longitudinal wheeze patterns, which might have important prognostic value and allow for a more personalized approach to wheeze and asthma treatment.	[Tse, Sze Man] St Justine Univ Hosp Ctr, Dept Pediat, Div Resp Med, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada; [Tse, Sze Man] Univ Montreal, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada; [Rifas-Shiman, Sheryl L.; Oken, Emily] Harvard Med Sch, Dept Populat Med, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Oken, Emily] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Coull, Brent A.] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Litonjua, Augusto A.; Gold, Diane R.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA USA; [Litonjua, Augusto A.; Gold, Diane R.] Harvard Med Sch, Boston, MA USA	Universite de Montreal; Universite de Montreal; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Tse, SM (corresponding author), St Justine Univ Hosp Ctr, Dept Pediat, Div Resp Med, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.; Tse, SM (corresponding author), Univ Montreal, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	sze.man.tse@umontreal.ca			NIH [K24 HD069408, P30 DK092924];  [R01 HL064925];  [R01 AI102960];  [R37 HD 034568]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K24HD069408, R01HD034568, R37HD034568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This article is subject to the National Institutes of Health (NIH) Public Access Policy (http://publicaccess.nih.gov). Project Viva is funded by R01 HL064925, R01 AI102960, and R37 HD 034568. E.O. received funding from the NIH (K24 HD069408 and P30 DK092924).	Akinbami Lara J, 2012, NCHS Data Brief, P1; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; Arshad SH, 2012, J ALLERGY CLIN IMMUN, V130, P427, DOI 10.1016/j.jaci.2012.03.042; Borrell LN, 2013, AM J RESP CRIT CARE, V187, P697, DOI 10.1164/rccm.201211-2116OC; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Burke H, 2012, PEDIATRICS, V129, P735, DOI 10.1542/peds.2011-2196; Caudri D, 2013, CLIN EXP ALLERGY, V43, P1395, DOI 10.1111/cea.12173; Chen QX, 2012, ANN ALLERG ASTHMA IM, V108, P311, DOI 10.1016/j.anai.2012.02.016; Chipps BE, 2004, ANN ALLERG ASTHMA IM, V93, P309, DOI 10.1016/S1081-1206(10)61388-9; Cox DW, 2013, AM J RESP CRIT CARE, V188, P1358, DOI 10.1164/rccm.201303-0498OC; Debley JS, 2004, PEDIATR PULM, V38, P443, DOI 10.1002/ppul.20108; Dratva J, 2010, J ALLERGY CLIN IMMUN, V125, P823, DOI 10.1016/j.jaci.2009.12.938; Fu Liang, 2014, Ann Am Thorac Soc, V11, P939, DOI 10.1513/AnnalsATS.201402-084OC; GOLD DR, 1994, AM J RESP CRIT CARE, V149, P1198, DOI 10.1164/ajrccm.149.5.8173760; Green CA, 2016, ARCH DIS CHILD, V101, P140, DOI 10.1136/archdischild-2015-308723; Hasegawa K, 2014, PEDIATR INFECT DIS J, V33, P11, DOI 10.1097/INF.0b013e3182a5f324; HIBBERT M, 1995, PEDIATR PULM, V19, P129, DOI 10.1002/ppul.1950190208; KHARITONOV SA, 1994, BRIT HEART J, V72, P243; Kopriva F, 2013, BIOMED PAP, V157, P367, DOI 10.5507/bp.2013.025; Kumar R, 2012, CLIN EXP ALLERGY, V42, P265, DOI 10.1111/j.1365-2222.2011.03873.x; Lodge CJ, 2014, J PEDIATR-US, V164, P289, DOI 10.1016/j.jpeds.2013.09.056; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Midodzi WK, 2008, RESPIROLOGY, V13, P537, DOI 10.1111/j.1440-1843.2008.01284.x; Midulla F, 2012, EUR RESPIR J, V39, P396, DOI 10.1183/09031936.00188210; Mikalsen IB, 2012, PEDIAT ALLERG IMM-UK, V23, P391, DOI 10.1111/j.1399-3038.2012.01283.x; Naumova AK, 2013, HUM GENET, V132, P811, DOI 10.1007/s00439-013-1298-z; Oken E, 2015, INT J EPIDEMIOL, V44, P37, DOI 10.1093/ije/dyu008; Paaso EMS, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0152-8; Pan W, 2002, STAT SINICA, V12, P475; Proust-Lima C, 2013, LCMM ESTIMATION LATE; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schatz M, 2003, ANN ALLERG ASTHMA IM, V91, P553, DOI 10.1016/S1081-1206(10)61533-5; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Sonnenschein-van der Voort AMM, 2012, EUR RESPIR J, V39, P81, DOI 10.1183/09031936.00178110; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; Tse SM, 2015, PEDIATR PULM, V50, P955, DOI 10.1002/ppul.23113; Turner S, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/962923; Valkonen H, 2009, ALLERGY, V64, P1359, DOI 10.1111/j.1398-9995.2009.02022.x; Venn A, 1998, BRIT MED J, V316, P1945, DOI 10.1136/bmj.316.7149.1945; Wegienka G, 2012, CLIN EXP ALLERGY, V42, P909, DOI 10.1111/j.1365-2222.2011.03946.x; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373; Yu Chun-Keung, 2002, Journal of Microbiology Immunology and Infection, V35, P199; Zhang Y, 2011, AM J RESP CRIT CARE, V183, P596, DOI 10.1164/rccm.200912-1863OC	47	31	32	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1561	+		10.1016/j.jaci.2016.04.005	http://dx.doi.org/10.1016/j.jaci.2016.04.005			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27246527	Green Accepted, Bronze			2022-12-18	WOS:000390019300009
J	Noster, R; de Koning, HD; Maier, E; Prelog, M; Lainka, E; Zielinski, CE				Noster, Rebecca; de Koning, Heleen D.; Maier, Elisabeth; Prelog, Martina; Lainka, Elke; Zielinski, Christina E.			Dysregulation of proinflammatory versus anti-inflammatory human T(H)17 cell functionalities in the autoinflammatory Schnitzler syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoinflammation; Schnitzler syndrome; T(H)17 cells; IL-10; IL-1 beta	REGULATORY T-CELLS; CYTOKINE GM-CSF; IL-1 BLOCKADE; BIG PICTURE; MECHANISMS; IL-1-BETA; DISEASES; GAMMA	Background: TH17 cells have so far been considered to be crucial mediators of autoimmune inflammation. Two distinct types of TH17 cells have been described recently, which differed in their polarization requirement for IL-1b and in their cytokine repertoire. Whether these distinct T(H)17 phenotypes translate into distinct T(H)17 cell functions with implications for human health or disease has not been addressed yet. Objective: We hypothesized the existence of proinflammatory and anti-inflammatory human T(H)17 cell functions based on the differential expression of IL-10, which is regulated by IL-1 beta. Considering the crucial role of IL-1 beta in the pathogenesis of autoinflammatory syndromes, we hypothesized that IL-1 beta mediates the loss of anti-inflammatory T(H)17 cell functionalities in patients with Schnitzler syndrome, an autoinflammatory disease. Methods: To assess proinflammatory versus anti-inflammatory T(H)17 cell functions, we performed suppression assays and tested the effects of IL-1 beta dependent and independent TH17 subsets on modulating proinflammatory cytokine secretion by monocytes. Patients with Schnitzler syndrome were analyzed for changes in T(H)17 cell functions before and during therapy with IL-1 beta-blocking drugs. Results: Both T(H)17 cell subsets differ in their ability to suppress T-cell proliferation and their ability to modulate proinflammatory cytokine production by antigen-presenting cells because of their differential IL-10 expression properties. In patients with Schnitzler syndrome, systemic overproduction of IL-1 beta translates into a profound loss of anti-inflammatoryT(H)17 cell functionalities, which can be reversed by anti-IL-1b treatment. Conclusion: IL-1 beta signaling determines the differential expression pattern of IL-10, which is necessary and sufficient to induce proinflammatory versus anti-inflammatory T(H)17 cell functions. Our data introduce T(H)17 cell subsets as novel players in autoinflammation and thus novel therapeutic targets in autoinflammatory syndromes including other IL-1 beta mediated diseases. This demonstrates for the first time alterations in the adaptive immune system in patients with autoinflammatory syndromes.	[Noster, Rebecca; Zielinski, Christina E.] Charite, Dept Dermatol & Allergol, Berlin, Germany; [Maier, Elisabeth; Zielinski, Christina E.] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-80290 Munich, Germany; [de Koning, Heleen D.] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, Nijmegen, Netherlands; [de Koning, Heleen D.] Nijmegen Ctr Immunodeficiency & Autoinflammat, Nijmegen, Netherlands; [Prelog, Martina] Univ Wurzburg, Dept Pediat, Wurzburg, Germany; [Lainka, Elke] Univ Childrens Hosp, Pediat Rheumatol, Essen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; Radboud University Nijmegen; University of Wurzburg; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf	Zielinski, CE (corresponding author), Inst Med Microbiol Immunol & Hyg, Trogerstr 30, D-81675 Munich, Germany.	christina.zielinski@tum.de	de Koning, Heleen/A-5374-2011; Zielinski, Christina/Y-3362-2019	Zielinski, Christina/0000-0002-8184-0858	German Research Foundation [SFB650, SFB1054, ZI 1262/2-1]; Celgene Award of the European Society for Dermatological Research; Else-Kroner-Research Foundation; Fritz-Thyssen Stiftung; Start-up Prize of the German Society for Rheumatology; Novartis; German Center for Infection Research; AID-Registry Federal Ministry of Education and Research [01GM08104, 01GM1112D, 01GM1512D]; Pfizer; Chugai Roche; Sobi	German Research Foundation(German Research Foundation (DFG)); Celgene Award of the European Society for Dermatological Research(Bristol-Myers SquibbCelgene Corporation); Else-Kroner-Research Foundation; Fritz-Thyssen Stiftung; Start-up Prize of the German Society for Rheumatology; Novartis(Novartis); German Center for Infection Research; AID-Registry Federal Ministry of Education and Research; Pfizer(Pfizer); Chugai Roche(Roche Holding); Sobi	Supported by the German Research Foundation (SFB650, SFB1054, and ZI 1262/2-1 to C.E.Z.), the Celgene Award of the European Society for Dermatological Research (to C.E.Z.), the Else-Kroner-Research Foundation (to C.E.Z.), the Fritz-Thyssen Stiftung (to C.E.Z), the Start-up Prize of the German Society for Rheumatology (to C.E.Z.), Novartis (to C.E.Z.), the German Center for Infection Research (to C.E.Z.), and the AID-Registry Federal Ministry of Education and Research (01GM08104, 01GM1112D, 01GM1512D, to E.L.).; Disclosure of potential conflict of interest: M. Prelog is a board member for Pfizer and Novartis; has received grants from Pfizer, Novartis, Chugai Roche, and Sobi; and has received payment for lectures from Pfizer, Novartis, and Chugai Roche. The rest of the authors declare that they have no relevant conflicts of interest.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Beriou G, 2009, BLOOD, V113, P4240, DOI 10.1182/blood-2008-10-183251; Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027; de Koning HD, 2007, SEMIN ARTHRITIS RHEU, V37, P137, DOI 10.1016/j.semarthrit.2007.04.001; de Koning HD, 2015, J ALLERGY CLIN IMMUN, V135, P561, DOI 10.1016/j.jaci.2014.07.050; El-Behi M, 2011, NAT IMMUNOL, V12, P568, DOI 10.1038/ni.2031; Facciotti F, 2016, J ALLERGY CLIN IMMUN, V137, P318, DOI 10.1016/j.jaci.2015.06.044; Goldbach-Mansky R, 2009, J ALLERGY CLIN IMMUN, V124, P1141, DOI 10.1016/j.jaci.2009.11.016; Guarda G, 2009, NATURE, V460, P269, DOI 10.1038/nature08100; Hori S, 2014, IMMUNOL REV, V259, P159, DOI 10.1111/imr.12175; Jesus AA, 2014, ANNU REV MED, V65, P223, DOI 10.1146/annurev-med-061512-150641; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Krause K, 2015, PEDIAT RHEUMATOL S1, V13, pO66; Launay D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059327; Lipsker D, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-38; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Noster R, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008706; Ryan JG, 2008, J ALLERGY CLIN IMMUN, V121, P260, DOI 10.1016/j.jaci.2007.09.021; Sallusto F, 2012, EUR J IMMUNOL, V42, P2215, DOI 10.1002/eji.201242741; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Stoffels M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00054; Yao Y, 2015, J IMMUNOL, V195, P488, DOI 10.4049/jimmunol.1403225; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957	26	31	33	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1161	+		10.1016/j.jaci.2015.12.1338	http://dx.doi.org/10.1016/j.jaci.2015.12.1338			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27040374	Green Published, hybrid			2022-12-18	WOS:000385499400022
J	Ruiz-Romeu, E; Ferran, M; Sagrista, M; Gomez, J; Gimenez-Arnau, A; Herszenyi, K; Hollo, P; Celada, A; Pujol, R; Santamaria-Babi, LF				Ruiz-Romeu, Ester; Ferran, Marta; Sagrista, Marc; Gomez, Julia; Gimenez-Arnau, Ana; Herszenyi, Krisztina; Hollo, Peter; Celada, Antonio; Pujol, Ramon; Santamaria-Babi, Luis F.			Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers T(H)17 responses in patients with guttate psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)17; streptococcal pharyngitis; guttate psoriasis; cutaneous lymphocyte antigen; HLA-Cw*0602	SELECTIVE HOMING RECEPTOR; DOWN-REGULATES FILAGGRIN; CLINICAL-RESPONSE; SKIN; EXPRESSION; LESIONS; THROAT; ONSET; TONSILLECTOMY; PATHOGENESIS	Background: Guttate psoriasis (GP) is characterized by acute onset of small, rounded psoriatic lesions. Although this particular phenotype of psoriasis is usually associated with streptococcal throat infections and mainly occurs in HLA-Cw6(+) patients, the specific immunologic response to this innate stimulus that causes these skin lesions is poorly understood. Objective: This study aims to elucidate how key cellular elements of patients with GP respond to Streptococcus pyogenes and whether this initial immune response is favored by the genetic and environmental background of these patients. Methods: Circulating memory T cells and autologous epidermal cells from samples from either patients with GP (n = 14) or healthy control subjects (n = 6) were cocultured ex vivo in the presence of an S pyogenes extract. Levels of the psoriasis-associated cytokines IL-17A, IL-17F, IFN-gamma, TNF-alpha, IL-6, and IL-8 were determined. The expression of several genes with increased (DEFB4, S100A7, LCN2, IL36G, IL8, CXCL9, CXCL10, and CXCL11) or decreased (FLG and LOR) transcripts in psoriatic lesions was examined in keratinocytes treated with coculture supernatants. Results: When skin-homing effector memory cutaneous lymphocyte antigen positive T cells were used in cocultures, a T(H)17-dominant response was observed, as reflected by the higher amounts of IL-17A and IL-17F than IFN-gamma. Moreover, a higher T(H)17 response was observed in cells isolated from patients with flares associated with a streptococcal tonsillitis and with the HLA-Cw6 allele (cohort 1). In addition, in normal keratinocytes the supernatants from these cocultures induced an increase in IL-17 associated genes, such as DEFB4, S100A7, LCN2, IL36G, and IL8 but a decrease in FLG and LOR, thereby confirming the role of activated T(H)17 cells. Conclusion: This study reveals a dominant T(H)17 response of cutaneous lymphocyte antigen positive T cells activated by epidermal cells and S pyogenes in patients with GP.	[Ruiz-Romeu, Ester; Santamaria-Babi, Luis F.] Univ Barcelona, Dept Cellular Biol Physiol & Immunol, Translat Immunol, Barcelona, Spain; [Celada, Antonio] Univ Barcelona, Dept Cellular Biol Physiol & Immunol, Macrophage Biol, Barcelona, Spain; [Ferran, Marta; Gimenez-Arnau, Ana; Pujol, Ramon] Univ Autonoma Barcelona, Hosp Mar, IMIM, Dept Dermatol,Res Grp Inflammatory Dermatol Dis, Barcelona, Spain; [Sagrista, Marc] Hosp Sant Jaume Calella, Barcelona, Spain; [Gomez, Julia] El Prat Llobregat, Lab Referencia Catalunya, Barcelona, Spain; [Herszenyi, Krisztina; Hollo, Peter] Semmelweis Egyetem, Dept Dermatovenerol & Oncodermatolgy, Budapest, Hungary	University of Barcelona; University of Barcelona; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Semmelweis University	Santamaria-Babi, LF (corresponding author), Univ Barcelona, Translat Immunol, 10 Barcelona, Barcelona 08028, Spain.	luis.santamaria@ub.edu	Holló, Peter/Q-6505-2018; Celada, Antonio/I-1714-2016	PUJOL, RAMON M/0000-0002-5622-6055; Celada, Antonio/0000-0003-3883-2171; Santamaria Babi, Luis F/0000-0002-1674-6654; Sagrista Garcia, Marc/0000-0002-4730-2466	Instituto de Salud Carlos III [PI09/2222, PI13/01845, PI09/07811, PI13/01716]; Ministerio de Educacion, Cultura y Deporte	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Ministerio de Educacion, Cultura y Deporte	Supported by ERDF grants from the Instituto de Salud Carlos III (PI09/2222 and PI13/01845 to L.F.S.-B., PI09/07811 to A.G.-A., and PI13/01716 to RP). L.F.S.-B. coordinated projects and grants. E.R.-R. was the recipient of a PhD fellowship from the Ministerio de Educacion, Cultura y Deporte.	Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Bergboer JGM, 2012, J INVEST DERMATOL, V132, P2320, DOI 10.1038/jid.2012.167; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Chiu HY, 2014, BRIT J DERMATOL, V171, P1181, DOI 10.1111/bjd.13056; Choe YB, 2012, BRIT J DERMATOL, V167, P762, DOI 10.1111/j.1365-2133.2012.11038.x; Christophers E, 2014, BRIT J DERMATOL, V170, P59, DOI 10.1111/bjd.12631; D'Erme AM, 2015, J INVEST DERMATOL, V135, P1025, DOI 10.1038/jid.2014.532; Davison SC, 2001, EXP DERMATOL, V10, P280, DOI 10.1034/j.1600-0625.2001.100408.x; Diluvio L, 2006, J IMMUNOL, V176, P7104, DOI 10.4049/jimmunol.176.11.7104; El-Rachkidy RG, 2007, J INVEST DERMATOL, V127, P1337, DOI 10.1038/sj.jid.5700744; Fahlen A, 2012, ARCH DERMATOL RES, V304, P15, DOI 10.1007/s00403-011-1189-x; Ferran M, 2013, EXP DERMATOL, V22, P439, DOI 10.1111/exd.12154; Ferran M, 2013, J INVEST DERMATOL, V133, P999, DOI 10.1038/jid.2012.418; Gudjonsson JE, 2003, BRIT J DERMATOL, V149, P530, DOI 10.1046/j.1365-2133.2003.05552.x; Gudjonsson JE, 2006, J INVEST DERMATOL, V126, P740, DOI 10.1038/sj.jid.5700118; Gudjonsson JE, 2010, J INVEST DERMATOL, V130, P1829, DOI 10.1038/jid.2010.36; Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Henry J, 2012, FRONT BIOSCI-LANDMRK, V17, P1517, DOI 10.2741/4001; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Kim BE, 2011, J INVEST DERMATOL, V131, P1272, DOI 10.1038/jid.2011.24; Ko HC, 2010, J DERMATOL, V37, P894, DOI 10.1111/j.1346-8138.2010.00871.x; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; LEUNG DYM, 1995, J CLIN INVEST, V96, P2106, DOI 10.1172/JCI118263; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Li N, 2014, J IMMUNOL, V193, P5140, DOI 10.4049/jimmunol.1302574; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Mallbris L, 2005, J INVEST DERMATOL, V124, P499, DOI 10.1111/j.0022-202X.2004.23611.x; Mallbris L, 2009, BMC DERMATOL, V9, DOI 10.1186/1471-5945-9-5; McFadden JP, 2009, BRIT J DERMATOL, V160, P929, DOI 10.1111/j.1365-2133.2009.09102.x; Morizane S, 2012, J DERMATOL, V39, P225, DOI 10.1111/j.1346-8138.2011.01483.x; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; PICKER LJ, 1993, J IMMUNOL, V150, P1122; Pont-Giralt M, 2006, J INVEST DERMATOL, V126, P227, DOI 10.1038/sj.jid.5700006; Prinz JC, 2001, CLIN EXP DERMATOL, V26, P326, DOI 10.1046/j.1365-2230.2001.00831.x; Rachakonda TD, 2015, J AM ACAD DERMATOL, V72, P261, DOI 10.1016/j.jaad.2014.10.013; Roberson EDO, 2010, TRENDS GENET, V26, P415, DOI 10.1016/j.tig.2010.06.006; Rottman JB, 2001, LAB INVEST, V81, P335, DOI 10.1038/labinvest.3780242; Sigurdardottir SL, 2013, CLIN EXP IMMUNOL, V174, P139, DOI 10.1111/cei.12153; Talamonti M, 2013, BRIT J DERMATOL, V169, P458, DOI 10.1111/bjd.12331; Thorleifsdottir RH, 2012, J IMMUNOL, V188, P5160, DOI 10.4049/jimmunol.1102834; Tortola L, 2012, J CLIN INVEST, V122, P3965, DOI 10.1172/JCI63451; Valdimarsson H, 2009, TRENDS IMMUNOL, V30, P494, DOI 10.1016/j.it.2009.07.008; Vissers WHPM, 2004, BRIT J DERMATOL, V150, P852, DOI 10.1111/j.1365-2133.2004.05863.x; Weisenseel P, 2005, ARCH DERMATOL RES, V296, P573, DOI 10.1007/s00403-005-0559-7; Weisenseel P, 2002, J MED GENET, V39, P767, DOI 10.1136/jmg.39.10.767	51	31	31	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					491	+		10.1016/j.jaci.2016.02.008	http://dx.doi.org/10.1016/j.jaci.2016.02.008			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27056267	Bronze			2022-12-18	WOS:000380835800020
J	Ramesh, M; Yuenyongviwat, A; Konstantinou, GN; Lieberman, J; Pascal, M; Masilamani, M; Sampson, HA				Ramesh, Manish; Yuenyongviwat, Araya; Konstantinou, George N.; Lieberman, Jay; Pascal, Mariona; Masilamani, Madhan; Sampson, Hugh A.			Peanut T-cell epitope discovery: Ara h 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ara h 1; peanut; food allergy; peptide epitope	FOOD ALLERGY; ORAL IMMUNOTHERAPY; DOUBLE-BLIND; PEPTIDES; DESENSITIZATION; PREDICTION; RESPONSES	Background: Identification of potential T-cell epitopes in the peanut major allergens is essential for development of peptide-based immunotherapy. Traditional methods of T-cell epitope discovery use overlapping short peptides spanning the full length of the protein in T-cell proliferation assays. Because large proteins, such as Ara h 1, require a large number of peptides, this limits screening to a small number of allergic subject-derived T-cell lines. Objective: We sought to identify candidate peptides of Ara h 1 that display promiscuous binding to MHC class II and induce T(H)2 cytokine production by T cells. Methods: In silico MHC class II binding prediction was performed with NetMHCIIpan 2.0 (peptide length, 15; 1-mer offset) and the most abundant class II alleles in the North American population and with an in vitro MHC class II peptide reporter assay performed in parallel, which used synthetic 15-mer peptides offset by 5 mer spanning the protein. High-resolution MHC class II typing and a T-cell proliferation assay using preselected peptides were performed with PBMCs from 98 subjects with peanut allergy and 14 healthy control subjects. IL-4, IL-13, IL-5, IFN-gamma, and TNF-alpha levels were measured in culture supernatants. Results: Thirty-six Ara h 1 peptides were identified by using in silico predictions and MHC class II binding assays. In combination with T-cell proliferation and cytokines secreted in T-cell assays, we have identified 4 vaccine candidate Ara h 1 peptides. Conclusions: Preselection of peptides by using in silico and in vitro approaches in combination with conventional methods appears to be an effective strategy for identifying peanut T-cell peptide vaccine candidates.	[Ramesh, Manish] Montefiore Med Ctr, Dept Med, Div Allergy & Immunol, Bronx, NY 10467 USA; [Yuenyongviwat, Araya; Konstantinou, George N.; Lieberman, Jay; Pascal, Mariona; Masilamani, Madhan; Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY USA; [Yuenyongviwat, Araya] Prince Songkla Univ, Fac Med, Dept Pediat, Div Pediat Allergy & Immunol, Hat Yai, Songkhla, Thailand; [Konstantinou, George N.] 424 Gen Mil Training Hosp, Dept Allergy & Clin Immunol, Thessaloniki, Greece; [Lieberman, Jay] Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA; [Pascal, Mariona] Univ Barcelona, CDB Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai; Prince of Songkla University; University of Tennessee System; University of Tennessee Health Science Center; University of Barcelona	Sampson, HA (corresponding author), Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, Box 1089, New York, NY 10029 USA.	hugh.sampson@mssm.edu	Pascal, Mariona/HCG-9380-2022	Konstantinou, George/0000-0003-1371-6764	David H. and Julia Koch Research Program in Food Allergy Therapeutics at Jaffe Food Allergy Institute, Mount Sinai School of Medicine	David H. and Julia Koch Research Program in Food Allergy Therapeutics at Jaffe Food Allergy Institute, Mount Sinai School of Medicine	Supported by the David H. and Julia Koch Research Program in Food Allergy Therapeutics at the Jaffe Food Allergy Institute, Mount Sinai School of Medicine.	Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Archila LD, 2015, J ALLERGY CLIN IMMUN, V136, P983; Berin MC, 2013, TRENDS IMMUNOL, V34, P390, DOI 10.1016/j.it.2013.04.003; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Couroux P, 2015, CLIN EXP ALLERGY, V45, P974, DOI 10.1111/cea.12488; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Hafner RP, 2012, J ALLERGY CLIN IMMUN, V129, pAB144, DOI 10.1016/j.jaci.2011.12.485; Larche M, 2013, J ALLERGY CLIN IMMUN, V131, pAB37, DOI 10.1016/j.jaci.2012.12.814; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Pascal M, 2013, CLIN EXP ALLERGY, V43, P116, DOI 10.1111/cea.12014; Prickett SR, 2013, CLIN EXP ALLERGY, V43, P684, DOI 10.1111/cea.12113; Rudders SA, 2011, J PEDIATR-US, V158, P326, DOI 10.1016/j.jpeds.2010.10.017; Rupa P, 2012, ALLERGY, V67, P74, DOI 10.1111/j.1398-9995.2011.02724.x; Schoell I., 2002, Clinical and Experimental Allergy, V32, P1583, DOI 10.1046/j.1365-2222.2002.01527.x; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Simms E, 2015, J ALLERGY CLIN IMMUN, V135, pAB158, DOI 10.1016/j.jaci.2014.12.1456; Smith TRF, 2004, ALLERGY, V59, P1097, DOI 10.1111/j.1398-9995.2004.00601.x; Stahl MC, 2011, ANN ALLERG ASTHMA IM, V106, P179, DOI 10.1016/j.anai.2010.08.009; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Van Hemelen D, 2015, ALLERGY, V70, P49, DOI 10.1111/all.12524; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Wang JL, 2012, IMMUNOL RES, V54, P83, DOI 10.1007/s12026-012-8309-3	29	31	36	2	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1764	+		10.1016/j.jaci.2015.12.1327	http://dx.doi.org/10.1016/j.jaci.2015.12.1327			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26953158	Bronze			2022-12-18	WOS:000377527200017
J	Salazar, F; Hall, L; Negm, OH; Awuah, D; Tighe, PJ; Shakib, F; Ghaemmaghami, AM				Salazar, Fabian; Hall, Laurence; Negm, Ola H.; Awuah, Dennis; Tighe, Patrick J.; Shakib, Farouk; Ghaemmaghami, Amir M.			The mannose receptor negatively modulates the Toll-like receptor 4-aryl hydrocarbon receptor-indoleamine 2,3-dioxygenase axis in dendritic cells affecting T helper cell polarization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; allergy; T(H)2; indoleamine 2,3-dioxygenase; C-type lectin receptor; mannose receptor; Toll-like receptor 4; aryl-hydrocarbon receptor; nuclear factor kappa B	NF-KAPPA-B; NONINTEGRIN DC-SIGN; HOUSE-DUST MITE; ALLERGIC SENSITIZATION; EXPERIMENTAL ASTHMA; IDO ACTIVITY; MOUSE MODEL; IN-VITRO; CYTOKINE PRODUCTION; HUMAN MONOCYTES	Background: Dendritic cells (DCs) are key players in the induction and re-elicitation of T(H)2 responses to allergens. We have previously shown that different C-type lectin receptors on DCs play a major role in allergen recognition and uptake. In particular, mannose receptor (MR), through modulation of Toll-like receptor (TLR) 4 signaling, can regulate indoleamine 2,3-dioxygenase (IDO) activity, favoring T(H)2 responses. Interestingly, the aryl hydrocarbon receptor (AhR), a ligand-dependent transcription factor with an emerging role in immune modulation, has been implicated in IDO activation in response to TLR stimulation. Objective: Here we investigated how allergens and lectins modulate the TLR4-AhR-IDO axis in human monocyte-derived DCs. Methods: Using a combination of genomics, proteomics, and immunologic studies, we investigated the role of MR and AhR in IDO regulation and its effect on T helper cell differentiation. Results: We have demonstrated that LPS induces both IDO isoforms (IDO1 and IDO2) in DCs, with partial involvement of AhR. Additionally, we found that, like mannan, different airborne allergens can effectively downregulate TLR4-induced IDO1 and IDO2 expression, most likely through binding to the MR. Mannose-based ligands were also able to downregulate IL-12p70 production by DCs, affecting T helper cell polarization. Interestingly, AhR and some components of the noncanonical nuclear factor kappa B pathway were shown to be downregulated after MR engagement, which could explain the regulatory effects of MR on IDO expression. Conclusion: Our work demonstrates a key role for MR in the modulation of the TLR4-AhR-IDO axis, which has a significant effect on DC behavior and the development of immune responses against allergens.	[Salazar, Fabian; Hall, Laurence; Negm, Ola H.; Awuah, Dennis; Tighe, Patrick J.; Shakib, Farouk; Ghaemmaghami, Amir M.] Univ Nottingham, Fac Med & Hlth Sci, Sch Life Sci, Div Immunol, Nottingham NG7 2UH, England; [Negm, Ola H.] Mansoura Univ, Med Microbiol & Immunol Dept, Mansoura, Egypt	University of Nottingham; Egyptian Knowledge Bank (EKB); Mansoura University	Ghaemmaghami, AM (corresponding author), Univ Nottingham, Queens Med Ctr, Fac Med & Hlth Sci, Div Immunol,Sch Life Sci, West Block,Floor, Nottingham NG7 2UH, England.	amg@nottingham.ac.uk	Ghaemmaghami, Amir/AAP-2968-2020; Awuah, Dennis/AAV-4776-2021; Salazar, Fabian/AAW-2488-2020; Dawkins-Hall CSci CBiol FIScT(Reg) FRSB, Laurence Stuart/L-8773-2016; Negm, Ola H/P-8241-2017; Ghaemmaghami, Amir/S-2627-2019	Ghaemmaghami, Amir/0000-0003-3160-8759; Dawkins-Hall CSci CBiol FIScT(Reg) FRSB, Laurence Stuart/0000-0002-6138-6715; Negm, Ola H/0000-0002-5999-6012; Salazar Lizama, Fabian/0000-0001-5139-2292; Tighe, Patrick/0000-0001-8326-093X; Awuah, Dennis/0000-0002-4295-5599	National Commission for Scientific and Technological Research (CONICYT), Chile	National Commission for Scientific and Technological Research (CONICYT), Chile(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT))	F.S. is a recipient of a PhD scholarship from the National Commission for Scientific and Technological Research (CONICYT), Chile.	Al-Ghouleh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033929; Baglole CJ, 2008, J BIOL CHEM, V283, P28944, DOI 10.1074/jbc.M800685200; Ball HJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00485; Bankoti J, 2010, TOXICOL APPL PHARM, V246, P18, DOI 10.1016/j.taap.2010.03.013; Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Braun D, 2005, BLOOD, V106, P2375, DOI 10.1182/blood-2005-03-0979; Cambi A, 2008, J BIOL CHEM, V283, P20590, DOI 10.1074/jbc.M709334200; DiNatale BC, 2010, TOXICOL SCI, V115, P89, DOI 10.1093/toxsci/kfq024; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Emara M, 2012, J BIOL CHEM, V287, P5756, DOI 10.1074/jbc.M111.312520; Emara M, 2011, J BIOL CHEM, V286, P13033, DOI 10.1074/jbc.M111.220657; Garcia-Nieto S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010123; Gringhuis SI, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4898; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Hansen AM, 2004, INT J PARASITOL, V34, P1309, DOI 10.1016/j.ijpara.2004.07.008; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Hayashi T, 2007, P NATL ACAD SCI USA, V104, P18619, DOI 10.1073/pnas.0709261104; Hentges F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00234; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; Hill M, 2007, EUR J IMMUNOL, V37, P3054, DOI 10.1002/eji.200636704; Hsu SC, 2010, J BIOL CHEM, V285, P7903, DOI 10.1074/jbc.M109.058370; Hwang SL, 2005, CELL RES, V15, P167, DOI 10.1038/sj.cr.7290282; Jeong KT, 2012, INT IMMUNOPHARMACOL, V13, P377, DOI 10.1016/j.intimp.2012.04.014; Jin GB, 2010, TOXICOL SCI, V116, P514, DOI 10.1093/toxsci/kfq153; Jurgens B, 2009, BLOOD, V114, P3235, DOI 10.1182/blood-2008-12-195073; Jux B, 2009, J IMMUNOL, V182, P6709, DOI 10.4049/jimmunol.0713344; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kim YK, 2007, J IMMUNOL, V178, P5375, DOI 10.4049/jimmunol.178.8.5375; Klaver EJ, 2013, INT J PARASITOL, V43, P191, DOI 10.1016/j.ijpara.2012.10.021; Kojima K, 2011, AM J RESP CRIT CARE, V184, P328, DOI 10.1164/rccm.201010-1566OC; Koorella C, 2014, J BIOL CHEM, V289, P7747, DOI 10.1074/jbc.M113.519686; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Li J, 2010, CLIN EXP IMMUNOL, V162, P251, DOI 10.1111/j.1365-2249.2010.04244.x; Litzenburger UM, 2014, ONCOTARGET, V5, P1038, DOI 10.18632/oncotarget.1637; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Manches O, 2012, P NATL ACAD SCI USA, V109, P14122, DOI 10.1073/pnas.1204032109; Martinez-Pomares L, 2012, J LEUKOCYTE BIOL, V92, P1177, DOI 10.1189/jlb.0512231; McBerry C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038384; Merlo LMF, 2014, J IMMUNOL, V192, P2082, DOI 10.4049/jimmunol.1303012; Metz R, 2014, INT IMMUNOL, V26, P357, DOI 10.1093/intimm/dxt073; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Montagnoli C, 2006, J IMMUNOL, V176, P1712, DOI 10.4049/jimmunol.176.3.1712; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Negm OH, 2014, EUR J IMMUNOL, V44, P2096, DOI 10.1002/eji.201344328; Nguyen NT, 2010, P NATL ACAD SCI USA, V107, P19961, DOI 10.1073/pnas.1014465107; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Odemuyiwa SO, 2009, ALLERGY, V64, P488, DOI 10.1111/j.1398-9995.2008.01809.x; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Onodera T, 2009, J IMMUNOL, V183, P5608, DOI 10.4049/jimmunol.0804116; Orabona C, 2012, MOL MED, V18, P834, DOI 10.2119/molmed.2012.00029; Pathak SK, 2005, J BIOL CHEM, V280, P42794, DOI 10.1074/jbc.M506471200; Platzer B, 2009, J IMMUNOL, V183, P66, DOI 10.4049/jimmunol.0802997; Puccetti P, 2007, NAT REV IMMUNOL, V7, P817, DOI 10.1038/nri2163; Raitala A, 2006, MOL IMMUNOL, V43, P1054, DOI 10.1016/j.molimm.2005.06.022; Royer PJ, 2010, J IMMUNOL, V185, P1522, DOI 10.4049/jimmunol.1000774; Salazar F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00356; Salazar F, 2013, J ALLERGY CLIN IMMUN, V132, P27, DOI 10.1016/j.jaci.2013.02.001; Sancho D, 2012, ANNU REV IMMUNOL, V30, P491, DOI 10.1146/annurev-immunol-031210-101352; Schulz VJ, 2013, IMMUNOBIOLOGY, V218, P1055, DOI 10.1016/j.imbio.2013.01.004; Schulz VJ, 2011, TOXICOL SCI, V123, P491, DOI 10.1093/toxsci/kfr175; Scotton CJ, 2005, J IMMUNOL, V174, P834, DOI 10.4049/jimmunol.174.2.834; Sharquie IK, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-54; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Simones T, 2011, TOXICOL SCI, V119, P293, DOI 10.1093/toxsci/kfq354; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177; Taher YA, 2008, J ALLERGY CLIN IMMUN, V121, P983, DOI 10.1016/j.jaci.2007.11.021; Tarkowski M, 2010, INT J OCCUP MED ENV, V23, P75, DOI 10.2478/v.10001-010-0006-7; Tas SW, 2007, BLOOD, V110, P1540, DOI 10.1182/blood-2006-11-056010; Terness P, 2005, BLOOD, V105, P2480, DOI 10.1182/blood-2004-06-2103; Thatcher TH, 2007, AM J PATHOL, V170, P855, DOI 10.2353/ajpath.2007.060391; Tian YA, 2009, BIOCHEM PHARMACOL, V77, P670, DOI 10.1016/j.bcp.2008.10.023; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Veldhoen M, 2009, J EXP MED, V206, P43, DOI 10.1084/jem.20081438; Vogel CFA, 2007, MOL ENDOCRINOL, V21, P2941, DOI 10.1210/me.2007-0211; Vogel CFA, 2014, J BIOL CHEM, V289, P1866, DOI 10.1074/jbc.M113.505578; Vogel CFA, 2013, IMMUNOL CELL BIOL, V91, P568, DOI 10.1038/icb.2013.43; Vogel CFA, 2009, BIOCHEM PHARMACOL, V77, P734, DOI 10.1016/j.bcp.2008.09.036; von Bubnoff D, 2004, CLIN EXP ALLERGY, V34, P1056, DOI 10.1111/j.1365-2222.2004.01984.x; Walsh KP, 2013, TRENDS IMMUNOL, V34, P521, DOI 10.1016/j.it.2013.07.006; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01; Xaplanteri P, 2009, EUR J IMMUNOL, V39, P730, DOI 10.1002/eji.200838872; Xu H, 2008, P NATL ACAD SCI USA, V105, P6690, DOI 10.1073/pnas.0708809105; Xu H, 2008, IMMUNOL LETT, V121, P1, DOI 10.1016/j.imlet.2008.08.008; Zhang JM, 2005, J LEUKOCYTE BIOL, V78, P665, DOI 10.1189/jlb.1204699	86	31	36	2	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1841	+		10.1016/j.jaci.2015.10.033	http://dx.doi.org/10.1016/j.jaci.2015.10.033			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26703454	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000377527200026
J	Yee, CS; Massaad, MJ; Bainter, W; Ohsumi, TK; Foger, N; Chan, AC; Akarsu, NA; Aytekin, C; Ayvaz, DC; Tezcan, I; Sanal, O; Geha, RS; Chou, J				Yee, Christina S.; Massaad, Michel J.; Bainter, Wayne; Ohsumi, Toshiro K.; Foeger, Niko; Chan, Andrew C.; Akarsu, Nurten A.; Aytekin, Caner; Ayvaz, Deniz Cagdas; Tezcan, Ilhan; Sanal, Ozden; Geha, Raif S.; Chou, Janet			Recurrent viral infections associated with a homozygous CORO1A mutation that disrupts oligomerization and cytoskeletal association	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Coronin-1A; immunodeficiency; T-cell lymphopenia	SEVERE COMBINED IMMUNODEFICIENCY; HEALTHY-CHILDREN; CORONIN 1A; ACTIN; PROTEIN; DEFICIENCY; ACTIVATION; SURVIVAL; SERUM; MYCOBACTERIA	Background: Coronin-1A (CORO1A) is a regulator of actin dynamics important for T-cell homeostasis. CORO1A deficiency causes T-B+ natural killer-positive severe combined immunodeficiency or T-cell lymphopenia with severe viral infections. However, because all known human mutations in CORO1A abrogate protein expression, the role of the protein's functional domains in host immunity is unknown. Objective: We sought to identify the cause of the primary immunodeficiency in 2 young adult siblings with a history of disseminated varicella, cutaneous warts, and CD4(+) T-cell lymphopenia. Methods: We performed immunologic, genetic, and biochemical studies in the patients, family members, and healthy control subjects. Results: Both patients had CD4(+) T-cell lymphopenia and decreased lymphocyte proliferation to mitogens. IgG, IgM, IgA, and specific antibody responses were normal. Whole-genome sequencing identified a homozygous frameshift mutation in CORO1A disrupting the last 2 C-terminal domains by replacing 61 amino acids with a novel 91-amino-acid sequence. The CORO1A(S401fs) mutant was expressed in the patients' lymphocytes at a level comparable with that of wild-type CORO1A in normal lymphocytes but did not oligomerize and had impaired cytoskeletal association. CORO1A(S401fs) was associated with increased filamentous actin accumulation in T cells, severely defective thymic output, and impaired T-cell survival but normal calcium flux and cytotoxicity, demonstrating the importance of CORO1A oligomerization and subcellular localization in T-cell homeostasis. Conclusions: We describe a truncating mutation in CORO1A that permits protein expression and survival into young adulthood. Our studies demonstrate the importance of intact CORO1A C-terminal domains in thymic egress and T-cell survival, as well as in defense against viral pathogens.	[Yee, Christina S.; Massaad, Michel J.; Bainter, Wayne; Geha, Raif S.; Chou, Janet] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Yee, Christina S.; Massaad, Michel J.; Bainter, Wayne; Geha, Raif S.; Chou, Janet] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Ohsumi, Toshiro K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Ohsumi, Toshiro K.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Chan, Andrew C.] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA; [Akarsu, Nurten A.] Hacettepe Univ, Fac Med, Dept Med Genet, TR-06100 Ankara, Turkey; [Aytekin, Caner] Dr Sami Ulus Childrens Hlth & Dis Training & Res, Ankara, Turkey; [Ayvaz, Deniz Cagdas; Tezcan, Ilhan; Sanal, Ozden] Hacettepe Univ, Ankara, Turkey; [Ayvaz, Deniz Cagdas; Tezcan, Ilhan; Sanal, Ozden] Ihsan Dogramaci Childrens Hosp, Ankara, Turkey	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Roche Holding; Genentech; Hacettepe University; Dr. Sami Ulus Education & Research Hospital; Hacettepe University; Hacettepe University	Geha, RS (corresponding author), Boston Childrens Hosp, Div Immunol, Boston, MA USA.; Geha, RS (corresponding author), Childrens Hosp, Div Immunol, Karp Bldg,10th Floor,1 Blackfan Circle, Boston, MA 02115 USA.	Raif.Geha@childrens.harvard.edu	Cagdas, Deniz/I-9104-2013; Akarsu, Nurten/E-9758-2013	Cagdas, Deniz/0000-0003-2213-4627; Akarsu, Nurten/0000-0001-5432-0032	National Institutes of Health [P01AI-076210, AI-094017, T32 AI-007512-26]; Dubai-Harvard Foundation for Medical Research; Perkins Fund; Jeffrey Modell Foundation; Hacettepe Scientific Research Projects Unit (BAP) [010-01-101-010]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI094017, T32AI007512, R01AI100315, P01AI076210, R21AI107097, K08AI116979] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dubai-Harvard Foundation for Medical Research; Perkins Fund; Jeffrey Modell Foundation; Hacettepe Scientific Research Projects Unit (BAP)(Hacettepe University); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants P01AI-076210 (to R.S.G.), AI-094017 (to R.S.G.), and T32 AI-007512-26 (to C.S.Y.); the Dubai-Harvard Foundation for Medical Research (to R.S.G.); the Perkins Fund (to R.S.G); a Jeffrey Modell Foundation Translational Research Program Grant Award (to J.C.); and the Hacettepe Scientific Research Projects Unit (BAP) Project 010-01-101-010 (to N.A.A., D.C.A., I.T., and O.S.).	Abraham RS, 2013, J ALLERGY CLIN IMMUN, V131, P1421, DOI 10.1016/j.jaci.2012.09.016; Ban SA, 2014, J CLIN IMMUNOL, V34, P941, DOI 10.1007/s10875-014-0088-2; Brieher WM, 2006, J CELL BIOL, V175, P315, DOI 10.1083/jcb.200603149; Cai L, 2005, J BIOL CHEM, V280, P31913, DOI 10.1074/jbc.M504146200; Carnevali P, 2012, J COMPUT BIOL, V19, P279, DOI 10.1089/cmb.2011.0201; Dobbs K, 2015, NEW ENGL J MED, V372, P2409, DOI 10.1056/NEJMoa1413462; Drmanac R, 2010, SCIENCE, V327, P78, DOI 10.1126/science.1181498; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Foger N, 2006, SCIENCE, V313, P839, DOI 10.1126/science.1130563; Gatfield J, 2005, MOL BIOL CELL, V16, P2786, DOI 10.1091/mbc.E05-01-0042; Grogan A, 1997, J CELL SCI, V110, P3071; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Jayachandran R, 2007, CELL, V130, P37, DOI 10.1016/j.cell.2007.04.043; JOLLIFF CR, 1982, CLIN CHEM, V28, P126; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; Kogkopoulou O, 2006, J LEUKOCYTE BIOL, V79, P1052, DOI 10.1189/jlb.0705418; Kuijpers TW, 2011, BLOOD, V117, P5892, DOI 10.1182/blood-2011-01-329052; Mace EM, 2014, P NATL ACAD SCI USA, V111, P6708, DOI 10.1073/pnas.1314975111; Moshous D, 2013, J ALLERGY CLIN IMMUN, V131, P1594, DOI 10.1016/j.jaci.2013.01.042; Moulding DA, 2007, J EXP MED, V204, P2213, DOI 10.1084/jem.20062324; Mueller P, 2008, NAT IMMUNOL, V9, P424, DOI 10.1038/ni1570; Mugnier B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003467; Nal B, 2004, INT IMMUNOL, V16, P231, DOI 10.1093/intimm/dxh022; Ohsumi TK, 2012, BIOINFORMATICS, V28, P2412, DOI 10.1093/bioinformatics/bts458; Oku T, 2003, BIOL PHARM BULL, V26, P409; Ono S, 2003, BIOCHEMISTRY-US, V42, P13363, DOI 10.1021/bi034600x; Rodal AA, 2005, NAT STRUCT MOL BIOL, V12, P26, DOI 10.1038/nsmb870; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Shiow LR, 2008, NAT IMMUNOL, V9, P1307, DOI 10.1038/ni.1662; Shiow LR, 2009, CLIN IMMUNOL, V131, P24, DOI 10.1016/j.clim.2008.11.002; SHOVLIN CL, 1994, J IMMUNOL, V153, P2331; Stray-Pedersen A, 2014, J CLIN IMMUNOL, V34, P871, DOI 10.1007/s10875-014-0074-8; Tchang VSY, 2013, MOL IMMUNOL, V56, P683, DOI 10.1016/j.molimm.2013.05.003; ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x; Zhang Q, 2014, J EXP MED, V211, P2549, DOI 10.1084/jem.20141307	35	31	33	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					879	+		10.1016/j.jaci.2015.08.020	http://dx.doi.org/10.1016/j.jaci.2015.08.020			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26476480	Green Accepted			2022-12-18	WOS:000371897500032
J	Junge, KM; Bauer, T; Geissler, S; Hirche, F; Thurmann, L; Bauer, M; Trump, S; Bieg, M; Weichenhan, D; Gu, L; Mallm, JP; Ishaque, N; Muecke, O; Roder, S; Herberth, G; Diez, U; Borte, M; Rippe, K; Plass, C; Hermann, C; Stangl, GI; Eils, R; Lehmann, I				Junge, Kristin M.; Bauer, Tobias; Geissler, Stefanie; Hirche, Frank; Thuermann, Loreen; Bauer, Mario; Trump, Saskia; Bieg, Matthias; Weichenhan, Dieter; Gu, Lei; Mallm, Jan-Philipp; Ishaque, Naveed; Muecke, Oliver; Roeder, Stefan; Herberth, Gunda; Diez, Ulrike; Borte, Michael; Rippe, Karsten; Plass, Christoph; Hermann, Carl; Stangl, Gabriele I.; Eils, Roland; Lehmann, Irina			Increased vitamin D levels at birth and in early infancy increase offspring allergy risk-evidence for involvement of epigenetic mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TSLP; EXPRESSION; DISEASE; COHORT		[Junge, Kristin M.; Thuermann, Loreen; Bauer, Mario; Trump, Saskia; Herberth, Gunda; Lehmann, Irina] UFZ Helmholtz Ctr Environm Res, Dept Environm Immunol, Leipzig, Germany; [Bauer, Tobias; Bieg, Matthias; Gu, Lei; Ishaque, Naveed; Hermann, Carl; Eils, Roland] German Canc Res Ctr, Div Theoret Bioinformat, Heidelberg, Germany; [Geissler, Stefanie; Stangl, Gabriele I.] Univ Halle Wittenberg, Inst Agr & Nutr Sci, D-06108 Halle, Germany; [Hirche, Frank; Bieg, Matthias; Ishaque, Naveed; Eils, Roland] German Canc Res Ctr, DKFZ HIPO, Heidelberg Ctr Personalized Oncol, Heidelberg, Germany; [Weichenhan, Dieter; Muecke, Oliver; Plass, Christoph] German Canc Res Ctr, Div Epigen & Canc Risk Factors, Heidelberg, Germany; [Mallm, Jan-Philipp; Rippe, Karsten] German Canc Res Ctr, Res Grp Genome Org & Funct, Heidelberg, Germany; [Mallm, Jan-Philipp; Rippe, Karsten] Bioquant, Heidelberg, Germany; [Roeder, Stefan; Lehmann, Irina] Helmholtz Ctr Environm Research UFZ, Core Facil Studies, Leipzig, Germany; [Diez, Ulrike; Borte, Michael] Municipal Hosp St Georg, Childrens Hosp, Leipzig, Germany; [Hermann, Carl; Eils, Roland] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Heidelberg, Germany; [Hermann, Carl; Eils, Roland] Heidelberg Univ, Bioquant Ctr, Heidelberg, Germany; [Eils, Roland] Heidelberg Univ, German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg, Heidelberg, Germany	Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Martin Luther University Halle Wittenberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Lehmann, I (corresponding author), UFZ Helmholtz Ctr Environm Res, Dept Environm Immunol, Leipzig, Germany.; Lehmann, I (corresponding author), Helmholtz Ctr Environm Research UFZ, Core Facil Studies, Leipzig, Germany.	irina.lehmann@ufz.de	Gu, Lei/GWQ-6785-2022; Bauer, Mario/AAZ-7540-2021; Ishaque, Naveed/AAF-3454-2020; Rippe, Karsten/A-3562-2012; Herrmann, Carl/AAR-3167-2020; Eils, Roland/B-6121-2009; Junge, Kristin M/L-2630-2019; Trump, Saskia/ABG-5182-2021	Ishaque, Naveed/0000-0002-8426-901X; Rippe, Karsten/0000-0001-9951-9395; Herrmann, Carl/0000-0003-4989-4722; Eils, Roland/0000-0002-0034-4036; Lehmann, Irina/0000-0001-8875-5587; Thurmann, Loreen/0000-0003-1109-1924; Trump, Saskia/0000-0002-9894-1807; Mallm, Jan-Philipp/0000-0002-7059-4030; Junge, Kristin/0000-0001-5016-110X; Bauer, Tobias/0000-0002-4961-3639; Herberth, Gunda/0000-0003-0212-3509				Fetahu IS, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00164; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Herberth G, 2010, ALLERGY, V65, P645; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Miyake Y, 2014, ANN ALLERG ASTHMA IM, V113, P82, DOI 10.1016/j.anai.2014.04.023; Ramagopalan SV, 2010, GENOME RES, V20, P1352, DOI 10.1101/gr.107920.110; Takai T, 2012, ALLERGOL INT, V61, P3, DOI 10.2332/allergolint.11-RAI-0395; Weisse K, 2013, ALLERGY, V68, P220, DOI 10.1111/all.12081; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183	9	31	31	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					610	613		10.1016/j.jaci.2015.06.040	http://dx.doi.org/10.1016/j.jaci.2015.06.040			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26282283				2022-12-18	WOS:000369235500032
J	Bouley, J; Groeme, R; Le Mignon, M; Jain, K; Chabre, H; Bordas-Le Floch, V; Couret, MN; Bussieres, L; Lautrette, A; Naveau, M; Baron-Bodo, V; Lombardi, V; Mascarell, L; Batard, T; Nony, E; Moingeon, P				Bouley, Julien; Groeme, Rachel; Le Mignon, Maxime; Jain, Karine; Chabre, Henri; Bordas-Le Floch, Veronique; Couret, Marie-Noelle; Bussieres, Laetitia; Lautrette, Aurelie; Naveau, Marie; Baron-Bodo, Veronique; Lombardi, Vincent; Mascarell, Laurent; Batard, Thierry; Nony, Emmanuel; Moingeon, Philippe			Identification of the cysteine protease Amb a 11 as a novel major allergen from short ragweed	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; Amb a 11; Ambrosia artemisiifolia; cysteine protease; mass spectrometry; short ragweed	CONTROLLED-TRIAL; MUGWORT POLLEN; IMMUNOTHERAPY; RESPONSES; SEQUENCE; IGE; SENSITIZATION; RECOGNITION; MECHANISMS; PROTEINS	Background: Allergy to pollen from short ragweed (Ambrosia artemisiifolia) is a serious and expanding health problem in the United States and in Europe. Objective: We sought to investigate the presence of undescribed allergens in ragweed pollen. Methods: Ragweed pollen proteins were submitted to high-resolution gel electrophoresis and tested for IgE reactivity by using sera from 92 American or European donors with ragweed allergy. Pollen transcriptome sequencing, mass spectrometry (MS), and recombinant DNA technologies were applied to characterize new IgE-binding proteins. Results: High-resolution IgE immunoblotting experiments revealed that 50 (54%) of 92 patients with ragweed allergy were sensitized to a 37-kDa allergen distinct from Amb a 1. The full-length cDNA sequence for this molecule was obtained by means of PCR cloning after MS sequencing of the protein combined with ragweed pollen RNA sequencing. The purified allergen, termed Amb a 11, was fully characterized by MS and confirmed to react with IgEs from 66% of patients. This molecule is a 262-amino-acid thiol protease of the papain family expressed as a combination of isoforms and glycoforms after proteolytic removal of N- and C-terminal propeptides from a proform. Three-dimensional modeling revealed a high structural homology with known cysteine proteases, including the mite Der p 1 allergen. The protease activity of Amb a 11, as well as its capacity to activate basophils from patients with ragweed allergy, were confirmed. The production of a nonglycosylated recombinant form of Amb a 11 in Escherichia coli established that glycosylation is not required for IgE binding. Conclusion: We identified the cysteine protease Amb a 11 as a new major allergen from ragweed pollen. Given the similar physicochemical properties shared by the 2 major allergens, we hypothesize that part of the allergenic activity previously ascribed to Amb a 1 is rather borne by Amb a 11.	[Bouley, Julien; Groeme, Rachel; Le Mignon, Maxime; Jain, Karine; Chabre, Henri; Bordas-Le Floch, Veronique; Couret, Marie-Noelle; Bussieres, Laetitia; Lautrette, Aurelie; Naveau, Marie; Baron-Bodo, Veronique; Lombardi, Vincent; Mascarell, Laurent; Batard, Thierry; Nony, Emmanuel; Moingeon, Philippe] Stallergenes, Res & Dev, F-92183 Antony, France	Stallergenes Greer	Moingeon, P (corresponding author), Stallergenes, Res & Dev, 6 Rue Alexis Tocqueville, F-92183 Antony, France.	pmoingeon@stallergenes.com		Nony, Emmanuel/0000-0003-1820-8881				Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Asero R, 2006, CLIN EXP ALLERGY, V36, P658, DOI 10.1111/j.1365-2222.2006.02477.x; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Chruszcz M, 2012, J BIOL CHEM, V287, P7388, DOI 10.1074/jbc.M111.311159; Chruszcz M, 2009, J MOL BIOL, V386, P520, DOI 10.1016/j.jmb.2008.12.049; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; Creticos PS, 2014, J ALLERGY CLIN IMMUN, V133, P751, DOI 10.1016/j.jaci.2013.10.041; Creticos PS, 2013, J ALLERGY CLIN IMMUN, V131, P1342, DOI 10.1016/j.jaci.2013.03.019; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; Gadermaier G, 2008, ALLERGY, V63, P1543, DOI 10.1111/j.1398-9995.2008.01780.x; Gadermaier G, 2014, METHODS, V66, P55, DOI 10.1016/j.ymeth.2013.06.014; GHOSH B, 1994, J IMMUNOL, V152, P2882; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grudkowska M, 2004, ACTA BIOCHIM POL, V51, P609; Gunawan H, 2008, INT ARCH ALLERGY IMM, V147, P276, DOI 10.1159/000144035; HUNT LT, 1985, J MOL EVOL, V21, P126, DOI 10.1007/BF02100086; Jahn-Schmid B, 2012, J IMMUNOL, V188, P1559, DOI 10.4049/jimmunol.1102445; Kamijo S, 2013, J IMMUNOL, V190, P4489, DOI 10.4049/jimmunol.1201212; Kikuchi Y, 2006, J IMMUNOL, V177, P1609, DOI 10.4049/jimmunol.177.3.1609; KLAPPER DG, 1980, BIOCHEMISTRY-US, V19, P5729, DOI 10.1021/bi00566a010; Le TM, 2013, J ALLERGY CLIN IMMUN, V131, P164, DOI 10.1016/j.jaci.2012.09.009; Leonard R, 2010, J BIOL CHEM, V285, P27192, DOI 10.1074/jbc.M110.127118; Malandain H, 2007, Eur Ann Allergy Clin Immunol, V39, P216; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Moingeon P, 2013, J ALLER CL IMM-PRACT, V1, P228, DOI 10.1016/j.jaip.2013.03.013; Nandy A, 2013, J ALLERGY CLIN IMMUN, V131, pAB16, DOI 10.1016/j.jaci.2012.12.736; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, P660, DOI 10.1016/j.jaci.2009.12.931; Takai T, 2005, J ALLERGY CLIN IMMUN, V115, P555, DOI 10.1016/j.jaci.2004.11.024; Takai Toshiro, 2011, Allergology International, V60, P25, DOI 10.2332/allergolint.10-RAI-0273; Than ME, 2004, J MOL BIOL, V336, P1103, DOI 10.1016/j.jmb.2003.12.075; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Wopfner N, 2008, ALLERGY, V63, P872, DOI 10.1111/j.1398-9995.2008.01635.x; Wopfner N, 2005, INT ARCH ALLERGY IMM, V138, P337, DOI 10.1159/000089188; Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108	37	31	32	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1055	1064		10.1016/j.jaci.2015.03.001	http://dx.doi.org/10.1016/j.jaci.2015.03.001			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25865353	Bronze			2022-12-18	WOS:000362976300024
J	Niederberger, V; Marth, K; Eckl-Dorna, J; Focke-Tejkl, M; Weber, M; Hemmer, W; Berger, U; Neubauer, A; Stolz, F; Henning, R; Valenta, R				Niederberger, Verena; Marth, Katharina; Eckl-Dorna, Julia; Focke-Tejkl, Margarete; Weber, Milena; Hemmer, Wolfgang; Berger, Uwe; Neubauer, Angela; Stolz, Frank; Henning, Rainer; Valenta, Rudolf			Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOTHERAPY; INFLAMMATION		[Niederberger, Verena; Marth, Katharina; Eckl-Dorna, Julia; Berger, Uwe] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Otorhinolaryngol, Vienna, Austria; [Marth, Katharina; Focke-Tejkl, Margarete; Weber, Milena; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Hemmer, Wolfgang] FAZ Floridsdorf Allergy Ctr, Vienna, Austria; [Neubauer, Angela; Stolz, Frank; Henning, Rainer] Biomay AG, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Niederberger, V (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Otorhinolaryngol, Vienna, Austria.	verena.niederberger@meduniwien.ac.at	Eckl-Dorna, Julia/AAY-6371-2020	Valenta, Rudolf/0000-0001-5944-3365; Eckl-Dorna, Julia/0000-0001-5981-1607	Austrian Science Fund FWF [F 4605] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Focke-Tejkl M, 2015, J ALLERGY CLIN IMMUN, V135, P1207, DOI 10.1016/j.jaci.2014.09.012; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Mudway IS, 2004, AM J RESP CRIT CARE, V169, P1089, DOI 10.1164/rccm.200309-1325PP; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Pellaton Celine, 2013, Clin Transl Allergy, V3, P17, DOI 10.1186/2045-7022-3-17; Stenfors N, 2010, INHAL TOXICOL, V22, P133, DOI 10.3109/08958370903005736; Valenta R, 2012, J INTERN MED, V272, P144, DOI 10.1111/j.1365-2796.2012.02556.x; Winther L, 2000, ALLERGY, V55, P827, DOI 10.1034/j.1398-9995.2000.00368.x	9	31	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1101	1103		10.1016/j.jaci.2015.03.034	http://dx.doi.org/10.1016/j.jaci.2015.03.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26048664	Bronze, Green Accepted			2022-12-18	WOS:000362976300032
J	Xiao, C; Myers, JMB; Ji, H; Metz, K; Martin, LJ; Lindsey, M; He, H; Powers, R; Ulm, A; Ruff, B; Ericksen, MB; Somineni, HK; Simmons, J; Strait, RT; Kercsmar, CM; Hershey, GKK				Xiao, Chang; Myers, Jocelyn M. Biagini; Ji, Hong; Metz, Kelly; Martin, Lisa J.; Lindsey, Mark; He, Hua; Powers, Racheal; Ulm, Ashley; Ruff, Brandy; Ericksen, Mark B.; Somineni, Hari K.; Simmons, Jeffrey; Strait, Richard T.; Kercsmar, Carolyn M.; Hershey, Gurjit K. Khurana			Vanin-1 expression and methylation discriminate pediatric asthma corticosteroid treatment response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; biomarker; vanin-1; treatment response; phenotype	ENHANCER-BLOCKING ACTIVITY; DNA HYPOMETHYLATION; CHILDHOOD ASTHMA; GENE; CTCF; SUBPHENOTYPES	Background: There is considerable heterogeneity in asthma treatment response. Objective: We sought to identify biomarkers of corticosteroid treatment response in children with asthma and evaluate the utility and mechanistic basis of these biomarkers. Methods: Children (5-18 years) presenting to the emergency department with an acute asthma exacerbation were recruited and followed during hospitalization. Nasal epithelial cells were collected on presentation to the emergency department (T-0) and 18 to 24 hours later (T-1), and T-1/T-0 gene expression ratios were analyzed to identify genes associated with good and poor corticosteroid treatment response phenotypes. The utility of these genes in discriminating between systemic corticosteroid treatment response groups was then tested prospectively in a new cohort of patients. A gene candidate (vanin-1 [VNN1]) that consistently distinguished good versus poor response phenotypes was further studied in an experimental asthma model, and VNN1 promoter methylation was measured by means of bisulfite pyrosequencing in patients. Results: VNN1 mRNA expression changes were associated with systemic corticosteroid treatment response in children with acute asthma, and VNN1 was required for optimal response to corticosteroid treatment in an experimental asthma model. A CpG site within the VNN1 promoter was differentially methylated between good versus poor treatment response groups, and methylation at this site correlated with VNN1 mRNA expression. Conclusions: We have identified a biological basis for poor corticosteroid treatment response that can be used to distinguish a subgroup of asthmatic children who respond poorly to systemic corticosteroid treatment. VNN1 contributes to corticosteroid responsiveness, and changes in VNN1 nasal epithelial mRNA expression and VNN1 promoter methylation might be clinically useful biomarkers of treatment response in asthmatic children.	[Xiao, Chang; Myers, Jocelyn M. Biagini; Ji, Hong; Lindsey, Mark; Powers, Racheal; Ulm, Ashley; Ruff, Brandy; Ericksen, Mark B.; Somineni, Hari K.; Hershey, Gurjit K. Khurana] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH USA; [Metz, Kelly] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA; [Martin, Lisa J.; He, Hua] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH USA; [Simmons, Jeffrey] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Hosp Med, Cincinnati, OH USA; [Strait, Richard T.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH USA; [Kercsmar, Carolyn M.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Pulm Med, Cincinnati, OH USA; [Kercsmar, Carolyn M.] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Cincinnati	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org	Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946; Biagini, Jocelyn/0000-0002-4378-6133; Ji, Hong/0000-0002-9558-0620; Khurana Hershey, Gurjit/0000-0001-6663-977X	NCATS NIH HHS [UL1 TR001425] Funding Source: Medline; NIAID NIH HHS [U19 AI070235, 2U19AI70235, R21AI101375, R21 AI101375] Funding Source: Medline; NIEHS NIH HHS [T32 ES010957] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235, R21AI101375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES010957] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akinbami, 2006, STATE CHILDHOOD ASTH, V381; Akinbami Lara J, 2012, NCHS Data Brief, P1; [Anonymous], EV BAS CAR GUID MAN; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bel EH, 2013, NEW ENGL J MED, V369, P2362, DOI [10.1056/NEJMc1313111, 10.1056/NEJMc.1313111]; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bell MC, 2013, J ALLER CL IMM-PRACT, V1, P110, DOI 10.1016/j.jaip.2013.01.005; Berruyer C, 2004, MOL CELL BIOL, V24, P7214, DOI 10.1128/MCB.24.16.7214-7224.2004; Berruyer C, 2006, J EXP MED, V203, P2817, DOI 10.1084/jem.20061640; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Desai D, 2009, CLIN EXP IMMUNOL, V158, P10, DOI 10.1111/j.1365-2249.2009.03998.x; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Fassl BA, 2012, PEDIATRICS, V130, P482, DOI 10.1542/peds.2011-3318; Gensollen T, 2013, INFLAMM BOWEL DIS, V19, P2315, DOI 10.1097/MIB.0b013e3182a32b03; Gerhardt WE, 2007, JT COMM J QUAL PATIE, V33, P226, DOI 10.1016/S1553-7250(07)33027-4; Guajardo JR, 2005, J ALLERGY CLIN IMMUN, V115, P243, DOI 10.1016/j.jaci.2004.10.032; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111; Hu SH, 2013, ELIFE, V2, DOI 10.7554/eLife.00726; Huang YS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002234; Kovacic MB, 2012, PEDIAT ALLER IMM PUL, V25, P104, DOI 10.1089/ped.2011.0116; Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443; Lewis CC, 2009, J ALLERGY CLIN IMMUN, V123; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P267, DOI 10.1016/j.jaci.2010.05.031; Muething SE, 2005, J PEDIATR-US, V147, P568, DOI 10.1016/j.jpeds.2005.08.058; Nan XS, 1998, CIBA F SYMP, V214, P6; Pitari G, 2000, FEBS LETT, V483, P149, DOI 10.1016/S0014-5793(00)02110-4; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Ripley BD., 1996; Sanchez-Munoz F, 2013, LUPUS, V22, P333, DOI 10.1177/0961203312474085; Wagner JR, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r37; Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhang B, 2011, BLOOD, V117, P4569, DOI 10.1182/blood-2010-09-304931; Zimmermann N, 2004, J IMMUNOL, V172, P1815, DOI 10.4049/jimmunol.172.3.1815	43	31	32	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					923	+		10.1016/j.jaci.2015.01.045	http://dx.doi.org/10.1016/j.jaci.2015.01.045			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25910714	Green Accepted			2022-12-18	WOS:000362976300011
J	Yamanaka, K; Mizutani, H				Yamanaka, Keiichi; Mizutani, Hitoshi			"Inflammatory skin march'': IL-1-mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Yamanaka, Keiichi; Mizutani, Hitoshi] Mie Univ, Grad Sch Med, Dept Dermatol, Tsu, Mie 514, Japan	Mie University	Yamanaka, K (corresponding author), Mie Univ, Grad Sch Med, Dept Dermatol, Tsu, Mie 514, Japan.	yamake@clin.medic.mie-u.ac.jp						Boehncke WH, 2011, EXP DERMATOL, V20, P303, DOI 10.1111/j.1600-0625.2011.01261.x; Prodanovich S, 2009, ARCH DERMATOL, V145, P700, DOI 10.1001/archdermatol.2009.94; Silverberg JI, 2015, J ALLERGY CLIN IMMUN, V135, P721, DOI 10.1016/j.jaci.2014.11.023; Yamanaka K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104479	4	31	32	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					823	+		10.1016/j.jaci.2015.06.009	http://dx.doi.org/10.1016/j.jaci.2015.06.009			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26220527				2022-12-18	WOS:000360913300045
J	Yaseen, FS; Saide, K; Kim, SH; Monshi, M; Tailor, A; Wood, S; Meng, XL; Jenkins, R; Faulkner, L; Daly, AK; Pirmohamed, M; Park, BK; Naisbitt, DJ				Yaseen, Fiazia S.; Saide, Katy; Kim, Seung-Hyun; Monshi, Manal; Tailor, Arun; Wood, Sally; Meng, Xiaoli; Jenkins, Rosalind; Faulkner, Lee; Daly, Ann K.; Pirmohamed, Munir; Park, B. Kevin; Naisbitt, Dean J.			Promiscuous T-cell responses to drugs and drug-haptens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INDUCED LIVER-INJURY; IN-VITRO; FLUCLOXACILLIN; HYPERSENSITIVITY; REACTIVITY		[Yaseen, Fiazia S.; Saide, Katy; Kim, Seung-Hyun; Monshi, Manal; Tailor, Arun; Wood, Sally; Meng, Xiaoli; Jenkins, Rosalind; Faulkner, Lee; Pirmohamed, Munir; Park, B. Kevin; Naisbitt, Dean J.] Univ Liverpool, Ctr Drug Safety Sci, MRC, Dept Clin & Mol Pharmacol, Liverpool L69 3BX, Merseyside, England; [Kim, Seung-Hyun] Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Suwon 441749, South Korea; [Daly, Ann K.] Newcastle Univ, Sch Med, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Liverpool; Ajou University; Newcastle University - UK	Yaseen, FS (corresponding author), Univ Liverpool, Ctr Drug Safety Sci, MRC, Dept Clin & Mol Pharmacol, Liverpool L69 3BX, Merseyside, England.	dnes@liv.ac.uk	Pirmohamed, Munir/H-6004-2011; Daly, Ann/H-3144-2011	Pirmohamed, Munir/0000-0002-7534-7266; Daly, Ann/0000-0002-7321-0629; Kim, Seung-Hyun/0000-0003-1789-8964; Tailor, Arun/0000-0002-9698-3480; Naisbitt, Dean/0000-0003-4107-7832	MRC [MR/L006758/1] Funding Source: UKRI; Medical Research Council [MR/L006758/1] Funding Source: Medline; Department of Health [NF-SI-0512-10064] Funding Source: Medline; National Institute for Health Research [NF-SI-0512-10064] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))		Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; Faulkner L, 2012, TOXICOL SCI, V127, P150, DOI 10.1093/toxsci/kfs080; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Jenkins RE, 2009, PROTEOM CLIN APPL, V3, P720, DOI 10.1002/prca.200800222; Lucena MI, 2011, GASTROENTEROLOGY, V141, P338, DOI 10.1053/j.gastro.2011.04.001; Monshi MM, 2013, HEPATOLOGY, V57, P727, DOI 10.1002/hep.26077; Mushtaq K, 2014, AMINO ACIDS, V46, P1265, DOI 10.1007/s00726-014-1692-4; Phillips EJ, 2011, J ALLERGY CLIN IMMUN, V127, pS60, DOI 10.1016/j.jaci.2010.11.046; Whitaker P, 2011, J IMMUNOL, V187, P200, DOI 10.4049/jimmunol.1100647; Wu Y, 2007, J ALLERGY CLIN IMMUN, V119, P973, DOI 10.1016/j.jaci.2006.12.617; Wuillemin N, 2013, J IMMUNOL, V190, P4956, DOI 10.4049/jimmunol.1202949; Yun J, 2014, J IMMUNOL, V192, P2984, DOI 10.4049/jimmunol.1302306	13	31	33	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					474	+		10.1016/j.jaci.2015.02.036	http://dx.doi.org/10.1016/j.jaci.2015.02.036			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25910715	Green Submitted			2022-12-18	WOS:000359004900029
J	Asero, R				Asero, Riccardo			Plasma D-dimer levels and clinical response to ciclosporin in severe chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC IDIOPATHIC URTICARIA; RESISTANT CHRONIC URTICARIA; TISSUE FACTOR; DOUBLE-BLIND; COAGULATION		Clin San Carlo, Ambulatorio Allergol, Paderno Dugnano, MI, Italy		Asero, R (corresponding author), Clin San Carlo, Ambulatorio Allergol, Paderno Dugnano, MI, Italy.	r.asero@libero.it						Asero R, 2008, ALLERGY, V63, P176, DOI 10.1111/j.1398-9995.2007.01514.x; Asero R, 2010, J INVEST ALLERG CLIN, V20, P386; Asero R, 2007, J ALLERGY CLIN IMMUN, V119, P705, DOI 10.1016/j.jaci.2006.08.043; Asero R, 2013, J ALLERGY CLIN IMMUN, V132, P983, DOI 10.1016/j.jaci.2013.04.037; Baiardini I, 2003, ALLERGY, V58, P621, DOI 10.1034/j.1398-9995.2003.00091.x; Cugno M, 2009, INT ARCH ALLERGY IMM, V148, P170, DOI 10.1159/000155748; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; Takeda T, 2011, ALLERGY, V66, P428, DOI 10.1111/j.1398-9995.2010.02506.x; Toubi E, 1997, ALLERGY, V52, P312, DOI 10.1111/j.1398-9995.1997.tb00996.x; Vena GA, 2006, J AM ACAD DERMATOL, V55, P705, DOI 10.1016/j.jaad.2006.04.078	10	31	31	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1401	1403		10.1016/j.jaci.2014.11.016	http://dx.doi.org/10.1016/j.jaci.2014.11.016			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25542882				2022-12-18	WOS:000353980700040
J	Dixon, AE; Dixon, AE; Castro, M; Cohen, RI; Gerald, LB; Holbrook, JT; Irvin, CG; Mohapatra, S; Peters, SP; Rayapudi, S; Sugar, EA; Wise, RA				Dixon, Anne E.; Dixon, Anne E.; Castro, Mario; Cohen, Rubin I.; Gerald, Lynn B.; Holbrook, Janet T.; Irvin, Charles G.; Mohapatra, Shyam; Peters, Stephen P.; Rayapudi, Sobharani; Sugar, Elizabeth A.; Wise, Robert A.		Amer Lung Assoc-Asthma Clinical	Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; rhinitis; sinusitis; sinonasal; asthma control; lung function; asthma exacerbation	QUALITY-OF-LIFE; ALLERGIC RHINITIS; CHRONIC RHINOSINUSITIS; BRONCHIAL RESPONSIVENESS; FLUTICASONE PROPIONATE; RESOURCE USE; CHILDREN; INFLAMMATION; INTRANASAL; SINUSITIS	Background: Chronic sinonasal disease is common in asthmatic patients and associated with poor asthma control; however, there are no long-term trials addressing whether chronic treatment of sinonasal disease improves asthma control. Objective: We sought to determine whether treatment of chronic sinonasal disease with nasal corticosteroids improves asthma control, as measured by the Childhood Asthma Control Test and Asthma Control Test in children and adults, respectively. Methods: A 24-week multicenter, randomized, placebo-controlled, double-blind trial of placebo versus nasal mometasone in adults and children with inadequately controlled asthma was performed. Treatments were randomly assigned, with concealment of allocation. Results: Two hundred thirty-seven adults and 151 children were randomized to nasal mometasone versus placebo, and 319 participants completed the study. There was no difference in the Childhood Asthma Control Test score (difference in change with mometasone 2 change with placebo [Delta M - Delta P], -0.38; 95% CI, -2.19 to 1.44; P = .68; age 6-11 years) or the Asthma Control Test score (Delta M - Delta P, 0.51; 95% CI, -0.46 to 1.48; P =.30; age >= 12 years) in those assigned to mometasone versus placebo. In children and adolescents (age 6-17 years) therewas nodifference in asthma or sinus symptoms but a decrease in episodes of poorly controlled asthmadefined by adecrease in peakflow. In adults therewas a small difference in asthma symptoms measured by using the Asthma Symptom Utility Index (Delta M - Delta P, 0.06; 95% CI, 0.01 to 0.11; P <.01) and in nasal symptoms (sinus symptom score Delta M - Delta P, -3.82; 95% CI, -7.19 to -0.45; P =.03) but nodifference in asthma quality of life, lung function, or episodes of poorly controlled asthma in adults assigned to mometasone versus placebo. Conclusions: Treatment of chronic sinonasal disease with nasal corticosteroids for 24 weeks does not improve asthma control. Treatment of sinonasal disease in asthmatic patients should be determined by the need to treat sinonasal disease rather than to improve asthma control.	[Dixon, Anne E.; Irvin, Charles G.] Univ Vermont, Dept Med, Burlington, VT 05405 USA; [Castro, Mario] Washington Univ, Sch Med, Dept Med, St Louis, MO 63130 USA; [Cohen, Rubin I.] North Shore Long Isl Jewish Sch Med, Thalheim Asthma Ctr Hofstra, New Hyde Pk, NY USA; [Gerald, Lynn B.] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Arizona Resp Ctr, Tucson, AZ USA; [Holbrook, Janet T.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA; [Rayapudi, Sobharani; Wise, Robert A.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Sugar, Elizabeth A.] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA; [Mohapatra, Shyam] Univ S Florida, Dept Med, Tampa, FL USA; [Peters, Stephen P.] Wake Forest Univ, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27109 USA	University of Vermont; Washington University (WUSTL); Northwell Health; University of Arizona; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; State University System of Florida; University of South Florida; Wake Forest University	Dixon, AE (corresponding author), Univ Vermont, Pulm & Crit Care, 792 Coll Pkwy,MOB 105, Colchester, VT 05446 USA.	anne.dixon@vtmednet.org	Cohen, Rubin I/ABC-2650-2021	, Rubin/0000-0002-1257-391X; Wise, Robert/0000-0002-8353-2349; Land, Michael/0000-0001-8016-5419; Castro, Mario/0000-0001-6328-8994	National Heart, Lung, and Blood Institute [UO1HL089464, U01 HL089510, UL1 TR000448]; American Lung Association; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL089510, U01HL089464] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Lung Association; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Heart, Lung, and Blood Institute (UO1HL089464 and U01 HL089510, UL1 TR000448) and the American Lung Association. Study drug and placebo were provided by Merck.	Abdalla S, 2012, CLIN OTOLARYNGOL, V37, P276, DOI 10.1111/j.1749-4486.2012.02527.x; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Asmussen L, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e71; AUBIER M, 1992, AM REV RESPIR DIS, V146, P122, DOI 10.1164/ajrccm/146.1.122; Bonay M, 2006, ALLERGY, V61, P111, DOI 10.1111/j.1398-9995.2006.00967.x; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P723, DOI 10.1111/j.1365-2222.2005.02251.x; Bousquet J, 2004, CLIN EXP ALLERGY, V34, P897, DOI 10.1111/j.1365-2222.2004.01969.x; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; BRUGMAN SM, 1993, AM REV RESPIR DIS, V147, P314, DOI 10.1164/ajrccm/147.2.314; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; Corren J, 2004, J ALLERGY CLIN IMMUN, V113, P415, DOI 10.1016/j.jaci.2003.11.034; Dahl R, 2005, ALLERGY, V60, P875, DOI 10.1111/j.1398-9995.2005.00819.x; Dixon AE, 2006, CHEST, V130, P429, DOI 10.1378/chest.130.2.429; Dixon AE, 2009, CHEST, V136, P1324, DOI 10.1378/chest.08-1983; Dunlop G, 1999, AM J RHINOL, V13, P261, DOI 10.2500/105065899782102809; Erwin EA, 2011, AM J RHINOL ALLERGY, V25, P327, DOI 10.2500/ajra.2011.25.3640; Georgalas C, 2010, PEDIAT ALLERG IMM-UK, V21, pE119, DOI 10.1111/j.1399-3038.2009.00934.x; Gillett S, 2009, CLIN OTOLARYNGOL, V34, P467, DOI 10.1111/j.1749-4486.2009.01975.x; Holbrook JT, 2012, JAMA-J AM MED ASSOC, V307, P373, DOI 10.1001/jama.2011.2035; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Katial RK, 2010, ALLERGY ASTHMA PROC, V31, P68, DOI 10.2500/aap.2010.31.3306; Kay DJ, 2003, OTOLARYNG HEAD NECK, V128, P17, DOI 10.1067/mhn.2003.41; Kocevar VS, 2005, ALLERGY, V60, P338, DOI 10.1111/j.1398-9995.2005.00712.x; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; Meltzer EO, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-5; Nathan RA, 2005, CHEST, V128, P1910, DOI 10.1378/chest.128.4.1910; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; NOLTE D, 1983, EUR J RESPIR DIS, V64, P110; Passariello A, 2012, AM J RHINOL ALLERGY, V26, pE15, DOI 10.2500/ajra.2012.26.3733; Pedroletti C, 2008, PEDIATR ALLERGY IMMU, V19, P219, DOI 10.1111/j.1399-3038.2007.00613.x; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920, DOI 10.1164/ajrccm.162.3.9912030; Ragab S, 2006, EUR RESPIR J, V28, P68, DOI 10.1183/09031936.06.00043305; Raithatha R, 2012, INT FORUM ALLERGY RH, V2, P144, DOI 10.1002/alr.21009; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Stelmach R, 2005, CHEST, V128, P3140, DOI 10.1378/chest.128.5.3140; Taegtmeyer AB, 2009, CURR MED RES OPIN, V25, P1073, DOI 10.1185/03007990902820733 ; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Thio BJ, 2000, THORAX, V55, P826, DOI 10.1136/thorax.55.10.826; Thomas M, 2005, PEDIATRICS, V115, P129, DOI 10.1542/peds.2004-0067; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Walker FDL, 2000, CLIN OTOLARYNGOL, V25, P482, DOI 10.1046/j.1365-2273.2000.00349.x; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U	47	31	31	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					701	+		10.1016/j.jaci.2014.06.038	http://dx.doi.org/10.1016/j.jaci.2014.06.038			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25174863	Green Accepted, Bronze			2022-12-18	WOS:000351065000016
J	Hannula-Jouppi, K; Laasanen, SL; Heikkila, H; Tuomiranta, M; Tuomi, ML; Hilvo, S; Kluger, N; Kivirikko, S; Hovnanian, A; Makinen-Kiljunen, S; Ranki, A				Hannula-Jouppi, Katariina; Laasanen, Satu-Leena; Heikkila, Hannele; Tuomiranta, Mirja; Tuomi, Marja-Leena; Hilvo, Sirpa; Kluger, Nicolas; Kivirikko, Sirpa; Hovnanian, Alain; Makinen-Kiljunen, Soili; Ranki, Annamari			IgE allergen component-based profiling and atopic manifestations in patients with Netherton syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DERMATITIS; CHILDREN		[Hannula-Jouppi, Katariina; Heikkila, Hannele; Kluger, Nicolas; Ranki, Annamari] Helsinki Univ Cent Hosp HUCH, Univ Helsinki & Skin & Allergy Hosp, Dept Dermatol & Allergol, Helsinki, Finland; [Hannula-Jouppi, Katariina] Univ Helsinki, Folkhalsan Inst Genet, Helsinki, Finland; [Laasanen, Satu-Leena; Tuomi, Marja-Leena] Tampere Univ Hosp, Dept Dermatol, Tampere, Finland; [Tuomiranta, Mirja] Seinajoki Cent Hosp, Dept Dermatol, Seinajoki, Finland; [Hilvo, Sirpa; Makinen-Kiljunen, Soili] HUCH, Skin & Allergy Hosp, Dept Allergol, Helsinki, Finland; [Kivirikko, Sirpa] HUCH, Dept Clin Genet, Helsinki, Finland; [Hovnanian, Alain] Necker Hosp Sick Children, INSERM UMR 1163, Lab Genet Skin Dis, Paris, France; [Hovnanian, Alain] Necker Hosp Sick Children, Paris Descartes Univ, Imagine Inst, Sorbonne Paris Cite, Paris, France; [Hovnanian, Alain] Necker Hosp Sick Children, Dept Genet, Paris, France	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Tampere University; Tampere University Hospital; Seinajoki Central Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Hannula-Jouppi, K (corresponding author), Helsinki Univ Cent Hosp HUCH, Univ Helsinki & Skin & Allergy Hosp, Dept Dermatol & Allergol, Helsinki, Finland.	Katariina.Hannula-Jouppi@hus.fi	Kluger, Nicolas/L-4220-2019; Hannula-Jouppi, Katariina SE/F-4476-2011; Hovnanian, Alain/I-4711-2017	Kluger, Nicolas/0000-0002-5225-8316; Hovnanian, Alain/0000-0003-3412-7512; Hannula-Jouppi, Katariina/0000-0003-3864-2853				Fortugno P, 2012, HUM MOL GENET, V21, P4187, DOI 10.1093/hmg/dds243; Fruth K, 2012, LARYNGOSCOPE, V122, P1198, DOI 10.1002/lary.23300; Hovnanian A, 2013, CELL TISSUE RES, V351, P289, DOI 10.1007/s00441-013-1558-1; Onell Annica, 2012, Clin Transl Allergy, V2, P24, DOI 10.1186/2045-7022-2-24; Ott H, 2014, J EUR ACAD DERMATOL, V28, P100, DOI 10.1111/jdv.12083; Pastore S, 2012, ALLERGOL IMMUNOPATH, V40, P316, DOI 10.1016/j.aller.2011.07.005; Sastre J, 2010, CLIN EXP ALLERGY, V40, P1442, DOI 10.1111/j.1365-2222.2010.03585.x; Scala E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024912; Sorser SA, 2013, J GASTROENTEROL, V48, P81, DOI 10.1007/s00535-012-0608-x	9	31	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					985	988		10.1016/j.jaci.2014.07.008	http://dx.doi.org/10.1016/j.jaci.2014.07.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25159469				2022-12-18	WOS:000343155700037
J	Tsoumakidou, M; Tousa, S; Semitekolou, M; Panagiotou, P; Panagiotou, A; Morianos, I; Litsiou, E; Trochoutsou, AI; Konstantinou, M; Potaris, K; Footitt, J; Mallia, P; Zakynthinos, S; Johnston, SL; Xanthou, G				Tsoumakidou, Maria; Tousa, Sofia; Semitekolou, Maria; Panagiotou, Panagiota; Panagiotou, Anna; Morianos, Ioannis; Litsiou, Eleni; Trochoutsou, Aikaterini I.; Konstantinou, Maria; Potaris, Konstantinos; Footitt, Joseph; Mallia, Patrick; Zakynthinos, Spyros; Johnston, Sebastian L.; Xanthou, Georgina			Tolerogenic signaling by pulmonary CD1c(+) dendritic cells induces regulatory T cells in patients with chronic obstructive pulmonary disease by IL-27/IL-10/inducible costimulator ligand	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic obstructive pulmonary disease; dendritic cells; regulatory T cells; IL-27; IL-10; inducible costimulator ligand	AIRWAY INFLAMMATION; NEUTROPHIL ELASTASE; RHINOVIRUS INFECTION; CD40/CD154 BLOCKADE; HUMAN LUNG; COPD; IL-27; DIFFERENTIATION; SMOKERS; EXPRESSION	Background: Increased mortality rates in patients with chronic obstructive pulmonary disease (COPD) are largely due to severe infectious exacerbations. Impaired respiratory immunity is linked to the enhanced susceptibility to infections. Dendritic cells (DCs) direct host immune responses toward immunity or tolerance. Pulmonary CD1c(+) DCs elicit robust antiviral immune responses in healthy subjects. Nevertheless, their functional specialization in patients with COPD remains unexplored. Objective: We sought to better understand the mechanisms that suppress respiratory immunity in patients with COPD by examining the immunostimulatory and tolerogenic properties of pulmonary CD1c(+) DCs. Methods: We analyzed the expression of costimulatory and tolerogenic molecules by pulmonary CD1c(+) DCs from patients with COPD (CD1c(+) DCCOPD) and former smokers without COPD. We isolated lung CD1c(+) DCs and determined their ability to stimulate allogeneic T-cell responses. The suppressive effects of lung CD1c(+) DCs and CD1c(+) DC-primed T cells on mixed leukocyte reactions were examined. An experimental human model of COPD exacerbation was used to investigate the levels of critical immunosuppressive molecules in vivo. Results: CD1c(+) DCs from patients with COPD hinder T-cell effector functions and favor the generation of suppressive IL-10-secreting CD4(+) T cells that function through IL-10 and TGF-beta. IL-27, IL-10, and inducible T-cell costimulator ligand signaling are essential for CD1c(+) DCCOPD-mediated differentiation of IL-10-producing suppressive T cells. Exposure of lung CD1c(+) DCs from nonobstructed subjects to lungs of patients with COPD confers tolerogenic properties. IL-27 and IL-10 levels are increased in the lung microenvironment on rhinovirus-induced COPD exacerbation in vivo. Conclusion: We identify a novel tolerogenic circuit encompassing suppressive CD1c(+) DCs and regulatory T cells in patients with COPD that might be implicated in impaired respiratory immunity and further highlight IL-10 and IL-27 as potent therapeutic targets.	[Tsoumakidou, Maria; Panagiotou, Panagiota; Panagiotou, Anna; Litsiou, Eleni; Zakynthinos, Spyros] Univ Athens, Sch Med, Evaggelismos Hosp, Dept Intens Care Med 1, GR-11527 Athens, Greece; [Tousa, Sofia; Semitekolou, Maria; Morianos, Ioannis; Trochoutsou, Aikaterini I.; Xanthou, Georgina] Acad Athens, Biomed Res Fdn, Ctr Basic Res, Cellular Immunol Lab, Athens, Greece; [Konstantinou, Maria; Potaris, Konstantinos] Sotiria Chest Hosp, Athens, Greece; [Footitt, Joseph; Mallia, Patrick; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Infect Sect, London SW7 2AZ, England	Athens Medical School; National & Kapodistrian University of Athens; Academy of Athens; Imperial College London	Xanthou, G (corresponding author), Acad Athens, Ctr Basic Res Fdn Biomed Res, Cellular Immunol Lab, 4 Soranou Efessiou St, Athens 11527, Greece.	tsoumak@yahoo.gr; gxanthou@bioacademy.gr	Johnston, Sebastian Lennox/I-2423-2012; Xanthou, Georgina/AAH-8682-2019	Johnston, Sebastian Lennox/0000-0003-3009-9200; Tsoumakidou, Maria/0000-0001-7959-4793; Semitekolou, Maria/0000-0002-0318-6774; Morianos, Ioannis/0000-0001-5207-0869	Hellenic Thoracic Society; First Department of Intensive Care Medicine of Evaggelismos Hospital; Hellenic Ministries of Health and Education; European Respiratory Society; Medical Research Council [G0600879]; British Medical Association H.C. Roscoe Fellowships; Welcome Trust for the Centre for Respiratory Infection [083567/Z/07/Z]; Imperial College and the National Institute for Health Research (NIHR) Biomedical Research Centre; NIHR Clinical Lecturer; GlaxoSmithKline; Pfizer UK; MRC [G0600879] Funding Source: UKRI; Medical Research Council [G1000758] Funding Source: researchfish; National Institute for Health Research [CL-2008-21-014] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, CH11SJ] Funding Source: researchfish	Hellenic Thoracic Society; First Department of Intensive Care Medicine of Evaggelismos Hospital; Hellenic Ministries of Health and Education; European Respiratory Society; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Medical Association H.C. Roscoe Fellowships; Welcome Trust for the Centre for Respiratory Infection(Wellcome Trust); Imperial College and the National Institute for Health Research (NIHR) Biomedical Research Centre; NIHR Clinical Lecturer; GlaxoSmithKline(GlaxoSmithKline); Pfizer UK(Pfizer); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	Supported by a research grant from the Hellenic Thoracic Society (to M. T.) and by funds from the First Department of Intensive Care Medicine of Evaggelismos Hospital (to S. Z.). G. X. was supported by the Hellenic Ministries of Health and Education and by the "Romain Pauwels Excellence Award'' from the European Respiratory Society. The rhinovirus studies were supported by Medical Research Council Programme Grant G0600879, British Medical Association H.C. Roscoe Fellowships (to J. F. and P. M.), Welcome Trust Grant 083567/Z/07/Z for the Centre for Respiratory Infection, Imperial College and the National Institute for Health Research (NIHR) Biomedical Research Centre funding scheme, the NIHR Clinical Lecturer funding scheme, an unrestricted grant from GlaxoSmithKline, and a grant from Pfizer UK.	Apetoh L, 2010, NAT IMMUNOL, V11, P854, DOI 10.1038/ni.1912; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barcelo B, 2006, CLIN EXP IMMUNOL, V145, P474, DOI 10.1111/j.1365-2249.2006.03167.x; Bratke K, 2008, AM J RESP CELL MOL, V38, P655, DOI 10.1165/rcmb.2007-0400OC; Brusselle GG, 2011, LANCET, V378, P1015, DOI 10.1016/S0140-6736(11)60988-4; Cao J, 2012, CHEST, V141, P121, DOI 10.1378/chest.10-3297; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Demedts IK, 2006, AM J RESP CELL MOL, V35, P387, DOI 10.1165/rcmb.2005-0382OC; Dong SS, 2013, AM J RESP CELL MOL, V48, P518, DOI 10.1165/rcmb.2012-0340OC; Ferrer IR, 2012, J IMMUNOL, V189, P4387, DOI 10.4049/jimmunol.1201757; Ferrer IR, 2011, P NATL ACAD SCI USA, V108, P20701, DOI 10.1073/pnas.1105500108; Freeman CM, 2009, AM J RESP CRIT CARE, V180, P1179, DOI 10.1164/rccm.200904-0552OC; Gamble E, 2007, EUR RESPIR J, V30, P467, DOI 10.1183/09031936.00013006; Gregori S, 2010, BLOOD, V116, P935, DOI 10.1182/blood-2009-07-234872; Ilarregui JM, 2009, NAT IMMUNOL, V10, P981, DOI 10.1038/ni.1772; Kessel CHG, 2008, MUCOSAL IMMUNOL, V1, P442, DOI 10.1038/mi.2008.39; Kroening PR, 2008, J IMMUNOL, V181, P1536, DOI 10.4049/jimmunol.181.2.1536; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Levings MK, 2005, BLOOD, V105, P1162, DOI 10.1182/blood-2004-03-1211; Ma DY, 2009, SEMIN IMMUNOL, V21, P265, DOI 10.1016/j.smim.2009.05.010; Maffia PC, 2007, AM J PATHOL, V171, P928, DOI 10.2353/ajpath.2007.061043; Maldonado RA, 2010, ADV IMMUNOL, V108, P111, DOI [10.1016/B978-0-12-380995-7.00004-5, 10.1016/S0065-2776(10)08004_1]; Mallia P, 2012, AM J RESP CRIT CARE, V186, P1117, DOI 10.1164/rccm.201205-0806OC; Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC; Maneechotesuwan K, 2013, THORAX, V68, P330, DOI 10.1136/thoraxjnl-2012-202127; Manicassamy S, 2011, IMMUNOL REV, V241, P206, DOI 10.1111/j.1600-065X.2011.01015.x; Masten BJ, 2006, J IMMUNOL, V177, P7784, DOI 10.4049/jimmunol.177.11.7784; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; Murugaiyan G, 2012, J IMMUNOL, V189, P5277, DOI 10.4049/jimmunol.1200808; Nouri-Shirazi M, 2012, J IMMUNOL, V188, P2359, DOI 10.4049/jimmunol.1102552; Perera PN, 2012, COPD, V9, P131, DOI 10.3109/15412555.2011.650239; Roghanian A, 2006, AM J RESP CRIT CARE, V174, P1189, DOI 10.1164/rccm.200605-632OC; Rojas D, 2010, IMMUNOL LETT, V132, P31, DOI 10.1016/j.imlet.2010.05.003; Sela U, 2011, J EXP MED, V208, P2489, DOI 10.1084/jem.20110466; Sethi S, 2010, EUR RESPIR J, V35, P1209, DOI 10.1183/09031936.00081409; Shan M, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranlsmed.3000154; Snider JT, 2012, COPD, V9, P513, DOI 10.3109/15412555.2012.696159; Soler N, 1999, EUR RESPIR J, V14, P1015, DOI 10.1183/09031936.99.14510159; Sun J, 2011, NAT IMMUNOL, V12, P327, DOI 10.1038/ni.1996; Tateosian NL, 2011, CELL IMMUNOL, V269, P128, DOI 10.1016/j.cellimm.2011.03.013; Tsoumakidou M, 2008, AM J RESP CRIT CARE, V177, P1180, DOI 10.1164/rccm.200711-1727PP; Tsoumakidou M, 2006, IMMUNOL CELL BIOL, V84, P267, DOI 10.1111/j.1440-1711.2006.01428.x; Tsoumakidou M, 2009, INT ARCH ALLERGY IMM, V150, P389, DOI 10.1159/000226240; Tsoumakidou M, 2009, CHEST, V136, P726, DOI 10.1378/chest.08-2824; Van Pottelberge GR, 2010, EUR RESPIR J, V36, P781, DOI 10.1183/09031936.00140409; Van Pottelberge GR, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-35; Willemse BWM, 2005, EUR RESPIR J, V26, P835, DOI 10.1183/09031936.05.00108904; Yu CI, 2013, IMMUNITY, V38, P818, DOI 10.1016/j.immuni.2013.03.004; Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777	50	31	34	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					944	U282		10.1016/j.jaci.2014.05.045	http://dx.doi.org/10.1016/j.jaci.2014.05.045			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25051954				2022-12-18	WOS:000343155700024
J	Hassan, A; Lee, P; Maggina, P; Xu, JH; Moreira, D; Slatter, M; Nademi, Z; Worth, A; Adams, S; Jones, A; Cale, C; Allwood, Z; Rao, K; Chiesa, R; Amrolia, P; Gaspar, H; Davies, EG; Veys, P; Gennery, A; Qasim, W				Hassan, Amel; Lee, Pamela; Maggina, Paraskevi; Xu, Jin Hua; Moreira, Diana; Slatter, Mary; Nademi, Zohreh; Worth, Austen; Adams, Stuart; Jones, Alison; Cale, Catherine; Allwood, Zoe; Rao, Kanchan; Chiesa, Robert; Amrolia, Persis; Gaspar, Hubert; Davies, E. Graham; Veys, Paul; Gennery, Andrew; Qasim, Waseem			Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; conditioning; natural killer cells; chimerism; engraftment; adenosine deaminase deficiency	BONE-MARROW-TRANSPLANTATION; CONDITIONING REGIMEN; STEM-CELL; SURVIVAL; MUTATION	Background: Severe combined immunodeficiency (SCID) can be cured by using allogeneic hematopoietic stem cell transplantation, and the absence of host immunity often obviates the need for preconditioning. Depending on the underlying genetic defect and when blocks in differentiation occur during lymphocyte ontogeny, infants with SCID have absent or greatly reduced numbers of functional T cells. Natural killer (NK) cell populations are usually absent in the SCID-X1 and Janus kinase 3 forms of SCID and greatly reduced in adenosine deaminase deficiency SCID but often present in other forms of the disorder. Objective: To determine if SCID phenotypes indicate host permissiveness to donor cell engraftment. Methods: A retrospective data analysis considered whether host NK cells influenced donor T-cell engraftment, immune reconstitution, and long-term outcomes in children who had undergone nonconditioned allogeneic stem cell transplantation between 1990 and 2011 in the United Kingdom. Detailed analysis of T- and B-cell immune reconstitution and donor chimerism was compared between the NK+ (n = 24) and NK- (n = 53) forms of SCID. Results: Overall, 77 children underwent transplantation, with survival of 90% in matched sibling donor/matched family donor transplants compared with 60% when alternative donors were used. Infants with NK- SCID were more likely to survive than NK+ recipients (87% vs 62%, P < .01) and had high-level donor T-cell chimerism with superior long-term recovery of CD4 T-cell immunity. Notably, 33% of children with NK+ SCID required additional transplantation procedures compared with only 8% of children with NK- SCID (P < .005). Conclusions: NK- SCID disorders are highly permissive for donor T-cell engraftment without preconditioning, whereas the presence of NK cells is a strong indicator that preparative conditioning is required for engraftment of T-cell precursors capable of supporting robust T-cell reconstitution.	[Hassan, Amel; Xu, Jin Hua; Worth, Austen; Adams, Stuart; Jones, Alison; Cale, Catherine; Allwood, Zoe; Rao, Kanchan; Chiesa, Robert; Veys, Paul] Great Ormond St Hosp Sick Children, Immunol Unit, London WC1N 3JH, England; [Hassan, Amel; Xu, Jin Hua; Worth, Austen; Adams, Stuart; Jones, Alison; Cale, Catherine; Allwood, Zoe; Rao, Kanchan; Chiesa, Robert; Veys, Paul] Great Ormond St Hosp Sick Children, Bone Marrow Transplant Unit, London WC1N 3JH, England; [Lee, Pamela; Amrolia, Persis; Gaspar, Hubert; Davies, E. Graham; Qasim, Waseem] UCL, Inst Child Hlth, London WC1E 6BT, England; [Maggina, Paraskevi; Moreira, Diana; Nademi, Zohreh] Royal Victoria Infirm, Great North Childrens Hosp, Bone Marrow Transplant Unit, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Slatter, Mary; Gennery, Andrew] Univ Newcastle, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Newcastle University - UK; Newcastle University - UK	Qasim, W (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	W.Qasim@ucl.ac.uk	; Lee, Pamela Pui-Wah/C-4331-2009	QASIM, WASEEM/0000-0001-8353-4494; Lee, Pamela Pui-Wah/0000-0002-5934-7338	GOSHCC	GOSHCC	W.Q. and H.G. are supported by GOSHCC trustees.	Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Bertrand Y, 1999, J PEDIATR-US, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; Buckley RH, 2013, J CLIN IMMUNOL, V33, P96, DOI 10.1007/s10875-012-9797-6; Buckley RH, 2010, J ALLERGY CLIN IMMUN, V125, P790, DOI 10.1016/j.jaci.2010.02.012; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Haddad E, 2013, J ALLERGY CLIN IMMUN, V131, P994, DOI 10.1016/j.jaci.2013.01.047; MEUWISSEN HJ, 1969, NEW ENGL J MED, V281, P691, DOI 10.1056/NEJM196909252811302; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Rao K, 2005, BLOOD, V105, P879, DOI 10.1182/blood-2004-03-0960; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Shizuru JA, 2010, BIOL BLOOD MARROW TR, V16, pS2, DOI 10.1016/j.bbmt.2009.11.005; Slatter MA, 2011, BLOOD, V117, P4367, DOI 10.1182/blood-2010-10-312082; Straathof KC, 2009, LANCET, V374, P912, DOI 10.1016/S0140-6736(09)60945-4; Teigland CL, 2013, BONE MARROW TRANSPL, V48, P1050, DOI 10.1038/bmt.2013.6	18	31	33	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1660	1666		10.1016/j.jaci.2014.02.042	http://dx.doi.org/10.1016/j.jaci.2014.02.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24794685	Green Published, hybrid			2022-12-18	WOS:000336672500019
J	Kelso, JM				Kelso, John M.			Potential food allergens in medications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Food allergy; medication allergy; vaccine allergy	IMMEDIATE-TYPE REACTIONS; MUMPS-RUBELLA VACCINE; PROTEINS CONTAMINATING LACTOSE; DRY POWDER INHALERS; INFLUENZA VACCINE; PARENTERAL-NUTRITION; ANAPHYLACTOID REACTIONS; MEASLES-VACCINE; COWS MILK; SYSTEMIC REACTIONS	Excipients are substances in pharmaceuticals other than the active ingredients. Some excipients are foods or substances derived from foods, raising the possibility that these substances would pose a hazard to patients with food allergy. This review describes which food-derived substances are used as pharmaceutical excipients in which medications and reviews published data regarding the safety of the administration of these medications to recipients with food allergy. Such reactions are rare, usually because the amount of food protein is not present in a large enough quantity to elicit a reaction. When a food protein appears as an unintentional contaminant, the amount, if any, that is present might be variable and might elicit reactions only from some lots of medication or only in some patients. In most circumstances these medications should not be routinely withheld from patients who have particular food allergies because most will tolerate the medications uneventfully. However, if a particular patient has had an apparent allergic reaction to the medication, potential allergy to the food component should be investigated.	Scripps Clin, Div Allergy Asthma & Immunol, San Diego, CA 92130 USA	Scripps Research Institute	Kelso, JM (corresponding author), Scripps Clin, Div Allergy Asthma & Immunol, 3811 Valley Ctr Dr, San Diego, CA 92130 USA.	kelso.john@scrippshealth.org			AAAAI; American College of Allergy, Asthma Immunology; American Academy of Pediatrics; American College of Physicians; Symposia Medicus	AAAAI; American College of Allergy, Asthma Immunology; American Academy of Pediatrics; American College of Physicians; Symposia Medicus	J. M. Kelso is a board member of the American Academy of Allergy, Asthma & Immunology (AAAAI); is employed by Scripps Clinic; and has received payment for lectures from the AAAAI, the American College of Allergy, Asthma & Immunology, the American Academy of Pediatrics, the American College of Physicians, and Symposia Medicus.	AICKIN R, 1994, BRIT MED J, V309, P223, DOI 10.1136/bmj.309.6949.223; AITKEN HA, 1988, ANAESTHESIA, V43, P170; [Anonymous], 1999, Ann Allergy Asthma Immunol, V83, P665; [Anonymous], 2006, Prescrire Int, V15, P139; [Anonymous], 2012, GELF PACK INS; [Anonymous], 2009, DIPRIVAN PROP INJ EM; [Anonymous], 2012, FLUCELVAX PACK INS; [Anonymous], 2013, PEDIATRICS 2013; [Anonymous], 2012, RED BOOK REP COMM IN; [Anonymous], 2010, YF VAX PACK INS; [Anonymous], 2006, INTR PACK INS; [Anonymous], 2005, DIPRIVAN PROP INJ EM; [Anonymous], 2005, AUST ADV DRUG REACT, V24, P23; Apostolou E, 2006, ANAESTHESIA, V61, P264, DOI 10.1111/j.1365-2044.2005.04529.x; Berasategui MTA, 2011, J INVEST ALLERG CLIN, V21, P496; AUKRUST L, 1980, ALLERGY, V35, P581, DOI 10.1111/j.1398-9995.1980.tb01808.x; Awazuhara H, 1998, CLIN EXP ALLERGY, V28, P1559, DOI 10.1046/j.1365-2222.1998.00431.x; Babakissa C, 2011, JPEN-PARENTER ENTER, V35, P402, DOI 10.1177/0148607110383430; Balhorn R, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-227; Bartels CL, 2012, JPEN-PARENTER ENTER, V36, P117, DOI 10.1177/0148607111399288; BASSETT CW, 1994, J ALLERGY CLIN IMMUN, V93, P242; BATES CM, 1995, GENITOURIN MED, V71, P414; BECK SA, 1991, PEDIATRICS, V88, P913; BIERMAN CW, 1977, J INFECT DIS, V136, pS652, DOI 10.1093/infdis/136.Supplement_3.S652; Biveau S, 2008, J CUTAN MED SURG, V12, P27, DOI 10.2310/7750.2007.00031; BLOCK MB, 1970, AM J DIG DIS, V15, P569, DOI 10.1007/BF02238117; Boden SR, 2011, J ALLERGY CLIN IMMUN, V127, pAB114, DOI 10.1016/j.jaci.2010.12.457; Bogdanovic J, 2009, J ALLERGY CLIN IMMUN, V124, P1108, DOI 10.1016/j.jaci.2009.06.021; Bollinger ME, 1999, J ALLERGY CLIN IMMUN, V104, P462, DOI 10.1016/S0091-6749(99)70394-5; BONE WD, 1993, CHEST, V103, P981, DOI 10.1378/chest.103.3.981b; Brady MT, 2013, PEDIATRICS, V132, pE1089, DOI 10.1542/peds.2013-2377; BRIGGS LP, 1982, ANAESTHESIA, V37, P1099, DOI 10.1111/j.1365-2044.1982.tb01753.x; BROWN FR, 1967, J PEDIATR-US, V71, P868, DOI 10.1016/S0022-3476(67)80013-1; BRUNO G, 1990, LANCET, V335, P739, DOI 10.1016/0140-6736(90)90863-Z; BUCHMAN AL, 1991, JPEN-PARENTER ENTER, V15, P345, DOI 10.1177/0148607191015003345; BULLOCK L, 1990, JPEN-PARENTER ENTER, V14, P98, DOI 10.1177/014860719001400198; BUSINCO L, 1994, ANN ALLERGY, V72, P1; Businco L, 1991, PEDIATR ALLERGY IMMU, V4, P195; CAPLAN SN, 1976, NEW ENGL J MED, V295, P172; Cesaro S, 1999, SUPPORT CARE CANCER, V7, P284, DOI 10.1007/s005200050262; Chew GY, 1999, MED J AUSTRALIA, V171, P387, DOI 10.5694/j.1326-5377.1999.tb123704.x; Chung EY, 2010, PEDIATRICS, V125, pE1024, DOI 10.1542/peds.2009-2512; COHEN HI, 1978, J PEDIATR-US, V92, P859, DOI 10.1016/S0022-3476(78)80191-7; CONNOLLY CK, 1982, BRIT MED J, V285, P934, DOI 10.1136/bmj.285.6346.934; Crevel RWR, 2000, FOOD CHEM TOXICOL, V38, P385, DOI 10.1016/S0278-6915(99)00158-1; DELEONCASASOLA OA, 1992, ANESTHESIOLOGY, V77, P384, DOI 10.1097/00000542-199208000-00026; Des Roches A, 2012, J ALLERGY CLIN IMMUN, V130, P1213, DOI 10.1016/j.jaci.2012.07.046; DOLD M, 1989, ANAESTHESIA, V44, P533, DOI 10.1111/j.1365-2044.1989.tb11422.x; Dorsey MJ, 2005, J ALLERGY CLIN IMM S, V115, pS250; Doshi AB, 2005, AM J OPHTHALMOL, V140, P936, DOI 10.1016/j.ajo.2005.05.033; Ducart AR, 2000, J CARDIOTHOR VASC AN, V14, P200, DOI 10.1016/S1053-0770(00)90020-X; DUFFY BL, 1994, ANAESTH INTENS CARE, V22, P90, DOI 10.1177/0310057X9402200116; Eda Asuka, 2009, Allergology International, V58, P137, DOI 10.2332/allergolint.C-07-59; Esposito S, 2008, VACCINE, V26, P4664, DOI 10.1016/j.vaccine.2008.06.095; Facchini G, 1996, Monaldi Arch Chest Dis, V51, P201; FASANO MB, 1992, J PEDIATR-US, V120, P878, DOI 10.1016/S0022-3476(05)81953-5; FINE SR, 1991, J ALLERGY CLIN IMMUN, V87, P600, DOI 10.1016/0091-6749(91)90025-J; Fiocchi A, 2003, PEDIATRICS, V112, P359, DOI 10.1542/peds.112.2.359; Martin-Munoz MF, 2012, PEDIAT ALLERG IMM-UK, V23, P778, DOI 10.1111/j.1399-3038.2012.01338.x; FLUBLOK Meriden, 2013, CT PROT SCI PACK INS; Ford SA, 2001, J CARDIOTHOR VASC AN, V15, P684, DOI 10.1053/jcan.2001.28310; Forsdahl BA, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000186; FREEMAN MK, 1979, ANAESTHESIA, V34, P341, DOI 10.1111/j.1365-2044.1979.tb04933.x; FREIGANG B, 1994, ANN ALLERGY, V73, P486; Fung I, 2012, J ALLERGY CLIN IMMUN, V129, P1157, DOI 10.1016/j.jaci.2011.11.038; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; Gray HC, 2004, J ALLERGY CLIN IMMUN, V114, P459, DOI 10.1016/j.jaci.2004.05.050; GREENBERG MA, 1988, J PEDIATR-US, V113, P504, DOI 10.1016/S0022-3476(88)80639-5; GREENBERGER PA, 1989, AM J MED SCI, V298, P104, DOI 10.1097/00000441-198908000-00006; Greenhawt MJ, 2012, ANN ALLERG ASTHMA IM, V109, P426, DOI 10.1016/j.anai.2012.09.011; Greenhawt MJ, 2010, ANN ALLERG ASTHMA IM, V105, P387, DOI 10.1016/j.anai.2010.08.015; Grohskopf LA, 2013, MMWR RECOMM REP, V62, P1; Gu XL, 2001, INT ARCH ALLERGY IMM, V126, P218, DOI 10.1159/000049517; Haeney MR, 1992, BMJ-BRIT MED J, V305, P10; Hakala T, 2000, ANN CHIR GYNAECOL, V89, P150; Haywood A, 2011, AUST PRESCR, V34, P112; Health Canada's Position on Highly Refined Oils Derived from Food Allergen Sources, 2013, HLTH CAN POS HIGHL R; HERMAN JJ, 1983, J PEDIATR-US, V102, P196, DOI 10.1016/S0022-3476(83)80519-8; HIYAMA DT, 1989, JPEN-PARENTER ENTER, V13, P318, DOI 10.1177/0148607189013003318; Hofer KN, 2003, ANN PHARMACOTHER, V37, P398, DOI 10.1345/aph.1C227; Hori H, 2002, J ALLERGY CLIN IMMUN, V110, P652, DOI 10.1067/mai.2002.127862; HORNER AA, 1992, J ALLERGY CLIN IMMUN, V89, P350; Horrow JC, 1996, ANESTH ANALG, V82, P386, DOI 10.1097/00000539-199602000-00031; Hotte SL, 2008, J ALLERGY CLIN IMMUN, V121, pS239, DOI 10.1016/j.jaci.2007.12.947; Howe LE, 2011, ANN ALLERG ASTHMA IM, V106, P446, DOI 10.1016/j.anai.2011.01.024; Huston RK, 2009, JPEN-PARENTER ENTER, V33, P691, DOI 10.1177/0148607109347643; JAMES JM, 1995, NEW ENGL J MED, V332, P1262, DOI 10.1056/NEJM199505113321904; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Jenkins SC, 2002, ANN ROY COLL SURG, V84, P206; KAMATH KR, 1981, NEW ENGL J MED, V304, P360; KAMIN PB, 1963, JAMA-J AM MED ASSOC, V185, P647, DOI 10.1001/jama.1963.03060080043012; KAMIN PB, 1965, J AMER MED ASSOC, V193, P1125; Kanny G, 1996, ALLERGY, V51, P952; Karch AM, 2003, AM J NURS, V103, P27, DOI 10.1097/00000446-200306000-00015; Kattan JD, 2011, J ALLERGY CLIN IMMUN, V128, P215, DOI 10.1016/j.jaci.2011.04.046; KATZ SL, 1978, J PEDIATR-US, V92, P859, DOI 10.1016/S0022-3476(78)80192-9; Kauffman CA, 1998, CLIN INFECT DIS, V26, P1237, DOI 10.1086/598356; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Kelso JM, 2012, J ALLERGY CLIN IMMUN, V130, P25, DOI 10.1016/j.jaci.2012.04.003; KEMP A, 1990, AM J DIS CHILD, V144, P33, DOI 10.1001/archpedi.1990.02150250039027; Khan FS, 2012, J ALLERGY CLIN IMMUN, V129, pAB70, DOI 10.1016/j.jaci.2011.12.756; Khoriaty E, 2012, ANN ALLERG ASTHMA IM, V108, P209, DOI 10.1016/j.anai.2011.12.012; Kimmel SE, 1998, J AM COLL CARDIOL, V32, P1916, DOI 10.1016/S0735-1097(98)00484-7; KLETZ MR, 1990, ANN ALLERGY, V64, P527; KNAPE JTA, 1981, ANESTHESIOLOGY, V55, P324, DOI 10.1097/00000542-198109000-00025; KORNBROT B, 1990, Harefuah, V119, P230; Kumagai T, 1997, J ALLERGY CLIN IMMUN, V100, P130, DOI 10.1016/S0091-6749(97)70204-5; Kumagai T, 2001, VACCINE, V19, P3273, DOI 10.1016/S0264-410X(00)00555-7; KUMAR CM, 1989, ANAESTHESIA, V44, P266, DOI 10.1111/j.1365-2044.1989.tb11264.x; Kuno-Sakai H, 2003, BIOLOGICALS, V31, P245, DOI 10.1016/S1045-1056(03)00063-0; LAING RBS, 1994, LANCET, V344, P682, DOI 10.1016/S0140-6736(94)92116-4; Land MH, 2013, J ALLER CL IMM-PRACT, V1, P99, DOI 10.1016/j.jaip.2012.09.004; Lasley Mary V., 2007, Pediatric Asthma Allergy & Immunology, V20, P201, DOI 10.1089/pai.2007.014; LAVI S, 1990, JAMA-J AM MED ASSOC, V263, P269, DOI 10.1001/jama.263.2.269; LAXENAIRE MC, 1992, ANESTHESIOLOGY, V77, P275, DOI 10.1097/00000542-199208000-00009; LAXENAIRE MC, 1988, LANCET, V2, P739; Leo S, 2010, ALLERGY ASTHMA CL IM, V6, pP4; LEVY JH, 1989, J THORAC CARDIOV SUR, V98, P200; LEVY M, 1990, JPEN-PARENTER ENTER, V14, P213, DOI 10.1177/0148607190014002213; Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009; LORENZ W, 1976, BRIT J ANAESTH, V48, P151, DOI 10.1093/bja/48.2.151; LORENZ W, 1977, ANAESTHESIST, V26, P644; LORENZ W, 1980, AGENTS ACTIONS, V10, P114, DOI 10.1007/BF02024192; LUND N, 1973, BRIT J ANAESTH, V45, P929, DOI 10.1093/bja/45.8.929; Lundsgaard-Hansen P, 1980, Dev Biol Stand, V48, P251; Lunn M, 2011, PEDIATRICS, V128, pE1025, DOI 10.1542/peds.2010-2771; Maiello N, 2011, ANN ALLERG ASTHMA IM, V107, P85, DOI 10.1016/j.anai.2011.04.001; Mark BJ, 2008, ALLERGY ASTHMA PROC, V29, P528, DOI 10.2500/aap.2008.29.3159; Market AD, 1998, J PEDIATR GASTR NUTR, V26, P229, DOI 10.1097/00005176-199802000-00022; Marrel J, 2011, BRIT J ANAESTH, V107, P647, DOI 10.1093/bja/aer281; Martin-Hernandez C, 2005, J AGR FOOD CHEM, V53, P8607, DOI 10.1021/jf0510687; Matheu V, 1999, ALLERGY, V54, P643, DOI 10.1034/j.1398-9995.1999.00139.x; MCHALE SP, 1992, ANAESTHESIA, V47, P864, DOI 10.1111/j.1365-2044.1992.tb03150.x; McKinney KK, 2011, J ALLERGY CLIN IMMUN, V127, P1629, DOI 10.1016/j.jaci.2011.02.003; Morisset M, 2006, J ALLERGY CLIN IMMUN, V117, pS95, DOI 10.1016/j.jaci.2005.12.379; Mukhtar M, 2011, AM J TROP MED HYG, V85, P644, DOI 10.4269/ajtmh.2011.10-0511; Murphy A, 2011, ANESTH ANALG, V113, P140, DOI 10.1213/ANE.0b013e31821b450f; Nakayama T, 2000, J ALLERGY CLIN IMMUN, V106, P591, DOI 10.1067/mai.2000.108433; Nakayama T, 1999, J ALLERGY CLIN IMMUN, V103, P321, DOI 10.1016/S0091-6749(99)70508-7; NAQUIB M, 1989, CAN J ANAESTH, V36, P358; NIEBURG PI, 1980, PEDIATRICS, V65, P365, DOI 10.1542/peds.65.2.365; Nishiyama T, 2001, ANESTH ANALG, V93, P645, DOI 10.1097/00000539-200109000-00022; Nowak-Wegrzyn A, 2004, J ALLERGY CLIN IMMUN, V113, P558, DOI 10.1016/j.jaci.2003.11.015; Nybo M, 2008, BASIC CLIN PHARMACOL, V103, P192, DOI 10.1111/j.1742-7843.2008.00274.x; Owens G, 2011, J ALLERGY CLIN IMMUN, V127, P264, DOI 10.1016/j.jaci.2010.10.005; Ozaki T, 2005, VACCINE, V23, P1205, DOI 10.1016/j.vaccine.2004.08.040; Parisi CAS, 2013, CLIN EXP ALLERGY, V43, P249, DOI 10.1111/cea.12059; Park AY, 2008, J ALLERGY CLIN IMMUN, V121, pS240, DOI 10.1016/j.jaci.2007.12.949; Paschall VL, 2011, J ALLERGY CLIN IMMUN, V127, pAB182, DOI 10.1016/j.jaci.2010.12.725; Patja A, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.2.e27; PETER G, 1989, J PEDIATR-US, V114, P1067, DOI 10.1016/S0022-3476(89)80472-X; Pien GC, 2010, ALLERGY ASTHMA PROC, V31, P507, DOI 10.2500/aap.2010.31.3396; Pitt T, 2011, ALLERGY ASTHMA CL IM, V7, P3; POMERANZ S, 1987, JPEN-PARENTER ENTER, V11, P314, DOI 10.1177/0148607187011003314; Pool V, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e71; PORRAS O, 1985, INT ARCH ALLER A IMM, V78, P30, DOI 10.1159/000233858; PUVVADA L, 1993, PEDIATRICS, V91, P835; RING J, 1977, LANCET, V1, P466; RING J, 1985, INT ANESTHESIOL CLIN, V23, P67; RINGDEN O, 1994, LANCET, V344, P1156, DOI 10.1016/S0140-6736(94)90663-7; Russell WJ, 2002, ANAESTH INTENS CARE, V30, P481, DOI 10.1177/0310057X0203000415; Sa AB, 2011, J ALLERGY CLIN IMMUN, V127, pAB241, DOI 10.1016/j.jaci.2010.12.961; SADDLER JM, 1987, ANAESTHESIA, V42, P998, DOI 10.1111/j.1365-2044.1987.tb05376.x; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V104, P695, DOI 10.1016/S0091-6749(99)70344-1; Sakaguchi M, 2000, VACCINE, V19, P431, DOI 10.1016/S0264-410X(00)00206-1; Sakaguchi M, 1999, IMMUNOLOGY, V96, P286, DOI 10.1046/j.1365-2567.1999.00696.x; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V103, P349, DOI 10.1016/S0091-6749(99)70512-9; Sakaguchi M, 1997, VACCINE, V15, P121, DOI 10.1016/S0264-410X(96)00170-3; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P720, DOI 10.1016/S0091-6749(97)70038-1; Sakaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P1033, DOI 10.1067/mai.2001.119412; Sakaguchi M, 2000, JPN J INFECT DIS, V53, P189; Sakaguchi M, 2001, ALLERGY, V56, P536, DOI 10.1034/j.1398-9995.2001.056006536.x; Sakaguchi M, 1998, VACCINE, V16, P68, DOI 10.1016/S0264-410X(97)00152-7; Saltzman RW, 2009, J ALLERGY CLIN IMMUN, V123, pS175, DOI 10.1016/j.jaci.2008.12.659; Schabelman E, 2010, J EMERG MED, V39, P701, DOI 10.1016/j.jemermed.2009.10.014; Schneider P, 1998, BRIT J HAEMATOL, V102, P1108, DOI 10.1046/j.1365-2141.1998.0952a.x; Schoning B, 1980, Dev Biol Stand, V48, P241; Schuler JE, 2011, CAN J PUBLIC HEALTH, V102, P196, DOI 10.1007/BF03404895; Shin CH, 2006, KOREAN J ANESTHESIOL, V50, pS68; Singer S, 1999, VACCINE, V17, P327, DOI 10.1016/S0264-410X(98)00209-6; Siret-Alatrista A, 2011, ALLERGY, V66, P298, DOI 10.1111/j.1398-9995.2010.02461.x; Slater JE, 2011, J ALLERGY CLIN IMMUN, V128, P434, DOI 10.1016/j.jaci.2011.06.028; Spencer HT, 2012, SPINE J, V12, pE1, DOI 10.1016/j.spinee.2012.08.425; STIEHM ER, 1990, AM J DIS CHILD, V144, P32, DOI 10.1001/archpedi.1990.02150250034026; Tallia Alfred F, 2002, J Am Board Fam Pract, V15, P481; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; Thanik ES, 2010, J ALLERGY CLIN IMMUN, V125, pAB25, DOI 10.1016/j.jaci.2009.12.130; Torre I, 1996, ANN PHARMACOTHER, V30, P1036, DOI 10.1177/106002809603000924; TOUNIAN P, 1993, ARCH FR PEDIATR, V50, P191; TROTTER AC, 1994, ANN ALLERGY, V72, P25; Tsai MH, 2001, J FORMOS MED ASSOC, V100, P424; Upton JEM, 2012, ALLERGY ASTHMA CL IM, V8, DOI 10.1186/1710-1492-8-2; Vaidya SJ, 2002, ANN PHARMACOTHER, V36, P1480, DOI 10.1345/aph.1C001; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P535, DOI 10.1016/0091-6749(83)90433-5; Villacis J, 2006, CLIN EXP ALLERGY, V36, P1457, DOI 10.1111/j.1365-2222.2006.02590.x; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P749, DOI 10.1016/j.jaci.2009.12.015; Webb L, 2011, J ALLERGY CLIN IMMUN, V128, P218, DOI 10.1016/j.jaci.2011.02.013; Weidmann B, 1997, SUPPORT CARE CANCER, V5, P504, DOI 10.1007/s005200050120; WEILER JM, 1990, J ALLERGY CLIN IMMUN, V85, P713, DOI 10.1016/0091-6749(90)90189-B; WEISS ME, 1989, NEW ENGL J MED, V320, P886, DOI 10.1056/NEJM198904063201402; WISBORG K, 1975, BRIT J ANAESTH, V47, P1116; Worm M, 2000, ACTA DERM-VENEREOL, V80, P232, DOI 10.1080/000155500750043186; You BC, 2012, ALLERGY ASTHMA IMMUN, V4, P46, DOI 10.4168/aair.2012.4.1.46; Zeiger RS, 2002, J ALLERGY CLIN IMMUN, V110, P834, DOI 10.1067/mai.2002.129372; 정인권, 2010, [The Korean Journal of Medicine, 대한내과학회지], V79, P549	208	31	31	1	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1509	1518		10.1016/j.jaci.2014.03.011	http://dx.doi.org/10.1016/j.jaci.2014.03.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24878443				2022-12-18	WOS:000336672500001
J	Hyde, ER; Petrosino, JF; Piedra, PA; Camargo, CA; Espinola, JA; Mansbach, JM				Hyde, Embriette R.; Petrosino, Joseph F.; Piedra, Pedro A.; Camargo, Carlos A., Jr.; Espinola, Janice A.; Mansbach, Jonathan M.			Nasopharyngeal Proteobacteria are associated with viral etiology and acute wheezing in children with severe bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE; ASTHMA		[Hyde, Embriette R.; Petrosino, Joseph F.] Baylor Coll Med, Integrat Mol & Biomed Sci Grad Program, Houston, TX 77030 USA; [Hyde, Embriette R.; Petrosino, Joseph F.] Baylor Coll Med, Alkek Ctr Metagen & Microbiome Res, Houston, TX 77030 USA; [Petrosino, Joseph F.; Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol & Pediat, Houston, TX 77030 USA; [Petrosino, Joseph F.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Camargo, Carlos A., Jr.; Espinola, Janice A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Mansbach, Jonathan M.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Med, Boston, MA USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School	Hyde, ER (corresponding author), Baylor Coll Med, Integrat Mol & Biomed Sci Grad Program, Houston, TX 77030 USA.	jonathan.mansbach@childrens.harvard.edu	Camargo, Carlos A./C-2145-2008; Petrosino, Joseph F./AAF-1621-2019	Camargo, Carlos A./0000-0002-5071-7654; 	NIAID NIH HHS [U01 AI-67693, K23 AI077801, U01 AI067693, K23 AI-77801] Funding Source: Medline; NIGMS NIH HHS [T32 GM008231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI067693, K23AI077801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077; Mallia P, 2012, AM J RESP CRIT CARE, V186, P1117, DOI 10.1164/rccm.201205-0806OC; Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669; Marri PR, 2012, J ALLERGY CLIN IMMUN, V131, P346; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Yorita KL, 2008, PEDIATRICS, V121, P244, DOI 10.1542/peds.2007-1392	10	31	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1220	1222		10.1016/j.jaci.2013.10.049	http://dx.doi.org/10.1016/j.jaci.2013.10.049			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24365140	Green Accepted			2022-12-18	WOS:000333531700038
J	Pravettoni, V; Piantanida, M; Primavesi, L; Forti, S; Pastorello, EA				Pravettoni, Valerio; Piantanida, Marta; Primavesi, Laura; Forti, Stella; Pastorello, Elide A.			Basal platelet-activating factor acetylhydrolase: Prognostic marker of severe Hymenoptera venom anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PLASMA; ALLERGY		[Pravettoni, Valerio; Piantanida, Marta; Primavesi, Laura] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Clin Allergy & Immunol Unit, Milan, Italy; [Forti, Stella] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Audiol Unit, Milan, Italy; [Pastorello, Elide A.] Osped Niguarda Ca Granda, Allergy & Immunol Unit, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda	Pravettoni, V (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Clin Allergy & Immunol Unit, Milan, Italy.	v.pravettoni@policlinico.mi.it	PASTORELLO, ELIDE ANNA/E-3897-2017	PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Fukuda Y, 2000, EUR J PHARMACOL, V390, P203, DOI 10.1016/S0014-2999(99)00920-6; Karasawa K, 2003, PROG LIPID RES, V42, P93, DOI 10.1016/S0163-7827(02)00049-8; Kuijpers TW, 2007, BLOOD, V109, P3529, DOI 10.1182/blood-2006-05-021402; Kuijpers TW, 2009, BLOOD, V113, P4740, DOI 10.1182/blood-2008-10-182154; KUIJPERS TW, 1991, BLOOD, V78, P1105; MIYAURA S, 1991, LIPIDS, V26, P1015, DOI 10.1007/BF02536494; Mueller H L, 1966, J Asthma Res, V3, P331; Triggiani M, 2008, CLIN EXP IMMUNOL, V153, P7, DOI 10.1111/j.1365-2249.2008.03714.x; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Yoshida H, 1996, AM J HEMATOL, V53, P158, DOI 10.1002/(SICI)1096-8652(199611)53:3<158::AID-AJH2>3.3.CO;2-8; Yost CC, 2010, BIOCHIMIE, V92, P692, DOI 10.1016/j.biochi.2010.02.011	12	31	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1218	1220		10.1016/j.jaci.2013.10.033	http://dx.doi.org/10.1016/j.jaci.2013.10.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24332861				2022-12-18	WOS:000333531700037
J	Sanchez-Lopez, J; Tordesillas, L; Pascal, M; Munoz-Cano, R; Garrido, M; Rueda, M; Vilella, R; Valero, A; Diaz-Perales, A; Picado, C; Bartra, J				Sanchez-Lopez, Jaime; Tordesillas, Leticia; Pascal, Mariona; Munoz-Cano, Rosa; Garrido, Maria; Rueda, Maria; Vilella, Ramon; Valero, Antonio; Diaz-Perales, Araceli; Picado, Cesar; Bartra, Joan			Role of Art v 3 in pollinosis of patients allergic to Pru p 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lipid transfer protein; food allergy; pollinosis; nasal allergen provocation test; Pru p 3; Art v 3	LIPID-TRANSFER PROTEIN; CROSS-REACTIVITY; RESPIRATORY ALLERGY; ARTEMISIA POLLEN; PLANT-FOODS; HYPERSENSITIVITY; IGE; IDENTIFICATION; SENSITIZATION	Background: Food allergy caused by lipid transfer protein (LTP) from peach (Pru p 3) is frequently associated with sensitization to mugwort LTP (Art v 3). Although in vitro cross-reactivity is already well known, it has yet to be elucidated whether a pollen LTP can induce rhinitis. Objective: The aim of this study was to investigate whether mugwort LTP could elicit respiratory symptoms and whether a primary food LTP allergy could lead to a respiratory allergy. Methods: Patients with confirmed Pru p 3 allergy and control subjects were selected. Immediate responses to nasal allergen provocation tests (NAPTs) with Art v 3, Pru p 3, and mugwort were assessed by using the visual analog scale score, total nasal symptom score, and acoustic rhinometry. Tryptase and cysteinyl leukotriene (cysLT) levels were measured in nasal lavage fluid. Immunoblotting, ELISAs, and ELISA inhibition assays were also performed. Results: Fifteen patients and 9 control subjects were selected. NAPT results with Art v 3 and Pru p 3 showed significant changes in acoustic rhinometry, visual analog scale scores, total nasal symptom scores, and cysLT levels (P < .001). Tryptase levels were only increased in NAPTs with Pru p 3. NAPTs with mugwort were used in those patients who were only sensitized to Art v 3, with similar results (P < .05). No significant changes were detected in control subjects. Conclusion: The results demonstrated that a pollen LTP can elicit rhinitis in sensitized patients. Findings also suggest that a primary sensitization to Pru p 3 can lead to a respiratory allergy through cross-reactivity.	[Sanchez-Lopez, Jaime; Munoz-Cano, Rosa; Rueda, Maria; Valero, Antonio; Picado, Cesar; Bartra, Joan] Univ Barcelona, Unitat AlIergia, Inst Clin Torax ICT, Hosp Clin,Inst Invest Biomed August Pi I Sunyer I, E-08007 Barcelona, Spain; [Tordesillas, Leticia; Garrido, Maria; Diaz-Perales, Araceli] Univ Politecn Madrid, Ctr Biotecnol Genom Plantas CBGP, Madrid, Spain; [Pascal, Mariona; Vilella, Ramon] Hosp Clin Barcelona, Serv Immunol, Ctr Diagnost Biomed CDB, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universidad Politecnica de Madrid; Centro de Investigacion en Biotecnologia Genomica de Plantas (CBGP); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Sanchez-Lopez, J (corresponding author), Hosp Clinic Prov, Villarroel 170, Barcelona 08036, Spain.	jasanche@clinic.ub.es	Díaz-Perales, Araceli/D-8433-2016; Garrido-Arandia, Maria/ABG-9760-2020; Muñoz, Rosa/AAC-7288-2020; Sánchez-López, Jaime/L-3020-2014; Bartra, Joan/L-4550-2014; /AFX-9519-2022; /AAL-7347-2021; Cano, Rosa Munoz/K-9413-2014; Pascal, Mariona/HCG-9380-2022	Díaz-Perales, Araceli/0000-0002-1093-3627; Muñoz, Rosa/0000-0001-8566-8285; Sánchez-López, Jaime/0000-0003-3600-8138; Bartra, Joan/0000-0001-7767-4730; Cano, Rosa Munoz/0000-0001-8566-8285; Garrido Arandia, Maria/0000-0001-6114-5754	Spanish Health Ministry (FIS) [PI11/01326]; FIS network RIRAAF [RD12/0013/0012]; Catalan Society of Allergy and Clinical Immunology (SCAIC); Spanish Health Ministry	Spanish Health Ministry (FIS)(Instituto de Salud Carlos IIISpanish Government); FIS network RIRAAF; Catalan Society of Allergy and Clinical Immunology (SCAIC); Spanish Health Ministry(Instituto de Salud Carlos IIISpanish Government)	Supported by grants from the Spanish Health Ministry (FIS; PI11/01326), FIS network RIRAAF (RD12/0013/0012), and the Catalan Society of Allergy and Clinical Immunology (SCAIC).; J. Sanchez Lopez has been supported by one or more grants from the Catalan Society of Allergy and Clinical Immunology (SCAIC) and the Spanish Health Ministry. L. Tordesillas, M. Pascal, R. Munoz-Cano, M. Garrido, R. Vilella, A. Diaz-Perales, and J. Bartra have been supported by one or more grants from the Spanish Health Ministry. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1989, ALLERGY, V44, P1; Asero R, 2002, ALLERGY, V57, P900, DOI 10.1034/j.1398-9995.2002.t01-1-23541.x; AYUSO R, 1993, MOL IMMUNOL, V30, P1347, DOI 10.1016/0161-5890(93)90095-S; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; Borghesan F, 2008, INT ARCH ALLERGY IMM, V147, P161, DOI 10.1159/000137285; Caballero T, 1998, J INVEST ALLERG CLIN, V8, P6; Cuesta-Herranz J, 2010, INT ARCH ALLERGY IMM, V153, P182, DOI 10.1159/000312636; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P926, DOI 10.1016/j.jaci.2005.05.041; Gao ZS, 2013, J ALLERGY CLIN IMMUN, V131, P224, DOI 10.1016/j.jaci.2012.07.015; Garcia BE, 2004, CLIN EXP ALLERGY, V34, P291, DOI 10.1111/j.1365-2222.2004.01871.x; Garcia-Selles FJ, 2002, INT ARCH ALLERGY IMM, V128, P115, DOI 10.1159/000059401; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; GodnicCvar J, 1997, J ALLERGY CLIN IMMUN, V99, P354, DOI 10.1016/S0091-6749(97)70053-8; Hauser Michael, 2010, Allergy Asthma Clin Immunol, V6, P1, DOI 10.1186/1710-1492-6-1; Hilberg O, 2000, RHINOLOGY, P3; Hiller KM, 1998, SCAND J IMMUNOL, V48, P26; Ibrahim ARN, 2010, BIOSCI BIOTECH BIOCH, V74, P504, DOI 10.1271/bbb.90685; JUHLIN-DANNFELT C, 1948, Acta Med Scand, V131, P563; Lauer I, 2007, CLIN EXP ALLERGY, V37, P261, DOI 10.1111/j.1365-2222.2007.02653.x; Lombardero M, 2004, CLIN EXP ALLERGY, V34, P1415, DOI 10.1111/j.1365-2222.2004.02053.x; NAVARROPULIDO AM, 2005, ALERGOLOGICA 2005 FA, P107; Palacin A, 2007, J ALLERGY CLIN IMMUN, V120, P1132, DOI 10.1016/j.jaci.2007.07.008; Pascal M, 2012, CLIN EXP ALLERGY, V42, P1529, DOI 10.1111/j.1365-2222.2012.04071.x; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V110, P310, DOI 10.1067/mai.2002.125830; Pastorello EA, 2004, MOL NUTR FOOD RES, V48, P356, DOI 10.1002/mnfr.200400047; Ruiz-Garcia M, 2011, J ALLERGY CLIN IMMUN, V128, P416, DOI 10.1016/j.jaci.2011.03.008; Salcedo G, 2007, BBA-MOL CELL BIOL L, V1771, P781, DOI 10.1016/j.bbalip.2007.01.001; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Tabar AI, 2004, CLIN EXP ALLERGY, V34, P131, DOI 10.1111/j.1365-2222.2004.01856.x; Tejera ML, 1999, J ALLERGY CLIN IMMUN, V104, P797, DOI 10.1016/S0091-6749(99)70290-3	31	31	31	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1018	+		10.1016/j.jaci.2013.08.005	http://dx.doi.org/10.1016/j.jaci.2013.08.005			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24080266	Bronze			2022-12-18	WOS:000333531700011
J	Dhingra, N; Suarez-Farinas, M; Fuentes-Duculan, J; Gittler, JK; Shemer, A; Raz, A; Fischetti, VA; Krueger, JG; Guttman-Yassky, E				Dhingra, Nikhil; Suarez-Farinas, Mayte; Fuentes-Duculan, Judilyn; Gittler, Julia K.; Shemer, Avner; Raz, Assaf; Fischetti, Vincent A.; Krueger, James G.; Guttman-Yassky, Emma			Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects T(H)17 pathway differences between these diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STAPHYLOCOCCUS-AUREUS; CYTOKINES; CELLS; SKIN		[Dhingra, Nikhil; Suarez-Farinas, Mayte; Fuentes-Duculan, Judilyn; Gittler, Julia K.; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10021 USA; [Dhingra, Nikhil] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Dhingra, Nikhil; Suarez-Farinas, Mayte] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10021 USA; [Gittler, Julia K.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Shemer, Avner] Tel Hashomer, Dept Dermatol, Tel Aviv, Israel; [Raz, Assaf; Fischetti, Vincent A.] Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA	Rockefeller University; Columbia University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Rockefeller University; Icahn School of Medicine at Mount Sinai	Dhingra, N (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA.	eguttman@rockefeller.edu	Suarez-Farinas, Mayte/I-3558-2012	Suarez-Farinas, Mayte/0000-0001-8712-3553	NCRR NIH HHS [UL1 RR024143, 5UL1RR024143-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Choy DF, 2012, J ALLERGY CLIN IMMUN, V130, P1335, DOI 10.1016/j.jaci.2012.06.044; Daniel A, 2010, ANTIMICROB AGENTS CH, V54, P1603, DOI 10.1128/AAC.01625-09; Fischetti VA, 2008, CURR OPIN MICROBIOL, V11, P393, DOI 10.1016/j.mib.2008.09.012; Gilani SJK, 2005, CLIN EXP DERMATOL, V30, P10, DOI 10.1111/j.1365-2230.2004.01679.x; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Leung DYM, 2008, ACTA DERM-VENEREOL, P21, DOI 10.2340/00015555-0388; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Oranje AP, 2011, CURR PROBL DERMATOL, V41, P149, DOI 10.1159/000323308; Pastagia M, 2011, ANTIMICROB AGENTS CH, V55, P738, DOI 10.1128/AAC.00890-10; Raz A, 2012, MOL MICROBIOL, V84, P631, DOI 10.1111/j.1365-2958.2012.08047.x; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957	16	31	35	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					498	+		10.1016/j.jaci.2013.04.043	http://dx.doi.org/10.1016/j.jaci.2013.04.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23777850	Green Accepted			2022-12-18	WOS:000322631700037
J	Schindewolf, M; Gobst, C; Kroll, H; Recke, A; Louwen, F; Wolter, M; Kaufmann, R; Boehncke, WH; Lindhoff-Last, E; Ludwig, RJ				Schindewolf, Marc; Gobst, Corinna; Kroll, Hartmut; Recke, Andreas; Louwen, Frank; Wolter, Manfred; Kaufmann, Roland; Boehncke, Wolf-Henning; Lindhoff-Last, Edelgard; Ludwig, Ralf J.			High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Heparin; low-molecular-weight heparin; delayed-type hypersensitivity reaction; pregnancy; heparin-induced thrombocytopenia; skin; allergy	LOW-MOLECULAR-WEIGHT; INDUCED SKIN-LESIONS; DEEP-VEIN THROMBOSIS; INDUCED THROMBOCYTOPENIA; FONDAPARINUX; DIAGNOSIS; DESENSITIZATION; TOLERANCE; MANAGEMENT; TRIMESTER	Background: Among the most frequent adverse effects of subcutaneous heparin treatment, heparin-induced skin lesions occur with an incidence of 10.3% in nonpregnant female patients. Clinical observations suggest an even higher risk during pregnancy. Objectives: We sought to determine the incidence and causes of heparin-induced skin reactions during pregnancy in a prospective cohort study. Methods: Pregnant women with subcutaneous heparin treatment were prospectively examined for skin reactions. If a skin lesion was observed, further diagnostics were performed (skin biopsy, subcutaneous provocation, clinical/laboratory assessment for thrombosis, bleeding, and heparin-induced thrombocytopenia [HIT]). Safety parameters were also analyzed (cross-allergies, frequency of thromboembolic and bleeding complications, HIT, and pregnancy outcome). Results: Among 111 pregnant patients, 22 (19.8%) had heparin-induced skin reactions (95% CI, 13% to 29%). All lesions were caused by allergic delayed-type hypersensitivity (DTH) reactions and not by HIT or other rare conditions. The median time of onset was 50.5 days (range, 5-184 days). The cross-reactivity rate was 33.3%. While nadroparin treatment exhibited a higher DTH risk than dalteparin (hazard ratio [HR], 26.7; 95% CI, 3.4-211.0; P = .00187), enoxaparin treatment was not significantly different from dalteparin treatment (HR, 5.6; 95% CI, 0.3-96.1; P = .238). Three thromboembolic events and 1 major bleeding event occurred. Conclusions: Among patients receiving long-term heparin anticoagulation during pregnancy, heparin-induced skin lesions are frequent (incidence, 19.8%) and are all caused by allergic DTH reactions. Nadroparin has the highest frequency of skin lesions (approximately 65% at 100 days), which is significantly higher than that of dalteparin (HR, 26.7). Therefore nadroparin use should be avoided in pregnancy when possible.	[Schindewolf, Marc; Gobst, Corinna; Lindhoff-Last, Edelgard] Goethe Univ Hosp Frankfurt, Dept Internal Med, Div Vasc Med & Hemostaseol, D-60590 Frankfurt, Germany; [Louwen, Frank] Goethe Univ Hosp Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany; [Wolter, Manfred; Kaufmann, Roland; Boehncke, Wolf-Henning; Ludwig, Ralf J.] Goethe Univ Hosp Frankfurt, Dept Dermatol, D-60590 Frankfurt, Germany; [Kroll, Hartmut] Red Cross Blood Transfus Serv NSTOB, Inst Transfus Med Dessau, Dessau, Germany; [Recke, Andreas; Ludwig, Ralf J.] Univ Lubeck, Dept Dermatol, Lubeck, Germany; [Boehncke, Wolf-Henning] Univ Hosp Geneva, Dept Dermatol, Geneva, Switzerland	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Lubeck; University of Geneva	Schindewolf, M (corresponding author), Goethe Univ Hosp Frankfurt, Dept Internal Med, Div Vasc Med & Hemostaseol, Theodor Stern Kai 7,Bldg 13A EG, D-60590 Frankfurt, Germany.	marc.schindewolf@yahoo.com	Ludwig, Ralf J/A-2629-2008; Ludwig, Ralf/F-3996-2018; Recke, Andreas/C-8963-2009	Ludwig, Ralf J/0000-0002-1394-1737; Ludwig, Ralf/0000-0002-1394-1737; Recke, Andreas/0000-0002-7674-1804	Department of Internal Medicine (Division of Vascular Medicine and Hemostaseology); Department of Dermatology; Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Excellence Cluster Inflammation at Interfaces [EXC 306/1]; GlaxoSmithKline; Bayer; Boehringer Ingelheim; Sanofi-Aventis; Biotest AG; Biogen-Idec	Department of Internal Medicine (Division of Vascular Medicine and Hemostaseology); Department of Dermatology; Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Excellence Cluster Inflammation at Interfaces; GlaxoSmithKline(GlaxoSmithKline); Bayer(Bayer AG); Boehringer Ingelheim(Boehringer Ingelheim); Sanofi-Aventis(Sanofi-Aventis); Biotest AG; Biogen-Idec(Biogen)	Supported by the Departments of Internal Medicine (Division of Vascular Medicine and Hemostaseology) and Dermatology; Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; and the Excellence Cluster Inflammation at Interfaces (EXC 306/1).; M. Schindewolf has received payment for lectures from GlaxoSmithKline and has received travel support from Bristol-Myers Squibb. E. Lindhoff-Last has received consulting fees from Bayer, Boehringer Ingelheim, GlaxoSmithKline, and Sanofi-Aventis. R. J. Ludwig has received payment for lectures from Biotest AG and Biogen-Idec. The rest of the authors declare that they have no relevant conflicts of interest.	Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x; ALERYANI AY, 1995, THROMB RES, V79, P523, DOI 10.1016/0049-3848(95)00142-E; Baglin TP, 1996, HAEMOSTASIS, V26, P10; Bank I, 2003, J THROMB HAEMOST, V1, P859, DOI 10.1046/j.1538-7836.2003.t01-7-00115.x; Bates SM, 2012, CHEST S, V141, pe691S; Carreras E, 2010, BLOOD, V115, P238, DOI 10.1182/blood-2009-08-236935; Dave S, 2008, J CARDIAC SURG, V23, P394, DOI 10.1111/j.1540-8191.2008.00583.x; Deruelle P, 2006, EUR J OBSTET GYN R B, V127, P73, DOI 10.1016/j.ejogrb.2005.09.010; Doria A, 2006, REPROD TOXICOL, V22, P234, DOI 10.1016/j.reprotox.2006.04.001; Eichler P, 1999, THROMB HAEMOSTASIS, V81, P625; Fausett MB, 2001, AM J OBSTET GYNECOL, V185, P148, DOI 10.1067/mob.2001.114690; Grassegger A, 2001, DERMATOL SURG, V27, P47; Harenberg J, 1999, ALLERGY, V54, P473, DOI 10.1034/j.1398-9995.1999.00048.x; Harr T, 2006, ALLERGY, V61, P787, DOI 10.1111/j.1398-9995.2006.01063.x; Harrison SJ, 2001, BLOOD COAGUL FIBRIN, V12, P157, DOI 10.1097/00001721-200103000-00011; Hochart H, 2006, BRIT J HAEMATOL, V133, P62, DOI 10.1111/j.1365-2141.2006.05959.x; Jappe U, 2006, BLOOD COAGUL FIBRIN, V17, P605, DOI 10.1097/01.mbc.0000198992.18384.5a; Kaandorp SP, 2010, NEW ENGL J MED, V362, P1586, DOI 10.1056/NEJMoa1000641; Koch P, 2000, J AM ACAD DERMATOL, V42, P612, DOI 10.1016/S0190-9622(00)90173-7; Lindhoff-Last E, 2005, THROMB HAEMOSTASIS, V93, P63, DOI 10.1160/TH04-06-0349; Lo GK, 2006, J THROMB HAEMOST, V4, P759, DOI 10.1111/j.1538-7836.2006.01787.x; Ludwig RJ, 2006, THROMB HAEMOSTASIS, V96, P611, DOI 10.1160/TH06-0B4-0210; Ludwig RJ, 2005, THROMB HAEMOSTASIS, V94, P1265, DOI 10.1160/TH05-05-0318; Ludwig RJ, 2003, CONTACT DERMATITIS, V49, P158, DOI 10.1111/j.0105-1873.2003.0185a.x; Mjosberg J, 2009, J IMMUNOL, V183, P759, DOI 10.4049/jimmunol.0803654; Nagler M, 2012, THROMB RES, V129, P407, DOI 10.1016/j.thromres.2011.10.037; PATRIARCA G, 1994, ALLERGY, V49, P292, DOI 10.1111/j.1398-9995.1994.tb02663.x; Peitsch WK, 2004, HAUTARZT, V55, P410, DOI 10.1007/s00105-003-0682-3; Schellong SM, 2003, THROMB HAEMOSTASIS, V89, P228; Schindewolf M, 2007, Hamostaseologie, V27, P89; Schindewolf M, 2010, PHLEBOLOGIE, V39, P226; Schindewolf M, 2010, J THROMB HAEMOST, V8, P1486, DOI 10.1111/j.1538-7836.2010.03795.x; Schindewolf M, 2012, LANCET, V380, P1867, DOI 10.1016/S0140-6736(12)60409-7; Schindewolf M, 2010, MAYO CLIN PROC, V85, P913, DOI 10.4065/mcp.2010.0346; Schindewolf M, 2009, CAN MED ASSOC J, V181, P477, DOI 10.1503/cmaj.081729; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Schulman S, 2010, J THROMB HAEMOST, V8, P202, DOI 10.1111/j.1538-7836.2009.03678.x; Trautmann A, 1997, Z HAUTKRANKHEITEN, V72, P447; Utikal J, 2005, THROMB HAEMOSTASIS, V94, P895; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; Warkentin TE, 1996, BRIT J HAEMATOL, V92, P494, DOI 10.1046/j.1365-2141.1996.d01-1481.x; Warkentin TE, 2005, CHEST, V127, P1857, DOI 10.1378/chest.127.5.1857; Warkentin TE, 2004, HEPARIN INDUCED THRO, P53; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X	44	31	33	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					131	139		10.1016/j.jaci.2013.02.047	http://dx.doi.org/10.1016/j.jaci.2013.02.047			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23726261				2022-12-18	WOS:000321052300018
J	Afshar, R; Strassner, JP; Seung, E; Causton, B; Cho, JL; Harris, RS; Hamilos, DL; Medoff, BD; Luster, AD				Afshar, Roshi; Strassner, James P.; Seung, Edward; Causton, Benjamin; Cho, Josalyn L.; Harris, R. Scott; Hamilos, Daniel L.; Medoff, Benjamin D.; Luster, Andrew D.			Compartmentalized chemokine-dependent regulatory T-cell inhibition of allergic pulmonary inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; regulatory T cells; chemokines; CCR4; CCR7; segmental allergen challenge	RECEPTOR EXPRESSION; AIRWAY INFLAMMATION; ASTHMA; CCR7; DISEASE; HYPERRESPONSIVENESS; INDUCTION; TOLERANCE; MIGRATION; SUBSETS	Background: Induction of endogenous regulatory T (Treg) cells represents an exciting new potential modality for treating allergic diseases, such as asthma. Treg cells have been implicated in the regulation of asthma, but the anatomic location in which they exert their regulatory function and the mechanisms controlling the migration necessary for their suppressive function in asthma are not known. Understanding these aspects of Treg cell biology will be important for harnessing their power in the clinic. Objective: We sought to determine the anatomic location at which Treg cells exert their regulatory function in the sensitization and effector phases of allergic asthma and to determine the chemokine receptors that control the migration of Treg cells to these sites in vivo in both mice and human subjects. Methods: The clinical efficacy and anatomic location of adoptively transferred chemokine receptor-deficient CD4(+)CD25(+) forkhead box protein 3-positive Treg cells was determined in the sensitization and effector phases of allergic airway inflammation in mice. The chemokine receptor expression profile was determined on Treg cells recruited into the human airway after bronchoscopic segmental allergen challenge of asthmatic patients. Results: We show that CCR7, but not CCR4, is required on Treg cells to suppress allergic airway inflammation during the sensitization phase. In contrast, CCR4, but not CCR7, is required on Treg cells to suppress allergic airway inflammation during the effector phase. Consistent with our murine studies, human subjects with allergic asthma had an increase in CCR4-expressing functional Treg cells in the lungs after segmental allergen challenge. Conclusion: The location of Treg cell function differs during allergic sensitization and allergen-induced recall responses in the lung, and this differential localization is critically dependent on differential chemokine function.	[Afshar, Roshi; Strassner, James P.; Seung, Edward; Causton, Benjamin; Cho, Josalyn L.; Hamilos, Daniel L.; Medoff, Benjamin D.; Luster, Andrew D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol,Ctr Immunol & Inf, Cambridge, MA 02138 USA; [Causton, Benjamin; Cho, Josalyn L.; Harris, R. Scott; Medoff, Benjamin D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pulm & Crit Care Unit, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Luster, AD (corresponding author), Massachusetts Gen Hosp, 149,13th St, Charlestown, MA 02129 USA.	aluster@mgh.harvard.edu	Luster, Andrew/ABE-6504-2020; Cho, Josalyn/ABF-8931-2021	Luster, Andrew/0000-0001-9679-7912; Cho, Josalyn/0000-0002-0367-4495; Strassner, James/0000-0002-0632-1169; Medoff, Benjamin/0000-0002-2558-0449	National Institutes of Health [R37AI0406, U19AI095261, T32 AI060548]; Merck; United Therapeutics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060548, R37AI040618, U19AI095261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Merck(Merck & Company); United Therapeutics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the National Institutes of Health (R37AI0406, U19AI095261, and T32 AI060548 to A.D.L.).; Disclosure of potential conflict of interest: D. L. Hamilos has consultant arrangements with and has received grants from Merck. R. S. Harris has consultant arrangements with Merck and has received grants from United Therapeutics. A. D. Luster has consultant arrangements with Amgen, Idera, Lilly, and Merck. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; Bystry RS, 2001, NAT IMMUNOL, V2, P1126, DOI 10.1038/ni735; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; Conroy DM, 2003, J LEUKOCYTE BIOL, V74, P558, DOI 10.1189/jlb.0103030; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; Eller K, 2010, J AM SOC NEPHROL, V21, P42, DOI 10.1681/ASN.2009020133; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hoerning A, 2011, EUR J IMMUNOL, V41, P2291, DOI 10.1002/eji.201041095; Iellem A, 2003, EUR J IMMUNOL, V33, P1488, DOI 10.1002/eji.200323658; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lee JH, 2007, CLIN EXP IMMUNOL, V148, P53, DOI 10.1111/j.1365-2249.2007.03329.x; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Lim HW, 2006, J IMMUNOL, V177, P840, DOI 10.4049/jimmunol.177.2.840; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Menning A, 2007, EUR J IMMUNOL, V37, P1575, DOI 10.1002/eji.200737201; Mikhak Z, 2009, J ALLERGY CLIN IMMUN, V123, P67, DOI 10.1016/j.jaci.2008.09.049; Sather BD, 2007, J EXP MED, V204, P1335, DOI 10.1084/jem.20070081; Schneider MA, 2007, J EXP MED, V204, P735, DOI 10.1084/jem.20061405; Seung E, 2011, J IMMUNOL, V186, P6830, DOI 10.4049/jimmunol.1001049; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Thomas SY, 2007, J IMMUNOL, V179, P1901, DOI 10.4049/jimmunol.179.3.1901; Ueha S, 2007, J LEUKOCYTE BIOL, V82, P1230, DOI 10.1189/jlb.0906574; Valmori D, 2005, J CLIN INVEST, V115, P1953, DOI 10.1172/JCI23963; Yuan Q, 2007, J EXP MED, V204, P1327, DOI 10.1084/jem.20062076	32	31	33	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1644	+		10.1016/j.jaci.2013.03.002	http://dx.doi.org/10.1016/j.jaci.2013.03.002			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23632297	Green Accepted			2022-12-18	WOS:000320532800025
J	Spergel, JM				Spergel, Jonathan M.			Natural history of cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Milk allergy; food allergy; specific IgE; skin testing	CLINICAL-COURSE; TOLERANCE; CHILDREN		[Spergel, Jonathan M.] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Spergel, Jonathan M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Spergel, JM (corresponding author), Childrens Hosp Philadelphia, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	spergel@email.chop.edu		Spergel, Jonathan/0000-0002-4658-5353				Ahrens B, 2012, CLIN EXP ALLERGY, V42, P1630, DOI 10.1111/cea.12001; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; BISHOP JM, 1990, J PEDIATR-US, V116, P862, DOI 10.1016/S0022-3476(05)80641-9; Elizur A, 2012, J PEDIAT, V161, P482; Fiocchi A, 2008, ANN ALLERG ASTHMA IM, V101, P166, DOI 10.1016/S1081-1206(10)60205-0; Fleischer DM, 2011, J PEDIATR-US, V158, P578, DOI 10.1016/j.jpeds.2010.09.027; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; Saarinen KM, 2005, J ALLERGY CLIN IMMUN, V116, P869, DOI 10.1016/j.jaci.2005.06.018; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473, DOI 10.1016/S1081-1206(10)62574-4; Vanto T, 2004, J PEDIATR-US, V144, P218, DOI 10.1016/j.jpeds.2003.10.063; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060	12	31	32	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					813	814		10.1016/j.jaci.2013.01.027	http://dx.doi.org/10.1016/j.jaci.2013.01.027			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23452903				2022-12-18	WOS:000315587800024
J	Alvarez-Twose, I; Bonadonna, P; Matito, A; Zanotti, R; Gonzalez-de-Olano, D; Sanchez-Munoz, L; Morgado, JM; Orfao, A; Escribano, L				Alvarez-Twose, Ivan; Bonadonna, Patrizia; Matito, Almudena; Zanotti, Roberta; Gonzalez-de-Olano, David; Sanchez-Munoz, Laura; Mario Morgado, Jose; Orfao, Alberto; Escribano, Luis			Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MAST-CELL DISORDERS; SPANISH NETWORK		[Alvarez-Twose, Ivan; Matito, Almudena; Sanchez-Munoz, Laura; Mario Morgado, Jose; Escribano, Luis] Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Toledo, Spain; [Alvarez-Twose, Ivan; Matito, Almudena; Gonzalez-de-Olano, David; Sanchez-Munoz, Laura; Mario Morgado, Jose; Orfao, Alberto; Escribano, Luis] Spanish Network Mastocitosis REMA, Madrid, Spain; [Bonadonna, Patrizia] Azienda Osped Univ Integrata, Allergy Unit, Verona, Italy; [Bonadonna, Patrizia; Zanotti, Roberta] Rete Italiana Mastocitosi RIMA, Bologna, Italy; [Zanotti, Roberta] Univ Verona, Sect Haematol, Dept Clin & Expt Med, I-37100 Verona, Italy; [Gonzalez-de-Olano, David] Hosp Fuenlabrada, Allergy Unit, Madrid, Spain; [Orfao, Alberto] USAL, CSIC, IBMCC, Serv Gen Citometria,Ctr Invest Canc, Salamanca, Spain; [Orfao, Alberto] Univ Salamanca, Dept Med, E-37008 Salamanca, Spain	Complejo Hospitalario de Toledo; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Hospital Universitario Fuenlabrada; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Alvarez-Twose, I (corresponding author), Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Toledo, Spain.	ivana@sescam.jccm.es	Orfao, Alberto/B-5801-2017	Alvarez-Twose, Ivan/0000-0002-1190-4473; Sanchez-Munoz, Laura/0000-0003-1757-7255; Matito, Almudena/0000-0002-9547-4844				Alvarez-Twose I, 2012, INT ARCH ALLERGY IMM, V157, P275, DOI 10.1159/000329856; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Escribano L, 2004, CYTOM PART B-CLIN CY, V58B, P1, DOI 10.1002/cyto.b.10072; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Orfao A, 1996, AM J PATHOL, V149, P1493; Stoevesandt J, 2012, J ALLERGY CLIN IMMUN, V130, P698, DOI 10.1016/j.jaci.2012.03.024	7	31	31	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					614	615		10.1016/j.jaci.2012.10.052	http://dx.doi.org/10.1016/j.jaci.2012.10.052			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23273956	Green Submitted			2022-12-18	WOS:000314661500054
J	Chou, J; Hanna-Wakim, R; Tirosh, I; Kane, J; Fraulino, D; Lee, YN; Ghanem, S; Mahfouz, I; Megarbane, A; Lefranc, G; Inati, A; Dbaibo, G; Giliani, S; Notarangelo, LD; Geha, RS; Massaad, MJ				Chou, Janet; Hanna-Wakim, Rima; Tirosh, Irit; Kane, Jennifer; Fraulino, David; Lee, Yu Nee; Ghanem, Soha; Mahfouz, Iman; Megarbane, Andre; Lefranc, Gerard; Inati, Adlette; Dbaibo, Ghassan; Giliani, Silvia; Notarangelo, Luigi D.; Geha, Raif S.; Massaad, Michel J.			A novel homozygous mutation in recombination activating gene 2 in 2 relatives with different clinical phenotypes: Omenn syndrome and hyper-IgM syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RAG MUTATIONS; DISEASE		[Chou, Janet; Tirosh, Irit; Kane, Jennifer; Fraulino, David; Lee, Yu Nee; Notarangelo, Luigi D.; Geha, Raif S.; Massaad, Michel J.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Chou, Janet; Tirosh, Irit; Kane, Jennifer; Fraulino, David; Lee, Yu Nee; Notarangelo, Luigi D.; Geha, Raif S.; Massaad, Michel J.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Hanna-Wakim, Rima; Ghanem, Soha; Mahfouz, Iman; Dbaibo, Ghassan] Amer Univ Beirut, Med Ctr, Dept Pediat & Adolescent Med, Beirut, Lebanon; [Megarbane, Andre] Univ St Joseph, Unite Genet Med, Beirut, Lebanon; [Lefranc, Gerard] CNRS, Inst Genet Humaine, Montpellier, France; [Lefranc, Gerard] Univ Montpellier 2, Montpellier, France; [Inati, Adlette] Rafik Hariri Univ Hosp, Childrens Ctr Canc & Blood Dis, Div Pediat Hematol & Oncol, Beirut, Lebanon; [Giliani, Silvia] Univ Brescia, Dept Pediat, Angelo Nocivelli Inst Mol Med, Brescia, Italy	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; American University of Beirut; Saint Joseph University Beirut; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; University of Brescia	Chou, J (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016; Megarbane, Andre/ABD-5574-2021; Dbaibo, Ghassan S./X-2978-2019; Lee, Yu Nee/T-2360-2017	Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; Lee, Yu Nee/0000-0001-8648-5253	NIAID NIH HHS [T32AI007512, 1P01AI076210-01A1, P01 AI076210, T32 AI007512, R03 AI094017] Funding Source: Medline; NIAMS NIH HHS [R01 AR047417] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, T32AI007512, R03AI094017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Couedel C, 2010, J CLIN INVEST, V120, P1337, DOI 10.1172/JCI41305; Dalal I, 2005, CLIN IMMUNOL, V115, P70, DOI 10.1016/j.clim.2004.08.016; De Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583; Gapud EJ, 2011, J IMMUNOL, V187, P1826, DOI 10.4049/jimmunol.1101388; JOLLIFF CR, 1982, CLIN CHEM, V28, P126; Marrella V, 2007, J CLIN INVEST, V117, P1260, DOI 10.1172/JCI30928; Niehues T, 2010, CLIN IMMUNOL, V135, P183, DOI 10.1016/j.clim.2010.01.013; Schatz DG, 2011, NAT REV IMMUNOL, V11, P251, DOI 10.1038/nri2941; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Vale AM, 2010, J ALLERGY CLIN IMMUN, V125, P778, DOI 10.1016/j.jaci.2010.02.018	11	31	31	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1414	1416		10.1016/j.jaci.2012.06.012	http://dx.doi.org/10.1016/j.jaci.2012.06.012			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22841008	Green Accepted			2022-12-18	WOS:000311641100024
J	Patel, M; Pilcher, J; Chan, A; Perrin, K; Black, P; Beasley, R				Patel, Mitesh; Pilcher, Janine; Chan, Amy; Perrin, Kyle; Black, Peter; Beasley, Richard			Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: Implications for asthma clinical trial use	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Patel, Mitesh; Pilcher, Janine; Perrin, Kyle; Beasley, Richard] Med Res Inst New Zealand, Wellington, New Zealand; [Patel, Mitesh; Pilcher, Janine; Perrin, Kyle; Beasley, Richard] Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Patel, Mitesh] Univ Nottingham, Sch Clin Sci, Div Resp Med, Nottingham NG7 2RD, England; [Chan, Amy; Black, Peter] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand; [Beasley, Richard] Univ Otago, Dept Med, Wellington, New Zealand	Medical Research Institute Of New Zealand; University of Nottingham; University of Auckland; University of Otago	Patel, M (corresponding author), Med Res Inst New Zealand, Wellington, New Zealand.	mitesh.patel@mrinz.ac.nz	Beasley, Richard/AAH-3908-2019	Beasley, Richard/0000-0003-0337-406X; Chan, Amy Hai Yan/0000-0002-1291-3902				Apter AJ, 2001, ANN ALLERG ASTHMA IM, V86, P421, DOI 10.1016/S1081-1206(10)62488-X; Burgess SW, 2006, RESP MED, V100, P841, DOI 10.1016/j.rmed.2005.09.004; Chan AHY, 2009, AUSTR PHARM SCI ASS; Julius SM, 2002, CHEST, V121, P871, DOI 10.1378/chest.121.3.871; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; Nexus 6 Limited, SMART TRACK PROD DET; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Simmons MS, 1998, J ALLERGY CLIN IMMUN, V102, P409, DOI 10.1016/S0091-6749(98)70128-9	9	31	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1420	1422		10.1016/j.jaci.2012.06.037	http://dx.doi.org/10.1016/j.jaci.2012.06.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22920492				2022-12-18	WOS:000311641100027
J	Lisciandro, JG; Prescott, SL; Nadal-Sims, MG; Devitt, CJ; Richmond, PC; Pomat, W; Siba, PM; Holt, PG; Strickland, DH; van den Biggelaar, AHJ				Lisciandro, Joanne G.; Prescott, Susan L.; Nadal-Sims, Marie G.; Devitt, Catherine J.; Richmond, Peter C.; Pomat, William; Siba, Peter M.; Holt, Patrick G.; Strickland, Deborah H.; van den Biggelaar, Anita H. J.			Neonatal antigen-presenting cells are functionally more quiescent in children born under traditional compared with modern environmental conditions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antigen-presenting cell; cord blood; hygiene hypothesis; neonatal; T cell; Papua New Guinea; Australia	EXPOSURE IN-UTERO; ATOPIC SENSITIZATION; HAY-FEVER; COSTIMULATORY MOLECULES; AIRWAY INFLAMMATION; DENDRITIC CELLS; FARM EXPOSURE; EXPRESSION; PHENOTYPE; MONOCYTES	Background: One explanation for the high burden of allergic and autoimmune diseases in industrialized countries is inappropriate immune development under modern environmental conditions. There is increasing evidence that the process of immune deviation already begins in utero, but the underlying immunologic mechanisms are not clear. Objective: We sought to identify differences in the function of neonatal antigen-presenting cells (APCs) in children born in settings that are more traditional versus those of modern societies. Methods: Cord blood mononuclear cells were collected from newborns from Papua New Guinea (PNG; traditional) and Australia (modern) and compared for differences in APCs and T-cell phenotype and function. Results: Australian cord naive T cells (CD4(+) CD25(-)CD127(+) cells) showed an enhanced and more rapid proliferative response in an autologous, APC-dependent culture system, a result of differences in neonatal APCs rather than T-cell function. This included an increased capacity to process antigen and to upregulate activation markers after stimulation. In contrast, resting PNG APCs exhibited higher baseline levels of activation and inhibitory markers and were less responsive or nonresponsive to stimulation in vitro. Conclusions: This study supports the hypothesis that prenatal environments can influence the developing immune system in utero. Children born under modern environmental conditions exhibit increased APC reactivity at birth compared with children born under traditional environmental conditions. The functionally more quiescent nature of PNG neonatal APCs might protect against the development of harmful inflammatory responses in early life. (J Allergy Clin Immunol 2012;130:1167-74.)	[Lisciandro, Joanne G.; Nadal-Sims, Marie G.; Devitt, Catherine J.; Holt, Patrick G.; Strickland, Deborah H.; van den Biggelaar, Anita H. J.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Lisciandro, Joanne G.; Prescott, Susan L.; Richmond, Peter C.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Pomat, William; Siba, Peter M.] Papua New Guinea Inst Med Res, Goroka, Papua N Guinea	Telethon Kids Institute; University of Western Australia; University of Western Australia; PNG Institute Of Medical Research	van den Biggelaar, AHJ (corresponding author), Crucell Innovat & Discovery Lab, Archimedesweg 4-6, NL-2333 CN Leiden, Netherlands.	Anita.vandenBiggelaar@Crucell.com	Prescott, Susan/H-5665-2014; Strickland, Deborah/AGV-6937-2022; Richmond, Peter C/G-3379-2012; strickland, deborah/K-4597-2019; Holt, Patrick/H-1548-2011	Strickland, Deborah/0000-0003-0114-4201; Richmond, Peter C/0000-0001-7562-7228; Holt, Patrick/0000-0003-1193-0935	Australian National Health and Medical Research Council (NHMRC) [513836]; University of Western Australia; Australian Postgraduate Award; Stan and Jean Perron Award; Perron Performance Award; NHRMC R Douglas Wright Biomedical Career Development Grant [458780]; ALK-Abello; Wellcome Trust; National Health and Medical Research Council of Australia; Telethon Institute for Child Health Research	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); University of Western Australia; Australian Postgraduate Award(Australian Government); Stan and Jean Perron Award; Perron Performance Award; NHRMC R Douglas Wright Biomedical Career Development Grant(National Health and Medical Research Council (NHMRC) of AustraliaGerman Research Foundation (DFG)); ALK-Abello; Wellcome Trust(Wellcome TrustEuropean Commission); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Telethon Institute for Child Health Research	Supported by an Australian National Health and Medical Research Council (NHMRC) Project Grant (513836) and a University of Western Australia Research Grants Scheme. J.G.L. received an Australian Postgraduate Award, a Stan and Jean Perron Award, and a Perron Performance Award, and A.H.J.B. was supported by a NHRMC R Douglas Wright Biomedical Career Development Grant (458780).; Disclosure of potential conflict of interest: S. L. Prescott is a Board member for the Nestle Nutrition Institute (Australasia) and for Danone and has received speakers' fees from ALK-Abello. P. C. Richmond has received support for research from the Wellcome Trust and the National Health and Medical Research Council of Australia. W. Pomat has received support for research from the Telethon Institute for Child Health Research and the University of Western Australia. P. M. Siba has received support for research from the Telethon Institute for Child Health Research. A. van den Biggelaar has received support for research from the National Health and Medical Research Council of Australia. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2011, UN HUM DEV IND; Ben-Smith A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-139; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Brown DP, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-56; CHEADLE WG, 1993, AM J SURG, V165, pS75, DOI 10.1016/S0002-9610(05)81210-3; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; de Silva HJ, 2008, T ROY SOC TROP MED H, V102, P857, DOI 10.1016/j.trstmh.2008.03.016; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Ellestad KK, 2009, J IMMUNOL, V183, P298, DOI 10.4049/jimmunol.0803576; Elliott AM, 2005, JAMA-J AM MED ASSOC, V294, P2032, DOI 10.1001/jama.294.16.2032-c; Fievet N, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-251; Gur-Wahnon D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006846; Herbert OC, 2009, WORLD ALLERGY ORGAN, V2, P130, DOI 10.1097/WOX.0b013e3181accf27; Holt PG, 2009, J EXP MED, V206, P2861, DOI 10.1084/jem.20092469; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Jiao L, 2009, EUR J IMMUNOL, V39, P469, DOI 10.1002/eji.200838367; Karp CL, 1998, EUR J IMMUNOL, V28, P3128, DOI 10.1002/(SICI)1521-4141(199810)28:10<3128::AID-IMMU3128>3.0.CO;2-T; Kohler C, 2008, PEDIATR RES, V64, P631, DOI 10.1203/PDR.0b013e31818718ba; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lambrecht BN, 2010, LANCET, V376, P835, DOI 10.1016/S0140-6736(10)61226-3; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Larche M, 1998, J IMMUNOL, V161, P6375; Lisciandro JG, 2012, PEDIAT ALLERG IMM-UK, V23, P173, DOI 10.1111/j.1399-3038.2011.01242.x; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Nolan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006600; Obeng BB, 2008, CURR OPIN ALLERGY CL, V8, P391, DOI 10.1097/ACI.0b013e32830ebb70; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI 10.1016/j.jaci.2008.04.042; RACKE MK, 1995, J CLIN INVEST, V96, P2195, DOI 10.1172/JCI118274; Rochat MK, 2010, CLIN EXP ALLERGY, V40, P786, DOI 10.1111/j.1365-2222.2009.03428.x; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schweitzer AN, 1997, J IMMUNOL, V158, P2713; Souza PEA, 2007, INFECT IMMUN, V75, P1886, DOI 10.1128/IAI.01931-06; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sudre B, 2009, ALLERGY, V64, P1068, DOI 10.1111/j.1398-9995.2009.01958.x; Thornton CA, 2010, CURR ALLERGY ASTHM R, V10, P444, DOI 10.1007/s11882-010-0148-5; Tulic MK, 2011, J ALLERGY CLIN IMMUN, V127, P470, DOI 10.1016/j.jaci.2010.09.020; Upham JW, 2004, J ALLERGY CLIN IMMUN, V114, P1202, DOI 10.1016/j.jaci.2004.06.051; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van den Biggelaar AHJ, 2011, VACCINE, V29, P5414, DOI 10.1016/j.vaccine.2011.05.065; van den Biggelaar AHJ, 2009, J ALLERGY CLIN IMMUN, V124, P544, DOI 10.1016/j.jaci.2009.03.040; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138; Yerkovich ST, 2007, PEDIATR RES, V62, P547, DOI 10.1203/PDR.0b013e3181568105; Zhao J, 2008, P NATL ACAD SCI USA, V105, P7528, DOI 10.1073/pnas.0800152105	48	31	33	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1167	+		10.1016/j.jaci.2012.06.005	http://dx.doi.org/10.1016/j.jaci.2012.06.005			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22818765				2022-12-18	WOS:000310571400019
J	Kast, JI; Wanke, K; Soyka, MB; Wawrzyniak, P; Akdis, D; Kingo, K; Rebane, A; Akdis, CA				Kast, Jeannette I.; Wanke, Kerstin; Soyka, Michael B.; Wawrzyniak, Paulina; Akdis, Deniz; Kingo, Kuelli; Rebane, Ana; Akdis, Cezmi A.			The broad spectrum of interepithelial junctions in skin and lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Kast, Jeannette I.; Wanke, Kerstin; Soyka, Michael B.; Wawrzyniak, Paulina; Akdis, Deniz; Rebane, Ana; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Soyka, Michael B.] Univ Zurich Hosp, Dept Otolaryngol Head & Neck Surg, CH-8091 Zurich, Switzerland; [Kingo, Kuelli] Tartu Univ Hosp, Dept Dermatol, Tartu, Estonia; [Kingo, Kuelli] Univ Tartu, Dept Physiol, Ctr Mol & Clin Med, EE-50090 Tartu, Estonia; [Rebane, Ana] Univ Tartu, Fac Med, EE-50090 Tartu, Estonia	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Zurich; University Zurich Hospital; University of Tartu; University of Tartu	Kast, JI (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.	akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; Wawrzyniak, Paulina/AAD-7265-2020; Rebane, Ana/D-4279-2013; Kast, Jeannette/I-2397-2013; Wawrzyniak, Paulina/AAG-3548-2019; Kingo, Külli/H-3603-2012; Wawrzyniak, Paulina/HCG-8924-2022	Akdis, Cezmi/0000-0001-8020-019X; Wawrzyniak, Paulina/0000-0001-9641-2103; Rebane, Ana/0000-0001-6051-1361; Kingo, Kulli/0000-0001-6301-9612				Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Fujita H, 2011, J ALLERGY CLIN IMMUN, V127, P1612, DOI 10.1016/j.jaci.2011.03.039; Furuse M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002907; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Lal-Nag M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-235; Lin HX, 2007, J PHARM SCI-US, V96, P341, DOI 10.1002/jps.20803; Mineta K, 2011, FEBS LETT, V585, P606, DOI 10.1016/j.febslet.2011.01.028; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038	10	31	36	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					544	547		10.1016/j.jaci.2012.04.044	http://dx.doi.org/10.1016/j.jaci.2012.04.044			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22704535				2022-12-18	WOS:000307002200043
J	Weiss, ST				Weiss, Scott T.			New approaches to personalized medicine for asthma: Where are we?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Personalized medicine; asthma; genomics; pharmacogenomics; drug treatment; whole genome sequencing	ALOX5 PROMOTER GENOTYPE; IMPROVED LUNG-FUNCTION; VITAMIN-D LEVELS; CLINICAL-RESPONSE; BETA(2)-ADRENERGIC RECEPTOR; TRANSCRIPTION FACTOR; BETA(2) AGONIST; T-BET; POLYMORPHISMS; ASSOCIATION	Access to an electronic medical record is essential for personalized medicine. Currently, only 40% of US physicians have such access, but this is rapidly changing. It is expected that 100,000 Americans will have their whole genome sequenced in 2012. The cost of such sequencing is rapidly dropping, and is estimated to be $1000 by 2013. These technological advances will make interpretation of whole genome sequence data a major clinical challenge for the foreseeable future. At present, a relatively small number of genes have been identified to determine drug treatment response phenotypes for asthma. It is anticipated that this will dramatically increase over the next 10 years as personalized medicine becomes more of a reality for asthma patients. (J Allergy Clin Immunol 2012;129:327-34.)	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Weiss, ST (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	scott.weiss@channing.harvard.edu			GlaxoSmithKline	GlaxoSmithKline(GlaxoSmithKline)	S. T. Weiss has consulted for GlaxoSmithKline, Genentech, Novartis, Merck, and Schering-Plough; received research support from GlaxoSmithKline; and collaborated with Genome Network Sciences (GNS).	Akinbami Lara J, 2011, Natl Health Stat Report, P1; Asano K, 2002, PHARMACOGENETICS, V12, P565, DOI 10.1097/00008571-200210000-00009; Banerjee A, 2008, BRIT J PHARMACOL, V155, P84, DOI 10.1038/bjp.2008.232; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Bleecker ER, 2007, LANCET, V370, P2118, DOI 10.1016/S0140-6736(07)61906-0; Bleecker ER, 2010, AM J RESP CRIT CARE, V181, P676, DOI [10.1164/rccm.200809-1511OC, 10.1164/200809-1511OC]; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Choudhry S, 2010, PHARMACOGENET GENOM, V20, P351, DOI 10.1097/FPC.0b013e328337f992; Damera G, 2009, BRIT J PHARMACOL, V158, P1429, DOI 10.1111/j.1476-5381.2009.00428.x; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Duan QL, 2011, AM J RESP CRIT CARE, V183, P449, DOI 10.1164/rccm.201005-0758OC; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; FISCHER A, 1990, IMMUNOLOGY, V71, P473; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, pe1, DOI DOI 10.1016/J.JACI.2009.07.035.PUBMED; Haselkorn T, 2010, ANN ALLERG ASTHMA IM, V104, P471, DOI 10.1016/j.anai.2010.04.006; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P895, DOI 10.1016/j.jaci.2009.07.035; Hawkins GA, 2006, AM J RESP CRIT CARE, V174, P1101, DOI 10.1164/rccm.200509-1405OC; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Klotsman M, 2007, PHARMACOGENET GENOM, V17, P189, DOI 10.1097/FPC.0b013e3280120043; Koster ES, 2011, ALLERGY, V66, P1546, DOI 10.1111/j.1398-9995.2011.02701.x; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Litonjua AA, 2008, AM J RESP CRIT CARE, V178, P688, DOI 10.1164/rccm.200709-1363OC; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Mastalerz L, 2002, EUR J CLIN INVEST, V32, P949, DOI 10.1046/j.1365-2362.2002.01088.x; Mougey EB, 2009, PHARMACOGENET GENOM, V19, P129, DOI 10.1097/FPC.0b013e32831bd98c; Ogawa Y, 2006, J ALLERGY CLIN IMMUN, V118, P789, DOI 10.1016/j.jaci.2006.08.009; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Raby BA, 2009, CURR PHARM DESIGN, V15, P3773, DOI 10.2174/138161209789649466; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; Scadding GW, 2010, CURR OPIN ALLERGY CL, V10, P370, DOI 10.1097/ACI.0b013e32833bfa20; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2011, J ALLERGY CLIN IMMUN, V128, P937, DOI 10.1016/j.jaci.2011.09.004; Tantisira KG, 2008, PHARMACOGENET GENOM, V18, P733, DOI 10.1097/FPC.0b013e3282fe6ebf; Tantisira KG, 2007, J ALLERGY CLIN IMMUN, V120, P1285, DOI 10.1016/j.jaci.2007.09.005; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; Telleria JJ, 2008, RESP MED, V102, P857, DOI 10.1016/j.rmed.2008.01.011; The United States Department of Defense, 2008, REP C ASS US GOV ADV, P11; U. S. Department of Health and Human Services, 2008, NIH PUBL, V11-1647; Umland SP, 2002, PULM PHARMACOL THER, V15, P35, DOI 10.1006/pupt.2001.0312; Vonk JM, 2010, PHARMACOGENET GENOM, V20, P179, DOI 10.1097/FPC.0b013e328336c7fd; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Wechsler ME, 2009, LANCET, V374, P1754, DOI 10.1016/S0140-6736(09)61492-6; Weiss ST, 2008, NAT REV DRUG DISCOV, V7, P568, DOI 10.1038/nrd2520; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	63	31	31	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					327	334		10.1016/j.jaci.2011.12.971	http://dx.doi.org/10.1016/j.jaci.2011.12.971			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22284929				2022-12-18	WOS:000299951700005
J	de la Fuente, MA; Recher, M; Rider, NL; Strauss, KA; Morton, DH; Adair, M; Bonilla, FA; Ochs, HD; Gelfand, EW; Pessach, IM; Walter, JE; King, A; Giliani, S; Pai, SY; Notarangelo, LD				de la Fuente, Miguel A.; Recher, Mike; Rider, Nicholas L.; Strauss, Kevin A.; Morton, D. Holmes; Adair, Margaret; Bonilla, Francisco A.; Ochs, Hans D.; Gelfand, Erwin W.; Pessach, Itai M.; Walter, Jolan E.; King, Alejandra; Giliani, Silvia; Pai, Sung-Yun; Notarangelo, Luigi D.			Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cartilage-hair hypoplasia; RMRP; immunodeficiency; T lymphocytes; thymus; cell cycle; apoptosis	RNA COMPONENT; IMPAIRMENT; EXPRESSION; MUTATIONS; FEATURES	Background: Cartilage-hair hypoplasia (CHH) is characterized by metaphyseal dysplasia, bone marrow failure, increased risk of malignancies, and a variable degree of immunodeficiency. CHH is caused by mutations in the RNA component of the mitochondrial RNA processing (RMRP) endoribonuclease gene, which is involved in ribosomal assembly, telomere function, and cell cycle control. Objectives: We aimed to define thymic output and characterize immune function in a cohort of patients with molecularly defined CHH with and without associated clinical immunodeficiency. Methods: We studied the distribution of B and T lymphocytes (including recent thymic emigrants), in vitro lymphocyte proliferation, cell cycle, and apoptosis in 18 patients with CHH compared with controls. Results: Patients with CHH have a markedly reduced number of recent thymic emigrants, and their peripheral T cells show defects in cell cycle control and display increased apoptosis, resulting in poor proliferation on activation. Conclusion: These data confirm that RMRP mutations result in significant defects of cell-mediated immunity and provide a link between the cellular phenotype and the immunodeficiency in CHH. (J Allergy Clin Immunol 2011; 128: 139-46.)	[de la Fuente, Miguel A.; Recher, Mike; Bonilla, Francisco A.; Pessach, Itai M.; Walter, Jolan E.; Notarangelo, Luigi D.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [de la Fuente, Miguel A.; Recher, Mike; Bonilla, Francisco A.; Pessach, Itai M.; Walter, Jolan E.; Notarangelo, Luigi D.] Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA; [Pai, Sung-Yun] Childrens Hosp, Div Hematol, Boston, MA 02115 USA; [Rider, Nicholas L.; Strauss, Kevin A.; Morton, D. Holmes] Clin Special Children, Strasbourg, France; [Adair, Margaret; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Ochs, Hans D.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Ochs, Hans D.] Seattle Childrens Res Inst, Seattle, WA USA; [King, Alejandra] Hosp Ninos Luis Calvo Mackenna, Immunol Unit, Santiago, Chile; [Giliani, Silvia] Univ Brescia, Angelo Nocivelli Inst Mol Med, I-25121 Brescia, Italy; [Giliani, Silvia] Univ Brescia, Dept Pediat, I-25121 Brescia, Italy; [Strauss, Kevin A.; Morton, D. Holmes] Franklin & Marshall Coll, Dept Biol, Lancaster, PA 17604 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; National Jewish Health; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Universidad de Chile; University of Brescia; University of Brescia; Franklin & Marshall College	Notarangelo, LD (corresponding author), Childrens Hosp, Div Immunol, Karp Res Bldg,Room 9210,1 Blackfan Circle, Boston, MA 02115 USA.	luigi.notarangelo@childrens.harvard.edu	de la Fuente, Miguel A/C-7478-2013; Pai, Sung-Yun/AAH-7762-2019; Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016	de la Fuente, Miguel A/0000-0003-4619-8756; Pai, Sung-Yun/0000-0002-0158-8147; Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; Recher, Mike/0000-0002-9121-6936	Manton Foundation; Swiss National Science Foundation [PASMP3-127678/1]; Talecris Biotherapeutics; NIH; Jeffrey Modell Foundation; CSL Behring; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210] Funding Source: NIH RePORTER	Manton Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Talecris Biotherapeutics; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jeffrey Modell Foundation; CSL Behring; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Manton Foundation. M. Recher was supported by the Swiss National Science Foundation (SSMB; grant PASMP3-127678/1). M. Adair was supported by a fellowship from Talecris Biotherapeutics.; Disclosure of potential conflict of interest: F. A. Bonilla receives research support from Talecris Biotherapeutics, has consultant arrangements with ENTRA Pharmaceuticals and CSL Behring, receives royalties from UpToDate, and is an advisor for the Immune Deficiency Foundation. H. D. Ochs has served on the advisory board for Baxter and receives research support from the NIH, the Jeffrey Modell Foundation, and CSL Behring. The rest of the authors have declared that they have no conflict of interest.	Bordon V, 2010, BLOOD, V116, P27, DOI 10.1182/blood-2010-01-259168; Cai T, 2002, GENETICS, V161, P1029; CASTIGLI E, 1995, CLIN EXP IMMUNOL, V102, P6; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Guggenheim R, 2006, BONE MARROW TRANSPL, V38, P751, DOI 10.1038/sj.bmt.1705520; Horn J, 2010, HUM IMMUNOL, V71, P916, DOI 10.1016/j.humimm.2010.06.002; Kavadas FD, 2008, J ALLERGY CLIN IMMUN, V122, P1178, DOI 10.1016/j.jaci.2008.07.036; Maida Y, 2009, NATURE, V461, P230, DOI 10.1038/nature08283; Makitie O, 1998, EUR J PEDIATR, V157, P816, DOI 10.1007/s004310050943; MAKITIE O, 1993, EUR J PEDIATR, V152, P211, DOI 10.1007/BF01956147; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Notarangelo LD, 2008, CURR OPIN ALLERGY CL, V8, P534, DOI 10.1097/ACI.0b013e328310fe7d; Poliani PL, 2009, BLOOD, V114, P105, DOI 10.1182/blood-2009-03-211029; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Rider NL, 2009, CLIN IMMUNOL, V131, P119, DOI 10.1016/j.clim.2008.11.001; Roifman CM, 2006, J ALLERGY CLIN IMMUN, V117, P897, DOI 10.1016/j.jaci.2006.01.003; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Thiel CT, 2007, AM J HUM GENET, V81, P519, DOI 10.1086/521034; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; Yel L, 1999, J CLIN IMMUNOL, V19, P428, DOI 10.1023/A:1020563018864	20	31	31	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					139	146		10.1016/j.jaci.2011.03.042	http://dx.doi.org/10.1016/j.jaci.2011.03.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21570718	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000292245600018
J	Krishnan, JA; Schatz, M; Apter, AJ				Krishnan, Jerry A.; Schatz, Michael; Apter, Andrea J.			A call for action: Comparative effectiveness research in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Comparative effectiveness research; comparative clinical effectiveness research; observational studies; effectiveness trials; efficacy trials; pragmatic trials; explanatory trials; asthma	CIGARETTE-SMOKING; ADULTS; RISK; CORTICOSTEROIDS; MULTICENTER; ADHERENCE; SMOKERS	Comparative effectiveness research (CER) has received considerable research attention in recent months, and efforts to promote CER are part of the newly enacted Patient Protection and Affordable Care Act. In this article we define CER and how it complements traditional efficacy research in asthma and discuss how CER can help provide the basis for rational decision making about the care of individual patients with asthma and how best to deliver this care in real-world settings. We present information about the challenges and opportunities to conduct CER, including enhanced patient registries for observational CER and effectiveness trials (also called pragmatic trials). We discuss the urgent need to define the appropriate methodologies for CER and to develop and prioritize a research agenda for CER studies in asthmatic subjects with the help of a diverse group of stakeholders. (J Allergy Clin Immunol 2011;127:123-7.)	[Krishnan, Jerry A.] Univ Chicago, Sect Pulm & Crit Care, Dept Med, Chicago, IL 60637 USA; [Krishnan, Jerry A.] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; [Schatz, Michael] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA USA; [Apter, Andrea J.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	University of Chicago; University of Chicago; Kaiser Permanente; University of Pennsylvania	Krishnan, JA (corresponding author), Univ Chicago, Asthma & COPD Ctr, Sect Pulm & Crit Care Med, 5841 S Maryland Ave,MC 6076,Room M644, Chicago, IL 60637 USA.	jkrishna@medicine.bsd.uchicago.edu			National Institutes of Health [HL101618, HL073932, HL088469, HL099612]; Agency for Healthcare Research and Quality [HS017894]; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI); Merck; GlaxoSmithKline; Aerocrine; Genentech; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R13HS017894] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073932, K02HL088469, RC1HL099612, RC2HL101618] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Merck(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); Aerocrine; Genentech(Roche HoldingGenentech); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the National Institutes of Health (HL101618, HL073932, HL088469, and HL099612) and the Agency for Healthcare Research and Quality (HS017894).; J. A. Krishnan has received research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) and the Agency for Healthcare Research and Quality. M. Schatz has consulted for Merck and Amgen and has received research support from Merck, GlaxoSmithKline, Aerocrine, and Genentech. A. J. Apter has received research support from the NIH/NHLBI.	[Anonymous], COPD OUTCOMES BASED; [Anonymous], 2010, 111 C US 2 SESS PAT; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bender BG, 2006, J ALLERGY CLIN IMMUN, V118, P899, DOI 10.1016/j.jaci.2006.07.002; Boulet LP, 2008, CAN RESPIR J, V15, P275, DOI 10.1155/2008/725074; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; Clancy C, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001235; [Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute (NHLBI)], RFAHL08010 NIH NHLBI; [Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute (NHLBI)], EPR3 NHLBI DEP HLTH; Eisner MD, 2007, NICOTINE TOB RES, V9, P53, DOI 10.1080/14622200601078293; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Graham DJ, 2010, JAMA-J AM MED ASSOC, V304, P411, DOI 10.1001/jama.2010.920; Greenberger PA, 2010, J ALLERGY CLIN IMMUN, V125, P305, DOI 10.1016/j.jaci.2009.11.038; Kato Z, 2009, WORLD J PEDIATR, V5, P316, DOI 10.1007/s12519-009-0061-y; Kiljander TO, 2010, AM J RESP CRIT CARE, V181, P1042, DOI 10.1164/rccm.200910-1537OC; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Krishnan JA, 2001, ARCH INTERN MED, V161, P1660, DOI 10.1001/archinte.161.13.1660; Krishnan JA, 2008, AM THOR SOC INT C MA; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; National Institutes of Health National Heart Lung and Blood Institute, MORB MORT 2009 CHART; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Stevens GD, 2009, ACAD PEDIATR, V9, P234, DOI 10.1016/j.acap.2009.01.006; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P285, DOI 10.1016/j.jaci.2009.10.026; Thorpe KE, 2009, CAN MED ASSOC J, V180, pE47, DOI 10.1503/cmaj.090523; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; Tsai CL, 2009, J ALLERGY CLIN IMMUN, V123, P354, DOI 10.1016/j.jaci.2008.10.051; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	33	31	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					123	127		10.1016/j.jaci.2010.08.032	http://dx.doi.org/10.1016/j.jaci.2010.08.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	20855111	Green Accepted			2022-12-18	WOS:000285917300018
J	Gould, W; Peterson, EL; Karungi, G; Zoratti, A; Gaggin, J; Toma, G; Yan, SQ; Levin, AM; Yang, JJ; Wells, K; Wang, MQ; Burke, RR; Beckman, K; Popadic, D; Land, SJ; Kumar, R; Seibold, MA; Lanfear, DE; Burchard, EG; Williams, LK				Gould, Wendy; Peterson, Edward L.; Karungi, Gloria; Zoratti, Amanda; Gaggin, John; Toma, Ghazwan; Yan, Shiqing; Levin, Albert M.; Yang, James J.; Wells, Karen; Wang, Mingqun; Burke, Robert R.; Beckman, Kenneth; Popadic, Danijela; Land, Susan J.; Kumar, Rajesh; Seibold, Max A.; Lanfear, David E.; Burchard, Esteban G.; Williams, L. Keoki			Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inhaled corticosteroids; asthma; race-ethnicity; continental population groups; ancestry; urban health	POPULATION-STRUCTURE; BRONCHODILATOR RESPONSIVENESS; RACIAL-DIFFERENCES; GENETIC-STRUCTURE; PUERTO-RICANS; UNITED-STATES; LUNG-FUNCTION; ADMIXTURE; CHILDREN; PHARMACOGENETICS	Background: African American patients disproportionately experience uncontrolled asthma. Treatment with an inhaled corticosteroid (ICS) is considered first-line therapy for persistent asthma. Objective: We sought to determine the degree to which African American patients respond to ICS medication and whether the level of response is influenced by other factors, including genetic ancestry. Methods: Patients aged 12 to 56 years who received care from a large health system in southeast Michigan and who resided in Detroit were recruited to participate if they had a diagnosis of asthma. Patients were treated with 6 weeks of inhaled beclomethasone dipropionate, and pulmonary function was remeasured after treatment. Ancestry was determined by genotyping ancestry-informative markers. The main outcome measure was ICS responsiveness defined as the change in prebronchodilator FEV1 over the 6-week course of treatment. Results: Among 147 participating African American patients with asthma, average improvement in FEV1 after 6 weeks of ICS treatment was 11.6%. The mean proportion of African ancestry in this group was 78.4%. The degree of baseline bronchodilator reversibility was the only factor consistently associated with ICS responsiveness, as measured by both an improvement in FEV1 and patient-reported asthma control (P = .001 and P = .021, respectively). The proportion of African ancestry was not significantly associated with ICS responsiveness. Conclusions: Although baseline pulmonary function parameters appear to be associated with the likelihood to respond to ICS treatment, the proportion of genetic African ancestry does not. This study suggests that genetic ancestry might not contribute to differences in ICS controller response among African American patients with asthma. (J Allergy Clin Immunol 2010;126:1131-8.)	[Karungi, Gloria; Zoratti, Amanda; Gaggin, John; Toma, Ghazwan; Yan, Shiqing; Wang, Mingqun; Lanfear, David E.; Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI 48202 USA; [Gould, Wendy; Burke, Robert R.; Lanfear, David E.; Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI 48202 USA; [Peterson, Edward L.; Levin, Albert M.; Yang, James J.; Wells, Karen; Williams, L. Keoki] Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; [Beckman, Kenneth] Univ Minnesota, Biomed Genom Ctr, Minneapolis, MN USA; [Popadic, Danijela; Land, Susan J.] Wayne State Univ, Appl Genom Technol Ctr, Detroit, MI USA; [Kumar, Rajesh] Northwestern Univ, Childrens Mem Hosp, Dept Pediat, Feinberg Sch Med, Chicago, IL 60614 USA; [Seibold, Max A.] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco Gen Hosp, San Francisco, CA USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University of Minnesota System; University of Minnesota Twin Cities; Wayne State University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; National Jewish Health; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Williams, LK (corresponding author), Henry Ford Hlth Syst, Ctr Hlth Serv Res, 1 Ford Pl,3A, Detroit, MI 48202 USA.	kwillia5@hfhs.org		Toma, Ghazwan/0000-0001-6836-7587; Kumar, Rajesh/0000-0002-1962-7108	Fund for Henry Ford Hospital; American Asthma Foundation; National Institute of Allergy and Infectious Diseases [AI79139, AI61774]; National Heart, Lung, and Blood Institute [HL79055]; National Institute of Diabetes and Digestive and Kidney Diseases [DK64695]; National Institutes of Health [HL078885, HL088133, ES015794, K23HL093023-01]; Robert Wood Johnson Foundation; Flight Attendant Medical Research Institute (FAMRI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078885, R01HL079055, K23HL093023, R01HL088133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061774, R01AI079139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER	Fund for Henry Ford Hospital; American Asthma Foundation; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Flight Attendant Medical Research Institute (FAMRI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants from the Fund for Henry Ford Hospital; the American Asthma Foundation; the National Institute of Allergy and Infectious Diseases (AI79139, AI61774); the National Heart, Lung, and Blood Institute (HL79055); and the National Institute of Diabetes and Digestive and Kidney Diseases (DK64695), National Institutes of Health (L. K. W.). E. G. B. receives support from the National Institutes of Health (HL078885, HL088133, ES015794), the Robert Wood Johnson Foundation Amos Medical Faculty Development Program, and the Flight Attendant Medical Research Institute (FAMRI). R. K. receives support from the National Institutes of Health (K23HL093023-01).	[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Bacon SL, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-125; Bryant-Stephens T, 2009, J ALLERGY CLIN IMMUN, V123, P1199, DOI 10.1016/j.jaci.2009.04.030; Bryc K, 2010, P NATL ACAD SCI USA, V107, P786, DOI 10.1073/pnas.0909559107; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Corvol H, 2008, PHARMACOGENOMICS, V9, P505, DOI 10.2217/14622416.9.5.505; Corvol H, 2009, PHARMACOGENET GENOM, V19, P489, DOI 10.1097/FPC.0b013e32832c440e; Daar AS, 2005, NAT REV GENET, V6, P241, DOI 10.1038/nrg1559; Eisner MD, 2005, THORAX, V60, P814, DOI 10.1136/thx.2004.037283; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Julius SM, 2002, CHEST, V121, P871, DOI 10.1378/chest.121.3.871; Kazani S, 2010, J ALLERGY CLIN IMMUN, V125, P295, DOI 10.1016/j.jaci.2009.12.014; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; Kessler RC, 2003, J OCCUP ENVIRON MED, V45, P156, DOI 10.1097/01.jom.0000052967.43131.51; Leffondre K, 2002, AM J EPIDEMIOL, V156, P813, DOI 10.1093/aje/kwf122; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; McKeigue PM, 2000, ANN HUM GENET, V64, P171, DOI 10.1017/S0003480000008022; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Naqvi M, 2008, ANN ALLERG ASTHMA IM, V100, P551, DOI 10.1016/S1081-1206(10)60055-5; Naqvi M, 2007, J ASTHMA, V44, P639, DOI 10.1080/02770900701554441; *NAT HEART LUNG BL, 2002, PUBL NAT HEART LUNG; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; O'Connor SL, 2004, J ASTHMA, V41, P663, DOI 10.1081/JAS-200026434; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Plan and operation of the Third National Health and Nutrition Examination Survey, 1994, PROGR COLL PROC V 1, V32, P1; Pritchard JK, 2000, GENETICS, V155, P945; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SAS Institute Inc, 2004, SAS STAT US GUID VER; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tang H, 2005, GENET EPIDEMIOL, V28, P289, DOI 10.1002/gepi.20064; Tantisira KG, 2007, J ALLERGY CLIN IMMUN, V120, P1285, DOI 10.1016/j.jaci.2007.09.005; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tantisira KG, 2005, HUM MOL GENET, V14, P1671, DOI 10.1093/hmg/ddi175; Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257; Trupin L, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-24; Tsai HJ, 2006, HUM GENET, V118, P626, DOI 10.1007/s00439-005-0080-2; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2007, J ALLERGY CLIN IMMUN, V119, P168, DOI 10.1016/j.jaci.2006.09.029; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Wilper AP, 2008, ANN INTERN MED, V149, P170, DOI 10.7326/0003-4819-149-3-200808050-00006; Wu BL, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-317; Yaeger R, 2008, CANCER EPIDEM BIOMAR, V17, P1329, DOI 10.1158/1055-9965.EPI-07-2505; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044	55	31	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1131	1138		10.1016/j.jaci.2010.08.002	http://dx.doi.org/10.1016/j.jaci.2010.08.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20864153	Green Accepted			2022-12-18	WOS:000284947800007
J	Prussin, C; Yin, YZ; Upadhyaya, B				Prussin, Calman; Yin, Yuzhi; Upadhyaya, Bhaskar			T(H)2 heterogeneity: Does function follow form?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)2; heterogeneity; T cell; IL-5; differentiation; lineage	T-CELL RESPONSES; AIRWAY INFLAMMATION; CYTOKINE PRODUCTION; IMMUNE-RESPONSES; TGF-BETA; MEMORY; TH2; DIFFERENTIATION; LINEAGE; SUBSET	T(H)2 immune responses are required for the 2 fundamental pathological processes characteristic of allergic disease: IgE-mediated hypersensitivity and eosinophilic inflammation. The 3 established T(H)2 cytokines, IL-4, IL-5, and IL-13, each play a nonredundant role in allergic disease pathology. The recent explosion of T-H subpopulations combined with the wide availability of polychromatic cytokine staining has facilitated the discovery of T(H)2 lineage heterogeneity. In this article we review T(H)2 heterogeneity and ask the following question: At what point do these subpopulations graduate from in vitro curiosities to immunologically robust therapeutic targets? We propose criteria to establish a T-cell subset as a biologically relevant entity and address the evidence to support these T(H)2 subpopulations having a unique function or specific contribution to allergic pathology or host defense. (J Allergy Clin Immunol 2010;126:1094-8.)	[Prussin, Calman; Yin, Yuzhi; Upadhyaya, Bhaskar] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Prussin, C (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Room 11C207, Bethesda, MD 20892 USA.	cprussin@niaid.nih.gov	Upadhyaya, Bhaskar/ADF-4660-2022	Prussin, Calman/0000-0002-3917-3326	National Institute of Allergy and Infectious Diseases, National Institutes of Health; Division of Intramural Research, National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000993, ZIAAI001128] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Division of Intramural Research, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Intramural Research Program.; Disclosure of potential conflict of interest: C. Prussin, Y. Yin, and B. Upadhyaya receive research support from the Division of Intramural Research, National Institute of Allergy and Infectious Diseases.	Adeeku E, 2008, P NATL ACAD SCI USA, V105, P9307, DOI 10.1073/pnas.0704807105; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Antoniu SA, 2010, CURR OPIN MOL THER, V12, P233; ASSENMACHER M, 2002, CURR PROTOC IMMUNOL, pCH6, DOI DOI 10.1002/0471142735.IM0627S46; Beriou G, 2010, J IMMUNOL, V185, P46, DOI 10.4049/jimmunol.1000356; Commins SP, 2010, J ALLERGY CLIN IMMUN, V125, pS53, DOI 10.1016/j.jaci.2009.07.008; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Fazilleau N, 2009, IMMUNITY, V30, P324, DOI 10.1016/j.immuni.2009.03.003; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; Foster Barbara, 2007, Curr Protoc Immunol, VChapter 6, DOI 10.1002/0471142735.im0624s78; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hegazy AN, 2010, IMMUNITY, V32, P116, DOI 10.1016/j.immuni.2009.12.004; Jankovic D, 2010, MUCOSAL IMMUNOL, V3, P239, DOI 10.1038/mi.2010.8; Johansson-Lindbom B, 2003, J IMMUNOL, V171, P1657, DOI 10.4049/jimmunol.171.4.1657; King IL, 2009, J EXP MED, V206, P1001, DOI 10.1084/jem.20090313; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Louten J, 2009, J ALLERGY CLIN IMMUN, V123, P1004, DOI 10.1016/j.jaci.2009.04.003; Medoff BD, 2008, ANNU REV IMMUNOL, V26, P205, DOI 10.1146/annurev.immunol.26.021607.090312; Mikhak Z, 2009, J ALLERGY CLIN IMMUN, V123, P67, DOI 10.1016/j.jaci.2008.09.049; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mucida D, 2009, J ALLERGY CLIN IMMUN, V123, P997, DOI 10.1016/j.jaci.2009.03.016; Nowak EC, 2009, J EXP MED, V206, P1653, DOI 10.1084/jem.20090246; O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Rivino L, 2004, J EXP MED, V200, P725, DOI 10.1084/jem.20040774; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Soroosh P, 2009, IMMUNOLOGY, V127, P450, DOI 10.1111/j.1365-2567.2009.03114.x; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Wang Y, 2009, J ALLERGY CLIN IMMUN, V123, pS143, DOI 10.1016/j.jaci.2008.12.534; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Woodfolk JA, 2007, J ALLERGY CLIN IMMUN, V119, P280, DOI 10.1016/j.jaci.2006.11.008; Woodfolk JA, 2006, CURR ALLERGY ASTHM R, V6, P40, DOI 10.1007/s11882-006-0008-5; Zaretsky AG, 2009, J EXP MED, V206, P991, DOI 10.1084/jem.20090303; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	46	31	31	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1094	1098		10.1016/j.jaci.2010.08.031	http://dx.doi.org/10.1016/j.jaci.2010.08.031			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20951419	Green Accepted			2022-12-18	WOS:000284947800002
J	Breton, MC; Beauchesne, MF; Lemiere, C; Rey, E; Forget, A; Blais, L				Breton, Marie-Claude; Beauchesne, Marie-France; Lemiere, Catherine; Rey, Evelyne; Forget, Amelie; Blais, Lucie			Risk of perinatal mortality associated with inhaled corticosteroid use for the treatment of asthma during pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; pregnancy; perinatal mortality; inhaled corticosteroids	INDUCED HYPERTENSION; BIRTH-WEIGHT; DRUG-USE; WOMEN; INFORMATION; RECALL; DATABASES; MORBIDITY; OUTCOMES	Background: Four studies investigating the association between inhaled corticosteroid (ICS) use during pregnancy and perinatal mortality reported no significantly increased risk. These studies must be interpreted with caution because they have insufficient statistical power and a lack of adjustment for potential confounders. Objectives: We sought to evaluate whether asthmatic women exposed to ICSs during pregnancy are more at risk of perinatal mortality than asthmatic women not exposed. We also sought to estimate the risk of perinatal mortality as a function of the daily ICS dose taken during pregnancy. Methods: From the linkage of 3 administrative databases from Quebec, a cohort including 13,004 single pregnancies from asthmatic women was constructed. We used a 2-stage sampling cohort design to obtain information on cigarette smoking from the medical charts of 487 mothers. The final estimates of the odds ratios (ORs) of perinatal mortality were estimated with a logistic regression model. Results: The cohort was formed of 4,140 women who used greater than 0 to 250 mu g/d ICS, 1,140 women who used greater than 250 mu g/d ICS, and 7,724 nonusers of ICSs during pregnancy. Women exposed to ICSs (any dose) had a nonsignificant increased risk of perinatal mortality (OR, 1.07; 95% CI, 0.70-1.61). The use of greater than 250 mu g/d ICS was associated with a nonsignificant 52% increased risk of perinatal mortality (OR, 1.52; 95% CI, 0.62-3.76). Conclusion: The risk of perinatal mortality was not found to be significantly associated with ICS use during pregnancy. The result associated with higher doses of ICSs is limited due to a lack of statistical power and a possibility of residual confounding by asthma severity and control. (J Allergy Clin Immunol 2010;126:772-7.)	[Breton, Marie-Claude; Beauchesne, Marie-France; Blais, Lucie] Univ Montreal, Fac Pharm, Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada; [Beauchesne, Marie-France; Lemiere, Catherine; Forget, Amelie; Blais, Lucie] Hop Sacre Coeur, Res Ctr, Montreal, PQ H4J 1C5, Canada; [Rey, Evelyne] CHU Ste Justine, Dept Obstet & Gynecol, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Blais, L (corresponding author), Univ Montreal, Fac Pharm, Succursale Ctr Ville, CP 6128, Montreal, PQ H3C 3J7, Canada.	lucie.blais@umontreal.ca			Fonds de la recherche en sante du Quebec (FRSQ); Canadian Institute for Health Research (CIHR); National Institute for Occupational Safety and Health; GlaxoSmithKline	Fonds de la recherche en sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); National Institute for Occupational Safety and Health(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); GlaxoSmithKline(GlaxoSmithKline)	Supported by grants from the Fonds de la recherche en sante du Quebec (FRSQ) and the Canadian Institute for Health Research (CIHR).; Disclosure of potential conflict of interest: M.-F. Beauchesne has received remuneration for lessons from GlaxoSmithKline and AstraZeneca. C. Lemiere has received research support from the National Institute for Occupational Safety and Health and GlaxoSmithKline. E. Rey is a speaker for Leo Pharma. The rest of the authors have declared that they have no conflict of interest.	Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; Bernstein IM, 2000, AM J OBSTET GYNECOL, V182, P198, DOI 10.1016/S0002-9378(00)70513-8; Blais L, 2006, PHARMACOEPIDEM DR S, V15, P245, DOI 10.1002/pds.1202; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; Chambers Karen, 2003, Case Manager, V14, P58, DOI 10.1016/j.casemgr.2003.09.003; Collet JP, 1998, EPIDEMIOLOGY, V9, P309, DOI 10.1097/00001648-199805000-00016; Dombrowski MP, 2004, AM J OBSTET GYNECOL, V190, P737, DOI 10.1016/j.ajog.2003.09.071; Enriquez R, 2006, AM J OBSTET GYNECOL, V195, P149, DOI 10.1016/j.ajog.2006.01.065; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; GORDON M, 1970, AM J OBSTET GYNECOL, V106, P421, DOI 10.1016/0002-9378(70)90371-6; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478, DOI 10.7326/0003-4819-98-4-478; GREENBERGER PA, 1988, NEW ENGL REG ALLERGY, V9, P539, DOI 10.2500/108854188778965555; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Kallen B, 2000, EUR J EPIDEMIOL, V16, P167, DOI 10.1023/A:1007678404911; Kleinbaum DG., 2002, LOGISTIC REGRESSION; Martel MJ, 2007, J ALLERGY CLIN IMMUN, V119, P576, DOI 10.1016/j.jaci.2006.10.034; Martel MJ, 2005, BMJ-BRIT MED J, V330, P230, DOI 10.1136/bmj.38313.624352.8F; MORRISON JC, 1990, OBSTET GYNECOL, V76, pS5; National Asthma Education and Prevention Program National Heart Lung and Blood Institute, 2007, NIH PUBL; Norjavaara E, 2003, J ALLERGY CLIN IMMUN, V111, P736, DOI 10.1067/mai.2003.1340; Olesen C, 1999, EUR J CLIN PHARMACOL, V55, P139, DOI 10.1007/s002280050608; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; *REG ASS MAL QUEB, 1997, STAT ANN; Scharfe M, 1997, OSTERR Z VOLSKUNDE, V100, P301; TILLEY BC, 1985, AM J EPIDEMIOL, V121, P269, DOI 10.1093/oxfordjournals.aje.a113997; Van den Berg LTWDJ, 1999, TERATOLOGY, V60, P33; VANDENBRANDT PA, 1991, PHARM WEEKBLAD, V13, P91, DOI 10.1007/BF01974987; Vilain A, 2008, PHARMACOEPIDEM DR S, V17, P345, DOI 10.1002/pds.1558; WEST SL, 1995, AM J EPIDEMIOL, V142, P1103, DOI 10.1093/oxfordjournals.aje.a117563; WILCOX AJ, 1992, AM J PUBLIC HEALTH, V82, P378, DOI 10.2105/AJPH.82.3.378	32	31	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					772	U138		10.1016/j.jaci.2010.08.018	http://dx.doi.org/10.1016/j.jaci.2010.08.018			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920768				2022-12-18	WOS:000282510000014
J	Holloway, JW; Arshad, SH; Holgate, ST				Holloway, John W.; Arshad, Syed H.; Holgate, Stephen T.			Using genetics to predict the natural history of asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; genetic; prediction; natural history	OBSTRUCTIVE PULMONARY-DISEASE; GENOME-WIDE ASSOCIATION; LUNG-FUNCTION DECLINE; CHILDHOOD ASTHMA; RISK-FACTORS; ATOPIC-DERMATITIS; EARLY-LIFE; FAMILIAL AGGREGATION; PROSPECTIVE COHORT; ALLERGIC DISEASE	Clinical practice reminds us that there is considerable variability in the course of asthma over time. Treatment of patients with asthma would be considerably improved if one could accurately predict the likely course of disease over the life course. Recently, with the advent of the era of genome-wide association studies, there has been a monumental shift in our understanding of the genetic factors that underlie inherited susceptibility to asthma. Genes have been identified that modulate many aspects of the natural history of asthma, such as susceptibility to atopy, altered lung development, and susceptibility to more severe disease. Heritability studies have even suggested a role for genetic factors in remission of asthma. However, although the discovery of novel genetic factors underlying disease susceptibility has undoubtedly improved our understanding of disease pathogenesis, whether these advances have improved the ability to predict the natural history in individual patients is questionable, and the application of genetic testing to clinical practice remains some way off. (J Allergy Clin Immunol 2010;126:200-9.)	[Holloway, John W.; Arshad, Syed H.; Holgate, Stephen T.] Univ Southampton, Sch Med, Div Infect Inflammat & Immun, Southampton SO9 5NH, Hants, England; [Holloway, John W.] Univ Southampton, Div Human Genet, Sch Med, Southampton SO9 5NH, Hants, England	University of Southampton; University of Southampton	Holloway, JW (corresponding author), Southampton Gen Hosp, Div 3, MP810, Southampton SO16 6YD, Hants, England.	J.W.Holloway@soton.ac.uk	Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464	Asthma, Allergy and Inflammation Research; National Institute of Health Research (NIHR), United Kingdom; National Institutes of Health; Medical Research Council [G19/34, G0900453, G0400473, G0800766] Funding Source: researchfish; MRC [G0400473, G0900453, G0800766, G19/34] Funding Source: UKRI	Asthma, Allergy and Inflammation Research; National Institute of Health Research (NIHR), United Kingdom(National Institute for Health Research (NIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	J.W. Holloway has received research funding from Asthma, Allergy and Inflammation Research and the National Institute of Health Research (NIHR), United Kingdom. S. H. Arshad has received research support from the National Institutes of Health. S. T. Holgate has shares in Synairgen and has consulted for Novartis, MSD, Almiral, Synairgen, Altair, and Amgen.	Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Andrews AL, 2006, J ALLERGY CLIN IMMUN, V118, P858, DOI 10.1016/j.jaci.2006.06.041; ARSHAD SH, 2008, AM J RESP CRIT CARE, V177, pA709; Balaci L, 2007, AM J HUM GENET, V80, P1103, DOI 10.1086/518259; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P240, DOI 10.1164/rccm.2604008; Barton SJ, 2009, J ALLERGY CLIN IMMUN, V123, P1391, DOI 10.1016/j.jaci.2009.03.014; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; BAZARAL M, 1971, J IMMUNOL, V107, P794; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Burke W, 2004, NAT REV GENET, V5, P955, DOI 10.1038/nrg1495; Calsbeek Hiske, 2007, J Genet Couns, V16, P493, DOI 10.1007/s10897-006-9085-9; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278, DOI 10.1164/ajrccm.160.1.9808032; Contopoulos-Ioannidis DG, 2005, J ALLERGY CLIN IMMUN, V115, P963, DOI 10.1016/j.jaci.2004.12.1119; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Cullen AC, 2008, RISK ANAL, V28, P877, DOI 10.1111/j.1539-6924.2008.01084.x; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Descatha A, 2007, ALLERGY, V62, P795, DOI 10.1111/j.1398-9995.2007.01424.x; Devereux G, 2007, PEDIATR PULM, V42, P663, DOI 10.1002/ppul.20640; Dykewicz MS, 2009, J ALLERGY CLIN IMMUN, V123, P519, DOI 10.1016/j.jaci.2009.01.061; EPSTEIN FH, 1968, B NEW YORK ACAD MED, V44, P916; Fenwick A, 2010, FAM CANCER, V9, P23, DOI 10.1007/s10689-009-9278-0; Gao J, 2006, THORAX, V61, P466, DOI 10.1136/thx.2005.051284; GERRARD JW, 1976, ANN ALLERGY, V36, P10; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hardy J, 2009, NEW ENGL J MED, V360, P1759, DOI 10.1056/NEJMra0808700; Hayashi T, 1995, ANN ALLERG ASTHMA IM, V75, P525; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Henderson J, 2008, EUR RESPIR J, V31, P547, DOI 10.1183/09031936.00086807; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hippisley-Cox J, 2008, BMJ-BRIT MED J, V336, P1475, DOI 10.1136/bmj.39609.449676.25; Hirschhorn JN, 2009, NEW ENGL J MED, V360, P1699, DOI 10.1056/NEJMp0808934; Holgate ST, 2007, EUR RESPIR J, V29, P793, DOI 10.1183/09031936.00087506; Holloway JW, 2008, J ALLERGY CLIN IMMUN, V121, P573, DOI 10.1016/j.jaci.2008.01.007; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V125, pS81, DOI 10.1016/j.jaci.2009.10.071; Holloway JW, 2000, CLIN EXP ALLERGY, V30, P1097; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Houlston RS, 1998, EUR J HUM GENET, V6, P80, DOI 10.1038/sj.ejhg.5200156; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Jamrozik E, 2009, RESPIROLOGY, V14, P814, DOI 10.1111/j.1440-1843.2009.01562.x; Janssens ACJW, 2006, GENET MED, V8, P395, DOI 10.1097/01.gim.0000229689.18263.f4; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; Jenkins MA, 1997, GENET EPIDEMIOL, V14, P317, DOI 10.1002/(SICI)1098-2272(1997)14:3<317::AID-GEPI9>3.0.CO;2-1; Katsanis SH, 2008, SCIENCE, V320, P53, DOI 10.1126/science.1156604; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; Kraft M, 2006, AM J RESP CRIT CARE, V174, P238, DOI 10.1164/rccm.2604007; Kraft M, 2006, AM J RESP CRIT CARE, V174, P243, DOI 10.1164/rccm.2604009; Kraft P, 2009, NEW ENGL J MED, V360, P1701, DOI 10.1056/NEJMp0810107; Kraft P, 2009, NAT REV GENET, V10, P264, DOI 10.1038/nrg2516; Kurukulaaratchy RJ, 2008, J ASTHMA, V45, P944, DOI 10.1080/02770900802404090; Kurukulaaratchy RJ, 2004, THORAX, V59, P563, DOI 10.1136/thx.2003.010462; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Lettre G, 2008, HUM MOL GENET, V17, pR116, DOI 10.1093/hmg/ddn246; Li X, 2010, J ALLERGY CLIN IMMUN, V125, pe11; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Lucas JS, 2004, AM J RESP CRIT CARE, V170, P534, DOI 10.1164/rccm.200311-1583OC; Ly NP, 2006, PEDIATRICS, V117, pE1132, DOI 10.1542/peds.2005-2271; Lyssenko V, 2008, NEW ENGL J MED, V359, P2220, DOI 10.1056/NEJMoa0801869; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Martinez FD, 2007, EUR RESPIR J, V29, P179, DOI 10.1183/09031936.00087906; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Marx-Stolting L, 2007, PHARMACOGENOMICS J, V7, P293, DOI 10.1038/sj.tpj.6500425; Meigs JB, 2008, NEW ENGL J MED, V359, P2208, DOI 10.1056/NEJMoa0804742; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Narayan KMV, 2009, NEW ENGL J MED, V360, P1360, DOI 10.1056/NEJMc082624; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Orie NGM, 1961, BRONCHITIS INT S; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Palmer LJ, 2000, EUR J HUM GENET, V8, P853, DOI 10.1038/sj.ejhg.5200551; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Pin I, 2002, AM J RESP CRIT CARE, V165, P185, DOI 10.1164/ajrccm.165.2.2012019; Postma Dirkje S, 2004, Chest, V126, p96S, DOI 10.1378/chest.126.2_suppl_1.96S; POSTMA DS, 2004, CHEST S, V126, pS59; Rahman M, 2008, FAM PRACT, V25, P191, DOI 10.1093/fampra/cmn024; RAZA A, 2009, EUR RESP SOC ANN C V; Reed CE, 2006, J ALLERGY CLIN IMMUN, V118, P543, DOI 10.1016/j.jaci.2006.06.020; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Robertson CF, 2002, MED J AUSTRALIA, V177, pS42; Ruse CE, 2007, RESP MED, V101, P340, DOI 10.1016/j.rmed.2006.05.017; Sadeghnejad A, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-21; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; SARAFINO EP, 1995, ARCH DIS CHILD, V73, P112, DOI 10.1136/adc.73.2.112; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Settipane GA, 2000, ANN ALLERG ASTHMA IM, V84, P499, DOI 10.1016/S1081-1206(10)62512-4; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Shaheen SO, 2007, EARLY HUM DEV, V83, pS59, DOI 10.1016/S0378-3782(07)70096-8; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Sheehan NA, 2008, PLOS MED, V5, P1205, DOI 10.1371/journal.pmed.0050177; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Smith GD, 2005, BMJ-BRIT MED J, V330, P1076, DOI 10.1136/bmj.330.7499.1076; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; Strachan DP, 1996, BRIT MED J, V312, P1195; Talmud PJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b4838; Tantisira KG, 2008, AM J RESP CRIT CARE, V178, P325, DOI 10.1164/rccm.200708-1174OC; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Teerlink CC, 2007, AM J RESP CRIT CARE, V176, P865, DOI 10.1164/rccm.200703-448OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; vonMutius E, 1996, AM J RESP CRIT CARE, V153, P1266, DOI 10.1164/ajrccm.153.4.8616552; Wacholder S, 2010, NEW ENGL J MED, V362, P986, DOI 10.1056/NEJMoa0907727; Wang M, 2003, HUM GENET, V113, P387, DOI 10.1007/s00439-003-1001-x; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Weiss ST, 2010, AM J RESP CRIT CARE, V181, P1170, DOI 10.1164/rccm.201001-0069PP; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132; Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864; Wu AC, 2010, PHARMACOGENET GENOM, V20, P86, DOI 10.1097/FPC.0b013e32833428d0; Wu H, 2009, ALLERGY, V64, P629, DOI 10.1111/j.1398-9995.2008.01912.x; Yao TC, 2003, J ALLERGY CLIN IMMUN, V111, P1285, DOI 10.1067/mai.2003.1506; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; Zheng SL, 2008, NEW ENGL J MED, V358, P910, DOI 10.1056/NEJMoa075819	136	31	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					200	211		10.1016/j.jaci.2010.06.006	http://dx.doi.org/10.1016/j.jaci.2010.06.006			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20688205				2022-12-18	WOS:000281203800002
J	Sun, XG; Ma, SF; Wade, MS; Flores, C; Pino-Yanes, M; Moitra, J; Ober, C; Kittles, R; Husain, AN; Ford, JG; Garcia, JGN				Sun, Xiaoguang; Ma, Shwu-Fan; Wade, Michael S.; Flores, Carlos; Pino-Yanes, Maria; Moitra, Jaideep; Ober, Carole; Kittles, Rick; Husain, Aliya N.; Ford, Jean G.; Garcia, Joe G. N.			Functional variants of the sphingosine-1-phosphate receptor 1 gene associate with asthma susceptibility	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; sphingosine-1-phosphate receptor 1; single nucleotide polymorphism; promoter activity	ENDOTHELIAL GROWTH-FACTOR; NUCLEOTIDE-POLYMORPHISM PANEL; MUSCLE-CELL PROLIFERATION; PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE; ADMIXTURE PROPORTIONS; S1P(1) RECEPTORS; TAGGING SNPS; KINASE; INFLAMMATION	Background: The genetic mechanisms underlying asthma remain unclear. Increased permeability of the microvasculature is a feature of asthma, and the sphingosine-1-phosphate receptor (S1PR1) is an essential participant regulating lung vascular integrity and responses to lung inflammation. Objective: We explored the contribution of polymorphisms in the S1PR1 gene to asthma susceptibility. Methods: A combination of gene resequencing for single nucleotide polymorphism (SNP) discovery, case-control association, functional evaluation of associated SNPs, and protein immunochemistry studies was used. Results: Immunohistochemistry studies demonstrated significantly decreased S1PR1 protein expression in pulmonary vessels in lungs of asthmatic patients compared with those of nonasthmatic subjects (P < .05). Direct DNA sequencing of 27 multiethnic samples identified 39 S1PR1 variants (18 novel SNPs). Association studies were performed based on genotyping results from cosmopolitan tagging SNPs in 3 case-control cohorts from Chicago and New York totaling 1,061 subjects (502 cases and 559 control subjects). The promoter SNP rs2038366 (-1557G/T) was found to be associated with asthma (P = .03) in European Americans. In African Americans an association was found for both asthma and severe asthma for intronic SNP rs3753194 (c.-164+170A/G; P = .006 and P = .040, respectively) and for promoter SNP rs59317557 (-532C/G) with severe asthma (P = .028). Consistent with predicted in silico functionality, alleles of the promoter SNPs rs2038366 (-1557G/T) and rs59317557 (-532C/G) influenced the activity of a luciferase S1PR1 reporter vector in transfected endothelial cells exposed to growth factors (epidermal growth factor, platelet-derived growth factor, and vascular endothelial growth factor) known to be increased in asthmatic airways. Conclusion: These data provide strong support for a role for S1PR1 gene variants in asthma susceptibility and severity. (J Allergy Clin Immunol 2010;126:241-9.)	[Sun, Xiaoguang; Ma, Shwu-Fan; Wade, Michael S.; Moitra, Jaideep; Garcia, Joe G. N.] Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; [Flores, Carlos; Pino-Yanes, Maria] Inst Salud Carlos III, CIBER Enfermedades Respiratorias, Madrid, Spain; [Flores, Carlos; Pino-Yanes, Maria] Hosp Univ NS Candelaria, Res Unit, Tenerife, Spain; [Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Kittles, Rick] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Husain, Aliya N.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Ford, Jean G.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	University of Chicago; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; University of Chicago; University of Chicago; University of Chicago; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Garcia, JGN (corresponding author), Univ Illinois, Dept Med, 1737 W Polk St,305D AOB, Chicago, IL 60612 USA.	jggarcia@uic.edu	Pino-Yanes, Maria/C-8498-2017	Pino-Yanes, Maria/0000-0003-0332-437X; Ober, Carole/0000-0003-4626-9809; Flores, Carlos/0000-0001-5352-069X	National Heart, Lung, and Blood Institute/National Institutes of Health [HL91899, HL58064, HL51492, GM07019]; Spanish Ministry of Science [EMER07/001, PI081383]; Instituto de Salud Carlos III; FUNCIS [EMER07/001]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051492, U01HL049596, P01HL058064, R01HL072414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007019] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Spanish Ministry of Science(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); FUNCIS; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the National Heart, Lung, and Blood Institute/National Institutes of Health grants HL91899 (J. G. N. G.), HL58064 (J. G. N. G.), HL51492 (J. G. F.), and GM07019 (X. S.) and by grants from the Spanish Ministry of Science EMER07/001 and PI081383 (C. F.). C. F. and M. P. Y. were supported by an agreement between Instituto de Salud Carlos III and FUNCIS (EMER07/001) under ENCYT 2015 framework.	Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Amundadottir LT, 2006, NAT GENET, V38, P652, DOI 10.1038/ng1808; Antonarakis SE, 1998, GENOMICS, V51, P1, DOI 10.1006/geno.1998.5335; Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; Baumruker T, 2000, INT ARCH ALLERGY IMM, V122, P85, DOI 10.1159/000024363; Brey EM, 2003, J HISTOCHEM CYTOCHEM, V51, P575, DOI 10.1177/002215540305100503; Brinkmann V, 2006, CURR OPIN PHARMACOL, V6, P244, DOI 10.1016/j.coph.2005.12.004; Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575; Chetta Alfredo, 2007, Inflammation & Allergy Drug Targets, V6, P41, DOI 10.2174/187152807780077273; Dantas APV, 2003, AM J PHYSIOL-HEART C, V284, pH2045, DOI 10.1152/ajpheart.01089.2002; Ding K, 2007, EUR J HUM GENET, V15, P228, DOI 10.1038/sj.ejhg.5201755; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Falush D, 2003, GENETICS, V164, P1567; Flores C, 2007, GENET EPIDEMIOL, V31, P296, DOI 10.1002/gepi.20210; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Greene CS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005639; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Hofmann U, 2009, CARDIOVASC RES, V83, P285, DOI 10.1093/cvr/cvp137; Huang YL, 2009, J BIOCHEM, V146, P815, DOI 10.1093/jb/mvp131; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100; Igarashi J, 2007, AM J PHYSIOL-CELL PH, V292, pC740, DOI 10.1152/ajpcell.00117.2006; Kanazawa H, 2004, AM J RESP CRIT CARE, V169, P1125, DOI 10.1164/rccm.200401-123OC; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; Kelly DJ, 2007, AM J PHYSIOL-HEART C, V293, pH2860, DOI 10.1152/ajpheart.01167.2006; Kosoy R, 2009, HUM MUTAT, V30, P69, DOI 10.1002/humu.20822; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V276, pL246, DOI 10.1152/ajplung.1999.276.2.L246; Kurz T, 2006, J ALLERGY CLIN IMMUN, V118, P396, DOI 10.1016/j.jaci.2006.04.036; Le Stunff H, 2004, J BIOL CHEM, V279, P34290, DOI 10.1074/jbc.M404907200; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Loza MJ, 2007, J ALLERGY CLIN IMMUN, V120, P578, DOI 10.1016/j.jaci.2007.05.019; Ma SF, 2008, GENET EPIDEMIOL, V32, P757, DOI 10.1002/gepi.20343; Marsh DG, 1997, NAT GENET, V15, P389; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; Meyer IH, 2001, J ASTHMA, V38, P531, DOI 10.1081/JAS-100107117; Moreno-Vinasco L, 2008, J ORGAN DYSFUNCTION, V4, P106, DOI [10.1080/17471060701505289, DOI 10.1080/17471060701505289]; Naureckas ET, 1999, AM J RESP CRIT CARE, V160, P2062, DOI 10.1164/ajrccm.160.6.9903131; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; OHNO I, 1995, AM J RESP CELL MOL, V13, P639, DOI 10.1165/ajrcmb.13.6.7576701; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Pesola GR, 2004, ACAD EMERG MED, V11, P944, DOI 10.1197/j.aem.2004.03.020; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Roviezzo F, 2007, AM J RESP CELL MOL, V36, P757, DOI 10.1165/rcmb.2006-0383OC; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; SAMMANI S, 2009, AM J RESP CELL MOL B; Simeone-Penney MC, 2008, AM J PHYSIOL-LUNG C, V294, pL698, DOI 10.1152/ajplung.00529.2007; Simoes DCM, 2008, AM J RESP CRIT CARE, V177, P1314, DOI 10.1164/rccm.200708-1141OC; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Singleton PA, 2006, J BIOL CHEM, V281, P34381, DOI 10.1074/jbc.M603680200; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tian C, 2007, AM J HUM GENET, V80, P1014, DOI 10.1086/513522; Tian C, 2006, AM J HUM GENET, V79, P640, DOI 10.1086/507954; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098; Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864; Yamashita N, 2001, J ALLERGY CLIN IMMUN, V107, P135, DOI 10.1067/mai.2001.111433; Yu LQ, 2005, PHYSIOL GENOMICS, V23, P89, DOI 10.1152/physiolgenomics.00068.2005	66	31	31	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					241	U9		10.1016/j.jaci.2010.04.036	http://dx.doi.org/10.1016/j.jaci.2010.04.036			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624651	Green Accepted			2022-12-18	WOS:000281203800007
J	Sicherer, SH; Leung, DYM				Sicherer, Scott H.; Leung, Donald Y. M.			Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2009	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dermatology; skin disease; urticaria; atopic dermatitis; anaphylaxis; allergy; hypersensitivity disorders; food; drug; insect venom	HYMENOPTERA VENOM ALLERGY; PRU P 3; ATOPIC-DERMATITIS; ANTIMICROBIAL PEPTIDES; BARRIER ABNORMALITY; T-CELLS; RISK; PEANUT; SERUM; CONTRIBUTE	This review highlights some of the research advances in anaphylaxis and hypersensitivity reactions to foods, drugs, and insects, as well as advances in allergic skin disease that were reported in the Journal in 2009. Among key epidemiologic observations, several westernized countries report that more than 1% of children have peanut allergy, and there is some evidence that environmental exposure to peanut is a risk factor. The role of regulatory T cells, complement, platelet-activating factor, and effector cells in the development and expression of food allergy were explored in several murine models and human studies. Delayed anaphylaxis to mammalian meats appears to be related to IgE binding to the carbohydrate moiety galactose-alpha-1,3-galactose, which also has implications for hypersensitivity to murine mAb therapeutics containing this oligosaccharide. Oral immunotherapy studies continue to show promise for the treatment of food allergy, but determining whether the treatment causes tolerance (cure) or temporary desensitization remains to be explored. Increased baseline serum tryptase levels might inform the risk of venom anaphylaxis and might indicate a risk for mast cell disorders in persons who have experienced such episodes. Reduced structural and immune barrier function contribute to local and systemic allergen sensitization in patients with atopic dermatitis, as well as increased propensity of skin infections in these patients. The use of increased doses of nonsedating antihistamines and potential usefulness of omalizumab for chronic urticaria was highlighted. These exciting advances reported in the Journal can improve patient care today and provide insights on how we can improve the diagnosis and treatment of these allergic diseases in the future. (J Allergy Clin Immunol 2010;125:85-97.)	[Sicherer, Scott H.] Mt Sinai Hosp, Div Allergy Immunol, Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst,Dept Pedi, New York, NY 10029 USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Div Allergy Immunol, Dept Pediat, Denver, CO USA	Icahn School of Medicine at Mount Sinai; National Jewish Health	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst,Dept Pedi, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			National Institutes of Health/National Institute of Allergy and Infectious Diseases	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S. H. Sicherer is a consultant for the Food Allergy Initiative and receives research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. D. Y. M. Leung has declared that he has no conflict of interest.	Albrecht M, 2009, J ALLERGY CLIN IMMUN, V124, P328, DOI 10.1016/j.jaci.2009.05.031; Arellano FM, 2009, J ALLERGY CLIN IMMUN, V123, P1111, DOI 10.1016/j.jaci.2009.02.028; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Atanaskovic-Markovic M, 2009, J ALLERGY CLIN IMMUN, V124, P167, DOI 10.1016/j.jaci.2009.02.031; Ayuso R, 2009, J ALLERGY CLIN IMMUN, V124, P114, DOI 10.1016/j.jaci.2009.04.016; Bauermeister K, 2009, J ALLERGY CLIN IMMUN, V124, P1273, DOI 10.1016/j.jaci.2009.07.033; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Behnecke A, 2009, J ALLERGY CLIN IMMUN, V124, P108, DOI 10.1016/j.jaci.2009.03.020; Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; Bin LH, 2009, J ALLERGY CLIN IMMUN, V124, P270, DOI 10.1016/j.jaci.2009.05.002; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P1355, DOI 10.1016/j.jaci.2009.03.046; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Boyano-Martinez T, 2009, J ALLERGY CLIN IMMUN, V123, P883, DOI 10.1016/j.jaci.2008.12.1125; Brandt EB, 2009, J ALLERGY CLIN IMMUN, V123, P53, DOI 10.1016/j.jaci.2008.10.001; Brennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009; Broccardo CJ, 2009, J ALLERGY CLIN IMMUN, V124, P1113, DOI 10.1016/j.jaci.2009.07.057; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; De Benedetto A, 2009, J ALLERGY CLIN IMMUN, V123, pS150, DOI 10.1016/j.jaci.2008.12.562; Duenas-Laita A, 2009, J ALLERGY CLIN IMMUN, V123, P504, DOI 10.1016/j.jaci.2008.12.005; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Faeste CK, 2009, J ALLERGY CLIN IMMUN, V123, P187, DOI 10.1016/j.jaci.2008.09.012; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Fukuda K, 2009, J ALLERGY CLIN IMMUN, V124, P827, DOI 10.1016/j.jaci.2009.06.012; Gaier S, 2009, J ALLERGY CLIN IMMUN, V124, P166, DOI 10.1016/j.jaci.2009.02.023; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Gao P, 2009, J ALLERGY CLIN IMMUN, V123, pS70, DOI 10.1016/j.jaci.2008.12.239; Glasser R, 2009, J ALLERGY CLIN IMMUN, V123, P1117, DOI 10.1016/j.jaci.2009.01.043; Golden DBK, 2009, J ALLERGY CLIN IMMUN, V123, P1371, DOI 10.1016/j.jaci.2009.03.017; Greenhawt MJ, 2009, J ALLERGY CLIN IMMUN, V124, P598, DOI 10.1016/j.jaci.2009.06.039; Greenhawt MJ, 2009, J ALLERGY CLIN IMMUN, V124, P323, DOI 10.1016/j.jaci.2009.05.028; Gros E, 2009, J ALLERGY CLIN IMMUN, V124, P753, DOI 10.1016/j.jaci.2009.07.004; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hamasaka A, 2009, J ALLERGY CLIN IMMUN, V124, P90, DOI 10.1016/j.jaci.2009.04.025; Hansen KS, 2009, J ALLERGY CLIN IMMUN, V123, P1134, DOI 10.1016/j.jaci.2009.02.005; He R, 2009, J ALLERGY CLIN IMMUN, V124, P761, DOI 10.1016/j.jaci.2009.07.040; Hesterberg PE, 2009, J ALLERGY CLIN IMMUN, V123, P1262, DOI 10.1016/j.jaci.2009.02.042; Hijnen D, 2009, J ALLERGY CLIN IMMUN, V124, P856, DOI 10.1016/j.jaci.2009.07.056; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Holzhauser T, 2009, J ALLERGY CLIN IMMUN, V123, P452, DOI 10.1016/j.jaci.2008.09.034; Honda T, 2009, J ALLERGY CLIN IMMUN, V124, P809, DOI 10.1016/j.jaci.2009.04.029; Hope AP, 2009, J ALLERGY CLIN IMMUN, V123, P406, DOI 10.1016/j.jaci.2008.09.048; Jacquenet S, 2009, J ALLERGY CLIN IMMUN, V124, P603, DOI 10.1016/j.jaci.2009.06.014; Jarvinen KM, 2009, J ALLERGY CLIN IMMUN, V124, P1267, DOI 10.1016/j.jaci.2009.10.006; Jensen JM, 2009, J ALLERGY CLIN IMMUN, V123, P1124, DOI 10.1016/j.jaci.2009.03.032; Jerath MR, 2009, J ALLERGY CLIN IMMUN, V123, P260, DOI 10.1016/j.jaci.2008.09.046; Jin HL, 2009, J ALLERGY CLIN IMMUN, V123, P875, DOI 10.1016/j.jaci.2009.02.007; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Joshi P, 2009, J ALLERGY CLIN IMMUN, V124, P383, DOI 10.1016/j.jaci.2009.06.033; Jung T, 2008, J ALLERGY CLIN IMMUN, V122, P1074, DOI 10.1016/j.jaci.2008.09.042; Kaplan AP, 2009, J ALLERGY CLIN IMMUN, V123, P713, DOI 10.1016/j.jaci.2008.10.050; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; Kumar R, 2009, J ALLERGY CLIN IMMUN, V124, P1031, DOI 10.1016/j.jaci.2009.06.052; LeBovidge JS, 2009, J ALLERGY CLIN IMMUN, V124, P1282, DOI 10.1016/j.jaci.2009.08.045; Leung DY, 2009, J ALLERGY CLIN IMMUN, V123, pS34, DOI 10.1016/j.jaci.2008.12.1072; Leung DYM, 2009, J ALLERGY CLIN IMMUN, V124, P494, DOI 10.1016/j.jaci.2009.07.041; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Lopez-Exposito I, 2009, J ALLERGY CLIN IMMUN, V124, P1039, DOI 10.1016/j.jaci.2009.08.024; Maintz L, 2009, J ALLERGY CLIN IMMUN, V123, P701, DOI 10.1016/j.jaci.2008.11.009; Metz M, 2009, J ALLERGY CLIN IMMUN, V123, P705, DOI 10.1016/j.jaci.2008.11.040; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Pali-Scholl I, 2009, J ALLERGY CLIN IMMUN, V123, P1012, DOI 10.1016/j.jaci.2009.01.045; Pieretti MM, 2009, J ALLERGY CLIN IMMUN, V124, P337, DOI 10.1016/j.jaci.2009.05.032; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Roumana A, 2009, J ALLERGY CLIN IMMUN, V124, P379, DOI 10.1016/j.jaci.2009.05.026; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Saverino D, 2009, J ALLERGY CLIN IMMUN, V123, P258, DOI 10.1016/j.jaci.2008.09.023; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Schulten V, 2009, J ALLERGY CLIN IMMUN, V124, P100, DOI 10.1016/j.jaci.2009.02.010; Setkowicz M, 2009, J ALLERGY CLIN IMMUN, V123, P174, DOI 10.1016/j.jaci.2008.09.005; Sheikh J, 2009, J ALLERGY CLIN IMMUN, V123, P1173, DOI 10.1016/j.jaci.2008.12.1130; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2009, J ALLERGY CLIN IMMUN, V123, P319, DOI 10.1016/j.jaci.2008.12.025; Siebenhaar F, 2009, J ALLERGY CLIN IMMUN, V123, P672, DOI 10.1016/j.jaci.2008.12.008; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P625, DOI 10.1016/j.jaci.2009.08.025; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P301, DOI 10.1016/j.jaci.2009.03.050; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Ueta M, 2009, J ALLERGY CLIN IMMUN, V123, P1187, DOI 10.1016/j.jaci.2009.03.008; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; Wittmann M, 2009, J ALLERGY CLIN IMMUN, V124, P81, DOI 10.1016/j.jaci.2009.04.026; Yamada A, 2009, J ALLERGY CLIN IMMUN, V123, P889, DOI 10.1016/j.jaci.2008.12.1115; Young MC, 2009, J ALLERGY CLIN IMMUN, V124, P175, DOI 10.1016/j.jaci.2009.04.004; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015	95	31	33	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					85	97		10.1016/j.jaci.2009.11.031	http://dx.doi.org/10.1016/j.jaci.2009.11.031			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109740				2022-12-18	WOS:000273660500009
J	Pascual, RM; Peters, SP				Pascual, Rodolfo M.; Peters, Stephen P.			The irreversible component of persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway remodeling; irreversible airway obstruction; irreversible airflow limitation	AIRWAY SMOOTH-MUSCLE; SUBEPITHELIAL COLLAGEN DEPOSITION; LUNG-FUNCTION DECLINE; 1ST 6 YEARS; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; BASEMENT-MEMBRANE; RISK-FACTORS; FOLLOW-UP; NATURAL-HISTORY	Irreversible airflow obstruction or limitation occurs in some patients with asthma, can develop early in life, and becomes more common as asthma becomes more severe. Efforts to understand irreversible airflow obstruction or limitation have been hampered by the lack of a standardized definition of the phenotype and by the lack of appropriate research models. Unfortunately, it appears that currently available asthma treatments do not prevent this important asthma complication. Herein, the evidence of an irreversible component of asthma, its underlying pathology, and the limitations of current asthma treatments are reviewed. (J Allergy Clin Immunol 2009; 124:883-90.)	[Pascual, Rodolfo M.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Pascual, RM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rpascual@wfubmc.edu			 [U10HL074225];  [1R21AI076699];  [1K12HL 089992]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL089992, U10HL074225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI076699] Funding Source: NIH RePORTER	; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by grants U10HL074225 and 1R21AI076699 to S.P.P. and IK12HL 089992 to R.M.P.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Apostol GG, 2002, AM J RESP CRIT CARE, V166, P166, DOI 10.1164/rccm.2007035; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; BOCHKOV YA, 2009, MUCOSAL IMMUNOL; Boulet LP, 2007, EUR RESPIR J, V30, P831, DOI 10.1183/09031936.00110107; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busse WW, 2008, J ALLERGY CLIN IMMUN, V121, P1167, DOI 10.1016/j.jaci.2008.02.029; Butcher EC, 2004, NAT BIOTECHNOL, V22, P1253, DOI 10.1038/nbt1017; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chen YZ, 2006, PEDIAT ALLERG IMM-UK, V17, P7, DOI 10.1111/j.1600-5562.2006.00379.x; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Damera G, 2009, PULM PHARMACOL THER, V22, P353, DOI 10.1016/j.pupt.2008.12.006; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Gaga M, 2005, CLIN EXP ALLERGY, V35, P954, DOI 10.1111/j.1365-2222.2005.02281.x; Goleva E, 2007, J ALLERGY CLIN IMMUN, V120, P1065, DOI 10.1016/j.jaci.2007.07.042; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830, DOI 10.1164/ajrccm.160.6.9812100; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; GUPTA S, 2009, CHEST; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Irvin CG, 2003, EUR RESPIR J, V22, P3, DOI 10.1183/09031936.03.00035703; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Lange P, 2006, THORAX, V61, P100, DOI 10.1136/thx.2004.037978; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Mauad T, 2007, J ALLERGY CLIN IMMUN, V120, P997, DOI 10.1016/j.jaci.2007.06.031; McClean MA, 2003, EUR RESPIR J, V22, P50, DOI 10.1183/09031936.03.00099802; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Orie NGM, 1961, BRONCHITIS INT S; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Panettieri RA, 2008, J ALLERGY CLIN IMMUN, V121, P607, DOI 10.1016/j.jaci.2008.01.006; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Romagnoli M, 2007, CLIN EXP ALLERGY, V37, P552, DOI 10.1111/j.1365-2222.2007.02683.x; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59; Slavin RG, 2006, ANN ALLERG ASTHMA IM, V96, P406, DOI 10.1016/S1081-1206(10)60907-6; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Spahn JD, 2008, J ALLERGY CLIN IMMUN, V121, P548, DOI 10.1016/j.jaci.2008.01.012; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 1999, J ALLERGY CLIN IMMUN, V103, P780, DOI 10.1016/S0091-6749(99)70420-3; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; van Veen IH, 2006, RESP MED, V100, P1534, DOI 10.1016/j.rmed.2006.01.009; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309	95	31	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					883	890		10.1016/j.jaci.2009.09.047	http://dx.doi.org/10.1016/j.jaci.2009.09.047			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895980	Green Accepted			2022-12-18	WOS:000272108000002
J	Schulten, V; Radakovics, A; Hartz, C; Mari, A; Vazquez-Cortes, S; Fernandez-Rivas, M; Lauer, I; Jahn-Schmid, B; Eiwegger, T; Scheurer, S; Bohle, B				Schulten, Veronique; Radakovics, Astrid; Hartz, Christina; Mari, Adriano; Vazquez-Cortes, Sonia; Fernandez-Rivas, Montserrat; Lauer, Iris; Jahn-Schmid, Beatrice; Eiwegger, Thomas; Scheurer, Stephan; Bohle, Barbara			Characterization of the allergic T-cell response to Pru p 3, the nonspecific lipid transfer protein in peach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peach allergy; food allergy; nonspecific lipid transfer protein; Pru p 3; T cells; T(H)1/T(H)2; IL-10	BIRCH POLLEN ALLERGEN; CUTANEOUS LYMPHOCYTE ANTIGEN; MAJOR ALLERGEN; FRUIT ALLERGY; PRU-P-3; EXPRESSION; IMMUNOTHERAPY; DIGESTION; EPITOPES; MILK	Background: Pru p 3, the nonspecific lipid transfer protein from peach, is an important plant food allergen that frequently induces systemic reactions. Objective: We sought to analyze the allergic T-cell response to Pru p 3. Methods: PBMCs from Italian and Spanish patients with peach allergy were stimulated with purified natural Pru p 3. Allergen-specific T-cell lines were used to identify T-cell epitopes of Pru p 3. Pru p 3-specific T-cell clones (TCCs) were analyzed for allergen-induced secretion of IL-4, IIFN-gamma, and EL-10 and expression of the integrin 07, a receptor critical for gut homing. Results: No difference in T-cell responses of Italian and Spanish patients was found. Among several T cell-activating regions, Pru p 3(13-27), Pru p 3(34-48), Pru p 3(43-57), and Pru p 3(61-75) were most frequently recognized in 18 Pro p 3-specific T-cell lines. The majority of 32 Pru p 3-specific TCCs belonged to the T(H)2 subset. In contrast to TCCs specific for other plant food and pollen allergens, only a limited number of Pru p 3-specific TCCs produced significant amounts of IL-10. The expression of integrin beta 7 on Pru p 3-specific TCCs was comparable with that observed on peanut-specific TCCs and higher compared with that seen in different pollen-specific TCCs. Conclusion: The T-cell response to Pru p 3 is dominated by TH2 cells presumably primed in the gut. The identification of relevant T cell-activating regions provides a basis for engineering hypoallergenic variants of Pru p 3 with less IgE binding and retained T-cell stimulatory capacity for safe immunotherapy of peach allergy. (J Allergy Clin Immunol 2009;17,4:100-7.)	[Schulten, Veronique; Radakovics, Astrid; Jahn-Schmid, Beatrice; Bohle, Barbara] Med Univ Vienna, Ctr Physiol Pathophysiol & Immunol, Dept Pathophysiol, A-1090 Vienna, Austria; [Hartz, Christina; Lauer, Iris; Scheurer, Stephan] Paul Ehrlich Inst, D-6070 Langen, Germany; [Mari, Adriano] IDI IRCCS, Ctr Clin & Expt Allergol, Rome, Italy; [Vazquez-Cortes, Sonia; Fernandez-Rivas, Montserrat] Hosp Clin San Carlos, Serv Alergia, Madrid, Spain; [Eiwegger, Thomas] Med Univ Vienna, Dept Pediat, A-1090 Vienna, Austria; [Bohle, Barbara] Christian Doppler Lab Immunomodulat, Vienna, Austria	Medical University of Vienna; Paul Ehrlich Institute; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Hospital Clinico San Carlos; Medical University of Vienna	Bohle, B (corresponding author), Med Univ Vienna, Ctr Physiol Pathophysiol & Immunol, Dept Pathophysiol, Waehringer Guertel 18-20,AKH-3Q, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at	Scheurer, Stephan/A-6509-2019	Scheurer, Stephan/0000-0002-2859-562X; Bohle, Barbara/0000-0002-5105-7985; Eiwegger, Thomas/0000-0002-2914-7829	Austrian Science Fund [SFB-F1807-B13, W1212-B13, P20011-B09]; German Science Foundation; DFG [SCHE 637]	Austrian Science Fund(Austrian Science Fund (FWF)); German Science Foundation(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	Supported by the Austrian Science Fund, projects SFB-F1807-B13, W1212-B13, and P20011-B09,and the German Science Foundation, project DFG SCHE 637.	ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Andrew DP, 1996, EUR J IMMUNOL, V26, P897, DOI 10.1002/eji.1830260427; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P688, DOI 10.1067/mai.2002.123235; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Borghesan F, 2008, INT ARCH ALLERGY IMM, V147, P161, DOI 10.1159/000137285; Brenna O, 2000, J AGR FOOD CHEM, V48, P493, DOI 10.1021/jf9906681; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Cuesta-Herranz J, 1998, ALLERGY, V53, P78, DOI 10.1111/j.1398-9995.1998.tb03777.x; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; Duffort OA, 2002, J AGR FOOD CHEM, V50, P7738, DOI 10.1021/jf0258398; EBNER C, 1995, J IMMUNOL, V154, P1932; Eigenmann PA, 1999, J ALLERGY CLIN IMMUN, V103, P931, DOI 10.1016/S0091-6749(99)70441-0; Eiwegger T, 2006, CLIN EXP ALLERGY, V36, P1281, DOI 10.1111/j.1365-2222.2006.02565.x; Farstad IN, 1997, GASTROENTEROLOGY, V112, P163, DOI 10.1016/S0016-5085(97)70231-2; Fernandez-Rivas M, 2003, J ALLERGY CLIN IMMUN, V112, P789, DOI 10.1016/S0091-6749(03)02016-5; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Ferreira Fatima, 2006, Inflammation & Allergy Drug Targets, V5, P5, DOI 10.2174/187152806775269295; Flinterman AE, 2008, CURR OPIN ALLERGY CL, V8, P261, DOI 10.1097/ACI.0b013e3282ffb145; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Gaier S, 2008, MOL NUTR FOOD RES, V52, pS220, DOI 10.1002/mnfr.200700274; Garcia-Casado G, 2003, J ALLERGY CLIN IMMUN, V112, P599, DOI 10.1037/mai.2003.1638; Hartz C, 2007, MOL IMMUNOL, V44, P2820, DOI 10.1016/j.molimm.2007.01.030; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Pacios LF, 2008, MOL IMMUNOL, V45, P2269, DOI 10.1016/j.molimm.2007.11.022; Pasquato N, 2006, J MOL BIOL, V356, P684, DOI 10.1016/j.jmb.2005.11.063; Pastorello EA, 2003, J ALLERGY CLIN IMMUN, V112, P775, DOI 10.1016/S0091-6749(03)01942-0; Pastorello EA, 2004, MOL NUTR FOOD RES, V48, P356, DOI 10.1002/mnfr.200400047; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 1999, BIOL CHEM, V380, P1315, DOI 10.1515/BC.1999.167; Salcedo G, 2007, BBA-MOL CELL BIOL L, V1771, P781, DOI 10.1016/j.bbalip.2007.01.001; San Miguel-Moncin M, 2003, ALLERGY, V58, P511, DOI 10.1034/j.1398-9995.2003.00097.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Santamaria-Babi LF, 2004, EUR J DERMATOL, V14, P13; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; Scheurer S, 2004, J ALLERGY CLIN IMMUN, V114, P900, DOI 10.1016/j.jaci.2004.06.017; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; Vassilopoulou E, 2006, J ALLERGY CLIN IMMUN, V118, P473, DOI 10.1016/j.jaci.2006.04.057; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Wosinska-Becler K, 2004, CLIN EXP ALLERGY, V34, P123, DOI 10.1111/j.1365-2222.2004.01850.x; Zuidmeer L, 2005, INT ARCH ALLERGY IMM, V137, P273, DOI 10.1159/000086420; Zuidmeer L, 2007, CURR OPIN ALLERGY CL, V7, P269, DOI 10.1097/ACI.0b013e32814a5401	51	31	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					100	107		10.1016/j.jaci.2009.02.010	http://dx.doi.org/10.1016/j.jaci.2009.02.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19356790				2022-12-18	WOS:000267909700012
J	Patel, NC; Chinen, J; Rosenblatt, HM; Hanson, IC; Brown, BS; Paul, ME; Abramson, SL; Ritz, J; Shearer, WT				Patel, Niraj C.; Chinen, Javier; Rosenblatt, Howard M.; Hanson, Imelda C.; Brown, Betty S.; Paul, Mary E.; Abramson, Stuart L.; Ritz, Jerome; Shearer, William T.			Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anti-CD6 mAb; transplantation; graft-versus-host disease; immune reconstitution; immunodeficiency; mismatched related donor	VERSUS-HOST-DISEASE; IMMUNE RECONSTITUTION; PERIPHERAL-BLOOD; SINGLE-CENTER; EUROPEAN EXPERIENCE; RISK-FACTORS; STEM-CELLS; FOLLOW-UP; CHILDREN; SURVIVAL	Background: Between 1981 and 1995, 20 children with severe combined immunodeficiency (SCID; median age at transplant, 6.5 [range, 0.5-145] mo, 12 with serious infection) were treated with haploidentical T cell-depleted (anti-CD6 antibody) bone marrow (median number of 5.7 [0.8-18.8] x 10(8) nucleated cells/kg) from mismatched related donors (MMRDs), and 5 children with SCID (median age at transplant, 1.8 [0.5-5.0] mo, 1 with serious infection) were given unmanipulated bone marrow from matched related donors (MRDs). No conditioning or graft-versus-host disease (GvHD) prophylaxis was used. Objective: To assess the outcomes of patients with SCID who received bone marrow from MMRDs or MRDs. Methods: We reviewed the medical records of these 25 consecutive patients with SCID (4 with Omenn syndrome). Results: Of the 20 patients who received bone marrow from MMRDs, 12 engrafted, 10 survived at a median age of 15.2 [10.0-19.1] years, 4 had chronic GvHD (lung, intestine, skin), 5 required intravenous immunoglobulin, and 8 attended school or college. Two of 5 patients who died had chronic GvHD, and 2 developed lymphoproliferative disease. Of the 5 patients who received bone marrow from MRDs, 5 engrafted, 5 survived at a median age of 23.3 [18.5-26] years, I had chronic GvHD (lung, skin), 2 required intravenous immunoglobulin, and 4 attended school or college. Conclusions: Treatment of critically ill patients with SCID with anti-CD6 antibody T cell-depleted MMRD marrow resulted in an overall 50% long-term survival of patients (83% survival of those engrafted). The principal barriers to long-term survival were delay in diagnosis, life-threatening infection, failure to engraft, and chronic GvHD. Educational goals were achieved in most of the survivors. (J Allergy Clin Immunol 2008;122:1185-93.)	[Patel, Niraj C.; Chinen, Javier; Hanson, Imelda C.; Brown, Betty S.; Paul, Mary E.; Abramson, Stuart L.; Shearer, William T.] Texas Childrens Hosp, Sect Allergy & Immunol, Dept Pediat, Baylor Coll Med, Houston, TX 77039 USA; [Rosenblatt, Howard M.] Dell Childrens Med Ctr Cent Texas, Austin, TX USA; [Ritz, Jerome] Harvard Univ, Sch Med, Div Hematol Malignancies, Boston, MA USA; [Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Ritz, Jerome] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA USA	Baylor College of Medicine; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Shearer, WT (corresponding author), Texas Childrens Hosp, Sect Allergy & Immunol, Dept Pediat, Baylor Coll Med, 6621 Fannin,FC 330-01, Houston, TX 77039 USA.	wtsheare@texaschildrenshospital.org	Paul, Mary/AAA-2722-2021; Ritz, Jerome/C-7929-2009	Ritz, Jerome/0000-0001-5526-4669; Shearer, William/0000-0002-2483-2130	General Clinical Research Center [RR-0188]; Immunology Research Fund; David Fund; Texas Children's Hospital; National Institutes of Health; Centers for Disease Control and Prevention; Ryan While; Dana-Farber Cancer institute	General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Immunology Research Fund; David Fund; Texas Children's Hospital; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Ryan While; Dana-Farber Cancer institute	Supported by the General Clinical Research Center (grant RR-0188), the Immunology Research Fund, and the David Fund. Texas Children's Hospital.; Disclosure of potential conflict of interest: I. C. Hanson is on the speakers' bureau for Sanofi-Pasteur. M. E. Paul has received research support from the National Institutes of Health, the Centers for Disease Control and Prevention, and Ryan While Part D. J. Ritz has received research support from the Dana-Farber Cancer institute and the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Bertrand Y, 1999, J PEDIATR-US, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; Bhattacharya A, 2005, BONE MARROW TRANSPL, V36, P295, DOI 10.1038/sj.bmt.1705054; BREARD J, 1980, J IMMUNOL, V124, P1943; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; Dickinson AM, 1997, BONE MARROW TRANSPL, V19, P323, DOI 10.1038/sj.bmt.1700669; DROR Y, 1993, BLOOD, V81, P2021; Dvorak C, 2008, BONE MARROW TRANSPL, V41, P119, DOI 10.1038/sj.bmt.1705890; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; Friedrich W, 2007, IMMUNOL RES, V38, P165, DOI 10.1007/s12026-007-0030-2; Gennery AR, 2001, CYTOTHERAPY, V3, P221, DOI 10.1080/146532401753174052; Godder KT, 2007, BONE MARROW TRANSPL, V39, P751, DOI 10.1038/sj.bmt.1705650; Gordon PR, 2002, BONE MARROW TRANSPL, V30, P69, DOI 10.1038/sj.bmt.1703619; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Handgretinger R, 2001, BONE MARROW TRANSPL, V27, P777, DOI 10.1038/sj.bmt.1702996; Keever-Taylor CA, 2001, BIOL BLOOD MARROW TR, V7, P620, DOI 10.1053/bbmt.2001.v7.pm11760150; KEMAN NA, 1993, NEW ENGL J MED, V328, P593; KERMAN NA, 1986, BLOOD, V68, P770; Koh LP, 2007, BIOL BLOOD MARROW TR, V13, P1249, DOI 10.1016/j.bbmt.2007.08.003; Martin P, 2003, BONE MARROW TRANSPL, V32, P881, DOI 10.1038/sj.bmt.1704239; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Nguyen S, 2005, BLOOD, V105, P4135, DOI 10.1182/blood-2004-10-4113; Novitzky N, 2002, TRANSPLANTATION, V74, P1551, DOI 10.1097/00007890-200212150-00012; Novitzky N, 2007, BIOL BLOOD MARROW TR, V13, P107, DOI 10.1016/j.bbmt.2006.09.004; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; REINHERZ EL, 1982, P NATL ACAD SCI-BIOL, V79, P6047, DOI 10.1073/pnas.79.19.6047; REISNER Y, 1983, BLOOD, V61, P341; ROHATINER A, 1986, TRANSPLANTATION, V42, P73, DOI 10.1097/00007890-198607000-00016; Roifman CM, 2008, BONE MARROW TRANSPL, V41, P947, DOI 10.1038/bmt.2008.11; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; SHEARER WT, 1985, NEW ENGL J MED, V312, P1151, DOI 10.1056/NEJM198505023121804; Smogorzewska Elzbieta M., 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P111; SOIFFER RJ, 1993, BLOOD, V82, P2216; SOIFFER RJ, 1992, J CLIN ONCOL, V10, P1191, DOI 10.1200/JCO.1992.10.7.1191; SOIFFER RJ, 1990, BLOOD, V75, P2076; Sun Y, 2007, TRANSL RES, V150, P197, DOI 10.1016/j.trsl.2007.06.003; VANLEEUWEN JEM, 1994, BLOOD, V84, P3936, DOI 10.1182/blood.V84.11.3936.bloodjournal84113936	42	31	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1185	1193		10.1016/j.jaci.2008.10.030	http://dx.doi.org/10.1016/j.jaci.2008.10.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	19084111	Bronze			2022-12-18	WOS:000261711800018
J	Yamin, M; Holbrook, EH; Gray, ST; Harold, R; Busaba, N; Sridhar, A; Powell, KJ; Hamilos, DL				Yamin, Moshe; Holbrook, Eric H.; Gray, Stacey T.; Harold, Rachel; Busaba, Nicolas; Sridhar, Avinash; Powell, Katia J.; Hamilos, Daniel L.			Cigarette smoke combined with Toll-like receptor 3 signaling triggers exaggerated epithelial regulated upon activation, normal T-cell expressed and secreted/CCL5 expression in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; epithelial; innate; cigarette smoke; viral; RANTES; exacerbations; eosinophilic	RANTES; ASTHMA; INFLAMMATION; RHINOVIRUS; RECRUITMENT	Background: Chronic rhinosinusitis (CRS) is characterized by persistent mucosal inflammation and frequent exacerbations. Objective: To determine whether innate epithelial responses to cigarette smoke or bacterial or viral pathogens may be abnormal in CRS leading to an inappropriate inflammatory response. Methods: Primary nasal epithelial cells (PNECs) were grown from middle turbinate biopsies of 9 healthy controls and 11 patients with CRS. After reaching 80% to 90% confluence, PNECs were exposed to medium or cigarette smoke extract (CSE) 5% (vol/vol) for I hour, washed, then stimulated with staphylococcal lipoteichoic acid, LPS, or double-stranded RNA (dsRNA). After 24 hours, gene expression was quantified by QRT-PCR. Results: At baseline, PNECs revealed elevated TNF-alpha and growth-related oncogene-alpha (a C-X-C chemokine)/CXCLI (GRO-alpha) (4-fold increase, P = .02; and 16-fold increase, P = .004, respectively) in subjects with CRS compared with controls with normal levels of IL-1 beta, 11-6, IL-8/CXCL8, human beta-defensin-2, monocyte chemoattractant protein 2/CCL8, monocyte chemoattractant protein 3/CCL7, and regulated upon activation, normal T-cell expressed and secreted (RANTES)/CCL5. Immunostaining of nasal biopsies, however, revealed comparable epithelial staining for TNF-alpha, GRO-alpha, and RANTES. There were no differences in mRNA induction bv CSE, TNF-alpha, lipoteichoic acid, LPS, or dsRNA alone. The combination of CSE+dsRNA induced exaggerated RANTES (12,115-fold vs 1500-fold; P = .03) and human beta-defensin-2 (1120-fold vs 12.5-fold; P =.05) in subjects with CRS. No other genes were differentially induced. Furthermore, CSE+dsRNA induced normal levels of IFN-beta, lFN-lambda 1, and IFN-lambda 2/3 mRNA in subjects with CRS. Conclusion: Cigarette smoke extract plus dsRNA induces exaggerated epithelial RANTES expression in patients with CRS. We propose that an analogous response to cigarette smoke plus viral infection may contribute to acute exacerbations and eosinophilic mucosal inflammation in CRS. (J Allergy Clin Immunol 2008;122:1145-53.)	[Yamin, Moshe; Harold, Rachel; Sridhar, Avinash; Powell, Katia J.; Hamilos, Daniel L.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Hamilos, DL (corresponding author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA.	dhamilos@partners.org			Flight Attendants Medical Research Institute; Merck; National Institutes of Health-National Institutes of Deafness and Other Communication Disorders	Flight Attendants Medical Research Institute; Merck(Merck & Company); National Institutes of Health-National Institutes of Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	D. L. Hamilos has received honoraria from Merck. Critical Therapeutics. Genentech. and Novartis: has consulting arrangements with GlaxoSmithKline, Novartis. Accentia, Schering-Plough. and Sinexus: has received research support from the Flight Attendants Medical Research Institute and Merck: and has received gifts from the GG Monks Foundation to purchase equipment. F. H. Holbrook has received research support from the National Institutes of Health-National Institutes of Deafness and Other Communication Disorders, S. T. Gray has served as a member of the American Academy of Otolaryngology and the American Rhinologic Society. N. Busaba is on the speakers' bureau for Sanofi-Aventis and Schering-Plough. The rest of the authors have declared that they have no conflict of interest.	Bachert Claus, 2007, Clin Allergy Immunol, V20, P163; Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; Bhattacharyya N, 2005, AM J RHINOL, V19, P544, DOI 10.1177/194589240501900602; Briggs RD, 2004, LARYNGOSCOPE, V114, P126, DOI 10.1097/00005537-200401000-00022; Brook I, 2001, ANN OTO RHINOL LARYN, V110, P148, DOI 10.1177/000348940111000210; Castro M, 2004, AM J RESP CRIT CARE, V169, P842, DOI 10.1164/rccm.200208-960OC; Chen Y, 2003, LARYNGOSCOPE, V113, P1199, DOI 10.1097/00005537-200307000-00016; Claeys S, 2003, ALLERGY, V58, P748, DOI 10.1034/j.1398-9995.2003.00180.x; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Hessler JL, 2007, AM J RHINOL, V21, P10, DOI 10.2500/ajr.2007.21.2960; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holtzman MJ, 2002, PHYSIOL REV, V82, P19, DOI 10.1152/physrev.00020.2001; Jang YJ, 2006, AM J RHINOL, V20, P634, DOI 10.2500/ajr.2006.20.2899; Jankowski R, 2002, RHINOLOGY, V40, P173; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; KEEBLER CM, 1993, MANUAL CYTOTECHNOLOG, P414; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kreindler JL, 2005, AM J PHYSIOL-LUNG C, V288, pL894, DOI 10.1152/ajplung.00376.2004; Lane AP, 2006, AM J RHINOL, V20, P117, DOI 10.1177/194589240602000122; Lieu JEC, 2000, ARCH OTOLARYNGOL, V126, P940, DOI 10.1001/archotol.126.8.940; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Pan ZZ, 2000, AM J PHYSIOL-LUNG C, V279, pL658, DOI 10.1152/ajplung.2000.279.4.L658; Ponikau Jens U, 2007, Clin Allergy Immunol, V20, P177; Proud D, 2006, AM J RESP CELL MOL, V35, P513, DOI 10.1165/rcmb.2006-0199TR; Ramadan HH, 2005, OTOLARYNG HEAD NECK, V132, P414, DOI 10.1016/j.otohns.2004.11.011; Schnyder B, 2005, CYTOKINE, V31, P191, DOI 10.1016/j.cyto.2005.02.012; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Venarske DL, 2006, J INFECT DIS, V193, P1536, DOI 10.1086/503809; Wiehler S, 2007, AM J PHYSIOL-LUNG C, V293, pL505, DOI 10.1152/ajplung.00066.2007; Yuan Q, 2006, EUR J IMMUNOL, V36, P2700, DOI 10.1002/eji.200636112	36	31	31	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1145	1153		10.1016/j.jaci.2008.09.033	http://dx.doi.org/10.1016/j.jaci.2008.09.033			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18986692				2022-12-18	WOS:000261711800012
J	Holbrook, JT; Harik-Khan, R				Holbrook, Janet T.; Harik-Khan, Raida			Montelukast and emotional well-being as a marker for depression: Results from 3 randomized, double-masked clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							QUALITY-OF-LIFE; ASTHMA		[Holbrook, Janet T.; Harik-Khan, Raida] Johns Hopkins Univ, Bloomberg Sch Publ Health, ALA ACRC Data Coordinating Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Holbrook, JT (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Health, ALA ACRC Data Coordinating Ctr, Baltimore, MD 21287 USA.	jholbroo@jhsph.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073494] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL073494] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brunlof Gertrud, 2008, BMC Clin Pharmacol, V8, P1, DOI 10.1186/1472-6904-8-1; Hann D, 1999, J PSYCHOSOM RES, V46, P437, DOI 10.1016/S0022-3999(99)00004-5; Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089; Irvin CG, 2007, AM J RESP CRIT CARE, V175, P235, DOI 10.1164/rccm.200603-416OC; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Peters SP, 2007, NEW ENGL J MED, V356, P2027; RADIOFF LS, 1977, APPL PSYCH MEAS, V1, P385; 2008, NY TIMES        0328	9	31	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					828	829		10.1016/j.jaci.2008.07.012	http://dx.doi.org/10.1016/j.jaci.2008.07.012			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18760460	Green Accepted			2022-12-18	WOS:000259989000031
J	Chen, WG; Tabata, Y; Gibson, AM; Daines, MO; Warrier, MR; Wills-Karp, M; Hershey, GKK				Chen, Weiguo; Tabata, Yasuhiro; Gibson, Aaron M.; Daines, Michael O.; Warrier, Manoi R.; Wills-Karp, Marsha; Hershey, Gurjit K. Khurana			Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha 2 in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						matrix metalloproteinase 8; IL-13; IL-13 receptor alpha 2	IL-13 RECEPTOR ALPHA-2; INTERLEUKIN (IL)-13 RESPONSES; MATRIX METALLOPROTEINASE-8; COLLAGENASE-2 MMP-8; TISSUE INHIBITOR; EPITHELIAL-CELLS; DECOY RECEPTOR; ASTHMA; EXPRESSION; MICE	Background: IL-13 receptor alpha 2 (IL-13R alpha 2) is a high-affinity receptor for 11,43, a central mediator of allergic asthma. It acts predominantly as a decoy receptor but can also contribute to IL-13 responses under certain conditions. IL-13R alpha 2 exists in soluble and membrane forms, which can both bind IL-13 and modulate its activity. Yet the proteolytic processes that contribute to the generation of soluble IL-13R alpha 2 are largely unknown. Objective: We sought to investigate the role of matrix metalloproteinases (MMPs) in the generation of soluble IL-13R alpha 2. Methods: Acellular cleavage assays by MMPs were performed by using glutathione-S-transferase fusion proteins of murine or human IL-13R alpha 2. IL-13R alpha 2 stable-transfected cells were used for analysis of surface expression and release of soluble IL-13R alpha 2. Wild-type and MMP-8-deficient mice were used for analysis of allergen-induced airway hyperresponsiveness and solubilization of IL-13R alpha 2. Results: Among several MMPs tested, only MMP-8 cleaved IL-13R alpha 2. Treatment of transfected human or murine cells expressing high levels of surface IL-13R alpha 2 with MMP-8 resulted in release of soluble IL-13R alpha 2 into the supernatants, with a concomitant decrease in surface IL-13R alpha 2 levels. The IL-13R alpha 2 solubilized by MMP-8 retained IL-13 binding activity. In an asthma model MMP-8-deficient mice displayed increased airway hyperresponsiveness and decreased soluble IL-13R alpha 2 protein levels in bronchoalveolar lavage fluid compared with those seen in wild-type mice after house dust mite challenge. Conclusion: MMP-8 cleaves IL-13R alpha 2 in vitro and contributes to the solubilization of IL-13R alpha 2 in vivo.	[Chen, Weiguo; Tabata, Yasuhiro; Gibson, Aaron M.; Daines, Michael O.; Warrier, Manoi R.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA; [Chen, Weiguo; Tabata, Yasuhiro; Gibson, Aaron M.; Daines, Michael O.; Warrier, Manoi R.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp, Med Ctr, Inst Personalized & Predict Med, Cincinnati, OH USA; [Wills-Karp, Marsha] Cincinnati Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH USA; [Wills-Karp, Marsha] Univ Cincinnati, Dept Pediat, Coll Med, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Childrens Hosp, Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org		Khurana Hershey, Gurjit/0000-0001-6663-977X; Daines, Michael/0000-0003-2464-9034	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046652, R01AI058157] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI046652, R01 AI058157, R01 AI058157-04, R01 AI58157] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atkinson JJ, 2003, AM J RESP CELL MOL, V28, P12, DOI 10.1165/rcmb.2002-0166TR; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Daines MO, 2007, J ALLERGY CLIN IMMUN, V119, P375, DOI 10.1016/j.jaci.2006.09.039; Daines MO, 2006, J IMMUNOL, V176, P7495, DOI 10.4049/jimmunol.176.12.7495; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; Demedts IK, 2005, CURR OPIN PHARMACOL, V5, P257, DOI 10.1016/j.coph.2004.12.005; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gueders MM, 2005, J IMMUNOL, V175, P2589, DOI 10.4049/jimmunol.175.4.2589; Gutierrez-Fernandez A, 2007, FASEB J, V21, P2580, DOI 10.1096/fj.06-7860com; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; HUANG SK, 1995, J IMMUNOL, V155, P2688; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kioi M, 2006, FASEB J, V20, P2378, DOI 10.1096/fj.06-5995fje; Kost TA, 2005, NAT BIOTECHNOL, V23, P567, DOI 10.1038/nbt1095; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; Liu LY, 2002, J IMMUNOL, V169, P6459, DOI 10.4049/jimmunol.169.11.6459; LUST JA, 1992, CYTOKINE, V4, P96, DOI 10.1016/1043-4666(92)90043-Q; Matsumura M, 2007, BIOCHEM BIOPH RES CO, V360, P464, DOI 10.1016/j.bbrc.2007.06.076; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Mentink-Kane MM, 2004, P NATL ACAD SCI USA, V101, P586, DOI 10.1073/pnas.0305064101; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Orlando S, 1997, J BIOL CHEM, V272, P31764, DOI 10.1074/jbc.272.50.31764; Owen CA, 2004, J IMMUNOL, V172, P7791, DOI 10.4049/jimmunol.172.12.7791; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Prikk K, 2002, LAB INVEST, V82, P1535, DOI 10.1097/01.LAB.0000035023.53893.B6; Sheu BC, 2001, CANCER RES, V61, P237; Tabata Y, 2007, CURR ALLERGY ASTHM R, V7, P338, DOI 10.1007/s11882-007-0051-x; Tabata Y, 2006, J IMMUNOL, V177, P7905, DOI 10.4049/jimmunol.177.11.7905; Trieu Y, 2004, CANCER RES, V64, P3271, DOI 10.1158/0008-5472.CAN-03-3764; Vernooy JHJ, 2004, CHEST, V126, P1802, DOI 10.1378/chest.126.6.1802; Walters DM, 2002, AM J RESP CELL MOL, V27, P413, DOI 10.1165/rcmb.4844; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Yasunaga S, 2003, CYTOKINE, V24, P293, DOI 10.1016/j.cyto.2003.08.006; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zheng L, 2002, EUR RESPIR J, V20, P170, DOI 10.1183/09031936.02.00282402; Zheng T, 2003, J ALLERGY CLIN IMMUN, V111, P720, DOI 10.1067/mai.2003.1383; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	49	31	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					625	632		10.1016/j.jaci.2008.06.022	http://dx.doi.org/10.1016/j.jaci.2008.06.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18694590	Green Accepted			2022-12-18	WOS:000259234000028
J	Esch, RE				Esch, Robert E.			Allergen immunotherapy: What can and cannot be mixed?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						allergenic extracts; mixing of extracts; allergen cross-reactivity			Greer Labs, Res & Dev, Lenoir, NC 28645 USA		Esch, RE (corresponding author), Greer Labs, Res & Dev, 639 Nuway Circle, Lenoir, NC 28645 USA.	esch@greerlabs.com						*AM AC ALL ASTHM I, 2006, ACAD NEWS, V12, P9; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Esch RE, 2000, ARB P EHRLICH I, V93, P57; Grier TJ, 2007, ANN ALLERG ASTHMA IM, V99, P151, DOI 10.1016/S1081-1206(10)60639-4; Mari A, 2006, INT ARCH ALLERGY IMM, V141, P57, DOI 10.1159/000094254; Weber RW, 2008, J ALLERGY CLIN IMMUN, V122, P219, DOI 10.1016/j.jaci.2008.05.034	6	31	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					659	660		10.1016/j.jaci.2008.07.018	http://dx.doi.org/10.1016/j.jaci.2008.07.018			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774400				2022-12-18	WOS:000259234000038
J	Ueda, T; Niimi, A; Matsumoto, H; Takemura, M; Yamaguchi, M; Matsuoka, H; Jinnai, M; Chin, K; Minakuchi, M; Cheng, L; Shirakawa, T; Mishima, M				Ueda, Tetsuya; Niimi, Akio; Matsumoto, Hisako; Takemura, Masaya; Yamaguchi, Masafumi; Matsuoka, Hirofumi; Jinnai, Makiko; Chin, Kazuo; Minakuchi, Masayoshi; Cheng, Lei; Shirakawa, Taro; Mishima, Michiaki			TGFB1 promoter polymorphism C-509T and pathophysiology of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway remodeling; airway inflammation; TGF-beta 1; C-509T; gene polymorphism; computed tomography; airway wall thickening; sputum eosinophil	GROWTH-FACTOR-BETA; AIRWAY WALL THICKNESS; TGF-BETA-1 GENE; COMPUTED-TOMOGRAPHY; EXPRESSION; INFLAMMATION; LUNG; EOSINOPHILS	Background: TGF-beta 1 can modulate airway inflammation and exaggerate airway remodeling. A polymorphism of a promoter region of TGFBI, C-509T, might be associated with the development of asthma, but its pathophysiologic relevance remains poorly understood. Objective: We investigated relations of the C-509T polymorphism to airflow obstruction, sputum eosinophilia, and airway wall thickening, as assessed by means of computed tomography, in 85 patients with stable asthma. Methods: The CC, CT, and TT genotypes were examined by means of PCR and restriction enzyme fragment length polymorphism. At a selected bronchus, 3 indices of airway wall thickness were measured with an automatic method. Results: The CC, CT, and TT genotypes were found in 22,46, and 17 patients, respectively. Serum TGF-beta 1 levels were significantly associated with the polymorphism and were increased in the CT/TT genotypes. FEV1 and sputum eosinophil percentages were also significantly associated with the polymorphism and were both decreased in the CT/TT genotypes. The polymorphism was unrelated to airway wall thickness. Conclusion: In addition to increased serum TGF-beta 1 levels, the T allele of the C-509T polymorphism is related to increased airflow obstruction but attenuated eosinophilic inflammation. The former relation is not attributed to thickening of the central airway walls. The latter relation might reflect the anti-inflammatory effect of TGF-beta 1. The C-509T polymorphism has a complex role in asthma pathophysiology, presumably because of the diverse functions of TGF-beta 1 and its various interactions with cells and humoral factors in vivo.	[Ueda, Tetsuya; Niimi, Akio; Matsumoto, Hisako; Takemura, Masaya; Yamaguchi, Masafumi; Matsuoka, Hirofumi; Jinnai, Makiko; Chin, Kazuo; Mishima, Michiaki] Kyoto Univ, Grad Sch Med, Dept Resp Med, Sakyo Ku, Kyoto 6068507, Japan; [Minakuchi, Masayoshi] Tenri Hosp, Dept Resp Med, Tenri, Nara 632, Japan; [Cheng, Lei] Nanjing Med Univ, Affiliated Hosp 1, Dept Otorhinolaryngol, Nanjing, Peoples R China; [Cheng, Lei] Nanjing Med Univ, Int Ctr Allergy Res, Nanjing, Peoples R China; [Shirakawa, Taro] Kyoto Univ, Dept Hlth Promot & Human Behav, Kyoto, Japan	Kyoto University; Tenri Hospital; Nanjing Medical University; Nanjing Medical University; Kyoto University	Niimi, A (corresponding author), Kyoto Univ, Grad Sch Med, Dept Resp Med, Sakyo Ku, Kyoto 6068507, Japan.	mimi@kuhp.kyoto-u.ac.jp	Cheng, Lei/AAT-2690-2021	Cheng, Lei/0000-0001-6541-7702; Matsuoka, Hirofumi/0000-0001-5219-7501				ALAM R, 1994, J EXP MED, V179, P1041, DOI 10.1084/jem.179.3.1041; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Boxall C, 2006, EUR RESPIR J, V27, P208, DOI 10.1183/09031936.06.00130004; Buckova D, 2001, ALLERGY, V56, P1236, DOI 10.1034/j.1398-9995.2001.00373.x; CLARE CG, 2007, AM J RESP CELL MOL B, V36, P721; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; de Jong PA, 2005, EUR RESPIR J, V26, P140, DOI 10.1183/09031936.05.00007105; Duvernelle C, 2003, PULM PHARMACOL THER, V16, P181, DOI 10.1016/S1094-5539(03)00051-8; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; Haneda K, 1997, J IMMUNOL, V159, P4484; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Heinzmann A, 2005, PEDIAT ALLERG IMM-UK, V16, P310, DOI 10.1111/j.1399-3038.2005.00287.x; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; King GG, 1999, AM J RESP CRIT CARE, V159, P992, DOI 10.1164/ajrccm.159.3.9805064; Leung SY, 2006, J PHARMACOL EXP THER, V319, P586, DOI 10.1124/jpet.106.109314; Luttmann W, 1998, SCAND J IMMUNOL, V47, P127; Mak JCW, 2006, J ALLERGY CLIN IMMUN, V117, P92, DOI 10.1016/j.jaci.2005.08.049; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Nagpal K, 2005, J ALLERGY CLIN IMMUN, V115, P527, DOI 10.1016/j.jaci.2004.11.048; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102, DOI 10.1164/ajrccm.162.3.9907120; *NIH NAT HEART LUN, 2004, PUBL NIH NAT HEART L; Niimi A, 2004, CLIN REV ALLERG IMMU, V27, P45, DOI 10.1385/CRIAI:27:1:045; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; Niimi A, 2004, AM J MED, V116, P725, DOI 10.1016/j.amjmed.2003.11.026; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Sato F, 2004, TISSUE ANTIGENS, V64, P35, DOI 10.1111/j.1399-0039.2004.00256.x; Scherf W, 2005, EUR J IMMUNOL, V35, P198, DOI 10.1002/eji.200425209; SILLABER C, 1992, BLOOD, V80, P634; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Takemura M, 2004, CHEST, V125, P1352, DOI 10.1378/chest.125.4.1352; Ueda T, 2006, J ALLERGY CLIN IMMUN, V118, P1019, DOI 10.1016/j.jaci.2006.07.032; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC	47	31	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					659	664		10.1016/j.jaci.2007.10.005	http://dx.doi.org/10.1016/j.jaci.2007.10.005			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18036644				2022-12-18	WOS:000253918900018
J	Makowska, JS; Grzegorczyk, J; Bienkiewicz, B; Wozniak, M; Kowalski, ML				Makowska, Joanna S.; Grzegorczyk, Janina; Bienkiewicz, Barbara; Wozniak, Maria; Kowalski, Marek L.			Systemic responses after bronchial aspirin challenge in sensitive patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin hypersensitivity; bronchial asthma; AERD; progenitor cells; CD34; aspirin bronchial challenge	BONE-MARROW; PROVOCATION TESTS; NATURAL-HISTORY; ATOPIC ASTHMA; CD34(+) CELLS; ALLERGEN; EXPRESSION; EOSINOPHILS; PATHOGENESIS; DIAGNOSIS	Background: In aspirin-sensitive patients with asthma, bronchial obstruction induced by oral aspirin may be associated with extrabronchial symptoms, suggesting the systemic character of the response. Objective: Go assess potential systemic effects of local aspirin challenge, hemopoietic progenitors were measured in the peripheral blood of challenged patients. Methods: In 19 patients with a history of aspirin-induced asthma, placebo-controlled bronchial challenges with lysineaspirin were performed. Peripheral blood was collected before and then 1 hour and 20 hours after challenge (placebo or aspirin). Using the flow-cytometric method, the numbers of leukocyte (CD34(+) cells) and eosinophil (CD34(+)CD125(+) cells) progenitors were determined. Results: The challenge was positive in 13 patients; 6 patients had isolated local bronchial reaction, and 7 patients developed systemic symptoms (bronchial and extrabronchial). In patients with positive challenge (n = 13), leukocyte progenitors increased significantly at 1 hour and 20 hours after challenge (mean, 0.04% at baseline, 0.066% at 1 hour after challenge, and 0.073% at 20 hours; P < .05). Eosinophil progenitors raised significantly from mean 0.017% before challenge to 0.04% (P < .05) at 20 hours after the challenge. At 20 hours after the challenge, the increase in leukocyte and eosinophil progenitors was observed only in patients with systemic reactions. Positive aspirin challenge was associated with a significant increase in eotaxin 2 serum concentration. Conclusion: This study demonstrated that bronchial challenge with aspirin may involve systemic reactions and is associated with mobilization of leukocyte and eosinophil progenitor cells from the bone marrow.	[Makowska, Joanna S.; Bienkiewicz, Barbara; Kowalski, Marek L.] Med Univ Lodz, Chair Immunol, Dept Rheumatol Immunol & Allergy, Fac Med, PL-92215 Lodz, Poland; [Grzegorczyk, Janina] Med Univ Lodz, Fac Pharm, Dept Immunol Diagnost, PL-92215 Lodz, Poland; [Wozniak, Maria] Allergy Clin, Plock, Poland	Medical University Lodz; Medical University Lodz	Kowalski, ML (corresponding author), Med Univ Lodz, Chair Immunol, Dept Rheumatol Immunol & Allergy, Fac Med, 251 Pomorska Str, PL-92215 Lodz, Poland.	marek.kowalski@csk.umed.lodz.pl	Makowska, Joanna S/F-6054-2013	Makowska, Joanna/0000-0003-2036-375X				Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Bochenek G, 2004, THORAX, V59, P459, DOI 10.1136/thx.2003.013573; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Dorman SC, 2004, AM J RESP CRIT CARE, V169, P565, DOI 10.1164/rccm.200307-1024OC; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; Gauvreau GM, 2000, AM J RESP CRIT CARE, V162, P2139, DOI 10.1164/ajrccm.162.6.2001120; GRZELEWSKARZYMOWSKA I, 1981, ALLERGOL IMMUNOPATH, V9, P533; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; Kowalski ML, 1996, CLIN EXP ALLERGY, V26, P807, DOI 10.1046/j.1365-2222.1996.d01-371.x; Kowalski ML, 2006, ALLERGY CLIN IMMUNOL, V18, P140; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; Li J, 2005, IMMUNOLOGY, V114, P386, DOI 10.1111/j.1365-2567.2005.02109.x; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; Nasser S, 1996, THORAX, V51, P64, DOI 10.1136/thx.51.1.64; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; Parameswaran K, 2004, AM J RESP CRIT CARE, V169, P915, DOI 10.1164/rccm.200312-1645OC; PARK HS, 1995, CLIN EXP ALLERGY, V25, P38, DOI 10.1111/j.1365-2222.1995.tb01000.x; Pods R, 2003, ALLERGY, V58, P1165, DOI 10.1034/j.1398-9995.2003.00276.x; Radinger M, 2004, J ALLERGY CLIN IMMUN, V113, P1109, DOI 10.1016/j.jaci.2004.03.022; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Sehmi R, 2003, IMMUNOLOGY, V109, P536, DOI 10.1046/j.1365-2567.2003.01686.x; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Stirling RG, 2001, AM J RESP CRIT CARE, V164, P1403, DOI 10.1164/ajrccm.164.8.2010002; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Swierczynska M, 2003, J ALLERGY CLIN IMMUN, V112, P995, DOI 10.1016/S0091-6749(03)02015-3; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Tomaz EM, 1997, ALLERGY ASTHMA PROC, V18, P319, DOI 10.2500/108854197778590515	32	31	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					348	354		10.1016/j.jaci.2007.09.039	http://dx.doi.org/10.1016/j.jaci.2007.09.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18086495				2022-12-18	WOS:000253337800011
J	Sugiura, H; Kornaki, Y; Koarai, A; Lchinose, M				Sugiura, Hisatoshi; Kornaki, Yuichi; Koarai, Akira; Lchinose, Masakazu			Nitrative stress in refractory asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						refractory asthma; induced sputum; steroids; nitrotyrosine; reactive oxygen species	NITRIC-OXIDE SYNTHASE; OBSTRUCTIVE PULMONARY-DISEASE; NITROGEN SPECIES PRODUCTION; IL-8 GENE-EXPRESSION; OXIDATIVE STRESS; AIRWAY HYPERRESPONSIVENESS; GUINEA-PIGS; PEROXYNITRITE; LUNG; INFLAMMATION	Background: Most asthma is mild and moderate and can be well controlled by low-dose inhaled steroid with or without bronchodilators. However, 5% to 10% of patients with asthma have more troublesome disease despite using such medication. Recent reports showed that nitrative stress induced tissue remodeling in vitro, which is associated with a component of refractoriness in asthma. However, there is no report that nitrative stress is involved in refractory asthma. Objective: The aim of this study is to evaluate whether patients with refractory asthma have more nitrative stress. Methods: Ten healthy subjects, 10 patients with well-controlled asthma, and 8 patients with refractory asthma took part in the current study. Exhaled nitric oxide, xanthine oxidase activity in the supernatant of the sputum, immunostaining for the inducible type of nitric oxide synthase, and 3-nitrotyrosine in induced sputum from the subjects were assessed. Results: All nitrative markers including exhaled nitric oxide (P < .01), immunopositivities for inducible nitric oxide synthase (P < .01), xanthine oxidase activities (P < .01), and 3-nitrotyrosine (P < .01) in sputum from the refractory asthma group were enhanced compared with the well-controlled group. All these nitrative markers in the sputum had a significant negative correlation with the %FEV1 values (P < .01). Conclusion: These results suggested that patients with refractory asthma have more nitrative stress in their airways compared with patients with well-controlled asthma.	[Sugiura, Hisatoshi; Koarai, Akira; Lchinose, Masakazu] Wakayama Med Univ, Sch Med, Dept Internal Med 3, Wakayama 6410012, Japan; [Kornaki, Yuichi] Tohoku Univ, Grad Sch Med, Div Resp & Infect Dis, Sendai, Miyagi 980, Japan	Wakayama Medical University; Tohoku University	Lchinose, M (corresponding author), Wakayama Med Univ, Sch Med, Dept Internal Med 3, 811-1 Kimiidera, Wakayama 6410012, Japan.	masakazu@wakayama-med.ac.jp	koarai, akira/T-6382-2019	Sugiura, Hisatoshi/0000-0002-4335-7048				Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Adcock IM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-21; AUERBACH I, 1993, THORAX, V48, P139, DOI 10.1136/thx.48.2.139; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P240, DOI 10.1164/rccm.2604008; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; Bellocq A, 1999, AM J RESP CELL MOL, V21, P128, DOI 10.1165/ajrcmb.21.1.3379; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035, DOI 10.1164/ajrccm.160.3.9902064; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Filep JG, 1998, J IMMUNOL, V161, P5656; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; Ichinose M, 2003, EUR RESPIR J, V22, P457, DOI 10.1183/09031936.03.00052002; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747, DOI 10.1016/S0091-6749(99)70283-6; Koarai A, 2000, PULM PHARMACOL THER, V13, P267, DOI 10.1006/pupt.2000.0254; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Meagher LC, 1996, J IMMUNOL, V156, P4422; Merker MP, 2000, AM J PHYSIOL-LUNG C, V279, pL413, DOI 10.1152/ajplung.2000.279.3.L413; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; SadeghiHashjin G, 1996, AM J RESP CRIT CARE, V153, P1697, DOI 10.1164/ajrccm.153.5.8630623; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Sugiura H, 1999, AM J RESP CRIT CARE, V160, P663, DOI 10.1164/ajrccm.160.2.9807160; Sugiura H, 2006, AM J RESP CELL MOL, V34, P592, DOI 10.1165/rcmb.2005-0339OC; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC	32	31	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					355	360		10.1016/j.jaci.2007.11.009	http://dx.doi.org/10.1016/j.jaci.2007.11.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18158173	Bronze			2022-12-18	WOS:000253337800012
J	Van Hoecke, H; Vastesaeger, N; Dewulf, L; De Bacquer, D; van Cauwenberge, P				Van Hoecke, Helen; Vastesaeger, Nathan; Dewulf, Lode; De Bacquer, Dirk; van Cauwenberge, Paul			Is the Allergic Rhinitis and its Impact on Asthma classification useful in daily primary care practice?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERMITTENT		Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium; Univ Ghent, Dept Publ Hlth, Ghent, Belgium; Schering Plough NV, Brussels, Belgium	Ghent University; Ghent University; Merck & Company	Van Hoecke, H (corresponding author), Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium.		De Bacquer, Dirk/HGU-3191-2022	De Bacquer, Dirk/0000-0002-3202-7238				Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V117, P158, DOI 10.1016/j.jaci.2005.09.047; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Demoly P, 2003, ALLERGY, V58, P672, DOI 10.1034/j.1398-9995.2003.t01-1-00202.x; Van Hoecke H, 2006, ALLERGY, V61, P705, DOI 10.1111/j.1398-9995.2006.01057.x	7	31	33	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					758	759		10.1016/j.jaci.2006.05.015	http://dx.doi.org/10.1016/j.jaci.2006.05.015			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950299	Green Published			2022-12-18	WOS:000240649000035
J	Steinhoff, M; Steinhoff, A; Homey, B; Luger, TA; Schneider, SW				Steinhoff, Martin; Steinhoff, Antie; Homey, Bernhard; Luger, Thomas A.; Schneider, Stefan W.			Role of vasculature in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopy; inflammation; endothelium; leukocyte; therapy	SOLUBLE E-SELECTIN; INTERCELLULAR-ADHESION MOLECULE-1; HUMAN SKIN; EOSINOPHIL RECRUITMENT; P-SELECTIN; T-CELLS; IN-VIVO; INFLAMMATION; EXPRESSION; DISEASES	Atopic dermatitis (AD) lesions are characterized by differences in the activation state of endothelial cells and vascular smooth muscle cells and the release of inflammatory mediators by and toward the vasculature. The vascular system, including endothelial cells and smooth muscle cells, is ultimately involved in clinical symptoms of AD, such as erythema, edema, leukocyte recruitment, and white dermographism. Various mediators and bidirectional neurovascular interactions regulate the inflammatory response during AD. T cell-endothelial cell interactions are a crucial component to establish acute AD. Various immune cells, including monocytes and mast cells, communicate with the endothelium by releasing inflammatory mediators, thereby stimulating inflammatory mediator release from activated endothelial cells. The process of adhesion, tethering, and transmigration of infiltrating cells is a highly regulated and an active communication process between endothelial cells and leukocytes. Endothelial cells play a pivotal role in the pathophysiology of AD and represent future targets for the treatment of AD.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Hosp Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Munster, Germany; Univ Hosp Munster, IZKF Munster, Munster, Germany; Univ Hosp Munster, Dept Dermatol, Munster, Germany	University of Munster; University of Munster; University of Munster; University of Munster	Steinhoff, M (corresponding author), Univ Munster, Dept Dermatol, Esmarch Str 58, D-48149 Munster, Germany.	martin_steinhoff@web.de	Steinhoff, Martin/F-6312-2013	Steinhoff, Martin/0000-0002-7090-2187				Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Biedermann T, 2002, EUR J IMMUNOL, V32, P3171, DOI 10.1002/1521-4141(200211)32:11<3171::AID-IMMU3171>3.0.CO;2-4; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V117, pS475, DOI 10.1016/j.jaci.2005.10.018; de Esch IJP, 2005, TRENDS PHARMACOL SCI, V26, P462, DOI 10.1016/j.tips.2005.07.002; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; GROVES RW, 1992, J INVEST DERMATOL, V98, P384, DOI 10.1111/1523-1747.ep12499816; Gutgesell C, 2002, BRIT J DERMATOL, V147, P914, DOI 10.1046/j.1365-2133.2002.04938.x; Hirai S, 1996, BRIT J DERMATOL, V134, P657, DOI 10.1111/j.1365-2133.1996.tb06965.x; Homey Bernhard, 2005, Adv Dermatol, V21, P251, DOI 10.1016/j.yadr.2005.04.001; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Jung K, 1997, INT ARCH ALLERGY IMM, V113, P495, DOI 10.1159/000237628; Kubo M, 2006, CURR ALLERGY ASTHM R, V6, P32, DOI 10.1007/s11882-006-0007-6; Laan MP, 1998, ALLERGY, V53, P51, DOI 10.1111/j.1398-9995.1998.tb03773.x; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Liang TW, 2002, J IMMUNOL, V168, P1618, DOI 10.4049/jimmunol.168.4.1618; Ludwig RJ, 2005, J INVEST DERMATOL, V125, P969, DOI 10.1111/j.0022-202X.2005.23912.x; Matsuzaki J, 2005, AUTOIMMUNITY, V38, P369, DOI 10.1080/08916930500124122; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Nockher WA, 2006, J ALLERGY CLIN IMMUN, V117, P583, DOI 10.1016/j.jaci.2005.11.049; Raap U, 2005, CURR OPIN ALLERGY CL, V5, P419, DOI 10.1097/01.all.0000183111.78558.4d; Raap U, 2005, J ALLERGY CLIN IMMUN, V115, P1268, DOI 10.1016/j.jaci.2005.02.007; Radeke HH, 2005, EXP DERMATOL, V14, P641, DOI 10.1111/j.0906-6705.2005.00350.x; Rowe A, 1997, BRIT J DERMATOL, V136, P18, DOI 10.1046/j.1365-2133.1997.d01-1136.x; Satoh T, 2002, EUR J IMMUNOL, V32, P1274, DOI 10.1002/1521-4141(200205)32:5<1274::AID-IMMU1274>3.0.CO;2-Q; Savage NDL, 2002, EUR J IMMUNOL, V32, P2905, DOI 10.1002/1521-4141(2002010)32:10<2905::AID-IMMU2905>3.0.CO;2-6; Schallreuter KU, 1997, ARCH DERMATOL RES, V289, P663, DOI 10.1007/s004030050258; Sigurdsson V, 2000, J CUTAN PATHOL, V27, P436, DOI 10.1034/j.1600-0560.2000.027009436.x; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Steinhoff M, 2003, ARCH DERMATOL, V139, P1479, DOI 10.1001/archderm.139.11.1479; Steinhoff M, 2003, J NEUROSCI, V23, P6176; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Taniuchi S, 2001, ALLERGY, V56, P693, DOI 10.1034/j.1398-9995.2001.00131.x; Teixeira MM, 2001, BRIT J PHARMACOL, V132, P596, DOI 10.1038/sj.bjp.0703857; Wolkerstorfer A, 1998, BRIT J DERMATOL, V138, P431; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050	36	31	34	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					190	197		10.1016/j.jaci.2006.04.025	http://dx.doi.org/10.1016/j.jaci.2006.04.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815154				2022-12-18	WOS:000239184800022
J	Puumalainen, TJ; Poikonen, S; Kotovuori, A; Vaali, K; Kaikkinen, N; Reunala, T; Turjanmaa, K; Palosuo, T				Puumalainen, TJ; Poikonen, S; Kotovuori, A; Vaali, K; Kaikkinen, N; Reunala, T; Turjanmaa, K; Palosuo, T			Napins, 2S albumins, are major allergens in oilseed rape and turnip rape	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; Brassicaceae; oilseed rape; turnip rape; 2S albumin; napin	PROTEIN-RICH FOODS; BRASSICA-NAPUS L; SUSTAINABLE PRODUCTION; OCCUPATIONAL ASTHMA; PRODUCTION CHAIN; WESTERN-EUROPE; 8 CROPS; IDENTIFICATION; POLLEN; SEED	Background: Children with IgE-mediated allergy to foods frequently react to seeds of oilseed rape (Brassica napus ssp. oleifera) and turnip rape (Brassica rapa ssp. oleifera) in skin prick tests (SPTs). Sensitization pathways are not known. Objective: We identified possible major allergens in oilseed rape and turnip rape using sera from 72 atopic children (mean age, 3.3 years) with positive SPT responses to oilseed rape and turnip rape. Methods: Allergens from oilseed rape and turnip rape seed extracts were purified by using gel filtration and cation exchange chromatography and characterized by means of reversed-phase chromatography, N-terminal amino acid sequencing, and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. IgE binding of sera from 72 children with positive SPT reactions to oilseed rape and turnip rape and 72 age- and sex-matched atopic control subjects with negative SPT responses were analyzed by means of IgE ELISA and immunoblotting. In vivo reactivity of the purified allergens was tested with SPTs in 6 children. Results: In IgE immunoblotting and IgE ELISA major reactivity was to a group of homologous, approximately 9.5- to 14.5-kd proteins. These allergens were identified as 2S albumins, also known as napins, by means of N-terminal amino acid sequencing. In ELISA approximately 80% of the patients had IgE to purified napins from both plants. In SPTs purified napins caused positive reactions in all 6 children tested. Conclusions: This study shows that 2S albumins in oilseed rape and turnip rape are new potential food allergens. Further studies are needed to clarify the routes of exposure and mechanisms of sensitization.	Natl Publ Hlth Inst, Immunobiol Lab, FIN-00300 Helsinki, Finland; Tampere Univ, Dept Dermatol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Univ Helsinki, Inst Biotechnol, Helsinki, Finland	Finland National Institute for Health & Welfare; Tampere University; Tampere University; Tampere University Hospital; University of Helsinki	Puumalainen, TJ (corresponding author), Natl Publ Hlth Inst, Immunobiol Lab, Mannerheimintie 166, FIN-00300 Helsinki, Finland.	Tuija.Puumalainen@ktl.fi	Vaali, Kirsi/G-5107-2012; Vaali, Kirsi/AGT-4056-2022	Vaali, Kirsi/0000-0001-5402-8656; 				Alvarez MJ, 2001, ALLERGY, V56, P185, DOI 10.1034/j.1398-9995.2001.056002185.x; ANDRE F, 1994, TOXICOLOGY, V93, P77, DOI 10.1016/0300-483X(94)90198-8; Chardin H, 2003, ALLERGY, V58, P407, DOI 10.1034/j.1398-9995.2003.00094.x; Chardin H, 2001, INT ARCH ALLERGY IMM, V125, P128, DOI 10.1159/000053806; CROUCH ML, 1981, PLANTA, V153, P64, DOI 10.1007/BF00385319; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; Dijkstra DS, 2003, CRIT REV FOOD SCI, V43, P481, DOI 10.1080/10408690390246332; FAO, 1995, REP FAO TECHN CONS F; Focke M, 1998, INT ARCH ALLERGY IMM, V117, P105, DOI 10.1159/000023996; Hefle SL, 1999, FOOD TECHNOL-CHICAGO, V53, P62; Hemmer W, 1997, CLIN EXP ALLERGY, V27, P156; *INF CTR MIN AGR F, 2004, YIELD MAIN CROPS; Kanny G, 1996, ALLERGY, V51, P952; Kelly JD, 2000, INT ARCH ALLERGY IMM, V121, P19, DOI 10.1159/000024293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linnemann AR, 2002, CRIT REV FOOD SCI, V42, P377, DOI 10.1080/20024091054193; LONNERDAL B, 1972, BIOCHIM BIOPHYS ACTA, V278, P175, DOI 10.1016/0005-2795(72)90119-5; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCARTNEY HA, 1991, J AEROSOL SCI, V22, P467, DOI 10.1016/0021-8502(91)90005-3; MENENDEZARIAS L, 1988, EUR J BIOCHEM, V177, P159, DOI 10.1111/j.1432-1033.1988.tb14357.x; Moneret-Vautrin DA, 1998, CLIN EXP ALLERGY, V28, P1113, DOI 10.1046/j.1365-2222.1998.00370.x; Moneret-Vautrin DA, 2004, CURR OPIN ALLERGY CL, V4, P215, DOI 10.1097/01.all.0000129454.42340.23; MONSALVE RI, 1993, BIOCHEM J, V293, P625, DOI 10.1042/bj2930625; Monsalve RI, 1997, CLIN EXP ALLERGY, V27, P833, DOI 10.1046/j.1365-2222.1997.660843.x; Murphy DJ, 1999, IMMUNOL TODAY, V20, P511, DOI 10.1016/S0167-5699(99)01538-8; Murtagh GJ, 2003, CLIN EXP ALLERGY, V33, P1147, DOI 10.1046/j.1365-2222.2003.01736.x; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; Pastorello EA, 2001, J CHROMATOGR B, V756, P85, DOI 10.1016/S0378-4347(01)00073-1; POIKONEN S, 2005, ALLERGY, DOI DOI 10.111/4.1398-9995.2005.009299.X.; POLYA GM, 1993, PLANT PHYSIOL, V101, P545, DOI 10.1104/pp.101.2.545; Rance F, 1999, PEDIAT ALLERG IMM-UK, V10, P33, DOI 10.1034/j.1399-3038.1999.101008.x; SCHONWEITZ C, 2003, P 11 INT RAP CONGR, V2, P528; Seppala U, 1999, J ALLERGY CLIN IMMUN, V103, P165, DOI 10.1016/S0091-6749(99)70541-5; SINGH BP, 1995, INT ARCH ALLERGY IMM, V108, P43, DOI 10.1159/000237116; *STAT OFF EUR COMM, 2000, AGR BAL SHEETS; Suh CH, 1998, CLIN EXP ALLERGY, V28, P1159, DOI 10.1046/j.1365-2222.1998.00349.x; TERRAS FRG, 1993, FEBS LETT, V316, P233, DOI 10.1016/0014-5793(93)81299-F; THORPE SC, 1988, J ALLERGY CLIN IMMUN, V82, P67, DOI 10.1016/0091-6749(88)90053-X; Toriyama K, 1995, PLANT MOL BIOL, V29, P1157, DOI 10.1007/BF00020459; van Ree R, 2004, CURR OPIN ALLERGY CL, V4, P235, DOI [10.1097/00130832-200406000-00017, 10.1097/01.all.0000129457.27092.8f]	40	31	33	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					426	432		10.1016/j.jaci.2005.10.004	http://dx.doi.org/10.1016/j.jaci.2005.10.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461144				2022-12-18	WOS:000235687300025
J	Burkart, KM; Barton, SJ; Holloway, JW; Yang, IA; Cakebread, JA; Cruikshank, W; Little, F; Jin, XY; Farrier, LA; Clough, JB; Keith, TP; Holgate, S; Center, DM; O'Connor, GT				Burkart, KM; Barton, SJ; Holloway, JW; Yang, IA; Cakebread, JA; Cruikshank, W; Little, F; Jin, XY; Farrier, LA; Clough, JB; Keith, TP; Holgate, S; Center, DM; O'Connor, GT			Association of asthma with a functional promoter polymorphism in the IL16 gene	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IL-16; genetic epidemiology; family-based association test; atopy; single nucleotide polymorphism	BRONCHOALVEOLAR LAVAGE FLUID; CHEMOATTRACTANT ACTIVITY; INTERLEUKIN 16; HAY-FEVER; IL-16; IDENTIFICATION; SUSCEPTIBILITY; DERMATITIS; ACTIVATION; EXPRESSION	Background: IL-16, a multifunctional cytokine with increased expression in the airways of asthmatic subjects, inhibits allergic airway inflammation in animal models. A T -> C single nucleotide polymorphism (SNP) at the -295 position in the promoter region of the IL16 gene has been described. Objective: We sought to examine the functional significance of this promoter SNP and its relationship to asthma. Methods: We examined the effect of the -295 SNP on promoter activity in cell-line (HBE4-E6/E7) transfection experiments. We investigated the association of the IL16 -295 genotype with asthma among 341 affected sib-pair white families and 184 unrelated nonasthmatic control subjects. We analyzed the association between the IL16 genotype and asthma using family-based association test and case-control analyses. Results: In in vitro transfection experiments the T allele in the -295 position was associated with substantially reduced promoter activity compared with the C allele. In the family study the more common T allele at the -295 position was significantly associated with all asthma phenotypes (P = .002 to P = .015). In the case-control analysis asthmatic subjects were more likely than unrelated nonasthmatic control subjects to have the -295 TT genotype, but this did not reach statistical significance (odds ratio, 1.36; 95% CI, 0.92-2.02). Conclusions: The T allele at the -295 position in the IL16 promoter region is associated with reduced promoter activity relative to the C allele and with asthma in this white population. Further investigation is needed to delineate the mechanisms underlying these findings and the relationship of the IL16 -295 genotype to asthma in other populations.	Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Genet Program, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; Univ Southampton, Human Genet Res Div, Sch Med, Southampton, Hants, England; Univ Southampton, Resp Cell & Mol Biol Infect Inflammat & Repair Di, Sch Med, Southampton, Hants, England; Oscient Pharmaceut, Dept Human Genet, Waltham, MA USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; University of Southampton; University of Southampton	O'Connor, GT (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Dept Med, 715 Albany St,R-304, Boston, MA 02118 USA.	goconnor@lung.bumc.bu.edu	Holloway, John W/B-5424-2009; Yang, Ian A/B-9609-2008	Holloway, John W/0000-0001-9998-0464; Yang, Ian A/0000-0001-8338-1993; Center, David/0000-0002-5879-7978; Cakebread, Julie/0000-0001-5937-6705; Barton, Sheila/0000-0003-4963-4242; Little, Frederic/0000-0003-4342-7007; Farrer, Lindsay/0000-0001-5533-4225; O'Connor, George/0000-0002-6476-3926	MRC [G19/34] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL074571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050516] Funding Source: NIH RePORTER; Medical Research Council [G19/34] Funding Source: Medline; NHLBI NIH HHS [HL74571] Funding Source: Medline; NIAID NIH HHS [AI50516] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akesson LS, 2005, CLIN EXP ALLERGY, V35, P327, DOI 10.1111/j.1365-2222.2005.02189.x; Baier M, 1997, P NATL ACAD SCI USA, V94, P5273, DOI 10.1073/pnas.94.10.5273; Barnes PJ, 2004, PHARMACOL REV, V56, P515, DOI 10.1124/pr.56.4.2; Beghe B, 2003, CLIN EXP ALLERGY, V33, P1111, DOI 10.1046/j.1365-2222.2003.01731.x; CENTER DM, 1982, J IMMUNOL, V128, P2563; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; de Bie J. J., 2002, Clinical and Experimental Allergy, V32, P1651, DOI 10.1046/j.1365-2222.2002.01528.x; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Glas J, 2003, CLIN IMMUNOL, V106, P197, DOI 10.1016/S1521-6616(03)00021-4; Hoffjan S, 2002, CURR OPIN IMMUNOL, V14, P709, DOI 10.1016/S0952-7915(02)00393-X; HOPPER JL, 1990, GENET EPIDEMIOL, V7, P277, DOI 10.1002/gepi.1370070406; Keane J, 1998, J IMMUNOL, V160, P5945; Kim HS, 1999, CYTOGENET CELL GENET, V84, P93, DOI 10.1159/000015224; Kitagaki H, 1997, J IMMUNOL, V159, P2484; Krug N, 2000, AM J RESP CRIT CARE, V162, P105, DOI 10.1164/ajrccm.162.1.9908055; Laberge S, 1997, AM J RESP CELL MOL, V17, P193, DOI 10.1165/ajrcmb.17.2.2750; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Lynch EA, 2003, J IMMUNOL, V171, P4965, DOI 10.4049/jimmunol.171.10.4965; Mashikian MV, 1998, J ALLERGY CLIN IMMUN, V101, P786, DOI 10.1016/S0091-6749(98)70403-8; Nakayama EE, 2000, GENES IMMUN, V1, P293, DOI 10.1038/sj.gene.6363672; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Reich K, 2003, J ALLERGY CLIN IMMUN, V112, P1191, DOI 10.1016/j.jaci.2003.09.012; Sayers I, 2003, CLIN EXP ALLERGY, V33, P1103, DOI 10.1046/j.1365-2222.2003.01733.x; Sayers I, 2003, THORAX, V58, P417, DOI 10.1136/thorax.58.5.417; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wu DMH, 1999, J IMMUNOL, V162, P1287; Yoshimoto T, 2000, BLOOD, V95, P2869, DOI 10.1182/blood.V95.9.2869.009k18_2869_2874; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144	29	31	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					86	91		10.1016/j.jaci.2005.10.011	http://dx.doi.org/10.1016/j.jaci.2005.10.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387589				2022-12-18	WOS:000235687100014
J	Tarzi, MD; Jenner, M; Hattotuwa, K; Faruqi, AZ; Diaz, GA; Longhurst, HJ				Tarzi, MD; Jenner, M; Hattotuwa, K; Faruqi, AZ; Diaz, GA; Longhurst, HJ			Sporadic case of warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						WHIM syndrome; myelokathexis; CXCR4; warts; combined immunodeficiency	CHEMOKINE RECEPTOR CXCR4; WHIM-SYNDROME; NEUTROPENIA; MUTATIONS; LYMPHOMA; DISORDER; PATIENT	The term WHIM syndrome (WHIMS) is an acronym describing a rare primary immunodeficiency disorder characterized by warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis, the unusual association of neutropenia with bone marrow myeloid hypercellularity. WHIMS was recently associated with mutations in the gene encoding the chemokine receptor CXCR4 and as such is the first disease ascribed to abnormalities of chemokine signaling. We report a sporadic case of WHIMS in a woman presenting with recurrent infections and human papilloma virus-related genital dysplasia.	St Bartholomews Hosp, Dept Immunol, London EC1A 7BE, England; St Bartholomews Hosp, Dept Hematol, London EC1A 7BE, England; Royal London Hosp, Dept Histopathol, London E1 1BB, England; Mt Sinai Sch Med, Dept Human Genet, New York, NY USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA	University of London; Queen Mary University London; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Tarzi, MD (corresponding author), St Bartholomews Hosp, Dept Immunol, London EC1A 7BE, England.	mike.tarzi@bartsandthelondon.nhs.uk	Diaz, George/AAF-6199-2021					Ansel KM, 2001, CURR OPIN IMMUNOL, V13, P172, DOI 10.1016/S0952-7915(00)00201-6; Balabanian K, 2005, BLOOD, V105, P2449, DOI 10.1182/blood-2004-06-2289; BEYNON DWG, 1993, INT J GYNECOL CANCER, V3, P405, DOI 10.1046/j.1525-1438.1993.03060405.x; Chae KM, 2001, J AM ACAD DERMATOL, V44, P124, DOI 10.1067/mjd.2001.111337; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Diaz GA, 2005, IMMUNOL REV, V203, P235, DOI 10.1111/j.0105-2896.2005.00226.x; Gennery AR, 2000, CLIN EXP IMMUNOL, V121, P1, DOI 10.1046/j.1365-2249.2000.01257.x; Gorlin RJ, 2000, AM J MED GENET, V91, P368, DOI 10.1002/(SICI)1096-8628(20000424)91:5<368::AID-AJMG10>3.0.CO;2-9; Gulino AV, 2003, CURR OPIN ALLERGY CL, V3, P443, DOI 10.1097/01.all.0000104449.09202.d8; Gulino AV, 2004, BLOOD, V104, P444, DOI 10.1182/blood-2003-10-3532; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Imashuku S, 2002, ANN HEMATOL, V81, P470, DOI 10.1007/s00277-002-0489-9; KRILL CE, 1964, NEW ENGL J MED, V270, P973, DOI 10.1056/NEJM196405072701902; Lougaris V, 2005, IMMUNOL REV, V203, P48, DOI 10.1111/j.0105-2896.2005.00229.x; Signoret N, 1998, J CELL SCI, V111, P2819; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; WESTON B, 1991, J PEDIATR-US, V118, P229, DOI 10.1016/S0022-3476(05)80488-3; WETZLER M, 1992, JAMA-J AM MED ASSOC, V267, P2179, DOI 10.1001/jama.267.16.2179; WETZLER M, 1990, AM J MED, V89, P663, DOI 10.1016/0002-9343(90)90187-I; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269; ZUELZER WW, 1964, NEW ENGL J MED, V270, P699, DOI 10.1056/NEJM196404022701402	22	31	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1101	1105		10.1016/j.jaci.2005.08.040	http://dx.doi.org/10.1016/j.jaci.2005.08.040			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275383				2022-12-18	WOS:000235686700024
J	Pochard, P; Hammad, H; Ratajczak, C; Charbonnier-Hatzfeld, AS; Just, N; Tonnel, AB; Pestel, J				Pochard, P; Hammad, H; Ratajczak, C; Charbonnier-Hatzfeld, AS; Just, N; Tonnel, AB; Pestel, J			Direct regulatory immune activity of lactic acid bacteria on Der p 1-pulsed dendritic cells from allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; T(H)1/T(H)2 cells; bacteria; allergy	MONONUCLEAR-CELLS; T-LYMPHOCYTES; IN-VIVO; RECEPTOR; ANTIGEN; MEMORY; INTERLEUKIN-12; LACTOBACILLI; ACTIVATION; GENERATION	Background: Lactic acid bacteria (LAB) are suggested to play a regulatory role in the development of allergic reactions. However, their potential effects on dendritic cells (DCs) directing the immune polarization remain unclear. Objective: The immunologic effect of Lactobacillus plantarum NCIMB 8826 (LAB1) on monocyte-derived dendritic cells (MD-DCs) from patients allergic to house dust mite was evaluated. Methods: MD-DCs were stimulated for 24 hours with the related allergen Der p 1 in the presence or absence of LAB1. Cell-surface markers were assessed by means of FACS analysis, and the key polarizing cytokines IL-12 and IL-10 were quantified. The subsequent regulatory effect of pulsed MD-DCs on naive or memory T cells was evaluated by determining the T-cell cytokine profile. Results: LAB1 induced the maturation of MD-DCs, even if pulsed with Der p 1. Interestingly, after incubation with LAB1 and Der p 1, MD-DCs produced higher amounts of IL-12 than Der p 1-pulsed DCs. Indeed, the T(H)2 cytokine (IL-4 and IL-5) production observed when naive or memory autologous T cells were cocultured with Der p 1-pulsed MD-DCs was highly reduced in the presence of LAB1. Finally, in contrast to naive or memory T cells exposed once to Der p 1-pulsed DCs, T cells stimulated by MD-DCs pulsed with Der p 1 and LAB1 failed to produce T(H)2 cytokines in response to a new stimulation with Der p 1-pulsed DCs. Conclusion: Thus in the presence of LAB1, MD-DCs from allergic patients tend to reorientate the T-cell response toward a beneficial T(H)1 proffle.	INSERM, U416, Inst Pasteur, F-59019 Lille, France; Inst Biol Lille, Lab Bacteriol Ecosyst, Lille, France; Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands; CHRU Lille, Hop A Calmette, Dept Pneumol, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Erasmus University Rotterdam; Erasmus MC; Universite de Lille - ISITE; CHU Lille	Pestel, J (corresponding author), INSERM, U416, Inst Pasteur, 1 Rue Prof Calmette,BP 245, F-59019 Lille, France.	jpestel@voila.fr	Hammad, Hamida/J-9391-2015	Hammad, Hamida/0000-0003-3762-8603; Pochard, Pierre/0000-0002-5608-7286				BRADLEY LM, 1993, J IMMUNOL, V150, P3119; BRADLEY LM, 1993, IMMUNOL TODAY, V14, P197, DOI 10.1016/0167-5699(93)90161-D; Byrne JA, 1989, INT IMMUNOL, V1, P29, DOI 10.1093/intimm/1.1.29; Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171; de Lafaille MAC, 2002, CURR OPIN IMMUNOL, V14, P771; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Lambrecht BN, 2001, CLIN EXP ALLERGY, V31, P206, DOI 10.1046/j.1365-2222.2001.01061.x; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MARSHALL JD, 1995, J IMMUNOL, V155, P111; Matsuzaki T, 2000, IMMUNOL CELL BIOL, V78, P67, DOI 10.1046/j.1440-1711.2000.00887.x; Miettinen M, 1998, INFECT IMMUN, V66, P6058, DOI 10.1128/IAI.66.12.6058-6062.1998; Modlin RL, 2002, ANN ALLERG ASTHMA IM, V88, P543, DOI 10.1016/S1081-1206(10)61883-2; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Pochard P, 2002, J ALLERGY CLIN IMMUN, V110, P617, DOI 10.1067/mai.2002.128528; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RASANEN L, 1982, IMMUNOLOGY, V46, P481; Rescigno M, 2001, IMMUNOBIOLOGY, V204, P572, DOI 10.1078/0171-2985-00094; SolisPereyra B, 1997, AM J CLIN NUTR, V66, P521; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Tough DF, 1997, J EXP MED, V185, P2089, DOI 10.1084/jem.185.12.2089; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008	26	31	37	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					198	204		10.1016/j.jaci.2005.02.037	http://dx.doi.org/10.1016/j.jaci.2005.02.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990795				2022-12-18	WOS:000235686300030
J	Nelson, HS				Nelson, HS			Advances in upper airway diseases and allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; allergic rhinitis; immunotherapy; skin testing; one airway	QUALITY-OF-LIFE; BLIND HYPOSENSITIZATION THERAPY; RAGWEED HAY-FEVER; SUBLINGUAL IMMUNOTHERAPY; CHRONIC RHINOSINUSITIS; ANTIFUNGAL TREATMENT; RHINITIS; ASTHMA; SINUSITIS; MODULATION	Evidence of an increased prevalence of rhinitis in patients with asthma, and asthma in patients with rhinitis, supports the 1 airway concept. However, there are basic differences between the upper and lower airways, such as the virtual absence of remodeling in the nose compared with the bronchi, despite the presence of similar inflammation. Etiologic factors in chronic rhinosinusitis (CRS) attract increasing interest. Peripheral blood monocytes from patients with CRS release IL-4, IL-13, and IFN-gamma on stimulation with fungal antigens, especially those from Alternaria. This is not seen with cells from normal controls. However, a double-blind trial of intranasal amphotericin in CRS was negative. Evidence continues to accumulate of the pivotal role of regulatory T-lymphocytes secretion of IL-10 in the response to allergen immunotherapy. In patients with asthma and house dust mite allergy who are receiving appropriate pharmacotherapy and have instituted environmental controls, house dust mite immunotherapy provides marginal additional benefits in asthma control. Immunotherapy with cat dander extract at a maintenance dose containing 15 mu g Fel d 1 produces a more consistent immunologic response than with maintenance doses containing 3.0 mu g, whereas doses containing only 0.6 mu g are no more effective than placebo. Sublingual immunotherapy for seasonal grass allergy can be safely administered by general practitioners, but symptom relief begins only in the second season of therapy. Sublingual immunotherapy for seasonal grass allergy in children reduced symptoms and onset of new asthma symptoms but, again, beginning only in the second year of treatment. A course of 6 weekly injections of ragweed Amb a 1 bound to cytosine phosphorothionate guanosine containing DNA produced a shift from T(H)2 to T(H)1 cytokine release both in peripheral blood cells and in the nose after allergen challenge. No symptom improvement was seen the first year, but symptoms were reduced the second year without further treatment.	Natl Jewish Ctr Immunol & Resp Med, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Ctr Immunol & Resp Med, 1400 Jackson St, Denver, CO 80206 USA.	nelsonh@njc.org						Aaronson DW, 2004, J ALLERGY CLIN IMMUN, V113, P1117, DOI 10.1016/j.jaci.2004.01.756; Bachert C, 2004, J ALLERGY CLIN IMMUN, V114, P838, DOI 10.1016/j.jaci.2004.05.070; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; BODTGE L, 2004, J ALLERGY CLIN IMMUN, V114, P1384; Bousquet J, 2004, J ALLERGY CLIN IMMUN, V113, P43, DOI 10.1016/j.jaci.2003.09.047; Casale TB, 2004, J ALLERGY CLIN IMMUN, V113, P1036, DOI 10.1016/j.jaci.2004.04.017; Chen H, 2004, J ALLERGY CLIN IMMUN, V114, P845, DOI 10.1016/j.jaci.2004.07.008; Cohen SG, 2004, J ALLERGY CLIN IMMUN, V113, P1227, DOI 10.1016/j.jaci.2003.12.003; Corren J, 2004, J ALLERGY CLIN IMMUN, V113, P415, DOI 10.1016/j.jaci.2003.11.034; Craig TJ, 2004, J ALLERGY CLIN IMMUN, V114, pS139, DOI 10.1016/j.jaci.2004.08.044; Deruaz U, 2004, J ALLERGY CLIN IMMUN, V113, P669, DOI 10.1016/j.jaci.2004.01.773; Dworetzky M, 2004, J ALLERGY CLIN IMMUN, V113, P1231, DOI 10.1016/j.jaci.2004.03.041; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Farkas L, 2004, J ALLERGY CLIN IMMUN, V114, P436, DOI 10.1016/j.jaci.2004.04.035; Jilek S, 2004, J ALLERGY CLIN IMMUN, V114, P943, DOI 10.1016/j.jaci.2004.05.065; Kelso JM, 2004, J ALLERGY CLIN IMMUN, V114, P452, DOI 10.1016/j.jaci.2004.05.011; Leynaert N, 2004, J ALLERGY CLIN IMMUN, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Liu Z, 2004, J ALLERGY CLIN IMMUN, V114, P783, DOI 10.1016/j.jaci.2004.04.052; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j.jaci.2004.03.013; Ludwig-Portugall I, 2004, J ALLERGY CLIN IMMUN, V114, P951, DOI 10.1016/j.jaci.2004.06.013; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Mitman G, 2004, J ALLERGY CLIN IMMUN, V114, P1230, DOI 10.1016/j.jaci.2004.08.016; Mitman G, 2004, J ALLERGY CLIN IMMUN, V114, P1229, DOI 10.1016/j.jaci.2004.07.041; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nelson HS, 2004, J ALLERGY CLIN IMMUN, V113, P1218, DOI 10.1016/j.jaci.2004.01.566; Nguyen LHP, 2004, J ALLERGY CLIN IMMUN, V114, P1110, DOI 10.1016/j.jaci.2004.07.061; Norman PS, 2004, J ALLERGY CLIN IMMUN, V113, P1013, DOI 10.1016/j.jaci.2004.03.020; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Platts-Mills TAE, 2004, J ALLERGY CLIN IMMUN, V114, P1359, DOI 10.1016/j.jaci.2004.09.036; Ponikau JU, 2002, J ALLERGY CLIN IMMUN, V110, P862, DOI 10.1067/mai.2002.130051; Portnoy J, 2004, J ALLERGY CLIN IMMUN, V114, P1235, DOI 10.1016/j.jaci.2004.07.062; Ricchetti A, 2002, J LARYNGOL OTOL, V116, P261, DOI 10.1258/0022215021910708; Roth-Walter F, 2004, J ALLERGY CLIN IMMUN, V114, P1362, DOI 10.1016/j.jaci.2004.08.010; Salib RJ, 2004, J ALLERGY CLIN IMMUN, V114, P799, DOI 10.1016/j.jaci.2004.07.010; Schubert MS, 2004, J ALLERGY CLIN IMMUN, V114, P1376, DOI 10.1016/j.jaci.2004.08.029; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Stuck BA, 2004, J ALLERGY CLIN IMMUN, V113, P663, DOI 10.1016/j.jaci.2003.12.589; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Vichyanond P, 2004, J ALLERGY CLIN IMMUN, V113, P355, DOI 10.1016/j.jaci.2003.10.065; Vissers JLM, 2004, J ALLERGY CLIN IMMUN, V113, P1204, DOI 10.1016/j.jaci.2004.02.041; Weschta M, 2004, J ALLERGY CLIN IMMUN, V113, P1122, DOI 10.1016/j.jaci.2004.03.038; Yu XH, 2004, J ALLERGY CLIN IMMUN, V114, P328, DOI 10.1016/j.jaci.2004.04.051; Zeng DW, 2004, J ALLERGY CLIN IMMUN, V114, P316, DOI 10.1016/j.jaci.2004.05.026	49	31	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					676	684		10.1016/j.jaci.2005.01.037	http://dx.doi.org/10.1016/j.jaci.2005.01.037			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805984				2022-12-18	WOS:000228373400003
J	Karisola, P; Kotovuori, A; Poikonen, S; Niskanen, E; Kalkkinen, N; Turjanmaa, K; Palosuo, T; Reunala, T; Alenius, H; Kulomaa, MS				Karisola, P; Kotovuori, A; Poikonen, S; Niskanen, E; Kalkkinen, N; Turjanmaa, K; Palosuo, T; Reunala, T; Alenius, H; Kulomaa, MS			Isolated hevein-like domains, but not 31-kd endochitinases, are responsible for 19E-mediated in vitro and in vivo reactions in latex-fruit syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; epitopes; cross-reactivity; hevein-like domain; antibodies; structural homology; latex-fruit syndrome	WHEAT-GERM-AGGLUTININ; CROSS-REACTIVITY; IGE ANTIBODIES; CHITIN-BINDING; MAJOR ALLERGEN; IDENTIFICATION; PROTEINS; AVOCADO; EXPRESSION; PROHEVEIN	Background: Individuals with natural rubber latex allergy often have immediate reactions to plant-derived foods and fresh fruits, such as avocado and banana. IgE of these patients has been shown to bind endochitinases containing an N-terminal hevein-like domain (HLD). However, evidence on 31-kd endochitinase-induced reactions in vivo is lacking. Objective: We sought to assess the clinical significance of 31-kd endochitinases and isolated HLDs in latex-fruit syndrome. Methods: The 31-kd endochitinases and corresponding HLDs were purified or produced from avocado, banana, latex, and wheat germ. Skin prick test reactivities against purified proteins were examined in 15 patients with natural rubber latex allergy. The binding efficiency of IgE to purified proteins was studied by using an inhibition ELISA. Experimentally resolved or modeled structures of the proteins were compared to clarify the molecular basis of clinical reactions. Results: Eleven (73%) patients had skin prick test reactions to isolated HLDs of avocado and banana, but only 1 (7%) patient reacted to their corresponding 31-kd endochitinases. HLDs from avocado and banana inhibited binding of IgE to prohevein (Hev b 6.01) in 59% and 38% of patients, respectively, whereas corresponding percentages for 31-kd endochitinases were 17% and 20%, respectively. Isolated HLDs of wheat germ agglutinin and 18-kd wheat germ agglutinin did not significantly inhibit IgE binding to hevein. Conclusion: The isolated HLD molecules alone, but not when linked to endochitinases, seem to be responsible for IgE-mediated clinical reactions in latex-fruit syndrome. Careful selection of relevant allergens in their proper molecular form is therefore crucial in forming a reliable diagnosis of latex-fruit syndrome.	Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla 40014, Finland; Univ Helsinki, Inst Biotechnol, Helsinki, Finland; Tampere Univ Hosp, Dept Dermatol, Tampere, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Finnish Inst Occupat Hlth, Helsinki, Finland	University of Jyvaskyla; University of Helsinki; Tampere University; Tampere University Hospital; Finland National Institute for Health & Welfare; Finnish Institute of Occupational Health	Karisola, P (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35, Jyvaskyla 40014, Finland.	karpiia@cc.jyu.fi	Kalkkinen, Nisse EJ/B-3923-2010; Kulomaa, Markku S/C-9063-2014; Niskanen, Einari A/F-2883-2017; Niskanen, Einari/O-1379-2019	Niskanen, Einari A/0000-0001-9471-7026; Alenius, Harri/0000-0003-0106-8923; Karisola, Piia/0000-0003-0635-2704				Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Airenne KJ, 1999, PROTEIN EXPRES PURIF, V17, P139, DOI 10.1006/prep.1999.1123; Alenius H, 1996, J IMMUNOL, V156, P1618; ANDERSEN NH, 1993, BIOCHEMISTRY-US, V32, P1407, DOI 10.1021/bi00057a004; BEERHUES L, 1994, PLANT MOL BIOL, V24, P353, DOI 10.1007/BF00020173; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BEINTEMA JJ, 1994, FEBS LETT, V350, P159, DOI 10.1016/0014-5793(94)00753-5; Blanco C, 1999, J ALLERGY CLIN IMMUN, V103, P507, DOI 10.1016/S0091-6749(99)70478-1; BLANCO C, 1994, ANN ALLERGY, V73, P309; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; ISELI B, 1993, PLANT PHYSIOL, V103, P221, DOI 10.1104/pp.103.1.221; Karisola P, 2004, J IMMUNOL, V172, P2621, DOI 10.4049/jimmunol.172.4.2621; Karisola P, 2002, J BIOL CHEM, V277, P22656, DOI 10.1074/jbc.M201076200; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; LEE H, 1991, J BIOL CHEM, V266, P15944; MANSFIELD MA, 1988, PLANTA, V173, P482, DOI 10.1007/BF00958961; Mikkola JH, 1998, J ALLERGY CLIN IMMUN, V102, P1005, DOI 10.1016/S0091-6749(98)70339-2; Nel A, 1998, ANN ALLERG ASTHMA IM, V81, P388, DOI 10.1016/S1081-1206(10)63135-3; Posch A, 1999, CLIN EXP ALLERGY, V29, P667, DOI 10.1046/j.1365-2222.1999.00502.x; Poutanen M, 2001, RAPID COMMUN MASS SP, V15, P1685, DOI 10.1002/rcm.424; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; Rihs HP, 1997, TISSUE ANTIGENS, V49, P92, DOI 10.1111/j.1399-0039.1997.tb02719.x; Rozynek P, 1998, CLIN EXP ALLERGY, V28, P1418; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salzman RA, 1999, PLANT MOL BIOL REP, V17, P11, DOI 10.1023/A:1007520314478; Sanchez-Monge R, 1999, CLIN EXP ALLERGY, V29, P673, DOI 10.1046/j.1365-2222.1999.00526.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SOEDJANAATMADJA UMS, 1995, FEBS LETT, V363, P211, DOI 10.1016/0014-5793(95)00309-W; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; Wagner S, 2002, BIOCHEM SOC T, V30, P935, DOI 10.1042/BST0300935; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; Xia JQ, 2001, J ALLERGY CLIN IMMUN, V107, pS320; Ylitalo L, 1998, J ALLERGY CLIN IMMUN, V102, P659, DOI 10.1016/S0091-6749(98)70284-2; Ylonen A, 1999, EUR J BIOCHEM, V266, P1066, DOI 10.1046/j.1432-1327.1999.00950.x	38	31	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					598	605		10.1016/j.jaci.2004.09.015	http://dx.doi.org/10.1016/j.jaci.2004.09.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753910				2022-12-18	WOS:000227687000025
J	Livingston, E; Darroch, CE; Chaudhuri, R; McPhee, I; McMahon, AD; MacKenzie, SJ; Thomson, NC				Livingston, E; Darroch, CE; Chaudhuri, R; McPhee, I; McMahon, AD; MacKenzie, SJ; Thomson, NC			Glucocorticoid receptor alpha :beta ratio in blood mononuclear cells is reduced in cigarette smokers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SMOKING; EXPRESSION		Univ Glasgow, Dept Resp Med, Glasgow, Lanark, Scotland; KSRL Scottish Biomed, Glasgow, Lanark, Scotland; Robertson Ctr Biostat, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow	Livingston, E (corresponding author), Univ Glasgow, Dept Resp Med, Glasgow, Lanark, Scotland.		McMahon, Alex D/C-4304-2008	Thomson, Neil/0000-0003-1632-6630				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Barber R, 2004, AM J PHYSIOL-LUNG C, V287, pL332, DOI 10.1152/ajplung.00384.2003; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; *NHLBI WHO NIH, 2002, 023659 NIH NHLBI WHO; Strickland I, 2001, J EXP MED, V193, P585, DOI 10.1084/jem.193.5.585	10	31	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1475	1478		10.1016/j.jaci.2004.10.015	http://dx.doi.org/10.1016/j.jaci.2004.10.015			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577857				2022-12-18	WOS:000225577400036
J	Jilek, S; Walter, E; Merkle, HP; Corthesy, B				Jilek, S; Walter, E; Merkle, HP; Corthesy, B			Modulation of allergic responses in mice by using biodegradable poly(lactide-co-glycolide) microspheres	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; microspheres; T(H)11TH(2) responses; immunomodulation	SURFACE-MODIFIED MICROPARTICLES; BEE VENOM IMMUNOTHERAPY; HUMAN DENDRITIC CELLS; DRUG-RELEASE RATE; MHC CLASS-I; PLASMID DNA; IMMUNE-RESPONSE; CATIONIC MICROPARTICLES; PHOSPHOLIPASE A(2); GENE-EXPRESSION	Background: Biodegradable poly(lactide-co-glycolide) (PLGA) microspheres are a promising carrier for vaccine delivery capable of maturing antigen-presenting cells to stimulate T-cell-mediated immune responses. However, the potential of microspheres to downregulate an allergic response in vivo is unknown. Objective: The aim of this study was to determine whether microspheres could potentiate DNA vaccination against allergy and to evaluate the immunomodulatory properties of microspheres alone. Methods: Mice were treated prophylactically with DNA-loaded plain PLGA microspberes before sensitization with phospholipase A2 (PLA2), the major allergen of bee venom. PLA2-specific IgG1, IgG2a, IgE in serum were measured for 8.5 months, and splenocyte proliferative responses and cytokine profiles were determined. Protection against anaphylaxis was evaluated after injection of an otherwise lethal dose of PLA2. Results: Phospholipase A2-specific IgG1 and IgG2a production turned out to be 2 times higher using cationic microspheres compared with anionic microspheres, but was not influenced by the presence of DNA. In contrast, reduction in IgE production and T-cell hyporesponsiveness were observed with all microsphere formulations. Recall challenge with PLA2 triggered combined expression of both IL-4 and IFN-gamma, together with sustained expression of IL-10 that can explain the protective effect against anaphylaxis. Conclusion: Our data suggest a dual mechanism that does initially rely on a T(H)2 to T(H)1 immune deviation and then on IL-10-mediated suppression. This is the first physiological demonstration that plain PLGA microspheres can induce tolerance in mice for as long as 6 months postsensitization.	CHU Vaudois, Div Immunol & Allergy, CH-1005 Lausanne, Switzerland; Swiss Fed Inst Technol, Dept Chem & Appl BioSci, Zurich, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Federal Institutes of Technology Domain; ETH Zurich	Corthesy, B (corresponding author), CHU Vaudois, Div Immunol & Allergy, HO 05-1542,4 Ave Pierre Decker, CH-1005 Lausanne, Switzerland.	blaise.corthesy@chuv.hospvd.ch	Merkle, Hans/A-4381-2014					Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Astori M, 2000, J IMMUNOL, V165, P3497, DOI 10.4049/jimmunol.165.6.3497; Audran R, 2003, VACCINE, V21, P1250, DOI 10.1016/S0264-410X(02)00521-2; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; BELLINGHAUSEN I, 2000, ALLERGY CLIN IMMUNOL, V12, P20; Berkland C, 2003, PHARMACEUT RES, V20, P1055, DOI 10.1023/A:1024466407849; Berkland C, 2002, J CONTROL RELEASE, V82, P137, DOI 10.1016/S0168-3659(02)00136-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Denis-Mize KS, 2000, GENE THER, V7, P2105, DOI 10.1038/sj.gt.3301347; Fattal E, 2002, INT J PHARM, V242, P15, DOI 10.1016/S0378-5173(02)00181-3; Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365; Jilek S, 2004, PHARM RES-DORDR, V21, P1240, DOI 10.1023/B:PHAM.0000033012.16152.5d; Jilek S, 2001, J IMMUNOL, V166, P3612, DOI 10.4049/jimmunol.166.5.3612; Johansen P, 2000, EUR J PHARM BIOPHARM, V50, P129, DOI 10.1016/S0939-6411(00)00079-5; Julia V, 1996, SCIENCE, V274, P421, DOI 10.1126/science.274.5286.421; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kammerer R, 1997, J ALLERGY CLIN IMMUN, V100, P96, DOI 10.1016/S0091-6749(97)70200-8; Kempf M, 2003, J DRUG TARGET, V11, P11, DOI 10.1080/1061186031000072978; Klencke B, 2002, CLIN CANCER RES, V8, P1028; Kubo S, 2003, J IMMUNOL, V170, P775, DOI 10.4049/jimmunol.170.2.775; Lunsford L, 2000, J DRUG TARGET, V8, P39, DOI 10.3109/10611860009009208; MANTHORPE M, 1993, HUM GENE THER, V4, P419, DOI 10.1089/hum.1993.4.4-419; Men Y, 1999, VACCINE, V17, P1047, DOI 10.1016/S0264-410X(98)00321-1; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Newman KD, 2002, J BIOMED MATER RES, V60, P480, DOI 10.1002/jbm.10019; O'Hagan D, 2001, J VIROL, V75, P9037, DOI 10.1128/JVI.75.19.9037-9043.2001; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; REISMAN RE, 1994, J ALLERGY CLIN IMMUN, V94, P651, DOI 10.1016/0091-6749(94)90167-8; Ring J, 2001, ANN ALLERG ASTHMA IM, V87, P2, DOI 10.1016/S1081-1206(10)62332-0; Romagnani S, 1995, CURR OPIN IMMUNOL, V7, P745, DOI 10.1016/0952-7915(95)80042-5; Romagnani S, 1998, ALLERGY, V53, P12, DOI 10.1111/j.1398-9995.1998.tb04951.x; Sheets EE, 2003, AM J OBSTET GYNECOL, V188, P916, DOI 10.1067/mob.2003.256; Shibata Y, 2000, J IMMUNOL, V164, P1314, DOI 10.4049/jimmunol.164.3.1314; Strong P, 2002, CLIN EXP ALLERGY, V32, P1794, DOI 10.1046/j.1365-2222.2002.01551.x; Thiele L, 2003, PHARM RES-DORDR, V20, P221, DOI 10.1023/A:1022271020390; Thomasin C, 1996, J CONTROL RELEASE, V41, P131, DOI 10.1016/0168-3659(96)01363-6; Tinsley-Bown AM, 2000, J CONTROL RELEASE, V66, P229, DOI 10.1016/S0168-3659(99)00275-8; von Garnier C, 2000, EUR J IMMUNOL, V30, P1638, DOI 10.1002/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R; Walter E, 2002, J DRUG TARGET, V10, P11, DOI 10.1080/10611860290007478; Walter E, 2001, J CONTROL RELEASE, V76, P149, DOI 10.1016/S0168-3659(01)00413-8; Walter E, 1999, J CONTROL RELEASE, V61, P361, DOI 10.1016/S0168-3659(99)00151-0; WILLEMS F, 1994, EUR J IMMUNOL, V24, P1007, DOI 10.1002/eji.1830240435	45	31	42	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					943	950		10.1016/j.jaci.2004.05.065	http://dx.doi.org/10.1016/j.jaci.2004.05.065			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480340				2022-12-18	WOS:000224439100034
J	Contreras, JP; Ly, NR; Gold, DR; He, HZ; Wand, M; Weiss, ST; Perkins, DL; Platts-Mills, TAE; Finn, PW				Contreras, JP; Ly, NR; Gold, DR; He, HZ; Wand, M; Weiss, ST; Perkins, DL; Platts-Mills, TAE; Finn, PW			Allergen-induced cytokine production, atopic disease, IgE, and wheeze in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; cytokines; IFN-gamma; IL-13; allergy; atopy; cockroach; dust mite	INTERFERON-GAMMA; ASTHMA; BLOOD; RISK; PREVALENCE; CHILDHOOD; BIRTH; CELLS	Background: The early childhood allergen-induced immune responses associated with atopic disease and IgE production in early life are not well understood. Objective: We assessed the relationship of allergen-induced cytokine production by PBMCs to both atopic disease and to IgE increase in a cohort of children with a parental history of allergy or asthma (n = 112) at a median of 2 years of age. We examined cockroach (Bla g I)-induced, house dust mite (Der f 1)-induced, and cat (Fel d 1)-induced cytokine secretion, including secretion of IFN-gamma, IL-13, IL-10, and TNF-alpha. We investigated whether distinct cytokine patterns associated with atopic disease can be detected in immune responses of children. Methods: PBMCs were isolated, and allergen-induced cytokine secretion was analyzed by means of ELISA. Atopic disease was defined as physician- or nurse-diagnosed eczema or hay fever. Increased IgE was defined as an IgE level of greater than 35 U/mL to dust mite, cockroach, cat, and egg white or a total IgE level of 60 U/mL or. greater. Results: Compared with children without atopic disease, children with atopic disease had lower Der f 1 (P = .005) and Bla g 2 (P = .03) allergen-induced IFN-gamma levels. Compared with children without increased IgE (n = 95), those with increased IgE (n = 16) had higher Der f 1-induced (P = .006) and Fel d I-induced (P = .005) IL-13 levels and lower Bla g 2-induced (P =.03) IFN-gamma levels. Compared with children with neither atopic disease nor repeated wheeze, children with both atopic disease and repeated wheeze had lower levels of allergen-induced IFN-gamma (P = .01 for Der f 1 and P = .02 for Bla g 2) cytokine secretion. Conclusion: In young children at risk for asthma or allergy, decreased allergen-induced IFN-gamma secretion is associated with atopic disease and, in some cases, with increased IgE levels. Increased allergen-induced IL-13 secretion is most strongly associated with early life increase of IgE.	Brigham & Womens Hosp, Pulm & Crit Care Div, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Lab Mol Immunol, Div Renal, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; University of Virginia	Finn, PW (corresponding author), Brigham & Womens Hosp, Pulm & Crit Care Div, 75 Francis St, Boston, MA 02115 USA.		; Wand, Matt/F-9413-2012	Platts-Mills, Thomas/0000-0002-1263-329X; Wand, Matt/0000-0003-2555-896X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI035786, R01AI045007, R01AI035786] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI20433] Funding Source: Medline; NIAID NIH HHS [AI/EHS45007, AI 45007, AI/EHS35786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Hollander M., 2014, NONPARAMETRIC STAT M; Lara-Marquez ML, 1998, J ALLERGY CLIN IMMUN, V101, P699, DOI 10.1016/S0091-6749(98)70180-0; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; MARTINEZ FD, 2000, J RESP CRIT CARE MED, V162, pS65; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079, DOI 10.1164/ajrccm.157.4.9704140; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	20	31	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1072	1077		10.1016/j.jaci.2003.08.036	http://dx.doi.org/10.1016/j.jaci.2003.08.036			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657861				2022-12-18	WOS:000187154200007
J	Park, JW; Taube, C; Yang, ES; Joetham, A; Balhorn, A; Takeda, K; Miyahara, N; Dakhama, A; Donaldson, DD; Gelfand, EW				Park, JW; Taube, C; Yang, ES; Joetham, A; Balhorn, A; Takeda, K; Miyahara, N; Dakhama, A; Donaldson, DD; Gelfand, EW			Respiratory syncytial virus-induced airway hyperresponsiveness is independent of IL-13 compared with that induced by allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory syncytial virus; airway hyperresponsiveness; IL-13	PULMONARY INFLAMMATORY RESPONSE; MUCUS PRODUCTION; IFN-GAMMA; T-CELLS; B-CELLS; INFECTION; MICE; INTERLEUKIN-13; CYTOKINE; SENSITIZATION	Background: IL-13 is a central mediator of allergen-induced airway hyperresponsiveness, (AHR), but its role in respiratory syncytial virus (RSV)-induced AHR is not defined. The combination of allergen exposure and RSV infection is known to increase AHR and lung inflammation, but whether IL-13 regulates this increase is similarly not known. Objective: Our objective was to determine the role of RSV infection and IL-13 on airway responsiveness and lung inflammation on sensitized and challenged mice. Methods: Using a murine model of RSV infection and allergen exposure, we examined the role of IL-13 in the development of AHR and lung inflammation in IL-13 knockout mice, as well as using a potent IL-13 inhibitor (IL-13i). Mice were sensitized and challenged to allergen, and 6 days after the last challenge, they were infected with RSV. IL-13 was inhibited using an IL-13 receptor alpha(2)-human IgG fusion protein. AHR to inhaled methacholine was measured 6 days after infection, as was bronchoalveolar lavage fluid and lung inflammatory and cytokine responses. Results: RSV-induced AHR was unaffected by the IL-13i, despite prevention of goblet cell hyperplasia. Similar results were seen in IL-13-deficient mice. In sensitized and challenged mice, RSV infection significantly increased AHR, and after IL-13i treatment, AHR was significantly reduced, but to the levels seen in RSV-infected mice alone. Conclusions: These results indicate that despite some similarities, the mechanisms leading to AHR induced by RSV are different from those that follow allergen sensitization and challenge. Because IL-13 inhibition is effective in preventing the increases in AHR and mucus production in sensitized and challenged mice infected with RSV, IL-13i could play an important role in preventing the consequences of viral infection in patients with allergic asthma.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; Wyeth Genet Inst, Cambridge, MA USA	National Jewish Health; Pfizer	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.			Park, Jung-Won/0000-0003-0249-8749	NHLBI NIH HHS [HL-36577, HL-61005] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061005, P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bancroft AJ, 2000, EUR J IMMUNOL, V30, P2083, DOI 10.1002/1521-4141(200007)30:7&lt;2083::AID-IMMU2083&gt;3.0.CO;2-3; Bessis N, 1996, EUR J IMMUNOL, V26, P2399, DOI 10.1002/eji.1830261020; BRINKMANN V, 1995, J IMMUNOL, V154, P3078; CASH E, 1994, J IMMUNOL, V153, P4258; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Chiaramonte MG, 1999, J IMMUNOL, V162, P920; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cohn L, 1999, J IMMUNOL, V162, P6178; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Durbin JE, 2002, J IMMUNOL, V168, P2944, DOI 10.4049/jimmunol.168.6.2944; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; HEILMAN CA, 1990, J INFECT DIS, V161, P402, DOI 10.1093/infdis/161.3.402; Isomaki P, 1996, ARTHRITIS RHEUM, V39, P1693, DOI 10.1002/art.1780391012; LI S, 1996, J IMMUNOL, V148, P4833; Lukacs NW, 2001, J IMMUNOL, V167, P1060, DOI 10.4049/jimmunol.167.2.1060; Makela MJ, 2002, AM J RESP CRIT CARE, V165, P824, DOI 10.1164/rccm.2105062; MALEFYT RD, 1995, INT IMMUNOL, V7, P1405, DOI 10.1093/intimm/7.9.1405; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Muchamuel T, 1997, J IMMUNOL, V158, P2898; OPENSHAW PJM, 1992, INT IMMUNOL, V4, P493, DOI 10.1093/intimm/4.4.493; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Peebles RS, 2001, J INFECT DIS, V184, P1374; Peebles RS, 2001, J MED VIROL, V63, P178, DOI 10.1002/1096-9071(20000201)63:2<178::AID-JMV1013>3.3.CO;2-F; Prieto J, 2000, RESP MED, V94, P806, DOI 10.1053/rmed.2000.0826; Schwarze J, 2000, AM J RESP CRIT CARE, V162, P380, DOI 10.1164/ajrccm.162.2.9903057; Schwarze J, 1999, J IMMUNOL, V162, P2997; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Srikiatkhachorn A, 1997, J VIROL, V71, P678, DOI 10.1128/JVI.71.1.678-685.1997; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Tekkanat KK, 2001, AM J PATHOL, V159, P631, DOI 10.1016/S0002-9440(10)61734-8; Tekkanat KK, 2001, J IMMUNOL, V166, P3542, DOI 10.4049/jimmunol.166.5.3542; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; Vannier E, 1996, BLOOD, V87, P3307, DOI 10.1182/blood.V87.8.3307.bloodjournal8783307; Varga SM, 2000, J IMMUNOL, V165, P6487, DOI 10.4049/jimmunol.165.11.6487; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Waris ME, 1997, J VIROL, V71, P6935, DOI 10.1128/JVI.71.9.6935-6939.1997; Waris ME, 1996, J VIROL, V70, P2852, DOI 10.1128/JVI.70.5.2852-2860.1996; Whittaker L, 2002, AM J RESP CELL MOL, V27, P593, DOI 10.1165/rcmb.4838; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wu CA, 2001, J IMMUNOL, V167, P2798, DOI 10.4049/jimmunol.167.5.2798; Young DA, 2000, J IMMUNOL, V164, P3563, DOI 10.4049/jimmunol.164.7.3563; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	47	31	36	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1078	1087		10.1016/j.jaci.2003.08.046	http://dx.doi.org/10.1016/j.jaci.2003.08.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657862				2022-12-18	WOS:000187154200008
J	Cho, YS; Park, SY; Lee, CK; Yoo, B; Moon, HB				Cho, YS; Park, SY; Lee, CK; Yoo, B; Moon, HB			Elevated substance P levels in nasal lavage fluids from patients with chronic nonproductive cough and increased cough sensitivity to inhaled capsaicin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cough syndrome; neuropepetide; sensory hyperreactivity	AIRWAY INFLAMMATION; NONASTHMATIC PATIENTS; INDUCED SPUTUM; REFLEX; ASTHMA; RESPONSES; SYMPTOMS	Background: The exact mechanism of a chronic nonproductive cough is sometimes unclear when patients who are without symptoms or signs indicating the major causes of chronic cough remain undiagnosed. Objective: We hypothesized that some neurochemical alterations in the sensory nerves in the cough reflex may occur in the upper airway of chronic nonproductive cough patients. Methods: We took nasal lavage fluid (NLF) specimens from 38 patients with a chronic nonproductive cough as the sole presenting symptom. All 38 had normal chest radiography, spirometry, and bronchial responsiveness. We likewise took NLF specimens from 14 healthy control subjects. We used a capsaicin cough provocation test to determine cough sensitivity and considered the value of C-5 (the lowest capsaicin concentration inducing 5 consecutive coughs) as an index of cough sensitivity. We measured levels of substance P of NLF specimens by using ELISA. In addition, we evaluated the clinical response of each patient after subsequent therapeutic trials with an antihistamine and decongestant for 2 weeks. Results: By using capsaicin cough sensitivity as the basis for grouping the study subjects, we divided the patients into 2 groups: an increased cough sensitivity group (ICS, C-5 <32 mu mol/L) and a normal cough sensitivity (NCS) group. Patients with ICS showed an elevated SP concentration in NLF (median value, 408 pg/mL) compared with that of the NCS group (237 pg/mL) and the control subjects (138 pg/mL) (P < .01). The median value of the percentage of remnant cough after therapeutic trial compared with the cough status before treatment was significantly higher in the ICS subgroup (70%) than that of NCS (25%) (P < .05). Conclusions: Elevated substance P contents in NLF specimens were associated with ICS in patients with chronic nonproductive cough, suggesting a neurochemical abnormality in the upper airway.	Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med,Div Allergy & Rheumatol, Seoul, South Korea	University of Ulsan; Asan Medical Center	Moon, HB (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med,Div Allergy & Rheumatol, 388-1 Pungnap Dong, Seoul, South Korea.							BARNES PJ, 1987, AM REV RESPIR DIS, V136, pS77, DOI 10.1164/ajrccm/136.6_Pt_2.S77; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Blom HM, 1998, CLIN EXP ALLERGY, V28, P1351; Bonham AC, 1996, J PHYSIOL-LONDON, V493, P229, DOI 10.1113/jphysiol.1996.sp021378; BOULET LP, 1994, AM J RESP CRIT CARE, V149, P482, DOI 10.1164/ajrccm.149.2.8306050; Brightling CE, 2000, EUR RESPIR J, V15, P682, DOI 10.1034/j.1399-3003.2000.15d10.x; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; BUCCA C, 1995, LANCET, V346, P791, DOI 10.1016/S0140-6736(95)91617-2; Carr MJ, 2002, AM J RESP CRIT CARE, V165, P1071, DOI 10.1164/ajrccm.165.8.2108065; CHOUDRY NB, 1992, EUR RESPIR J, V5, P296; FERRARI M, 1995, AM J RESP CRIT CARE, V151, P557, DOI 10.1164/ajrccm.151.2.7842220; Fujimura M, 2000, CLIN EXP ALLERGY, V30, P41; FULLER RW, 1987, BMJ-BRIT MED J, V295, P1025, DOI 10.1136/bmj.295.6605.1025-a; GIBSON PG, 1989, LANCET, V1, P1346; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; Jatakanon A, 1999, THORAX, V54, P234, DOI 10.1136/thx.54.3.234; KATSUMATA U, 1989, TOHOKU J EXP MED, V158, P105, DOI 10.1620/tjem.158.105; KOHROGI H, 1988, J CLIN INVEST, V82, P2063, DOI 10.1172/JCI113827; LACROIX JS, 1991, CLIN EXP ALLERGY, V21, P595, DOI 10.1111/j.1365-2222.1991.tb00852.x; Lee SY, 2001, CHEST, V120, P1114, DOI 10.1378/chest.120.4.1114; Millqvist E, 1998, ALLERGY, V53, P1208, DOI 10.1111/j.1398-9995.1998.tb03843.x; Millqvist E, 2001, RESP MED, V95, P19, DOI 10.1053/rmed.2000.0965; MORICE AH, 1992, EUR RESPIR J, V5, P841; NIEBER K, 1993, CLIN EXP ALLERGY, V23, P69, DOI 10.1111/j.1365-2222.1993.tb02486.x; OCONNELL F, 1995, AM J RESP CRIT CARE, V152, P2068, DOI 10.1164/ajrccm.152.6.8520777; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818; POE RH, 1989, CHEST, V95, P723, DOI 10.1378/chest.95.4.723; PRABHAKAR NR, 1987, ACTA PHYSIOL SCAND, V131, P63, DOI 10.1111/j.1748-1716.1987.tb08206.x; PRATTER MR, 1993, ANN INTERN MED, V119, P977, DOI 10.7326/0003-4819-119-10-199311150-00003; Tanaka S, 1996, THORAX, V51, P810, DOI 10.1136/thx.51.8.810; Ternesten-Hasseus E, 2002, ALLERGY, V57, P501, DOI 10.1034/j.1398-9995.2002.23380.x; Tomaki M, 1996, THORAX, V51, P199, DOI 10.1136/thx.51.2.199; TOMAKI M, 1995, AM J RESP CRIT CARE, V151, P613; WIDDICOMBE JG, 1995, EUR RESPIR J, V8, P1193, DOI 10.1183/09031936.95.08071193	34	31	36	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					695	701		10.1016/S0091-6749(03)01784-6	http://dx.doi.org/10.1016/S0091-6749(03)01784-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564346	Bronze			2022-12-18	WOS:000185831200007
J	Mochizuki, A; McEuen, AR; Buckley, MG; Walls, AF				Mochizuki, A; McEuen, AR; Buckley, MG; Walls, AF			The release of basogranulin in response to IgE-dependent and IgE-independent stimuli: Validity of basogranulin measurement as an indicator of basophil activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; basogranulin; histamine; IgE; a23187; f-Met-Leu-Phe; C5a; wortmannin; nonreleaser; BB1	UNIQUE SECRETORY PRODUCT; HISTAMINE-RELEASE; MAST-CELL; IMMUNOHISTOCHEMICAL DETECTION; ALLERGIC REACTIONS; PROSTAGLANDIN D-2; ANTIGEN CHALLENGE; CHRONIC URTICARIA; TYROSINE KINASE; BLOOD-CELLS	Background: Basogranulin, the novel basophil granule protein recognized by the monoclonal antibody BB1, can be released by stimulation with anti-IgE antibody or calcium ionophore. However, the kinetics and regulation of its secretion are unknown. Objective: We quantified basogranulin and histamine release in response to a range of stimuli to assess whether basogranulin secretion is a reliable marker of basophil activation. Methods: Isolated peripheral blood basophils were stimulated with anti-IgE antibody, calcium ionophore, N-formyl-Met-Leu-Phe, and complement C5a. The released basogranulin and histamine were quantified by dot blotting with BB1 and a fluorometric method, respectively. Basogranulin localization was confirmed by flow cytometry. Results: Both basogranulin and histamine displayed a bell-shaped response curve when basophils were challenged with anti-IgE. Half-maximal release occurred within 30 seconds. Basogranulin levels were maximal by 15 minutes, whereas those for histamine continued increasing to 30 minutes. Wortmannin, a PI3-K inhibitor, suppressed the release of both mediators. Basophils from donors with the "nonreleaser" phenotype secreted neither mediator in response to anti-IgE. Non-IgE-dependent stimuli released both mediators in parallel in a concentration-dependent manner. The correlation between the relative amounts of each mediator released was highly significant (r = .901, P < .0001, n = 87). Flow cytometry revealed that some of the secreted basogranulin adhered to the cell surface. Conclusions: Basogranulin is secreted along with histamine in response to both Fc epsilon R I-related and unrelated stimuli. It is therefore a valid marker of basophil activation and could provide the basis for an immunoassay that distinguishes between basophil and mast cell activation.	Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO16 6YD, Hants, England	University of Southampton	Walls, AF (corresponding author), Southampton Gen Hosp, Immunopharmacol Grp, Mail Point 837,Tremona Rd, Southampton SO16 6YD, Hants, England.			Walls, Andrew/0000-0003-4803-4595				ANDERSSON M, 1990, J ALLERGY CLIN IMMUN, V86, P815, DOI 10.1016/S0091-6749(05)80188-5; Asero R, 2001, CLIN EXP ALLERGY, V31, P1105, DOI 10.1046/j.1365-2222.2001.01131.x; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; Braunstahl GJ, 2001, AM J RESP CRIT CARE, V164, P858, DOI 10.1164/ajrccm.164.5.2006082; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHURCH MK, 1997, ALLERGY ALLERGIC DIS, V1, P149; Dvorak AM, 1997, ALLERGY, V52, P14, DOI 10.1111/j.1398-9995.1997.tb04807.x; Foster B, 2002, J ALLERGY CLIN IMMUN, V109, P287, DOI 10.1067/mai.2002.121454; FUREDER W, 1995, J IMMUNOL, V155, P3152; Gibbs BF, 1999, J LEUKOCYTE BIOL, V65, P883, DOI 10.1002/jlb.65.6.883; GILBERT HS, 1975, BLOOD, V46, P279; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; KleinJan A, 2000, J ALLERGY CLIN IMMUN, V106, P677, DOI 10.1067/mai.2000.109621; Kobayashi H, 2000, CLIN EXP ALLERGY, V30, P1205; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MacGlashan Donald Jr, 2002, Curr Allergy Asthma Rep, V2, P126, DOI 10.1007/s11882-002-0007-0; McEuen AR, 1999, LAB INVEST, V79, P27; McEuen AR, 2001, J ALLERGY CLIN IMMUN, V107, P842, DOI 10.1067/mai.2001.114650; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; Monneret G, 2002, CLIN IMMUNOL, V102, P192, DOI 10.1006/clim.2001.5156; Nissen D, 1998, INFLAMM RES, V47, P501, DOI 10.1007/s000110050365; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; Platz IJ, 2001, INT ARCH ALLERGY IMM, V126, P335, DOI 10.1159/000049531; SKOV PS, 1985, ALLERGY, V40, P213; Taira M, 2002, J ASTHMA, V39, P315, DOI 10.1081/JAS-120002288; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Tedeschi A, 2000, INT J IMMUNOPHARMACO, V22, P797, DOI 10.1016/S0192-0561(00)00041-2; Walls A. F., 2001, Clinical and Experimental Allergy Reviews, V1, P68, DOI 10.1046/j.1472-9725.2001.00009.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Winther L, 1999, ALLERGY, V54, P436, DOI 10.1034/j.1398-9995.1999.00910.x; Ying S, 1999, J IMMUNOL, V163, P3976	40	31	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					102	108		10.1067/mai.2003.1511	http://dx.doi.org/10.1067/mai.2003.1511			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847486				2022-12-18	WOS:000184010600017
J	Shimizu, T; Shimizu, S; Hattori, R; Majima, Y				Shimizu, T; Shimizu, S; Hattori, R; Majima, Y			A mechanism of antigen-induced goblet cell degranulation in the nasal epithelium of sensitized rats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mucus secretion; goblet cell; allergy; nose; rat; ovalbumin; histamine; leukotriene	ALLERGIC RHINITIS; MURINE MODEL; GUINEA-PIGS; SECRETION; HISTAMINE; HYPERSECRETION; INFLAMMATION; CHALLENGE; ENDOTOXIN; ASTHMA	Background: We have produced hypertrophic and metaplastic changes of goblet cells in nasal epithelium of ovalbumin (OVA)-sensitized rats by intranasal challenge with OVA. A variety of allergic mediators and inflammatory cells are capable of stimulating goblet cell degranulation (epithelial mucus secretion); however, little is known about the mechanism by which antigen induces mucus hypersecretion. Objective: Our aim was to explain the mechanism of goblet cell degranulation in allergic inflammation. Methods: Antigen-induced goblet cell degranulation was evaluated by the transient decrease of epithelial mucosubstance 1 to 6 hours after intranasal challenge with OVA in nasal epithelium of OVA-sensitized rats. The effects of the H-1-antagonist (d-chlorpheniramine malate), H-2-antagonist (cimetidine), atropine, indomethacin, cysteinyl leukotriene (cysLT) antagonist (ONO1078), and antirat PMN antiserum on OVA-induced goblet cell degranulation were examined. Results: Goblet cell secretion 1 hour after OVA challenge was significantly inhibited by H-1-antagonist, atropine, and cysLT antagonist, whereas the secretion 6 hours after the challenge was significantly inhibited by cysLT antagonist and antirat PMN antiserum. Circulating PMN cells and mucosal infiltrating eosinophils were completely abolished by antirat PMN antiserum. Conclusions: These results indicate the different mechanisms of goblet cell secretion between early-phase (1 hour after OVA challenge) and late-phase (6 hours after the challenge) reactions. Histamine stimulates early-phase secretion through the H-1-receptor of cholinergic nerve terminals, and infiltrating inflammatory cells (eosinophils and/or neutrophils) play a role in late-phase secretion. CysLTs (leukotrienes C-4, D-4, and E-4) are important for both early-phase and late-phase secretion.	Mie Univ, Sch Med, Dept Otorhinolaryngol, Tsu, Mie 514, Japan	Mie University	Shimizu, T (corresponding author), Mie Univ, Sch Med, Dept Otorhinolaryngol, 2-174 Edobashi, Tsu, Mie 514, Japan.			Shimizu, Shino/0000-0002-0704-9048; Shimizu, Takeshi/0000-0002-1344-7210				Agusti C, 1998, AM J RESP CRIT CARE, V158, P1253, DOI 10.1164/ajrccm.158.4.9801041; BARANIUK JN, 1997, J ALLERGY CLIN IMMUN, V99, P763; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; GAWIN AZ, 1992, AM J PHYSIOL, V262, pL590, DOI 10.1152/ajplung.1992.262.5.L590; Haile S, 1999, AM J RESP CELL MOL, V20, P891, DOI 10.1165/ajrcmb.20.5.3446; HARKEMA JR, 1988, AM J PATHOL, V130, P605; Liu YC, 1998, BRIT J PHARMACOL, V124, P563, DOI 10.1038/sj.bjp.0701886; OKUDA M, 1988, ANN ALLERGY, V60, P537; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; Shimizu T, 1996, AM J RESP CRIT CARE, V153, P1412, DOI 10.1164/ajrccm.153.4.8616574; Shimizu T, 2001, AM J RESP CRIT CARE, V164, P1077, DOI 10.1164/ajrccm.164.6.2012058; Shimizu T, 2000, AM J RESP CRIT CARE, V161, P1648, DOI 10.1164/ajrccm.161.5.9908101; Shimizu T, 2000, ANN OTO RHINOL LARYN, V109, P1049, DOI 10.1177/000348940010901111; SOVOIE C, 1995, AM J RESP CELL MOL B, V13, P133; STURGESS J, 1973, BRIT J EXP PATHOL, V54, P388; Takeyama K, 1996, AM J RESP CRIT CARE, V154, P231, DOI 10.1164/ajrccm.154.1.8680685; Temann UA, 1997, AM J RESP CELL MOL, V16, P471, DOI 10.1165/ajrcmb.16.4.9115759; TOKUYAMA K, 1990, AM J PHYSIOL, V259, pL108, DOI 10.1152/ajplung.1990.259.2.L108; WHITE MV, 1992, J ALLERGY CLIN IMMUN, V90, P699, DOI 10.1016/0091-6749(92)90155-U	21	31	33	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					119	125		10.1067/mai.2003.1512	http://dx.doi.org/10.1067/mai.2003.1512			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847488				2022-12-18	WOS:000184010600019
J	Apter, AJ				Apter, AJ			Early exposure to allergen: Is this the cat's meow, or are we barking up the wrong tree?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; adult; children; sensitization; cat; dog; epidemiology; selection bias; effect modification	HORMONE REPLACEMENT THERAPY; DECREASED PREVALENCE; 1ST YEAR; ASTHMA; SENSITIZATION; CHILDREN; PETS; RISK; DOG; OWNERSHIP	Several recent studies have suggested that exposure to cat and dog allergen in infancy is protective against the subsequent risk of allergic sensitization and asthma. The methodologic problems to be overcome in clinical research addressing these hypotheses are complex. Appreciation of these studies requires an assessment of the design and adequacy of variables measuring exposures, outcomes, and confounders. It includes understanding the role of effect modification. This article discusses some of the epidemiologic issues in interpreting these studies. Review of relevant epidemiology demonstrates that much research remains to be performed before these interesting hypothesis are proved or disproved.	Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.							Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Bener A, 1995, Allerg Immunol (Paris), V27, P190; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Celedon JC, 2001, AM J RESP CRIT CARE, V163, P1108, DOI 10.1164/ajrccm.163.5.2005086; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Custovic A, 2001, CURR OPIN ALLERGY CL, V1, P133; Fletcher R, 1996, CLIN EPIDEMIOLOGY; Hamilton RG, 1997, METHODS, V13, P25, DOI 10.1006/meth.1997.0493; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Holscher B, 2002, PEDIAT ALLERG IMM-UK, V13, P334, DOI 10.1034/j.1399-3038.2002.02063.x; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2001, MEDIAT INFLAMM, V10, P288, DOI 10.1080/09629350152700902; PLATTSMILLS M, 2002, JAMA-J AM MED ASSOC, V288, P1012; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rothman KJ, 2002, EPIDEMIOLOGY INTRO; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; [No title captured]	34	31	33	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					938	946		10.1067/mai.2003.1417	http://dx.doi.org/10.1067/mai.2003.1417			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743555				2022-12-18	WOS:000182904500005
J	Bureau, F; Seumois, G; Jaspar, F; Vanderplasschen, A; Detry, B; Pastoret, PP; Louis, R; Lekeux, P				Bureau, F; Seumois, G; Jaspar, F; Vanderplasschen, A; Detry, B; Pastoret, PP; Louis, R; Lekeux, P			CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; apoptosis; asthma; atopy; CD40; eosinophils; granulocytes; inflammation; neutrophils	COLONY-STIMULATING FACTOR; B-CELLS; 3T3 FIBROBLASTS; WEHI-231 CELLS; LIGAND; ACTIVATION; ANTIBODY; DEATH; MICE; INTERLEUKIN-3	Background: CD40 engagement enhances eosinophil survival, suggesting a role for this receptor in the development of eosinophilia. Objective: We examined whether CD40 enhances eosinophil survival by inducing the expression of antiapoptotic proteins. Three members of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and XIAP, and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-x(L) and Bfl-1/A1, were investigated. Methods: Blood and sputum were obtained from healthy subjects and atopic asthmatic patients. Blood eosinophils were isolated by means of magnetic selection. Expression of CD40, IAPs, and Bcl-2 proteins was investigated by using flow cytometry, immunoblotting, or both. CD40 stimulation was achieved with agonistic antibodies or soluble ligands. Apoptosis was assessed by staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2 expression was inhibited with antisense oligonucleotides. Results: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely, eosinophils expressed CD40 spontaneously when cultured for 48 hours. At this time point, CD40 stimulation significantly delayed eosinophil apoptosis. Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, XIAP, Bcl-x(L), or Bfl-1/A1 expression. Antisense knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic patients, unlike those from healthy subjects, substantially expressed CD40 and c-IAP2. Moreover, a strong correlation was found between the percentage of eosinophils in the sputum from asthmatic patients and the sputum level of CD40 and c-IAP2 expression. Conclusion: The results demonstrate that CD40 engagement enhances eosinophil survival through induction of c-IAP2 expression and suggest a role for this mechanism in allergic inflammation.	Univ Liege, Fac Vet Med, Dept Physiol, B-4000 Liege, Belgium; Univ Liege, Fac Vet Med, Dept Immunol Vaccinol, B-4000 Liege, Belgium; Univ Liege, Fac Med, Dept Pneumol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Bureau, F (corresponding author), Univ Liege, Fac Vet Med, Dept Physiol, Bat B42, B-4000 Liege, Belgium.			Seumois, Gregory/0000-0002-8164-6852				Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Cataldo D, 2000, INT ARCH ALLERGY IMM, V123, P259, DOI 10.1159/000024452; Clem RJ, 1997, TRENDS CELL BIOL, V7, P337, DOI 10.1016/S0962-8924(97)01088-X; Craxton A, 1998, J IMMUNOL, V161, P3225; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; GAUCHAT JF, 1995, EUR J IMMUNOL, V25, P863, DOI 10.1002/eji.1830250335; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Ishihara C, 1997, CLIN EXP IMMUNOL, V110, P524, DOI 10.1046/j.1365-2249.1997.4511469.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lei XF, 1998, J CLIN INVEST, V101, P1342, DOI 10.1172/JCI1662; Mehlhop PD, 2000, AM J RESP CELL MOL, V23, P646, DOI 10.1165/ajrcmb.23.5.3954; MERINO R, 1995, J IMMUNOL, V155, P3830; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; Simon HU, 1997, J IMMUNOL, V158, P3902; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; WALKER C, 1991, J IMMUNOL, V146, P1829; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7	31	31	31	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					443	449		10.1067/mai.2002.126781	http://dx.doi.org/10.1067/mai.2002.126781			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209092	Green Submitted			2022-12-18	WOS:000177936900015
J	Zarei, S; Leuba, F; Arrighi, JF; Hauser, C; Piguet, V				Zarei, S; Leuba, F; Arrighi, JF; Hauser, C; Piguet, V			Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; lentiviral rectors; HIV; LCMV; antigen presentation; TAP	COLONY-STIMULATING-FACTOR; VIVO GENE DELIVERY; MOUSE BONE-MARROW; LARGE QUANTITIES; HEMATOPOIETIC PROGENITORS; LARGE NUMBERS; T-CELLS; MATURE; GENERATION; EXPRESSION	Background: Because antigen-presenting dendritic cells (DCs) play a major role in the polarization of T cells, including T(H)2 cells involved in allergy, strategies to modify DCs genetically are required. Objective: The purpose of this investigation was to transduce murine bone marrow-derived DCs with lentiviral vectors encoding antigen to demonstrate antigen processing and MHC class I-dependent presentation. Methods: Bone marrow leukocytes were incubated with antigen-encoding lentiviral constructs and cultured with GM-CSF, IL-4, and Flt-3 ligand. The capacity of the resulting DCs to express, process, and present antigen was tested in vitro. Results: An average of 40% of DCs expressed antigen after I week of culture when antigen encoded by the lentiviral vector construct was green fluorescent protein. To demonstrate that transduced antigen can be presented by DCs on MHC class 1, we chose the lymphocytic choriomeningitis virus glycoprotein (gp) as a model antigen, inasmuch as it is recognized by CD8 T cells from transgenic mice expressing an MHC class I-restricted T-cell receptor specific for the epitope of positions 33 through 41 of gp. DCs transduced with lentiviral construct encoding gp and matured with LPS activated transgenic T cells in an antigen-specific fashion. Using transporter associated with antigen presentation (TAP)-deficient mice, we show that presentation of the gp33-41 epitope is TAP-dependent, confirming processing of gp by the endogenous pathway. Conclusions: These results demonstrate that CD8 T cells can recognize MHC class I epitopes processed from antigen in DCs, transduced with lentiviral vectors. Lentiviral transduction of DCs and antigen presentation to CD8 T cells could be exploited for immunotherapy, because allergen-specific CD8 T cells have been shown to be suppressive in IgE-dependent allergy models.	Univ Hosp Geneva, Dept Dermatol, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Div Allergy & Immunol, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Div Hematol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva	Piguet, V (corresponding author), Univ Hosp Geneva, Dept Dermatol, 24 Rue Micheli du Crest, CH-1211 Geneva, Switzerland.							AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Arrighi JF, 1999, BLOOD, V93, P2244, DOI 10.1182/blood.V93.7.2244.407a29_2244_2252; Banchereau J, 2001, CANCER RES, V61, P6451; Broide DH, 2001, J ALLERGY CLIN IMMUN, V108, pS65, DOI 10.1067/mai.2001.116436; Caux C, 1997, BLOOD, V90, P1458, DOI 10.1182/blood.V90.4.1458.1458_1458_1470; Dyall J, 2001, BLOOD, V97, P114, DOI 10.1182/blood.V97.1.114; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jenne L, 2001, TRENDS IMMUNOL, V22, P102, DOI 10.1016/S1471-4906(00)01813-5; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KYBURZ D, 1993, EUR J IMMUNOL, V23, P1956, DOI 10.1002/eji.1830230834; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; MacAry PA, 1998, J IMMUNOL, V160, P580; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Salmon P, 2000, BLOOD, V96, P3392; Salmon P, 2001, J GENE MED, V3, P311, DOI 10.1002/1521-2254(200107/08)3:4<311::AID-JGM198>3.0.CO;2-B; Thomas MJ, 2002, J IMMUNOL, V168, P216, DOI 10.4049/jimmunol.168.1.216; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Thurner B, 1999, J IMMUNOL METHODS, V223, P1, DOI 10.1016/S0022-1759(98)00208-7; Van den Eynde BJ, 2001, CURR OPIN IMMUNOL, V13, P147, DOI 10.1016/S0952-7915(00)00197-7; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; von Bubnoff D, 2001, J ALLERGY CLIN IMMUN, V108, P329, DOI 10.1067/mai.2001.117457; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	32	31	44	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					988	994		10.1067/mai.2002.124663	http://dx.doi.org/10.1067/mai.2002.124663			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063529				2022-12-18	WOS:000176442700015
J	Kino, T; Chrousos, GP				Kino, T; Chrousos, GP			Tissue-specific glucocorticoid resistance-hypersensitivity syndromes: Multifactorial states of clinical importance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							PITUITARY-ADRENAL AXIS; RECEPTOR TRANSCRIPTIONAL ACTIVATION; INHALED CORTICOSTEROID-THERAPY; DNA-BINDING; COACTIVATOR; SUPPRESSION; SENSITIVITY; STRESS		NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kino, T (corresponding author), NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bldg 10,Rm 9D42,10 Ctr Dr,MSC 1583, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD000618] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Chrousos GP, 2000, INT J OBESITY, V24, pS50, DOI 10.1038/sj.ijo.0801278; Chrousos GP, 1998, NEUROIMMUNOMODULAT, V5, P277, DOI 10.1159/000026348; Chrousos GP, 1998, NEUROIMMUNOMODULAT, V5, P288, DOI 10.1159/000026349; Franchimont D, 1999, J CLIN ENDOCR METAB, V84, P2834, DOI 10.1210/jc.84.8.2834; Franchimont D, 1999, DIGEST DIS SCI, V44, P1208, DOI 10.1023/A:1026644711530; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V108, P3, DOI 10.1067/mai.2001.115758; Galigniana MD, 1999, MOL PHARMACOL, V55, P317, DOI 10.1124/mol.55.2.317; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; KAM JC, 1993, J IMMUNOL, V151, P3460; Kino T, 2002, J BIOL CHEM, V277, P2396, DOI 10.1074/jbc.M106312200; Kino T, 2001, Endocr Pract, V7, P480; Kino T, 2001, J ENDOCRINOL, V169, P437, DOI 10.1677/joe.0.1690437; Kino T, 2001, J CLIN ENDOCR METAB, V86, P5600, DOI 10.1210/jc.86.11.5600; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; Ma H, 1999, MOL CELL BIOL, V19, P6164; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; MEDURI GU, 2002, IN PRESS AM J RESP C; Miura T, 2001, J BIOL CHEM, V276, P47371, DOI 10.1074/jbc.M107098200; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Schneikert J, 2000, EMBO J, V19, P6508, DOI 10.1093/emboj/19.23.6508; Spahn JD, 1996, J IMMUNOL, V157, P2654; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; Vottero A, 1999, TRENDS ENDOCRIN MET, V10, P333, DOI 10.1016/S1043-2760(99)00179-4; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153	31	31	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					609	613		10.1067/mai.2002. 123708	http://dx.doi.org/10.1067/mai.2002. 123708			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941307	Bronze			2022-12-18	WOS:000175132600005
J	Ott, VL; Fong, DC; Cambier, JC				Ott, VL; Fong, DC; Cambier, JC			Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CALIFORNIA	Bayer Biol		IVIG; Fc gamma RIIB; SHIP; inhibitory receptors; signal transduction	B-CELL RECEPTOR; NEGATIVE REGULATION; PROTEIN P62(DOK); MOTIFS; SHIP2; SHC	ability of the immune system to respond appropriately to foreign antigen is dependent on a delicate balance of activating and inhibitory signals. Recently, the role of cell surface inhibitory receptors in attenuating immune responses, thereby preventing pathologic conditions including autoimmunity and atopy, has been recognized. It is postulated that the beneficial effects of intravenous gamma globulin in the treatment of immune disorders may be attributable, at least in part, to engagement of Fc gamma RIIB, a member of the recently described family of immune inhibitory receptors. Recent genetic and biochemical studies have identified the SH2 domain-containing inositol 5-phosphatase (SHIP) as a critical effector in Fc gamma RIIB inhibitory signaling. This review summarizes recent work from our laboratory and others aimed to define the mechanism(s) by which Fc gamma RIIB and its effector, SHIP, inhibit immune responses. Elucidation of these mechanisms may lead to the development of therapeutic strategies for the treatment of autoimmune and inflammatory pathologies that specifically target Fc gamma RIIB or its effector(s).	Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Cambier, JC (corresponding author), 1400 Jackson St,K1004, Denver, CO 80206 USA.			Cambier, John/0000-0002-7803-242X				Brauweiler A, 2001, J IMMUNOL, V167, P204, DOI 10.4049/jimmunol.167.1.204; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Cambier JC, 1999, CURR TOP MICROBIOL, V244, P43; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; Lesourne R, 2001, J BIOL CHEM, V276, P6327, DOI 10.1074/jbc.M006537200; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Malbec O, 1999, CURR TOP MICROBIOL, V244, P13; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Sato K, 1998, J IMMUNOL, V161, P2716; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Yamanashi Y, 2000, GENE DEV, V14, P11	17	31	51	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S95	S98		10.1067/mai.2001.117822	http://dx.doi.org/10.1067/mai.2001.117822			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	487KL	11586273				2022-12-18	WOS:000171874200003
J	Tarlo, SM; Broder, I; Corey, P; Chan-Yeung, M; Ferguson, A; Becker, A; Rogers, C; Okada, M; Manfreda, J				Tarlo, SM; Broder, I; Corey, P; Chan-Yeung, M; Ferguson, A; Becker, A; Rogers, C; Okada, M; Manfreda, J			The role of symptomatic colds in asthma exacerbations: Influence of outdoor allergens and air pollutants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma exacerbations; air pollutants; colds; viral respiratory infections	HOSPITAL ADMISSIONS; VIRAL-INFECTIONS; CHILDREN; ONTARIO; POLLUTION; OZONE; SENSITIZATION; CHILDHOOD; VIRUSES; TORONTO	Background: Both air pollutants and respiratory viral infections have been recognized to be important triggers of asthma exacerbations. but the possible interaction of these has not been assessed in an epidemiologic study. Objective: In this study, we aimed to assess the possible associations of symptomatic colds with outdoor allergens and air pollutants in exacerbating asthma. Methods: A total of 57 adults and children with asthma participated in a 1-year study in Vancouver, British Columbia. Diary cards recording symptoms of asthma and colds, medication usage, and peak expiratory flow rates were completed twice daily. Outdoor air pollutant levels and levels of pollen and fungal spores were measured. Levels were examined for associations with exacerbations of asthma with symptoms of a cold, as compared with asthma exacerbations with no cold symptoms and colds in the absence of asthma exacerbations. Results: Of 130 asthma exacerbations, 47% were associated with cold symptoms (accounting for 44% of episodes of colds). Asthma exacerbations with colds were associated with higher levels of sulfur dioxide, and nitric oxide during March to November in comparison with asthma exacerbations without cold symptoms (P < .018). Cold-symptom days overall were more common in winter and were significantly associated with lower temperatures, lower ozone levels. and higher sulfur dioxide, nitrogen dioxide, nitrogen oxide (NO and NOx), and carbon monoxide levels. Conclusions: Asthma exacerbations are commonly associated with cold symptoms. These episodes are associated with higher levels of sulfur dioxide and nitrogen oxides from March to November in comparison with asthma exacerbations without cold symptoms.	Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ British Columbia, Dept Paediat, Vancouver, BC, Canada; Univ Manitoba, Dept Med, Winnipeg, MB, Canada; Univ Manitoba, Dept Paediat, Winnipeg, MB, Canada; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of Toronto; University of Toronto; University of British Columbia; University of British Columbia; University of Manitoba; University of Manitoba; Harvard University; Harvard T.H. Chan School of Public Health	Tarlo, SM (corresponding author), Gage Occupat & Environm Hlth Unit, 223 Coll St, Toronto, ON M5T 1R4, Canada.		Rogers, Christine A/M-6007-2017; Rogers, Christine A/A-2189-2008	Rogers, Christine A/0000-0003-0887-9606; Rogers, Christine A/0000-0003-0887-9606; Tarlo, Susan/0000-0002-4746-5310; Ferguson, Alexander C./0000-0002-3143-5619				BATES DV, 1983, CAN J PUBLIC HEALTH, V74, P117; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; Bayram H, 1999, J ALLERGY CLIN IMMUN, V104, P93, DOI 10.1016/S0091-6749(99)70119-3; BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; BURNETT RT, 1994, ENVIRON RES, V65, P172, DOI 10.1006/enrs.1994.1030; CARLSEN KH, 1984, ARCH DIS CHILD, V59, P310, DOI 10.1136/adc.59.4.310; COFFIN DL, 1976, ENVIRON HEALTH PERSP, V13, P11, DOI 10.2307/3428230; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; EHRLICH R, 1980, ENVIRON HEALTH PERSP, V35, P89, DOI 10.2307/3428977; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; *EPA, 1982, EPA450582002 OFF AIR; FOX JP, 1985, AM J EPIDEMIOL, V122, P830, DOI 10.1093/oxfordjournals.aje.a114166; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23; JENNINGS LC, 1987, NEW ZEAL MED J, V100, P488; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1997, PEDIATR PULM, P88; Kiehl MG, 1997, INTENS CARE MED, V23, P561, DOI 10.1007/s001340050373; Lippmann M, 1987, APPL IND HYG, V2, P188; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; MARSH JH, 1988, CANADIAN ENCY; MONTO AS, 1972, AM J EPIDEMIOL, V96, P352, DOI 10.1093/oxfordjournals.aje.a121466; MONTO AS, 1992, PUBLIC HLTH PREVENTI, P125; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; POTTER PC, 1984, S AFR MED J, V66, P397; Rusznak C, 1996, EUR RESPIR J, V9, P2298, DOI 10.1183/09031936.96.09112298; SCHLESINGER RB, 1987, J TOXICOL ENV HEALTH, V20, P125, DOI 10.1080/15287398709530966; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; SOKHANDAN M, 1995, CHEST, V107, P1570, DOI 10.1378/chest.107.6.1570; TARLO S, 1979, CLIN ALLERGY, V9, P293, DOI 10.1111/j.1365-2222.1979.tb01556.x; Tarlo S M, 2000, Can Respir J, V7, P42; TEO J, 1986, J TROP PEDIATRICS, V32, P87, DOI 10.1093/tropej/32.2.87; THURSTON GD, 1994, ENVIRON RES, V65, P254, DOI 10.1006/enrs.1994.1036; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; WEEKS J, 1995, J ALLERGY CLIN IMMUN, V95, P209; ZWICK H, 1991, AM REV RESPIR DIS, V144, P1075, DOI 10.1164/ajrccm/144.5.1075	36	31	31	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					52	58		10.1067/mai.2001.116574	http://dx.doi.org/10.1067/mai.2001.116574			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447382				2022-12-18	WOS:000170171200007
J	Kim, SS; Park, HS; Kim, HY; Lee, SK; Nahm, DH				Kim, SS; Park, HS; Kim, HY; Lee, SK; Nahm, DH			Anaphylaxis caused by the new ant, Pachycondyla chinensis: Demonstration of specific IgE and IgE-binding components	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pachycondyla chinensis; major allergen specific IgE and IgG4; cross-reactivity	OCCUPATIONAL ASTHMA; VENOM; HYPERSENSITIVITY; ALLERGENS	Background: There have been no reports dealing with the pathogenic mechanism and IgE-binding components in patients with anaphylaxis caused by a sting from Pachycondyla chinensis. Objectives: This study was conducted to observe the clinical features of patients with P chinensis-induced anaphylaxis. The roles of specific (s) IBE and sIgG4 antibodies were evaluated, and IgE-binding components were identified. Methods: Seven patients with P chinensis-induced anaphylaxis and 15 unexposed control subjects were enrolled, P chinensis ants were collected at the patients' homes, and venom was prepared as P chinensis extract. Five patients complained of bee venom-induced anaphylaxis and had positive sIgE levels to yellow jacket venom, wasp venom, or both as well. Serum sIgE and sIgG4 were detected by means of ELISA. To identify IgE-binding components within P chinensis extracts, 12% SDS-PAGE with immunoblot analysis was applied. Results: Ail patients had positive skin prick test responses to P chinensis antigen and positive sIgE levels. Five (71%) patients had positive sIgG4 levels, Eight IgE-binding components (58, 46,31, 29, 27, 25, 22, and 12 kd) were noted, and the component at 12 kd was the most frequently found allergen (85%), IgE ELISA inhibition tests were performed on 2 groups of sera: one from patients with anaphylaxis induced by both P chinensis and bee venom (group A) and the other from patients with anaphylaxis induced by P chinensis venom alone without bee venom allergy (group B), ELISA inhibition tests with serum from group A showed significant inhibitions with addition of P chinensis extract, partial inhibitions with yellow jacket antigen, and minimal inhibitions with wasp or imported fire ant antigens, However, ELISA inhibition tests with serum from group B showed significant inhibitions with P chinensis antigen but no inhibition with wasp, yellow jacket, or imported fire ant antigens, Conclusions: IgE-mediated reactions contributed to the development of P chinensis-induced anaphylaxis. Eight IgE-binding components and one major allergen (12 kd) were identified. Further studies will be needed to clarify the role of sIgG4 and to identify allergenic relationships with major bee and wasp allergens.	Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Suwon, South Korea; Nowon Eulgi Hosp, Dept Internal Med, Seoul, South Korea	Ajou University	Park, HS (corresponding author), Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, San 5, Suwon, South Korea.		Park, Hae-Sim/S-7974-2019	Park, Hae-Sim/0000-0003-2614-0303				ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; Douglas RG, 1998, J ALLERGY CLIN IMMUN, V101, P129, DOI 10.1016/S0091-6749(98)70206-4; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; Kemp SF, 2000, J ALLERGY CLIN IMMUN, V105, P683, DOI 10.1067/mai.2000.105707; Kim Byung-Jin, 1998, Korean Journal of Entomology, V28, P145; Kim HY, 1999, ANN ALLERG ASTHMA IM, V82, P174, DOI 10.1016/S1081-1206(10)62593-8; KING TP, 1999, ALLERGENS ALLERGEN I, P155; Palma-Carlos M L, 1999, Allerg Immunol (Paris), V31, P71; Park HS, 1996, CLIN EXP ALLERGY, V26, P423, DOI 10.1046/j.1365-2222.1996.d01-331.x; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; REED MA, 1990, J ALLERGY CLIN IMMUN, V85, P737, DOI 10.1016/0091-6749(90)90192-7; Stafford CT, 1996, ANN ALLERG ASTHMA IM, V77, P87, DOI 10.1016/S1081-1206(10)63493-X; Yun YY, 1999, J ALLERGY CLIN IMMUN, V104, P879, DOI 10.1016/S0091-6749(99)70302-7	14	31	32	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1095	1099		10.1067/mai.2001.114341	http://dx.doi.org/10.1067/mai.2001.114341			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398091	Green Published			2022-12-18	WOS:000169454800025
J	Kanazawa, H; Hirata, K; Yoshikawa, J				Kanazawa, H; Hirata, K; Yoshikawa, J			Role of endogenous nitric oxide in exercise-induced airway narrowing in patients with bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise-induced bronchoconstriction; nitric oxide; branchial asthma; induced sputum	EXHALED AIR; LUNG; SYNTHASE; INFLAMMATION; EXPRESSION; GENE	Background: Increased amounts of nitric oxide (NO) in expired air and induced sputum have been found in asthmatic patients, and the role of excessively produced NO in the pathogenesis of bronchial asthma is under active investigation. Objective: This study was designed to investigate the involvement of endogenous NO in exercise-induced bronchoconstriction (EIB) in asthmatic patients by using the sputum induction method. Methods: The concentration of NO derivatives and inflammatory indices in induced sputum were examined in 18 asthmatic subjects and 10 normal control subjects. All asthmatic subjects performed an exercise test for 6 minutes. For 8 weeks after the first exercise testing, 400 mug of beclomethasone dipropionate twice daily was administered for asthmatic subjects with EIB, and the exercise testing and sputum induction were repeated in these patients, Results: The concentration of NO derivatives in induced sputum was significantly higher in 9 asthmatic subjects with EIB (1580 +/- 280 mu mol/L) than in 9 asthmatic subjects without EIB (1130 +/- 210 mu mol/L) and normal control subjects (510 +/- 150 mu mol/L). Moreover, there was a significant correlation between the concentration of NO derivatives and the percentage of maximal fall in FEV1 (r = 0.569, P = .019). The concentration of NO derivatives was also more closely correlated with the area under the curve of the percentage fall in FEV1 plotted against time for 30 minutes (AUC(0-30); r = 0.812, P < .001). After treatment with inhaled beclomethasone dipropionate in asthmatic subjects with EIB, there was a significant decrease in the concentration of NO derivatives in induced sputum, The change in the concentration of NO derivatives was significantly correlated with the change in the AUC(0-30) (r = 0.896, P = .0114) but not with the change in the percentage of maximal. fall in FEV1. Conclusion: These findings suggest that excessive production of NO is associated with EIB in patients with asthma and contributes to the prolonged airway narrowing phase rather than to the maximal airway narrowing evoked by exercise.	Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka 5458585, Japan	Osaka Metropolitan University	Kanazawa, H (corresponding author), Osaka City Univ, Grad Sch Med, Dept Resp Med, 1-4-3 Asahimachi, Osaka 5458585, Japan.							ALVING K, 1993, EUR RESPIR J, V6, P1368; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1995, ANN MED, V27, P91; EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V58, P414, DOI 10.1016/0091-6749(76)90122-6; Grasemann H, 1999, CLIN EXP ALLERGY, V29, P39; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Ichinose M, 1996, AM J RESP CRIT CARE, V153, P936, DOI 10.1164/ajrccm.153.3.8630576; Kanazawa H, 1998, CLIN EXP ALLERGY, V28, P1244; Kanazawa H, 1997, J ALLERGY CLIN IMMUN, V99, P624, DOI 10.1016/S0091-6749(97)70024-1; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; Miura M, 1996, J ALLERGY CLIN IMMUN, V98, P144, DOI 10.1016/S0091-6749(96)70236-1; Moody A, 2000, J ALLERGY CLIN IMMUN, V105, P895, DOI 10.1067/mai.2000.105318; PHIZACKERLEY PJR, 1983, ANAL BIOCHEM, V131, P242, DOI 10.1016/0003-2697(83)90161-6; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323, DOI 10.1016/S0091-6749(99)70031-X; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; Sato M, 1998, CLIN EXP ALLERGY, V28, P597; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879	26	31	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1081	1087		10.1067/mai.2000.110803	http://dx.doi.org/10.1067/mai.2000.110803			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112890	Bronze			2022-12-18	WOS:000165930300009
J	Khan, DA; Cody, DT; George, TJ; Gleich, GJ; Leiferman, KM				Khan, DA; Cody, DT; George, TJ; Gleich, GJ; Leiferman, KM			Allergic fungal sinusitis: An immunohistologic analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic fungal sinusitis; eosinophil; major basic protein; mast cell tryptase; neutrophil elastase	MAJOR BASIC-PROTEIN; NEWLY RECOGNIZED FORM; LATE-PHASE REACTION; MAST-CELLS; ASPERGILLUS SINUSITIS; ATOPIC-DERMATITIS; GRANULE PROTEINS; EOSINOPHIL; DIAGNOSIS; LOCALIZATION	Background: Allergic fungal sinusitis is a noninvasive form of fungal sinusitis that has recently been delineated as a distinct clinicopathologic entity. It is increasingly recognized as a cause of chronic sinusitis, with the primary causative agents being members of the Dematiaceae fungus family, Although its immunopathogenesis has not been elucidated, the eosinophil is a prominent inflammatory cell on histologic examination. Objective: We sought to characterize the involvement of eosinophils in sinus tissue and accompanying mucin from patients with allergic fungal sinusitis. As a comparison, neutrophil and mast cell involvement was also evaluated in the same group of patients. Methods: Tissue specimens from 8 patients with allergic fungal sinusitis, along with 8 nasal polyp specimens from patients without allergic fungal sinusitis, were stained by using indirect immunofluorescence for eosinophil granule major basic protein (MBP). Neutrophil elastase and mast cell tryptase staining was also performed on the same allergic fungal sinusitis and nasal polyp tissues. Results: MBP was diffusely localized within the mucin, showing intense staining at the periphery and variable staining of degenerated cell clusters throughout, Extracellular MBP in the mucin was strikingly greater than intact eosinophil staining. Diffuse Extracellular neutrophil elastase was also present in the mucin, Mucinous areas showed no tryptase localization. Adjacent nonmucinous areas of respiratory mucosa showed predominantly cellular staining with eosinophil MBP, neutrophil elastase, and mast cell tryptase, MBP staining of nasal polyps showed a predominantly cellular pattern with focal areas of extracellular deposition. Conclusions: Given the known toxicities of eosinophil granule MBP and neutrophil elastase, their extracellular presence supports the contribution of these proteins in the pathogenesis of allergic fungal sinusitis and further indicates that eosinophil and neutrophil activation occurs in the disease.	Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med & Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Leiferman, KM (corresponding author), Mayo Clin & Mayo Fdn, Dept Dermatol, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015231, U01AI034577, U19AI034577, R01AI015231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R23AR036008, R01AR036008] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15231, AI 34577] Funding Source: Medline; NIAMS NIH HHS [AR 36008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLPHIN AL, 1991, LARYNGOSCOPE, V101, P815, DOI 10.1288/00005537-199108000-00003; BARTYNSKI JM, 1990, OTOLARYNG HEAD NECK, V103, P32, DOI 10.1177/019459989010300105; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRUMMUND W, 1986, JAMA-J AM MED ASSOC, V256, P3249; Clarke S R, 1998, J La State Med Soc, V150, P248; CODY DT, 1994, LARYNGOSCOPE, V104, P1074, DOI 10.1288/00005537-199409000-00005; COREY JP, 1995, OTOLARYNG HEAD NECK, V113, P110, DOI 10.1016/S0194-5998(95)70153-2; COREY JP, 1990, OTOLARYNG HEAD NECK, V103, P1012, DOI 10.1177/019459989010300621; DAMIANO VV, 1986, J CLIN INVEST, V78, P482, DOI 10.1172/JCI112600; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; DeShazo RD, 1997, NEW ENGL J MED, V337, P254, DOI 10.1056/NEJM199707243370407; Feger TA, 1997, ANN ALLERG ASTHMA IM, V79, P221, DOI 10.1016/S1081-1206(10)63005-0; FRIEDMAN GC, 1991, AM J CLIN PATHOL, V96, P368, DOI 10.1093/ajcp/96.3.368; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; GARCIA JGN, 1987, AM REV RESPIR DIS, V133, P255; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; GOLDSTEIN MF, 1992, J ALLERGY CLIN IMMUN, V90, P394, DOI 10.1016/S0091-6749(05)80020-X; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P583, DOI 10.1016/0091-6749(90)90097-N; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; JANOFF A, 1985, ANNU REV MED, V36, P207; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KATZENSTEIN ALA, 1983, AM J SURG PATHOL, V7, P439, DOI 10.1097/00000478-198307000-00006; Kupferberg SB, 1997, OTOLARYNG HEAD NECK, V117, P35, DOI 10.1016/S0194-5998(97)70203-1; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; LEIFERMAN KM, 1984, J INVEST DERMATOL, V82, P414; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; MANNING SC, 1993, LARYNGOSCOPE, V103, P717, DOI 10.1288/00005537-199307000-00002; MANNING SC, 1994, CURRENT THERAPY OTOL, P406; MILLAR JW, 1981, THORAX, V36, P710; Morpeth JF, 1996, ANN ALLERG ASTHMA IM, V76, P128, DOI 10.1016/S1081-1206(10)63411-4; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; PEREZ GL, 1993, ARCH DERMATOL, V129, P861, DOI 10.1001/archderm.129.7.861; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Quraishi HA, 1997, OTOLARYNG HEAD NECK, V117, P29, DOI 10.1016/S0194-5998(97)70202-X; SCHEER L, 1992, ANN ALLERGY, V68, P1185; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P387, DOI 10.1016/S0091-6749(98)70125-3; SCHWARTZ LB, 1990, NEUTRAL PROTEASES MA, P90; SPITZNAGEL JK, 1974, LAB INVEST, V30, P774; STEFFEN M, 1989, IMMUNOLOGY, V66, P445; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715, DOI 10.1002/jlb.63.6.715; TROCME SD, 1989, AM J OPHTHALMOL, V108, P57, DOI 10.1016/S0002-9394(14)73261-1	47	31	35	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1096	1101		10.1067/mai.2000.110929	http://dx.doi.org/10.1067/mai.2000.110929			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112892				2022-12-18	WOS:000165930300011
J	Anibarro, B; Seoane, FJ; Vila, C; Lombardero, M				Anibarro, B; Seoane, FJ; Vila, C; Lombardero, M			Allergy to eggs from duck and goose without sensitization to hen egg proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						egg allergy; duck; goose; hen; ovalbumin; egg proteins; food allergy	WHITE	Background: Eggs are among the foods most frequently causing allergy, Hen eggs are the most important. Those of other birds are of lesser significance. Objective: We report an unusual case of food allergy after consumption of eggs from duck and goose in an adult patient without hen egg allergy. Methods: Skin prick tests were performed with fresh white and yolk from eggs of duck and goose and egg white, egg yolk, ovalbumin, and ovomucoid from hen egg. Specific serum IgE was measured to hen egg proteins. SDS-PAGE and IgE immunoblotting were carried out with egg white extracts from hen, duck, and goose. Results: Skin tests were positive to egg whites from duck and goose. The skin tests and specific serum IgE were negative to hen egg proteins. Immunoblotting demonstrated the presence of specific IgE to a proteic band of molecular weight around 45 kd. Conclusions: We report a patient with an IgE-mediated allergy to egg white from duck and goose without hen egg allergy. Ovalbumin seems to be the responsible protein. The antigenic determinant of this protein seems to be specific of order Anseriforme and it is not present in the ovalbumin of order Galliforme.	Hosp Severo Ochon, Secc Alergia, Madrid, Spain; ALK Abello, Madrid, Spain	Severo Ochoa University Hospital; ALK-Abello AS	Anibarro, B (corresponding author), C Arzobispo Morcillo 42 9C, Madrid 28029, Spain.							DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGELAND T, 1983, ALLERGY, V38, P399, DOI 10.1111/j.1398-9995.1983.tb05083.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	5	31	32	0	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					834	836		10.1067/mai.2000.104547	http://dx.doi.org/10.1067/mai.2000.104547			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756237	Bronze			2022-12-18	WOS:000086604100025
J	De Wit, D; Amraoui, Z; Vincart, B; Michel, O; Michils, A; Van Overvelt, L; Willems, F; Goldman, M				De Wit, D; Amraoui, Z; Vincart, B; Michel, O; Michils, A; Van Overvelt, L; Willems, F; Goldman, M			Helper T-cell responses elicited by Der p 1-pulsed dendritic cells and recombinant IL-12 in atopic and healthy subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Der p 1; dendritic cell; IL-12; atopy; T-H2 cell	PERIPHERAL-BLOOD; AIRWAY HYPERRESPONSIVENESS; T-HELPER-2 POPULATIONS; SENSITIZED MICE; TH2; IMMUNOTHERAPY; ACTIVATION; ANTIGEN; EXPRESSION; ASTHMA	Background: Environmental allergens, such as Dermatophagoides pteronyssinus group 1 antigen (Der p 1), induce T-H2-type responses in atopic patients, whereas healthy individuals have T-H1-type responses to the same antigens, Because of their efficient synthesis of IL-12, dendritic cells (DCs) are potent inducers of T-H1-type immune responses. Objective: We sought to determine whether DCs would skew allergen-specific T-H2-type responses from atopic individuals. Methods: Purified CD4(+) T cells from healthy donors or atopic individuals were cultured in the absence or presence of recombinant (r)IL-12 with DCs derived from PBMCs and pulsed with Der p 1. Supernatants of DC-T cell cocultures were assayed by ELISA for IL-5 and IFN-gamma. Results: A T-H1-type response developed in purified CD4(+) T cells from healthy donors in response to Der p 1-pulsed DCs, as indicated by high levels of IFN-gamma in culture supernatants. In contrast, CD4(+) T cells from atopic donors displayed a T-H2-type profile characterized by high levels of IL-5 and low levels of IFN-gamma. The addition of rIL-12 (10 ng/mL) to DC-T cell cocultures resulted in the induction of IFN-gamma secretion by Der p 1-specific CD4(+) T cells from atopic patients, whereas their production of IL-5 was not inhibited. Using flow cytometry after intracytoplasmic staining, we found that IFN-gamma and IL-5 were secreted by distinct CD4(+) T-cell subpopulations. Conclusion: The cytokine profile of Der p 1-specific T-H2-like cells from atopic individuals is maintained when the allergen is presented by DCs, even in the presence of exogenous IL-12.	Free Univ Brussels, Expt Immunol Lab, Brussels, Belgium; Free Univ Brussels, Ctr Rech Interuniv Vaccinol, Brussels, Belgium; St Pierre Univ Hosp, Clin Allergol & Resp Dis, Brussels, Belgium; CUB Erasme, Chest Dept, Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles	Goldman, M (corresponding author), Hop Erasme, Dept Immunol, Route Lennik 808, B-1070 Brussels, Belgium.		michel, olivier/G-5016-2010	michel, olivier/0000-0002-1528-1277				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BELLINI A, 1993, CHEST, V103, P997, DOI 10.1378/chest.103.4.997; Bliss J, 1996, J IMMUNOL, V156, P887; Carballido JM, 1997, J IMMUNOL, V159, P4316; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lee YL, 1999, SCAND J IMMUNOL, V49, P229; Li Y, 1998, J IMMUNOL, V161, P7007; Majori M, 1997, J ALLERGY CLIN IMMUN, V100, P379, DOI 10.1016/S0091-6749(97)70252-5; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; Moriggl R, 1998, J IMMUNOL, V160, P3385; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Nakagawa S, 1998, EXP DERMATOL, V7, P112, DOI 10.1111/j.1600-0625.1998.tb00310.x; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Okano Y, 1998, INT ARCH ALLERGY IMM, V115, P83, DOI 10.1159/000023834; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Sung SSJ, 1999, SCAND J IMMUNOL, V49, P96; Till S, 1997, CLIN EXP ALLERGY, V27, P981, DOI 10.1111/j.1365-2222.1997.tb01244.x; van den Heuvel MM, 1998, J ALLERGY CLIN IMMUN, V101, P90, DOI 10.1016/S0091-6749(98)70198-8; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Vezzio N, 1996, INT IMMUNOL, V8, P1963, DOI 10.1093/intimm/8.12.1963; YSSEL H, 1994, INT IMMUNOL, V6, P1091, DOI 10.1093/intimm/6.7.1091	33	31	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				346	352		10.1016/S0091-6749(00)90086-1	http://dx.doi.org/10.1016/S0091-6749(00)90086-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669857				2022-12-18	WOS:000085402200021
J	Barry, PW; O'Callaghan, C				Barry, PW; O'Callaghan, C			An in vitro analysis of the output of budesonide from different nebulizers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nebulizers and vaporizers; budesonide; drug administration-inhalation; asthma	CYSTIC-FIBROSIS; DRUG-DELIVERY; YOUNG-CHILDREN; DEPOSITION; AEROSOLS; SYSTEM; LUNG	Background: Inhaled corticosteroids are increasingly used in the treatment of asthma, and many different nebulizers are available to aerosolize steroid medications. There are few comparative data on their ability to do so. Objective: Our purpose was to determine the particle size and mass output of budesonide nebulizer suspension from different nebulizers. Methods: In vitro measurement of drug particle size and total drug output from 3 nebulizers (the Pari LC Plus, the Prtri LC Star, and the Medicaid Ventstream) was performed under simulated breathing conditions. Nebulizers were charged with 2 mt (500 mu g) of budesonide suspension. A sinus pump a as used to draw aerosol from the nebulizers onto a filter during simulated inspiration at tidal volumes of 150 and 600 mt, mimicking pediatric and adult use. Aerosol particle size was determined separately by inertial impaction. Results: The LC Plus nebulizer had the highest initial output rate and delivered the most budesonide at both breathing patterns. The maximal output rates of the Ventstream and LC Star nebulizers was half that of the LC Plus, but the LC Star nebulizer continued nebulization for longer and delivered twice as much budesonide as the Ventstream did. However, the Ventstream produced the smallest particles, mass median diameter 3.1 mu m compared with 3.8 mu m for the LC Star and 4.1 mu m for the LC Plus. Conclusions: This study has identified differences among the nebulizers that would not have been apparent with current standards for nebulizer assessment. Incorporation of breathing simulation in the study imitates patient use and allows effective nebulization times to be predicted. The results suggest that the nebulizers studied would deliver different masses of budesonide to the lungs and to the upper airway. This may have important consequences in determining the efficacy and side effect profile of budesonide.	Univ Leicester, Leicester Royal Infirm, Dept Child Hlth, Leicester LE2 7LX, Leics, England	University of Leicester	Barry, PW (corresponding author), Univ Leicester, Leicester Royal Infirm, Dept Child Hlth, Clin Sci Bldg,POB 65, Leicester LE2 7LX, Leics, England.							AGERTOFT L, 1994, ARCH DIS CHILD, V71, P217, DOI 10.1136/adc.71.3.217; ALDERSON PO, 1974, J PEDIATR-US, V84, P479, DOI 10.1016/S0022-3476(74)80664-5; Barry PW, 1997, THORAX, V52, pS78, DOI 10.1136/thx.52.2008.S78; Barry PW, 1998, EUR RESPIR J, V12, P463, DOI 10.1183/09031936.98.12020463; BERG E, 1988, J AEROSOL SCI, V19, P1093, DOI 10.1016/0021-8502(88)90109-7; Bisgaard H, 1997, EUR RESPIR REV, V7, P376; CHUA HL, 1994, EUR RESPIR J, V7, P2185, DOI 10.1183/09031936.94.07122185; CLAY MM, 1987, J ROY SOC MED, V80, P38, DOI 10.1177/014107688708000115; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DENYER J, 1993, EUR RESPIR J, V6, P188; Devadason SG, 1997, EUR RESPIR J, V10, P2479, DOI 10.1183/09031936.97.10112479; HICKS JF, 1985, J AEROSOL SCI, V16, P521, DOI 10.1016/0021-8502(85)90004-7; Hinds WC., 1999, AEROSOL TECHNOLOGY P; Kendrick AH, 1997, THORAX, V52, pS92, DOI 10.1136/thx.52.2008.S92; KNOCH M, 1994, P RESP DRUG DEL 1994, V4, P265; MAY KR, 1966, BACTERIOL REV, V30, P559, DOI 10.1128/MMBR.30.3.559-570.1966; MUKHOPADHYAY S, 1994, RESP MED, V88, P203, DOI 10.1016/S0954-6111(05)80348-8; Newhouse MT, 1997, THORAX, V52, P585; NEWNHAM DM, 1994, THORAX, V49, P762, DOI 10.1136/thx.49.8.762; NIKANDER K, 1994, J AEROSOL MED, V7, pS19; NIKANDER K, 1996, P INT SOC AER MED FO; OCALLAGHAN C, 1989, ARCH DIS CHILD, V64, P1270, DOI 10.1136/adc.64.9.1270; OCallaghan C, 1997, THORAX, V52, pS31, DOI 10.1136/thx.52.2008.S31; ODOHERTY MJ, 1993, THORAX, V48, P220, DOI 10.1136/thx.48.3.220; Stapleton KW, 1998, J AEROSOL MED, V11, pS80; VikreJorgensen J, 1997, PEDIATR PULM, V23, P270, DOI 10.1002/(SICI)1099-0496(199704)23:4<270::AID-PPUL4>3.0.CO;2-Q	26	31	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1168	1173		10.1016/S0091-6749(99)70009-6	http://dx.doi.org/10.1016/S0091-6749(99)70009-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588997				2022-12-18	WOS:000084289200008
J	Brockow, K; Becker, EW; Worret, WI; Ring, J				Brockow, K; Becker, EW; Worret, WI; Ring, J			Late skin test reactions to radiocontrast medium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylactoid late reaction; radiocontrast media; exanthematous drug eruption	CONTRAST-MEDIA		Tech Univ Munich, Klin Dermatol & Allergol Biederstein, D-80802 Munich, Germany; Univ Tubingen, Dept Internal Med, D-7400 Tubingen, Germany	Technical University of Munich; Eberhard Karls University of Tubingen	Brockow, K (corresponding author), Tech Univ Munich, Klin Dermatol & Allergol Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				BARBAULD AM, 1997, ARCH DERMATOL, V13, P481; BERG PA, 1995, J HEPATOL, V22, P115, DOI 10.1016/0168-8278(95)80270-3; Brockow K, 1997, ALLERGOLOGIE, V20, P400; Kanzaki T, 1991, J Dermatol, V18, P528; PANTO PN, 1986, BRIT J RADIOL, V59, P41, DOI 10.1259/0007-1285-59-697-41	5	31	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1107	1108		10.1016/S0091-6749(99)70096-5	http://dx.doi.org/10.1016/S0091-6749(99)70096-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550760				2022-12-18	WOS:000083778400039
J	Metzger, WJ; Nyce, JW				Metzger, WJ; Nyce, JW			Oligonucleotide therapy of allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; oligonucleotide therapy; antisense; DNA vaccination; CpG DNA	CUTTING EDGE; CPG OLIGODEOXYNUCLEOTIDES; SUBEPITHELIAL FIBROSIS; MONOCLONAL-ANTIBODY; MAST-CELLS; IGE; DNA; ADENOSINE; INFLAMMATION; HYPERRESPONSIVENESS	The recent increase in the prevalence of and mortality from asthma has inspired several new molecular techniques to improve treatment. Because asthma is a disease of gene polymorphism, gene therapy is unlikely to be effective. Alternative methods use oligonucleotides (ODNs) in the form of (1) DNA vaccination expressing CpG motifs that mimic bacterial DNA or (2) antisense ODNs inhaled and locally deposited into pulmonary airways to specifically modulate receptors for inflammatory mediators. DNA vaccination, a form of "molecular immune surveillance," attenuates a TH2 predominance. Antisense directed against the adenosine A(1) receptor abrogates A(1) sensitivity, improves allergen-induced immediate airway obstruction, and inhibits the expected increase in histamine responsiveness in allergic rabbits. Adenosine receptor inhibition lasts for an average of 7 days and the majority of the antisense remains in the lung. ODN therapy for asthma seem unlimited, but confirmation awaits the extension from animal models to human studies.	E Carolina Univ, Sch Med, Sect Allergy Asthma & Immunol, Greenville, NC 27858 USA; EpiGenesis Pharmaceut, Dept Mol Pharmacol & Therapeut, Princeton, NJ USA	University of North Carolina; East Carolina University	Metzger, WJ (corresponding author), E Carolina Univ, Sch Med, Sect Allergy Asthma & Immunol, 4S-22 Brody, Greenville, NC 27858 USA.							Adelroth E, 1998, Can Respir J, V5 Suppl A, p18A; Ali S, 1999, AM J RESP CRIT CARE, V159, pA626; ALI S, 1994, J PHARMACOL EXP THER, V268, P1328; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Broide D, 1998, J IMMUNOL, V161, P7054; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; Coward WR, 1998, CLIN EXP ALLERGY, V28, P42; Drazen JM, 1997, PHARMACOTHERAPY, V17, pS22; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Field AK, 1998, ANTIVIR RES, V37, P67; Frew AJ, 1998, THORAX, V53, pS52, DOI 10.1136/thx.53.2008.S52; Galant SP, 1998, PEDIATR ASTHMA ALLER, V12, P241, DOI 10.1089/pai.1998.12.241; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; HAKONARSON H, 1998, AM J RESP CRIT CARE, V157, pA662; Huang SK, 1998, J ALLERGY CLIN IMMUN, V102, P887, DOI 10.1016/S0091-6749(98)70323-9; Ichino M, 1999, J IMMUNOL, V162, P3814; JAIN KK, 1998, TXB GENE THERAPY; Kim HM, 1998, IMMUNOLOGY, V93, P589; Kim JJ, 1998, VACCINE, V16, P1828, DOI 10.1016/S0264-410X(98)00177-7; Kline JN, 1998, J IMMUNOL, V160, P2555; Kovarik J, 1999, J IMMUNOL, V162, P1611; Krieg AM, 1998, BIODRUGS, V10, P341, DOI 10.2165/00063030-199810050-00001; KRIEG AM, 1995, CLIN IMMUNOTHER, V4, P169, DOI 10.1007/BF03259283; LINDEN J, 1994, TRENDS PHARMACOL SCI, V15, P298, DOI 10.1016/0165-6147(94)90011-6; Matveeva O, 1998, NAT BIOTECHNOL, V16, P1374, DOI 10.1038/4362; McCluskie MJ, 1998, J IMMUNOL, V161, P4463; METZGER WJ, 1985, CHEST, V87, pS155, DOI 10.1378/chest.87.5_Supplement.155S; METZGER WJ, 1995, SPRINGER SEMIN IMMUN, V16, P467; Metzger WJ, 1998, ASTHMA AND ALLERGIC DISEASES, P375, DOI 10.1016/B978-012473340-4/50031-X; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; NYCE J, 1999, TRENDS PHARMACOL SCI, V37, P67; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; O'Connor BJ, 1999, TRENDS PHARMACOL SCI, V20, P9, DOI 10.1016/S0165-6147(98)01280-2; Polosa R, 1997, THORAX, V52, P494; ROCHE WR, 1989, LANCET, V1, P520; ROMAGNANI S, 1998, ACI INT, V10, P158; ROSENSTREICH D, 1999, ENGL J MED, V36, P1356; Schramm G, 1999, J IMMUNOL, V162, P2406; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Spiegelberg HL, 1998, ALLERGY, V53, P93, DOI 10.1111/j.1398-9995.1998.tb04948.x; SPINA D, 1994, DRUGS LUNG, P1; Stepkowski SM, 1998, TRANSPLANT P, V30, P2142, DOI 10.1016/S0041-1345(98)00567-3; Sur S, 1999, J IMMUNOL, V162, P6284; Turner MO, 1998, AM J RESP CRIT CARE, V157, P1804, DOI 10.1164/ajrccm.157.6.9708092; VILLAR MTA, 1995, AM J RESP CRIT CARE, V151, P656, DOI 10.1164/ajrccm/151.3_Pt_1.656; Vogel G, 1997, SCIENCE, V276, P1643, DOI 10.1126/science.276.5319.1643; Yi AK, 1998, J IMMUNOL, V161, P4493; Zeiler T, 1997, J ALLERGY CLIN IMMUN, V100, P721, DOI 10.1016/S0091-6749(97)70264-1	58	31	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				260	266		10.1016/S0091-6749(99)70361-1	http://dx.doi.org/10.1016/S0091-6749(99)70361-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452739				2022-12-18	WOS:000082364800008
J	Senechal, H; Geny, S; Desvaux, FX; Busson, M; Mayer, C; Aron, Y; Oster, JP; Bessot, JC; Peltre, G; Pauli, G; Swierczewski, E				Senechal, H; Geny, S; Desvaux, FX; Busson, M; Mayer, C; Aron, Y; Oster, JP; Bessot, JC; Peltre, G; Pauli, G; Swierczewski, E			Genetics and specific immune response in allergy to birch pollen and food: Evidence of a strong, positive association between atopy and the HLA class II allele HLA-DR7	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; birch pollen; food; specific immune responses; HLA class II genes	RECOMBINANT ALLERGENS; RAGWEED POLLEN; OLIVE POLLEN; IGE; ANTIBODIES; PROFILIN; LINKAGE; FAMILY; GEL; RA5	Background: In some geographic areas birch pollen represents the most prominent cause for airborne allergic diseases. Up to 70% of patients allergic to birch pollen are hypersensitive to fruits, especially apples. Associations have been found, in some instances, with a sensitivity to aeroallergens and HLA class II genes. Objectives: We investigated whether susceptibility or resistance to birch pollen allergy with and without food allergy was associated with HLA class II genes. Methods: Blood samples were obtained from 2 groups of unrelated European-born white adults: 42 atopic patients (31 of them with asthma) and 42 healthy control subjects with no personal or familial history of asthma or atopy. Their antibody responses to birch pollen, apples, grass, and weed pollens were evaluated by skin tests, RASTs, and immunoprints. Genomic DNA was extracted from PBLs. The exons of DQA1, DQB1, DRB1, and DPB1 genes were selectively amplified by using the PCR method. Genotyping was carried out by digestion of the amplified DNA products with allele-specific endonucleases (PCR-RFLP), which recognize allelic variations in the polymorphic exon. Results: We found no significant differences in the frequency of DPB1 alleles between patients and control subjects. HLA class II DR4 and/or DR7 alleles were present in 42.6% of the patients and in only 2.4% of the healthy subjects. These results confirm a previous study of a group of polysensitized atopic patients, which showed that DR4 and DR7 alleles were rare in healthy control subjects and frequently observed in atopic subjects with or without concomitant asthma. Conclusion: We conclude that the allele HLA-DR7 is significantly involved in the presentation of apple and pollen allergens. However, we suggest that this susceptibility is more related to atop, than to specific responses to allergens.	Inst Pasteur, Unite Immunoallergie, F-75015 Paris, France; Hop Civil, Dept Pneumol, Strasbourg, France; Hop St Louis, Lab Immunogenet Humaine, INSERM, U396, Paris, France; Univ Paris 05, Physiol Resp Lab, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Senechal, H (corresponding author), Inst Pasteur, Unite Immunoallergie, 28 Rue Dr Roux, F-75015 Paris, France.							ANSARI AA, 1989, HUM IMMUNOL, V25, P59, DOI 10.1016/0198-8859(89)90070-0; ARN Y, 1996, CLIN EXP ALLERGY, V2, P821; ARON Y, 1994, ALLERGY, V49, P788, DOI 10.1111/j.1398-9995.1994.tb02105.x; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; BATARD T, 1993, INT ARCH ALLERGY IMM, V100, P68, DOI 10.1159/000236390; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; BUSSON M, 1986, PATHOL BIOL, V34, P711; Cardaba B, 1996, CLIN EXP ALLERGY, V26, P316, DOI 10.1111/j.1365-2222.1996.tb00097.x; CHARRON D, 1990, ADV IMMUNOL, V48, P105; COLOMBANI J, 1993, FONCTIONS IMMUNITAIR; CORRIGAN CJ, 1992, CLIN EXP ALLERGY, V22, P869, DOI 10.1111/j.1365-2222.1992.tb02834.x; DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; DESVAUX FX, 1990, ELECTROPHORESIS, V11, P37, DOI 10.1002/elps.1150110109; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; FISCHER GF, 1992, HUM IMMUNOL, V33, P259, DOI 10.1016/0198-8859(92)90333-I; GORG A, 1980, J BIOCHEM BIOPH METH, V3, P273, DOI 10.1016/0165-022X(80)90008-1; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; LYMPANY P, 1992, CLIN EXP ALLERGY, V22, P1085, DOI 10.1111/j.1365-2222.1992.tb00134.x; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; PELTRE G, 1982, IMMUNOL LETT, V5, P127, DOI 10.1016/0165-2478(82)90096-7; ROEBBER M, 1985, J IMMUNOL, V134, P3062; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x	27	31	36	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				395	401		10.1016/S0091-6749(99)70384-2	http://dx.doi.org/10.1016/S0091-6749(99)70384-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452762				2022-12-18	WOS:000082364800033
J	Raphael, GD; Lanier, RQ; Baker, J; Edwards, L; Rickard, K; Lincourt, WR				Raphael, GD; Lanier, RQ; Baker, J; Edwards, L; Rickard, K; Lincourt, WR			A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	54th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-18, 1998	WASHINGTON, D.C.	Amer Acad Allergy Asthma & Immunol		fluticasone propionate; beclomethasone dipropionate; asthma; comparative efficacy; inhaled corticosteroid	TRIAMCINOLONE ACETONIDE; INHALED CORTICOSTEROIDS; MODERATE ASTHMA; ADRENAL SUPPRESSION; HEALTHY-VOLUNTEERS; SYSTEMIC ACTIVITY; BRONCHIAL HYPERRESPONSIVENESS; EFFICACY; BUDESONIDE; POWDER	Background: Inhaled corticosteroids are recommended for the treatment of persistent asthma. Comparative clinical studies evaluating 2 or more doses of these agents are few. Objective: We sought to compare the efficacy and safety of 2 doses of fluticasone propionate (88 mu g twice daily and 220 mu g twice daily) with 2 doses of beclomethasone dipropionate (168 mu g twice daily and 336 mu g twice daily) in subjects with persistent asthma, Methods: Three hundred ninety-nine subjects participated in this randomized, double-blind, parallel-group clinical trial. Eligible subjects were using daily inhaled corticosteroids and had an FEV1 of 45% to 80% of predicted value. Clinic visits, including spirometry; were conducted every 1 to 2 weeks. Subjects recorded symptoms, use of albuterol, and peak expiratory Bows on daily diary cards. Results: Fluticasone propionate treatment resulted in significantly (P less than or equal to .034) greater improvements in objective pulmonary function parameters than did beclomethasone dipropionate; treatment and significantly greater reductions in daily albuterol use (P less than or equal to .010) and asthma symptoms (P less than or equal to .027). Both low-dose (88 mu g twice daily) and medium-dose (220 mu g twice daily) fluticasone propionate significantly increased FEV1 compared with higher doses of beclomethasone dipropionate (P = .006), Low-dose and medium-dose fluticasone propionate improved FEV1 by 0.31 L (14%) and 0.36 L (15%), respectively, compared with improvements of 0.18 L (8%) and 0.21 L (9%) with low-dose and medium-dose beclomethasone dipropionate. The adverse event profiles were similar for both medications. Conclusion: Fluticasone propionate provides greater asthma control at roughly half the dose of beclomethasone dipropignate, with a comparable adverse event profile.	Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; SW Med Sch, Dept Family Med, Dallas, TX USA; Allergy Associates Res Ctr, Portland, OR USA	GlaxoSmithKline; University of Texas System; University of Texas Southwestern Medical Center Dallas	Lincourt, WR (corresponding author), Glaxo Wellcome Inc, POB 13398, Res Triangle Pk, NC 27709 USA.			Edwards, Lisa/0000-0002-4867-2151				[Anonymous], 1997, NIH PUBLICATION; BARNES NC, 1993, EUR RESPIR J, V6, P877; Barnes NC, 1998, RESP MED, V92, P95, DOI 10.1016/S0954-6111(98)90039-7; BOE J, 1994, EUR RESPIR J, V7, P2179, DOI 10.1183/09031936.94.07122179; Bootsma GP, 1996, AM J RESP CRIT CARE, V153, P924, DOI 10.1164/ajrccm.153.3.8630574; BOOTSMA GP, 1995, THORAX, V50, P1044, DOI 10.1136/thx.50.10.1044; Bronsky E, 1998, ANN ALLERG ASTHMA IM, V80, P295, DOI 10.1016/S1081-1206(10)62972-9; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Clark DJ, 1997, THORAX, V52, P55, DOI 10.1136/thx.52.1.55; Cochran W, 1950, EXPT DESIGNS; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; Derendorf H, 1998, J ALLERGY CLIN IMMUN, V101, pS440, DOI 10.1016/S0091-6749(98)70156-3; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; GRAHNEN A, 1994, BRIT J CLIN PHARMACO, V38, P521, DOI 10.1111/j.1365-2125.1994.tb04393.x; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Gross GN, 1998, AM J MANAG CARE, V4, P233; GROVE A, 1994, BRIT J CLIN PHARMACO, V38, P527, DOI 10.1111/j.1365-2125.1994.tb04394.x; GUSTAFSSON P, 1993, ARCH DIS CHILD, V69, P206, DOI 10.1136/adc.69.2.206; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Johnson M, 1998, J ALLERGY CLIN IMMUN, V101, pS434, DOI 10.1016/S0091-6749(98)70155-1; KAMADA AK, 1994, ANN PHARMACOTHER, V28, P904, DOI 10.1177/106002809402800716; Kamada AK, 1997, J ALLERGY CLIN IMMUN, V99, P735, DOI 10.1016/S0091-6749(97)80004-8; Lawrence M, 1997, AM J RESP CRIT CARE, V156, P744, DOI 10.1164/ajrccm.156.3.9608058; LEBLANC P, 1994, ALLERGY, V49, P284; Lonnebo A, 1996, EUR J CLIN PHARMACOL, V49, P459; Lorentzen KA, 1996, RESP MED, V90, P609, DOI 10.1016/S0954-6111(96)90019-0; LUNDBACK B, 1993, RESP MED, V87, P609, DOI 10.1016/S0954-6111(05)80264-1; MCCUBBIN MM, 1995, CLIN PHARMACOL THER, V57, P455, DOI 10.1016/0009-9236(95)90216-3; *NAT ASTHM ED PROG, 1991, NIH PUBL; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Noonan MJ, 1998, J ASTHMA, V35, P153, DOI 10.3109/02770909809068203; Pauwels RA, 1998, AM J RESP CRIT CARE, V157, P827, DOI 10.1164/ajrccm.157.3.9610009; Pearlman DS, 1997, ANN ALLERG ASTHMA IM, V78, P356, DOI 10.1016/S1081-1206(10)63196-1; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; VANESSENZANDVLI.EF, 1992, AM REV RESPIR DIS, V146, P546; Wilson AM, 1997, EUR J CLIN PHARMACOL, V53, P33, DOI 10.1007/s002280050333; Wilson AM, 1997, AM J RESP CRIT CARE, V156, P1274, DOI 10.1164/ajrccm.156.4.97-03029; Wolfe JD, 1996, CLIN THER, V18, P635, DOI 10.1016/S0149-2918(96)80214-1; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; 1997, PHYSICIANS DESK REFE	43	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				796	803		10.1016/S0091-6749(99)70422-7	http://dx.doi.org/10.1016/S0091-6749(99)70422-7			8	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329812	Bronze			2022-12-18	WOS:000080470200013
J	Li, JTC; Goldstein, MF; Gross, GN; Noonan, MJ; Weisberg, S; Edwards, L; Reed, KD				Li, JTC; Goldstein, MF; Gross, GN; Noonan, MJ; Weisberg, S; Edwards, L; Reed, KD			Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fluticasone propionate; triamcinolone acetonide; hypothalamic-pituitary-adrenal axis; inhaled corticosteroids; asthma	INHALED CORTICOSTEROID-THERAPY; HEALTHY-VOLUNTEERS; SUPPRESSION; BUDESONIDE; GLUCOCORTICOIDS; ASTHMATICS; SINGLE	Background: Many clinicians are reluctant to prescribe inhaled corticosteroids because of concerns over potential effects on the hypothalamic-pituitary-adrenal axis. Objective: The purpose of this study was to compare the adrenal responses to 6-hour cosyntropin infusion after treatment with fluticasone propionate aerosol, triamcinolone acetonide aerosol, prednisone, and placebo for 4 weeks, a sufficient time interval to assess any effects on the adrenal response to stress. Methods: This double-blind, triple-dummy, randomized, placebo-controlled study was conducted in 128 patients to evaluate adrenal response to 6-hour cosyntropin infusion (a clinically relevant method for evaluating adrenal function) after 28 days of treatment with fluticasone propionate aerosol 88 mu g or 220 mu g twice daily, triamcinolone acetonide aerosol 200 mu g 4 times daily or 400 mu g twice daily, prednisone 10 mg once daily, and placebo. Results: After 28 days of treatment, mean plasma cortisol response to cosyntropin over 12 hours after initiation of the 6-hour infusion was similar among fluticasone, triamcinolone, and placebo groups; cortisol response was significantly (P < .05) reduced after treatment with prednisone compared with the other treatment groups. Mean I-hour area under the plasma cortisol concentration-time curves and peak plasma cortisol concentrations were significantly (P less than or equal to.003) lower with prednisone than any other treatment; no significant differences were noted between placebo and either of the fluticasone groups in any assessment. Mean reductions From baseline in area under the plasma cortisol concentration time curves and peak cortisol concentrations mere significantly (P <.05) greater with triamcinolone 400 pg twice daily compared with placebo. Conclusion: These results suggest that fluticasone propionate at therapeutic doses has effects on the hypothalamic-pituitary-adrenal axis comparable to that of placebo and has significantly less effect than prednisone as measured hy 6-hour cosyntropin infusion after 28 days of treatment.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Larchmont Med Ctr 2, Mt Laurel, NJ USA; Dallas Allergy & Asthma Ctr, Dallas, TX USA; Allergy Associates, Res Ctr, Portland, OR USA; Criter Grp, Minneapolis, MN USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	Mayo Clinic; GlaxoSmithKline	Li, JTC (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.			Edwards, Lisa/0000-0002-4867-2151				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Boorsma M, 1996, EUR RESPIR J, V9, P1427, DOI 10.1183/09031936.96.09071427; BROWN PH, 1991, RESP MED, V85, P501, DOI 10.1016/S0954-6111(06)80268-4; Clark DJ, 1996, THORAX, V51, P262, DOI 10.1136/thx.51.3.262; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; CORREN J, 1996, CHEST, V110, pS83; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DROSZCZ W, 1980, ANN ALLERGY, V44, P174; FORD LB, 1997, AM J RESP CRIT CARE, V155, pA354; GARDNER RM, 1988, ANN INTERN MED, V108, P217, DOI 10.7326/0003-4819-108-2-217; GRAHNEN A, 1994, BRIT J CLIN PHARMACO, V38, P521, DOI 10.1111/j.1365-2125.1994.tb04393.x; Gross GN, 1998, AM J MANAG CARE, V4, P233; HOLLMAN GA, 1988, PEDIATRICS, V81, P452; HOLT PR, 1990, CLIN EXP ALLERGY, V20, P145, DOI 10.1111/j.1365-2222.1990.tb02659.x; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; Kamada AK, 1997, J ALLERGY CLIN IMMUN, V99, P735, DOI 10.1016/S0091-6749(97)80004-8; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; Kellerman D., 1996, European Respiratory Journal Supplement, V9, p162S; LEMANSKE RF, 1993, ALLERGY PRINCIPLES P, P1; Lipworth BJ, 1996, LANCET, V348, P820, DOI 10.1016/S0140-6736(05)65234-8; Lonnebo A, 1996, EUR J CLIN PHARMACOL, V49, P459; *NIH, 1997, NIH PUBL; Storms W., 1997, Journal of Allergy and Clinical Immunology, V99, pS318; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P321; Wilson AM, 1997, AM J RESP CRIT CARE, V156, P1274, DOI 10.1164/ajrccm.156.4.97-03029; ZWAAN CM, 1992, LANCET, V340, P1289, DOI 10.1016/0140-6736(92)92991-N	29	31	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					622	629		10.1016/S0091-6749(99)70234-4	http://dx.doi.org/10.1016/S0091-6749(99)70234-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200011				2022-12-18	WOS:000079723900015
J	De Lucca, S; Sporik, R; O'Meara, T; Tovey, ER				De Lucca, S; Sporik, R; O'Meara, T; Tovey, ER			Mite allergen (Der p 1) is not only carried on mite feces	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DUST MITE; ASTHMA		Univ Sydney, Inst Resp Med, Sydney, NSW 2006, Australia	University of Sydney	Tovey, ER (corresponding author), Univ Sydney, Inst Resp Med, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				FERGUSON P, 1995, AM J RESP CRIT CARE, V151, P71, DOI 10.1164/ajrccm.151.1.7812575; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; TOVEY ER, 1990, J MED ENTOMOL, V27, P368, DOI 10.1093/jmedent/27.3.368; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0	5	31	32	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				174	175		10.1016/S0091-6749(99)70543-9	http://dx.doi.org/10.1016/S0091-6749(99)70543-9			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893203	Bronze			2022-12-18	WOS:000078112300027
J	Otsuka, H; Kusumi, T; Kanai, S; Koyama, M; Kuno, Y; Takizawa, R				Otsuka, H; Kusumi, T; Kanai, S; Koyama, M; Kuno, Y; Takizawa, R			Stem cell factor mRNA expression and production in human nasal epithelial cells: Contribution to the accumulation of mast cells in the nasal epithelium of allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						stem cell factor; allergic rhinitis; epithelial cell; mast cell; cyclosporin A; steroid	C-KIT LIGAND; BLOOD MONONUCLEAR-CELLS; FETAL LIVER-CELLS; RECOMBINANT HUMAN; GROWTH-FACTOR; MEDIATOR RELEASE; CUTANEOUS MASTOCYTOSIS; METACHROMATIC CELLS; IN-VIVO; ACTIVATION	Background: In allergic rhinitis, mast cells are increased in number in the epithelium of the nasal mucosa and play an important role in the immediate response. However, the mechanism of the accumulation is not known. Objective: The purpose of this study was to determine whether the nasal epithelial tells produce stem cell factor (SCF), the mast cell growth and chemoattractant factor, and contribute mast cell hyperplasia in the epithelium of allergic rhinitis. Methods: We have characterized the cellular localization of SCF using immunohistochemistry, reverse transcribed-PCR, and ELISA; compared SCF production of cultured epithelial cells between patients with allergic rhinitis and nonallergic subjects; and compared the SCF production with the number of mast cells and the histamine content in the nasal epithelial scrapings. Results: Immunohistochemically, SCF was identified in the nasal epithelium of the biopsy specimens and in cultured nasal epithelial cells, SCF mRNA was expressed by cultured nasal epithelial cells not only in patients with allergy but also in subjects with no allergy. However, the SCF/beta-actin mRNA ratio and SCF production in day 7 cultured epithelial cells was significantly higher in allergic than in nonallergic subjects (P = .0124, P = .0085, respectively). SCF production from nasal scrapings in culture was strongly correlated with the number of mast cells (r = 0.506, P = .0023) and the histamine content (r = 0.180, P = .0040). Conclusions: These findings demonstrate that nasal epithelial cells produce SCF and mag be important in the attraction, proliferation, and activation of mast cells in allergic inflammation in the nose.	Dai 2 Hosp, Nippon Med Sch, Dept Otorhinolaryngol, Allergy & Immunol Lab,Nakahara Ku, Kawasaki, Kanagawa 211, Japan; Toray Res Ctr Ltd, Kanagawa, Japan	Nippon Medical School; Toray Research Center, Inc.	Otsuka, H (corresponding author), Dai 2 Hosp, Nippon Med Sch, Dept Otorhinolaryngol, Allergy & Immunol Lab,Nakahara Ku, 1-396 Kosugi Cho, Kawasaki, Kanagawa 211, Japan.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; Bischoff SC, 1997, J IMMUNOL, V159, P5560; Calderon MA, 1997, J ALLERGY CLIN IMMUN, V99, P65, DOI 10.1016/S0091-6749(97)70302-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLUMBO M, 1992, J IMMUNOL, V149, P599; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80, DOI 10.1164/ajrccm/148.1.80; HAMANN K, 1995, BRIT J DERMATOL, V133, P203, DOI 10.1111/j.1365-2133.1995.tb02616.x; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AA, 1995, IMMUNOLOGY, V84, P72; IRANI AMA, 1992, BLOOD, V80, P3009; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; KAGEYAMA Y, 1994, EUR J IMMUNOL, V24, P1122, DOI 10.1002/eji.1830240517; Kawabori Shinichi, 1993, Japanese Journal of Allergology, V42, P894; KENNEY JS, 1994, J ALLERGY CLIN IMMUN, V93, P1060, DOI 10.1016/S0091-6749(94)70055-9; Kim YK, 1997, J ALLERGY CLIN IMMUN, V100, P389, DOI 10.1016/S0091-6749(97)70254-9; LEE LA, 1995, J CLIN INVEST, V95, P900, DOI 10.1172/JCI117741; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; NILSSON G, 1994, J IMMUNOL, V153, P3717; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; OKUDA M, 1983, ANN ALLERGY, V50, P116; OKUDA M, 1985, ANN ALLERGY, V54, P69; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; OTSUKA H, 1995, J ALLERGY CLIN IMMUN, V96, P528, DOI 10.1016/S0091-6749(95)70297-0; OTSUKA H, 1995, J JPN IMMUNOL ALLERG, V13, P33; PESCI A, 1993, AM REV RESPIR DIS, V147, P684, DOI 10.1164/ajrccm/147.3.684; RUITENBERG EJ, 1982, INT ARCH ALLER A IMM, V67, P233, DOI 10.1159/000233024; Saito H, 1996, J IMMUNOL, V157, P343; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SPERR WR, 1993, INT ARCH ALLERGY IMM, V102, P170, DOI 10.1159/000236568; STELLATO C, 1995, J IMMUNOL, V155, P410; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; SZEBO KM, 1990, CELL, V63, P213; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; UNDEM BJ, 1994, AM J RESP CELL MOL, V11, P646, DOI 10.1165/ajrcmb.11.6.7524570; VALENT P, 1992, BLOOD, V80, P2237; Wen LP, 1996, BBA-MOL CELL RES, V1314, P183, DOI 10.1016/S0167-4889(96)00138-3; YAMATODANI A, 1985, J CHROMATOGR, V344, P115, DOI 10.1016/S0378-4347(00)82012-5; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	48	31	31	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					757	764		10.1016/S0091-6749(98)70015-6	http://dx.doi.org/10.1016/S0091-6749(98)70015-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819292				2022-12-18	WOS:000077033400009
J	Hizawa, N; Collins, G; Rafnar, T; Huang, SK; Duffy, DL; Weber, JL; Freidhoff, LR; Ehrlich, E; Marsh, DG; Beaty, TH; Barnes, KC				Hizawa, N; Collins, G; Rafnar, T; Huang, SK; Duffy, DL; Weber, JL; Freidhoff, LR; Ehrlich, E; Marsh, DG; Beaty, TH; Barnes, KC		Collaborative Study Genetics Asthma	Linkage analysis of Dermatophagoides pteronyssinus-specific IgE responsiveness with polymorphic markers on chromosome 6p21 (HLA-D region) in Caucasian families by the transmission/disequilibrium test	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IMMUNOGLOBULIN-E RESPONSES; HUMAN IMMUNE-RESPONSE; P-I; ASTHMA; ALLERGEN; ANTIGEN; ASSOCIATION; ACTIVATION; GENOTYPES; GENETICS	Background: Recently, we have obtained evidence for linkage between Der p 1-specific IgE antibodies and markers on chromosome 6p21 (HLA-D region) in a genome-wide screening in Caucasian families recruited as a part of the Collaborative Study on the Genetics of Asthma (CSGA). Objective: Specific IgE antibodies toward different Dermatophagoides pteronyssinus (Der p) polypeptides were detected by immunoblotting analysis, and the transmission/disequilibrium test (TDT) was performed between specific IgE responsiveness toward each different Der p polypeptide and markers on chromosome 6p21 to better clarify the genetic contribution of HLA-D genes. Methods: We studied 299 individuals in 45 Caucasian families participating in the CSGA. Serum samples from 137 individuals that showed elevated specific IgE antibodies toward the Der p crude allergen (> -0.5 log IU/mL) by ACCESS immunoassay were subjected to immunoblotting analysis. TDT was conducted between the presence of specific IgE antibodies toward each of It different Der p polypeptides and 4 polymorphic markers on chromosome 6p21. Results: The 196-bp allele of D6S1281 and the 104-bp allele of DQCAR showed significant excess transmission to specific IgE responders toward a particular Der p polypeptide (120 kd, 55 kd, 45 kd, or 37 kd), In contrast, the 200-bp allele of D6S1281 and the 204-bp allele of D6S291 showed significantly decreased transmission to specific IgE responders toward a particular Der p polypeptide (120 kd, 90 kd, 52 kd, or 45 kd). Deviation from the expected 50% transmission in heterozygous parents was statistically significant after correcting for multiple comparisons. Conclusion: This study supported our previous findings that genes on chromosome 6p21 (HLA-D region) may influence the expression of Der p-specific IgE responsiveness in this Caucasian population. Our results, however, reveal the complexity of genetic regulations of Der p-specific IgE responsiveness by HLA-D genes, suggesting the strong influence of non-HLA loci and perhaps environmental factors for the development of Der p-specific IgE responsiveness.	Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA; NIA, Immunol Lab, NIH, Baltimore, MD 21224 USA; Iceland Canc Soc, Reykjavik, Iceland; Johns Hopkins Sch Hyg, Dept Epidemiol, Baltimore, MD USA; Queensland Inst Med Res, Epidemiol & Pollut Hlth Unit, Brisbane, Qld 4006, Australia; NHLBI, Bethesda, MD 20892 USA; Marshfield Med Res Fdn, Marshfield, WI 54449 USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; QIMR Berghofer Medical Research Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Huang, SK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Duffy, David L/B-7392-2013; Huang, Shau-Ku/F-5509-2010	Duffy, David L/0000-0001-7227-632X; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020059] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/AI49612] Funding Source: Medline; NIAID NIH HHS [AI20059] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Bennett ST, 1997, NAT GENET, V17, P350, DOI 10.1038/ng1197-350; BLAND M, 1995, INTRO MED STAT MULTI; BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; CARABALLO LR, 1990, TISSUE ANTIGENS, V35, P182, DOI 10.1111/j.1399-0039.1990.tb01777.x; CARDABA B, 1993, HUM IMMUNOL, V38, P293, DOI 10.1016/0198-8859(93)90557-H; Duffy DL, 1997, AM J HUM GENET, V61, pA197; FISCHER GF, 1992, HUM IMMUNOL, V25, P59; FREIDHOFF LR, 1988, TISSUE ANTIGENS, V31, P211, DOI 10.1111/j.1399-0039.1988.tb02083.x; HIRAYAMA K, 1987, NATURE, V327, P426, DOI 10.1038/327426a0; HIZAWA N, 1998, J ALLERGY CLIN IMMUN, V102, P435; Holloway JW, 1996, CLIN EXP ALLERGY, V26, P1142, DOI 10.1111/j.1365-2222.1996.tb00500.x; Ismail A, 1997, J ALLERGY CLIN IMMUN, V99, P216, DOI 10.1016/S0091-6749(97)70099-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Moffatt MF, 1997, IMMUNOGENETICS, V46, P226, DOI 10.1007/s002510050266; MURRAY JS, 1989, J EXP MED, V170, P2135, DOI 10.1084/jem.170.6.2135; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schountz T, 1996, J IMMUNOL, V157, P3893; SHIBASAKI M, 1994, INT ARCH ALLERGY IMM, V103, P53, DOI 10.1159/000236605; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; *WHO INT UN IMM SO, 1997, ALL NOM SUBC; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x; YSSEL H, 1992, J IMMUNOL, V148, P738	28	31	33	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					443	448		10.1016/S0091-6749(98)70133-2	http://dx.doi.org/10.1016/S0091-6749(98)70133-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768586				2022-12-18	WOS:000076212800018
J	Tang, CB; Rolland, JM; Ward, C; Thien, F; Li, X; Gollant, S; Walters, EH				Tang, CB; Rolland, JM; Ward, C; Thien, F; Li, X; Gollant, S; Walters, EH			Differential regulation of allergen-specific T-H2- but not T-H1-type responses by alveolar macrophages in atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TH1; TH2; alveolar macrophage; CD4+ T cell; asthma	T-CELL ACTIVATION; TUMOR-NECROSIS-FACTOR; CD4+ LYMPHOCYTES-T; BRONCHOALVEOLAR LAVAGE; PERIPHERAL-BLOOD; IL-5 PRODUCTION; CLONE D10.G4.1; SECRETION; INTERLEUKIN-6; EOSINOPHILIA	Background and Objective: Previous studies have suggested that quantitative differences in T-H2-type cytokine responses in the airways are of particular importance in the pathogenesis of asthma, In this study we investigated whether alveolar macrophages (AMs) and peripheral blood monocytes (PMNs) are able to significantly influence the profiles of allergen-induced T-H1 (IFN-gamma) and T-H2 (IL-4 and IL-5) cytokine production by CD4+ T cells in atopic asthmatic subjects versus atopic nonasthmatic subjects and nonatopic normal subjects. Methods: Peripheral blood CD4+ T cells were cultured alone or cocultured with either PMNs or AMs with allergen stimulation in the 3 groups. Results: Although allergen stimulation did not change TH1 or T-H2 cytokine responses in cultures of CD4+ T cells alone, the addition of PMNs to the cultures induced a significant increase in production of IL-4, IL-5, and IFN-gamma (P <.01 or P <.001) in atopic asthmatic subjects and atopic nonasthmatic subjects. However, PMNs induced a significant increase for IFN-gamma (P < .05) only in normal subjects. AMs from atopic asthmatic subjects significantly enhanced production of all 3 cytokines (P < .01 or P <.001), whereas the AMs from atopic nonasthmatic subjects significantly increased only production of IL-4 (P < .01) and IFN-gamma (P <.05) but not IL-5. Furthermore, IL-4 (P = .066) and IL-5 (P <.01) production in allergen-stimulated AM- CD4+ cell cocultures was higher in atopic asthmatic subjects but significantly lower in atopic nonasthmatic subjects (P < .05) as compared with the PMN-cocultures. For IFN-gamma, no difference was found between the AM and PMN cocultures in either atopic group. Allergen-stimulated IL-5 production in coculture with both AMs and PMNs inversely correlated with both baseline FEV1 percent predicted and PD20 methacholine in atopic asthmatic subjects (P <.05, P <.01, or P <.001). Conclusion: These data suggest that AMs from atopic asthmatic subjects but not atopic nonasthmatic subjects, play a significant role in airway pathogenic immunity through enhancing T-H2-type cytokine production.	Alfred Hosp, Dept Resp Med, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Allergy & Clin Immunol, Melbourne, Vic 3181, Australia; Monash Univ, Sch Med, Dept Med, Melbourne, Vic 3004, Australia; Monash Univ, Sch Med, Dept Pathol & Immunol, Melbourne, Vic 3004, Australia	Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University	Walters, EH (corresponding author), Alfred Hosp, Dept Resp Med, Melbourne, Vic 3181, Australia.		WALTERS, Eugene/AAL-2264-2021; Rolland, Jennifer/E-7543-2011; Ward, Christopher/B-8175-2013	Ward, Christopher/0000-0002-6954-9611; Thien, Francis/0000-0003-0925-6566				[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; AUBAS P, 1984, AM REV RESPIR DIS, V130, P875; BEACH JR, 1993, THORAX, V48, P239, DOI 10.1136/thx.48.3.239; Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1111/j.1365-2222.1996.tb00607.x; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; CORRIGAN CJ, 1995, CLIN EXP ALLERGY, V25, P485, DOI 10.1111/j.1365-2222.1995.tb01084.x; CORRIGAN CJ, 1995, AM J RESP CELL MOL, V12, P567, DOI 10.1165/ajrcmb.12.5.7742019; DAMLE NK, 1992, J IMMUNOL, V148, P1985; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; GANT V, 1992, AM REV RESPIR DIS, V146, P900, DOI 10.1164/ajrccm/146.4.900; GOLDSTEIN RA, 1985, AM REV RESPIR DIS, V132, P180; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; Hilkens CMU, 1996, EUR RESPIR J, V9, pS90; Hilkens CMU, 1996, J IMMUNOL, V156, P1722; Holt PG, 1996, EUR RESPIR J, V9, pS85; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; KALINSKI P, 1995, J IMMUNOL, V154, P3753; Kremer IB, 1996, J IMMUNOL, V157, P1913; Lee NA, 1997, AM J RESP CELL MOL, V16, P497, DOI 10.1165/ajrcmb.16.5.9160831; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; NAORA H, 1995, EXP HEMATOL, V23, P597; NAORA H, 1994, J IMMUNOL, V152, P5691; PARRONCHI P, 1992, EUR J IMMUNOL, V22, P1615, DOI 10.1002/eji.1830220640; POULTER LW, 1994, IMMUNOL TODAY, V15, P258, DOI 10.1016/0167-5699(94)90004-3; RICCI M, 1993, CLIN EXP ALLERGY, V23, P360, DOI 10.1111/j.1365-2222.1993.tb00340.x; RICH EA, 1991, AM J RESP CELL MOL, V4, P287, DOI 10.1165/ajrcmb/4.3.287; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHAUBLE TL, 1993, AM J RESP CELL MOL, V8, P89, DOI 10.1165/ajrcmb/8.1.89; Tang C, 1997, EUR RESPIR J, V10, P624; Tang C, 1997, Respirology, V2, P45, DOI 10.1111/j.1440-1843.1997.tb00053.x; TANG C, IN PRESS AM J RESP C; Tang CB, 1996, AM J RESP CRIT CARE, V154, P1615, DOI 10.1164/ajrccm.154.6.8970344; UMESTSU DT, 1997, J ALLERGY CLIN IMMUN, V100, P1; VINK A, 1990, EUR J IMMUNOL, V20, P1, DOI 10.1002/eji.1830200102; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	41	31	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					368	375		10.1016/S0091-6749(98)70122-8	http://dx.doi.org/10.1016/S0091-6749(98)70122-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768575				2022-12-18	WOS:000076212800006
J	Stiehm, ER; Casillas, AM; Finkelstein, JZ; Gallagher, KT; Groncy, PM; Kobayashi, RH; Oleske, JM; Roberts, RL; Sandberg, ET; Wakim, ME				Stiehm, ER; Casillas, AM; Finkelstein, JZ; Gallagher, KT; Groncy, PM; Kobayashi, RH; Oleske, JM; Roberts, RL; Sandberg, ET; Wakim, ME			Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: Use of an old method with a new product	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intravenous immunoglobulin; subcutaneous intravenous immunoglobulin; clysis; immunodeficiency; antibody deficiency	GAMMA-GLOBULIN; INFUSIONS		Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; Allergy Asthma & Immunol Associates, Omaha, NE USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, Newark, NJ 07103 USA; Jonathon Jacques Canc Ctr, Long Beach, CA USA; Kelsey Seybold Clin, Houston, TX USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Rutgers State University New Brunswick; Rutgers State University Medical Center	Stiehm, ER (corresponding author), Univ Calif Los Angeles, Childrens Hosp, 22-387 MDCC,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Oleske, James M/C-1951-2016	Oleske, James M/0000-0003-2305-5605				Abrahamsen TG, 1996, PEDIATRICS, V98, P1127; BERGER M, 1982, JAMA-J AM MED ASSOC, V247, P2824, DOI 10.1001/jama.247.20.2824; GARDULF A, 1993, CLIN EXP IMMUNOL, V92, P200; GARDULF A, 1991, LANCET, V338, P162; WANIEWSKI J, 1994, J CLIN IMMUNOL, V14, P90, DOI 10.1007/BF01541341	5	31	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				848	849		10.1016/S0091-6749(98)70314-8	http://dx.doi.org/10.1016/S0091-6749(98)70314-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648714				2022-12-18	WOS:000074414200021
J	Ditto, AM; Krasnick, J; Greenberger, PA; Kelly, KJ; McGrath, K; Patterson, R				Ditto, AM; Krasnick, J; Greenberger, PA; Kelly, KJ; McGrath, K; Patterson, R			Pediatric idiopathic anaphylaxis: Experience with 22 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; idiopathic anaphylaxis; pediatric; airway obstruction; urticaria; angioedema	OBSTRUCTION; RECURRENT; HISTAMINE; THERAPY	Idiopathic anaphylaxis in the pediatric population is being increasingly recognized, with symptoms (and therefore classifications) the same as those described in adults, We present a series of 22 patients with special attention to considerations relatively unique to the pediatric population. Prednisone, hydroxyzine, and albuterol were used to control symptoms and induce remission. No deaths occurred during treatment, One adolescent who presented with corticosteroid-dependent idiopathic anaphylaxis was diagnosed with undifferentiated somatoform-idiopathic anaphylaxis, Local physician reluctance to participate in management complicated care for some patients.	NW MEM HOSP, DEPT MED, DIV ALLERGY IMMUNOL, CHICAGO, IL 60611 USA; NW MEM HOSP, ERNEST S BAZLEY ASTHMA & ALLERG DIS CTR, CHICAGO, IL 60611 USA; MED COLL WISCONSIN, DEPT PEDIAT, DIV ALLERGY IMMUNOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT MED, DIV ALLERGY IMMUNOL, MILWAUKEE, WI 53226 USA	Northwestern Memorial Hospital; Northwestern Memorial Hospital; Medical College of Wisconsin; Medical College of Wisconsin	Ditto, AM (corresponding author), NORTHWESTERN UNIV, SCH MED, DIV ALLERGY IMMUNOL, MC S207, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498; Kelly, Kevin/0000-0002-2954-6117				BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; Choy AC, 1995, J ALLERGY CLIN IMMUN, V96, P893, DOI 10.1016/S0091-6749(95)70225-3; Ditto AM, 1996, ANN ALLERG ASTHMA IM, V77, P285, DOI 10.1016/S1081-1206(10)63322-4; DITTO AM, 1995, PEDIATR ASTHMA ALLER, V9, P107, DOI 10.1089/pai.1995.9.107; DYKEWICZ M S, 1990, Pediatric Asthma Allergy and Immunology, V4, P217, DOI 10.1089/pai.1990.4.217; FRIEDMAN BS, 1989, AM J MED, V87, P649; GRAMMER LC, 1995, J INVEST MED, V43, pA33; GREENBERGER PA, 1991, J ALLERGY CLIN IMMUN, V87, P867, DOI 10.1016/0091-6749(91)90135-B; KEFFER JM, 1989, J ALLERGY CLIN IMMUN, V83, P595, DOI 10.1016/0091-6749(89)90071-7; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Krasnick J, 1996, PEDIATR ASTHMA ALLER, V10, P29, DOI 10.1089/pai.1996.10.29; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; Moneret-Vautrin D A, 1991, Allerg Immunol (Paris), V23, P89; MYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305, DOI 10.1016/0091-6749(81)90026-9; Olalde Sanchez S, 1989, Rev Clin Esp, V184, P305; PATTERSON R, 1990, J ALLERGY CLIN IMMUN, V85, P86, DOI 10.1016/0091-6749(90)90226-T; PATTERSON R, 1995, PEDIATR ASTHMA ALLER, V9, P43, DOI 10.1089/pai.1995.9.43; PATTERSON R, 1995, ARCH INTERN MED, V155, P869, DOI 10.1001/archinte.155.8.869; PATTERSON R, 1993, ANN ALLERGY, V71, P40; PATTERSON R, 1993, ALLERGY PROC, V14, P365, DOI 10.2500/108854193778774010; PATTERSON R, 1974, CLIN ALLERGY, V4, P307, DOI 10.1111/j.1365-2222.1974.tb01390.x; SANSAN W, 1991, ANN ALLERGY, V67, P359; TANUS T, 1994, ANN EMERG MED, V24, P104, DOI 10.1016/S0196-0644(94)70169-5; TEJEDOR MA, 1984, J ALLERGY CLIN IMMUN, V74, P600; WIGGINS CA, 1988, J ALLERGY CLIN IMMUN, V82, P849, DOI 10.1016/0091-6749(88)90089-9; WONG S, 1991, ANN INTERN MED, V114, P133, DOI 10.7326/0003-4819-114-2-133	26	31	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					320	326		10.1016/S0091-6749(97)70244-6	http://dx.doi.org/10.1016/S0091-6749(97)70244-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314343				2022-12-18	WOS:A1997XX47900008
J	Fiocchi, A; Mirri, GP; Santini, I; Bernardo, L; Ottoboni, F; Riva, E				Fiocchi, A; Mirri, GP; Santini, I; Bernardo, L; Ottoboni, F; Riva, E			Exercise-induced anaphylaxis after food contaminant ingestion in double-blinded, placebo-controlled, food-exercise challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MILAN, DEPT PAEDIAT, I-20122 MILAN, ITALY; LAB FARMACEUT LOFARMA, RES DEPT, MILAN, ITALY	University of Milan	Fiocchi, A (corresponding author), SAN PAOLO BIOMED INST, DEPT PAEDIAT, VIA DI RUDINI 8, I-20142 MILAN, ITALY.		Fiocchi, Alessandro/K-9235-2016	Fiocchi, Alessandro/0000-0002-2549-0523				BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; ERBEN AM, 1993, J ALLERGY CLIN IMMUN, V92, P846, DOI 10.1016/0091-6749(93)90062-K; ROMANO A, 1995, ALLERGY, V50, P817, DOI 10.1111/j.1398-9995.1995.tb05055.x; TILLES S, 1995, J PEDIATR-US, V127, P587, DOI 10.1016/S0022-3476(95)70118-4; WEST I, 1995, CONTACT DERMATITIS, V32, P121, DOI 10.1111/j.1600-0536.1995.tb00770.x	5	31	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					424	425		10.1016/S0091-6749(97)70258-6	http://dx.doi.org/10.1016/S0091-6749(97)70258-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314357				2022-12-18	WOS:A1997XX47900022
J	ZuWallack, RL; Rosen, JP; Cohen, L; Rachelefsky, GS; Gong, H; Goldsobel, AB; Kaliner, MA; White, MV; Bronsky, EA; Chervinsky, P; Lotner, GZ; Corren, J; Bodenheimer, S				ZuWallack, RL; Rosen, JP; Cohen, L; Rachelefsky, GS; Gong, H; Goldsobel, AB; Kaliner, MA; White, MV; Bronsky, EA; Chervinsky, P; Lotner, GZ; Corren, J; Bodenheimer, S			The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inhaled steroids; outcome measures; daily dosing	CHRONOTHERAPY; EFFICACY	Objective: The purpose of this study was to evaluate the feasibility of switching to once-daily (qd) administration of flunisolide in patients with asthma that was controlled by twice-daily (bid) dosing of this inhaled steroid. Methods: Three hundred sixty-six adults and children with bronchial asthma that was controlled with inhaled steroids were recruited for this prospective, double-blind, parallel-group study. After a 4-week, stable baseline period of flunisolide administration, 2 inhalations (500 mu g) twice daily, each patient was randomized into one of four 12-week flunisolide treatment groups: group 1, 2 inhalations (500 mu g) bid; group 2, 4 inhalations (1000 mu g) qd in the morning; group 3, 4 inhalations (1000 mu g) qd in the evening; or group 4, 2 inhalations (500 mu g) qd in the morning. Outcome measures included morning and evening asthma symptoms (scale of 0 to 3), daytime and nighttime albuterol use, morning and evening peak expiratory flow rate (PEFR), FEV(1), and methacholine PC20. In addition, a subset of patients in each group had 24-hour urinary cortisol levels measured before and after randomization. Results: Outcome measures in the four groups mere not significantly different at baseline before randomization. The three groups that received maintenance therapy with flunisolide, 1000 mu g daily, did not show significant changes from baseline values and remained comparable in all outcome areas. Asthma control in the group randomized to flunisolide 500 mu g qd, however, deteriorated significantly: morning symptoms increased by 0.21 units (48%), evening symptoms increased by 0.15 units (31%), daytime albuterol use increased by 0.42 inhalations per day (37%), nighttime albuterol use increased by 0.48 inhalations per night (91%), morning PEFR decreased by 17.1 L/min (4%), and evening PEFR decreased by 12.6 L/min (3%). There were no significant changes in PC20 or 24-hour urinary cortisol levels in any group. Conclusions: For patients with asthma that was stabilized by 2 inhalations of flunisolide (500 mu g) bid, switching to 4 inhalations (1000 mu g) gd in either the morning or evening is effective in maintaining asthma control. Reducing the dose to 2 inhalations (500 mu g) qd in the morning, however, leads to a deterioration in asthma control.	UNIV CONNECTICUT,DEPT MED,HARTFORD,CT 06112; UNIV CONNECTICUT,SCH MED,DEPT PEDIAT,HARTFORD,CT 06112; UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV SO CALIF,RANCHO LOS AMIGOS MED CTR,DOWNEY,CA 90242; UNIV SO CALIF,SCH MED,DOWNEY,CA 90242; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; STANFORD UNIV,MED CTR,DEPT PEDIAT,STANFORD,CA 94305; WASHINGTON HOSP CTR,INST ASTHMA & ALLERGY,WASHINGTON,DC 20010; UNIV UTAH,SALT LAKE CITY,UT; NEW ENGLAND RES CTR,N DARTMOUTH,MA; MED COLL GEORGIA,ATLANTA,GA; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA; FOREST LABS INC,NEW YORK,NY	University of Connecticut; University of Connecticut; University of California System; University of California Los Angeles; University of Southern California; University of Southern California; University of California System; University of California San Francisco; Stanford University; MedStar Washington Hospital Center; Utah System of Higher Education; University of Utah; University System of Georgia; Augusta University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	ZuWallack, RL (corresponding author), ST FRANCIS HOSP & MED CTR,HARTFORD,CT 06105, USA.							AYD FL, 1974, JAMA-J AM MED ASSOC, V230, P363; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; GAGNON M, 1994, CHEST, V105, P1732, DOI 10.1378/chest.105.6.1732; JONES AH, 1994, RESP MED, V88, P293, DOI 10.1016/0954-6111(94)90059-0; MANN M, 1992, CHEST, V101, P496, DOI 10.1378/chest.101.2.496; PINCUS DJ, 1995, CLIN CHEST MED, V16, P699; PINCUS DJ, 1995, J ALLERGY CLIN IMMUN, V95, P1172, DOI 10.1016/S0091-6749(95)70073-0; 1991, J ALLERGY CLIN IMMUN, V88, P451	9	31	31	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					278	285		10.1016/S0091-6749(97)70043-5	http://dx.doi.org/10.1016/S0091-6749(97)70043-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058681				2022-12-18	WOS:A1997WM42200002
J	Hsieh, KH; Chou, CC; Chiang, BL				Hsieh, KH; Chou, CC; Chiang, BL			Immunotherapy suppresses the production of monocyte chemotactic and activating factor and augments the production of IL-8 in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HRF; MCAF; MIP-1 alpha; RANTES; IL-8; GRO alpha; mite; immunotherapy; asthma; children	HISTAMINE-RELEASING-FACTOR; HUMAN MONONUCLEAR-CELLS; HOUSE-DUST; HUMAN BASOPHILS; FACTOR HRF; CYTOKINE FAMILY; RESPONSIVENESS; HYPOSENSITIZATION; INVITRO; RANTES	Background: Histamine-releasing factor consists of a group of cytokines that can cause basophils or mast cells to release histamine. However, the composition of histamine-releasing factor remains undefined. Objective: This study was done to measure the concentrations, in plasma and mononuclear cell culture supernatants from children with asthma, of chemokines that are known to contribute to histamine-releasing factor activity. Results: Plasma and mononuclear cell culture supernatants were obtained from 25 children newly diagnosed with asthma, 25 good responders to immunotherapy, 23 poor responders, 25 patients with acute attacks, and 13 normal subjects. All the patient groups produced, spontaneously and after stimulation with phytohemagglutinin and mite allergen, greater amounts of monocyte chemotactic and activating factor, macrophage inflammatory protein-1 alpha, and RANTES (beta chemokines) and IL-8 and growth-related gene alpha (alpha chemokines) than did normal subjects. Successful immunotherapy resulted in decreased production, especially the spontaneous type, of beta chemokines that cause histamine release and in increased production of alpha chemokines that inhibit histamine release. Conclusion: Abnormal chemokine production may contribute to the pathogenesis of bronchial asthma, and restoration of normal chemokine production may be used to explain, in part, the clinical efficacy of immunotherapy.	NATL TAIWAN UNIV, COLL MED, DEPT PEDIAT, TAIPEI 10764, TAIWAN	National Taiwan University				CHIANG, BOR-LUEN/0000-0002-6705-0286				AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; ALAM R, 1984, ANN ALLERGY, V53, P66; ALAM R, 1988, J CLIN INVEST, V82, P2056, DOI 10.1172/JCI113826; BAEZA ML, 1988, J IMMUNOL, V141, P2688; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; CHANG YC, 1989, ANN ALLERGY, V62, P101; COLOTTA F, 1984, J IMMUNOL, V132, P936; DVORAK HF, 1974, LAB INVEST, V31, P111; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; HSIEH KH, 1988, J CLIN IMMUNOL, V8, P171, DOI 10.1007/BF00917563; HSIEH KH, 1987, J ASTHMA, V24, P19, DOI 10.3109/02770908709073189; HSIEH KH, 1984, J ALLERGY CLIN IMMUN, V74, P34, DOI 10.1016/0091-6749(84)90084-8; HSIEH KH, 1984, ASIAN PAC J ALLERGY, V2, P56; HSIEH KH, 1993, J ALLERGY CLIN IMMUN, V91, P650, DOI 10.1016/0091-6749(93)90271-G; HSIEH KH, 1993, ALLERGY CLIN IMMUNOL, V5, P42; KAM KL, 1994, ANN ALLERGY, V73, P329; KAPLAN AP, 1991, ADV IMMUNOL, V50, P237; KAYY AB, 1986, ASTHMA CLIN PHARM TH, P1; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; KUNA P, 1993, J IMMUNOL, V150, P1932; KUNA P, 1991, J IMMUNOL, V147, P1920; KUNA P, 1994, J ALLERGY CLIN IMMUN, V93, P216; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LI CS, 1994, J ALLERGY CLIN IMMUN, V94, P131, DOI 10.1016/0091-6749(94)90080-9; LIAO TN, 1992, J CLIN IMMUNOL, V12, P248, DOI 10.1007/BF00918148; LIAO TN, 1990, J ALLERGY CLIN IMMUN, V86, P894, DOI 10.1016/S0091-6749(05)80152-6; LIAO TN, 1993, J ALLERGY CLIN IMMUN, V91, P300; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; STADLER BM, 1985, INT ARCH ALLER A IMM, V77, P151, DOI 10.1159/000233770; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; THUESON DO, 1979, J IMMUNOL, V123, P626; WANG JY, 1992, J ASTHMA, V29, P193, DOI 10.3109/02770909209099027	41	31	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					580	587		10.1016/S0091-6749(96)70092-1	http://dx.doi.org/10.1016/S0091-6749(96)70092-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828536				2022-12-18	WOS:A1996VJ42800015
J	Chan, S; Henderson, WR; Li, SH; Hanifin, JM				Chan, S; Henderson, WR; Li, SH; Hanifin, JM			Prostaglandin E(2) control of T cell cytokine production is functionally related to the reduced lymphocyte proliferation in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						prostaglandin E(2); T cell; cytokine; proliferation; atopic dermatitis	INCREASED INTERLEUKIN-4 PRODUCTION; CYCLIC-AMP-PHOSPHODIESTERASE; RECOMBINANT INTERFERON-GAMMA; MEDIATED-IMMUNITY; IFN-GAMMA; TH2; INVITRO; CLONES; IGE	Past studies of peripheral blood mononuclear cells (PBMC) from patients with atopic dermatitis (AD) have demonstrated reduced proliferation. We have studied phytohemagglutinin-induced lymphocyte proliferation in the context of interleukin-4 (IL-4), interferon-gamma (IFN-gamma), and prostaglandin E(2) (PGE(2)) production in cultures of PBMC from patients without and with AD. The production index was found to correlate proportionally to IFN-gamma production and inversely to T-cell IL-4 and monocyte PGE(2) production. Assays in parallel cultures showed significantly increased PGE(2) production by purified AD monocytes. The proliferation index in PBMC from persons with AD was significantly reduced compared with normal PBMC. This difference was normalized in the presence of extrinsic IFN-gamma but exaggerated when IL-4 was added. Increased AD monocyte production of inflammatory factors (e.g., PGE(2)) and cytokines appears to increase IL-4 production by Th2 while suppressing IFN-gamma by Tk1. Restoration of the normal proliferation of PBMC by the addition of IFN-gamma may represent one mechanism for the clinical efficacy of IFN-gamma treatment of AD.	OREGON HLTH SCI UNIV, DEPT DERMATOL, PORTLAND, OR 97201 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA USA	Oregon Health & Science University; University of Washington; University of Washington Seattle								BETZ M, 1991, J IMMUNOL, V146, P108; CHAN SC, 1993, J IMMUNOL, V151, P3345; CHAN SC, 1993, J ALLERGY CLIN IMMUN, V91, P1179, DOI 10.1016/0091-6749(93)90321-6; CHAN SC, 1993, J INVEST DERMATOL, V100, P681, DOI 10.1111/1523-1747.ep12472344; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P1424, DOI 10.1001/archderm.115.12.1424; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GEISSLER FT, 1989, PROSTAGLANDINS, V38, P145, DOI 10.1016/0090-6980(89)90078-6; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOLDEN CA, 1986, J INVEST DERMATOL, V87, P372, DOI 10.1111/1523-1747.ep12524844; JAFFE BM, 1974, HORMONE RADIOIMMUNOA, P19; JAKOB T, 1990, CLIN EXP IMMUNOL, V79, P380; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KAPP A, 1989, ACTA DERM-VENEREOL, P97; LI SH, 1993, J INTERFERON RES, V13, P197, DOI 10.1089/jir.1993.13.197; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; MIZOGUCHI M, 1985, J INVEST DERMATOL, V84, P303; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; RASANEN L, 1989, ACTA DERM-VENEREOL, P64; REINHOLD U, 1990, CLIN EXP IMMUNOL, V79, P374; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; STRANNEGARD IL, 1976, INT ARCH ALLER A IMM, V50, P684, DOI 10.1159/000231547; THESTRUPPEDERSEN K, 1991, PHARM SKIN, V4, P188; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; VERCELLI D, 1990, J IMMUNOL, V144, P570	27	31	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				85	94		10.1016/S0091-6749(96)70286-5	http://dx.doi.org/10.1016/S0091-6749(96)70286-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568141				2022-12-18	WOS:A1996TR94700011
J	LEE, TDG; XIE, CY				LEE, TDG; XIE, CY			IGE REGULATION BY NEMATODES - THE BODY-FLUID OF ASCARIS CONTAINS A B-CELL MITOGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEMATODE; IGE; ASCARIS; MITOGEN	T-CELL; NIPPOSTRONGYLUS-BRASILIENSIS; TRICHURIS-MURIS; RESPONSES; IL-4; MICE; INTERLEUKIN-4; INFECTION; IMMUNITY; PURIFICATION	Nematode infection of human beings or laboratory animals leads to markedly increased levels of circulating IgE, most of which is not specific to worm antigens. This phenomenon is known to be interleukin-4-dependent but little is known about the mechanism of activation of the response. In an attempt to elucidate this mechanism, we have used a reductive approach with worm products rather than infections. lit a previous article we showed that injection of the body fluid of the nematode Ascaris yields a marked increase in circulating IgE. In this study we demonstrate that the body fluid contains a B-cell mitogen. Incubation with purified splenic B cells with 50 mu g/ml body fluid yields marked proliferation of B cells, as measured by tritiated thymidine uptake. Similarly, Ascaris body fluid stimulates G(0) B cells to enter the cell cycle. T cells are unaffected by the mitogen and the response is dependent on viable accessory cells. Contamination of Ascaris body fluid or reagents by bacterial lipopolysaccharide has been ruled out as a source of artefactual data. A model is proposed, which suggests that the B-cell mitogen in Ascaris body fluid stimulates polyclonal B-cell activity and that other nematode factors either stimulate the release of interleukin-4 or act in an interleukin-4-like manner to cause class switch to IgE.			LEE, TDG (corresponding author), DALHOUSIE UNIV,FAC MED,DEPT IMMUNOL & MICROBIOL,HALIFAX,NS B3H 4H7,CANADA.							BECK L, 1993, CELL IMMUNOL, V123, P1; BENBERNOU N, 1993, EUR J IMMUNOL, V23, P659, DOI 10.1002/eji.1830230313; BOND JF, 1991, J IMMUNOL, V146, P3380; CHEN SSA, 1991, SCAND J IMMUNOL, V34, P519, DOI 10.1111/j.1365-3083.1991.tb01575.x; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COLIGAN JE, 1992, CURRENT PROTOCOLS IM; CORBEL C, 1983, EUR J IMMUNOL, V13, P528, DOI 10.1002/eji.1830130703; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1989, J IMMUNOL, V142, P403; GRONOWICZ E, 1974, EUR J IMMUNOL, V4, P771, DOI 10.1002/eji.1830041113; HAYGLASS KT, 1990, CLIN EXP IMMUNOL, V82, P429; HUSSAIN R, 1973, J IMMUNOL, V111, P260; ISHIZAKA T, 1976, J ALLERGY CLIN IMMUN, V58, P523, DOI 10.1016/0091-6749(76)90196-2; JARRETT EEE, 1976, CLIN EXP IMMUNOL, V24, P346; KING CL, 1993, J IMMUNOL, V150, P1873; LEE TDG, 1993, INT ARCH ALLERGY IMM, V102, P185, DOI 10.1159/000236570; LEE TDG, 1983, INT J PARASITOL, V13, P349, DOI 10.1016/S0020-7519(83)80039-3; LEE TDG, 1982, INT ARCH ALLER A IMM, V67, P302, DOI 10.1159/000233037; MAIZELS RM, 1993, NATURE, V365, P7497; MCGIBBON AM, 1990, MOL BIOCHEM PARASIT, V39, P163, DOI 10.1016/0166-6851(90)90055-Q; MILLER HRP, 1984, VET IMMUNOL IMMUNOP, V6, P167, DOI 10.1016/0165-2427(84)90051-5; MILLS FC, 1992, J IMMUNOL, V149, P1075; MOSMANN TR, 1991, IMMUNOL RES, V10, P183, DOI 10.1007/BF02919690; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PETIT A, 1980, MOL IMMUNOL, V17, P1341, DOI 10.1016/0161-5890(80)90003-6; PRITCHARD DI, 1993, PARASITE IMMUNOL, V15, P5, DOI 10.1111/j.1365-3024.1993.tb00566.x; RODRIGUEZ GM, 1992, J IMMUNOL, V149, P2894; ROSENBERG SA, 1981, J IMMUNOL, V126, P1341; ROSENSTREICH DL, 1975, J IMMUNOL, V115, P777; SAVELKOUL HFJ, 1991, J IMMUNOL, V146, P1801; SCHOENFELD R, 1992, INFECT IMMUN, V60, P455, DOI 10.1128/IAI.60.2.455-464.1992; SNAPPER CM, 1988, IMMUNOL REV, V102, P51, DOI 10.1111/j.1600-065X.1988.tb00741.x; SNAPPER CM, 1991, J IMMUNOL, V147, P1163; SPIEGELBERG HL, 1990, SPRINGER SEMIN IMMUN, V12, P365; THIELE DL, 1983, J IMMUNOL, V131, P2282; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; YAMADA M, 1993, IMMUNOLOGY, V78, P298; ZHANG XH, 1992, EUR J IMMUNOL, V22, P829, DOI 10.1002/eji.1830220330	39	31	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1246	1254		10.1016/S0091-6749(95)70082-X	http://dx.doi.org/10.1016/S0091-6749(95)70082-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797793				2022-12-18	WOS:A1995RD30900013
J	MUSMAND, JJ; HORNER, WE; LOPEZ, M; LEHRER, SB				MUSMAND, JJ; HORNER, WE; LOPEZ, M; LEHRER, SB			IDENTIFICATION OF IMPORTANT ALLERGENS IN GERMAN-COCKROACH EXTRACTS BY SODIUM DODECYL-SULFATE POLYACRYLAMIDE-GEL ELECTROPHORESIS AND WESTERN-BLOT-ANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						GERMAN COCKROACH ALLERGY; WHOLE BODY ALLERGENS; FECAL ALLERGENS	AMERICAN PERIPLANETA-AMERICANA; WHOLE-BODY; HOUSE DUST; BLATTELLA-GERMANICA; FECAL EXTRACTS; PURIFICATION; HYPERSENSITIVITY; ANTIGENS; ASTHMA; INHIBITION	Background: Despite recent advances in the purification and characterization of cockroach allergens, identification of clinically important allergens and their source have not been completely elucidated. This study investigated the allergen content of German cockroach (Blattella germanica) whole body (GWBE) and fecal (GFE) extracts. Methods: Sera from 37 subjects with asthma, with positive skin test results to cockroach, were used for RAST and Western blot (after sodium dodecyl sulfate-polyacrylamide gel electrophoresis [SDS-PAGE] under reducing conditions); this serum panel is the largest used to date for cockroach allergen analysis. Results: RAST reactivity to GWBE and GFE were highly correlated (r = 0.882, p < 0.001). SDS-PAGE and Western blotting showed that GWBE and GFE had similar patterns of IgE binding. Furthermore, Western blot inhibition investigations revealed that either GWBE or GFE could almost completely inhibit the reactivity of the other extract. SDS-PAGE and Western blotting demonstrated in both extracts numerous bands that displayed a high prevalence of IgE binding. A protein bands at 67, 50, 45, and 36 kd bound more than 50%, and the band at 60 kd bound approximately 80% of the sera tested. Conclusions: In summary, this investigation identified German cockroach allergens, established their relative importance by prevalence of reactivity to a large serum panel and demonstrated that cockroach feces possess significant allergenic activity. Five allergens identified demonstrated reactivity with up to 50% to 80% of the 37 subjects' sera tested.	TULANE UNIV, SCH MED, DEPT MED, ALLERGY & CLIN IMMUNOL SECT, NEW ORLEANS, LA 70112 USA	Tulane University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022918] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22918] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1970, ANN ALLERGY, V28, P543; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHAPMAN MD, 1988, CHEST, V94, P185, DOI 10.1378/chest.94.1.185; CHOOVIVATHANAVA.P, 1970, LANCET, V2, P362; CHOOVIVATHANAVANICH P, 1974, J MED ASSOC THAILAND, V57, P237; DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; FRASER BN, 1976, S AFR MED J, V17, P90; FROMER JM, 1980, J ALLERGY CLIN IMMUN, V65, P203; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154, DOI 10.1159/000235207; HELM RM, 1988, INT ARCH ALLER A IMM, V87, P230, DOI 10.1159/000234678; HORNER WE, 1990, INT ARCH ALLER A IMM, V93, P256; HULETT AC, 1979, ANN ALLERGY, V42, P160; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1989, ANN ALLERGY, V63, P207; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V88, P895, DOI 10.1016/0091-6749(91)90246-K; MARCHAND AM, 1966, B ASOC MED PR, V88, P49; MENDOZA J, 1976, J ALLERGY CLIN IMMUN, V58, P357; MENON P, 1991, ANN ALLERGY, V67, P573; MORRIS EC, 1986, J ALLERGY CLIN IMMUN, V77, P206; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; SANDERS G, 1985, J ALLERGY CLIN IMMUN, V75, P146, DOI 10.1016/0091-6749(85)90302-1; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULANER FA, 1970, PEDIATRICS, V45, P465; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; THONG Y H, 1976, SMJ Singapore Medical Journal, V17, P90; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; ZWICK H, 1991, J ALLERGY CLIN IMMUN, V87, P626, DOI 10.1016/0091-6749(91)90380-7	41	31	32	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					877	885		10.1016/S0091-6749(95)70132-X	http://dx.doi.org/10.1016/S0091-6749(95)70132-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722169				2022-12-18	WOS:A1995QT46800014
J	BURKS, AW; COCKRELL, G; CONNAUGHTON, C; KARPAS, A; HELM, RM				BURKS, AW; COCKRELL, G; CONNAUGHTON, C; KARPAS, A; HELM, RM			EPITOPE SPECIFICITY OF THE MAJOR PEANUT ALLERGEN, ARA-H-II	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PEANUT; EPITOPE SPECIFICITY; MONOCLONAL ANTIBODIES; IGE	ATOPIC-DERMATITIS; ELECTROPHORETIC TRANSFER; ANAPHYLACTIC REACTIONS; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; P-I; FOOD; DERMATOPHAGOIDES; IDENTIFICATION; ANTIGENS	The antigenic and allergenic structure of Ara h II, a major allergen of peanuts, was investigated with the use of four monoclonal antibodies obtained from BALB/c mice immunized with purified Ara h II. Our previous studies with monoclonal antibodies generated to peanut allergens showed this method to be useful for epitope mapping. When used as a solid phase in an ELISA, these monoclonal antibodies captured peanut antigen, which bound human IgE from patients with positive peanut challenge responses. The Ara h II monoclonal antibodies were found to be specific for peanut antigens when binding for other legumes was examined. In ELISA inhibition studies with the monoclonal antibodies, we identified two different antigenic sites on Ara h II. In similar studies with pooled human IgE serum from patients with positive challenge responses to peanuts, we identified two closely related IgE-binding epitopes. These characterized monoclonal antibodies to Ara h II will be useful for future studies to immunoaffinity purify the Ara h II allergen and to use in conjunction with recombinant technology for determining structure-function relationships.	US FDA,ALLERGY & IMMUNOCHEM LAB,ROCKVILLE,MD	US Food & Drug Administration (FDA)	BURKS, AW (corresponding author), UNIV ARKANSAS MED SCI HOSP,ARKANSAS CHILDRENS HOSP,DEPT PEDIAT,800 MARSHALL ST,LITTLE ROCK,AR 72202, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026629] Funding Source: NIH RePORTER; NIAID NIH HHS [R29AI26629-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNETT D, 1985, P SYDNEY ALLERGY GRO, V4, P104; BURKS AW, 1994, J ALLERGY CLIN IMMUN, V93, P743, DOI 10.1016/0091-6749(94)90254-2; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1989, CURR OPIN IMMUNOL, V1, P647, DOI 10.1016/0952-7915(89)90035-6; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; MARSH DG, 1975, ANTIGENS, V3, P271; MOURAD W, 1988, J IMMUNOL, V141, P3486; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; ROUSE DA, 1990, INFECT IMMUN, V58, P1445, DOI 10.1128/IAI.58.5.1445-1449.1990; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; YUNGINGER JW, 1987, 4TH P INT P EHRL SEM, P251	19	31	36	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					607	611		10.1016/S0091-6749(95)70323-3	http://dx.doi.org/10.1016/S0091-6749(95)70323-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7531731				2022-12-18	WOS:A1995QH69700013
J	SELTZER, JM				SELTZER, JM			BUILDING-RELATED ILLNESSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Symposium on Building-Related and Home-Related Complaints and Illnesses: Sick Building Syndrome	DEC 03-05, 1992	LAKE BUENA VISTA, FL			BUILDING-RELATED ILLNESS; HVAC; IRRITANTS; VENTILATION; INDOOR AIR; CONTAMINATION	LEGIONELLA-PNEUMOPHILA; UNITED-STATES; OUTBREAK; TRANSMISSION; HYPERREACTIVITY; TUBERCULOSIS; ENVIRONMENT; ENDOTOXIN; MODE	As we develop a better understanding of the adverse effects of the indoor environment on health, the pathophysiologic mechanisms contributing illnesses caused by indoor environmental factors will become more clearly defined. The term building-related illness applies to those adverse health effects for which we have a well-defined link between environmental agents in a specific building and the resultant health disorders. This class of illnesses frequently involves the skin and respiratory tract because of the ease with which indoor environmental contaminants come in contact with these tissues. Agents that cause building-related illnesses generally induce illness by one of four mechanisms: (1) immunologic, (2) infectious, (3) toxic, or (4) irritant. Some agents may work through more than one mechanism. This article discusses the different mechanisms that cause building-related illness, the different types of this class of illnesses, and, the evidence validating the connection between the environmental agents and the diseases they cause.	UNIV CALIF SAN DIEGO,SAN DIEGO,CA; SAN DIEGO STATE UNIV,SAN DIEGO,CA	University of California System; University of California San Diego; California State University System; San Diego State University								ABENHAIM L, 1991, J OCCUP ENVIRON MED, V33, P1091; ARLETTE J, 1981, CONTACT DERMATITIS, V7, P129, DOI 10.1111/j.1600-0536.1981.tb04584.x; BENEZRA C, 1985, PLANT CONTACT DERMAT; BLANC P, 1987, CHEST, V92, P613, DOI 10.1378/chest.92.4.613; BLOCH AB, 1985, PEDIATRICS, V75, P676; BRONSON G, 1986, WASHINGTON POST 0916; BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; COUCH RB, 1981, B NEW YORK ACAD MED, V57, P907; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; CULLEN MR, 1987, WORKERS MULTIPLE CHE, P655; DISTASIO AJ, 1990, MIL MED, V155, P347; EDWARDS JH, 1982, J R SOC HLTH, V102, P7; ENGLAND AC, 1981, ANN INTERN MED, V94, P164, DOI 10.7326/0003-4819-94-2-164; FANGER PO, 1988, ENERG BUILDINGS, V12, P7, DOI 10.1016/0378-7788(88)90052-7; FINNEGAN MJ, 1984, BRIT MED J, V289, P1573, DOI 10.1136/bmj.289.6458.1573; FLAHERTY DK, 1974, J LAB CLIN MED, V84, P298; GUBERAN E, 1985, BRIT MED J, V290, P321, DOI 10.1136/bmj.290.6464.321-b; HARRISON J, 1987, INDOOR AIR 87, P487; HODGSON MJ, 1989, AM J IND MED, V16, P45, DOI 10.1002/ajim.4700160106; HODGSON MJ, 1989, OCCUPATIONAL MED PRO, P593; KAPLAN AP, 1988, ALLERGY PRINCIPLES P, P1377; KAUFMANN AF, 1981, AM J EPIDEMIOL, V114, P337, DOI 10.1093/oxfordjournals.aje.a113200; MAIBACH HI, 1988, ALLERGY PRINCIPLES P, P1429; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; MUDER RR, 1986, ARCH INTERN MED, V146, P1607, DOI 10.1001/archinte.146.8.1607; NELSON HS, 1985, ANN ALLERGY, V55, P411; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PICKERING CA, 1982, EUR J RESP DIS S, V123, P104; PLATTSMILLS TAE, 1982, LANCET, V2, P675; Riley E C, 1980, Ann N Y Acad Sci, V353, P25, DOI 10.1111/j.1749-6632.1980.tb18902.x; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; SALVAGGIO JE, 1992, IMMUNOLOGY ALLERGY C, P711; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; SCHACHTER J, 1975, J ALLERGY CLIN IMMUN, V55, P249, DOI 10.1016/0091-6749(75)90144-X; SKOV P, 1987, ENVIRON INT, V13, P339, DOI 10.1016/0160-4120(87)90190-5; SLAVN RG, 1992, IMMUNOLOGY ALLERGY C, P769; SMITH JM, 1988, ALLERGY PRINCIPLES P, V2, P891; SPENDLOVE JC, 1983, PUBLIC HEALTH REP, V98, P229; SULLIVAN JB, 1992, HAZARDOUS MAT TOXICO, P2; TAGER IB, 1990, SEMIN RESPIR MED, V11, P297, DOI 10.1055/s-2007-1006213; WOODS JE, 1991, NIH91218 US DEP HLTH, P15; WOODS JE, 1988, SEP CIB C HLTH BUILD; 1991, J ALLERGY CLIN IMM S, V88, P425; [No title captured]; 1988, NIOSH89136 US DEP HL	48	31	32	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				351	361		10.1053/ai.1994.v94.a57114	http://dx.doi.org/10.1053/ai.1994.v94.a57114			11	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077589	Bronze			2022-12-18	WOS:A1994PG77000011
J	SPECTOR, SL; RAIZMAN, MB				SPECTOR, SL; RAIZMAN, MB			CONJUNCTIVITIS MEDICAMENTOSA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											SPECTOR, SL (corresponding author), ALLERGY MED CLIN,11620 WILSHIRE BLVD,SUITE 200,LOS ANGELES,CA 90025, USA.							ABELSON MB, 1984, OPHTHALMOLOGY, V91, P1364; FENNENBAUM JL, 1980, ALLERGIC DIS DIAGNOS, P87; JONES HS, 1989, BRIT J CLIN PRACT, V43, P30; 1992, PHYSICIANS DESK REFE	4	31	33	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					134	136		10.1016/0091-6749(94)90081-7	http://dx.doi.org/10.1016/0091-6749(94)90081-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027493				2022-12-18	WOS:A1994NX39300018
J	KNUTSEN, AP; MUELLER, KR; HUTCHESON, PS; SLAVIN, RG				KNUTSEN, AP; MUELLER, KR; HUTCHESON, PS; SLAVIN, RG			SERUM ANTI-ASPERGILLUS FUMIGATUS ANTIBODIES BY IMMUNOBLOT AND ELISA IN CYSTIC-FIBROSIS WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CYSTIC FIBROSIS; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTI-ASPERGILLUS FUMIGATUS ANTIBODIES; ELISA; IMMUNOBLOT	IGE	Allergic bronchopulmonary aspergillosis (ABPA) occurs with a prevalence of 5% to 15% in patients with cystic fibrosis (CF). Because of the frequent colonization with Aspergillus fumigatus (Af) in CF; the causative agent of ABPA, antibody reactivity to Af proteins is frequently observed, which obscures the diagnosis of ABPA. Patients with CF are also categorized according to the presence of positive skin test responses to Af and/or the presence of positive precipitins. In this study we used ELISA and immunoblot assay to detect IgE and IgG anti-Af antibodies in patients with CF and ABPA (n = 13) compared with other groups of patients with CF: those with positive skin test and positive precipitin results (n = 18), those with positive skin test and negative precipitin results (n = 14), those with negative skin test and positive precipitin results (n = 10), and those with negative skin test and negative precipitin results (n = 35). IgE and IgG anti-Af antibodies were significantly elevated in patients with ABPA as determined by both immunoblot assay (p < 0.01) and ELISA (p < O.01). However, detection of Af antibodies by ELISA was more sensitive in discriminating patients with CF and ABPA from patients with CF who had positive skin test and positive precipitin results but lacked radiographic and clinical evidence of ABPA. In patients with CF and ABPA the immunoblot assays demonstrated a multitude of IgE, IgG, and IgA antibody responses to Af proteins which ranged in molecular weight from 14 kd to greater than 106 kd. The level of IgE anti-Af antibody to individual proteins decreased during remissions of ABPA. IgG and IgA anti-Af antibodies, however once developed did not decrease nearly as much.			KNUTSEN, AP (corresponding author), ST LOUIS UNIV, SCH MED, PEDIAT RES INST, 1465 S GRAND BLVD, ST LOUIS, MO 63104 USA.							BAUR X, 1989, J ALLERGY CLIN IMMUN, V83, P839, DOI 10.1016/0091-6749(89)90023-7; BERNSTEIN JA, 1990, J ALLERGY CLIN IMMUN, V86, P532, DOI 10.1016/S0091-6749(05)80209-X; BROUWER J, 1988, INT ARCH ALLER A IMM, V85, P244, DOI 10.1159/000234510; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; HUTCHESON PS, 1991, J ALLERGY CLIN IMMUN, V88, P390, DOI 10.1016/0091-6749(91)90102-T; Knutsen A, 1992, Semin Respir Infect, V7, P179; KNUTSEN AP, 1990, J LAB CLIN MED, V116, P724; KURUP VP, 1988, INT ARCH ALLER A IMM, V86, P176, DOI 10.1159/000234568; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; LEUNG PSC, 1988, INT ARCH ALLER A IMM, V85, P416, DOI 10.1159/000234544; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; SCHONHEYDER H, 1988, INT ARCH ALLER A IMM, V85, P472, DOI 10.1159/000234554; SLAVIN RG, 1987, INT ARCH ALLER A IMM, V83, P337, DOI 10.1159/000234365; TALBOT PJ, 1984, J IMMUNOL METHODS, V73, P177, DOI 10.1016/0022-1759(84)90043-7; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; ZEASKE R, 1988, J ALLERGY CLIN IMMUN, V82, P73, DOI 10.1016/0091-6749(88)90054-1	18	31	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					926	931		10.1016/0091-6749(94)90387-5	http://dx.doi.org/10.1016/0091-6749(94)90387-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182235				2022-12-18	WOS:A1994NL91900018
J	DACHMAN, WD; BEDARIDA, G; BLASCHKE, TF; HOFFMAN, BB				DACHMAN, WD; BEDARIDA, G; BLASCHKE, TF; HOFFMAN, BB			HISTAMINE-INDUCED VENODILATION IN HUMAN-BEINGS INVOLVES BOTH H-1 AND H-2-RECEPTOR SUBTYPES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ENDOTHELIUM-DERIVED RELAXING FACTOR; DORSAL HAND-VEIN COMPLIANCE TECHNIQUE; CIMETIDINE; BROMPHENIRAMINE	ANAPHYLACTOID REACTIONS; H2-RECEPTOR ANTAGONISTS; INFUSED HISTAMINE; ISOLATED MONKEY; SMOOTH-MUSCLE; ENDOTHELIUM; RELAXATION; RESPONSES; PREVENTION; ARTERIES	Histamine is a potent vasodilatory substance released during anaphylaxis. The purpose of this study was to investigate the mechanism by which histamine produces venodilation in humans in vivo with the use of the dorsal hand-vein compliance technique. In healthy volunteers full dose-response curves were constructed by infusing histamine, before and after administration of an H-1 or H-2 antagonist or both antagonists, into dorsal hand veins preconstricted with the alpha-adrenergic agonist phenylephrine. In the presence of the H-1 antagonist brompheniramine (530 ng/min), the maximal venodilatory response to histamine decreased from 128% +/- 57% to 78% +/- 15% (p < 0.05). In the presence of H-2 antagonist cimetidine (49 mug/min), the maximal venodilatory response to histamine decreased from 120% +/- 33% to 48% +/- 26% (p < 0.01). Concurrent infusion of histamine with the combination of cimetidine and diphenhydramine resulted in almost complete abolishment of histamine-induced venodilation. Methylene blue (6.8 mug/min), an inhibitor of the action of endothelium-derived relaxing factor, decreased the vasodilatory response to histamine from 131% +/- 23% to 73% +/- 24% (p = 0.01). The results suggest that the venodilatory response of histamine is mediated through both H-1 and H-2 receptor subtypes and that this response is mediated in part by endothelium-derived relaxing factor.	STANFORD UNIV,MED CTR,DIV CLIN PHARMACOL,S-169,STANFORD,CA 94305; VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN CTR,PALO ALTO,CA 94304	Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Blaschke, Terrence/0000-0001-5307-2620	NIA NIH HHS [AG 05627] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AELLIG WH, 1981, BRIT J CLIN PHARMACO, V11, P237, DOI 10.1111/j.1365-2125.1981.tb00527.x; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BARACH EM, 1984, JAMA-J AM MED ASSOC, V251, P2118, DOI 10.1001/jama.251.16.2118; BENEDITO S, 1991, INVEST OPHTH VIS SCI, V32, P32; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; DACHMAN WD, 1993, J CARDIOVASC PHARM, V21, P241, DOI 10.1097/00005344-199302000-00009; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EICHLER HG, 1987, CLIN PHARMACOL THER, V42, P521, DOI 10.1038/clpt.1987.191; FLEMING WW, 1972, J PHARMACOL-PARIS, V181, P339; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; HAAKSMA EEJ, 1990, PHARMACOL THERAPEUT, V47, P73, DOI 10.1016/0163-7258(90)90046-5; HILL SJ, 1990, PHARMACOL REV, V42, P45; IGNARRO LJ, 1991, WESTERN J MED, V154, P51; JUAN H, 1980, N-S ARCH PHARMACOL, V314, P183, DOI 10.1007/BF00504536; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; LIEBERMAN P, 1990, J ALLERGY CLIN IMMUN, V86, P684, DOI 10.1016/S0091-6749(05)80241-6; MATSUKI T, 1990, AM J PHYSIOL, V259, pH1032, DOI 10.1152/ajpheart.1990.259.4.H1032; MOSS J, 1985, ANESTH ANALG, V64, P1197; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; OWEN DAA, 1982, KLIN WOCHENSCHR, V60, P972, DOI 10.1007/BF01716957; PAN HYM, 1986, J PHARMACOL EXP THER, V239, P802; RING J, 1985, INT ARCH ALLER A IMM, V78, P9, DOI 10.1159/000233854; SCHELLENBERG RR, 1986, PROSTAGLANDINS, V32, P201, DOI 10.1016/0090-6980(86)90125-5; SCHOEFFTER P, 1989, PHARMACOL TOXICOL, V64, P64, DOI 10.1111/j.1600-0773.1989.tb00603.x; SCHONING B, 1982, KLIN WOCHENSCHR, V60, P1048, DOI 10.1007/BF01716970; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; TODA N, 1990, AM J PHYSIOL, V258, pH311, DOI 10.1152/ajpheart.1990.258.2.H311; VANDEVOORDE J, 1983, PFLUG ARCH EUR J PHY, V397, P290, DOI 10.1007/BF00580263; VINCENT J, 1992, J CARDIOVASC PHARM, V19, P447, DOI 10.1097/00005344-199203000-00023	31	31	31	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					606	614		10.1016/S0091-6749(94)70072-9	http://dx.doi.org/10.1016/S0091-6749(94)70072-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	8151062				2022-12-18	WOS:A1994ND14000007
J	WAGENMANN, M; BAROODY, FM; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM				WAGENMANN, M; BAROODY, FM; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM			THE EFFECT OF TERFENADINE ON UNILATERAL NASAL CHALLENGE WITH ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TERFENADINE; SECRETION WEIGHT; NASAL AIRWAY RESISTANCE; HISTAMINE	HISTAMINE-RELEASE; THERAPEUTIC EFFICACY; ANTIGEN CHALLENGE; MUCOSAL SECRETION; RHINITIS; H-1; ANTIHISTAMINES; ANTAGONISTS; RECEPTORS; PROTEIN	To investigate the role of H-1 receptor-mediated effects in allergic rhinitis, we challenged 12 allergic volunteers with allergen 2 hours after administration of either placebo or 60 mg of terfenadine. Filter paper discs were used for the unilateral administration of allergen and the collection of nasal secretions. Secretion weights, levels of histamine in recovered nasal secretions, and nasal airway resistance (NAR) were measured for each nostril separately, and the number of sneezes was counted. After placebo treatment, allergen challenge led to significant increases in ipsilateral and contralateral secretion weights, ipsilateral histamine levels, ipsilateral NAR, and sneezing. Contralateral histamine levels were not elevated. H-1 antagonism with terfenadine markedly reduced the number of sneezes and partially decreased ipsilateral and contralateral secretion weights, without affecting the increase in NAR. Terfenadine premedication also lowered the amount of histamine in ipsilateral secretions after allergen challenge. Performing identical nasal challenges with a 10-fold lower dose of antigen produced similar results. Previous studies showed that terfenadine had no effect on methacholine provocation and completely abolished ipsilateral and contralateral secretion weights after histamine challenge. We conclude that sneezing after allergen challenge is caused almost exclusively by a reflex initiated through H-1 receptors and that H-1 antagonism has no influence on allergen-induced increases in NAR Unilateral allergen challenge leads to bilateral increases in secretion weights, which are only partially inhibited by terfenadine, suggesting the involvement of mediators other than histamine in the nasonasal reflex. As reported earlier, terfenadine also decreases allergen-induced histamine release after challenge with the highest dose of antigen.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,BALTIMORE,MD 21205	Johns Hopkins University	WAGENMANN, M (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205, USA.		Wagenman, Martin/B-2524-2012	Wagenman, Martin/0000-0002-9734-0241	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031335, R01AI008270, R37AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 31335, AI 08270] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALVING K, 1991, ACTA PHYSIOL SCAND, V141, P1; ANDERSSON KE, 1984, ANN OTO RHINOL LARYN, V93, P179, DOI 10.1177/000348948409300216; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661, DOI 10.1152/jappl.1993.74.6.2661; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BRAUNSTEIN G, 1991, AM REV RESPIR DIS, V144, P630, DOI 10.1164/ajrccm/144.3_Pt_1.630; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; CAUNA N, 1982, NOSE UPPER AIRWAY PH, P42; DELCARPIO J, 1989, J ALLERGY CLIN IMMUN, V84, P741; GAWIN AZ, 1992, AM J PHYSIOL, V262, pL590, DOI 10.1152/ajplung.1992.262.5.L590; HAVAS TE, 1986, J ALLERGY CLIN IMMUN, V78, P856, DOI 10.1016/0091-6749(86)90230-7; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; KARIM SMM, 1978, PROSTAGLANDINS, V15, P457, DOI 10.1016/0090-6980(78)90129-6; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; MAJCHEL AM, 1990, CLIN EXP ALLERGY, V20, P701, DOI 10.1111/j.1365-2222.1990.tb02711.x; MAJCHEL AM, 1992, LARYNGOSCOPE, V102, P330; MALM L, 1974, ACTA OTO-LARYNGOL, V78, P90, DOI 10.3109/00016487409126331; MCTAVISH D, 1990, DRUGS, V39, P552, DOI 10.2165/00003495-199039040-00006; MITSUHASHI M, 1992, J INVEST DERMATOL, V98, pS8, DOI 10.1111/1523-1747.ep12462089; MULLOL J, 1992, J ALLERGY CLIN IMMUN, V89, P584, DOI 10.1016/0091-6749(92)90326-W; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; OKAYAMA M, 1992, J ALLERGY CLIN IMMUN, V89, P1144, DOI 10.1016/0091-6749(92)90298-G; OKUDA M, 1988, ANN ALLERGY, V39, P537; PHILIP G, 1992, J ALLERGY CLIN IMMUN, V89, P205; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; RAJAKULASINGAM K, 1992, J APPL PHYSIOL, V72, P1418, DOI 10.1152/jappl.1992.72.4.1418; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; RICHERSON HB, 1968, J ALLERGY, V41, P269, DOI 10.1016/0021-8707(68)90032-4; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SHIN MH, 1992, CLIN EXP ALLERGY, V22, P289, DOI 10.1111/j.1365-2222.1992.tb03085.x; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; SORKIN EM, 1985, DRUGS, V29, P34, DOI 10.2165/00003495-198529010-00002; TONNESEN P, 1985, ALLERGY, V40, P616, DOI 10.1111/j.1398-9995.1985.tb00892.x	36	31	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					594	605		10.1016/S0091-6749(94)70071-0	http://dx.doi.org/10.1016/S0091-6749(94)70071-0			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	7512101				2022-12-18	WOS:A1994ND14000006
J	KESTEN, S; REBUCK, AS; CHAPMAN, KR				KESTEN, S; REBUCK, AS; CHAPMAN, KR			TRENDS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY-DISEASE THERAPY IN CANADA, 1985 TO 1990	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; BETA-2-AGONIST; THEOPHYLLINE; INHALED STEROID; IPRATROPIUM BROMIDE; CROMOGLYCATE	BRONCHIAL-ASTHMA; UNITED-STATES; DEATH; MORBIDITY; MORTALITY; AUSTRALIA; DRUGS	Background: In the mid and late 1980s, numerous changes were recommended in the management of obstructive lung diseases. We analyzed drug sales to determine whether these recommendations have resulted in recent changes in prescription drugs used in airway management. Methods: Data on prescription sales in Canada from 1985 to 1990 were obtained from an international pharmaceutical market research organization. Data from a random sampling of physicians that reported patients seen along with the diagnosis and prescriptions given were also reviewed. Results: From 1985 to 1990, there was a 38% increase in prescriptions of all airway drugs. Prescriptions increased significantly for inhaled drugs as follows inhaled beta2-agonists, 70%, inhaled steroids, 139%; cromoglycate, 88%; and ipratropium bromide, 204%. Theophylline prescriptions, by contrast, fell significantly, by 19%. Although theophylline was the most commonly prescribed airway medication in 1985, inhaled beta2-agonists were the most commonly prescribed drug in 1990, and these changes in proportional use were significant. Increases in ipratropium bromide usage was accounted for by increases in prescriptions for chronic obstructive pulmonary disease. Increases in nonsteroidal antiinflammatory drugs were accounted for by asthma prescriptions Conclusions: The increase in airway medication prescriptions dispensed in Canada is consistent with an increase in the number of patients treated, an increase in the severity of disease treated, or both.			KESTEN, S (corresponding author), TORONTO HOSP, CTR ASTHMA, 399 BATHURST ST, EDITH CAVELL WING 4-009, TORONTO M5T 2S8, ON, CANADA.			Kesten, Steven/0000-0002-5522-7910				BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BOOTH S, 1965, ARCH ENVIRON HEALTH, V101, P152; BOSCO LA, 1987, J ALLERGY CLIN IMMUN, V80, P398, DOI 10.1016/0091-6749(87)90058-3; CHAPMAN KR, 1992, CAN MED ASSOC J, V147, P420; FEINLEIB M, 1989, AM REV RESPIR DIS, V140, pS9, DOI 10.1164/ajrccm/140.3_Pt_2.S9; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HOLGATE ST, 1977, LANCET, V2, P375; JENKINS MA, 1990, MED J AUSTRALIA, V153, P323, DOI 10.5694/j.1326-5377.1990.tb136939.x; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; KESTEN S, 1993, CHEST, V104, P254, DOI 10.1378/chest.104.1.254; MANFREDA J, 1989, AM REV RESPIR DIS, V140, pS19, DOI 10.1164/ajrccm/140.3_Pt_2.S19; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; NIKLAS RA, 1982, NEW ENGL J MED, V307, P557; ROBIN ED, 1988, CHEST, V93, P614, DOI 10.1378/chest.93.3.614; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SPREIGHT AN, 1978, BMJ-BRIT MED J, V2, P331; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; WOOLCOCK AJ, 1989, J ALLERGY CLIN IMMUN, V84, P975, DOI 10.1016/0091-6749(89)90397-7; 1987, AM REV RESPIR DIS, V136, P225	22	31	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					499	506		10.1016/0091-6749(93)90073-O	http://dx.doi.org/10.1016/0091-6749(93)90073-O			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8409111				2022-12-18	WOS:A1993MC59000001
J	DEBLAY, F; ZANA, H; OFFNER, M; VEROT, A; VELTEN, M; PAULI, G				DEBLAY, F; ZANA, H; OFFNER, M; VEROT, A; VELTEN, M; PAULI, G			RECEIVER OPERATING CHARACTERISTIC ANALYSIS - A USEFUL METHOD FOR A COMPARISON OF THE CLINICAL RELEVANCE OF 2 IN-VITRO IGE TESTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ROC ANALYSIS; IN-VITRO IGE TESTS; CLINICAL RELEVANCE; COMPARISON	ROC ANALYSIS; PRICK-TESTS; ASTHMA; DISEASE; ALLERGY; AREA	Background: The objectives of this study were to demonstrate the usefulness of Receiver Operating Characteristic (ROC) analysis in the definition of a positive threshold in the comparison of two in vitro tests for detecting IgE antibodies and to determine the clinical relevance of specific IgE tests according to the sensitivity and specificity determined by ROC analysis. Methods: Specific IgE levels were compared with the use of both MATRIX (Abbott Laboratories, Chicago, Ill.) and PHADEZYM (Pharmacia, Uppsala, Sweden) tests in 109 patients. 86 allergic patients and 23 control subjects. All allergic patients had a clinical history of allergy to mite, cat, grass pollen, or birch pollen and positive skin prick test results to the suspected allergen. Using various levels of specific IgE, we determined the points of the ROC curves with the best ratio of true positives to false positives for four aeroallergens (i. e., mite, cat, grass pollen, and birch pollen). Results: Except for mite allergen there was no correspondence between the positive threshold values determined by ROC analysis with MATRIX and PHADEZYM tests. In terms of class, when ROC analysis was used, the threshold was class III with the MATRIX test and class II with PHADEZYM test for cat, grass pollen, and birch pollen and class III for mite. According to the threshold value, sensitivity and specificity for MATRIX and PHADEZYM tests were similar except for cat, for which the PHADEZYM test had a lower sensitivity (0. 71) than the MATRIX test (0.90). With mite allergen the predictive value of only one positive MATRIX test result was 0.96. The specificities of MATRIX and PHADEZYM tests were 100% in both nonatopic and atopic control groups Conclusions: We conclude that ROC analysis is a reliable method for comparing IgE in vitro tests and that it emphasizes the lack of correspondence between arbitrary units given for each in vitro test. ROC analysis appears to be a good method for helping to standardize IgE in vitro tests.	UNIV STRASBOURG,HOP CIVIL,PAVILLON POINCARE,STRASBOURG,FRANCE; CTR PAUL STRAUSS,STRASBOURG,FRANCE	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Paul Strauss	DEBLAY, F (corresponding author), UNIV STRASBOURG,HOP CIVIL,PAVILLON LAENNEC,BP 426,F-67091 STRASBOURG,FRANCE.							ADKINSON NF, 1990, ACI NEWS, V2, P43; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; CAMPISTRON G, 1988, NOUV BIOL, V108, P50; CHARPIN D, 1989, REV MAL RESPIR, V6, P325; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; DONOHUE J, 1989, CLIN CHEM, V35, P1874; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; FINNERTY JP, 1989, CLIN EXP ALLERGY, V19, P51, DOI 10.1111/j.1365-2222.1989.tb02343.x; FRAISSE P, 1987, Revue de Pneumologie Clinique, V43, P282; GOHAGAN JK, 1984, INVEST RADIOL, V19, P587, DOI 10.1097/00004424-198411000-00022; HALPERN GM, 1981, NEW TRENDS ALLERGY, P137; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOFFMAN DR, 1980, ANN ALLERGY, V45, P343; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; MOISE A, 1986, REV EPIDEMIOL SANTE, V34, P209; MONERETVAUTRIN DA, 1990, REV FR ALLERGOL, V30, P225, DOI 10.1016/S0335-7457(05)80259-X; OLLIER S, 1989, CLIN EXP ALLERGY, V19, P457, DOI 10.1111/j.1365-2222.1989.tb02414.x; PATTON DD, 1978, SEMIN NUCL MED, V8, P273, DOI 10.1016/S0001-2998(78)80013-0; REYNAUD C, 1990, EUR RESPIR J, V3, P1155; SOUILLE B, 1987, REV MAL RESPIR, V4, P225; SWETS JA, 1979, INVEST RADIOL, V14, P109, DOI 10.1097/00004424-197903000-00002; WILLIAM SC, 1961, ANN INTERN MED, V55, P777; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T; 1992, J ALLERGY CLIN IMMUN, V90, P263	25	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					255	263		10.1016/0091-6749(93)90169-G	http://dx.doi.org/10.1016/0091-6749(93)90169-G			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349936				2022-12-18	WOS:A1993LT46900006
J	GRAMMER, LC; HARRIS, KE; CUGELL, DW; PATTERSON, R				GRAMMER, LC; HARRIS, KE; CUGELL, DW; PATTERSON, R			EVALUATION OF A WORKER WITH POSSIBLE FORMALDEHYDE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FORMALDEHYDE; ASTHMA; ANTIBODY; IGG; IGE; INHALATION CHALLENGE	HUMAN-SERUM-ALBUMIN; IMMUNOLOGICAL EVALUATION; GASEOUS FORMALDEHYDE; OCCUPATIONAL ASTHMA; LUNG-DISEASE; CHALLENGE; ANTIBODIES; IGG; HYPERRESPONSIVENESS; EXPOSURE	Background: We describe the evaluation of a worker with clinical symptoms compatible with bronchospasm caused by formaldehyde exposure. Methods: The worker was evaluated by means of enzyme-linked immunosorbent assay, cutaneous tests, and methacholine and formaldehyde inhalation challenges. The worker's serum was injected intradermally into the skin of a normal rhesus monkey to determine whether hypersensitivity could be transferred from human to primate. Results: An enzyme-linked immunosorbent assay showed that the worker had positive IgE and IgG titers to formaldehyde-human serum albumin. The worker had a positive cutaneous test for formaldehyde-human serum albumin, and this cutaneous reactivity was transferred to a rhesus monkey through the worker's serum. The worker had a negative methacholine challenge at 25 mg/ml and negative formaldehyde inhalation challenges at 0.3, 1, 3, and 5 ppm for 20 minutes. It is possible that the worker would have had a positive result if a higher concentration of F were used for the challenge, but it is more probable that the worker's symptoms were not caused by immunologically mediated asthma. We have studied individuals exposed to formaldehyde, their clinical syndromes, and serologic results for a decade. This worker is the one subject with the most compatible history and immunology, but the worker had a negative challenge. Conclusion: Immunologically mediated asthma caused by formaldehyde is extremely rare, if it exists at all.	NORTHWESTERN UNIV, SCH MED, DEPT MED, DIV PULM MED, CHICAGO, IL 60611 USA	Northwestern University	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, DIV ALLERGY IMMUNOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.			Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANKS DE, 1986, CHEST, V89, P389, DOI 10.1378/chest.89.3.389; BIAGINI RE, 1989, ARCH ENVIRON HEALTH, V44, P12, DOI 10.1080/00039896.1989.9935866; BOOTH BH, 1985, ALLERGIC DISEASES DI, P113; BOUSQUET J, 1987, CLIN ALLERGY, V17, P499, DOI 10.1111/j.1365-2222.1987.tb02045.x; BURGE PS, 1985, THORAX, V40, P255, DOI 10.1136/thx.40.4.255; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DYKEWICZ MS, 1991, J ALLERGY CLIN IMMUN, V87, P48, DOI 10.1016/0091-6749(91)90212-7; FRANK NR, 1962, J APPL PHYSIOL, V17, P252, DOI 10.1152/jappl.1962.17.2.252; FRIGAS E, 1984, MAYO CLIN PROC, V59, P295, DOI 10.1016/S0025-6196(12)61423-2; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V86, P177, DOI 10.1016/S0091-6749(05)80063-6; GRAMMER LC, 1987, ANN ALLERGY, V58, P151; GRAMMER LC, 1989, J ALLERGY CLIN IMMUN, V84, P805, DOI 10.1016/0091-6749(89)90343-6; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; HENDRICK DJ, 1982, J OCCUP ENVIRON MED, V24, P893; NORDMAN H, 1985, J ALLERGY CLIN IMMUN, V75, P91, DOI 10.1016/0091-6749(85)90018-1; PATTERSON R, 1987, J ALLERGY CLIN IMMUN, V79, P705, DOI 10.1016/0091-6749(87)90199-0; PATTERSON R, 1985, J LAB CLIN MED, V106, P93; PATTERSON R, 1989, J ALLERGY CLIN IMMUN, V84, P359, DOI 10.1016/0091-6749(89)90421-1; PATTERSON R, 1986, INT ARCH ALLER A IMM, V79, P53, DOI 10.1159/000233942; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; ZEISS CR, 1982, J ALLERGY CLIN IMMUN, V70, P15, DOI 10.1016/0091-6749(82)90195-6; 1984, 84100 US DEP HLTH HU	25	31	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				29	33		10.1016/0091-6749(93)90033-C	http://dx.doi.org/10.1016/0091-6749(93)90033-C			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335851				2022-12-18	WOS:A1993LQ35300005
J	JOHNSTON, SL; SMITH, S; HARRISON, J; RITTER, W; HOWARTH, PH				JOHNSTON, SL; SMITH, S; HARRISON, J; RITTER, W; HOWARTH, PH			THE EFFECT OF BAY-U-3405, A THROMBOXANE RECEPTOR ANTAGONIST, ON PROSTAGLANDIN-D(2)-INDUCED NASAL BLOCKAGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RHINITIS; NASAL BLOCKAGE; THROMBOXANE RECEPTOR; PROSTAGLANDIN-D(2) RECEPTOR; ANTAGONIST	MAST-CELLS; INFLAMMATORY MEDIATORS; ALLERGIC RHINITIS; SMOOTH-MUSCLE; HAY-FEVER; RESPONSES; POTENT; CLASSIFICATION; METHACHOLINE; BRADYKININ	Background: Nasal lavage and challenge studies in allergic rhinitis implicate prostaglandin (PG) D2 in the genesis of nasal blockage. PG D2 is known to act via at least two receptors, the thromboxane prostanoid receptor and the PG D2 prostanoid (DP) receptor; the lower airway effects are mediated chiefly by the TP receptor. The receptor involved in the genesis of PG D2-induced nasal blockage is unknown. BAY u 3405 is a potent selective competitive TP receptor antagonist, which inhibits the lower airway response to PG D2, and shifts the dose-response curve to the right by up to 16-fold. Methods: The efficacy of a single oral dose of 20 mg of BAY u 3405 was examined in comparison with PG D2 nasal insufflation in a randomized, double-blind, placebo-controlled crossover study, with objective measurement of nasal resistance by active posterior rhinomanometry. Results: BAY u 3405 afforded no protection against PG D2-induced nasal blockage. Conclusions: This suggests that PG D2-induced nasal blockage may be mediated by the DP receptor rather than the TP receptor and that TP receptor antagonists are unlikely to be of benefit in the treatment of allergic rhinitis. In vivo investigation with specific potent DP receptor antagonists is awaited.	BAYER UK LTD,NEWBURY,ENGLAND; BAYER AG,INST CLIN PHARMACOL,W-5600 WUPPERTAL 1,GERMANY	Bayer AG; Bayer AG	JOHNSTON, SL (corresponding author), SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,CTR BLOCK,LEVEL D,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; Howarth, Peter/0000-0003-0619-7927				BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BROOKS CD, 1988, J ALLERGY CLIN IMMUN, V81, P1110, DOI 10.1016/0091-6749(88)90877-9; Clement P A, 1984, Rhinology, V22, P151; COLEMAN RA, 1989, BRIT J PHARMACOL, V96, P688, DOI 10.1111/j.1476-5381.1989.tb11869.x; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; ENERBACK L, 1986, INT ARCH ALLER A IMM, V81, P289, DOI 10.1159/000234152; FLOWER RJG, 1975, BRIT J PHARMACOL, V56, P229; FUJIMURA M, 1991, J ALLERGY CLIN IMMUN, V87, P23, DOI 10.1016/0091-6749(91)90208-6; GARDINER PJ, 1990, ADV PROSTAG THROMB L, V20, P110; GILES H, 1989, BRIT J PHARMACOL, V96, P291, DOI 10.1111/j.1476-5381.1989.tb11816.x; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213; HARRISON K, 1990, 7TH INT C PROST REL, P323; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; HOWARTH P, 1990, Journal of Allergy and Clinical Immunology, V85, P223; HOWARTH PH, 1989, RESP MED, V83, P179, DOI 10.1016/S0954-6111(89)80029-0; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; JOHNSTON S, 1992, THORAX, V47, P232; JOHNSTON SL, 1992, BRIT J CLIN PHARMACO, V34, P402, DOI 10.1111/j.1365-2125.1992.tb05649.x; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MCKENNIFF M, 1988, EUR J PHARMACOL, V153, P149, DOI 10.1016/0014-2999(88)90601-2; MCKENNIFF MG, 1991, BRIT J PHARMACOL, V104, P585, DOI 10.1111/j.1476-5381.1991.tb12473.x; MCLEAN JA, 1983, J ALLERGY CLIN IMMUN, V72, P187, DOI 10.1016/0091-6749(83)90528-6; NACLERIO RM, 1986, CLIN ALLERGY, V16, P101, DOI 10.1111/j.1365-2222.1986.tb00753.x; NOREL X, 1991, BRIT J PHARMACOL, V104, P591, DOI 10.1111/j.1476-5381.1991.tb12474.x; PEDERSEN PA, 1981, ALLERGY, V36, P375, DOI 10.1111/j.1398-9995.1981.tb01841.x; RAJAKULASINGAM K, 1991, J PHYSIOL-LONDON, V437, P557; RAJAKULASINGAM K, 1992, CLIN EXP ALLERGY, V22, P717, DOI 10.1111/j.1365-2222.1992.tb00196.x; RITTER W, 1990, ARCH PHARM, V323, P809; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414	32	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					903	909		10.1016/0091-6749(93)90348-J	http://dx.doi.org/10.1016/0091-6749(93)90348-J			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473679				2022-12-18	WOS:A1993KY25100011
J	KIVITY, S; SOLOMON, A; SOFERMAN, R; SCHWARZ, Y; MUMCUOGLU, KY; TOPILSKY, M				KIVITY, S; SOLOMON, A; SOFERMAN, R; SCHWARZ, Y; MUMCUOGLU, KY; TOPILSKY, M			MITE ASTHMA IN CHILDHOOD - A STUDY OF THE RELATIONSHIP BETWEEN EXPOSURE TO HOUSE DUST MITES AND DISEASE-ACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHIAL ASTHMA; MITE COUNT; METHACHOLINE PC20; SYMPTOM SCORE	DERMATOPHAGOIDES-PTERONYSSINUS; CHILDREN	Background: Children with asthma are commonly sensitized to the house dust mite. Methods: We took monthly measurements from July to December of the amount of mites in the mattresses of asthmatic children and correlated them with symptom score, pulmonary function, and airway hyperreactivity to methacholine. Results: In spite of the high number of Dermatophagoides pteronyssinus throughout this period, symptom and treatment scores, as well as PC20 to methacholine, worsened during the months of September and October. Conclusions: It is concluded that when asthmatic children allergic to mites are exposed to high levels of mite allergen, the number of mites in the mattress dust no longer correlate with increased symptoms, and that other factors are more likely to be associated with exacerbation.	ICHILOV HOSP,TEL AVIV SOURASKY MED CTR,ALLERGY UNIT,6 WEIZMAN ST,IL-64239 TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,TEL AVIV SOURASKY MED CTR,INST PULM DIS,IL-69978 TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,TEL AVIV SOURASKY MED CTR,ALLERGY UNIT,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MED ENTOMOL,IL-91010 JERUSALEM,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Hebrew University of Jerusalem			Mumcuoglu, Kosta/AAY-2122-2020	Mumcuoglu, Kosta/0000-0001-8125-6099				[Anonymous], 1989, J ALLERGY CLIN IMMUN, V83, P416; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; FELDMANMUHSAM B, 1988, J MED ENTOMOL, V22, P663; KOMSGAARD J, 1989, AM REV RESPIR DIS, V128, P231; KORESGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LANG JD, 1977, ENVIRON ENTOMOL, V6, P213, DOI 10.1093/ee/6.2.213; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; MURRAY AB, 1983, PEDIATRICS, V71, P418; PAULI G, 1977, CLIN ALLERGY, V7, P337, DOI 10.1111/j.1365-2222.1977.tb01461.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1982, LANCET, V2, P1334; PLATTSMILLS TAE, 1989, 12 P INT C ALL CLIN; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P78; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P635; 1962, AM REV RESPIR DIS, V85, P762	19	31	31	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					844	849		10.1016/0091-6749(93)90341-C	http://dx.doi.org/10.1016/0091-6749(93)90341-C			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473672				2022-12-18	WOS:A1993KY25100004
J	WEGNER, CD; GUNDEL, RH; ABRAHAM, WM; SCHULMAN, ES; KONTNY, MJ; LAZER, ES; HOMON, CA; GRAHAM, AG; TORCELLINI, CA; CLARKE, CC; JAGER, P; WOLYNIEC, WW; LETTS, LG; FARINA, PR				WEGNER, CD; GUNDEL, RH; ABRAHAM, WM; SCHULMAN, ES; KONTNY, MJ; LAZER, ES; HOMON, CA; GRAHAM, AG; TORCELLINI, CA; CLARKE, CC; JAGER, P; WOLYNIEC, WW; LETTS, LG; FARINA, PR			THE ROLE OF 5-LIPOXYGENASE PRODUCTS IN PRECLINICAL MODELS OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LEUKOTRIENES; LATE-PHASE RESPONSE; AIRWAY HYPERRESPONSIVENESS; LEUKOCYTES; PROSTAGLANDINS	INDUCED AIRWAY HYPERRESPONSIVENESS; INDUCED LATE RESPONSES; LUNG MAST-CELLS; HISTAMINE-RELEASE; GUINEA-PIGS; BRONCHIAL HYPERREACTIVITY; LIPOXYGENASE INHIBITORS; BRONCHOALVEOLAR LAVAGE; RESPIRATORY MECHANICS; RECEPTOR ANTAGONIST	Background: The action of 5-lipoxygenase on arachidonic acid generates potent inflammatory mediators that may contribute to the pathophysiology of asthma. Methods: Using the potent and selective 5-lipoxygenase inhibitor BI-L-239, we have examined the role of 5-lipoxygenase products in three animal models of asthma. Results: In vitro BI-L-239 inhibited 5-lipoxygenase product generation from human lung mast cells, alveolar macrophages, and peripheral blood leukocytes with a concentration that would provide 50% inhibition values of 28 to 340 nmol/L. A 36-fold selectivity for immunoreactive leukotriene C4 versus immunoreactive prostaglandin D2 inhibition was demonstrated in mast cells. In anesthetized cynomolgus monkeys, inhaled BI-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced immunoreactive leukotriene C4 release (maximum, 73%; bronchoalveolar lavage [BAL], 20 minutes), late-phase bronchoconstriction (maximum, 41%; +6 to 8 hours), and neutrophil infiltration (maximum, 63%; BAL, +8 hours). In conscious sheep, inhaled BI-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced late-phase bronchoconstriction (maximum, 66%; +6 to 8 hours) and increase in airway responsiveness (maximum, 82%; carbachol, +24 hours). The acute bronchoconstriction was shortened, and neutrophil infiltration diminished (maximum, 61%; BAL, +8 hours) in this model. Finally in conscious actively sensitized guinea pigs pretreated with pyrilamine and indomethacin, inhaled BI-L-239 attenuated acute bronchoconstriction (maximum, 80%; +5 to 15 minutes), leukocyte infiltration (58%; BAL, +3 days) and increase in airway responsiveness (100%; methacholine, +3 days) induced by three alternate-day ovalbumin inhalations. Conclusions: In conclusion, results in these three animal models indicate that 5-lipoxygenase products may be major contributors to the bronchoconstriction (especially late phase), leukocyte infiltration, and airway hyperresponsiveness that characterize asthma.	MT SINAI MED CTR, MIAMI BEACH, FL 33140 USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA	Mount Sinai Medical Center; Drexel University	WEGNER, CD (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC, 900 RIDGEBURY RD, POB 368, RIDGEFIELD, CT 06877 USA.		Jager, Pieter/A-3672-2017	Jager, Pieter/0000-0003-4033-7559				ABRAHAM WM, 1987, AM REV RESPIR DIS, V135, pS49; ABRAHAM WM, 1988, AM REV RESPIR DIS, V138, P1565, DOI 10.1164/ajrccm/138.6.1565; ABRAHAM WM, 1986, B EUR PHYSIOPATH RES, V22, P387; ABRAHAM WM, 1989, J APPL PHYSIOL, V66, P2351, DOI 10.1152/jappl.1989.66.5.2351; ABRAHAM WM, 1988, J PHARMACOL EXP THER, V247, P1004; AHMED T, 1986, AM REV RESPIR DIS, V134, P1149; AIZAWA H, 1985, J APPL PHYSIOL, V59, P1918, DOI 10.1152/jappl.1985.59.6.1918; ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BISGAARD H, 1982, PROSTAGLANDINS, V23, P797, DOI 10.1016/0090-6980(82)90124-1; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; CHENG JB, 1989, ADV PROSTAG THROMB L, V19, P187; CHUNG KF, 1986, AM REV RESPIR DIS, V134, P258; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FINDLAY SR, 1992, J ALLERGY CLIN IMMUN, V89, P1040, DOI 10.1016/0091-6749(92)90227-S; FREELAND HS, 1989, J ALLERGY CLIN IMMUN, V83, P634, DOI 10.1016/0091-6749(89)90076-6; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GUNDEL RH, 1989, AM REV RESPIR DIS, V140, P629, DOI 10.1164/ajrccm/140.3.629; GUNDEL RH, 1991, ANN NY ACAD SCI, V629, P205; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; GUNDEL RH, 1991, AM REV RESPIR DIS, V144, P76, DOI 10.1164/ajrccm/144.1.76; HENSON PM, 1978, J IMMUNOL, V121, P851; HOLFORD NHG, 1982, PHARMACOL THERAPEUT, V16, P143, DOI 10.1016/0163-7258(82)90051-1; HOLFORD NHG, 1981, CRC CR REV BIOM ENG, V5, P273; HUI KP, 1991, LANCET, V337, P1062, DOI 10.1016/0140-6736(91)91709-4; ISHIDA K, 1989, J APPL PHYSIOL, V67, P1133, DOI 10.1152/jappl.1989.67.3.1133; ISHIZAKA T, 1983, J IMMUNOL, V130, P2357; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; JACKSON AC, 1979, J APPL PHYSIOL, V47, P462, DOI 10.1152/jappl.1979.47.2.462; KIRBY JG, 1989, J APPL PHYSIOL, V66, P578, DOI 10.1152/jappl.1989.66.2.578; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; KREUTNER W, 1989, AGENTS ACTIONS, V28, P173, DOI 10.1007/BF01967398; LANES S, 1986, J APPL PHYSIOL, V61, P864, DOI 10.1152/jappl.1986.61.3.864; LAZER ES, 1989, J MED CHEM, V32, P100, DOI 10.1021/jm00121a021; LAZER ES, 1990, J MED CHEM, V33, P1892, DOI 10.1021/jm00169a010; LEE HK, 1985, AM REV RESPIR DIS, V132, P1005; LETTS LG, 1988, PROG CLIN BIOL RES, V263, P91; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OBYRNE PM, 1984, PROSTAGLANDINS, V28, P537, DOI 10.1016/0090-6980(84)90242-9; OBYRNE PM, 1985, J APPL PHYSIOL, V59, P1941, DOI 10.1152/jappl.1985.59.6.1941; PETERS SP, 1984, J IMMUNOL, V132, P1972; PETERS SP, 1982, J IMMUNOL, V129, P797; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; SOLER M, 1989, J APPL PHYSIOL, V67, P406, DOI 10.1152/jappl.1989.67.1.406; TAYLOR GW, 1989, LANCET, V1, P584; TORPHY TJ, 1991, ANN NY ACAD SCI, V629, P157; WANNER A, 1975, J APPL PHYSIOL, V39, P950, DOI 10.1152/jappl.1975.39.6.950; WEGNER CD, 1991, AGENT ACTION SUPPL, V34, P529; WEGNER CD, 1991, J ALLERGY CLIN IMMUN, V87, P835, DOI 10.1016/0091-6749(91)90130-G; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WEGNER CD, 1984, RESP PHYSIOL, V55, P47, DOI 10.1016/0034-5687(84)90116-6; WOODWARD DF, 1983, PROSTAGLANDINS, V25, P131, DOI 10.1016/0090-6980(83)90142-9; ZAWRZEWSKI JT, 1985, BR CLIN PHARM, V19, pP574	66	31	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					917	929		10.1016/0091-6749(93)90350-O	http://dx.doi.org/10.1016/0091-6749(93)90350-O			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473681				2022-12-18	WOS:A1993KY25100013
J	JUERGENS, UR; CHRISTIANSEN, SC; STEVENSON, DD; ZURAW, BL				JUERGENS, UR; CHRISTIANSEN, SC; STEVENSON, DD; ZURAW, BL			ARACHIDONIC-ACID METABOLISM IN MONOCYTES OF ASPIRIN-SENSITIVE ASTHMATIC-PATIENTS BEFORE AND AFTER ORAL ASPIRIN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPIRIN-SENSITIVE ASTHMA; ARACHIDONIC ACID METABOLISM; MONOCYTES; ASPIRIN CHALLENGE; THROMBOXANE-B2; LEUKOTRIENE B	HUMAN-BLOOD MONOCYTES; ALVEOLAR MACROPHAGES; MEDIATOR RELEASE; HUMAN BRONCHUS; LEUKOTRIENES; MODULATION; HISTAMINE; RHINOSINUSITIS; INDOMETHACIN; CONTRACTION	Aspirin and nonsteroidal antiinflammatory drugs induce bronchospastic reactions in patients with aspirin-sensitive respiratory disease. Although the mechanism of this reaction is unknown, all drugs that induce the respiratory reaction also inhibit the cyclooxygenase enzyme. The ensuing changes in arachidonate metabolism are presumed to play a role in the pathogenesis of the reaction. We measured generation of leukotrienes and thromboxane by calcium ionophore stimulated blood monocytes. Before aspirin challenge, monocytes released significantly more thromboxane B2 in patients with aspirin sensitivity than in patients without aspirin sensitivity or in healthy control subjects (p < 0.02). During aspirin-induced bronchospasm, release of leukotriene B4 increased significantly (45.5%, p = 0.018), whereas release of thromboxane B2 decreased (-46.9%, p = 0.028). Two hours after ingestion of 60 mg aspirin, normal monocyte release of thromboxane B2 did not drop, whereas leukotriene B4 release increased. Monocytes formed only minimal amounts of leukotriene C4. We conclude that the profile of released eicosanoids from aspirin-sensitive monocytes is distinct from non-aspirin-sensitive subjects, and that these differences could contribute to the development of bronchospasm after aspirin ingestion.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute				Zuraw, Bruce/0000-0003-0640-6768	NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI10386] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GK, 1985, AM REV RESPIR DIS, V131, P8; ADCOCK JJ, 1978, PROSTAGLANDINS, V16, P163, DOI 10.1016/0090-6980(78)90019-9; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; ASMIS R, 1990, EUR J BIOCHEM, V187, P475, DOI 10.1111/j.1432-1033.1990.tb15328.x; BIGBY TD, 1987, J IMMUNOL, V138, P1546; BIGBY TD, 1989, J IMMUNOL, V143, P1948; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; BOYUM A, 1983, SCAND J IMMUNOL, V17, P429, DOI 10.1111/j.1365-3083.1983.tb00809.x; BURKA JF, 1980, PROSTAGLANDINS, V19, P499, DOI 10.1016/S0090-6980(80)80001-3; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FERRERI NR, 1986, J IMMUNOL, V136, P4188; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; GORMAN RR, 1990, METHOD ENZYMOL, V187, P535; HENDERSON WR, 1987, AM REV RESPIR DIS, V135, P1176; HITCHCOCK M, 1980, BRIT J PHARMACOL, V71, P65, DOI 10.1111/j.1476-5381.1980.tb10910.x; JONES CM, 1989, AM J HEMATOL, V31, P145, DOI 10.1002/ajh.2830310302; KORT WJ, 1989, PROSTAG LEUKOTR ESS, V37, P113, DOI 10.1016/0952-3278(89)90107-5; KOUZAN S, 1988, AM REV RESPIR DIS, V137, P38, DOI 10.1164/ajrccm/137.1.38; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RANKIN JA, 1989, J ALLERGY CLIN IMMUN, V83, P722, DOI 10.1016/0091-6749(89)90005-5; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMUELSSON B, 1980, ALLERGY, V35, P375, DOI 10.1111/j.1398-9995.1980.tb01782.x; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1983, DRUGS, V25, P533, DOI 10.2165/00003495-198325060-00001; UNDEM BJ, 1987, AM REV RESPIR DIS, V136, P1183, DOI 10.1164/ajrccm/136.5.1183; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; YOSS EB, 1990, AM J RESP CELL MOL, V2, P69, DOI 10.1165/ajrcmb/2.1.69	35	31	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				636	645		10.1016/0091-6749(92)90137-Q	http://dx.doi.org/10.1016/0091-6749(92)90137-Q			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1328344				2022-12-18	WOS:A1992JT99500010
J	IRVIN, CG				IRVIN, CG			SINUSITIS AND ASTHMA - AN ANIMAL-MODEL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SINUSITIS; ASTHMA	INHIBITS AIRWAY HYPERRESPONSIVENESS; BRONCHIAL-ASTHMA; BRONCHOALVEOLAR LAVAGE; NEUTROPHIL INFLUX; AEROSOL HISTAMINE; OZONE EXPOSURE; GUINEA-PIGS; HYPERREACTIVITY; RESPONSIVENESS; REACTIVITY	We have developed an animal model in which nonspecific lower airways hyperresponsiveness to inhaled histamine was elicited in rabbits after complement-induced maxillary sinusitis. The most likely mechanism to explain this occurrence is the direct passage ("postnasal drip") of inflammatory mediators from the upper to the lower respiratory tract. The contribution of other potential mechanisms, such as the blood-borne delivery of inflammatory mediators, nasobronchial reflexes, and passage of cells with the induction of a secondary inflammatory process, could not be demonstrated. Rather, the most likely explanation for the current finding is the passage of mediators elaborated from activated inflammatory cells into the lower airways. Whether these findings explain the common clinical association of upper airways disease to lower airways dysfunction in sinusitis and asthma remains to be determined. These results suggest that even small numbers of granulocytes, when activated, can exert significant effect on lower airways function. It is perhaps appropriate to speculate at this point about the anecdotal but dramatic improvement in the asthma of patients with sinusitis who undergo surgery. The current results cause us to suggest that this success is due to the removal of the source of inflammatory products that drip into the lung. More important, these current results may have an important implication in the diagnosis of asthma. Finally, there is the clear conclusion that airways dysfunction can be caused by a mechanism that is associated with inflammation but without evidence of cell migration into the airways.	UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	IRVIN, CG (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DIV PULM SCI, 1400 JACKSON ST, DENVER, CO 80206 USA.				NHLBI NIH HHS [NHLBI 37665] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADINOFF AD, 1987, SEMIN RESPIR MED, V8, P308, DOI 10.1055/s-2007-1012669; ADINOFF AD, 1983, PEDIATR RES, V17, P373; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEHRENS BL, 1987, LAB INVEST, V56, P101; BRUGMAN SM, UNPUB MECHANISM INCR; BUCKNER CK, 1985, AM REV RESPIR DIS, V132, P305; BULLEN SS, 1932, J ALLERGY, V4, P402; BUSINCO L, 1981, INT J PEDIATR OTORHI, V3, P287, DOI 10.1016/0165-5876(81)90053-7; Chobot R, 1930, AM J DIS CHILD, V39, P257; CIBULAS W, 1986, J ALLERGY CLIN IMMUN, V77, P828, DOI 10.1016/0091-6749(86)90380-5; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; CORREN J, 1990, American Review of Respiratory Disease, V141, pA177; CUMMINGS NP, 1983, J ALLERGY CLIN IMM S, V73, P143; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EVANS TW, 1988, AM REV RESPIR DIS, V138, P140, DOI 10.1164/ajrccm/138.1.140; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; FRIDAY GA, 1988, CLIN CHEST MED, V9, P557; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; GLEICH GJ, 1987, J ALLERGY CLIN IMMUN, V80, P412, DOI 10.1016/0091-6749(87)90063-7; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; HASLETT C, 1989, J IMMUNOL, V142, P3510; HELLEMANS A, 1988, TIMETABLE SCI; HINSON JM, 1984, J APPL PHYSIOL, V56, P411, DOI 10.1152/jappl.1984.56.2.411; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; HOGG JC, 1984, CLIN CHEST MED, V5, P567; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HUTCHISON AA, 1983, J APPL PHYSIOL, V54, P1463, DOI 10.1152/jappl.1983.54.6.1463; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; IRVIN C G, 1989, Respiratory Care, V34, P455; IRVIN CG, 1986, AM REV RESPIR DIS, V134, P777; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNTUNEN K, 1984, LARYNGOSCOPE, V94, P249, DOI 10.1288/00005537-198402000-00022; KARCZEWSKI W, 1969, J PHYSIOL-LONDON, V201, P271, DOI 10.1113/jphysiol.1969.sp008755; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KAY AB, 1989, ROLE INFLAMMATORY PR, P151; LARSEN GL, 1985, CHEST, V87, pS184, DOI 10.1378/chest.87.5_Supplement.184S; LARSEN GL, 1984, ASTHMA PHYSL IMMUNOP, P245; LARSEN GL, 1991, LUNG SCI F, P953; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; MURLAS CG, 1985, AM REV RESPIR DIS, V131, P314; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NADEL JA, 1962, J APPL PHYSIOL, V17, P861, DOI 10.1152/jappl.1962.17.6.861; NICOLL CS, 1991, FASEB J, V5, P2888, DOI 10.1096/fasebj.5.14.1752356; NOLTE D, 1983, EUR J RESPIR DIS, V64, P110; NOLTE P, 1983, EUR J RESPIR DIS S, V64, P128; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OGUARA SH, 1964, T AM LARYNGOL ASS, V85, P40; PAUWELS R, 1985, EUR J RESPIR DIS, V66, P98; PETERS SP, 1985, CHEST, V87, pS162, DOI 10.1378/chest.87.5_Supplement.162S; PHIPATAN.CS, 1974, ARCH OTOLARYNGOL, V100, P109; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RALL JE, 1945, J LAB CLIN MED, V30, P953; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SCHWARTZ HJ, 1987, ARCH INTERN MED, V147, P2194, DOI 10.1001/archinte.147.12.2194; Settipane GA, 1985, IMMUNOL ALLERGY PRAC, V7, P29; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; Sluder G, 1919, J AMER MED ASSOC, V73, P589, DOI 10.1001/jama.1919.02610340021006; THOMPSON JE, 1986, AM REV RESPIR DIS, V134, P1213; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; VALENTINE MD, 1987, JAMA-J AM MED ASSOC, V258, P2881, DOI 10.1001/jama.258.20.2881; WANNER A, 1990, AM REV RESPIR DIS, V141, P253, DOI 10.1164/ajrccm/141.1.253; WEBSTER RO, 1980, IMMUNOPHARMACOLOGY, V2, P201, DOI 10.1016/0162-3109(80)90050-8; Weille FL, 1936, NEW ENGL J MED, V215, P235, DOI 10.1056/NEJM193608062150602; WERTH G, 1984, IMMUNOLOGY ALLERGY P, V7, P45; WHICKER TH, 1973, ANN OTOLARYNGOL, V82, P355; WIDDICOMBE JG, 1986, CLIN CHEST MED, V7, P159	78	31	35	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			521	533		10.1016/0091-6749(92)90179-6	http://dx.doi.org/10.1016/0091-6749(92)90179-6			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1382085				2022-12-18	WOS:A1992JP52100020
J	WEINSTEIN, AG; FAUST, DS; MCKEE, L; PADMAN, R				WEINSTEIN, AG; FAUST, DS; MCKEE, L; PADMAN, R			OUTCOME OF SHORT-TERM HOSPITALIZATION FOR CHILDREN WITH SEVERE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CHILDHOOD ASTHMA; REHABILITATION; MEDICAL AND PSYCHOLOGIC ASSESSMENT; PHARMACOLOGICAL AND FAMILY TREATMENT	SELF-MANAGEMENT PROGRAMS; CHILDHOOD ASTHMA; THEOPHYLLINE COMPLIANCE; CORTICOSTEROID-THERAPY; FAMILY-THERAPY; BECLOMETHASONE; AEROSOL	This study presents results of a family-centered, short-term residential program in which medical, behavioral, and treatment assessments were provided to the child with severe asthma and the family. After a median stay of 15 days, forty-four consecutively admitted children with severe asthma achieved a 93% reduction in hospital days (median, 7 hospital days for the year before treatment versus median 0 hospital days per patient per year at 20 1/2-month follow-up; p < 0.001) and an 81% reduction in emergency care (median, 4 visits for the year previously versus median, 0.4 visits per patient per year at follow-up; p < 0.01). There was also a significant reduction in corticosteroid bursts and improvement in FEV1. Unique to this program was mandatory family participation focusing on the child's and family's adaptation to severe asthma and development of family-specific interventions to promote compliance with the treatment regimen. Child and family functioning was assessed at admission and follow-up. Hospital use at follow-up was greater for children from dysfunctional families. Families demonstrating difficulties in disciplining the child with asthma required more hospital days both before admission and at follow-up. Short-term hospitalization for children with severe asthma is associated with significant improvement in pulmonary morbidity when the family of the child is included in assessment and treatment.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT INFORMAT SYST,PHILADELPHIA,PA 19107	Jefferson University	WEINSTEIN, AG (corresponding author), ALFRED I DUPONT INST,DEPT PEDIAT,DIV ALLERGY & IMMUNOL PSYCHOL & PULM,BOX 269,WILMINGTON,DE 19899, USA.							ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; CREER TL, 1987, J ALLERGY CLIN IMMUN, V80, P500, DOI 10.1016/0091-6749(87)90086-8; CREER TL, 1980, EYDEV EVALUATION SEL; ELLIS EF, 1987, J ALLERGY CLIN IMMUN, V80, P515, DOI 10.1016/0091-6749(87)90001-7; FERRON GA, 1976, AM REV RESPIR DIS, V14, P899; GODDEN DJ, 1981, BRIT J DIS CHEST, V75, P165, DOI 10.1016/0007-0971(81)90049-8; GREENBLATT DJ, 1973, NEW ENGL J MED, V288, P1215, DOI 10.1056/NEJM197306072882306; GUSTAFSSON PA, 1986, J PSYCHOSOM RES, V30, P369, DOI 10.1016/0022-3999(86)90015-2; KAGAN SG, 1976, J PSYCHOSOM RES, V20, P135, DOI 10.1016/0022-3999(76)90040-4; KRAVIS LP, 1987, J ALLERGY CLIN IMMUN, V80, P467, DOI 10.1016/0091-6749(87)90077-7; LASK B, 1979, J FAM THER, V1, P33; LEWIS CE, 1987, J ALLERGY CLIN IMMUN, V80, P498, DOI 10.1016/0091-6749(87)90085-6; LIEBMAN R, 1974, AM J PSYCHIAT, V131, P535; MRAZEK DA, 1985, P ANN M AM ACADEMY C; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; Peshkin MM, 1930, AM J DIS CHILD, V39, P774, DOI 10.1001/archpedi.1930.01930160092010; PETERSON JW, 1971, BR J DIS CHEST, V65, P21; PURCELL K, 1969, PSYCHOSOM MED, V31, P144, DOI 10.1097/00006842-196903000-00008; PURCELL K, 1970, SYMPTOMS PSYCHOPATHO; RACHELEFSKY GS, 1987, J ALLERGY CLIN IMMUN, V80, P506, DOI 10.1016/0091-6749(87)90087-X; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P17, DOI 10.1016/0091-6749(89)90473-9; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P472, DOI 10.1016/0091-6749(87)90078-9; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; Weinstein A G, 1991, Del Med J, V63, P291; WEINSTEIN AG, 1985, ANN ALLERGY, V54, P19; WEINSTEIN AG, 1986, ANN ALLERGY, V57, P181; WEINSTEIN AG, 1987, ANN ALLERGY, V59, P256; WEINSTEIN AG, 1985, ANN ALLERGY, V55, P16; WEINSTEIN AG, 1983, PROCESS CHANGE, P121; 1984, PHS NIH852362 US DEP	32	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					66	75		10.1016/S0091-6749(06)80012-6	http://dx.doi.org/10.1016/S0091-6749(06)80012-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	JE255	1629509	Bronze			2022-12-18	WOS:A1992JE25500008
J	LAURENT, J; MALET, R; SMIEJAN, JM; MADELENAT, P; HERMAN, D				LAURENT, J; MALET, R; SMIEJAN, JM; MADELENAT, P; HERMAN, D			LATEX HYPERSENSITIVITY AFTER NATURAL DELIVERY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							GLOVES		HOP BICHAT,SERV MED INTERNE & ALLERGOL,F-75877 PARIS 18,FRANCE; SERV GYNECOL & OBSTET,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP								AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; CHARPIN D, 1989, REV FR ALLERGOL IMMU, V29, P100; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029	5	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					779	780		10.1016/0091-6749(92)90389-J	http://dx.doi.org/10.1016/0091-6749(92)90389-J			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545100				2022-12-18	WOS:A1992HJ34000021
J	ORGEL, HA; MELTZER, EO; BIERMAN, CW; BRONSKY, E; CONNELL, JT; LIEBERMAN, PL; NATHAN, R; PEARLMAN, DS; PENCE, HL; SLAVIN, RG; NAADIMUTHU, A				ORGEL, HA; MELTZER, EO; BIERMAN, CW; BRONSKY, E; CONNELL, JT; LIEBERMAN, PL; NATHAN, R; PEARLMAN, DS; PENCE, HL; SLAVIN, RG; NAADIMUTHU, A			INTRANASAL FLUOCORTIN BUTYL IN PATIENTS WITH PERENNIAL RHINITIS - A 12-MONTH EFFICACY AND SAFETY STUDY INCLUDING NASAL BIOPSY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FLUOCORTIN BUTYL; PERENNIAL RHINITIS; NASAL BIOPSY	MUCOSAL MAST-CELLS; LONG-TERM SAFETY; BECLOMETHASONE DIPROPIONATE; ALLERGIC RHINITIS; FOLLOW-UP; HAY-FEVER; AEROSOL; SPRAY; SECRETIONS; TRIAL	Fluocortin butyl (FCB) is a recently developed topical intranasal corticosteroid that is inhaled as a powder and has been demonstrated to be well tolerated and to improve symptoms and signs of perennial rhinitis in previous short-term studies. This multicenter, open-label study evaluated the efficacy and safety of FCB during a 12-month treatment period in patients with perennial rhinitis. Treatment was initiated with one inhalation of FCB in each nostril three times a day (total dosage, 3 mg/day). In subsequent months, one third of the patients was maintained at the dosage of 3 mg/day, one third at a lower dosage of 2 mg/day, and the remaining one third of the patients at a larger dosage of 4 to 8 mg/day. Of 109 patients enrolled in the study, 90 patients (82.6%) completed all 12 months of treatment. Symptom and sign scores decreased significantly (p < 0.001) at the 2-month evaluation compared to scores at baseline, and the improvement was maintained throughout the 12-month study period. After 12 months, > 80% of the patients had substantial control of symptoms. Specimens of nasal biopsies, performed at the beginning and end of treatment, revealed a decrease in eosinophils and other cellular infiltrates, a slight tendency of an increase in mast cell counts, and a trend toward normalization of the nasal mucosa. There were few adverse effects. Mean plasma cortisol levels were normal before and after corticotropin stimulation at baseline and after 12 months of FCB therapy. This study demonstrated FCB to have a good safety profile for long-term administration with no evidence of loss of efficacy during a 12-month treatment period at dosages of 2 to 8 mg/day (twice-daily to four-times-a-day regimens).	ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA									ARBESMAN C, 1983, J ALLERGY CLIN IMMUN, V71, P597, DOI 10.1016/0091-6749(83)90442-6; BROWN HM, 1977, BRIT J CLIN PHARMACO, V4, pS283, DOI 10.1111/j.1365-2125.1977.tb04522.x; BUSSE W, 1988, J ALLERGY CLIN IMMUN, V82, P890, DOI 10.1016/0091-6749(88)90031-0; CLAYTON DE, 1981, J ALLERGY CLIN IMMUN, V67, P2, DOI 10.1016/0091-6749(81)90037-3; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; GOMEZ E, 1988, BRIT MED J, V296, P1572, DOI 10.1136/bmj.296.6636.1572-a; HANSEL FK, 1966, ANN ALLERGY, V24, P564; HARTLEY TF, 1985, J ALLERGY CLIN IMMUN, V75, P501, DOI 10.1016/S0091-6749(85)80024-5; HASTIE R, 1979, LAB INVEST, V40, P554; HOLOPAINEN E, 1977, ACTA ALLERGOL, V32, P263, DOI 10.1111/j.1398-9995.1977.tb01358.x; HOLOPAINEN E, 1982, ACTA OTOLARYNGOL, V386, pS270; KAPP JF, 1982, N ENGL SOC ALLERGY P, V3, P482; LAVKER RM, 1985, J IMMUNOL, V135, P2368; LINDQVIST N, 1986, ALLERGY, V41, P179, DOI 10.1111/j.1398-9995.1986.tb00298.x; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; MELTZER EO, 1987, AM J RHINOL, V1, P141; Mutzel W, 1977, Arzneimittelforschung, V27, P2230; MYGIND N, 1982, CLIN OTOLARYNGOL, V7, P343, DOI 10.1111/j.1365-2273.1982.tb01918.x; OKUDA M, 1983, ANN ALLERGY, V50, P116; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OKUDA M, 1980, CLIN OTOLARYNGOL, V5, P315, DOI 10.1111/j.1365-2273.1980.tb00897.x; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; PIPKORN U, 1988, INT ARCH ALLER A IMM, V87, P349, DOI 10.1159/000234700; PIPKORN U, 1988, CLIN ALLERGY, V18, P253, DOI 10.1111/j.1365-2222.1988.tb02867.x; Pipkorn U, 1985, ALLERGIC VASOMOTOR R, P165; SHERMAN B, 1982, J ALLERGY CLIN IMMUN, V69, P208, DOI 10.1016/0091-6749(82)90101-4; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; VIEGAS M, 1987, INT ARCH ALLER A IMM, V82, P275, DOI 10.1159/000234205; VLASSES PH, 1981, CLIN PHARMACOL THER, V29, P643, DOI 10.1038/clpt.1981.89; Wendt H, 1977, Arzneimittelforschung, V27, P2236; 1980, CLIN ALLERGY, V10, P239	34	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					257	264		10.1016/0091-6749(91)90336-M	http://dx.doi.org/10.1016/0091-6749(91)90336-M			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880325	Bronze			2022-12-18	WOS:A1991GB22500015
J	CASALE, TB				CASALE, TB			NEUROPEPTIDES AND THE LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							VASOACTIVE INTESTINAL PEPTIDE; BRONCHIAL SMOOTH-MUSCLE; GENE-RELATED PEPTIDE; ANGIOTENSIN-CONVERTING ENZYME; AUTONOMIC NERVOUS-SYSTEM; MAMMALS INCLUDING MAN; GUINEA-PIG AIRWAYS; SUBSTANCE-P; CALCITONIN GENE; NEUROKININ-A		UNIV IOWA, COLL MED, IOWA CITY, IA 52242 USA; VET ADM MED CTR, DEPT INTERNAL MED, IOWA CITY, IA 52240 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377	NIAID NIH HHS [AI 19093] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019093] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIAKBARI J, 1987, BIOCHEM BIOPH RES CO, V148, P1440, DOI 10.1016/S0006-291X(87)80293-0; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMIRANOFF B, 1978, BIOCHIM BIOPHYS ACTA, V544, P474, DOI 10.1016/0304-4165(78)90321-5; ANDREWS PC, 1987, EXPERIENTIA, V43, P784, DOI 10.1007/BF01945356; BARNES PJ, 1987, AM REV RESPIR DIS, V136, pS77, DOI 10.1164/ajrccm/136.6_Pt_2.S77; BARNES PJ, 1987, J ALLERGY CLIN IMMUN, V79, P285, DOI 10.1016/0091-6749(87)90143-6; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; BARNES PJ, 1984, AM REV RESPIR DIS, V130, P162; BARNES PJ, 1989, TRENDS PHARMACOL SCI, V10, P264, DOI 10.1016/0165-6147(89)90024-2; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1989, THORAX, V44, P161, DOI 10.1136/thx.44.3.161; BARSHAVIT Z, 1980, BIOCHEM BIOPH RES CO, V94, P1445, DOI 10.1016/0006-291X(80)90581-1; BROWN M J, 1987, Journal of Cardiovascular Pharmacology, V10, pS82, DOI 10.1097/00005344-198710012-00011; BUCKNALL CE, 1988, BRIT MED J, V296, P86, DOI 10.1136/bmj.296.6615.86; BUNNETT NW, 1987, AM REV RESPIR DIS, V136, pS27, DOI 10.1164/ajrccm/136.6_Pt_2.S27; BURGER E, 1988, ARZNEIMITTEL-FORSCH, V38-1, P754; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; CAMERON AR, 1983, Q J EXP PHYSIOL CMS, V68, P413, DOI 10.1113/expphysiol.1983.sp002735; CARSTAIRS JR, 1986, J PHARMACOL EXP THER, V239, P249; CASALE TB, 1987, ANN ALLERGY, V59, P391; CASALE TB, 1983, ANN ALLERGY, V51, P423; CASALE TB, 1989, ALLERGY PRINCIPLES P, V2, P1; CASTAIRS JR, 1986, EUR J PHARMACOL, V127, P295, DOI 10.1016/0014-2999(86)90380-8; CLARKE B, 1987, CLIN SCI, V72, pP41; COBURN RF, 1973, AM J PHYSIOL, V224, P1072, DOI 10.1152/ajplegacy.1973.224.5.1072; COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715; COSTA M, 1988, ANN NY ACAD SCI, V527, P103; CRIMI N, 1988, CLIN ALLERGY, V18, P375, DOI 10.1111/j.1365-2222.1988.tb02885.x; CUTZ E, 1978, NATURE, V275, P661, DOI 10.1038/275661a0; DEFENDINI R, 1983, NEUROENDOCRINOLOGY, V37, P32, DOI 10.1159/000123512; DEVILLIER P, 1986, PHARMACOLOGY, V32, P340, DOI 10.1159/000138190; DEY RD, 1981, CELL TISSUE RES, V220, P231; DIXON CMS, 1987, BRIT J CLIN PHARMACO, V23, P91, DOI 10.1111/j.1365-2125.1987.tb03015.x; DOCKRAY GJ, 1987, AM REV RESPIR DIS, V136, pS9, DOI 10.1164/ajrccm/136.6_Pt_2.S9; DRAPEAU G, 1987, NEUROPEPTIDES, V10, P43, DOI 10.1016/0143-4179(87)90088-6; DREW PA, 1985, AUST J EXP BIOL MED, V63, P313, DOI 10.1038/icb.1985.35; ERDOS EG, 1985, BIOCHEM SOC T, V13, P42, DOI 10.1042/bst0130042; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; ERSPAMER V, 1981, TRENDS NEUROSCI, V4, P267, DOI 10.1016/0166-2236(81)90084-9; FINE JM, 1989, J APPL PHYSIOL, V66, P232, DOI 10.1152/jappl.1989.66.1.232; FOREMAN J, 1983, AGENTS ACTIONS, V13, P105, DOI 10.1007/BF01967311; FOREMAN JC, 1983, J PHYSIOL-LONDON, V335, P449, DOI 10.1113/jphysiol.1983.sp014543; FRANCONI GM, 1989, J PHARMACOL EXP THER, V248, P947; FULLER RW, 1985, J APPL PHYSIOL, V58, P1080, DOI 10.1152/jappl.1985.58.4.1080; FULLER RW, 1987, J APPL PHYSIOL, V62, P1473, DOI 10.1152/jappl.1987.62.4.1473; GAMSE R, 1985, EUR J PHARMACOL, V114, P61, DOI 10.1016/0014-2999(85)90520-5; GOETZL EJ, 1985, J IMMUNOL, V135, pS802; GRUNDSTROM N, 1981, ACTA PHARMACOL TOX, V49, P150; GRUNDSTROM N, 1984, ACTA PHARMACOL TOX, V54, P8; GRUNDSTROM N, 1981, LIFE SCI, V28, P2981, DOI 10.1016/0024-3205(81)90275-7; GUARD S, 1988, BRIT J PHARMACOL, V94, P148, DOI 10.1111/j.1476-5381.1988.tb11509.x; HARTUNG HP, 1986, J IMMUNOL, V136, P3856; HOKFELT T, 1987, EXPERIENTIA, V43, P768; ICHINOSE M, 1989, BRIT J PHARMACOL, V97, P13, DOI 10.1111/j.1476-5381.1989.tb11917.x; ICHINOSE M, 1988, AM REV RESPIR DIS, V138, P31, DOI 10.1164/ajrccm/138.1.31; ICHINOSE M, 1989, EUR J PHARMACOL, V163, P383, DOI 10.1016/0014-2999(89)90212-4; ITA Y, 1982, J PHYSL, V330, P497; ITOH N, 1983, NATURE, V304, P547, DOI 10.1038/304547a0; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; JIANG ZG, 1982, BRAIN RES, V235, P185, DOI 10.1016/0006-8993(82)90211-6; JOHANSSON IGM, 1989, ACTA PHYSIOL SCAND, V135, P411, DOI 10.1111/j.1748-1716.1989.tb08595.x; JOHNSON AR, 1985, AM REV RESPIR DIS, V132, P564; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; JOOS GF, 1989, J ALLERGY CLIN IMMUN, V83, P663, DOI 10.1016/0091-6749(89)90080-8; JOOS GF, 1988, AM REV RESPIR DIS, V137, P1038, DOI 10.1164/ajrccm/137.5.1038; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KAUFMAN MP, 1980, J APPL PHYSIOL, V48, P511, DOI 10.1152/jappl.1980.48.3.511; KONISHI S, 1980, BIOMED RES-TOKYO, V1, P528, DOI 10.2220/biomedres.1.528; KONISHI S, 1981, NATURE, V294, P80, DOI 10.1038/294080a0; KONISHI S, 1979, NATURE, V282, P515, DOI 10.1038/282515a0; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; LAITINEN A, 1985, HISTOCHEMISTRY, V82, P313, DOI 10.1007/BF00494059; LAITINEN LA, 1987, AM REV RESPIR DIS, V136, pS59, DOI 10.1164/ajrccm/136.6_Pt_2.S59; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAZARUS SC, 1987, INT ARCH ALLER A IMM, V82, P372, DOI 10.1159/000234230; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; LUNDBERG JM, 1984, PEPTIDES, V5, P593, DOI 10.1016/0196-9781(84)90090-1; LUNDBERG JM, 1987, AM REV RESPIR DIS, V136, pS16, DOI 10.1164/ajrccm/136.6_Pt_2.S16; LUNDBERG JM, 1984, CELL TISSUE RES, V235, P251; LUNDBERG JM, 1983, P NATL ACAD SCI-BIOL, V80, P1120, DOI 10.1073/pnas.80.4.1120; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P477, DOI 10.1111/j.1748-1716.1982.tb07171.x; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P473, DOI 10.1111/j.1748-1716.1982.tb07170.x; LUNDBERG JM, 1983, ACTA PHYSIOL SCAND, V119, P49, DOI 10.1111/j.1748-1716.1983.tb07304.x; LUNDBERG JM, 1985, TACHYKININ ANTAGONIS, P159; LYGREN I, 1984, SCAND J CLIN LAB INV, V44, P347, DOI 10.3109/00365518409083818; MACLEAN DB, 1987, ENDOCRINOLOGY, V121, P1540, DOI 10.1210/endo-121-4-1540; MARASCO WA, 1981, BIOCHEM BIOPH RES CO, V99, P1065, DOI 10.1016/0006-291X(81)90727-0; MARTINS M A, 1989, American Review of Respiratory Disease, V139, pA239; MARTLING CR, 1987, LIFE SCI, V40, P1633, DOI 10.1016/0024-3205(87)90130-5; MARTLING CR, 1988, REGUL PEPTIDES, V20, P125, DOI 10.1016/0167-0115(88)90046-8; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MATSUDA H, 1989, J IMMUNOL, V142, P927; MATSUZAKI Y, 1980, SCIENCE, V210, P1252, DOI 10.1126/science.6254154; MAZUREK N, 1981, NEUROPHARMACOLOGY, V20, P1025, DOI 10.1016/0028-3908(81)90091-5; MOORE TC, 1984, IMMUNOLOGY, V52, P511; MORICE A, 1983, LANCET, V2, P1225; MORICE AH, 1986, PEPTIDES, V7, P279, DOI 10.1016/0196-9781(86)90202-0; MORRIS JL, 1985, NEUROSCI LETT, V62, P31, DOI 10.1016/0304-3940(85)90280-0; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; NICHOL GM, 1990, AM REV RESPIR DIS, V142, P576, DOI 10.1164/ajrccm/142.3.576; OLLERENSHAW S, 1989, NEW ENGL J MED, V320, P1244, DOI 10.1056/NEJM198905113201904; OLLERENSHAW S L, 1989, American Review of Respiratory Disease, V139, pA237; PAINTER RG, 1988, J BIOL CHEM, V263, P9456; PALMER JBD, 1987, BRIT J PHARMACOL, V91, P95, DOI 10.1111/j.1476-5381.1987.tb08987.x; PALMER JBD, 1986, J APPL PHYSIOL, V61, P1322, DOI 10.1152/jappl.1986.61.4.1322; PALMER JBD, 1986, THORAX, V41, P663, DOI 10.1136/thx.41.9.663; PAYAN DG, 1983, J IMMUNOL, V131, P1613; POLAK JM, 1982, EXP LUNG RES, V3, P313, DOI 10.3109/01902148209069660; REGOLI D, 1989, PHARMACOLOGY, V38, P1, DOI 10.1159/000138512; RICHARDSON J, 1976, J APPL PHYSIOL, V41, P764, DOI 10.1152/jappl.1976.41.5.764; ROBBERECHT P, 1976, J BIOL CHEM, V251, P4635; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; SARIA A, 1983, N-S ARCH PHARMACOL, V324, P212, DOI 10.1007/BF00503897; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; SCHWARTZ JC, 1981, LIFE SCI, V29, P1715, DOI 10.1016/0024-3205(81)90182-X; SHEPPARD D, 1988, J CLIN INVEST, V81, P1111, DOI 10.1172/JCI113424; SHEPPARD MN, 1984, THORAX, V39, P326, DOI 10.1136/thx.39.5.326; STANISZ AM, 1988, ANN NY ACAD SCI, V527, P478; STANISZ AM, 1986, J IMMUNOL, V136, P152; STEENBERGH PH, 1985, FEBS LETT, V183, P408, DOI 10.1016/0014-5793(85)80820-6; STIMLERGERARD NP, 1987, J CLIN INVEST, V79, P1819, DOI 10.1172/JCI113023; STRETTON CD, 1988, BRIT J PHARMACOL, V93, P672, DOI 10.1111/j.1476-5381.1988.tb10325.x; STRUTHERS AD, 1986, CLIN SCI, V70, P389, DOI 10.1042/cs0700389; TATEMOTO K, 1985, BIOCHEM BIOPH RES CO, V128, P947, DOI 10.1016/0006-291X(85)90138-X; THOMPSON JE, 1988, AM REV RESPIR DIS, V137, P337, DOI 10.1164/ajrccm/137.2.337; TISSOT M, 1988, INFLAMMATION, V12, P25, DOI 10.1007/BF00915889; TURNER AJ, 1987, NEUROPEPTIDES THEIR, P183; UCHIDA Y, 1987, AM REV RESPIR DIS, V136, P718, DOI 10.1164/ajrccm/136.3.718; UNDEM BJ, 1983, EUR J PHARMACOL, V88, P247, DOI 10.1016/0014-2999(83)90012-2; WHARTON J, 1979, INVEST CELL PATHOL, V2, P3; ZAIDI M, 1987, Q J EXP PHYSIOL CMS, V72, P371, DOI 10.1113/expphysiol.1987.sp003084	133	31	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					1	16		10.1016/0091-6749(91)90292-V	http://dx.doi.org/10.1016/0091-6749(91)90292-V			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	1649209				2022-12-18	WOS:A1991FY20400001
J	MITTMAN, RJ; BERNSTEIN, DI; ADLER, TR; KORBEE, L; NATH, V; GALLAGHER, JS; BERNSTEIN, IL				MITTMAN, RJ; BERNSTEIN, DI; ADLER, TR; KORBEE, L; NATH, V; GALLAGHER, JS; BERNSTEIN, IL			SELECTIVE DESENSITIZATION TO SEMINAL PLASMA-PROTEIN FRACTIONS AFTER IMMUNOTHERAPY FOR POSTCOITAL ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article								A 24-year-old white woman reported sexual intercourse-related pruritus, hives, wheezing, and dyspnea within 5 minutes after ejaculation. Systemic reactions (SRs) were prevented by use of condoms. Prick testing confirmed sensitization to five Sephadex G-100-separated fractions of her husband's seminal plasma. The intradermal end point threshold concentrations (ETC) were 10(-4) and 10(-1)-mu-g of protein per milliliter to fractions 2 and 3, respectively. Leukocyte histamine release studies exhibited 100% release to fraction 2 and 37% release to fraction 3. A 2-day protocol of rapid immunotherapy (IT) was performed with subcutaneous incremental doses of human seminal plasma (HuSePl) fractions 2 and 3. The patient experienced an SR after receiving a cumulative dose of 38.55-mu-g of fraction 2 on day 1. On day 2, rapid IT with fraction 2 was administered until the patient experienced a mild SR after having received a cumulative dose of 102.8-mu-g. There was a one-log10 increase in the intradermal ETC to both fractions 2 and 3 at the end of day 2. IT was continued three times weekly for 4 months until the patient tolerated 100-mu-g doses of both fractions 2 and 3. At 4 months, coitus was resumed without SRs, and HuSePl IT was stopped. The intradermal ETC to fractions 1, 3, 4, and 5 was increased 6 months after cessation of HuSePl injections, but there was a one-log decrease in the ETC to fraction 2. Our experience demonstrated that systemic tolerance can be achieved by parenteral administration of selected HuSePl fractions. Partial immunologic desensitization of patients with anaphylactic sensitivity can be achieved. This appears to be selective for most, but not all, allergenic fractions contained in HuSePl.	UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,SUITE 563,CINCINNATI,OH 45267; WILSON CTR,ROCHESTER,NY; DEACONESS HOSP,CINCINNATI,OH	University of Cincinnati								Bernstein I L, 1985, Contrib Gynecol Obstet, V14, P151; BERNSTEIN IL, 1981, ANN INTERN MED, V94, P459, DOI 10.7326/0003-4819-94-4-459; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; FOLIN O, 1964, EXPT IMMUNOCHEMISTRY, P556; FRIEDMAN SA, 1984, JAMA-J AM MED ASSOC, V251, P2684, DOI 10.1001/jama.251.20.2684; HADDAD ZH, 1978, PERSPECT ALLERGY, V1, P2; HALPERN BN, 1967, IMMUNOLOGY, V12, P247; LEVINE BB, 1973, NEW ENGL J MED, V288, P894, DOI 10.1056/NEJM197304262881707; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MARCUS ZH, 1978, CLIN IMMUNOL IMMUNOP, V9, P318, DOI 10.1016/0090-1229(78)90103-4; OHMAN JL, 1990, J ALLERGY CLIN IMMUN, V85, P103, DOI 10.1016/0091-6749(90)90230-2; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WIDE L, 1967, LANCET, V57, P2	14	31	31	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				954	960		10.1016/S0091-6749(05)80159-9	http://dx.doi.org/10.1016/S0091-6749(05)80159-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262650				2022-12-18	WOS:A1990EQ04500017
J	GANZ, MA; UNTERMAN, T; ROBERTS, M; UY, R; SAHGAL, S; SAMTER, M; GRAMMER, LC				GANZ, MA; UNTERMAN, T; ROBERTS, M; UY, R; SAHGAL, S; SAMTER, M; GRAMMER, LC			RESISTANCE AND ALLERGY TO RECOMBINANT HUMAN INSULIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; UNIV ILLINOIS,COLL MED,DEPT MED,CHICAGO,IL 60680; UNIV ILLINOIS,COLL MED,DEPT PATHOL,CHICAGO,IL 60680; VET ADM W SIDE MED CTR,CHICAGO,IL 60680	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Grammer, Leslie/0000-0001-6860-2014				ALBERT SG, 1984, DIABETES CARE, V7, P285, DOI 10.2337/diacare.7.3.285; ANDERSEN OO, 1973, ACTA ENDOCRINOL-COP, V72, P33, DOI 10.1530/acta.0.0720033; ARKINS JA, 1962, J ALLERGY, V33, P69, DOI 10.1016/0021-8707(62)90065-5; BARRETT EJ, 1982, DIABETES, V31, P923, DOI 10.2337/diabetes.31.10.923; BENSON EA, 1984, ARCH INTERN MED, V144, P2351, DOI 10.1001/archinte.144.12.2351; BODENDORFER TW, 1985, DRUG INTEL CLIN PHAR, V19, P827, DOI 10.1177/106002808501901106; CHILD DF, 1984, ALLERGY, V39, P630, DOI 10.1111/j.1398-9995.1984.tb01984.x; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; Deckert T, 1985, Diabetes, V34 Suppl 2, P94; DELEEUW I, 1982, DIABETES CARE, V5, P168, DOI 10.2337/diacare.5.2.S168; FIELD JB, 1979, ENDOCRINOLOGY, P1069; FIREMAN P, 1982, DIABETES CARE, V5, P119, DOI 10.2337/diacare.5.2.S119; FRANKLAND AW, 1982, LANCET, V2, P1468; FREYCHET P, 1971, BIOCHEM BIOPH RES CO, V43, P400, DOI 10.1016/0006-291X(71)90767-4; GARCIAORTEGA P, 1984, BRIT MED J, V288, P1271, DOI 10.1136/bmj.288.6426.1271; GOLDMAN J, 1978, DIABETES, V27, P653, DOI 10.2337/diab.27.6.653; GOLDMAN J, 1979, J CLIN INVEST, V63, P1050, DOI 10.1172/JCI109374; GOSSAIN VV, 1985, ANN ALLERGY, V55, P116; GRAMMER L, 1985, ALLERGIC DISEASES DI, P631; GRAMMER LC, 1985, J LAB CLIN MED, V105, P108; GRAMMER LC, 1984, JAMA-J AM MED ASSOC, V251, P1459, DOI 10.1001/jama.251.11.1459; GRAMMER LC, 1987, J LAB CLIN MED, V109, P141; HEDING LG, 1980, DIABETOLOGIA, V19, P511; KURTZ AB, 1980, DIABETOLOGIA, V19, P329, DOI 10.1007/BF00280515; MAISLOS M, 1988, DIABETES, V37, P1059, DOI 10.2337/diabetes.37.8.1059; NAKAGAWA S, 1973, DIABETES, V22, P590, DOI 10.2337/diab.22.8.590; OHNEDA A, 1974, DIABETES, V23, P41, DOI 10.2337/diab.23.1.41; PATTERSON R, 1973, Journal of Immunology, V110, P1135; PATTERSON R, 1984, IMMUNOLOGY CLIN EXPT, P401; RUDKOWSKI R, 1986, DIABETES, V35, P253, DOI 10.2337/diabetes.35.3.253; SAKATA S, 1986, IMMUNOL INVEST, V15, P791, DOI 10.3109/08820138609036363; SCHADE DS, 1986, NEW ENGL J MED, V315, P147, DOI 10.1056/NEJM198607173150302; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SERVICE FJ, 1976, MAYO CLIN PROC, V51, P417; SILVERSTONE P, 1986, BRIT MED J, V292, P933, DOI 10.1136/bmj.292.6525.933; SKLENAR I, 1987, DIABETES CARE, V10, P152, DOI 10.2337/diacare.10.2.152; SMALL P, 1984, ANN ALLERGY, V54, P39; TAYLOR SI, 1987, CLIN RES, V35, P49; VANHAEFTEN TW, 1987, DIABETES CARE, V10, P160, DOI 10.2337/diacare.10.2.160; VANHAEFTEN TW, 1986, METABOLISM, V35, P649, DOI 10.1016/0026-0495(86)90173-3; WALDHAUSL WK, 1985, DIABETES, V34, P166, DOI 10.2337/diabetes.34.2.166; WITTERS LA, 1977, AM J MED, V63, P703, DOI 10.1016/0002-9343(77)90155-3	42	31	38	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					45	52		10.1016/S0091-6749(05)80122-8	http://dx.doi.org/10.1016/S0091-6749(05)80122-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2196303	Bronze			2022-12-18	WOS:A1990DQ68800008
J	HOFFMAN, DR; SMITH, AM; SCHMIDT, M; MOFFITT, JE; GURALNICK, M				HOFFMAN, DR; SMITH, AM; SCHMIDT, M; MOFFITT, JE; GURALNICK, M			ALLERGENS IN HYMENOPTERA VENOM .22. COMPARISON OF VENOMS FROM 2 SPECIES OF IMPORTED FIRE ANTS, SOLENOPSIS-INVICTA AND SOLENOPSIS-RICHTERI	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VESPA LABS INC,SPRING MILLS,PA; E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858; UNIV MISSISSIPPI,MED CTR,DEPT PEDIAT,JACKSON,MS 39216	University of North Carolina; East Carolina University; University of Mississippi; University of Mississippi Medical Center	HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27858, USA.				NIAID NIH HHS [AI-17162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CIANFRIGLIA M, 1986, METHOD ENZYMOL, V121, P193; Hoffman D R, 1981, Methods Enzymol, V73, P656; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P300, DOI 10.1016/0091-6749(87)90035-2; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; LANE RD, 1986, METHOD ENZYMOL, V121, P183; LITALIEN JJ, 1986, METHODS PROTEIN MICR, P298; RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9; ROSS KG, 1987, EVOLUTION, V41, P280, DOI 10.1111/j.1558-5646.1987.tb05797.x; STABLEIN JJ, 1987, CLIN REV ALLERG, V5, P161; STAFFORD CT, 1989, SOUTHERN MED J, V82, P1515, DOI 10.1097/00007611-198912000-00014; VANDERMEER RK, 1985, FLA ENTOMOL, V68, P501, DOI 10.2307/3495147; WEISS S J, 1990, Journal of Allergy and Clinical Immunology, V85, P212	17	31	36	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					988	996		10.1016/0091-6749(90)90042-3	http://dx.doi.org/10.1016/0091-6749(90)90042-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2355158	Bronze			2022-12-18	WOS:A1990DK50900003
J	VANASPEREN, PP; KEMP, AS; MUKHI, A				VANASPEREN, PP; KEMP, AS; MUKHI, A			ATOPY IN INFANCY PREDICTS THE SEVERITY OF BRONCHIAL HYPERRESPONSIVENESS IN LATER CHILDHOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,DEPT IMMUNOL,CAMPERDOWN,NSW 2050,AUSTRALIA		VANASPEREN, PP (corresponding author), CHILDRENS HOSP,DEPT RESP MED,CAMPERDOWN,NSW 2050,AUSTRALIA.							ASHER MI, 1988, AM REV RESPIR DIS, V138, P524, DOI 10.1164/ajrccm/138.3.524; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66, DOI 10.1136/adc.62.1.66; CLOUGH JB, 1987, CLIN ALLERGY, V17, P265, DOI 10.1111/j.1365-2222.1987.tb02014.x; GALVEZ RA, 1987, J ALLERGY CLIN IMMUN, V79, P331, DOI 10.1016/0091-6749(87)90150-3; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; HOGG JC, 1970, NEW ENGL J MED, V282, P1283, DOI 10.1056/NEJM197006042822302; LONGO G, 1987, AM J DIS CHILD, V141, P331, DOI 10.1001/archpedi.1987.04460030109037; PAUWELS R, 1988, CLIN ALLERGY, V18, P317, DOI 10.1111/j.1365-2222.1988.tb02878.x; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; PEPYS J, 1972, P ROY SOC MED, V75, P271; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; VANASPEREN PP, 1989, ACTA PAEDIATR SCAND, V78, P239; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VANASPEREN PP, 1984, ACTA PAEDIATR SCAND, V73, P80; WALPOLE RE, 1982, INTRO STATISTICS, P328; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x; WOOLCOCK AJ, 1985, AIRWAY RESPONSIVENES, P80; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	21	31	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					790	795		10.1016/0091-6749(90)90200-N	http://dx.doi.org/10.1016/0091-6749(90)90200-N			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2324417				2022-12-18	WOS:A1990DA43700017
J	MORGAN, JE; ONEIL, CE; DAUL, CB; LEHRER, SB				MORGAN, JE; ONEIL, CE; DAUL, CB; LEHRER, SB			SPECIES-SPECIFIC SHRIMP ALLERGENS - RAST AND RAST-INHIBITION STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALTON OCHSNER MED FDN & OCHSNER CLIN,ALLERGY & CLIN IMMUNOL SECT,NEW ORLEANS,LA 70121	Ochsner Health System	MORGAN, JE (corresponding author), TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL & ALLERGY SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112, USA.				NIAID NIH HHS [AI 19266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019266] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUCKLEY RH, 1982, JAMA-J AM MED ASSOC, V248, P2627, DOI 10.1001/jama.248.20.2627; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; COUTURIER P, 1982, J ALLERGY CLIN IMMUN, V70, P145, DOI 10.1016/0091-6749(82)90246-9; DAUL CB, 1987, J ALLERGY CLIN IMMUN, V80, P716, DOI 10.1016/0091-6749(87)90293-4; DAUL CB, 1988, J ALLERGY CLIN IMMUN, V81, P1180, DOI 10.1016/0091-6749(88)90888-3; HALMEPURO L, 1987, INT ARCH ALLER A IMM, V84, P165, DOI 10.1159/000234418; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; KETTELHUT BV, 1986, 12 P INT C ALL CLIN, P475; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; LEHRER SB, 1985, INT ARCH ALLER A IMM, V77, P192, DOI 10.1159/000233783; LEHRER SB, 1986, ANN ALLERGY, V57, P267; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; NAGPAL S, 1987, J IMMUNOL, V138, P4169; STRICKER WE, 1986, J ALLERGY CLIN IMMUN, V77, P516, DOI 10.1016/0091-6749(86)90188-0; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4	16	31	36	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1112	1117		10.1016/0091-6749(89)90454-5	http://dx.doi.org/10.1016/0091-6749(89)90454-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2732411				2022-12-18	WOS:A1989AC23500016
J	BAUR, X; WEISS, W; JAROSCH, B; MENZ, G; SCHOCH, C; SCHMITZSCHUMANN, M; VIRCHOW, C				BAUR, X; WEISS, W; JAROSCH, B; MENZ, G; SCHOCH, C; SCHMITZSCHUMANN, M; VIRCHOW, C			IMMUNOPRINT PATTERN IN PATIENTS WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS IN DIFFERENT STAGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MUNICH,PNEUMOL ABT,MED KLIN 1,D-8000 MUNICH 2,FED REP GER; HOCHGEBIRKSGLIN DAVOS WOLFGANG,ASTHMA & ALLERGIEKLIN,DAVOS WOLFGANG,SWITZERLAND	University of Munich								BAUR X, 1985, SCHWEIZ MED WSCHR, V115, P757; BAUR X, IN PRESS INT SYNOPSE; DEWAIR M, 1984, J IMMUNOL METHODS, V75, P117, DOI 10.1016/0022-1759(84)90231-X; HARVEY C, 1986, CLIN EXP IMMUNOL, V65, P206; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P18, DOI 10.1016/0091-6749(86)90109-0; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIECHURA JE, 1983, IMMUNOLOGY, V49, P657; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLENBECK I, 1984, INT ARCH ALLER A IMM, V73, P166, DOI 10.1159/000233459	12	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					839	844		10.1016/0091-6749(89)90023-7	http://dx.doi.org/10.1016/0091-6749(89)90023-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2651510	Bronze			2022-12-18	WOS:A1989U342000020
J	BOUSQUET, J; MAURICE, F; RIVORY, JP; SKASSABROCIEK, W; FLORENCE, P; CHOUZENOUX, R; MION, C; MICHEL, FB				BOUSQUET, J; MAURICE, F; RIVORY, JP; SKASSABROCIEK, W; FLORENCE, P; CHOUZENOUX, R; MION, C; MICHEL, FB			ALLERGY IN LONG-TERM HEMODIALYSIS .2. ALLERGIC AND ATOPIC PATTERNS OF A POPULATION OF PATIENTS UNDERGOING LONG-TERM HEMODIALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR HEMODIALYSE LANGUEDOC MEDITERRANEEN, MONTPELLIER, FRANCE; CLIN NEPHROL, MONTPELLIER, FRANCE		BOUSQUET, J (corresponding author), CLIN MALAD RESP, AVE MAJOR FLANDRE, F-34059 MONTPELLIER, FRANCE.		Bousquet, Jean/O-4221-2019					BHAT K, 1984, ANN ALLERGY, V52, P282; BODNER G, 1982, NEPHRON, V32, P63, DOI 10.1159/000182805; BOMMER J, 1985, LANCET, V2, P1382; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1982, ALLERGY, V37, P397, DOI 10.1111/j.1398-9995.1982.tb02318.x; BOUSQUET J, 1987, CLIN ALLERGY, V17, P499, DOI 10.1111/j.1365-2222.1987.tb02045.x; BUTCHER BT, 1984, ARTIF ORGANS, V8, P318, DOI 10.1111/j.1525-1594.1984.tb04298.x; CARUANA RJ, 1985, AM J NEPHROL, V5, P271, DOI 10.1159/000166946; CHESTER EH, 1977, CLIN ALLERGY, V7, P15, DOI 10.1111/j.1365-2222.1977.tb01419.x; DAUGIRDAS JT, 1985, ARCH INTERN MED, V145, P489, DOI 10.1001/archinte.145.3.489; DOLOVICH J, 1978, J ALLERGY CLIN IMMUN, V62, P30, DOI 10.1016/0091-6749(78)90069-6; DOLOVICH J, 1984, ARTIF ORGANS, V8, P334, DOI 10.1111/j.1525-1594.1984.tb04301.x; DOLOVICH J, 1986, J ALLERGY CLIN IMMUN, V77, P133; DRATWA M, 1981, NEW ENGL J MED, V305, P960; GILCHREST B, 1978, DIALYSIS TRANSPLANT, V7, P1021; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V74, P544, DOI 10.1016/0091-6749(84)90392-0; KEY J, 1983, AM J KIDNEY DIS, V2, P664, DOI 10.1016/S0272-6386(83)80050-X; KJELLSTRAND CM, 1978, T AM SOC ART INT ORG, V24, P764; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MARSHALL C, 1984, CLIN NEPHROL, V21, P346; MARSHALL CP, 1985, J ALLERGY CLIN IMMUN, V75, P563, DOI 10.1016/0091-6749(85)90030-2; MAURICE F, 1982, KIDNEY INT, V22, P326; MAURICE F, 1986, J ALLERGY CLIN IMMUN, V77, P594, DOI 10.1016/0091-6749(86)90351-9; MUELLER HL, 1959, PEDIATR CLIN N AM, V6, P917; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NICHOLLS A, 1986, BRIT MED J, V292, P1221, DOI 10.1136/bmj.292.6530.1221; NICHOLLS AJ, 1982, BRIT MED J, V285, P1607, DOI 10.1136/bmj.285.6355.1607; NICHOLLS AJ, 1984, P EDTA, V21, P173; OGDEN DA, 1980, NEW ENGL J MED, V302, P1262; OY WE, 1979, J DIALYSIS, V3, P73; PATTERSON R, 1986, INT ARCH ALLER A IMM, V79, P53, DOI 10.1159/000233942; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PEPYS J, 1984, CLIN IMMUNOL ALLERGY, V4, P131; Pepys J., 1975, BR J HOSP MED, V14, P412; POOTHULLIL J, 1975, ANN INTERN MED, V82, P58, DOI 10.7326/0003-4819-82-1-58; ROCKEL A, 1986, LANCET, V1, P382; RUMPF KW, 1985, LANCET, V2, P1385; SKASSABROCIEK W, 1985, J ALLERGY CLIN IMMUN, V75, P195, DOI 10.1016/0091-6749(85)90497-X; STEPHENS GW, 1985, CLIN NEPHROL, V24, P99; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANARSDEL PP, 1984, ALLERGY PRINCIPLES P, P1389; VILLARROEL F, 1984, ARTIF ORGANS, V8, P278, DOI 10.1111/j.1525-1594.1984.tb04290.x	42	31	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					590	597		10.1016/0091-6749(88)90201-1	http://dx.doi.org/10.1016/0091-6749(88)90201-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181	3346488	Bronze			2022-12-18	WOS:A1988M618100017
J	KRAVIS, LP				KRAVIS, LP			AN ANALYSIS OF 15 CHILDHOOD ASTHMA FATALITIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,DIV ALLERGY IMMUNOL BONE MARROW TRANSPLANTAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania								CARSWELL F, 1985, ARCH DIS CHILD, V60, P25, DOI 10.1136/adc.60.1.25; COLLINSWILLIAMS C, 1981, CAN MED ASSOC J, V125, P341; CUSHLEY MJ, 1983, J ROY SOC MED, V76, P662, DOI 10.1177/014107688307600808; FUJISAWA T, 1987, J ALLERGY CLIN IMMUN, V79, P262; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; KARETZKY MS, 1975, MEDICINE, V54, P471; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; MULLALLY DI, 1985, J ALLERGY CLIN IMMUN, V75, P197, DOI 10.1016/0091-6749(85)90505-6; NGUYEN M, 1985, ANN ALLERGY, V35, P448; RUBINSTEIN S, 1984, ANN ALLERGY, V53, P311; SIEGEL SC, 1978, ALLERGY PRINCIPLES P; SLY RM, 1984, ANN ALLERGY, V53, P20; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; WOOD DW, 1976, CLIN PEDIATR, V15, P677, DOI 10.1177/000992287601500804	15	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			467	472		10.1016/0091-6749(87)90077-7	http://dx.doi.org/10.1016/0091-6749(87)90077-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624700				2022-12-18	WOS:A1987K103700025
J	SHEFFER, AL; BUIST, AS				SHEFFER, AL; BUIST, AS			PROCEEDINGS OF THE ASTHMA MORTALITY TASK-FORCE, NOVEMBER 13-16, 1986 BETHESDA, MARYLAND - PREFACE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																			0	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			361	363		10.1016/0091-6749(87)90047-9	http://dx.doi.org/10.1016/0091-6749(87)90047-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037					2022-12-18	WOS:A1987K103700001
J	SAMET, JM; MARBURY, MC; SPENGLER, JD				SAMET, JM; MARBURY, MC; SPENGLER, JD			RESPIRATORY EFFECTS OF INDOOR AIR-POLLUTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV NEW MEXICO,MED CTR,DEPT FAMILY,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,MED CTR,DEPT COMMUNITY & EMERGENCY MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,MED CTR,NEW MEXICO TUMOR REGISTRY,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,MED CTR,INTERDEPT PROGRAM EPIDEMIOL,ALBUQUERQUE,NM 87131; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM SCI & PHYSIOL,BOSTON,MA 02115	University of New Mexico; University of New Mexico; University of New Mexico; University of New Mexico; Harvard University; Harvard T.H. Chan School of Public Health	SAMET, JM (corresponding author), UNIV NEW MEXICO,MED CTR,DEPT MED,ALBUQUERQUE,NM 87131, USA.				NCI NIH HHS [N01-CN-55426] Funding Source: Medline; NIEHS NIH HHS [ES00002, ES-01108] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN055426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, R01ES001108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHLSTROM R, 1984, INDOOR AIR, V3, P461; ALEXANDERSSON R, 1982, ARCH ENVIRON HEALTH, V37, P279, DOI 10.1080/00039896.1982.10667579; ANDERSON HR, 1978, INT J EPIDEMIOL, V7, P63, DOI 10.1093/ije/7.1.63; ANDERSON HR, 1979, THORAX, V34, P647, DOI 10.1136/thx.34.5.647; BERGLUND B, 1984, INDOOR AIR, V1; BERKEY CS, 1986, AM J EPIDEMIOL, V123, P250, DOI 10.1093/oxfordjournals.aje.a114233; BLAND M, 1978, ARCH DIS CHILD, V53, P100, DOI 10.1136/adc.53.2.100; BREYSSE PA, 1980, HHS NIOSH80139 US DE; BRUNEKREEF B, 1985, INT J EPIDEMIOL, V14, P227, DOI 10.1093/ije/14.2.227; BURCHFIEL CM, 1984, THESIS U MICHIGAN; CHARLTON A, 1984, BRIT MED J, V288, P1647, DOI 10.1136/bmj.288.6431.1647; COLLEY JRT, 1974, BRIT MED J, V2, P201, DOI 10.1136/bmj.2.5912.201; COMSTOCK GW, 1981, AM REV RESPIR DIS, V124, P143; DAHMS TE, 1981, CHEST, V80, P530, DOI 10.1378/chest.80.5.530; DALLY KA, 1981, ARCH ENVIRON HEALTH, V36, P277, DOI 10.1080/00039896.1981.10667638; DODGE R, 1982, ARCH ENVIRON HEALTH, V37, P151, DOI 10.1080/00039896.1982.10667555; EKWO EE, 1983, CHEST, V84, P662, DOI 10.1378/chest.84.6.662; Fergusson D M, 1985, Pediatr Pulmonol, V1, P99, DOI 10.1002/ppul.1950010208; FINNEGAN MJ, 1984, BRIT MED J, V289, P1573, DOI 10.1136/bmj.289.6458.1573; FISCHER P, 1985, INT J EPIDEMIOL, V14, P221, DOI 10.1093/ije/14.2.221; FLOREY CDV, 1979, INT J EPIDEMIOL, V8, P347, DOI 10.1093/ije/8.4.347; FRIEDMAN GD, 1983, AM J PUBLIC HEALTH, V73, P401, DOI 10.2105/AJPH.73.4.401; FRIGAS E, 1984, MAYO CLIN PROC, V59, P295, DOI 10.1016/S0025-6196(12)61423-2; FRIGAS E, 1981, CHEST, V79, P706, DOI 10.1378/chest.79.6.706; Gammage R. B., 1985, INDOOR AIR HUMAN HLT; GILLIS CR, 1984, EUR J RESPIR DIS, V65, P121; GODISH T, 1981, J ENVIRON HEALTH, V44, P116; GORTMAKER SL, 1982, AM J PUBLIC HEALTH, V72, P574, DOI 10.2105/AJPH.72.6.574; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; HARLAP S, 1974, LANCET, V1, P529; HASSELBLAD V, 1981, AM REV RESPIR DIS, V123, P479; HENDRICK DJ, 1982, J OCCUP ENVIRON MED, V24, P893; HENDRICK DJ, 1977, BRIT J IND MED, V34, P11; HONICKY RE, 1983, PEDIATRICS, V71, P126; HONICKY RE, 1985, PEDIATRICS, V75, P587; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; IMBUS HR, 1985, J ALLERGY CLIN IMMUN, V76, P831, DOI 10.1016/0091-6749(85)90757-2; JARVIS MJ, 1985, BRIT MED J, V291, P927, DOI 10.1136/bmj.291.6500.927; JONES JR, 1983, ARCH ENVIRON HEALTH, V38, P219, DOI 10.1080/00039896.1983.10545806; KAUFFMANN F, 1983, AM J EPIDEMIOL, V117, P269, DOI 10.1093/oxfordjournals.aje.a113539; KELLER MD, 1979, ENVIRON RES, V19, P495, DOI 10.1016/0013-9351(79)90073-2; KELLER MD, 1979, ENV RES, V11, P504; KENTNER M, 1984, PREV MED, V13, P656, DOI 10.1016/S0091-7435(84)80015-8; KOSSOVE D, 1982, S AFR MED J, V61, P622; LEBOWITZ MD, 1976, CHEST, V69, P48, DOI 10.1378/chest.69.1.48; LEBOWITZ MD, 1984, EUR J RESPIR DIS, V65, P90; LEEDER SR, 1976, BRIT J PREV SOC MED, V30, P203; LEEDER SR, 1976, BRIT J PREV SOC MED, V30, P213; LEVINE RJ, 1984, J OCCUP ENVIRON MED, V26, P91; LOVE GJ, 1982, ARCH ENVIRON HEALTH, V37, P75, DOI 10.1080/00039896.1982.10667539; MAIN DM, 1983, J OCCUP ENVIRON MED, V25, P896, DOI 10.1097/00043764-198312000-00013; MASTER KM, 1974, JAMA-J AM MED ASSOC, V228, P1653, DOI 10.1001/jama.228.13.1653; MCCONNOCHIE KM, 1985, AM J DIS CHILD, V139, P625, DOI 10.1001/archpedi.1985.02140080095042; MELIA RJ, 1983, 6TH P WORLD C AIR QU, P263; MELIA RJW, 1977, BRIT MED J, V2, P149, DOI 10.1136/bmj.2.6080.149; MELIA RJW, 1982, INT J EPIDEMIOL, V11, P164, DOI 10.1093/ije/11.2.164; MELIA RJW, 1979, INT J EPIDEMIOL, V8, P333, DOI 10.1093/ije/8.4.333; MOLHAVE L, 1984, INDOOR AIR, V3, P431; NORSTED SW, 1985, ENVIRON RES, V37, P93, DOI 10.1016/0013-9351(85)90052-0; OGSTON SA, 1985, BRIT MED J, V290, P957, DOI 10.1136/bmj.290.6473.957; OLSEN JH, 1982, AM IND HYG ASSOC J, V43, P366, DOI 10.1080/15298668291409866; Pandey M R, 1985, Tokai J Exp Clin Med, V10, P471; PANDEY MR, 1984, THORAX, V39, P337, DOI 10.1136/thx.39.5.337; POPA V, 1969, DIS CHEST, V56, P395, DOI 10.1378/chest.56.5.395; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; QUACKENBOSS JJ, 1982, ENVIRON INT, V8, P249; RANTAKALLIO P, 1978, ACTA PAEDIATR SCAND, V67, P621, DOI 10.1111/j.1651-2227.1978.tb17813.x; REMIJN B, 1985, INT J EPIDEMIOL, V14, P215, DOI 10.1093/ije/14.2.215; ROBERTSON AS, 1985, BRIT MED J, V291, P373, DOI 10.1136/bmj.291.6492.373; Robinson JP., 1972, USE TIME; SARDINAS AV, 1979, J ENVIRON HEALTH, V41, P270; SCHENKER MB, 1983, AM REV RESPIR DIS, V128, P1038; SCHENKER MB, 1982, AM REV RESPIR DIS, V125, P684; SCHILLING RSF, 1977, AM J EPIDEMIOL, V106, P274, DOI 10.1093/oxfordjournals.aje.a112463; SEXTON K, 1984, ATMOS ENVIRON, V18, P1357, DOI 10.1016/0004-6981(84)90044-1; SHEPHARD RJ, 1979, ENVIRON RES, V20, P392, DOI 10.1016/0013-9351(79)90015-X; SPEIZER FE, 1980, NITROGEN OXIDES THEI, P343; SPENGLER JD, 1981, ATMOS ENVIRON, V15, P23, DOI 10.1016/0004-6981(81)90121-9; SPENGLER JD, 1985, ENVIRON SCI TECHNOL, V19, P700, DOI 10.1021/es00138a008; SPENGLER JD, 1983, SCIENCE, V221, P9, DOI 10.1126/science.6857273; SPENGLER JD, 1984, ENVIRON SCI TECHNOL, V18, pA268, DOI 10.1021/es00127a001; SPENGLER JD, 1983, ENVIRON SCI TECHNOL, V17, P164, DOI 10.1021/es00109a008; STERLING E, 1983, ARCHITECTURE-AIA J, V72, P64; TAGER IB, 1979, AM J EPIDEMIOL, V110, P15, DOI 10.1093/oxfordjournals.aje.a112783; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TASHKIN DP, 1984, AM REV RESPIR DIS, V129, P891; THUN MJ, 1982, ENVIRON RES, V29, P320, DOI 10.1016/0013-9351(82)90034-2; TURIEL I, 1983, ATMOS ENVIRON, V17, P51, DOI 10.1016/0004-6981(83)90007-0; TUTHILL RW, 1984, AM J EPIDEMIOL, V120, P952, DOI 10.1093/oxfordjournals.aje.a113966; VEDAL S, 1984, AM REV RESPIR DIS, V130, P187; WALLACE LA, 1985, INDOOR AIR HUMAN HLT, P361; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; WEISS ST, 1983, AM REV RESPIR DIS, V128, P933; WEISS ST, 1980, AM REV RESPIR DIS, V122, P697, DOI 10.1164/arrd.1980.122.5.697; WHITE JR, 1980, NEW ENGL J MED, V302, P720, DOI 10.1056/NEJM198003273021304; WIEDEMANN HP, 1986, CHEST, V89, P180, DOI 10.1378/chest.89.2.180; 1976, NITROGEN OXIDES; 1984, DHHSPHS845020S US DE; [No title captured]; 1981, INDOOR POLLUTANTS; 1981, FORMALDEHYDE OTHER A	101	31	32	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					685	700		10.1016/0091-6749(87)90197-7	http://dx.doi.org/10.1016/0091-6749(87)90197-7			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3571762	Bronze			2022-12-18	WOS:A1987H434900001
J	MATTOLI, S; FORESI, A; CORBO, GM; VALENTE, S; CIAPPI, G				MATTOLI, S; FORESI, A; CORBO, GM; VALENTE, S; CIAPPI, G			THE EFFECT OF INDOMETHACIN ON THE REFRACTORY PERIOD OCCURRING AFTER THE INHALATION OF ULTRASONICALLY NEBULIZED DISTILLED WATER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR AUXOLOGICO ITALIANO, DIV PNEUMOL PEDIAT, MILANO, ITALY	IRCCS Istituto Auxologico Italiano	MATTOLI, S (corresponding author), UNIV CATTOLICA SACRO CUORE, POLICLIN A GEMELLI, SERV FISIOPATOL RESP, LARGO S VITO 8, I-00168 ROME, ITALY.		CORBO, Giuseppe Maria/AAB-9964-2019; Mattoli, Sabrina/H-8211-2014	CORBO, Giuseppe Maria/0000-0002-8104-4659; Mattoli, Sabrina/0000-0002-6866-604X				ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; BIANCO S, 1978, PHARMACOL RES COMMUN, V10, P657, DOI 10.1016/S0031-6989(78)80009-5; BUZKA JF, 1981, PROSTAGLANDINS, V22, P683; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V130, P363; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; FABBRI LM, 1983, J ALLERGY CLIN IMMUN, V71, P468, DOI 10.1016/0091-6749(83)90463-3; GRODZINSKA L, 1975, J PHARM PHARMACOL, V27, P88, DOI 10.1111/j.2042-7158.1975.tb09414.x; HIGENBOTTAM T, 1983, BRIT MED J, V286, P1012, DOI 10.1136/bmj.286.6370.1012; HIGGS GA, 1980, EUR J PHARMACOL, V66, P81, DOI 10.1016/0014-2999(80)90297-6; HIGGS GA, 1976, ADV PROSTAG THROMB R, V1, P105; KALINER M, 1974, J IMMUNOL, V112, P664; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1986, J ALLERGY CLIN IMM S, V77, P173; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MASON RP, 1980, J BIOL CHEM, V255, P5019; MATTOLI S, IN PRESS ANN ALLERGY; MORMILE F, 1985, PROG RESPIR RES, V19, P256; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; PASARGIKLIAN M, 1977, RESPIRATION, V34, P79, DOI 10.1159/000193780; PASARGIKLIAN M, 1976, ADV PROSTAG THROMB R, V1, P461; RANDALL RW, 1980, AGENTS ACTIONS, V10, P553, DOI 10.1007/BF02024164; SCHLEIMER RP, 1984, J ALLERGY CLIN IMMUN, V74, P473, DOI 10.1016/0091-6749(84)90381-6; SHAW RJ, 1985, ALLERGY, V40, P48, DOI 10.1111/j.1398-9995.1985.tb04154.x; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; SMITH RJ, 1980, BIOCHEM PHARMACOL, V29, P2389, DOI 10.1016/0006-2952(80)90274-9; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; SWEATMAN WJ, 1968, NATURE, V217, P69, DOI 10.1038/217069a0; WASSERMAN MA, 1980, EUR J PHARMACOL, V66, P53, DOI 10.1016/0014-2999(80)90294-0; 1962, AM REV RESPIR DIS, V5, P762	33	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					678	683		10.1016/S0091-6749(87)80165-3	http://dx.doi.org/10.1016/S0091-6749(87)80165-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	3549843				2022-12-18	WOS:A1987G972000018
J	PLATTSMILLS, TAE; FIOCCO, GP; HAYDEN, ML; GUERRANT, JL; POLLART, SM; WILKINS, SR				PLATTSMILLS, TAE; FIOCCO, GP; HAYDEN, ML; GUERRANT, JL; POLLART, SM; WILKINS, SR			SERUM IGE ANTIBODIES TO TRICHOPHYTON IN PATIENTS WITH URTICARIA, ANGIOEDEMA, ASTHMA, AND RHINITIS - DEVELOPMENT OF A RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PLATTSMILLS, TAE (corresponding author), UNIV VIRGINIA,DIV ALLERGY & CLIN IMMUNOL,BOX 225,CHARLOTTESVILLE,VA 22908, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NCRR NIH HHS [RRO 0847] Funding Source: Medline; PHS HHS [A1-20565] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; DAVIES RR, 1983, CLIN ALLERGY, V13, P309, DOI 10.1111/j.1365-2222.1983.tb02605.x; FIOCCO GP, 1986, J ALLERGY CLIN IMMUN, V77, P189; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; HAY RJ, 1984, T ROY SOC TROP MED H, V78, P653, DOI 10.1016/0035-9203(84)90231-1; HAY RJ, 1983, BRIT J DERMATOL, V108, P581, DOI 10.1111/j.1365-2133.1983.tb01060.x; HONBO S, 1984, J INVEST DERMATOL, V82, P287, DOI 10.1111/1523-1747.ep12260385; KEMENY DM, 1981, CLIN ALLERGY, V11, P463, DOI 10.1111/j.1365-2222.1981.tb01620.x; MASAKAZU A, 1982, J INVEST DERMATOL, V78, P38; PLATTSMILLS TAE, 1986, ANN ALLERGY, V56, P454; SULZBERGER MB, 1930, JAMA, V99, P1504; SVEJGAARD E, 1984, ACTA DERM-VENER    S, V64, P495; TUFT L, 1949, CLIN ALLERGY, P571; WAREN RP, 1974, URTICARIA, P59; WEARY PE, 1967, ARCH DERMATOL, V95, P400, DOI 10.1001/archderm.95.4.400	15	31	31	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					40	45		10.1016/S0091-6749(87)80014-3	http://dx.doi.org/10.1016/S0091-6749(87)80014-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3805546				2022-12-18	WOS:A1987F881000010
J	HOFFMAN, DR				HOFFMAN, DR			ALLERGENS IN HYMENOPTERA VENOM-XVI - STUDIES OF THE STRUCTURES AND CROSS-REACTIVITIES OF VESPID VENOM PHOSPHOLIPASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27834, USA.							ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; HOFFMAN DR, 1978, ANN ALLERGY, V40, P171; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1982, ANN ALLERGY, V48, P82; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P606, DOI 10.1016/0091-6749(85)90037-5; HOFFMAN DR, 1981, ANN ALLERGY, V47, P304; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; LAM KS, 1980, ANAL BIOCHEM, V108, P220, DOI 10.1016/0003-2697(80)90572-2; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P553, DOI 10.1016/0091-6749(85)90028-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X	20	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					337	343		10.1016/S0091-6749(86)80086-0	http://dx.doi.org/10.1016/S0091-6749(86)80086-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3734285	Bronze			2022-12-18	WOS:A1986D726100016
J	GUERRA, IC; FAWCETT, WA; REDMON, AH; LAWRENCE, EC; ROSENBLATT, HM; SHEARER, WT				GUERRA, IC; FAWCETT, WA; REDMON, AH; LAWRENCE, EC; ROSENBLATT, HM; SHEARER, WT			PERMANENT INTRINSIC B-CELL IMMUNODEFICIENCY CAUSED BY PHENYTOIN HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BAYLOR COLL MED, DEPT PEDIAT, ALLERGY & IMMUNOL SECT, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MICROBIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT IMMUNOL, HOUSTON, TX 77030 USA; TEXAS CHILDRENS HOSP, DAVID CTR, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Shearer, William/0000-0002-2483-2130				AARLI JA, 1976, ARCH NEUROL-CHICAGO, V33, P296, DOI 10.1001/archneur.1976.00500040080014; ANTHONY JJ, 1970, ARCH NEUROL-CHICAGO, V22, P450, DOI 10.1001/archneur.1970.00480230068008; BARDANA EJ, 1983, AM J MED, V74, P289, DOI 10.1016/0002-9343(83)90630-7; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; DOSCH HM, 1982, NEW ENGL J MED, V306, P406, DOI 10.1056/NEJM198202183060707; EISEN SA, 1972, IMMUNOL COMMUN, V1, P571, DOI 10.3109/08820137209022965; GILHUS NE, 1981, J NEUROL, V226, P53, DOI 10.1007/BF00313318; GOODMANGILMAN A, 1980, PHARMACOL BASIS THER, P452; Greaves M F, 1970, Transplant Rev, V5, P45; JOSEPHS SH, 1980, J ALLERGY CLIN IMMUN, V66, P166, DOI 10.1016/0091-6749(80)90065-2; KNUTSEN AP, 1984, J PEDIATR-US, V105, P558, DOI 10.1016/S0022-3476(84)80419-9; LAWRENCE EC, 1978, J CLIN INVEST, V62, P832, DOI 10.1172/JCI109195; LAWRENCE EC, 1982, CLIN EXP IMMUNOL, V49, P96; LILLIE MA, 1983, ARCH DERMATOL, V119, P415, DOI 10.1001/archderm.119.5.415; RALLISON ML, 1961, AM J DIS CHILD, V101, P725, DOI 10.1001/archpedi.1961.04020070039007; RODRIGUEZ MCG, 1983, J CLIN LAB IMMUNOL, V11, P55; SEAGER J, 1975, LANCET, V2, P632; SLAVIN BN, 1974, J NEUROL SCI, V23, P353, DOI 10.1016/0022-510X(74)90153-1; WYBRAN J, 1972, J CLIN INVEST, V51, P2537, DOI 10.1172/JCI107069	19	31	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					603	607		10.1016/0091-6749(86)90353-2	http://dx.doi.org/10.1016/0091-6749(86)90353-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3082959				2022-12-18	WOS:A1986A938100013
J	HOFFMAN, DR				HOFFMAN, DR			ALLERGENS IN HYMENOPTERA VENOM .14. IGE BINDING ACTIVITIES OF VENOM PROTEINS FROM 3 SPECIES OF VESPIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27834, USA.							HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1982, ANN ALLERGY, V48, P82; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; HOFFMAN DR, 1981, ANN ALLERGY, V47, P304; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8	13	31	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					606	609		10.1016/0091-6749(85)90037-5	http://dx.doi.org/10.1016/0091-6749(85)90037-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	3989146				2022-12-18	WOS:A1985AHV0700011
J	IRWIN, RB; LIEBERMAN, P; FRIEDMAN, MM; KALINER, M; KAPLAN, R; BALE, G; TREADWELL, G; YOO, TJ				IRWIN, RB; LIEBERMAN, P; FRIEDMAN, MM; KALINER, M; KAPLAN, R; BALE, G; TREADWELL, G; YOO, TJ			MEDIATOR RELEASE IN LOCAL HEAT URTICARIA - PROTECTION WITH COMBINED H-1 AND H-2 ANTAGONISTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TENNESSEE, CTR HLTH SCI, MEMPHIS, TN 38163 USA; GEORGETOWN UNIV, MED CTR, SCH MED, DIV MOLEC VIROL & IMMUNOL, WASHINGTON, DC 20007 USA; NIAID, ALLERG DIS SECT, BETHESDA, MD 20205 USA; BAPTIST MEM HOSP, MEMPHIS, TN 38146 USA	University of Tennessee System; University of Tennessee Health Science Center; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baptist Memorial Hospital Memphis								ATKINS PC, 1981, J ALLERGY CLIN IMMUN, V68, P286, DOI 10.1016/0091-6749(81)90153-6; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; DAMAN L, 1978, J ALLERGY CLIN IMMUN, V61, P273, DOI 10.1016/0091-6749(78)90203-8; DELORME P, 1969, J ALLERGY, V43, P284, DOI 10.1016/0021-8707(69)90149-X; Duke WW, 1924, J AMER MED ASSOC, V83, P3, DOI 10.1001/jama.1924.02660010007002; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V67, P75, DOI 10.1016/0091-6749(81)90049-X; GREAVES MW, 1974, BRIT J DERMATOL, V90, P289, DOI 10.1111/j.1365-2133.1974.tb06404.x; HARBERT LC, 1978, IMMUNOLOGIC DISEASES, P1020; Kabat EA, 1961, EXPT IMMUNOHISTOCHEM, P133; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KAPLAN AP, 1983, ALLERGY PRINCIPLES P, P1341; LEIGH IM, 1975, BRIT J DERMATOL, V92, P191, DOI 10.1111/j.1365-2133.1975.tb03057.x; LEMANSKE R, 1982, CRC CRIT REV IMMUNOL, V1, P547; LEWIS GM, 1939, ARCH DERM SYPH SOC T, V39, P365; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; MICHAELSSON G, 1979, ACTA DERM-VENEREOL, V51, P279; MORAGAS JMD, 1973, ARCH DERMATOL, V108, P684; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1980, J ALLERGY CLIN IMMUN, V66, P358, DOI 10.1016/0091-6749(80)90114-1; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; STARR JC, 1980, ANN ALLERGY, V44, P164; TENNENBA.JI, 1973, J ALLERGY CLIN IMMUN, V51, P57, DOI 10.1016/0091-6749(73)90009-2; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WISE RD, 1978, ARCH DERMATOL, V114, P1079, DOI 10.1001/archderm.114.7.1079	26	31	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					35	39		10.1016/0091-6749(85)90801-2	http://dx.doi.org/10.1016/0091-6749(85)90801-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	2861221				2022-12-18	WOS:A1985AMV8400004
J	JOHANSSON, SGO; WUTHRICH, B; ZORTEACAFLISCH, C				JOHANSSON, SGO; WUTHRICH, B; ZORTEACAFLISCH, C			NIGHTLY ASTHMA CAUSED BY ALLERGENS IN SILK-FILLED BED QUILTS - CLINICAL AND IMMUNOLOGICAL STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP ZURICH,DERMATOL CLIN,ALLERGY STN,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital	JOHANSSON, SGO (corresponding author), KAROLINSKA HOSP,DEPT CLIN IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN.							BENNICH H, 1970, VOX SANG, V19, P1, DOI 10.1111/j.1423-0410.1970.tb01490.x; FIGLEY KARL D., 1933, JOUR ALLERGY, V5, P60, DOI 10.1016/S0021-8707(33)90171-9; FIGLEY KD, 1950, J ALLERGY, V21, P545, DOI 10.1016/0021-8707(50)90106-7; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; FUCHS E, 1955, DEUT MED WOCHENSCHR, V80, P36; HACKI, 1982, DEUT MED WOCHENSCHR, V107, P166; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; KOBAYASHI S, 1974, ALLERGOLOGIE, P124; LOWRY OH, 1951, J BIOL CHEM, V193, P265; REUNALA T, 1983, CLIN ALLERGY, V13, P383, DOI 10.1111/j.1365-2222.1983.tb02612.x; WIDE L, 1967, LANCET, V2, P1105; ZORTEACAFLISCH C, 1983, 14TH P RAST S KOLN, P209; 1983, SERICOLOGIA, V23, P5	13	31	33	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	4					452	459		10.1016/S0091-6749(85)80017-8	http://dx.doi.org/10.1016/S0091-6749(85)80017-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AFY44	3980881				2022-12-18	WOS:A1985AFY4400004
J	MARSHALL, CP; PEARSON, FC; SAGONA, MA; LEE, W; WATHEN, RL; WARD, RA; DOLOVICH, J				MARSHALL, CP; PEARSON, FC; SAGONA, MA; LEE, W; WATHEN, RL; WARD, RA; DOLOVICH, J			REACTIONS DURING HEMODIALYSIS CAUSED BY ALLERGY TO ETHYLENE-OXIDE GAS STERILIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,FAC HLTH SCI,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA; TRAVENOL LABS INC,MICROBIOL RES & DEV,MORTON GROVE,IL 60053; UNIV LOUISVILLE,HLTH SCI CTR,SCH MED,DIV NEPHROL,LOUISVILLE,KY 40202	McMaster University; University of Louisville								BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CRADDOCK PR, 1977, NEW ENGL J MED, V296, P769, DOI 10.1056/NEJM197704072961401; DOLOVICH J, 1978, J ALLERGY CLIN IMMUN, V62, P30, DOI 10.1016/0091-6749(78)90069-6; HOY WE, 1979, J DIALYSIS, V3, P73, DOI 10.3109/08860227909064913; JACOB AI, 1980, KIDNEY INT, V18, P505, DOI 10.1038/ki.1980.164; JOHANSSON SG, 1974, CLIN ALLERGY, V4, P255, DOI 10.1111/j.1365-2222.1974.tb01383.x; LAZARUS JM, 1980, KIDNEY INT, V18, P783, DOI 10.1038/ki.1980.197; NICHOLLS AJ, 1982, BRIT MED J, V285, P1607, DOI 10.1136/bmj.285.6355.1607; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; POOTHULLIL J, 1975, ANN INTERN MED, V82, P58, DOI 10.7326/0003-4819-82-1-58; RASKOVA J, 1983, FED PROC, V42, P949; Takahashi S, 1979, Nihon Jinzo Gakkai Shi, V21, P959; UEDE T, 1982, J IMMUNOL, V129, P1391	14	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					563	567		10.1016/0091-6749(85)90030-2	http://dx.doi.org/10.1016/0091-6749(85)90030-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	3989141	Bronze			2022-12-18	WOS:A1985AHV0700004
J	MATTOLI, S; ROSATI, G; MORMILE, F; CIAPPI, G				MATTOLI, S; ROSATI, G; MORMILE, F; CIAPPI, G			THE IMMEDIATE AND SHORT-TERM EFFECTS OF CORTICOSTEROIDS ON CHOLINERGIC HYPERREACTIVITY AND PULMONARY-FUNCTION IN SUBJECTS WITH WELL-CONTROLLED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR AUXOL ITALIANO PIANCAUALLO, MILANO, ITALY	IRCCS Istituto Auxologico Italiano	MATTOLI, S (corresponding author), UNIV CATTOLICA SACRO CUORE, POLICLIN A GEMELLI, SERV FISIOPATOL RESP, LARGO A GEMELLI 8, I-00168 ROME, ITALY.		Mattoli, Sabrina/H-8211-2014	Mattoli, Sabrina/0000-0002-6866-604X				ARKINS JA, 1968, J ALLERGY, V41, P209, DOI 10.1016/0021-8707(68)90043-9; ARNAUD A, 1979, LUNG, V156, P43, DOI 10.1007/BF02713990; AVIADO DM, 1970, J CLIN PHARMACOL N D, V10, P3; BOUHUYS A, 1969, J CLIN INVEST, V48, P1159, DOI 10.1172/JCI106073; EASTON JG, 1981, J ALLERGY CLIN IMMUN, V67, P388, DOI 10.1016/0091-6749(81)90084-1; ELLULMICALLEF R, 1975, THORAX, V30, P312, DOI 10.1136/thx.30.3.312; FABBRI L M, 1984, American Review of Respiratory Disease, V129, pA159; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KLAUSTERMEYER WB, 1976, ANN ALLERGY, V37, P80; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MORRIS HG, 1980, ALLERGIC DISEASES IN, P666; PIERSON WE, 1974, PEDIATRICS, V54, P282; RAMSDELL JW, 1983, J ALLERGY CLIN IMMUN, V72, P69, DOI 10.1016/0091-6749(83)90054-4; Snedecor G.W., 1980, STAT METHODS, V7; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; SVEDMYR N, 1983, EUR J RESPIR DIS, V64, P313; TIFFENEAU R, 1956, PRESSE MED, V64, P719; WEBB J, 1981, THORAX, V36, P18, DOI 10.1136/thx.36.1.18; WOLFE JD, 1979, J ALLERGY CLIN IMMUN, V63, P162; 1974, LANCET, V2, P303	23	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					214	222		10.1016/0091-6749(85)90704-3	http://dx.doi.org/10.1016/0091-6749(85)90704-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	4019953				2022-12-18	WOS:A1985APE8800016
J	FINDLAY, SR; KAGEYSOBOTKA, A; LICHTENSTEIN, LM				FINDLAY, SR; KAGEYSOBOTKA, A; LICHTENSTEIN, LM			INVITRO BASOPHIL HISTAMINE-RELEASE INDUCED BY MANNITOL IN A PATIENT WITH A MANNITOL-INDUCED ANAPHYLACTOID REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University					NIAID NIH HHS [AI 05802, AI 07290] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CZARNY D, 1980, MED J AUSTRALIA, V2, P255, DOI 10.5694/j.1326-5377.1980.tb131845.x; DESWARTE RD, 1980, ALLERGIC DISEASES DI, P452; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; GOREVIC P, 1979, J ALLERGY CLIN IMMUN, V63, P225, DOI 10.1016/0091-6749(79)90105-2; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; PARISH HM, 1965, AM J MED SCI, V245, P129; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603	8	31	31	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					578	583		10.1016/0091-6749(84)90514-1	http://dx.doi.org/10.1016/0091-6749(84)90514-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6201521				2022-12-18	WOS:A1984SS04500007
J	FREIDHOFF, LR; MARSH, DG; MEYERS, DA; HUSSAIN, R				FREIDHOFF, LR; MARSH, DG; MEYERS, DA; HUSSAIN, R			THE STRUCTURING OF AN ALLERGY INDEX BASED ON IGE-MEDIATED SKIN SENSITIVITY TO COMMON ENVIRONMENTAL ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FREIDHOFF, LR (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.		Hussain, Rabia/E-9982-2015		NIAID NIH HHS [AI-13370] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1972, ACTA ALLERGOL, V27, P439; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; DAVIS JB, 1976, CLIN ALLERGY, V6, P329, DOI 10.1111/j.1365-2222.1976.tb01913.x; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; FREIDHOFF LR, UNPUB GENETIC EPIDEM, V2; Garvey JS, 1977, METHODS IMMUNOLOGY, V3rd; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HANNAWAY PJ, 1970, ANN ALLERGY, V28, P413; HERXHEIMER H, 1954, Acta Allergol, V7, P380, DOI 10.1111/j.1398-9995.1954.tb03534.x; HUSSAIN R, 1981, J ALLERGY CLIN IMMUN, V67, P217, DOI 10.1016/0091-6749(81)90064-6; JOHNSON P, 1965, EUR POLYM J, V1, P63; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LOWENSTEIN H, 1981, J IMMUNOL, V126, P943; LOWENSTEIN H, 1983, J IMMUNOL, V130, P727; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; LOWENSTEIN H, 1981, J IMMUNOL, V126, P2501; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MARSH DG, 1973, SCIENCE, V179, P691, DOI 10.1126/science.179.4074.691; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V67, P206, DOI 10.1016/0091-6749(81)90063-4; MEYERS DA, 1981, J ALLERGY CLIN IMMUN, V67, P167, DOI 10.1016/0091-6749(81)90056-7; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V62, P314, DOI 10.1016/0091-6749(78)90164-1; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1966, CLINICAL PHARMACOLOG, V2, P639; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; ROEBBER M, 1982, J IMMUNOL, V129, P120; ROEBBER M, 1983, J IMMUNOL, V131, P706; SANTILLI J, 1980, J ALLERGY CLIN IMMUN, V65, P406, DOI 10.1016/0091-6749(80)90232-8; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SIEGEL S, 1956, NONPARAMETRIC STAT, P47; SMITH J M, 1973, Clinical Allergy, V3, P269, DOI 10.1111/j.1365-2222.1973.tb01333.x; SQUIRE JR, 1950, CLIN SCI, V9, P127; TUFT L, 1955, J ALLERGY, V26, P359, DOI 10.1016/0021-8707(55)90064-2; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	41	31	31	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					274	287		10.1016/0091-6749(83)90032-5	http://dx.doi.org/10.1016/0091-6749(83)90032-5			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6411796				2022-12-18	WOS:A1983RH93800008
J	HASEGAWA, M; TOWNLEY, RG				HASEGAWA, M; TOWNLEY, RG			DIFFERENCE BETWEEN LUNG AND SPLEEN SUSCEPTIBILITY OF BETA-ADRENERGIC RECEPTORS TO DESENSITIZATION BY TERBUTALINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,CTR ALLERG DIS,OMAHA,NE 68178	Creighton University					NHLBI NIH HHS [HL24396-03] Funding Source: Medline; NIAID NIH HHS [AI 1202907] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARONS RD, 1980, J CLIN INVEST, V65, P949, DOI 10.1172/JCI109781; AVNER BP, 1978, J PHARMACOL EXP THER, V207, P23; BARNES P, 1979, LIFE SCI, V25, P1207, DOI 10.1016/0024-3205(79)90462-4; BARNETT DB, 1977, BRIT J PHARMACOLOGY, V61, P459; BENOY CJ, 1975, BRIT J PHARMACOL, V55, P547, DOI 10.1111/j.1476-5381.1975.tb07431.x; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; CONOLLY ME, 1977, BRIT J PHARMACOL, V59, P17, DOI 10.1111/j.1476-5381.1977.tb06971.x; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GALANT SP, 1980, J CLIN INVEST, V65, P577, DOI 10.1172/JCI109702; HASEGAWA M, 1982, LIFE SCI, V30, P1035, DOI 10.1016/0024-3205(82)90522-7; HOFFMAN BB, 1979, J CYCLIC NUCL PROT, V5, P355; HOLGATE ST, 1977, LANCET, V2, P375; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; JOHNSON GL, 1978, J BIOL CHEM, V253, P1472; KENT RS, 1980, MOL PHARMACOL, V17, P14; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGI A, 1980, SCIENCE, V207, P645, DOI 10.1126/science.6101510; MANO K, 1979, LIFE SCI, V25, P1925, DOI 10.1016/0024-3205(79)90614-3; MINATOYA H, 1975, BRIT J PHARMACOL, V53, P333, DOI 10.1111/j.1476-5381.1975.tb07368.x; MINNEMAN KP, 1979, MOL PHARMACOL, V16, P21; MORRIS HG, 1977, J CYCLIC NUCL PROT, V3, P439; SANO Y, 1980, CLIN RES, V28, P431; SHEAR M, 1976, J BIOL CHEM, V251, P7572; SOMAN VR, 1980, J CLIN ENDOCR METAB, V50, P294, DOI 10.1210/jcem-50-2-294; STILES GL, 1981, J CLIN INVEST, V68, P1450, DOI 10.1172/JCI110397; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; TIPTON WR, 1979, AM REV RESPIR DIS, V119, P84; TOHMEH JF, 1980, J CLIN INVEST, V65, P836, DOI 10.1172/JCI109735; TORDA T, 1981, J PHARMACOL EXP THER, V216, P334; WESSELS MR, 1979, MOL PHARMACOL, V16, P10; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1; WOLFE BB, 1976, P NATL ACAD SCI USA, V73, P1343, DOI 10.1073/pnas.73.4.1343	35	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	2					230	238		10.1016/0091-6749(83)90104-5	http://dx.doi.org/10.1016/0091-6749(83)90104-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC188	6296215				2022-12-18	WOS:A1983QC18800009
J	HEMSTREET, MP; MILES, MV; RUTLAND, RO				HEMSTREET, MP; MILES, MV; RUTLAND, RO			EFFECT OF INTRAVENOUS ISOPROTERENOL ON THEOPHYLLINE KINETICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SAMFORD UNIV,CHILDRENS HOSP,BIRMINGHAM,AL 35209; SAMFORD UNIV,SCH PHARM,BIRMINGHAM,AL 35209; UNIV ALABAMA,DEPT PEDIAT,DIV ALLERGY,BIRMINGHAM,AL 35294	Samford University; Samford University; University of Alabama System; University of Alabama Birmingham				Miles, Michael/0000-0002-6624-330X				BRODIE BB, 1952, J BIOL CHEM, V194, P215; ELLIS EF, 1976, PEDIATRICS, V58, P542; GUSHAW JB, 1977, CLIN CHEM, V23, P1144; KOZAK PP, 1977, J ALLERGY CLIN IMMUN, V60, P149, DOI 10.1016/0091-6749(77)90042-2; LEUNG P, 1977, J ALLERGY CLIN IMMUN, V59, P440, DOI 10.1016/0091-6749(77)90007-0; LEVY G, 1976, J CLIN PHARMACOL, V16, P329, DOI 10.1002/j.1552-4604.1976.tb01528.x; NIES A S, 1976, Clinical Pharmacokinetics, V1, P135, DOI 10.2165/00003088-197601020-00005; OGILVIE RI, 1978, CLIN PHARMACOKINET, V3, P267, DOI 10.2165/00003088-197803040-00002; PARRY WH, 1976, AM J DIS CHILD, V130, P39, DOI 10.1001/archpedi.1976.02120020041006; PIAFSKY KM, 1977, CLIN PHARMACOL THER, V22, P336; RESAR RK, 1979, CHEST, V76, P11, DOI 10.1378/chest.76.1.11; TRUITT EB, 1959, J PHARM EXP THER, V100, P309; WALSON PD, 1977, J PEDIATR-US, V91, P321, DOI 10.1016/S0022-3476(77)80844-5; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; WOLFE JD, 1978, N ENGL J MED, V298, P397; WOOD DW, 1972, J ALLERGY CLIN IMMUN, V50, P75, DOI 10.1016/0091-6749(72)90002-4	16	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					360	364		10.1016/0091-6749(82)90146-4	http://dx.doi.org/10.1016/0091-6749(82)90146-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL280	7069071	Bronze			2022-12-18	WOS:A1982NL28000005
J	PATERSON, NAM; BURKA, JF; CRAIG, ID				PATERSON, NAM; BURKA, JF; CRAIG, ID			RELEASE OF SLOW-REACTING SUBSTANCE OF ANAPHYLAXIS FROM DISPERSED PIG LUNG-CELLS - EFFECT OF CYCLO-OXYGENASE AND LIPOXYGENASE INHIBITORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO,LONDON N6A 3K7,ONTARIO,CANADA; VICTORIA HOSP CORP,DEPT PHARMACOL,LONDON N6A 4S2,ONTARIO,CANADA; VICTORIA HOSP CORP,DEPT PATHOL,LONDON N6A 4S2,ONTARIO,CANADA	Western University (University of Western Ontario); Dalhousie University; Western University (University of Western Ontario); Dalhousie University; Western University (University of Western Ontario)	PATERSON, NAM (corresponding author), VICTORIA HOSP CORP,DEPT MED,LONDON N6A 4S2,ONTARIO,CANADA.							AUGSTEIN J, 1973, NATURE-NEW BIOL, V245, P215, DOI 10.1038/newbio245215a0; BACH MK, 1979, J IMMUNOL, V122, P160; BACH MK, 1980, BIOCHEM BIOPH RES CO, V93, P1121, DOI 10.1016/0006-291X(80)90605-1; BERRY PA, 1964, BRIT J PHARM CHEMOTH, V23, P201, DOI 10.1111/j.1476-5381.1964.tb01579.x; BLACKWELL GJ, 1978, PROSTAG OTH LIPID M, V16, P417, DOI 10.1016/0090-6980(78)90220-4; BLACKWELL GJ, 1980, BRIT J PHARMACOL, V68, P33, DOI 10.1111/j.1476-5381.1980.tb10696.x; BLOOM GD, 1974, INFLAMMATORY PROCESS, V1, P545; BONE RC, 1979, CHEST              S, V75, pS218; BRINKMAN GL, 1968, J ULTRA MOL STRUCT R, V23, P115, DOI 10.1016/S0022-5320(68)80035-8; BROCKLEHURST WE, 1962, PROG ALLERGY, V6, P539, DOI 10.1159/000313810; BURKA JF, 1975, INT ARCH ALLER A IMM, V49, P774, DOI 10.1159/000231461; DOWNING DT, 1970, BIOCHEM BIOPH RES CO, V40, P218, DOI 10.1016/0006-291X(70)91069-7; ENGINEER DM, 1978, BRIT J PHARMACOL, V62, P61, DOI 10.1111/j.1476-5381.1978.tb07006.x; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; FRAZIER ME, 1975, LAB INVEST, V33, P231; GUERZON GM, 1979, AM REV RESPIR DIS, V119, P59; JAKSCHIK BA, 1977, J IMMUNOL, V119, P618; JAKSCHIK BA, 1977, P NATL ACAD SCI USA, V74, P4577, DOI 10.1073/pnas.74.10.4577; KAY AB, 1976, IMMUNOLOGY, V30, P83; LERNER SA, 1977, AM REV RESPIR DIS, V115, pA62; LEWIS RA, 1974, J EXP MED, V140, P1133, DOI 10.1084/jem.140.5.1133; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; MEZEY RJ, 1978, AM REV RESPIR DIS, V118, P677, DOI 10.1164/arrd.1978.118.4.677; MORRIS HR, 1980, PROSTAG OTH LIPID M, V19, P185, DOI 10.1016/0090-6980(80)90019-2; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; ORANGE RP, 1973, J IMMUNOL, V110, P760; ORANGE RP, 1974, J IMMUNOL, V113, P316; ORNING L, 1980, P NATL ACAD SCI-BIOL, V77, P2014, DOI 10.1073/pnas.77.4.2014; PARKER CW, 1980, BIOCHEM BIOPH RES CO, V94, P1037, DOI 10.1016/0006-291X(80)90523-9; PATERSON NAM, 1976, J IMMUNOL, V117, P1356; PATERSON NAM, 1976, LUNG CELLS DISEASE, P223; PATTERSON R, 1978, J CLIN INVEST, V62, P519, DOI 10.1172/JCI109155; PEARCE FL, 1977, AGENTS ACTIONS, V7, P45, DOI 10.1007/BF01964880; PIPER PJ, 1979, BRIT J PHARMACOL, V67, P67; SIROIS P, 1979, PROSTAGLANDINS, V17, P395, DOI 10.1016/S0090-6980(79)80007-6; TROTTER CM, 1973, CLIN ALLERGY, V3, P411, DOI 10.1111/j.1365-2222.1973.tb01349.x; TURNBULL LS, 1977, LANCET, V2, P526; TURNBULL LW, 1978, LANCET, V2, P184; WANNER A, 1975, J APPL PHYSIOL, V39, P950, DOI 10.1152/jappl.1975.39.6.950; Weibel E, 1977, LUNG BIOL HLTH DISEA, V3, P1	41	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	6					426	434		10.1016/0091-6749(81)90095-6	http://dx.doi.org/10.1016/0091-6749(81)90095-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LU068	6809801				2022-12-18	WOS:A1981LU06800003
J	ROSE, JQ; NICKELSEN, JA; ELLIS, EF; MIDDLETON, E; JUSKO, WJ				ROSE, JQ; NICKELSEN, JA; ELLIS, EF; MIDDLETON, E; JUSKO, WJ			PREDNISOLONE DISPOSITION IN STEROID-DEPENDENT ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,SCH PHARM,DEPT PHARMACEUT,BUFFALO,NY 14214; SUNY BUFFALO,SCH PHARM,DEPT PEDIAT,BUFFALO,NY 14214; SUNY BUFFALO,SCH PHARM,DEPT ALLERGY & IMMUNOL,BUFFALO,NY 14214; SUNY BUFFALO,SCH MED,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Jusko, William J/G-4885-2015		NCI NIH HHS [CA-24215] Funding Source: Medline; NHLBI NIH HHS [HL-10628-03] Funding Source: Medline; NIGMS NIH HHS [GM-24211] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024211, R01GM024211] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAPLIN MD, 1979, J ALLERGY CLIN IMMUN, V63, P219; GREEN OC, 1978, J PEDIATR-US, V93, P299, DOI 10.1016/S0022-3476(78)80529-0; LOWELL FC, 1970, J ALLERGY, V45, P131; ROSE JQ, 1980, BIOPHARM DRUG DISPOS, V1, P247, DOI 10.1002/bdd.2510010504; ROSE JQ, 1980, J ALLERGY CLIN IMMUN, V66, P366, DOI 10.1016/0091-6749(80)90115-3; ROSE JQ, 1979, J CHROMATOGR, V162, P273, DOI 10.1016/S0378-4347(00)81514-5; ROSE JQ, J PHARMACOKINET BIOP; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; WEST KM, 1958, METABOLISM, V7, P441	9	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					188	193		10.1016/0091-6749(81)90060-9	http://dx.doi.org/10.1016/0091-6749(81)90060-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	7462536				2022-12-18	WOS:A1981LG77800005
J	JUTO, P				JUTO, P			ELEVATED SERUM IMMUNOGLOBULIN-E IN T-CELL-DEFICIENT INFANTS FED COWS MILK	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UMEA UNIV HOSP,DEPT CLIN VIROL,S-90185 UMEA,SWEDEN	Umea University	JUTO, P (corresponding author), UMEA UNIV HOSP,DEPT PEDIAT,S-90185 UMEA,SWEDEN.							BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; JARRETT, 1977, LANCET, V2, P223; JUTO P, 1979, J ALLERGY CLIN IMMUN, V64, P38, DOI 10.1016/0091-6749(79)90081-2; JUTO P, CLIN ALLERGY; KATZ DH, 1978, J ALLERGY CLIN IMMUN, V62, P44, DOI 10.1016/0091-6749(78)90072-6; STRANNEGARD IL, 1979, INT ARCH ALLER A IMM, V58, P175, DOI 10.1159/000232190; STRANNEGARD O, 1978, IMMUNOL REV, V41, P149, DOI 10.1111/j.1600-065X.1978.tb01463.x; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; TAYLOR, 1973, LANCET, V2, P111	9	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	5					402	407		10.1016/0091-6749(80)90120-7	http://dx.doi.org/10.1016/0091-6749(80)90120-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KQ965	6969270				2022-12-18	WOS:A1980KQ96500009
J	KING, TP				KING, TP			IMMUNOCHEMICAL PROPERTIES OF SOME ATOPIC ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KING, TP (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.							ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578; ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; ATASSI MZ, 1977, IMMUNOCHEMISTRY PROT, V2, P77; Berrens L, 1971, CHEM ATOPIC ALLERGEN; BOREL Y, 1979, J ALLERGY CLIN IMMUN, V63, P176; CHOUDHURY AM, 1978, FED PROC, V37, P1553; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; GEHA RS, 1978, J IMMUNOL, V121, P1518; GOODFRIEND L, 1979, FED PROC, V38, P1415; GOODFRIEND L, 1974, INT ARCH ALLERGY APP, V46, P215; GOODFRIEND L, 1976, ALLERGY CLIN IMMUNOL, P151; GOODMAN JW, 1975, ANTIGENS, V3, P127; GRIFFITHS BW, 1971, CAN J BIOCHEM CELL B, V49, P396, DOI 10.1139/o71-058; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; ISHIZAKA K, 1973, ANTIGENS, V1, P479; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1979, J EXP MED, V149, P424, DOI 10.1084/jem.149.2.424; KING TP, 1967, ANN ALLERGY, V25, P541; KING TP, 1978, BIOCHEMISTRY-US, V17, P1499, DOI 10.1021/bi00601a022; KING TP, 1972, BIOCHEMISTRY-US, V11, P367, DOI 10.1021/bi00753a010; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; KING TP, 1978, IMMUNOLOGICAL DISEAS, V2, P787; KLAPPER DG, UNPUBLISHED; LEE WY, 1978, IMMUNOL REV, V41, P200, DOI 10.1111/j.1600-065X.1978.tb01466.x; LEVINE BB, 1972, NEW ENGL J MED, V286, P42, DOI 10.1056/NEJM197201062860112; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; MARSH DG, 1975, ANTIGENS, V3, P271; MOLE LE, 1975, BIOCHEMISTRY-US, V14, P1216, DOI 10.1021/bi00677a019; SCHELLENBERG RR, 1979, J ALLERGY CLIN IMMUN, V63, P15, DOI 10.1016/0091-6749(79)90156-8; STANWORTH DR, 1973, IMMEDIATE HYPERSENSI; TAKATSU K, 1975, CELL IMMUNOL, V20, P276, DOI 10.1016/0008-8749(75)90105-7; TAKATSU K, 1975, J IMMUNOL, V115, P1469; UNANUE ER, 1978, FED PROC, V37, P77; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; [No title captured]	37	31	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	3					159	163		10.1016/0091-6749(79)90090-3	http://dx.doi.org/10.1016/0091-6749(79)90090-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HL221	89128				2022-12-18	WOS:A1979HL22100002
J	KATZ, P; FAUCI, AS				KATZ, P; FAUCI, AS			ACTIVATION OF HUMAN B-LYMPHOCYTES .7. REGULATORY EFFECT OF CYCLIC ADENOSINE-MONOPHOSPHATE ON HUMAN B-CELL ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KATZ, P (corresponding author), NIAID,CLIN INVEST LAB,CLIN PHYSIOL SECT,BETHESDA,MD 20014, USA.							BERENBAUM MC, 1976, IMMUNOLOGY, V30, P815; BOURNE HR, 1974, CYCLIC AMP CELL GROW, P99; DERUBERTIS FR, 1974, J IMMUNOL, V113, P151; DIAMANTSTEIN T, 1975, IMMUNOLOGY, V28, P113; FAUCI AS, 1976, P NATL ACAD SCI USA, V73, P3676, DOI 10.1073/pnas.73.10.3676; FAUCI AS, 1976, J EXP MED, V144, P674, DOI 10.1084/jem.144.3.674; FAUCI AS, 1977, J IMMUNOL, V119, P598; FAUCI AS, 1975, J CLIN INVEST, V56, P98, DOI 10.1172/JCI108085; FAUCI AS, 1976, J IMMUNOL, V117, P2100; HADDEN JW, 1972, P NATL ACAD SCI USA, V69, P3024, DOI 10.1073/pnas.69.10.3024; HAYNES BF, 1977, J IMMUNOL, V118, P2281; JOHNSON HM, 1977, NATURE, V265, P154, DOI 10.1038/265154a0; Katz D H, 1972, Adv Immunol, V15, P1, DOI 10.1016/S0065-2776(08)60683-5; KISHIMOTO T, 1976, J IMMUNOL, V116, P534; MELMON KL, 1974, J CLIN INVEST, V53, P13, DOI 10.1172/JCI107530; MORETTA L, 1977, J EXP MED, V146, P184, DOI 10.1084/jem.146.1.184; NIAUDET P, 1976, EUR J IMMUNOL, V6, P834, DOI 10.1002/eji.1830061117; PARKER CW, 1974, ADV CYCLIC NUCLEOTID, P1; SIEGAL FP, 1977, J IMMUNOL, V118, P642; Strom T B, 1977, Prog Clin Immunol, V3, P115; TEH HS, 1976, CELL IMMUNOL, V24, P220, DOI 10.1016/0008-8749(76)90207-0; TEH HS, 1976, CELL IMMUNOL, V24, P209, DOI 10.1016/0008-8749(76)90206-9; WAKSMAN BH, 1976, CELL IMMUNOL, V21, P161, DOI 10.1016/0008-8749(76)90337-3; Waldmann T A, 1977, Prog Clin Immunol, V3, P155; WEINER MS, 1973, BLOOD, V42, P939, DOI 10.1182/blood.V42.6.939.939; WEINSTEIN Y, 1975, J IMMUNOL, V115, P112	26	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	5					334	338		10.1016/0091-6749(78)90056-8	http://dx.doi.org/10.1016/0091-6749(78)90056-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EY714	205567	Bronze			2022-12-18	WOS:A1978EY71400010
J	KAPLAN, AP				KAPLAN, AP			MEDIATORS OF URTICARIA AND ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID, ALLERG DIS SECT, CLIN INVEST LAB, BETHESDA, MD 20014 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALPER CA, 1972, P NATL ACAD SCI USA, V69, P2910, DOI 10.1073/pnas.69.10.2910; AOYAMA H, 1970, JPN J DERMATOL, V80, P122; ARBESMAN CE, 1971, IMMUNOLOGIC DISEASES, V1, P405; AUSTEN KF, 1965, NEW ENGL J MED, V272, P649, DOI 10.1056/NEJM196504012721301; BAER RL, 1971, IMMUNOLOGICAL DISEAS, P973; BALLOW M, 1975, LANCET, V2, P248; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BLACK JT, 1969, ANN INTERN MED, V70, P989, DOI 10.7326/0003-4819-70-5-989; BRAVERMAN IM, 1975, J INVEST DERMATOL, V64, P105, DOI 10.1111/1523-1747.ep12510321; CARPENTER CB, 1969, J CLIN INVEST, V48, P1495, DOI 10.1172/JCI106116; COLMAN RW, 1969, BIOCHEM BIOPH RES CO, V35, P273, DOI 10.1016/0006-291X(69)90278-2; COPEMAN PWM, 1970, BR J DERM         S5, V82, P2; Costanzi J J, 1967, Clin Exp Immunol, V2, P167; COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; DAVIS PJ, 1974, JOHNS HOPKINS MED J, V135, P391; DOEGLAS HMG, 1974, ARCH DERMATOL, V110, P382, DOI 10.1001/archderm.110.3.382; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1969, J CLIN INVEST, V48, P642, DOI 10.1172/JCI106022; DONALDSON VH, 1968, J EXP MED, V127, P411, DOI 10.1084/jem.127.3.411; FORBES CD, 1970, J LAB CLIN MED, V76, P809; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GIGLI I, 1970, J IMMUNOL, V104, P574; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; HARBER LC, 1963, J INVEST DERMATOL, V41, P439, DOI 10.1038/jid.1963.138; HARPEL PC, 1975, J CLIN INVEST, V55, P593, DOI 10.1172/JCI107967; HARPEL PC, 1970, J CLIN INVEST, V49, pA40; HERXHEIMER A, 1956, CLIN SCI, V15, P195; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KAPLAN AP, 1977, MAR AM C ALL IMM NEW; KAPLAN AP, ALLERGY PRINCIPLES P; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; LAURELL AB, 1975, INT ARCH ALLER A IMM, V49, P86, DOI 10.1159/000231380; LEVER WF, 1975, HISTOPATHOLOGY SKIN; LUNDH B, 1968, Clinical and Experimental Immunology, V3, P733; MACLE TJ, 1962, QJ MED, V31, P235; MANDLE R, 1977, J BIOL CHEM, V252, P6097; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MARDER RJ, 1976, AM J MED, V61, P560, DOI 10.1016/0002-9343(76)90338-7; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; MCDUFFIE FC, 1973, MAYO CLIN PROC, V48, P340; MEIER HL, 1977, J CLIN INVEST, V60, P18, DOI 10.1172/JCI108754; METZGER WJ, 1976, J ALLERGY CLIN IMMUN, V57, P605, DOI 10.1016/0091-6749(76)90012-9; MOOREROBINSON M, 1708, BRIT J DERMATOL, V80, P794; MOROZ LA, 1971, IMMUNOLOGICAL DISEAS, P459; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; Paver W K, 1971, Australas J Dermatol, V12, P113, DOI 10.1111/j.1440-0960.1971.tb00759.x; RATNOFF OD, 1967, J EXP MED, V125, P337, DOI 10.1084/jem.125.2.337; RATNOFF OD, 1969, J EXP MED, V129, P315, DOI 10.1084/jem.129.2.315; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; ROSSE WF, 1976, CLIN RES, V24, pA482; RUDDY S, 1968, ALLERGOLOGIE, P351; SAAVEDRA JM, 1973, J PHARMACOL EXP THER, V186, P508; SAMS WM, 1969, ARCH DERMATOL, V99, P390, DOI 10.1001/archderm.99.4.390; SCHREIBER AD, 1973, J CLIN INVEST, V52, P1402, DOI 10.1172/JCI107313; SCHREIBER AD, 1973, J CLIN INVEST, V52, P1394, DOI 10.1172/JCI107312; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; SISSONS JGP, 1974, LANCET, V2, P1350; SOTER NA, 1974, J INVEST DERMATOL, V63, P485, DOI 10.1111/1523-1747.ep12680443; SOTER NA, 1977, J ALLERGY CLIN IMMUN, V59, P294, DOI 10.1016/0091-6749(77)90050-1; SOTER NA, 1976, J INVEST DERMATOL, V66, P344, DOI 10.1111/1523-1747.ep12482901; SOTER NA, 1975, J IMMUNOL, V114, P928; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; TALAMO RC, 1969, J LAB CLIN MED, V74, P816; THOMPSON RA, 1977, CLIN EXP IMMUNOL, V27, P23; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P366, DOI 10.1016/0091-6749(71)90083-2; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WARIN RP, 1974, MAJOR PROBLEMS DERMA; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WEBB DR, 1975, J ALLERGY CLIN IMMUN, V55, P106; WUEPPER KD, 1972, CLIN EXP IMMUNOL, V11, P13	74	31	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	5					324	332		10.1016/0091-6749(77)90113-0	http://dx.doi.org/10.1016/0091-6749(77)90113-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA243	144147	Bronze			2022-12-18	WOS:A1977EA24300009
J	PATTERSON, R; SUSZKO, IM; PRUZANSKY, JJ; ZEISS, CR; METZGER, WJ; ROBERTS, M				PATTERSON, R; SUSZKO, IM; PRUZANSKY, JJ; ZEISS, CR; METZGER, WJ; ROBERTS, M			POLYMERIZATION OF MIXTURES OF GRASS ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University								METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; MORAN DM, 1976, INT ARCH ALLER A IMM, V50, P693, DOI 10.1159/000231548; PATTERSON R, 1974, J IMMUNOL, V112, P1855; PATTERSON R, 1973, J IMMUNOL, V110, P1402; PATTERSON R, 1974, University of Michigan Medical Center Journal, V40, P151; PATTERSON R, 1975, AM J MED, V58, P787, DOI 10.1016/0002-9343(75)90633-6; PATTERSON R, 1976, J ALLERGY CLIN IMMUN, V57, P168, DOI 10.1016/0091-6749(76)90036-1; PATTERSON R, 1973, J IMMUNOL, V110, P1413; PATTERSON R, 1972, ALLERGIC DISEASES DI; PATTERSON R, 1975, PEDIATRICS, V56, P3	10	31	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					314	319		10.1016/0091-6749(77)90053-7	http://dx.doi.org/10.1016/0091-6749(77)90053-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	66243	Bronze			2022-12-18	WOS:A1977DB88600007
J	PINNAS, JL; STRUNK, RC; WANG, TM; THOMPSON, HC				PINNAS, JL; STRUNK, RC; WANG, TM; THOMPSON, HC			HARVESTER ANT SENSITIVITY - INVITRO AND INVIVO STUDIES USING WHOLE-BODY EXTRACTS AND VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ARIZONA,HLTH SCI CTR,DEPT INTERNAL MED,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PEDIAT,TUCSON,AZ 85724; ARIZONA MED CTR,CLIN IMMUNOL RES LAB,TUCSON,AZ 85724	University of Arizona; University of Arizona Health Sciences; University of Arizona								ARBESMAN CE, 1965, J ALLERGY, V36, P147, DOI 10.1016/0021-8707(65)90163-2; BROWN LL, 1972, SOUTHERN MED J, V65, P273, DOI 10.1097/00007611-197203000-00003; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; Cole AC, 1968, POGONOMYRMEX HARVEST; HAKANSON R, 1972, ANAL BIOCHEM, V47, P356, DOI 10.1016/0003-2697(72)90129-7; Helmly R B, 1970, Hawaii Med J, V29, P368; JAMES MT, 1969, HERMS MEDICAL ENTOMO, P396; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MCCOOK HC, 1879, NATURAL HISTORY AGRI, P168; OUCHTERLONY O, 1962, PROG ALLERGY, V6, P30, DOI 10.1159/000313795; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V56, P84, DOI 10.1016/0091-6749(75)90112-8; VANSELOW NA, 1967, MANUAL CLINICAL ALLE; WEBER NEAL A., 1959, ENT NEWS, V70, P85	17	31	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					10	16		10.1016/0091-6749(77)90170-1	http://dx.doi.org/10.1016/0091-6749(77)90170-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CS828	64481				2022-12-18	WOS:A1977CS82800002
J	SHAIKH, W; UMEMOTO, L; POOTHULLIL, J; HARGREAVE, FE; DOLOVICH, J				SHAIKH, W; UMEMOTO, L; POOTHULLIL, J; HARGREAVE, FE; DOLOVICH, J			RELATIVE REFRACTORY STATE FOR LATE CUTANEOUS ALLERGIC RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,MED CTR,DEPT PEDIAT,HAMILTON L8S 4J9,ONTARIO,CANADA; MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8S 4J9,ONTARIO,CANADA	McMaster University; McMaster University								AUSTEN KF, 1975, AM REV RESPER DIS, V112, P422; BENTLEYPHILLIPS CB, 1976, LANCET, V2, P63; Blackley CH., 1873, EXPT RESEARCHES CAUS; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; Cooke RA, 1922, J IMMUNOL, V7, P219; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FEINBERG SM, 1973, CLIN ALLERGY, V3, P403, DOI 10.1111/j.1365-2222.1973.tb01348.x; Gell PGH., 1975, CLIN ASPECTS IMMUNOL, V3; ISHIZAKA K, 1969, J IMMUNOL, V103, P588; ISHIZAKA K, 1974, PROG IMMUNOL 2, V4, P7; LICHTENSTEIN L M, 1973, P91; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; PEPYS J, 1975, CLIN ASPECTS IMMUNOL, P67; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; PRAUSNITZ C, 1962, CLIN ASPECTS IMMUNOL, P808; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X	19	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	4					242	246		10.1016/0091-6749(77)90138-5	http://dx.doi.org/10.1016/0091-6749(77)90138-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DX458	302842				2022-12-18	WOS:A1977DX45800008
J	FALLIERS, CJ				FALLIERS, CJ			TRIAMCINOLONE ACETONIDE AEROSOLS FOR ASTHMA .1. EFFECTIVE REPLACEMENT OF SYSTEMIC CORTICOSTEROID-THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGY & ASTHMA CLIN,155 COOK ST,DENVER,CO 80206									ARBESMAN CE, 1963, J ALLERGY, V34, P354, DOI 10.1016/0021-8707(63)90053-4; BURRY JN, 1973, MED J AUSTRALIA, V1, P393, DOI 10.5694/j.1326-5377.1973.tb118065.x; CAMERON SJ, 1973, BRIT MED J, V4, P205, DOI 10.1136/bmj.4.5886.205; CLARK TJH, 1972, LANCET, V1, P1361; DICKSON W, 1973, ARCH DIS CHILD, V48, P671, DOI 10.1136/adc.48.9.671; FALLIERS CJ, 1974, JAMA-J AM MED ASSOC, V230, P537, DOI 10.1001/jama.1974.03240040015009; FALLIERS CJ, 1973, LANCET, V1, P606; FALLIERS CJ, 1970, ANN ALLERGY, V28, P513; FALLIERS CJ, 1972, ANN ALLERGY, V30, P443; FALLIERS CJ, IN PRESS; FALLIERS CJ, 1972, J ALLERG CLIN IMMUNO, V49, P155; FALLIERS CJ, UNPUBLISHED SURVEY; GADDIE J, 1973, LANCET, V1, P691; GODFREY S, 1973, ARCH DIS CHILD, V48, P665, DOI 10.1136/adc.48.9.665; HERXHEIMER H, 1973, LANCET, V1, P374; JONES RS, 1973, ARCH DIS CHILD, V48, P663, DOI 10.1136/adc.48.9.663; JORGENSEN JR, 1966, J AMER MED ASSOC, V198, P773; LAB S, 1972, BRIT MED J, V3, P314; Lusted LB, 1968, INTRO MEDICAL DECISI; MABERLY DJ, 1973, BRIT MED J, V1, P778, DOI 10.1136/bmj.1.5856.778; MAUNSELL K, 1968, BMJ-BRIT MED J, V1, P661, DOI 10.1136/bmj.1.5593.661; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; Morrow-Brown H., 1972, BRIT MED J, V1, P585; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; SIEGEL SC, 1964, PEDIATRICS, V33, P245; SILVERGLADE A, 1973, LANCET, V1, P1325; TOOGOOD JH, 1965, J ALLERGY, V36, P321, DOI 10.1016/0021-8707(65)90039-0; WOOD JB, 1965, LANCET, V1, P243; 1972, PRECLINICAL TRIAL BR; 1972, LANCET, V2, P1239; 1973, LANCET, V1, P870	31	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	1					1	11		10.1016/0091-6749(76)90073-7	http://dx.doi.org/10.1016/0091-6749(76)90073-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BC141	1245679	Bronze			2022-12-18	WOS:A1976BC14100001
J	KATZ, RM; LIEBERMAN, J; SIEGEL, SC				KATZ, RM; LIEBERMAN, J; SIEGEL, SC			ALPHA-1 ANTITRYPSIN LEVELS AND PREVALENCE OF PI VARIANT PHENOTYPES IN ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CITY HOPE NATL MED CTR,LOS ANGELES,CA; UNIV CALIF,SCH MED,8540 S SEPULVEDA BLVD,SUITE 820,LOS ANGELES,CA 90045	City of Hope; University of California System; University of California Los Angeles								ERIKSSON S, 1964, ACTA MED SCAND, V175, P197; ERIKSSON S, 1965, ACTA MED SCAND  S177; ERKSTAM G, 1968, SCAND J RESPIR DIS, V49, P311; FAGERHOL MK, 1970, PROG MED GENET, V7, P96; FAGERHOL MK, 1969, ACTA ALLERGOL, V24, P107, DOI 10.1111/j.1398-9995.1969.tb03760.x; FREINKEL RL, 1973, W PEDIATR PULM RES; KUEPPERS F, 1969, SCIENCE, V165, P899, DOI 10.1126/science.165.3896.899; LIEBERMA.J, 1973, AM J HUM GENET, V25, P610; LIEBERMA.J, 1969, NEW ENGL J MED, V281, P279, DOI 10.1056/NEJM196908072810601; LIEBERMAN J, 1972, Chest, V62, P557; LIEBERMAN J, 1969, J AMER MED ASSOC, V210, P2055, DOI 10.1001/jama.210.11.2055; MITTMAN C, 1971, CHEST, V60, P214, DOI 10.1378/chest.60.3.214; TARKOFF MP, 1968, AM J MED, V45, P220, DOI 10.1016/0002-9343(68)90040-5; WEBB DR, 1973, AM REV RESPIR DIS, V108, P918; WELCH MH, 1969, ANN INTERN MED, V71, P533, DOI 10.7326/0003-4819-71-3-533	15	31	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	1					41	45		10.1016/0091-6749(76)90077-4	http://dx.doi.org/10.1016/0091-6749(76)90077-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BC141	812896	Bronze			2022-12-18	WOS:A1976BC14100005
J	LOVERA, J; COOPER, DM; COLLINSWILLIAMS, C; LEVISON, H; BAILEY, JD; ORANGE, RP				LOVERA, J; COOPER, DM; COLLINSWILLIAMS, C; LEVISON, H; BAILEY, JD; ORANGE, RP			CLINICAL AND PHYSIOLOGICAL ASSESSMENT OF ASTHMATIC-CHILDREN TREATED WITH BECLOMETHASONE DIPROPIONATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TORONTO,HOSP SICK CHILDREN,DEPT PAEDIAT,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DEPT IMMUNOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ARBESMAN CE, 1963, J ALLERGY, V34, P354, DOI 10.1016/0021-8707(63)90053-4; BROCKBANK W, 1958, LANCET, V1, P187; BROWN HM, 1973, BRIT MED J, V3, P161, DOI 10.1136/bmj.3.5872.161; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; BUISSERET PD, 1973, ACTA ALLERGOL, V28, P126, DOI 10.1111/j.1398-9995.1973.tb01318.x; CAMERON SJ, 1973, BRIT MED J, V4, P205, DOI 10.1136/bmj.4.5886.205; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; CHOO-KANG Y F J, 1972, British Journal of Diseases of the Chest, V66, P101, DOI 10.1016/S0007-0971(72)80031-7; CLARK TJH, 1972, LANCET, V1, P1361; CREPEA SB, 1963, J ALLERGY, V34, P119, DOI 10.1016/0021-8707(63)90065-0; DICKSON W, 1973, ARCH DIS CHILD, V48, P671, DOI 10.1136/adc.48.9.671; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; EPSTEIN E, 1962, CLIN CHIM ACTA, V7, P735, DOI 10.1016/0009-8981(62)90161-4; FRAINBELL W, 1967, BRIT J DERMATOL, V79, P487; FREARS JF, 1973, ARCH DIS CHILD, V48, P856, DOI 10.1136/adc.48.11.856; GADDIE J, 1973, LANCET, V1, P691; GADDIE J, 1973, LANCET, V2, P280; GODFREY S, 1973, ARCH DIS CHILD, V48, P665, DOI 10.1136/adc.48.9.665; HARRIS D M, 1973, Clinical Allergy, V3, P243, DOI 10.1111/j.1365-2222.1973.tb01329.x; HARTOG M, 1964, LANCET, V2, P376; JONES RS, 1973, ARCH DIS CHILD, V48, P663, DOI 10.1136/adc.48.9.663; LAL S, 1972, BMJ-BRIT MED J, V3, P314, DOI 10.1136/bmj.3.5822.314; MALONE DNS, 1970, LANCET, V2, P733; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; PETERSON RE, 1957, ANAL CHEM, V29, P144, DOI 10.1021/ac60121a042; PINES A, 1973, PRACTITIONER, V211, P86; SILBER RH, 1954, J BIOL CHEM, V210, P923; SILVERMAN M, 1972, BMJ-BRIT MED J, V3, P378, DOI 10.1136/bmj.3.5823.378; SMITH J M, 1973, Clinical Allergy, V3, P249, DOI 10.1111/j.1365-2222.1973.tb01330.x; SMITH JM, 1958, LANCET, V2, P1248; TOOGOOD JH, 1965, J ALLERGY, V36, P321, DOI 10.1016/0021-8707(65)90039-0; VESTERGAARD P, 1951, ACTA ENDOCRINOL-COP, V8, P193, DOI 10.1530/acta.0.0080193; WALFISH PE, 1972, MOD MED CANADA, V27, P348; WALSH SD, 1966, BMJ-BRIT MED J, V2, P796, DOI 10.1136/bmj.2.5517.796; ZAPLETAL A, 1969, J APPL PHYSIOL, V26, P308, DOI 10.1152/jappl.1969.26.3.308	37	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	2					112	123		10.1016/0091-6749(76)90030-0	http://dx.doi.org/10.1016/0091-6749(76)90030-0			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BE952	765382				2022-12-18	WOS:A1976BE95200003
J	METZGER, WJ; KAPLAN, AP; BEAVEN, MA; IRONS, JS; PATTERSON, R				METZGER, WJ; KAPLAN, AP; BEAVEN, MA; IRONS, JS; PATTERSON, R			HEREDITARY VIBRATORY ANGIOEDEMA - CONFIRMATION OF HISTAMINE-RELEASE IN A TYPE OF PHYSICAL HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; NHLI,PULM BRANCH,BETHESDA,MD 20014; NIAID,CLIN INVEST LAB,BETHESDA,MD 20014	Northwestern University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BEALL GN, 1963, J ALLERGY, V34, P8, DOI 10.1016/0021-8707(63)90080-7; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; Beaven MA., 1975, HDB PSYCHOPHARMACOLO, V1, P253; ILLIG L, 1967, ARCH KLIN EXP DERM, V229, P360, DOI 10.1007/BF00509213; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P104; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; SAAVEDRA JM, 1973, J PHARMACOL EXP THER, V186, P508; TALAMO RC, 1969, J LAB CLIN MED, V74, P816	8	31	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					605	608		10.1016/0091-6749(76)90012-9	http://dx.doi.org/10.1016/0091-6749(76)90012-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	58881				2022-12-18	WOS:A1976BV05400012
J	Bachert, C; Han, JK; Desrosiers, MY; Gevaert, P; Heffler, E; Hopkins, C; Tversky, JR; Barker, P; Cohen, D; Emson, C; Martin, UJ; Shih, VH; Necander, S; Kreindler, JL; Jison, M; Werkstrom, V				Bachert, Claus; Han, Joseph K.; Desrosiers, Martin Y.; Gevaert, Philippe; Heffler, Enrico; Hopkins, Claire; Tversky, Jody R.; Barker, Peter; Cohen, David; Emson, Claire; Martin, Ubaldo J.; Shih, Vivian H.; Necander, Sofia; Kreindler, James L.; Jison, Maria; Werkstrom, Viktoria			Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; eosinophilia; type 2 inflammation; nasal polyposis; biologic; IL-5 receptor; sinonasal polyposis; systemic corticosteroids; intranasal corticosteroids; nasal blockage	SINUS SURGERY; ASTHMA; ENDOTYPES; SYSTEM; IMPACT; LIFE	Background: Eosinophilic inflammation has been implicated in the pathogenesis, severity, and treatment responsiveness of chronic rhinosinusitis with nasal polyps (CRSwNP). Objective: We sought to assess the efficacy and safety of benralizumab-mediated eosinophil depletion for treating CRSwNP. Methods: The phase 3 OSTRO study enrolled patients with severe CRSwNP who were symptomatic despite treatment with intranasal corticosteroids and who had a history of systemic corticosteroid (SCS) use and/or surgery for nasal polyps (NP). Patients were randomized 1:1 to treatment with benralizumab 30 mg or placebo every 4 weeks for the first 3 doses and every 8 weeks thereafter. Coprimary end points were change from baseline to week 40 in NP score (NPS) and patient-reported mean nasal blockage score reported once every 2 weeks. Results: The study population comprised 413 randomized patients (207 in the benralizumab group and 206 in the placebo group). Benralizumab significantly improved NPS and nasal blockage score compared to placebo at week 40 (P <= .005). Improvements in Sinonasal Outcome Test 22 score at week 40, time to first NP surgery and/or SCS use for NP, and time to first NP surgery were not statistically significant between treatment groups. Nominal significance was obtained for improvement in difficulty in sense of smell score at week 40 (P = .003). Subgroup analyses suggested influences of comorbid asthma, number of NP surgeries, sex, body mass index, and baseline blood eosinophil count on treatment effects. Benralizumab was safe and well tolerated. Conclusion: Benralizumab, when added to standard-of-care therapy, reduced NPS, decreased nasal blockage, and reduced difficulty with sense of smell compared to placebo in patients with CRSwNP.	[Bachert, Claus; Gevaert, Philippe] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Han, Joseph K.] Eastern Virginia Med Sch, Norfolk, VA USA; [Desrosiers, Martin Y.] Univ Montreal, Ctr hosp, Ctr Rech, CRCHUM, Montreal, PQ, Canada; [Heffler, Enrico] IRCCS, Human Clin & Res Ctr, Rozzano, Italy; [Heffler, Enrico] Human Univ, Pieve Emanuele, Italy; [Hopkins, Claire] Guys & St Thomas NHS Trust, London, England; [Tversky, Jody R.] Johns Hopkins Univ, Baltimore, MD USA; [Barker, Peter; Cohen, David; Martin, Ubaldo J.; Shih, Vivian H.; Kreindler, James L.; Jison, Maria] AstraZeneca, Gaithersburg, MD USA; [Emson, Claire] AstraZeneca, Res & Early Dev Resp & Immunol BioPharmaceut R&D, Translat Sci & Expt Med, Gaithersburg, MD USA; [Necander, Sofia; Werkstrom, Viktoria] AstraZeneca, Gothenburg, Sweden; [Bachert, Claus] Univ Ghent, Upper Airways Res Lab, B-9000 Ghent, Belgium	Ghent University; Eastern Virginia Medical School; Universite de Montreal; Guy's & St Thomas' NHS Foundation Trust; Johns Hopkins University; AstraZeneca; AstraZeneca; AstraZeneca; Ghent University	Bachert, C (corresponding author), Univ Ghent, Upper Airways Res Lab, B-9000 Ghent, Belgium.	Claus.Bachert@UGent.be	Heffler, Enrico/F-9455-2010	Heffler, Enrico/0000-0002-0492-5663				[Anonymous], FAS BENR PRESCR INF, P2021; Baba S, 2015, ALLERGY ASTHMA CL IM, V11, DOI 10.1186/s13223-015-0100-2; Bachert C, 2021, J ALLERGY CLIN IMMUN, V147, P29, DOI 10.1016/j.jaci.2020.11.013; Bachert C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00218-1; Bachert C, 2020, J ALLER CL IMM-PRACT, V8, P1514, DOI 10.1016/j.jaip.2020.03.007; Barros R, 2017, CLIN NUTR, V36, P1068, DOI 10.1016/j.clnu.2016.06.023; Calus L, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0269-4; Cardell LO, 2020, J ALLERGY CLIN IMMUN, V145, P752, DOI 10.1016/j.jaci.2020.01.019; Chen S, 2020, CURR MED RES OPIN, V36, P1897, DOI 10.1080/03007995.2020.1815682; Chitguppi C, 2021, AM J RHINOL ALLERGY, V35, P559, DOI 10.1177/1945892420978351; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Han JK, 2021, LANCET RESP MED, V9, P1141, DOI 10.1016/S2213-2600(21)00097-7; Harrison TW, 2021, LANCET RESP MED, V9, P260, DOI 10.1016/S2213-2600(20)30414-8; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Hopkins C, 2007, OTOLARYNG HEAD NECK, V137, P555, DOI 10.1016/j.otohns.2007.02.004; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Kountakis SE, 2004, LARYNGOSCOPE, V114, P1895, DOI 10.1097/01.mlg.0000147917.43615.c0; Laidlaw TM, 2019, LARYNGOSCOPE, V129, pE61, DOI 10.1002/lary.27564; Lombardo N, 2020, INT J IMMUNOPATH PH, V34, DOI 10.1177/2058738420950851; Orlandi RR, 2021, INT FORUM ALLERGY RH, V11, P213, DOI 10.1002/alr.22741; Radabaugh JP, 2019, AM J RHINOL ALLERGY, V33, P507, DOI 10.1177/1945892419846263; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Staikuniene J, 2008, MEDICINA-LITHUANIA, V44, P257, DOI 10.3390/medicina44040033; Stevens WW, 2019, J ALLER CL IMM-PRACT, V7, P2812, DOI 10.1016/j.jaip.2019.05.009; Stevens WW, 2016, J ALLER CL IMM-PRACT, V4, P565, DOI 10.1016/j.jaip.2016.04.012; Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631; Tajudeen BA, 2019, LARYNGOSCOPE, V129, P794, DOI 10.1002/lary.27693; Takabayashi T, AM J RHINOL ALLERGY, V2021; Tokunaga T, 2015, ALLERGY, V70, P995, DOI 10.1111/all.12644; Pham TH, 2016, RESP MED, V111, P21, DOI 10.1016/j.rmed.2016.01.003; Tversky J, 2021, CLIN EXP ALLERGY, V51, P836, DOI 10.1111/cea.13852; van der Veen J, 2017, ALLERGY, V72, P282, DOI 10.1111/all.12983; Vlaminck S, 2014, AM J RHINOL ALLERGY, V28, P260, DOI 10.2500/ajra.2014.28.4024; Wang M, 2020, CLIN TRANSL ALLERGY, V10, DOI 10.1186/s13601-020-00332-z; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Zuo KJ, 2014, EUR ARCH OTO-RHINO-L, V271, P2461, DOI 10.1007/s00405-014-2910-0	38	30	30	7	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2022	149	4					1309	+		10.1016/j.jaci.2021.08.030	http://dx.doi.org/10.1016/j.jaci.2021.08.030			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	0Z8PK	34599979				2022-12-18	WOS:000791333500007
J	Matsumoto, K; Saito, H				Matsumoto, Kenji; Saito, Hirohisa			Does asthma affect morbidity or severity of COVID-19?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Coronavirus disease 2019; asthma; angiotensin-converting enzyme 2; IFN; T2 cytokines	INFECTIONS		[Matsumoto, Kenji; Saito, Hirohisa] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan	National Center for Child Health & Development - Japan	Matsumoto, K (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Setagaya Ku, Tokyo 1578535, Japan.	matsumoto-k@ncchd.go.jp		Saito, Hirohisa/0000-0002-6630-8337	National Center for Child Health and Development of Japan [2020B-4]	National Center for Child Health and Development of Japan	This work was supported in part by a grant from the National Center for Child Health and Development of Japan (grant no. 2020B-4 to K.M.).	Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Kimura H, 2020, J ALLERGY CLIN IMMUN, V146, P80, DOI 10.1016/j.jaci.2020.05.004; Li X, J ALLERGY CLIN IMMUN, DOI [10.1016/j.jaci.2020.04., DOI 10.1016/J.JACI.2020.04]; Meyers K, 2020, ANN EMERG MED; Van Bever HP, 2004, PEDIAT ALLERG IMM-UK, V15, P206, DOI 10.1111/j.1399-3038.2004.00137.x; Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027; Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035	10	30	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					55	57		10.1016/j.jaci.2020.05.017	http://dx.doi.org/10.1016/j.jaci.2020.05.017			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32470485	Bronze, Green Published			2022-12-18	WOS:000579170500008
J	Li, SL; Kang, P; Zhang, WF; Jian, Z; Zhang, Q; Yi, XL; Guo, S; Guo, WN; Shi, Q; Li, B; He, YM; Song, P; Liu, L; Li, K; Wang, G; Gao, TW; Li, CY				Li, Shuli; Kang, Pan; Zhang, Weigang; Jian, Zhe; Zhang, Qian; Yi, Xiuli; Guo, Sen; Guo, Weinan; Shi, Qiong; Li, Bing; He, Yuanmin; Song, Pu; Liu, Ling; Li, Kai; Wang, Gang; Gao, Tianwen; Li, Chunying			Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NLR family pyrin domain containing 3 inflammasome; vitiligo; keratinocyte; oxidative stress; transient receptor potential cation channel subfamily M member 2; calcium influx; T-cell response; chemokine; cytokine	UNFOLDED PROTEIN RESPONSE; NF-KAPPA-B; SIGNALING PATHWAY; UP-REGULATION; IL-1; EXPRESSION; RECEPTORS; MECHANISM; CD4(+); MELANOCYTES	Background: Keratinocytes can function as innate immune cells under oxidative stress and aggravate the cutaneous T-cell response that undermines melanocytes in the setting of vitiligo. The NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a regulator of innate immunity that exists in keratinocytes. However, the role of the NLRP3 inflammasome in the pathogenesis of vitiligo has not been investigated. Objective: We sought to explicate the contribution of the activated NLRP3 inflammasome in keratinocytes to the autoimmune response in patients with vitiligo. Methods: Perilesional and serum samples from patients with vitiligo were collected to examine the status of the NLRP3 inflammasome in the setting of vitiligo. Cultured keratinocytes were treated with H2O2 to investigate the mechanism for NLRP3 inflammasome activation under oxidative stress. Peripheral blood T cells were extracted from patients with vitiligo to explore the influence of the NLRP3 inflammasome on the T-cell response in patients with vitiligo. Results: Expressions of NLRP3 and downstream cytokine IL-1 beta were consistently increased in perilesional keratinocytes of patients with vitiligo. Notably, serum IL-1 beta levels were increased in patients with vitiligo, correlated with disease activity and severity, and decreased after effective therapy. Furthermore, oxidative stress promoted NLRP3 inflammasome activation in keratinocytes through transient receptor potential cation channel subfamily M member 2 (TRPM2), a redox-sensitive cation channel, which was dependent on TRPM2-mediated calcium influx. More importantly, blocking TRPM2-induced NLRP3 inflammasome activation in keratinocytes impaired chemotaxis for CD81(+) T cells and inhibited the production of cytokines in T cells in patients with vitiligo. Conclusion: Oxidative stress-induced NLRP3 inflammasome activation in keratinocytes promotes the cutaneous T-cell response, which could be targeted for the treatment of vitiligo.	[Li, Shuli; Kang, Pan; Zhang, Weigang; Jian, Zhe; Zhang, Qian; Yi, Xiuli; Guo, Sen; Guo, Weinan; Shi, Qiong; Li, Bing; Song, Pu; Liu, Ling; Li, Kai; Wang, Gang; Gao, Tianwen; Li, Chunying] Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, 127 West Changle Rd, Xian 710032, Shaanxi, Peoples R China; [He, Yuanmin] Southwest Med Univ Luzhou, Affiliated Hosp, Dept Dermatol, Luzhou, Peoples R China	Air Force Military Medical University	Li, CY (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, 127 West Changle Rd, Xian 710032, Shaanxi, Peoples R China.	lichying@fmmu.edu.cn	Jian, Zhe/AAJ-7339-2020; Wang, Gang/H-6710-2019; guo, sen/GWQ-3573-2022	Li, Shuli/0000-0002-2335-507X; Wang, Gang/0000-0002-5842-8080; Guo, Weinan/0000-0002-3517-3898; Li, Bing/0000-0002-8080-9883	National Natural Science Foundation of China [91742201, 81930087, 81472863, 81803112, 81602764, 81803122]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The research has received funding from the National Natural Science Foundation of China (nos. 91742201, 81930087, 81472863, 81803112, 81602764, and 81803122).	Bastonini E, 2019, EXP DERMATOL, V28, P667, DOI 10.1111/exd.13868; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Ben-Sasson SZ, 2013, J EXP MED, V210, P491, DOI 10.1084/jem.20122006; Bradshaw EM, 2009, J IMMUNOL, V183, P4432, DOI 10.4049/jimmunol.0900576; Burian M, 2018, J INVEST DERMATOL, V138, P2507, DOI 10.1016/j.jid.2018.08.004; Coccia M, 2012, J EXP MED, V209, P1595, DOI 10.1084/jem.20111453; Curtsinger JM, 1999, J IMMUNOL, V162, P3256; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P2095, DOI 10.1016/j.jaci.2018.11.031; Dani P, 2018, BRIT J DERMATOL, V178, P482, DOI 10.1111/bjd.15391; Engelbertsen D, 2018, CARDIOVASC RES, V114, P180, DOI 10.1093/cvr/cvx196; Fenini G, 2018, J INVEST DERMATOL, V138, P2644, DOI 10.1016/j.jid.2018.07.016; Feriotti C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00786; FISCHER H, 1990, J IMMUNOL, V145, P3767; Frisoli ML, 2017, J ALLERGY CLIN IMMUN, V140, P654, DOI 10.1016/j.jaci.2017.07.011; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gris D, 2010, J IMMUNOL, V185, P974, DOI 10.4049/jimmunol.0904145; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; HALVORSEN R, 1987, SCAND J IMMUNOL, V26, P197, DOI 10.1111/j.1365-3083.1987.tb02252.x; He Y, 2016, NATURE, V530, P354, DOI 10.1038/nature16959; Hope JC, 2001, J LEUKOCYTE BIOL, V69, P271; Hu CY, 2015, P NATL ACAD SCI USA, V112, P11318, DOI 10.1073/pnas.1513509112; Inoue M, 2012, P NATL ACAD SCI USA, V109, P10480, DOI 10.1073/pnas.1201836109; Jain A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05489-7; Jian Z, 2014, J INVEST DERMATOL, V134, P2221, DOI 10.1038/jid.2014.152; Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5; Kang P, 2018, FREE RADICAL BIO MED, V126, P259, DOI 10.1016/j.freeradbiomed.2018.08.022; KLARNET JP, 1989, J IMMUNOL, V142, P2187; Kulkarni NN, 2017, J INVEST DERMATOL, V137, P2417, DOI 10.1016/j.jid.2017.07.814; Laddha NC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107020; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Lee DJ, 2015, J INVEST DERMATOL, V135, P2012, DOI 10.1038/jid.2015.119; Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588; Levandowski CB, 2013, P NATL ACAD SCI USA, V110, P2952, DOI 10.1073/pnas.1222808110; Li SL, 2017, J ALLERGY CLIN IMMUN, V140, P177, DOI 10.1016/j.jaci.2016.10.013; LOWENTHAL JW, 1987, J IMMUNOL, V138, P1; Ma ZY, 2017, CELL MOL IMMUNOL, V14, P997, DOI 10.1038/cmi.2017.43; Marie J, 2014, BRIT J DERMATOL, V170, P816, DOI 10.1111/bjd.12691; Martinotti S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030764; Mitra S, 2017, FREE RADICAL RES, V51, P986, DOI 10.1080/10715762.2017.1402303; MIZUOCHI T, 1988, J IMMUNOL, V141, P1571; Novais FO, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006196; PANZER S, 1990, SCAND J IMMUNOL, V32, P359, DOI 10.1111/j.1365-3083.1990.tb02930.x; Qin M, 2015, J INVEST DERMATOL, V135, P2723, DOI 10.1038/jid.2015.277; Rashighi M, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.11.36; Richmond JM, 2017, J INVEST DERMATOL, V137, P350, DOI 10.1016/j.jid.2016.09.016; Richmond JM, 2013, CURR OPIN IMMUNOL, V25, P676, DOI 10.1016/j.coi.2013.10.010; Rimessi A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7201; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Taieb A, 2007, PIGM CELL RES, V20, P27, DOI 10.1111/j.1600-0749.2006.00355.x; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Toosi S, 2012, J INVEST DERMATOL, V132, P2601, DOI 10.1038/jid.2012.181; Tu CX, 2003, J DERMATOL SCI, V31, P73, DOI 10.1016/S0923-1811(02)00151-2; van den Boorn JG, 2009, J INVEST DERMATOL, V129, P2220, DOI 10.1038/jid.2009.32; Zhang C, 2018, J INVEST DERMATOL, V138, P375, DOI 10.1016/j.jid.2017.09.005; Zhang WG, 2017, J PATHOL, V241, P392, DOI 10.1002/path.4848; Zhang X, 2015, J IMMUNOL, V194, P5139, DOI 10.4049/jimmunol.1401680; Zhang YJ, 2014, J INVEST DERMATOL, V134, P183, DOI 10.1038/jid.2013.268; Zhang Z., 2018, ELIFE, V7; Zhen Y, 2016, ARCH DERMATOL RES, V308, P703, DOI 10.1007/s00403-016-1690-3; Zhong ZY, 2018, NATURE, V560, P198, DOI 10.1038/s41586-018-0372-z; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	62	30	31	4	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					632	645		10.1016/j.jaci.2019.10.036	http://dx.doi.org/10.1016/j.jaci.2019.10.036			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31756352	Bronze			2022-12-18	WOS:000512887400025
J	Barnes, PJ; Szefler, SJ; Reddel, HK; Chipps, BE				Barnes, Peter J.; Szefler, Stanley J.; Reddel, Helen K.; Chipps, Bradley E.			Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; dyspnea; breathlessness; perception; overperception; underperception; patient behavior	HISTAMINE-INDUCED BRONCHOCONSTRICTION; INHALED CORTICOSTEROIDS; RESPIRATORY SENSATION; FATAL ASTHMA; DYSPNEA; METHACHOLINE; RESPONSES; INFLAMMATION; CHILDREN; HOSPITALIZATION	Background: Asthma causes the unpleasant sensation of breathlessness (dyspnea) caused by airway obstruction. Patients with poor perception of airway obstruction are at risk of delay in seeking medical attention and undertreatment, which can lead to avoidable deaths. Conversely, those with heightened perception are at risk of overtreatment and iatrogenic adverse effects with reliever medications, anxiety, and unnecessary use of health care resources. Objective: We sought to review evidence about symptom misperception in asthmatic patients and how to identify and manage affected patients, particularly with regard to reliever medications. Methods: We conducted a systematic literature search for studies of perception of airway function in asthmatic patients. We searched the OVID (Medline and Medline [R] in process [PubMed]), Embase, and Adisearch/Odyssey databases, restricting our search to human studies published in English from 1990-2018, with no restrictions on age, sex, or racial origin. Results: We found that both underperception and overperception assessed during induced bronchoconstriction or bronchodilation or during changes in airway resistance were common across all age groups and that aging, disease severity, smoking, sex, ethnicity, psychologic factors, and medication are all associated with differences in perception. Importantly, airway inflammation was associated with impaired perception and a history of severe or near-fatal asthma. We also identified knowledge gaps, such as whether an individual patient's perception varies over time and the influence perception has on patients' use of reliever medication. Conclusion: We found that abnormal perception of airway obstruction has important clinical implications for the management of patients with asthma.	[Barnes, Peter J.] Imperial Coll, Natl Heart & Lung Inst, Guy Scadding Bldg,Dovehouse St, London SW3 6LY, England; [Szefler, Stanley J.] Childrens Hosp Colorado, Paediat Asthma Res Program, Aurora, CO USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Breathing Inst, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Reddel, Helen K.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia; [Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA	Imperial College London; Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Sydney; Woolcock Institute of Medical Research	Barnes, PJ (corresponding author), Imperial Coll, Natl Heart & Lung Inst, Guy Scadding Bldg,Dovehouse St, London SW3 6LY, England.	p.j.barnes@imperial.ac.uk	Reddel, Helen/AAC-3394-2020; Reddel, Helen/ABD-6338-2021	Reddel, Helen/0000-0002-6695-6350; Barnes, Peter/0000-0002-5122-4018	AstraZeneca, Gothenburg, Sweden	AstraZeneca, Gothenburg, Sweden(AstraZeneca)	We thank Sophieanne Wastling and David Candlish of inScience Communications, Springer Healthcare, United Kingdom, for providing medical writing support, which was funded by AstraZeneca, Gothenburg, Sweden in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).	Ambrosino N, 2004, BREATHE, V1, P100, DOI [10.1183/18106838.0102.100, DOI 10.1183/18106838.0102.100]; [Anonymous], EUR RESP J; Asthma Australia, 2018, OV SHORT ACT BETA2 A; Baker RR, 2000, J ASTHMA, V37, P613, DOI 10.3109/02770900009090817; Banzett RB, 2000, AM J RESP CRIT CARE, V162, P1178, DOI 10.1164/ajrccm.162.3.9909112; Barbaro MPF, 2011, RESP MED, V105, P195, DOI 10.1016/j.rmed.2010.09.013; Barnes CB, 2015, RESP CARE, V60, P455, DOI 10.4187/respcare.03200; Barreiro E, 2004, EUR RESPIR J, V24, P219, DOI 10.1183/09031936.04.00074703; Bijl-Hofland ID, 2000, CHEST, V117, P954, DOI 10.1378/chest.117.4.954; Bijl-Hofland ID, 1999, THORAX, V54, P15, DOI 10.1136/thx.54.1.15; Binks AP, 2014, RESP PHYSIOL NEUROBI, V204, P78, DOI 10.1016/j.resp.2014.09.005; BONER AL, 1992, J ASTHMA, V29, P323, DOI 10.3109/02770909209044792; Boudreau M, 2017, PSYCHOSOM MED, V79, P576, DOI 10.1097/PSY.0000000000000443; BOULET LP, 1994, CHEST, V105, P1430, DOI 10.1378/chest.105.5.1430; Boulet LP, 1998, CHEST, V114, P373, DOI 10.1378/chest.114.2.373; BOULET LP, 1994, THORAX, V49, P965, DOI 10.1136/thx.49.10.965; CONNOLLY MJ, 1992, THORAX, V47, P410, DOI 10.1136/thx.47.6.410; De Peuter S, 2007, RESP MED, V101, P925, DOI 10.1016/j.rmed.2006.09.018; Deesomchok A, 2010, AM J RESP CRIT CARE, V181, P125, DOI 10.1164/rccm.200906-0934OC; Ekici A, 2010, ALLERGY ASTHMA PROC, V31, pE106, DOI 10.2500/aap.2010.31.3408; Ekici M, 2001, J ASTHMA, V38, P691, DOI 10.1081/JAS-100107547; Forno E, 2018, PEDIAT ALLER IMM PUL, V31, P139, DOI 10.1089/ped.2018.0906; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Grant S, 1999, CHEST, V116, P1208, DOI 10.1378/chest.116.5.1208; Hardie G, 2010, J ASTHMA, V47, P388, DOI 10.3109/02770903.2010.481341; Higgs CMB, 1996, CLIN SCI, V90, P227, DOI 10.1042/cs0900227; Jang AS, 2000, ANN ALLERG ASTHMA IM, V84, P79, DOI 10.1016/S1081-1206(10)62744-5; Jonkers RE, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-141; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; Kopel SJ, 2010, BIOL PSYCHOL, V84, P135, DOI 10.1016/j.biopsycho.2009.11.007; Lavorini F, 2004, BRIT J CLIN PHARMACO, V58, P512, DOI 10.1111/j.1365-2125.2004.02185.x; Lemaigre V, 2006, RESP MED, V100, P348, DOI 10.1016/j.rmed.2005.05.013; LOUGHEED MD, 1993, AM REV RESPIR DIS, V148, P1452, DOI 10.1164/ajrccm/148.6_Pt_1.1452; MADOR MJ, 1995, CHEST, V107, P1590, DOI 10.1378/chest.107.6.1590; Magadle R, 2002, CHEST, V121, P329, DOI 10.1378/chest.121.2.329; Malpass A, 2018, BMJ OPEN RESPIR RES, V5, DOI 10.1136/bmjresp-2018-000309; Marks GB, 1996, THORAX, V51, P793, DOI 10.1136/thx.51.8.793; Massasso D H, 1999, Respirology, V4, P393, DOI 10.1046/j.1440-1843.1999.00210.x; McFadden ER, 2003, AM J RESP CRIT CARE, V168, P740, DOI 10.1164/rccm.200208-902SO; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Nannini LJ, 2007, RESP MED, V101, P246, DOI 10.1016/j.rmed.2006.05.013; Nigro CA, 2010, MEDICINA-BUENOS AIRE, V70, P321; NOSEDA A, 1992, EUR RESPIR J, V5, P1043; NOSEDA A, 1993, EUR RESPIR J, V6, P636; O'Byrne PM, 2018, NEW ENGL J MED, V378, P1865, DOI 10.1056/NEJMoa1715274; O'Byrne PM, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01103-2017; OLLERENSHAW SL, 1991, EUR RESPIR J, V4, P673; Panditi S, 2003, ARCH DIS CHILD, V88, P807, DOI 10.1136/adc.88.9.807; Partridge Martyn R, 2006, BMC Pulm Med, V6, P13, DOI 10.1186/1471-2466-6-13; Petsky HL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011440.pub2; Price D, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.9; ROISMAN GL, 1995, J CLIN INVEST, V96, P12, DOI 10.1172/JCI118011; Rosi E, 2006, LUNG, V184, P251, DOI 10.1007/s00408-005-2590-z; Salome CM, 2003, THORAX, V58, P1042, DOI 10.1136/thorax.58.12.1042; Salome CM, 2002, AM J RESP CRIT CARE, V165, P15, DOI 10.1164/ajrccm.165.1.2106130; Scano G, 2006, CURR OPIN PULM MED, V12, P18, DOI 10.1097/01.mcp.0000199003.46038.82; Spinhoven P, 1997, THORAX, V52, P149, DOI 10.1136/thx.52.2.149; Stravinskaite Kristina, 2005, Medicina (Kaunas), V41, P747; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; SUISSA S, 1994, EUR RESPIR J, V7, P1602, DOI 10.1183/09031936.94.07091602; Szefler SJ, 2018, J ALLERGY CLIN IMMUN, V142, P773, DOI 10.1016/j.jaci.2018.03.010; van der Woude HJ, 2004, RESP MED, V98, P816, DOI 10.1016/j.rmed.2004.03.001; van der Woude HJ, 2004, PULM PHARMACOL THER, V17, P89, DOI 10.1016/j.pupt.2003.11.001; vanPeskiOosterbaan AS, 1996, BEHAV RES THER, V34, P333, DOI 10.1016/0005-7967(95)00080-1; Veen JCCMI, 1998, AM J RESP CRIT CARE, V158, P1134, DOI 10.1164/ajrccm.158.4.9710087; von Leupoldt A, 2007, RESP MED, V101, P411, DOI 10.1016/j.rmed.2006.06.011; von Leupoldt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023739; Wamboldt MZ, 2000, J ALLERGY CLIN IMMUN, V106, P1102	68	30	30	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1180	1186		10.1016/j.jaci.2019.06.040	http://dx.doi.org/10.1016/j.jaci.2019.06.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	JK7EU	31330221	hybrid			2022-12-18	WOS:000495004700011
J	Patil, SU; Steinbrecher, J; Calatroni, A; Smith, N; Ma, A; Ruiter, B; Virkud, Y; Schneider, M; Shreffler, WG				Patil, Sarita U.; Steinbrecher, Johanna; Calatroni, Agustin; Smith, Neal; Ma, Alex; Ruiter, Bert; Virkud, Yamini; Schneider, Michael; Shreffler, Wayne G.			Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophil activation; immunotherapy; immunoglobulin; oral immunotherapy; food allergy; peanut allergy; Ara h 2; IgE; IgG(4)	FC-EPSILON-RI; ACTIVATION TEST; IGE; REPERTOIRE; ALLERGY; DESENSITIZATION; PARAMETERS; THRESHOLD; DIAGNOSIS; IGG4	Background: Only some patients with peanut allergy undergoing oral immunotherapy (OIT) achieve sustained clinical response. Basophil activation could provide a functional surrogate of efficacy. Objective: We hypothesized that changes in basophil sensitivity and area under the curve (AUC) to the immunodominant allergen Ara h 2 correlate with clinical responses to OIT. Methods: Children with peanut allergy aged 7 to 13 years were enrolled in a single-center, open-label peanut OIT trial. Levels of specific immunoglobulins were measured throughout OIT. Peripheral blood from multiple time points was stimulated in vitro with peanut allergens for flow cytometric assessment of the percentage of CD63(hi) activated basophils. Results: Twenty-two of 30 subjects were successfully treated with OIT; after avoidance, 9 achieved sustained unresponsiveness (SU), and 13 had transient desensitization (TD). Basophil sensitivity, measured by using the dose that induces 50% of the maximal basophil response, to Ara h 2 stimulation decreased from baseline in subjects with SU (after OIT, P = .0041; after avoidance, P = .0011). At 3 months of OIT, basophil sensitivity in subjects with SU decreased from baseline compared with that in subjects with TD (median, 18-fold vs 3-fold; P = .01), with a receiver operating characteristic of 0.84 and optimal fold change of 4.9. Basophil AUC to Ara h 2 was suppressed after OIT equally in subjects with SU and those with TD (P = .4). After avoidance, basophil AUC rebounded in subjects with TD but not those with SU (P < .001). Passively sensitized basophils suppressed with postavoidance SU plasma had a lower AUC than TD plasma (6.4% vs 38.9%, P = .03). Conclusions: Early decreases in basophil sensitivity to Ara h 2 correlate with SU. Basophil AUC rebounds after avoidance in subjects with TD. Therefore, different aspects of basophil activation might be useful for monitoring of OIT efficacy.	[Patil, Sarita U.; Steinbrecher, Johanna; Smith, Neal; Ma, Alex; Ruiter, Bert; Virkud, Yamini; Shreffler, Wayne G.] Massachusetts Gen Hosp, Food Allergy Ctr, Boston, MA 02114 USA; [Patil, Sarita U.; Ruiter, Bert; Virkud, Yamini; Shreffler, Wayne G.] Harvard Med Sch, Boston, MA 02115 USA; [Patil, Sarita U.; Ruiter, Bert; Shreffler, Wayne G.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; [Patil, Sarita U.; Ruiter, Bert; Virkud, Yamini; Shreffler, Wayne G.] Broad Inst MIT & Harvard, Food Allergy Sci Initiat, Boston, MA USA; [Calatroni, Agustin] Rho, Chapel Hill, NC USA; [Schneider, Michael] BUHLMANN Labs, Schonenbuch, Switzerland	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Rho	Patil, SU (corresponding author), 55 Fruit St,Cox 201, Boston, MA 02114 USA.	sarita.patil@mgh.harvard.edu		Ruiter, Bert/0000-0003-3945-3202	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases [K23AI121491]; American Academy of Allergy, Asthma & Immunology/Food Allergy Research Education; 2012 Howard Gittis Memorial 3rd/4th Year Fellowship/New Faculty Research Award; BUHLMANN Laboratories AG; National Center for Advancing Translational Sciences [1UL1TR001102, 8UL1TR000170]; National Center for Research Resources [1UL1 RR025758]; NIH Shared Instrumentation program [1S10OD012027-01A1, 1S10OD016372-01, 1S10RR020936-01, 1S10RR023440-01A1]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI121491] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American Academy of Allergy, Asthma & Immunology/Food Allergy Research Education; 2012 Howard Gittis Memorial 3rd/4th Year Fellowship/New Faculty Research Award; BUHLMANN Laboratories AG; National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Shared Instrumentation program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (grant K23AI121491 to S.U.P.); the American Academy of Allergy, Asthma & Immunology/Food Allergy Research Education; the 2012 Howard Gittis Memorial 3rd/4th Year Fellowship/New Faculty Research Award (to S.U.P.), and research support from BUHLMANN Laboratories AG (to W.G.S.). The clinical trial work was performed in the Harvard Clinical and Translational Science Center supported by grants 1UL1TR001102 and 8UL1TR000170 from the National Center for Advancing Translational Sciences and 1UL1 RR025758 from the National Center for Research Resources. Cytometry performed in the MGH Department of Pathology Flow and Image Cytometry Research Core was supported by the NIH Shared Instrumentation program with grants 1S10OD012027-01A1, 1S10OD016372-01, 1S10RR020936-01, and 1S10RR023440-01A1.	[Anonymous], 2015, R LANG ENV STAT COMP; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Ellis B., 2018, FLOWVIZ VISUALIZATIO; Ellis B, 2022, FLOWCORE FLOWCORE BA; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Gromping U, 2006, J STAT SOFTW, V17, DOI 10.18637/jss.v017.i01; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; Hourihane JO, 2011, PEDIATR CLIN N AM, V58, P445, DOI 10.1016/j.pcl.2011.02.004; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kulis MD, 2018, J ALLERGY CLIN IMMUN, V141, P491, DOI 10.1016/j.jaci.2017.12.979; Lund G, 2012, J IMMUNOL METHODS, V383, P4, DOI 10.1016/j.jim.2012.05.021; MacGlashan D, 2012, CLIN EXP ALLERGY, V42, P1060, DOI 10.1111/j.1365-2222.2012.04013.x; MacGlashan D, 2016, J ALLERGY CLIN IMMUN, V137, P1256, DOI 10.1016/j.jaci.2015.10.043; Patil SU, 2012, CLIN EXP IMMUNOL, V167, P59, DOI 10.1111/j.1365-2249.2011.04503.x; Patil SU, 2018, CYTOM PART B-CLIN CY, V94, P667, DOI 10.1002/cyto.b.21537; Patil SU, 2015, J ALLERGY CLIN IMMUN, V136, P125, DOI 10.1016/j.jaci.2015.03.026; Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021; Santos AF, 2017, CLIN EXP ALLERGY, V47, P1115, DOI 10.1111/cea.12964; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; van Buuren S, 2011, J STAT SOFTW, V45, P1; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wright BL, 2016, ALLERGY, V71, P1552, DOI 10.1111/all.12895	36	30	31	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1310	+		10.1016/j.jaci.2019.07.028	http://dx.doi.org/10.1016/j.jaci.2019.07.028			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31377342	Bronze, Green Accepted			2022-12-18	WOS:000495004700021
J	Abuabara, K; Ye, M; McCulloch, CE; Sullivan, A; Margolis, DJ; Strachan, DP; Paternoster, L; Yew, YW; Williams, HC; Langan, SM				Abuabara, Katrina; Ye, Morgan; McCulloch, Charles E.; Sullivan, Alice; Margolis, David J.; Strachan, David P.; Paternoster, Lavinia; Yew, Yik Weng; Williams, Hywel C.; Langan, Sinead M.			Clinical onset of atopic eczema: Results from 2 nationally representative British birth cohorts followed through midlife	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic eczema; atopic dermatitis; natural history; epidemiology	CHILDHOOD ECZEMA; DIAGNOSTIC-CRITERIA; NATURAL-HISTORY; ADULT ECZEMA; DERMATITIS; PREVALENCE; ASTHMA; DISEASE; FILAGGRIN; PROFILE	Background: Atopic eczema onset is described primarily in early childhood, and the frequency and characteristics of adult onset disease remain controversial. Objective: We sought to determine the proportion of subjects who report atopic eczema symptoms between birth and midadulthood and to examine demographic, immunologic, and genetic factors associated with period of symptom onset. Methods: We conducted a longitudinal study using data from 2 nationally representative community-based birth cohorts from the United Kingdom: the British Cohort Studies 1958 and 1970. Subjects were followed from birth through age 42 to 50 years. The primary outcome was the age period of self-reported atopic eczema symptom onset based on repeated measures of self reported atopic eczema at each survey wave. Results: The annual period prevalence of atopic eczema ranged from 5% to 15% in 2 cohorts of more than 17,000 participants each followed from birth through middle age. There was no clear trend in prevalence by age, and among adults reporting active atopic eczema during a given year, only 38% had symptom onset reported in childhood. When compared with subjects whose eczema started in childhood, those with adult onset disease were more likely to be women, from Scotland or Northern England, of lower childhood socioeconomic group, smokers in adulthood, and less likely to have a history of asthma. In a subanalysis using data from the 1958 cohort only, genetic mutations previously associated with atopic eczema, including filaggrin-null mutations, and allergen-specific IgE were more common among those with childhood-onset disease. Conclusion: Rates of self-reported atopic eczema remain high after childhood, and adult-onset atopic eczema has different risk factor associations than childhood-onset eczema.	[Abuabara, Katrina; Ye, Morgan] Univ Calif San Francisco, Dept Dermatol, Program Clin Res, Sch Med, San Francisco, CA 94143 USA; [McCulloch, Charles E.] Univ Calif San Francisco, Sch Med, Div Biostat, San Francisco, CA USA; [Sullivan, Alice] UCL, UCL Inst Educ, London, England; [Margolis, David J.] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Margolis, David J.] Univ Penn, Ctr Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Strachan, David P.] St Georges Univ London, Populat Hlth Res Inst, London, England; [Paternoster, Lavinia] Univ Bristol, Bristol Med Sch, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Yew, Yik Weng] Natl Skin Ctr, Singapore, Singapore; [Williams, Hywel C.] Univ Nottingham, Ctr Evidence Based Dermatol, Fac Med & Hlth Sci, Nottingham, England; [Langan, Sinead M.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of London; University College London; UCL Institute of Education; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; St Georges University London; University of Bristol; National Skin Centre; University of Nottingham; University of London; London School of Hygiene & Tropical Medicine	Abuabara, K (corresponding author), UCSF, 2341 Sutter St,N421, San Francisco, CA 94115 USA.	Katrina.abuabara@ucsf.edu		williams, hywel/0000-0002-5646-3093; Langan, Sinead/0000-0002-7022-7441	Medical Research Council [G0000934]; Wellcome Trust [068545/Z/02, 076113/B/04/Z]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); National Human Genome Research Institute (NHGRI); Juvenile Diabetes Research Foundation International (JDRF); Juvenile Diabetes Research Foundation International; Wellcome Trust; National Institute for Health Research Cambridge Biomedical Research Centre; Wellcome Trust Strategic Award [079895]; European Commission Framework Programme 6 [018996]; French Ministry of Research; MRC centenary award; National Institute of Child Health and Human Development (NICHD);  [U01 DK062418]; Medical Research Council [HDR-9002, HDR-9006] Funding Source: researchfish; National Institute for Health Research [NIHR/CS/010/014] Funding Source: researchfish; Wellcome Trust [205039/Z/16/Z] Funding Source: researchfish; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR073915] Funding Source: NIH RePORTER; ESRC [ES/S008349/1, ES/M001660/1] Funding Source: UKRI; MRC [MR/N01104X/2] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Human Genome Research Institute (NHGRI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Juvenile Diabetes Research Foundation International (JDRF)(Juvenile Diabetes Research Foundation); Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation); Wellcome Trust(Wellcome Trust); National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Wellcome Trust Strategic Award(Wellcome Trust); European Commission Framework Programme 6(European Commission); French Ministry of Research(Ministry of Research, FranceEuropean Commission); MRC centenary award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); ; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We acknowledge use of phenotype and genotype data from the British 1958 Birth Cohort DNA collection funded by Medical Research Council grant G0000934 andWellcome Trust grant 068545/Z/02. Genotyping for the B58C-WTCCC subset was funded by Wellcome Trust grant 076113/B/04/Z. B58C-T1DGC genotyping used resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Child Health and Human Development (NICHD), and Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. B58C-T1DGC GWAS data were deposited by the Diabetes and Inflammation Laboratory, Cambridge Institute forMedical Research (CIMR), University of Cambridge, which is funded by the Juvenile Diabetes Research Foundation International, the Wellcome Trust, and the National Institute for Health Research Cambridge Biomedical Research Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award (079895). B58C-GABRIEL genotyping was supported by a contract from the European Commission Framework Programme 6 (018996) and grants from the French Ministry of Research. FLG genotyping was funded by an MRC centenary award (to L.P.). The funding agencies did not have any influence on design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.	Abuabara K, 2018, ALLERGY, V73, P696, DOI 10.1111/all.13320; Brenninkmeijer EEA, 2008, BRIT J DERMATOL, V158, P754, DOI 10.1111/j.1365-2133.2007.08412.x; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; Butland BK, 2007, ANN ALLERG ASTHMA IM, V98, P337, DOI 10.1016/S1081-1206(10)60879-4; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Elliott J, 2006, INT J EPIDEMIOL, V35, P836, DOI 10.1093/ije/dyl174; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Garmhausen D, 2013, ALLERGY, V68, P498, DOI 10.1111/all.12112; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Hanifin JM, 2017, DERMATOL CLIN, V35, P299, DOI 10.1016/j.det.2017.02.009; Hawkes D, 2006, J R STAT SOC A STAT, V169, P479, DOI 10.1111/j.1467-985X.2006.00401.x; Ingordo V, 2003, DERMATOLOGY, V206, P197, DOI 10.1159/000068890; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; JAAFAR RB, 1993, CLIN EXP DERMATOL, V18, P496, DOI 10.1111/j.1365-2230.1993.tb01016.x; Kantor R, 2016, J AM ACAD DERMATOL, V75, P1119, DOI 10.1016/j.jaad.2016.07.017; Lee CH, 2011, BRIT J DERMATOL, V164, P483, DOI 10.1111/j.1365-2133.2010.10116.x; Lee HH, 2019, J AM ACAD DERMATOL, V80, P1526, DOI 10.1016/j.jaad.2018.05.1241; McNally NJ, 2000, BRIT J DERMATOL, V142, P712, DOI 10.1046/j.1365-2133.2000.03416.x; Megna M, 2017, ARCH DERMATOL RES, V309, P443, DOI 10.1007/s00403-017-1739-y; Mostafa H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9941; Mostafa T, 2014, CLS WORKING PAPERS S; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Naleway AL, 2003, ANN INTERN MED, V139, P1, DOI 10.7326/0003-4819-139-1-200307010-00006; Nnoruka EN, 2004, INT J DERMATOL, V43, P739, DOI 10.1111/j.1365-4632.2004.02360.x; Ozkaya E, 2005, J AM ACAD DERMATOL, V52, P579, DOI 10.1016/j.jaad.2004.11.037; Paller AS, 2017, J ALLERGY CLIN IMMUN, V140, P633, DOI 10.1016/j.jaci.2017.07.006; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Pesce G, 2015, J EUR ACAD DERMATOL, V29, P1180, DOI 10.1111/jdv.12784; Power C, 2006, INT J EPIDEMIOL, V35, P34, DOI 10.1093/ije/dyi183; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Rupnik H, 2015, BRIT J DERMATOL, V172, P455, DOI 10.1111/bjd.13477; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Silverberg JI, 2017, ALLERGY, V72, P2026, DOI 10.1111/all.13225; Silverberg JI, 2015, BRIT J DERMATOL, V173, P1400, DOI 10.1111/bjd.14031; Silverberg JI, 2018, J ALLER CL IMM-PRACT, V6, P1306, DOI 10.1016/j.jaip.2017.10.005; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Son JH, 2017, J KOREAN MED SCI, V32, P1360, DOI 10.3346/jkms.2017.32.8.1360; Strachan DP, 2007, INT J EPIDEMIOL, V36, P522, DOI 10.1093/ije/dyl309; Tay YK, 1999, INT J DERMATOL, V38, P689, DOI 10.1046/j.1365-4362.1999.00667.x; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; Taylor-Robinson DC, 2016, BRIT J DERMATOL, V174, P569, DOI 10.1111/bjd.14310; Vakharia PP, 2018, AM J CLIN DERMATOL, V19, P15, DOI 10.1007/s40257-017-0299-4; Wang X, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006317; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132; Williams HC, 1998, BRIT J DERMATOL, V139, P834; Williams HC, 2000, NATURAL HIST ATOPIC; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Williams HC, 2013, VET DERMATOL, V24, P3, DOI 10.1111/j.1365-3164.2012.01079.x	52	30	30	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					710	719		10.1016/j.jaci.2019.05.040	http://dx.doi.org/10.1016/j.jaci.2019.05.040			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	31260715	Green Published, Green Accepted, hybrid, Green Submitted			2022-12-18	WOS:000485222300016
J	Chen, KW; Zieglmayer, P; Zieglmayer, R; Lemell, P; Horak, F; Bunu, CP; Valenta, R; Vrtala, S				Chen, Kuan-Wei; Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick; Horak, Friedrich; Bunu, Carmen Panaitescu; Valenta, Rudolf; Vrtala, Susanne			Selection of house dust mite-allergic patients by molecular diagnosis may enhance success of specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Chen, Kuan-Wei; Valenta, Rudolf; Vrtala, Susanne] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Chen, Kuan-Wei; Bunu, Carmen Panaitescu] Cty Clin Emergency Hosp Pius Branzeu, OncoGen Ctr, Timisoara, Romania; [Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick; Horak, Friedrich] Allergy Ctr Vienna West, Vienna Challenge Chamber, Vienna, Austria; [Valenta, Rudolf] NRC Inst Immunol FMBA Russia, Moscow, Russia; [Valenta, Rudolf] Sechenov First Moscow State Med Univ, Lab Immunopathol, Dept Clin Immunol & Allergy, Moscow, Russia	Medical University of Vienna; NRC Institute of Immunology FMBA of Russia; Sechenov First Moscow State Medical University	Vrtala, S (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.	susanne.vrtala@meduniwien.ac.at	Zieglmayer, Petra/AAG-1006-2020	Lemell, Patrick/0000-0003-0262-4047; Chen, Kuan-Wei/0000-0001-5899-5766; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243	Austrian Science Fund [F4602, F4605]; Christian Doppler Research Association, Vienna, Austria; Government of the Russian Federation [14.W03.31.0024]	Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association, Vienna, Austria; Government of the Russian Federation	This work was supported by the Austrian Science Fund (grant nos. F4602 and F4605) and by the Christian Doppler Research Association, Vienna, Austria. R.V. is recipient of a Megagrant of the Government of the Russian Federation, grant number 14.W03.31.0024.	Boyden SE, 2016, NEW ENGL J MED, V374, P656, DOI 10.1056/NEJMoa1500611; Casset A, 2012, INT ARCH ALLERGY IMM, V159, P253, DOI 10.1159/000337654; Dhami S, 2017, ALLERGY, V72, P1597, DOI 10.1111/all.13201; Huang HJ, 2018, J ALLERGY CLIN IMMUN, V142, P1656, DOI 10.1016/j.jaci.2018.07.010; Niederberger V, 2018, J ALLERGY CLIN IMMUN, V142, P497, DOI 10.1016/j.jaci.2017.09.052; Platts-Mills TA, 2009, AM J RESP CRIT CARE, V180, P120; Platts-Mills TAE, 2009, AM J RESP CRIT CARE, V180, P109, DOI 10.1164/rccm.200811-1756PR; Sanchez-Borges M, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-017-0145-4; Valenta R, 2018, J ALLER CL IMM-PRACT, V6, P1845, DOI 10.1016/j.jaip.2018.08.032; Weber M, 2017, J ALLERGY CLIN IMMUN, V140, P1433, DOI 10.1016/j.jaci.2017.03.048; Zieglmayer P, 2017, J ALLERGY CLIN IMMUN, V140, P266, DOI 10.1016/j.jaci.2016.12.986	11	30	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1248	+		10.1016/j.jaci.2018.10.048	http://dx.doi.org/10.1016/j.jaci.2018.10.048			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30445063	hybrid			2022-12-18	WOS:000460272900053
J	Quiros-Alcala, L; Hansel, NN; McCormack, MC; Matsui, EC				Quiros-Alcala, Lesliam; Hansel, Nadia N.; McCormack, Meredith C.; Matsui, Elizabeth C.			Paraben exposures and asthma-related outcomes among children from the US general population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Parabens; children; asthma; respiratory; antimicrobials; endocrine disruptors	URINARY TRICLOSAN LEVELS; ALLERGEN SENSITIZATION; IMMUNE-SYSTEM; ENVIRONMENTAL CHEMICALS; ENDOCRINE DISRUPTERS; BISPHENOL-A; MICROBIOME; PHTHALATE; HEALTH; PATHOPHYSIOLOGY	Background: Parabens are synthetic preservatives present in many consumer products. Their antimicrobial and endocrine-disrupting properties have raised concerns that they might play a role in respiratory and allergic diseases; however, studies exploring these associations are scarce. Objective: We examined the cross-sectional association between parabens and asthma morbidity among 450 children with asthma and with asthma prevalence among 4023 children in the US general population participating in the National Health and Nutrition Examination Survey (2005-2014). Methods: We conducted multivariable logistic regression to examine associations between urinary paraben biomarker concentrations (butyl paraben, ethyl paraben, methyl paraben [MP], and propyl paraben [PP]) and asthma attacks and emergency department visits among children with asthma and with a current asthma diagnosis among all children. We also examined heterogeneity of associations by sex. Results: We observed an increased prevalence odds of reporting emergency department visits for every 10-fold increase in MP and PP concentrations among boys with asthma (adjusted prevalence odds ratio, 2.61 [95% CI, 1.40-4.85] and 2.18 [95% CI, 1.22-3.89, respectively; Pinteraction-MP 5.002 and Pinteraction-PP 5.003); associations remained after adjusting for other phenolic compounds previously linked to respiratory outcomes. No other dimorphic effects of exposure by sex were observed. Among children in the general population, no overall associations with current asthma were observed, although there was a positive trend with PP and a current asthma diagnosis. Conclusion: We identified differential effects of exposure to select parabens by sex on asthma morbidity. Further studies are needed to replicate these findings and elucidate mechanisms by which parabens could affect respiratory health and elicit dimorphic effects by sex.	[Quiros-Alcala, Lesliam] Univ Maryland, Maryland Inst Appl Environm Hlth, Sch Publ Hlth, College Pk, MD 20742 USA; [Hansel, Nadia N.; McCormack, Meredith C.; Matsui, Elizabeth C.] Johns Hopkins Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA; [Hansel, Nadia N.; McCormack, Meredith C.; Matsui, Elizabeth C.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	University System of Maryland; University of Maryland College Park; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Quiros-Alcala, L (corresponding author), Univ Maryland, 2234U Sch Publ Hlth Bldg, College Pk, MD 20742 USA.	lquiros@umd.edu		McCormack, Meredith/0000-0003-1702-3201; Pham, Hewlett/0000-0003-0330-6104; Matsui, Elizabeth/0000-0001-8134-5593; Koehl, Rachelle/0000-0002-7797-7456	NHLBI NIH HHS [K01 HL138124] Funding Source: Medline; NIAID NIH HHS [K24 AI114769] Funding Source: Medline; NIEHS NIH HHS [P50 ES018176, R01 ES023447, R01 ES026170, R01 ES023500, R01 ES022607, R21 ES025840] Funding Source: Medline; NIMHD NIH HHS [P50 MD010431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL138124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI114769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES023500, R01ES023447, R01ES026170, P50ES018176, R21ES025840, R01ES022607] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P50MD010431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; Ahmed SR, 2000, TOXICOLOGY, V150, P191; Alfardan AS, 2018, ENVIRON RES, V164, P327, DOI 10.1016/j.envres.2018.02.039; Andersen FA, 2008, INT J TOXICOL, V27, P1, DOI 10.1080/10915810802548359; Balzano G, 2001, ALLERGY, V56, P13, DOI 10.1034/j.1398-9995.2001.00128.x; Bonds RS, 2013, CURR OPIN ALLERGY CL, V13, P92, DOI 10.1097/ACI.0b013e32835a6dd6; Buckley JP, 2018, ENVIRON INT, V115, P79, DOI 10.1016/j.envint.2018.03.016; Calafat AM, 2010, ENVIRON HEALTH PERSP, V118, P679, DOI 10.1289/ehp.0901560; Canguyen U, 2011, MED HYPOTHESES, V76, P585, DOI 10.1016/j.mehy.2011.01.006; Card Jeffrey W, 2009, Proc Am Thorac Soc, V6, P588, DOI 10.1513/pats.200904-020RM; Centers for Disease Control and Prevention, NAT HLTH NUTR EX SUR; Centers for Disease Control and Prevention (CDC), 2013, PAR FACTSH; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Chen JG, 2007, TOXICOL APPL PHARM, V221, P278, DOI 10.1016/j.taap.2007.03.015; Cho YJ, 2016, PHYSIOLOGY, V31, P108, DOI 10.1152/physiol.00045.2015; Choi IS, 2011, ALLERGY ASTHMA IMMUN, V3, P74, DOI 10.4168/aair.2011.3.2.74; Cole SR, 2009, INT J EPIDEMIOL, V38, P1674, DOI 10.1093/ije/dyp269; Dewalque L, 2015, ENVIRON RES, V142, P414, DOI 10.1016/j.envres.2015.07.015; DeWitt C, 2017, CURR OPINION TOXICOL; Dickson RP, 2014, LANCET, V384, P691, DOI 10.1016/S0140-6736(14)61136-3; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P736, DOI 10.1016/j.jaci.2012.12.1573; El Hussein S, 2007, EXP DERMATOL, V16, P830, DOI 10.1111/j.1600-0625.2007.00625.x; Fisher M, 2017, ENVIRON SCI TECHNOL, V51, P4009, DOI 10.1021/acs.est.6b04302; Gadre SK, 2017, AM J RESP CRIT CARE, V195; Habib M. Rowshanul, 2009, Mycobiology, V37, P31, DOI 10.4489/MYCO.2009.37.1.031; Hauptman M, 2016, J ALLERGY CLIN IMMUN, V137, pAB192, DOI 10.1016/j.jaci.2015.12.760; Holladay SD, 2000, ENVIRON HEALTH PERSP, V108, P463, DOI 10.2307/3454538; Hornung RW, 1990, APPL OCCUP ENV HYG, V5, P46, DOI DOI 10.1080/1047322X.1990.10389587; Hu JZ, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0173-2; Jerschow E, 2014, ANN ALLERG ASTHMA IM, V112, P511, DOI 10.1016/j.anai.2014.03.011; Jerschow E, 2012, ANN ALLERG ASTHMA IM, V109, P420, DOI 10.1016/j.anai.2012.09.005; Ku HY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123309; Kuo CH, 2012, KAOHSIUNG J MED SCI, V28, pS37, DOI 10.1016/j.kjms.2012.05.008; Laffont S, 2017, J EXP MED, V214, P1581, DOI 10.1084/jem.20161807; Lee-Sarwar K, 2018, J ALLERGY CLIN IMMUN, V142, P269, DOI 10.1016/j.jaci.2017.09.029; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; Lisciandro JG, 2010, CLIN EXP ALLERGY, V40, P1719, DOI 10.1111/j.1365-2222.2010.03629.x; Liu Chong-hai, 2007, Zhonghua Er Ke Za Zhi, V45, P450; Lombardi C, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-016-0138-8; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; McHugh BM, 2011, ALLERGY ASTHMA PROC, V32, P372, DOI 10.2500/aap.2011.32.3456; Miller MD, 2010, ENVIRON HEALTH PERSP, V118, P1155, DOI 10.1289/ehp.0901856; Mohanan S, 2014, EXP BIOL MED, V239, P1531, DOI 10.1177/1535370214525302; Moos RK, 2016, ARCH TOXICOL, V90, P2699, DOI 10.1007/s00204-015-1636-0; Nath JB, 2015, ACAD PEDIATR, V15, P225, DOI 10.1016/j.acap.2014.10.011; O'Connor GT, 2018, J ALLERGY CLIN IMMUN, V141, P1468, DOI 10.1016/j.jaci.2017.06.040; Oishi S, 2002, FOOD CHEM TOXICOL, V40, P1807, DOI 10.1016/S0278-6915(02)00204-1; Pollack AZ, 2016, ENVIRON RES, V151, P513, DOI 10.1016/j.envres.2016.08.016; Quiros-Alcala L, 2018, INT J HYG ENVIR HEAL, V221, P652, DOI 10.1016/j.ijheh.2018.03.006; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Savage JH, 2014, ANN ALLERG ASTHMA IM, V112, P179, DOI 10.1016/j.anai.2013.11.017; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P453, DOI 10.1016/j.jaci.2012.05.006; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; Singanayagam A, 2017, CURR OPIN PULM MED, V23, P41, DOI [10.1097/MCP.0000000000000333, 10.1097/mcp.0000000000000333]; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; Soni MG, 2002, FOOD CHEM TOXICOL, V40, P1335, DOI 10.1016/S0278-6915(02)00107-2; Spanier AJ, 2014, ALLERGY ASTHMA PROC, V35, P475, DOI 10.2500/aap.2014.35.3803; Stiemsma LT, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-016-0173-6; Sturm JJ, 2004, AM J PUBLIC HEALTH, V94, P308, DOI 10.2105/AJPH.94.2.308; Taylor SL, 2018, J ALLERGY CLIN IMMUN, V141, P94, DOI 10.1016/j.jaci.2017.03.044; *USEPA, 1992, EPA PUBL; Vo TTB, 2010, REPROD TOXICOL, V29, P306, DOI 10.1016/j.reprotox.2010.01.013; Wang J, 2009, CLIN EXP ALLERGY, V39, P1381, DOI 10.1111/j.1365-2222.2009.03225.x; Xie MY, 2016, REPROD TOXICOL, V65, P224, DOI 10.1016/j.reprotox.2016.08.007; Ye XY, 2006, J CHROMATOGR B, V844, P53, DOI 10.1016/j.jchromb.2006.06.037; Zipf George, 2013, Vital Health Stat 1, P1	67	30	30	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					948	+		10.1016/j.jaci.2018.08.021	http://dx.doi.org/10.1016/j.jaci.2018.08.021			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30194988	Green Accepted, Bronze			2022-12-18	WOS:000460272900015
J	Kolkhir, P; Grakhova, M; Bonnekoh, H; Krause, K; Maurer, M				Kolkhir, Pavel; Grakhova, Maria; Bonnekoh, Hanna; Krause, Karoline; Maurer, Marcus			Treatment of urticarial vasculitis: A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Urticarial vasculitis; review; treatment	CUTANEOUS LEUKOCYTOCLASTIC VASCULITIS; HEPATITIS-C VIRUS; CHRONIC IDIOPATHIC URTICARIA; LUPUS-ERYTHEMATOSUS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; SCHNITZLERS-SYNDROME; MANIFESTATIONS; ASSOCIATION; DERMATOSIS; EFFICACY	Urticarial vasculitis (UV) is a difficult-to-treat condition characterized by long-lasting urticarial rashes and histopathologic findings of leukocytoclastic vasculitis. Treatment is dictated by the severity of skin and systemic involvement and the underlying systemic disease. This is a comprehensive systematic review of the efficacy of current UV treatment options. We searched for relevant studies in 7 databases, including MEDLINE, Scopus, and Web of Science. In total, 261 eligible studies and 789 unique patients with UV were included in the systematic review. Most patients with UV are adult women with chronic (>= 6 weeks) and systemic disease. UV is mostly idiopathic but can be associated with drugs, malignancy, autoimmunity, and infections. It usually resolves with their withdrawal or cure. Corticosteroids are effective for the treatment of skin symptoms in more than 80% of patients with UV. However, their long-term administration can lead to potentially serious adverse effects. The addition of immunomodulatory or immunosuppressive agents often allows corticosteroid tapering and improves the efficacy of therapy. Biologicals, including omalizumab, as well as corticosteroids, cyclophosphamide, dapsone, mycophenolate mofetil, plasmapheresis, colchicine, hydroxychloroquine, intravenous immunoglobulin, nonsteroidal anti-inflammatory drugs, and cyclosporine, can be effective for both skin and systemic symptoms in patients with UV. H-1-antihistamines, montelukast, danazol, H-2-antihistamines, pentoxifylline, doxepin, and tranexamic acid are not effective in most patients with UV. As of yet, no drugs have been approved for UV, and management recommendations are based mostly on case reports and retrospective studies. Prospective studies investigating the effects of treatment on the signs and symptoms of UV are needed.	[Kolkhir, Pavel; Bonnekoh, Hanna; Krause, Karoline; Maurer, Marcus] Charite Univ Med Berlin, Berlin, Germany; [Kolkhir, Pavel; Bonnekoh, Hanna; Krause, Karoline; Maurer, Marcus] Free Univ Berlin, Berlin, Germany; [Kolkhir, Pavel; Bonnekoh, Hanna; Krause, Karoline; Maurer, Marcus] Humboldt Univ, Berlin, Germany; [Kolkhir, Pavel; Bonnekoh, Hanna; Krause, Karoline; Maurer, Marcus] Allergie Ctr Charite, Dept Dermatol & Allergy, Berlin Inst Hlth, Berlin, Germany; [Kolkhir, Pavel] IM Sechenov First Moscow State Med Univ, Div Immune Mediated Skin Dis, Moscow, Russia; [Grakhova, Maria] Reg Clin Hosp 1, Tyumen, Russia	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sechenov First Moscow State Medical University	Maurer, M (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Krause, Karoline/G-5218-2018; Maurer, Marcus/ABG-2174-2020	Krause, Karoline/0000-0001-9711-9654; Maurer, Marcus/0000-0002-4121-481X; Grakhova, Mary/0000-0002-1657-0695; Bonnekoh, Hanna/0000-0002-3567-0149; Kolkhir, Pavel/0000-0001-5380-8132				ABOOBAKER J, 1986, CLIN EXP DERMATOL, V11, P436, DOI 10.1111/j.1365-2230.1986.tb00490.x; Adler M, 2005, J ROY SOC MED, V98, P271, DOI 10.1258/jrsm.98.6.271; AFEKENSTAM E, 1984, ARCH DERMATOL, V120, P484; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; Agnello V, 1997, ARTHRITIS RHEUM, V40, P2007, DOI 10.1002/art.1780401113; Alexopoulos A, 2017, INT J DERMATOL, V56, P1130, DOI 10.1111/ijd.13749; Arora A, 2014, MAYO CLIN PROC, V89, P1515, DOI 10.1016/j.mayocp.2014.04.015; Arslan Z, 2011, TURK J MED SCI, V41, P87, DOI 10.3906/sag-0912-422; ASHERSON RA, 1991, SEMIN ARTHRITIS RHEU, V20, P285, DOI 10.1016/0049-0172(91)90029-Y; Bachmeyer C, 2005, DERMATOLOGY, V210, P8, DOI 10.1159/000081475; BERG RE, 1988, INT J DERMATOL, V27, P468, DOI 10.1111/j.1365-4362.1988.tb00921.x; Botsios C, 2007, SCAND J RHEUMATOL, V36, P236, DOI 10.1080/03009740600938647; Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P289, DOI 10.1097/00004836-200110000-00006; CALLEN JP, 1982, BRIT J DERMATOL, V107, P87, DOI 10.1111/j.1365-2133.1982.tb00295.x; CARDOSO PA, 1990, ALLERGOL IMMUNOPATH, V18, P191; Davis MDP, 1998, J AM ACAD DERMATOL, V38, P899; Davis MDP, 2004, IMMUNOL ALLERGY CLIN, V24, P183, DOI 10.1016/j.iac.2004.01.007; Demitsu T, 2010, J DERMATOL, V37, P827, DOI 10.1111/j.1346-8138.2010.00881.x; Dincy CVP, 2008, J EUR ACAD DERMATOL, V22, P789, DOI 10.1111/j.1468-3083.2007.02641.x; DUPIN N, 1995, ARCH DERMATOL, V131, P1124, DOI 10.1001/archderm.131.10.1124; Ferri C, 2006, CURR OPIN RHEUMATOL, V18, P54; Foschi Francesco Giuseppe, 2010, World J Gastrointest Pharmacol Ther, V1, P72, DOI 10.4292/wjgpt.v1.i2.72; Fueyo-Casado A, 2017, CLIN EXP DERMATOL, V42, P403, DOI 10.1111/ced.13076; Galaria NA, 2000, J RHEUMATOL, V27, P2041; Gheerbrant H, 2017, PRESSE MED, V46, P547, DOI 10.1016/j.lpm.2017.01.020; GILLIAM JN, 1982, CLIN RHEUM DIS, V8, P207; Grotz W, 2009, DTSCH ARZTEBL INT, V106, P756, DOI 10.3238/arztebl.2009.0756; Guitart J, 2008, J AM ACAD DERMATOL, V59, P353, DOI 10.1016/j.jaad.2008.02.028; Hamid S, 1998, J AM ACAD DERMATOL, V39, P278, DOI 10.1016/S0190-9622(98)70089-1; Hauser B, 2017, INT J RHEUM DIS, V20, P1850, DOI 10.1111/1756-185X.12360; Husa P, 2005, VNITR LEK, V51, P238; Jachiet M, 2015, ARTHRITIS RHEUMATOL, V67, P527, DOI 10.1002/art.38956; Johnson EF, 2017, J EUR ACAD DERMATOL, V31, P544, DOI 10.1111/jdv.13952; JONES RR, 1983, BRIT J DERMATOL, V108, P695, DOI 10.1111/j.1365-2133.1983.tb01082.x; Keidel SM, 2014, RHEUMATOLOGY, V53, P573, DOI 10.1093/rheumatology/ket211; Chan YK, 2016, EUR ANN ALLERGY CLIN, V48, P247; Khasnis A, 2009, J ALLERGY CLIN IMMUN, V123, P1226, DOI 10.1016/j.jaci.2009.04.024; Kieffer C, 2009, MEDICINE, V88, P23, DOI 10.1097/MD.0b013e3181943f5e; Kolkhir P, 2016, CLIN EXP ALLERGY, V46, P275, DOI 10.1111/cea.12673; Krause K, 2013, J ALLERGY CLIN IMMUN, V132, P751, DOI 10.1016/j.jaci.2013.04.008; Kulthanan K, 2009, ASIAN PAC J ALLERGY, V27, P95; LACOUR JP, 1993, AM J MED, V94, P104, DOI 10.1016/0002-9343(93)90128-C; Lath K, 2018, AM J DERMATOPATH, V40, P661, DOI 10.1097/DAD.0000000000001170; Lee JSS, 2007, J AM ACAD DERMATOL, V56, P994, DOI 10.1016/j.jaad.2006.10.962; LEWIS JE, 1990, ACTA DERM-VENEREOL, V70, P345; Li MM, 2013, J DERMATOL, V40, P891, DOI 10.1111/1346-8138.12251; Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; Mahajan VK, 2015, INDIAN J PHARMACOL, V47, P560, DOI 10.4103/0253-7613.165180; Makol A, 2012, JCR-J CLIN RHEUMATOL, V18, P92, DOI 10.1097/RHU.0b013e31823ecd73; Mansard C, 2015, ALLERGY, V70, P483; Maurer M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00689; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; MCCOMBS RP, 1956, NEW ENGL J MED, V255, P251, DOI 10.1056/NEJM195608092550601; MCDUFFIE FC, 1973, MAYO CLIN PROC, V48, P340; MCLEAN DI, 1986, ARCH DERMATOL, V122, P765, DOI 10.1001/archderm.122.7.765; MEHREGAN DR, 1992, J AM ACAD DERMATOL, V26, P441, DOI 10.1016/0190-9622(92)70069-R; MITCHELL GG, 1983, AM J MED, V75, P875, DOI 10.1016/0002-9343(83)90419-9; Nucera E, 2017, J INVEST ALLERG CLIN, V27, P382, DOI 10.18176/jiaci.0191; ODONNELL B, 1995, INT ANGIOL, V14, P166; Ozcakar ZB, 2013, RHEUMATOL INT, V33, P763, DOI 10.1007/s00296-010-1645-5; Papi M, 1998, ARCH DERMATOL, V134, P447, DOI 10.1001/archderm.134.4.447; Pascual-Lopez M, 2002, J EUR ACAD DERMATOL, V16, P267, DOI 10.1046/j.1468-3083.2002.00459.x; Pasini A, 2014, RHEUMATOLOGY, V53, P1409, DOI 10.1093/rheumatology/keu023; PETEIRO C, 1989, AM J DERMATOPATH, V11, P528, DOI 10.1097/00000372-198912000-00003; PETERS MS, 1985, BRIT J DERMATOL, V113, P25, DOI 10.1111/j.1365-2133.1985.tb02040.x; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P436, DOI 10.1016/0091-6749(80)90237-7; PROVOST TT, 1980, J INVEST DERMATOL, V75, P495, DOI 10.1111/1523-1747.ep12524310; ROGER D, 1995, DERMATOLOGY, V191, P164, DOI 10.1159/000246539; Saeb-Lima M, 2013, AM J DERMATOPATH, V35, P655, DOI 10.1097/DAD.0b013e3182840f7f; Saeki T, 2001, NEPHRON, V88, P174, DOI 10.1159/000045981; Saigal K, 2003, J AM ACAD DERMATOL, V49, pS283, DOI 10.1067/S0190-9622(03)00744-8; SAIS G, 1995, ARCH DERMATOL, V131, P1399, DOI 10.1001/archderm.131.12.1399; Salam A, 2018, CLIN EXP DERMATOL, V43, P311, DOI 10.1111/ced.13344; SANCHEZ NP, 1982, J AM ACAD DERMATOL, V7, P599, DOI 10.1016/S0190-9622(82)70139-2; SCHWARTZ HR, 1982, MAYO CLIN PROC, V57, P231; Solans-Laque R, 2008, J RHEUMATOL, V35, P294; Sunderkotter C, 2005, J DERMATOL TREAT, V16, P193, DOI 10.1080/09546630500277971; Svobodova R, 2005, CES REVMATOL, V13, P110; Tanneberger O, 2007, INTERNIST, V48, P1432, DOI 10.1007/s00108-007-1956-0; Teng MC, 2012, J MICROBIOL IMMUNOL, V45, P22, DOI 10.1016/j.jmii.2011.09.024; Tosoni C, 2009, CLIN EXP DERMATOL, V34, P166, DOI 10.1111/j.1365-2230.2008.02891.x; Varricchi G, 2012, WORLD ALLERGY ORG S, V5, pS106, DOI DOI 10.1097/01.W0X.0000412032.39383.49; Wills L, 1890, LANCET, V135, P1296; Wilson D, 2002, RHEUMATOLOGY, V41, pA476, DOI 10.1093/rheumatology/41.4.476; Xu LY, 2009, SEMIN ARTHRITIS RHEU, V38, P348, DOI 10.1016/j.semarthrit.2008.01.007; Zaja F, 2003, BLOOD, V101, P3827, DOI 10.1182/blood-2002-09-2856; Zhang Y, 2004, J DERMATOL, V31, P661, DOI 10.1111/j.1346-8138.2004.tb00573.x; Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397	88	30	35	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					458	466		10.1016/j.jaci.2018.09.007	http://dx.doi.org/10.1016/j.jaci.2018.09.007			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30268388				2022-12-18	WOS:000457718700002
J	Elfeky, RA; Furtado-Silva, JM; Chiesa, R; Rao, K; Amrolia, P; Lucchini, G; Gilmour, K; Adams, S; Bibi, S; Worth, A; Thrasher, AJ; Qasim, W; Veys, P				Elfeky, Reem Ahmed; Furtado-Silva, Juliana M.; Chiesa, Robert; Rao, Kanchan; Amrolia, Persis; Lucchini, Giovanna; Gilmour, Kimberly; Adams, Stuart; Bibi, Shahnaz; Worth, Austen; Thrasher, Adrian J.; Qasim, Waseem; Veys, Paul			One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							STEM-CELL TRANSPLANTATION; IMMUNODEFICIENCY; BLOOD		[Elfeky, Reem Ahmed; Furtado-Silva, Juliana M.; Chiesa, Robert; Rao, Kanchan; Amrolia, Persis; Lucchini, Giovanna; Gilmour, Kimberly; Adams, Stuart; Bibi, Shahnaz; Worth, Austen; Thrasher, Adrian J.; Qasim, Waseem; Veys, Paul] UCL, Great Ormond St Hosp NHS Trust, Blood & Marrow Transplant Unit, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Elfeky, RA (corresponding author), UCL, Great Ormond St Hosp NHS Trust, Blood & Marrow Transplant Unit, London, England.	r.elfeky@ucl.ac.uk		QASIM, WASEEM/0000-0001-8353-4494; Thrasher, Adrian/0000-0002-6097-6115	National Institute for Health Research (NIHR) [RP-2014-05-007]; Great Ormond Street Biomedical Research Centre [IS-BRC-1215-20012]	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Great Ormond Street Biomedical Research Centre	Supported by the National Institute for Health Research (NIHR; RP-2014-05-007) and the Great Ormond Street Biomedical Research Centre (IS-BRC-1215-20012). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. A.J.T. is a Wellcome Trust Principal Research Fellow.	Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253; Balashov D, 2018, BIOL BLOOD MARROW TR, V24, P1432, DOI 10.1016/j.bbmt.2018.03.006; Chiesa R, 2012, BRIT J HAEMATOL, V156, P656, DOI 10.1111/j.1365-2141.2011.08994.x; Cohen JM, 2006, BLOOD, V108, P2124, DOI 10.1182/blood-2006-03-009712; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Pai SY, 2006, BONE MARROW TRANSPL, V38, P671, DOI 10.1038/sj.bmt.1705512; Slatter MA, 2018, BIOL BLOOD MARROW TR, V24, P529, DOI 10.1016/j.bbmt.2017.11.009	9	30	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1654	1656		10.1016/j.jaci.2018.06.042	http://dx.doi.org/10.1016/j.jaci.2018.06.042			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30055182	Green Submitted, Bronze			2022-12-18	WOS:000449429800033
J	Lee-Sarwar, K; Hauser, R; Calafat, AM; Ye, XY; O'Connor, GT; Sandel, M; Bacharier, LB; Zeiger, RS; Laranjo, N; Gold, DR; Weiss, ST; Litonjua, AA; Savage, JH				Lee-Sarwar, Kathleen; Hauser, Russ; Calafat, Antonia M.; Ye, Xiaoyun; O'Connor, George T.; Sandel, Megan; Bacharier, Leonard B.; Zeiger, Robert S.; Laranjo, Nancy; Gold, Diane R.; Weiss, Scott T.; Litonjua, Augusto A.; Savage, Jessica H.			Prenatal and early-life triclosan and paraben exposure and allergic outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Triclosan; paraben; prenatal sensitization; asthma	HPLC-MS/MS METHOD; URINARY CONCENTRATIONS; ENVIRONMENTAL PHENOLS; PHTHALATE METABOLITES; TEMPORAL VARIABILITY; BISPHENOL-A; FOOD SENSITIZATION; VITAMIN-D; CHILDREN; PREGNANCY	Background: In cross-sectional studies triclosan and parabens, ubiquitous ingredients in personal care and other products, are associated with allergic disease. Objectives: We investigated the association between prenatal and early-life triclosan and paraben exposure and childhood allergic disease in a prospective longitudinal study. Methods: Subjects were enrollees in the Vitamin D Antenatal Asthma Reduction Trial. Triclosan, methyl paraben, and propyl paraben concentrations were quantified in maternal plasma samples pooled from the first and third trimesters and urine samples from children at age 3 or 4 years. Outcomes were parental report of physician-diagnosed asthma or recurrent wheezing and allergic sensitization to food or environmental antigens based on serum specific IgE levels at age 3 years in high-risk children. Results: The analysis included 467 mother-child pairs. Overall, there were no statistically significant associations of maternal plasma or child urine triclosan or paraben concentrations with asthma or recurrent wheeze or food or environmental sensitization at age 3 years. A trend toward an inverse association between triclosan and paraben exposure and allergic sensitization was observed. There was evidence of effect measure modification by sex, with higher odds of environmental sensitization associated with increasing paraben concentrations in male compared with female subjects. Conclusions: We did not identify a consistent association between prenatal and early-life triclosan or paraben concentrations and childhood asthma, recurrent wheeze, or allergic sensitization in the overall study population. The differential effects of triclosan or paraben exposure on allergic sensitization by sex observed in this study warrant further exploration.	[Lee-Sarwar, Kathleen; Savage, Jessica H.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Lee-Sarwar, Kathleen; Hauser, Russ; Laranjo, Nancy; Gold, Diane R.; Weiss, Scott T.; Litonjua, Augusto A.; Savage, Jessica H.] Harvard Med Sch, Boston, MA USA; [Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Hauser, Russ] Massachusetts Gen Hosp, Fertil Ctr, Boston, MA 02114 USA; [Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA; [O'Connor, George T.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02215 USA; [O'Connor, George T.] Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA; [Sandel, Megan] Boston Med Ctr, Dept Pediat, Boston, MA USA; [Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, Div Pediat Allergy Immunol & Pulm Med, St Louis, MO 63110 USA; [Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Zeiger, Robert S.] Kaiser Permanente Southern Calif, San Diego, CA USA; [Laranjo, Nancy; Gold, Diane R.; Weiss, Scott T.; Litonjua, Augusto A.] Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA; [Savage, Jessica H.] Vertex Pharmaceut, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Centers for Disease Control & Prevention - USA; Boston University; Boston University; Boston Medical Center; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Kaiser Permanente; Harvard University; Brigham & Women's Hospital; Vertex Pharmaceuticals	Lee-Sarwar, K (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	klee-sarwar@bwh.harvard.edu	Calafat, Antonia/GOP-1115-2022; Calafat, Antonia/N-1183-2019	Calafat, Antonia/0000-0002-9796-7482; Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063	National Heart, Lung, and Blood Institute [U01HL091528]; American Academy of Allergy; Asthma & Immunology/Food Allergy Research Education; Hood Foundation; National Institutes of Health (NIH) grant [K23AI110522]; NIH grant [5T32AI007306-30]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL091528, T32HL007427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007306, K23AI110522] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Academy of Allergy; Asthma & Immunology/Food Allergy Research Education; Hood Foundation; National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Vitamin D Antenatal Asthma Reduction Trial was funded by U01HL091528 from the National Heart, Lung, and Blood Institute. Additional funding came from the American Academy of Allergy, Asthma & Immunology/Food Allergy Research & Education, Hood Foundation, National Institutes of Health (NIH) grant K23AI110522, and NIH grant 5T32AI007306-30. The findings expressed in this article are the opinions of the authors and do not necessarily reflect the official position of the US Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the US Centers for Disease Control and Prevention, the Public Health Service, or the US Department of Health and Human Services.	Alduraywish SA, 2016, PEDIAT ALLERG IMM-UK, V27, P83, DOI 10.1111/pai.12480; Andersen FA, 2008, INT J TOXICOL, V27, P1, DOI 10.1080/10915810802548359; Bertelsen RJ, 2013, ALLERGY, V68, P84, DOI 10.1111/all.12058; Bertelsen RJ, 2014, J EXPO SCI ENV EPID, V24, P517, DOI 10.1038/jes.2013.95; Braun JM, 2017, NAT REV ENDOCRINOL, V13, P161, DOI 10.1038/nrendo.2016.186; Bredin J, 2005, J ANTIMICROB CHEMOTH, V55, P1013, DOI 10.1093/jac/dki110; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P303, DOI 10.1289/ehp.10768; Calafat Antonia M, 2016, Curr Epidemiol Rep, V3, P145, DOI 10.1007/s40471-016-0075-7; Calafat AM, 2015, ENVIRON HEALTH PERSP, V123, pA166, DOI 10.1289/ehp.1510041; Calafat AM, 2010, ENVIRON HEALTH PERSP, V118, P679, DOI 10.1289/ehp.0901560; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Crofton KM, 2007, ENVIRON TOXICOL PHAR, V24, P194, DOI 10.1016/j.etap.2007.04.008; Dann AB, 2011, J APPL TOXICOL, V31, P285, DOI 10.1002/jat.1660; Dewalque L, 2015, ENVIRON RES, V142, P414, DOI 10.1016/j.envres.2015.07.015; Frederiksen H, 2011, J EXPO SCI ENV EPID, V21, P262, DOI 10.1038/jes.2010.6; Gee RH, 2008, J APPL TOXICOL, V28, P78, DOI 10.1002/jat.1316; Goldhahn K, 2009, ANN ALLERG ASTHMA IM, V102, P487, DOI 10.1016/S1081-1206(10)60122-6; Guidry VT, 2015, ENVIRON HEALTH PERSP, V123, P705, DOI 10.1289/ehp.1408325; Hines EP, 2015, REPROD TOXICOL, V54, P120, DOI 10.1016/j.reprotox.2014.11.006; Hornung RW, 1990, APPL OCCUP ENV HYG, V5, P46, DOI DOI 10.1080/1047322X.1990.10389587; Janjua NR, 2008, INT J ANDROL, V31, P118, DOI 10.1111/j.1365-2605.2007.00841.x; Koch HM, 2014, TOXICOL LETT, V231, P261, DOI 10.1016/j.toxlet.2014.06.023; Larsson K, 2014, ENVIRON INT, V73, P323, DOI 10.1016/j.envint.2014.08.014; Litonjua AA, 2016, JAMA-J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589; Litonjua AA, 2014, CONTEMP CLIN TRIALS, V38, P37, DOI 10.1016/j.cct.2014.02.006; Markle JGM, 2013, SCIENCE, V339, P1084, DOI 10.1126/science.1233521; Meeker JD, 2013, ENVIRON SCI TECHNOL, V47, P3439, DOI 10.1021/es400510g; Overgaard LEK, 2017, ALLERGY, V72, P1768, DOI 10.1111/all.13157; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Russell AD, 2004, J ANTIMICROB CHEMOTH, V53, P693, DOI 10.1093/jac/dkh171; Savage JH, 2014, ANN ALLERG ASTHMA IM, V112, P179, DOI 10.1016/j.anai.2013.11.017; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P453, DOI 10.1016/j.jaci.2012.05.006; Schnabel E, 2010, CLIN EXP ALLERGY, V40, P450, DOI 10.1111/j.1365-2222.2009.03400.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; Shekhar S, 2017, GEN COMP ENDOCR, V241, P100, DOI 10.1016/j.ygcen.2016.05.025; Smith KW, 2012, ENVIRON HEALTH PERSP, V120, P1538, DOI 10.1289/ehp.1104614; Spanier AJ, 2014, ALLERGY ASTHMA PROC, V35, P475, DOI 10.2500/aap.2014.35.3803; Teitelbaum SL, 2008, ENVIRON RES, V106, P257, DOI 10.1016/j.envres.2007.09.010; Tse SM, 2016, J ALLERGY CLIN IMMUN, V138, P1561, DOI 10.1016/j.jaci.2016.04.005; Weiss L, 2015, INT J HYG ENVIR HEAL, V218, P507, DOI 10.1016/j.ijheh.2015.04.003; Witorsch RJ, 2010, CRIT REV TOXICOL, V40, P1, DOI 10.3109/10408444.2010.515563; Wu YF, 2016, TOXICOL IN VITRO, V32, P310, DOI 10.1016/j.tiv.2016.01.014; Ye X, 2008, TALANTA, V76, P865, DOI 10.1016/j.talanta.2008.04.034; Ye XY, 2006, ENVIRON HEALTH PERSP, V114, P1843, DOI 10.1289/ehp.9413; Ye XY, 2006, J CHROMATOGR B, V844, P53, DOI 10.1016/j.jchromb.2006.06.037; Ye XY, 2012, ENVIRON SCI TECHNOL, V46, P12664, DOI 10.1021/es303109c; Ye XY, 2005, ANAL CHEM, V77, P5407, DOI 10.1021/ac050390d; Zorrilla LM, 2009, TOXICOL SCI, V107, P56, DOI 10.1093/toxsci/kfn225	48	30	31	3	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					269	+		10.1016/j.jaci.2017.09.029	http://dx.doi.org/10.1016/j.jaci.2017.09.029			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29111213	Bronze, Green Accepted			2022-12-18	WOS:000437837500029
J	Wen, HC; Czarnowicki, T; Noda, S; Malik, K; Pavel, AB; Nakajima, S; Honda, T; Shin, JU; Lee, H; Chou, M; Estrada, Y; Zheng, XZ; Xu, H; Krueger, JG; Lee, KH; Kabashima, K; Guttman-Yassky, E				Wen, Huei-Chi; Czarnowicki, Tali; Noda, Shinji; Malik, Kunal; Pavel, Ana B.; Nakajima, Saeko; Honda, Tetsuya; Shin, Jung U.; Lee, Hemin; Chou, Margaret; Estrada, Yeriel; Zheng, Xiuzhong; Xu, Hui; Krueger, James G.; Lee, Kwang-Hoon; Kabashima, Kenji; Guttman-Yassky, Emma			Serum from Asian patients with atopic dermatitis is characterized by T(H)2/T(H)22 activation, which is highly correlated with nonlesional skin measures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HOUSE-DUST MITE; T-CELL SUBSETS; ALLERGIC RHINITIS; IMMUNOTHERAPY; RESPONSES		[Wen, Huei-Chi; Czarnowicki, Tali; Malik, Kunal; Pavel, Ana B.; Chou, Margaret; Estrada, Yeriel; Xu, Hui; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Wen, Huei-Chi; Czarnowicki, Tali; Malik, Kunal; Pavel, Ana B.; Chou, Margaret; Estrada, Yeriel; Xu, Hui; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA; [Czarnowicki, Tali; Noda, Shinji; Zheng, Xiuzhong; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Malik, Kunal] SUNY Downstate, Coll Med, Brooklyn, NY USA; [Nakajima, Saeko; Honda, Tetsuya; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Shin, Jung U.; Lee, Hemin; Lee, Kwang-Hoon] Yonsei Univ, Coll Med, Dept Dermatol, Seoul, South Korea; [Shin, Jung U.; Lee, Hemin; Lee, Kwang-Hoon] Yonsei Univ, Coll Med, Cutaneous Biol Res Inst, Seoul, South Korea	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Kyoto University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA.	emma.guttman@mountsinai.org	Nakajima, Saeko/AAB-1577-2021; Wen, Huei-Chi/ABD-7417-2021	Nakajima, Saeko/0000-0003-0831-1447	Leo Pharma	Leo Pharma(LEO Pharma)	Supported by a research grant (to E.G.-Y.) from Leo Pharma.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Antonelli A, 2010, CYTOKINE, V50, P260, DOI 10.1016/j.cyto.2010.01.009; Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Chen JJ, 2017, AM J RHINOL ALLERGY, V31, P156, DOI 10.2500/ajra.2017.31.4434; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; He J, 2016, NAT MED, V22, P991, DOI 10.1038/nm.4148; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Li X, 2016, AM J RHINOL ALLERGY, V30, P201, DOI 10.2500/ajra.2016.30.4316; Lim Eunjung, 2015, Hawaii J Med Public Health, V74, P302; Michalak-Stoma A, 2013, DIS MARKERS, V2013, DOI 10.1155/2013/856056; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Qi SS, 2016, INT ARCH ALLERGY IMM, V171, P234, DOI 10.1159/000452333; Shimada Y, 2004, J DERMATOL SCI, V34, P201, DOI 10.1016/j.jdermsci.2004.01.001; Thijs JL, 2017, J ALLERGY CLIN IMMUN, V140, P730, DOI 10.1016/j.jaci.2017.03.023; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Wei YB, 2015, METHODS MOL BIOL, V1291, P199, DOI 10.1007/978-1-4939-2498-1_17; Zhang YN, 2016, J ALLERGY CLIN IMMUN, V137, P462, DOI 10.1016/j.jaci.2015.07.025	21	30	30	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					324	328		10.1016/j.jaci.2018.02.047	http://dx.doi.org/10.1016/j.jaci.2018.02.047			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29653116				2022-12-18	WOS:000437837500044
J	McWilliam, VL; Koplin, JJ; Field, MJ; Sasaki, M; Dharmage, SC; Tang, MLK; Sawyer, SM; Peters, RL; Allen, KJ				McWilliam, Vicki L.; Koplin, Jennifer J.; Field, Michael J.; Sasaki, Mari; Dharmage, Shyamali C.; Tang, Mimi L. K.; Sawyer, Susan M.; Peters, Rachel L.; Allen, Katrina J.		SchoolNuts Investigators	Self-reported adverse food reactions and anaphylaxis in the SchoolNuts study: A population-based study of adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; anaphylaxis; adolescents; schools; peanut allergy; asthma	ALLERGIC REACTIONS; NATURAL-HISTORY; PEANUT ALLERGY; UNITED-KINGDOM; CHILDREN; PREVALENCE; FATALITIES; METAANALYSIS; TRENDS; IGE	Background: Adolescents are at the highest risk of death from anaphylaxis, yet few population-based studies have described the frequencies and risk factors for allergic reactions caused by accidental allergen ingestion in this group. Methods: We describe the prevalence, frequency, and associated risk factors for recent adverse food reactions in 10-to 14-year-olds in Melbourne, Australia, recruited from a stratified, random, population-based sample of schools (SchoolNuts, n = 9663; 48% response rate). Self-reported food allergy and adverse reaction details, including anaphylaxis, were identified by using a student questionnaire over the past year. Results: Of 547 students with possible IgE-mediated food allergy, 243 (44.4%; 95% CI, 40.3% to 48.7%) reported a reaction to a food. Fifty-three (9.7%; 95% CI, 7.2% to 12.2%) students reported 93 anaphylaxis episodes. Peanut and tree nuts were the most common food triggers. Among students with current IgE-mediated food allergy, those with resolved or current asthma (adjusted odds ratio [aOR], 1.9 [95% CI, 1.1-1.3] and 1.7 [95% CI, 1.1-2.6]) and those with more than 2 food allergies (aOR, 1.9 [95% CI, 1.1-3.1]) were at greatest risk of any adverse food reaction, and those with nut allergy were most at risk of severe reactions (aOR, 2.9 [95% CI, 1.1-4.4]). Resolved or current asthma was not associated with increased risk of severe reactions (aOR, 0.8 [95% CI, 0.3-2.2] and 1.6 [95% CI, 0.7-3.7]). Conclusions: Adolescents with food allergy are frequently exposed to food allergens. Those with asthma and more than 2 food allergies were at the greatest risk for adverse food reactions. Those with nut allergies were most at risk of severe reactions.	[McWilliam, Vicki L.; Koplin, Jennifer J.; Field, Michael J.; Sasaki, Mari; Dharmage, Shyamali C.; Tang, Mimi L. K.; Sawyer, Susan M.; Peters, Rachel L.; Allen, Katrina J.] Royal Childrens Hosp Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [McWilliam, Vicki L.; Tang, Mimi L. K.; Allen, Katrina J.] Royal Childrens Hosp Melbourne, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Sawyer, Susan M.] Royal Childrens Hosp Melbourne, Ctr Adolescent Hlth, Melbourne, Vic, Australia; [McWilliam, Vicki L.; Tang, Mimi L. K.; Sawyer, Susan M.; Allen, Katrina J.] Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Melbourne, Vic, Australia; [Dharmage, Shyamali C.] Univ Melbourne, Ctr Epidemiol & Biostat, Allergy & Lung Hlth Unit, Melbourne, Vic, Australia; [Allen, Katrina J.] Univ Manchester, Inst Inflammat & Repair, Manchester, Lancs, England	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Allen, Katrina/I-4361-2018; McWilliam, Vicki/S-9462-2019; Tang, Mimi/ABD-8350-2020	Allen, Katrina/0000-0002-1921-4493; Tang, Mimi/0000-0002-3839-5293; Peters, Rachel/0000-0002-2411-6628; Koplin, Jennifer/0000-0002-7576-5142; Sasaki, Mari/0000-0003-1590-3838; McWilliam, Vicki/0000-0002-5000-2181	National Health and Medical Research Council of Australia (NHMRC) [APP1047396]; NHMRC; NHMRC funded Centre for Food and Allergy Research (CFAR)	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); NHMRC funded Centre for Food and Allergy Research (CFAR)(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council of Australia (NHMRC grant APP1047396). J.J.K., S.C.D., and K.J.A. hold NHMRC fellowships. V.L.M.'s PhD scholarship was funded by NHMRC funded Centre for Food and Allergy Research (CFAR).	[Anonymous], 2016, AUSTRALASIAN SOC CLI; Australian Bureau of Statistics, 2011, 2011 CENS DAT; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Boyano-Martinez T, 2009, J ALLERGY CLIN IMMUN, V123, P883, DOI 10.1016/j.jaci.2008.12.1125; Cianferoni A, 2004, ANN ALLERG ASTHMA IM, V92, P464, DOI 10.1016/S1081-1206(10)61784-X; Clark AT, 2008, J ALLERGY CLIN IMMUN, V122, P286, DOI 10.1016/j.jaci.2008.05.015; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Grabenhenrich LB, 2016, J ALLERGY CLIN IMMUN, V137, P1128, DOI 10.1016/j.jaci.2015.11.015; Johnson J, 2014, ACTA PAEDIATR, V103, P862, DOI 10.1111/apa.12687; Kaya A, 2013, PEDIAT ALLERG IMM-UK, V24, P456, DOI 10.1111/pai.12097; Motosue MS, 2017, J ALLER CL IMM-PRACT, V5, P171, DOI 10.1016/j.jaip.2016.08.013; Mullins RJ, 2016, CLIN EXP ALLERGY, V46, P1099, DOI 10.1111/cea.12748; Mullins RJ, 2015, J ALLERGY CLIN IMMUN, V136, P367, DOI 10.1016/j.jaci.2015.05.009; Neuman-Sunshine DL, 2012, ANN ALLERG ASTHMA IM, V108, P326, DOI 10.1016/j.anai.2011.11.010; Nha UNL, 2012, PEDIAT ALLERG IMM-UK, V23, P134, DOI 10.1111/j.1399-3038.2011.01235.x; Nwaru BI, 2014, ALLERGY, V69, P992, DOI 10.1111/all.12423; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Roehr CC, 2004, CLIN EXP ALLERGY, V34, P1534, DOI 10.1111/j.1365-2222.2004.02080.x; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Rudders SA, 2010, J ALLERGY CLIN IMMUN, V126, P385, DOI 10.1016/j.jaci.2010.05.018; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Sicherer SH, 2015, J ALLERGY CLIN IMMUN, V135, P357, DOI 10.1016/j.jaci.2014.12.1906; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Turner PJ, 2016, ALLERGY, V71, P1241, DOI 10.1111/all.12924; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Turner PJ, 2013, PEDIAT ALLERG IMM-UK, V24, P624, DOI 10.1111/pai.12148; Umasunthar T, 2015, CLIN EXP ALLERGY, V45, P1621, DOI 10.1111/cea.12477; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Vetander M, 2015, CLIN TRANSL ALLERGY, V5, pO25; Victoria Department of Education and Early Childhood Development, SUMM STAT VICT SCH; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	38	30	30	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					982	990		10.1016/j.jaci.2017.09.012	http://dx.doi.org/10.1016/j.jaci.2017.09.012			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29174346	Bronze			2022-12-18	WOS:000426974800018
J	Alam, R; Good, J; Rollins, D; Verma, M; Chu, HW; Pham, TH; Martin, RJ				Alam, Rafeul; Good, James; Rollins, Donald; Verma, Mukesh; Chu, HongWei; Tuyet-Hang Pham; Martin, Richard J.			Airway and serum biochemical correlates of refractory neutrophilic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Refractory asthma; neutrophilic asthma; bronchoalveolar lavage; cytokines; infection	NLRP3 INFLAMMASOME; IFN-GAMMA; PHENOTYPES; INNATE; CELLS; ACTIVATION; EXPRESSION; INTERLEUKIN-18; CONTRIBUTES; PNEUMONIAE	Background: Despite progress in the diagnosis and management of asthma, many patients have poorly controlled or refractory asthma (RA). The mechanism of this RA is not well understood. Objective: We sought to explore the relationship between neutrophils and other biomarkers of RA. Method: Sixty patients with RA, 30 patients with nonrefractory asthma (NRA), and 20 healthy subjects were enrolled. We performed a comprehensive characterization of these study subjects, which included laboratory and pulmonary function studies, chest computed tomography, and bronchoscopy with bronchoalveolar lavage (BAL). We analyzed BAL fluid and serum for a total of 244 biomolecules using a multiplex assay and correlated them with clinical and other laboratory parameters. Results: RA was significantly different from NRA with regard to pulmonary function indices, bronchial basement membrane thickness, and BAL fluid neutrophil and lymphocyte counts but not eosinophil counts. BAL fluid neutrophil counts negatively and positively correlated with forced vital capacity and age, respectively. Of the 244 biomolecules studied, 52 and 14 biomolecules from BAL fluid and serum, respectively, were significantly different among the study groups. Thirteen of these 52 molecules correlated with BAL fluid neutrophil counts. BAL fluid from 40% of patients with RA was positive for a pathogenic microbe. Infection-negative neutrophilic RA was associated with an increase in levels of select biomarkers of inflammation in the serum, suggesting the presence of systemic inflammation. Conclusions: RA was associated with increased numbers of neutrophils and proneutrophilic biomolecules in the airways. Subclinical infection was present in 40% of patients with RA, which likely contributed to neutrophilic inflammation. A subgroup of patients with noninfected neutrophilic RA was associated with systemic inflammation.	[Alam, Rafeul; Good, James; Rollins, Donald; Verma, Mukesh; Chu, HongWei; Martin, Richard J.] Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA; [Tuyet-Hang Pham] MedImmune, Gaithersburg, MD USA	National Jewish Health; AstraZeneca; Medimmune	Alam, R (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	alamr@njhealth.org			National Institutes of Health [RO1 AI091614, HL126895, AI102943]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102943, R01AI091614] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants RO1 AI091614, HL126895, AI102943, and HL126895 and a donation from Michele and Martin Cohen.	Andersson C, 2016, ATHEROSCLEROSIS, V248, P245, DOI 10.1016/j.atherosclerosis.2016.02.013; Ather JL, 2011, J IMMUNOL, V187, P64, DOI 10.4049/jimmunol.1100500; Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Brasier AR, 2010, CTS-CLIN TRANSL SCI, V3, P147, DOI 10.1111/j.1752-8062.2010.00204.x; Brooks CR, 2013, RESPIROLOGY, V18, P857, DOI 10.1111/resp.12079; Brown DA, 2002, LANCET, V359, P2159, DOI 10.1016/S0140-6736(02)09093-1; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; de Jesus AA, 2015, ANNU REV IMMUNOL, V33, P823, DOI 10.1146/annurev-immunol-032414-112227; DeKruyff RH, 2014, IMMUNOL REV, V260, P235, DOI 10.1111/imr.12187; Di Paolo NC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004035; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Fujimori T, 2015, MUCOSAL IMMUNOL, V8, P1021, DOI 10.1038/mi.2014.129; Gelfand EW, 2015, J ALLERGY CLIN IMMUN, V135, P1196, DOI 10.1016/j.jaci.2015.01.032; Gern JE, 2015, ANN AM THORAC SOC, V12, pS137, DOI 10.1513/AnnalsATS.201503-153AW; Ghasemzadeh M, 2013, BLOOD, V121, P4555, DOI 10.1182/blood-2012-09-459636; Gibson PG, 2015, THORAX, V70, P683, DOI 10.1136/thoraxjnl-2014-206740; Good JT, 2012, CHEST, V141, P599, DOI 10.1378/chest.11-0741; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; He RL, 2009, BLOOD, V113, P429, DOI 10.1182/blood-2008-03-139923; Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042; Hinks Timothy, 2015, Lancet, V385 Suppl 1, pS42, DOI 10.1016/S0140-6736(15)60357-9; Hinks TSC, 2016, J ALLERGY CLIN IMMUN, V138, P61, DOI 10.1016/j.jaci.2015.11.020; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Hosoki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126035; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Jackson DJ, 2015, CLIN INFECT DIS, V60, P1528, DOI 10.1093/cid/civ062; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP; Kelly FJ, 2011, CLIN EXP ALLERGY, V41, P1059, DOI 10.1111/j.1365-2222.2011.03776.x; Kempf T, 2007, J AM COLL CARDIOL, V50, P1054, DOI 10.1016/j.jacc.2007.04.091; Ketelut-Carneiro N, 2015, J IMMUNOL, V194, P4507, DOI 10.4049/jimmunol.1402321; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; McGeough MD, 2012, J IMMUNOL, V189, P2707, DOI 10.4049/jimmunol.1101737; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Michalec L, 2002, J IMMUNOL, V168, P846, DOI 10.4049/jimmunol.168.2.846; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Munoz M, 2015, IMMUNITY, V42, P321, DOI 10.1016/j.immuni.2015.01.011; Munthe-Fog L, 2009, NEW ENGL J MED, V360, P2637, DOI 10.1056/NEJMoa0900381; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Ottonello L, 2005, CELL SIGNAL, V17, P355, DOI 10.1016/j.cellsig.2004.08.002; Park H, 2016, ONCOTARGET, V7, P9634, DOI 10.18632/oncotarget.7457; Raundhal M, 2015, J CLIN INVEST, V125, P3037, DOI 10.1172/JCI80911; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rovina N, 2015, RESP MED, V109, P580, DOI 10.1016/j.rmed.2015.03.002; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; Soeki T, 2016, INT HEART J, V57, P134, DOI 10.1536/ihj.15-346; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; The ATS report on the criteria-American Thoracic Society, 2005, AM J RESP CRIT CARE, V173, P149; Thompson AMS, 2010, ENVIRON HEALTH PERSP, V118, P120, DOI 10.1289/ehp.0900550; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wong EHC, 2014, LANCET RESP MED, V2, P657, DOI 10.1016/S2213-2600(14)70107-9; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhao Y, 2015, MUCOSAL IMMUNOL, V8, P896, DOI 10.1038/mi.2014.120; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957	62	30	33	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1004	+		10.1016/j.jaci.2016.12.963	http://dx.doi.org/10.1016/j.jaci.2016.12.963			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28163052	Green Published, Bronze, Green Accepted			2022-12-18	WOS:000412172900012
J	Dawicki, W; Li, CY; Town, J; Zhang, XB; Gordon, JR				Dawicki, Wojciech; Li, Chunyan; Town, Jennifer; Zhang, Xiaobei; Gordon, John R.			Therapeutic reversal of food allergen sensitivity by mature retinoic acid-differentiated dendritic cell induction of LAG3(+)CD49b(-)Foxp3(-) regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory dendritic cells; immunotherapy; food allergy; anaphylaxis; tolerance	AIRWAY HYPERRESPONSIVENESS; CUTTING EDGE; C-MAF; TR1 CELLS; TOLERANCE; IL-27; IL-10; PROMOTE; ANTIGEN; ASTHMA	Background: Anaphylaxis is a life-threatening condition for which we have limited therapeutic options. Although specific immunotherapy for food allergies is becoming more effective, it is still laborious and carries substantial risk of adverse events. On the other hand, regulatory dendritic cell (DC) therapy is effective in mouse models of allergic disease and has been shown to work with T(H)2 cells from atopic asthmatic patients. Objective: We assessed whether DC immunotherapy could reverse food allergen sensitivity in mouse models to provide proof of concept relating to their use in the clinic. Methods: We generated and characterized mature retinoic acid-skewed dendritic cells (DC-RAs) and assessed their abilities to reverse ovalbumin or peanut allergies in mouse models, as well as their operative mechanisms. Results: DC-RAs displayed a mature yet tolerogenic phenotype, expressing IL-10, TGF-beta, IL-27, and aldehyde dehydrogenase 1A2 but not IL-12 or IL-35; IL-10 and TGF-beta together drove their suppression of T(H)2 cell proliferation. Delivery of specific allergen-presenting DC-RAs to half-maximally sensitized mice with ovalbumin or peanut allergy reduced anaphylactic responses to oral allergen challenge by 84% to 90%, as well as diarrhea, mast cell activation, and T(H)2 cytokine responses and serum allergen-specific IgE/IgG(1) levels. DC-RA expression of IL-27 was important to their induction of CD25(+) lymphocyte activation gene 3 (LAG3)(+), CD49b(-), forkhead box P3 (Foxp3)(-) regulatory T cells in vitro, such that b subunit of IL-27 (Ebi)(-/-) (ie, IL-27-incompetent) DC-RAs were ineffective in inducing food allergen tolerance. Conclusion: Our data indicate that regulatory DC immunotherapy can be effective for food allergies and suggest that induction of Foxp3(-) regulatory T cells might be a useful strategy for tolerance induction in this context.	[Dawicki, Wojciech; Zhang, Xiaobei; Gordon, John R.] Univ Saskatchewan, Dept Med, Saskatoon, SK, Canada; [Li, Chunyan; Town, Jennifer] Univ Saskatchewan, Dept Vet Microbiol, Saskatoon, SK, Canada	University of Saskatchewan; University of Saskatchewan	Gordon, JR (corresponding author), Div Respirol Crit Care & Sleep Med, Rm 3D30-8 Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	john.gordon@usask.ca		Town, Jennifer/0000-0002-9054-2369	Canadian Institutes of Health Research [MOP53167]; AllerGen Networks of Centers of Excellence [CanFAST6]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); AllerGen Networks of Centers of Excellence	Supported by grants from the Canadian Institutes of Health Research (MOP53167) and the AllerGen Networks of Centers of Excellence (CanFAST6).	Apetoh L, 2010, NAT IMMUNOL, V11, P854, DOI 10.1038/ni.1912; Awasthi A, 2007, NAT IMMUNOL, V8, P1380, DOI 10.1038/ni1541; Batten M, 2008, J IMMUNOL, V180, P2752, DOI 10.4049/jimmunol.180.5.2752; Brosbol-Ravnborg A, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/807971; Chang J, 2013, EUR J IMMUNOL, V43, P967, DOI 10.1002/eji.201242772; Chappert P, 2010, CURR OPIN IMMUNOL, V22, P552, DOI 10.1016/j.coi.2010.08.005; Chen Y, 2009, J HEPATOL, V51, P510, DOI 10.1016/j.jhep.2009.04.026; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Do JS, 2016, MUCOSAL IMMUNOL, V9, P137, DOI 10.1038/mi.2015.45; Gagliani N, 2013, NAT MED, V19, P739, DOI 10.1038/nm.3179; Gordon JR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00007; Henry E, 2008, J IMMUNOL, V181, P7230, DOI 10.4049/jimmunol.181.10.7230; Holt PG, 2004, CURR OPIN ALLERGY CL, V4, P39, DOI 10.1097/01.all.0000113677.18759.dc; Huang H, 2013, J IMMUNOL, V191, P1136, DOI 10.4049/jimmunol.1201899; Huang H, 2010, J IMMUNOL, V185, P5003, DOI 10.4049/jimmunol.0903446; Iliev ID, 2009, GUT, V58, P1481, DOI 10.1136/gut.2008.175166; Khare A, 2013, J IMMUNOL, V191, P25, DOI 10.4049/jimmunol.1300193; Koya T, 2007, J ALLERGY CLIN IMMUN, V119, P1241, DOI 10.1016/j.jaci.2007.01.039; Kubo S, 2003, J IMMUNOL, V170, P775, DOI 10.4049/jimmunol.170.2.775; Li XL, 2010, AM J RESP CELL MOL, V42, P190, DOI 10.1165/rcmb.2009-0023OC; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Lu M, 2011, ALLERGY, V66, P612, DOI 10.1111/j.1398-9995.2010.02526.x; Naranjo-Gomez M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-89; Nayyar A, 2012, J IMMUNOL, V189, P72, DOI 10.4049/jimmunol.1103286; Pot C, 2009, J IMMUNOL, V183, P797, DOI 10.4049/jimmunol.0901233; Saurer L, 2007, J IMMUNOL, V179, P3504, DOI 10.4049/jimmunol.179.6.3504; Schneider AM, 2001, CELL IMMUNOL, V212, P101, DOI 10.1006/cimm.2001.1854; Vasanthakumar A, 2013, EUR J IMMUNOL, V43, P882, DOI 10.1002/eji.201343479; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Xu JN, 2009, J IMMUNOL, V182, P6226, DOI 10.4049/jimmunol.0900123; Yao Y, 2015, J IMMUNOL, V195, P488, DOI 10.4049/jimmunol.1403225; Yoshida H, 2009, J LEUKOCYTE BIOL, V86, P1295, DOI 10.1189/jlb.0609445; Yurchenko E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035572; Zeller JC, 1999, J IMMUNOL, V163, P3684; Zhang Y, 2006, P NATL ACAD SCI USA, V103, P11695, DOI 10.1073/pnas.0601347103	35	30	31	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1608	+		10.1016/j.jaci.2016.07.042	http://dx.doi.org/10.1016/j.jaci.2016.07.042			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	28277274	Bronze			2022-12-18	WOS:000400465300022
J	Park, YH; Fitzpatrick, AM; Medriano, CA; Jones, DP				Park, Youngja H.; Fitzpatrick, Anne M.; Medriano, Carl Angelo; Jones, Dean P.			High-resolution metabolomics to identify urine biomarkers in corticosteroid-resistant asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Metabolomics; LC-MS; pediatric asthma; corticosteroid resistance	MOLECULAR-MECHANISMS; GENE POLYMORPHISMS; OXIDATIVE STRESS; RISK-FACTORS; RESPONSIVENESS; METABOLISM; THERAPY; KEGG	Background: Corticosteroid (CS) treatment has been established as the first anti-inflammatory treatment for adults and children with asthma. However, a subset of patients fails to respond to combined systemic and inhaled CS treatment. Objective: This study was aimed at further understanding CS resistance among children with severe asthma. Methods: High-resolution metabolomics was performed on urine samples from CS-respondent (n = 15) and CS-nonrespondent (n = 15) children to determine possible urine biomarkers related to CS resistance. The metabolic phenotypes of CS responders and CS nonresponders were analyzed using bioinformatics including Manhattan plot with false- discovery rate, hierarchical cluster analysis, Kyoto Encyclopedia Genes and Genomes, and Mummichog pathway analysis. Results: The 2-way hierarchical cluster analysis study determined 30 metabolites showing significantly different levels between CS responders and CS nonresponders. The important metabolites annotated were 3,6-dihydronicotinic acid (126.05 m/z, RT: 106, [M1H](+)), 3-methoxy-4-hydroxyphenyl(ethylene) glycol (185.05 m/z, RT: 155, [M1H](+)), 3,4-dihydroxy-phenylalanine (198.07 m/z, RT: 446, [M1H](+)), gamma-glutamylcysteine (236.06 m/z, RT: 528, [M1S(34)+H](+)), Cys-Gly, (253.06 m/z, RT: 528, [M-NH3+H](+)), and reduced Flavin mononucleotide (517.0794 m/z, RT: 533, [M+NaCl](+)). Tyrosine metabolism, degradation of aromatic compounds, and glutathione metabolism are suggested to be significant pathways relating to CS resistance. Conclusions: High-resolution metabolomics is a promising approach in asthma research. Five candidate markers were identified to be related to CS-resistant children with severe asthma. These compounds, upon validation, may contribute further in the understanding of CS resistance among children with severe asthma through the use ofurine.	[Park, Youngja H.; Medriano, Carl Angelo] Korea Univ, Coll Pharm, Sejong City 30019, South Korea; [Fitzpatrick, Anne M.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Jones, Dean P.] Emory Univ, Dept Med, Atlanta, GA 30322 USA	Korea University; Emory University; Emory University	Park, YH (corresponding author), Korea Univ, Coll Pharm, Sejong City 30019, South Korea.	yjhwang@korea.ac.kr		Medriano, Carl Angelo/0000-0002-8286-4843; Fitzpatrick, Anne/0000-0002-2933-5926	Emory University [R01 NR012021]; National Research Fund of Korea [NRF-2014R4A4A5286787]; Korea University (Korea Health Industry Development Institute) [HI14C2686]	Emory University; National Research Fund of Korea; Korea University (Korea Health Industry Development Institute)	This research was supported in part by Emory University (grant no. R01 NR012021), the National Research Fund of Korea (grant no. NRF-2014R4A4A5286787), and Korea University (Korea Health Industry Development Institute grant no. HI14C2686).	Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Adcock IM, 2006, CURR DRUG TARGETS, V7, P649, DOI 10.2174/138945006777435344; Adcock IM, 1996, AM J RESP CRIT CARE, V154, pS58, DOI 10.1164/ajrccm/154.2_Pt_2.S58; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Cover RA, 2000, J ALLERGY CLIN IMMUN, V106, P651; de Blic J, 2002, EUR RESPIR J, V20, P1271, DOI 10.1183/09031936.02.02072001; Fahy JV, 2010, AM J RESP CRIT CARE, V181, P296, DOI 10.1164/rccm.200911-1702ED; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2014, J ALLERGY CLIN IMMUN, V133, P258, DOI 10.1016/j.jaci.2013.10.012; Fitzpatrick AM, 2011, PEDIATR RES, V69, P154, DOI 10.1203/PDR.0b013e3182026370; Gika HG, 2014, J PHARMACEUT BIOMED, V87, P12, DOI 10.1016/j.jpba.2013.06.032; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Ivaschenko TE, 2002, J MOL MED, V80, P39, DOI 10.1007/s001090100274; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Johnson JM, 2010, ANALYST, V135, P2864, DOI 10.1039/c0an00333f; Kanehisa M, 2002, NOVART FDN SYMP, V247, P91; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KANEHISA M., 2002, NOVART FDN SYMP, V247, P19; KERREBIJN KF, 1976, J PEDIATR-US, V89, P821, DOI 10.1016/S0022-3476(76)80816-5; Keun HC, 2002, CHEM RES TOXICOL, V15, P1380, DOI 10.1021/tx0255774; Li LB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141909; Li SZ, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003123; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708; Park SJ, 2006, MINI-REV MED CHEM, V6, P235, DOI 10.2174/138955706775475948; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Saude EJ, 2009, AM J RESP CRIT CARE, V179, P25, DOI 10.1164/rccm.200711-1716OC; Smith CA, 2005, THER DRUG MONIT, V27, P747, DOI 10.1097/01.ftd.0000179845.53213.39; Tamer L, 2004, RESPIROLOGY, V9, P493, DOI 10.1111/j.1440-1843.2004.00657.x; Vijverberg SJH, 2011, CLIN EXP ALLERGY, V41, P615, DOI 10.1111/j.1365-2222.2011.03694.x; WILLIAMS MH, 1981, ANN INTERN MED, V95, P464, DOI 10.7326/0003-4819-95-4-464; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489; YOUNG L, 1947, BIOCHEM J, V41, P417, DOI 10.1042/bj0410417; Yu TW, 2009, BIOINFORMATICS, V25, P1930, DOI 10.1093/bioinformatics/btp291; Zhang AH, 2012, CLIN CHIM ACTA, V414, P65, DOI 10.1016/j.cca.2012.08.016	41	30	32	2	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1518	+		10.1016/j.jaci.2016.08.018	http://dx.doi.org/10.1016/j.jaci.2016.08.018			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27658760	Bronze			2022-12-18	WOS:000400465300012
J	Chen, JB; James, LK; Davies, AM; Wu, YCB; Rimmer, J; Lund, VJ; Chen, JH; McDonnell, JM; Chan, YC; Hutchins, GH; Chang, TW; Sutton, BJ; Kariyawasam, HH; Gould, HJ				Chen, Jiun-Bo; James, Louisa K.; Davies, Anna M.; Wu, Yu-Chang Bryan; Rimmer, Joanne; Lund, Valerie J.; Chen, Jou-Han; McDonnell, James M.; Chan, Yih-Chih; Hutchins, George H.; Chang, Tse Wen; Sutton, Brian J.; Kariyawasam, Harsha H.; Gould, Hannah J.			Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis with nasal polyps; aspirin-exacerbated respiratory disease; Staphylococcus aureus enterotoxin; superantigen; superantibody; basophil	STAPHYLOCOCCUS-AUREUS ENTEROTOXINS; GRASS-POLLEN ALLERGEN; BET V 1; CLASS SWITCH RECOMBINATION; IGG MONOCLONAL-ANTIBODIES; B-CELL RECEPTORS; IMMUNOGLOBULIN-E; SOMATIC HYPERMUTATION; ATOPIC-DERMATITIS; CRYSTAL-STRUCTURE	Background: Chronic rhinosinusitis with nasal polyps is associated with local immunoglobulin hyperproduction and the presence of IgE antibodies against Staphylococcus aureus enterotoxins (SAEs). Aspirin-exacerbated respiratory disease is a severe form of chronic rhinosinusitis with nasal polyps in which nearly all patients express anti-SAEs. Objectives: We aimed to understand antibodies reactive to SAEs and determine whether they recognize SAEs through their complementarity-determining regions (CDRs) or framework regions. Methods: Labeled staphylococcal enterotoxin (SE) A, SED, and SEE were used to isolate single SAE-specific B cells from the nasal polyps of 3 patients with aspirin-exacerbated respiratory disease by using fluorescence-activated cell sorting. Recombinant antibodies with "matched" heavy and light chains were cloned as IgG(1), and those of high affinity for specific SAEs, assayed by means of ELISA and surface plasmon resonance, were recloned as IgE and antigen-binding fragments. IgE activities were tested in basophil degranulation assays. Results: Thirty-seven SAE-specific, IgG- or IgA-expressing B cells were isolated and yielded 6 anti-SAE clones, 2 each for SEA, SED, and SEE. Competition binding assays revealed that the anti-SEE antibodies recognize nonoverlapping epitopes in SEE. Unexpectedly, each anti-SEE mediated SEE-induced basophil degranulation, and IgG(1) or antigen-binding fragments of each anti-SEE enhanced degranulation by the other anti-SEE. Conclusions: SEEs can activate basophils by simultaneously binding as antigens in the conventional manner to CDRs and as superantigens to framework regions of anti-SEE IgE in anti-SEE IgE-Fc epsilon RI complexes. Anti-SEE IgG(1)s can enhance the activity of anti-SEE IgEs as conventional antibodies through CDRs or simultaneously as conventional antibodies and as "superantibodies" through CDRs and framework regions to SEEs in SEE-anti-SEE IgE-Fc epsilon RI complexes.	[Chen, Jiun-Bo; James, Louisa K.; Davies, Anna M.; Wu, Yu-Chang Bryan; McDonnell, James M.; Chan, Yih-Chih; Hutchins, George H.; Sutton, Brian J.; Gould, Hannah J.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Chen, Jiun-Bo; Chen, Jou-Han; Chang, Tse Wen] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [James, Louisa K.; Davies, Anna M.; Wu, Yu-Chang Bryan; McDonnell, James M.; Chan, Yih-Chih; Sutton, Brian J.; Gould, Hannah J.] Kings Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, Guys Campus, London WC2R 2LS, England; [Rimmer, Joanne; Lund, Valerie J.; Kariyawasam, Harsha H.] Royal Natl Throat Nose Ear Hosp, Allergy & Rhinol, London, England	University of London; King's College London; Academia Sinica - Taiwan; University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Gould, HJ (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England.	hannah.gould@kcl.ac.uk	Davies, Anna Marie/G-4575-2014; WU, YU-CHANG BRYAN/K-9566-2019; James, Louisa/C-9831-2010; Chang, Tse Wen/H-5955-2011; Wu, Bryan Yu-Chang/L-3996-2019	Davies, Anna Marie/0000-0003-1498-1594; WU, YU-CHANG BRYAN/0000-0003-3191-3163; James, Louisa/0000-0002-2252-4636; McDonnell, James/0000-0001-9037-2980; Gould, Hannah/0000-0003-0411-688X	Medical Research Council [G1100090]; London Law Trust; Medical Research Council; National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London; Wellcome Trust [085944]; MRC [G0200485, G0200486, MR/M022943/1, G0501494, G1100238, G0400106, G1100090] Funding Source: UKRI; Medical Research Council [G0200486, G1000758, G1000758B, G1100238, G0200485, MR/M022943/1, G0400106, G0501494] Funding Source: researchfish; Asthma UK [AUK-PG-2013-183, MRC-Asthma UK Centre, AUK-IG-2014-255] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); London Law Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London; Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Supported by the Medical Research Council (grant no. G1100090), the London Law Trust (to L.K.J.), Medical Research Council (Y.-C.B. Wu), the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London (to H.J.G., B.J.S., and J.M.M.), and the Wellcome Trust for support of the King's Biomolecular Spectroscopy Facility (085944). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	Bachert C, 2012, J INTERN MED, V272, P133, DOI 10.1111/j.1365-2796.2012.02559.x; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI DOI 10.1016/J.JACI.2010.07.007; Bachert C, 2012, J ALLERGY CLIN IMMUN, V130, P376, DOI 10.1016/j.jaci.2012.05.012; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Balaban N, 2000, INT J FOOD MICROBIOL, V61, P1, DOI 10.1016/S0168-1605(00)00377-9; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Chen JB, 2010, J IMMUNOL, V184, P1748, DOI 10.4049/jimmunol.0902437; Chow SK, 2012, TOXINS, V4, P430, DOI 10.3390/toxins4060430; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Cui YB, 2014, CLIN REV ALLERG IMMU, V47, P344, DOI 10.1007/s12016-013-8396-5; De Schryver E, 2015, ALLERGY ASTHMA IMMUN, V7, P321, DOI 10.4168/aair.2015.7.4.321; DeLalla C, 1996, MOL IMMUNOL, V33, P1049, DOI 10.1016/S0161-5890(96)00061-2; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; Dodev TS, 2015, ALLERGY, V70, P720, DOI 10.1111/all.12607; Domiati-Saad R, 1998, J IMMUNOL, V161, P1257; DomiatiSaad R, 1996, J IMMUNOL, V156, P3608; Dullaers M, 2012, J ALLERGY CLIN IMMUN, V129, P635, DOI 10.1016/j.jaci.2011.10.029; Dutta K, 2015, J BIOL CHEM, V290, P6715, DOI 10.1074/jbc.M114.630715; Eibensteiner P, 1999, INT ARCH ALLERGY IMM, V118, P190, DOI 10.1159/000024063; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Huvenne W, 2013, INT ARCH ALLERGY IMM, V161, P304, DOI 10.1159/000350329; James LK, 2012, J ALLERGY CLIN IMMUN, V130, P663, DOI 10.1016/j.jaci.2012.04.006; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Kato A, 2013, J ALLERGY CLIN IMMUN, V131, P933, DOI 10.1016/j.jaci.2013.02.023; KOZLOWSKI LM, 1995, J CLIN IMMUNOL, V15, P145, DOI 10.1007/BF01543106; Krakauer T, 2013, VIRULENCE, V4, P759, DOI 10.4161/viru.23905; KRISTIANSEN SV, 1994, J IMMUNOL, V153, P2974; Kumar S, 2010, TOXINS, V2, P1898, DOI 10.3390/toxins2071898; Leung AD, 2008, CLIN EXP ALLERGY, V38, P789, DOI 10.1111/j.1365-2222.2008.02964.x; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Levin M, 2014, CLIN EXP ALLERGY, V44, P288, DOI 10.1111/cea.12230; LEVINSON AI, 1995, J CLIN IMMUNOL, V15, pS26, DOI 10.1007/BF01540891; MERKENSCHLAGER M, 1992, P NATL ACAD SCI USA, V89, P4255, DOI 10.1073/pnas.89.10.4255; MORRIS CA, 1972, LANCET, V2, P1375; Persson H, 2007, J ALLERGY CLIN IMMUN, V120, P1186, DOI 10.1016/j.jaci.2007.06.041; Pinto JM, 2010, RHINOLOGY, V48, P318, DOI [10.4193/Rhin09.144, 10.4193/Rhino09.144]; Rodstrom KEJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131988; Rossi RE, 2004, INT ARCH ALLERGY IMM, V133, P261, DOI 10.1159/000076833; Schlievert PM, 2014, J EXP MED, V211, P2326, DOI 10.1084/jem.21112insight1; Selb R, 2013, ALLERGY, V68, P1199, DOI 10.1111/all.12204; Shiung YY, 2012, IMMUNOBIOLOGY, V217, P676, DOI 10.1016/j.imbio.2011.11.006; Skov L, 2000, J ALLERGY CLIN IMMUN, V105, P820, DOI 10.1067/mai.2000.105524; Snow RE, 1997, EUR J IMMUNOL, V27, P162, DOI 10.1002/eji.1830270124; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; Spaulding AR, 2014, J INFECT DIS, V209, P1955, DOI 10.1093/infdis/jit823; Steinberger P, 1996, J BIOL CHEM, V271, P10967, DOI 10.1074/jbc.271.18.10967; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; Thomas Damien, 2007, Chem Immunol Allergy, V93, P24, DOI 10.1159/000100856; Thomas WR, 2015, ALLERGOL INT, V64, P304, DOI 10.1016/j.alit.2015.05.004; Tomassen P, 2013, ALLERGY, V68, P1289, DOI 10.1111/all.12230; van der Burg M, 2001, BLOOD, V97, P1001, DOI 10.1182/blood.V97.4.1001; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Varshney AK, 2013, J INFECT DIS, V208, P2058, DOI 10.1093/infdis/jit421; Visco V, 1996, J IMMUNOL, V157, P956; Wiegand TW, 1996, J IMMUNOL, V157, P221; Wu YCB, 2014, J ALLERGY CLIN IMMUN, V134, P604, DOI 10.1016/j.jaci.2014.07.010; YAN XJ, 1993, J IMMUNOL, V150, P3873; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x	71	30	30	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1195	+		10.1016/j.jaci.2016.06.066	http://dx.doi.org/10.1016/j.jaci.2016.06.066			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27658758	Green Submitted, Green Published, hybrid			2022-12-18	WOS:000398771800015
J	Cahill, KN; Boyce, JA				Cahill, Katherine N.; Boyce, Joshua A.			Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Aspirin-exacerbated respiratory disease; cysteinyl leukotrienes; prostaglandin D-2; innate immune mechanisms; future targets	DRIVEN		[Cahill, Katherine N.; Boyce, Joshua A.] Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA USA; [Cahill, Katherine N.; Boyce, Joshua A.] Harvard Med Sch, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Boyce, JA (corresponding author), Brigham & Womens Hosp, 1 Jimmy Fund Way,Rm 638, Boston, MA 02115 USA.	jboyce@partners.org		Cahill, Katherine/0000-0002-8549-1835	National Institutes of Health [AI118804, AI078908, AI095219, AT002782, AI082369, HL111113, HL117945]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI118804] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (AI118804, AI078908, AI095219, AT002782, AI082369, HL111113, and HL117945) and by generous contributions from the Vinik Family.	Bankova LG, 2016, P NATL ACAD SCI USA, V113, P6242, DOI 10.1073/pnas.1605957113; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; CHRISTIE PE, 1993, EUR RESPIR J, V6, P1468; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Hayashi H, 2016, J ALLERGY CLIN IMMUN, V137, P1585, DOI 10.1016/j.jaci.2015.09.034; Laidlaw TM, 2016, NEW ENGL J MED, V374, P484, DOI 10.1056/NEJMcibr1514013; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110	10	30	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					764	766		10.1016/j.jaci.2016.09.025	http://dx.doi.org/10.1016/j.jaci.2016.09.025			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27771324	Bronze			2022-12-18	WOS:000397295800005
J	van der Plaat, DA; de Jong, K; Lahousse, L; Faiz, A; Vonk, JM; van Diemen, CC; Nedeljkovic, I; Amin, N; Brusselle, GG; Hofman, A; Brandsma, CA; Bosse, Y; Sin, DD; Nickle, DC; van Duijn, CM; Postma, DS; Boezen, HM				van der Plaat, Diana A.; de Jong, Kim; Lahousse, Lies; Faiz, Alen; Vonk, Judith M.; van Diemen, Cleo C.; Nedeljkovic, Ivana; Amin, Najaf; Brusselle, Guy G.; Hofman, Albert; Brandsma, Corry-Anke; Bosse, Yohan; Sin, Don D.; Nickle, David C.; van Duijn, Cornelia M.; Postma, Dirkje S.; Boezen, H. Marike			Genome-wide association study on the FEV1/FVC ratio in never-smokers identifies HHIP and FAM13A	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Genome-wide association study; never-smokers; genetics; pulmonary function; chronic obstructive pulmonary disease	OBSTRUCTIVE PULMONARY-DISEASE; LUNG-FUNCTION; POPULATION; POLYMORPHISMS; COPD; GENE; ROTTERDAM; LEVEL; TOOL	Background: Although a striking proportion (25% to 45%) of patients with chronic obstructive pulmonary disease are never-smokers, most genetic susceptibility studies have not focused on this group exclusively. Objective: The aim of this study was to identify common genetic variants associated with FEV1 and its ratio to forced vital capacity (FVC) in never-smokers. Methods: Genome-wide association studies were performed in 5070 never-smokers of the identification cohort LifeLines, and results (P < 10(-5)) were verified by using a meta-analysis of the Vlagtwedde-Vlaardingen study and the Rotterdam Study I-III (total n = 1966). Furthermore, we aimed to assess the effects of the replicated variants in more detail by performing genetic risk score, expression quantitative trait loci, and variant*ever-smoking interaction analyses. Results: We identified associations between the FEV1/ FVC ratio and 5 common genetic variants in the identification cohort, and 2 of these associations were replicated. The 2 variants annotated to the genes hedgehog interacting protein (HHIP) and family with sequence similarity 13 member A (FAM13A) were shown to have an additive effect on FEV1/ FVC levels in the genetic risk score analysis; were associated with gene expression of HHIP and FAM13A in lung tissue, respectively; and were genome-wide significant in a meta-analysis including both identification and 4 verification cohorts (P < 2.19 3 10 27). Finally, we did not identify significant interactions between the variants and ever smoking. Results of the FEV1 identification analysis were not replicated. Conclusion: The genes HHIP and FAM13A confer a risk for airway obstruction in general that is not driven exclusively by cigarette smoking, which is the main risk factor for chronic obstructive pulmonary disease.	[van der Plaat, Diana A.; de Jong, Kim; Vonk, Judith M.; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Hanzepl 1, NL-9700 AB Groningen, Netherlands; [Faiz, Alen; Brandsma, Corry-Anke] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, NL-9700 AB Groningen, Netherlands; [van Diemen, Cleo C.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 AB Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, NL-9700 AB Groningen, Netherlands; [van der Plaat, Diana A.; de Jong, Kim; Faiz, Alen; Vonk, Judith M.; Brandsma, Corry-Anke; Postma, Dirkje S.; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, NL-9700 AB Groningen, Netherlands; [Lahousse, Lies; Nedeljkovic, Ivana; Amin, Najaf; Brusselle, Guy G.; Hofman, Albert; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Brusselle, Guy G.] Erasmus MC, Dept Resp Med, Rotterdam, Netherlands; [Lahousse, Lies; Brusselle, Guy G.] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [Bosse, Yohan] Univ Laval, Dept Mol, Med, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Sin, Don D.] Univ British Columbia, Div Resp Med, Dept Med, Vancouver, BC, Canada; [Sin, Don D.] Univ British Columbia, Ctr Heart Lung Innovat, St Pauls Hosp, Vancouver, BC, Canada	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Ghent University; Ghent University Hospital; Laval University; University of British Columbia; St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Boezen, HM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Hanzepl 1, NL-9700 AB Groningen, Netherlands.	h.m.boezen@umcg.nl	Faiz, Alen/AAB-7132-2019; Nickle, David/ABF-2727-2020; Lahousse, Lies/O-9426-2019; Vonk, Judith M/ABA-3009-2020; Sin, Don/AAC-2219-2021; van der Plaat, Diana A/Z-6194-2019; Nedeljkovic, Ivana P/B-3815-2013; Vonk, Judith/K-8477-2019	Faiz, Alen/0000-0003-1740-3538; Lahousse, Lies/0000-0002-3494-4363; Vonk, Judith M/0000-0001-7531-4547; van der Plaat, Diana A/0000-0002-0361-357X; Vonk, Judith/0000-0001-7531-4547; Prokic (Nedeljkovic), Ivana/0000-0002-0370-1473; van Diemen, Cleo/0000-0001-9283-2207; Brusselle, Guy/0000-0001-7021-8505; de Jong, Kim/0000-0002-3948-1046; Van Duijn, Cornelia/0000-0002-2374-9204; Amin, Najaf/0000-0002-8944-1771	Lung Foundation (Longfonds), The Netherlands [4.1.13.007]; Postdoctoral Fellow of the Research Foundation- Flanders (FWO); Dutch Ministry of Health, Welfare, and Sport; Ministry of EconomicAffairs, Agriculture, and Innovation; Province of Groningen; European Union (regional development fund); Northern Netherlands Provinces (SNN); Scientific Research (NWO); University Medical Center Groningen (UMCG); University of Groningen, de Nierstichting (the Dutch Kidney Foundation); Diabetes Fonds (the Diabetic Foundation); Ministry of Health and Environmental Hygiene of The Netherlands; The Netherlands Asthma Fund [187, 3.2.02.51]; Stichting Astma Bestrijding, BBMRI- NL (Complementation project); European Respiratory Society COPD research award 2011; Erasmus MC; Erasmus University Rotterdam; Netherlands Organisation for Scientific Research (NWO); Netherlands Organisation for Health Research and Development (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative (NGI); Ministry of Education, Culture, and Science; Ministry of Health, Welfare, and Sports; European Commission (DG XII); Municipality of Rotterdam; Merck Research Laboratories	Lung Foundation (Longfonds), The Netherlands; Postdoctoral Fellow of the Research Foundation- Flanders (FWO)(FWO); Dutch Ministry of Health, Welfare, and Sport; Ministry of EconomicAffairs, Agriculture, and Innovation; Province of Groningen; European Union (regional development fund); Northern Netherlands Provinces (SNN); Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); University Medical Center Groningen (UMCG); University of Groningen, de Nierstichting (the Dutch Kidney Foundation); Diabetes Fonds (the Diabetic Foundation); Ministry of Health and Environmental Hygiene of The Netherlands; The Netherlands Asthma Fund; Stichting Astma Bestrijding, BBMRI- NL (Complementation project); European Respiratory Society COPD research award 2011; Erasmus MC; Erasmus University Rotterdam; Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative (NGI); Ministry of Education, Culture, and Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Welfare, and Sports; European Commission (DG XII)(European CommissionEuropean Commission Joint Research Centre); Municipality of Rotterdam; Merck Research Laboratories(Merck & Company)	Supported by grant number 4.1.13.007 from the Lung Foundation (Longfonds), The Netherlands. D.A.v.d.P. and K.d.J. are supported by grant number 4.1.13.007 from Longfonds. L. L. is a Postdoctoral Fellow of the Research Foundation Flanders (FWO). The LifeLines cohort study was supported by the Dutch Ministry of Health, Welfare, and Sport; the Ministry of EconomicAffairs, Agriculture, and Innovation; the Province of Groningen; the European Union (regional development fund); the Northern Netherlands Provinces (SNN); The Netherlands Organization for Scientific Research (NWO); University Medical Center Groningen (UMCG); University of Groningen, de Nierstichting (the Dutch Kidney Foundation); and the Diabetes Fonds (the Diabetic Foundation). The Vlagtwedde- Vlaardingen cohort study was supported by the Ministry of Health and Environmental Hygiene of The Netherlands and The Netherlands Asthma Fund (grant 187) and The Netherlands Asthma Fund grant no. 3.2.02.51, the Stichting Astma Bestrijding, BBMRI- NL (Complementation project), and the European Respiratory Society COPD research award 2011 (to H. M. B.). The Rotterdam Study was supported by the Erasmus MC and Erasmus University Rotterdam; The Netherlands Organisation for Scientific Research (NWO); The Netherlands Organisation for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); The Netherlands Genomics Initiative (NGI); the Ministry of Education, Culture, and Science; the Ministry of Health, Welfare, and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. The Lung eQTL study was funded by Merck Research Laboratories.	American Thoracic Society, 2004, STAND DIAGN MAN PAT; Artigas MS, 2011, AM J RESP CRIT CARE, V184, P786, DOI 10.1164/rccm.201102-0192OC; Budulac SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033386; Chen W, 2015, ANN AM THORAC SOC, V12, P340, DOI 10.1513/AnnalsATS.201408-380OC; Cho MH, 2010, NAT GENET, V42, P200, DOI 10.1038/ng.535; Corvol H, 2014, J MED GENET, V51, P646, DOI 10.1136/jmedgenet-2014-102525; de Jong K, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-83; Estrada K, 2009, BIOINFORMATICS, V25, P2750, DOI 10.1093/bioinformatics/btp497; Halbert RJ, 2006, EUR RESPIR J, V28, P523, DOI 10.1183/09031936.06.00124605; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; Hofman A, 2013, EUR J EPIDEMIOL, V28, P889, DOI 10.1007/s10654-013-9866-z; IBM, 2020, IBM SPSS STAT WINDOW; Jiang ZQ, 2016, AM J RESP CRIT CARE, V194, P185, DOI 10.1164/rccm.201505-0999OC; Kim S, 2015, J HUM GENET, V60, P139, DOI 10.1038/jhg.2014.118; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; Siedlinski M, 2009, EUR RESPIR J, V33, P986, DOI 10.1183/09031936.00171507; Siedlinski M, 2009, PHARMACOGENET GENOM, V19, P675, DOI 10.1097/FPC.0b013e32832f5eff; Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941; Stolk RP, 2008, EUR J EPIDEMIOL, V23, P67, DOI 10.1007/s10654-007-9204-4; van der Lende R, 1969, THESIS; van Diemen CC, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-89; Viegi G, 2007, EUR RESPIR J, V30, P993, DOI 10.1183/09031936.00082507; Wain LV, 2015, LANCET RESP MED, V3, P769, DOI 10.1016/S2213-2600(15)00283-0; Wang B, 2013, GENE, V531, P101, DOI 10.1016/j.gene.2013.08.069; Wilk JB, 2012, AM J RESP CRIT CARE, V186, P622, DOI 10.1164/rccm.201202-0366OC; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Young RP, 2011, APPL CLIN GENET, V4, P1, DOI 10.2147/TACG.S15758; Zhou XB, 2013, GENOMICS, V101, P263, DOI 10.1016/j.ygeno.2013.02.010; Zhou XB, 2012, HUM MOL GENET, V21, P1325, DOI 10.1093/hmg/ddr569	37	30	30	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					533	540		10.1016/j.jaci.2016.06.062	http://dx.doi.org/10.1016/j.jaci.2016.06.062			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27612410				2022-12-18	WOS:000397002400019
J	Carroll, KN; Gebretsadik, T; Escobar, GJ; Wu, PS; Li, SX; Walsh, EM; Mitchel, E; Sloan, CD; Dupont, WD; Hartert, TV				Carroll, Kecia N.; Gebretsadik, Tebeb; Escobar, Gabriel J.; Wu, Pingsheng; Li, Sherian Xu; Walsh, Eileen M.; Mitchel, Ed; Sloan, Chantel D.; Dupont, William D.; Hartert, Tina V.			Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory syncytial virus; lower respiratory tract infection; bronchiolitis; respiratory syncytial virus immunoprophylaxis; palivizumab; wheezing; asthma; primary prevention	PALIVIZUMAB PROPHYLAXIS; UNITED-STATES; INFECTION; ALLERGY; BRONCHIOLITIS; WHEEZE; GROWTH; BIRTH	Background: Respiratory syncytial virus (RSV) lower respiratory tract infection is implicated in asthma development. RSV immunoprophylaxis during infancy is efficacious in preventing RSV-related hospitalizations and has been associated with decreased wheezing in the first years of life. Objective: We investigated whether greater adherence to immunoprophylaxis in infants at high risk for severe RSV would be associated with decreased childhood asthma. Methods: We conducted a retrospective cohort investigation including children born from 1996-2003 who were enrolled in Kaiser Permanente Northern California or Tennessee Medicaid and eligible to receive RSV immunoprophylaxis. Asthma was defined at 4.5 to 6 years of age by using asthma-specific health care visits and medication fills. We classified children into immunoprophylaxis eligibility groups and calculated adherence (percentage receipt of recommended doses). We used a set of statistical strategies (multivariable logistic regression and propensity score [PS]-adjusted and PS-matched analyses) to overcome confounding by medical complexity because infants with higher adherence (>= 70%) have higher prevalence of chronic lung disease, lower birth weight, and longer nursery stays. Results: By using multivariable logistic regression and PS-adjusted models in the combined group, higher adherence to RSV immunoprophylaxis was not associated with decreased asthma. However, in PS-matched analysis, treated children with 70% or greater adherence had decreased odds of asthma compared with those with 20% or less adherence (odds ratio, 0.62; 95% CI, 0.50-0.78). Conclusions: This investigation of RSV immunoprophylaxis in high-risk children primarily found nonsignificant associations on prevention of asthma in specific preterm groups. Our findings highlight the need for larger studies and prospective cohorts and provide estimates of potential preventive effect sizes in high-risk children.	[Carroll, Kecia N.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; [Gebretsadik, Tebeb; Wu, Pingsheng; Dupont, William D.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Wu, Pingsheng; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Mitchel, Ed] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA; [Carroll, Kecia N.; Gebretsadik, Tebeb; Wu, Pingsheng; Mitchel, Ed; Sloan, Chantel D.; Dupont, William D.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Asthma & Environm Hlth Sci Res, Nashville, TN 37212 USA; [Escobar, Gabriel J.] Kaiser Permanente Med Care Program, Oakland, CA USA; [Escobar, Gabriel J.; Li, Sherian Xu; Walsh, Eileen M.] Kaiser Permanente, Perinatal Res Unit, Div Res, Oakland, CA USA; [Escobar, Gabriel J.] Kaiser Permanente Med Ctr, Dept Inpatient Pediat, Walnut Creek, CA USA; [Sloan, Chantel D.] Brigham Young Univ, Provo, UT 84602 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Brigham Young University	Hartert, TV (corresponding author), Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Div Allergy Pulm & Crit Care Med, 6107 MCE, Nashville, TN 37232 USA.	tina.hartert@vanderbilt.edu	Sloan-Aagard, Chantel/GWC-7572-2022		Agency for Healthcare Research and Quality [R01 HS018454]; National Institutes of Health [K24 AI 077930]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS018454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI077930, U19AI095227] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a grant from the Agency for Healthcare Research and Quality (R01 HS018454) and National Institutes of Health (K24 AI 077930).	Abramson JS, 2003, PEDIATRICS, V112, P1442; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; American Academy of Pediatrics Committee on Infectious Diseases, 2006, RED BOOK REP COMM IN; [Anonymous], 2006, R LANG ENV STAT COMP; Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Bocchini JA, 2009, PEDIATRICS, V124, P1216, DOI [10.1542/peds.2009-1806, 10.1542/peds.2009-2345]; Boyce TG, 2000, J PEDIATR-US, V137, P865, DOI 10.1067/mpd.2000.110531; Brady MT, 2014, PEDIATRICS, V134, P415, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Connor E, 1997, PEDIATRICS, V99, P93; Dombkowski KJ, 2008, ANN EPIDEMIOL, V18, P290, DOI 10.1016/j.annepidem.2007.11.012; Escobar GJ, 2013, J PEDIATR INFECT DIS, V2, P205, DOI 10.1093/jpids/pit007; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; Halsey NA, 1997, PEDIATRICS, V99, P645, DOI 10.1542/peds.99.4.645; Halsey NA, 1998, PEDIATRICS, V102, P1211, DOI 10.1542/peds.102.5.1211; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Kallen B, 2013, EUR RESPIR J, V41, P671, DOI 10.1183/09031936.00041912; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; National Advisory Committee on Immunization, 2003, Can Commun Dis Rep, V29, P1; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; PIPER JM, 1990, AM J EPIDEMIOL, V132, P561, DOI 10.1093/oxfordjournals.aje.a115692; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; Sekhon JS, 2011, J STAT SOFTW, V42, P1; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Wakefield DB, 2006, PEDIATR PULM, V41, P962, DOI 10.1002/ppul.20476; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yoshihara S, 2013, PEDIATRICS, V132, P811, DOI 10.1542/peds.2013-0982	41	30	31	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					66	+		10.1016/j.jaci.2016.01.055	http://dx.doi.org/10.1016/j.jaci.2016.01.055			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27212083	Green Accepted, Bronze			2022-12-18	WOS:000393996800008
J	van Erp, FC; Knol, EF; Pontoppidan, B; Meijer, Y; van der Ent, CK; Knulst, AC				van Erp, Francine C.; Knol, Edward F.; Pontoppidan, Bo; Meijer, Yolanda; van der Ent, Cornelis K.; Knulst, Andre C.			The IgE and basophil responses to Ara h 2 and Ara h 6 are good predictors of peanut allergy in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ORAL FOOD CHALLENGES; ACTIVATION TEST; DOUBLE-BLIND; ADULTS		[van Erp, Francine C.; Meijer, Yolanda; van der Ent, Cornelis K.] Univ Med Ctr Utrecht, Dept Paediat Pulmonol & Allergol, Utrecht, Netherlands; [Knol, Edward F.; Knulst, Andre C.] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands; [Knol, Edward F.] Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands; [Pontoppidan, Bo] ThermoFisher Sci, Uppsala, Sweden	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	van Erp, FC (corresponding author), Univ Med Ctr Utrecht, Dept Paediat Pulmonol & Allergol, Utrecht, Netherlands.	f.c.vanerp@umcutrecht.nl		Van der Ent, Cornelis/0000-0002-2501-4121; Knulst, Andre/0000-0002-1056-3179; Knol, Edward/0000-0001-7368-9820	ThermoFisher	ThermoFisher	E.F. Knol receives payment for lectures from ThermoFisher and receives travel support from ThermoFisher. B. Pontoppidan is an employee of ThermoFisher Scientific. A. C. Knulst receives fees for lectures from ThermoFisher. The rest of the authors declare that they have no relevant conflicts of interest.	Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Klemans RJB, 2014, ALLERGY, V69, P1112, DOI 10.1111/all.12424; Klemans RJB, 2013, J ALLERGY CLIN IMMUN, V131, P157, DOI 10.1016/j.jaci.2012.08.010; Koppelman SJ, 2005, CLIN EXP ALLERGY, V35, P490, DOI 10.1111/j.1365-2222.2005.02204.x; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Rentzos G, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0064-9; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; van Erp FC, 2013, PEDIAT ALLERG IMM-UK, V24, P596, DOI 10.1111/pai.12107; Vlieg-Boerstra BJ, 2011, ALLERGY, V66, P948, DOI 10.1111/j.1398-9995.2010.02539.x	12	30	30	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					358	+		10.1016/j.jaci.2016.06.041	http://dx.doi.org/10.1016/j.jaci.2016.06.041			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27516216	Bronze			2022-12-18	WOS:000393996800039
J	Kim, AS; Doherty, TA; Karta, MR; Das, S; Baum, R; Rosenthal, P; Beppu, A; Miller, M; Kurten, R; Broide, DH				Kim, Alexander S.; Doherty, Taylor A.; Karta, Maya R.; Das, Sudipta; Baum, Rachel; Rosenthal, Peter; Beppu, Andrew; Miller, Marina; Kurten, Richard; Broide, David H.			Regulatory B cells and T follicular helper cells are reduced in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNE-RESPONSES; MILK ALLERGY		[Kim, Alexander S.; Doherty, Taylor A.; Karta, Maya R.; Das, Sudipta; Baum, Rachel; Rosenthal, Peter; Beppu, Andrew; Miller, Marina; Broide, David H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Kurten, Richard] Univ Arkansas Med Sci, Arkansas Childrens Hosp Res Inst, Dept Physiol & Biophys, Little Rock, AR 72205 USA	University of California System; University of California San Diego; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	Kim, AS (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	ask011@ucsd.edu		Broide, David/0000-0001-8405-9090; Doherty, Taylor/0000-0003-3256-0398; Das, Sudipta/0000-0001-9380-2907; Baum, Rachel/0000-0002-8227-7462	NIAID NIH HHS [R37 AI038425, T32 AI007469, R01 AI107779, R01 AI072115, U19 AI070535, R01 AI114585] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072115, R37AI038425, T32AI007469, U19AI070535, R01AI114585, R01AI107779] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Braza F, 2014, ALLERGY, V69, P1454, DOI 10.1111/all.12490; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Karnekura R, 2015, CLIN IMMUNOL, V158, P204, DOI 10.1016/j.clim.2015.02.016; Lee SJ, 2013, ALLERGY ASTHMA IMMUN, V5, P48, DOI 10.4168/aair.2013.5.1.48; Noh J, 2012, CELL IMMUNOL, V274, P109, DOI 10.1016/j.cellimm.2012.01.005; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; van der Vlugt LEPM, 2014, CLIN EXP ALLERGY, V44, P517, DOI 10.1111/cea.12238; Yoshizaki A, 2012, NATURE, V491, P264, DOI 10.1038/nature11501	10	30	33	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1192	1195		10.1016/j.jaci.2016.03.017	http://dx.doi.org/10.1016/j.jaci.2016.03.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27142393	Green Accepted, Bronze			2022-12-18	WOS:000385499400026
J	Hong, XM; Ladd-Acosta, C; Hao, K; Sherwood, B; Ji, HK; Keet, CA; Kumar, R; Caruso, D; Liu, X; Wang, GY; Chen, Z; Ji, YL; Mao, GY; Walker, SO; Bartell, TR; Ji, ZC; Sun, YF; Tsai, HJ; Pongracic, JA; Weeks, DE; Wang, XB				Hong, Xiumei; Ladd-Acosta, Christine; Hao, Ke; Sherwood, Ben; Ji, Hongkai; Keet, Corinne A.; Kumar, Rajesh; Caruso, Deanna; Liu, Xin; Wang, Guoying; Chen, Zhu; Ji, Yuelong; Mao, Guanyun; Walker, Sheila Ohlsson; Bartell, Tami R.; Ji, Zhicheng; Sun, Yifei; Tsai, Hui-Ju; Pongracic, Jacqueline A.; Weeks, Daniel E.; Wang, Xiaobin			Epigenome-wide association study links site-specific DNA methylation changes with cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENES; TH1		[Hong, Xiumei; Caruso, Deanna; Wang, Guoying; Chen, Zhu; Ji, Yuelong; Mao, Guanyun; Walker, Sheila Ohlsson; Wang, Xiaobin] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Early Life Origins Dis, Dept Populat Family & Reprod Hlth, Baltimore, MD 21218 USA; [Ladd-Acosta, Christine] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Hao, Ke] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Sherwood, Ben; Ji, Hongkai; Ji, Zhicheng; Sun, Yifei] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Keet, Corinne A.] Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD USA; [Kumar, Rajesh; Pongracic, Jacqueline A.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Allergy & Immunol, Chicago, IL 60611 USA; [Liu, Xin] Chinese Acad Sci, Beijing Inst Genom, Key Lab Genom & Precis Med, Beijing, Peoples R China; [Liu, Xin] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Mao, Guanyun] Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, Dept Prevent Med, Wenzhou, Peoples R China; [Walker, Sheila Ohlsson] Arizona State Univ, Inst Interdisciplinary Salivary Biosci Res, Tempe, AZ USA; [Walker, Sheila Ohlsson] Johns Hopkins Sch Educ, Baltimore, MD USA; [Bartell, Tami R.] Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60611 USA; [Tsai, Hui-Ju] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan; [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA; [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Wang, Xiaobin] Johns Hopkins Univ, Dept Pediat, Div Gen Pediat & Adolescent Med, Sch Med, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Ann & Robert H. Lurie Children's Hospital of Chicago; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Northwestern University; Feinberg School of Medicine; Wenzhou Medical University; Arizona State University; Arizona State University-Tempe; Johns Hopkins University; Ann & Robert H. Lurie Children's Hospital of Chicago; National Health Research Institutes - Taiwan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University	Wang, XB (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Early Life Origins Dis, Dept Populat Family & Reprod Hlth, Baltimore, MD 21218 USA.	xwang82@jhu.edu	Weeks, Daniel E/B-2995-2012; Ji, Zhicheng/I-5650-2019; Wang, Guoying/F-8908-2011	Weeks, Daniel E/0000-0001-9410-7228; Ji, Zhicheng/0000-0002-9457-4704; JI, Yuelong/0000-0001-6901-5030; Sherwood, Ben/0000-0002-4419-8288; Kumar, Rajesh/0000-0002-1962-7108	NIAID NIH HHS [R21 AI088609, R56 AI080627, K23 AI103187, U01 AI090727, R21 AI079872] Funding Source: Medline; NICHD NIH HHS [R01 HD041702, R21 HD085556, R01 HD086013, R21 HD066471] Funding Source: Medline; NIEHS NIH HHS [R21 ES011666] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD086013, R01HD041702, R21HD085556] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD066471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI088609, R21AI079872, K23AI103187, R56AI080627, U01AI090727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES011666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Canani RB, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0070-8; Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259; Haileselassie Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077893; Hong XM, 2012, SEMIN IMMUNOPATHOL, V34, P655, DOI 10.1007/s00281-012-0323-y; Johansson MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023031; Kumar R, 2009, J ALLERGY CLIN IMMUN, V124, P1031, DOI 10.1016/j.jaci.2009.06.052; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Lund RJ, 2007, J IMMUNOL, V178, P3648, DOI 10.4049/jimmunol.178.6.3648; Martino D, 2015, J ALLERGY CLIN IMMUN, V135, P1319, DOI 10.1016/j.jaci.2014.12.1933; Nilsson C, 2005, J ALLERGY CLIN IMMUN, V116, P438, DOI 10.1016/j.jaci.2005.04.027; Roessler Jessica, 2012, BMC Res Notes, V5, P210, DOI 10.1186/1756-0500-5-210; Scotton CJ, 2005, J IMMUNOL, V174, P834, DOI 10.4049/jimmunol.174.2.834; Su RC, 2008, J ALLERGY CLIN IMMUN, V121, P57, DOI 10.1016/j.jaci.2007.09.004	13	30	31	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					908	+		10.1016/j.jaci.2016.01.056	http://dx.doi.org/10.1016/j.jaci.2016.01.056			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27236499	Green Accepted, Bronze			2022-12-18	WOS:000385496000032
J	Lieberman, PL; Umetsu, DT; Carrigan, GJ; Rahmaoui, A				Lieberman, Phillip L.; Umetsu, Dale T.; Carrigan, Gillis J.; Rahmaoui, Abdelkader			Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							JAPANESE CYPRESS POLLEN; CHA O 2; MAJOR ALLERGEN; FOOD ALLERGY; RISK-FACTORS; ASTHMA; PURIFICATION; PREVALENCE; CLONING; HEALTH		[Lieberman, Phillip L.] Univ Tennessee, Coll Med, Dept Internal Med, Div Allergy, Memphis, TN 37996 USA; [Lieberman, Phillip L.] Univ Tennessee, Coll Med, Dept Pediat, Div Immunol, Memphis, TN 37996 USA; [Umetsu, Dale T.; Rahmaoui, Abdelkader] Genentech Inc, Global Prod Dev, San Francisco, CA 94080 USA; [Carrigan, Gillis J.] Genentech Inc, Real World Data Sci, San Francisco, CA 94080 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Roche Holding; Genentech; Roche Holding; Genentech	Lieberman, PL (corresponding author), Univ Tennessee, Coll Med, Dept Internal Med, Div Allergy, Memphis, TN 37996 USA.; Lieberman, PL (corresponding author), Univ Tennessee, Coll Med, Dept Pediat, Div Immunol, Memphis, TN 37996 USA.	phillieberman@hotmail.com						Cox L, 2011, J ALLERGY CLIN IMMUN, V128, P210, DOI 10.1016/j.jaci.2011.04.010; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Iribarren C, 2010, ANN ALLERG ASTHMA IM, V104, P371, DOI 10.1016/j.anai.2010.03.004; Lieberman P, 2007, ALLERGY ASTHMA PROC, V28, P259, DOI 10.2500/108854107781285717; Lieberman P, 2010, ANN ALLERG ASTHMA IM, V105, P493, DOI 10.1016/j.anai.2010.10.008; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Mori T, 1999, BIOCHEM BIOPH RES CO, V263, P166, DOI 10.1006/bbrc.1999.1261; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; Okano M, 2008, CLIN EXP ALLERGY, V38, P1891, DOI 10.1111/j.1365-2222.2008.03116.x; Okano M, 2001, J ALLERGY CLIN IMMUN, V108, P101, DOI 10.1067/mai.2001.115757; Price KS, 2007, ALLERGY ASTHMA PROC, V28, P313, DOI 10.2500/aap.2007.28.3003; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sone Toshio, 2009, Allergology International, V58, P237, DOI 10.2332/allergolint.08-OA-0027; Suzuki M, 1996, MOL IMMUNOL, V33, P451, DOI 10.1016/0161-5890(95)00147-6	15	30	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					913	+		10.1016/j.jaci.2016.03.030	http://dx.doi.org/10.1016/j.jaci.2016.03.030			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27236498	hybrid			2022-12-18	WOS:000385496000034
J	Fujishima, H; Okada, N; Matsumoto, K; Fukagawa, K; Igarashi, A; Matsuda, A; Ono, J; Ohta, S; Mukai, H; Yoshikawa, M; Izuhara, K				Fujishima, Hiroshi; Okada, Naoko; Matsumoto, Kenji; Fukagawa, Kazumi; Igarashi, Ayako; Matsuda, Akio; Ono, Junya; Ohta, Shoichiro; Mukai, Hideki; Yoshikawa, Mamoru; Izuhara, Kenji			The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic keratoconjunctivitis; periostin; biomarker; IL-13; serum; tear	SCANNING LASER MICROSCOPY; ATOPIC KERATOCONJUNCTIVITIS; VERNAL KERATOCONJUNCTIVITIS; JAPANESE GUIDELINE; CONJUNCTIVAL FIBROBLASTS; BRONCHIAL-ASTHMA; TH2 CYTOKINES; EYE DISEASE; INFLAMMATION; CORNEAL	Background: Chronic ocular allergic diseases such as vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) are accompanied by serious comorbidities; however, the underlying pathogenesis remains obscure. Furthermore, diagnosing conjunctival lesions in patients with atopic dermatitis and estimating the severity in AKC are important for the treatment of ocular allergic diseases. Objective: We addressed whether periostin, a novel mediator and biomarker in allergic inflammation, is involved in the pathogenesis of ocular allergic diseases and whether periostin can be a biomarker for these diseases. Methods: We investigated tear periostin in patients with seasonal allergic conjunctivitis (SAC), VKC, and AKC and allergic patients without conjunctivitis and compared it with tear IL-13 and serum periostin. Furthermore, in patients with AKC, we measured tear periostin before and after topical treatment with tacrolimus. Results: Tears from patients with ocular allergic disease showed significantly high periostin levels than did tears from allergic patients without conjunctivitis and from patients with AKC, VKC, and SACin descending order. Tear periostin was associated with serious comorbidities such as large papilla formation and corneal damage in AKC, although both tear IL-13 and serum periostin had little to no such abilities. Furthermore, after topical tacrolimus treatment, tear periostin tended to decrease in most patients with AKC along with their clinical improvement. Conclusions: Periostin produced in conjunctival tissues stimulated by IL-13 may contribute to the pathogenesis of ocular allergic diseases. Furthermore, tear periostin can be potentially applied as a biomarker to diagnose conjunctivitis in allergic patients and to evaluate disease severity as well as the efficacy of treatments in AKC.	[Fujishima, Hiroshi] Tsurumi Univ, Sch Dent Med, Dept Ophthalmol, Yokohama, Kanagawa, Japan; [Okada, Naoko; Matsumoto, Kenji; Matsuda, Akio] Natl Res Inst Child Hlth & Dev Lab, Dept Allergy & Clin Immunol, Tokyo, Japan; [Fukagawa, Kazumi] Ryogoku Eye Clin, Tokyo, Japan; [Fukagawa, Kazumi] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan; [Matsuda, Akio] Ichikawa Gen Hosp, Tokyo Dent Coll, Dept Ophthalmol, Ichikawa, Japan; [Ono, Junya] Shino Test Corp, Sagamihara, Kanagawa, Japan; [Ohta, Shoichiro] Saga Med Sch, Dept Lab Med, Saga, Japan; [Mukai, Hideki] Saga Med Sch, Dept Biomol Sci, Div Med Biochem, 5-1-1 Nabeshima, Saga 8498501, Japan; [Yoshikawa, Mamoru] Toho Univ, Sch Med, Dept Dermatol, Tokyo, Japan; [Izuhara, Kenji] Toho Univ, Sch Med, Dept Otorhinolaryngol, Tokyo, Japan	Tsurumi University; National Center for Child Health & Development - Japan; Keio University; Tokyo Dental College; Shino Test Corporation; Saga University; Saga University; Toho University; Toho University	Izuhara, K (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Med Biochem, 5-1-1 Nabeshima, Saga 8498501, Japan.; Fujishima, H (corresponding author), Tsurumi Univ, Sch Dent Med, Dept Ophthalmol, Tsurumi Ku, 2-1-3 Tsurumi, Yokohama, Kanagawa 2308501, Japan.	fujishima117@gmail.com; kizuhara@cc.saga-u.ac.jp	岡田, 直子/GRI-9555-2022	岡田, 直子/0000-0002-3378-5778	Tsurumi University, Yokohama, Japan; National Institute of Biomedical Innovation [ID10-43]; Grants-in-Aid for Scientific Research [24592582] Funding Source: KAKEN	Tsurumi University, Yokohama, Japan; National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was funded by Tsurumi University, Yokohama, Japan (to H.F.) and by the National Institute of Biomedical Innovation (grant no. ID10-43 to K.M.).	Asano-Kato N, 2005, EXP EYE RES, V80, P555, DOI 10.1016/j.exer.2004.11.006; Bentley JK, 2014, J ALLERGY CLIN IMMUN, V134, P1433, DOI 10.1016/j.jaci.2014.05.029; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Elliott CG, 2012, J CELL SCI, V125, P121, DOI 10.1242/jcs.087841; Fujishima H, 2000, JPN J OPHTHALMOL, V44, P511, DOI 10.1016/S0021-5155(00)00210-0; FUJISHIMA H, 1995, CLIN EXP IMMUNOL, V102, P395; Fukagawa Kazumi, 2009, Allergology International, V58, P499, DOI 10.2332/allergolint.09-OA-0092; Fukushima A, 2014, BRIT J OPHTHALMOL, V98, P1023, DOI 10.1136/bjophthalmol-2013-304453; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hu YQ, 2008, OPHTHALMOLOGY, V115, P2004, DOI 10.1016/j.ophtha.2008.05.010; Hu Y, 2007, MOL VIS, V13, P1379; Izuhara K, 2014, ALLERGOL INT, V63, P143, DOI 10.2332/allergolint.13-RAI-0663; Kanemitsu Y, 2013, J ALLERGY CLIN IMMUN, V132, P305, DOI 10.1016/j.jaci.2013.04.050; Katayama I, 2014, ALLERGOL INT, V63, P377, DOI 10.2332/allergolint.14-RAI-0769; Kou K, 2014, BRIT J DERMATOL, V171, P283, DOI 10.1111/bjd.12943; Leonardi A, 1999, INVEST OPHTH VIS SCI, V40, P3036; Leonardi A, 2006, CLIN EXP ALLERGY, V36, P777, DOI 10.1111/j.1365-2222.2006.02499.x; Leonardi A, 2009, ALLERGY, V64, P710, DOI 10.1111/j.1398-9995.2008.01858.x; Leonardi A, 2013, CURR OPIN ALLERGY CL, V13, P558, DOI 10.1097/ACI.0b013e328364ec7a; Martinez R, 2011, Arch Soc Esp Oftalmol, V86, P187, DOI 10.1016/j.oftal.2011.01.002; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Matsumoto H, 2014, ALLERGOL INT, V63, P153, DOI 10.2332/allergolint.13-RAI-0678; Nagasaki T, 2014, J ALLERGY CLIN IMMUN, V133, P1474, DOI 10.1016/j.jaci.2013.12.1084; Nakamura Y, 2015, ALLERGOL INT, V64, P209, DOI 10.1016/j.alit.2015.01.001; Nishiyama T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018410; Nivenius E, 2004, CLIN EXP ALLERGY, V34, P725, DOI 10.1111/j.1365-2222.2004.1950.x; Okamoto M, 2011, EUR RESPIR J, V37, P1119, DOI 10.1183/09031936.00059810; Okubo K, 2014, ALLERGOL INT, V63, P357, DOI 10.2332/allergolint.14-RAI-0768; Ontsuka K, 2012, EXP DERMATOL, V21, P331, DOI 10.1111/j.1600-0625.2012.01454.x; Oray M, 2013, CORNEA, V32, P1149, DOI 10.1097/ICO.0b013e31828ffdf8; Saban DR, 2013, CURR EYE RES, V38, P317, DOI 10.3109/02713683.2012.747617; Shoda T, 2013, ALLERGY, V68, P1467, DOI 10.1111/all.12240; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Sy H, 2013, ALLERGY ASTHMA PROC, V34, P33, DOI 10.2500/aap.2013.34.3612; Takamura Etsuko, 2011, Allergology International, V60, P191, DOI 10.2332/allergolint.11-RAI-0335; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Wakamatsu TH, 2012, BRIT J OPHTHALMOL, V96, P581, DOI 10.1136/bjophthalmol-2011-300143; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972	38	30	31	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					459	+		10.1016/j.jaci.2015.11.039	http://dx.doi.org/10.1016/j.jaci.2015.11.039			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	26964692	Bronze			2022-12-18	WOS:000380835800016
J	Grabenhenrich, L; Lange, L; Hartl, M; Kalb, B; Ziegert, M; Finger, A; Harandi, N; Schlags, R; Gappa, M; Puzzo, L; Stephan, V; Heigele, T; Busing, S; Ott, H; Niggemann, B; Beyer, K				Grabenhenrich, Linus; Lange, Lars; Haertl, Magdalena; Kalb, Birgit; Ziegert, Mandy; Finger, Antje; Harandi, Neda; Schlags, Ruppert; Gappa, Monika; Puzzo, Letizia; Stephan, Volker; Heigele, Thomas; Buesing, Susanne; Ott, Hagen; Niggemann, Bodo; Beyer, Kirsten			The component-specific to total IgE ratios do not improve peanut and hazelnut allergy diagnoses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food hypersensitivity; IgE; Ara h 2 allergen; peanut; Cor a 14 allergen; hazelnut	SYMPTOMATIC FOOD ALLERGY; ARA H 2; RESOLVED DIAGNOSTICS; CHILDREN; CHALLENGES; ANAPHYLAXIS; PREDICTION; GUIDELINES; TOLERANCE; UTILITY	Background: Specific IgE measurement predicts the outcome of oral food challenges with considerable uncertainty when evaluating food allergy. Objective: Our aim was to assess whether accounting for the ratio of component- or allergen-specific to total IgE can improve this prediction. Methods: This multicenter study collected blood samples from children with suspected peanut or hazelnut allergy referred to allergy specialist clinics for food challenges. Specific IgE to peanuts, hazelnuts, and their components (Ara h 1, Ara h 2, Ara h 3, Ara h 8, Cor a 1, Cor a 8, Cor a 9, and Cor a 14) and total IgE levels were determined by using the ImmunoCAP-FEIA. Specific to total IgE ratios were compared with raw IgE levels in terms of discrimination and prediction. Results: Eighty-eight (43%) of 207 children with suspected peanut allergy and 44 (31%) of 142 children with suspected hazelnut allergy had symptoms during food challenge. Discrimination was similar for raw and ratio measures: areas under the curve of 0.93 for Ara h 2-specific IgE versus 0.92 for the Ara h 2-specific/total IgE ratio and 0.89 for Cor a 14-specific IgE versus 0.87 for the Cor a 14-specific/total IgE ratio. The probability for a positive peanut challenge with 0.35 kU/L Ara h 2-specific IgE was 16% when the total IgE level was greater than 500 kU/L compared with 51%/48% for low/medium total IgE levels (<100/100-500 kU/L). A positive hazelnut challenge with 0.35 kU/L Cor a 14-specific IgE was estimated in 7% when total IgE levels were high compared with 34%/32% with low/medium total IgE levels. Conclusions: Raw Ara h 2- and Cor a 14-specific IgE levels were the best single predictors for pediatric peanut and hazelnut allergies, suggesting the omission of challenges at very high levels. Calculating ratio measures did not improve prediction in this population. However, estimation of individual probabilities for challenge outcomes could be supported by total IgE levels because high levels might indicate lower probabilities at a given component-specific IgE level.	[Grabenhenrich, Linus] Charite, Inst Social Med Epidemiol & Hlth Econ, Luisenstr 57, D-10117 Berlin, Germany; [Lange, Lars; Finger, Antje] St Marien Hosp, Dept Pediat, Bonn, Germany; [Haertl, Magdalena; Kalb, Birgit; Niggemann, Bodo; Beyer, Kirsten] Charite, Dept Pediat Pneumol & Immunol, D-10117 Berlin, Germany; [Ziegert, Mandy; Niggemann, Bodo] German Red Cross Hosp, Dept Pediat, Berlin, Germany; [Harandi, Neda; Schlags, Ruppert] Childrens Hosp, Wangen Im Allgau, Germany; [Gappa, Monika; Puzzo, Letizia] Marien Hosp, Childrens Dept, Wesel, Germany; [Stephan, Volker] Childrens Hosp Lichtenberg, Berlin, Germany; [Heigele, Thomas] Childrens Hosp, Stuttgart, Germany; [Buesing, Susanne] Childrens Hosp Osnabruck, Dept Pediat, Osnabruck, Germany; [Ott, Hagen] Childrens Hosp Bult, Hannover, Germany; [Beyer, Kirsten] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; St. Marien Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; St. Marien Hospital; University of Stuttgart; Icahn School of Medicine at Mount Sinai	Grabenhenrich, L (corresponding author), Charite, Inst Social Med Epidemiol & Hlth Econ, Luisenstr 57, D-10117 Berlin, Germany.	linus.grabenhenrich@charite.de		Grabenhenrich, Linus/0000-0002-9300-6625; Kalb, Birgit/0000-0002-3104-6736	Thermo Fisher Diagnostics; German Research Foundation [DFG-BE3991/1-1]	Thermo Fisher Diagnostics; German Research Foundation(German Research Foundation (DFG))	Supported in part by Thermo Fisher Diagnostics through the provision of funding for reagents and by the German Research Foundation (DFG-BE3991/1-1).	Beyer K, 2015, ALLERGY, V70, P90, DOI 10.1111/all.12530; Burks AW, 2011, PEDIATRICS, V128, P955, DOI 10.1542/peds.2011-0539; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; DunnGalvin A, 2011, J ALLERGY CLIN IMMUN, V127, pe1; DunnGalvin A, 2011, J ALLERGY CLIN IMMUN, V127, P633, DOI 10.1016/j.jaci.2010.12.004; Eller E, 2013, ALLERGY, V68, P190, DOI 10.1111/all.12075; Federly TJ, 2013, ANN ALLERG ASTHMA IM, V111, P20, DOI 10.1016/j.anai.2013.05.012; Gupta RS, 2014, J ALLER CL IMM-PRACT, V2, P300, DOI 10.1016/j.jaip.2013.12.006; Hompes S, 2011, PEDIAT ALLERG IMM-UK, V22, P568, DOI 10.1111/j.1399-3038.2011.01154.x; Horimukai K, 2015, ALLERGY, V70, P334, DOI 10.1111/all.12562; Jarvinen KM, 2011, CURR OPIN ALLERGY CL, V11, P255, DOI 10.1097/ACI.0b013e32834694d8; Johansson SGO, 2009, ALLERGY, V64, P1472, DOI 10.1111/j.1398-9995.2009.02051.x; Klemans RJB, 2013, J ALLERGY CLIN IMMUN, V131, P157, DOI 10.1016/j.jaci.2012.08.010; Machinena-Spera A, 2014, PEDIAT ALLERG IMM-UK, V25, P823, DOI 10.1111/pai.12278; Masthoff LJN, 2013, J ALLERGY CLIN IMMUN, V132, P393, DOI 10.1016/j.jaci.2013.02.024; Mehl A, 2005, ALLERGY, V60, P1034, DOI 10.1111/j.1398-9995.2005.00806.x; Muraro A, 2014, ALLERGY, V69, P1046, DOI 10.1111/all.12441; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Niggemann B, 2012, J ALLERGY CLIN IMMUN, V130, P261, DOI 10.1016/j.jaci.2012.03.021; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Soares-Weiser K, 2014, ALLERGY, V69, P76, DOI 10.1111/all.12333; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896	26	30	30	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1751	+		10.1016/j.jaci.2016.01.043	http://dx.doi.org/10.1016/j.jaci.2016.01.043			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27087317	Bronze			2022-12-18	WOS:000377527200015
J	Sneeboer, MMS; Majoor, CJ; de Kievit, A; Meijers, JCM; van der Poll, T; Kamphuisen, PW; Bel, EH				Sneeboer, Marlous M. S.; Majoor, Christof J.; de Kievit, Anne; Meijers, Joost C. M.; van der Poll, Tom; Kamphuisen, Pieter W.; Bel, Elisabeth H.			Prothrombotic state in patients with severe and prednisolone-dependent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; severity; airway inflammation; hemostasis; coagulation; fibrinolysis; comorbidity	PLASMINOGEN-ACTIVATOR INHIBITOR-1; BRONCHIAL EPITHELIAL-CELLS; DEEP-VEIN THROMBOSIS; HUMAN MAST-CELLS; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; RISK; INFLAMMATION; GLUCOCORTICOIDS; COAGULATION	Background: Epidemiologic studies have shown that asthmatic patients, in particular those with severe disease, have increased risk of pulmonary embolism. It is unknown whether these patients have a prothrombotic state under stable conditions. Objective: We sought to compare coagulation and fibrinolysis parameters between healthy subjects and patients with mild, severe, and prednisolone-dependent asthma under stable conditions and to investigate whether hemostatic markers correlate with airway inflammation. Methods: In 126 adults (33 healthy control subjects, 31 patients with mild asthma, 32 patients with severe asthma, and 30 patients with prednisolone-dependent asthma) parameters of inflammation (peripheral blood eosinophils and neutrophils) and markers of hemostasis (endogenous thrombin potential [ETP], thrombin-antithrombin complex, plasmin-alpha(2)-antiplasmin complex, plasminogen activator inhibitor type 1 [PAI-1], D-dimer, and von Willebrand factor [vWF]) were measured in plasma. One-way ANOVA with the post hoc Bonferroni test was used for group comparison, and linear regression analysis was used for correlations. Results: We observed increased ETP (121% vs 99%, overall P<.01), plasmin-alpha(2)-antiplasmin complex (520 vs 409 mu g/L, overall P = .04), PAI-1 (10 vs 7 ng/mL, overall P = .02), and vWF (142% vs 87%, overall P < .01) levels in asthmatic patients compared with healthy control subjects. ETP, PAI-1, and vWF levels increased with increasing asthma severity. In addition, we found a correlation between ETP and vWF with neutrophil but not eosinophil counts. Conclusion: Asthmatic patients have a prothrombotic state that increases with asthma severity. This might explain why patients with asthma, in particular those with severe disease, have an increased risk of venous thromboembolism.	[Sneeboer, Marlous M. S.; Majoor, Christof J.; de Kievit, Anne; Bel, Elisabeth H.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1100 Amsterdam, Netherlands; [Meijers, Joost C. M.] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, NL-1100 Amsterdam, Netherlands; [van der Poll, Tom] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, NL-1100 Amsterdam, Netherlands; [Meijers, Joost C. M.] Sanquin Res, Dept Plasma Proteins, Amsterdam, Netherlands; [Kamphuisen, Pieter W.] Univ Groningen, Univ Med Ctr Groningen, Dept Vasc Med, NL-9713 AV Groningen, Netherlands	University of Amsterdam; University of Amsterdam; University of Amsterdam; University of Groningen	Sneeboer, MMS (corresponding author), Univ Amsterdam, Acad Med Ctr F5 260, Dept Resp Med, POB 22700, NL-1100 Amsterdam, Netherlands.	m.sneeboer@amc.uva.nl	Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780; Kamphuisen, Pieter/0000-0002-6263-0177; Majoor, Christof/0000-0003-2677-9684	Dutch Lung foundation [3.2.11.021]	Dutch Lung foundation	Supported by a grant for the Dutch Lung foundation (grant no. 3.2.11.021).	Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; Brims FJH, 2009, THORAX, V64, P1037, DOI 10.1136/thx.2009.114439; Cho S, 2011, ANN ALLERG ASTHMA IM, V106, P371, DOI 10.1016/j.anai.2010.12.021; Cho SH, 2015, AM J RESP CELL MOL, V52, P88, DOI 10.1165/rcmb.2013-0399OC; Cho SH, 2014, J ALLERGY CLIN IMMUN, V133, P1465, DOI 10.1016/j.jaci.2013.11.009; Cho SH, 2000, J IMMUNOL, V165, P3154, DOI 10.4049/jimmunol.165.6.3154; Cho SH, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Chung WS, 2014, EUR J INTERN MED, V25, P941, DOI 10.1016/j.ejim.2014.10.023; Chung WS, 2014, EUR J CLIN INVEST, V44, P1025, DOI 10.1111/eci.12336; Chung WS, 2014, EUR RESPIR J, V43, P801, DOI 10.1183/09031936.00043313; Gabazza EC, 1999, LUNG, V177, P253, DOI 10.1007/PL00007645; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Goldhaber SZ, 2012, LANCET, V379, P1835, DOI 10.1016/S0140-6736(11)61904-1; Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636; Johannesdottir SA, 2013, JAMA INTERN MED, V173, P743, DOI 10.1001/jamainternmed.2013.122; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Majoor CJ, 2013, EUR RESPIR J, V42, P655, DOI 10.1183/09031936.00150312; Matta F, 2009, THROMB HAEMOSTASIS, V101, P134, DOI 10.1160/TH08-08-0551; Middeldorp S, 2000, THROMB HAEMOSTASIS, V84, P4; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moosbauer C, 2007, BLOOD, V109, P995, DOI 10.1182/blood-2006-02-004945; Murthy SK, 2011, AM J GASTROENTEROL, V106, P713, DOI 10.1038/ajg.2011.53; Park JA, 2012, J ALLERGY CLIN IMMUN, V130, P1375, DOI 10.1016/j.jaci.2012.05.031; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; Sabit R, 2010, CHEST, V138, P47, DOI 10.1378/chest.09-2764; Stuijver DJE, 2013, CHEST, V143, P1337, DOI 10.1378/chest.12-1446; Tutluoglu B, 2005, CLIN APPL THROMB-HEM, V11, P77, DOI 10.1177/107602960501100109; van Zaane B, 2010, J THROMB HAEMOST, V8, P2483, DOI 10.1111/j.1538-7836.2010.04034.x; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411	29	30	33	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1727	1732		10.1016/j.jaci.2015.10.038	http://dx.doi.org/10.1016/j.jaci.2015.10.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26714414	Bronze			2022-12-18	WOS:000377527200012
J	Kwon, HJ; Bang, DW; Kim, EN; Wi, CI; Yawn, BP; Wollan, PC; Lahr, BD; Ryu, E; Juhn, YJ				Kwon, Hyo Jin; Bang, Duk Won; Kim, Eun Na; Wi, Chung-Il; Yawn, Barbara P.; Wollan, Peter C.; Lahr, Brian D.; Ryu, Euijung; Juhn, Young J.			Asthma as a risk factor for zoster in adults: A population-based case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; herpes zoster; risk; adults; epidemiology	MEDICAL-RECORDS-LINKAGE; HERPES-ZOSTER; ATOPIC CONDITIONS; UNITED-STATES; EPIDEMIOLOGY; DISEASE; VACCINE; ASSOCIATION; CHILDREN; IMMUNITY	Background: We recently reported an increased risk of herpes zoster shingles or zoster) in children with asthma, but little is known about whether the same is true for adults with asthma. Objective: We determined whether asthma is associated with an increased risk of zoster in adults. Methods: This study was designed as a population-based case-control study. Zoster cases during the study period were identified among adults aged >= 50 years) who resided in Olmsted County, Minnesota. We compared the frequency of asthma between zoster cases and birthday-and sex-matched control subjects 1:2 matching) without a history of zoster. Asthma status was ascertained based on predetermined criteria. A conditional logistic regression model was used to assess the association of asthma with risk of zoster. Results: A total of 371 zoster cases and their 742 matched control subjects were enrolled. Of the 371 cases, 246 (66%) were female, 348 (94%) were white, and the mean +/- SD age was 66.8 +/- 10.7 years. Twenty-three percent n = 87) of zoster cases had a history of asthma compared with 15% n = 114) of control subjects. Controlling for pertinent covariates and confounders, there was a significant association between a history of asthma and risk of zoster adjusted odds ratio, 1.70; 95% CI, 1.20-2.42; P = .003). The population attributable risk percentage for asthma was about 10%. Conclusions: Asthma is an unrecognized risk factor for zoster in adults. Consideration should be given to immunizing adults with asthma aged more than 50 years as a target group.	[Kwon, Hyo Jin; Bang, Duk Won; Kim, Eun Na; Wi, Chung-Il; Juhn, Young J.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; [Lahr, Brian D.; Ryu, Euijung; Juhn, Young J.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; [Juhn, Young J.] Mayo Clin, Dept Internal Med, Rochester, MN 55905 USA; [Kwon, Hyo Jin] Catholic Univ Korea, Coll Med, Dept Pediat, Seoul, South Korea; [Bang, Duk Won; Kim, Eun Na] Soonchunhyang Univ Hosp, Dept Internal Med, Seoul, South Korea; [Yawn, Barbara P.; Wollan, Peter C.] Olmsted Med Ctr, Dept Res, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Catholic University of Korea; Soonchunhyang University; Soonchunhyang University Hospital; Olmsted Medical Center	Juhn, YJ (corresponding author), Mayo Clin, Div Community Pediat & Adolescent Med, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.; Juhn, YJ (corresponding author), Mayo Clin, Dept Internal Med, Div Allergy, 200 1st St SW, Rochester, MN 55905 USA.	juhn.young@mayo.edu		Wi, Chung-Il/0000-0001-8938-2997	National Institute of Allergy and Infectious Diseases [R21 AI101277]; Mayo Foundation; National Institute on Aging of the National Institutes of Health [R01AG034676]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI101277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034676] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Mayo Foundation; National Institute on Aging of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by the National Institute of Allergy and Infectious Diseases (R21 AI101277) and the Scholarly Clinician Award from the Mayo Foundation. Also, this study was made possible using the rgesources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health under award no. R01AG034676.	Arvin A, 2005, NEW ENGL J MED, V352, P2266, DOI 10.1056/NEJMp058091; Asquith KL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001339; BEARD CM, 1992, J CLIN EPIDEMIOL, V45, P1013; Bjur KA, 2012, ALLERGY ASTHMA PROC, V33, P289, DOI 10.2500/aap.2012.33.3529; Borkar DS, 2014, JAMA OPHTHALMOL, V132, P326, DOI 10.1001/jamaophthalmol.2013.6277; Capili CR, 2012, J ALLERGY CLIN IMMUN, V129, P957, DOI 10.1016/j.jaci.2011.11.020; Cohen J, 2013, SCIENCE, V342, P413, DOI 10.1126/science.342.6157.413; Combescure C, 2003, EUR RESPIR J, V22, P298, DOI 10.1183/09031936.03.00081102; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Ernst P, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-59; Esteban-Vasallo MD, 2014, HUM VACC IMMUNOTHER, V10, P1650, DOI 10.4161/hv.28620; Forbes HJ, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2911; Frey D, 2009, ALLERGY ASTHMA PROC, V30, P540, DOI 10.2500/aap.2009.30.3268; Gershon AA, 2010, J CLIN VIROL, V48, pS2, DOI 10.1016/S1386-6532(10)70002-0; Habibzay M, 2012, MUCOSAL IMMUNOL, V5, P524, DOI 10.1038/mi.2012.28; Hales BJ, 2012, THORAX, V67, P321, DOI 10.1136/thoraxjnl-2011-200650; Halford WP, 2011, VIRUSES AND INTERFERON: CURRENT RESEARCH, P85; Insinga RP, 2005, J GEN INTERN MED, V20, P748, DOI 10.1111/j.1525-1497.2005.0150.x; Juhn YJ, 2008, J ALLERGY CLIN IMMUN, V122, P719, DOI 10.1016/j.jaci.2008.07.029; Juhn YJ, 2014, J ALLERGY CLIN IMMUN, V134, P247, DOI 10.1016/j.jaci.2014.04.024; Jung JA, 2010, POSTGRAD MED, V122, P116, DOI 10.3810/pgm.2010.09.2208; Kilgore Paul E., 2003, Journal of Medical Virology, V70, pS111, DOI 10.1002/jmv.10364; Kim BS, 2013, J PEDIATR-US, V163, P816, DOI 10.1016/j.jpeds.2013.03.010; Kloepfer KM, 2012, AM J RESP CRIT CARE, V185, P1275, DOI 10.1164/rccm.201109-1635OC; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LETHBRIDGECEJKU M, 2005, VITAL HLTH STAT, V10, P1; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung J, 2011, CLIN INFECT DIS, V52, P332, DOI 10.1093/cid/ciq077; Levin MJ, 2003, J INFECT DIS, V188, P1336, DOI 10.1086/379048; Lynch BA, 2012, J ASTHMA, V49, P23, DOI 10.3109/02770903.2011.637596; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; Mullooly JP, 2005, EPIDEMIOL INFECT, V133, P245, DOI 10.1017/S095026880400281X; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Pesce G, 2014, EUR RESP J S58, V44; Platts-Mills TAE, 2015, ANN AM AC ALL ASTHM; RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reynolds MA, 2010, PUBLIC HEALTH REP, V125, P860, DOI 10.1177/003335491012500613; Rocca WA, 2012, MAYO CLIN PROC, V87, P1202, DOI 10.1016/j.mayocp.2012.08.012; Schmader KE, 2012, CLIN INFECT DIS, V54, P922, DOI 10.1093/cid/cir970; Siegle JS, 2011, CLIN EXP IMMUNOL, V165, P19, DOI 10.1111/j.1365-2249.2011.04392.x; Slifka MK, 2014, J ALLERGY CLIN IMMUN, V133, P439, DOI 10.1016/j.jaci.2013.10.037; St Sauver JL, 2012, INT J EPIDEMIOL, V41, P1614, DOI 10.1093/ije/dys195; St Sauver JL, 2013, MAYO CLIN PROC, V88, P56, DOI 10.1016/j.mayocp.2012.08.020; St Sauver JL, 2011, AM J EPIDEMIOL, V173, P1059, DOI 10.1093/aje/kwq482; Stanton MW., 2006, HIGH CONCENTRATION U; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Thomas SL, 2004, LANCET INFECT DIS, V4, P26, DOI 10.1016/S1473-3099(03)00857-0; Valet RS, 2011, ANN ALLERG ASTHMA IM, V106, P467, DOI 10.1016/j.anai.2011.02.013; Yawn BP, 2007, MAYO CLIN PROC, V82, P1341, DOI 10.4065/82.11.1341; Yawn BP, 2009, MAYO CLIN PROC, V84, P787, DOI [10.4065/84.9.787, 10.1016/S0025-6196(11)60488-6]; Yawn BP, 2002, J PEDIATR-US, V140, P576, DOI 10.1067/mpd.2002.123764; Yawn BP, 1998, J FAM PRACTICE, V47, P361; Yoo KH, 2014, PEDIATR INFECT DIS J, V33, P1016, DOI 10.1097/INF.0000000000000375; Yoo KH, 2010, ALLERGY ASTHMA PROC, V31, P499, DOI 10.2500/aap.2010.31.3399; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547	58	30	30	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1406	1412		10.1016/j.jaci.2015.10.032	http://dx.doi.org/10.1016/j.jaci.2015.10.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26739414	Green Accepted, Bronze			2022-12-18	WOS:000376180200015
J	Nakamura, Y; Nakano, N; Ishimaru, K; Ando, N; Katoh, R; Suzuki-Inoue, K; Koyanagki, S; Ogawa, H; Okumura, K; Shibata, S; Nakao, A				Nakamura, Yuki; Nakano, Nobuhiro; Ishimaru, Kayoko; Ando, Noriko; Katoh, Ryohei; Suzuki-Inoue, Katsue; Koyanagki, Satoru; Ogawa, Hideoki; Okumura, Ko; Shibata, Shigenobu; Nakao, Atsuhito			Inhibition of IgE-mediated allergic reactions by pharmacologically targeting the circadian clock	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Circadian clock; mast cells; basophils; IgE; allergy	EPSILON-RI EXPRESSION; MAST-CELLS; KINASE; PHOSPHORYLATION; ACTIVATION; COMPONENT; RECEPTOR; RELEASE; CK1	Background: The circadian clock temporally gates signaling through the high-affinity IgE receptor (Fc epsilon RI) in mast cells, thereby generating a marked day/night variation in allergic reactions. Thus manipulation of the molecular clock in mast cells might have therapeutic potential for IgE-mediated allergic reactions. Objective: We determined whether pharmacologically resetting the molecular clock in mast cells or basophils to times when FceRI signaling was reduced (ie, when core circadian protein period 2 [PER2] is upregulated) resulted in suppression of IgE-mediated allergic reactions. Methods: We examined the effects of PF670462, a selective inhibitor of the key clock component casein kinase 1 delta/epsilon, or glucocorticoid, both of which upregulated PER2 in mast cells, on IgE-mediated allergic reactions both in vitro and in vivo. Results: PF670462 or corticosterone (or dexamethasone) suppressed IgE-mediated allergic reactions in mouse bone marrow-derived mast cells or basophils and passive cutaneous anaphylactic reactions in mice in association with increased PER2 levels in mast cells or basophils. PF670462 or dexamethasone also ameliorated allergic symptoms in a mouse model of allergic rhinitis and downregulated allergen-specific basophil reactivity in patients with allergic rhinitis. Conclusion: Pharmacologically resetting the molecular clock in mast cells or basophils to times when Fc epsilon RI signaling is reduced can inhibit IgE-mediated allergic reactions. The results suggest a new strategy for controlling IgE-mediated allergic diseases. Additionally, this study suggests a novel mechanism underlying the antiallergic actions of glucocorticoids that relies on the circadian clock, which might provide a novel insight into the pharmacology of this drug in allergic patients.	[Nakamura, Yuki; Ishimaru, Kayoko; Nakao, Atsuhito] Univ Yamanashi, Fac Med, Dept Immunol, 1110 Shimokato, Yamanashi 4093898, Japan; [Ando, Noriko] Univ Yamanashi, Fac Med, Dept Dermatol, 1110 Shimokato, Yamanashi 4093898, Japan; [Katoh, Ryohei] Univ Yamanashi, Fac Med, Dept Pathol, 1110 Shimokato, Yamanashi 4093898, Japan; [Suzuki-Inoue, Katsue] Univ Yamanashi, Fac Med, Dept Clin & Lab Med, 1110 Shimokato, Yamanashi 4093898, Japan; [Nakano, Nobuhiro; Ogawa, Hideoki; Okumura, Ko; Nakao, Atsuhito] Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo 113, Japan; [Koyanagki, Satoru] Grad Sch Pharmaceut Sci, Dept Pharmaceut, Fukuoka, Japan; [Shibata, Shigenobu] Waseda Univ, Sch Adv Sci & Engn, Dept Physiol & Pharmacol, Tokyo, Japan	University of Yamanashi; University of Yamanashi; University of Yamanashi; University of Yamanashi; Juntendo University; Waseda University	Nakao, A (corresponding author), Univ Yamanashi, Fac Med, Dept Immunol, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	anakao@yamanashi.ac.jp		Nakano, Nobuhiro/0000-0002-5317-5950	JSPS from the Ministry of Education, Culture, Sports, Science, and Technology, Japan [90580465]; Grants-in-Aid for Scientific Research [15K09784] Funding Source: KAKEN	JSPS from the Ministry of Education, Culture, Sports, Science, and Technology, Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by JSPS KAKEN grant no. 90580465 from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.	Ando N, 2015, ALLERGY, V70, P319, DOI 10.1111/all.12552; Arjona A, 2012, TRENDS IMMUNOL, V33, P607, DOI 10.1016/j.it.2012.08.007; Bechtold DA, 2010, TRENDS PHARMACOL SCI, V31, P191, DOI 10.1016/j.tips.2010.01.002; BENHAMOU M, 1986, J IMMUNOL, V136, P1385; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Chen Z, 2013, CELL MOL LIFE SCI, V70, P2985, DOI 10.1007/s00018-012-1207-y; COSTA M, 1975, BIOCHEM BIOPH RES CO, V65, P75, DOI 10.1016/S0006-291X(75)80063-5; Curtis AM, 2014, IMMUNITY, V40, P178, DOI 10.1016/j.immuni.2014.02.002; Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821; Gibbs J, 2014, NAT MED, V20, P919, DOI 10.1038/nm.3599; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; Isojima Y, 2009, P NATL ACAD SCI USA, V106, P15744, DOI 10.1073/pnas.0908733106; Koyanagi S, 2011, J BIOL CHEM, V286, P32416, DOI 10.1074/jbc.M111.258970; Kraft S, 2004, INT ARCH ALLERGY IMM, V135, P62, DOI 10.1159/000080231; Lee H, 2009, P NATL ACAD SCI USA, V106, P21359, DOI 10.1073/pnas.0906651106; Meng QJ, 2010, P NATL ACAD SCI USA, V107, P15240, DOI 10.1073/pnas.1005101107; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Nakamura Y, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/474217; Nakamura Y, 2014, J ALLERGY CLIN IMMUN, V133, P568, DOI 10.1016/j.jaci.2013.07.040; Nakamura Y, 2011, J ALLERGY CLIN IMMUN, V127, P1038, DOI 10.1016/j.jaci.2011.02.006; Nakao A, 2015, ALLERGY, V70, P467, DOI 10.1111/all.12596; Pincus DJ, 1997, J ALLERGY CLIN IMMUN, V100, P771, DOI 10.1016/S0091-6749(97)70272-0; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Rivera J, 2008, ADV IMMUNOL, V98, P85, DOI 10.1016/S0065-2776(08)00403-3; ROBIN JL, 1985, J IMMUNOL, V135, P2719; Scheiermann C, 2013, NAT REV IMMUNOL, V13, P190, DOI 10.1038/nri3386; Schmutz I, 2010, GENE DEV, V24, P345, DOI 10.1101/gad.564110; Storz SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054189; Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Ukai H, 2010, ANNU REV PHYSIOL, V72, P579, DOI 10.1146/annurev-physiol-073109-130051; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Walton KM, 2009, J PHARMACOL EXP THER, V330, P430, DOI 10.1124/jpet.109.151415; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yamaguchi M, 2001, INT IMMUNOL, V13, P843, DOI 10.1093/intimm/13.7.843; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	37	30	32	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1226	1235		10.1016/j.jaci.2015.08.052	http://dx.doi.org/10.1016/j.jaci.2015.08.052			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26559325	Bronze			2022-12-18	WOS:000373351200030
J	Nagao, M; Fujisawa, T; Ihara, T; Kino, Y				Nagao, Mizuho; Fujisawa, Takao; Ihara, Toshiaki; Kino, Yoichiro			Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine-associated anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; influenza vaccine; hemagglutinin; IgE; basophil activation	LONG-TERM PERSISTENCE; VIRUS-ANTIBODIES; IMMUNIZATION; HYPERSENSITIVITY; ANTIINFLUENZA; GELATIN; ALLERGY; SERUM	Background: Influenza vaccines produced in embryonated eggs might pose a risk to patients with egg allergy. However, patients experiencing influenza vaccine-associated anaphylaxis (IVA) do not always have egg allergy. In the 2011-2012 season, an unusually high incidence of IVA was reported in Japan. Objective: We sought to identify the cause of the increase in anaphylactic events in 2011-2012 in Japan. Methods: We collected blood specimens from patients with IVA from all areas of Japan. We analyzed 19 patients with confirmed IVA and 25 age-matched control subjects, including 10 with egg allergy who had no adverse events after corresponding vaccination. ELISA was used to measure specific IgE levels to the trivalent vaccines of several manufacturers and hemagglutinin proteins derived from both egg and cell cultures. Antigen-induced basophil activation was evaluated by measuring CD203c expression by means of flow cytometry. Vaccine excipients were also examined for effects on CD203c expression. Results: None of the patients with IVA had severe egg allergy. Levels of specific IgE antibodies to influenza vaccine antigens, whole-vaccine products from different manufacturers, and hemagglutinin proteins (A H1, H3, and B) derived from both egg and cell cultures were significantly increased in patients with IVA compared with those in control subjects. Influenza vaccine-induced CD203c expression in basophils was also highly enhanced in patients with IVA but not in control subjects. Because IVA was most frequent in patients who received 2-phenoxyethanol (2-PE)-containing vaccine, the effect of this preservative on basophil activation was examined, and the activation was slightly enhanced by 2-PE but not thimerosal. Conclusions: The 2011-2012 IVA spike in Japan was caused by specific IgE antibodies to influenza vaccine components. Excipients could not be implicated, except for a modest effect of 2-PE.	[Nagao, Mizuho; Fujisawa, Takao] Mie Natl Hosp, Allergy Ctr, 357 Osato Kubota, Tsu, Mie 5140125, Japan; [Ihara, Toshiaki] Mie Natl Hosp, Ctr Infect Dis, Tsu, Mie 5140125, Japan; [Kino, Yoichiro] Chemoserotherapeut Res Inst Kaketsuken, Kumamoto, Japan		Fujisawa, T (corresponding author), Mie Natl Hosp, Allergy Ctr, 357 Osato Kubota, Tsu, Mie 5140125, Japan.; Fujisawa, T (corresponding author), Mie Natl Hosp, Dept Clin Res, 357 Osato Kubota, Tsu, Mie 5140125, Japan.	fujisawa@mie-m.hosp.go.jp	Fujisawa, Takao/ABB-2359-2021	Fujisawa, Takao/0000-0002-9196-9436	Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Kumamoto, Japan	Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Kumamoto, Japan	Supported by an unconditional grant from the Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Kumamoto, Japan.	Barbaud A, 2013, EUR J DERMATOL, V23, P135, DOI 10.1684/ejd.2012.1842; Birnie AJ, 2006, CONTACT DERMATITIS, V54, P349, DOI 10.1111/j.0105-1873.2006.0645g.x; Bohn S, 2001, ALLERGY, V56, P922, DOI 10.1034/j.1398-9995.2001.00218.x; Centers for Disease Control and Prevention, FREQ ASK QUEST THIM; Des Roches A, 2012, J ALLERGY CLIN IMMUN, V130, P1213, DOI 10.1016/j.jaci.2012.07.046; Erlewyn-Lajeunesse M, 2011, CLIN EXP ALLERGY, V41, P1367, DOI 10.1111/j.1365-2222.2011.03842.x; Forsdahl BA, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000186; Greenhawt MJ, 2012, ANN ALLERG ASTHMA IM, V109, P426, DOI 10.1016/j.anai.2012.09.011; Grohskopf LA, 2014, MMWR-MORBID MORTAL W, V63, P691; Grotto I, 1998, VACCINE, V16, P329, DOI 10.1016/S0264-410X(97)00214-4; Hernandez B, 2002, CONTACT DERMATITIS, V47, P54, DOI 10.1034/j.1600-0536.2002.470116.x; Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009; Nakayama T, 2000, J ALLERGY CLIN IMMUN, V106, P591, DOI 10.1067/mai.2000.108433; Orjales RN, 2010, J INVEST ALLERG CLIN, V20, P354; Parisi CAS, 2013, CLIN EXP ALLERGY, V43, P249, DOI 10.1111/cea.12059; Rouleau I, 2012, J ALLERGY CLIN IMMUN, V130, P1423, DOI 10.1016/j.jaci.2012.07.019; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Russell M, 2004, VACCINE, V23, P664, DOI 10.1016/j.vaccine.2004.06.042; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Smith-Norowitz TA, 2012, J INFLAMM RES, V5, P111, DOI 10.2147/JIR.S34152; Smith-Norowitz TA, 2011, INT J MED SCI, V8, P239, DOI 10.7150/ijms.8.239; Woo EJ, 2015, CLIN INFECT DIS, V60, P777, DOI 10.1093/cid/ciu948; World Health Organization (WHO), 2005, WHO TECHN REP SER, V927, P99	23	30	30	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					861	867		10.1016/j.jaci.2015.08.001	http://dx.doi.org/10.1016/j.jaci.2015.08.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26365388	hybrid			2022-12-18	WOS:000371897500030
J	Facciotti, F; Gagliani, N; Haringer, B; Alfen, JS; Penatti, A; Maglie, S; Paroni, M; Iseppon, A; Moro, M; Crosti, MC; Stolzel, K; Romagnani, C; Moroni, G; Ingegnoli, F; Torretta, S; Pignataro, L; Annoni, A; Russo, F; Pagani, M; Abrignani, S; Meroni, P; Flavell, R; Geginat, J				Facciotti, Federica; Gagliani, Nicola; Haeringer, Barbara; Alfen, Johanna Sophie; Penatti, Alessandra; Maglie, Stefano; Paroni, Moira; Iseppon, Andrea; Moro, Monica; Crosti, Maria Cristina; Stoelzel, Katharina; Romagnani, Chiara; Moroni, Gabriella; Ingegnoli, Francesca; Torretta, Sara; Pignataro, Lorenzo; Annoni, Andrea; Russo, Fabio; Pagani, Massimiliano; Abrignani, Sergio; Meroni, Pierluigi; Flavell, Richard; Geginat, Jens			IL-10-producing forkhead box protein 3-negative regulatory T cells inhibit B-cell responses and are involved in systemic lupus erythematosus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECEPTOR; CD40		[Facciotti, Federica; Alfen, Johanna Sophie; Maglie, Stefano; Paroni, Moira; Moro, Monica; Crosti, Maria Cristina; Pagani, Massimiliano; Abrignani, Sergio; Geginat, Jens] INGM Natl Inst Mol Genet Romeo & Enrica Invernizz, Milan, Italy; [Haeringer, Barbara; Romagnani, Chiara] DRFZ German Rheumatol Res Inst, Berlin, Germany; [Gagliani, Nicola; Iseppon, Andrea; Flavell, Richard] Yale Univ, Dept Immunobiol, New Haven, CT USA; [Flavell, Richard] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; [Haeringer, Barbara; Stoelzel, Katharina] Charite, Dept Med, Div Clin Immunol & Rheumatol, D-13353 Berlin, Germany; [Alfen, Johanna Sophie; Ingegnoli, Francesca] Univ Milan, Dipartimento Fisiopatol Med Chirurg & Trapianti, Milan, Italy; [Penatti, Alessandra; Abrignani, Sergio; Meroni, Pierluigi] Univ Milan, DISCCO Dept Clin Sci & Community Hlth, Milan, Italy; [Pagani, Massimiliano] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy; [Moroni, Gabriella] Fdn Ca Granda Osped Maggiore Policlin, Unita Operat Nefrol & Dialisi, Milan, Italy; [Torretta, Sara; Pignataro, Lorenzo] Fdn Ca Granda Osped Maggiore Policlin, Otorinolaringoiatria, Milan, Italy; [Annoni, Andrea; Russo, Fabio] IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy, Milan, Italy; [Annoni, Andrea; Russo, Fabio] IRCCS San Raffaele Sci Inst, Div Regenerat Med Stem Cells & Gene Therapy, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Yale University; Howard Hughes Medical Institute; Yale University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Milan; University of Milan; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Facciotti, F (corresponding author), INGM Natl Inst Mol Genet Romeo & Enrica Invernizz, Milan, Italy.	geginat@ingm.org	Penatti, Alessandra Emiliana/G-5750-2017; Penatti, Alessandra Emiliana/G-5597-2017; Moroni, Gabriella/J-8183-2015; Annoni, Andrea/AAN-3447-2020; Facciotti, Federica/AAA-3518-2019; meroni, pier luigi/K-8473-2016; Ingegnoli, Francesca/B-6226-2017; Torretta, Sara/J-6497-2017; Geginat, Jens/AAA-5818-2019; Romagnani, Chiara/E-4708-2016; Torretta, Sara/P-5156-2019; Paroni, Moira/K-6470-2016	Penatti, Alessandra Emiliana/0000-0003-2874-1436; Penatti, Alessandra Emiliana/0000-0003-2874-1436; Moroni, Gabriella/0000-0003-4955-6061; Annoni, Andrea/0000-0002-8541-2578; Facciotti, Federica/0000-0002-2541-9428; meroni, pier luigi/0000-0002-3394-1451; Ingegnoli, Francesca/0000-0002-6727-1273; Torretta, Sara/0000-0002-8461-6042; Geginat, Jens/0000-0003-4813-0384; Romagnani, Chiara/0000-0002-5167-7463; Torretta, Sara/0000-0002-8461-6042; Paroni, Moira/0000-0001-8199-3128; Pignataro, Lorenzo/0000-0003-1619-5124; Pagani, Massimiliano/0000-0002-7017-9304; Gagliani, Nicola/0000-0001-8514-1395; Abrignani, Sergio/0000-0002-0794-3285	NATIONAL CANCER INSTITUTE [P30CA016359] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Desreumaux P, 2012, GASTROENTEROLOGY, V143, P1207, DOI 10.1053/j.gastro.2012.07.116; Fuchs A, 2009, EUR J IMMUNOL, V39, P3097, DOI 10.1002/eji.200939392; Haringer B, 2009, J EXP MED, V206, P1009, DOI 10.1084/jem.20082238; Lim HW, 2007, J IMMUNOL, V179, P7448, DOI 10.4049/jimmunol.179.11.7448; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Lougaris V, 2005, IMMUNOL REV, V203, P48, DOI 10.1111/j.0105-2896.2005.00229.x; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; Rivino L, 2010, J EXP MED, V207, P565, DOI 10.1084/jem.20091021; Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002	11	30	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					318	321		10.1016/j.jaci.2015.06.044	http://dx.doi.org/10.1016/j.jaci.2015.06.044			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26318071	Bronze			2022-12-18	WOS:000367724300029
J	Barmettler, S; Price, C				Barmettler, Sara; Price, Christina			Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab-for how long?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHEUMATOID-ARTHRITIS; IMMUNOGLOBULIN; DEFICIENCY; MUTATIONS; DIAGNOSIS; DISEASE		[Barmettler, Sara] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Price, Christina] Yale Univ, Sch Med, Sect Allergy & Clin Immunol, New Haven, CT USA	Yale University; Yale University	Barmettler, S (corresponding author), Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.	christina.price@yale.edu						Belot A, 2013, ARTHRITIS RHEUM-US, V65, P2161, DOI 10.1002/art.38008; Buch MH, 2011, ANN RHEUM DIS, V70, P909, DOI 10.1136/ard.2010.144998; Cameron PU, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023164; Casulo C, 2013, CL LYMPH MYELOM LEUK, V13, P106, DOI 10.1016/j.clml.2012.11.011; Cunningham-Rundles C, 2008, J CLIN IMMUNOL, V28, pS42, DOI 10.1007/s10875-008-9182-7; Diwakar L, 2010, J CLIN PATHOL, V63, P275, DOI 10.1136/jcp.2009.068940; Drewniak A, 2010, BLOOD, V115, P4588, DOI 10.1182/blood-2009-11-253245; Herrero-Turrion MJ, 2008, J IMMUNOL, V181, P3793, DOI 10.4049/jimmunol.181.6.3793; Kimby E, 2005, CANCER TREAT REV, V31, P456, DOI 10.1016/j.ctrv.2005.05.007; Koker MY, 2009, EUR J CLIN INVEST, V39, P942, DOI 10.1111/j.1365-2362.2009.02195.x; Kuijpers TW, 2007, BLOOD, V109, P3529, DOI 10.1182/blood-2006-05-021402; Makatsori M, 2014, QJM-INT J MED, V107, P821, DOI 10.1093/qjmed/hcu094; Roberts DM, 2015, J AUTOIMMUN, V57, P24, DOI 10.1016/j.jaut.2014.11.004; Roll P, 2008, ARTHRITIS RHEUM-US, V58, P1566, DOI 10.1002/art.23473; Roos D, 2014, CLIN EXP IMMUNOL, V175, P139, DOI 10.1111/cei.12202; Salzer E, 2013, BLOOD, V121, P3112, DOI 10.1182/blood-2012-10-460741; van BR, 2010, J INNATE IMMUN, V2, P280; Zhao XW, 2013, BLOOD, V122, P109, DOI 10.1182/blood-2013-03-494039	18	30	31	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1407	1409		10.1016/j.jaci.2015.06.035	http://dx.doi.org/10.1016/j.jaci.2015.06.035			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26277594				2022-12-18	WOS:000364787200034
J	Kitzmuller, C; Zulehner, N; Roulias, A; Briza, P; Ferreira, F; Fae, I; Fischer, GF; Bohle, B				Kitzmueller, Claudia; Zulehner, Nora; Roulias, Anargyros; Briza, Peter; Ferreira, Fatima; Fae, Ingrid; Fischer, Gottfried F.; Bohle, Barbara			Correlation of sensitizing capacity and T-cell recognition within the Bet v 1 family	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic sensitization; Bet v 1; birch pollen-associated food allergy; immunodominant T-cell epitope; molecular allergology	BIRCH POLLEN ALLERGEN; LIPID TRANSFER PROTEIN; MAJOR PEACH ALLERGEN; PRU P 3; DENDRITIC CELLS; HIGH-RESOLUTION; HLA-DR; EPITOPES; RESPONSES; BINDING	Background: Bet v 1 is the main sensitizing allergen in birch pollen. Like many other major allergens, it contains an immunodominant T cell-activating region (Bet v 1(142-156)). Api g 1, the Bet v 1 homolog in celery, lacks the ability to sensitize and is devoid of major T-cell epitopes. Objective: We analyzed the T-cell epitopes of Mal d 1, the nonsensitizing Bet v 1 homolog in apple, and assessed possible differences in uptake and antigen processing of Bet v 1, Api g 1, and Mal d 1. Methods: For epitope mapping, Mal d 1-specific T-cell lines were stimulated with overlapping synthetic 12-mer peptides. The surface binding, internalization, and intracellular degradation of Bet v 1, Api g 1, and Mal d 1 by antigen-presenting cells were compared by using flow cytometry. All proteins were digested with endolysosomal extracts, and the resulting peptides were identified by means of mass spectrometry. The binding of Bet v 1(142-156) and the homologous region in Mal d 1 by HLA class II molecules was analyzed in silico. Results: Like Api g 1, Mal d 1 lacked dominant T-cell epitopes. The degree of surface binding and the kinetics of uptake and endolysosomal degradation of Bet v 1, Api g 1, and Mal d 1 were comparable. Endolysosomal degradation of Bet v 1 and Mal d 1 resulted in very similar fragments. The Bet v 1(142-156) and Mal d 1(141-155) regions showed no striking difference in their binding affinities to the most frequent HLA-DR alleles. Conclusion: The sensitizing activity of different Bet v 1 homologs correlates with the presence of immunodominant T-cell epitopes. However, the presence of Bet v 1(142-156) is not conferred by differential antigen processing.	[Kitzmueller, Claudia; Bohle, Barbara] Med Univ Vienna, Christian Doppler Lab Immunomodulat, A-1090 Vienna, Austria; [Kitzmueller, Claudia; Zulehner, Nora; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria; [Roulias, Anargyros; Briza, Peter; Ferreira, Fatima] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Ferreira, Fatima] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therap, A-5020 Salzburg, Austria; [Fae, Ingrid; Fischer, Gottfried F.] Med Univ Vienna, Dept Blood Grp Serol & Transfus Med, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Salzburg University; Salzburg University; Medical University of Vienna	Bohle, B (corresponding author), Med Univ Vienna, Div Expt Allergol, Dept Pathophysiol & Allergy Res, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at	Briza, Peter/D-7309-2012; Roulias, Anargyros/L-5576-2015; Ferreira, Fatima/AAB-4321-2019; Ferreira, Fatima/E-4889-2011	Briza, Peter/0000-0002-4941-6782; Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Kitzmuller, Claudia/0000-0002-3829-8020; Bohle, Barbara/0000-0002-5105-7985	Christian Doppler Research Association, Biomay AG, Austria; Austrian Science Fund [SFB F4610, W1212, W1213]	Christian Doppler Research Association, Biomay AG, Austria; Austrian Science Fund(Austrian Science Fund (FWF))	Supported by the Christian Doppler Research Association, Biomay AG, Austria, and the Austrian Science Fund, projects SFB F4610 and W1212 and W1213.	Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bohle B, 2005, CLIN EXP ALLERGY, V35, P367, DOI 10.1111/j.1365-2222.2005.02180.x; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; De Knop KJ, 2011, PEDIAT ALLERG IMM-UK, V22, pe139, DOI 10.1111/j.1399-3038.2011.01112.x; de Silva HD, 2004, CLIN EXP ALLERGY, V34, P611, DOI 10.1111/j.1365-2222.2004.1919.x; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Delamarre L, 2006, J EXP MED, V203, P2049, DOI 10.1084/jem.20052442; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; Egger M, 2010, PLOS ONE, V6; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P423, DOI 10.1016/j.jaci.2007.10.009; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Geroldinger-Simic M, 2013, J ALLERGY CLIN IMMUN, V131, P94, DOI 10.1016/j.jaci.2012.06.039; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Immonen A, 2007, CLIN EXP ALLERGY, V37, P939, DOI 10.1111/j.1365-2222.2007.02722.x; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; Jahn-Schmid B, 2010, J ALLERGY CLIN IMMUN, V126, P1068, DOI 10.1016/j.jaci.2010.05.038; Klitz W, 2003, TISSUE ANTIGENS, V62, P296, DOI 10.1034/j.1399-0039.2003.00103.x; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; Moneo I, 1999, ANN ALLERG ASTHMA IM, V83, P71, DOI 10.1016/S1081-1206(10)63516-8; Moreno-Ancillo A, 2005, Allergol Immunopathol (Madr), V33, P288, DOI 10.1157/13080934; Mutschlechner S, 2010, J ALLERGY CLIN IMMUN, V125, P711, DOI 10.1016/j.jaci.2009.10.052; Nagato T, 2007, J IMMUNOL, V178, P1189, DOI 10.4049/jimmunol.178.2.1189; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; Pastorello EA, 2010, INT ARCH ALLERGY IMM, V153, P1, DOI 10.1159/000301573; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Radauer C, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-286; Schulten V, 2011, ALLERGY, V66, P1005, DOI 10.1111/j.1398-9995.2011.02567.x; Schulten V, 2009, J ALLERGY CLIN IMMUN, V124, P100, DOI 10.1016/j.jaci.2009.02.010; Seutter von Loetzen C, 2014, BIOCHEM J, V457, P379, DOI 10.1042/BJ20130413; Sone T, 1998, J IMMUNOL, V161, P448; Tordesillas L, 2009, MOL IMMUNOL, V46, P722, DOI 10.1016/j.molimm.2008.10.018; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568; Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048; Williams F, 2004, HUM IMMUNOL, V65, P66, DOI 10.1016/j.humimm.2003.10.004; YSSEL H, 1992, J IMMUNOL, V148, P738; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	44	30	31	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					151	158		10.1016/j.jaci.2014.12.1928	http://dx.doi.org/10.1016/j.jaci.2014.12.1928			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25670010	Green Published, hybrid			2022-12-18	WOS:000357542200017
J	Sumpter, TL; Ho, CH; Pleet, AR; Tkacheva, OA; Shufesky, WJ; Rojas-Canales, DM; Morelli, AE; Larregina, AT				Sumpter, Tina L.; Ho, Chin H.; Pleet, Anna R.; Tkacheva, Olga A.; Shufesky, William J.; Rojas-Canales, Darling M.; Morelli, Adrian E.; Larregina, Adriana T.			Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hemokinin-1; substance P; neurokinin-1 receptor; mast cells; IgE; Fc epsilon RI; TNF; IL-6; passive anaphylaxis; airway inflammation	NF-KAPPA-B; SUBSTANCE-P; NEUROKININ-1 RECEPTOR; GRANULOCYTE INFILTRATION; CYTOKINE PRODUCTION; GENE-EXPRESSION; DENDRITIC CELLS; IN-VIVO; ACTIVATION; MICE	Background: Efficient development of atopic diseases requires interactions between allergen and adjuvant to initiate and amplify the underlying inflammatory responses. Substance P (SP) and hemokinin-1 (HK-1) are neuropeptides that signal through the neurokinin-1 receptor (NK1R) to promote inflammation. Mast cells initiate the symptoms and tissue effects of atopic disorders, secreting TNF and IL-6 after Fc epsilon RI cross-linking by antigen-IgE complexes (Fc epsilon RI-activated mast cells [Fc epsilon RI-MCs]). Additionally, MCs express the NK1R, suggesting an adjuvant role for NK1R agonists in Fc epsilon RI-MC-mediated pathologies; however, in-depth research addressing this relevant aspect of MC biology is lacking. Objective: We sought to investigate the effect of NK1R signaling and the individual roles of SP and HK-1 as potential adjuvants for Fc epsilon RI-MC-mediated allergic disorders. Methods: Bone marrow-derived mast cells (BMMCs) from C57BL/6 wild-type (WT) or NK1R(-/-) mice were used to investigate the effects of NK1R signaling on Fc epsilon RI-MCs. BMMCs generated from Tac1(-/-) mice or after culture with Tac4 small interfering RNA were used to address the adjuvancy of SP and HK-1. WT, NK1R(-/-), and c-Kit(W-sh/W-sh) mice reconstituted with WT or NK1R(-/-) BMMCs were used to evaluate NK1R signaling on Fc epsilon RI-MC-mediated passive local and systemic anaphylaxis and on airway inflammation. Results: Fc epsilon RI-activated MCs upregulated NK1R and HK-1 transcripts and protein synthesis, without modifying SP expression. In a positive signaling loop HK-1 promoted TNF and IL-6 secretion by MC degranulation and protein synthesis, the latter through the phosphoinositide 3-kinase/Akt/nuclear factor kappa B pathways. In vivo NK1R signaling was necessary for the development of passive local and systemic anaphylaxis and airway inflammation. Conclusions: Fc epsilon RI stimulation of MCs promotes autocrine secretion of HK-1, which signals through NK1R to provide adjuvancy for efficient development of Fc epsilon RI-MC-mediated disorders.	[Sumpter, Tina L.; Ho, Chin H.; Pleet, Anna R.; Tkacheva, Olga A.; Larregina, Adriana T.] Univ Pittsburgh, Sch Med, Dept Dermatol, Pittsburgh, PA 15261 USA; [Morelli, Adrian E.; Larregina, Adriana T.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [Shufesky, William J.; Rojas-Canales, Darling M.; Morelli, Adrian E.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; [Shufesky, William J.; Rojas-Canales, Darling M.; Morelli, Adrian E.] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA; [Larregina, Adriana T.] Univ Pittsburgh, Sch Med, McGowan Inst Regenerat Med, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Larregina, AT (corresponding author), Presbyterian Hosp, Dept Dermatol, Suite 3880,South Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	adrianal@pitt.edu	Ho, Chien/O-6112-2016	Ho, Chien/0000-0002-4094-9232	National Institutes of Health [AI077511]; T.E. Starzl Postdoctoral Fellowship in Transplantation Biology; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077511] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); T.E. Starzl Postdoctoral Fellowship in Transplantation Biology; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant AI077511 (to A.T.L.) and the T.E. Starzl Postdoctoral Fellowship in Transplantation Biology (to D.M.R.-C.).	ANSEL JC, 1993, J IMMUNOL, V150, P4478; Beinborn M, 2010, P NATL ACAD SCI USA, V107, P4293, DOI 10.1073/pnas.0905877107; Bohnacker T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000259; Chiu IM, 2012, NAT NEUROSCI, V15, P1063, DOI 10.1038/nn.3144; Cunin P, 2011, J IMMUNOL, V186, P4175, DOI 10.4049/jimmunol.1002535; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Douglas SD, 2011, ANN NY ACAD SCI, V1217, P83, DOI 10.1111/j.1749-6632.2010.05826.x; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Feistritzer C, 2003, REGUL PEPTIDES, V116, P119, DOI 10.1016/S0167-0115(03)00193-9; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gilfillan AM, 2011, CRIT REV IMMUNOL, V31, P475, DOI 10.1615/CritRevImmunol.v31.i6.30; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Green PG, 2005, ARTHRITIS RES THER, V7, P111, DOI 10.1186/ar1746; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Hohman R.J., 2001, CURR PROTOC IMMUNOL, V7, P26; Hsu CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011944; Janelsins BM, 2013, BLOOD, V121, P2923, DOI 10.1182/blood-2012-07-446054; Janelsins BM, 2009, BLOOD, V113, P3017, DOI 10.1182/blood-2008-06-163121; Jensen BM, 2006, CURR PROTOC IMMUNOL, P3; Kingeter LM, 2010, J IMMUNOL, V185, P4520, DOI 10.4049/jimmunol.1001051; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Koh YH, 2010, J PHARMACOL EXP THER, V332, P940, DOI 10.1124/jpet.109.160416; Kuehn HS, 2007, IMMUNOL LETT, V113, P59, DOI 10.1016/j.imlet.2007.08.007; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; MacGlashan DW, 2012, TRENDS PHARMACOL SCI, V33, P502, DOI 10.1016/j.tips.2012.06.002; Margolis KG, 2009, CURR OPIN GASTROEN, V25, P503, DOI 10.1097/MOG.0b013e328331b69e; Mathers AR, 2007, J IMMUNOL, V178, P7006, DOI 10.4049/jimmunol.178.11.7006; MATSUDA H, 1989, J IMMUNOL, V142, P927; MICAN JAM, 1992, J ALLERGY CLIN IMMUN, V90, P815, DOI 10.1016/0091-6749(92)90107-D; Monaco-Shawver L, 2011, J LEUKOCYTE BIOL, V89, P113, DOI 10.1189/jlb.0410200; Nakae S, 2007, J ALLERGY CLIN IMMUN, V120, P48, DOI 10.1016/j.jaci.2007.02.046; Nakae S, 2007, J ALLERGY CLIN IMMUN, V119, P680, DOI 10.1016/j.jaci.2006.11.701; Oskeritzian CA, 2010, J EXP MED, V207, P465, DOI 10.1084/jem.20091513; Palomaki VAB, 2006, BRIT J PHARMACOL, V147, P596, DOI 10.1038/sj.bjp.0706671; Ramalho R, 2013, ALLERGY, V68, P48, DOI 10.1111/all.12052; Sakai A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032268; Simeonidis S, 2003, P NATL ACAD SCI USA, V100, P2957, DOI 10.1073/pnas.0530112100; Tran AH, 2009, NEUROPEPTIDES, V43, P1, DOI 10.1016/j.npep.2008.10.002; van der Kleij HPM, 2003, J IMMUNOL, V171, P2074, DOI 10.4049/jimmunol.171.4.2074; Vibhuti A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019585; Wang W, 2010, J IMMUNOL, V184, P3590, DOI 10.4049/jimmunol.0901278; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; Williams MR, 2011, TRENDS IMMUNOL, V32, P461, DOI 10.1016/j.it.2011.06.009; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; Zhang Y, 2000, NAT IMMUNOL, V1, P392, DOI 10.1038/80826; Zhang Y, 2003, BLOOD, V102, P2165, DOI 10.1182/blood-2002-11-3572	46	30	31	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1019	+		10.1016/j.jaci.2014.07.036	http://dx.doi.org/10.1016/j.jaci.2014.07.036			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25201259	Green Accepted			2022-12-18	WOS:000352238600025
J	Brix, S; Eriksen, C; Larsen, JM; Bisgaard, H				Brix, Susanne; Eriksen, Carsten; Larsen, Jeppe Madura; Bisgaard, Hans			Metagenomic heterogeneity explains dual immune effects of endotoxins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDHOOD ASTHMA; EXPOSURE		[Brix, Susanne; Eriksen, Carsten; Larsen, Jeppe Madura] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, DK-2800 Lyngby, Denmark; [Bisgaard, Hans] Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood COP, Gentofte, Denmark; [Bisgaard, Hans] Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Gentofte, Denmark	Technical University of Denmark; University of Copenhagen; University of Copenhagen	Brix, S (corresponding author), Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, DK-2800 Lyngby, Denmark.	sbp@bio.dtu.dk	Bisgaard, Hans/N-4761-2016; Larsen, Jeppe Madura/K-6518-2019; Pedersen, Susanne Brix/B-3484-2009	Bisgaard, Hans/0000-0003-4131-7592; Larsen, Jeppe Madura/0000-0003-1492-0708; Pedersen, Susanne Brix/0000-0001-8951-6705; Eriksen, Carsten/0000-0003-4400-3855	Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Lambrecht BN, 2013, NEW ENGL J MED, V369, P1964, DOI 10.1056/NEJMcibr1311045; Larsen JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031976; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830	9	30	30	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					277	+		10.1016/j.jaci.2014.09.036	http://dx.doi.org/10.1016/j.jaci.2014.09.036			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25445821				2022-12-18	WOS:000347298200039
J	Campillo-Gimenez, L; Casulli, S; Dudoit, Y; Seang, S; Carcelain, G; Lambert-Niclot, S; Appay, V; Autran, B; Tubiana, R; Elbim, C				Campillo-Gimenez, Laure; Casulli, Sarah; Dudoit, Yasmine; Seang, Sophie; Carcelain, Guislaine; Lambert-Niclot, Sidonie; Appay, Victor; Autran, Brigitte; Tubiana, Roland; Elbim, Carole			Neutrophils in antiretroviral therapy-controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Neutrophils; HIV; inflammation; IL-18; IL-17; IL-22	IMMUNODEFICIENCY-VIRUS-INFECTION; T-CELL-ACTIVATION; DENDRITIC CELLS; OXIDATIVE BURST; MOUSE MODEL; TNF-ALPHA; INFLAMMATION; INTERLEUKIN-18; INDIVIDUALS; IL-22	Background: Despite control of HIV infection under antiretroviral therapy (ART), immune T-cell activation persists in patients with controlled HIV infection, who are at higher risk of inflammatory diseases than the general population. PMNs play a key role in host defenses against invading microorganisms but also potentiate inflammatory reactions in cases of excessive or misdirected responses. Objective: The aim of our study was to analyze PMN functions in 60 ART-treated and controlled HIV-infected patients (viral load, <20 RNA copies/mL; CD4 count, >= 350 cells/mm(3)) with (HIV[I] group) and without (HIV[NI] group) diseases related to an inflammatory process and to compare them with 22 healthy control subjects. Methods: Flow cytometry was used to evaluate PMN functions in whole-blood conditions. We studied in parallel the activation markers of T lymphocytes and monocytes and the proinflammatory cytokine environment. Results: Blood samples from HIV-infected patients revealed basal PMN hyperactivation associated with deregulation of the apoptosis/necrosis equilibrium. Interestingly, this hyperactivation was greater in HIV(I) than HIV(NI) patients and contrasted with a lack of monocyte activation in both groups. The percentage of circulating cells producing IL-17 was also significantly higher in HIV-infected patients than in control subjects and was positively correlated with markers of basal PMN activation. In addition, the detection of IL-22 overproduction in HIV(NI) patients suggests that it might contribute to counteracting chronic inflammatory processes during HIV infection. Conclusions: This study thus demonstrates the presence of highly activated PMNs in HIV-infected patients receiving effective ART and the association of these cells with a specific IL-17/IL-22 environment.	[Campillo-Gimenez, Laure; Casulli, Sarah; Elbim, Carole] UPMC Univ Paris 06, Sorbonne Univ, Paris, France; [Campillo-Gimenez, Laure; Casulli, Sarah; Carcelain, Guislaine; Appay, Victor; Autran, Brigitte; Elbim, Carole] INSERM, Ctr Immunol & Malad Infect, UMR S CR7, U1135, F-75013 Paris, France; [Dudoit, Yasmine; Seang, Sophie; Tubiana, Roland] Hop La Pitie Salpetriere, AP HP, Serv Malad Infect & Trop, Paris, France; [Dudoit, Yasmine; Seang, Sophie; Lambert-Niclot, Sidonie; Tubiana, Roland] UPMC Univ Paris 06, Sorbonne Univ, Pierre Louis Inst Epidemiol & Publ Hlth, UMR S 1136, Paris, France; [Carcelain, Guislaine; Autran, Brigitte] Hop La Pitie Salpetriere, AP HP, Lab Immunol Cellulaire & Tissulaire, Paris, France; [Lambert-Niclot, Sidonie] Hop La Pitie Salpetriere, AP HP, Lab Virol, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Elbim, C (corresponding author), INSERM, Ctr Immunol & Malad Infect, UMR S CR7, U1135, F-75013 Paris, France.	carole.elbim@upmc.fr	Appay, Victor/AAM-7701-2021; Appay, Victor/M-4830-2017	Campillo-Gimenez, Laure/0000-0002-8869-4224; Appay, Victor/0000-0001-5434-3963	Agence Nationale de la Recherche sur le SIDA (ANRS)	Agence Nationale de la Recherche sur le SIDA (ANRS)(ANRSFrench National Research Agency (ANR))	Supported by Agence Nationale de la Recherche sur le SIDA (ANRS).	Almeida M, 2007, CYTOM PART B-CLIN CY, V72B, P22, DOI 10.1002/cyto.b.20144; Baker JV, 2011, JAIDS-J ACQ IMM DEF, V56, P36, DOI 10.1097/QAI.0b013e3181f7f61a; BOROS P, 1990, CLIN IMMUNOL IMMUNOP, V54, P281, DOI 10.1016/0090-1229(90)90089-9; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; Burdo TH, 2011, J INFECT DIS, V204, P154, DOI 10.1093/infdis/jir214; Calmy A, 2009, AIDS, V23, P929, DOI 10.1097/QAD.0b013e32832995fa; Campillo-Gimenez L, 2010, J IMMUNOL, V184, P984, DOI 10.4049/jimmunol.0902316; Cave AC, 2006, ANTIOXID REDOX SIGN, V8, P691, DOI 10.1089/ars.2006.8.691; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cossarizza A, 2011, MITOCHONDRION, V11, P750, DOI 10.1016/j.mito.2011.06.005; Cozzi-Lepri A, 2011, AIDS, V25, P1207, DOI 10.1097/QAD.0b013e3283471f10; d'Ettorre G, 2011, AIDS RES HUM RETROV, V27, P355, DOI 10.1089/aid.2010.0342; de Baey A, 2003, J IMMUNOL, V170, P5089, DOI 10.4049/jimmunol.170.10.5089; Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172; Dutertre CA, 2012, BLOOD, V120, P2259, DOI 10.1182/blood-2012-03-418681; El-Benna J, 2008, SEMIN IMMUNOPATHOL, V30, P279, DOI 10.1007/s00281-008-0118-3; Elbim C, 2005, CLIN DIAGN LAB IMMUN, V12, P436, DOI 10.1128/CDLI.12.3.436-446.2005; ELBIM C, 1994, BLOOD, V84, P2759, DOI 10.1182/blood.V84.8.2759.bloodjournal8482759; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Fernandez S, 2011, DIS MARKERS, V31, P337, DOI [10.1155/2011/217860, 10.3233/DMA-2011-0847]; Fontao L, 2012, BRIT J DERMATOL, V166, P687, DOI 10.1111/j.1365-2133.2011.10647.x; Fortin CF, 2009, FASEB J, V23, P194, DOI 10.1096/fj.08-110213; Francois S, 2005, J IMMUNOL, V174, P3633, DOI 10.4049/jimmunol.174.6.3633; Funderburg NT, 2012, BLOOD, V120, P4599, DOI 10.1182/blood-2012-05-433946; Garg Himanshu, 2013, Cardiovascular & Hematological Agents in Medicinal Chemistry, V11, P58; Garlichs CD, 2004, J LEUKOCYTE BIOL, V75, P828, DOI 10.1189/jlb.0703358; Gelderblom M, 2012, BLOOD, V120, P3793, DOI 10.1182/blood-2012-02-412726; He Y, 2012, AIDS RES HUM RETROV, V28, P339, DOI [10.1089/aid.2011.0140, 10.1089/AID.2011.0140]; Heit B, 2006, J IMMUNOL, V177, P6405, DOI 10.4049/jimmunol.177.9.6405; Iannello A, 2010, J INFECT DIS, V201, P608, DOI 10.1086/650314; Kim CJ, 2012, MUCOSAL IMMUNOL, V5, P670, DOI 10.1038/mi.2012.72; Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853; Gabelloni ML, 2013, SEMIN IMMUNOPATHOL, V35, P423, DOI 10.1007/s00281-013-0364-x; Levine AM, 2006, ARCH INTERN MED, V166, P405, DOI 10.1001/.405; Longenecker CT, 2013, HIV MED, V14, P385, DOI 10.1111/hiv.12013; Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263; Michailidis C, 2012, CLIN EXP IMMUNOL, V167, P499, DOI 10.1111/j.1365-2249.2011.04526.x; Mirshafiey A, 2008, IRAN J ALLERGY ASTHM, V7, P195, DOI 07.04/ijaai.195202; Moldovan I, 1999, IMMUNOL LETT, V68, P125, DOI 10.1016/S0165-2478(99)00041-3; Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020; Payne BAI, 2011, NAT GENET, V43, P806, DOI 10.1038/ng.863; Pontillo A, 2012, AIDS, V26, P11, DOI 10.1097/QAD.0b013e32834d697f; Regidor DL, 2011, AIDS, V25, P303, DOI 10.1097/QAD.0b013e32834273ad; Ricevuti G, 1997, ANN NY ACAD SCI, V832, P426, DOI 10.1111/j.1749-6632.1997.tb46269.x; Sadik CD, 2011, TRENDS IMMUNOL, V32, P452, DOI 10.1016/j.it.2011.06.008; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Sugimoto K, 2008, J CLIN INVEST, V118, P534, DOI [10.1172/JC133194, 10.1172/JCI33194]; Torre D, 2002, CLIN DIAGN LAB IMMUN, V9, P983, DOI 10.1128/CDLI.9.5.983-986.2002; van de Veerdonk Frank L, 2011, Trends Immunol, V32, P110, DOI 10.1016/j.it.2011.01.003; Venturi GM, 2003, IMMUNITY, V19, P713, DOI 10.1016/S1074-7613(03)00295-4; Vinikoor MJ, 2013, JAIDS-J ACQ IMM DEF, V62, P505, DOI 10.1097/QAI.0b013e318285cd33; Wang ZK, 2011, SCAND CARDIOVASC J, V45, P54, DOI 10.3109/14017431.2010.491123; Wyman TH, 2002, J LEUKOCYTE BIOL, V72, P401; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	56	30	30	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1142	+	1152.e1	10.1016/j.jaci.2014.05.040	http://dx.doi.org/10.1016/j.jaci.2014.05.040			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25042982				2022-12-18	WOS:000344938900020
J	Muraro, A; Polloni, L; Lazzarotto, F; Toniolo, A; Baldi, I; Bonaguro, R; Gini, G; Masiello, M				Muraro, Antonella; Polloni, Laura; Lazzarotto, Francesca; Toniolo, Alice; Baldi, Ileana; Bonaguro, Roberta; Gini, Gianluca; Masiello, Matthew			Comparison of bullying of food-allergic versus healthy schoolchildren in Italy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PEANUT ALLERGY; CHILDREN		[Muraro, Antonella; Polloni, Laura; Lazzarotto, Francesca; Toniolo, Alice; Bonaguro, Roberta] Padua Univ Hosp, Referral Ctr Food Allergy Diag & Treatment Veneto, Dept Women & Child Hlth, Padua, Italy; [Baldi, Ileana] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Unit Biostat Epidemiol & Publ Hlth, Padua, Italy; [Gini, Gianluca] Univ Padua, Dept Dev & Social Psychol, Padua, Italy; [Masiello, Matthew] Windber Res Inst, Ctr Hlth Promot & Dis Prevent, Windber, PA USA	University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; University of Padua; Windber Research Institute	Muraro, A (corresponding author), Padua Univ Hosp, Referral Ctr Food Allergy Diag & Treatment Veneto, Dept Women & Child Hlth, Padua, Italy.	muraro@centroallergiealimentari.eu	Baldi, Ileana/J-2788-2019	Baldi, Ileana/0000-0002-8578-9164; Gini, Gianluca/0000-0002-8251-7550; Polloni, Laura/0000-0002-0158-359X				Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Genta ML, 1996, EUR J PSYCHOL EDUC, V11, P97, DOI 10.1007/BF03172938; Gini G, 2013, PEDIATRICS, V132, P720, DOI 10.1542/peds.2013-0614; Lieberman JA, 2010, ANN ALLERG ASTHMA IM, V105, P282, DOI 10.1016/j.anai.2010.07.011; Mirandola M, 2011, YOUTH VENETO ANAL RE; Oppenheimer J, 2010, ANN ALLERG ASTHMA IM, V105, P410, DOI 10.1016/j.anai.2010.10.003; Reijntjes A, 2010, CHILD ABUSE NEGLECT, V34, P244, DOI 10.1016/j.chiabu.2009.07.009; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; Shemesh E, 2013, PEDIATRICS, V131, pE10, DOI 10.1542/peds.2012-1180; Ttofi MM, 2011, J AGGRESS CONFL PEAC, V3, P63, DOI 10.1108/17596591111132873	10	30	31	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					749	751		10.1016/j.jaci.2014.05.043	http://dx.doi.org/10.1016/j.jaci.2014.05.043			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25042742				2022-12-18	WOS:000341372400037
J	van der Valk, RJP; Duijts, L; Timpson, NJ; Salam, MT; Standl, M; Curtin, JA; Genuneit, J; Kerhof, M; Kreiner-Moller, E; Caceres, A; Gref, A; Liang, LML; Taal, HR; Bouzigon, E; Demenais, F; Nadif, R; Ober, C; Thompson, EE; Estrada, K; Hofman, A; Uitterlinden, AG; van Duijn, C; Rivadeneira, F; Li, X; Eckel, SP; Berhane, K; Gauderman, WJ; Granell, R; Evans, DM; St Pourcain, B; McArdle, W; Kemp, JP; Smith, GD; Tiesler, CMT; Flexeder, C; Simpson, A; Murray, CS; Fuchs, O; Postma, DS; Bonnelykke, K; Torrent, M; Andersson, M; Sleiman, P; Hakonarson, H; Cookson, WO; Moffatt, MF; Paternoster, L; Melen, E; Sunyer, J; Bisgaard, H; Koppelman, GH; Ege, M; Custovic, A; Heinrich, J; Gilliland, FD; Henderson, AJ; Jaddoe, VWV; de Jongste, JC				van der Valk, Ralf J. P.; Duijts, Liesbeth; Timpson, Nicolas J.; Salam, Muhammad T.; Standl, Marie; Curtin, John A.; Genuneit, Jon; Kerhof, Marjan; Kreiner-Moller, Eskil; Caceres, Alejandro; Gref, Anna; Liang, Liming L.; Taal, H. Rob; Bouzigon, Emmanuelle; Demenais, Florence; Nadif, Rachel; Ober, Carole; Thompson, Emma E.; Estrada, Karol; Hofman, Albert; Uitterlinden, Andre G.; van Duijn, Cornelia; Rivadeneira, Fernando; Li, Xia; Eckel, Sandrah P.; Berhane, Kiros; Gauderman, W. James; Granell, Raquel; Evans, David M.; St Pourcain, Beate; McArdle, Wendy; Kemp, John P.; Smith, George Davey; Tiesler, Carla M. T.; Flexeder, Claudia; Simpson, Angela; Murray, Clare S.; Fuchs, Oliver; Postma, Dirkje S.; Bonnelykke, Klaus; Torrent, Maties; Andersson, Martin; Sleiman, Patrick; Hakonarson, Hakon; Cookson, William O.; Moffatt, Miriam F.; Paternoster, Lavinia; Melen, Erik; Sunyer, Jordi; Bisgaard, Hans; Koppelman, Gerard H.; Ege, Markus; Custovic, Adnan; Heinrich, Joachim; Gilliland, Frank D.; Henderson, Alexander J.; Jaddoe, Vincent W. V.; de Jongste, Johan C.		EAGLE Consortium	Fraction of exhaled nitric oxide values in childhood are associated with 17q11.2-q12 and 17q12-q21 variants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway inflammation; asthma phenotypes; biomarker; genetics; genome-wide association study	GENOME-WIDE ASSOCIATION; ASTHMA; COMPLEX; GALECTIN-9; GENES; EPITHELIUM; SEVERITY; CHILDREN; SYNTHASE; 17Q21	Background: The fraction of exhaled nitric oxide (FENO) value is a biomarker of eosinophilic airway inflammation and is associated with childhood asthma. Identification of common genetic variants associated with childhood FENO values might help to define biological mechanisms related to specific asthma phenotypes. Objective: We sought to identify the genetic variants associated with childhood FENO values and their relation with asthma. Methods: FENO values were measured in children age 5 to 15 years. In 14 genome-wide association studies (N = 8,858), we examined the associations of approximately 2.5 million single nucleotide polymorphisms (SNPs) with FENO values. Subsequently, we assessed whether significant SNPs were expression quantitative trait loci in genome-wide expression data sets of lymphoblastoid cell lines (n = 1,830) and were related to asthma in a previously published genome-wide association data set (cases, n = 10,365; control subjects: n = 16,110). Results: We identified 3 SNPs associated with FENO values: rs3751972 in LYR motif containing 9 (LYRM9; P = 1.97 x 10(-10)) and rs944722 in inducible nitric oxide synthase 2 (NOS2; P = 1.28 x 10(-9)), both of which are located at 17q11.2-q12, and rs8069176 near gasdermin B (GSDMB; P = 1.88 x 10(-8)) at 17q12-q21. We found a cis expression quantitative trait locus for the transcript soluble galactoside-binding lectin 9 (LGALS9) that is in linkage disequilibrium with rs944722. rs8069176 was associated with GSDMB and ORM1-like 3 (ORMDL3) expression. rs8069176 at 17q12-q21, but not rs3751972 and rs944722 at 17q11.2-q12, were associated with physician-diagnosed asthma. Conclusion: This study identified 3 variants associated with FENO values, explaining 0.95% of the variance. Identification of functional SNPs and haplotypes in these regions might provide novel insight into the regulation of FENO values. This study highlights that both shared and distinct genetic factors affect FENO values and childhood asthma.	[van der Valk, Ralf J. P.; Taal, H. Rob; Uitterlinden, Andre G.; Jaddoe, Vincent W. V.] Erasmus MC, Generat Study Grp R, Rotterdam, Netherlands; [van der Valk, Ralf J. P.; Duijts, Liesbeth; Taal, H. Rob; de Jongste, Johan C.] Erasmus MC, Dept Pediat, Rotterdam, Netherlands; [van der Valk, Ralf J. P.; Duijts, Liesbeth; Taal, H. Rob; Estrada, Karol; Hofman, Albert; Uitterlinden, Andre G.; van Duijn, Cornelia; Rivadeneira, Fernando] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Duijts, Liesbeth; Timpson, Nicolas J.; Granell, Raquel; Evans, David M.; St Pourcain, Beate; McArdle, Wendy; Kemp, John P.; Smith, George Davey; Paternoster, Lavinia; Henderson, Alexander J.] Univ Bristol IEU, Sch Social & Community Med, Bristol, Avon, England; [Timpson, Nicolas J.; Evans, David M.; Kemp, John P.; Smith, George Davey; Paternoster, Lavinia] Univ Bristol IEU, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Salam, Muhammad T.; Li, Xia; Eckel, Sandrah P.; Berhane, Kiros; Gauderman, W. James; Gilliland, Frank D.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Standl, Marie; Tiesler, Carla M. T.; Flexeder, Claudia; Heinrich, Joachim] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany; [Curtin, John A.; Simpson, Angela; Murray, Clare S.; Custovic, Adnan] Univ Manchester, Manchester Acad Hlth Sci Ctr, Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Kerhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp, Groningen, Netherlands; [Kreiner-Moller, Eskil; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Fac Hlth Sci, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark; [Kreiner-Moller, Eskil; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen Hosp, Danish Pediat Asthma Ctr, DK-2100 Copenhagen, Denmark; [Caceres, Alejandro; Sunyer, Jordi] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Caceres, Alejandro; Sunyer, Jordi] Inst Hosp Mar Invest Med IMIM, Barcelona, Spain; [Caceres, Alejandro; Torrent, Maties; Sunyer, Jordi] Spanish Consortium Res Epidemiol & Publ Hlth CIBE, Barcelona, Spain; [Gref, Anna; Melen, Erik] Karolinska Inst, Inst Environm Med & Ctr Allergy Res, Stockholm, Sweden; [Liang, Liming L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Liang, Liming L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Bouzigon, Emmanuelle; Demenais, Florence] INSERM, UMR 946, Genet Variat & Human Dis Unit, Paris, France; [Bouzigon, Emmanuelle; Demenais, Florence] Univ Paris Diderot, Sorbonne Paris Cite, Inst Univ Hematol, F-75007 Paris, France; [Nadif, Rachel] INSERM, Ctr Res Epidemiol & Populat Hlth CEPH, U1018, Resp & Environm Epidemiol Team, F-94807 Villejuif, France; [Nadif, Rachel] Univ Paris 11, UMRS 1018, F-94807 Villejuif, France; [Ober, Carole; Thompson, Emma E.] Univ Chicago, Dept Human Genet, Chicago, IL USA; [Estrada, Karol; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands; [Fuchs, Oliver] Univ Spital Bern, Inselspital, Univ Klin Kinderheilkunde, Bern, Switzerland; [Fuchs, Oliver; Ege, Markus] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; [Postma, Dirkje S.; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 AB Groningen, Netherlands; [Postma, Dirkje S.; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, GRIAC, NL-9700 AB Groningen, Netherlands; [Andersson, Martin] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Andersson, Martin] South Cent Hosp, Dept Physiol, Stockholm, Sweden; [Sleiman, Patrick; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA; [Sleiman, Patrick; Hakonarson, Hakon] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Cookson, William O.; Moffatt, Miriam F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Melen, Erik] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; [Sunyer, Jordi] UPF, Barcelona, Spain	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Bristol; University of Southern California; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Ulm University; University of Groningen; University of Copenhagen; University of Copenhagen; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Karolinska Institutet; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; University of Chicago; Erasmus University Rotterdam; Erasmus MC; University of Bern; University Hospital of Bern; University of Munich; University of Groningen; University of Groningen; Karolinska Institutet; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Imperial College London; Karolinska Institutet; Pompeu Fabra University	de Jongste, JC (corresponding author), Erasmus Univ, Med Ctr, Sophias Childrens Hosp, Dept Pediat, Rotterdam, Netherlands.	j.c.dejongste@erasmusmc.nl	Caceres, Alejandro/ABF-4180-2021; Demenais, Florence/G-3298-2013; Fox, Laura J/C-6249-2016; Bouzigon, Emmanuelle/L-2766-2017; Granell, Raquel/AAB-5256-2022; Davey Smith, George/A-7407-2013; Cookson, William/HHC-1790-2022; Ege, Markus/C-1962-2012; Sunyer, Jordi/G-6909-2014; Genuneit, Jon/I-9323-2012; Attrill, Lauren/V-1688-2018; Rivadeneira, Fernando/O-5385-2015; Heinrich, Joachim/N-1720-2013; Evans, David M/H-6325-2013; Nadif, Rachel/R-2876-2016; Taal, Hendrik R/B-4847-2018; St Pourcain, Beate/K-8004-2017; Timpson, Nicholas John/O-7548-2015; Koppelman, Gerard/AAG-9187-2020; Granell, Raquel/AAY-4846-2020; Kemp, John P./R-3091-2018; Bisgaard, Hans/N-4761-2016; Custovic, Adnan/A-2435-2012; Paternoster, Lavinia/C-1292-2015	Demenais, Florence/0000-0001-8361-0936; Bouzigon, Emmanuelle/0000-0001-5756-4286; Granell, Raquel/0000-0002-4890-4012; Davey Smith, George/0000-0002-1407-8314; Ege, Markus/0000-0001-6643-3923; Sunyer, Jordi/0000-0002-2602-4110; Genuneit, Jon/0000-0001-5764-1528; Rivadeneira, Fernando/0000-0001-9435-9441; Heinrich, Joachim/0000-0002-9620-1629; Evans, David M/0000-0003-0663-4621; Nadif, Rachel/0000-0003-4938-9339; St Pourcain, Beate/0000-0002-4680-3517; Timpson, Nicholas John/0000-0002-7141-9189; Kemp, John P./0000-0002-9105-2249; Bisgaard, Hans/0000-0003-4131-7592; Custovic, Adnan/0000-0001-5218-7071; Murray, Clare/0000-0002-8961-8055; Ober, Carole/0000-0003-4626-9809; Van Duijn, Cornelia/0000-0002-2374-9204; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Curtin, John/0000-0001-6299-9110; Simpson, Angela/0000-0003-2733-6666; Kreiner, Eskil/0000-0003-1204-2438; Koppelman, Gerard/0000-0001-8567-3252; Paternoster, Lavinia/0000-0003-2514-0889; Standl, Marie/0000-0002-5345-2049; s, hema/0000-0002-3440-9475; Bonnelykke, Klaus/0000-0003-2003-1018; Caceres, Alejandro/0000-0001-8551-6695	NIH [R01 HL085197]; UK Medical Research Council Centre [G0600705]; Wellcome Trust [WT083431MA]; European Respiratory Society; European Community [PCOFUND-GA-2008-229571, MC 1226-2009]; GlaxoSmithKline; Netherlands Organization for Health Research and Development [ZonMw 90700303, 916.10159]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085197, R01HL076647, R01HL061768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES023262, R01ES021801, P01ES009581, P30ES007048, P01ES011627, K22ES022987] Funding Source: NIH RePORTER; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish; Medical Research Council [G1000758, G9815508, MC_PC_15018, MR/K002449/1, MC_UU_12013/1, MC_UU_12013/4, MC_UU_12013/3, MR/J012165/1, G0601361, G0600705] Funding Source: researchfish; Wellcome Trust [096964/Z/11/Z] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre] Funding Source: researchfish; MRC [G0600705, MC_UU_12013/1, MC_UU_12013/4, MC_UU_12013/3, MR/J012165/1, G0601361, MR/K002449/1] Funding Source: UKRI	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UK Medical Research Council Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); European Respiratory Society; European Community(European Commission); GlaxoSmithKline(GlaxoSmithKline); Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Lundbeck Foundation(Lundbeckfonden); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	C.O. is supported by a NIH grant that supported the Hutterite studies (R01 HL085197). D. E. is supported by UK Medical Research Council Centre (G0600705). G. S. is supported by UK Medical Research Council Centre (G0600705). J.K. is funded by a Wellcome Trust 4-year PhD studentship in molecular, genetic, and life course epidemiology (WT083431MA). L. D. is supported by a European Respiratory Society/Marie Curie Joint Research Fellowship of the European Respiratory Society and the European Community's Seventh Framework Programme FP7/2007 2013 Marie Curie Actions under grant agreement RESPIRE, PCOFUND-GA-2008-229571 (no. MC 1226-2009). N.T. is supported by UK Medical Research Council Centre (G0600705). R. V. was partly supported by an unrestricted personal grant from GlaxoSmithKline, NL. V.J. is supported by the Netherlands Organization for Health Research and Development (ZonMw 90700303, 916.10159).	Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; [Anonymous], 2006, LANCET, V368, P705; Bouzigon E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036672; Breton CV, 2011, AM J RESP CRIT CARE, V184, P191, DOI 10.1164/rccm.201012-2029OC; Castro-Giner F, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-128; Dahgam S, 2012, J MED GENET, V49, P200, DOI 10.1136/jmedgenet-2011-100584; Franklin PJ, 2008, PAEDIATR RESPIR REV, V9, P122, DOI 10.1016/j.prrv.2007.12.004; Fujii T, 2008, GENESIS, V46, P418, DOI 10.1002/dvg.20412; Granell R, 2013, J ALLERGY CLIN IMMUN, V131, P685, DOI 10.1016/j.jaci.2012.09.021; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; Holloway JW, 2008, NEW ENGL J MED, V359, P2043, DOI 10.1056/NEJMe0807576; Imboden M, 2012, J ALLERGY CLIN IMMUN, V129, P1218, DOI 10.1016/j.jaci.2012.01.074; Katoh S, 2007, AM J RESP CRIT CARE, V176, P27, DOI 10.1164/rccm.200608-1243OC; Liang LM, 2013, GENOME RES, V23, P716, DOI 10.1101/gr.142521.112; Lund MB, 2007, EUR RESPIR J, V29, P292, DOI 10.1183/09031936.00044805; Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; McCarthy MI, 2008, HUM MOL GENET, V17, pR156, DOI 10.1093/hmg/ddn289; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Niki T, 2009, J BIOL CHEM, V284, P32344, DOI 10.1074/jbc.M109.035196; Pijnenburg MWH, 2008, CLIN EXP ALLERGY, V38, P246, DOI 10.1111/j.1365-2222.2007.02897.x; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Salam MT, 2011, ALLERGY, V66, P412, DOI 10.1111/j.1398-9995.2010.02492.x; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Stern G, 2011, J ALLERGY CLIN IMMUN, V128, P293, DOI 10.1016/j.jaci.2011.03.010; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Tamura M, 2007, GENOMICS, V89, P618, DOI 10.1016/j.ygeno.2007.01.003; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; van der Valk RJP, 2012, CLIN EXP ALLERGY, V42, P1329, DOI 10.1111/j.1365-2222.2012.04010.x; van der Valk RJP, 2012, ALLERGY, V67, P265, DOI 10.1111/j.1398-9995.2011.02734.x; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Vonk JM, 2010, PHARMACOGENET GENOM, V20, P179, DOI 10.1097/FPC.0b013e328336c7fd; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Wilk JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000429; Yamamoto H, 2007, INT ARCH ALLERGY IMM, V143, P95, DOI 10.1159/000101414; Yamamoto M, 2012, CLIN EXP ALLERGY, V42, P760, DOI 10.1111/j.1365-2222.2011.03860.x; Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608	46	30	31	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					46	55		10.1016/j.jaci.2013.08.053	http://dx.doi.org/10.1016/j.jaci.2013.08.053			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24315451	Green Accepted			2022-12-18	WOS:000338930300007
J	Cabauatan, CR; Lupinek, C; Scheiblhofer, S; Weiss, R; Focke-Tejkl, M; Bhalla, PL; Singh, MB; Knight, PA; van Hage, M; Ramos, JDA; Valenta, R				Cabauatan, Clarissa R.; Lupinek, Christian; Scheiblhofer, Sandra; Weiss, Richard; Focke-Tejkl, Margarete; Bhalla, Prem L.; Singh, Mohan B.; Knight, Paul A.; van Hage, Marianne; Ramos, John Donnie A.; Valenta, Rudolf			Allergen microarray detects high prevalence of asymptomatic IgE sensitizations to tropical pollen-derived carbohydrates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Cabauatan, Clarissa R.; Lupinek, Christian; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Cabauatan, Clarissa R.] St Marys Univ, Sch Arts & Sci, Ctr Nat Sci, Bayombong, Nueva Vizcaya, Philippines; [Cabauatan, Clarissa R.; Ramos, John Donnie A.] Univ Santo Tomas, Grad Sch, Manila, Philippines; [Cabauatan, Clarissa R.; Ramos, John Donnie A.] Univ Santo Tomas, Res Ctr Nat & Appl Sci, Manila, Philippines; [Scheiblhofer, Sandra; Weiss, Richard] Salzburg Univ, Dept Mol Biol, Christian Doppler Lab Allergy Diagnost & Therapy, A-5020 Salzburg, Austria; [Focke-Tejkl, Margarete; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Christian Doppler Lab Allergy Res, Dept Pathophysiol & Allergy Res,Dept Pathophysiol, Vienna, Austria; [Bhalla, Prem L.; Singh, Mohan B.; Knight, Paul A.] Univ Melbourne, Melbourne Sch Land & Environm, Plant Mol Biol & Biotechnol Lab, Parkville, Vic 3052, Australia; [van Hage, Marianne] Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, Stockholm, Sweden; [van Hage, Marianne] St Gorans Univ Hosp, S-11281 Stockholm, Sweden	Medical University of Vienna; University of Santo Tomas; University of Santo Tomas; Salzburg University; Medical University of Vienna; University of Melbourne; Karolinska Institutet; Saint Goran's Hospital	Cabauatan, CR (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Lupinek, Christian/I-3311-2019; van Hage, Marianne/A-9678-2017; Weiss, Richard/N-7279-2013	Lupinek, Christian/0000-0002-8612-8245; van Hage, Marianne/0000-0003-3091-1596; Weiss, Richard/0000-0003-3185-7253; Valenta, Rudolf/0000-0001-5944-3365; Ramos, John Donnie/0000-0002-1404-4093; Scheiblhofer, Sandra/0000-0003-2867-9054; Bhalla, Prem/0000-0002-2910-0393; Singh, Mohan/0000-0001-9427-8975	Austrian Science Fund FWF [F 4605] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Arkestal K, 2011, J ALLERGY CLIN IMMUN, V127, P1024, DOI 10.1016/j.jaci.2011.01.033; Burbach GJ, 2009, ALLERGY, V64, P1507, DOI 10.1111/j.1398-9995.2009.02089.x; Cabauatan CR, 2012, ASIA PAC ALLERGY, V2, P136, DOI 10.5415/apallergy.2012.2.2.136; Connett GJ, 2012, INT ARCH ALLERGY IMM, V159, P384, DOI 10.1159/000338940; Katelaris CH, 2011, AM J RHINOL ALLERGY, V25, pS3, DOI [10.2500/ajra.2011.25.3674, 10.2500/ajr.2011.25.3674]; Linhart B, 2002, FASEB J, V16, P1301, DOI 10.1096/fj.01-1012fje; Shek LPC, 2010, J ALLERGY CLIN IMMUN, V126, P324, DOI 10.1016/j.jaci.2010.06.003; Tiwari Ruby, 2009, Allergology International, V58, P557, DOI 10.2332/allergolint.09-OA-0094	9	30	30	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					910	914		10.1016/j.jaci.2013.10.004	http://dx.doi.org/10.1016/j.jaci.2013.10.004			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24315449	Green Accepted			2022-12-18	WOS:000332397600045
J	Chen, WG; Sivaprasad, U; Gibson, AM; Ericksen, MB; Cunningham, CM; Bass, SA; Kinker, KG; Finkelman, FD; Wills-Karp, M; Hershey, GKK				Chen, Weiguo; Sivaprasad, Umasundari; Gibson, Aaron M.; Ericksen, Mark B.; Cunningham, Christie M.; Bass, Stacey A.; Kinker, Kayla G.; Finkelman, Fred D.; Wills-Karp, Marsha; Hershey, Gurjit K. Khurana			IL-13 receptor alpha 2 contributes to development of experimental allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; IL-13 receptor; lung; airway hyperresponsiveness; airway inflammation	INTERLEUKIN-13 RECEPTOR; EXPRESSION; CLONING; IL-13R-ALPHA-2; BINDING; COMPONENT; MEMBRANE; DISTINCT; PROTEIN; CHAIN	Background: IL-13 receptor alpha 2 (IL-13R alpha 2) binds IL-13 with high affinity and modulates IL-13 responses. There are soluble and membrane forms of IL-13R alpha 2 generated by alternative splicing in mice, but human subjects express only the membrane form of IL-13R alpha 2 (memIL-13R alpha 2). Objective: We determined the role of memIL-13R alpha 2 in the development of allergic inflammation in mouse models of asthma. Methods: IL-13R alpha 2-deficient and memIL-13R alpha 2 lung epithelium-specific transgenic mice were challenged with house dust mite (HDM). Airway hyperresponsiveness (AHR) and inflammation were assessed based on the airway pressure-time index, bronchoalveolar lavage (BAL) cell counts, and lung histology. Mucus production was determined by means of periodic acid-Schiff staining of lung sections, Western blot analysis of chloride channel calcium activated 3 (CLCA3) expression in lung homogenates, and ELISA of Muc5ac in BAL fluid. The expression of cytokines and chemokines was determined by using RT-quantitative PCR. Results: In IL-13R alpha 2-deficient mice AHR and airway inflammation were attenuated compared with levels seen in wild-type mice after HDM challenge. Lung epithelial overexpression of memIL-13R alpha 2 in the IL-13R alpha 2-deficient mice reconstituted AHR and inflammation to levels similar to those observed in HDM-challenged wild-type mice. Mucus production was attenuated in lungs from HDM-treated IL-13R alpha 2-deficient mice, whereas lung epithelial overexpression of memIL-13R alpha 2 increased mucus production. Lung epithelial overexpression of memIL-13R alpha 2 had no effect on levels of the soluble form of IL-13R alpha 2 in serum or BAL fluid and did not affect IL-13-dependent signal transducer and activator of transcription 6 activation in the lungs. Conclusion: These data collectively support a distinct role for memIL-13R alpha 2 in the lung and suggest that memIL-13R alpha 2 might contribute to allergic inflammation.	[Chen, Weiguo; Sivaprasad, Umasundari; Gibson, Aaron M.; Ericksen, Mark B.; Cunningham, Christie M.; Bass, Stacey A.; Kinker, Kayla G.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA; [Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Finkelman, Fred D.; Wills-Karp, Marsha] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Med, Div Immunol, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org		Khurana Hershey, Gurjit/0000-0001-6663-977X	National Institutes of Health [R01 AI058157, R01 AR054490, P01 HL076383, R56 AI084414, R01 HL097360]; Department of Veterans Affairs; UpToDate; Elsevier; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097360, P01HL076383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI084414, R01AI058157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); UpToDate; Elsevier; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health grants R01 AI058157 (to G.K.K.H.), R01 AR054490 (to G.K.K.H.), P01 HL076383 (to G.K.K.H.), R56 AI084414 (to G.K.K.H.), P01 HL076383 (to F.D.F.), R01 HL097360 (to F.D.F.), and a Merit Award from the Department of Veterans Affairs (to F.D.F.).; Disclosure of potential conflict of interest: W. Chen has been supported by one or more grants from the National Institutes of Health (NIH). G. K. Khurana Hershey has received one or more grants from or has one or more grants pending with the NIH. M. Wills-Karp has been supported by one or more grants from the NIH. F. D. Finkelman has consultancy arrangements with Abbott Labs, Amgen, Johnson & Johnson, Quintiles Phase One Services, and the Eli and Edythe Broad Foundation; is employed by the Journal of Allergy Clinical Immunology; has provided expert testimony for Freud, Freeze, & Arnold; has provided expert testimony for Robinson and Epling, PSC; has provided expert testimony for McKool Smith; has provided expert testimony for Darby & Gazak, PSC; has received one or more grants from or has one or more grants pending with the NIH, the Department of Defense, and Johnson & Johnson; has received one or more payments for lecturing from or is on the speakers' bureau for Temple University, Creative Educational Concepts, and Children's Hospital Boston, the Cleveland Clinic, and the University of Chicago; has one or more patents (planned, pending, or issued) with Becton-Dickinson and eBioscience; has received royalties from UpToDate and Elsevier; and has received one or more payments for travel/accommodations/meeting expenses from FASEB, the NIH, and the American Association of Immunology. The rest of the authors declare that they have no relevant conflicts of interest.	Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen WG, 2008, J ALLERGY CLIN IMMUN, V122, P625, DOI 10.1016/j.jaci.2008.06.022; Chen WG, 2009, J IMMUNOL, V183, P7870, DOI 10.4049/jimmunol.0901028; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044; Daines MO, 2006, J IMMUNOL, V176, P7495, DOI 10.4049/jimmunol.176.12.7495; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Fichtner-Feigl S, 2008, GASTROENTEROLOGY, V135, P2003, DOI 10.1053/j.gastro.2008.08.055; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Junttila IS, 2008, J EXP MED, V205, P2595, DOI 10.1084/jem.20080452; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Khodoun M, 2007, J IMMUNOL, V179, P6429, DOI 10.4049/jimmunol.179.10.6429; Mandal D, 2010, INFLAMM BOWEL DIS, V16, P753, DOI 10.1002/ibd.21133; Mentink-Kane MM, 2004, P NATL ACAD SCI USA, V101, P586, DOI 10.1073/pnas.0305064101; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Morimoto M, 2006, J IMMUNOL, V176, P491, DOI 10.4049/jimmunol.176.1.491; Morimoto M, 2009, J IMMUNOL, V183, P1934, DOI 10.4049/jimmunol.0804299; O'Toole M, 2008, CLIN EXP ALLERGY, V38, P594, DOI 10.1111/j.1365-2222.2007.02921.x; Sivaprasad U, 2010, J IMMUNOL, V185, P6802, DOI 10.4049/jimmunol.1002118; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Tabata Y, 2006, J IMMUNOL, V177, P7905, DOI 10.4049/jimmunol.177.11.7905; Walters DM, 2002, AM J RESP CELL MOL, V27, P413, DOI 10.1165/rcmb.4844; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson MS, 2011, GASTROENTEROLOGY, V140, P254, DOI 10.1053/j.gastro.2010.09.047; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	29	30	34	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					951	+		10.1016/j.jaci.2013.04.016	http://dx.doi.org/10.1016/j.jaci.2013.04.016			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23763980	Green Accepted			2022-12-18	WOS:000325096500023
J	Agarwal, S; Cunningham-Rundles, C				Agarwal, Shradha; Cunningham-Rundles, Charlotte			Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MEMORY B; CELLS; DEFICIENCY; INFLAMMATION; ACTIVATION		[Agarwal, Shradha; Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Med, Div Clin Immunol & Allergy, New York, NY USA	Icahn School of Medicine at Mount Sinai	Agarwal, S (corresponding author), Mt Sinai Sch Med, Dept Med, Div Clin Immunol & Allergy, New York, NY USA.	shradha.agarwal@mssm.edu			NIAID NIH HHS [P01 AI061093, U24 AI086037, R18 AI048693] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R18AI048693, P01AI061093, U24AI086037] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 2009, J ALLERGY CLIN IMMUN, V124, P658, DOI 10.1016/j.jaci.2009.06.018; Akimova T, 2010, CLIN IMMUNOL, V136, P348, DOI 10.1016/j.clim.2010.04.018; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Chen Y, 2011, J ALLERGY CLIN IMMUN, V127, P1414, DOI 10.1016/j.jaci.2011.03.041; Grausenburger R, 2010, J IMMUNOL, V185, P3489, DOI 10.4049/jimmunol.0903610; Hodgkin PD, 1996, J EXP MED, V184, P277, DOI 10.1084/jem.184.1.277; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Lv J, 2012, J BIOL CHEM, V287, P28656, DOI 10.1074/jbc.M112.356584; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Podjasek JC, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00189; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Rezaei N, 2011, J ALLERGY CLIN IMMUN, V127, P1329, DOI 10.1016/j.jaci.2011.02.047; Saouaf SJ, 2009, EXP MOL PATHOL, V87, P99, DOI 10.1016/j.yexmp.2009.06.003; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Shlomchik MJ, 2012, IMMUNOL REV, V247, P52, DOI 10.1111/j.1600-065X.2012.01124.x; Skov S, 2003, BLOOD, V101, P1430, DOI 10.1182/blood-2002-07-2073; Smith KGC, 1996, EUR J IMMUNOL, V26, P444, DOI 10.1002/eji.1830260226; Sorensen RU, 2000, PEDIATR CLIN N AM, V47, P1225, DOI 10.1016/S0031-3955(05)70269-8; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Yong PL, 2010, CLIN IMMUNOL, V135, P255, DOI 10.1016/j.clim.2009.10.003; Zhang Z, 2008, CELL MOL LIFE SCI, V65, P4055, DOI 10.1007/s00018-008-8521-4	22	30	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1699	1701		10.1016/j.jaci.2013.01.036	http://dx.doi.org/10.1016/j.jaci.2013.01.036			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23518142	Green Accepted			2022-12-18	WOS:000320532800033
J	Raedler, D; Illi, S; Pinto, LA; von Mutius, E; Illig, T; Kabesch, M; Schaub, B				Raedler, Diana; Illi, Sabina; Pinto, Leonardo Araujo; von Mutius, Erika; Illig, Thomas; Kabesch, Michael; Schaub, Bianca			IL10 polymorphisms influence neonatal immune responses, atopic dermatitis, and wheeze at age 3 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; atopic dermatitis; cord blood; cytokines; IL-10; single nucleotide polymorphisms; regulatory T cells; wheeze	SINGLE-NUCLEOTIDE POLYMORPHISMS; INTERFERON-GAMMA PRODUCTION; GENE PROMOTER POLYMORPHISM; REGULATORY T-CELLS; INTERLEUKIN-10 PROMOTER; CORD BLOOD; CYTOKINE PRODUCTION; IL-10 PRODUCTION; ASTHMA; EXPOSURE	Background: IL10 encodes for IL-10, an important anti-inflammatory cytokine with pleiotropic effects. It is crucial for development of immune tolerance, downregulates expression of T(H)1 cytokines, and is relevant for T-cell regulation. Several IL10 single nucleotide polymorphisms (SNPs) were associated with inflammatory diseases, such as atopic diseases, which might have their onset during early immune maturation. Objective: We hypothesized that IL10 SNPs are associated with decreased regulatory T (Treg) cell numbers, T(H)2-skewed immune responses, and decreased IFN-gamma levels in cord blood parallel with increased proinflammatory markers, subsequently leading to increased atopic diseases until 3 years. Methods: Eight genetic IL10 variants, represented by 4 linkage disequilibrium blocks (R-2 > 0.80) and 2 distal promoter SNPs, were genotyped in cord blood mononuclear cells of 200 healthy neonates. Cord blood mononuclear cells were cultured unstimulated or after stimulation with lipid A, peptidoglycan, PHA, house dust mite (Der p 1), or Der p 1 plus lipid A. mRNA expression of Treg cell-associated genes (forkhead box protein P3 [FOXP3], glucocorticoid-induced TNF receptor [GITR], lymphocyte activation gene 3 [LAG3]), T(H)1/T(H)2 cytokines, TNF-alpha, and GM-CSF were assessed. Atopic and respiratory outcomes (atopic dermatitis [AD] and wheeze) were assessed by means of questionnaire at age 3 years. Results: Carriers of 3 IL10 SNP blocks and both distal promoter SNPs showed reduced expression of Treg cell markers, reduced IL-5 levels, proinflammatory TNF-alpha and GM-CSF, and partially increased IFN-gamma levels. The same SNPs presented as determinant for AD, wheeze, or symptoms of AD, wheeze, or both at age 3 years. Conclusions: Polymorphisms in IL10 influenced Treg cell marker expression and T(H)1/T(H)2 and proinflammatory cytokine secretion early in life. This was relevant for further development of immune-mediated diseases, such as AD and wheeze, in early childhood. (J Allergy Clin Immunol 2013;131:789-96.)	[Raedler, Diana; Illi, Sabina; von Mutius, Erika; Schaub, Bianca] Ludwig Maximilians Univ Munchen, Univ Childrens Hosp Munich, Dept Pulm & Allergy, Munich, Germany; [Pinto, Leonardo Araujo] Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Porto Alegre, RS, Brazil; [Illig, Thomas] German Res Ctr Environm Hlth, Inst Epidemiol, Helmholtz Ctr Munich, Neuherberg, Germany; [Illig, Thomas] Hannover Unified Biobank, Hannover, Germany; [Kabesch, Michael] Hannover Med Sch, Clin Paediat Pneumol Allergol & Neonatol, Hannover, Germany	University of Munich; Pontificia Universidade Catolica Do Rio Grande Do Sul; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Hannover Medical School	Schaub, B (corresponding author), Univ Childrens Hosp Munich, Lindwurmstr 4, D-80337 Munich, Germany.	Bianca.Schaub@med.uni-muenchen.de	Kabesch, Michael/AAB-5701-2020; Kabesch, Michael/GZM-1583-2022; Pinto, Leonardo A./C-6866-2008; Schaub, Bianca/B-9935-2019; Pinto, Leonardo A./AAG-2800-2020	Pinto, Leonardo A./0000-0002-3906-5456; Schaub, Bianca/0000-0003-1652-8873; Pinto, Leonardo A./0000-0002-3906-5456; von Mutius, Erika/0000-0002-8893-4515	Bavarian Research Association [PIZ-140-08]; German Research Foundation [DFG SFB TR22/A22]; Comprehensive Pulmonary Centre (CPC); German Ministry of Education and Research (BMBF); National Genome Research Network (NGFN) [NGFN 01GS0810]; Airsonnett AB; Deutsche Forschungsgemeinschaft (DFG); BMBF; European Union (EU)	Bavarian Research Association; German Research Foundation(German Research Foundation (DFG)); Comprehensive Pulmonary Centre (CPC); German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); National Genome Research Network (NGFN); Airsonnett AB; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF)); European Union (EU)(CGIAREuropean Commission)	Supported by Bavarian Research Association PIZ-140-08 (to B.S.) and the German Research Foundation as part of the transregional collaborative research program TR22 "allergic immune responses of the lung,'' grant DFG SFB TR22/A22 (to D.R. and B.S.). Further funding was provided by the Comprehensive Pulmonary Centre (CPC for B.S.) and by the German Ministry of Education and Research (BMBF) as part of the National Genome Research Network (NGFN), with grant NGFN 01GS0810 (to L.A.P. and M.K.). Genotyping was performed in collaboration with the Genome Analysis Centre of the Helmholtz Centre Munich.; Disclosure of potential conflict of interest: E. von Mutius is a consultant for Novartis, GlaxoSmithKline, ALK-Abello, and Protectimmun; has received speakers' fees from InfectoPharm; has been supported by Airsonnett AB; is a member of the expert panel for the UK Research Excellence Framework; and is an Associate Editor of the Journal of Allergy and Clinical Immunology. M. Kabesch has financial interests in Roxall, GlaxoSmithKline, Novartis, Sanofi Aventis, Allergopharma, and AstraZeneca GmbH and has been supported by Deutsche Forschungsgemeinschaft (DFG), the BMBF, and the European Union (EU). B. Schaub has been supported by DFG and the EU. The rest of the authors declare that they have no relevant conflicts of interest.	Asadullah K, 2001, J INVEST DERMATOL, V116, P975, DOI 10.1046/j.1523-1747.2001.01350.x; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Borrego LM, 2009, CLIN EXP ALLERGY, V39, P1160, DOI 10.1111/j.1365-2222.2009.03253.x; Bosse Y, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-98; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Casaca VI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031069; Chatterjee R, 2005, CLIN EXP ALLERGY, V35, P914, DOI 10.1111/j.1365-2222.2005.02273.x; Contreras JP, 2003, J ALLERGY CLIN IMMUN, V112, P1072, DOI 10.1016/j.jaci.2003.08.036; Corinti S, 2001, J IMMUNOL, V166, P4312, DOI 10.4049/jimmunol.166.7.4312; Dabbagh K, 2002, J IMMUNOL, V168, P4524, DOI 10.4049/jimmunol.168.9.4524; Ding CM, 2003, P NATL ACAD SCI USA, V100, P3059, DOI 10.1073/pnas.0630494100; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Gibson AW, 2001, J IMMUNOL, V166, P3915, DOI 10.4049/jimmunol.166.6.3915; Grutz G, 2005, J LEUKOCYTE BIOL, V77, P3, DOI 10.1189/jlb.0904484; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Hayden CM, 2011, J ALLERGY CLIN IMMUN, V128, P237, DOI 10.1016/j.jaci.2011.02.032; Hee Chee Seng, 2007, Mod Rheumatol, V17, P429, DOI 10.1007/s10165-007-0612-9; Hijnen D, 2009, J ALLERGY CLIN IMMUN, V124, P856, DOI 10.1016/j.jaci.2009.07.056; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Jung T, 1999, CLIN EXP ALLERGY, V29, P912; Kiyohara Chikako, 2008, Allergol Int, V57, P39, DOI 10.2332/allergolint.R-07-150; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; KUBE D, 1995, CYTOKINE, V7, P1, DOI 10.1006/cyto.1995.1001; Kube D, 2003, GENES IMMUN, V4, P459, DOI 10.1038/sj.gene.6364003; Kube D, 2008, CLIN CANCER RES, V14, P3777, DOI 10.1158/1078-0432.CCR-07-5182; Liu J, 2011, ALLERGY, V66, P1020, DOI 10.1111/j.1398-9995.2011.02573.x; Ly NP, 2007, PEDIATRICS, V119, pE171, DOI 10.1542/peds.2006-0524; Lyon H, 2004, GENET EPIDEMIOL, V26, P155, DOI 10.1002/gepi.10298; Mege JL, 2006, LANCET INFECT DIS, V6, P557, DOI 10.1016/S1473-3099(06)70577-1; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097; Paradowska-Gorycka A, 2010, INT J IMMUNOGENET, V37, P225, DOI 10.1111/j.1744-313X.2010.00913.x; Rees LEN, 2002, CELL MOL LIFE SCI, V59, P560, DOI 10.1007/s00018-002-8448-0; Rieth H, 2004, EUR CYTOKINE NETW, V15, P153; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Schaub B, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-40; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Shin HD, 2000, P NATL ACAD SCI USA, V97, P14467, DOI 10.1073/pnas.97.26.14467; Sohn MH, 2007, J PEDIATR-US, V150, P106, DOI 10.1016/j.jpeds.2006.08.065; Spergel JM, 2005, CURR OPIN ALLERGY CL, V5, P17, DOI 10.1097/00130832-200502000-00005; SPITS H, 1992, INT ARCH ALLERGY IMM, V99, P8, DOI 10.1159/000236329; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Vukmanovic-Stejic M, 2005, BRIT J DERMATOL, V153, P750, DOI 10.1111/j.1365-2133.2005.06675.x; Wilk JB, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S8; Willwerth BM, 2006, ANN ALLERG ASTHMA IM, V96, P445, DOI 10.1016/S1081-1206(10)60912-X; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Zhu JF, 2010, CELL RES, V20, P4, DOI 10.1038/cr.2009.138	49	30	30	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					789	796		10.1016/j.jaci.2012.08.008	http://dx.doi.org/10.1016/j.jaci.2012.08.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23021880				2022-12-18	WOS:000315587800021
J	Keet, CA; Wood, RA; Matsui, EC				Keet, Corinne A.; Wood, Robert A.; Matsui, Elizabeth C.			Limitations of reliance on specific IgE for epidemiologic surveillance of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FILAGGRIN GENE; RISK-FACTORS; SENSITIZATION; PREVALENCE; VARIANTS; CHILDREN; PROTEIN; ASTHMA		[Keet, Corinne A.; Wood, Robert A.; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Keet, Corinne A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Keet, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA.	ckeet1@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593; Keet, Corinne/0000-0002-6585-239X	NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025006] Funding Source: NIH RePORTER; NCRR NIH HHS [KL2 RR025006, 1KL2RR025006-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Eugen-Olsen J, 2010, J INTERN MED, V268, P296, DOI 10.1111/j.1365-2796.2010.02252.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; John JMM, 2010, ALLERGY, V65, P875, DOI 10.1111/j.1398-9995.2009.02297.x; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P169, DOI 10.1016/j.jaci.2011.10.002; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Ruckert IM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022932; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; SPICER CC, 1980, BMJ-BRIT MED J, V281, P592, DOI 10.1136/bmj.281.6240.592; Thyssen JP, 2010, BRIT J DERMATOL, V162, P1278, DOI 10.1111/j.1365-2133.2010.09708.x; Thyssen JP, 2009, BRIT J DERMATOL, V161, P95, DOI 10.1111/j.1365-2133.2009.09157.x; von Berg A, 2010, CLIN EXP ALLERGY, V40, P627, DOI 10.1111/j.1365-2222.2009.03444.x; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004	19	30	29	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1207	1209		10.1016/j.jaci.2012.07.020	http://dx.doi.org/10.1016/j.jaci.2012.07.020			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22964106	Green Accepted			2022-12-18	WOS:000310571400027
J	Rotiroti, G; Shamji, M; Durham, SR; Till, SJ				Rotiroti, Giuseppina; Shamji, Mohamed; Durham, Stephen R.; Till, Stephen J.			Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tolerance; immunotherapy; intradermal; grass; late response; IgE	GRASS-POLLEN IMMUNOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; MESSENGER-RNA EXPRESSION; T-REGULATORY-CELLS; HAY-FEVER; DENDRITIC CELLS; TGF-BETA; B-CELLS; IGE; IL-10	Background: Subcutaneous immunotherapy with high-dose grass pollen was first described more than 100 years ago. This treatment suppresses allergen-induced cutaneous late responses, with lesser effects on early responses. In contrast, low-dose subcutaneous immunotherapy has not shown clinical benefit. Uncontrolled reports from the early 20th century describe low-dose allergen inoculation directly into the dermis, an immunologically active area containing abundant dendritic cells and lymphatics. Objective: We sought to investigate the effect of low-dose intradermal grass pollen administration on cutaneous reactivity to allergen. Methods: Thirty adults sensitized to grass and tree pollens were randomized to receive (1) 6 repeat intradermal injections at 2-week intervals of grass pollen extract (estimated 7 ng of the major grass allergen Phl p 5 per injection), (2) 2 intradermal injections separated by 10 weeks, or (3) a single intradermal injection at 10 weeks. At the end of the study, cutaneous early and late responses were measured after double-blind intradermal injection with grass and birch pollen. Results: Participants who received 6 fortnightly intradermal grass pollen injections had markedly smaller cutaneous late responses to grass pollen than control subjects who received 2 injections separated by 10 weeks (P < .01) or a single injection (P < .001) and showed induction of grass pollen-specific IgG antibodies. Suppression was observed whether late responses were measured on the arms or the back. However, early responses were equivalent in all groups. Conclusion: Low-dose intradermal allergen, like conventional subcutaneous high-dose immmunotherapy, suppresses allergen-induced cutaneous late responses in a manner that is allergen specific, systemic, and associated with induction of IgG antibodies. (J Allergy Clin Immunol 2012; 130:918-24.)	[Rotiroti, Giuseppina; Shamji, Mohamed; Durham, Stephen R.; Till, Stephen J.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Till, Stephen J.] Kings Coll London, London WC2R 2LS, England; [Shamji, Mohamed; Durham, Stephen R.; Till, Stephen J.] MRC, London, England; [Shamji, Mohamed; Durham, Stephen R.; Till, Stephen J.] Asthma UK Ctr Allerg Mech Asthma, London, England	Imperial College London; University of London; King's College London; University of London; King's College London	Durham, SR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	s.durham@imperial.ac.uk	Shamji, Mohamed/AAD-1788-2019; Shamji, Mohamed/AAU-8811-2020	Shamji, Mohamed/0000-0003-3425-3463; Till, Stephen/0000-0003-4518-3093	Health Foundation and Academy of Medical Sciences; Royal Brompton and Harefield Hospitals Charitable Trust; ALK-Abello; Merck; Circassia; GlaxoSmithKline; Boehringer Ingelheim; MRC [MC_PC_12038, G0601303] Funding Source: UKRI; Medical Research Council [MC_PC_12038, G0601303] Funding Source: researchfish	Health Foundation and Academy of Medical Sciences; Royal Brompton and Harefield Hospitals Charitable Trust; ALK-Abello; Merck(Merck & Company); Circassia; GlaxoSmithKline(GlaxoSmithKline); Boehringer Ingelheim(Boehringer Ingelheim); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	S.J.T. was supported by a Clinician Scientist Fellowship from the Health Foundation and Academy of Medical Sciences. This study was also supported by the Royal Brompton and Harefield Hospitals Charitable Trust.; G. Rotiroti has received travel expenses from ALK-Abello, GlaxoSmithKline, and Allergy Therapeutics. S.R. Durham has received consultancy fees from ALK-Abello, Merck, Circassia, GlaxoSmithKline, and Boehringer Ingelheim; has provided expert testimony for Weil; has received research support from ALK-Abello and Merck; and has received lecture fees from Merck, ALK-Abello, and GlaxoSmithKline. S.J. Till has received research support from ALK-Abello. M. Shamji declares that he has no relevant conflicts of interest.	Aslam A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011028; Belshe RB, 2004, NEW ENGL J MED, V351, P2286, DOI 10.1056/NEJMoa043555; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; FLING JA, 1989, J ALLERGY CLIN IMMUN, V83, P101, DOI 10.1016/0091-6749(89)90483-1; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; FRANKLAND AW, 1954, LANCET, V1, P1055; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Kenney RT, 2004, NEW ENGL J MED, V351, P2295, DOI 10.1056/NEJMoa043540; Kersey TW, 2001, J SURG RES, V96, P255, DOI 10.1006/jsre.2000.6075; Krishna MT, 2011, CLIN EXP ALLERGY, V41, P1201, DOI 10.1111/j.1365-2222.2011.03788.x; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Matriano JA, 2002, PHARMACEUT RES, V19, P63, DOI 10.1023/A:1013607400040; Maurer D, 1996, J IMMUNOL, V157, P607; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; Noon L, 1911, LANCET, V1, P1572; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Novak N, 2008, J ALLERGY CLIN IMMUN, V121, pS370, DOI 10.1016/j.jaci.2007.06.001; O'Mahony S, 2006, AM J ROENTGENOL, V186, P1349, DOI 10.2214/AJR.04.1341; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Peng ZK, 2004, ANN ALLERG ASTHMA IM, V93, P553, DOI 10.1016/S1081-1206(10)61262-8; Phillips E, 1933, J ALLERGY, V5, P29; Phillips EW, 1926, J AMER MED ASSOC, V86, P182, DOI 10.1001/jama.1926.02670290022008; Propst T, 1998, AM J KIDNEY DIS, V32, P1041, DOI 10.1016/S0272-6386(98)70081-2; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; REUNALA T, 1994, ANN MED, V26, P301, DOI 10.3109/07853899409147906; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P205; Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118; Satoguina JS, 2008, EUR J IMMUNOL, V38, P3101, DOI 10.1002/eji.200838193; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Walker SM, 2011, CLIN EXP ALLERGY, V41, P1177, DOI 10.1111/j.1365-2222.2011.03794.x; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029	42	30	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					918	+		10.1016/j.jaci.2012.06.052	http://dx.doi.org/10.1016/j.jaci.2012.06.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22971521	Bronze			2022-12-18	WOS:000309594800013
J	Fiorentino, R; Liu, GM; Pariser, AR; Mulberg, AE				Fiorentino, Robert; Liu, Gumei; Pariser, Anne R.; Mulberg, Andrew E.			Cross-sector sponsorship of research in eosinophilic esophagitis: A collaborative model for rational drug development in rare diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Clinical outcome assessment; eosinophilic esophagitis; the International Gastrointestinal Eosinophil Researchers; US Food and Drug Administration; Study Endpoints and Labeling Development	PLACEBO-CONTROLLED TRIAL; CLINICAL-RESEARCH; CHILDREN; ADULTS	Like many rare diseases, eosinophilic esophagitis (EoE) is a poorly understood disorder, and assessment tools to accurately determine disease activity, remission, and natural history have long been inadequate. Clinical outcome end points able to assess the effectiveness of candidate therapeutic agents in clinical trials have been a particular deficiency and are urgently needed. With no approved therapy available to patients and with the prevalence of EoE on the increase, collaborative approaches to drug development are becoming ever more important. We describe a collaborative effort mobilized across institutions, including both the public and private sectors, that was initiated within the past 18 months expressly to address the need for further clinical research into the cause and treatment of EoE. Collaborators include the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition; the International Gastrointestinal Eosinophilic Researchers; and the US Food and Drug Administration. This effort has resulted in the elucidation of several parameters essential for effective EoE registration trials, including the need for clinically meaningful end points that measure changes in clinical symptoms in addition to the assessment of intraepithelial mucosal eosinophilia. The development and use of biomarkers, particularly in early-phase drug development, have become an important focus for investigations that might reduce clinical reliance on serial invasive monitoring. The concerted efforts described here to develop rational therapeutics and drug development paradigms in EoE also appear to provide a model for effective collaboration in the context of drug development for rare diseases and perhaps more generally for public health initiatives. (J Allergy Clin Immunol 2012;130:613-6.)	[Fiorentino, Robert; Mulberg, Andrew E.] US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Div Gastroenterol & Inborn Errors Prod, Silver Spring, MD 20993 USA; [Liu, Gumei; Pariser, Anne R.] US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Rare Dis Program, Silver Spring, MD 20993 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Mulberg, AE (corresponding author), US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Div Gastroenterol & Inborn Errors Prod, 10903 New Hampshire Ave,Bldg 22,Rm 5114, Silver Spring, MD 20993 USA.	Andrew.mulberg@fda.hhs.gov	MULBERG, ANDREW/AAJ-2249-2020					Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781; Dellon ES, 2007, AM J GASTROENTEROL, V102, P2300, DOI 10.1111/j.1572-0241.2007.01396.x; Dohil R, 2010, GASTROENTEROLOGY, V139, P418, DOI 10.1053/j.gastro.2010.05.001; Franciosi JP, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-126; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Griggs RC, 2009, MOL GENET METAB, V96, P20, DOI 10.1016/j.ymgme.2008.10.003; Hirano I, 2012, GUT; Hruz P, 2011, J ALLERGY CLIN IMMUN, V128, P1349, DOI 10.1016/j.jaci.2011.09.013; Institute of Medicine, 2010, REP BRIEF FUT NURS L, P1; Landy DC, 2012, GENET MED, V14, P223, DOI [10.1038/GIM.0b013e3182310ba0, 10.1038/gim.0b013e3182310ba0]; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; de la Paz MP, 2010, ADV EXP MED BIOL, V686, P17, DOI 10.1007/978-90-481-9485-8_2; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Taft TH, 2011, J CLIN GASTROENTEROL, V45, P769, DOI 10.1097/MCG.0b013e3182166a5a; US Food and Drug Administration, 2015, DRUG DEV TOOLS DDT Q	19	30	30	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					613	616		10.1016/j.jaci.2012.07.011	http://dx.doi.org/10.1016/j.jaci.2012.07.011			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22857796	Bronze			2022-12-18	WOS:000308463500006
J	Sumino, K; Tucker, J; Shahab, M; Jaffee, KF; Visness, CM; Gern, JE; Bloomberg, GR; Holtzman, MJ				Sumino, Kaharu; Tucker, Jennifer; Shahab, Muhammad; Jaffee, Katy F.; Visness, Cynthia M.; Gern, James E.; Bloomberg, Gordon R.; Holtzman, Michael J.			Antiviral IFN-gamma responses of monocytes at birth predict respiratory tract illness in the first year of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Viral respiratory tract infection; cord blood monocytes; infants; asthma; allergic disease	LUNG DENDRITIC CELLS; SYNCYTIAL VIRUS; INTERFERON-GAMMA; CYTOKINE RESPONSES; IMMUNE-RESPONSE; VIRAL-INFECTION; HIGH-RISK; DAY-CARE; INNATE; ASTHMA	Background: Viral respiratory tract infections are the leading cause of acute illness during infancy and are closely linked to chronic inflammatory airway diseases later in life. However, the determinants of susceptibility to acute respiratory tract infections still need to be defined. Objective: We investigated whether the individual variation in antiviral response at birth determines the risk for acute respiratory tract illness in the first year of life. Methods: We studied 82 children who were enrolled in a birth cohort study of inner-city children with at least 1 parent with allergy or asthma. We cultured cord blood monocytes and assessed IFNG and CCL5 mRNA production at 24 hours after inoculation with respiratory syncytial virus. We also monitored the frequency of acute respiratory tract illness at 3-month intervals and analyzed nasal lavage samples for respiratory tract viruses at the time of illness during the first year. Results: Respiratory tract infection was reported for 88% of subjects, and respiratory tract viruses were recovered in 74% of symptomatic children. We observed a wide range of antiviral responses in cord blood monocytes across the population. Furthermore, a decrease in production of IFNG (but not CCL5) mRNA in response to respiratory syncytial virus infection of monocytes was associated with a significant increase in the frequency of upper respiratory tract infections (r = -0.42, P < .001) and the prevalence of ear and sinus infections, pneumonias, and respiratory-related hospitalizations. Conclusion: Individual variations in the innate immune response to respiratory tract viruses are detectable even at birth, and these differences predict the susceptibility to acute respiratory tract illness during the first year of life. (J Allergy Clin Immunol 2012;129:1267-73.)	[Sumino, Kaharu; Tucker, Jennifer; Shahab, Muhammad; Holtzman, Michael J.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Bloomberg, Gordon R.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Holtzman, Michael J.] Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; [Jaffee, Katy F.; Visness, Cynthia M.] Rho Fed Syst, Chapel Hill, NC USA; [Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison	Holtzman, MJ (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8052,660 Euclid Ave, St Louis, MO 63110 USA.	holtzmanm@wustl.edu	Shahab, Muhammad/F-9132-2015; Sumino, Kaharu/AAA-2028-2021	Sumino, Kaharu/0000-0002-6214-2966	National Institutes of Health (National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute); National Institutes of Health (NIH); AstraZeneca; NIH/National Institute of Allergy and Infectious Diseases; Hoffman-La Roche; Forest Laboratories; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070489] Funding Source: NIH RePORTER	National Institutes of Health (National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AstraZeneca(AstraZeneca); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Hoffman-La Roche; Forest Laboratories; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute).; Disclosure of potential conflict of interest: K. Sumino has received research support from the National Institutes of Health (NIH). J. E. Gern is on the scientific advisory board for and owns stock options in 3V Biosciences; has consulted for Centocor, Boeheringer Ingelheim, GlaxoSmithKline, Biota, MedImmune, and Theraclone; and has received research support from AstraZeneca. G. R. Bloomberg has received research support from the NIH/National Institute of Allergy and Infectious Diseases. M. J. Holtzman has consulted for and received research support from Hoffman-La Roche and Forest Laboratories. The rest of the authors declare that they have no relevant conflicts of interest.	Aberle JH, 2004, CLIN EXP IMMUNOL, V137, P146, DOI 10.1111/j.1365-2249.2004.02504.x; Amanatidou V, 2008, PEDIATR INFECT DIS J, V27, P38, DOI 10.1097/INF.0b013e31814d4e42; Ball TM, 2002, ARCH PEDIAT ADOL MED, V156, P121, DOI 10.1001/archpedi.156.2.121; Broughton S, 2005, THORAX, V60, P1039, DOI 10.1136/thx.2004.037853; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Cheung DS, 2010, J IMMUNOL, V185, P4983, DOI 10.4049/jimmunol.1002456; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Domachowske JB, 1999, CLIN MICROBIOL REV, V12, P298, DOI 10.1128/CMR.12.2.298; Durbin JE, 2002, J IMMUNOL, V168, P2944, DOI 10.4049/jimmunol.168.6.2944; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gold DR, 2009, J ALLERGY CLIN IMMUN, V124, P1078, DOI 10.1016/j.jaci.2009.08.021; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Grayson MH, 2007, J IMMUNOL, V179, P1438, DOI 10.4049/jimmunol.179.3.1438; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Holtzman MJ, 2011, CURR OPIN IMMUNOL, V23, P487, DOI 10.1016/j.coi.2011.05.010; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Koga T, 1999, P NATL ACAD SCI USA, V96, P5680, DOI 10.1073/pnas.96.10.5680; Legg JP, 2003, AM J RESP CRIT CARE, V168, P633, DOI 10.1164/rccm.200210-1148OC; Lo MS, 2005, J VIROL, V79, P9315, DOI 10.1128/JVI.79.14.9315-9319.2005; Ly NP, 2007, PEDIATRICS, V119, pE171, DOI 10.1542/peds.2006-0524; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; Shornick LP, 2008, J IMMUNOL, V180, P3319, DOI 10.4049/jimmunol.180.5.3319; Shreffler WG, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-29; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Spann KM, 2004, J VIROL, V78, P4363, DOI 10.1128/JVI.78.8.4363-4369.2004; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tyner JW, 2005, NAT MED, V11, P1180, DOI 10.1038/nm1303; World Health Organization, 2005, WORLD HLTH REP 2005, P106; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC	38	30	31	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1267	U380		10.1016/j.jaci.2012.02.033	http://dx.doi.org/10.1016/j.jaci.2012.02.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22460071	Green Published, Green Accepted, Bronze			2022-12-18	WOS:000303418000013
J	Meyer-Bahlburg, A; Renner, ED; Rylaarsdam, S; Reichenbach, J; Schimke, LF; Marks, A; Tcheurekdjian, H; Hostoffer, R; Brahmandam, A; Torgerson, TR; Belohradsky, BH; Rawlings, DJ; Ochs, HD				Meyer-Bahlburg, Almut; Renner, Ellen D.; Rylaarsdam, Stacey; Reichenbach, Janine; Schimke, Lena F.; Marks, Amy; Tcheurekdjian, Haig; Hostoffer, Robert; Brahmandam, Archana; Torgerson, Troy R.; Belohradsky, Bernd H.; Rawlings, David J.; Ochs, Hans D.			Heterozygous signal transducer and activator of transcription 3 mutations in hyper-IgE syndrome result in altered B-cell maturation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; RESPONSES; LYMPHOMA		[Meyer-Bahlburg, Almut; Renner, Ellen D.; Rylaarsdam, Stacey; Brahmandam, Archana; Torgerson, Troy R.; Rawlings, David J.; Ochs, Hans D.] Seattle Childrens Res Inst, Seattle, WA 98101 USA; [Renner, Ellen D.; Torgerson, Troy R.; Rawlings, David J.; Ochs, Hans D.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Rawlings, David J.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA; [Renner, Ellen D.; Schimke, Lena F.; Belohradsky, Bernd H.] Univ Munich, Univ Childrens Hosp, Dr von Haunersches Kinderspital, Munich, Germany; [Reichenbach, Janine] Univ Childrens Hosp, Div Immunol Hematol & BMT, Zurich, Switzerland; [Reichenbach, Janine] Childrens Res Ctr, Zurich, Switzerland; [Marks, Amy] Univ Hosp, Richmond Med Ctr, Dept Pediat, Cleveland, OH USA; [Tcheurekdjian, Haig; Hostoffer, Robert] Allergy Immunol Associates Inc, Cleveland, OH USA; [Tcheurekdjian, Haig; Hostoffer, Robert] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Tcheurekdjian, Haig; Hostoffer, Robert] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Meyer-Bahlburg, Almut] Hannover Med Sch, Dept Pediat Pneumol Allergol & Neonatol, D-3000 Hannover, Germany	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University Children's Hospital Zurich; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University; Hannover Medical School	Meyer-Bahlburg, A (corresponding author), Seattle Childrens Res Inst, Seattle, WA 98101 USA.	meyer-bahlburg.almut@mh-hannover.de; Ellen.Renner@med.lmu.de	Renner, Ellen/R-7168-2016; Reichenbach, Janine/U-2171-2018; Rawlings, David/CAI-4751-2022	Renner, Ellen/0000-0001-9816-8538; Reichenbach, Janine/0000-0002-9008-1312; Hostoffer, Robert/0000-0001-8296-3588	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037091, R01HD017427, R37HD017427] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 17427-43, HD037091, R01 HD037091] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Higashi N, 2002, CLIN EXP ALLERGY, V32, P1484, DOI 10.1046/j.1365-2745.2002.01507.x; Higashi N, 2010, J ALLERGY CLIN IMMUN, V125, P1084, DOI 10.1016/j.jaci.2009.12.977; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Jee HM, 2010, CLIN EXP DERMATOL, V35, P593, DOI 10.1111/j.1365-2230.2009.03635.x; Kuo SH, 2008, BLOOD, V112, P2927, DOI 10.1182/blood-2008-02-137513; Leonard GD, 2004, LEUKEMIA LYMPHOMA, V45, P2521, DOI 10.1080/10428190400004463; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; MITA H, 1988, J CHROMATOGR-BIOMED, V430, P299, DOI 10.1016/S0378-4347(00)83165-5; Mita H, 2001, ALLERGY, V56, P1061; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; Schimke LF, 2010, J ALLERGY CLIN IMMUN, V126, P611, DOI 10.1016/j.jaci.2010.06.029; Sellam J, 2007, ANN RHEUM DIS, V66, P790, DOI 10.1136/ard.2006.065656; SHEERIN KA, 1991, J ALLERGY CLIN IMMUN, V87, P803, DOI 10.1016/0091-6749(91)90126-9; Speckmann C, 2008, CLIN IMMUNOL, V129, P448, DOI 10.1016/j.clim.2008.08.002	14	30	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					559	562		10.1016/j.jaci.2011.09.017	http://dx.doi.org/10.1016/j.jaci.2011.09.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22030463	Bronze			2022-12-18	WOS:000299951700039
J	Sorkness, RL; Teague, WG; Penugonda, M; Fitzpatrick, AM				Sorkness, Ronald L.; Teague, W. Gerald; Penugonda, Madhuri; Fitzpatrick, Anne M.		Natl Heart Lung Blood Inst	Sex dependence of airflow limitation and air trapping in children with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LUNG-FUNCTION; OBSTRUCTION; PROGRAM; AGE		[Sorkness, Ronald L.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Sorkness, Ronald L.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA; [Sorkness, Ronald L.] Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; [Teague, W. Gerald] Univ Virginia, Dept Pediat, Charlottesville, VA USA; [Penugonda, Madhuri; Fitzpatrick, Anne M.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Fitzpatrick, Anne M.] Childrens Healthcare Atlanta Ctr Lung Biol, Atlanta, GA USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Virginia; Emory University; Children's Healthcare of Atlanta (CHOA)	Sorkness, RL (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.	anne.fitzpatrick@emory.edu		Fitzpatrick, Anne/0000-0002-2933-5926	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069170, R01HL069116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR012021] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000454] Funding Source: Medline; NHLBI NIH HHS [R01 HL069170-10, R01 HL069116, R01 HL69116, R01 HL69170, R01 HL069116-10, R01 HL069170, U10 HL109250] Funding Source: Medline; NINR NIH HHS [R01 NR012021, R01 NR012021-01] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Corazza GR, 2007, CLIN GASTROENTEROL H, V5, P838, DOI 10.1016/j.cgh.2007.03.019; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Manzke H, 2001, EUR J PEDIATR, V160, P300, DOI 10.1007/s004310100724; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204	9	30	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1073	1074		10.1016/j.jaci.2010.12.1079	http://dx.doi.org/10.1016/j.jaci.2010.12.1079			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21310476	Green Accepted			2022-12-18	WOS:000289055800036
J	Busse, WW; Peters, SP; Fenton, MJ; Mitchell, H; Bleecker, ER; Castro, M; Wenzel, S; Erzurum, SC; Fitzpatrick, AM; Teague, WG; Jarjour, N; Moore, WC; Sumino, K; Simeone, S; Ratanamaneechat, S; Penugonda, M; Gaston, B; Ross, TM; Sigelman, S; Schiepan, JR; Zaccaro, DJ; Crevar, CJ; Carter, DM; Togias, A				Busse, William W.; Peters, Stephen P.; Fenton, Matthew J.; Mitchell, Herman; Bleecker, Eugene R.; Castro, Mario; Wenzel, Sally; Erzurum, Serpil C.; Fitzpatrick, Anne M.; Teague, W. Gerald; Jarjour, Nizar; Moore, Wendy C.; Sumino, Kaharu; Simeone, Scott; Ratanamaneechat, Suphagaphan; Penugonda, Madhuri; Gaston, Benjamin; Ross, Ted M.; Sigelman, Steve; Schiepan, Joella R.; Zaccaro, Daniel J.; Crevar, Corey J.; Carter, Donald M.; Togias, Alkis			Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						H1N1; asthma; influenza; vaccine; seroprotection; severe asthma	CHILDREN; SAFETY; ADULTS; TRIAL; AGE; IMMUNOGENICITY; ADOLESCENTS; EFFICACY; OLDER	Background: Asthma was the most common comorbidity of patients hospitalized with 2009 H1N1 influenza. Objective: We sought to assess the immunogenicity and safety of an unadjuvanted, inactivated 2009 H1N1 vaccine in patients with severe versus mild-to-moderate asthma. Methods: We conducted an open-label study involving 390 participants (age, 12-79 years) enrolled in October-November 2009. Severe asthma was defined as need for 880 mu g/d or more of inhaled fluticasone equivalent, systemic corticosteroids, or both. Within each severity group, participants were randomized to receive intramuscularly 15 or 30 mu g of 2009 H1N1 vaccine twice 21 days apart. Immunogenicity end points were seroprotection (hemagglutination inhibition assay titer >= 40) and seroconversion (4-fold or greater titer increase). Safety was assessed through local and systemic reactogenicity, asthma exacerbations, and pulmonary function. Results: In patients with mild-to-moderate asthma (n =217), the 2009 H1N1 vaccine provided equal seroprotection 21 days after the first immunization at the 15-mu g (90.6%; 95% CI, 83.5% to 95.4%) and 30-mu g (95.3%; 95% CI, 89.4% to 98.5%) doses. In patients with severe asthma (n = 173), seroprotection 21 days after the first immunization was 77.9% (95% CI, 67.7% to 86.1%) and 94.1% (95% CI, 86.8% to 98.1%) at the 15- and 30-mg doses, respectively (P = .004). The second vaccination did not provide further increases in seroprotection. Participants with severe asthma who are older than 60 years showed the lowest seroprotection (44.4% at day 21) with the 15-mg dose but had adequate seroprotection with 30 mg. The 2 dose groups did not differ in seroconversion rates. There were no safety concerns. Conclusion: Monovalent inactivated 2009 H1N1 pandemic influenza vaccine was safe and provided overall seroprotection as a surrogate of efficacy. In patients older than 60 years with severe asthma, a 30-mg dose might be more appropriate. (J Allergy Clin Immunol 2011;127:130-7.)	[Busse, William W.; Jarjour, Nizar] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Peters, Stephen P.; Bleecker, Eugene R.; Moore, Wendy C.] Wake Forest Univ, Hlth Sci Ctr Genom & Personalized Med Res, Winston Salem, NC 27109 USA; [Fenton, Matthew J.; Sigelman, Steve; Togias, Alkis] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Castro, Mario; Sumino, Kaharu] Washington Univ, Sch Med, St Louis, MO USA; [Mitchell, Herman; Schiepan, Joella R.; Zaccaro, Daniel J.] Rho Fed Syst Div Inc, Chapel Hill, NC USA; [Wenzel, Sally; Simeone, Scott] Univ Pittsburgh, Asthma Inst, Pittsburgh, PA USA; [Erzurum, Serpil C.; Ratanamaneechat, Suphagaphan] Cleveland Clin, Cleveland, OH 44106 USA; [Fitzpatrick, Anne M.; Penugonda, Madhuri] Emory Univ, Atlanta, GA 30322 USA; [Teague, W. Gerald; Gaston, Benjamin] Univ Virginia, Childrens Hosp, Div Resp Med, Charlottesville, VA USA; [Ross, Ted M.; Crevar, Corey J.; Carter, Donald M.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA	University of Wisconsin System; University of Wisconsin Madison; Wake Forest University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cleveland Clinic Foundation; Emory University; University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Busse, WW (corresponding author), Univ Wisconsin Hosp & Clin, K4-910 CSC,MC 9988,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu	Sumino, Kaharu/AAA-2028-2021	Sumino, Kaharu/0000-0002-6214-2966; Fitzpatrick, Anne/0000-0002-2933-5926	US National Institutes of Health (NIH) through National Institute of Allergy and Infectious Diseases (NIAID) [3 R01 HL069116-09S1]; Rho, Inc; NIAID [NO1-AI-25482]; NIH [RO1 HL69170, HL081064]; National Center for Research Resources [1UL1RR024989, UL1RR025008]; Novartis; AstraZeneca; GlaxoSmithKline; MedImmune; Ception; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); NIH/National Heart, Lung, and Blood Institute (NHLBI); Elsevier; NIH; Genentech; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989, UL1RR025008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069170, R01HL069116, P01HL081064] Funding Source: NIH RePORTER	US National Institutes of Health (NIH) through National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Rho, Inc; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Novartis(Novartis); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Ception; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Elsevier; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech(Roche HoldingGenentech); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funding for this study was provided by the US National Institutes of Health (NIH) through a supplement contribution from the National Institute of Allergy and Infectious Diseases (NIAID) to the National Heart, Lung, and Blood Institute (NHLBI)-funded grant 3 R01 HL069116-09S1. Rho, Inc, the Data and Statistical Coordinating Center for this study, was funded by NIAID contract number NO1-AI-25482. Additional funds were provided by the NIH Research Project grants RO1 HL69170 and HL081064 and by the National Center for Research Resources under grants 1UL1RR024989 and UL1RR025008. NIAID and NHLBI scientists and project managers were involved in the design of the study and the writing of the protocol, as well as in study medical monitoring, data analysis, and manuscript preparation. Vaccine was purchased from Novartis Vaccines and Diagnostics Ltd by the US Government BioMedical Advanced Research and Development Authority (BARDA), which coordinated the 2009 H1N1 pandemic influenza vaccination in the United Sates. BARDA had no other role in this study.; W. W. Busse is on advisory boards for Altair, Amgen, Centocor, GlaxoSmithKline, Merck, Pfizer, Wyeth, and Johnson & Johnson; has consultant arrangements with AstraZeneca, Boehringer Ingelheim, Novartis, TEVA, and GlaxoSmithKline; is a speaker for Merck; and receives research support from Novartis, AstraZeneca, GlaxoSmithKline, MedImmune, Ception, the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID), and the NIH/National Heart, Lung, and Blood Institute (NHLBI). S. P. Peters receives research support from the NIH/NHLBI and Novartis. H. Mitchell receives research support from the NIH. E. R. Bleecker receives research support from the NIH/NHLBI and Novartis. M. Castro has consultant arrangements with Electrocore, NKTT, Schering-Plough, Asthmatx, and Cephalon; is on the advisory board for Genentech; is a speaker for AstraZeneca, Boehringer Ingelheim, Pfizer, Merck, and GlaxoSmithKline; has received institutional grant support from Asthmatx, Amgen, Ception, Genentech, MedImmune, Merck, Novartis, the NIH, and GlaxoSmithKline; has received royalties from Elsevier; and has received research support from the NIH. W. G. Teague is a speaker for Merck and receives research support from the NIH. N. Jarjour has consultant arrangements with Asthmatx and Genentech; receives research support from GlaxoSmithKline, MedImmune, and Genentech; and receives honoraria from Merck. W. C. Moore receives research support from the NHLBI. K. Sumino receives research support from the NIH and the VA. B. Gaston receives research support from the NIH. J. R. Schiepan receives research support from the NIH. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341; [Anonymous], FLUMIST INFL VACC LI; [Anonymous], 2010, 2009 H1N1 FLU UND HL; Bergen R, 2004, PEDIATR INFECT DIS J, V23, P138, DOI 10.1097/01.inf.0000109392.96411.4f; Bloom Barbara, 2009, Vital Health Stat 10, P1; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; Centers for Disease Control and Prevention, 2010, CDC EST 2009 H1N1 IN; Clark TW, 2009, NEW ENGL J MED, V361, P2424, DOI 10.1056/NEJMoa0907650; Department of health and human services. Food and drug administration. Center for biologics evaluation and research, 2007, GUID IND CLIN DAT NE; Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790; Fiore Anthony E., 2008, Morbidity and Mortality Weekly Report, V57, P1; Fleming DM, 2006, PEDIATR INFECT DIS J, V25, P860, DOI 10.1097/01.inf.0000237797.14283.cf; Glezen WP, 2006, J ALLERGY CLIN IMMUN, V118, P1199, DOI 10.1016/j.jaci.2006.08.032; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Greenberg ME, 2009, NEW ENGL J MED, V361, P2405, DOI 10.1056/NEJMoa0907413; Hanania NA, 2004, J ALLERGY CLIN IMMUN, V113, P717, DOI 10.1016/j.jaci.2003.12.584; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; KEITEL WA, 1988, AM J EPIDEMIOL, V127, P353, DOI 10.1093/oxfordjournals.aje.a114809; Keitel WA, 2006, ARCH INTERN MED, V166, P1121, DOI 10.1001/archinte.166.10.1121; McElhaney JE, 2005, VACCINE, V23, pS10, DOI 10.1016/j.vaccine.2005.04.019; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; National Heart Lung and Blood Institute, 2007, EPR3 NAT HEART LUNG; Oh CE, 2010, VACCINE, V28, P5857, DOI 10.1016/j.vaccine.2010.06.060; Pleis John R, 2009, Vital Health Stat 10, P1; Plennevaux E, 2010, LANCET, V375, P41, DOI 10.1016/S0140-6736(09)62026-2; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Treanor J, 2002, VACCINE, V20, P1099, DOI 10.1016/S0264-410X(01)00440-6; World Health Organization, WHO MAN AN INFL DIAG; Zhu FC, 2009, NEW ENGL J MED, V361, P2414, DOI 10.1056/NEJMoa0908535	32	30	30	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					130	U215		10.1016/j.jaci.2010.11.014	http://dx.doi.org/10.1016/j.jaci.2010.11.014			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21145578	Green Accepted			2022-12-18	WOS:000285917300019
J	Sivaprasad, U; Askew, DJ; Ericksen, MB; Gibson, AM; Stier, MT; Brandt, EB; Bass, SA; Daines, MO; Chakir, J; Stringer, KF; Wert, SE; Whitsett, JA; Le Cras, TD; Wills-Karp, M; Silverman, GA; Hershey, GKK				Sivaprasad, Umasundari; Askew, David J.; Ericksen, Mark B.; Gibson, Aaron M.; Stier, Matthew T.; Brandt, Eric B.; Bass, Stacey A.; Daines, Michael O.; Chakir, Jamila; Stringer, Keith F.; Wert, Susan E.; Whitsett, Jeffrey A.; Le Cras, Timothy D.; Wills-Karp, Marsha; Silverman, Gary A.; Hershey, Gurjit K. Khurana			A nonredundant role for mouse Serpinb3a in the induction of mucus production in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Goblet cells; SPDEF; IL-13; hyperplasia	BRONCHIAL EPITHELIAL-CELLS; CARCINOMA-RELATED ANTIGEN; CATHEPSIN-G; GENE; SUPPRESSION; INTERLEUKIN-13; SECRETION; CHILDREN; ALLERGEN; SERINE	Background: Asthma is a major public health burden worldwide. Studies from our group and others have demonstrated that SERPINB3 and SERPINB4 are induced in patients with asthma; however, their mechanistic role in asthma has yet to be determined. Objective: To evaluate the role of Serpin3a, the murine homolog of SERPINB3 and SERPINB4, in asthma. Methods: We studied wild-type Balb/c and Serpinb3a-null mice in house dust mite or IL-13-induced asthma models and evaluated airway hyperresponsiveness, inflammation, and goblet cell hyperplasia. Results: Airway hyperresponsiveness and goblet cell hyperplasia were markedly attenuated in the Serpinb3a-null mice compared with the wild-type mice after allergen challenge, with minimal effects on inflammation. Expression of sterile alpha motif pointed domain containing v-ets avian erythroblastosis virus E26 oncogene homolog transcription factor (SPDEF), a transcription factor that mediates goblet cell hyperplasia, was decreased in the absence of Serpinb3a. IL13-treated Serpinb3a-null mice showed attenuated airway hyperresponsiveness, inflammation, and mucus production. Conclusion: Excessive mucus production and mucus plugging are key pathologic features of asthma, yet the mechanisms responsible for mucus production are not well understood. Our data reveal a novel nonredundant role for Serpinb3a in mediating mucus production through regulation of SPDEF expression. This pathway may be used to target mucus hypersecretion effectively. (J Allergy Clin Immunol 2011;127:254-61.)	[Sivaprasad, Umasundari; Ericksen, Mark B.; Gibson, Aaron M.; Stier, Matthew T.; Brandt, Eric B.; Bass, Stacey A.; Hershey, Gurjit K. Khurana] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Asthma Res, Cincinnati, OH 45229 USA; [Stringer, Keith F.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Pathol, Cincinnati, OH 45229 USA; [Wert, Susan E.; Whitsett, Jeffrey A.; Le Cras, Timothy D.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Neonatol Pulm & Perinatal Biol, Cincinnati, OH 45229 USA; [Wills-Karp, Marsha] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Immunobiol, Cincinnati, OH 45229 USA; [Hershey, Gurjit K. Khurana] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Askew, David J.; Silverman, Gary A.] Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; [Daines, Michael O.] Univ Arizona, Inst Bio5, Arizona Resp Ctr, Tucson, AZ USA; [Chakir, Jamila] Hop Laval, Ctr Rech, Dept Med, Laval, PQ, Canada	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Arizona; Laval University	Hershey, GKK (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Asthma Res, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org	Silverman, Gary/AAJ-1269-2020	Khurana Hershey, Gurjit/0000-0001-6663-977X; Daines, Michael/0000-0003-2464-9034; Brandt, Eric/0000-0003-0617-4100; Le Cras, Timothy/0000-0001-8538-2703	NIH [U19AI70235-01, AI58157-01]; American Heart Association [740069N, PO1 HL076383, U19AI070235, NIH DK081422]; Cystic Fibrosis Foundation; NIH; American Heart Association;  [HL090156]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076383, R01HL095580, R01HL090156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083403, U19AI070235, R01AI058157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081422] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by NIH U19AI70235-01 and AI58157-01 (G. K. K. H.), American Heart Association grant 740069N (T. D. L. C.), PO1 HL076383 and U19AI070235 (M.W.-K.), NIH DK081422 and Cystic Fibrosis Foundation grant (G. A. S.), and HL090156 (J.A.W.).; G. K. Khurana Hershey receives research support from the NIH. M. O. Daines receives research support from the NIH. S. E. Wert receives grant support from the NIH. T. D. Le Cras receives research support from the NIH and the American Heart Association. M. Wills-Karp receives research support from the NIH. The rest of the authors have declared that they have no conflict of interest.	Al-Khunaizi M, 2002, BIOCHEMISTRY-US, V41, P3189, DOI 10.1021/bi015999x; [Anonymous], 2007, J ALLERGY CLIN IMMUN, V120, pS94, DOI 10.1016/j.jaci.2007.09.029; Askew DJ, 2004, GENOMICS, V84, P166, DOI 10.1016/j.ygeno.2004.01.014; Askew DJ, 2004, GENOMICS, V84, P176, DOI 10.1016/j.ygeno.2004.01.015; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Evans CM, 2009, PHARMACOL THERAPEUT, V121, P332, DOI 10.1016/j.pharmthera.2008.11.001; Guajardo JR, 2005, J ALLERGY CLIN IMMUN, V115, P243, DOI 10.1016/j.jaci.2004.10.032; Hamada K, 2001, BBA-GENE STRUCT EXPR, V1518, P124, DOI 10.1016/S0167-4781(01)00174-9; Hashimoto K, 2005, TUMOR BIOL, V26, P165, DOI 10.1159/000086949; He SH, 2004, ACTA PHARMACOL SIN, V25, P827; Izuhara K, 2003, CLIN CHEM LAB MED, V41, P860, DOI 10.1515/CCLM.2003.130; Katagiri C, 2006, J CELL BIOL, V172, P983, DOI 10.1083/jcb.200508064; KATO H, 1977, CANCER, V40, P1621, DOI 10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I; Kawashima H, 2000, PEDIATR INT, V42, P448, DOI 10.1046/j.1442-200x.2000.01253.x; Law RHP, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-216; Leverkoehne I, 2002, J HISTOCHEM CYTOCHEM, V50, P829, DOI 10.1177/002215540205000609; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Mattoli S, 2001, ENVIRON HEALTH PERSP, V109, P553, DOI 10.2307/3454668; Mejias Asuncion, 2005, Pediatr Infect Dis J, V24, pS189, DOI 10.1097/01.inf.0000188196.87969.9a; Mitsuishi K, 2005, CLIN EXP ALLERGY, V35, P1327, DOI 10.1111/j.1365-2222.2005.02353.x; Murakami A, 2006, INT J ONCOL, V29, P1231; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Nishi N, 2005, ANN ALLERG ASTHMA IM, V94, P391, DOI 10.1016/S1081-1206(10)60993-3; Oh Jae-Won, 2006, Allergol Int, V55, P369; Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Ray R, 2005, J BIOL CHEM, V280, P9761, DOI 10.1074/jbc.C400581200; Sakata Y, 2004, J BIOL CHEM, V279, P5081, DOI 10.1074/jbc.M311585200; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SOMMERHOFF CP, 1990, J CLIN INVEST, V85, P682, DOI 10.1172/JCI114492; Uemura Y, 2000, INT J CANCER, V89, P368, DOI 10.1002/1097-0215(20000720)89:4<368::AID-IJC9>3.0.CO;2-6; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972	36	30	30	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					254	U418		10.1016/j.jaci.2010.10.009	http://dx.doi.org/10.1016/j.jaci.2010.10.009			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21126757	Green Accepted			2022-12-18	WOS:000285917300036
J	Qi, YL; Operario, DJ; Oberholzer, CM; Kobie, JJ; Looney, RJ; Georas, SN; Mosmann, TR				Qi, Yilin; Operario, Darwin J.; Oberholzer, Christopher M.; Kobie, James J.; Looney, R. John; Georas, Steve N.; Mosmann, Tim R.			Human basophils express amphiregulin in response to T cell-derived IL-3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophils; amphiregulin; IL-3	EPIDERMAL-GROWTH-FACTOR; HUMAN MAST-CELLS; MAMMARY-GLAND DEVELOPMENT; MIXED LEUKOCYTE-CULTURES; HUMAN PERIPHERAL-BLOOD; HISTAMINE-RELEASE; EPITHELIAL-CELLS; DISTINCT ROLES; PRODUCE IL-4; RECEPTOR	Background: Amphiregulin, a member of the epidermal growth factor family, is expressed by activated mouse T H 2 cells. Amphiregulin produced by mouse hematopoietic cells contributes to the elimination of a nematode infection by a type 2 effector response. Objective: To identify the human peripheral blood cell population expressing amphiregulin. Methods: Amphiregulin-expressing cells were identified by flow cytometry of cell surface markers and histologic staining. Histamine and amphiregulin in supernatants were measured by enzyme immunoassay. Quantitative real-time PCR was used to measure mRNA expression. Results: Stimulation of human PBMCs by anti-CD31+ anti-CD28 antibodies induced expression of amphiregulin mRNA and protein by a non-T-cell population. The amphiregulin-producing cells were basophils, as judged by morphology and expression of CD203c and CD123 ( IL-3 receptor a chain). Activated mouse basophils also produced amphiregulin. Amphiregulin expression by basophils in response to anti-TCR stimulation required IL-3 produced by T cells, and IL-3 alone induced high levels of amphiregulin expression by purified basophils. Amphiregulin was expressed at much higher levels when human basophils were stimulated by IL-3 than by IgE cross-linking, whereas the opposite was true for IL-4 expression and histamine release. Heparin-binding epidermal growth factor-like growth factor was also expressed by IL-3-stimulated human basophils. PBMCs from human subjects with asthma contained significantly higher numbers of basophils able to produce amphiregulin compared with controls with or without allergy. Conclusion: IL-3 can induce basophils to express high levels of amphiregulin, which may contribute to tissue remodeling during type 2 immune responses such as asthma. (J Allergy Clin Immunol 2010;126:1260-6.)	[Qi, Yilin; Operario, Darwin J.; Oberholzer, Christopher M.; Kobie, James J.; Mosmann, Tim R.] Univ Rochester, Med Ctr, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY 14642 USA; [Looney, R. John; Georas, Steve N.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Mosmann, TR (corresponding author), Univ Rochester, Med Ctr, David H Smith Ctr Vaccine Biol & Immunol, 601 Elmwood Ave,Box 609, Rochester, NY 14642 USA.	Tim_Mosmann@urmc.rochester.edu			American Asthma Foundation; NIH [R24 AI054953]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R24AI054953] Funding Source: NIH RePORTER	American Asthma Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the American Asthma Foundation (formerly the Sandler Program in Asthma Research) and NIH R24 AI054953.; T. R. Mosmann receives research support from the American Asthma Foundation and the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Agis H, 1996, IMMUNOLOGY, V87, P535, DOI 10.1046/j.1365-2567.1996.493578.x; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; Buhring HJ, 2004, INT ARCH ALLERGY IMM, V133, P317, DOI 10.1159/000077351; Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104; Cliffe LJ, 2005, SCIENCE, V308, P1463, DOI 10.1126/science.1108661; DELPRETE G, 1992, ALLERGY, V47, P450; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Enomoto Y, 2009, J ALLERGY CLIN IMMUN, V124, P913, DOI 10.1016/j.jaci.2009.08.044; Hauswirth AW, 2007, INT J IMMUNOPATH PH, V20, P267, DOI 10.1177/039463200702000207; Heijink IH, 2006, PHARMACOL THERAPEUT, V112, P489, DOI 10.1016/j.pharmthera.2006.05.005; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Johansson CC, 2004, ENDOCRINOLOGY, V145, P5177, DOI 10.1210/en.2004-0232; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kim KW, 2009, CHEST, V136, P805, DOI 10.1378/chest.08-2972; Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Matsumoto K, 2009, INT ARCH ALLERGY IMM, V149, P39, DOI 10.1159/000210652; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; OKAYAMA Y, 1993, CLIN EXP ALLERGY, V23, P901, DOI 10.1111/j.1365-2222.1993.tb00274.x; Okumura S, 2005, J ALLERGY CLIN IMMUN, V115, P272, DOI 10.1016/j.jaci.2004.10.004; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Redrup AC, 1998, J IMMUNOL, V160, P1957; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schroeder JT, 2009, J IMMUNOL, V182, P2432, DOI 10.4049/jimmunol.0801782; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Wang SW, 2005, J ALLERGY CLIN IMMUN, V115, P287, DOI 10.1016/j.jaci.2004.11.037; Warner SM, 2008, CURR OPIN ALLERGY CL, V8, P44, DOI 10.1097/ACI.0b013e3282f3b5cb; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Yoshimura C, 2002, J ALLERGY CLIN IMMUN, V109, pS272, DOI 10.1016/S0091-6749(02)81965-0; Zaiss DM, 2006, SCIENCE, V314, P1746, DOI 10.1126/science.1133715	39	30	30	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1260	U294		10.1016/j.jaci.2010.08.040	http://dx.doi.org/10.1016/j.jaci.2010.08.040			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21036386	Green Accepted, Bronze			2022-12-18	WOS:000284947800026
J	Jin, Y; Hu, DL; Peterson, EL; Eng, C; Levin, AM; Wells, K; Beckman, K; Kumar, R; Seibold, MA; Karungi, G; Zoratti, A; Gaggin, J; Campbell, J; Galanter, J; Chapela, R; Rodriguez-Santana, JR; Watson, HG; Meade, K; LeNoir, M; Rodriguez-Cintron, W; Avila, PC; Lanfear, DE; Burchard, EG; Williams, LK				Jin, Ying; Hu, Donglei; Peterson, Edward L.; Eng, Celeste; Levin, Albert M.; Wells, Karen; Beckman, Kenneth; Kumar, Rajesh; Seibold, Max A.; Karungi, Gloria; Zoratti, Amanda; Gaggin, John; Campbell, Janis; Galanter, Joshua; Chapela, Rocio; Rodriguez-Santana, Jose R.; Watson, H. Geoffrey; Meade, Kelley; LeNoir, Michael; Rodriguez-Cintron, William; Avila, Pedro C.; Lanfear, David E.; Burchard, Esteban G.; Williams, L. Keoki			Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; inhaled corticosteroids; dual-specificity phosphatase 1; DUSP1; corticosteroid responsiveness	BRONCHODILATOR RESPONSIVENESS; GENETIC ASSOCIATION; MAP KINASE; GLUCOCORTICOID REGULATION; ALVEOLAR MACROPHAGES; AFRICAN-AMERICANS; PUERTO-RICANS; CORTICOSTEROIDS; EXPRESSION; DEXAMETHASONE	Background: Inhaled corticosteroids (ICSs) are considered firstline treatment for persistent asthma, yet there is significant variability in treatment response. Dual-specificity phosphatase 1 (DUSP1) appears to mediate the anti-inflammatory action of corticosteroids. Objective: We sought to determine whether variants in the DUSP1 gene are associated with clinical response to ICS treatment. Methods: Study participants with asthma were drawn from the following multiethnic cohorts: the Genetics of Asthma in Latino Americans (GALA) study; the Study of African Americans, Asthma, Genes & Environments (SAGE); and the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE). We screened GALA study participants for genetic variants that modified the relationship between ICS use and bronchodilator response. We then replicated our findings in SAGE and SAPPHIRE participants. In a group of SAPPHIRE participants treated with ICSs for 6 weeks, we examined whether a DUSP1 polymorphism was associated with changes in FEV1 and self-reported asthma control. Results: The DUSP1 polymorphisms rs881152 and rs34507926 localized to different haplotype blocks and appeared to significantly modify the relationship between ICS use and bronchodilator response among GALA study participants. This interaction was also seen for rs881152 among SAPPHIRE but not SAGE participants. Among the group of SAPPHIRE participants prospectively treated with ICSs for 6 weeks, rs881152 genotype was significantly associated with changes in self-reported asthma control but not FEV1. Conclusion: DUSP1 polymorphisms were associated with clinical response to ICS therapy and therefore might be useful in the future to identify asthmatic patients more likely to respond to this controller treatment. (J Allergy Clin Immunol 2010;126:618-25.)	[Williams, L. Keoki] Henry Ford Hosp, Ctr Hlth Serv Res, Detroit, MI 48202 USA; [Jin, Ying; Karungi, Gloria; Zoratti, Amanda; Gaggin, John; Campbell, Janis; Lanfear, David E.] Ctr Hlth Serv Res, Henry Ford Hlth Syst, Detroit, MI USA; [Jin, Ying] Wayne State Univ, Sch Med, Detroit, MI USA; [Hu, Donglei; Eng, Celeste; Galanter, Joshua; Burchard, Esteban G.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA; [Peterson, Edward L.; Levin, Albert M.; Wells, Karen; Williams, L. Keoki] Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI USA; [Beckman, Kenneth] Univ Minnesota, Biomed Genom Ctr, Minneapolis, MN USA; [Kumar, Rajesh] NW Univ Feinberg, Sch Med, Childrens Mem Hosp, Dept Pediat, Chicago, IL USA; [Seibold, Max A.] Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; [Chapela, Rocio] Inst Nacl Enfermedades Respiratorias, Mexico City, DF, Mexico; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, CSP, San Juan, PR USA; [Watson, H. Geoffrey] James Watson Wellness Ctr, Oakland, CA USA; [Meade, Kelley] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; [LeNoir, Michael] Bay Area Pediat, Oakland, CA USA; [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR USA; [Avila, Pedro C.] Northwestern Univ, Div Allergy Immunol, Chicago, IL 60611 USA; [Lanfear, David E.; Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Wayne State University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Henry Ford Health System; Henry Ford Hospital; University of Minnesota System; University of Minnesota Twin Cities; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; National Jewish Health; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Northwestern University; Henry Ford Health System; Henry Ford Hospital; University of California System; University of California San Francisco	Williams, LK (corresponding author), Henry Ford Hosp, Ctr Hlth Serv Res, 1 Ford Pl,3A CHSR, Detroit, MI 48202 USA.	kwillia5@hfhs.org		Kumar, Rajesh/0000-0002-1962-7108; Galanter, Joshua/0000-0002-2561-6384	American Asthma Foundation Strategic Program for Asthma Research; National Institutes of Health [AI079139, AI061774, HL079055, DK064695, HL078885, AI077439, HL088133, U01 GM61390, ES015794]; Fund for Henry Ford Hospital; Flight Attendant Medical Research Institute (FAMRI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079055, R01HL088133, R01HL078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439, R01AI061774, R01AI079139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546, U01GM061390] Funding Source: NIH RePORTER	American Asthma Foundation Strategic Program for Asthma Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fund for Henry Ford Hospital; Flight Attendant Medical Research Institute (FAMRI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the American Asthma Foundation Strategic Program for Asthma Research, the National Institutes of Health (AI079139, AI061774, HL079055, and DK064695), and the Fund for Henry Ford Hospital to L. K. W. and the National Institutes of Health (HL078885, AI077439, HL088133, U01 GM61390, ES015794) and the Flight Attendant Medical Research Institute (FAMRI) to E. G. B.	Abraham SM, 2006, BIOCHEM SOC T, V34, P1018, DOI 10.1042/BST0341018; Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336; Aksoy MO, 2002, J ALLERGY CLIN IMMUN, V109, P491, DOI 10.1067/mai.2002.122154; *AM THOR SOC, 2007, AM J RESP CRIT CARE, V152, P1107; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Choudhry S, 2006, HUM GENET, V118, P652, DOI 10.1007/s00439-005-0071-3; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Clark AR, 2003, CURR OPIN PHARMACOL, V3, P404, DOI 10.1016/S1471-4892(03)00073-0; Clark AR, 2003, J ENDOCRINOL, V178, P5, DOI 10.1677/joe.0.1780005; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Gao XY, 2008, GENET EPIDEMIOL, V32, P361, DOI 10.1002/gepi.20310; Goleva E, 2007, J ALLERGY CLIN IMMUN, V120, P1065, DOI 10.1016/j.jaci.2007.07.042; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Johansson-Haque K, 2008, J MOL ENDOCRINOL, V41, P239, DOI 10.1677/JME-08-0015; Kang BN, 2008, AM J PHYSIOL-LUNG C, V295, pL186, DOI 10.1152/ajplung.00352.2007; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Mak JCW, 2002, BRIT J PHARMACOL, V135, P987, DOI 10.1038/sj.bjp.0704545; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Naqvi M, 2008, ANN ALLERG ASTHMA IM, V100, P551, DOI 10.1016/S1081-1206(10)60055-5; Naqvi M, 2007, J ASTHMA, V44, P639, DOI 10.1080/02770900701554441; *NAT HEART LUNG BL, 2002, PUBL NAT HEART LUNG; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Pelaia G, 2005, J CELL PHYSIOL, V202, P642, DOI 10.1002/jcp.20169; Pritchard JK, 2000, GENETICS, V155, P945; RCore Team, 2022, R LANG ENV STAT COMP; SAS Institute Inc, 2004, SAS STAT US GUID VER; Shore SA, 2003, RESP PHYSIOL NEUROBI, V137, P179, DOI 10.1016/S1569-9048(03)00146-0; Sobande PO, 2008, RESP CARE, V53, P625; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tang H, 2005, GENET EPIDEMIOL, V28, P289, DOI 10.1002/gepi.20064; Tchen CR, 2010, J BIOL CHEM, V285, P2642, DOI 10.1074/jbc.M109.037309; Tcheurekdjian H, 2009, ANN ALLERG ASTHMA IM, V102, P510, DOI 10.1016/S1081-1206(10)60126-3; Tsai HJ, 2006, HUM GENET, V118, P626, DOI 10.1007/s00439-005-0080-2; Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Wu BL, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-317; Yaeger R, 2008, CANCER EPIDEM BIOMAR, V17, P1329, DOI 10.1158/1055-9965.EPI-07-2505; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044; Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120; Zhao Q, 2005, J BIOL CHEM, V280, P8101, DOI 10.1074/jbc.M411760200	49	30	30	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					618	U360		10.1016/j.jaci.2010.06.007	http://dx.doi.org/10.1016/j.jaci.2010.06.007			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20673984	Green Accepted			2022-12-18	WOS:000281512500031
J	Balloch, A; Licciardi, PV; Russell, FM; Mulholland, EK; Tang, MLK				Balloch, Anne; Licciardi, Paul V.; Russell, Fiona M.; Mulholland, Edward K.; Tang, Mimi L. K.			Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONJUGATE VACCINE; CONTROLLED-TRIAL; LOCALIZATION		[Balloch, Anne; Tang, Mimi L. K.] Murdoch Childrens Res Inst, Pneumococcal Lab, Melbourne, Vic, Australia; [Licciardi, Paul V.; Russell, Fiona M.; Mulholland, Edward K.] Murdoch Childrens Res Inst, Ctr Int Child Hlth, Melbourne, Vic, Australia; [Mulholland, Edward K.] London Sch Hyg & Trop Med, London WC1, England; [Mulholland, Edward K.] Menzies Sch Hlth Res, Darwin, NT, Australia; [Russell, Fiona M.; Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia	Murdoch Children's Research Institute; Murdoch Children's Research Institute; University of London; London School of Hygiene & Tropical Medicine; Charles Darwin University; Menzies School of Health Research; University of Melbourne; Royal Children's Hospital Melbourne	Balloch, A (corresponding author), Murdoch Childrens Res Inst, Pneumococcal Lab, Melbourne, Vic, Australia.	anne.balloch@mcri.edu.au	Tang, Mimi/ABD-8350-2020	Tang, Mimi/0000-0002-3839-5293	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI052337] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI052337-05, 2 U01 AI052337-05, U01 AI052337] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balloch A, 2010, VACCINE, V28, P1333, DOI 10.1016/j.vaccine.2009.11.011; Blum MD, 2000, VACCINE, V18, P2359, DOI 10.1016/S0264-410X(00)00021-9; Breukels MA, 2005, SCAND J IMMUNOL, V61, P322, DOI 10.1111/j.1365-3083.2005.01584.x; Llopis MJP, 1996, J ALLERGY CLIN IMMUN, V97, P1015, DOI 10.1016/S0091-6749(96)80078-9; POMAT WS, 1994, INFECT IMMUN, V62, P1848, DOI 10.1128/IAI.62.5.1848-1853.1994; Russell FM, 2010, VACCINE, V28, P3341, DOI 10.1016/j.vaccine.2010.02.087; Shann F, 1998, LANCET, V351, P1600, DOI 10.1016/S0140-6736(05)77683-2; Sorensen RU, 1998, J ALLERGY CLIN IMMUN, V102, P215, DOI 10.1016/S0091-6749(98)70089-2; Zielen S, 2000, INFECT IMMUN, V68, P1435, DOI 10.1128/IAI.68.3.1435-1440.2000	9	30	30	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2								10.1016/j.jaci.2010.05.008	http://dx.doi.org/10.1016/j.jaci.2010.05.008			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20584544	Green Accepted			2022-12-18	WOS:000281203800031
J	Su, RC; Becker, AB; Kozyrskyj, AL; HayGlass, KT				Su, Ruey-Chyi; Becker, Allan B.; Kozyrskyj, Anita L.; HayGlass, Kent T.			Altered epigenetic regulation and increasing severity of bronchial hyperresponsiveness in atopic asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE		[Su, Ruey-Chyi; Becker, Allan B.; HayGlass, Kent T.] Univ Manitoba, Canadian Inst Hlth Res, Natl Training Program Allergy & Asthma Res, Winnipeg, MB, Canada; [Su, Ruey-Chyi; Becker, Allan B.; HayGlass, Kent T.] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada; [Becker, Allan B.; HayGlass, Kent T.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Kozyrskyj, Anita L.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada	Institute for Work & Health; University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba	Su, RC (corresponding author), Univ Manitoba, Canadian Inst Hlth Res, Natl Training Program Allergy & Asthma Res, Winnipeg, MB, Canada.	hayglass@cc.umanitoba.ca		HayGlass, Kent/0000-0002-4621-7737	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Adcock IM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-21; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Kozyrskyj AL, 2009, ALLERGY, V64, P1185, DOI 10.1111/j.1398-9995.2009.02033.x; Su RC, 2008, J ALLERGY CLIN IMMUN, V121, P57, DOI 10.1016/j.jaci.2007.09.004; Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50, DOI 10.1164/ajrccm.162.1.9811005	8	30	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1116	1118		10.1016/j.jaci.2009.08.033	http://dx.doi.org/10.1016/j.jaci.2009.08.033			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895998				2022-12-18	WOS:000272108000040
J	Yong, PL; Werner, RM				Yong, Pierre L.; Werner, Rachel M.			Process quality measures and asthma exacerbations in the Medicaid population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; quality of care; Healthcare Effectiveness Data and Information Set; Medicaid	PLAN EMPLOYER DATA; INHALED CORTICOSTEROIDS; OF-CARE; ADMINISTRATIVE DATA; PERSISTENT ASTHMA; INFORMATION SET; RISK; VALIDATION; PREVENTION; OUTCOMES	Background: Asthma quality assessment often focuses on controller medication use, yet claims-based studies find conflicting associations between this care process and clinical outcomes. Objective: We sought to compare the association between 3 controller-based quality measures and asthma exacerbations to gain better understanding of how processes of care are related to clinical outcomes. Methods: Identifying a cohort of Medicaid beneficiaries with persistent asthma by using Healthcare Effectiveness Data and Information Set (HEDIS) criteria for asthma in 2001-2002 in California and New York, we assessed 3 asthma quality metrics in 2002: (1) the current HEDIS measure of at least I controller medication filling; (2) at least 4 controller medication prescription fillings; and (3) a controller-to-total asthma medication ratio of at least 0.5. We calculated the odds of having an asthma exacerbation in 2003 as a function of performance on each quality metric, adjusting for race, sex, age, and prior outpatient and acute care use for asthma. Results: Of 90,909 subjects with persistent asthma in California (48.1%) and New York (51.9%), those who obtained at least I or at least 4 controller medications had increased likelihood of poor outcomes (adjusted odds ratios, 1.80 [95% CI, 1.73-1.87] and 1.44 [95% CI 1.40-1.48], respectively). Beneficiaries meeting the controller-to-total asthma medication ratio measure were 23.0% less likely to have exacerbations (adjusted odds ratio, 0.77 [95% CI, 0.75-0.80]). Conclusions: A higher controller medication ratio indicated a lower likelihood of asthma exacerbations, whereas assessing the number of controller medication-dispensing events was associated with a higher odds of exacerbation. (J Allergy Clin Immunol 2009;124:961-6.)	[Yong, Pierre L.] Univ Penn, Robert Wood Johnson Clin Scholars Program, Sch Med, Philadelphia, PA 19106 USA; [Yong, Pierre L.; Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA; [Yong, Pierre L.] Hosp Univ Penn, Dept Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA; [Yong, Pierre L.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19106 USA; [Yong, Pierre L.] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19106 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Yong, PL (corresponding author), Univ Penn, Robert Wood Johnson Clin Scholars Program, Sch Med, 1303A Blockley Hall,423 Guardian Dr, Philadelphia, PA 19106 USA.	pyong@nas.edu		Werner, Rachel/0000-0003-3435-4221	Philadelphia Veterans Affairs Medical Center; Robert Wood Johnson Clinical Scholars; Veterans Affairs HSR&D Career Development; Clinical and Translational Science [UL1-RR024134]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024134] Funding Source: NIH RePORTER	Philadelphia Veterans Affairs Medical Center(US Department of Veterans Affairs); Robert Wood Johnson Clinical Scholars; Veterans Affairs HSR&D Career Development; Clinical and Translational Science; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	P. L. Y. is supported by a training grant from the Philadelphia Veterans Affairs Medical Center and the Robert Wood Johnson Clinical Scholars Program. R. M. W is supported in part by a Veterans Affairs HSR&D Career Development Award. The study was supported by pilot grant funding from the Leonard Davis Institute of Health Economics and resources supported by the Clinical and Translational Science Awards (UL1-RR024134).	*AM LUNG ASS EP ST, 2007, TRENDS ASTHM MORB MO, P2991; Barnes NC, 2000, THORAX, V55, P478, DOI 10.1136/thorax.55.6.478; Bennett AV, 2008, AM J MANAG CARE, V14, P450; Berger WE, 2004, ANN ALLERG ASTHMA IM, V93, P538, DOI 10.1016/S1081-1206(10)61260-4; Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; Camargo CA, 2007, AM J HEALTH-SYST PH, V64, P1054, DOI 10.2146/ajhp060256; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Firoozi F, 2007, THORAX, V62, P581, DOI 10.1136/thx.2006.061572; Fuhlbrigge AL, 2005, AM J MANAG CARE, V11, P325; Gelfand EW, 2006, ANN ALLERG ASTHMA IM, V97, P298, DOI 10.1016/S1081-1206(10)60793-4; Hennessy S, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P281; Higashi T, 2007, NEW ENGL J MED, V356, P2496, DOI 10.1056/NEJMsa066253; *KAIS FAM FDN, STAT HLTH FACTS TOT, P2991; Kerr EA, 2007, J GEN INTERN MED, V22, P1635, DOI 10.1007/s11606-007-0313-2; *NAT COMM QUAL ASS, 2008, HEDIS TECHN SPEC, P2991; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Samnaliev M, 2009, CHEST, V135, P1193, DOI 10.1378/chest.07-2962; Schatz M, 2005, CHEST, V128, P1968, DOI 10.1378/chest.128.4.1968; Schatz M, 2003, J ALLERGY CLIN IMMUN, V111, P503, DOI 10.1067/mai.2003.178; Schatz M, 2004, AM J MANAG CARE, V10, P25; Schatz M, 2008, ANN ALLERG ASTHMA IM, V101, P235, DOI 10.1016/S1081-1206(10)60487-5; Schatz M, 2006, CHEST, V130, P43, DOI 10.1378/chest.130.1.43; Smith JR, 2005, J ASTHMA, V42, P437, DOI 10.1081/JAS-200067949; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Werner RM, 2008, J GEN INTERN MED, V23, P1729, DOI 10.1007/s11606-008-0734-6	26	30	30	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					961	966		10.1016/j.jaci.2009.07.027	http://dx.doi.org/10.1016/j.jaci.2009.07.027			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19748660				2022-12-18	WOS:000272108000013
J	Vinh, DC; Freeman, AF; Shea, YR; Malech, HL; Abinun, M; Weinberg, GA; Holland, SM				Vinh, Donald C.; Freeman, Alexandra F.; Shea, Yvonne R.; Malech, Harry L.; Abinun, Mario; Weinberg, Geoffrey A.; Holland, Steven M.			Mucormycosis in chronic granulomatous disease: Association with iatrogenic immunosuppression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							KETOACIDOSIS; ZYGOMYCOSIS		[Vinh, Donald C.; Malech, Harry L.; Holland, Steven M.] NIAID, Dept Lab Med, NIH, Bethesda, MD 20892 USA; [Shea, Yvonne R.] NIH, Microbiol Serv, Dept Lab Med, Bethesda, MD 20892 USA; [Freeman, Alexandra F.] NCI, Lab Clin Infect Dis, SAIC Frederick Inc, Frederick, MD 21701 USA; [Abinun, Mario] Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Weinberg, Geoffrey A.] Univ Rochester, Sch Med & Dent, Rochester, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Rochester	Vinh, DC (corresponding author), NIAID, Dept Lab Med, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	smh@nih.gov	Weinberg, Geoffrey A./W-7510-2019	Weinberg, Geoffrey A./0000-0002-3900-379X; VINH, DONALD/0000-0003-1347-7767; Malech, Harry/0000-0001-5874-5775	Intramural NIH HHS [Z01 AI000646-16] Funding Source: Medline; NCI NIH HHS [N01CO12400, N01-CO-12400] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646, ZIAAI000645] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bingel SA, 2002, CONTEMP TOP LAB ANIM, V41, P33; BRUUN JN, 1976, ACTA PATH MICRO IM C, V84, P93; De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; Dekkers R, 2008, MED MYCOL, V46, P491, DOI 10.1080/13693780801946577; Kitabchi AE, 2008, J CLIN ENDOCR METAB, V93, P1541, DOI 10.1210/jc.2007-2577; Kontoyiannis DP, 2006, INFECT DIS CLIN N AM, V20, P581, DOI 10.1016/j.idc.2006.06.003; Morena Marion, 2005, Hemodial Int, V9, P37, DOI 10.1111/j.1492-7535.2005.01116.x; Siddiqui S, 2007, CLIN INFECT DIS, V45, P673, DOI 10.1086/520985; STEWART J, 1991, DIABETIC MED, V8, P213, DOI 10.1111/j.1464-5491.1991.tb01574.x	9	30	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1411	1413		10.1016/j.jaci.2009.02.020	http://dx.doi.org/10.1016/j.jaci.2009.02.020			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19368967	Bronze, Green Accepted			2022-12-18	WOS:000266799100038
J	Kato, A; Xiao, HQ; Chustz, RT; Liu, MC; Schleimer, RP				Kato, Atsushi; Xiao, HuiQing; Chustz, Regina T.; Liu, Mark C.; Schleimer, Robert P.			Local release of B cell-activating factor of the TNF family after segmental allergen challenge of allergic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Local immunoglobulin production; segmental allergen challenge; B cell-activating factor of the TNF family; allergic diseases; B cells; eosinophils	BRONCHOALVEOLAR LAVAGE FLUID; GERMLINE GENE TRANSCRIPTS; AIRWAY EPITHELIAL-CELLS; SERUM BAFF LEVELS; IGE ANTIBODIES; NASAL-MUCOSA; T-CELLS; IL-13; EXPRESSION; CYTOKINES	Background: Local production of IgA and IgE in the airways has been proposed to be an important event in both immune protection from pathogens and the pathogenesis of airway allergic diseases. Objective: The objective of this study was to investigate the production of B cell-activating factor of the TNF family (BAFF), an important regulator of B-cell survival and immunoglobulin class-switch recombination, in bronchoalveolar lavage (BAL) fluid after segmental allergen challenge of allergic subjects. Methods: Segmental allergen challenge with saline or allergen was performed in 16 adult allergic subjects. BAL was performed at both saline- and allergen-challenged sites 20 to 24 hours after challenge. Concentrations of B cell-active cytokines, including BAFF, IL-6, and IL-13, were measured by using specific ELISA and cytometric head array assays. Results: Levels of BAFF protein were significantly increased in BAL fluid after allergen challenge (53.8 pg/mL [range, 0-407.4 pg/mL], P = .001) compared with those at saline-challenged sites (0 pg/mL [0-34.7 pg/mL]). In the BAL. fluid after allergen challenge, BAFF levels were significantly correlated with absolute numbers of total cells (r = 0.779, P < .001), lymphocytes (r = 0.842, P < .001), neutrophils (r = 0.809, P < .001), and eosinophils (r = 0.621, P = .010) but did not correlate with macrophages. Normalization to albumin indicated that BAFF production occurred locally in the airways. BAFF levels were also significantly correlated with the other B cell-activating cytokines IL-6 (r = 0.875, P < .001) and IL-13 (r = 0.812, P < .001). Conclusion: The antigen-induced production of BAFF in the airway might contribute to local class-switch recombination and immunoglobulin synthesis by B cells. (J Allergy Clin Immunol 2009;123:369-75.)	[Kato, Atsushi; Chustz, Regina T.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Xiao, HuiQing; Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Div Allergy, Baltimore, MD USA; [Xiao, HuiQing; Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA; [Xiao, HuiQing; Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care Med, Baltimore, MD USA	Northwestern University; Feinberg School of Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy & Immunol, 240 E Huron, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu		Kato, Atsushi/0000-0001-9144-3138	National Institutes of Health [R01 HL068546, R01 HL078860, 1R01 AI072570, R01 AI063184]; Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R01HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063184, R01AI072570] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in pan by National Institutes of Health grants R01 HL068546, R01 HL078860, 1R01 AI072570, and R01 AI063184 and by a grant from the Ernest S. Bazley Trust.	Batra V, 2004, CLIN EXP ALLERGY, V34, P437, DOI 10.1111/j.1365-2222.2004.01885.x; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Bratke K, 2007, THORAX, V62, P168, DOI 10.1136/thx.2006.067793; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; Darce JR, 2007, J IMMUNOL, V178, P5612, DOI 10.4049/jimmunol.178.9.5612; Fiset PO, 2005, J ALLERGY CLIN IMMUN, V116, P233, DOI 10.1016/j.jaci.2005.03.019; Gould HJ, 2006, TRENDS IMMUNOL, V27, P446, DOI 10.1016/j.it.2006.08.007; HUANG SK, 1995, J IMMUNOL, V155, P2688; Huard B, 2004, INT IMMUNOL, V16, P467, DOI 10.1093/intimm/dxh043; Julius P, 2008, J ALLERGY CLIN IMMUN, V121, P712, DOI 10.1016/j.jaci.2007.08.058; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; KleinJan A, 2000, EUR RESPIR J, V15, P491, DOI 10.1034/j.1399-3003.2000.15.11.x; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Liu MC, 2001, J ALLERGY CLIN IMMUN, V108, P29; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; Mackay F, 2007, CURR OPIN IMMUNOL, V19, P327, DOI 10.1016/j.coi.2007.04.008; Matsushita T, 2007, EXP DERMATOL, V16, P87, DOI 10.1111/j.1600-0625.2006.00485.x; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; Migita K, 2007, HUM IMMUNOL, V68, P586, DOI 10.1016/j.humimm.2007.03.010; NAKAJIMA S, 1975, CLIN EXP IMMUNOL, V21, P306; Oettgen HC, 2000, CURR OPIN IMMUNOL, V12, P618, DOI 10.1016/S0952-7915(00)00153-9; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Peebles RS, 1998, J ALLERGY CLIN IMMUN, V101, P265, DOI 10.1016/S0091-6749(98)70392-6; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SMALL P, 1985, ANN ALLERGY, V55, P736; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; TSE KS, 1970, J ALLERGY, V46, P352, DOI 10.1016/0021-8707(70)90086-9; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; Wilson DR, 2002, AM J RESP CRIT CARE, V165, P22, DOI 10.1164/ajrccm.165.1.2010112; Xu WF, 2007, NAT IMMUNOL, V8, P294, DOI 10.1038/ni1434; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339	42	30	32	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					369	375		10.1016/j.jaci.2008.11.022	http://dx.doi.org/10.1016/j.jaci.2008.11.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19135236	Green Accepted			2022-12-18	WOS:000263495000012
J	Appleton, SL; Ruffin, RE; Wilson, DH; Taylor, AW; Adams, RJ				Appleton, Sarah L.; Ruffin, Richard E.; Wilson, David H.; Taylor, Anne W.; Adams, Robert J.		North West Adelaide Cohort Hlth St	Cardiovascular disease risk associated with asthma and respiratory morbidity might be mediated by short-acting beta(2)-agonists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adrenergic beta-agonists; asthma; cardiovascular system; epidemiology; lung diseases; obstructive	INHALED CORTICOSTEROID USE; CORONARY-HEART-DISEASE; ADULT-ONSET ASTHMA; BETA-AGONISTS; MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS RISK; LUNG-FUNCTION; SELF-REPORTS; MORTALITY; SYMPTOMS	Background: Studies examining the asthma-related risks of cardiovascular disease (CVD) events have generally used selected samples or did not control for the effects Of beta(2)-agonist use, itself associated with CVD events. Objectives: We assessed the relationship between incident CVD/stroke and asthma and the effect of atopy while controlling for beta(2)-agonist use in a representative adult population cohort free of CVD at baseline. Methods: The North West Adelaide Health Study (stage 1, n = 3812; stage 2, n = 3113) assessed spirometry, anthropometry, atopy, blood pressure, and lipid levels. Questionnaires assessed doctor-diagnosed asthma and CVD (myocardial infarction and angina)/stroke, smoking status, and demographics. Asthma was defined by self-report or FEV1 reversibility. Current short- and long-acting beta(2)-agonist use was identified at follow-up. Results: Results are expressed as odds ratios (ORs) and 95% CIs. By using multivariable logistic regression, after adjustment for risk factors, in female subjects incident CVD/stroke events were associated with asthma (OR, 3.24; 95% CI, 1.55-6.78), with no effect modification by atopy (P for interaction = .61), and with as-required short-acting beta(2)-agonist use (OR, 2.66; 95% CI, 1.06-6.61). In male subjects events were associated with daily cough/sputum (OR, 1.92; 95% CI, 1.05-3.50) and FEV1 of less than 80% of predicted value but an FEV1/forced vital capacity ratio of greater than 0.70 (OR, 2.15; 95% CI, 0.91-5.09; P = .08). Although few CVD/stroke events occurred in male subjects with asthma, a significant interaction with atopic status was found (P = .05). Conclusions: Studies are required to elucidate how asthma exposes older women to excess macrovascular risk and prospectively determine the short-acting beta(2)-agonist-related risk in persons without existing CVD. CVD risk in relation to atopic status of asthma also requires further investigation. (J Allergy Clin Immunol 2009;123:124-30.)	[Appleton, Sarah L.; Ruffin, Richard E.; Wilson, David H.; Adams, Robert J.] Univ Adelaide, Dept Med, Hlth Observ, Woodville, SA 5011, Australia; [Taylor, Anne W.] S Australian Dept Hlth, Populat Res & Outcome Studies Unit, Adelaide, SA, Australia	University of Adelaide	Appleton, SL (corresponding author), Univ Adelaide, Dept Med, Hlth Observ, Queen Elizabeth Hosp Campus,Woodville Rd, Woodville, SA 5011, Australia.	sarah.appleton@adelaide.edu.au	Appleton, Sarah/Y-5206-2019; Adams, Robert/Z-3197-2019; Taylor, Anne w/F-5708-2010; Appleton, Sarah/E-9149-2017	Taylor, Anne w/0000-0002-4422-7974; Appleton, Sarah/0000-0001-7292-9714	University of Adelaide and the South Australian Department of Health	University of Adelaide and the South Australian Department of Health	Supported by the University of Adelaide and the South Australian Department of Health.	ADAMS R, 2009, OBESITY IN PRESS; Andersson CK, 2008, AM J RESP CELL MOL, V39, P648, DOI 10.1165/rcmb.2007-0443OC; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Appleton SL, 2008, OBES RES CLIN PRACT, V2, P91, DOI 10.1016/j.orcp.2008.04.005; Appleton SL, 2005, J ALLERGY CLIN IMMUN, V116, P976, DOI 10.1016/j.jaci.2005.08.034; Au DH, 2002, CHEST, V121, P846, DOI 10.1378/chest.121.3.846; Au DH, 2000, AM J RESP CRIT CARE, V161, P827, DOI 10.1164/ajrccm.161.3.9904006; *AUSTR BUR STAT, 2001, 2001 CENS BAS COMM P; *AUSTR CTR ASTHM M, 2007, ASTHM AUSTR FIND 200; Babu KS, 2004, IMMUNOL ALLERGY CLIN, V24, P583, DOI 10.1016/j.iac.2004.06.010; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Camargo CA, 2008, CHEST, V134, P546, DOI 10.1378/chest.07-3126; Dogra S, 2007, J ASTHMA, V44, P849, DOI 10.1080/02770900701752391; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Frostad A, 2007, RESP MED, V101, P2289, DOI 10.1016/j.rmed.2007.06.023; Global Initiative for Chronic Obstructive Lung Disease, GLOB STRAT DIAGN MAN; Grant Janet F, 2006, Epidemiol Perspect Innov, V3, P4, DOI 10.1186/1742-5573-3-4; Hancox RJ, 1999, EUR RESPIR J, V14, P283, DOI 10.1034/j.1399-3003.1999.14b08.x; Hospers JJ, 1999, AM J EPIDEMIOL, V150, P482; Huiart L, 2005, EUR RESPIR J, V25, P634, DOI 10.1183/09031936.05.00079004; Huo YQ, 2004, CIRCULATION, V110, P2024, DOI 10.1161/01.CIR.0000143628.37680.F6; Iribarren C, 2004, INT J EPIDEMIOL, V33, P743, DOI 10.1093/ije/dyh081; Jensen-Jarolim E, 2008, ALLERGY, V63, P610, DOI 10.1111/j.1398-9995.2008.01645.x; KITCH B, 2000, DRUGS AGING, V17, P395; Knoflach M, 2005, ARCH INTERN MED, V165, P2521, DOI 10.1001/archinte.165.21.2521; Kriegsman DMW, 1996, J CLIN EPIDEMIOL, V49, P1407, DOI 10.1016/S0895-4356(96)00274-0; Lofdahl CG, 2007, EUR RESPIR J, V29, P1115, DOI 10.1183/09031936.00128806; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; Mueller CFH, 2008, CIRCULATION, V117, P2912, DOI 10.1161/CIRCULATIONAHA.107.747667; MUSK AW, 1987, MED J AUSTRALIA, V147, P423, DOI 10.5694/j.1326-5377.1987.tb133582.x; *NAT CHOL ED PROGR, 2002, NHLBI 3 REP EXP PAN; Nelson Harold S, 2006, Prim Care Respir J, V15, P271, DOI 10.1016/j.pcrj.2006.08.006; O'Flaherty M, 2008, HEART, V94, P178, DOI 10.1136/hrt.2007.118323; Onufrak S, 2007, ATHEROSCLEROSIS, V195, P129, DOI 10.1016/j.atherosclerosis.2006.09.004; Onufrak SJ, 2008, AM J CARDIOL, V101, P1247, DOI 10.1016/j.amjcard.2007.12.024; Pearce N, 1998, EPIDEMIOL REV, V20, P173, DOI 10.1093/oxfordjournals.epirev.a017979; Rahman A, 2005, AM J EPIDEMIOL, V162, P491, DOI 10.1093/aje/kwi215; Real FG, 2008, J ALLERGY CLIN IMMUN, V121, P72, DOI 10.1016/j.jaci.2007.08.057; Real FG, 2007, J ALLERGY CLIN IMMUN, V120, P557, DOI 10.1016/j.jaci.2007.04.041; Salpeter SR, 2004, CHEST, V125, P2309, DOI 10.1378/chest.125.6.2309; Schanen JG, 2005, THORAX, V60, P633, DOI 10.1136/thx.2004.026484; Selim AJ, 1997, CHEST, V111, P1607, DOI 10.1378/chest.111.6.1607; Sin DD, 2005, CHEST, V127, P1952, DOI 10.1378/chest.127.6.1952; Suissa S, 2003, AM J MED, V115, P377, DOI 10.1016/S0002-9343(03)00393-0; Suissa S, 2003, THORAX, V58, P43, DOI 10.1136/thorax.58.1.43; Taylor AW, 1998, AUST NZ J PUBL HEAL, V22, P223, DOI 10.1111/j.1467-842X.1998.tb01177.x; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Toren K, 1996, INT J EPIDEMIOL, V25, P617, DOI 10.1093/ije/25.3.617; World Health Organization, 1997, OB PREV MAN GLOB EP; Zaitsu M, 2007, MOL IMMUNOL, V44, P1977, DOI 10.1016/j.molimm.2006.09.030	51	30	30	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					124	130		10.1016/j.jaci.2008.10.032	http://dx.doi.org/10.1016/j.jaci.2008.10.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130933				2022-12-18	WOS:000262793900021
J	Coogan, PF; Palmer, JR; O'Connor, GT; Rosenberg, L				Coogan, Patricia F.; Palmer, Julie R.; O'Connor, George T.; Rosenberg, Lynn			Body mass index and asthma incidence in the Black Women's Health Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; body mass index; cohort studies; African Americans; incidence; longitudinal studies	US ADULTS; OBESITY; RISK; QUESTIONNAIRE; MEN	Background: Evidence from prospective studies consistently links obesity to asthma onset in white women, although there is controversy as to whether the association is causal. There are few data on this topic in black women, among whom the prevalence of obesity and asthma is high. Objective: We prospectively assessed the relation of body mass index (BMI) to asthma incidence in the Black Women's Health Study. Methods: We followed 46,435 women from 1995 through 2005 with biennial mailed questionnaires. Cox regression models were used to estimate incidence rate ratios and 95% CIs. Results: During 403,394 person-years of follow-up, 1068 participants reported physician-diagnosed asthma and concurrent use of asthma medication. Compared with women with BMIs of 20 to 24, the multivariate incidence rate ratios for higher categories of BMI increased from 1.26 (95% CI, 1.05-1.5.1) for BMIs of 25 to 29 to 2.85 (95% CI, 2.19-3.72) for BMIs of 40 or greater, with a significant trend. The association of BMI with asthma risk was consistent across strata of smoking status, age, presence of sleep apnea, parental history of asthma, BMI at age 18 years, and energy expenditure and intake. Conclusion: In this large cohort of African American women, there was a positive association between BMI and asthma risk that was similar in magnitude to those observed in longitudinal studies of white women. (J Allergy Clin Immunol 2009;123:89-95.)	[O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Coogan, Patricia F.; Palmer, Julie R.; Rosenberg, Lynn] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA	Boston University; Boston University	Coogan, PF (corresponding author), Boston Univ, Slone Epidemiol Ctr, 1010 Common Wealth Ave, Boston, MA 02215 USA.	pcoogan@bu.edu		Rosenberg, Lynn/0000-0003-2760-2987; O'Connor, George/0000-0002-6476-3926; Coogan, Patricia/0000-0003-3671-7663; Palmer, Julie/0000-0002-6534-335X	National Cancer Institute [CA58420]; NATIONAL CANCER INSTITUTE [R01CA058420] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by it grant from the National Cancer Institute (CA58420).	Adams RJ, 2003, THORAX, V58, P846, DOI 10.1136/thorax.58.10.846; Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045, DOI 10.1164/ajrccm.164.11.2004235; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Block G, 1990, Epidemiology, V1, P58, DOI 10.1097/00001648-199001000-00013; Boulet LP, 2007, CAN RESPIR J, V14, P217, DOI 10.1155/2007/101640; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Chinn S, 2006, EUR RESPIR J, V28, P763, DOI 10.1183/09031936.06.00150505; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Ford ES, 2004, EUR RESPIR J, V24, P740, DOI 10.1183/09031936.04.00088003; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Guerra S, 2002, CHEST, V122, P1256, DOI 10.1378/chest.122.4.1256; Gurski Richard Ricachenevski, 2006, J. bras. pneumol., V32, P150, DOI 10.1590/S1806-37132006000200011; Gwynn RC, 2004, J ASTHMA, V41, P91, DOI 10.1081/JAS-120026066; Huovinen E, 2003, RESP MED, V97, P273, DOI 10.1053/rmed.2003.1419; Kasasbeh A, 2007, SLEEP MED REV, V11, P47, DOI 10.1016/j.smrv.2006.05.001; Kim S, 2003, ANN EPIDEMIOL, V13, P666, DOI 10.1016/S1047-2797(03)00054-1; Kumanyika SK, 2003, ANN EPIDEMIOL, V13, P111, DOI 10.1016/S1047-2797(02)00253-3; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Peat JK, 2001, THORAX, V56, P406, DOI 10.1136/thorax.56.5.406; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Romieu I, 2003, AM J EPIDEMIOL, V158, P165, DOI 10.1093/aje/kwg131; Rosenberg L, 1995, J Am Med Womens Assoc (1972), V50, P56; Russell C, 2001, AM J EPIDEMIOL, V154, P845, DOI 10.1093/aje/154.9.845; SAMPSON MG, 1983, J APPL PHYSIOL, V55, P1269, DOI 10.1152/jappl.1983.55.4.1269; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Therneau T, 1997, P 1 SEATTL S BIOST S, P51; *US CENSUSBUREAU, ED ATT US MARCH 1999; Watson RA, 2005, J APPL PHYSIOL, V98, P512, DOI 10.1152/japplphysiol.00430.2004	34	30	30	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					89	95		10.1016/j.jaci.2008.09.040	http://dx.doi.org/10.1016/j.jaci.2008.09.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18980776	Green Accepted			2022-12-18	WOS:000262793900013
J	Beyer, K; Chung, D; Schulz, G; Mishoe, M; Niggenmann, B; Wahn, U; Sompson, HA				Beyer, Kirsten; Chung, Danna; Schulz, Gabriele; Mishoe, Michelle; Niggenmann, Bodo; Wahn, Ulrich; Sompson, Hugh A.			The role of wheat omega-5 gliadin IgE antibodies as a diagnostic tool for wheat allergy in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD CHALLENGES; CHILDREN		[Beyer, Kirsten; Schulz, Gabriele; Niggenmann, Bodo; Wahn, Ulrich] Univ Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany; [Chung, Danna; Mishoe, Michelle; Sompson, Hugh A.] Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY USA; [Chung, Danna; Mishoe, Michelle; Sompson, Hugh A.] Mt Sinai Sch Med, Jaffe Food Allergy Res Inst, New York, NY USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Beyer, K (corresponding author), Univ Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany.	kirsten.beyer@charite.de						Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Constantin C, 2005, INT ARCH ALLERGY IMM, V138, P257, DOI 10.1159/000088727; Lauriere M, 2007, ALLERGY, V62, P890, DOI 10.1111/j.1398-9995.2007.01456.x; Matsuo H, 2008, ALLERGY, V63, P233, DOI 10.1111/j.1398-9995.2007.01504.x; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Palosuo K, 2003, CURR OPIN ALLERGY CL, V3, P205, DOI [10.1097/00130832-200306000-00009, 10.1097/01.all.0000072717.82112.cc]; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7	7	30	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					419	421		10.1016/j.jaci.2008.06.006	http://dx.doi.org/10.1016/j.jaci.2008.06.006			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18619665				2022-12-18	WOS:000258426300035
J	Sicherer, SH; Dhillon, G; Laughery, KA; Hamilton, RG; Wood, RA				Sicherer, Scott H.; Dhillon, Gitika; Laughery, Katie A.; Hamilton, Robert G.; Wood, Robert A.			Caution: The Phadia hazelnut ImmunoCAP (f17) has been supplemented with recombinant Cor a 1 and now detects Bet v 1-specific IgE, which leads to elevated values for persons with birch pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN		[Sicherer, Scott H.] Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Dhillon, Gitika; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA; [Laughery, Katie A.; Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA	Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins University	Sicherer, SH (corresponding author), Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY 10029 USA.	scott.sicherer@mssm.edu						Andersson K, 2007, ALLERGY, V62, P897, DOI 10.1111/j.1398-9995.2007.01450.x; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P423, DOI 10.1016/j.jaci.2007.10.009; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V118, P1186, DOI 10.1016/j.jaci.2006.08.017; Lidholm J, 2006, CURR OPIN ALLERGY CL, V6, P234, DOI 10.1097/01.all.0000225166.90768.d6; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052	5	30	30	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					413	414		10.1016/j.jaci.2008.05.012	http://dx.doi.org/10.1016/j.jaci.2008.05.012			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18586316				2022-12-18	WOS:000258426300031
J	Zeiger, RS; Hay, JW; Contreras, R; Chen, WS; Quinn, VP; Seal, B; Schatz, M				Zeiger, Robert S.; Hay, Joel W.; Contreras, Richard; Chen, Wansu; Quinn, Virginia P.; Seal, Brian; Schatz, Michael			Asthma costs and utilization in a managed care organization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; combination controllers; drugs; health care; costs; inhaled corticosteroids; leukotriene modifiers; long-acting beta-agonists; managed care organization; health resource utilization	MILD PERSISTENT ASTHMA; FLUTICASONE PROPIONATE; INHALED CORTICOSTEROIDS; RESOURCE USE; SALMETEROL/FLUTICASONE PROPIONATE; COMBINATION THERAPY; ECONOMIC-IMPACT; PHARMACY DATA; ADULT ASTHMA; MONTELUKAST	Background: Medical costs and health care utilization associated with asthma and the variation by treatment are poorly understood. Objective: To compare single controller inhaled corticosteroid (ICS) to other asthma drug regimens on medical costs and utilization. Methods: Direct medical costs and utilization were captured from administrative electronic databases from continuously enrolled members with asthma age 5 years or older with drug coverage. Asthma patients were identified during 2002, categorized into 14 asthma drug groups on the basis of 2003 prescription records, and had total medical costs and utilization determined in 2004 adjusting for demographics, insurance types, asthma risk, comorbidity, and propensity scores. Results: A total of 96,631 patients met the study eligibility criteria. Patients were (mean +/- SD) age 38 +/- 23 years and were 57% female, 14% Medicare, 4% Medicaid, and had a median family income (mean +/- SD) of $64,967 +/- $29,285. Total unadjusted direct medical costs/patientlyear averaged $3745 ($3298 low asthma risk vs $6797 high asthma risk; P <.001). Adjusted total and asthma drug costs were significantly lower with single controller ICS compared with single controller leukotriene modifiers, long-acting beta-agonists, and theophylline and most combination controller regimens (P <.001 for all comparisons). In addition, single controller ICS compared with single controller leukotriene modifiers and combination controllers was associated with significantly lower asthma-related utilization. Conclusion: Total direct costs and asthma-related utilizations are meaningfully less in the year after being dispensed single controller ICS compared with single controller leukotriene modifiers or most combination controllers.	[Zeiger, Robert S.; Contreras, Richard; Chen, Wansu; Quinn, Virginia P.; Schatz, Michael] Kaiser Permanente So Calif, San Diego, CA USA; [Hay, Joel W.] Univ So Calif, Sch Pharm, Los Angeles, CA USA; [Seal, Brian] Sanofi Aventis Pharmaceut, Bridgewater, MA USA	Kaiser Permanente; University of Southern California; Sanofi-Aventis	Zeiger, RS (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	robert.s.zeiger@kp.org		Zeiger, Robert/0000-0001-5788-5063				Akazawa M, 2006, PHARMACOECONOMICS, V24, P971, DOI 10.2165/00019053-200624100-00005; Allen-Ramey FC, 2005, PHARMACOTHERAPY, V25, P1752, DOI 10.1592/phco.2005.25.12.1752; Allen-Ramey FC, 2003, ALLERGY ASTHMA PROC, V24, P43; Allen-Ramey FC, 2006, CURR MED RES OPIN, V22, P1453, DOI 10.1185/030079906X115522; Allen-Ramey FC, 2006, J MANAGE CARE PHARM, V12, P310, DOI 10.18553/jmcp.2006.12.4.310; Balkrishnan R, 2005, J ASTHMA, V42, P35, DOI 10.1081/JAS-200044769; Bukstein DA, 2001, CLIN THER, V23, P1589, DOI 10.1016/S0149-2918(01)80130-2; Cisternas MG, 2003, J ALLERGY CLIN IMMUN, V111, P1212, DOI 10.1067/mai.2003.1449; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; Ducharme Francine M, 2004, Treat Respir Med, V3, P399, DOI 10.2165/00151829-200403060-00006; Fishman PA, 2003, MED CARE, V41, P84, DOI 10.1097/00005650-200301000-00011; Foster EM, 2003, MED CARE, V41, P1183, DOI 10.1097/01.MLR.0000089629.62884.22; Friedman HS, 2007, CURR MED RES OPIN, V23, P427, DOI 10.1185/030079906X167417; Guevara JP, 2006, COCHRANE DB SYST REV, V2; Halpern MT, 2003, J FAM PRACTICE, V52, P382; Hay JW, 2004, EXPERT OPIN PHARMACO, V5, P1867, DOI 10.1517/14656566.5.9.1867; Jonsson B, 2004, RESP MED, V98, P1146, DOI 10.1016/j.rmed.2004.04.005; Kennedy WA, 2003, INT J TECHNOL ASSESS, V19, P8, DOI 10.1017/S0266462303000023; Lyseng-Williamson KA, 2003, PHARMACOECONOMICS, V21, P951, DOI 10.2165/00019053-200321130-00004; Macy E, 2005, J ASTHMA, V42, P213, DOI 10.1081/JAS-200054645; Masoli M, 2005, THORAX, V60, P730, DOI 10.1136/thx.2004.039180; Meenan RT, 2003, MED CARE, V41, P1301, DOI 10.1097/01.MLR.0000094480.13057.75; Menendez R, 2001, PHARMACOECONOMICS, V19, P865, DOI 10.2165/00019053-200119080-00008; Ni CM, 2005, COCHRANE DB SYST REV, V4; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Connor RD, 2006, ANN ALLERG ASTHMA IM, V97, P236, DOI 10.1016/S1081-1206(10)60020-8; Orsini L, 2004, ANN ALLERG ASTHMA IM, V92, P523, DOI 10.1016/S1081-1206(10)61759-0; Ostrom NK, 2005, J PEDIATR-US, V147, P213, DOI 10.1016/j.jpeds.2005.03.052; Pathak DS, 2002, PHARMACOTHERAPY, V22, P166, DOI 10.1592/phco.22.3.166.33548; Pieters Willem R, 2005, Treat Respir Med, V4, P129, DOI 10.2165/00151829-200504020-00007; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Schatz M, 2004, AM J MANAG CARE, V10, P25; Schatz M, 2006, J ALLERGY CLIN IMMUN, V118, P1048, DOI 10.1016/j.jaci.2006.07.057; Schatz M, 2006, AM J MANAG CARE, V12, P478; Sheth K, 2002, PHARMACOECONOMICS, V20, P909, DOI 10.2165/00019053-200220130-00004; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Stempel DA, 2007, J PEDIATR-US, V150, P162, DOI 10.1016/j.jpeds.2006.10.069; Wang SW, 2001, AM J MANAG CARE, V7, P913; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Zeiger RS, 2005, AM J MED, V118, P649, DOI 10.1016/j.amjmed.2005.03.003	40	30	30	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					885	892		10.1016/j.jaci.2007.12.1178	http://dx.doi.org/10.1016/j.jaci.2007.12.1178			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18313133				2022-12-18	WOS:000254884000012
J	Campana, R; Mothes, N; Rauter, I; Vrtala, S; Reininger, R; Focke-Tejkl, M; Lupinek, C; Balic, N; Spitzauer, S; Valenta, R				Campana, Raffaela; Mothes, Nadine; Rauter, Ingrid; Vrtala, Susanne; Reininger, Renate; Focke-Tejkl, Margarete; Lupinek, Christian; Balic, Nadja; Spitzauer, Susanne; Valenta, Rudolf			Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BIRCH POLLEN ALLERGEN; ATOPY PATCH TEST; AEROALLERGENS		[Campana, Raffaela; Mothes, Nadine; Rauter, Ingrid; Vrtala, Susanne; Reininger, Renate; Focke-Tejkl, Margarete; Lupinek, Christian; Valenta, Rudolf] Med Univ Vienna, Vienna Gen Hosp, Ctr Physiol & Pathophysiol, Dept Pathophysiol,Div Immunopathol, Vienna, Austria; [Mothes, Nadine] Med Univ Vienna, Vienna Gen Hosp, Dept Dermatol, Vienna, Austria; [Balic, Nadja; Spitzauer, Susanne] Med Univ Vienna, Vienna Gen Hosp, Inst Med, Chem Lab, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Valenta, R (corresponding author), Med Univ Vienna, Vienna Gen Hosp, Ctr Physiol & Pathophysiol, Dept Pathophysiol,Div Immunopathol, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Lupinek, Christian/I-3311-2019	Lupinek, Christian/0000-0002-8612-8245; Vrtala, Susanne/0000-0003-4250-8243; Campana, Raffaela/0000-0001-9309-9908; Valenta, Rudolf/0000-0001-5944-3365				Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P379, DOI 10.1159/000237609; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Stuetz A, 2006, INT ARCH ALLERGY IMM, V141, P199, DOI 10.1159/000095289; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330	9	30	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					528	530		10.1016/j.jaci.2007.09.014	http://dx.doi.org/10.1016/j.jaci.2007.09.014			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18269928				2022-12-18	WOS:000253337800038
J	Lee, JH; Chang, HS; Kim, JH; Park, SM; Lee, YM; Uh, ST; Rhim, T; Chung, Y; Kim, YH; Park, BL; Park, CS; Shin, HD				Lee, June-Hyuk; Chang, Hun Soo; Kim, Ji Hyun; Park, Se-Min; Lee, Yong Mok; Uh, Soo Taek; Rhim, Taiyoun; Chung, Yup; Kim, Yong-Hoon; Park, Byung Lae; Park, Choon-Sik; Shin, Hyoung Doo			Genetic effect of CCR3 and IL5RA gene polymorphisms on eosinophilia in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eosinophilia; single nucleotide polymorphism; CC chemokine receptor 3; IL-5 receptor alpha	SINGLE-NUCLEOTIDE POLYMORPHISMS; CHEMOKINE RECEPTOR-3; ATOPIC-DERMATITIS; MESSENGER-RNA; IL-5 RECEPTOR; ALPHA-SUBUNIT; INTERLEUKIN-5; EXPRESSION; INFLAMMATION; ASSOCIATION	Background: Eosinophilic infiltration and peripheral blood eosinophilia in asthma require the cooperation of eosinophil-specific cytokines and chemokines and their receptors. Objective: We investigated the association of polymorphisms in CCR3 and IL5RA with asthma susceptibility or peripheral blood eosinophilia and the effects of the polymorphisms on receptor expression. Methods: Polymorphisms in CCR3 and IL5RA were identified and genotyped in 576 asthmatic patients and 180 healthy control subjects. CCR3 and IL-5 receptor a (IL-5R alpha) protein expression on eosinophils was measured by means of flow cytometry. Results: Although polymorphisms in CCR3 were not associated with asthma susceptibility, the CCR3 haplotype ht2 showed a negative gene dose effect on the eosinophil count (P =.003-.009). IL5RA c. -5091G>A was weakly associated with eosinophil count. The effects of ht2 were greater when paired with IL5RA c. -5091A (P =.001-002). CCR3 protein expression was higher on eosinophils of asthmatic patients without ht2 than in those with W. Asthmatic patients with the IL5RA c. -5091A allele showed higher IL-5R alpha expression than those who were homozygous for the G allele. Conclusion: The genetic association between CCR3 polymorphisms and the number of circulating eosinophils was revealed as a novel finding. These associations were more pronounced when the CCR3 polymorphisms were paired with polymorphisms in IL5RA. The protein expression levels of CCR3 and IL-5R alpha on peripheral blood eosinophils are associated with the polymorphisms on their own genes. Clinical implications: The identification of single nucleotide polymorphisms and haplotypes of CCR3 and IL5RA might be useful in developing markers for intermediate phenotypes of eosinophil number and in designing strategies to control diseases related to hypereosinophilia.	Soonchunhyang Univ, Bucheon Hosp, Genome Res Ctr Allergy & Resp Dis, Gyeonggi Do, South Korea; Hanyang Univ, Coll Sci & Technol, Div Mol & Life Sci, Gyeonggi Do, South Korea; SNP Genet, Dept Genet Epidemiol, Seoul, South Korea	Soonchunhyang University; Hanyang University; SNP Genetics	Park, CS (corresponding author), Soonchunhyang Univ, Bucheon Hosp, Div Allergy & Resp Med, Dept Internal Med, 1174 Jung Dong, Puchon 420021, Gyeonggi Do, South Korea.	mdcspark@unitel.co.kr		Park, Choon-Sik/0000-0003-2977-0255				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BOULAY JL, 1992, CURR OPIN IMMUNOL, V4, P294, DOI 10.1016/0952-7915(92)90079-T; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Cheong HS, 2005, J HUM GENET, V50, P628, DOI 10.1007/s10038-005-0304-2; Ciprandi G, 2004, CLIN EXP ALLERGY, V34, P891, DOI 10.1111/j.1365-2222.2004.01970.x; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Daugherty BL, 1997, GENOMICS, V41, P294, DOI 10.1006/geno.1997.4626; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Fukunaga K, 2001, EUR RESPIR J, V17, P59, DOI 10.1183/09031936.01.17100590; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Hamid Q, 2004, J ALLERGY CLIN IMMUN, V113, P182, DOI 10.1016/j.jaci.2003.10.058; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HEDRIC PW, 1978, GENETICS, V117, P331; ISOBE M, 1992, GENOMICS, V14, P755, DOI 10.1016/S0888-7543(05)80180-6; KAPLAN N, 1992, AM J HUM GENET, V51, P333; Kay AB, 2005, TRENDS MOL MED, V11, P148, DOI 10.1016/j.molmed.2005.02.002; Kotsimbos ATC, 1997, MEM I OSWALDO CRUZ, V92, P75, DOI 10.1590/S0074-02761997000800012; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Park CS, 2005, INT ARCH ALLERGY IMM, V136, P295, DOI 10.1159/000083957; Ravensberg AJ, 2005, J ALLERGY CLIN IMMUN, V115, P779, DOI 10.1016/j.jaci.2004.11.045; Rothenberg ME, 2001, IMMUNOL REV, V179, P139, DOI 10.1034/j.1600-065X.2001.790114.x; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Unoki M, 2000, HUM GENET, V106, P440, DOI 10.1007/s004390000267; van Rensen ELJ, 2001, THORAX, V56, P935, DOI 10.1136/thorax.56.12.935; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; WEIL GJ, 1981, BLOOD, V57, P1099; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413, DOI 10.1164/ajrccm.155.4.9105087; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zeibecoglou K, 1999, J ALLERGY CLIN IMMUN, V103, P99, DOI 10.1016/S0091-6749(99)70532-4; Zimmermann N, 2000, BLOOD, V96, P2346; Zimmermann N, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-7; Zimmermann N, 1998, BBA-GENE STRUCT EXPR, V1442, P170, DOI 10.1016/S0167-4781(98)00162-6	41	30	30	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1110	1117		10.1016/j.jaci.2007.08.041	http://dx.doi.org/10.1016/j.jaci.2007.08.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17983872				2022-12-18	WOS:000250973400020
J	Garcia-Laorden, MI; Garcia-Saavedra, A; de Castro, FR; Violan, LS; Rajas, O; Blanquer, J; Borderias, L; Rodriguez-Gallego, C				Garcia-Laorden, M. Isabel; Garcia-Saavedra, Ayoze; Rodriguez de Castro, Felipe; Violan, Lordi Sole; Rajas, Olga; Blanquer, Jose; Borderias, Luis; Rodriguez-Gallego, Carlos			Low clinical penetrance of mannose-binding lectin-associated serine protease 2 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							2 PARTS; POPULATION; IMMUNOLOGY		Hosp Univ Gran Canaria Dr Negrin, Dept Immunol, Las Palmas Gran Canaria, Spain; Hosp Univ Gran Canaria Dr Negrin, Dept Resp Dis, Las Palmas Gran Canaria, Spain; Hosp Univ Gran Canaria Dr Negrin, Dept Immunol, Las Palmas Gran Canaria, Spain; Hosp Univ Gran Canaria Dr Negrin, Dept Resp Dis, Las Palmas Gran Canaria, Spain; Hosp Univ Gran Canaria Dr Negrin, Intens Care Unit, Las Palmas Gran Canaria, Spain; Hosp La Princesa, Dept Resp Dis, Madrid, Spain; Hosp Clin & Univ, Intens Care Unit, Valencia, Spain; Hosp San Jorge, Dept Resp Dis, Huesca, Spain	Hospital de La Princesa; Hospital Clinic Universitari de Valencia; Hospital Universidad San Jorge	Garcia-Laorden, MI (corresponding author), Hosp Univ Gran Canaria Dr Negrin, Dept Immunol, Las Palmas Gran Canaria, Spain.	jrodgal@gobiernodecanarias.org	de Castro, Felipe Rodriguez/R-8416-2019; RODRIGUEZ-GALLEGO, CARLOS/AAB-7516-2022; García-Laorden, M. Isabel/B-3649-2019	Rodriguez de Castro, Felipe/0000-0002-6812-2739; Borderias, Luis/0000-0003-3296-9644; Rodriguez-Gallego, Carlos/0000-0002-4344-8644				Casanova JL, 2004, J EXP MED, V199, P1295, DOI 10.1084/jem.20040537; Cedzynski M, 2004, CLIN EXP IMMUNOL, V136, P304, DOI 10.1111/j.1365-2249.2004.02453.x; Garcia-Laorden MI, 2006, MOL IMMUNOL, V43, P2143, DOI 10.1016/j.molimm.2006.01.008; Garcia-Laorden MI, 2001, GENES IMMUN, V2, P292, DOI 10.1038/sj.gene.6363778; Lozano F, 2005, TISSUE ANTIGENS, V66, P131, DOI 10.1111/j.1399-0039.2005.00436.x; Notarangelo L, 2006, J ALLERGY CLIN IMMUN, V117, P883, DOI 10.1016/j.jaci.2005.12.1347; Seyfarth J, 2005, HUM MOL GENET, V14, P2859, DOI 10.1093/hmg/ddi318; Sorensen R, 2005, SPRINGER SEMIN IMMUN, V27, P299, DOI 10.1007/s00281-005-0006-z; Stengaard-Pedersen K, 2003, NEW ENGL J MED, V349, P554, DOI 10.1056/NEJMoa022836; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506	11	30	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1383	1386		10.1016/j.jaci.2006.08.004	http://dx.doi.org/10.1016/j.jaci.2006.08.004			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17137870				2022-12-18	WOS:000242880300029
J	Gold, DR; Willwerth, BM; Tantisira, KG; Finn, PW; Schaub, B; Perkins, DL; Tzianabos, A; Ly, NP; Schroeter, C; Gibbons, F; Campos, H; Oken, E; Gillman, MW; Palmer, LJ; Ryan, LM; Weiss, ST				Gold, DR; Willwerth, BM; Tantisira, KG; Finn, PW; Schaub, B; Perkins, DL; Tzianabos, A; Ly, NP; Schroeter, C; Gibbons, F; Campos, H; Oken, E; Gillman, MW; Palmer, LJ; Ryan, LM; Weiss, ST			Associations of cord blood fatty acids with lymphocyte proliferation, IL-13, and IFN-gamma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; child; cord blood; cytokine; fatty acids; lymphocyte proliferation	EICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; CYTOKINE PRODUCTION; INTERFERON-GAMMA; ASTHMA; SUPPLEMENTATION; PREGNANCY; RESPONSES; OUTCOMES; CELLS	Background: N-3 and n-6 polyunsaturated fatty acids (PUFAs) have been hypothesized to have opposing influences on neonatal immune responses that might influence the risk of allergy or asthma. However, both n-3 eicosapentaenoic acid (EPA) and n-6 arachidonic acid (AA) are required for normal fetal development. Objective: We evaluated whether cord blood fatty acid levels were related to neonatal immune responses and whether n-3 and n-6 PUFA responses differed. Methods: We examined the relation of cord blood plasma n-3 and n-6 PUFAs (n = 192) to antigen- and mitogen-stimulated cord blood lymphocyte proliferation (n = 191) and cytokine (IL-13 and TFN-gamma; n = 167) secretion in a US birth cohort. Results: Higher levels of n-6 linoleic acid were correlated with higher IL-13 levels in response to Bla g 2 (cockroach, P = .009) and Der f 1 (dust mite, P = .02). Higher n-3 EPA and n-6 AA levels were each correlated with reduced lymphocyte proliferation and IFN-gamma levels in response to Bla g 2 and Der f 1 stimulation. Controlling for potential confounders, EPA and AA had similar independent effects on reduced allergen-stimulated IFN-gamma levels. If neonates had either EPA or AA levels in the highest quartile, their Der f 1 IFN-gamma levels were 90% lower (P = .0001) than those with both EPA and AA levels in the lowest 3 quartiles. Reduced AA/EPA ratio was associated with reduced allergen-stimulated IFN-gamma level. Conclusion: Increased levels of fetal n-3 EPA and n-6 AA might have similar effects on attenuation of cord blood lymphocyte proliferation and IFN-gamma secretion. Clinical implications: The implications of these findings for allergy or asthma development are not yet known.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Childrens Hosp, Div Emergency Med, Boston, MA USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Cambridge, MA 02138 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA; Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Pilgrim Health Care; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center	Gold, DR (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	diane.gold@channing.harvard.edu	Ryan, Louise M/A-4562-2009; Schaub, Bianca/B-9935-2019; Palmer, Lyle John/K-3196-2014; Palmer, Lyle John/N-1948-2019	Ryan, Louise M/0000-0001-5957-2490; Schaub, Bianca/0000-0003-1652-8873; Palmer, Lyle John/0000-0002-1628-3055; Palmer, Lyle John/0000-0002-1628-3055	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034568, R37HD034568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL068041, R01HL061907, R01HL064925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI035786, R01AI035786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68041, HL64925, K24 HL068041, R01 HL61907, R01 HL064925] Funding Source: Medline; NIAID NIH HHS [AI35786, R01 AI035786] Funding Source: Medline; NICHD NIH HHS [R37 HD034568, R01 HD034568, HD34568] Funding Source: Medline; NIDDK NIH HHS [P30 DK040561-11, P30 DK040561] Funding Source: Medline; PHS HHS [EHS35786] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baylin A, 2002, AM J CLIN NUTR, V76, P750, DOI 10.1093/ajcn/76.4.750; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Byleveld PM, 1999, J NUTR, V129, P328, DOI 10.1093/jn/129.2.328; Calder PC, 1998, IMMUNOL TODAY, V19, P244, DOI 10.1016/S0167-5699(98)01264-X; Dooper MMBW, 2002, IMMUNOLOGY, V107, P152, DOI 10.1046/j.1365-2567.2002.01474.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Fritsche KL, 2000, J INFECT DIS, V182, pS54, DOI 10.1086/315925; Herrera E, 2002, PLACENTA, V23, pS9, DOI 10.1053/plac.2002.0771; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Newson RB, 2004, J ALLERGY CLIN IMMUN, V114, P531, DOI 10.1016/j.jaci.2004.05.010; Ngoc LP, 2005, CURR OPIN ALLERGY CL, V5, P161, DOI 10.1097/01.all.0000162309.97480.45; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Thies F, 2001, J NUTR, V131, P1918, DOI 10.1093/jn/131.7.1918; Thornton CA, 2004, J IMMUNOL, V173, P3084, DOI 10.4049/jimmunol.173.5.3084; Verlengia R, 2004, J NUTR BIOCHEM, V15, P657, DOI 10.1016/j.jnutbio.2004.04.008	17	30	31	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					931	938		10.1016/j.jaci.2005.12.1322	http://dx.doi.org/10.1016/j.jaci.2005.12.1322			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630954	Green Accepted, Bronze			2022-12-18	WOS:000236862800032
J	Shanmugam, G; Schwartz, LB; Khan, DA				Shanmugam, G; Schwartz, LB; Khan, DA			Prolonged elevation of serum tryptase in idiopathic anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Internal Med, Div Rheumatol, Richmond, VA 23298 USA; Univ Texas, SW Med Ctr, Div Allergy & Immunol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Virginia Commonwealth University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shanmugam, G (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							Lenchner K, 2003, CURR OPIN ALLERGY CL, V3, P305, DOI 10.1097/01.all.0000083959.99396.1a; Schwartz Lawrence B, 2004, Novartis Found Symp, V257, P65; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; TANUS T, 1994, ANN EMERG MED, V24, P104, DOI 10.1016/S0196-0644(94)70169-5	5	30	31	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					950	951		10.1016/j.jaci.2005.12.1356	http://dx.doi.org/10.1016/j.jaci.2005.12.1356			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630958	Bronze			2022-12-18	WOS:000236862800036
J	Gore, RB; Curbishley, L; Truman, N; Hadley, E; Woodcock, A; Langley, SJ; Custovic, A				Gore, RB; Curbishley, L; Truman, N; Hadley, E; Woodcock, A; Langley, SJ; Custovic, A			Intranasal air sampling in homes: Relationships among reservoir allergen concentrations and asthma severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen exposure; sensitization; nasal air sampling; asthma severity; bronchial reactivity	EXHALED NITRIC-OXIDE; MAJOR DOG ALLERGEN; CAT ALLERGEN; BRONCHIAL RESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; PERSONAL EXPOSURE; INDOOR ALLERGENS; MITE ALLERGEN; F-I; CHILDREN	Background: The relationship among inhaled allergen exposure, sensitization, and asthma severity is unknown. Objectives: To investigate the relationship among personal allergen exposure, reservoir dust allergen concentrations, and physiological measures of asthma severity; to examine the numbers of particles inspired that react with autologous IgE and IgG(4). Methods: A total of 117 patients with asthma wore 5 nasal air samplers (NASs) at home: I each for exposure to mile, cat and dog allergens, NAS-IgE, and NAS-IgG(4). NASs were processed by HALOgen assay for allergen measurement and incubated with autologous serum for detection of NAS-IgE and NAS-IgG(4). Reservoir allergen concentrations were measured by HASA. Subjects' asthma severity was ascertained by measurement of lung function, exhaled nitric oxide, and nonspecific bronchial reactivity to histamine. Results: Nasal air sampler counts correlated with reservoir concentrations for cat (r = 0.31, P = .001) and dog (r = 0.20; P = .03) but not mite allergen (r = 0.001; P = 1.0). There was no significant relationship between sensitization with exposure measured by NAS to any allergen and PD20FEV1 (F[3,60] = 1.60; P = .20); however, sensitization with exposure in dust reservoirs had significant effects on PD20FEV1 for any allergen (F[3,59] = 3.12; P = .03), cat (F[3,59] = 3.77; P = .01), and mite (F[3,59] = 2.78; P = .05), but not clog (F[3,59] = 1.06; P = .37). We repeated the analysis with separate variables for sensitization and exposure, controlling for the confounders; sensitization but not exposure conferred lower PD20FEV1 values. However, increasing cat allergen exposure was associated with improving bronchial reactivity in not cat-sensitized patients. NAS-IgE and NAS-IgG(4) counts bore no relationship to any measure of asthma severity. Conclusion: Nasal air samplers confer no advantage over reservoir dust analysis for studies of asthma severity. Clinical implications: In common with other measures of exposure, single nasal air samples do not provide a useful measure of home allergen exposure for the individual patient with allergic asthma.	Univ Manchester, Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Gore, RB (corresponding author), Univ Manchester, Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578				Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Altman DG, 1991, PRACTICAL STAT MED R, P122; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860, DOI 10.1164/ajrccm.164.10.2010138; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262, DOI 10.1164/ajrccm.159.1.9804063; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gore RB, 2003, CLIN EXP ALLERGY, V33, P765, DOI 10.1046/j.1365-2222.2003.01678.x; Gore RB, 2003, J ALLERGY CLIN IMMUN, V111, P784, DOI 10.1067/mai.2003.1378; Gore RB, 2002, CLIN EXP ALLERGY, V32, P856, DOI 10.1046/j.1365-2222.2002.01403.x; Graham JAH, 2000, ANN ALLERG ASTHMA IM, V84, P599, DOI 10.1016/S1081-1206(10)62410-6; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Karlsson AS, 2002, CLIN EXP ALLERGY, V32, P1776, DOI 10.1046/j.1365-2222.2002.01553.x; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; Mitakakis TZ, 2002, CLIN EXP ALLERGY, V32, P1166, DOI 10.1046/j.1365-2745.2002.01432.x; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; O'Meara TJ, 1998, LANCET, V351, P1488, DOI 10.1016/S0140-6736(05)78870-X; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323, DOI 10.1016/S0091-6749(99)70031-X; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Poulos LM, 1999, CLIN EXP ALLERGY, V29, P1232, DOI 10.1046/j.1365-2222.1999.00613.x; Preller L, 2004, ANN OCCUP HYG, V48, P643, DOI 10.1093/annhyg/meh045; Renstrom A, 2002, CLIN EXP ALLERGY, V32, P1769, DOI 10.1046/j.1365-2222.2002.01545.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1040, DOI 10.1016/S0091-6749(96)70255-5; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; Tanaka H, 2002, INFLAMM RES, V51, P307, DOI 10.1007/PL00000309; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Wong TW, 2002, OCCUP ENVIRON MED, V59, P30, DOI 10.1136/oem.59.1.30; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	45	30	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					649	655		10.1016/j.jaci.2005.12.1351	http://dx.doi.org/10.1016/j.jaci.2005.12.1351			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522466	Bronze			2022-12-18	WOS:000236263100022
J	Roponen, M; Hyvarinen, A; Hirvonen, MR; Keski-Nisula, L; Pekkanen, J				Roponen, M; Hyvarinen, A; Hirvonen, MR; Keski-Nisula, L; Pekkanen, J			Change in IFN-gamma-producing capacity in early life and exposure to environmental microbes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; cord blood; cytokines; endotoxin; IFN-gamma; IL; microbes; T-H cell	HOUSE-DUST ENDOTOXIN; TOLL-LIKE RECEPTORS; INTERFERON-GAMMA; ALLERGIC SENSITIZATION; CYTOKINE PRODUCTION; DOG OWNERSHIP; 1ST YEAR; ATOPY; BLOOD; PREVALENCE	Background: Exposure to environmental microbes in early life might lead to type 1-skewed T cell responses and therefore reduce the risk of allergic diseases. Objective: To investigate whether the cytokine responses at birth and at age 3 months are associated with environmental factors, especially exposure to microbes. Living in a farm, level of house dust endotoxin, cleanliness of the home, and presence of cats and dogs in the household were studied as possible determinants of cytokine production. Methods: Twelve farmers' and 17 nonfarmers' children were studied. Production of IL-4, IL-6, TNF-alpha, and IFN-gamma in cord blood and in peripheral blood at 3 months was measured after 8-hour and 24-hour stimulation with phorbol ester plus concanavalin A. Results: IFN-gamma responses at age 3 months were associated with farming (median, 53 vs 17 pg/mL; P =.019) and cats and dogs (49 vs 14 pg/mL; P =.014) (8 hours). Change in IFN-gamma-producing capacity from birth to 3 months was larger in children with higher than median endotoxin concentration in bed dust (P =.038) and in children with a cat or dog (P =.005) (8 hours). Increased IL-6 responses at birth were associated with cat or dog exposure (P =.004; 8 hours) and endotoxin level in settled dust (P =.039; 24 hours). Conclusion: The development of IFN-gamma-producing capacity during the first 3 months of life is associated with farming, endotoxin in house dust, and cat and dog exposure. These environmental characteristics may indicate some microbial exposure capable of driving developing immune system toward T(H)1 responses.	Kuopio Univ Hosp, Dept Obstet, SF-70210 Kuopio, Finland; Natl Publ Hlth Inst, Dept Environm Hlth, FI-70101 Kuopio, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland	Kuopio University Hospital; University of Eastern Finland; Finland National Institute for Health & Welfare; University of Eastern Finland	Roponen, M (corresponding author), Natl Publ Hlth Inst, Dept Environm Hlth, POB 95, FI-70101 Kuopio, Finland.	Marjut.Roponen@ktl.fi	Roponen, Marjut/C-2086-2017	Roponen, Marjut/0000-0002-4442-9090; Hyvarinen, Anne/0000-0002-2823-0866				Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Benson M, 2000, PEDIAT ALLERG IMM-UK, V11, P20, DOI 10.1034/j.1399-3038.2000.00051.x; Bischof W, 2002, INDOOR AIR, V12, P2, DOI 10.1034/j.1600-0668.2002.120102.x; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2003, CLIN EXP ALLERGY, V33, P409, DOI 10.1046/j.1365-2222.2003.01650.x; Chalmers IMH, 1998, BLOOD, V92, P11, DOI 10.1182/blood.V92.1.11.413a39_11_18; Dabbagh K, 2003, CURR OPIN INFECT DIS, V16, P199, DOI 10.1097/00001432-200306000-00003; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Eisenbarth SC, 2003, CURR OPIN IMMUNOL, V15, P620, DOI 10.1016/j.coi.2003.09.003; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Hagendorens MM, 2000, PEDIATR ALLERGY IMMU, V11, P12, DOI 10.1034/j.1399-3038.2000.00054.x; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Holt Patrick G, 2004, Paediatr Respir Rev, V5 Suppl A, pS27, DOI 10.1016/S1526-0542(04)90006-1; HYVARINEN A, IN PRESS INDOOR AIR; Jokic M, 2000, BRIT J OBSTET GYNAEC, V107, P420, DOI 10.1111/j.1471-0528.2000.tb13241.x; Keski-Nisula L, 2004, EUR CYTOKINE NETW, V15, P67; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; TANG MLK, 1994, CLIN EXP IMMUNOL, V97, P483; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230	37	30	31	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1048	1052		10.1016/j.jaci.2005.08.039	http://dx.doi.org/10.1016/j.jaci.2005.08.039			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275374				2022-12-18	WOS:000235686700015
J	Enrique, E; Ahrazem, O; Bartra, J; Latorre, MD; Castello, JV; de Mateo, JA; Montoya, E; Malek, T; Barber, D; Salcedo, G				Enrique, E; Ahrazem, O; Bartra, J; Latorre, MD; Castello, JV; de Mateo, JA; Montoya, E; Malek, T; Barber, D; Salcedo, G			Lipid transfer protein is involved in rhinoconjunctivitis and asthma produced by rice inhalation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGENS; FOOD		Hosp Gen Castellon, Dept Allergy, Castellon 12004, Spain; ETS Ingn Agronomos, Unidad Bioquim, Dept Biotecnol, Madrid, Spain; Hosp Gen Girona Dr Joseph Trueta, Dept Allergy, Girona, Spain; Hosp Prov Castellon, RIA Dept, Castellon, Spain; ALK Abello, Dept I&D, Madrid, Spain	Universitat de Girona; Girona University Hospital Dr. Josep Trueta; ALK-Abello AS	Enrique, E (corresponding author), Hosp Gen Castellon, Dept Allergy, Avda Benicasim S-N, Castellon 12004, Spain.		Ahrazem, Oussama/E-5602-2016; Bartra, Joan/L-4550-2014; Barber, Domingo/Y-9516-2019; Ahrazem, oussama/AAV-1392-2021	Ahrazem, Oussama/0000-0001-9183-9319; Bartra, Joan/0000-0001-7767-4730; Barber, Domingo/0000-0002-5488-5700; Ahrazem, oussama/0000-0001-9183-9319				Asero R, 2001, ANN ALLERG ASTHMA IM, V87, P65, DOI 10.1016/S1081-1206(10)62325-3; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; Fiocchi A, 2003, J ALLERGY CLIN IMMUN, V111, P193, DOI 10.1067/mai.2003.12; Garcia-Casado G, 2001, J ALLERGY CLIN IMMUN, V108, P647, DOI 10.1067/mai.2001.118793; Gonzalez-Mendiola R, 2003, ALLERGY, V58, P1202, DOI 10.1046/j.0105-4538.2003.00311.x; Lee JY, 1998, J MOL BIOL, V276, P437, DOI 10.1006/jmbi.1997.1550; Nakase M, 1998, ALLERGY, V53, P55, DOI 10.1111/j.1398-9995.1998.tb04962.x; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Salcedo G, 2004, CLIN EXP ALLERGY, V34, P1336, DOI 10.1111/j.1365-2222.2004.02018.x; Salcedo G., 2004, PLANT FOOD ALLERGENS, P70, DOI DOI 10.1002/9780470995174.CH5	10	30	31	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					926	928		10.1016/j.jaci.2005.05.041	http://dx.doi.org/10.1016/j.jaci.2005.05.041			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210073	Bronze			2022-12-18	WOS:000235686600033
J	Reisinger, J; Triendl, A; Kuchler, E; Bohle, B; Krauth, MT; Rauter, I; Valent, P; Koenig, F; Valenta, R; Niederberger, V				Reisinger, J; Triendl, A; Kuchler, E; Bohle, B; Krauth, MT; Rauter, I; Valent, P; Koenig, F; Valenta, R; Niederberger, V			IFN-gamma-enhanced allergen penetration across respiratory epithelium augments allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; allergen penetration; respiratory epithelium; IFN-gamma	MESSENGER-RNA EXPRESSION; COLONY-STIMULATING FACTOR; BIRCH POLLEN ALLERGEN; NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; T-CELLS; ATOPIC-DERMATITIS; BARRIER FUNCTION; MAJOR ALLERGEN; TIMOTHY-GRASS	Background: Respiratory allergen contact is the critical event in the elicitation and boosting of allergen-specific immune responses, as well as in the induction of immediate and late inflammatory reactions. Objective: We sought to investigate the influence of various factors of allergic inflammation on the integrity and barrier function of respiratory epithelium for allergens. Methods: We cultured the human bronchial epithelial cell line 16HBE14o- in a transwell culture system as a surrogate of intact respiratory epithelium and used purified iodine 125-labeled recombinant major birch pollen allergen (rBet v 1) to study the extent, kinetics, and factors influencing transepithelial allergen penetration. Results: Culture supernatants from activated allergen-specific T(H)1 clones decreased transepithelial resistance. A screening of various factors (histamine, IFN-gamma, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-8, IL-12, and TNF-alpha) identified IFN-gamma as a potent factor capable of reducing epithelial barrier properties and enhancing transepithelial allergen penetration. Increased submucosal allergen concentrations caused by IFN-gamma-mediated reduction of epithelial barrier function provoked a more than 7-fold augmentation of histamine release from sensitized basophils. Conclusion: These results demonstrate that the T(H)1 cell-derived cytokine IFN-gamma facilitates allergen penetration through the respiratory epithelium and thereby can aggravate allergic inflammation.	Med Univ Vienna, Dept Otorhinolaryngol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Med Biochem, A-1090 Vienna, Austria; Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Internal Med, A-1090 Vienna, Austria; Med Univ Vienna, Dept Med Stat, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Niederberger, V (corresponding author), Med Univ Vienna, Dept Otorhinolaryngol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Verena.Niederberger@meduniwien.ac.at	Valent, Peter/B-8533-2016; Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Gamperl, Susi/V-2715-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Bohle, Barbara/0000-0002-5105-7985; Konig, Franz/0000-0002-6893-3304; Valenta, Rudolf/0000-0001-5944-3365				ADAMS RB, 1993, J IMMUNOL, V150, P2356; Bischoff SC, 2000, INT ARCH ALLERGY IMM, V121, P270, DOI 10.1159/000024340; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BUFE A, 1995, FEBS LETT, V363, P6, DOI 10.1016/0014-5793(95)00259-C; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Denburg J, 1999, ALLERGY, V54, P73, DOI 10.1111/j.1398-9995.1999.tb04408.x; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128, DOI 10.1159/000237525; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1998, CLIN EXP ALLERGY, V28, P11; EBNER C, 1993, J IMMUNOL, V150, P1047; Fish SM, 1999, GUT, V45, P191, DOI 10.1136/gut.45.2.191; Forbes B, 2003, INT J PHARM, V257, P161, DOI 10.1016/S0378-5173(03)00129-7; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Sambrook J, 1989, MOL CLONING LAB MANU, V1, P1; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; Tedelind S, 2003, EUR J ENDOCRINOL, V149, P215, DOI 10.1530/eje.0.1490215; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VRTALA S, 1993, J IMMUNOL, V151, P4773; Wan H, 2000, EUR RESPIR J, V15, P1058, DOI 10.1034/j.1399-3003.2000.01514.x; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; YOUAKIM A, 1993, GASTROINTEST LIVER P, V39, pG1279; Yssel H, 2000, INT ARCH ALLERGY IMM, V121, P10, DOI 10.1159/000024292	32	30	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					973	981		10.1016/j.jaci.2005.01.021	http://dx.doi.org/10.1016/j.jaci.2005.01.021			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867854				2022-12-18	WOS:000229055100012
J	Schatz, M; Mosen, D; Apter, AJ; Zeiger, RS; Vollmer, WM; Stibolt, TB; Leong, A; Johnson, MS; Mendoza, G; Cook, EF				Schatz, M; Mosen, D; Apter, AJ; Zeiger, RS; Vollmer, WM; Stibolt, TB; Leong, A; Johnson, MS; Mendoza, G; Cook, EF			Relationship of validated psychometric tools to subsequent medical utilization for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						quality of life; psychometric tools; asthma control; asthma severity; hospitalization; emergency care; antiasthmatic drugs	QUALITY-OF-LIFE; HEALTH-CARE UTILIZATION; COMPUTER-BASED MODELS; RISK-FACTORS; QUESTIONNAIRE; PROGRAM; ADULTS; MANAGEMENT; HOSPITALIZATION; ASSOCIATION	Background: Risk stratification is used to identify patients with asthma at increased risk of experiencing morbidity and resource utilization. Validated psychometric tools are infrequently studied sources of data for this purpose. Purpose: To evaluate 4 types of validated psychometric tools as predictors for subsequent asthma utilization and determine their clinical usefulness. Methods: Eleven hundred patients with active asthma from a Health Maintenance Organization completed surveys that included demographic information and validated psychometric tools measuring generic quality of life (physical and mental components), asthma-specific quality of life, asthma control, and asthma symptom severity. Survey records were linked to administrative data that captured emergency department and hospital care, short-acting beta-agonist, and oral corticosteroid utilization for the year of and the year following the survey. Relationships of survey variables with subsequent utilization were assessed, adjusting for both baseline demographic and asthma utilization factors. Results: Scores of each psychometric tool were significantly related to subsequent utilization in univariate analyses and after adjusting for baseline utilization and demographic risk factors. Patients with higher scale-defined morbidity were as much as 4 times more likely to have subsequent utilization (sensitivity as high as 58%; specificity as high as 78%). Addition of an asthma-specific tool to either demographic or utilization prediction models added sensitivity (as much as 15%) but did not substantially improve the prediction properties of models containing both demographic and utilization predictors. Conclusion: Validated psychometric tools appear useful for asthma risk stratification in individuals and in populations in which both utilization and demographic predictors are not available.	Dept Allergy, San Diego, CA USA; Dept Allergy, Sacramento, CA USA; Dept Allergy, Vacaville, CA USA; Ctr Hlth Res, Portland, OR USA; Care Management Inst, Oakland, CA USA; Kaiser Permanente Med Care Program, Portland, OR USA; Univ Penn, Sch Med, Dept Pulm & Crit Care Med, Div Allergy Immunol, Philadelphia, PA 19104 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Kaiser Permanente; University of Pennsylvania; Harvard University; Harvard T.H. Chan School of Public Health	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	michael.x.schatz@kp.org	Leong, Albin/AAF-7215-2019	Zeiger, Robert/0000-0001-5788-5063				Abramson MJ, 2001, AM J RESP CRIT CARE, V163, P12, DOI 10.1164/ajrccm.163.1.9910042; Apter AJ, 1999, J ALLERGY CLIN IMMUN, V103, P72, DOI 10.1016/S0091-6749(99)70528-2; Balkrishnan R, 2000, J ASTHMA, V37, P415, DOI 10.3109/02770900009055467; Bayliss MS, 2000, QUAL LIFE RES, V9, P451, DOI 10.1023/A:1008939328060; BAYLISS MS, 1999, ASTHMA OUTCOMES MONI; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; Castro M, 2003, AM J RESP CRIT CARE, V168, P1095, DOI 10.1164/rccm.200208-877OC; Cote J, 2001, AM J RESP CRIT CARE, V163, P1415, DOI 10.1164/ajrccm.163.6.2006069; Cowie RL, 2001, J ASTHMA, V38, P179, DOI 10.1081/JAS-100000037; Eisner MD, 2002, ANN ALLERG ASTHMA IM, V89, P46, DOI 10.1016/S1081-1206(10)61910-2; Eisner MD, 2001, RESP RES, V2, P53, DOI 10.1186/rr37; George MR, 1999, ARCH INTERN MED, V159, P1710, DOI 10.1001/archinte.159.15.1710; Grana J, 1997, Am J Med Qual, V12, P113, DOI 10.1177/0885713X9701200205; Jones K, 1999, BRIT J GEN PRACT, V49, P23; Jowers JR, 2000, AM J MANAG CARE, V6, P585; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Katz PP, 1999, J CLIN EPIDEMIOL, V52, P667, DOI 10.1016/S0895-4356(99)00026-8; LI D, 1995, AM J RESP CRIT CARE, V151, P647; Lieu TA, 1998, AM J RESP CRIT CARE, V157, P1173, DOI 10.1164/ajrccm.157.4.9708124; Lieu TA, 1999, J ASTHMA, V36, P359, DOI 10.3109/02770909909068229; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Ng TP, 2000, BRIT J GEN PRACT, V50, P7; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Osman LM, 2000, AM J RESP CRIT CARE, V161, P498, DOI 10.1164/ajrccm.161.2.9904063; Rhodes L., 2004, Morbidity and Mortality Weekly Report, V53, P145; Ried LD, 1999, QUAL LIFE RES, V8, P491, DOI 10.1023/A:1008974406669; Schatz M, 2004, AM J MANAG CARE, V10, P25; Schatz M, 2003, AM J MANAG CARE, V9, P538; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STEEN N, 1994, BRIT MED J, V309, P1065, DOI 10.1136/bmj.309.6961.1065; TIEMEY WM, 2004, J GEN INTERN MED, V19, P237; Tough S C, 1999, Can Respir J, V6, P429; Van Ganse E, 2001, J ASTHMA, V38, P637, DOI 10.1081/JAS-100107541; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Wakefield M, 1997, CHEST, V112, P1527, DOI 10.1378/chest.112.6.1527; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	40	30	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					564	570		10.1016/j.jaci.2004.12.005	http://dx.doi.org/10.1016/j.jaci.2004.12.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753905				2022-12-18	WOS:000227687000020
J	Pignatti, P; Moscato, G; Casarini, S; Delmastro, M; Poppa, M; Brunetti, G; Pisati, P; Balbi, B				Pignatti, P; Moscato, G; Casarini, S; Delmastro, M; Poppa, M; Brunetti, G; Pisati, P; Balbi, B			Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; chronic obstructive pulmonary disease; neutrophils; CXC chemokine receptor 1; CXC chemokine receptor 2; CXCL8/IL-8	EXPRESSION; SPUTUM; ASTHMA; INTERLEUKIN-8; INFLAMMATION; EOSINOPHILS; CHEMOKINE; CXCR1; DITHIOTHREITOL; METHODOLOGY	Background: CXCL8/IL-8 is the most significant chemokine for neutrophils, and CXC chemokine receptor (CXCR) 1 and 2 are its 2 receptors, which are downmodulated by CXCL8/IL-8 and endotoxin on activated neutrophils. Objective: We sought to evaluate the expression of the CXCL8/ IL-8 receptors and the activation marker CD11b on neutrophils in peripheral blood and in the site of airway inflammation. Methods: The flow cytometric expression of CXCR1, CXCR2, and CD11b was evaluated on peripheral blood and induced sputum neutrophils in patients with nonsevere asthma with greater than 60% sputum neutrophils, in patients with chronic obstructive pulmonary disease (COPD), and in healthy control subjects. Results: Asthmatic patients and patients with COPD had comparable expressions of CXCR1, CXCR2, and CD11b on peripheral blood and sputum neutrophils. Compared with control subjects, the peripheral neutrophil expression of CXCR2 was lower in patients with COPD (P =.03) and that of CD11b was higher in asthmatic patients and patients with COPD (P <.02 and P <.002). The expression of the CXCL8/ IL-8 receptors on sputum neutrophils was markedly lower than on peripheral blood neutrophils (P <.0001). The downmodulation of CXCL8/IL-8 receptors was also present in healthy control subjects but less than that seen in asthmatic patients. The difference between peripheral blood and sputum expression of CXCL8/IL-8 receptors correlated with serum CXCL8/IL-8 levels. In asthmatic patients the expression of CXCR1 and CXCR2 on sputum neutrophils negatively correlated with sputum neutrophils. Conclusion: In neutrophilic asthma the expression of CXCL8/ IL-8 receptors on peripheral and sputum neutrophils is similar to COPD and negatively correlated with the inflammatory infiltrate in the airways. The downmodulation of CXCL8/IL-8 receptors detected in the airways should be taken into account for an eventual therapeutic inhibition of these receptors.	IRCCS, Fdn Salvatore Maugeri, Div Pneumol, I-27100 Pavia, Italy; IRCCS, Fdn Salvatore Maugeri, Ist Sci Pavia, Serv Med Nucl, I-27100 Pavia, Italy; IRCCS, Fdn Salvatore Maugeri, Clin Laboro & Riabilitaz, Inst Sci Gussago,Div Pneumol, I-27100 Pavia, Italy	Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia	Pignatti, P (corresponding author), Ctr Med Pavia, Fdn Salvatore Maugeri, Serv Autonomo Allergol & Immunol, Loc Cravino,Via Ferrata 8, I-27100 Pavia, Italy.	ppignatti@fsm.it	Balbi, Bruno/E-8380-2019; Pignatti, Patrizia/K-9595-2016	Balbi, Bruno/0000-0002-4439-1424; Pignatti, Patrizia/0000-0001-5283-3897				CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Cummings CJ, 1999, J IMMUNOL, V162, P2341; Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Eddleston J, 2003, J ALLERGY CLIN IMMUN, V111, P106, DOI 10.1067/mai.2003.19; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Gauvreau Gail M, 2002, Can Respir J, V9, P26; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Khandaker MH, 1999, BLOOD, V93, P2173, DOI 10.1182/blood.V93.7.2173.407a06_2173_2185; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Li F, 2002, BIOCHEM BIOPH RES CO, V293, P939, DOI 10.1016/S0006-291X(02)00318-2; Little SA, 2002, AM J MED, V112, P446, DOI 10.1016/S0002-9343(02)01047-1; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Mackarel AJ, 2000, AM J RESP CELL MOL, V23, P154, DOI 10.1165/ajrcmb.23.2.3853; *NAT ASTHM ED PREV, 1997, GUID DIAGN MAN ASTH; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pignatti P, 2002, J ALLERGY CLIN IMMUN, V110, P667, DOI 10.1067/mai.2002.128279; Podolin PL, 2002, J IMMUNOL, V169, P6435, DOI 10.4049/jimmunol.169.11.6435; Qiu DW, 1999, J ALLERGY CLIN IMMUN, V103, P873, DOI 10.1016/S0091-6749(99)70432-X; Qiu YS, 2003, AM J RESP CRIT CARE, V168, P968, DOI 10.1164/rccm.200208-794OC; Sabroe I, 2003, J IMMUNOL, V170, P5268, DOI 10.4049/jimmunol.170.10.5268; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172, DOI 10.1164/ajrccm.162.3.9908057; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wolf M, 1998, EUR J IMMUNOL, V28, P164, DOI 10.1002/(SICI)1521-4141(199801)28:01<164::AID-IMMU164>3.0.CO;2-S; Wuyts Anja, 1998, P271	29	30	30	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					88	94		10.1016/j.jaci.2004.08.048	http://dx.doi.org/10.1016/j.jaci.2004.08.048			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637552	Bronze			2022-12-18	WOS:000226267000012
J	Sidorchuk, A; Wickman, M; Pershagen, G; Lagarde, F; Linde, A				Sidorchuk, A; Wickman, M; Pershagen, G; Lagarde, F; Linde, A			Cytomegalovirus infection and development of allergic diseases in early childhood: Interaction with EBV infection?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; children; cytomegalovirus; Epstein-Barr virus; risk factor; sensitization; seroprevalence	BARR-VIRUS-ANTIBODIES; ATOPIC-DERMATITIS; IMMUNE-RESPONSES; VIRAL-INFECTIONS; NO EVIDENCE; T-CELLS; ASTHMA; CHILDREN; TRANSMISSION; LYMPHOCYTES	Background: Chronic replication of cytomegalovirus and EBV in early life may affect the immune system and play a role in the development of allergy in children. Objective: To assess the relation between cytomegalovirus infection and allergic disorders in children, including a possible interaction with EBV infection. Methods: From a prospective birth cohort study in Stockholm, on factors of importance for development of allergy, 2581 four-year-old children were enrolled. The classification of allergic diseases was based on questionnaire answers and determination of IgE antibodies to common airborne and food allergens. IgG to cytomegalovirus was determined by a commercial ELISA and to EBV by indirect immunofluorescence. Results: A total of 1191 (46%) children were cytomegalovirus-seropositive. There were no significant associations between seropositivity to cytomegalovirus and allergic manifestations, such as bronchial asthma, suspected allergic rhinitis, or atopic dermatitis. Seropositivity to cytomegalovirus alone, ie, without seropositivity to EBV, was related to IgE antibodies to airborne and food allergens (adjusted odds ratio, 1.8; 95% CI, 1.2.. 2.9).An antagonism between cytomegalovirus and EBV in relation to sensitization to airborne and food allergens was suggested (P = .05). Conclusion: The study does not support the hypothesis that previous cytomegalovirus infection plays an important role in the pathogenesis of bronchial asthma, suspected allergic rhinitis, or atopic dermatitis in children. However, in the absence of EBV infection, cytomegalovirus infection may be related to sensitization to airborne and food allergens.	Karolinska Inst, Dept Virol, Swedish Inst Infect Dis Control, SE-17182 Solna, Sweden; Karolinska Inst, Dept Environm Epidemiol, Inst Environm Med, SE-17182 Solna, Sweden; Karolinska Inst, Microbiol & Tumorbiol Ctr, SE-17182 Solna, Sweden; Mech State Med Acad, Dept Epidemiol, St Petersburg, Russia; Stockholm Cty Council, Dept Occupat & Environm Hlth, Stockholm, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Karolinska Institutet; Karolinska Institutet; Stockholm County Council	Linde, A (corresponding author), Karolinska Inst, Dept Virol, Swedish Inst Infect Dis Control, SE-17182 Solna, Sweden.	annika.linde@smi.ki.se		Pershagen, Goran/0000-0002-9701-1130				Aarnisalo J, 2003, SCAND J INFECT DIS, V35, P750, DOI 10.1080/00365540310015881; Ahlfors K, 1999, SCAND J INFECT DIS, V31, P443, DOI 10.1080/00365549950163969; Aihara M, 2001, BRIT J DERMATOL, V144, P1231, DOI 10.1046/j.1365-2133.2001.04239.x; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; ANDERSSONELLSTROM A, 1995, SCAND J INFECT DIS, V27, P315, DOI 10.3109/00365549509032723; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; BAUMANN MA, 1992, BLOOD, V79, P1763; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Busse WW, 2000, J ALLERGY CLIN IMMUN, V105, pS593; Calvani M, 1997, PEDIATR ALLERGY IMMU, V8, P91, DOI 10.1111/j.1399-3038.1997.tb00150.x; CHANDLER SH, 1985, J INFECT DIS, V152, P249, DOI 10.1093/infdis/152.2.249; Chen SF, 2004, J INFECT DIS, V189, P1619, DOI 10.1086/383249; DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315; Docke WD, 2003, BRIT J DERMATOL, V148, P954, DOI 10.1046/j.1365-2133.2003.05263.x; FOWLER KB, 1993, J INFECT DIS, V168, P552, DOI 10.1093/infdis/168.3.552; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; Gern JE, 2000, J ALLERGY CLIN IMMUN, V106, P201, DOI 10.1067/mai.2000.108604; Gershon AA, 1997, VIRAL INFECT HUMANS, P229; GRILLNER L, 1988, J INFECT DIS, V157, P1080, DOI 10.1093/infdis/157.5.1080; GUTIERREZ J, 1994, J CLIN MICROBIOL, V32, P2603, DOI 10.1128/JCM.32.10.2603-2605.1994; Isolauri E, 1999, J PEDIATR-US, V134, P27, DOI 10.1016/S0022-3476(99)70368-9; JonkhoffSlok TW, 1997, EUR J PEDIATR, V156, P528, DOI 10.1007/s004310050654; Kallas EG, 1998, IMMUNOL LETT, V64, P63, DOI 10.1016/S0165-2478(98)00080-7; Klein SC, 1996, LEUKEMIA RES, V20, P633, DOI 10.1016/0145-2126(96)00029-X; Laske N, 2003, J ALLERGY CLIN IMMUN, V112, P210, DOI 10.1067/mai.2003.1548; Laske N, 2002, J ALLERGY CLIN IMMUN, V110, P811, DOI 10.1067/mai.2002.128593; LINDE A, 1987, J MED VIROL, V21, P109, DOI 10.1002/jmv.1890210203; LUCHT E, 1995, J INFECTION, V31, P189, DOI 10.1016/S0163-4453(95)80025-5; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Martinez FD, 1997, CIBA F SYMP, V206, P233; Message SD, 2002, BRIT MED BULL, V61, P29, DOI 10.1093/bmb/61.1.29; Numazaki K, 2001, LANCET, V357, P1799, DOI 10.1016/S0140-6736(00)04913-8; Ohnishi E, 1997, J INTERF CYTOK RES, V17, P597, DOI 10.1089/jir.1997.17.597; Okudaira H, 1999, INT ARCH ALLERGY IMM, V120, P177, DOI 10.1159/000024265; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Sheikh A, 2003, J ALLERGY CLIN IMMUN, V111, P131, DOI 10.1067/mai.2003.8; Sidorchuk A, 2003, PEDIATR INFECT DIS J, V22, P642, DOI 10.1097/00006454-200307000-00014; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; *STATA, 2001, STAT SOFTW REL 7 0 C; STRANNEGARD IL, 1981, INT ARCH ALLER A IMM, V64, P314, DOI 10.1159/000232709; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Vargas AL, 2001, CLIN EXP IMMUNOL, V125, P432, DOI 10.1046/j.1365-2249.2001.01614.x; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; WILSON CB, 1991, J PEDIATR-US, V118, pS4, DOI 10.1016/S0022-3476(05)82182-1	47	30	30	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1434	1440		10.1016/j.jaci.2004.08.009	http://dx.doi.org/10.1016/j.jaci.2004.08.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577849				2022-12-18	WOS:000225577400028
J	Salib, RJ; Kumar, S; Wilson, SJ; Howarth, PH				Salib, RJ; Kumar, S; Wilson, SJ; Howarth, PH			Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; immunohistochemistry; human; mast cells; antibodies; allergy; chemotaxis; TGF-beta; eotaxin; stem cell factor	INFLAMMATION; CHEMOKINES; MIGRATION; CCR3	Background: Allergic rhinitis is characterized by the epithelial accumulation of cells, particularly mast cells and eosinophils. There is little information relating to the chemotaxins responsible for mast cell epithelial accumulation in this disease. Objective: Expression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors was investigated in tissue sections from biopsy specimens obtained from patients with naturally occurring allergic rhinitis. Methods: Specific immunohistochemical staining was performed on thin sections of inferior turbinate biopsy specimens from patients with perennial and seasonal allergic rhinitis and, for comparison, from nonatopic and, where relevant, atopic healthy volunteers without rhinitis. Sequential staining of adjacent 2-mum sections was undertaken to colocalize TGF-beta receptors to mast cells. Results: Evidence was found of significantly increased epithelial immunoreactivity for TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta receptor I, TGF-beta receptor II, and TGF-beta receptor III in patients with perennial and seasonal allergic rhinitis compared with that seen in healthy control subjects. TGF-beta receptors I and II were found to colocalize to mast cells. Eotaxin epithelial immunoreactivity was significantly increased in the perennial group, although there were no corresponding disease-related differences found in relation to CCR-3 immunoreactivity at this site. There was no increase in stem cell factor immunoreactivity within the epithelium in naturally occurring disease. Significant correlations were found between epithelial immunoreactivity for TGF-beta1, TGF-beta2, TGF-beta receptor I, TGF-beta receptor II, and the number of epithelial mast cells. Conclusion: These findings of enhanced epithelial TGF-beta immunoreactivity in patients with rhinitis, the correlation with intraepithelial mast cell numbers, and the colocalization of TGF-beta receptors to mast cells suggest that the epithelial expression of TGF-beta might represent an important biologic process involved in either the recruitment or retention of mast cells within the epithelium in naturally occurring allergic rhinitis.	Univ Southampton, Sch Med, Div Asthma Allergy & Inflammat, Dept Resp Cell & Mol Biol, Southampton, Hants, England	University of Southampton	Salib, RJ (corresponding author), Southampton Gen Hosp, Dept Resp Cell & Mol Biol, Mailpoint 810,Tremona Rd, Southampton SO16 6YD, Hants, England.	rjs4@soton.ac.uk		Salib, Rami/0000-0002-6753-7844; Howarth, Peter/0000-0003-0619-7927				Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; de Boer WI, 1998, AM J RESP CRIT CARE, V158, P1951, DOI 10.1164/ajrccm.158.6.9803053; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; FINOTTO S, 1994, CLIN EXP IMMUNOL, V95, P343; Fujikura T, 1998, ARCH OTOLARYNGOL, V124, P1331, DOI 10.1001/archotol.124.12.1331; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Olsson N, 2000, J LEUKOCYTE BIOL, V67, P350, DOI 10.1002/jlb.67.3.350; Price KS, 2003, AM J RESP CELL MOL, V28, P420, DOI 10.1165/rcmb.2002-0155OC; Pullerits T, 2000, CLIN EXP ALLERGY, V30, P1469, DOI 10.1046/j.1365-2222.2000.00993.x; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Wilson SJ, 1998, CLIN EXP ALLERGY, V28, P220	14	30	33	1	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					799	806		10.1016/j.jaci.2004.07.010	http://dx.doi.org/10.1016/j.jaci.2004.07.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480318				2022-12-18	WOS:000224439100012
J	Hoff, M; Trueb, RM; Ballmer-Weber, BK; Vieths, S; Wuethrich, B				Hoff, M; Trueb, RM; Ballmer-Weber, BK; Vieths, S; Wuethrich, B			Immediate-type hypersensitivity reaction to ingestion of mycoprotein (Quorn) in a patient allergic to molds caused by acidic ribosomal protein P2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						case report; mold allergy; food allergy; crass-reactivity; DBPCFC; recombinant allergen	ADVERSE	Background: Quorn is the brand name for a fine of foods made with so-called "mycoprotein," which springs from the mold Fusarium venenatum. Since;he introduction on the food markets there have been complaints from consumers reporting adverse gastrointestinal reactions after ingestion of mycoprotein. To date, it is not clear whether the reported symptoms are IgE-mediated. Objective: The aim of the study was to describe for the first time a case history of an asthmatic patient with severe hypersensitivity reactions to ingested mycoprotein and to identify and characterize the potential allergen that might be responsible for this. Methods: The sensitization pattern of the asthmatic subject was characterized, and food allergy to mycoprotein was assessed by double-blinded placebo-controlled food challenge. Afterward, specific IgE antibodies of the serum of this patient were used to screen a Fusarium culmorum cDNA expression library. The coding sequence of one enriched eDNA-clone was expressed in Escherichia coli to produce a recombinant protein that was further purified and immunologically characterized. Results: The patient showed high sensitization to many known aeroallergens but apart from Quorn not to any other tested food samples. The deduced amino acid sequence of the enriched cDNA-done (Fus c 1) showed large identity to the 60S acidic ribosomal protein V2 which is highly conserved among several species and also described as minor allergen in other mold species. The frequency of IgE reactivity of sera from F culmorum-sensitized subjects to rFus c 1 was approximately 35%. By enzyme allergosorbent test inhibition, we found 65% inhibition of mycoprotein IgE reactivity by rFus c 1. On the opposite we found reduced IgE reactivity of rFus c 1 of 68% by using mycoprotein as inhibitor. Conclusions: Sensitization to mold allergens by the respiratory tract and subsequent oral ingestion of cross-reactive proteins may lead to severe food-allergic reactions. Thus, the 60S acidic ribosomal protein P2 of F venenatum probably is the reason for the described severe hypersensitivity reactions of the patient to Quorn-mycoprotein because of its potential cross-reactivity to the F culmorum allergen Fus c 1.	Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland	Paul Ehrlich Institute; University of Zurich; University Zurich Hospital	Vieths, S (corresponding author), Paul Ehrlich Inst, Dept Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.							Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Hoff M, 2002, J ALLERGY CLIN IMMUN, V109, P96, DOI 10.1067/mai.2002.120560; HOFF M, 2003, IN PRESS MOL IMMUNOL; TEE RD, 1993, CLIN EXP ALLERGY, V23, P257, DOI 10.1111/j.1365-2222.1993.tb00319.x; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698	5	30	31	1	23	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1106	1110		10.1067/mai.2003.1339	http://dx.doi.org/10.1067/mai.2003.1339			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743577	Bronze			2022-12-18	WOS:000182904500027
J	Sato, E; Hirahara, K; Wada, Y; Yoshitomi, T; Azuma, T; Matsuoka, K; Kubo, S; Taya, C; Yonekawa, H; Karasuyama, H; Shiraishi, A				Sato, E; Hirahara, K; Wada, Y; Yoshitomi, T; Azuma, T; Matsuoka, K; Kubo, S; Taya, C; Yonekawa, H; Karasuyama, H; Shiraishi, A			Chronic inflammation of the skin can be induced in IgE transgenic mice by means of a single challenge of multivalent antigen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; transgenic; atopic dermatitis; chronic inflammation; skin; mouse; multivalent antigen; Fc epsilon RI	CYCLOSPORINE-A; MAST-CELLS; AGGREGATION; ROLES	Background: It is now widely accepted that IgE mediates immediate-type allergic response. However, the pathologic role of IgE is controversial in the chronic allergic inflammation observed in atopic diseases, such as asthma and atopic dermatitis. Objective: We investigated the role of IgE in cutaneous allergic reactions by using 2 newly developed lines of antigen-specific IgE transgenic mice. Methods: IgE transgenic mice were administered subcutaneously with corresponding antigens, and the subsequent ear swelling was measured. Results: A single subcutaneous administration of TNP-conjugated ovalbumin (OVA) into the ears of nonimmunized mice carrying the TNP-specific IgE transgene elicited immediate-phase and late-phase ear swelling as expected, which peaked at 20 minutes and 8 hours later, respectively. Interestingly, however, 2 to 3 days after the antigen challenge, more intense ear swelling appeared. Its magnitude and duration were dependent on the valency of TNP in OVA, as well as the dose of TNP-OVA, and it lasted over 1 month when 100 mug of OVA conjugated with 11 molecules of TNP was given. Interestingly, administration of OVA to OVA specific IgE transgenic mice elicited immediate-phase and late-phase ear swelling but not third-phase ear swelling. Massive infiltration of inflammatory cells was observed in the third-phase ear swelling of TNP-specific IgE transgenic mice. Cyclosporine A almost completely inhibited the third-phase ear swelling and cellular infiltration, whereas an antihistamine, cyproheptadine, did not show any significant effect on the third-phase reaction. Conclusion: These results indicate that IgE can trigger not only immediate-type hypersensitivity but also chronic allergic inflammation. Our findings highlight a novel immunopathologic role of IgE in chronic atopic disorders.	Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Tokyo Med & Dent Univ, Grad Sch, Tokyo, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan; Sci Univ Tokyo, Chiba, Japan	Daiichi Sankyo Company Limited; Tokyo Medical & Dental University (TMDU); Tokyo Metropolitan Institute of Medical Science; Tokyo University of Science	Sato, E (corresponding author), Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, 2-58 Hiromachi 1 Chome, Tokyo 1408710, Japan.		Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836				CHURCH MK, 1998, ALLERGY PRINCIPLES P, P146; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; LITTLE JR, 1967, METHODS IMMUNOLOGY I, V1, P128; Mancuso G, 1999, CONTACT DERMATITIS, V41, P35, DOI 10.1111/j.1600-0536.1999.tb06205.x; Matsuoka K, 1999, INT IMMUNOL, V11, P987, DOI 10.1093/intimm/11.6.987; Naeyaert JM, 1999, DERMATOLOGY, V198, P145, DOI 10.1159/000018091; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; Rumsaeng V, 1997, J IMMUNOL, V158, P1353; Schramm G, 2001, CLIN EXP ALLERGY, V31, P331, DOI 10.1046/j.1365-2222.2001.01049.x; Schulman ES, 2001, AM J RESP CRIT CARE, V164, pS6, DOI 10.1164/ajrccm.164.supplement_1.2103025; Tahara Eiichi, 1999, Allergology International, V48, P265, DOI 10.1046/j.1440-1592.1999.00143.x; Torigoe C, 1996, IMMUNOL LETT, V49, P169, DOI 10.1016/0165-2478(96)02499-6	14	30	31	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					143	148		10.1067/mai.2003.9	http://dx.doi.org/10.1067/mai.2003.9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532110				2022-12-18	WOS:000180465500022
J	Rihs, HP; Chen, ZP; Rueff, F; Cremer, R; Raulf-Heimsoth, M; Baur, X; Moneret-Vautrin, DA; Bruning, T				Rihs, HP; Chen, ZP; Rueff, F; Cremer, R; Raulf-Heimsoth, M; Baur, X; Moneret-Vautrin, DA; Bruning, T			HLA-DQ8 and the HLA-DQ8-DR4 haplotype are positively associated with the hevein-specific IgE immune response in health care workers with latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; MHC class II association; hevein; HLA-DRB1*04; DR4; HLA-DQB1*0302; DQ8	RUBBER ELONGATION-FACTOR; SPINA-BIFIDA PATIENTS; MAJOR ALLERGEN; HYPERSENSITIVITY; HEV-B-1; IDENTIFICATION; BRASILIENSIS; CLONING	Background: Hevein is one of the most important latex allergens affecting health care workers (HCWs). Objective: Because the genetically determined susceptibility is one important factor regulating type I allergy, the association between the hevein-specific IgE immune response and HLA class II alleles of DQB1 and DRB1, DRB3, DRB4, and DRB5 was studied. Methods: The distribution of HLA-DQB1 and DRB1, DRB3, DRB4, and DRB5 in 269 HCWs with latex allergy, 56 latex-sensitized patients with spina bifida (SB), and 90 nonatopic control subjects under special consideration for hevein-specific IgE was examined. Results: Seventy percent (189/269) of the HCWs with latex allergy and 39% (22/56) of the latex-sensitized patients with SB had increased hevein-specific IgE antibody concentrations (>0.35 kU/L). HLA data analysis revealed significantly increased phenotype frequencies for DQB1*0302 (DQ8; 91/189 [48%]) and DRB1*04 (DR4; 102/189 [54%]) in hevein-positive HCWs with latex allergy compared with the 80 hevein-negative HCWs with latex allergy (DQB1*0302: 16/80 [20%], corrected P value [P-c] = 7.1 x 10(-4); DRB1*04: 23/80 [29%], P-c = .01) and with control subjects (DQB1*0302: 16/89 [18%], P-c 1 x 10(-4); DRB1*04: 22/90 [24%], P-c = 3.2 x 10(-4)). The DRB1*04 haplotype frequency was significantly elevated in HCWs with hevein-specific IgE antibodies when compared with that in HCWs without hevein-specific IgE antibodies (47% vs 18%, P-c = 5.3 x 10(-4)) or control subjects (47% vs 18%, P-c = 9.6 x 10(-4)). In contrast, latex-sensitized patients with SB with hevein-specific IgE antibodies showed an increased but not significant DQB1*0302 frequency (7/22 [32%] vs 2/34 [6%], P = .02, P-c = not significant) compared with that seen in those without hevein-specific IgE antibodies. Conclusion: The DQB1*0302 (DQ8) alone, the DQB1*0302 (DQ8)-DRB1*04 (DR4) haplotype, or both are significantly involved in the hevein-specific IgE immune response in HCWs with latex allergy.	Ruhr Univ Bochum, Res Inst Occupat Med Berufsgenossenschaften, Dept Mol Med, D-44789 Bochum, Germany; Univ Munich, Dermatol Clin & Policlin, Munich, Germany; Childrens Hosp Cologne, Cologne, Germany; Clin Immunol & Allergol Univ Hosp, Hop Cent, Nancy, France	Ruhr University Bochum; University of Munich; CHU de Nancy	Rihs, HP (corresponding author), Ruhr Univ Bochum, Res Inst Occupat Med Berufsgenossenschaften, Dept Mol Med, Buerkle de la Camp Pl 1, D-44789 Bochum, Germany.		Brüning, Thomas/G-8120-2015	Brüning, Thomas/0000-0001-9560-5464				Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; Alenius H, 1996, J IMMUNOL, V156, P1618; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V100, P684, DOI 10.1016/S0091-6749(97)70174-X; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; KIMURA A, 1992, HLA 1991, P395; KONZ KR, 1995, J ALLERGY CLIN IMMUN, V95, P950, DOI 10.1016/S0091-6749(95)70094-3; LU LJ, 1995, J IMMUNOL, V155, P2721; MARSH DG, 1992, P 11 INT HIST WORKSH, P765; NEVINNYSTICKEL C, 1991, EUR J IMMUNOGENET, V18, P323, DOI 10.1111/j.1744-313X.1991.tb00032.x; NUNEZ R, 1997, ALLERGY S, V52, P61; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; RaulfHeimsoth M, 1996, J ALLERGY CLIN IMMUN, V98, P640, DOI 10.1016/S0091-6749(96)70098-2; RAULFHEIMSOTH M, 2000, ALLERGY S, V55, P63; Rihs HP, 1997, TISSUE ANTIGENS, V49, P92, DOI 10.1111/j.1399-0039.1997.tb02719.x; Rihs HP, 1998, CLIN EXP ALLERGY, V28, P175; RIHS HP, 1993, INT ARCH ALLERGY IMM, V101, P7, DOI 10.1159/000236492; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; Szepfalusi Z, 1999, J PEDIATR-US, V134, P344, DOI 10.1016/S0022-3476(99)70461-0; TAUTZ C, 1994, J ALLERGY CLIN IMMUN, V93, P918, DOI 10.1016/0091-6749(94)90386-7; YASSIN MS, 1994, ANN ALLERGY, V72, P245	21	30	34	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					507	514		10.1067/mai.2002.127282	http://dx.doi.org/10.1067/mai.2002.127282			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209103				2022-12-18	WOS:000177936900026
J	Cho, YS; Lee, YM; Lee, CK; Yoo, B; Park, HS; Moon, HB				Cho, YS; Lee, YM; Lee, CK; Yoo, B; Park, HS; Moon, HB			Prevalence of Pachycondyla chinensis venom allergy in an ant-infested area in Korea	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pachycondyla chinensis; anaphylaxis; epidemiology	IMPORTED FIRE ANT; SOLENOPSIS-INVICTA; ANAPHYLAXIS	Recently, immediate allergic reactions, including anaphylaxis, after Pachycondyla chinensis ant stings have been frequently reported in Korea. To estimate the prevalence of these reactions and the sensitization rate to P chinensis, we undertook a visit-questionnaire survey of the 327 adult residents living in a town in an ant-infested area in Korea. Skin prick tests with 6 common inhalant allergens, 3 bee venom allergens, and P chinensis whole body extract were performed on all ant-allergic subjects, on 86 asymptomatic residents, and on 37 controls outside the area. The serum-specific IgE to P chinensis extract was determined by, ELISA. Seven subjects (2.1%) reported that they had experienced systemic allergic reactions to P chinensis stings; 4 of them had anaphylactic reactions. Large local reactions occurred in an additional 5 subjects (1.6%). All subjects with systemic allergic reactions had positive skin prick test results to P chinensis extract, whereas 23.% of asymptomatic residents and 2.7% of the controls showed positive skin prick test results. The serum-specific IgE level was significantly higher in the subjects with systemic reactions than in the subjects with local reactions, the asymptomatic sensitizers, and the nonatopic controls. Sensitization to bee venom was found in 25% of the P chinensis-allergic subjects; this was significantly higher than the 3% rate seen in nonsensitized subjects. In conclusion, we report a 2.1% prevalence of systemic allergic reactions after P chinensis stings, based on self-reported symptoms, in an ant-infested area in Korea.	Univ Ulsan, Coll Med, Asam Med Ctr, Dept Allergy & Rhematol, Seoul 138736, South Korea; Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Suwon 441749, South Korea	University of Ulsan; Ajou University	Moon, HB (corresponding author), Univ Ulsan, Coll Med, Asam Med Ctr, Dept Allergy & Rhematol, 388-1,Pungnap Dong, Seoul 138736, South Korea.		Park, Hae-Sim/S-7974-2019	Lee, Young Mok/0000-0003-4039-0456; Cho, You Sook/0000-0001-8767-2667; Park, Hae-Sim/0000-0003-2614-0303				Douglas RG, 1998, J ALLERGY CLIN IMMUN, V101, P129, DOI 10.1016/S0091-6749(98)70206-4; Freeman TM, 1997, ANN ALLERG ASTHMA IM, V78, P369, DOI 10.1016/S1081-1206(10)63198-5; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; Kemp SF, 2000, J ALLERGY CLIN IMMUN, V105, P683, DOI 10.1067/mai.2000.105707; Kim SS, 2001, J ALLERGY CLIN IMMUN, V107, P1095, DOI 10.1067/mai.2001.114341; Stafford CT, 1996, ANN ALLERG ASTHMA IM, V77, P87, DOI 10.1016/S1081-1206(10)63493-X; STAFFORD CT, 1989, SO MED J, V82, P151; TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7; TRIPLETT RF, 1976, SOUTHERN MED J, V69, P258, DOI 10.1097/00007611-197603000-00002; Yun YY, 1999, J ALLERGY CLIN IMMUN, V104, P879, DOI 10.1016/S0091-6749(99)70302-7	10	30	33	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					54	57		10.1067/mai.2002.124890	http://dx.doi.org/10.1067/mai.2002.124890			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110820	Green Published			2022-12-18	WOS:000176870300012
J	Tanaka, A; Minoguchi, K; Oda, N; Yokoe, T; Matsuo, H; Okada, S; Tasaki, T; Adachi, M				Tanaka, A; Minoguchi, K; Oda, N; Yokoe, T; Matsuo, H; Okada, S; Tasaki, T; Adachi, M			Inhibitory effect of lidocaine on T cells from patients with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; lidocaine; T cell; IL-5; IFN-gamma; apoptosis; steroid	BRONCHOALVEOLAR LAVAGE; MAST-CELLS; ACTIVATION; GLUCOCORTICOIDS; NA+; BRONCHOCONSTRICTION; INFLAMMATION; EXPRESSION; INCREASE	Background: Nebulized lidocaine enables dosages of oral corticosteroids to be tapered in the treatment of severe asthma. Objective: We sought to investigate the effect of lidocaine on T cells from patients with allergic asthma. Methods: PBMCs and CD4(+) T cells were isolated from 6 patients with asthma and house dust mite allergy. PBMCs were cultured with lidocaine for up to 7 days and then stained with propidium iodide to evaluate the involvement of apoptosis. In addition, the viability of CD4(+) T cells when cultured with lidocaine was investigated. Effects of lidocaine on proliferative response, mRNA expression, and protein production of IL-5 and IFN-gamma by PBMCs were investigated after stimulation with Dermatophagoides farinae, purified protein derivative, and phorbol 12-myristate 13-acetate plus calcium ionophore. The effects of lidocaine on the proliferative response of steroid-insensitive PBMCs from 6 nonallergic donors induced by preculture with IL-2 and IL-4 were also investigated. Results: No significant increase in the staining of PBMCs with propidium iodide was observed in the presence of 100 mumol/L lidocaine. The viability of CD4(+) T cells was not significantly affected by culture with lidocaine at this concentration. However, lidocaine inhibited, in a dose-dependent manner, the proliferative response and mRNA expression and protein production of IL-5 and IFN-gamma of PBMCs stimulated with D farinae, purified protein derivatives, or phorbol 12-myristate 13-acetate plus calcium ionophore. Preincubation of PBMCs with IL-2 and IL-4 significantly decreased the inhibitory effects of both corticosteroids and lidocaine compared with that after preincubation with medium alone. Conclusion: Lidocaine has immunoregulatory effects on T cells. Therefore, lidocaine might be studied as an anti-inflammatory agent in the treatment of severe steroid-dependent asthma.	Showa Univ, Sch Med, Dept Internal Med 1, Shinagawa Ku, Tokyo 142, Japan	Showa University	Minoguchi, K (corresponding author), Showa Univ, Sch Med, Dept Internal Med 1, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.							CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; Decco ML, 1999, ANN ALLERG ASTHMA IM, V82, P29, DOI 10.1016/S1081-1206(10)62656-7; ENRIGHT PL, 1980, AM REV RESPIR DIS, V122, P823; Groeben H, 1999, AM J RESP CRIT CARE, V159, P530, DOI 10.1164/ajrccm.159.2.9806102; HIVROZBURGAUD C, 1991, EUR J IMMUNOL, V21, P2811, DOI 10.1002/eji.1830211124; Hunt LW, 1996, MAYO CLIN PROC, V71, P361, DOI 10.4065/71.4.361; KAI T, 1993, ANESTHESIOLOGY, V78, P954, DOI 10.1097/00000542-199305000-00021; KAM JC, 1993, J IMMUNOL, V151, P3460; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; KANBARA T, 1993, BIOCHEM PHARMACOL, V45, P1593, DOI 10.1016/0006-2952(93)90299-C; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; Lai ZF, 2000, J IMMUNOL, V165, P83, DOI 10.4049/jimmunol.165.1.83; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Lu HR, 1999, EUR J PHARMACOL, V365, P233, DOI 10.1016/S0014-2999(98)00878-4; MAKKER HK, 1993, J ALLERGY CLIN IMMUN, V92, P82, DOI 10.1016/0091-6749(93)90041-D; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; *NIH, 1997, NIH PUBL; Ohnishi T, 1996, CLIN EXP IMMUNOL, V104, P325, DOI 10.1046/j.1365-2249.1996.32737.x; OHSAKA A, 1994, EXP HEMATOL, V22, P460; Okada S, 1998, J IMMUNOL, V160, P4010; SHAPIRO DN, 1985, J IMMUNOL, V135, P2256; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; WACHOLTZ MC, 1992, J IMMUNOL, V149, P1912; Yanagi H, 1996, ACTA ANAESTH SCAND, V40, P1138, DOI 10.1111/j.1399-6576.1996.tb05577.x	26	30	35	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					485	490		10.1067/mai.2002.122155	http://dx.doi.org/10.1067/mai.2002.122155			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897996				2022-12-18	WOS:000174586400016
J	Guerra, F; Carracedo, J; Solana-Lara, R; Sanchez-Guijo, P; Ramirez, R				Guerra, F; Carracedo, J; Solana-Lara, R; Sanchez-Guijo, P; Ramirez, R			T(H)2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; apoptosis; immunotherapy; lymphocytes; T(H)1; T(H)2	HOMOCYTOTROPIC ANTIBODY-FORMATION; IMMUNOLOGICAL CHANGES; IN-VITRO; T-CELLS; RESPONSES; EXPRESSION; CYTOKINES; TH2; RAT	Background: In atopic patients treatment with specific immunotherapy (SIT) induced a shift in the balance of T-cell immune response away from a T(H)2-type (producing mostly IL-4) in favor of a T(H)1-type T-lymphocyte response (with the preferential production of IFN-gamma). However, the mechanisms through which SIT acts are less clear. We have recently shown that allergens may induce an activation-induced cell death process in lymphocytes from SIT-treated atopic patients. Objective: This study aimed to determine whether allergen-induced apoptosis ran occur in a specific subset of cells, Methods: The study was performed in lymphocytes from normal subjects and atopic patients, some of whom were treated with SIT, Cells were cultured in the presence of gramineous pollen (Lolium perenne) allergenic extracts. Cell phenotype and intracellular cytokine expression were measured by means of fluorescent mAbs. Apoptosis was measured by using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling. Fluorescence was analyzed in a FAC-Scan flow cytometer, and the data were evaluated with Consort 30 software. R Results: Our results showed that allergens induce apoptosis of lymphocytes in SIT-treated atopic patients. Apoptosis occurs mainly in T(H)2 lymphocytes with the IL-4(+)/CD4(+) phenotype and subsequently increases the percentage of IFN-gamma (+) cells in the culture. Conclusion: These results suggest that the shift from T(H)2 to T(H)1 induced by SIT in atopic patients may be mediated, at least in part, by the induction of an activation-induced cell death process in allergen-responder T(H)2 cells.	Hosp Univ Reina Sofia, Serv Alergia, Cordoba 14004, Spain; Hosp Univ Reina Sofia, Unidad Invest, Cordoba 14004, Spain; Hosp Univ Reina Sofia, Serv Inmunol, Cordoba 14004, Spain	Hospital Universitario Reina Sofia - Cordoba; Hospital Universitario Reina Sofia - Cordoba; Hospital Universitario Reina Sofia - Cordoba	Ramirez, R (corresponding author), Hosp Univ Reina Sofia, Serv Alergia, Avda Menendez Pidal S-N, Cordoba 14004, Spain.		Ramirez, Rafael/B-3249-2019; Solana, Rafael/R-9978-2019; Carracedo, Julia/ABG-2464-2020; Carracedo, Julia/L-2012-2015	Solana, Rafael/0000-0001-8985-0295; Carracedo, Julia/0000-0002-8422-812X; Carracedo, Julia/0000-0002-8422-812X; Rafael, Ramirez/0000-0003-4598-339X				Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; BEYER K, 1997, J ALLERGY CLIN IMMUN, V112, P133; BLAISS MS, 1995, ANN ALLERG ASTHMA IM, V74, P359; Blaiss MS, 1996, ALLERGY ASTHMA PROC, V17, P355, DOI 10.2500/108854196778606455; BONIFAZI F, 1991, J INVEST ALLERG CLIN, V1, P37; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Carter LL, 1998, J IMMUNOTHER, V21, P181, DOI 10.1097/00002371-199805000-00003; Clerici M, 1997, ANN MED, V29, P185, DOI 10.3109/07853899708999334; COMBADIERE B, 1998, IMMUNITY, V102, P421; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS559, DOI 10.1016/S0091-6749(00)90060-5; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Forzy M L, 1996, Allerg Immunol (Paris), V28, P7; Gabrielsson S, 1997, CLIN EXP ALLERGY, V27, P808, DOI 10.1046/j.1365-2222.1997.560878.x; Gabrielsson S, 1997, ALLERGY, V52, P860, DOI 10.1111/j.1398-9995.1997.tb02158.x; Guenounou M, 1998, ANN BIOL CLIN-PARIS, V56, P297; Guerra F, 1999, HUM IMMUNOL, V60, P840, DOI 10.1016/S0198-8859(99)00066-X; GUERRA F, 1993, J INVEST ALLERG CLIN, V3, P182; Hedlin G, 1999, J ALLERGY CLIN IMMUN, V103, P609, DOI 10.1016/S0091-6749(99)70232-0; IMADA M, 1995, IMMUNOLOGY, V85, P373; Koning H, 1996, PEDIATR RES, V40, P363, DOI 10.1203/00006450-199609000-00001; Kovacs B, 1997, AUTOIMMUNITY, V25, P213, DOI 10.3109/08916939708994730; Kung JT, 1998, CELL IMMUNOL, V185, P158, DOI 10.1006/cimm.1998.1282; Norman PS, 1998, J ALLERGY CLIN IMMUN, V102, P1, DOI 10.1016/S0091-6749(98)70046-6; OKUMURA K, 1971, J IMMUNOL, V107, P1682; OKUMURA K, 1971, J IMMUNOL, V106, P1019; Patterson R, 1998, J ALLERGY CLIN IMMUN, V101, pS403, DOI 10.1016/S0091-6749(98)70231-3; Pawlik I, 1997, TOHOKU J EXP MED, V182, P1, DOI 10.1620/tjem.182.1; Scherer JM, 1999, CYTOMETRY, V37, P184, DOI 10.1002/(SICI)1097-0320(19991101)37:3<184::AID-CYTO4>3.0.CO;2-X; Stevens WJ, 1998, ACTA CLIN BELG, V53, P66, DOI 10.1080/17843286.1998.11754145; UMETSU DT, 1997, P SOC EXP BIOL MED, V99, P522	31	30	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					647	653		10.1067/mai.2001.112263	http://dx.doi.org/10.1067/mai.2001.112263			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295653				2022-12-18	WOS:000168190100016
J	Shearer, WT; Easley, KA; Goldfarb, J; Rosenblatt, HM; Jenson, HB; Kovacs, A; McIntosh, K				Shearer, WT; Easley, KA; Goldfarb, J; Rosenblatt, HM; Jenson, HB; Kovacs, A; McIntosh, K		P2C2 HIV Study Grp	Prospective 5-year study of peripheral blood CD4(+), CD8(+), and CD19(+)/CD20(+) lymphocytes and serum Igs in children born to HIV-1(+) women	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pediatric HIV-1 infection; survival; CD4(+) T cells; CD8(+) T cells; CD19(+)/20(+) B cells; serum Igs	HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED INFANTS; T-CELLS; BACTERIAL-INFECTIONS; DISEASE PROGRESSION; PREDICTIVE VALUE; VIRAL LOAD; TYPE-1; ANTIBODY; SURVIVAL	Background: Peripheral blood CD4(+) and CD8(+) T cells, CD19(+)/20(+) B cells, and serum Igs are known to be altered by the progression of pediatric HIV-1 infection, but their evaluation as predictors of survival needs further definition. Objective: To determine the natural history of these immune factors and their importance in predicting survival, we studied 298 HIV-1 vertically infected (HIV-1(+)) children over a 5-year period. Methods: These immune factors and serum HIV-1 RNA levels were measured in two groups: (1) a birth cohort of children enrolled up to age 28 days postnatally, including 93 HIV-1(+) and 463 HIV-1 uninfected infants (HIV-1(-)), and (2) an older cohort of 205 HIV-1(+) children enrolled after the age of 28 days, who were classified as survivors or nonsurvivors. Results: In the birth cohort HIV-1(+) children had significantly lower CD4(+) T-cell counts, higher CD8(+) T-cell counts, and lower CD19(+)/20(+) B-cell counts and higher IgG, IgA, and IgM levels than HIV-1(-) children. In the older cohort survivors had significantly higher CD4(+) and CD8(+) T-cell and CD19(+)/CD20(+) B-cell counts and higher IgG, lower IgA, and lower IgM levels than did nonsurvivors. In univariable analysis factors affecting survival in the older cohort were baseline CD4(+) and CD8(+) T-cell and CD19(+)/20(+) B-cell counts and IgG and HIV-1 RNA levels tall P < .05). In multivariable analysis high baseline CD4(+) T-cell count and low baseline HIV-1 RNA load remained important. Conclusion: The longitudinal mean profiles of CD4 and CD8 T-cell and CD19/20 B-cell counts and serum IgG levels helped to describe the natural progression of HIV-1 disease in children. However, only baseline CD4 T-cell count independently predicted survival.	Baylor Coll Med, Houston, TX 77030 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; LAC, Los Angeles, CA USA; Univ So Calif, Med Ctr, Los Angeles, CA USA; Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA	Baylor College of Medicine; Cleveland Clinic Foundation; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; Harvard University; Boston Children's Hospital; Harvard Medical School	Shearer, WT (corresponding author), Texas Childrens Hosp, 6621 Fannin St,MC 1-3291, Houston, TX 77030 USA.		Easley, Kirk A/K-6910-2015	Easley, Kirk A/0000-0003-4419-2617; Jenson, Hal/0000-0002-6549-860X; Shearer, William/0000-0002-2483-2130	DIVISION OF LUNG DISEASES [N01HR096038, N01HR096039, N01HR096037] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533, M01RR000865, K01RR000188, M01RR000645, M01RR002172, M01RR000071, M01RR000188] Funding Source: NIH RePORTER; NCRR NIH HHS [K01 RR000188, M01 RR000645, M01 RR002172, M01 RR000188, M01 RR000865, M01 RR000533, M01 RR000071] Funding Source: Medline; NHLBI NIH HHS [N01-HR-96039, N01-HR-96038, N01 HR096037] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BERNSTEIN LJ, 1985, J PEDIATR-US, V107, P352, DOI 10.1016/S0022-3476(85)80505-9; BERNSTEIN LJ, 1985, PEDIATR INFECT DIS J, V4, P472, DOI 10.1097/00006454-198509000-00005; Betensky RA, 1999, CLIN DIAGN LAB IMMUN, V6, P247, DOI 10.1128/CDLI.6.2.247-253.1999; BLANCHE S, 1986, J PEDIATR-US, V109, P965, DOI 10.1016/S0022-3476(86)80277-3; BORKOWSKY W, 1987, J PEDIATR-US, V110, P563, DOI 10.1016/S0022-3476(87)80549-8; BORKOWSKY W, 2000, IN PRESS J INFECT DI; *CDCP, 1997, MMWR-MORBID MORTAL W, V36, P1; DEMARTINO M, 1994, LANCET, V343, P191; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; FULEIHAN RL, 1997, IMMUNOLOGIST, V5, P133; Gaulton GN, 1997, AIDS, V11, P403, DOI 10.1097/00002030-199704000-00002; IBEGBU C, 1994, CLIN IMMUNOL IMMUNOP, V71, P27, DOI 10.1006/clin.1994.1047; Jenson H, 1999, J INFECT DIS, V179, P1395, DOI 10.1086/314764; Kattan M, 1996, J CLIN EPIDEMIOL, V49, P1285; Kline MW, 1995, PEDIATR AIDS HIV INF, V6, P350; Kourtis AP, 1996, NEW ENGL J MED, V335, P1431, DOI 10.1056/NEJM199611073351904; Kovacs A, 1999, NEW ENGL J MED, V341, P77, DOI 10.1056/NEJM199907083410203; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; KRASINSKI K, 1988, PEDIATR INFECT DIS J, V7, P323, DOI 10.1097/00006454-198805000-00006; LANGSTON C, 1995, J INFECT DIS, V172, P1451, DOI 10.1093/infdis/172.6.1451; LIPSHULTZ SE, IN PRESS CIRCULATION; Mofenson LM, 1999, AIDS, V13, P31, DOI 10.1097/00002030-199901140-00005; PAHWA S, 1986, DIAGN CLIN IMMUNOL, V4, P24; Palumbo PE, 1998, JAMA-J AM MED ASSOC, V279, P756, DOI 10.1001/jama.279.10.756; Patke CL, 2000, J ALLERGY CLIN IMMUN, V105, P975, DOI 10.1067/mai.2000.105315; Pitt J, 1998, J ACQ IMMUN DEF SYND, V19, P462, DOI 10.1097/00042560-199812150-00004; Pollack H, 1997, AIDS, V11, pF9, DOI 10.1097/00002030-199701000-00002; RAUTONEN J, 1991, AIDS, V5, P1319, DOI 10.1097/00002030-199111000-00006; RODRIGUEZ C, 1993, ANN NY ACAD SCI, V693, P291, DOI 10.1111/j.1749-6632.1993.tb26287.x; Rubinstein A, 2000, AIDS, V14, pF55, DOI 10.1097/00002030-200003100-00004; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; Shearer WT, 1998, PRIMARY CARE, V25, P759, DOI 10.1016/S0095-4543(05)70086-5; SHEARER WT, 1993, ANN NY ACAD SCI, V693, P35, DOI 10.1111/j.1749-6632.1993.tb26255.x; Shearer WT, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.1.e9; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Shearer WT, 1997, ACTA PAEDIATR, V86, P60; Sleasman JW, 1999, J PEDIATR-US, V134, P597, DOI 10.1016/S0022-3476(99)70247-7; STAPRANS SI, 1997, MED MANAGEMENT AIDS, P29; TEEUWSEN VJP, 1991, AIDS, V5, P971, DOI 10.1097/00002030-199108000-00008; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; Wilson CC, 1999, J VIROL, V73, P3975, DOI 10.1128/JVI.73.5.3975-3985.1999	43	30	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					559	566		10.1067/mai.2000.109433	http://dx.doi.org/10.1067/mai.2000.109433			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984378	Green Accepted			2022-12-18	WOS:000089471900021
J	Tan, JQ; Jacobi, HH; Jing, C; Reimert, CM; Quan, S; Dissing, S; Poulsen, LK; Skov, PS				Tan, JQ; Jacobi, HH; Jing, C; Reimert, CM; Quan, S; Dissing, S; Poulsen, LK; Skov, PS			Chemokine stromal cell-derived factor 1 alpha activates basophils by means of CXCR4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokine; receptor; chemotaxis; histamine release; inflammation; basophils	MESSENGER-RNA EXPRESSION; CC CHEMOKINE; LYMPHOCYTE CHEMOTAXIS; RECEPTOR CXCR4; BLOOD; EOSINOPHIL; LEUKOCYTES; EOTAXIN; PROTEIN-3; MONOCYTES	Background: The CXC chemokine receptor 4 (CXCR4) is predominantly expressed on inactivated naive T lymphocytes, B lymphocytes, dendritic cells, and endothelial cells. CXC chemokine stromal cell-derived factor 1 alpha (SDF-1 alpha) is the only known ligand for CXCR4 To date, the CXCR4 expression and function of SDF-1 alpha in basophils are unknown. Objective: The purpose of this study was to investigate the expression of CXCR4 and functions of SDF-1 alpha in basophils and to characterize the role of the CXCR4-SDF-1 alpha receptor ligand pair in the allergic inflammation. Methods: Basophil purification, flow cytometry, real-time quantitative RT-PCR assay, Northern blotting, intracellular free Ca2+ change, chemotaxis assay, and histamine release assay were used, Results: CXCR4 is abundantly expressed on peripheral blood resting basophils (91%), Likewise, CXCR4 messenger (m)RNA is expressed in resting basophils (3.2 x 10(3) copies per 2 x 10(2) cells). The existence of CXCR4 mRNA was also confirmed in basophils by means of Northern blot analysis. SDF-1 alpha. induces an increase in intracellular free Ca2+ in basophils, SDF-1 alpha activates basophils to chemotaxis (chemotactic index = 3.8) and histamine release (36% of total content) through CXCR4 on the cells. The chemokines SDF-1 alpha, eotaxin, RANTES, monocyte chemoattractant protein (MCP) 1, and macrophage inflammatory protein (MIP) 1 alpha have been demonstrated at different potencies in induction of chemotaxis (eotaxin > SDF-1 alpha > RANTES congruent to MCP-1 >> MIP-1 alpha) and histamine release (MCP-1 congruent to SDF-1 alpha > eotaxin > RANTES > MIP-1 alpha), The optimal concentration seen for SDF-1 alpha effects (chemotaxis and histamine release) on basophils was 100 ng/mL, Conclusion: These results indicate that the CXCR4-SDF-1 alpha receptor ligand pair may be important for the recruitment and activation of the basophils, which is a characteristic effector cell of the allergic inflammation.	Natl Univ Hosp, Lab Med Allergol 7542, DK-2100 Copenhagen N, Denmark; Natl Univ Hosp, Reference Lab, Allergy Unit, DK-2100 Copenhagen N, Denmark; Univ Copenhagen, Dept Med Physiol, Copenhagen, Denmark	University of Copenhagen	Skov, PS (corresponding author), Natl Univ Hosp, Lab Med Allergol 7542, Blegdamsvej 9, DK-2100 Copenhagen N, Denmark.		Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X; Dissing, Steen/0000-0002-0741-907X				Akoum H, 1998, CYTOKINE, V10, P706, DOI 10.1006/cyto.1998.0348; ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1998, J EXP MED, V187, P753, DOI 10.1084/jem.187.5.753; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; BURGI B, 1994, EUR J IMMUNOL, V24, P1583, DOI 10.1002/eji.1830240720; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DISSING S, 1990, PFLUG ARCH EUR J PHY, V417, P1, DOI 10.1007/BF00370762; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GEISER T, 1993, J BIOL CHEM, V268, P15419; Hamada T, 1998, J EXP MED, V188, P539, DOI 10.1084/jem.188.3.539; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; JINQUAN T, 1995, J IMMUNOL, V155, P5359; Jinquan Tan, 1995, Journal of Immunology, V154, P3742; Kampen GT, 1997, J IMMUNOL METHODS, V210, P185, DOI 10.1016/S0022-1759(97)00187-7; Kruse N, 1997, J IMMUNOL METHODS, V210, P195, DOI 10.1016/S0022-1759(97)00188-9; Ochensberger B, 1999, EUR J IMMUNOL, V29, P11, DOI 10.1002/(SICI)1521-4141(199901)29:01<11::AID-IMMU11>3.0.CO;2-B; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969; Sozzani S, 1997, J IMMUNOL, V159, P1993; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Tan JQ, 1997, J IMMUNOL, V158, P475; TAN JQ, 1993, J IMMUNOL, V151, P4545; TERSTAPPEN LWMM, 1990, J LEUKOCYTE BIOL, V48, P138, DOI 10.1002/jlb.48.2.138; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Volin MV, 1998, BIOCHEM BIOPH RES CO, V242, P46, DOI 10.1006/bbrc.1997.7890; WEBER M, 1995, J IMMUNOL, V154, P4166; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	31	30	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					313	320		10.1067/mai.2000.108108	http://dx.doi.org/10.1067/mai.2000.108108			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932076				2022-12-18	WOS:000088708100015
J	Kelly, MM; Leigh, R; Horsewood, P; Gleich, GJ; Cox, G; Hargreave, FE				Kelly, MM; Leigh, R; Horsewood, P; Gleich, GJ; Cox, G; Hargreave, FE			Induced sputum: Validity of fluid-phase IL-5 measurement	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inflammation; sputum; IL-5	AIRWAY INFLAMMATION; ASTHMA; CELL; INTERLEUKIN-5; EOSINOPHIL; CYTOKINES; RECEPTOR; REPRODUCIBILITY; PREDNISONE; CHALLENGE	Background: IL-5 measurement in the fluid phase of induced sputum is considered to be important in the assessment of asthma, but the validity of these measurements is uncertain. Objective: We investigated the validity of sputum IL-5 measurements through a series of spiking experiments and examined the effect of dithiothreitol (DTT) on these measurements. Methods: Induced sputum from 26 asthmatic subjects was spiked with IL-5 and processed, and the percentage of recovery was measured by means of immunoassay. In 6 of the 26 samples the effect of adding albumin to the processing fluids was studied. In 3 separate samples radiolabeled IL-5 was added, and the recovery measured by means of gamma counting and immunoassay were compared. In addition, the effect of DTT on the immunoassay was examined. Results: The mean +/- SD recovery of spiked IL-5 was 26.1% +/- 14.6% measured by means of immunoassay; adding albumin increased the recovery to 47.7% +/- 8.0% (P < .001). The mean recovery measured by means of gamma counting was 84.8% +/- 5.7% (P < .001); adding albumin had no effect on recovery. DTT had no significant effect on IL-5 measurement. Conclusion: The validity of IL-5 measurement by means of current methods is poor. The discrepancy in recovery as measured by gamma counting compared with immunoassay suggests that there is a problem with the recognition of IL-5 epitopes by immunoassay in induced sputum. This cannot be attributed to DTT but may be due to other interfering substances present in sputum, such as sputum proteases, soluble receptors, or autoantibodies.	McMaster Univ, St Josephs Hosp, Dept Med, Firestone Reg Chest & Allergy Unit,Asthma Res Grp, Hamilton, ON L8N 4A6, Canada; McMaster Univ, St Josephs Hosp, Dept Pathol, Hamilton, ON, Canada; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA	McGill University; McMaster University; McGill University; McMaster University; Mayo Clinic; Mayo Clinic	Hargreave, FE (corresponding author), McMaster Univ, St Josephs Hosp, Dept Med, Firestone Reg Chest & Allergy Unit,Asthma Res Grp, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.		Kelly, Margaret M/G-4128-2012	Kelly, Margaret M/0000-0002-1629-3210	NIAID NIH HHS [AI 34577] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034577, U01AI034577] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER AG, 1994, THORAX, V49, P1231, DOI 10.1136/thx.49.12.1231; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Barnes A, 1998, LANCET, V352, P324, DOI 10.1016/S0140-6736(05)60303-0; Bendtzen K, 1998, IMMUNOL TODAY, V19, P209, DOI 10.1016/S0167-5699(98)01252-3; CANNON JG, 1992, MANUAL CLIN LAB IMMU, P237; CLAMAN DM, 1994, J ALLERGY CLIN IMMUN, V94, P861, DOI 10.1016/0091-6749(94)90154-6; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Kelly EAB, 1997, AM J RESP CRIT CARE, V156, P1421, DOI 10.1164/ajrccm.156.5.9703054; KIKUCHI Y, 1994, J IMMUNOL METHODS, V167, P289, DOI 10.1016/0022-1759(94)90098-1; LEDUR A, 1995, J IMMUNOL METHODS, V186, P171, DOI 10.1016/0022-1759(95)00184-C; MIRESLUIS AR, 1995, J IMMUNOL METHODS, V186, P157, DOI 10.1016/0022-1759(95)00128-W; Monahan J, 1997, J IMMUNOL, V159, P4024; MOTOJIMA S, 1993, ALLERGY, V48, P98, DOI 10.1111/j.1398-9995.1993.tb04709.x; *NIH, 1997, PRACT GUID DIAGN MAN; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1998, EUR RESPIR J, V11, P828, DOI 10.1183/09031936.98.11040828; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849; POPOV T, 1994, CLIN EXP ALLERGY, V24, P778, DOI 10.1111/j.1365-2222.1994.tb00990.x; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442, DOI 10.1164/ajrccm.155.2.9032176; Spanevello A, 1997, CLIN EXP ALLERGY, V27, P1138; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; SUR S, 1995, J ALLERGY CLIN IMMUN, V96, P661, DOI 10.1016/S0091-6749(95)70265-2; TAKAHASHI T, 1990, MOL IMMUNOL, V27, P911, DOI 10.1016/0161-5890(90)90158-V; Veen JCCMI, 1996, EUR RESPIR J, V9, P2441, DOI 10.1183/09031936.96.09122441; WADHWA M, 1998, ASSAYS CYTOKINES, P855; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413, DOI 10.1164/ajrccm.155.4.9105087	32	30	33	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1162	1168		10.1067/mai.2000.106375	http://dx.doi.org/10.1067/mai.2000.106375			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856151				2022-12-18	WOS:000087781800018
J	Creticos, PS				Creticos, PS			The consideration of immunotherapy in the treatment of allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; asthma; allergic respiratory disease; aeroallergens	GRASS-POLLEN IMMUNOTHERAPY; HISTAMINE-RELEASING-FACTOR; DUST MITE ALLERGENS; CAT-INDUCED ASTHMA; DOUBLE-BLIND TRIAL; RAGWEED HAY-FEVER; DERMATOPHAGOIDES-PTERONYSSINUS; NASAL CHALLENGE; HOUSE DUST; INFLAMMATORY MEDIATORS	Immunotherapy has undergone rigorous trials to assess its therapeutic benefit in the treatment of allergic respiratory disease, The tools of molecular biology have provided a framework with which to begin to understand the mechanistic effects of immunotherapy on the underlying inflammatory component of allergic respiratory disease. The clinical relevance of these observations belies our understanding of allergic inflammation as the subsoil for the development of abnormal airway physiology, heightened bronchial reactivity, and the development of chronic asthmatic symptoms. Immunotherapy provides the potential to downregulate this inflammatory cascade, reduce IgE antibody production, and attenuate symptoms. Conceptually, early intervention of allergic disease holds the most promise as a therapeutic intervention capable of arresting the progression of the disease, altering the severity of the disease, and/or preventing the development of the respiratory disease process.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA	Johns Hopkins University	Creticos, PS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 2B-57, Baltimore, MD 21224 USA.							AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; ALAM R, 1987, J ALLERGY CLIN IMMUN, V79, P103, DOI 10.1016/S0091-6749(87)80023-4; ARMENTIAMEDINA A, 1989, ANN ALLERGY, V63, P127; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P76, DOI 10.1016/S0091-6749(05)80043-0; BRUUN EGON, 1949, ACTA ALLERGOL, V2, P122, DOI 10.1111/j.1398-9995.1949.tb03295.x; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CHAPMAN MD, 1993, INSIGHTS ALLERGY, V8, P1; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Cousins DJ, 1998, ASTHMA AND ALLERGIC DISEASES, P193, DOI 10.1016/B978-012473340-4/50018-7; CRETICOS PS, 1992, IMMUNOL ALLERGY CLIN, V12, P13; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; Creticos PS, 1998, ASTHMA AND ALLERGIC DISEASES, P407, DOI 10.1016/B978-012473340-4/50033-3; CRETICOS PS, 1997, ALLERGY, P726; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DUBUSKE LM, 1992, IMMUNOL ALLERGY CLIN, V12, P145; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; FRANKLAND AW, 1954, LANCET, V1, P1055; FROSTAD AB, 1983, CLIN ALLERGY, V13, P337, DOI 10.1111/j.1365-2222.1983.tb02609.x; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; ILIOPOULOS O, 1987, J ALLERGY CLIN IMMUN, V79, P253; ISHIZAKA T, 1980, P NATL ACAD SCI-BIOL, V77, P1903, DOI 10.1073/pnas.77.4.1903; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kay AB, 1998, ASTHMA AND ALLERGIC DISEASES, P207, DOI 10.1016/B978-012473340-4/50019-9; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Loveless MH, 1943, J IMMUNOL, V47, P165; MACDONALD SM, 1987, J ALLERGY CLIN IMMUN, V79, P248; MAJCHEL AM, 1992, J ALLERGY CLIN IMMUN, V90, P85, DOI 10.1016/S0091-6749(06)80014-X; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NELSON BL, 1986, ANN ALLERGY, V56, P331; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OWNBY DR, 1994, INDICATIONS CONTRAIN, P1; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PENG ZK, 1992, J ALLERGY CLIN IMMUN, V89, P519, DOI 10.1016/0091-6749(92)90318-V; PETERSEN BN, 1988, ALLERGY, V43, P353, DOI 10.1111/j.1398-9995.1988.tb00429.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROSENBERG GL, 1975, J ALLERGY CLIN IMMUN, V55, P126; SCINTO JD, 1992, IMMUNOL ALLERGY CLIN, V12, P53; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TUNONDELARA JM, 1992, LANCET, V340, P908, DOI 10.1016/0140-6736(92)93314-D; VALOVIRTA E, 1984, ANN ALLERGY, V53, P85; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; WARNER JO, 1978, LANCET, V2, P912; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; WOOD RA, 1992, IMMUNOL ALLERGY CLIN, V12, P69; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	77	30	32	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S559	S574		10.1016/S0091-6749(00)90060-5	http://dx.doi.org/10.1016/S0091-6749(00)90060-5			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669541				2022-12-18	WOS:000085439600018
J	Williams, LW; Reinfried, P; Brenner, RJ				Williams, LW; Reinfried, P; Brenner, RJ			Cockroach extermination does not rapidly reduce allergen in settled dust	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXPOSURE; BLATTELLIDAE; ORTHOPTERA; CHILDREN; ASTHMA		Duke Univ, Med Ctr, Div Pediat Allergy & Immunol, Durham, NC 27710 USA; USDA ARS, Imported Fire Ants & Household Insects Res Unit, Gainesville, FL USA	Duke University; United States Department of Agriculture (USDA)	Williams, LW (corresponding author), Duke Univ, Med Ctr, Div Pediat Allergy & Immunol, Box 3559, Durham, NC 27710 USA.				NCRR NIH HHS [M01RR00030] Funding Source: Medline; NIAID NIH HHS [AI38550] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038550] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Gergen PJ, 1998, J ALLERGY CLIN IMMUN, V101, pS157; MILIO JF, 1986, J ECON ENTOMOL, V79, P1280, DOI 10.1093/jee/79.5.1280; OGG CL, 1993, J ECON ENTOMOL, V86, P61, DOI 10.1093/jee/86.1.61; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D	6	30	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				702	703		10.1016/S0091-6749(99)70346-5	http://dx.doi.org/10.1016/S0091-6749(99)70346-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482850				2022-12-18	WOS:000082870000039
J	Bollinger, ME; Hamilton, RG; Wood, RA				Bollinger, ME; Hamilton, RG; Wood, RA			Protamine allergy as a complication of insulin hypersensitivity: A case report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						insulin allergy; protamine allergy; desensitization; IgE; IgG	NPH INSULIN; ANAPHYLAXIS	Background: Although most patients receiving insulin produce insulin-specific IgE, significant allergic symptoms develop in very few of them. Patients receiving neutral protamine Hagedorn (NPH) insulin are at increased risk for the development of protamine hypersensitivity. The case of a 19-year-old woman with insulin-dependent diabetes and regular and NPH insulin hypersensitivity is presented. Objective: The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin. Methods: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose. She underwent a standard protocol for insulin desensitization twice in a 2-month period, with persistence in her symptoms. She was found to have high protamine-specific, as well as insulin-specific, IgE levels, and because of her poor response to regular insulin desensitization, she was desensitized to both regular and NPH insulin. Results: Dual desensitization resulted in marked improvement in her symptoms. The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin. She continued to receive regular insulin 4 times per day over the following 3 years with only occasional hives. Conclusion: Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy. These patients may require protamine/NPH desensitization, an alternative insulin preparation, or both.	Univ Maryland, Sch Med, Div Pediat Allergy & Immunol, Dept Pediat, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University	Bollinger, ME (corresponding author), Univ Maryland, Sch Med, Div Pediat Allergy & Immunol, Dept Pediat, 120 Penn St, Baltimore, MD 21201 USA.							ARKINS JA, 1962, J ALLERGY, V33, P69, DOI 10.1016/0021-8707(62)90065-5; Blanco C, 1996, ALLERGY, V51, P421, DOI 10.1111/j.1398-9995.1996.tb00153.x; deShazo R D, 1978, Postgrad Med, V63, P85; DYKEWICZ MS, 1994, J ALLERGY CLIN IMMUN, V93, P117, DOI 10.1016/0091-6749(94)90240-2; FEDERLIN K, 1971, IMMUNOPATHOLOGY INSU, P19; FINEBERG SE, 1983, DIABETOLOGIA, V25, P465; Galloway J A, 1980, Med Times, V108, P91; GALLOWAY JA, 1990, MED EXAM, P506; GOTTSCHLICH GM, 1988, ANN ALLERGY, V61, P277; GRAMMER L, 1986, CLIN REV ALLERG, V4, P189; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V71, P250, DOI 10.1016/0091-6749(83)90107-0; HAGEDORS H. C., 1936, Journal of the American Medical Association, V106, P177; HAMILTON RG, MANUAL CLIN LAB IMMU, P881; HANAUER L, 1961, DIABETES, V10, P105, DOI 10.2337/diab.10.2.105; LAMKIN N, 1976, J ALLERGY CLIN IMMUN, V58, P213, DOI 10.1016/0091-6749(76)90157-3; LIEBERMAN P, 1971, J AMER MED ASSOC, V215, P1106; Oh HK, 1998, CLIN TRANSPLANT, V12, P593; ROSS JM, 1984, PEDIATR CLIN N AM, V31, P675; SANCHEZ MB, 1982, LANCET, V1, P1243; SHARATH MD, 1985, J THORAC CARDIOV SUR, V90, P86; STEWART WJ, 1984, CIRCULATION, V70, P788, DOI 10.1161/01.CIR.70.5.788; THOMPSON DM, 1993, DIABETES CARE, V16, P957, DOI 10.2337/diacare.16.6.957; WEISS ME, 1989, NEW ENGL J MED, V320, P886, DOI 10.1056/NEJM198904063201402; WENTWORTH SM, 1976, DIABETES, V25, P326	24	30	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				462	465		10.1016/S0091-6749(99)70394-5	http://dx.doi.org/10.1016/S0091-6749(99)70394-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452772				2022-12-18	WOS:000082364800043
J	Shimada, Y; Sato, S; Hasegawa, M; Tedder, TF; Takehara, K				Shimada, Y; Sato, S; Hasegawa, M; Tedder, TF; Takehara, K			Elevated serum L-selectin levels and abnormal regulation of L-selectin expression on leukocytes in atopic dermatitis: Soluble L-selectin levels indicate disease severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						L-selectin; atopic dermatitis; soluble L-selectin; leukocyte rolling; leukocyte activation	ADHESION MOLECULE-1 LAM-1; DEFICIENT MICE; CELL-ADHESION; LYMPHOCYTE; RECEPTOR; SKIN; ACTIVATION; MIGRATION; SITES	Background: L-selectin mediates leukocyte rolling on endothelium at sites of inflammation, suggesting that L-selectin may be involved in the development of cutaneous lesions of atopic dermatitis (AD), After leukocyte activation, L-selectin is rapidly shed from the cell surface, Objective: The purpose of this study was to assess leukocyte L-selectin expression and quantitate levels of serum soluble L-selectin (sL-selectin) in patients with AD. Methods: Serum sL-selectin levels in patients with AD (n = 70), contact dermatitis (n = 18), and psoriasis (n = 23), as well as normal control subjects (n = 30), were examined by using an ELISA, The L-selectin expression on leukocytes in heparinized blood samples from patients with AD (n = 18) and normal control subjects (n = 10) was also examined by flow cytometry. Results: Serum levels of sL-selectin in patients with AD were significantly higher than those found in normal control subjects, Furthermore, sL-selectin levels correlated positively with disease severity and total serum IgE levels in AD. The expression of L-selectin on B cells, monocytes, and neutrophils was significantly decreased in patients with AD compared with normal control subjects, although those on CD4(+) or CD8(+) T cells from patients with AD were similar to those from normal control subjects. Conclusion: Elevated sL-selectin levels and the abnormal expression of L-selectin on some leukocyte subsets in patients with AD may correlate with inflammation associated with AD. Furthermore, the Level of sL-selectin may be a useful immunologic indicator for disease activity in AD.	Kanazawa Univ, Sch Med, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan; Duke Univ, Med Ctr, Dept Immunol, Durham, NC USA	Kanazawa University; Duke University	Sato, S (corresponding author), Kanazawa Univ, Sch Med, Dept Dermatol, 13-1 Talaramachi, Kanazawa, Ishikawa 9208641, Japan.				NATIONAL CANCER INSTITUTE [R01CA054464, R55CA054464] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Czech W, 1996, BRIT J DERMATOL, V134, P17, DOI 10.1046/j.1365-2133.1996.d01-740.x; DONNELLY SC, 1994, LANCET, V344, P215, DOI 10.1016/S0140-6736(94)92995-5; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; JORAPONGSANANUR.O, 1998, J IMMUNOL, V160, P422; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; RABB H, 1995, J AM SOC NEPHROL, V6, P1445; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPERTINI O, 1994, BLOOD, V84, P1249, DOI 10.1182/blood.V84.4.1249.bloodjournal8441249; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; Takeshita S, 1997, CLIN EXP IMMUNOL, V108, P446, DOI 10.1046/j.1365-2249.1997.3852128.x; Tang MLK, 1998, J IMMUNOL, V160, P5113; Tang MLK, 1997, J IMMUNOL, V158, P5191; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; TEDDER TF, 1991, AM J RESP CELL MOL, V5, P305, DOI 10.1165/ajrcmb/5.4.305; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; WAKITA H, 1994, J CUTAN PATHOL, V21, P33, DOI 10.1111/j.1600-0560.1994.tb00688.x; Yamashita N, 1997, J ALLERGY CLIN IMMUN, V99, P410, DOI 10.1016/S0091-6749(97)70060-5	24	30	33	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					163	168		10.1016/S0091-6749(99)70128-4	http://dx.doi.org/10.1016/S0091-6749(99)70128-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400854	Bronze			2022-12-18	WOS:000081738900024
J	Wamboldt, FS; Bender, BG; O'Connor, SL; Gavin, LA; Wamboldt, MZ; Milgrom, H; Szefler, SJ; Ikle, D; Rand, C				Wamboldt, FS; Bender, BG; O'Connor, SL; Gavin, LA; Wamboldt, MZ; Milgrom, H; Szefler, SJ; Ikle, D; Rand, C			Reliability of the Model MC-311 MDI Chronolog	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	1997 American-Lung-Association/American-Thoracic-Society International Conference	MAY, 1997	SAN FRANCISCO, CALIFORNIA	Amer Lung Assoc, Amer Thorac Soc		metered-dose inhaler; MDI Chronolog; asthma treatment adherence	NEBULIZER CHRONOLOG; INHALER ADHERENCE; CLINICAL-TRIAL; ASTHMA; MEDICATION; USAGE	Background: The Model MC-311 MDI Chronolog (Medtrac Technologies, Lakewood, Cole) is an electronic device for monitoring adherence to metered-dose inhalers (MDIs), It is a thermistor-actuated, microprocessor-equipped device that dispenses inhaled medication while recording the date and time of each canister activation. Objective: We evaluated the reliability of the MC-311 MDI Chronolog to determine whether the model could accurately record and report the date, time, and number of MDI actuations. Methods: Twenty-four of the MC-311 Chronologs were discharged at 8 hourly intervals across 8 days, Battery voltage was assessed before and after the experiment. The mouthpieces of 12 Chronologs were washed daily. Results: By using generous criteria for acceptable reliability, only 10 of 24 (42%) were rated as acceptable. None of these 10 Chronologs recorded 320 or greater actuations (mean +/- SD, 293.9 +/- 13.3; range, 266 to 308); all reliable Chronologs underestimated MDI activation. An additional 6 devices had an initial signature of erroneous recordings dating from device initialization. After removing this signature, the remaining data showed acceptable reliability. All the remaining Chronologs judged to be unacceptable showed time series patterns of seizures tie, bursts of clustered, erroneous records). Seizures were distributed across trial days, were associated with washing, and preceded all 4 cases of battery failure. Damage to the thermistor is the likely cause of seizure-pattern failures. Conclusions: In summary, because of a combination of a clear underreporting bias with frequent initialization and seizure-pattern failures, the Model MC-311 MDI Chronolog is not recommended for use in clinical care or research.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Johns Hopkins Univ, Med Ctr, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Wamboldt, FS (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St,F301, Denver, CO 80206 USA.		Ikle, David/AAK-7541-2020	Ikle, David/0000-0003-0091-5246	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL048999, R01HL053391] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL48999, N01-HL 16044, R01-HL53391] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDER B, 1996, ASTHMA MANAGEMENT 20, V1, P7; BENDER B, 1997, AM J RESP CRIT CARE, V155, pA259; Brueckner JW, 1997, J ALLERGY CLIN IMMUN, V100, P488, DOI 10.1016/S0091-6749(97)70140-4; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; CREER TL, 1994, HDB PEDIAT PSYCHOL; GONG H, 1988, J ALLERGY CLIN IMMUN, V82, P5, DOI 10.1016/0091-6749(88)90043-7; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; MAWHINNEY H, 1993, J ASTHMA, V30, P61, DOI 10.3109/02770909309066381; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; NIDES MA, 1993, CHEST, V104, P501, DOI 10.1378/chest.104.2.501; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Simmons MS, 1998, J ALLERGY CLIN IMMUN, V102, P409, DOI 10.1016/S0091-6749(98)70128-9; SPECTOR SL, 1991, PATIENT COMPLIANCE M; TASHKIN DP, 1991, AM J MED, V91, P335	14	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					53	57		10.1016/S0091-6749(99)70113-2	http://dx.doi.org/10.1016/S0091-6749(99)70113-2			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400839				2022-12-18	WOS:000081738900008
J	Bar-Sela, S; Reshef, T; Mekori, YA				Bar-Sela, S; Reshef, T; Mekori, YA			IgE antithyroid microsomal antibodies in a patient with chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Meir Hosp, Dept Med B, Allergy Clin Immunol Lab, IL-44281 Kefar Sava, Israel; Hebrew Univ Jerusalem, Occupat & Environm Med Unit, Jerusalem, Israel; Hadassah Sch Publ Hlth, Jerusalem, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine	Mekori, YA (corresponding author), Meir Hosp, Dept Med B, Allergy Clin Immunol Lab, IL-44281 Kefar Sava, Israel.							LENZOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66; Turktas I, 1997, INT J DERMATOL, V36, P187, DOI 10.1046/j.1365-4362.1997.00187.x	2	30	32	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1216	1217		10.1016/S0091-6749(99)70204-6	http://dx.doi.org/10.1016/S0091-6749(99)70204-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359911				2022-12-18	WOS:000080929500038
J	Dworzak, MN; Froschl, G; Printz, D; Fleischer, C; Potschger, U; Fritsch, G; Gadner, H; Emminger, W				Dworzak, MN; Froschl, G; Printz, D; Fleischer, C; Potschger, U; Fritsch, G; Gadner, H; Emminger, W			Skin-associated lymphocytes in the peripheral blood of patients with atopic dermatitis: Signs of subset expansion and stimulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; T cell; cutaneous lymphocyte-associated antigen; skin association; peripheral blood	MEMORY T-CELLS; MONOCLONAL-ANTIBODY; HOMING RECEPTOR; ANTIGEN CLA; EXPRESSION; CD4+; PHENOTYPE; FREQUENCY; HECA-452; MOLECULE	Background: Skin-associated T cells are defined by the cutaneous lymphocyte-associated antigen (CLA), In atopic dermatitis (AD), CLA(+) T cells harbor allergen-reactive memory cells, spontaneously secrete T,, cytokines, and display signs of increased in vivo activation, thus relating the subset to the central disease pathomechanisms. Objectives: It is not known whether the proportion of circulating CLA(+) T cells might be expanded in AD. We were therefore prompted to compare the peripheral blood lymphocyte subpopulations of patients with AD with those of control subjects. Methods: We used 3-color flow cytometry to investigate age-matched peripheral blood samples of pediatric and young adult patients with mild (n = 21) or severe (n = 15) AD, patients with allergic/atopic diseases not involving the skin (n = 9), and healthy control subjects (n = 14), Results: We found no differences among the study groups with respect to the general proportions of T cells, CD4(+) T cells, CD8(+) T cells, B cells, NK cells, CD103(+) T cells, and CD25(+) T cells among total circulating lymphocytes. However, there were slightly more CD4(+) memory cells and clearly more HLA-DR+ T cells in patients with severe AD. Most remarkably, patients with severe AD had a significantly expanded proportion of CLA+ T cells (P = .024) and CLA(+)/CD4(+) T cells (P = .006) but similar proportions of CLA(+)/CD8(+) T cells compared with control subjects. Patients with severe AD also had distinctly more HLA-DR+/CLA(+) T cells than control subjects (P = .005). Similar alterations were seen in patients with mild AD, but these mere not statistically significant. After correction for age, all differences were significant only in probands less than 10 years of age. Conclusion: Circulating skin-associated T cells (CLA(+)) show signs of subset expansion and enhanced activation in patients with AD. These alterations, compared with control values, affect CD4(+) memory T cells in particular and are prominent only in children less than 10 years of age.	Childrens Canc Res Inst, Vienna, Austria; Allergieambulatori Rennweg, Vienna, Austria	Saint Anna Children's Hospital	Dworzak, MN (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.			Potschger, Ulrike/0000-0001-7024-7082				ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Akdis M, 1997, J IMMUNOL, V159, P4611; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; BABI LFS, 1995, J IMMUNOL, V154, P1543; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BOS JD, 1993, ARCH DERMATOL RES, V285, P179, DOI 10.1007/BF00372006; BOS JD, 1989, ARCH DERMATOL RES, V281, P24, DOI 10.1007/BF00424268; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; Gonzalez FJ, 1997, INT ARCH ALLERGY IMM, V113, P345, DOI 10.1159/000237597; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; KRUSCHWITZ M, 1991, J CLIN PATHOL, V44, P636, DOI 10.1136/jcp.44.8.636; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; MULLER KM, 1993, J IMMUNOL, V150, P5576; PEPYS J, 1968, CLINICAL ASPECTS IMM, P189; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; Rajka G, 1989, ESSENTIAL ASPECTS AT, P216; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SANDERS ME, 1988, J IMMUNOL, V140, P1401; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; VOLLENWEIDER S, 1991, J ALLERGY CLIN IMMUN, V87, P1088, DOI 10.1016/0091-6749(91)92154-S; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	28	30	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				901	906		10.1016/S0091-6749(99)70436-7	http://dx.doi.org/10.1016/S0091-6749(99)70436-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329826				2022-12-18	WOS:000080470200027
J	Knutsen, AP; Wall, DA				Knutsen, AP; Wall, DA			Kinetics of T-cell development of umbilical cord blood transplantation in severe T-cell immunodeficiency disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						umbilical cord blood transplantation; severe combined immunodeficiency; combined immunodeficiency; graft-versus-host disease	BONE-MARROW TRANSPLANTATION; HEMATOPOIETIC STEM-CELLS; ANTIGEN RECOGNITION; DEFICIENCY; PATIENT; RECONSTITUTION; LYMPHOCYTES; DEPLETION; CHILDREN; ANEMIA	Background: Hematopoietic stein-cell transplantation is the treatment of choice for severe primary T-cell immunodeficiencies. When an HLA-identical sibling donor is not available, an alternative donor stem-cell source is needed. In primary T-cell immunodeficiencies, T-cell-depleted HLA-haploidentical bone marrow transplantation has been particularly successful in reconstituting the T-cell immune system in many of the severe combined immunodeficiency syndrome types. However, there are some problems associated with this preparation as a stem donor source, such as increased resistance to engraftment, a long period of time for T-cell engraftment to occur, and failure to engraft B cells and B-cell functions. These problems can be especially troublesome if the patient is infected before the transplantation. Objective: Umbilical cord blood was evaluated as a stem-cell source for immune reconstitution in children with severe primary T-cell immunodeficiency disorders, such as severe combined immunodeficiency syndrome, reticular dysgenesis, thymic dysplasia, and combined immunodeficiency disease, when a matched sibling donor was unavailable, Methods: From January 1996 through July 1997, 6 children received unrelated cord blood stem-cell transplantation after a preparative regimen for the treatment of combined immunodeficiency diseases, The patients ranged in age from 2 weeks to 6 gears. The cord blood units mere 3 of 6 HLA antigen matches in 2 children, 4 of 6 HLA antigen matches in 3 children, and 5 of 6 HLA antigen matches in 1 child, with molecular HLA-DR mismatch in 3 of the children, Results: The average time for neutrophil engraftment (absolute neutrophil count, >500/mm(3)) was 12 days (range, 10 to 15 days), and the average time for platelet engraftment (platelet count, >20,000/mm(3)) was 36 days (range, 24 to 50 days). In a patient with reticular dysgenesis, the first transplant failed to engraft but fully engrafted after a second unrelated donor cord blood transplantation. Five of 6 patients exhibited grade I graft-versus-host disease (GvHD), although 1 child experienced grade IV skin and gut GvHD. Immunologic reconstitution demonstrated that cord blood stem-cell transplantation resulted in consistent and stable T-cell, B-cell, and natural killer-cell development. The kinetics of recovery of phenotypic expression and function of T cells occurred between 60 to 100 days and that of natural killer cells at approximately 180 days. B cells engrafted early, and a study of functional B-cell antibody responses revealed that 2 of 2 patients in whom intravenous immune globulin was discontinued have low detectable antibody responses to tetanus and diphtheria toroid immunizations more than 1 gear after the transplantation. Conclusions: Unrelated umbilical donor cord blood is an excellent source of stem cells for transplantation of children with immune deficiency disorders. Benefits include rapid and reliable recovery of immune function, low risk of GvHD, and low viral transmission rate.	St Louis Univ, Ctr Hlth Sci, Div Allergy Immunol, St Louis, MO 63103 USA; St Louis Univ, Ctr Hlth Sci, Div Hematol Oncol Bone Marrow Transplantat, Dept Pediat, St Louis, MO 63103 USA; Cardinal Glennon Mem Hosp Children, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Knutsen, AP (corresponding author), Pediat Res Inst, 3662 Pk Ave, St Louis, MO 63110 USA.							BALDUZZI A, 1995, BLOOD, V86, P3247; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; BUCKLEY RH, 1993, SEMIN HEMATOL, V30, P92; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; Cairo MS, 1997, BLOOD, V90, P4665, DOI 10.1182/blood.V90.12.4665.4665_4665_4678; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; DeSantes KB, 1996, BONE MARROW TRANSPL, V17, P1171; Dickinson AM, 1997, BONE MARROW TRANSPL, V19, P323, DOI 10.1038/sj.bmt.1700669; FILIPOVICH AH, 1992, BLOOD, V80, P270; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; FISCHER A, 1994, BLOOD, V83, P1149; GEHA RS, 1989, J IMMUNOL, V143, P84; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Kapelushnik J, 1997, BONE MARROW TRANSPL, V20, P1109, DOI 10.1038/sj.bmt.1701016; KIESSLING R, 1977, EUR J IMMUNOL, V7, P655, DOI 10.1002/eji.1830070915; Knutsen AP, 1996, J CLIN IMMUNOL, V16, P151, DOI 10.1007/BF01540913; KNUTSEN AP, 1989, ANN ALLERGY, V63, P189; KNUTSEN AP, 1989, J ALLERGY CLIN IMMUN, V84, P640, DOI 10.1016/0091-6749(89)90203-0; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Mayani H, 1998, STEM CELLS, V16, P153, DOI 10.1002/stem.160153; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; O'Marcaigh A S, 1997, Curr Opin Oncol, V9, P126; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; O'Reilly RJ, 1994, BONE MARROW TRANSPL, P849; OREILLY RJ, 1986, VOX SANG, V51, P81, DOI 10.1111/j.1423-0410.1986.tb02013.x; OREILLY RJ, 1988, BLOOD, V72, pA399; PETER HH, 1986, PROGR IMMUNODEFICIEN, V2, P287; ROBERTS JL, 1989, J IMMUNOL, V143, P1575; RONCAROLO MG, 1988, J EXP MED, V168, P2139, DOI 10.1084/jem.168.6.2139; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; Wagner J E, 1997, Curr Opin Hematol, V4, P413; WAGNER JE, 1995, LANCET, V346, P214, DOI 10.1016/S0140-6736(95)91268-1; Wall D A, 1997, J Matern Fetal Med, V6, P320, DOI 10.1002/(SICI)1520-6661(199711/12)6:6<320::AID-MFM4>3.0.CO;2-Q	36	30	31	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				823	832		10.1016/S0091-6749(99)70426-4	http://dx.doi.org/10.1016/S0091-6749(99)70426-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329816				2022-12-18	WOS:000080470200017
J	Kurosawa, M; Amano, H; Kanbe, N; Igarashi, Y; Nagata, H; Yamashita, T; Kurimoto, F; Miyachi, Y				Kurosawa, M; Amano, H; Kanbe, N; Igarashi, Y; Nagata, H; Yamashita, T; Kurimoto, F; Miyachi, Y			Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology 1997	JUL   12, 1997	TOKYO, JAPAN	Novartis Pharma K K Tokyo		mast cell; tryptase; chymase; mediator; cytokine; aggressive systemic mastocytosis; methylprednisolone; cyclosporin	HUMAN MAST-CELLS; BLOOD MONONUCLEAR-CELLS; HISTAMINE-RELEASE; GUINEA-PIGS; ANTIBODIES; RADIOIMMUNOASSAY; ANTAGONIST; TRYPTASE; ONO-1078; DISEASE	Background: There is no effective treatment for aggressive systemic mastocytosis. Objective: The purpose of this study was to investigate the effect of cyclosporin and low-dose methylprednisolone in a 64-year-old man with aggressive systemic mastocytosis. Methods: Immunohistochemical studies were done on biopsy specimens from the skin and other organs. Mast cells, predominantly containing tryptase, were derived from human umbilical cord blood cells cultured in the presence of stem-cell factor and IL-6. IgE-sensitized cultured human mast cells were activated by anti-IgE, and the effect of cyclosporin on histamine release was investigated. In addition, blood and urine levels of various mediators were measured in the patient before and after therapy. Results: Biopsy specimens of the patient's skin lesions showed an increase of mast cells; cells containing tryptase (but not chymase) comprised 20% to 50% of the skin mast cells. Histamine release from activated cultured mast cells was inhibited by cyclosporin in a concentration-dependent manner. When the patient was treated with cyclosporin and low-dose methylprednisolone, he showed a good response. Conclusion: Cyclosporin combined with low-dose methylprednisolone may be a reasonable therapy for aggressive systemic mastocytosis.	Hirosaki Univ, Sch Med, Dept Geriatr Med, Hirosaki, Aomori 0368652, Japan; Gunma Univ, Sch Med, Dept Dermatol, Maebashi, Gumma, Japan; Chiba Univ, Sch Med, Dept Otolaryngol, Chiba, Japan; Mitsubishi Kagaku Bio Clin Labs Inc, Res & Dev, Tokyo, Japan; Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan	Hirosaki University; Gunma University; Chiba University; Mitsubishi Kagaku Bio-Clinical Laboratories; Kyoto University	Kurosawa, M (corresponding author), Hirosaki Univ, Sch Med, Dept Geriatr Med, 5 Zaifu Cho, Hirosaki, Aomori 0368652, Japan.		Kambe, Naotomo/H-3987-2017	Kambe, Naotomo/0000-0001-9610-4952				Algermissen B, 1994, Exp Dermatol, V3, P290, DOI 10.1111/j.1600-0625.1994.tb00291.x; ENANDER I, 1991, J IMMUNOL METHODS, V138, P39, DOI 10.1016/0022-1759(91)90062-K; FIEHN C, 1995, EUR J CLIN INVEST, V25, P615, DOI 10.1111/j.1365-2362.1995.tb01754.x; GASIORCHRZAN B, 1992, DERMATOLOGY, V184, P149, DOI 10.1159/000247526; Igarashi Y, 1996, CLIN EXP ALLERGY, V26, P597; IRANI AA, 1990, CLIN EXP ALLERGY, V20, P53, DOI 10.1111/j.1365-2222.1990.tb02775.x; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; KLUINNELEMANS HC, 1992, NEW ENGL J MED, V326, P619, DOI 10.1056/NEJM199202273260907; KUROSAWA M, 1994, CLIN EXP ALLERGY, V24, P960, DOI 10.1111/j.1365-2222.1994.tb02729.x; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; MARONE G, 1988, RES CLIN LAB, V18, P53, DOI 10.1007/BF02918819; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS55, DOI 10.1111/1523-1747.ep12469049; MUTTER RD, 1963, ANN INTERN MED, V59, P887, DOI 10.7326/0003-4819-59-6-887; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NAVEH Y, 1975, ACTA DERM-VENEREOL, V55, P443; OBATA T, 1992, LIFE SCI, V51, P1577, DOI 10.1016/0024-3205(92)90620-5; OLAFSSON JH, 1986, ACTA DERM-VENEREOL, V66, P16; PARDINI S, 1991, ACTA HAEMATOL-BASEL, V85, P220; Saito H, 1996, J IMMUNOL, V157, P343; Sperr WR, 1996, J ALLERGY CLIN IMMUN, V98, P389, DOI 10.1016/S0091-6749(96)70163-X; STELLATO C, 1992, J INVEST DERMATOL, V98, P800, DOI 10.1111/1523-1747.ep12499960; STEPHAN V, 1990, J ALLERGY CLIN IMMUN, V86, P862, DOI 10.1016/S0091-6749(05)80147-2; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; TRIGGIANI M, 1989, INT ARCH ALLER A IMM, V88, P25	26	30	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	2	S			S412	S420		10.1016/S0091-6749(99)70156-9	http://dx.doi.org/10.1016/S0091-6749(99)70156-9			9	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199TV	10329843				2022-12-18	WOS:000080500200002
J	Swystun, VA; Bhagat, R; Kalra, S; Jennings, B; Cockcroft, DW				Swystun, VA; Bhagat, R; Kalra, S; Jennings, B; Cockcroft, DW			Comparison of 3 different doses of budesonide and placebo on the early asthmatic response to inhaled allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial allergen challenge; corticosteroid; dose-response	BRONCHIAL RESPONSIVENESS; AIRWAY RESPONSIVENESS; DOUBLE-BLIND; BECLOMETHASONE; HISTAMINE; CORTICOSTEROIDS; METHACHOLINE; INFLAMMATION	Background: A simple laboratory method to evaluate relative potency of inhaled corticosteroids in asthma would be valuable. Single-dose studies with the allergen-induced late asthmatic response have failed to show a useful dose-response relationship. Treatment for several days with inhaled corticosteroids will also inhibit the allergen-induced early asthmatic response. Methods: Twelve atopic asthmatic subjects were studied during a season when no medications were required except ipratropium bromide as needed. These subjects had positive allergen and methacholine inhalation tests and FEV1 greater than 70% of predicted value. A double-blind, randomized, cross-over study compared placebo and budesonide 100, 200, and 400 mu g administered by means of Turbuhaler twice daily for 7 days with 6-day washout periods. Methacholine PC20 was measured before and after 6 days of treatment, and allergen PC15 was measured after 7 days of treatment. Results: The allergen PC15 (n = 11) was significantly larger (P = .0001) for all doses of budesonide compared with placebo, but there was no significant difference between the 3 doses of budesonide, and no dose response was demonstrated. The methacholine PC20 was significantly larger after all budesonide treatments compared with placebo (P = .024), but there was no difference between the 3 doses. There was a progressive increase in the allergen PC15 chronologically (sequence effect) that was not explained by improvement in FEV1 or airway responsiveness; sequence effects were not seen for FEV1 or for pretreatment or posttreatment methacholine PC20. Statistical adjustment for sequence effect did not alter allergen PC15 statistics. Conclusion: A 7-day course of budesonide administered by means of Turbuhaler at 200, 400, or 800 mu g per day provided marked and significant inhibition of the allergen-induced early asthmatic response compared with placebo. There was, however, no difference between the 3 doses. Therefore this method with these doses is not useful for providing assessment of relative potency.	Univ Saskatchewan, Royal Univ Hosp, Div Resp Med, Dept Med, Saskatoon, SK S7N 0W8, Canada; Astra Pharma Inc, Mississauga, ON, Canada	University of Saskatchewan	Cockcroft, DW (corresponding author), Univ Saskatchewan, Royal Univ Hosp, Div Resp Med, Dept Med, Saskatoon, SK S7N 0W8, Canada.							BURGE PS, 1982, CLIN ALLERGY, V12, P523, DOI 10.1111/j.1365-2222.1982.tb02551.x; COCKCROFT DW, 1995, AM J RESP CRIT CARE, V152, P1485, DOI 10.1164/ajrccm.152.5.7582281; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1993, J ALLERGY CLIN IMMUN, V91, P1163, DOI 10.1016/0091-6749(93)90319-B; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Juniper E, 1994, HISTAMINE METHACHOLI; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65, DOI 10.1016/S0091-6749(97)70196-9; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Marshik P. L., 1996, Journal of Allergy and Clinical Immunology, V97, P316, DOI 10.1016/S0091-6749(96)80752-4; MCCUBBIN MM, 1995, CLIN PHARMACOL THER, V57, P455, DOI 10.1016/0009-9236(95)90216-3; WONG BJ, 1992, AM REV RESPIR DIS, V146, P1158; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x	16	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					363	367		10.1016/S0091-6749(98)70121-6	http://dx.doi.org/10.1016/S0091-6749(98)70121-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768574				2022-12-18	WOS:000076212800005
J	Borger, P; Vellenga, E; Gringhuis, SI; Timmerman, JAB; Lummen, C; Postma, DS; Kauffman, HF				Borger, P; Vellenga, E; Gringhuis, SI; Timmerman, JAB; Lummen, C; Postma, DS; Kauffman, HF			Prostaglandin E-2 differentially modulates IL-5 gene expression in activated human T lymphocytes depending on the costimulatory signal	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; IL-5; prostaglandin E-2; protein kinase A; transcription factors	COLONY-STIMULATING FACTOR; INTERLEUKIN-5 GENE; PROTEIN-KINASE; NUCLEAR FACTOR; TRANSCRIPTION FACTOR; CYTOKINE SECRETION; CELLS; CAMP; PROMOTER; PATHWAY	Background: Protein kinase A (PKA) activation is documented to be inhibitory for T helper cell (T-H1)-like cytokines (IL-2, IFN-gamma), whereas T-H2-like cytokines (IL-4, IL-5) are not affected or upregulated. We have recently shown that IL-4 gene expression can be inhibited by PKA activation but depends on the mode of T-cell activation. For IL-5 gene expression, we hypothesized that the mode of T-cell activation also determines the ultimate effect of simultaneous PKA activation. Objectives: The objective of this study was the examination of IL-5 gene expression in healthy T cells activated with various mitogenic stimuli after simultaneous activation of PKA by dibutyryl-cAMP or prostaglandin E-2 (PGE(2)). Methods: IL-5 mRNA was measured by semiquantitative reverse transcription-polymerase chain reaction or Northern analysis. IL-5 protein was measured by ELISA. Transcriptional mechanisms involved in IL-5 gene expression were determined by nuclear run-on experiments and electrophoretic mobility shift assays. Posttranscriptional mechanisms were determined by actinomycin D chase studies. Results: Anti-CD2-, anti-CD3-, and anti-CD3 plus anti-CD28-induced IL-5 mRNA were completely inhibited by dibutyryl cyclic AMP (10(-3) mol/L) and PGE(2) (10(-5) mol/L), whereas concanavalin A-induced IL-5 mRNA was partially reduced. The effect of PGE(2) was accomplished at the transcriptional level, probably as the result of inhibition of DNA binding of nuclear factor-kappa B. Anti-CD3 plus anti-CD28-induced IL-5 protein (504 +/- 56 pg/ml) was significantly reduced by PGE(2) (122 +/- 42 pg/ml, p < 0.001). Addition of cytokines that use the IL-2 receptor gamma(C) chain (IL-2, IL-7, IL-15) abrogated the PGE(2)-induced inhibition of IL-5 protein. In contrast, concanavalin A plus PMA-induced IL-5 protein (75 +/- 8 pg/ml) was significantly upregulated by the simultaneous addition of PGE(2) (128 +/- 17 pg/ml, p < 0.03). Conclusions: PKA activation differentially modulates IL-5 gene expression and depends on the mode of T-cell activation.	Univ Groningen, Dept Internal Med, Dvi Allergol, Groningen, Netherlands; Univ Groningen, Dept Internal Med, Div Pulmonol, Groningen, Netherlands; Univ Groningen, Dept Internal Med, Div Hematol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Kauffman, HF (corresponding author), State Univ Hosp Groningen, Dept Allergol, Clin Internal Med, POB 30001, NL-9700 RB Groningen, Netherlands.			Gringhuis, Sonja/0000-0003-0383-4978				Borger P, 1996, BLOOD, V87, P691, DOI 10.1182/blood.V87.2.691.bloodjournal872691; Borger P, 1996, EXP HEMATOL, V24, P108; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; CLUTTERBUCK CJ, 1989, BLOOD, V73, P504; DELAMERE F, 1994, BRIT J PHARMACOL, V111, P983, DOI 10.1111/j.1476-5381.1994.tb14840.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOODWIN JS, 1981, CELL IMMUNOL, V60, P298, DOI 10.1016/0008-8749(81)90271-9; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112; HOEKSTRA MO, IN PRESS CLIN EXP AL; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; Ivashkiv LB, 1996, J IMMUNOL, V157, P1415; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22, DOI 10.1164/ajrccm/145.2_Pt_2.S22; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LEE HJ, 1994, J ALLERGY CLIN IMMUN, V94, P594, DOI 10.1016/0091-6749(94)90135-X; LEE HJ, 1993, J IMMUNOL, V151, P6135; LI TK, 1993, J IMMUNOL, V150, P1680; Maniatis T., 1982, MOL CLONING LAB MANU; OKUDAIRA H, 1994, ACI NEWS, V6, P19; OZAKI T, 1987, J APPL PHYSIOL, V62, P219, DOI 10.1152/jappl.1987.62.1.219; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; STRANICK KS, 1995, J BIOL CHEM, V270, P20575, DOI 10.1074/jbc.270.35.20575; Tsuruta L, 1995, J ALLERGY CLIN IMMUN, V96, P1126, DOI 10.1016/S0091-6749(95)70197-4; VANSTRAATEN JFM, 1994, CYTOKINE, V6, P229, DOI 10.1016/1043-4666(94)90017-5; VELLENGA E, 1988, BLOOD, V71, P1529; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I	40	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				231	240		10.1016/S0091-6749(98)70388-4	http://dx.doi.org/10.1016/S0091-6749(98)70388-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500757				2022-12-18	WOS:000072244800013
J	Woods, RK; Weiner, JM; Abramson, M; Thien, F; Walters, EH				Woods, RK; Weiner, JM; Abramson, M; Thien, F; Walters, EH			Do dairy products induce bronchoconstriction in adults with asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dairy product; asthma; double-blind challenge; food hypersensitivity	FOOD CHALLENGE; DOUBLE-BLIND; DIETS; CHILDREN; RICKETS; ALLERGY; ECZEMA	Background: Dairy products have often been implicated as a cause of exacerbation of asthma, but there is little scientific evidence to support this hypothesis. Objective: We sought to determine whether dairy products induce bronchoconstriction in a group of adults with asthma. Methods: Twenty subjects with asthma (13 women and 7 men) were recruited from respondents who had previously completed a food and asthma questionnaire. Ten subjects perceived that their asthma became worse with ingestion of dairy products (positive perceivers), whereas ten were negative perceivers. None of the subjects had positive skin prick test results with cow's milk The study was a randomized, cross-over, double-blind, placebo-controlled trial. Subjects complied with a dairy-free diet throughout the study. The active challenge was a single-dose drink equivalent to 300 ml of cow's milk. A positive reaction was defined as a 15% reduction in both FEV1 and peak expiratory dow (PEF) on the active challenge day compared with results obtained at the same time on the placebo day. Results: For both FEV1 and PEF there were no statistically significantly differences in group means between active challenge and placebo challenge, between sequence of administration, or between perceptions. Nine subjects showed FEV1 or PEF changes that were greater than 15% of baseline values: four patients shelved changes after both active and placebo treatment; two after treatment with placebo only; and three after active treatment alone. Of the latter group, two subjects showed changes only in PEF, and when one of these subjects underwent a further detailed study, no asthmatic reaction could be demonstrated. Conclusion: It is unlikely that dairy products have a specific bronchoconstrictor effect in most patients with asthma, regardless of their perception.	Alfred Hosp, Dept Resp Med, Prahran, Vic 3181, Australia; Monash Univ Sch Med, Dept Resp Med, Melbourne, Vic, Australia; Monash Univ Sch Med, Dept Med, Melbourne, Vic, Australia; Monash Univ Sch Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; Monash Univ Sch Med, Dept Allergy & Clin Immunol, Melbourne, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; Monash University; Monash University	Woods, RK (corresponding author), Alfred Hosp, Dept Resp Med, Commercial Rd, Prahran, Vic 3181, Australia.		Abramson, Michael/AAQ-2671-2020; WALTERS, Eugene/AAL-2264-2021	Abramson, Michael/0000-0002-9954-0538; Walters, Eugene/0000-0002-0993-4374; Weiner, John/0000-0001-5895-8973; Thien, Francis/0000-0003-0925-6566				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1993, SPSS WINDOWS BASE SY; BIERMAN CW, 1978, J ALLERGY CLIN IMMUN, V61, P119; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; COSMAN MP, 1983, ANNU REV NUTR, V3, P1, DOI 10.1146/annurev.nu.03.070183.000245; DAVID TJ, 1984, ARCH DIS CHILD, V59, P323, DOI 10.1136/adc.59.4.323; DAVIDOVITS M, 1993, J PEDIATR-US, V122, P249, DOI 10.1016/S0022-3476(06)80124-1; DAWSON KP, 1990, NEW ZEAL MED J, V103, P239; *GESNT 5 COMM, 1990, GENST 5 REL 2 2 REF; HAAS F, 1991, J ASTHMA, V28, P349, DOI 10.3109/02770909109089462; JOHNS DP, 1993, AM REV RESPIR DIS, V147, P1245, DOI 10.1164/ajrccm/147.5.1245; Lester I.H., 1994, AUSTR FOOD NUTR; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; METCALFE DD, 1990, J ALLERGY CLIN IMMUN, V86, P421, DOI 10.1016/S0091-6749(05)80252-0; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; PINNOCK CB, 1990, AM REV RESPIR DIS, V141, P352, DOI 10.1164/ajrccm/141.2.352; *RISK FACT PREV ST, 1990, 3 NAT HEART FDN AUST; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SIMPSON SI, 1980, NEW ZEAL MED J, V92, P457; STENTON SC, 1994, EUR RESPIR J, V7, P806, DOI 10.1183/09031936.94.07040806; THIEN F, 1997, IN PRESS CLIN ASTHMA; Woods RK, 1996, AUST NZ J MED, V26, P504, DOI 10.1111/j.1445-5994.1996.tb00596.x; Woods RK, 1997, J ALLERGY CLIN IMMUN, V99, P1993; *WORK PART EUR COM, 1983, B EUR PHYSIOPATHO S5, V19	25	30	30	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				45	50		10.1016/S0091-6749(98)70192-7	http://dx.doi.org/10.1016/S0091-6749(98)70192-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449500				2022-12-18	WOS:000071539800008
J	Munoz-Fernandez, MA; Navarro, J; Garcia, A; Punzon, C; Fernandez-Cruz, E; Fresno, M				Munoz-Fernandez, MA; Navarro, J; Garcia, A; Punzon, C; Fernandez-Cruz, E; Fresno, M			Replication of human immunodeficiency virus-1 in primary human T cells is dependent on the autocrine secretion of tumor necrosis factor through the control of nuclear factor-kappa B activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acute infection; activation; human immunodeficiency virus; nuclear factor-kappa B; primary T lymphocytes; tumor necrosis factor; cytokines	BLOOD MONONUCLEAR-CELLS; FACTOR-ALPHA; HIV-INFECTION; LYMPHOCYTES-T; BINDING PROTEINS; EXPRESSION; INDUCTION; TRANSCRIPTION; ENHANCER; TYPE-1	Tumor necrosis factor (TNF)-alpha controls T-cell activation and is a major inducer of human immunodeficiency virus (HIV)-1 replication in chronically infected cells. Therefore, we have investigated its role in primary cultures of HIV-infected human T lymphocytes by using neutralizing anti-TNF-alpha antibodies or TNF-alpha. Primary resting T lymphocytes produced TNF-alpha and supported HIV replication after T-cell receptor activation. Addition of neutralizing anti-TNF-alpha antibodies drastically reduced p24 antigen release and prevented CD4(+) cell depletion associated with infection. Anti-TNF-alpha also prevented nuclear factor-kappa B (NF-kappa B) activation, and a good correlation between this inhibition and inhibition of HIV replication was observed. Moreover, supplementing the cultures with high doses of IL-2 reverted anti-TNF-alpha inhibition of cell proliferation but did not affect the inhibition of HIV p24 antigen release or NF-kappa B activation in the same cultures. Moreover, anti-TNF-alpha inhibited HIV-1 long terminal repeat (LTR)-driven transcription of a reporter gene in primary T cells in response to activation, either in the presence or the absence of HIV-1 Tat. Our results support an important role for autocrine TNF-alpha secretion in controlling HIV replication in primary T cells because of its ability to maintain NF-kappa B elevated in the nucleus of T cells.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain; Hosp Univ Gregorio Maranon, Div Immunol, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); General University Gregorio Maranon Hospital	Fresno, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain.			Fresno Escudero, Manuel/0000-0002-9223-5477; Munoz-Fernandez/0000-0002-0813-4500; Holguin, Africa/0000-0002-1330-8050				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ANTONI BA, 1994, ADV VIRUS RES, V43, P53, DOI 10.1016/S0065-3527(08)60047-0; AUKRUST P, 1994, J INFECT DIS, V169, P420, DOI 10.1093/infdis/169.2.420; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BISWAS DK, 1995, J VIROL, V69, P7437, DOI 10.1128/JVI.69.12.7437-7444.1995; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUTERA ST, 1993, J IMMUNOL, V150, P625; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P423; DEBUZE BJ, 1994, CLIN INFECT DIS, V18, P285; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; JAMIESON C, 1991, J IMMUNOL, V147, P416; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KINTER AL, 1995, J IMMUNOL, V154, P2448; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O; MERILL JE, 1989, J VIROL, V63, P4404; MOLINA JM, 1989, J CLIN INVEST, V84, P733, DOI 10.1172/JCI114230; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Navarro J, 1996, AIDS, V10, P469, DOI 10.1097/00002030-199605000-00004; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIMENTELMUINOS FX, 1995, EUR J IMMUNOL, V25, P179, DOI 10.1002/eji.1830250130; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; Poli G, 1993, Semin Immunol, V5, P165, DOI 10.1006/smim.1993.1020; POLI G, 1992, PATHOBIOLOGY, V60, P246, DOI 10.1159/000163729; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; REISINGER EC, 1990, LANCET, V335, P679, DOI 10.1016/0140-6736(90)90802-C; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; STEFFEN M, 1988, J IMMUNOL, V140, P2621; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VYAKARNAM A, 1990, AIDS, V4, P21, DOI 10.1097/00002030-199001000-00003; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	46	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				838	845		10.1016/S0091-6749(97)70282-3	http://dx.doi.org/10.1016/S0091-6749(97)70282-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438495				2022-12-18	WOS:000071353600019
J	Renstrom, A; Larsson, PH; Malmberg, P; Bayard, C				Renstrom, A; Larsson, PH; Malmberg, P; Bayard, C			A new amplified monoclonal rat allergen assay used for evaluation of ventilation improvements in animal rooms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						air sampling; ELISA; laboratory animal allergy; monoclonal antibody; rat urinary allergen; alpha(2u)-globulin	POLYACRYLAMIDE-GEL-ELECTROPHORESIS; BRONCHIAL RESPONSIVENESS; LABORATORY-ANIMALS; PROTEINS; URINE; SENSITIZATION; WORKERS; DUST; IMMUNOASSAYS; MANAGEMENT	Background: Available methods for the measurement of airborne laboratory animal allergens are not standardized and are often insufficiently sensitive for measurements in laboratories or in undisturbed animal rooms. Although low, the levels may be clinically relevant, because many scientists not involved in cleaning out cages or handling animals have rodent allergies. Objective: The purpose of this study was to develop a sensitive monoclonal assay to determine airborne rat allergen and test it in the evaluation of a sliding curtain system installed in refurbished rat rooms, with perforated, transparent polycarbonate screens, behind which were the cage racks. Methods: Monoclonal antibodies mere produced against male rat urine by immunization in mice and fusion with mouse cell line Sp2/0. A novel biotinylated phenol compound was synthesized for immunoassay signal amplification in conjunction with horseradish peroxidase. Air filter samples were collected at a rate of 2 L/min, and allergen content in the filter eluates was determined. Results: Two monoclonal antibodies were produced and used in a sandwich ELISA, which bound alpha(2u)-globulin (Rat n 1.02). The assay detection limit was 3.2 pg/ml, about tenfold increased sensitivity compared with the unamplified assay. Allergen levels mere lower in rooms when curtains were closed (median, 0.2 ng/m(3)) than behind the curtains (0.9 ng/m(3), p = 0.01) or if the curtains were open (0.9 ng/m(3), p = 0.001). However, allergen levels during cage cleaning, when curtains were drawn apart, were high (18 ng/m(3)). Conclusion: We have developed a method for measurement of airborne rat allergen that can be standardized, measures an important allergen, and is sufficiently sensitive to measure low allergen levels with personal samplers.			Renstrom, A (corresponding author), NATL INST WORKING LIFE, DEPT OCCUPAT HLTH, DIV ALLERGY & IMMUNOL, S-17184 SOLNA, SWEDEN.		Tuluc, Petronel/C-2527-2011					AOYAMA K, 1992, BRIT J IND MED, V49, P41; Bayard C, 1996, BBA-GEN SUBJECTS, V1290, P129, DOI 10.1016/0304-4165(96)00006-2; BEATTY JD, 1987, J IMMUNOL METHODS, V100, P173, DOI 10.1016/0022-1759(87)90187-6; BIRD CR, 1988, J IMMUNOL METHODS, V106, P175, DOI 10.1016/0022-1759(88)90194-9; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; COCKCROFT A, 1981, LANCET, V1, P827; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; EDWARDS RG, 1983, LAB ANIM, V17, P235, DOI 10.1258/002367783781070696; EGGLESTON PA, 1990, J ALLERGY CLIN IMMUN, V86, P63, DOI 10.1016/S0091-6749(05)80124-1; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; EGGLESTON PA, 1992, ALLERGY PROC, V13, P289, DOI 10.2500/108854192778816942; EKINS R, 1989, J BIOLUM CHEMILUM, V4, P59, DOI 10.1002/bio.1170040113; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GORDON S, 1992, ANN OCCUP HYG, V36, P575, DOI 10.1093/annhyg/36.6.575; GORDON S, 1992, BRIT J IND MED, V49, P416; GORDON S, 1993, J ALLERGY CLIN IMMUN, V92, P298, DOI 10.1016/0091-6749(93)90173-D; Gordon S, 1996, CLIN EXP ALLERGY, V26, P533, DOI 10.1111/j.1365-2222.1996.tb00573.x; HUNSKAAR S, 1993, LAB ANIM, V27, P206, DOI 10.1258/002367793780745372; HUNSKAAR S, 1990, LAB ANIM, V24, P358, DOI 10.1258/002367790780865877; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; Jonsson U., 1992, ADV BIOSENSOR, P291; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; KUMAR TKS, 1994, J BIOCHEM BIOPH METH, V28, P243; Larsson P. H., 1996, Journal of Allergy and Clinical Immunology, V97, P421, DOI 10.1016/S0091-6749(96)81173-0; Lindqvist C, 1996, SCAND J LAB ANIM SCI, V23, P135; LUTSKY I, 1985, J ALLERGY CLIN IMMUN, V75, P279, DOI 10.1016/0091-6749(85)90058-2; MANCINI MA, 1989, J HISTOCHEM CYTOCHEM, V37, P149, DOI 10.1177/37.2.2463299; NIEUWENHUIJSEN M, 1994, OCCUP ENVIRON MED, V51, P593, DOI 10.1136/oem.51.9.593; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PRICE JA, 1988, CLIN ALLERGY, V18, P95, DOI 10.1111/j.1365-2222.1988.tb02848.x; RENSTROM A, 1994, ALLERGY, V49, P548, DOI 10.1111/j.1398-9995.1994.tb01127.x; RENSTROM A, 1995, EUR RESPIR J, V8, P1514; SLOVAK AJM, 1985, AM IND HYG ASSOC J, V46, P411, DOI 10.1202/0002-8894(1985)046<0411:EOTHRI>2.3.CO;2; STEWART GA, 1997, IN PRESS CLIN EXP AL; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; VESTERBERG O, 1995, ELECTROPHORESIS, V16, P1390, DOI 10.1002/elps.11501601230; WALLS AF, 1985, J ALLERGY CLIN IMMUN, V75, P242, DOI 10.1016/0091-6749(85)90053-3; ZIEMANN B, 1992, AM IND HYG ASSOC J, V53, P138, DOI 10.1202/0002-8894(1992)053<0138:TEOTDB>2.0.CO;2	38	30	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					649	655		10.1016/S0091-6749(97)70169-6	http://dx.doi.org/10.1016/S0091-6749(97)70169-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389295				2022-12-18	WOS:A1997YG20200012
J	Tovey, ER; McDonald, LG				Tovey, ER; McDonald, LG			A simple washing procedure with eucalyptus oil for controlling house dust mites and their allergens in clothing and bedding	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DYSDERCUS-KOENIGII; TEMPERATURE				Tovey, ER (corresponding author), UNIV SYDNEY,DEPT MED,D06,SYDNEY,NSW 2006,AUSTRALIA.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				FLIESS JL, 1981, STAT METHODS RATES P, P14; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; MCDONALD LG, 1993, J ALLERGY CLIN IMMUN, V92, P771, DOI 10.1016/0091-6749(93)90022-8; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SRIVASTAVA RK, 1990, J ADV ZOOL, V11, P103; SRIVASTAVA SK, 1992, INSECT SCI APPL, V13, P145, DOI 10.1017/S1742758400014004; WEB NJA, 1993, J PAEDIAT CHILD HLTH, V29, P368	7	30	30	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					464	466		10.1016/S0091-6749(97)70136-2	http://dx.doi.org/10.1016/S0091-6749(97)70136-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338538	Bronze			2022-12-18	WOS:A1997YA52900006
J	deSiqueira, ALP; Russo, M; Steil, AA; Facincone, S; Mariano, M; Jancar, S				deSiqueira, ALP; Russo, M; Steil, AA; Facincone, S; Mariano, M; Jancar, S			A new murine model of pulmonary eosinophilic hypersensitivity: Contribution to experimental asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; late-phase reaction; eosinophil; mice; eosinophil peroxidase	MAJOR BASIC-PROTEIN; MAST-CELL; BRONCHIAL HYPERREACTIVITY; DIFFERENTIATION FACTORS; INTERFERON-GAMMA; MILD ASTHMA; AIRWAY; HYPERRESPONSIVENESS; DEGRANULATION; INTERLEUKIN-4	Background: We have recently described a model of hypersensitivity reaction in the mouse paw, which induces a typical late-phase reaction with a marked eosinophilic infiltrate. Objective: In the search for a murine model of asthma, this model was adapted to the Lungs and compared with other models of pulmonary hypersensitivity. Methods: A fragment of heat-coagulated hen's egg white was implanted subcutaneously, and 14 days later, the mice were challenged intratracheally with aggregated ovalbumin. Comparison was made with a group that received subcutaneous injection of soluble ovalbumin in alumen, challenged as described above and with four additional protocols of immunization and challenge. Results: Forty-eight hours after challenge, the percentage of eosinophils was higher in the egg white implant group (35%) then in the group immunized with ovalbumin in alumen (10.4%). The eosinophil peroxidase activity in lung homogenates of the first group was also significantly higher (529 ng/ml) than that of the second group (43 ng/ml). These results were reproduced in five different mouse strains. Compared with five different models of lung hypersensitivity, the egg white implant model was unique in terms of persistence of the pulmonary eosinophilia. Histopathologic analysis of the lungs of mice immunized with egg white implant showed peribronchial, perivascular, and intraepithelial eosinophil infiltration; morphologic characteristics of bronchoconstriction; and patchy epithelial shedding. At 21 days, in addition to persistence of eosinophil infiltrate, enlarged alveoli, reflecting air trapping, were observed. Conclusion: On the basis of the characteristics of the model described here, we propose it as a suitable murine model of asthma.	UNIV SAO PAULO,INST CIENCIAS BIOMED,DEPT IMUNOL,BR-05508900 SAO PAULO,BRAZIL; UNIV SAO PAULO,SCH VET MED,DEPT PATHOL,BR-05508900 SAO PAULO,BRAZIL	Universidade de Sao Paulo; Universidade de Sao Paulo			Jancar, Sonia/C-5153-2012; Mariano, Mario/L-2557-2015	Jancar, Sonia/0000-0001-7983-3459; 				BARNES PJ, 1988, PHARMACOL REV, V40, P49; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; CROMWELL O, 1990, J IMMUNOL, V145, P3862; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENBURG JA, 1989, CLIN EXP ALLERGY, V19, P249, DOI 10.1111/j.1365-2222.1989.tb02379.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Facincone S, 1997, MEDIAT INFLAMM, V6, P127, DOI 10.1080/09629359791820; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FRIGAS E, 1980, LAB INVEST, V42, P35; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; KIPS JC, 1995, INT ARCH ALLERGY IMM, V107, P115, DOI 10.1159/000236947; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; NAKAJIMA H, 1993, AM REV RESPIR DIS, V148, P1102, DOI 10.1164/ajrccm/148.4_Pt_1.1102; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PRETOLANI M, 1994, AM J RESP CRIT CARE, V149, P1167, DOI 10.1164/ajrccm.149.5.8173756; PRETOLANI M, 1993, BIOCHEM PHARMACOL, V45, P791, DOI 10.1016/0006-2952(93)90161-O; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X; TITUS RG, 1981, J IMMUNOL METHODS, V45, P65, DOI 10.1016/0022-1759(81)90094-6; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WARDLAW AJ, 1990, AM REV RESPIR DIS, V142, P1407; WOOLLEY KL, 1994, EUR RESPIR J, V7, P1576, DOI 10.1183/09031936.94.07091576	28	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					383	388		10.1016/S0091-6749(97)70253-7	http://dx.doi.org/10.1016/S0091-6749(97)70253-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314352				2022-12-18	WOS:A1997XX47900017
J	Garrett, JE; Town, GI; Rodwell, P; Kelly, AM				Garrett, JE; Town, GI; Rodwell, P; Kelly, AM			Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ipratropium bromide; salbutamol; acute severe asthma	OBSTRUCTIVE-AIRWAYS-DISEASE; EMERGENCY ROOM; BETA-AGONISTS; PLASMA-LEVELS	Background: Routine addition of ipratropium bromide to beta-agonist therapy in acute asthma is of uncertain benefit. Objective: This study was carried out to evaluate: (1) whether nebulized ipratropium (0.5 mg) plus salbutamol (2.5 mg) (Combivent) confers additional bronchodilation over nebulized salbutamol (2.5 mg) alone in patients with acute asthma and (2) whether adjustment for prognostic indicators of outcome influences any benefit seen with ipratropium. Methods: A double-blind, two-center, randomized, single-dose study was performed in 338 patients with asthma, aged 18 to 55 years, who attended the emergency department for treatment of acute asthma, The primary end point was FEV1 at 90 minutes. Results: The mean absolute difference in FEV1 at 90 minutes for Combivent compared with salbutamol was 113 ml (SEM +/- 48 ml, p < 0.05), Independent of the study drug received, a poor response to treatment was predicted by frequent use of inhaled P-agonist before presentation (p < 0.0001), severity of the attack (p < 0.05), and longer duration of attack (p < 0.05), Subjects who had taken more than 10 puffs of inhaled beta-agonist through a metered-dose inhaler or who had serum salbutamol levels of greater than 2 mmol/L on presentation demonstrated no benefit from the addition of ipratropium. Patients with an FEV1 less than 1 L on presentation also responded less well to C ombivent, which was explained by the association between severity of attack and greater use of inhaled beta-agonist therapy. Conclusion: A single dose of nebulized Combivent confers additional bronchodilation over salbutamol alone (p < 0.05) in acute asthma, Patients who exhibited most benefit from the addition of ipratropium were those who had consumed the least inhaled beta-agonist before presentation, not those with the most severe asthma.	CANTERBURY RESP RES GRP, CHRISTCHURCH, NEW ZEALAND; MIDDLEMORE HOSP, EMERGENCY DEPT, AUCKLAND 6, NEW ZEALAND; WESTERN HOSP, EMERGENCY DEPT, FOOTSCRAY, VIC, AUSTRALIA	Western Hospital	Garrett, JE (corresponding author), GREEN LANE HOSP, DEPT RESP SERV, AUCKLAND 3, NEW ZEALAND.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARNES PJ, 1995, LIFE SCI, V56, P853, DOI 10.1016/0024-3205(95)00020-7; BOE J, 1984, RESPIRATION, V45, P430, DOI 10.1159/000194650; BOE J, 1985, EUR J RESPIR DIS, V67, P261; *BRIT THOR SOC, 1993, THORAX, V48, pS1; BRYANT D, 1988, CHEST, V88, P24; CRAPO RO, 1987, AM REV RESPIR DIS, V135, P1221; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; GARRETT J, 1995, AM J RESP CRIT CARE, V151, pA380; HIGGINS RM, 1988, CHEST, V94, P718, DOI 10.1378/chest.94.4.718; JANSON C, 1992, EUR RESPIR J, V5, P80; LEAHY BC, 1983, BRIT J DIS CHEST, V77, P159, DOI 10.1016/0007-0971(83)90022-0; MACFIE AE, 1981, AUST NZ J MED, V11, P517, DOI 10.1111/j.1445-5994.1981.tb04622.x; *NAT ASTHM CAMP LT, 1996, ASTHM MAN HDB, P32; ODRISCOLL BR, 1989, LANCET, V1, P1418; REBUCK AS, 1987, AM J MED, V82, P59, DOI 10.1016/0002-9343(87)90378-0; ROESELER J, 1987, ACTA THERAP, V13, P571; ROSSING TH, 1983, AM J MED, V75, P781, DOI 10.1016/0002-9343(83)90407-2; ROSSING TH, 1981, AM REV RESPIR DIS, V123, P190; SUMMERS QA, 1990, CHEST, V97, P425, DOI 10.1378/chest.97.2.425; WARD MJ, 1981, BRIT MED J, V282, P598, DOI 10.1136/bmj.282.6264.598; WARD MJ, 1993, ANTICHOLINERGIC THER, P155; WATSON WTA, 1988, J ALLERGY CLIN IMMUN, V82, P1012, DOI 10.1016/0091-6749(88)90138-8	25	30	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					165	170		10.1016/S0091-6749(97)70219-7	http://dx.doi.org/10.1016/S0091-6749(97)70219-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275135				2022-12-18	WOS:A1997XR35100004
J	Ridout, SM; Tariq, SM				Ridout, SM; Tariq, SM			Cetirizine overdose in a young child	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter											Ridout, SM (corresponding author), ST MARYS HOSP,DAVID HIDE ASTHMA & ALLERGY RES CTR,NEWPORT PO30 5TG,WIGHT,ENGLAND.							HVIDBERG EF, 1992, MEYLERS SIDE EFFECTS, P366	1	30	30	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				860	861		10.1016/S0091-6749(97)80028-0	http://dx.doi.org/10.1016/S0091-6749(97)80028-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215262				2022-12-18	WOS:A1997XH19300027
J	Ulbrecht, M; Eisenhut, T; Bonisch, J; Kruse, R; Wjst, M; Heinrich, J; Wichmann, HE; Weiss, EH; Albert, ED				Ulbrecht, M; Eisenhut, T; Bonisch, J; Kruse, R; Wjst, M; Heinrich, J; Wichmann, HE; Weiss, EH; Albert, ED			High serum IgE concentrations: Association with HLA-DR and markers on chromosome 5q31 and chromosome 11q31	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						association; IgE; allergy; atopy; interleukins; HLA-DR; simple repetitive sequence; microsatellites; genetic marker	IMMUNOGLOBULIN-E-RECEPTOR; SHORT RAGWEED ALLERGEN; FC-EPSILON-RI; GENETIC-ANALYSIS; BETA-SUBUNIT; MAST-CELLS; B-CELLS; ATOPY; LINKAGE; ASTHMA	Background: Linkage studies mapped a locus regulating total serum IgE concentrations in a noncognate fashion to chromosome 5q31 and a locus for atopy to chromosome 11q13, In contrast, antigen-driven IgE production seems to be largely controlled by major histocompatibility complex class II genes, Objective: We therefore analyzed the association between the phenotype of high IgE serum levels and six microsatellite markers on chromosomes 5q31 and 11q13, as well as HLA-DRB1, in a random sample of the adult East German population. Methods: One hundred twenty-nine persons identified as ''cases'' (serum IgE level >200 kU/L) and 266 control subjects (serum IgE level less than or equal to 200 kU/L) were genotyped for five 5q31 microsatellites (D5S436, D5S393, D5S210, IL-4, and IL-9) and an 11q13 microsatellite (FCERIB). Cases and controls were also typed for HLA-DRB1. Allele frequencies were compared between cases and controls by means of a two-sided Fisher's exact test. Results: None of the markers was significantly associated although a weak association to the markers within the IL-9 gene and the FCERIB gene and to the HLA-DRB1*01 allele was found when specific IgE-positive cases were compared with negative controls. Conclusions: The weak associations after stratification for specific IgE might point to a contribution of genes in these regions to the development of allergy.	UNIV MUNICH, KINDERPOLIKLIN, LAB IMMUNGENET, MUNICH, GERMANY; INST MED STAT DOKUMENTAT & DATENVERARBEITUNG, BONN, GERMANY; GSF MUNICH, INST EPIDEMIOL, NEUHERBERG, GERMANY	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Ulbrecht, M (corresponding author), UNIV MUNICH, INST ANTHROPOL & HUMAN GENET, LUISENSTR 37, D-80333 MUNICH, GERMANY.		Heinrich, Joachim/N-1720-2013; Wichmann, Heinz Erich/AAA-5695-2022	Heinrich, Joachim/0000-0002-9620-1629; 				AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BAUR MP, 1980, HISTOCOMPATIBILITY T, P922; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BLUMENTHAL MN, 1981, AM J MED GENET, V10, P219, DOI 10.1002/ajmg.1320100304; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRERETON HM, 1994, CLIN EXP ALLERGY, V24, P868, DOI 10.1111/j.1365-2222.1994.tb01809.x; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COLLEE JM, 1993, LANCET, V342, P936, DOI 10.1016/0140-6736(93)91988-X; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; CrouauRoy B, 1996, IMMUNOGENETICS, V43, P255, DOI 10.1007/s002510050061; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DANIELS SE, 1994, HUM MOL GENET, V3, P213, DOI 10.1093/hmg/3.1.213; DUFFY DL, 1995, NAT GENET, V10, P260, DOI 10.1038/ng0795-260a; *EX COMM SP STAND, 1978, AM REV RESPIR DIS, V118, P7; FREIDHOFF LR, 1993, INT ARCH ALLERGY IMM, V100, P355, DOI 10.1159/000236438; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GERRARD JW, 1978, AM J HUM GENET, V30, P46; Gorham JD, 1996, P NATL ACAD SCI USA, V93, P12467, DOI 10.1073/pnas.93.22.12467; HASSTEDT SJ, 1983, AM J MED GENET, V14, P61, DOI 10.1002/ajmg.1320140110; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; HIZAWA N, 1992, CLIN EXP ALLERGY, V22, P1065, DOI 10.1111/j.1365-2222.1992.tb00131.x; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; LYMPANY P, 1992, CLIN EXP ALLERGY, V22, P1085, DOI 10.1111/j.1365-2222.1992.tb00134.x; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSH DG, 1990, IMMUNOLOGICAL RECOGN, P459; MARTINEZ FD, 1994, AM J HUM GENET, V55, P555; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MEYERS DA, 1991, GENET EPIDEMIOL, V8, P351, DOI 10.1002/gepi.1370080507; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; NEELY JD, 1994, J ALLERGY CLIN IMMUN, V93, P220; NEVINNYSTICKEL C, 1991, P 11 INT HIST WORKSH, P302; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PURKERSON JM, 1992, J EXP MED, V175, P973, DOI 10.1084/jem.175.4.973; RICH SS, 1992, CLIN EXP ALLERGY, V22, P1070, DOI 10.1111/j.1365-2222.1992.tb00132.x; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SHER A, 1988, IMMUNOLOGICAL DISEAS, P923; SHERRILL DL, 1994, J ALLERGY CLIN IMMUN, V94, P954, DOI 10.1016/0091-6749(94)90113-9; SHIRAKAWA T, 1994, CLIN GENET, V46, P228; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; VANHERWERDEN L, 1995, LANCET, V346, P1262, DOI 10.1016/S0140-6736(95)91863-9; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; XU J, 1995, AM J HUM GENET, V57, P423; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236; ZWOLLO P, 1991, IMMUNOGENETICS, V33, P141	63	30	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				828	836		10.1016/S0091-6749(97)80018-8	http://dx.doi.org/10.1016/S0091-6749(97)80018-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215252				2022-12-18	WOS:A1997XH19300017
J	Yagi, T; Sato, A; Hayakawa, H; Ide, K				Yagi, T; Sato, A; Hayakawa, H; Ide, K			Failure of aged rats to accumulate eosinophils in allergic inflammation of the airway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aging; bronchial asthma; eosinophil; lymphocyte; rat	CD4+ T-CELLS; LYMPHOCYTES-T; IFN-GAMMA; BRONCHIAL BIOPSIES; MESSENGER-RNA; IGE SYNTHESIS; EXPRESSION; ASTHMA; INTERLEUKIN-5; MACROPHAGES	To investigate the effect of aging on the allergic airway response, we examined the bronchoconstrictive responses and cellular inflammatory changes in a rat model of bronchial asthma by evaluating young and old animals. Two different age groups of Brown-Norway rats, actively sensitized by injection of ovalbumin into the foot pads, were used: 7 to 8 weeks old (young group) and 100 to 120 weeks old (aged group). Both the aged and young rats produced an ovalbumin-specific IgE antibody and exhibited an immediate asthmatic response after exposure to ovalbumin, but the degree of specific IgE antibody was significantly higher in young rats. The young group showed a marked increase in the number of eosinophils and neutrophils in bronchoalveolar lavage fluid 2 days after exposure to ovalbumin, whereas no eosinophilia was seen in the aged group. To evaluate the mechanism of the decreased accumulation of eosinophils in aged rats, cells from popliteal lymph nodes from ovalbumin-sensitized rats were incubated with ovalbumin for 48 hours. Although eosinophil chemotactic activity, determined by a modified Boyden chamber method, was present in the supernatant of cultured lymph node cells from young rats, it was absent from those of aged rats. In vivo administration of anti-IL-5 monoclonal antibody revealed that one of the factors of eosinophil chemotactic activity was IL-5. Lymph node cells from aged rats tended to produce greater amounts of interferon-gamma than did those from young animals. Findings indicate that aged rats have a defect in eosinophil accumulation in sites exposed to antigen, probably because of an age-dependent alteration in T cells.			Yagi, T (corresponding author), HAMAMATSU UNIV SCH MED, DEPT INTERNAL MED 2, HAMAMATSU, SHIZUOKA 43131, JAPAN.							ALRAYES H, 1992, J ALLERGY CLIN IMMUN, V90, P630, DOI 10.1016/0091-6749(92)90136-P; AMDUR MO, 1958, AM J PHYSIOL, V192, P364, DOI 10.1152/ajplegacy.1958.192.2.364; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BHUTANI VK, 1981, RESP PHYSIOL, V43, P221, DOI 10.1016/0034-5687(81)90104-3; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CAI NS, 1990, CELL IMMUNOL, V130, P311, DOI 10.1016/0008-8749(90)90274-U; CARSWELL F, 1978, IMMUNOLOGY, V34, P465; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DIAZSANCHEZ D, 1993, IMMUNOLOGY, V78, P226; EIDELMAN DH, 1988, AM REV RESPIR DIS, V137, P1033, DOI 10.1164/ajrccm/137.5.1033; ERNST DN, 1993, J IMMUNOL, V151, P575; ERNST DN, 1990, J IMMUNOL, V145, P1295; FONG TC, 1989, CELL IMMUNOL, V118, P199, DOI 10.1016/0008-8749(89)90369-9; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; FUJIWARA M, 1979, J IMMUNOL, V123, P263; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GEHA RS, 1992, J ALLERGY CLIN IMMUN, V90, P143, DOI 10.1016/0091-6749(92)90064-9; GERALD J, 1990, J ALLERGY CLIN IMMUN, V85, P422; GILLIS S, 1981, J CLIN INVEST, V67, P937, DOI 10.1172/JCI110143; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HANNAPIECHUTA ME, 1979, IMMUNOLOGY, V38, P385; HANNEUSE Y, 1978, CLIN ALLERGY, V8, P165, DOI 10.1111/j.1365-2222.1978.tb00461.x; HAYAKAWA H, 1995, MECH AGEING DEV, V80, P199, DOI 10.1016/0047-6374(95)01573-I; HOBBS MV, 1993, J IMMUNOL, V150, P3602; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; KUBO M, 1990, EUR J IMMUNOL, V20, P1289, DOI 10.1002/eji.1830200614; MACKENZIE CD, 1981, J PATHOL, V133, P161, DOI 10.1002/path.1711330207; MARSHA WK, 1991, LIFE SCI, V49, P1039; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Nagai Hiroichi, 1993, Life Sciences, V53, P243; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; PAUWELS P, 1979, IMMUNOLOGY, V36, P145; PAUWELS R, 1979, IMMUNOLOGY, V36, P151; SMITH JM, 1988, ALLERGY PRINCIPLES P, P891; TAKAYANAGI I, 1990, GEN PHARMACOL-VASC S, V21, P299, DOI 10.1016/0306-3623(90)90826-8; WALKER C, 1991, J IMMUNOL, V146, P1829; WASERMAN S, 1992, J ALLERGY CLIN IMMUN, V90, P661, DOI 10.1016/0091-6749(92)90140-W	40	30	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				38	47		10.1016/S0091-6749(97)70298-7	http://dx.doi.org/10.1016/S0091-6749(97)70298-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003209				2022-12-18	WOS:A1997WD06100006
J	Bircher, AJ; Czendlik, CH; Messmer, SL; Muller, P; Howald, H				Bircher, AJ; Czendlik, CH; Messmer, SL; Muller, P; Howald, H			Acute urticaria caused by subcutaneous recombinant hirudin: Evidence for an IgG-mediated hypersensitivity reaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LEECH EXTRACT; ANTIBODIES		CIBA GEIGY LTD,BASEL,SWITZERLAND	Novartis	Bircher, AJ (corresponding author), KANTONSSPITAL,DEPT DERMATOL,ALLERGY UNIT,CH-4031 BASEL,SWITZERLAND.							BICHLER J, 1991, THROMB RES, V61, P39, DOI 10.1016/0049-3848(91)90167-U; BRIGHTON WD, 1980, CLIN ALLERGY, V10, P97, DOI 10.1111/j.1365-2222.1980.tb02085.x; CLOSE P, 1994, CORONARY ARTERY DIS, V5, P943; COLEMAN JW, 1990, CLIN EXP ALLERGY, V20, P79, DOI 10.1111/j.1365-2222.1990.tb02779.x; DEJOBERT Y, 1991, CONTACT DERMATITIS, V24, P366, DOI 10.1111/j.1600-0536.1991.tb01752.x; GALL H, 1993, DERMATOS BER UMWELT, V41, P77; KRAFT D, 1982, ALLERGY, V37, P481, DOI 10.1111/j.1398-9995.1982.tb02331.x; PROEBSTLE TM, 1995, J ALLERGY CLIN IMMUN, V95, P1059, DOI 10.1016/S0091-6749(95)70111-7; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; WEISS ME, 1989, NEW ENGL J MED, V320, P886, DOI 10.1056/NEJM198904063201402	11	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				994	996		10.1016/S0091-6749(96)80018-2	http://dx.doi.org/10.1016/S0091-6749(96)80018-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939165				2022-12-18	WOS:A1996VU76400018
J	Gupta, N; Martin, BM; Metcalfe, DD; Rao, PVS				Gupta, N; Martin, BM; Metcalfe, DD; Rao, PVS			Parthenium pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Parthenium; glycoprotein; allergen; hydroxyproline	LOLIUM-PERENNE; ALLERGENS; HYSTEROPHORUS; PROTEINS; GLYCOPROTEIN; IGE; PURIFICATION; IDENTIFICATION; CARBOHYDRATE; TROPOMYOSIN	Background: The airborne pollen of the Compositae weed, Parthenium hysterophorus, is a major cause of allergic rhinitis in the Indian subcontinent and in certain parts of the southern United States and western Australia. Earlier studies have identified a 31 kd protein as the major allergen in Parthenium pollen. Objective: This study was undertaken to carry out the purification, immunochemical characterization, sequencing and epitope analysis of this major allergen, designated as Pal h 1. Methods: The IgE-binding activity of the allergen was evaluated by immunoblot and inhibition ELISAs. Pronase digestion, periodate oxidation, and chemical deglycosylation were performed to determine the role of peptide and carbohydrate components of the allergen-in IgE binding. Results: The data provide evidence for the involvement of carbohydrate moieties on Par h 1 in its IgE-binding ability. The N-terminal 91 amino acid sequence of Par h 1 shows 81% identity with a protein from sunflower anther, and the hydroxyproline-rich region of Par h 1 is 30% to 40% identical to similar stretches in extensins, a class of hydroxyproline-rich cell wall glycoproteins from different plant species. IgE antibodies in the sera of individuals allergic to Parthenium cross-reacted with a 50 kd hydroxproline-arabinose-rich extensin precursor from potato tuber, and this binding was periodate-sensitive. Conclusions: It appears that a group of soluble plant glycoproteins, which are related td the ubiquitous extensins, have certain car carbohydrate-containing IgE-binding epitopes that may contribute to allergenic cross-reactivity among specific pollens and foods.	INDIAN INST SCI,DEPT BIOCHEM,LAB IMMUNOL & ALLERG DIS,BANGALORE 560012,KARNATAKA,INDIA; NIMH,CLIN NEUROSCI BRANCH,NIH,BETHESDA,MD 20892; NIAID,ALLERG DIS SECT,NIH,BETHESDA,MD 20892	Indian Institute of Science (IISC) - Bangalore; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Srinivasa Rao, Prof. P/ABG-1688-2021	Srinivasa Rao, Prof. P/0000-0003-1379-4906				ALLEN AK, 1978, BIOCHEM J, V171, P665, DOI 10.1042/bj1710665; ALLEN AK, 1973, BIOCHEM J, V135, P307, DOI 10.1042/bj1350307; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CHAY CH, 1992, PLANT PHYSIOL, V100, P756, DOI 10.1104/pp.100.2.756; CHEN J, 1985, P NATL ACAD SCI USA, V82, P4399, DOI 10.1073/pnas.82.13.4399; CONDIT CM, 1986, NATURE, V323, P178, DOI 10.1038/323178a0; DASHEK WV, 1980, ANN BOT-LONDON, V45, P1; DE CESARE F, 1993, ALLERGY, V48, P248; DOEKES G, 1993, ALLERGY, V48, P401, DOI 10.1111/j.1398-9995.1993.tb00737.x; DOMON C, 1990, PLANT MOL BIOL, V15, P643, DOI 10.1007/BF00017838; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FINNE J, 1982, METHOD ENZYMOL, V83, P269; GUPTA N, 1995, INT ARCH ALLERGY IMM, V107, P557, DOI 10.1159/000237099; HAAVIK S, 1987, INT ARCH ALLER A IMM, V83, P225, DOI 10.1159/000234301; HONG JC, 1987, J BIOL CHEM, V262, P8367; HOWLETT BJ, 1981, BIOCHEM J, V197, P707, DOI 10.1042/bj1970707; KIELISZEWSKI MJ, 1995, TANDEM MASS SPECTROM, V270, P2541; KLYSNER S, 1992, CLIN EXP ALLERGY, V22, P491, DOI 10.1111/j.1365-2222.1992.tb00152.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OHTA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P151, DOI 10.1016/0003-9861(89)90359-7; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SRIRAMARAO P, 1993, CLIN EXP ALLERGY, V23, P638, DOI 10.1111/j.1365-2222.1993.tb01790.x; SRIRAMARAO P, 1991, CLIN EXP ALLERGY, V21, P55, DOI 10.1111/j.1365-2222.1991.tb00804.x; SRIRAMARAO P, 1993, INT ARCH ALLERGY IMM, V100, P79, DOI 10.1159/000236391; STICHER L, 1992, SCIENCE, V257, P655, DOI 10.1126/science.1496378; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWERS GHN, 1977, J SCI IND RES INDIA, V36, P672; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VENKATRAMAN G, 1989, P 7 INT C IMM, V78, P41; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; WEDNER HJ, 1989, J ALLERGY CLIN IMMUN, V84, P263, DOI 10.1016/0091-6749(89)90334-5; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	36	30	32	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				903	912		10.1016/S0091-6749(96)80006-6	http://dx.doi.org/10.1016/S0091-6749(96)80006-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939153				2022-12-18	WOS:A1996VU76400006
J	Miura, M; Ichinose, M; Kageyama, N; Tomaki, M; Takahashi, T; Ishikawa, J; Ohuchi, Y; Oyake, T; Endoh, N; Shirato, K				Miura, M; Ichinose, M; Kageyama, N; Tomaki, M; Takahashi, T; Ishikawa, J; Ohuchi, Y; Oyake, T; Endoh, N; Shirato, K			Endogenous nitric oxide modifies antigen-induced microvascular leakage in sensitized guinea pig airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						L-NAME; L-arginine; ovalbumin; histamine; leukotriene D-4; mast cell; degranulation	LEUKOCYTE ADHESION; PLASMA EXUDATION; MAST-CELLS; PERMEABILITY; SYNTHASE; SUPEROXIDE; ENDOTHELIUM; INHIBITION; DISEASES; INJURY	To examine the role of endogenous nitric oxide in allergic airway inflammation, we investigated the effect of a nitric oxide synthase inhibitor, N omega-nitro-L-arginine methyl ester (L-NAME), on antigen-induced airway microvascular leakage in actively senstitized guinea pigs by using Evans blue dye. Three weeks after sensitization with obalbumin (10 mu g), the tracheas were cannulated, and lungs were artifically ventilated. Animals were pretreated with atropine and propranolol (both 1 mg/kg, intravenously) to avoid neural modification. Ovalbumin inhalation (3 mg/ml, 1 minute) challenge caused significant microvascular leakage in all airway portions, which was significantly suppressed in a dose-dependent manner by pretreatment with intravenous injection of L-NAME (1 and 10 mg/kg) but not with the inactive enantiomer D-NAME (10 mg/kg). This inhibition by L-NAME was significantly reversed by co-administration of L-arginine (100 mg/kg, intravenously). Pretreatment with a vasoconstrictor, phenylephrine (20 mu g/kg, intravenously), had no inhibitory effects on antigen-induced airway microvascular leakage despite increasing systemic blood pressure. Inhalation of representative mast cell-derived mediators, histamine (2 mg/ml, 1 minute) or leukotriene D-4 (5 mu g/ml, 1 minute), produced significant microvascular leakage in all airways. L-NAME (10 mg/kg, intravenously) partially but significantly inhibited leukotriene D-4-induced leakage, whereas histamine-induced leakage was not affected. These results suggest that endogenous nitric oxide acts to increase airway microvascular leakage after airway allergic reaction.	TOHOKU UNIV, SCH MED, DEPT INTERNAL MED 1, AOBA KU, SENDAI, MIYAGI, JAPAN	Tohoku University			Ishikawa, Jun/AAG-7603-2020	Ishikawa, Jun/0000-0002-2946-7988				BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOSCHETTO P, 1989, AM REV RESPIR DIS, V139, P416, DOI 10.1164/ajrccm/139.2.416; CAPRON M, 1984, J IMMUNOL, V132, P462; DRAZEN JM, 1975, J APPL PHYSIOL, V39, P916, DOI 10.1152/jappl.1975.39.6.916; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; EVANS TW, 1988, AM REV RESPIR DIS, V138, P395, DOI 10.1164/ajrccm/138.2.395; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HENDERSON WR, 1978, J CLIN INVEST, V61, P187, DOI 10.1172/JCI108917; HUGHES SR, 1990, EUR J PHARMACOL, V191, P481, DOI 10.1016/0014-2999(90)94184-Y; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1993, FASEB J, V7, P1293, DOI 10.1096/fasebj.7.13.8405815; KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611; KUO HP, 1992, EUR J PHARMACOL, V221, P385; LIU SF, 1994, AM J RESP CRIT CARE, V149, P744, DOI 10.1164/ajrccm.149.3.7906995; MAJINO G, 1961, J BIOPHYS BIOCH CYTO, V11, P607; MAYHAN WG, 1992, INFLAMMATION, V16, P295, DOI 10.1007/BF00917622; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MCDONALD DM, 1994, AM J PHYSIOL, V266, pL61, DOI 10.1152/ajplung.1994.266.1.L61; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MILLER MJS, 1993, J PHARMACOL EXP THER, V264, P11; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; NAKAJIMA N, 1994, AM J RESP CRIT CARE, V149, pA818; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PERSSON MG, 1993, EUR J PHARMACOL, V249, pR7, DOI 10.1016/0014-2999(93)90532-M; REES DD, 1990, INT CONGR SER, V897, P427; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; ROGERS DF, 1989, J PHARMACOL METHOD, V21, P309, DOI 10.1016/0160-5402(89)90068-5; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHIMOSEGAWA T, 1994, AM J RESP CRIT CARE, V150, P1402, DOI 10.1164/ajrccm.150.5.7524981; TEIXEIRA MM, 1993, BRIT J PHARMACOL, V110, P1515, DOI 10.1111/j.1476-5381.1993.tb13994.x; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4; Ziche M., 1993, Life Sciences, V53, P229	39	30	31	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					144	151		10.1016/S0091-6749(96)70236-1	http://dx.doi.org/10.1016/S0091-6749(96)70236-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765828				2022-12-18	WOS:A1996VA69200017
J	Wahl, R; SchmidGrendelmeier, P; Cromwell, O; Wuthrich, B				Wahl, R; SchmidGrendelmeier, P; Cromwell, O; Wuthrich, B			In vitro investigation of cross-reactivity between birch and ash pollen allergen extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birch pollen; ash pollen; cross-reactivity; Western Blot inhibition; Bet v 1	IMMUNOCHEMICAL CHARACTERIZATION; MULTI-CENTRE; HAY-FEVER; ASSAY; SWITZERLAND; PROTEINS; ALDER	Allergenic cross-reactivity between members of the Fagales family (birch, alder, hazel, and beech) and between members of the Oleaceae family (ash, olive, lilac, and privet) is well known, but little is known about possible cross-reactivity between these two groups of trees, in particular between birch and ash, both of which flower in the spring. Various immunochemical methods including RAST inhibition, Western blot, and Western blot inhibition have been used in this study to show that there is partial cross-reactivity between birch and ash pollens. Enzyme allergosorbent test measurements were performed on sera from 35 patients with hay fever in spring by using birch and ash pollen allergen disks. The major allergen of birch, Bet v 1, was readily detectable in the birch pollen extract, but a homologous allergen in the ash pollen extract was barely detectable. Common allergens could be determined in the high molecular weight region. Ash pollen should be included in diagnostic procedures for spring pollinosis and should be considered for use in specific immunotherapy.	JOACHIM GANZER KG,DEPT RES & DEV,ALLERGOPHARMA,D-21465 REINBEK,GERMANY; UNIV ZURICH HOSP,DEPT DERMATOL,ALLERGY UNIT,ZURICH,SWITZERLAND	Allergopharma; University of Zurich; University Zurich Hospital								BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; BLANCA M, 1983, CLIN ALLERGY, V13, P473, DOI 10.1111/j.1365-2222.1983.tb02624.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DIRKSEN A, 1988, ALLERGY, V33, P299; ERIKSSON NE, 1984, ALLERGY, V39, P610, DOI 10.1111/j.1398-9995.1984.tb01981.x; ERIKSSON NE, 1987, ALLERGY, V42, P205, DOI 10.1111/j.1398-9995.1987.tb02201.x; FRANKE D, 1990, INT ARCH ALLER A IMM, V92, P309, DOI 10.1159/000235195; IPSEN H, 1985, ALLERGY, V40, P510, DOI 10.1111/j.1398-9995.1985.tb00259.x; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUZURICA P, 1988, MOL IMMUNOL, V25, P337, DOI 10.1016/0161-5890(88)90028-4; LAUZURICA P, 1988, MOL IMMUNOL, V25, P329, DOI 10.1016/0161-5890(88)90027-2; LEWIS WH, 1983, AIRBORNE ALLERGENIC, P2; Lewis WH, 1983, AIRBORNE ALLERGENIC, P73; MAASCH HJ, 1985, ARBEITEN PAULEHRLICH, V80, P123; MACCHIA L, 1991, ALLERGENIC POLLEN PO, P87; OBISPO TM, 1993, CLIN EXP ALLERGY, V23, P311, DOI 10.1111/j.1365-2222.1993.tb00328.x; PEETERS AG, 1994, ALLERGOLOGIE, V17, P501; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; SCHMID P, 1993, J ALLERGY CLIN IMMUN, V91, P277; SCHMIDGRENDELME.P, 1994, ALLERGOLOGIE, V11, P535; WAHL R, 1983, ANAL BIOCHEM, V134, P189, DOI 10.1016/0003-2697(83)90282-8; WAHL R, 1985, BIOL CHEM H-S, V366, P979, DOI 10.1515/bchm3.1985.366.2.979; WAHL R, 1985, J CHROMATOGR, V329, P153, DOI 10.1016/S0021-9673(01)81909-9; WAHL R, 1986, ALLERGOLOGIE, V9, P59; WAHL R, 1992, ALLERGY S, P47; WAHL R, 1993, IDENTIFIZIERUNG ALLE, V6, P46; WEBER BW, 1992, ALLERGY S, V47, P12; WHEELER A, 1990, MOL IMMUNOL, V7, P631; Yman L, 1975, Dev Biol Stand, V29, P151	32	30	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					99	106		10.1016/S0091-6749(96)70231-2	http://dx.doi.org/10.1016/S0091-6749(96)70231-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765823				2022-12-18	WOS:A1996VA69200012
J	Ulrik, CS				Ulrik, CS			Factors associated with increased bronchial responsiveness in adolescents and young adults: The importance of adjustment for prechallenge FEV(1)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial responsiveness; risk factors; allergy; eosinophils; asthma; prechallenge FEV(1)	FORCED EXPIRATORY VOLUME; DOSE-RESPONSE CURVES; AIRWAY RESPONSIVENESS; PULMONARY-FUNCTION; INHALED HISTAMINE; SERUM IGE; ASTHMA; REACTIVITY; METHACHOLINE; POPULATION	Background: Asymptomatic increased bronchial responsiveness (BR) appears to be a major risk factor for later development of asthma, but risk factors for increased BR are not well established. Objective: The relationship of age, gender, house dust mite allergy, number of blood eosinophils, and FEV(1) to the degree of nonspecific BR was studied in a population sample of 665 adolescents and young adults, aged 13 to 23 years. Methods: Case history, especially concerning smoking habits and respiratory symptoms, was obtained by interview and a self-administered questionnaire. Pulmonary function, number of blood eosinophils, BR to inhaled histamine, and skin test reactivity to house dust mites were measured with standard techniques. BR was analyzed as both a continuous variable (dose-response slope) and a categorical variable (cutoff: PC20 16 mg/ml). Results: Increasing number of blood eosinophils, sensitivity to house dust mite, and former or current symptoms of asthma were associated with increasing levels of BR, independently the level of FEV(1). Adjustment for prechallenge FEV(1) revealed a strong association between lower prechallenge FEV(1) and increasing level of BR (p < 0.0001), whereas the previously observed association between female gender and higher level of BR vanished. Repeating the analyses after exclusion of subjects with former or current asthma (n = 85) showed an unchanged relationship between house dust mite allergy and level of BR whether or not prechallenge FEV(1) was included in the regression model, whereas gender only influenced the level of BR when no adjustment was made for prechallenge FEV(1). On the contrary, the number of blood eosinophils was only significantly associated with BR after adjustment for baseline FEV(1). Comparable findings were patients with former or current symptoms of asthma and subjects with a prechallenge FEV(1) less than 80% of predicted value (n = 46) were excluded from the analyses. Conclusion: This analysis suggests that adjustment for prechallenge level of FEV(1) should be considered in studies concerned with risk factors for symptomatic and asymptomatic bronchial hyperresponsiveness.	NATL UNIV HOSP, RIGSHOSP, DEPT CLIN PHYSIOL & NUCL MED, COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen								ASTARITA C, 1988, CLIN ALLERGY, V18, P341, DOI 10.1111/j.1365-2222.1988.tb02881.x; BAKKE PS, 1991, AM REV RESPIR DIS, V143, P317, DOI 10.1164/ajrccm/143.2.317; BEAUPRE A, 1981, THORAX, V36, P731, DOI 10.1136/thx.36.10.731; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CERVERI I, 1988, CHEST, V93, P26, DOI 10.1378/chest.93.1.26; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; Dreborg S, 1987, THESIS LINKOPING U; ENGEL T, 1989, EUR RESPIR J, V2, P929; FELARCA AB, 1967, J ALLERGY, V40, P16, DOI 10.1016/0021-8707(67)90055-X; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FRETTE C, 1991, AM REV RESPIR DIS, V143, P987, DOI 10.1164/ajrccm/143.5_Pt_1.987; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; JUNIPER EF, 1991, CANADIAN THORACIC SO, P28; LIVINGSTO, 1961, LANCET, V1, P1310; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEAT JK, 1992, EUR RESPIR J, V5, P921; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SPARROW D, 1991, AM REV RESPIR DIS, V143, P978, DOI 10.1164/ajrccm/143.5_Pt_1.978; TATTERSFIELD AE, 1981, THORAX, V36, P561, DOI 10.1136/thx.36.8.561; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; UHRBRAND H, 1952, Ugeskr Laeger, V114, P385; ULRIK CS, 1995, J ASTHMA, V32, P295, DOI 10.3109/02770909509044837; ULRIK CS, 1993, J ALLERGY CLIN IMMUN, V91, P120, DOI 10.1016/0091-6749(93)90304-X; ULRIK CS, IN PRESS XLIN EXP AL; US Department of Health Education and Welfare, 1971, P 1 NHLBI EP WORKSH; YAN K, 1985, AM REV RESPIR DIS, V132, P25; ZAMEL N, 1984, J APPL PHYSIOL, V56, P129, DOI 10.1152/jappl.1984.56.1.129	34	30	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					761	767		10.1016/S0091-6749(96)80153-9	http://dx.doi.org/10.1016/S0091-6749(96)80153-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613632				2022-12-18	WOS:A1996UA97500006
J	DEBENEDICTIS, FM; TUTERI, G; PAZZELLI, P; BERTOTTO, A; BRUNI, L; VACCARO, R				DEBENEDICTIS, FM; TUTERI, G; PAZZELLI, P; BERTOTTO, A; BRUNI, L; VACCARO, R			CROMOLYN VERSUS NEDOCROMIL - DURATION OF ACTION IN EXERCISE-INDUCED ASTHMA IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EXERCISE-INDUCED ASTHMA; CROMOLYN SODIUM; NEDOCROMIL SODIUM; CHILDREN	LUNG MAST-CELLS; SODIUM CROMOGLYCATE; DOSE-RESPONSE; AEROSOL; STANDARDIZATION; ACTIVATION; INHIBITION; HISTAMINE; TESTS	Cromolyn sodium (10 mg), nedocromil sodium (4 mg), and placebo, all delivered by a metered dose inhaler, were compared in their efficacy and duration of action in preventing exercise-induced asthma in children. After a screening test was performed, 13 patients with asthma performed standard exercise texts 20 minutes and 140 minutes after drug inhalation in a randomized, double-blind, crossover study. Both drugs were significantly more protective than placebo after 20 minutes, but no significant difference between active drugs and placebo was found 140 minutes after inhalation. At these clinically recommended doses both cromolyn sodium and nedocromil sodium provide equal protection against exercise-induced asthma, and the duration of action of both lasts for less than 2 hours.	UNIV PERUGIA, CHILDRENS HOSP, I-06100 PERUGIA, ITALY	University of Perugia								ALBAZZAZ MK, 1989, THORAX, V44, P816, DOI 10.1136/thx.44.10.816; ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BARYISHAY E, 1983, ARCH DIS CHILD, V58, P624, DOI 10.1136/adc.58.8.624; BRUIJNZEEL PLB, 1990, BRIT J PHARMACOL, V30, P371; COMIS A, 1993, EUR RESPIR J, V6, P523; CRIMI N, 1988, CLIN ALLERGY, V18, P367, DOI 10.1111/j.1365-2222.1988.tb02884.x; DEBENEDICTIS FM, 1994, J ALLERGY CLIN IMMUN, V94, P684, DOI 10.1016/0091-6749(94)90175-9; DEJONG JW, 1993, EUR RESPIR REV, V15, P511; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; KONIG P, 1987, J ALLERGY CLIN IMMUN, V79, P64, DOI 10.1016/S0091-6749(87)80018-0; KONIG P, 1974, THESIS U LONDON; LEUNG KBP, 1988, THORAX, V43, P756, DOI 10.1136/thx.43.10.756; LEUNG KBP, 1986, EUR J RESPIR DIS, V69, P223; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MOQBEL R, 1988, ALLERGY, V43, P268, DOI 10.1111/j.1398-9995.1988.tb00899.x; MORTON AR, 1992, ANN ALLERGY, V68, P143; Novembre E, 1994, Pediatr Allergy Immunol, V5, P107, DOI 10.1111/j.1399-3038.1994.tb00226.x; PATEL KR, 1982, THORAX, V37, P663, DOI 10.1136/thx.37.9.663; PATEL KR, 1986, EUR J RESPIR DIS, V69, P256; RAND TH, 1988, INT ARCH ALLER A IMM, V87, P151, DOI 10.1159/000234665; RICHARDS R, 1989, CLIN EXP ALLERGY, V19, P285, DOI 10.1111/j.1365-2222.1989.tb02385.x; SEDGWICK JB, 1992, J ALLERGY CLIN IMMUN, V90, P202, DOI 10.1016/0091-6749(92)90072-A; SHAPIRO GG, 1985, PHARMACOTHERAPY, V5, P156; SILVERMAN M, 1973, THORAX, V28, P574, DOI 10.1136/thx.28.5.574; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; TAUSSIG LM, 1980, J PEDIATR-US, V97, P668, DOI 10.1016/S0022-3476(80)80039-4; THOREL T, 1988, INT ARCH ALLER A IMM, V85, P232, DOI 10.1159/000234508; TULLETT WM, 1985, THORAX, V40, P41, DOI 10.1136/thx.40.1.41; WOOLLEY M, 1990, CHEST, V97, P39, DOI 10.1378/chest.97.1.39	32	30	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					510	514		10.1016/S0091-6749(95)70295-4	http://dx.doi.org/10.1016/S0091-6749(95)70295-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560663				2022-12-18	WOS:A1995TA09500012
J	WU, CH; LEE, MF; LIAO, SC				WU, CH; LEE, MF; LIAO, SC			ISOLATION AND PRELIMINARY CHARACTERIZATION OF CDNA-ENCODING AMERICAN COCKROACH ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CDNA CLONING AMERICAN COCKROACH; CR-PI ALLERGENS	GERMAN BLATTELLA-GERMANICA; PERIPLANETA-AMERICANA; BRONCHIAL-ASTHMA; MAJOR ALLERGENS; RNA-POLYMERASE; CLONED GENES; HYPERSENSITIVITY; PURIFICATION; IDENTIFICATION; EXPRESSION	Background: Two prominent proteins of 78 and 72 kd in Cr-PI have been found to be the major allergens of American cockroach (Periplaneta americana). Methods: A lambda gt22A cDNA library generated from messenger RNA of American cockroach was packaged into Escherichia coli Y1090(r(-)) and initially screened with rabbit polyclonal antiserum raised to crude extract of American cockroach (CRa-A). Results: Twenty-nine anti-CRa-A-positive clones were isolated and 11 clones were recognized by rabbit anti-Cr-PI and reactive with IgE antibodies of atopic serum pool. Among these 11 clones, eight were recognized by murine anti-Cr-PI monoclonal antibodies Four clones (C7, C8, C12 and C29) were found to contain inserts of 26 kilobases (kb), and clones C5 and C20 were found to contain inserts of 24 kb. The remaining clones (C13, C23, C25, C28, and C35) were found to contain inserts of 1.8, 1.6, 2.5, 1.7, and 0.9 kb, respectively. Clones C12, C20, C13, and C28 were selected, subcloned into the expression pET vectors, and used to transform E. coli BL21(DE3). Immunoblot analyses of clones C12, C20, C13, and C28 with anti-Cr-PI monoclonal antibodies revealed fusion proteins with molecular weights of 78 and 50 kd 72 and 43 kd, 54 kd, and 46 kd respectively. However, among those fusion proteins only those with molecular weights of 78, 72, 54, and 46 kd were able to bind human specific IgE antibodies. Conclusions: The cDNA clones are expected to code for the major and principal allergens of American cockroach, and recombinant allergens may therefore be valuable for diagnostic and therapeutic purposes.			WU, CH (corresponding author), TAICHUNG VET GEN HOSP, DEPT MED RES, TAICHUNG 407, TAIWAN.							BENSON S A, 1984, Biotechniques, V2, P126; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAN JH, 1987, NUCLEIC ACIDS RES, V15, P6304, DOI 10.1093/nar/15.15.6304; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154, DOI 10.1159/000235207; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; Maniatis T, 1989, MOL CLONING; Marchand A M, 1966, Bol Asoc Med P R, V58, P49; MENDOZA J, 1970, ANN ALLERGY, V28, P159; SCHEINER O, 1992, INT ARCH ALLERGY IMM, V98, P93, DOI 10.1159/000236170; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULANER FA, 1970, PEDIATRICS, V45, P465; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1; WU CH, 1993, CLIN EXP ALLERGY, V23, P493, DOI 10.1111/j.1365-2222.1993.tb03236.x; WU CH, 1990, CLIN EXP ALLERGY, V20, P675, DOI 10.1111/j.1365-2222.1990.tb02707.x; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	30	30	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					352	359		10.1016/S0091-6749(95)70054-4	http://dx.doi.org/10.1016/S0091-6749(95)70054-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560637				2022-12-18	WOS:A1995RU66000007
J	STEINBERGER, P; BOHLE, B; DIPADOVA, F; WRANN, M; LIEHL, E; SCHEINER, O; KRAFT, D; VALENTA, R				STEINBERGER, P; BOHLE, B; DIPADOVA, F; WRANN, M; LIEHL, E; SCHEINER, O; KRAFT, D; VALENTA, R			ALLERGEN-SPECIFIC IGE PRODUCTION OF COMMITTED B-CELLS FROM ALLERGIC PATIENTS IN-VITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; SPECIFIC IGE; INTERLEUKIN-4; ANTI-CD40; RECOMBINANT ALLERGENS	PHLEUM-PRATENSE POLLEN; MONOCLONAL-ANTIBODIES; HUMAN-LYMPHOCYTES; BINDING-FACTORS; IFN-GAMMA; INTERLEUKIN-13; INVITRO; IL-4; CD40; INDIVIDUALS	The allergen-specific in vitro IgE synthesis in blood leukocytes from patients with allergy was monitored outside the pollen season with recombinant and natural pollen allergens and was compared with the total IgE production. The addition of interleukin-4 (IL-4) and antibody to CD40 increased the amount of total IgE by up to 2D-fold in the culture supernatants of peripheral blood leukocytes from patients with allergy that could be antagonized by a neutralizing anti-IL-4 antibody in a dose-dependent manner. In contrast to total IgE, the amount of allergen-specific IgE was not affected by IL-4, and anti-CD40 or anti-IL-4 treatment. With oligonucleotides specific for IgE, complementary DNA from the amino terminal of the IgE heavy chain could be reversely transcribed and amplified by polymerase chain reaction from RNA of patients' unstimulated blood leukocytes, indicating that the IgE secretion in the cultures is due to a de novo IgE synthesis. It is concluded that the peripheral blood of patients with allergy contains long-lived allergen-specific B cells, which ave not responsive to IL-4-mediated signals. These results may have implications for attempts to modulate specific IgE production in allergic patients with cytokines or cytokine antagonists.	UNIV VIENNA,GEN HOSP,INST GEN & EXPTL PATHOL,VIENNA,AUSTRIA; SANDOZ AG,DEPT IMMUNOL,BASEL,SWITZERLAND; SANDOZ RES CTR,VIENNA,AUSTRIA	University of Vienna; Novartis; Sandoz; Novartis; Sandoz				Bohle, Barbara/0000-0002-5105-7985; Steinberger, Peter/0000-0001-6848-4097; Valenta, Rudolf/0000-0001-5944-3365				BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; DEVRIES JE, 1991, CURR OPIN IMMUNOL, V3, P851, DOI 10.1016/S0952-7915(05)80003-2; GAUCHAT JF, 1992, INT IMMUNOL, V4, P397, DOI 10.1093/intimm/4.3.397; HAYGLASS KT, 1991, J EXP MED, V173, P279, DOI 10.1084/jem.173.2.279; HEUSSER CH, 1991, ALLERGY CLIN IMMUNOL, V3, P47; ISHIZAKA K, 1981, J IMMUNOL, V126, P1692; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; ISHIZAKA K, 1985, INT ARCH ALLER A IMM, V77, P13, DOI 10.1159/000233746; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; MACKENZIE T, 1989, J EXP MED, V169, P407, DOI 10.1084/jem.169.2.407; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OKUDAIRA H, 1981, CELL IMMUNOL, V58, P188, DOI 10.1016/0008-8749(81)90160-X; PENE J, 1988, J IMMUNOL, V141, P1218; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; QUESNIAUX VFJ, 1987, MOL IMMUNOL, V24, P1159, DOI 10.1016/0161-5890(87)90162-3; ROMAGNANI S, 1980, CLIN EXP IMMUNOL, V42, P167; Sambrook J., 1989, MOL CLONING LAB MANU; SARFATI M, 1984, IMMUNOLOGY, V53, P187; SEGAL DM, 1977, P NATL ACAD SCI USA, V41, P457; STAHLI C, 1980, J IMMUNOL METHODS, V32, P297, DOI 10.1016/0022-1759(80)90194-5; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P37; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; ZHANG K, 1991, J IMMUNOL, V146, P1836	34	30	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					209	218		10.1016/S0091-6749(95)70010-2	http://dx.doi.org/10.1016/S0091-6749(95)70010-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7543502				2022-12-18	WOS:A1995RQ00100010
J	KAISER, HB; FINDLAY, SR; GEORGITIS, JW; GROSSMAN, J; RATNER, PH; TINKELMAN, DG; ROSZKO, P; ZEGARELLI, E; WOOD, CC				KAISER, HB; FINDLAY, SR; GEORGITIS, JW; GROSSMAN, J; RATNER, PH; TINKELMAN, DG; ROSZKO, P; ZEGARELLI, E; WOOD, CC			LONG-TERM TREATMENT OF PERENNIAL ALLERGIC RHINITIS WITH IPRATROPIUM BROMIDE NASAL SPRAY 0.06-PERCENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PERENNIAL ALLERGIC RHINITIS; IPRATROPIUM BROMIDE; NASAL SPRAY; RHINORRHEA; LONG-TERM	QUALITY-OF-LIFE; VASOMOTOR RHINITIS; METHACHOLINE; ATROVENT	The purpose of this study was to assess the safety and efficacy of ipratropium bromide nasal spray 0.06 % (aqueous solution), 84 mu g per nostril three times a day, in reducing nasal hypersecretion in the long-term treatment of patients with perennial allergic rhinitis (PAR). This was an open-label I-year trial. In the first 6 months all patients were treated with two puffs ipratropium bromide nasal spray 0.06 %, 84 mu g per nostril three times per day, unless they were unable to tolerate the dose. lit the last 6 months the dose could be reduced to the lowest amount required to control rhinorrhea. Ninety-sir patients entered the trial, and 47 completed it. Sixty-three patients completed more than 6 months of treatment. Patient and physician global evaluation suggested that ipratropium bromide nasal spray 0.06 % is effective in controlling rhinorrhea associated with PAR and can contribute to control of congestion, postnasal drip, and sneezing. There was also a trend toward reduction of mucosal edema and improvement in quality of life. The most common drug-related adverse events were nasal dryness, epistaxis/nose bleed, and increased rhinitis. Most adverse events were mild and resulted in drug discontinuation in less than 10 % of patients. Ipratropium bromide nasal spray was well tolerated and not associated with serious drug-related adverse events or clinically significant anticholinergic side effects. Use of ipratropium bromide nasal spray alone or with other standard medications should be considered in treating patients with PAR.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27103; SYLVANIA RES,SAN ANTONIO,TX; BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877	Wake Forest University; Wake Forest Baptist Medical Center; Boehringer Ingelheim	KAISER, HB (corresponding author), UNIV MINNESOTA,1149 MED ARTS BLDG,MINNEAPOLIS,MN 55402, USA.							Andersen, 1982, NOSE UPPER AIRWAY PH, P45; BAROODY FM, 1992, J ALLERGY CLIN IMMUN, V89, P1065, DOI 10.1016/0091-6749(92)90290-I; BORUM P, 1978, Rhinology (Utrecht), V16, P225; DOLOVICH J, 1987, J ALLERGY CLIN IMMUN, V80, P274, DOI 10.1016/0091-6749(87)90031-5; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; DRUCE HM, 1992, ANN ALLERGY, V69, P53; JOKINEN K, 1983, Rhinology (Utrecht), V21, P341; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; KNIGHT A, 1986, ANN ALLERGY, V57, P348; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P242, DOI 10.1016/0091-6749(92)90078-G; MYGIND N, 1983, ALLERGY PRINCIPLES P, P1107; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; SANWIKARJA S, 1986, ANN ALLERGY, V56, P162; SMITH JM, 1988, ALLERGY PRINCIPLES P, V2, P891; TOS M, 1976, Rhinology (Utrecht), V14, P155	16	30	31	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1128	1132		10.1016/S0091-6749(95)70217-2	http://dx.doi.org/10.1016/S0091-6749(95)70217-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7751529	Bronze			2022-12-18	WOS:A1995QY91800009
J	TARLO, SM; DOLOVICH, J; LISTGARTEN, C				TARLO, SM; DOLOVICH, J; LISTGARTEN, C			ANAPHYLAXIS TO CARRAGEENAN - A PSEUDO-LATEX ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANAPHYLAXIS; FOOD ALLERGY; CARRAGEENAN; BARIUM ENEMA REACTION	HYPERSENSITIVITY; INFLAMMATION	Background: Anaphylactic reactions during a barium enema have been attributed to allergy to latex on the barium enema device. The observation of anaphylaxis during barium enema without Eater exposure or latex allergy led to the performance of an allergy skin test to the barium enema solution. Methods: Individual components of the barium enema solution were obtained for double-blind skin testing. A RAST to identify specific IgE antibodies to the skin test active agent was established. Results: Carrageenan, a component the barium enema solution, produced positive reactions to allergy skin test and RAST. Gastrointestinal symptoms for which the patient was being investigated by the barium enema subsequently disappeared with a diet free of carrageenan. Conclusions: Carrageenan is a previously unreported cause of anaphylaxis duning barium enema. It is an allergen widely distributed in common foods and potentially could account for some symptoms related to milk products or baby formula.	MCMASTER UNIV,MED CTR,HAMILTON,VIC,AUSTRALIA; NORTHWESTERN HOSP,TORONTO,ON,CANADA		TARLO, SM (corresponding author), TORONTO HOSP,WESTERN DIV,EC4-008,399 BATHURST ST,TORONTO,ON M5T 2S8,CANADA.			Tarlo, Susan/0000-0002-4746-5310				ABRAHAM R, 1974, GASTROENTEROLOGY, V67, P1169; BENITZ KF, 1973, FOOD COSMET TOXICOL, V11, P565, DOI 10.1016/S0015-6264(73)80327-X; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COHEN AJ, 1993, CHEST, V103, P309, DOI 10.1378/chest.103.1.309; DININNO V, 1978, IMMUNOCHEMISTRY, V15, P273, DOI 10.1016/0161-5890(78)90066-4; FLEISS PM, 1980, W J MED, V132, P4; JOHNSTON KH, 1968, J IMMUNOL, V101, P556; LAM FY, 1989, ANN RHEUM DIS, V48, P928, DOI 10.1136/ard.48.11.928; LAWSON CJ, 1973, J CHEM SOC PERK T 1, P2177, DOI 10.1039/p19730002177; MANKES R, 1975, P SOC EXP BIOL MED, V150, P166; MARCUS R, 1981, LANCET, V1, P338; MARCUS R, 1980, LANCET, V1, P602; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MIZUSHIM.Y, 1973, EXPERIENTIA, V29, P605, DOI 10.1007/BF01926693; MIZUSHIMA Y, 1974, INT ARCH ALLER A IMM, V47, P532, DOI 10.1159/000231247; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; POPPER H, 1982, IMMUNOLOGY, V46, P589; SIMON L, 1979, J RETICULOENDOTH SOC, V25, P133; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; WARPINSKI JR, 1991, AM J MED, V90, P769; WATT J, 1973, GUT, V14, P506, DOI 10.1136/gut.14.6.506; YOSHINO S, 1982, J PHARMACOBIO-DYNAM, V5, P266; 1993, NEW ENCY BRITANNICA, V6, P385	23	30	30	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				933	936		10.1016/S0091-6749(95)70091-9	http://dx.doi.org/10.1016/S0091-6749(95)70091-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751512				2022-12-18	WOS:A1995QY91700002
J	VALDIVIESO, R; SUBIZA, J; VARELALOSADA, S; SUBIZA, JL; NARGANES, MJ; MARTINEZCOCERA, C; CABRERA, M				VALDIVIESO, R; SUBIZA, J; VARELALOSADA, S; SUBIZA, JL; NARGANES, MJ; MARTINEZCOCERA, C; CABRERA, M			BRONCHIAL-ASTHMA, RHINOCONJUNCTIVITIS, AND CONTACT-DERMATITIS CAUSED BY ONION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									CTR ALERGIA & IMMUNOL CLIN GEN PARDINAS,E-28006 MADRID,SPAIN; HOSP UNIV SAN CARLOS,SERV IMMUNOL,MADRID,SPAIN; HOSP UNIV SAN CARLOS,SERV ALERGIA,MADRID,SPAIN									BRODNITZ MH, 1971, J AGR FOOD CHEM, V19, P269, DOI 10.1021/jf60174a009; MICHEL FB, 1987, J ALLERGY CLIN IMMUN, V79, P247; PEARSON RSB, 1966, ACTA ALLERGOL, V21, P507, DOI 10.1111/j.1398-9995.1966.tb03170.x; SUBIZA J, 1991, J ALLERGY CLIN IMMUN, V88, P731, DOI 10.1016/0091-6749(91)90179-R	4	30	30	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					928	930		10.1016/0091-6749(94)90161-9	http://dx.doi.org/10.1016/0091-6749(94)90161-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963160				2022-12-18	WOS:A1994PR24000018
J	WICKERN, GM				WICKERN, GM			FUSARIUM ALLERGIC FUNGAL SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							BIPOLARIS		WILFORD HALL USAF MED CTR,DEPT ALLERGY IMMUNOL,LACKLAND AFB,TX 78236	United States Department of Defense; United States Air Force								ADAM RD, 1986, MEDICINE, V65, P203, DOI 10.1097/00005792-198607000-00001; BRUMMUND W, 1986, JAMA-J AM MED ASSOC, V256, P3249; FRIEDMAN GC, 1991, AM J CLIN PATHOL, V96, P368, DOI 10.1093/ajcp/96.3.368; GOLDSTEIN MF, 1992, J ALLERGY CLIN IMMUN, V90, P394, DOI 10.1016/S0091-6749(05)80020-X; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P583, DOI 10.1016/0091-6749(90)90097-N; MILLAR JW, 1981, THORAX, V36, P710; ONEIL CE, 1986, J ALLERGY CLIN IMMUN, V77, P842, DOI 10.1016/0091-6749(86)90382-9; SCHEER L, 1992, ANN ALLERGY, V68, P1185	8	30	32	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					624	625		10.1016/0091-6749(93)90087-V	http://dx.doi.org/10.1016/0091-6749(93)90087-V			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8409122				2022-12-18	WOS:A1993MC59000015
J	ACEVES, M; GRIMALT, JO; SUNYER, J; ANTO, JM; REED, CE				ACEVES, M; GRIMALT, JO; SUNYER, J; ANTO, JM; REED, CE			IDENTIFICATION OF SOYBEAN DUST AS AN EPIDEMIC ASTHMA AGENT IN URBAN AREAS BY MOLECULAR MARKER AND RAST ANALYSIS OF AEROSOLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EPIDEMIC ASTHMA; SOYBEAN; MOLECULAR MARKERS; BETA-SITOSTEROL; STIGMASTEROL; N-TRIACONTAN-1-OL; RAST; URBAN AEROSOL	HYPERSENSITIVITY PNEUMONITIS; ORLEANS ASTHMA; OUTBREAKS; POLLEN; HYDROCARBONS; ALLERGENS; PETROLEUM; TIME	From 1981 to 1987, 26 outbreaks of asthma have occurred in the city of Barcelona, Spain, affecting a total of 687 subjects and causing 1155 emergency room admissions. Assays of urban aerosols collected with high-volume samplers between October 1986 and May 1989 have indicated that soybean dust originating from harbor activities (and not traffic or industrial pollution) is the causal agent for these epidemics. Soybean particulates in the filters have been characterized from the composition of the alcohol fraction, namely, campesterol, stigmasterol, beta-sitosterol, n-triacontan-1-ol, and n-dotriacontan-1-ol, constituting a series of aerosol components correlated with the epidemiologic data. This result has also been confirmed by immunochemical assay of specific soybean allergens. The concentration of these sterols in the air corresponds to a 24-hour average level of soybean dust in the order of 25-mu-g/m3 on epidemic days. These results suggest the advisability of monitoring soybean dust in air particulates of populated areas surrounding soybean storage or processing plants. The techniques presented here afford a simple way for the recognition of soybean dust in aerosols containing high concentrations of organic pollutants of traffic or industrial origin.	CSIC,CID,DEPT ENVIRONM CHEM,JORDI GIRONA 18,E-08034 BARCELONA,SPAIN; ENTITAT METROPOLITANA BARCELONA,UO ENVIRONM CONTROL,BARCELONA,SPAIN; MUNICIPAL INST MED RES,DEPT EPIDEMIOL,BARCELONA,SPAIN; MAYO CLIN & MAYO GRAD SCH MED,ROCHESTER,MN 55901	Consejo Superior de Investigaciones Cientificas (CSIC); Mayo Clinic			Grimalt, Joan O/E-2073-2011; Sunyer, Jordi/G-6909-2014; Anto, J M/H-2676-2014	Grimalt, Joan O/0000-0002-7391-5768; Sunyer, Jordi/0000-0002-2602-4110; Anto, J M/0000-0002-4736-8529				ACEVES M, 1988, J CHROMATOGR, V436, P503, DOI 10.1016/S0021-9673(00)94612-0; AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; ANTO JM, 1986, LANCET, V1, P900, DOI 10.1016/S0140-6736(86)90999-2; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; ANTO JM, 1986, LANCET, V2, P1096; GOLDSTEIN IF, 1978, ENVIRON RES, V17, P266, DOI 10.1016/0013-9351(78)90029-4; HARRIES MG, 1981, LANCET, V1, P5; Himmelblau D M, 1970, PROCESS ANAL STAT ME, P463; KNIGHTS BA, 1968, PHYTOCHEMISTRY, V7, P1707, DOI 10.1016/S0031-9422(00)88632-X; Knox E G, 1982, Stat Med, V1, P183, DOI 10.1002/sim.4780010210; KVANTA E, 1968, ACTA CHEM SCAND, V22, P2161, DOI 10.3891/acta.chem.scand.22-2161; MENDES E, 1954, J ALLERGY, V25, P253, DOI 10.1016/0021-8707(54)90183-5; OPUTE FI, 1975, PHYTOCHEMISTRY, V14, P1023, DOI 10.1016/0031-9422(75)85180-6; PACKE GE, 1983, LANCET, V2, P280; REED CE, 1985, CHEST, V87, pS40; REED CE, 1983, J OCCUP ENVIRON MED, V25, P207, DOI 10.1097/00043764-198303000-00014; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SICRE MA, 1987, ATMOS ENVIRON, V21, P2247, DOI 10.1016/0004-6981(87)90356-8; SIMONEIT BRT, 1985, INT J ENVIRON AN CH, V22, P203, DOI 10.1080/03067318508076422; SIMONEIT BRT, 1984, ATMOS ENVIRON, V18, P51, DOI 10.1016/0004-6981(84)90228-2; STANDIFER LN, 1968, PHYTOCHEMISTRY, V7, P1361, DOI 10.1016/S0031-9422(00)85638-1; Suarez-Cervera M, 1983, COLLECT BOT, V14, P587; SUNYER J, 1989, LANCET, V1, P179; SWANSON WC, 1991, J ALLERGY CLIN IMMUN, V87, P783; THOMPSON MJ, 1978, PHYTOCHEMISTRY, V17, P1053, DOI 10.1016/S0031-9422(00)94279-1; USETLI P, 1984, LANCET, V1, P156; USETTI P, 1983, LANCET, V2, P280; WALLENSTEIN S, 1980, AM J EPIDEMIOL, V111, P367, DOI 10.1093/oxfordjournals.aje.a112908; WEILL H, 1964, JAMA-J AM MED ASSOC, V190, P811; WOODARD ED, 1988, JAMA-J AM MED ASSOC, V259, P1965, DOI 10.1001/jama.259.13.1965; 1986, LANCET, V2, P786	33	30	31	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					124	134		10.1016/0091-6749(91)90309-C	http://dx.doi.org/10.1016/0091-6749(91)90309-C			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071776				2022-12-18	WOS:A1991FY20400015
J	BOUSQUET, J; CHANAL, I; SKASSABROCIEK, W; LEMONIER, C; MICHEL, FB				BOUSQUET, J; CHANAL, I; SKASSABROCIEK, W; LEMONIER, C; MICHEL, FB			LACK OF SUBSENSITIVITY TO LORATADINE DURING LONG-TERM DOSING DURING 12 WEEKS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LABS SCHERING PLOUGH,LEVALLOIS PERRET,FRANCE	Merck & Company; Schering-Plough Research Institute	BOUSQUET, J (corresponding author), CHU MONTPELLIER,HOP AIGUELONGUE,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					AHN HS, 1986, EUR J PHARMACOL, V127, P153, DOI 10.1016/0014-2999(86)90219-0; BELIN L, 1985, ALLERGY S4, V40, P60; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; BYE CE, 1977, EUR J CLIN PHARMACOL, V12, P181, DOI 10.1007/BF00609857; CHANAL I, 1988, J ALLERGY CLIN IMMUN, V82, P878, DOI 10.1016/0091-6749(88)90093-0; CLISSOLD SP, 1989, DRUGS, V37, P42, DOI 10.2165/00003495-198937010-00003; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; MICHEL FB, 1986, J ALLERGY CLIN IMMUN, V77, P222; MONASH S, 1950, J INVEST DERMATOL, V15, P1, DOI 10.1038/jid.1950.61; MONROE EW, 1988, AM J ACAD DERMATOL, V19, P138; OEI HD, 1988, ANN ALLERGY, V61, P436; OSTERBALLE O, 1989, ALLERGY, V44, P356, DOI 10.1111/j.1398-9995.1989.tb00458.x; PIPKORN U, 1988, ALLERGY, V43, P81, DOI 10.1111/j.1398-9995.1988.tb00398.x; RADWANSKI E, 1987, J CLIN PHARMACOL, V27, P530, DOI 10.1002/j.1552-4604.1987.tb03061.x; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; SIMONS FER, 1989, ANN ALLERGY, V63, P266; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V82, P1068; SKASSABROCIEK W, 1988, J ALLERGY CLIN IMMUN, V81, P175, DOI 10.1016/0091-6749(88)90262-X; SKASSABROCIEK W, 1988, J ALLERGY CLIN IMMUN, V81, P725, DOI 10.1016/0091-6749(88)91045-7; TAYLOR RJ, 1985, J ALLERGY CLIN IMMUN, V76, P103, DOI 10.1016/0091-6749(85)90811-5; TEMPLE DM, 1988, PROSTAGLANDINS, V35, P549, DOI 10.1016/0090-6980(88)90030-5; TRZECIAKOWSKI JP, 1988, ALLERGY PRINCIPLES P, P715; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8; WINER BJ, 1962, STATISTICAL PRINCIPL	28	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					248	253		10.1016/S0091-6749(05)80072-7	http://dx.doi.org/10.1016/S0091-6749(05)80072-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	1974561				2022-12-18	WOS:A1990DV31600016
J	GRAMMER, LC; ROBERTS, M; LERNER, C; PATTERSON, R				GRAMMER, LC; ROBERTS, M; LERNER, C; PATTERSON, R			CLINICAL AND SEROLOGIC FOLLOW-UP OF 4 CHILDREN AND 5 ADULTS WITH BIRD-FANCIERS LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611	Northwestern University	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,OCCUPAT MED & ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER PM, 1984, BRIT J DIS CHEST, V78, P404; CHANDRA S, 1972, ARCH DIS CHILD, V47, P716, DOI 10.1136/adc.47.255.716; CUNNINGHAM AS, 1976, PEDIATRICS, V58, P436; GRAMMER LC, 1986, INTERNAL MED; GREENBERGER PA, 1989, AM J MED, V86, P119, DOI 10.1016/0002-9343(89)90243-X; HARGREAV.FE, 1966, LANCET, V1, P445; KRAUSEHOOYMAN L, 1983, INT ARCH ALLER A IMM, V71, P245, DOI 10.1159/000233398; MOORE VL, 1980, J ALLERGY CLIN IMMUN, V65, P365, DOI 10.1016/0091-6749(80)90214-6; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; OUCHTERLONY O, 1968, HDB IMMUNODIFFUSION, P4; PURTILO DT, 1975, J PEDIATR-US, V86, P569, DOI 10.1016/S0022-3476(75)80150-8; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; REISS JS, 1974, ANN ALLERGY, V32, P208; SHANNON DC, 1969, AM J DIS CHILD, V117, P504, DOI 10.1001/archpedi.1969.02100030506002; STIEHM ER, 1967, PEDIATRICS, V39, P904; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55	16	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					655	660		10.1016/0091-6749(90)90107-F	http://dx.doi.org/10.1016/0091-6749(90)90107-F			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2107243				2022-12-18	WOS:A1990CU66800018
J	NORMAN, PS; VANMETRE, TE				NORMAN, PS; VANMETRE, TE			THE SAFETY OF ALLERGENIC IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											NORMAN, PS (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,DIV CLIN IMMUNOL,301 BAYVIEW BLVD,BALTIMORE,MD 21224, USA.							[Anonymous], 1986, BMJ-BRIT MED J, V293, P948; BICKELL WH, 1984, ANN EMERG MED, V13, P189, DOI 10.1016/S0196-0644(84)80611-3; CLAUSEN RW, 1983, J ALLERGY CLIN IMMUN, V72, P199, DOI 10.1016/0091-6749(83)90530-4; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MCCOMBS CC, 1980, NEW ENGL J MED, V303, P1179; Noon L, 1911, LANCET, V1, P1572; PHANUPHAK P, 1980, AM J MED, V68, P479, DOI 10.1016/0002-9343(80)90285-5; THOMPSON RA, 1989, LANCET, V1, P259; UMETSU DT, 1985, J ALLERGY CLIN IMMUN, V76, P713, DOI 10.1016/0091-6749(85)90676-1; VANARSDEL PP, 1957, J ALLERGY, V28, P251, DOI 10.1016/0021-8707(57)90130-2; WEBER RW, 1988, J ALLERGY CLIN IMMUN, V81, P295, DOI 10.1016/0091-6749(88)90744-0; WOLPOW ER, 1975, JAMA-J AM MED ASSOC, V234, P620, DOI 10.1001/jama.234.6.620; 1986, J ALLERGY CLIN IMMUN, V77, P271	15	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					522	525		10.1016/0091-6749(90)90165-Z	http://dx.doi.org/10.1016/0091-6749(90)90165-Z			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2303651				2022-12-18	WOS:A1990CP51100016
J	ARAKI, H; SLY, PD				ARAKI, H; SLY, PD			INHALATION OF HYPERTONIC SALINE AS A BRONCHIAL CHALLENGE IN CHILDREN WITH MILD ASTHMA AND NORMAL-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL CHILDRENS HOSP,DEPT THORAC MED,FLEMINGTON RD,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne			Sly, Peter D/F-1486-2010	Sly, Peter D/0000-0001-6305-2201				ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1985, CLIN REV ALLERG, V3, P427; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; AQUILINA AT, 1983, THORAX, V38, P766, DOI 10.1136/thx.38.10.766; ASSOUFI BK, 1986, B EUR PHYSIOPATH RES, V22, P349; BOULET LP, 1987, THORAX, V42, P953, DOI 10.1136/thx.42.12.953; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; FABBRI LM, 1984, ANN ALLERGY, V53, P172; FORESI A, 1986, CHEST, V90, P822, DOI 10.1378/chest.90.6.822; GALDESSEBALDT M, 1985, J PEDIATR-US, V107, P526, DOI 10.1016/S0022-3476(85)80009-3; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; MCLAUGHLIN FJ, 1983, PEDIATRICS, V72, P503; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; PHELAN PD, 1982, RESPIRATORY ILLNESS; REISMAN J, 1987, PEDIATR PULM, V3, P251, DOI 10.1002/ppul.1950030410; RYAN G, 1981, J ALLERGY CLIN IMMUN, V67, P156, DOI 10.1016/0091-6749(81)90012-9; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SHAW RJ, 1985, ALLERGY, V40, P48, DOI 10.1111/j.1398-9995.1985.tb04154.x; SMITH CM, 1987, J ALLERGY CLIN IMMUN, V79, P85, DOI 10.1016/S0091-6749(87)80021-0; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SMITH CM, IN PRESS J ALLERGY C; TAL A, 1984, J PEDIATR-US, V104, P516, DOI 10.1016/S0022-3476(84)80539-9; WENG TR, 1969, AM REV RESPIR DIS, V99, P879; YAN K, 1983, THORAX, V38, P523; ZACH M, 1984, PEDIATR RES, V18, P469, DOI 10.1203/00006450-198405000-00016; 1962, AM REV RESPIR DIS, V85, P762	31	30	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					99	107		10.1016/0091-6749(89)90183-8	http://dx.doi.org/10.1016/0091-6749(89)90183-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2754150				2022-12-18	WOS:A1989AG12000014
J	ARM, JP; WALPORT, MJ; LEE, TH				ARM, JP; WALPORT, MJ; LEE, TH			EXPRESSION OF COMPLEMENT RECEPTORS TYPE-1 (CR-1) AND TYPE-3 (CR3) ON CIRCULATING GRANULOCYTES IN EXPERIMENTALLY PROVOKED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,4TH FLOOR HUNTS HOUSE,LONDON SE1 9RT,ENGLAND; ROYAL POSTGRAD MED SCH,DEPT MED,RHEUMATOL UNIT,LONDON W12 0HS,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Walport, Mark/0000-0001-7220-5273				ARM JP, 1978, J ALLERGY CLIN IMMUN, V79, P129; CARROLL MP, 1985, J ALLERGY CLIN IMMUN, V75, P290, DOI 10.1016/0091-6749(85)90060-0; CHOWIENCZYK PJ, 1981, J APPL PHYSIOL, V50, P672, DOI 10.1152/jappl.1981.50.3.672; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CHUNG KF, 1984, THORAX, V74, P49; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; EDDY A, 1984, CLIN IMMUNOL IMMUNOP, V31, P371, DOI 10.1016/0090-1229(84)90090-4; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; EISER NM, 1980, CLIN SCI, V58, P537, DOI 10.1042/cs0580537; FARBER HW, 1986, J IMMUNOL, V137, P2918; FEARON DT, 1983, J IMMUNOL, V130, P370; FORESI A, 1986, J ALLERGY CLIN IMMUN, V78, P1130, DOI 10.1016/0091-6749(86)90262-9; GIN W, 1985, J ALLERGY CLIN IMMUN, V76, P675, DOI 10.1016/0091-6749(85)90670-0; GIN W, 1985, AM REV RESPIR DIS, V132, P1199; HAYES JA, 1976, BRONCHIAL ASTHMA MEC, P347; HOGG N, 1984, EUR J IMMUNOL, V14, P236, DOI 10.1002/eji.1830140307; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEE TH, IN PRESS CLIN SCI; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MOORE FD, 1986, NEW ENGL J MED, V314, P948, DOI 10.1056/NEJM198604103141503; MOQBEL R, 1986, AM REV RESPIR DIS, V133, P609; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; OBYRNE PM, 1986, CHEST, V90, P575, DOI 10.1378/chest.90.4.575; PAPAGEORGIOU N, 1983, LANCET, V2, P1220; RICHERSON HB, 1985, CLIN EXP IMMUNOL, V62, P442; ROSS GD, 1985, ADV IMMUNOL, V37, P217, DOI 10.1016/S0065-2776(08)60341-7; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225	31	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					649	655		10.1016/0091-6749(89)90078-X	http://dx.doi.org/10.1016/0091-6749(89)90078-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2926084	Bronze			2022-12-18	WOS:A1989T859600012
J	MULLARKEY, MF				MULLARKEY, MF			EOSINOPHILIC NONALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MULLARKEY, MF (corresponding author), VIRGINIA MASON CLIN,ALLERGY IMMUNOL & RHEUMAT DIS,SEATTLE,WA, USA.							FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; MULLARKEY MF, 1981, MED CLIN N AM, V65, P977, DOI 10.1016/S0025-7125(16)31484-5; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MULLARKEY MF, 1981, J ALLERGY CLIN IMMUN, V67, P251, DOI 10.1016/0091-6749(81)90018-X; MULLARKEY MF, 1979, POSTGRAD MED, V65, P97, DOI 10.1080/00325481.1979.11715114; SCHATZ M, 1978, J ALLERGY CLIN IMMUN, V61, P150, DOI 10.1016/0091-6749(78)90312-3	7	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	2	S			941	949		10.1016/0091-6749(88)90037-1	http://dx.doi.org/10.1016/0091-6749(88)90037-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2353	3057047				2022-12-18	WOS:A1988R235300008
J	OHNISHI, M; RUHNO, J; DOLOVICH, J; DENBURG, JA				OHNISHI, M; RUHNO, J; DOLOVICH, J; DENBURG, JA			ALLERGIC RHINITIS NASAL MUCOSAL CONDITIONED MEDIUM STIMULATES GROWTH AND DIFFERENTIATION OF BASOPHIL MAST-CELL AND EOSINOPHIL PROGENITORS FROM ATOPIC BLOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University; McMaster University; McMaster University								BAGBY GC, 1986, J CLIN INVEST, V78, P1316, DOI 10.1172/JCI112717; DENBURG JA, 1980, IMMUNOLOGY, V41, P195; DENBURG JA, 1985, CLIN RES, V33, pA160; DENBURG JA, 1986, LYMPHOKINE RES, V5, P261; DENBURG JA, 1985, BLOOD, V66, P312; DENBURG JA, 1980, J CLIN INVEST, V65, P390, DOI 10.1172/JCI109682; DENBURG JA, 1983, BLOOD, V61, P775; DENBURG JA, 1985, EXP HEMATOL, V13, P185; DENBURG JA, 1986, INT ARCH ALLER A IMM, V79, P312, DOI 10.1159/000233993; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; DENBURG JA, 1986, MAST CELL DIFFERENTI, P379; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; HANSEL FK, 1953, CLIN ALLERGY, P411; ISHIZAKA T, 1985, J IMMUNOL, V134, P532; KURLAND JI, 1979, P NATL ACAD SCI USA, V76, P2326, DOI 10.1073/pnas.76.5.2326; LEARY AG, 1984, BLOOD, V64, P78; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LUGER TA, 1985, J IMMUNOL, V134, P915; MAYRHOFER G, 1981, INT ARCH ALLER A IMM, V64, P320, DOI 10.1159/000232710; MITCHELL EB, 1982, LANCET, V1, P127; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; OGAWA M, 1983, P NATL ACAD SCI-BIOL, V80, P4494, DOI 10.1073/pnas.80.14.4494; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; OTSUKA H, 1987, AM REV RESPIR DIS, V136, P710, DOI 10.1164/ajrccm/136.3.710; OTSUKA H, 1981, ARCH OTORHINOLARYNGO, V233, P227; OTSUKA H, 1977, ARCH OTORHINOLARYNGO, V314, P283; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; SULLIVAN R, 1983, J IMMUNOL, V130, P800; TADOKORO K, 1983, J EXP MED, V158, P857, DOI 10.1084/jem.158.3.857; TANNO Y, 1987, EXP HEMATOL, V15, P24; TOMIDA M, 1984, J BIOL CHEM, V259, P978	33	30	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1149	1154		10.1016/0091-6749(88)90883-4	http://dx.doi.org/10.1016/0091-6749(88)90883-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3379227				2022-12-18	WOS:A1988P002300013
J	HOLMBERG, K; BAKE, B; PIPKORN, U				HOLMBERG, K; BAKE, B; PIPKORN, U			NASAL MUCOSAL BLOOD-FLOW AFTER INTRANASAL ALLERGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GOTHENBURG UNIV, LUNDBY HOSP, DEPT OTORHINOLARYNGOL, S-41124 GOTHENBURG, SWEDEN; UNIV LUND, DEPT OTORHINOLARYNGOL, S-22101 LUND, SWEDEN; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN PHYSIOL, S-41345 GOTHENBURG, SWEDEN	University of Gothenburg; Lund University; Sahlgrenska University Hospital; University of Gothenburg								ASCHAN GUNNAR, 1958, ANN ACAD REG SCI UPSALIENSIS, V2, P111; BENDE M, 1984, ACTA OTO-LARYNGOL, V97, P99, DOI 10.3109/00016488409130969; BENDE M, 1983, ACTA OTO-LARYNGOL, V96, P277, DOI 10.3109/00016488309132900; BENDE M, 1983, ACTA OTO-LARYNGOL, V96, P523, DOI 10.3109/00016488309132740; BROMS P, 1980, THESIS U LUND LUND; CLAIRMONT AA, 1973, ANN OTO RHINOL LARYN, V82, P69, DOI 10.1177/000348947308200115; CLEMENT PAR, 1984, RHINOMANOMETRY REV O, V46, P173; Connell J T, 1968, Trans Am Acad Ophthalmol Otolaryngol, V72, P422; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DRUCE HM, 1984, J APPL PHYSIOL, V57, P4; HENRIKSEN O, 1983, ACTA PHYSIOL SCAND, V117, P171, DOI 10.1111/j.1748-1716.1983.tb07194.x; HENRIKSEN O, 1983, CIRC RES, V52, P534, DOI 10.1161/01.RES.52.5.534; HILEY CR, 1978, ACTA OTO-LARYNGOL, V85, P444; INGELSTEDT S, 1964, Acta Otolaryngol, V57, P119, DOI 10.3109/00016486409136952; KONNO A, 1982, ACTA OTO-LARYNGOL, V94, P131, DOI 10.3109/00016488209128897; LASSEN NA, 1964, LANCET, V1, P686; MALCOMSON K G, 1959, J Laryngol Otol, V73, P73, DOI 10.1017/S0022215100054980; MYGIND N, 1978, Rhinology (Utrecht), V16, P79; Mygind N., 1979, NASAL ALLERGY; OLSSON P, 1986, THESIS U LUND LUND; PAULSSON B, 1985, ACTA OTO-LARYNGOL, V99, P140, DOI 10.3109/00016488509119156; PELIKAN Z, 1974, ACTA ALLERGOL, V29, P337, DOI 10.1111/j.1398-9995.1974.tb01470.x; PIPKORN U, 1984, ALLERGY, V39, P141, DOI 10.1111/j.1398-9995.1984.tb01946.x; PIPKORN U, 1987, PATHOPHYSIOLOGICAL A, P149; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; TANIMOTO H, 1983, Rhinology (Utrecht), V21, P59	26	30	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					531	537		10.1016/0091-6749(88)90192-3	http://dx.doi.org/10.1016/0091-6749(88)90192-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181					2022-12-18	WOS:A1988M618100008
J	AHMED, T; DBROT, J; ABRAHAM, W				AHMED, T; DBROT, J; ABRAHAM, W			THE ROLE OF CALCIUM-ANTAGONISTS IN BRONCHIAL REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											AHMED, T (corresponding author), UNIV MIAMI, MT SINAI MED CTR, SCH MED, DIV PULM DIS, 4300 ALTON RD, MIAMI BEACH, FL 33140 USA.							ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; AHMED T, 1986, AM REV RESPIR DIS, V133, pA281; AHMED T, 1985, CHEST, V88, P176, DOI 10.1378/chest.88.2.176; AHMED T, 1981, AM REV RESPIR DIS, V124, P110; AHMED T, 1986, CHEST, V89, pS535; AHMED T, 1985, CHEST, V88, pS142; ALBAZZAZ F, 1981, EXP LUNG RES, V2, P121, DOI 10.3109/01902148109052308; ATKINSON G, 1979, BRIT J PHARMACOL, V65, P395, DOI 10.1111/j.1476-5381.1979.tb07843.x; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BALFRE K, 1978, J PHYSIOL-LONDON, V275, pP80; BARNES PJ, 1981, THORAX, V36, P726, DOI 10.1136/thx.36.10.726; BEDARD RM, 1983, AM REV RESPIR DIS, V127, P70; BENDOV I, 1986, AM REV RESPIR DIS, V133, P116, DOI 10.1164/arrd.1986.133.1.116; BOGART BI, 1977, PEDIATR RES, V11, P131, DOI 10.1203/00006450-197702000-00010; BRUGMAN TM, 1983, AM REV RESPIR DIS, V127, P14, DOI 10.1164/arrd.1983.127.1.14; CARPENTER N, 1986, AM REV RESPIR DIS, V133, pA14; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CERRINA J, 1981, American Review of Respiratory Disease, V123, P44; CERRINA J, 1982, AM REV RESPIR DIS, V125, P64; CERRINA J, 1981, AM REV RESPIR DIS, V123, P156; COBURN RF, 1977, J PHARMACOL EXP THER, V201, P276; COBURN RF, 1977, FED PROC, V36, P2692; COLES SJ, 1982, CHEST, V81, pS34, DOI 10.1378/chest.81.5_Supplement.34S; CREESE BR, 1981, CLIN EXP PHARMACOL P, V8, P175, DOI 10.1111/j.1440-1681.1981.tb00149.x; D'BROT J, 1987, American Review of Respiratory Disease, V135, pA312; DEAL EC, 1984, CHEST, V86, P762, DOI 10.1378/chest.86.5.762; DELEHUNT JC, 1984, AM REV RESPIR DIS, V130, P748; DOUGLAS WW, 1978, CIBA F S, V54, P61; DRAZEN JM, 1983, BRIT J PHARMACOL, V78, P687, DOI 10.1111/j.1476-5381.1983.tb09421.x; DUNCAN PG, 1984, J PHARMACOL EXP THER, V228, P612; ESCOUBET B, 1986, BIOCHEM PHARMACOL, V35, P1879, DOI 10.1016/0006-2952(86)90306-0; FANTA CH, 1982, AM REV RESPIR DIS, V125, P61; FARLEY JM, 1977, J PHARMACOL EXP THER, V201, P199; FARLEY JM, 1978, J PHARMACOL EXP THER, V207, P340; FEIGAL RJ, 1979, NATURE, V278, P276, DOI 10.1038/278276a0; FEIGAL RJ, 1979, PEDIATR RES, V13, P764, DOI 10.1203/00006450-197906000-00009; FEWTRELL CMS, 1977, NATURE, V265, P635, DOI 10.1038/265635a0; FLECKENSTEIN A, 1977, ANNU REV PHARMACOL, V17, P149, DOI 10.1146/annurev.pa.17.040177.001053; FLECKENSTEIN A, 1984, GALLOPAMIL PHARM CLI, P1; FLECKENSTEINGRU.G, 1984, GALLOPAMIL PHARM CLI, P33; FOREMAN JC, 1973, NATURE, V245, P249, DOI 10.1038/245249a0; GIBSON LE, 1971, PEDIATRICS, V48, P695; GONZALEZ JM, 1983, AM REV RESPIR DIS, V127, P155; GRAVES S, 1978, EUR J PHARMACOL, V47, P29, DOI 10.1016/0014-2999(78)90370-9; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HENDERSON AF, 1983, THORAX, V38, P512, DOI 10.1136/thx.38.7.512; HENDERSON AF, 1983, AM REV RESPIR DIS, V127, P549, DOI 10.1164/arrd.1983.127.5.549; HENRY PD, 1980, AM J CARDIOL, V46, P1047, DOI 10.1016/0002-9149(80)90366-5; HIMORI N, 1980, BRIT J PHARMACOL, V68, P595, DOI 10.1111/j.1476-5381.1980.tb10848.x; ISHIZAKA T, 1979, P NATL ACAD SCI USA, V76, P5858, DOI 10.1073/pnas.76.11.5858; JAKSCHIK BA, 1980, BIOCHEM BIOPH RES CO, V95, P103, DOI 10.1016/0006-291X(80)90710-X; JENSEN C, 1983, ALLERGY, V38, P233, DOI 10.1111/j.1398-9995.1983.tb01616.x; KIRKPATRICK CT, 1975, CLIN EXP PHARM PHYSL, V5, P599; KOHROGI H, 1985, AM REV RESPIR DIS, V132, P299; KOSHINO T, 1985, ALLERGY, V40, P311, DOI 10.1111/j.1398-9995.1985.tb00241.x; LEE VY, 1983, THORAX, V38, P386, DOI 10.1136/thx.38.5.386; LEVER AML, 1984, THORAX, V39, P576, DOI 10.1136/thx.39.8.576; MAGNUSSEN H, 1984, THORAX, V39, P579, DOI 10.1136/thx.39.8.579; MALAGODI MH, 1974, EUR J PHARMACOL, V27, P25, DOI 10.1016/0014-2999(74)90198-8; MALO PE, 1982, J PHARMACOL EXP THER, V221, P410; MARIN MG, 1978, J APPL PHYSIOL, V44, P900, DOI 10.1152/jappl.1978.44.6.900; MARTHAN R, 1987, AM REV RESPIR DIS, V135, P185; MCFADDEN ER, 1980, AM J MED, V68, P471, DOI 10.1016/0002-9343(80)90282-X; MCINTYRE E, 1983, J ALLERGY CLIN IMMUN, V71, P375, DOI 10.1016/0091-6749(83)90065-9; MEISHERI KD, 1981, J MEMBRANE BIOL, V59, P19, DOI 10.1007/BF01870817; MIDDLETON E, 1981, BIOCHEM PHARMACOL, V30, P2867, DOI 10.1016/0006-2952(81)90428-7; MIDDLETON E, 1980, J PHARM SCI-US, V69, P243, DOI 10.1002/jps.2600690244; MIDDLETON E, 1981, J IMMUNOL, V127, P546; MILEDI R, 1980, PROC R SOC SER B-BIO, V211, P143, DOI 10.1098/rspb.1980.0162; MONGAR JL, 1972, BRIT J PHARMACOL, V46, P741, DOI 10.1111/j.1476-5381.1972.tb06899.x; NEUSS H, 1984, GALLOPAMIL PHARM CLI, P99; NORN S, 1983, EUR J RESPIR DIS, V64, P394; OZENNE G, 1985, EUR J RESPIR DIS, V67, P238; PATAKAS D, 1983, J ALLERGY CLIN IMMUN, V72, P269, DOI 10.1016/0091-6749(83)90031-3; PATEL KR, 1985, EUR J RESPIR DIS, V67, P269; PATEL KR, 1981, BRIT MED J, V282, P932, DOI 10.1136/bmj.282.6268.932; PATEL KR, 1981, CLIN ALLERGY, V11, P441, DOI 10.1111/j.1365-2222.1981.tb01617.x; PATEL KR, 1983, CLIN ALLERGY, V13, P119, DOI 10.1111/j.1365-2222.1983.tb02578.x; PAYNE A, 1977, THESIS LONDON U, pCH8; POPA VT, 1984, AM REV RESPIR DIS, V130, P1006; ROBERTS JA, 1986, THORAX, V41, P12, DOI 10.1136/thx.41.1.12; RUSSI EW, 1983, AM REV RESPIR DIS, V127, P675; RUSSI EW, 1984, CHEST, V86, P475, DOI 10.1378/chest.86.3.475; RUSSI EW, 1984, J APPL PHYSIOL, V57, P1182, DOI 10.1152/jappl.1984.57.4.1182; RUSSI EW, 1985, CHEST, V88, P74, DOI 10.1378/chest.88.1.74; SO SY, 1982, CLIN ALLERGY, V12, P595, DOI 10.1111/j.1365-2222.1982.tb02558.x; SOLWAY J, 1985, AM REV RESPIR DIS, V132, P666; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; SORSCHER EJ, 1982, LANCET, V1, P368; TANIZAKI Y, 1985, ACTA MED OKAYAMA, V39, P247; TANIZAKI Y, 1983, ACTA MED OKAYAMA, V37, P207; TRIGGLE DJ, 1980, CHEST, V78, P174, DOI 10.1378/chest.78.1_Supplement.174; WAWROSE SF, 1986, IRCS MED SCI-BIOCHEM, V14, P908; WEICHMAN BM, 1983, J PHARMACOL EXP THER, V225, P310; WEISS E B, 1981, American Review of Respiratory Disease, V123, P42; WEISS EB, 1983, PROSTA LEUKOTR MED, V12, P53, DOI 10.1016/0262-1746(83)90067-7; WEISS EB, 1979, RESPIRATION, V38, P266, DOI 10.1159/000194091; WILLIAMS DO, 1981, BRIT MED J, V283, P348, DOI 10.1136/bmj.283.6287.348	98	30	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					133	152		10.1016/0091-6749(88)90232-1	http://dx.doi.org/10.1016/0091-6749(88)90232-1			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3276758				2022-12-18	WOS:A1988M027400021
J	GONZALEZ, EB; SWEDO, JL; RAJARAMAN, S; DANIELS, JC; GRANT, JA				GONZALEZ, EB; SWEDO, JL; RAJARAMAN, S; DANIELS, JC; GRANT, JA			ULTRASTRUCTURAL AND IMMUNOHISTOCHEMICAL EVIDENCE FOR RELEASE OF EOSINOPHILIC GRANULES INVIVO - CYTOTOXIC POTENTIAL IN CHRONIC EOSINOPHILIC PNEUMONIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DIV ALLERGY,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT PATHOL,DIV SURG PATHOL,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	GONZALEZ, EB (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV RHEUMATOL IMMUNOL,405 CLIN SCI BLDG G-59,GALVESTON,TX 77550, USA.							AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; BOLIBAR CP, 1980, MED CLIN BARC, V77, P7; CAPRON M, 1981, J IMMUNOL, V126, P2087; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; CROFTON JW, 1952, THORAX, V7, P1, DOI 10.1136/thx.7.1.1; DESSEIN AJ, 1982, J EXP MED, V156, P90, DOI 10.1084/jem.156.1.90; FILLEY WV, 1982, LANCET, V2, P11; FOX B, 1980, THORAX, V35, P570, DOI 10.1136/thx.35.8.570; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GRANTHAM JG, 1986, AM J MED, V80, P89, DOI 10.1016/0002-9343(86)90053-7; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; JORG A, 1982, J EXP MED, V155, P390, DOI 10.1084/jem.155.2.390; KANNER RE, 1977, CHEST, V71, P95, DOI 10.1378/chest.71.1.95; LIEBOW AA, 1969, MEDICINE, V48, P251, DOI 10.1097/00005792-196907000-00001; MCEVOY JDS, 1978, AM J MED, V64, P529, DOI 10.1016/0002-9343(78)90248-6; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OKUDA M, 1981, IMMUNOBIOLOGY EOSINO, P201; PEARSON DJ, 1978, MAYO CLIN PROC, V53, P73; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; PETERS MS, 1983, BRIT J DERMATOL, V109, P141, DOI 10.1111/j.1365-2133.1983.tb07074.x; REEDER WH, 1952, ANN INTERN MED, V36, P1217, DOI 10.7326/0003-4819-36-5-1217; SCHATZ M, 1981, MED CLIN N AM, V65, P1055, DOI 10.1016/S0025-7125(16)31489-4; TURNERWARWICK M, 1976, CLIN ALLERGY, V6, P135, DOI 10.1111/j.1365-2222.1976.tb01891.x; VEITH MC, 1983, J EXP MED, V157, P1828, DOI 10.1084/jem.157.6.1828; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; Weller P F, 1979, Adv Immunol, V27, P339, DOI 10.1016/S0065-2776(08)60264-3; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626	29	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					755	762		10.1016/0091-6749(87)90207-7	http://dx.doi.org/10.1016/0091-6749(87)90207-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3553278				2022-12-18	WOS:A1987H434900010
J	SMITH, CM; ANDERSON, SD; BLACK, JL				SMITH, CM; ANDERSON, SD; BLACK, JL			METHACHOLINE RESPONSIVENESS INCREASES AFTER ULTRASONICALLY NEBULIZED WATER BUT NOT AFTER ULTRASONICALLY NEBULIZED HYPERTONIC SALINE IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL PRINCE ALFRED HOSP,DEPT THORAC MED,MISSENDEN RD,CAMPERDOWN,NSW 2050,AUSTRALIA; UNIV SYDNEY,DEPT PHARMACOL,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney; University of Sydney			Black, Judith L/C-6559-2008	Anderson, Sandra/0000-0002-6308-8770				ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; ANDERSON SD, 1985, AIRWAY RESPONSIVENES, P39; ASSOULINE G, 1977, EUR J PHARMACOL, V44, P271, DOI 10.1016/0014-2999(77)90073-5; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BERNSTEIN IL, 1964, DIS CHEST, V46, P469, DOI 10.1378/chest.46.4.469; BLACK J L, 1985, American Review of Respiratory Disease, V131, pA275; BLACK JL, 1985, THORAX, V40, P427, DOI 10.1136/thx.40.6.427; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; Ferron G. A., 1977, Journal of Aerosol Science, V8, P251, DOI 10.1016/0021-8502(77)90045-3; FINNEY MJB, CLIN EXP PHARM PHYSL; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; HAHN AG, 1984, THORAX, V39, P919, DOI 10.1136/thx.39.12.919; HIGENBOTTAM T, 1985, CHEST, V87, pS156, DOI 10.1378/chest.87.5_Supplement.156S; KAY AB, 1984, ASTHMA PHYSL IMMUNOP, P211; KIVILOOG J, 1975, PAEDIATRICS, V56, pS908; MAGYAR P, 1984, SCHWEIZ MED WSCHR, V114, P910; NADEL JA, 1984, ASTHMA PHYSL IMMUNOP, P129; Polgar G, 1971, PULMONARY FUNCTION T; ROSENTHAL RR, 1984, J ALLERGY CLIN IMMUN, V73, pA179; SCHOEFFEL RE, 1981, BRIT MED J, V63, P459; SHAW RJ, 1985, ALLERGY, V40, P48, DOI 10.1111/j.1398-9995.1985.tb04154.x; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; WEISS JW, 1983, J ALLERGY CLIN IMMUN, V72, P140, DOI 10.1016/0091-6749(83)90521-3; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	28	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					85	92		10.1016/S0091-6749(87)80021-0	http://dx.doi.org/10.1016/S0091-6749(87)80021-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3543095				2022-12-18	WOS:A1987F881000017
J	GRAMMER, LC; SHAUGHNESSY, MA; FINKLE, SM; SHAUGHNESSY, JJ; PATTERSON, R				GRAMMER, LC; SHAUGHNESSY, MA; FINKLE, SM; SHAUGHNESSY, JJ; PATTERSON, R			A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF POLYMERIZED WHOLE GRASS ADMINISTERED IN AN ACCELERATED DOSAGE SCHEDULE FOR IMMUNOTHERAPY OF GRASS POLLINOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOPE COLL,HOLLAND,MI 49423	Hope College	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P448, DOI 10.1016/0091-6749(83)90580-8; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; HENDRIX SG, 1982, J CLIN IMMUNOL, V2, P10, DOI 10.1007/BF00915972; LEVY DA, 1980, REGULATORY CONTROL S, P178; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V72, P129, DOI 10.1016/0091-6749(83)90519-5; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; PATTERSON R, 1981, J ALLERGY CLIN IMMUN, V68, P85, DOI 10.1016/0091-6749(81)90163-9; SNEDECOR GW, 1973, STATISTICAL METHODS, P128; Solomon W. R., 1983, ALLERGY PRINCIPLES P, P1143; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55	12	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1180	1184		10.1016/0091-6749(86)90269-1	http://dx.doi.org/10.1016/0091-6749(86)90269-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3537093				2022-12-18	WOS:A1986F302600015
J	BUTTERFIELD, JH; ACKERMAN, SJ; WEILER, D; EISENBREY, AB; GLEICH, GJ				BUTTERFIELD, JH; ACKERMAN, SJ; WEILER, D; EISENBREY, AB; GLEICH, GJ			EFFECTS OF GLUCOCORTICOIDS ON EOSINOPHIL COLONY GROWTH	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA	Mayo Clinic	BUTTERFIELD, JH (corresponding author), MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, ALLERG DIS RES LAB, ROCHESTER, MN 55905 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, R01AI020416, R37AI015231] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15231, AI 20416] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1980, J IMMUNOL, V125, P2118; ACKERMAN SJ, 1982, J EXP MED, V155, P1597, DOI 10.1084/jem.155.6.1597; ACKERMAN SJ, 1983, J EXP MED, V158, P946, DOI 10.1084/jem.158.3.946; BEST WR, 1951, BLOOD, V6, P61, DOI 10.1182/blood.V6.1.61.61; BJORNSON BH, 1985, J CLIN INVEST, V76, P924, DOI 10.1172/JCI112091; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; BUTTERFIELD JH, 1982, BRIT J HAEMATOL, V51, P209, DOI 10.1111/j.1365-2141.1982.tb08477.x; COULOMBEL L, 1983, BLOOD, V62, P291; DALE DC, 1976, J LAB CLIN MED, V87, P487; FORSHAM PH, 1948, J CLIN ENDOCRINOL, V8, P15, DOI 10.1210/jcem-8-1-15; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GLEICH GJ, 1980, EOSINOPHIL HLTH DISE, P79; GODLOWSKI ZZ, 1948, BRIT MED J, V1, P46, DOI 10.1136/bmj.1.4540.46; GODLOWSKI ZZ, 1952, J ENDOCRINOL, V8, P102, DOI 10.1677/joe.0.0080102; HALLGREN R, 1979, BRIT J HAEMATOL, V42, P147, DOI 10.1111/j.1365-2141.1979.tb03707.x; HAYS WL, 1981, STATISTICS, P286; HILLS AG, 1948, BLOOD, V3, P755, DOI 10.1182/blood.V3.7.755.755; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; KAPLOW LS, 1965, BLOOD-J HEMATOL, V26, P215, DOI 10.1182/blood.V26.2.215.215; KELLGREN JH, 1951, BRIT MED J, V2, P1183, DOI 10.1136/bmj.2.4741.1183; KRIPPAEHNE MARION LARSEN, 1955, ACTA HAEMATOL, V13, P145; NAVARETTE JV, 1962, ACTA ENDOCRINOL-COP, V39, P135, DOI 10.1530/acta.0.0390135; NISSEN C, 1983, BRIT J HAEMATOL, V54, P519, DOI 10.1111/j.1365-2141.1983.tb02130.x; PIKE BL, 1970, J CELL PHYSIOL, V76, P77, DOI 10.1002/jcp.1040760111; POTTER CG, 1981, CLIN LAB HAEMATOL, V3, P245; RAMESH KS, 1985, CELL IMMUNOL, V92, P366, DOI 10.1016/0008-8749(85)90018-8; ROSENTHAL RL, 1950, P SOC EXP BIOL MED, V75, P740; SAKAI N, 1981, AM J ANAT, V161, P11, DOI 10.1002/aja.1001610103; SJOGREN U, 1976, ACTA HAEMATOL-BASEL, V55, P153; SLOVICK FT, 1984, EXP HEMATOL, V12, P464; SUDA T, 1983, EXP HEMATOL, V11, P114; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WELLER PF, 1982, J IMMUNOL, V128, P1346; WELLER PF, 1980, EOSINOPHIL HLTH DISE, P121; ZUCKERFRANKLIN D, 1976, J HISTOCHEM CYTOCHEM, V24, P1270, DOI 10.1177/24.12.63511	36	30	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				450	457		10.1016/0091-6749(86)90032-1	http://dx.doi.org/10.1016/0091-6749(86)90032-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	3760404				2022-12-18	WOS:A1986E114800013
J	HANNAN, CJ; STAFFORD, CT; RHOADES, RB; WRAY, BB; BAER, H; ANDERSON, MC				HANNAN, CJ; STAFFORD, CT; RHOADES, RB; WRAY, BB; BAER, H; ANDERSON, MC			SEASONAL-VARIATION IN ANTIGENS OF THE IMPORTED FIRE ANT SOLENOPSIS-INVICTA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL GEORGIA,ALLERGY IMMUNOL SECT,AUGUSTA,GA 30912; DWIGHT DAVID EISENHOWER ARMY MED CTR,DEPT CLIN INVEST,FT GORDON,GA 30905; DWIGHT DAVID EISENHOWER ARMY MED CTR,ALLERGY IMMUNOL SERV,FT GORDON,GA 30905; US FDA,OFF BIOL,BETHESDA,MD 20014	University System of Georgia; Augusta University; United States Department of Defense; United States Army; United States Department of Defense; United States Army; US Food & Drug Administration (FDA)								ADAMS CT, 1981, J MED ENTOMOL, V18, P378, DOI 10.1093/jmedent/18.5.378; BAER H, 1979, TOXICON, V17, P397, DOI 10.1016/0041-0101(79)90267-8; BLUM MS, 1958, SCIENCE, V128, P306, DOI 10.1126/science.128.3319.306-a; BRAND JM, 1973, TOXICON, V11, P325, DOI 10.1016/0041-0101(73)90029-9; CAMI J, 1982, ANTIMICROB AGENTS CH, V21, P1013, DOI 10.1128/AAC.21.6.1013; GLANCEY B M, 1973, Journal of the Georgia Entomological Society, V8, P237; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JAMES FK, 1976, J ALLERGY CLIN IMMUN, V58, P110, DOI 10.1016/0091-6749(76)90112-3; KING TP, CLIN REV ALLERGY ALL; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V68, P254, DOI 10.1016/0091-6749(81)90148-2; PAULL B R, 1984, Journal of Allergy and Clinical Immunology, V73, P142; PAULL BR, 1983, J ALLERGY CLIN IMMUN, V71, P448, DOI 10.1016/0091-6749(83)90460-8; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V56, P84, DOI 10.1016/0091-6749(75)90112-8; RHOADES RB, 1977, J FLA MED ASSOC, V64, P247; RICHMAN PG, 1980, ANAL BIOCHEM, V109, P376, DOI 10.1016/0003-2697(80)90663-6; SCHREUDER G D, 1972, Journal of the Georgia Entomological Society, V7, P188; STROM GB, 1983, J ALLERGY CLIN IMMUN, V72, P46, DOI 10.1016/0091-6749(83)90051-9; STROM GB, 1980, J ALLERGY CLIN IMMUN, V65, P202; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; VAUGHN WT, 1954, PRACTICE ALLERGY, P263; 1982, BIOCH IMMUNOCHEMICAL	23	30	30	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					331	336		10.1016/S0091-6749(86)80085-9	http://dx.doi.org/10.1016/S0091-6749(86)80085-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3734284				2022-12-18	WOS:A1986D726100015
J	PINNAS, JL; LINDBERG, RE; CHEN, TMW; MEINKE, GC				PINNAS, JL; LINDBERG, RE; CHEN, TMW; MEINKE, GC			STUDIES OF KISSING BUG SENSITIVE PATIENTS - EVIDENCE FOR THE LACK OF CROSS-REACTIVITY BETWEEN TRIATOMA-PROTRACTA AND TRIATOMA-RUBIDA SALIVARY-GLAND EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ARIZONA,DEPT MICROBIOL & IMMUNOL,TUCSON,AZ 85724	University of Arizona	PINNAS, JL (corresponding author), UNIV ARIZONA,DEPT INTERNAL MED,TUCSON,AZ 85724, USA.				NIAID NIH HHS [AI 16514] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Jones JP., 1962, CALIF VECTOR VIEWS, V9, P33; LENT H, 1979, B AM MUSEUM NATURAL, V163, P179; LINDBERG RE, 1981, FED PROC, V40, P970; LINDBERG RE, 1981, J ALLERGY CLIN IMMUN, V67, P25; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH PJ, 1978, CUTIS, V22, P585; MARSHALL NA, 1982, J MED ENTOMOL, V19, P248, DOI 10.1093/jmedent/19.3.248; MATHISON DA, 1981, J ALLERGY CLIN IMMUN, V67, P31; MORTENSEN EARL W., 1963, PROC PAPERS ANN CONF CALIFORNIA MOSQUITO CONTROL ASSOC INC, V31, P44; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; PINNAS JL, 1978, FED PROC, V37, P1555; PINNAS JL, 1977, J ALLERGY CLIN IMMUN, V59, P10, DOI 10.1016/0091-6749(77)90170-1; RILEY CV, 1894, US DEPT AGR DIV ENTO, V6, P267; ROHR AS, 1984, J ALLERGY CLIN IMMUN, V73, P369, DOI 10.1016/0091-6749(84)90410-X; RYCKMAN RE, 1966, INSECT COLONIZATION, P183; SCHMIDT J O, 1984, Journal of Allergy and Clinical Immunology, V73, P158; USINGER RL, 1944, US PHS B, V288, P1	17	30	31	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					364	370		10.1016/S0091-6749(86)80119-1	http://dx.doi.org/10.1016/S0091-6749(86)80119-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	2418092				2022-12-18	WOS:A1986A089900017
J	KOENIG, JQ; MORGAN, MS; HORIKE, M; PIERSON, WE				KOENIG, JQ; MORGAN, MS; HORIKE, M; PIERSON, WE			THE EFFECTS OF SULFUR-OXIDES ON NASAL AND LUNG-FUNCTION IN ADOLESCENTS WITH EXTRINSIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KOENIG, JQ (corresponding author), UNIV WASHINGTON,DEPT ENVIRONM HLTH SC34,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002366] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES 02366] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSEN I, 1974, ARCH ENVIRON HEALTH, V28, P31, DOI 10.1080/00039896.1974.10666429; BEAUPRE A, 1982, THORAX, V37, P124, DOI 10.1136/thx.37.2.124; BRAIN JD, 1979, AM REV RESPIR DIS, V120, P1325; COLE P, 1979, ACTA OTO-LARYNGOL, V88, P148, DOI 10.3109/00016487909137154; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FISH JE, 1981, J APPL PHYSL, V50, P1078; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; KIRKPATRICK MB, 1982, AM REV RESPIR DIS, V125, P627; KOENIG JQ, 1983, J TOXICOL ENV HEALTH, V11, P129, DOI 10.1080/15287398309530327; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; LINN WS, 1983, ENVIRON RES, V30, P340, DOI 10.1016/0013-9351(83)90219-0; PIERSON W E, 1984, Journal of Allergy and Clinical Immunology, V73, P145; PIERSON WE, 1983, J ALLERGY CLIN IMMUN, V71, P156, DOI 10.1016/0091-6749(83)90393-7; PROCTOR DF, 1981, AM REV RESPIR DIS, V123, P242; SHAPIRO GG, 1984, CLIN REV ALLERG, V2, P225; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P242; Siegel S., 1956, NONPARAMETRIC STAT B; SNEDECOR GW, 1966, STATISTICAL METHODS; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; SPEIZER FE, 1966, BRIT J IND MED, V23, P75; SPEIZER FE, 1966, ARCH ENVIRON HEALTH, V12, P725, DOI 10.1080/00039896.1966.10664471; UTELL MJ, 1984, AM REV RESPIR DIS, V129, P145	23	30	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					813	818		10.1016/0091-6749(85)90754-7	http://dx.doi.org/10.1016/0091-6749(85)90754-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	4067130				2022-12-18	WOS:A1985AWX9300010
J	OHMAN, JL; BAER, H; ANDERSON, MC; LEITERMANN, K; BROWN, P				OHMAN, JL; BAER, H; ANDERSON, MC; LEITERMANN, K; BROWN, P			SURFACE WASHES OF LIVING CATS - AN IMPROVED METHOD OF OBTAINING CLINICALLY RELEVANT ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									US FDA,OFF BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20205; VET ADM OUTPATIENT CLIN,MED SERV,BOSTON,MA; TUFTS UNIV,SCH MED & VET MED,BOSTON,MA 02111	US Food & Drug Administration (FDA); Tufts University								ANDERSON MC, 1981, J IMMUNOL, V127, P972; Axelsen N. H., 1973, SCAND J IMMUNOL S1, V2, P1; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P319; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; PHELAN MA, 1980, J BIOL STAND, V8, P233, DOI 10.1016/S0092-1157(80)80039-4	11	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					288	293		10.1016/0091-6749(83)90033-7	http://dx.doi.org/10.1016/0091-6749(83)90033-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6886260				2022-12-18	WOS:A1983RH93800009
J	BOUSHEY, HA				BOUSHEY, HA			BRONCHIAL HYPERREACTIVITY TO SULFUR-DIOXIDE - PHYSIOLOGIC AND POLITICAL IMPLICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											BOUSHEY, HA (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL-24136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BUECHLEY RW, 1973, ARCH ENVIRON HEALTH, V27, P134, DOI 10.1080/00039896.1973.10666341; CHIARAMONTE LT, 1970, NEW YORK STATE J MED, V70, P394; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; FRANK NR, 1962, J APPL PHYSIOL, V17, P252, DOI 10.1152/jappl.1962.17.2.252; FRANK NR, 1969, ARCH ENVIRON HEALTH, V18, P315, DOI 10.1080/00039896.1969.10665414; FREEDMAN BJ, 1980, BRIT J DIS CHEST, V74, P128, DOI 10.1016/0007-0971(80)90023-6; HOLTZMAN MJ, 1980, AM REV RESPIR DIS, V122, P17; KIRKPATRICK MB, AM REV RESPIR DIS; KOENIG JQ, 1980, ENVIRON RES, V22, P145, DOI 10.1016/0013-9351(80)90126-7; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; LAWTHER PJ, 1975, ENVIRON RES, V10, P355, DOI 10.1016/0013-9351(75)90031-6; LOGAN WPD, 1953, LANCET, V1, P336; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; NIINIMAA VMJ, 1979, THESIS U TORONTO; PROCTOR DF, 1981, AM REV RESPIR DIS, V123, P242; SCHACHTER EN, 1982, AM REV RESPIR DIS, V125, P125; Schrenk HH, 1949, PUBLIC HLTH B, V306; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SIMMONSSON BG, 1967, J CLIN INVEST, V46, P1812; SULTZ HA, 1970, AM J PUBLIC HEALTH N, V60, P891, DOI 10.2105/AJPH.60.5.891; WIDDICOMBE JG, 1954, J PHYSIOL-LONDON, V123, P71, DOI 10.1113/jphysiol.1954.sp005034; ZEIDBERG LD, 1961, AM REV RESPIR DIS, V84, P489	25	30	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					335	338		10.1016/0091-6749(82)90142-7	http://dx.doi.org/10.1016/0091-6749(82)90142-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	NL280	7069068				2022-12-18	WOS:A1982NL28000001
J	FAIRSHTER, RD; THORNTON, DB; GOTTSCHALK, HR; SLATER, LM; GALANT, SP				FAIRSHTER, RD; THORNTON, DB; GOTTSCHALK, HR; SLATER, LM; GALANT, SP			INVIVO AND INVITRO CELL-MEDIATED-IMMUNITY TO TETANUS TOXOID IN ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,DEPT PHARM,ORANGE,CA 92668	University of California System; University of California Irvine	FAIRSHTER, RD (corresponding author), UNIV CALIF IRVINE,DEPT MED,ORANGE,CA 92668, USA.							BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; DEAN JH, 1975, J IMMUNOL, V115, P1449; FACKTOR MA, 1973, J ALLERGY CLIN IMMUN, V52, P1, DOI 10.1016/0091-6749(73)90115-2; FRANZ ML, 1976, J PEDIATR-US, V88, P975, DOI 10.1016/S0022-3476(76)81053-0; FUDENBERG H, 1971, PEDIATRICS, V47, P927; GALANT SP, 1977, J ALLERGY CLIN IMMUN, V60, P247, DOI 10.1016/0091-6749(77)90139-7; HASSETT AM, 1977, IRISH J MED SCI, V146, P167, DOI 10.1007/BF03030954; KERR AA, 1978, NEW ZEAL MED J, V88, P57; LACHAND AT, 1979, EUR UROL, V5, P117; MUNOZ AI, 1977, J PEDIATR-US, V91, P565, DOI 10.1016/S0022-3476(77)80503-9; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P834; PALMER DL, 1974, J INFECT DIS, V130, P132, DOI 10.1093/infdis/130.2.132; PINKSY CM, 1976, IN VIVO TESTING, P97; ROLLEY RT, 1977, SURG FORUM, V28, P314; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; STEELE RW, 1976, AM J DIS CHILD, V130, P1218, DOI 10.1001/archpedi.1976.02120120052008; STIMPSON PG, 1976, SOUTHERN MED J, V69, P424, DOI 10.1097/00007611-197604000-00013; THOMPSON CD, 1975, CAN MED ASSOC J, V112, P1078; WALLS RS, 1974, S AFR MED J, V48, P2073	19	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	6					452	457		10.1016/0091-6749(80)90005-6	http://dx.doi.org/10.1016/0091-6749(80)90005-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KV363	7430503	Bronze			2022-12-18	WOS:A1980KV36300004
J	KORDANSKY, DW; ROSENTHAL, RR; NORMAN, PS				KORDANSKY, DW; ROSENTHAL, RR; NORMAN, PS			EFFECT OF VITAMIN-C ON ANTIGEN-INDUCED BRONCHOSPASM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239	Johns Hopkins University								BRISCOE WA, 1958, J CLIN INVEST, V37, P1279, DOI 10.1172/JCI103715; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; DUBOIS AB, 1956, J CLIN INVEST, V35, P336; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; GOLDBERG ND, 1975, NEW DIRECTION ASTHMA, P111; KREISMAN H, 1977, LUNG, V154, P223; PUGLISI L, 1976, ADV PROSTAG THROMB R, V1, P503; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; VALIC F, 1973, BRIT J IND MED, V30, P381; WHITE RD, 1977, CHEST, V72, P512; ZUSKIN E, 1973, J ALLERGY CLIN IMMUN, V51, P218, DOI 10.1016/0091-6749(73)90141-3; ZUSKIN E, 1975, J OCCUP ENVIRON MED, V17, P357, DOI 10.1097/00043764-197506000-00005; ZUSKIN E, 1976, LUNG, V154, P17, DOI 10.1007/BF02713515	15	30	32	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	1					61	64		10.1016/0091-6749(79)90163-5	http://dx.doi.org/10.1016/0091-6749(79)90163-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	GE110	363773				2022-12-18	WOS:A1979GE11000009
J	REISMAN, RE				REISMAN, RE			STINGING INSECT ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; GREEN AW, 1979, J ALLERGY CLIN IMMUN, V63, P135; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; REISMAN RE, 1979, CLIN ALLERGY, V9, P167, DOI 10.1111/j.1365-2222.1979.tb01538.x; REISMAN RE, CLIN ALLERGY; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SOBOTKA AK, 1978, J ALLERGY CLIN IMMUN, V61, P136, DOI 10.1016/0091-6749(78)90263-4; 1965, JAMA, V193, P109	8	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	1					3	4		10.1016/0091-6749(79)90074-5	http://dx.doi.org/10.1016/0091-6749(79)90074-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HC424	447948				2022-12-18	WOS:A1979HC42400002
J	SCHAAF, L; HENDELES, L; WEINBERGER, M				SCHAAF, L; HENDELES, L; WEINBERGER, M			SUPPRESSION OF SEASONAL ALLERGIC RHINITIS SYMPTOMS WITH DAILY HYDROXYZINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL PHARM,CLIN RES RES CTR,IOWA CITY,IA 52242; VET ADM HOSP,COLL PHARM,DIV PEDIAT ALLERGY & PULM,IOWA CITY,IA 52240	University of Iowa			Weinberger, Miles/H-6743-2019					ARBESMAN CE, 1947, NEW YORK STATE J MED, V47, P1775; BARAF CS, 1976, CURR THER RES CLIN E, V19, P32; BENSON MK, 1971, EUR J CLIN PHARMACOL, V3, P182, DOI 10.1007/BF00572461; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; DUNDAS E, 1971, J ALLERGY, V32, P1; DURHAM OC, 1946, J ALLERGY, V17, P79, DOI 10.1016/0021-8707(46)90025-1; EMPEY DW, 1975, ANN ALLERGY, V34, P41; RATNER B, 1947, J PEDIATR, V30, P583, DOI 10.1016/S0022-3476(47)80051-4; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V55, P180, DOI 10.1016/0091-6749(75)90014-7; WEISS WI, 1948, J ALLERGY, V19, P271, DOI 10.1016/0021-8707(48)90064-1; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; 1977, AMA DRUG EVALUATIONS, P416	12	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	2					129	133		10.1016/0091-6749(79)90203-3	http://dx.doi.org/10.1016/0091-6749(79)90203-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GJ748	365920	Bronze			2022-12-18	WOS:A1979GJ74800011
J	HIRSCH, DJ; HIRSCH, SR; KALBFLEISCH, JH				HIRSCH, DJ; HIRSCH, SR; KALBFLEISCH, JH			EFFECT OF CENTRAL AIR-CONDITIONING AND METEOROLOGIC FACTORS ON INDOOR SPORE COUNTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM CTR,ALLERGY & PULM RES LABS,RES SERV 151,WOOD,WI 53193; MED COLL WISCONSIN,DEPT MED,ALLERGY SECT,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT BIOSTAT,MILWAUKEE,WI 53233	Medical College of Wisconsin; Medical College of Wisconsin								ALVAREZ JC, 1952, J ALLERGY, V23, P259, DOI 10.1016/0021-8707(52)90025-7; ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; ANSCOMBE FJ, 1968, INT ENCYCLOPEDIA SOC, V15, P178; COLLIER T W, 1953, Ann Allergy, V11, P480; GAY LN, 1933, JAMA, V100, P1132; GILMAN J. C., 1966, MANUAL SOIL FUNGI; HAMILTON ELIZABETH D., 1959, ACTA ALLERGOL, V13, P143, DOI 10.1111/j.1398-9995.1959.tb02761.x; HIRSCH SR, 1976, ANN ALLERGY, V36, P30; LEFCOE NM, 1971, ARCH ENVIRON HEALTH, V22, P230, DOI 10.1080/00039896.1971.10665836; Nelson T, 1933, J AMER MED ASSOC, V100, P1385, DOI 10.1001/jama.1933.02740180007003; RANDOLPH TG, 1942, WIS MED J, V41, P988; RICHARDS M, 1954, J ALLERGY, V25, P429, DOI 10.1016/0021-8707(54)90007-6; SHAPIRO RS, 1965, ANN ALLERGY, V23, P484; SMALL WS, 1961, J ALLERGY, V32, P458, DOI 10.1016/0021-8707(61)90025-9; SOLOMON WR, 1970, J ALLERGY, V45, P1, DOI 10.1016/0021-8707(70)90012-2; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; SPIEGELMAN J, 1968, J ALLERGY, V42, P193, DOI 10.1016/S0021-8707(68)90116-0; SPIEGELMAN J, 1963, J ALLERGY, V34, P426, DOI 10.1016/0021-8707(63)90007-8; SUTTON DJ, 1965, J AM SOC HEATING REF, V7, P55; Vaughan W.T., 1933, J ALLERGY, V5, P37, DOI [10.1016/S0021-8707(33)90168-9, DOI 10.1016/S0021-8707(33)90168-9]	20	30	30	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	1					22	26		10.1016/0091-6749(78)90067-2	http://dx.doi.org/10.1016/0091-6749(78)90067-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG870	659736	Bronze			2022-12-18	WOS:A1978FG87000005
J	MCDUFFIE, FC				MCDUFFIE, FC			IMMUNE-COMPLEXES IN RHEUMATIC DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55901	Mayo Clinic	MCDUFFIE, FC (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,ROCHESTER,MN 55901, USA.							BLOCK SR, 1975, AM J MED, V59, P533, DOI 10.1016/0002-9343(75)90261-2; BRENTJENS J, 1977, ARTHRITIS RHEUM, V20, P962, DOI 10.1002/art.1780200408; CHODIRKER WB, 1963, J CLIN INVEST, V42, P876, DOI 10.1172/JCI104780; CONN DL, 1976, ARTHRITIS RHEUM, V19, P15, DOI 10.1002/art.1780190102; CONN DL, 1972, ARTHRITIS RHEUM-US, V15, P135, DOI 10.1002/art.1780150202; DAVIS JS, 1978, ARTHRITIS RHEUM, V21, P17, DOI 10.1002/art.1780210104; DIXON FJ, 1958, ARCH PATHOL, V65, P18; FISH AJ, 1966, ARTHRITIS RHEUM-US, V9, P267, DOI 10.1002/art.1780090202; FRANKLIN EC, 1957, J EXP MED, V105, P425, DOI 10.1084/jem.105.5.425; GELFAND MC, 1976, NEW ENGL J MED, V295, P10, DOI 10.1056/NEJM197607012950103; GERMUTH FG, 1953, J EXP MED, V97, P257, DOI 10.1084/jem.97.2.257; GRUMET FC, 1971, NEW ENGL J MED, V285, P193, DOI 10.1056/NEJM197107222850403; HARBECK RJ, 1973, J CLIN INVEST, V52, P789, DOI 10.1172/JCI107242; HEDBERG H, 1963, ACTA RHEUM SCAND, V9, P169; HUNDER GG, 1977, J LAB CLIN MED, V90, P971; HUNDER GG, 1973, AM J MED, V54, P461, DOI 10.1016/0002-9343(73)90042-9; HURD ER, 1977, CLIN EXP IMMUNOL, V28, P413; IVANYI D, 1976, TISSUE ANTIGENS, V8, P91; IZUI S, 1976, J EXP MED, V144, P428, DOI 10.1084/jem.144.2.428; IZUI S, 1977, J EXP MED, V145, P1115, DOI 10.1084/jem.145.5.1115; KOFFLER D, 1969, SCIENCE, V166, P1648, DOI 10.1126/science.166.3913.1648; KOFFLER D, 1967, J EXP MED, V126, P607, DOI 10.1084/jem.126.4.607; KRISHNAN C, 1967, J CLIN INVEST, V46, P569, DOI 10.1172/JCI105558; KUNKEL HG, 1977, ARTHRITIS RHEUM, V20, P5139; KURLAND LT, 1969, MAYO CLIN PROC, V44, P649; LAMBERT PH, CLIN EXP IMMUNOL; LUTHRA HS, 1975, J CLIN INVEST, V56, P458, DOI 10.1172/JCI108112; MANNIK M, 1977, ARTHRITIS RHEUM, V20, P5148; MCDUFFIE FC, 1972, J CLIN INVEST, V51, P3007, DOI 10.1172/JCI107128; MCDUFFIE FC, CLIN EXP IMMUNOL; MCMICHAEL AJ, 1977, ARTHRITIS RHEUM, V20, P1037, DOI 10.1002/art.1780200501; MOWAT AG, 1971, J CLIN INVEST, V50, P2541, DOI 10.1172/JCI106754; NYDEGGER UE, 1974, J CLIN INVEST, V54, P297, DOI 10.1172/JCI107765; PEKIN TJ, 1964, J CLIN INVEST, V43, P1372, DOI 10.1172/JCI105013; POPE RM, 1975, ANN NY ACAD SCI, V256, P82, DOI 10.1111/j.1749-6632.1975.tb36037.x; RODMAN WS, 1967, J LAB CLIN MED, V69, P141; SCHUR PH, 1968, NEW ENGL J MED, V278, P533, DOI 10.1056/NEJM196803072781004; STASTNY P, 1976, J CLIN INVEST, V57, P1148, DOI 10.1172/JCI108382; TAN EM, 1966, J CLIN INVEST, V45, P1732, DOI 10.1172/JCI105479; THEOFILOPOULOS AN, 1974, J EXP MED, V140, P1230, DOI 10.1084/jem.140.5.1230; UTSINGER PD, 1977, J CLIN INVEST, V60, P626, DOI 10.1172/JCI108814; VAUGHAN JH, 1951, J LAB CLIN MED, V37, P698; VAZQUEZ JJ, 1957, LAB INVEST, V6, P205; WINCHESTER RJ, 1970, CLIN EXP IMMUNOL, V6, P689; WINCHESTER RJ, 1977, ARTHRIT RHEUM, V20, P5159; WINFIELD JB, 1977, J CLIN INVEST, V59, P90, DOI 10.1172/JCI108626	46	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	1					37	43		10.1016/0091-6749(78)90071-4	http://dx.doi.org/10.1016/0091-6749(78)90071-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG870	149152				2022-12-18	WOS:A1978FG87000009
J	GRANT, JA; DUPREE, E; THUESON, DO				GRANT, JA; DUPREE, E; THUESON, DO			COMPLEMENT-MEDIATED RELEASE OF HISTAMINE FROM HUMAN BASOPHILS .3. POSSIBLE REGULATORY ROLE OF MICROTUBULES AND MICROFILAMENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DEPT MED,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT PEDIAT,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston								ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; Beaven MA., 1975, HDB PSYCHOPHARMACOLO, V1, P253; BOS CJ, 1974, CHEM-BIOL INTERACT, V8, P349, DOI 10.1016/0009-2797(74)90013-1; COLTEN HR, 1972, J CLIN INVEST, V51, P1927, DOI 10.1172/JCI106998; GALLIN JI, 1974, J CELL BIOL, V62, P594, DOI 10.1083/jcb.62.3.594; GELL PGH, 1975, CLINICAL ASPECTS IMM; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; GILLESPIE E, 1975, ANN NY ACAD SCI, V253, P771, DOI 10.1111/j.1749-6632.1975.tb19245.x; GOLDSTEIN I, 1973, P NATL ACAD SCI USA, V70, P2916, DOI 10.1073/pnas.70.10.2916; GRANT JA, 1976, J IMMUNOL, V117, P450; GRANT JA, 1975, J IMMUNOL, V114, P1101; HASTIE R, 1977, LAB INVEST, V36, P173; HASTIE R, 1974, LAB INVEST, V31, P223; HERZIG DJ, 1975, J PHARMACOL EXP THER, V194, P457; HOOK WA, 1975, J IMMUNOL, V114, P1185; HOOK WA, 1977, J IMMUNOL, V118, P679; LAGUNOFF D, 1976, J CELL BIOL, V71, P182, DOI 10.1083/jcb.71.1.182; LEVY DA, 1969, P SOC EXP BIOL MED, V130, P1333; LICHTENS.LM, 1969, AM J MED, V46, P163, DOI 10.1016/0002-9343(69)90001-1; ORANGE RP, 1975, J IMMUNOL, V114, P182; ORANGE RP, 1974, PROGR IMMUNOLOGY 2, V4, P29; PATTERSON R, 1976, J LAB CLIN MED, V87, P1016; PATTERSON R, 1977, J CLIN INVEST, V59, P217, DOI 10.1172/JCI108631; PATTERSON R, 1975, CLIN EXP IMMUNOL, V19, P335; PETERSSON BA, 1975, J IMMUNOL, V114, P1581; SIRAGANIAN RP, 1976, J IMMUNOL, V116, P639; STADLER J, 1974, J CELL BIOL, V60, P297, DOI 10.1083/jcb.60.1.297; VOGT W, 1974, PHARMACOL REV, V26, P125; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; WILSON L, 1974, ADV CELL MOLECULAR B, V3, P253; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; WUEPPER KD, 1972, CLIN EXP IMMUNOL, V11, P13; WUNDERLICH F, 1973, SCIENCE, V182, P1136, DOI 10.1126/science.182.4117.1136; ZIGMOND SH, 1972, SCIENCE, V176, P1432, DOI 10.1126/science.176.4042.1432	34	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	5					306	311		10.1016/0091-6749(77)90110-5	http://dx.doi.org/10.1016/0091-6749(77)90110-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA243	72086	Bronze			2022-12-18	WOS:A1977EA24300006
J	OREHEK, J; GAYRARD, P; GRIMAUD, C; CHARPIN, J				OREHEK, J; GAYRARD, P; GRIMAUD, C; CHARPIN, J			BRONCHIAL RESPONSE TO INHALED PROSTAGLANDIN-F2ALPHA IN PATIENTS WITH WITH COMMON OR ASPIRIN-SENSITIVE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FAC MED MARSEILLE, MED EXPTL LAB, F-13385 MARSEILLE, FRANCE; FAC MED MARSEILLE, PNEUMOPHTISIOL CLIN, F-13385 MARSEILLE, FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite								ALANKO K, 1973, BRIT MED J, V1, P294, DOI 10.1136/bmj.1.5848.294-a; ALINESCU R, 1976, REV FR MAL RESP   S1, V4, P11; CHARPIN J, 1976, 40EME C FRANC MED DA, V1; DAWSON W, 1974, NATURE, V250, P331, DOI 10.1038/250331a0; DOUGLAS J S, 1972, Federation Proceedings, V31, P336; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; ENGELHARDT A, 1975, POSTGRAD MED J, V51, P82; MATHE AA, 1975, AM REV RESPIR DIS, V111, P313; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; NEWBALL HH, 1974, FED PROC, V33, P366; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; PATEL KR, 1976, POSTGRAD MED J, V52, P275, DOI 10.1136/pgmj.52.607.275; PATEL KR, 1975, BRIT MED J, V2, P360, DOI 10.1136/bmj.2.5967.360; SAID SI, 1974, B PHYSIO-PATHOL RESP, V10, P411; SELLICK H, 1971, J APPL PHYSIOL, V31, P15, DOI 10.1152/jappl.1971.31.1.15; SMITH AP, 1975, CLIN SCI MOL MED, V48, P421, DOI 10.1042/cs0480421; SWEATMAN WJ, 1968, NATURE, V217, P69, DOI 10.1038/217069a0; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; TATRA N, 1973, LIFE SCI, V13, P501; WIDDICOMBE JG, 1974, RECENT ADV PHYSIOLOG, V1, P467	20	30	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	6					414	419		10.1016/0091-6749(77)90003-3	http://dx.doi.org/10.1016/0091-6749(77)90003-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DJ990	864100				2022-12-18	WOS:A1977DJ99000002
J	ANDRASCH, RH; BARDANA, EJ; KOSTER, F; PIROFSKY, B				ANDRASCH, RH; BARDANA, EJ; KOSTER, F; PIROFSKY, B			CLINICAL AND BRONCHIAL PROVOCATION STUDIES IN PATIENTS WITH MEAT-WRAPPERS ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV OREGON,HLTH SCI CTR,DIV IMMUNOL ALLERGY & RHEUMATOL,PORTLAND,OR 97201	University of Oregon								ANDRASCH RH, 1976, JAMA-J AM MED ASSOC, V235, P937; ANDRASCH RH, 1975, J ALLERGY CLIN IMMUN, V55, P130; BEALL GN, 1975, WESTERN J MED, V122, P490; BREYSSE PA, 1974, ENV HLTH SAF NEWS, V22, P1; BRUCKNER HC, 1968, ARCH ENVIRON HEALTH, V16, P619, DOI 10.1080/00039896.1968.10665117; GREENBERG M, 1970, BMJ-BRIT MED J, V2, P629, DOI 10.1136/bmj.2.5710.629; KIJKMAN JH, 1975, CLIN ALLERGY, V5, P25; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; PEPYS J, 1969, LANCET, V1, P1181; POLAKOFF PL, 1975, ARCH ENVIRON HEALTH, V30, P269, DOI 10.1080/00039896.1975.10666697; PORTER JM, 1975, SURGERY, V77, P11; SCHLUETER DP, 1974, AM J MED, V57, P476, DOI 10.1016/0002-9343(74)90141-7; SOKOL WN, 1973, JAMA-J AM MED ASSOC, V226, P639, DOI 10.1001/jama.226.6.639	13	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	2					291	298		10.1016/0091-6749(76)90134-2	http://dx.doi.org/10.1016/0091-6749(76)90134-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	CA661	947981	Bronze			2022-12-18	WOS:A1976CA66100006
J	ROSENFELD, SI; STAPLES, PJ; LEDDY, JP				ROSENFELD, SI; STAPLES, PJ; LEDDY, JP			ANGIOEDEMA AND HYPOCOMPLEMENTEMIA - UNUSUAL FEATURES OF LYMPHOMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	2					104	104						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V5498					2022-12-18	WOS:A1975V549800088
J	TALMAGE, DW; HEMMINGSEN, H				TALMAGE, DW; HEMMINGSEN, H			IS MACROPHAGE STIMULATING CELL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,DEPT MICROBIOL,DENVER,CO; UNIV COLORADO,MED CTR,WEBB WARING LUNG INST,4200 E 9TH AVE,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ANDERSON CL, 1974, J EXP MED, V139, P117; ASKONAS BA, 1970, DEVELOPMENTAL ASPECT, P531; BACH FH, 1968, BIRTH DEFECTS OAS, V4, P245; BACH ML, 1972, TRANSPLANT P, V4, P451; BENACERR.B, 1972, SCIENCE, V175, P273, DOI 10.1126/science.175.4019.273; Brondz B D, 1972, Transplant Rev, V10, P112; DiGeorge A. M., 1968, BIRTH DEFECTS OAS, V4, P116; GREINEDER DK, IN PRESS; Lawrence H S, 1969, Adv Immunol, V11, P195, DOI 10.1016/S0065-2776(08)60480-0; LAWRENCE HS, 1959, PHYSIOL REV, V39, P811, DOI 10.1152/physrev.1959.39.4.811; LOPEZ LR, 1975, FED PROC, V34, P958; LOPEZ LR, 1974, J ALLERGY CLIN IMMUN, V53, P336, DOI 10.1016/0091-6749(74)90117-1; MAGE MG, 1973, J IMMUNOL, V111, P652; MISHEL RI, 1967, J EXP MED, V126, P443; MITCHISON NA, 1970, DEVELOPMENTAL ASPECT, P547; Raff M C, 1970, Nature, V226, P1257, DOI 10.1038/2261257a0; ROSENSTREICH DL, 1973, J IMMUNOL, V110, P934; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; RUBIN B, 1973, J EXP MED, V137, P911, DOI 10.1084/jem.137.4.911; SHEVACH EM, 1972, J EXP MED, V136, P1207, DOI 10.1084/jem.136.5.1207; TALMAGE DW, 1974, FED PROC, V33, P742; VITETTA ES, 1972, J EXP MED, V136, P81, DOI 10.1084/jem.136.1.81; WALDRON JA, 1974, J IMMUNOL, V112, P746	23	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	6					442	450		10.1016/0091-6749(75)90083-4	http://dx.doi.org/10.1016/0091-6749(75)90083-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AE593	124322				2022-12-18	WOS:A1975AE59300011
J	JOINER, PD; WALL, M; DAVIS, LB; HAHN, F				JOINER, PD; WALL, M; DAVIS, LB; HAHN, F			ROLE OF AMINES IN ANAPHYLACTIC CONTRACTION OF GUINEA-PIG ISOLATED SMOOTH-MUSCLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FREIBURG, PHARMAKOL INST, FREIBURG, WEST GERMANY; TULANE UNIV, SCH MED, DEPT PHARMACOL, 1430 TULANE AVE, NEW ORLEANS, LA 70112 USA	University of Freiburg; Tulane University								ALONSODEFLORIDA F, 1968, J GEN PHYSIOL, V51, P677, DOI 10.1085/jgp.51.5.677; AUSTEN KF, 1963, ADV IMMUNOL, V3, P1, DOI 10.1016/S0065-2776(08)60810-X; AVIADO DM, 1972, PHARMACOLOGIC PRINCI, pCH51; BERGSTROM S, 1968, PHARMACOL REV, V20, P1; BERRY PA, 1963, J PHYSIOL-LONDON, V165, pP41; BROCKLEHURST WE, 1962, J PHYSIOL-LONDON, V160, pP15; CIRSTEA M, 1968, ARCH INT PHYS BIOCH, V76, P344, DOI 10.3109/13813456809058711; CSABA B, 1971, ACTA PHYSIOL HUNG, V39, P369; Dale HH, 1913, J PHARMACOL EXP THER, V4, P167; DALE MM, 1969, BRIT J PHARMACOL, V37, pP518; DALE MM, 1969, IMMUNOLOGY, V17, P653; DANIELOPOLU D, 1948, CR SOC BIOL, V142, P757; DOEPFNER W, 1958, INT ARCH ALLER A IMM, V12, P89, DOI 10.1159/000228445; Dragstedt CA, 1941, PHYSIOL REV, V21, P563, DOI 10.1152/physrev.1941.21.4.563; ERSPAMER V, 1954, PHARMACOL REV, V6, P425; EYRE P, 1973, BRIT J PHARMACOL, V47, P504, DOI 10.1111/j.1476-5381.1973.tb08182.x; GADDUM J H, 1955, Q J Exp Physiol Cogn Med Sci, V40, P49; GEIGER WB, 1959, J ALLERGY, V30, P316, DOI 10.1016/0021-8707(59)90039-5; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; KURIHARA N, 1972, JPN J PHARMACOL, V22, P581, DOI 10.1254/jjp.22.581; NAKAMURA K., 1941, Jikken Igaku Zasshi = Japanese Journal of Experimental Medicine, V19, P31; NOSAL R, 1970, ACTA PHYSIOL SCAND, V80, P215, DOI 10.1111/j.1748-1716.1970.tb04785.x; Orange R P, 1969, Adv Immunol, V10, P105, DOI 10.1016/S0065-2776(08)60416-2; PATON WDM, 1951, BRIT J PHARM CHEMOTH, V6, P499, DOI 10.1111/j.1476-5381.1951.tb00661.x; PIPER P, 1971, ANN NY ACAD SCI, V180, P363, DOI 10.1111/j.1749-6632.1971.tb53205.x; ROTHSCHILD AM, 1970, BRIT J PHARMACOL, V38, P253, DOI 10.1111/j.1476-5381.1970.tb10354.x; Schultz WH, 1910, J PHARMACOL EXP THER, V1, P551; TIMMERMA.H, 1968, J PHARM PHARMACOL, V20, P78, DOI 10.1111/j.2042-7158.1968.tb09629.x; VANROSSUM JM, 1963, ARCH INT PHARMACOD T, V143, P240	29	30	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	5					261	270		10.1016/0091-6749(74)90104-3	http://dx.doi.org/10.1016/0091-6749(74)90104-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S9114	4150792				2022-12-18	WOS:A1974S911400002
J	OH, SH; PATTERSON, R				OH, SH; PATTERSON, R			SURGERY IN CORTICOSTEROID-DEPENDENT ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, MCGAW MED CTR,DEPT MED,SECT ALLERGY IMMUNOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University								ALDRETE JA, 1968, POSTGRAD MED, V44, P93, DOI 10.1080/00325481.1968.11693455; FALLERONI AE, 1972, ALLERGIC DISEASE DIA; Gaarde FW, 1942, J AMER MED ASSOC, V120, P431, DOI 10.1001/jama.1942.02830410019005; GOLD MI, 1963, ANESTH ANALG, V42, P283; King DS, 1933, SURG GYNECOL OBSTET, V56, P43; PALMER K N, 1955, Postgrad Med J, V31, P25; PALMER KNV, 1953, LANCET, V264, P164; PARIS J, 1961, P STAFF M MAYO CLIN, V36, P305; PRICKMAN LE, 1959, DIS CHEST, V35, P30, DOI 10.1378/chest.35.1.30; PRICKMAN LE, 1944, MED CLIN N AM, V28, P991; REISBERG BE, 1972, INFECTIOUS DISEASE S; ROBERTS JC, 1970, SURG CLIN N AM, V50, P363; SHNIDER SM, 1961, ANESTHESIOLOGY, V22, P886, DOI 10.1097/00000542-196111000-00003; STEIN M, 1970, J AMER MED ASSOC, V211, P787, DOI 10.1001/jama.211.5.787; STEIN M, 1962, JAMA-J AM MED ASSOC, V181, P765, DOI 10.1001/jama.1962.03050350027006; WIGHTMAN JA, 1968, BRIT J SURG, V55, P85, DOI 10.1002/bjs.1800550202	16	30	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	6					345	351		10.1016/0091-6749(74)90118-3	http://dx.doi.org/10.1016/0091-6749(74)90118-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T2239	4827905				2022-12-18	WOS:A1974T223900004
J	PENCE, HL; EVANS, R; GUERNSEY, LH; GERHARD, RC				PENCE, HL; EVANS, R; GUERNSEY, LH; GERHARD, RC			PROPHYLACTIC USE OF EPSILON AMINOCAPROIC ACID FOR ORAL-SURGERY IN A PATIENT WITH HEREDITARY ANGIONEUROTIC EDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USA WALTER REED GEN HOSP,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,WASHINGTON,DC; WALTER REED ARMY MED CTR,DEPT DENT & ORAL SURG,WASHINGTON,DC	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								COHEN G, 1972, ANN ALLERGY, V30, P690; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; KORSANBERGSTEN K, 1969, ACTA MED SCI, V135, P341; LANDERMAN MS, 1960, LANCET, V1, P1053; LANDERMAN NS, 1962, J ALLERGY, V33, P330, DOI 10.1016/0021-8707(62)90032-1; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; LANDERMAN NS, 1959, LANCET, V2, P183; Landerman NS, 1959, CLIN RES, V7, P139; PICKERING RJ, 1969, LANCET, V1, P326; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739	11	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	5					298	302		10.1016/0091-6749(74)90109-2	http://dx.doi.org/10.1016/0091-6749(74)90109-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S9114	4822489	Bronze			2022-12-18	WOS:A1974S911400007
J	SEN, DK; ARORA, S; GUPTA, S; SANYAL, RK				SEN, DK; ARORA, S; GUPTA, S; SANYAL, RK			STUDIES OF ADRENERGIC MECHANISMS IN RELATION TO HISTAMINE SENSITIVITY IN CHILDREN IMMUNIZED WITH BORDETELLA-PERTUSSIS VACCINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAULANA AZAD MED COLL,DEPT PEDIAT,NEW DELHI,INDIA; IRWIN & GB PANT HOSP,NEW DELHI,INDIA; MAULANA AZAD MED COLL,DEPT PHARMACOL,NEW DELHI,INDIA; MED COLL WISCONSIN,561 N FIFTEENTH ST,MILWAUKEE,WI 53233	Maulana Azad Medical College; Govind Ballabh Pant Institute of Postgraduate Medical Education & Research; Maulana Azad Medical College; Medical College of Wisconsin								ARORA S, 1968, INT ARCH ALLER A IMM, V33, P299, DOI 10.1159/000230047; ARORA S, 1970, INT ARCH ALLER A IMM, V37, P357, DOI 10.1159/000230798; ARORA S, 1969, ASPECTS ALLERGY APPL, V3; BERGMAN RK, 1968, BACTERIOL REV, V32, P103; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; FISHEL CW, 1963, J ALLERGY, V34, P439, DOI 10.1016/0021-8707(63)90009-1; FISHEL CW, 1962, J IMMUNOL, V89, P8; FISHEL CW, 1964, BACTERIAL ENDOTOXINS; HALPERN BN, 1949, CR SOC BIOL, V143, P923; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; LECKS HI, 1969, J ALLERGY, V44, P261, DOI 10.1016/0021-8707(69)90031-8; MASELLI R, 1970, J ALLERGY, V45, P117; MATHOV ENRIQUE, 1962, ACTA ALLERGOL, V17, P400, DOI 10.1111/j.1398-9995.1962.tb02975.x; MUNOZ J, 1966, J IMMUNOL, V97, P120; OUELLETTE J J, 1967, Journal of Allergy, V39, P160, DOI 10.1016/0021-8707(67)90033-0; PARFENTJEV IA, 1948, J PHARMACOL EXP THER, V92, P411; PIERSON RN, 1969, AM REV RESPIR DIS, V100, P533; SANYA RK, 1960, NATURE, V165, P537; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2	19	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	1					25	31		10.1016/S0091-6749(74)80005-9	http://dx.doi.org/10.1016/S0091-6749(74)80005-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T5232	4151776				2022-12-18	WOS:A1974T523200004
J	MENDES, NF; MUSATTI, CC; LEAO, RC; MENDES, E; NASPITZ, CK				MENDES, NF; MUSATTI, CC; LEAO, RC; MENDES, E; NASPITZ, CK			LYMPHOCYTE CULTURES AND SKIN ALLOGRAFT SURVIVAL IN PATIENTS WITH SOUTH AMERICAN BLASTOMYCOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AISENBERG AC, 1962, J CLIN INVEST, V41, P1964, DOI 10.1172/JCI104654; AISENBERG AC, 1965, NATURE, V205, P1233, DOI 10.1038/2051233b0; BRAY GA, 1960, ANAL BIOCHEM, V1, P279, DOI 10.1016/0003-2697(60)90025-7; BROWN RS, 1967, ANN INTERN MED, V67, P291, DOI 10.7326/0003-4819-67-2-291; BUCKLEY CE, 1966, ANN INTERN MED, V64, P508, DOI 10.7326/0003-4819-64-3-508; BULLOCK WE, 1968, NEW ENGL J MED, V278, P298, DOI 10.1056/NEJM196802082780603; CALCIATI A, 1963, Minerva Med, V54, P2679; CHASE MW, 1966, CANCER RES, V26, P1097; CONE L, 1964, J CLIN INVEST, V43, P2241, DOI 10.1172/JCI105098; DiGeorge A, 1965, J PEDIAT, V67, P907, DOI [DOI 10.1016/S0022-3476(65)81796-6, 10.1016/S0022-3476(65)82145-X]; ELVES MW, 1967, ACTA HAEMATOL-BASEL, V37, P100, DOI 10.1159/000209057; FAVA NC, 1961, REV I MED TROP S PAU, V3, P161; FRIOU J, 1952, YALE J BIOL MED, V24, P533; GOOD RA, 1962, PROG ALLERGY, V6, P187, DOI 10.1159/000313800; HAN T, 1970, AM J MED, V48, P728, DOI 10.1016/S0002-9343(70)80008-0; HERSH EM, 1965, NEW ENGL J MED, V273, P1006, DOI 10.1056/NEJM196511042731903; HIRSCHHORN K, 1964, LANCET, V2, P842; Holm G, 1967, Clin Exp Immunol, V2, P351; ISRAEL HL, 1965, NEW ENGL J MED, V273, P1003, DOI 10.1056/NEJM196511042731902; LEIKIN SL, 1966, J PEDIATR-US, V68, P477, DOI 10.1016/S0022-3476(66)80255-X; LEVENTHAL BG, 1967, J CLIN INVEST, V46, P1338, DOI 10.1172/JCI105626; LISCHNER HW, 1967, TRANSPLANTATION, V5, P55; MENDES E, 1971, J ALLERGY, V47, P17, DOI 10.1016/S0091-6749(71)80313-5; NASPITZ CK, 1968, INT ARCH ALLER A IMM, V33, P217, DOI 10.1159/000230041; OPPENHEI.JJ, 1965, BLOOD-J HEMATOL, V26, P121, DOI 10.1182/blood.V26.2.121.121; OPPENHEIM JJ, 1968, FED PROC, V27, P21; SOKAL JE, 1966, CANCER RES, V26, P1161; SOKAL JE, 1961, CANCER-AM CANCER SOC, V14, P597, DOI 10.1002/1097-0142(199005/06)14:3<597::AID-CNCR2820140321>3.0.CO;2-X; SOMMER E, 1964, ACTA MED SCAND SUPPL, V425, P195; TRUBOWITZ S, 1966, CANCER-AM CANCER SOC, V19, P2019, DOI 10.1002/1097-0142(196612)19:12<2019::AID-CNCR2820191228>3.0.CO;2-H; WALDORF DS, 1966, LANCET, V2, P773	31	30	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	1					40	&		10.1016/0091-6749(71)90054-6	http://dx.doi.org/10.1016/0091-6749(71)90054-6			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J8503	4932975				2022-12-18	WOS:A1971J850300007
J	Quatrini, L; Vacca, P; Tumino, N; Besi, F; Di Pace, AL; Scordamaglia, F; Martini, S; Munari, E; Mingari, MC; Ugolini, S; Moretta, L				Quatrini, Linda; Vacca, Paola; Tumino, Nicola; Besi, Francesca; Di Pace, Anna Laura; Scordamaglia, Francesca; Martini, Stefania; Munari, Enrico; Mingari, Maria Cristina; Ugolini, Sophie; Moretta, Lorenzo			Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NK cells; glucocorticoids; PD-1; immune checkpoint; translational control; immunotherapy; cancer immunology	NK CELLS; DEATH 1; CANCER; EFFUSIONS; THERAPY	Background: Programmed cell death protein 1 (PD-1)-immune checkpoint blockade has provided significant clinical efficacy across various types of cancer by unleashing both T and natural killer (NK) cell-mediated antitumor responses. However, resistance to immunotherapy occurs for many patients, rendering the identification of the mechanisms that control PD-1 expression extremely important to increase the response to the therapy. Objective: We sought to identify the stimuli and the molecular mechanisms that induce the de novo PD-1 expression on human NK cells in the tumor setting. Methods: NK cells freshly isolated from peripheral blood of healthy donors were stimulated with different combinations of molecules, and PD-1 expression was studied at the mRNA and protein levels. Moreover, ex vivo analysis of tumor microenvironment and NK cell phenotype was performed. Results: Glucocorticoids are indispensable for PD-1 induction on human NK cells, in cooperation with a combination of cytokines that are abundant at the tumor site. Mechanistically, glucocorticoids together with IL-12, IL-15, and IL-18 not only upregulate PDCD1 transcription, but also activate a previously unrecognized transcriptional program leading to enhanced mRNA translation and resulting in an increased PD-1 amount in NK cells. Conclusions: These results provide evidence of a novel immune suppressive mechanism of glucocorticoids involving the transcriptional and translational control of an important immune checkpoint.	[Quatrini, Linda; Vacca, Paola; Tumino, Nicola; Besi, Francesca; Di Pace, Anna Laura; Moretta, Lorenzo] Bambino Gesu Pediat Hosp, Dept Immunol, Ist Ricovero & Cura Carattere Sci, Rome, Italy; [Scordamaglia, Francesca] Azienda Osped Villa Scassi, Dept Pneumol, Genoa, Italy; [Martini, Stefania; Mingari, Maria Cristina] Ist Ricovero & Cura Carattere Sci Osped Policlin, Immunol Unit, Genoa, Italy; [Munari, Enrico] Sacro Cuore Don Calabria, Dept Pathol, Negrar, Italy; [Mingari, Maria Cristina] Univ Genoa, Dept Expt Med, Genoa, Italy; [Mingari, Maria Cristina] Univ Genoa, Ctr Excellence Biomed Res, Genoa, Italy; [Ugolini, Sophie] Aix Marseille Univ, CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France	IRCCS Bambino Gesu; IRCCS Sacro Cuore Don Calabria; University of Genoa; University of Genoa; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Quatrini, L; Moretta, L (corresponding author), Viale San Paolo 15, I-00146 Rome, Italy.	linda.quatrini@opbg.net; lorenzo.moretta@opbg.net	Besi, Francesca/AAH-9352-2019; Quatrini, Linda/AAA-4580-2019; Tumino, Nicola/Y-4761-2019; Vacca, Paola/ABC-9416-2021; Moretta, Lorenzo/AAA-7239-2020; Di Pace, Anna Laura/K-6494-2016	Besi, Francesca/0000-0002-9401-300X; Quatrini, Linda/0000-0002-6994-2595; Tumino, Nicola/0000-0003-3773-8829; Vacca, Paola/0000-0002-0757-0108; Moretta, Lorenzo/0000-0003-4658-1747; Di Pace, Anna Laura/0000-0002-1712-9033	Associazione Italiana per la Ricerca sul Cancro (AIRC); European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant [800924]; AIRC-Special Program Metastatic Disease: The Key Unmet Need in Oncology 5X1000 2018 [21147]; AIRC [19920]; Ministero della Salute [RF-2013 GR-201302356568, RC-2019 OPBG]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant; AIRC-Special Program Metastatic Disease: The Key Unmet Need in Oncology 5X1000 2018; AIRC(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy)	Supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) and from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant agreement no. 800924 (L.Q.), AIRC-Special Program Metastatic Disease: The Key Unmet Need in Oncology 5X1000 2018 Id. 21147 (L.M.), AIRC IG 2017 Id. 19920 (L.M.), Ministero della Salute RF-2013 GR-201302356568 (P.V.), and RC-2019 OPBG (L.M., P.V.). N.T. and A.L.D.P. are recipient of fellowships awarded by AIRC.	Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; BRYANT J, 1992, J IMMUNOL METHODS, V146, P91, DOI 10.1016/0022-1759(92)90052-U; Cerezo M, 2018, NAT MED, V24, P1877, DOI 10.1038/s41591-018-0217-1; Cerwenka A, 2018, SCIENCE, V359, P1460, DOI 10.1126/science.aat2184; Chu J, 2016, TRENDS CELL BIOL, V26, P918, DOI 10.1016/j.tcb.2016.06.005; Croxatto D, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1293210; Della Chiesa M, 2006, BLOOD, V108, P3851, DOI 10.1182/blood-2006-02-004028; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Franco LM, 2019, J EXP MED, V216, P384, DOI 10.1084/jem.20180595; Herr I, 2006, LANCET ONCOL, V7, P425, DOI 10.1016/S1470-2045(06)70694-5; Hodi FS, 2018, LANCET ONCOL, V19, P1480, DOI 10.1016/S1470-2045(18)30700-9; Kassis J, 2005, DIAGN CYTOPATHOL, V33, P316, DOI 10.1002/dc.20280; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maeda N, 2019, J BIOL CHEM, V294, P19896, DOI 10.1074/jbc.RA119.010379; Mariotti FR, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1557030; Merlotti FR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00910; Michel T, 2016, J IMMUNOL, V196, P2923, DOI 10.4049/jimmunol.1502570; Mingari MC, 2019, TRENDS IMMUNOL, V40, P83, DOI 10.1016/j.it.2018.12.009; Neri S, 2001, CLIN DIAGN LAB IMMUN, V8, P1131, DOI 10.1128/CDLI.8.6.1131-1135.2001; Obradovic MMS, 2019, NATURE, V567, P540, DOI 10.1038/s41586-019-1019-4; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Palucka K, 2016, NAT MED, V22, P1390, DOI 10.1038/nm.4249; Pesce S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01242; Pesce S, 2017, J ALLERGY CLIN IMMUN, V139, P335, DOI 10.1016/j.jaci.2016.04.025; Quatrini L, 2018, IMMUNOL REV, V286, P120, DOI 10.1111/imr.12707; Quatrini L, 2018, NAT IMMUNOL, V19, P954, DOI 10.1038/s41590-018-0185-0; Quatrini L, 2017, J EXP MED, V214, P3531, DOI 10.1084/jem.20171048; Rautela J, 2018, IMMUNOL CELL BIOL, V96, P477, DOI 10.1111/imcb.12045; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Ribas A, 2012, NEW ENGL J MED, V366, P2517, DOI 10.1056/NEJMe1205943; Rudak PT, 2019, BRAIN BEHAV IMMUN, V80, P793, DOI 10.1016/j.bbi.2019.05.027; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Singh K, 2019, J EXP MED, V216, P1509, DOI 10.1084/jem.20181726; Tokunaga A, 2019, J EXP MED, V216, P2701, DOI 10.1084/jem.20190738; Truitt ML, 2016, NAT REV CANCER, V16, P288, DOI 10.1038/nrc.2016.27; Tumino N, 2019, INT J CANCER, V145, P1660, DOI 10.1002/ijc.32262; Vacca P, 2013, EUR J IMMUNOL, V43, P550, DOI 10.1002/eji.201242783; Xing KL, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0103-2; Xu YC, 2019, NAT MED, V25, P301, DOI 10.1038/s41591-018-0321-2; Yang H, 2019, NAT MED, V25, P1428, DOI 10.1038/s41591-019-0566-4	42	29	31	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					349	360		10.1016/j.jaci.2020.04.044	http://dx.doi.org/10.1016/j.jaci.2020.04.044		JAN 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PS2UA	32417134	hybrid			2022-12-18	WOS:000607781700008
J	Chambers, ES; Akbar, AN				Chambers, Emma S.; Akbar, Arne N.			Can blocking inflammation enhance immunity during aging?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inflammaging; senescence; p38-MAP Kinase; senolytics	NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; T-CELL RESPONSES; SENESCENT CELLS; SECRETORY PHENOTYPE; MICROBIOTA COMPOSITION; SYSTEMIC INFLAMMATION; COGNITIVE DECLINE; IN-VIVO; EXPRESSION	Aging is a global burden, and the increase in life span does not increase in parallel with health span. Therefore, older adults are currently living longer with chronic diseases, increased infections, and cancer. A characteristic of aging is the presence of chronic low-grade inflammation that is characterized by elevated concentrations of IL-6, TNF-alpha, and C-reactive protein, which has been termed inflammaging. Previous studies have demonstrated that chronic inflammation interferes with T-cell response and macrophage function and is also detrimental for vaccine responses. This raises the question of whether therapeutic strategies that reduce inflammation may be useful for improving immunity in older adults. In this review we discuss the potential causes of inflammaging, the cellular source of the inflammatory mediators, and the mechanisms by which inflammation may inhibit immunity. Finally, we describe existing interventions that target inflammation that have been used to enhance immunity during aging.	[Chambers, Emma S.; Akbar, Arne N.] UCL, Div Infect & Immun, London, England; [Chambers, Emma S.] Queen Mary Univ London, Blizard Inst, Ctr Immunobiol, 4 Newark St, London E1 2AT, England	University of London; University College London; University of London; Queen Mary University London	Chambers, ES (corresponding author), Queen Mary Univ London, Blizard Inst, Ctr Immunobiol, 4 Newark St, London E1 2AT, England.	emma.chambers@qmul.ac.uk	Chambers, Emma/AAI-3521-2021	Chambers, Emma/0000-0003-0990-8835	Medical Research Council Grand Challenge in Experimental Medicine (MICA) grant [MR/M003833/1]	Medical Research Council Grand Challenge in Experimental Medicine (MICA) grant	This work was funded by the Medical Research Council Grand Challenge in Experimental Medicine (MICA) grant (grant no. MR/M003833/1).	Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Agius E, 2009, J EXP MED, V206, P1929, DOI 10.1084/jem.20090896; Akbar AN, 2013, CLIN EXP IMMUNOL, V173, P163, DOI 10.1111/cei.12107; Akbar AN, 2016, TRENDS IMMUNOL, V37, P866, DOI 10.1016/j.it.2016.09.002; Alimbetov D, 2016, BIOGERONTOLOGY, V17, P305, DOI 10.1007/s10522-015-9610-z; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Arai Y, 2015, EBIOMEDICINE, V2, P1549, DOI 10.1016/j.ebiom.2015.07.029; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Baratelli F, 2005, J IMMUNOL, V175, P1483, DOI 10.4049/jimmunol.175.3.1483; Bartlett DB, 2012, AGING CELL, V11, P912, DOI 10.1111/j.1474-9726.2012.00849.x; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Biran A, 2017, AGING CELL, V16, P661, DOI 10.1111/acel.12592; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Bruunsgaard H, 2003, CLIN EXP IMMUNOL, V132, P24, DOI 10.1046/j.1365-2249.2003.02137.x; Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010; Callender LA, 2018, AGING CELL, V17; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Chen JH, 2015, NAT MED, V21, P327, DOI 10.1038/nm.3831; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen X, 2007, J IMMUNOL, V179, P154, DOI 10.4049/jimmunol.179.1.154; Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010; Claesson MJ, 2012, NATURE, V488, P178, DOI 10.1038/nature11319; Claesson MJ, 2011, P NATL ACAD SCI USA, V108, P4586, DOI 10.1073/pnas.1000097107; Clark RI, 2015, CELL REP, V12, P1656, DOI 10.1016/j.celrep.2015.08.004; Cohen HB, 2013, BLOOD, V122, P1935, DOI 10.1182/blood-2013-04-496216; Cohen HJ, 1997, J GERONTOL A-BIOL, V52, pM201, DOI 10.1093/gerona/52A.4.M201; Cope AP, 1997, J EXP MED, V185, P1573, DOI 10.1084/jem.185.9.1573; Dagouassat M, 2013, AM J RESP CRIT CARE, V187, P703, DOI 10.1164/rccm.201208-1361OC; Davalos AR, 2013, J CELL BIOL, V201, P613, DOI 10.1083/jcb.201206006; de Gonzalo-Calvo D, 2012, EUR J CLIN INVEST, V42, P1037, DOI 10.1111/j.1365-2362.2012.02689.x; De Maeyer RPH, 2020, NAT IMMUNOL, V21, P615, DOI 10.1038/s41590-020-0646-0; Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012; Di Mitri D, 2011, J IMMUNOL, V187, P2093, DOI 10.4049/jimmunol.1100978; Diffey BL, 2005, BRIT J DERMATOL, V153, P679, DOI 10.1111/j.1365-2133.2005.06799.x; Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928; Feldman N, 2015, AGEING RES REV, V24, P29, DOI 10.1016/j.arr.2015.01.003; Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x; Franceschi C, 2017, TRENDS ENDOCRIN MET, V28, P199, DOI 10.1016/j.tem.2016.09.005; Frasca D, 2017, FRONT IMMUNOL, V8, DOI [10.3389/fimmu.2017.01745, 10.3389/fimmu.2017.01003]; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Fuhrmann-Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00314-z; Furman D, 2017, NAT MED, V23, P174, DOI 10.1038/nm.4267; Gavazzi G, 2002, LANCET INFECT DIS, V2, P659, DOI 10.1016/S1473-3099(02)00437-1; Gilroy D, 2015, SEMIN IMMUNOL, V27, P161, DOI 10.1016/j.smim.2015.05.003; Giovannini S, 2011, J AM GERIATR SOC, V59, P1679, DOI 10.1111/j.1532-5415.2011.03570.x; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; Hadrup SR, 2006, J IMMUNOL, V176, P2645, DOI 10.4049/jimmunol.176.4.2645; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hazeldine J, 2012, AGING CELL, V11, P751, DOI 10.1111/j.1474-9726.2012.00839.x; Henson SM, 2009, BLOOD, V113, P6619, DOI 10.1182/blood-2009-01-199588; Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446; Hunter Gary R, 2010, Int J Body Compos Res, V8, P103; Jacinto TA, 2018, BIOL RES, V51, DOI 10.1186/s40659-018-0182-7; Kabir TD, 2016, AGING-US, V8, P1608, DOI 10.18632/aging.100987; Karin O, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13192-4; Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984; Kim KA, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0625-7; Korn T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02634; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lasry A, 2015, TRENDS IMMUNOL, V36, P217, DOI 10.1016/j.it.2015.02.009; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Lin T, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00236; Liu Y, 2009, AGING CELL, V8, P439, DOI 10.1111/j.1474-9726.2009.00489.x; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Mannick JB, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1564; Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892; Melk A, 2004, KIDNEY INT, V65, P510, DOI 10.1111/j.1523-1755.2004.00438.x; Muller-Durovic B, 2016, J IMMUNOL, V197, P2891, DOI 10.4049/jimmunol.1600590; Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429; Okano M, 2006, IMMUNOLOGY, V118, P343, DOI 10.1111/j.1365-2567.2006.02376.x; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816; Pereira BI, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10335-5; Puchta A, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005368; Rampelli S, 2013, AGING-US, V5, P902, DOI 10.18632/aging.100623; Ressler S, 2006, AGING CELL, V5, P379, DOI 10.1111/j.1474-9726.2006.00231.x; Riddell NE, 2015, IMMUNOLOGY, V144, P549, DOI 10.1111/imm.12409; Roos CM, 2016, AGING CELL, V15, P973, DOI 10.1111/acel.12458; Schram MT, 2007, J AM GERIATR SOC, V55, P708, DOI 10.1111/j.1532-5415.2007.01159.x; Sharma S, 2005, CANCER RES, V65, P5211, DOI 10.1158/0008-5472.CAN-05-0141; Shaw AC, 2010, CURR OPIN IMMUNOL, V22, P507, DOI 10.1016/j.coi.2010.05.003; Simanek AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016103; Spielmann G, 2014, CLIN EXP IMMUNOL, V176, P246, DOI 10.1111/cei.12267; Sweeney SE, 2009, NAT REV RHEUMATOL, V5, P475, DOI 10.1038/nrrheum.2009.171; Thevaranjan N, 2017, CELL HOST MICROBE, V21, P455, DOI 10.1016/j.chom.2017.03.002; Tilly G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00778; Valencia WM, 2017, DIABETOLOGIA, V60, P1630, DOI 10.1007/s00125-017-4349-5; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Victorelli S, 2019, EMBO J, V38, DOI 10.15252/embj.2019101982; Vukmanovic-Stejic M, 2008, J CLIN INVEST, V118, P3639, DOI 10.1172/JCI35834; Vukmanovic-Stejic M, 2018, J ALLERGY CLIN IMMUN, V142, P844, DOI 10.1016/j.jaci.2017.10.032; Vukmanovic-Stejic M, 2015, J INVEST DERMATOL, V135, P1752, DOI 10.1038/jid.2015.63; Vukmanovic-Stejic M, 2013, J IMMUNOL, V190, P977, DOI 10.4049/jimmunol.1201331; Watanabe R, 2017, J CLIN INVEST, V127, P2725, DOI 10.1172/JCI92167; Weaver JD, 2002, NEUROLOGY, V59, P371, DOI 10.1212/WNL.59.3.371; Weichhart T, 2015, NAT REV IMMUNOL, V15, P599, DOI 10.1038/nri3901; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Youm YH, 2013, CELL METAB, V18, P519, DOI 10.1016/j.cmet.2013.09.010; Zhu Y, 2017, AGING-US, V9, P955, DOI 10.18632/aging.101202; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344	107	29	30	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2020	145	5					1323	1331		10.1016/j.jaci.2020.03.016	http://dx.doi.org/10.1016/j.jaci.2020.03.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	LK7TB	32386656	Green Submitted, Bronze			2022-12-18	WOS:000531063400002
J	Cardell, LO; Stjarne, P; Jonstam, K; Bachert, C				Cardell, Lars-Olaf; Stjarne, Par; Jonstam, Karin; Bachert, Claus			Endotypes of chronic rhinosinusitis: Impact on management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						chronic rhinosinusitis; nasal polyps; endotypes; type 2 inflammation; surgery; biologics	STAPHYLOCOCCUS-AUREUS; ASTHMA	Following the trend in asthma, endotypes for chronic rhinosinusitis with nasal polyps have been established, with type 2 immune reactions representing >80% of nasal polyp cases in Europe and the United States. Endotyping is without doubt useful to predict the natural course of disease, to determine pharmacotherapy and the extent of surgery, and lately also to select patients for treatment with type 2 biologics. However, with the opening of this new era of treatment, limitations of the current possibilities in subgrouping patients also became apparent, as (1) mixed endotypes often can be found and (2) predictions as to the best biologic to be used in an individual patient are not yet possible. Some of the questions to address in the near future are discussed.	[Cardell, Lars-Olaf; Stjarne, Par; Jonstam, Karin; Bachert, Claus] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div ENT Dis, Stockholm, Sweden; [Cardell, Lars-Olaf; Stjarne, Par; Jonstam, Karin] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden; [Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Bachert, Claus] Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Ghent University; Ghent University	Cardell, LO (corresponding author), Karolinska Inst, Dept Clin Sci Intervent & Technol, Div ENT Dis, Stockholm, Sweden.	lars-olaf.cardell@ki.se	Bachert, Claus/J-8825-2012					Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Alsharif S, 2019, LARYNGOSCOPE, V129, P1286, DOI 10.1002/lary.27815; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Arebro J, 2019, ALLERGY, V74, P2499, DOI 10.1111/all.13919; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bousquet J, 2017, EUR RESPIR J, V50; Chalermwatanachai T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136068; Crombruggen K, 2018, EUR RESPIR J, V52; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; Derycke L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097581; Dimitrova D, 2019, RESP MED, V154, P144, DOI 10.1016/j.rmed.2019.06.024; Ekstedt S, 2019, CLIN EXP ALLERGY, V49, P285, DOI 10.1111/cea.13311; Gevaert E, 2020, J ALLERGY CLIN IMMUN, V145, P427, DOI 10.1016/j.jaci.2019.08.027; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Jonstam K, 2019, ALLERGY, V74, P743, DOI 10.1111/all.13685; Lan F, 2018, AM J RESP CRIT CARE, V198, P452, DOI 10.1164/rccm.201710-2112OC; Nelson RK, 2020, J ALLER CL IMM-PRACT, V8, P465, DOI 10.1016/j.jaip.2019.11.024; Persson EK, 2019, SCIENCE NEW YORK NY, V24, P364; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Song WJ, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0880-4; Stevens WW, 2019, J ALLER CL IMM-PRACT, V7, P2812, DOI 10.1016/j.jaip.2019.05.009; Teufelberger AR, 2018, J ALLERGY CLIN IMMUN, V141, P549, DOI 10.1016/j.jaci.2017.05.004; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041	30	29	33	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					752	756		10.1016/j.jaci.2020.01.019	http://dx.doi.org/10.1016/j.jaci.2020.01.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	32001254	Bronze			2022-12-18	WOS:000518756700004
J	Cibrian, D; Castillo-Gonzalez, R; Fernandez-Gallego, N; de la Fuente, H; Jorge, I; Saiz, ML; Punzon, C; Ramirez-Huesca, M; Vicente-Manzanares, M; Fresno, M; Dauden, E; Fraga-Fernandez, J; Vazquez, J; Aragones, J; Sanchez-Madrid, F				Cibrian, Danay; Castillo-Gonzalez, Raquel; Fernandez-Gallego, Nieves; de la Fuente, Hortensia; Jorge, Inmaculada; Laura Saiz, Maria; Punzon, Carmen; Ramirez-Huesca, Marta; Vicente-Manzanares, Miguel; Fresno, Manuel; Dauden, Esteban; Fraga-Fernandez, Javier; Vazquez, Jesus; Aragones, Julian; Sanchez-Madrid, Francisco			Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						L-type amino acid transporter 1; SLC7A5; psoriasis; gamma delta T cells; T(H)17; mammalian target of rapamycin	PSORIASIS; IL-17; EXPRESSION; ACTIVATION; EXPANSION; PATHWAYS; MEMORY; MYD88; LAT1	Background: Psoriasis is a frequent inflammatory skin disease that is mainly mediated by IL-23, IL-1 beta, and IL-17 cytokines. Although psoriasis is a hyperproliferative skin disorder, the possible role of amino acid transporters has remained unexplored. Objective: We sought to investigate the role of the essential amino acid transporter L-type amino acid transporter (LAT) 1 (SLC7A5) in psoriasis. Methods: LAT1 floxed mice were crossed to Cre-expressing mouse strains under the control of keratin 5, CD4, and retinoic acid receptor-related orphan receptor gamma. We produced models of skin inflammation induced by imiquimod (IMQ) and IL-23 and tested the effect of inhibiting LAT1 (JPH2O3) and mammalian target of rapamycin (mTOR [rapamycin]). Results: LAT1 expression is increased in keratinocytes and skin-infiltrating lymphocytes of psoriatic lesions in human subjects and mice. LAT1 deletion in keratinocytes does not dampen the inflammatory response or their proliferation, which could be maintained by increased expression of the alternative amino acid transporters LAT2 and LAT3. Specific deletion of LAT1 in gamma delta and CD4 T cells controls the inflammatory response induced by IMQ. LAT1 deletion or inhibition blocks expansion of IL-17-secreting gamma 4(+)delta 4(+) and CD4 T cells and dampens the release of IL-1 beta, IL-17, and IL-22 in the IMQ-induced model. Moreover, inhibition of LAT1 blocks expansion of human gamma delta T cells and IL-17 secretion by human CD4 T cells. IL-23 and IL-1 beta stimulation upregulates LAT1 expression and induces mTOR activation in IL-17 + gamma delta and T(H)17 cells. Deletion or inhibition of LAT1 efficiently controls IL-23- and IL-1 beta-induced phosphatidylinositol 3-kinase/AKT/mTOR activation independent of T-cell receptor signaling. Conclusion: Targeting LAT1-mediated amino acid uptake is a potentially useful immunosuppressive strategy to control skin inflammation mediated by the IL-23/IL-1 beta/IL-17 axis.	[Cibrian, Danay; Castillo-Gonzalez, Raquel; Fernandez-Gallego, Nieves; de la Fuente, Hortensia; Laura Saiz, Maria; Sanchez-Madrid, Francisco] UAM, Hosp Princesa, Inst Invest Sanitaria Princesa, Immunol Serv, Madrid, Spain; [Cibrian, Danay; Castillo-Gonzalez, Raquel; Fernandez-Gallego, Nieves; de la Fuente, Hortensia; Jorge, Inmaculada; Laura Saiz, Maria; Ramirez-Huesca, Marta; Vazquez, Jesus; Sanchez-Madrid, Francisco] CNIC, Madrid, Spain; [Cibrian, Danay; de la Fuente, Hortensia; Jorge, Inmaculada; Vazquez, Jesus; Aragones, Julian; Sanchez-Madrid, Francisco] Carlos III Hlth Inst, CIBER Enfermedades Cardiovasc, Madrid, Spain; [Punzon, Carmen; Fresno, Manuel] CSIC UAM, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Vicente-Manzanares, Miguel] Univ Salamanca, CIC, IBMCC, CSIC, Salamanca, Spain; [Dauden, Esteban; Fraga-Fernandez, Javier] Hosp Princesa, Dermatol Serv, Madrid, Spain; [Aragones, Julian] Univ Autonoma Madrid, Hosp Princesa, Inst Invest Sanitaria Princesa, Res Unit, Madrid, Spain	Autonomous University of Madrid; Hospital de La Princesa; Centro Nacional de Investigaciones Cardiovasculares (CNIC); CIBER - Centro de Investigacion Biomedica en Red; CIBERCV; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Autonomous University of Madrid; Hospital de La Princesa	Sanchez-Madrid, F (corresponding author), Inst Invest Sanitaria Princesa IIS IP, Diego Leon 62, Madrid 28006, Spain.	fsmadrid@salud.madrid.org	Fernández Gallego, Nieves/AAB-8794-2022; Vazquez, Jesus/B-7697-2015; Sanchez-Madrid, Francisco/M-7889-2016; Vicente-Manzanares, Miguel/H-1010-2018	Vazquez, Jesus/0000-0003-1461-5092; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Vicente-Manzanares, Miguel/0000-0001-5943-3220; Fernandez-Gallego Anaya, Nieves/0000-0002-6968-1444; Castillo-Gonzalez, Raquel/0000-0002-9877-2126; Saiz Alvarez, Maria Laura/0000-0002-3966-212X	Spanish Ministry of Economy and Competitiveness [SAF 2017-82886-R, PI17/01972, SAF 2013-42850-R]; Comunidad de Madrid [S2017/BMD-3671-INFLAMUNE-CM]; CIBERCV; Instituto de Salud Carlos III [BIOIMID PIE13/041]; Fundacion La Marato TV3 [20152330 31]; FUNDACION BBVA A EQUIPOS DE INVESTIGACION CIENTIFICA 2018; "la Caixa'' Banking Foundation [HR17-00016]; Agencia Estatal de Investigacion, Fondo Europeo de Desarrollo Regional, European Union	Spanish Ministry of Economy and Competitiveness(Spanish Government); Comunidad de Madrid(Comunidad de Madrid); CIBERCV; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Fundacion La Marato TV3; FUNDACION BBVA A EQUIPOS DE INVESTIGACION CIENTIFICA 2018; "la Caixa'' Banking Foundation(La Caixa Foundation); Agencia Estatal de Investigacion, Fondo Europeo de Desarrollo Regional, European Union	Supported by grants SAF 2017-82886-R (to F.S.-M.), PI17/01972 (to E.D.), and SAF 2013-42850-R (to M.F.) from the Spanish Ministry of Economy and Competitiveness; CAM (S2017/BMD-3671-INFLAMUNE-CM) from the Comunidad de Madrid (to F.S.-M.); and CIBERCV, BIOIMID PIE13/041 from Instituto de Salud Carlos III and Fundacion La Marato TV3 (20152330 31). The project leading to these results has also received funding from FUNDACION BBVA A EQUIPOS DE INVESTIGACION CIENTIFICA 2018 and from "la Caixa'' Banking Foundation under the project code HR17-00016 (to F.S.-M.) and from Agencia Estatal de Investigacion, Fondo Europeo de Desarrollo Regional, European Union.	Andreakos E, 2004, BLOOD, V103, P2229, DOI 10.1182/blood-2003-04-1356; Aterido A, 2016, J INVEST DERMATOL, V136, P593, DOI 10.1016/j.jid.2015.11.026; Beringer A, 2016, TRENDS MOL MED, V22, P230, DOI 10.1016/j.molmed.2016.01.001; Brucklacher-Waldert V, 2009, J IMMUNOL, V183, P5494, DOI 10.4049/jimmunol.0901000; Buerger C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02786; Buerger C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180853; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Chang J, 2013, P NATL ACAD SCI USA, V110, P2270, DOI 10.1073/pnas.1206048110; Cho ML, 2006, J IMMUNOL, V176, P5652, DOI 10.4049/jimmunol.176.9.5652; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Cibrian D, 2016, NAT IMMUNOL, V17, P985, DOI 10.1038/ni.3504; Cochez PM, 2016, EUR J IMMUNOL, V46, P1449, DOI 10.1002/eji.201546070; Deason K, 2018, J EXP MED, V215, P2413, DOI 10.1084/jem.20171810; Di Meglio P, 2016, J ALLERGY CLIN IMMUN, V138, P274, DOI 10.1016/j.jaci.2015.10.046; Duan JY, 2010, CELL HOST MICROBE, V7, P140, DOI 10.1016/j.chom.2010.01.005; Eberl G, 2004, SCIENCE, V305, P248, DOI 10.1126/science.1096472; Guo YX, 2016, CELL REP, V17, P3206, DOI 10.1016/j.celrep.2016.11.073; Hartwig T, 2015, EUR J IMMUNOL, V45, P3022, DOI 10.1002/eji.201545883; Hawkes JE, 2017, J ALLERGY CLIN IMMUN, V140, P645, DOI 10.1016/j.jaci.2017.07.004; Hayase S, 2017, ONCOL LETT, V14, P7410, DOI 10.3892/ol.2017.7148; Hayashi K, 2017, WORLD J GASTRO ONCOL, V9, P21, DOI 10.4251/wjgo.v9.i1.21; Hayashi K, 2013, J IMMUNOL, V191, P4080, DOI 10.4049/jimmunol.1300923; Hirano K, 2014, PATHOL RES PRACT, V210, P634, DOI 10.1016/j.prp.2014.05.001; Jones RG, 2017, IMMUNITY, V46, P730, DOI 10.1016/j.immuni.2017.04.028; Keijsers RRMC, 2014, EXP DERMATOL, V23, P799, DOI 10.1111/exd.12487; Kim J, 2017, ANNU REV MED, V68, P255, DOI 10.1146/annurev-med-042915-103905; Kondo M, 2008, CYTOTHERAPY, V10, P842, DOI 10.1080/14653240802419328; Laggner U, 2011, J IMMUNOL, V187, P2783, DOI 10.4049/jimmunol.1100804; Loftus RM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04719-2; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Matos TR, 2017, J CLIN INVEST, V127, P4031, DOI 10.1172/JCI93396; Muschaweckh A, 2017, J IMMUNOL, V199, P2668, DOI 10.4049/jimmunol.1700287; Nishimoto S, 2013, J IMMUNOL, V191, P3065, DOI 10.4049/jimmunol.1300348; OKANO N, 2018, J CLIN ONCOL S, V36; Palacin M, 2005, PHYSIOLOGY, V20, P112, DOI 10.1152/physiol.00051.2004; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Papotto PH, 2017, EMBO REP, V18, P1957, DOI 10.15252/embr.201744200; Ramirez-Valle F, 2015, P NATL ACAD SCI USA, V112, P8046, DOI 10.1073/pnas.1508990112; Rizzo HL, 2011, J IMMUNOL, V186, P1495, DOI 10.4049/jimmunol.1001001; Roller A, 2012, J IMMUNOL, V189, P4612, DOI 10.4049/jimmunol.1103173; Sallusto F, 2012, EUR J IMMUNOL, V42, P2215, DOI 10.1002/eji.201242741; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Serre K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00431; Shimizu A, 2015, MELANOMA RES, V25, P399, DOI 10.1097/CMR.0000000000000181; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Taylor PM, 2014, AM J CLIN NUTR, V99, p223S, DOI 10.3945/ajcn.113.070086; Tina E, 2019, BRIT J DERMATOL, V180, P130, DOI 10.1111/bjd.16905; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; Yamanaka K, 2015, J ALLERGY CLIN IMMUN, V136, P823, DOI 10.1016/j.jaci.2015.06.009; Yan RH, 2019, NATURE, V568, P127, DOI 10.1038/s41586-019-1011-z; Yoon BR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00053	54	29	29	4	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					199	+		10.1016/j.jaci.2019.09.025	http://dx.doi.org/10.1016/j.jaci.2019.09.025			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31605740	hybrid, Green Published			2022-12-18	WOS:000505590800027
J	Galeotti, C; Stephen-Victor, E; Karnam, A; Das, M; Gilardin, L; Maddur, MS; Wymann, S; Vonarburg, C; Chevailler, A; Dimitrov, JD; Benveniste, O; Bruhns, P; Kaveri, SV; Bayry, J				Galeotti, Caroline; Stephen-Victor, Emmanuel; Karnam, Anupama; Das, Mrinmoy; Gilardin, Laurent; Maddur, Mohan S.; Wymann, Sandra; Vonarburg, Cedric; Chevailler, Alain; Dimitrov, Jordan D.; Benveniste, Olivier; Bruhns, Pierre; Kaveri, Srini V.; Bayry, Jagadeesh			Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fc epsilon RI; anti-IgE IgG; antisynthetase syndrome; polymyositis; dermatomyositis; dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin; dendritic cell immunoreceptor; Fc gamma RIIB	FC-GAMMA RECEPTOR; COLONY-STIMULATING FACTOR; ANTIINFLAMMATORY ACTIVITY; ANTIIDIOTYPIC ANTIBODIES; T-CELLS; IVIG; INDUCTION; AUTOIMMUNE; ACTIVATION; INTERLEUKIN-3	Background: Therapeutic normal IgG or intravenous immunoglobulin (IVIG) exerts anti-inflammatory effects through several mutually nonexclusive mechanisms. Recent data in mouse models of autoimmune disease suggest that IVIG induces IL-4 in basophils by enhancing IL-33 in SIGN-related 1-positive innate cells. However, translational insight on these data is lacking. Objective: We sought to investigate the effect of IVIG on human basophil functions. Methods: Isolated circulating basophils from healthy donors were cultured in the presence of IL-3, IL-33, GM-CSF, thymic stromal lymphopoietin, or IL-25. The effect of IVIG and F(ab')(2) and Fc IVIG fragments was examined based on expression of various surface molecules, phosphorylation of spleen tyrosine kinase, induction of cytokines, and histamine release. Basophil phenotypes were also analyzed from IVIG-treated patients with myopathy. Approaches, such as depletion of anti-IgE reactivity from IVIG, blocking antibodies, or inhibitors, were used to investigate the mechanisms. Results: We report that IVIG directly induces activation of IL-3-primed human basophils, but IL-33 and other cytokines were dispensable for this effect. Activation of basophils by IVIG led to enhanced expression of CD69 and secretion of IL-4, IL-6, and IL-8. IVIG-treated patients with myopathy displayed enhanced expression of CD69 on basophils. The spleen tyrosine kinase pathway is implicated in these functions of IVIG and were mediated by F(ab')(2) fragments. Mechanistically, IVIG induced IL-4 in human basophils by interacting with basophil surface-bound IgE but independent of FcgRII, type II Fc receptors, C-type lectin receptors, and sialic acid-binding immunoglobulin-like lectins. Conclusion: These results uncovered a pathway of promoting the T(H)2 response by IVIG through direct interaction of IgG with human basophils.	[Galeotti, Caroline; Stephen-Victor, Emmanuel; Karnam, Anupama; Das, Mrinmoy; Gilardin, Laurent; Maddur, Mohan S.; Dimitrov, Jordan D.; Kaveri, Srini V.; Bayry, Jagadeesh] Sorbonne Univ, INSERM, Paris, France; [Galeotti, Caroline; Stephen-Victor, Emmanuel; Karnam, Anupama; Das, Mrinmoy; Gilardin, Laurent; Maddur, Mohan S.; Dimitrov, Jordan D.; Kaveri, Srini V.; Bayry, Jagadeesh] Sorbonne Univ, Ctr Rech Cordeliers, Equipe Immunopathol & Immunointervent Therapeut, Paris, France; [Galeotti, Caroline] CHU Bicetre, Ctr Reference Malad Auto Inflammatoires Rares & A, Serv Rhumatol Pediat, Le Kremlin Bicetre, France; [Gilardin, Laurent; Benveniste, Olivier] Hop La Pitie Salpetriere, AP HP, Dept Med Interne & Immunol Clin, Paris, France; [Maddur, Mohan S.; Dimitrov, Jordan D.; Kaveri, Srini V.; Bayry, Jagadeesh] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Wymann, Sandra; Vonarburg, Cedric] CSL Behring AG, Res Dept, Bern, Switzerland; [Chevailler, Alain] Univ Angers, Lab Immunol & Allergol, CHU Angers, INSERM,Unite 1232,LabEx IGO Immunograft Onco, Angers, France; [Benveniste, Olivier] Sorbonne Univ, INSERM, Unite 974, Paris, France; [Bruhns, Pierre] Inst Pasteur, Dept Immunol, Unit Antibodies Therapy & Pathol, Paris, France; [Bruhns, Pierre] INSERM, U1222, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; CSL; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bayry, J (corresponding author), Ctr Rech Cordeliers, INSERM, Unite 1138, 15 Rue Ecole Med, F-75006 Paris, France.	jagadeesh.bayry@crc.jussieu.fr	Bayry, Jagadeesh/A-6589-2011; Stephen Victor, Emmanuel/HDN-0252-2022; Bruhns, Pierre/F-5567-2013; Das, Mrinmoy/AAS-5750-2021; Gilardin, Laurent/AAS-1145-2020	Bayry, Jagadeesh/0000-0003-0498-9808; Stephen Victor, Emmanuel/0000-0001-5049-7017; Bruhns, Pierre/0000-0002-4709-8936; Das, Mrinmoy/0000-0002-5785-5697; Gilardin, Laurent/0000-0001-9212-0859; Dimitrov, Jordan/0000-0001-8536-8995	Institut National de la Sante et de la Recherche Medicale (INSERM); Sorbonne Universite; Universite Paris Descartes; CSL Behring AG, Switzerland; La Fondation pour la Recherche Medicale, France [FDM20150633674]; Indo-French Center for Promotion of Advanced Research (CEFIPRA)	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Sorbonne Universite; Universite Paris Descartes; CSL Behring AG, Switzerland; La Fondation pour la Recherche Medicale, France(Fondation pour la Recherche Medicale); Indo-French Center for Promotion of Advanced Research (CEFIPRA)	Supported by Institut National de la Sante et de la Recherche Medicale (INSERM), Sorbonne Universite, Universite Paris Descartes, and CSL Behring AG, Switzerland. C.G. is a recipient of fellowship from La Fondation pour la Recherche Medicale (FDM20150633674), France. E.S.-V. and A.K. are recipient of fellowships from Indo-French Center for Promotion of Advanced Research (CEFIPRA).	Aloulou M, 2012, BLOOD, V119, P3084, DOI 10.1182/blood-2011-08-376046; Amar SM, 2008, J ALLERGY CLIN IMMUN, V121, pS98, DOI 10.1016/j.jaci.2007.12.389; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Audia S, 2017, CLIN EXP IMMUNOL, V188, P275, DOI 10.1111/cei.12935; Bayry J, 2004, P NATL ACAD SCI USA, V101, P14210, DOI 10.1073/pnas.0402183101; BISCHOFF SC, 1990, P NATL ACAD SCI USA, V87, P6813, DOI 10.1073/pnas.87.17.6813; Blank M, 2007, INT IMMUNOL, V19, P857, DOI 10.1093/intimm/dxm052; Braselmann S, 2006, J PHARMACOL EXP THER, V319, P998, DOI 10.1124/jpet.106.109058; Bruhns P, 2003, IMMUNITY, V18, P573, DOI 10.1016/S1074-7613(03)00080-3; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; Campbell IK, 2014, J IMMUNOL, V192, P5031, DOI 10.4049/jimmunol.1301611; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Chan YC, 2014, J ALLERGY CLIN IMMUN, V134, P1394, DOI 10.1016/j.jaci.2014.06.029; Crow AR, 2016, SEMIN HEMATOL, V53, pS20, DOI 10.1053/j.seminhematol.2016.04.007; Das M, 2017, J ALLERGY CLIN IMMUN, V139, P1403, DOI 10.1016/j.jaci.2016.09.062; Egawa M, 2013, IMMUNITY, V38, P570, DOI 10.1016/j.immuni.2012.11.014; Fiebiger BM, 2015, P NATL ACAD SCI USA, V112, pE2385, DOI 10.1073/pnas.1505292112; Galeotti C, 2017, INT IMMUNOL, V29, P491, DOI 10.1093/intimm/dxx039; Gelfand EW, 2012, NEW ENGL J MED, V367, P2015, DOI 10.1056/NEJMra1009433; Gilardin L, 2015, CAN MED ASSOC J, V187, P257, DOI 10.1503/cmaj.130375; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; Grodzki ACG, 2009, MOL IMMUNOL, V46, P2539, DOI 10.1016/j.molimm.2009.05.013; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hida S, 2009, NAT IMMUNOL, V10, P214, DOI 10.1038/ni.1686; Kaplan AP, 2009, CLIN EXP ALLERGY, V39, P777, DOI 10.1111/j.1365-2222.2009.03256.x; Karasuyama H, 2018, J ALLERGY CLIN IMMUN, V142, P370, DOI 10.1016/j.jaci.2017.10.042; Le Pottier L, 2007, J CLIN IMMUNOL, V27, P257, DOI 10.1007/s10875-007-9082-2; Leontyev D, 2012, BLOOD, V119, P5261, DOI 10.1182/blood-2012-03-415695; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Lunemann JD, 2015, NAT REV NEUROL, V11, P80, DOI 10.1038/nrneurol.2014.253; Lundberg K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052875; Maddur MS, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0818-5; Maddur MS, 2011, J ALLERGY CLIN IMMUN, V127, P823, DOI 10.1016/j.jaci.2010.12.1102; Massoud AH, 2014, J ALLERGY CLIN IMMUN, V133, P853, DOI 10.1016/j.jaci.2013.09.029; Miyake K, 2017, P NATL ACAD SCI USA, V114, P1111, DOI 10.1073/pnas.1615973114; Nagelkerke SQ, 2014, BLOOD, V124, P3709, DOI 10.1182/blood-2014-05-576835; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nutku E., 2004, Journal of Allergy and Clinical Immunology, V113, pS84, DOI 10.1016/j.jaci.2003.12.281; Othy S, 2013, J IMMUNOL, V190, P4535, DOI 10.4049/jimmunol.1201965; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Pellefigues C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03129-8; Perez EE, 2017, J ALLERGY CLIN IMMUN, V139, pS1, DOI 10.1016/j.jaci.2016.09.023; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939; Prasad NKA, 1998, J IMMUNOL, V161, P3781; Salabert-Le Guen N, 2018, J ALLERGY CLIN IMMUN, V141, P1476, DOI 10.1016/j.jaci.2017.11.012; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Schneider C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01404-0; Schroeder JT, 2011, IMMUNOL REV, V242, P144, DOI 10.1111/j.1600-065X.2011.01023.x; Schwab I, 2014, EUR J IMMUNOL, V44, P1444, DOI 10.1002/eji.201344230; Schwab I, 2013, NAT REV IMMUNOL, V13, P176, DOI 10.1038/nri3401; Seite JF, 2010, BLOOD, V116, P1698, DOI 10.1182/blood-2009-12-261461; Sharma M, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan0829; Sharma M, 2015, NAT REV RHEUMATOL, V11, P129, DOI 10.1038/nrrheum.2014.199; Sharma M, 2014, SCI REP-UK, V4, DOI 10.1038/srep05672; Shoenfeld Y, 2002, INT IMMUNOL, V14, P1303, DOI 10.1093/intimm/dxf099; Siraganian RP, 2010, FEBS LETT, V584, P4933, DOI 10.1016/j.febslet.2010.08.006; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Stephen-Victor E, 2017, HAEMATOLOGICA, V102, pE233, DOI 10.3324/haematol.2016.163451; Strickland DH, 2010, CURR OPIN IMMUNOL, V22, P789, DOI 10.1016/j.coi.2010.10.019; Suzukawa M, 2008, J IMMUNOL, V181, P5981, DOI 10.4049/jimmunol.181.9.5981; Tackenberg B, 2009, P NATL ACAD SCI USA, V106, P4788, DOI 10.1073/pnas.0807319106; Tedeschi A, 1999, IMMUNOLOGY, V96, P164; Trinath J, 2013, BLOOD, V122, P1419, DOI 10.1182/blood-2012-11-468264; Voehringer D, 2012, EUR J IMMUNOL, V42, P2544, DOI 10.1002/eji.201142318; von Gunten S, 2007, J ALLERGY CLIN IMMUN, V119, P1005, DOI 10.1016/j.jaci.2007.01.023; Wiedeman AE, 2013, ARTHRITIS RHEUM-US, V65, P2713, DOI 10.1002/art.38082; Yoshimura C, 2002, J ALLERGY CLIN IMMUN, V109, P817, DOI 10.1067/mai.2002.123532; Zhuang QL, 2001, J ALLERGY CLIN IMMUN, V108, P229, DOI 10.1067/mai.2001.116291	70	29	29	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					524	+		10.1016/j.jaci.2018.10.064	http://dx.doi.org/10.1016/j.jaci.2018.10.064			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	30529242	Bronze, Green Submitted			2022-12-18	WOS:000478789300020
J	Hashimoto, T; Yosipovitch, G				Hashimoto, Takashi; Yosipovitch, Gil			Itching as a systemic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Itch; pruritus; systemic disease	ACID-INDUCED ITCH; POLYCYTHEMIA-VERA; MAST-CELLS; UREMIC PRURITUS; LYSOPHOSPHATIDIC ACID; HEMODIALYSIS-PATIENTS; RECEPTOR; IL-31; SYMPTOM	Pruritus is a sensation that emanates from the skin and is transferred through peripheral nerve fibers to the central nervous system. It is easily understood that primary skin disorders, such as atopic eczema, skin dryness, psoriasis, and urticaria, can elicit pruritus. However, certain systemic diseases can cause chronic pruritus, which has a significant effect on the patient's quality of life. In this rostrum we provide an overview of the characteristics, pathophysiology, and mechanisms of pruritus of major systemic underlying diseases, including end-stage renal disease, cholestatic liver disease, endocrine/metabolic diseases, and hematologic/lymphoproliferative diseases.	Univ Miami, Miller Sch Med, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Miami Itch Ctr, Miami, FL 33136 USA	University of Miami; University of Miami	Yosipovitch, G (corresponding author), 1600 NW 10th Ave,RMSB 2067B, Miami, FL 33136 USA.	gyosipovitch@med.miami.edu	Hashimoto, Takashi/N-5419-2017	Hashimoto, Takashi/0000-0001-6779-5598				Alemi F, 2013, J CLIN INVEST, V123, P1513, DOI 10.1172/JCI64551; Andoh T, 2017, EUR J PHARMACOL, V810, P134, DOI 10.1016/j.ejphar.2017.07.007; Beuers U, 2014, HEPATOLOGY, V60, P399, DOI 10.1002/hep.26909; Cedeno-Laurent F, 2015, CLIN IMMUNOL, V158, P1, DOI 10.1016/j.clim.2015.02.014; Chou FF, 2000, J AM COLL SURGEONS, V190, P65, DOI 10.1016/S1072-7515(99)00212-4; Cowan A, 2015, HANDB EXP PHARMACOL, V226, P291, DOI 10.1007/978-3-662-44605-8_16; Dull MM, 2018, DERMATOL CLIN, V36, P293, DOI 10.1016/j.det.2018.02.008; Dugas-Breit Susanne, 2005, J Dtsch Dermatol Ges, V3, P343, DOI 10.1111/j.1610-0387.2005.05706.x; Fallahzadeh MK, 2011, NEPHROL DIAL TRANSPL, V26, P3338, DOI 10.1093/ndt/gfr053; Ferretti E, 2017, ONCOTARGET, V8, P85263, DOI 10.18632/oncotarget.19665; Garssen J, 1999, IMMUNOLOGY, V97, P506; GOBBI PG, 1983, CANCER, V51, P1934, DOI 10.1002/1097-0142(19830515)51:10<1934::AID-CNCR2820511030>3.0.CO;2-R; Hashimoto T, 2018, POSSIBLE ROLE NEUTRO, V1; Hashimoto T, 2018, EXP DERMATOL; Hsu CW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35217-6; Ishii T, 2009, BLOOD, V113, P5942, DOI 10.1182/blood-2008-09-179416; JACKSON N, 1987, BRIT J DERMATOL, V116, P21, DOI 10.1111/j.1365-2133.1987.tb05787.x; Jin X, 2014, J IMMUNOL, V193, P477, DOI 10.4049/jimmunol.1301946; Kamimura K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178991; Kirito K, 2018, INT J HEMATOL, V107, P173, DOI 10.1007/s12185-017-2333-y; Kittaka H, 2017, J PHYSIOL-LONDON, V595, P2681, DOI 10.1113/JP273961; Ko MJ, 2014, J AM ACAD DERMATOL, V71, P1151, DOI 10.1016/j.jaad.2014.08.004; Kowdley KV, 2018, HEPATOLOGY, V67, P1890, DOI 10.1002/hep.29569; Kremer AE, 2010, GASTROENTEROLOGY, V139, P1008, DOI 10.1053/j.gastro.2010.05.009; Kumagai H, 2010, NEPHROL DIAL TRANSPL, V25, P1251, DOI 10.1093/ndt/gfp588; Ladizinski B, 2012, J AM ACAD DERMATOL, V67, pE197, DOI 10.1016/j.jaad.2012.02.008; Leiferman KM, 2015, J ALLERGY CLIN IMMUN, V135, P488, DOI 10.1016/j.jaci.2014.11.036; Lelonek E, 2018, ACTA DERM-VENEREOL, V98, P496, DOI 10.2340/00015555-2906; Lewis DJ, 2018, J EUR ACAD DERMATOL, V32, P1652, DOI 10.1111/jdv.15075; Mathur VS, 2017, AM J NEPHROL, V46, P450, DOI 10.1159/000484573; Meixiong J, 2019, ELIFE, V8, DOI 10.7554/eLife.44116; Mollanazar NK, 2016, J AM ACAD DERMATOL, V75, DOI 10.1016/j.jaad.2016.05.035; Nattkemper LA, 2016, ACTA DERM-VENEREOL, V96, P894, DOI 10.2340/00015555-2417; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Papoiu ADP, 2014, J NEUROPHYSIOL, V112, P1729, DOI 10.1152/jn.00827.2013; Patel TS, 2007, AM J KIDNEY DIS, V50, P11, DOI 10.1053/j.ajkd.2007.03.010; Pisoni RL, 2006, NEPHROL DIAL TRANSPL, V21, P3495, DOI 10.1093/ndt/gfl461; Rabenhorst A, 2012, BLOOD, V120, P2042, DOI 10.1182/blood-2012-03-415638; Rowe B, 2016, EUR J PAIN, V20, P19, DOI 10.1002/ejp.760; Schocket AL, 2006, ALLERGY ASTHMA PROC, V27, P90; Singer EM, 2013, J INVEST DERMATOL, V133, P2783, DOI 10.1038/jid.2013.227; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stander S, 2016, CURR PROBL DERMATOL, V50, P1, DOI 10.1159/000446009; Suga H, 2013, ACTA DERM-VENEREOL, V93, P144, DOI 10.2340/00015555-1428; Takahashi N, 2016, CANCER RES, V76, P6241, DOI 10.1158/0008-5472.CAN-16-0992; Vannucchi AM, 2008, LEUKEMIA, V22, pCP5, DOI 10.1038/leu.2008.113; Yamaoka H, 2010, DIABETES CARE, V33, P150, DOI 10.2337/dc09-0632; Yosipovitch G, 2018, J ALLERGY CLIN IMMUN, V142, P1375, DOI 10.1016/j.jaci.2018.09.005; Zic JA, 2018, JAMA DERMATOL, V154, P1221, DOI 10.1001/jamadermatol.2018.2510; Zucker I, 2003, J AM ACAD DERMATOL, V49, P842, DOI 10.1016/S0190-9622(03)02478-2	50	29	31	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					375	380		10.1016/j.jaci.2019.04.005	http://dx.doi.org/10.1016/j.jaci.2019.04.005			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	31004615	Bronze			2022-12-18	WOS:000478789300003
J	Legrand, F; Cao, Y; Wechsler, JB; Zhu, X; Zimmermann, N; Rampertaap, S; Monsale, J; Romito, K; Youngblood, BA; Brock, EC; Makiya, MA; Tomasevic, N; Bebbington, C; Maric, I; Metcalfe, DD; Bochner, BS; Klion, AD				Legrand, Fanny; Cao, Yun; Wechsler, Joshua B.; Zhu, Xiang; Zimmermann, Nives; Rampertaap, Shakuntala; Monsale, Joseph; Romito, Kimberly; Youngblood, Bradford A.; Brock, Emily C.; Makiya, Michelle A.; Tomasevic, Nenad; Bebbington, Christopher; Maric, Irina; Metcalfe, Dean D.; Bochner, Bruce S.; Klion, Amy D.			Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Siglec-8; eosinophil; mast cell; soluble receptor; inhibitory receptor; apoptosis; hypereosinophilic syndrome; eosinophilic gastrointestinal disease; mastocytosis; monoclonal antibody	DECREASED EXPRESSION; ALPHA; CELL; MECHANISM; ASSAY	Background: Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 is selectively expressed on eosinophils, mast cells, and basophils and, when engaged on eosinophils, can cause cell death. Objective: We sought to characterize surface and soluble Siglec-8 (sSiglec-8) levels in normal donors (NDs) and eosinophilic donors (EOs) and assess the efficacy of anti-Siglec-8 antibodies in inducing eosinophil cell death in vitro. Methods: Eosinophil expression of Siglec-8 was assessed by using flow cytometry and quantitative PCR. Serum sSiglec-8 levels were measured by means of ELISA. Induction of eosinophil death by IgG(4) (chimeric 2E2 IgG(4)) and afucosylated IgG(1) (chimeric 2E2 IgG(1) [c2E2 IgG(1)]) anti-Siglec-8 antibodies was evaluated in vitro by using flow cytometry and in vivo in humanized mice. Results: Siglec-8 was consistently expressed on eosinophils from NDs and EOs and did not correlate with absolute eosinophil count or disease activity. sSiglec-8 levels were measurable in sera from most donors unrelated to absolute eosinophil counts or Siglec-8 surface expression. c2E2 IgG(1) and chimeric 2E2 IgG(4) were equally effective at inducing cell death (Annexin-V positivity) of purified eosinophils from NDs and EOs after overnight IL-5 priming. In contrast, killing of purified eosinophils without IL-5 was only seen in EOs, and natural killer cell-mediated eosinophil killing was seen only with c2E2 IgG(1). Finally, treatment of humanized mice with anti-Siglec antibody led to robust depletion of IL-5-induced eosinophilia in vivo. Conclusions: Siglec-8 is highly expressed on blood eosinophils from EOs and NDs and represents a potential therapeutic target for eosinophilic disorders. Enhanced killing of eosinophils in the presence of IL-5 might lead to increased efficacy in patients with IL-5-driven eosinophilia.	[Legrand, Fanny; Makiya, Michelle A.; Klion, Amy D.] NIAID, Lab Parasit Dis, Human Eosinophil Sect, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Metcalfe, Dean D.] NIAID, Mast Cell Biol Sect, Lab Allerg Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Cao, Yun; Bochner, Bruce S.] Northwestern Univ, Dept Med, Div Allergy & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Wechsler, Joshua B.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Pediat Gastroenterol Hepatol & Nutr, Chicago, IL 60611 USA; [Zhu, Xiang; Zimmermann, Nives] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Zhu, Xiang; Zimmermann, Nives] Univ Cincinnati, Dept Pediat, Coll Med, Cincinnati, OH 45221 USA; [Rampertaap, Shakuntala; Monsale, Joseph; Romito, Kimberly] NIH, Dept Lab Med, Warren Magnusson Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Maric, Irina] NIH, Hematol Sect, Dept Lab Med, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Youngblood, Bradford A.; Brock, Emily C.; Tomasevic, Nenad; Bebbington, Christopher] Allakos Inc, San Carlos, CA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Legrand, F; Klion, AD (corresponding author), NIAID, Lab Parasit Dis, NIH, Bldg 4,Rm B1-28, Bethesda, MD 20892 USA.	fanny.legrand@nih.gov; aklion@nih.gov	Youngblood, Bradford/ABC-9081-2020; Legrand, Fanny/I-4880-2017	Makiya, Michelle/0000-0002-5673-3815; Legrand, Fanny/0000-0001-9373-7789	Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH); NIH [AI097073]; American Partnership for Eosinophilic Diseases (APFED); Buckeye Foundation; Allakos, Inc.;  [K08 1K08DK097721-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072265, ZIAAI000249, U19AI136443, U01AI097073, ZIAAI001130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK097721] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL080004] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Partnership for Eosinophilic Diseases (APFED); Buckeye Foundation; Allakos, Inc.; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); CLINICAL CENTER	Supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH). Development of the soluble Siglec-8 ELISA in the Bochner laboratory was supported in part by NIH grant AI097073. Collection of patient specimens/data at the Ann & Robert H. Lurie Children's Hospital funded by the American Partnership for Eosinophilic Diseases (APFED) and Buckeye Foundation. J. B. W. is funded by K08 1K08DK097721-01. Anti-Siglec-8 antibodies and funding for N.Z. for this project were provided by Allakos, Inc.	Carroll DJ, 2018, J ALLERGY CLIN IMMUN, V141, P2196, DOI 10.1016/j.jaci.2017.08.013; Herndler-Brandstetter D, 2017, P NATL ACAD SCI USA, V114, pE9626, DOI 10.1073/pnas.1705301114; Hudson SA, 2011, J CLIN IMMUNOL, V31, P1045, DOI 10.1007/s10875-011-9589-4; Kano G, 2013, J ALLERGY CLIN IMMUN, V132, P437, DOI 10.1016/j.jaci.2013.03.024; Kim DK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162831; Klion AD, 2015, BLOOD, V126, P1069, DOI 10.1182/blood-2014-11-551614; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Legrand F, 2015, J ALLER CL IMM-PRACT, V3, P167, DOI 10.1016/j.jaip.2015.01.013; Legrand F, 2014, J ALLERGY CLIN IMMUN, V133, P1439, DOI 10.1016/j.jaci.2013.11.041; Liu LY, 2002, J IMMUNOL, V169, P6459, DOI 10.4049/jimmunol.169.11.6459; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Na HJ, 2012, J IMMUNOL METHODS, V383, P39, DOI 10.1016/j.jim.2012.05.017; Na HJ, 2012, CYTOKINE, V57, P169, DOI 10.1016/j.cyto.2011.10.007; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Roufosse F, 2010, J ALLERGY CLIN IMMUN, V126, P828, DOI 10.1016/j.jaci.2010.06.049; Wilson TM, 2011, J ALLERGY CLIN IMMUN, V128, P1086, DOI 10.1016/j.jaci.2011.05.032; Wu YL, 2015, AAPS J, V17, P1417, DOI 10.1208/s12248-015-9798-5; Wunderlich M, 2010, LEUKEMIA, V24, P1785, DOI 10.1038/leu.2010.158; Yokoi H, 2008, J ALLERGY CLIN IMMUN, V121, P499, DOI 10.1016/j.jaci.2007.10.004	19	29	30	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2227	+		10.1016/j.jaci.2018.10.066	http://dx.doi.org/10.1016/j.jaci.2018.10.066			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30543818	Green Accepted, Bronze			2022-12-18	WOS:000470113200026
J	Cardet, JC; Casale, TB				Cardet, Juan Carlos; Casale, Thomas B.			New insights into the utility of omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						IgE; Fc epsilon RI alpha; mAb; biologic therapy; allergy; antiviral immunity; asthma; chronic urticaria; food allergy; immunotherapy	CHRONIC SPONTANEOUS URTICARIA; ANTI-IGE; SERUM IGE; ASTHMA; RHINOVIRUS; DESENSITIZATION; RESPONSES; SYMPTOMS; EFFICACY; THERAPY		[Cardet, Juan Carlos; Casale, Thomas B.] Univ S Florida, Dept Internal Med, Div Allergy & Immunol, Morsani Coll Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Casale, TB (corresponding author), Univ S Florida, Dept Internal Med, Div Allergy & Immunol, 12901 Bruce B Downs Blvd,MDC19, Tampa, FL 33612 USA.	tbcasale@health.usf.edu			Culverhouse family fund;  [K23AI125785];  [R01HL116849]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI125785] Funding Source: NIH RePORTER	Culverhouse family fund; ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants K23AI125785 (to J.C.C.) and R01HL116849 (to T.B.C.) and by generous contributions by the Culverhouse family fund (to J.C.C. and T.B.C.).	Altrichter S, 2016, J EUR ACAD DERMATOL, V30, P454, DOI 10.1111/jdv.12831; Asero R, 2017, J ALLER CL IMM-PRACT, V5, P1740, DOI 10.1016/j.jaip.2017.07.009; Belloni B, 2007, J ALLERGY CLIN IMMUN, V120, P1223, DOI 10.1016/j.jaci.2007.08.060; Broesby-Olsen S, 2018, ALLERGY, V73, P230, DOI 10.1111/all.13237; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Casale TB, 2018, ALLERGY, V73, P490, DOI 10.1111/all.13302; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Casale TB, 2019, J ALLERGY CLIN IMMUN, V7; Chervinsky P, 2003, ANN ALLERG ASTHMA IM, V91, P160, DOI 10.1016/S1081-1206(10)62171-0; Deza G, 2017, ACTA DERM-VENEREOL, V97, P698, DOI 10.2340/00015555-2654; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Ertas R, 2018, ALLERGY, V73, P705, DOI 10.1111/all.13345; Esquivel A, 2017, AM J RESP CRIT CARE, V196, P985, DOI 10.1164/rccm.201701-0120OC; Gericke J, 2017, J ALLERGY CLIN IMMUN, V139, P1059, DOI 10.1016/j.jaci.2016.07.047; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gill MA, 2018, J ALLERGY CLIN IMMUN, V141, P1735, DOI 10.1016/j.jaci.2017.07.035; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Kanters TA, 2018, BRIT J DERMATOL, V179, P702, DOI 10.1111/bjd.16476; Kantor DB, 2016, J ALLERGY CLIN IMMUN, V138, P1467, DOI 10.1016/j.jaci.2016.04.044; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lang DM, 2018, ANN ALLERG ASTHMA IM, V121, P98, DOI 10.1016/j.anai.2018.05.007; Loizou D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0113483; MacGinnitie AJ, 2017, J ALLERGY CLIN IMMUN, V139, P873, DOI 10.1016/j.jaci.2016.08.010; Maltby S, 2017, CHEST, V151, P78, DOI 10.1016/j.chest.2016.09.035; Marzano AV, 2018, J EUR ACAD DERMATOL; Maurer M, 2018, J ALLERGY CLIN IMMUN, V141, P638, DOI 10.1016/j.jaci.2017.06.032; McQueen RB, 2018, PHARMACOECONOMICS, V36, P957, DOI 10.1007/s40273-018-0658-x; Palacios T, 2016, J ALLER CL IMM-PRACT, V4, P529, DOI 10.1016/j.jaip.2015.11.025; Pillai P, 2016, EUR RESPIR J, V48, P1593, DOI 10.1183/13993003.01501-2015; Pineros YSS, 2019, AM J RESP CRIT CARE, V199, P508, DOI 10.1164/rccm.201803-0461OC; Straesser MD, 2018, J ALLER CL IMM-PRACT, V6, P1386, DOI 10.1016/j.jaip.2017.10.030; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Voskamp AL, 2015, J ALLER CL IMM-PRACT, V3, P192, DOI 10.1016/j.jaip.2014.12.008; Waldram J, 2018, J ALLERGY CLIN IMMUN, V141, P250, DOI 10.1016/j.jaci.2017.05.006; Warrier P, 2009, ANN ALLERG ASTHMA IM, V102, P257, DOI 10.1016/S1081-1206(10)60091-9; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005	36	29	32	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					923	+		10.1016/j.jaci.2019.01.016	http://dx.doi.org/10.1016/j.jaci.2019.01.016			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30690050	Green Accepted			2022-12-18	WOS:000460272900008
J	Cheon, IS; Son, YM; Jiang, L; Goplen, NP; Kaplan, MH; Limper, AH; Kita, H; Paczesny, S; Prakash, YS; Tepper, R; Ahlfeld, SK; Sun, J				Cheon, In Su; Son, Young Min; Jiang, Li; Goplen, Nicholas P.; Kaplan, Mark H.; Limper, Andrew H.; Kita, Hirohito; Paczesny, Sophie; Prakash, Y. S.; Tepper, Robert; Ahlfeld, Shawn K.; Sun, Jie			Neonatal hyperoxia promotes asthma-like features through IL-33-dependent ILC2 responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Neonatal hyperoxia; oxidative stress; asthma; IL-33; ILC2s	INNATE LYMPHOID-CELLS; THYMIC STROMAL LYMPHOPOIETIN; ALLERGIC LUNG INFLAMMATION; BIRTH-WEIGHT INFANTS; INFLUENZA-A VIRUS; BRONCHOPULMONARY DYSPLASIA; ADULT MICE; RESPIRATORY OUTCOMES; OXIDATIVE STRESS; TYPE-2 IMMUNITY	Background: Premature infants often require oxygen supplementation and, therefore, are exposed to oxidative stress. Following oxygen exposure, preterm infants frequently develop chronic lung disease and have a significantly increased risk of asthma. Objective: We sought to identify the underlying mechanisms by which neonatal hyperoxia promotes asthma development. Methods: Mice were exposed to neonatal hyperoxia followed by a period of room air recovery. A group of mice was also intranasally exposed to house dust mite antigen. Assessments were performed at various time points for evaluation of airway hyperresponsiveness, eosinophilia, mucus production, inflammatory gene expression, and T-H and group 2 innate lymphoid cell (ILC2) responses. Sera from term-and preterm-born infants were also collected and levels of IL-33 and type 2 cytokines were measured. Results: Neonatal hyperoxia induced asthma-like features including airway hyperresponsiveness, mucus hyperplasia, airway eosinophilia, and type 2 pulmonary inflammation. In addition, neonatal hyperoxia promoted allergic TH responses to house dust mite exposure. Elevated IL-33 levels and ILC2 responses were observed in the lungs most likely due to oxidative stress caused by neonatal hyperoxia. IL-33 receptor signaling and ILC2s were vital for the induction of asthma-like features following neonatal hyperoxia. Serum IL-33 levels correlated significantly with serum levels of IL-5 and IL-13 but not IL-4 in preterm infants. Conclusions: These data demonstrate that an axis involving IL-33 and ILC2s is important for the development of asthma-like features following neonatal hyperoxia and suggest therapeutic potential for targeting IL-33, ILC2s, and oxidative stress to prevent and/ or treat asthma development related to prematurity.	[Cheon, In Su; Son, Young Min; Jiang, Li; Kaplan, Mark H.; Paczesny, Sophie; Tepper, Robert; Ahlfeld, Shawn K.; Sun, Jie] Indiana Univ Sch Med, Dept Pediat, 201 1st St SW, Indianapolis, IN 46202 USA; [Cheon, In Su; Son, Young Min; Jiang, Li; Goplen, Nicholas P.; Limper, Andrew H.; Sun, Jie] Mayo Clin, Coll Med & Sci, Dept Med, Div Pulm & Crit Care Med, Rochester, MN USA; [Kita, Hirohito; Sun, Jie] Mayo Clin, Coll Med & Sci, Dept Immunol, Rochester, MN USA; [Prakash, Y. S.] Mayo Clin, Coll Med & Sci, Dept Anesthesiol, Rochester, MN USA; [Prakash, Y. S.] Mayo Clin, Coll Med & Sci, Dept Physiol & Biomed Engn, Rochester, MN USA; [Ahlfeld, Shawn K.] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA	Indiana University System; Indiana University Bloomington; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University System of Ohio; University of Cincinnati	Sun, J (corresponding author), Indiana Univ Sch Med, Dept Pediat, 201 1st St SW, Indianapolis, IN 46202 USA.	Sun.Jie@mayo.edu	Paczesny, Sophie/AAR-5119-2021; Paczesny, Sophie/I-4682-2019	Paczesny, Sophie/0000-0001-5571-2775; Prakash, Y S/0000-0002-2968-224X	Huvis Foundation; Indiana Pediatric Scientist Award;  [RO1 AI112844];  [AG047156];  [HL126647];  [RO1 AI095282];  [AI129241];  [HL62150];  [RO1 HL62150];  [RO1 HL117823];  [RO1 AI128729];  [R01 CA168814];  [K12 HD068371];  [RO1 HL056470]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD068371] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA168814] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126647, R01HL056470, R01HL062150, R01HL117823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI095282, R01AI129241, R01AI112844, R01AI128729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG049672, R01AG047156] Funding Source: NIH RePORTER	Huvis Foundation; Indiana Pediatric Scientist Award; ; ; ; ; ; ; ; ; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grants RO1 AI112844, AG047156, and HL126647 to J.S.; RO1 AI095282, AI129241, and HL62150 to M.H.K.; RO1 HL62150 and Huvis Foundation grant to A.H.L; RO1 HL117823 and RO1 AI128729 to H.K.; R01 CA168814 to S.P.; Indiana Pediatric Scientist Award and K12 HD068371 to S.K.A; and RO1 HL056470 to Y.S.P.	Ahlfeld SK, 2015, AM J PATHOL, V185, P913, DOI 10.1016/j.ajpath.2014.12.007; Ahlfeld SK, 2014, BIRTH DEFECTS RES A, V100, P168, DOI 10.1002/bdra.23226; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Asikainen TM, 2005, TOXICOL APPL PHARM, V203, P177, DOI 10.1016/j.taap.2004.07.008; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Been JV, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001596; Bhat R, 2012, PEDIATRICS, V129, pE682, DOI 10.1542/peds.2011-1827; Bouch S, 2015, AM J PHYSIOL-LUNG C, V309, pL488, DOI 10.1152/ajplung.00359.2014; Cazzato S, 2013, PEDIATR PULM, V48, P830, DOI 10.1002/ppul.22676; Cohen ES, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9327; Cox AM, 2017, PEDIATR PULM, V52, P616, DOI 10.1002/ppul.23654; Datta A, 2015, AM J PHYSIOL-LUNG C, V309, pL369, DOI 10.1152/ajplung.00176.2014; Dauger S, 2003, CHEST, V123, P530, DOI 10.1378/chest.123.2.530; de Kleer IM, 2016, IMMUNITY, V45, P1285, DOI 10.1016/j.immuni.2016.10.031; Divekar R, 2015, CURR OPIN ALLERGY CL, V15, P98, DOI 10.1097/ACI.0000000000000133; Domm W, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00055; Doyle LW, 2017, NEW ENGL J MED, V377, P329, DOI 10.1056/NEJMoa1700827; Espinosa-Diez C, 2015, REDOX BIOL, V6, P183, DOI 10.1016/j.redox.2015.07.008; Fawke J, 2010, AM J RESP CRIT CARE, V182, P237, DOI 10.1164/rccm.200912-1806OC; Gasteiger G, 2014, NAT REV IMMUNOL, V14, P631, DOI 10.1038/nri3726; Giannandrea M, 2012, CLIN VACCINE IMMUNOL, V19, P1432, DOI 10.1128/CVI.00265-12; Gibson AM, 2014, SEMIN FETAL NEONAT M, V19, P105, DOI 10.1016/j.siny.2013.10.006; Gluck J, 2016, INT ARCH ALLERGY IMM, V169, P51, DOI 10.1159/000444017; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Goncalves C, 2016, ALLERGOL IMMUNOPATH, V44, P489, DOI 10.1016/j.aller.2016.04.008; Guo Z, 2014, J ASTHMA, V51, P863, DOI 10.3109/02770903.2014.921196; Halim TYF, 2016, NAT IMMUNOL, V17, P57, DOI 10.1038/ni.3294; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halterman JS, 2009, ARCH DIS CHILD, V94, P28, DOI 10.1136/adc.2008.137349; Halvorsen T, 2005, PEDIAT ALLERG IMM-UK, V16, P487, DOI 10.1111/j.1399-3038.2005.00314.x; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Islam JY, 2015, AM J RESP CRIT CARE, V192, P134, DOI 10.1164/rccm.201412-2142PP; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Jacob SV, 1998, J PEDIATR-US, V133, P193, DOI 10.1016/S0022-3476(98)70220-3; Jensen EA, 2014, BIRTH DEFECTS RES A, V100, P145, DOI 10.1002/bdra.23235; Johnston LK, 2016, J IMMUNOL, V197, P3445, DOI 10.4049/jimmunol.1600611; Keller RL, 2017, J PEDIATR-US, V187, P89, DOI 10.1016/j.jpeds.2017.04.026; Kumar RK, 2014, J LEUKOCYTE BIOL, V96, P391, DOI [10.1189/jlb.3RI0314-129R, 10.118]; Kumar VHS, 2016, PEDIATR PULM, V51, P1131, DOI 10.1002/ppul.23430; Laughon M, 2009, PEDIATRICS, V123, P1124, DOI 10.1542/peds.2008-0862; Laughon MM, 2011, AM J RESP CRIT CARE, V183, P1715, DOI 10.1164/rccm.201101-0055OC; Lei Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133774; Lewis David B, 2006, Curr Probl Pediatr Adolesc Health Care, V36, P189, DOI 10.1016/j.cppeds.2005.11.001; Liao J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9977; Martinez-Gonzalez I, 2016, IMMUNITY, V45, P198, DOI 10.1016/j.immuni.2016.06.017; Martinez-Gonzalez I, 2015, TRENDS IMMUNOL, V36, P189, DOI 10.1016/j.it.2015.01.005; McGrath-Morrow SA, 2014, CYTOKINE, V65, P4, DOI 10.1016/j.cyto.2013.09.021; Monticelli LA, 2016, NAT IMMUNOL, V17, P656, DOI 10.1038/ni.3421; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mourani PM, 2015, AM J RESP CRIT CARE, V191, P87, DOI 10.1164/rccm.201409-1594OC; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Ni Juan, 2015, Sichuan Da Xue Xue Bao Yi Xue Ban, V46, P399; Nyp M, 2012, J PERINATOL, V32, P64, DOI 10.1038/jp.2011.131; O'Reilly M, 2013, CLIN EXP PHARMACOL P, V40, P765, DOI 10.1111/1440-1681.12068; O'Reilly MA, 2008, AM J RESP CRIT CARE, V177, P1103, DOI 10.1164/rccm.200712-1839OC; Poggi C, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/721043; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Regal JF, 2014, PEDIAT ALLERG IMM-UK, V25, P180, DOI [10.1111/pai.12218, 10.1111/pai.12206]; Rieger-Fackeldey E, 2014, AM J PATHOL, V184, P1010, DOI 10.1016/j.ajpath.2013.12.021; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Ronkainen E, 2015, PEDIATR PULM, V50, P1090, DOI 10.1002/ppul.23153; Rubens CE, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009871; Saravia J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005217; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Steer CA, 2017, J ALLERGY CLIN IMMUN, V140, P593, DOI 10.1016/j.jaci.2016.12.984; Stevens TP, 2010, PEDIATR PULM, V45, P371, DOI 10.1002/ppul.21199; Stier MT, 2016, J ALLERGY CLIN IMMUN, V138, P814, DOI 10.1016/j.jaci.2016.01.050; Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120; Tashiro H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157571; Uchida M, 2017, ALLERGY, V72, P1521, DOI 10.1111/all.13158; Vogel ER, 2015, CAN J PHYSIOL PHARM, V93, P119, DOI 10.1139/cjpp-2014-0387; Vollsaeter M, 2013, THORAX, V68, P767, DOI 10.1136/thoraxjnl-2012-202980; Wang H, 2014, AM J PHYSIOL-LUNG C, V307, pL295, DOI 10.1152/ajplung.00208.2013; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Yee M, 2009, AM J PHYSIOL-LUNG C, V297, pL641, DOI 10.1152/ajplung.00023.2009	76	29	29	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1100	1112		10.1016/j.jaci.2017.11.025	http://dx.doi.org/10.1016/j.jaci.2017.11.025			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29253513	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000446327300011
J	Berin, MC; Grishin, A; Masilamani, M; Leung, DYM; Sicherer, SH; Jones, SM; Burks, AW; Henning, AK; Dawson, P; Grabowska, J; Agashe, C; Davidson, WF; Wood, RA; Sampson, HA				Berin, M. Cecilia; Grishin, Alexander; Masilamani, Madhan; Leung, Donald Y. M.; Sicherer, Scott H.; Jones, Stacie M.; Burks, A. Wesley; Henning, Alice K.; Dawson, Peter; Grabowska, Joanna; Agashe, Charuta; Davidson, Wendy F.; Wood, Robert A.; Sampson, Hugh A.			Egg-specific IgE and basophil activation but not egg-specific T-cell counts correlate with phenotypes of clinical egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg allergy; food allergy; IgE; IgG(4); basophil; CD4(+) T lymphocyte; regulatory T cell; T(H)2	BAKED EGG; MILK; TOLERANCE; CHILDREN; ANTIBODIES; EPITOPES; WHITE	Background: Egg allergy is phenotypically heterogeneous. A subset of patients with egg allergy can tolerate egg in an extensively heated form. Inclusion of baked egg (BE) into the diet accelerates resolution of egg allergy. Conversely, BE reactivity is associated with persistent disease. The immune basis of this clinical heterogeneity is unknown. Objectives: We sought to study egg-specific antibody, basophil, and T-cell responses in children with reactivity or tolerance to BE. Methods: All participants underwent double-blind, placebo-controlled challenges to BE, and those who tolerated BE were challenged with unheated egg white protein to confirm clinical egg reactivity. Laboratory studies included serum antibody measurements, basophil activation tests, and CD154-based detection of egg-responsive T cells by using flow cytometry. Results: Of the 129 children studied, BE-reactive participants had significantly greater levels of egg-, ovalbumin-, and ovomucoid-specific IgE; lower ratios of egg-specific IgG(4)/IgE; and increased basophil activation in response to egg. Among all participants, CD154-based profiling revealed egg-responsive T cells producing IL-4 and IL-13 but little IL-10 or IFN-gamma, as well as the presence of egg-responsive Foxp3(+)CD25(+)CD127(low) regulatory T cells. Egg-responsive T cells expressed CCR4, CCR6, and CXCR5, indicating capacity for homing to the skin, mucosa, and B-cell follicles. However, neither the frequency nor phenotype of egg-responsive T cells was different in those with tolerance or reactivity to BE. Conclusions: Egg-specific antibody and basophil responses, but not T-cell responses, are greater in those with reactivity versus tolerance to BE. Egg-specific antibody and T-cell responses were highly heterogeneous in this cohort. The clinical implications of this immune heterogeneity will need to be studied longitudinally.	[Berin, M. Cecilia; Grishin, Alexander; Masilamani, Madhan; Sicherer, Scott H.; Grabowska, Joanna; Agashe, Charuta; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA; [Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27515 USA; [Henning, Alice K.; Dawson, Peter] EMMES Corp, Rockville, MD USA; [Davidson, Wendy F.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Icahn School of Medicine at Mount Sinai; National Jewish Health; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of North Carolina; University of North Carolina Chapel Hill; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Berin, MC (corresponding author), Icahn Sch Med Mt Sinai, Pediat Allergy & Immunol, One Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	cecilia.berin@mssm.edu	Agashe, Charuta/AFP-8581-2022; Agashe, Charuta/AAF-3847-2020	Agashe, Charuta/0000-0001-8820-8655; berin, cecilia/0000-0002-9051-9249; Grishin, Alexander/0000-0003-4799-4324	National Institutes of Health/National Institute of Allergy and Infectious Diseases [U19AI066738, U01AI066560]; National Center for Research Resources (NCRR) [UL1 TR000154, UL1 TR000067, UL1 TR000039, UL1 TR000083, UL1 TR000424]; National Institutes of Health (NIH); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000039, UL1TR000154, UL1TR000067, UL1TR000424, UL1TR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066560, U19AI066738] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases grants U19AI066738 and U01AI066560. The project was also supported by grant numbers UL1 TR000154 (National Jewish Health), UL1 TR000067 (Mount Sinai), UL1 TR000039 (Arkansas), UL1 TR000083 (North Carolina), and UL1 TR000424 (Johns Hopkins) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH).	Bartnikas LM, 2015, ALLERGY RHINOL, V6, pE198, DOI 10.2500/ar.2015.6.0135; Bartnikas LM, 2013, J ALLER CL IMM-PRACT, V1, P354, DOI 10.1016/j.jaip.2013.04.002; Bloom KA, 2014, PEDIAT ALLERG IMM-UK, V25, P740, DOI 10.1111/pai.12283; Chiang D, 2018, J ALLERGY CLIN IMMUN, V141, P2107, DOI 10.1016/j.jaci.2017.11.060; Cooke SK, 1997, J IMMUNOL, V159, P2026; Cortot CF, 2012, ALLERGY ASTHMA PROC, V33, P275, DOI 10.2500/aap.2012.33.3544; Des Roches A, 2006, ALLERGY, V61, P1487, DOI 10.1111/j.1398-9995.2006.01200.x; Golias J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037156; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Kosoy R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163831; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Leonard SA, 2016, IMMUNOL ALLERGY CLIN, V36, P147, DOI 10.1016/j.iac.2015.08.013; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V130, P473, DOI 10.1016/j.jaci.2012.06.006; Martos G, 2011, J ALLERGY CLIN IMMUN, V127; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Qamar N, 2015, CLIN EXP ALLERGY, V45, P1663, DOI 10.1111/cea.12570; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017	19	29	29	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					149	+		10.1016/j.jaci.2018.01.044	http://dx.doi.org/10.1016/j.jaci.2018.01.044			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29518422	Green Accepted			2022-12-18	WOS:000437837500019
J	O'Sullivan, JA; Carroll, DJ; Cao, Y; Salicru, AN; Bochner, BS				O'Sullivan, Jeremy A.; Carroll, Daniela J.; Cao, Yun; Salicru, Adriano N.; Bochner, Bruce S.			Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Siglec-8; endocytosis; eosinophil; mast cell; allergic diseases; chronic eosinophilic leukemia; systemic mastocytosis; immunotoxin; targeting	RIBOSOME-INACTIVATING PROTEINS; RECEPTOR-MEDIATED ENDOCYTOSIS; COATED PIT FORMATION; DEPENDENT ENDOCYTOSIS; SYSTEMIC MASTOCYTOSIS; POTASSIUM-DEPLETION; HYPERTONIC MEDIUM; IMMUNE-SYSTEM; CD22 SIGLEC-2; IN-VITRO	Background: Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a cell-surface protein expressed selectively on human eosinophils, mast cells, and basophils, making it an ideal target for the treatment of diseases involving these cell types. However, the effective delivery of therapeutic agents to these cells requires an understanding of the dynamics of Siglec-8 surface expression. Objectives: We sought to determine whether Siglec-8 is endocytosed in human eosinophils and malignant mast cells, identify mechanisms underlying its endocytosis, and demonstrate whether a toxin can be targeted to Siglec-8-bearing cells to kill these cells. Methods: Siglec-8 surface dynamics were examined by flow cytometry using peripheral blood eosinophils, mast cell lines, and Siglec-8-transduced cells in the presence of inhibitors targeting components of endocytic pathways. Siglec-8 intracellular trafficking was followed by confocal microscopy. The ribosome-inhibiting protein saporin was conjugated to a Siglec-8-specific antibody to examine the targeting of an agent to these cells through Siglec-8 endocytosis. Results: Siglec-8 endocytosis required actin rearrangement, tyrosine kinase and protein kinase C activities, and both clathrin and lipid rafts. Internalized Siglec-8 localized to the lysosomal compartment. Maximal endocytosis in Siglec-8-transduced HEK293T cells required an intact immunoreceptor tyrosine-based inhibitory motif. Siglec-8 was also shuttled to the surface via a distinct pathway. Sialidase treatment of eosinophils revealed that Siglec-8 is partially masked by sialylated cis ligands. Targeting saporin to Siglec-8 consistently caused extensive cell death in eosinophils and the human mast cell leukemia cell line HMC-1.2. Conclusions: Therapeutic payloads can be targeted selectively to eosinophils and malignant mast cells by exploiting this Siglec-8 endocytic pathway.	[O'Sullivan, Jeremy A.; Carroll, Daniela J.; Cao, Yun; Bochner, Bruce S.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Salicru, Adriano N.; Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA	Northwestern University; Feinberg School of Medicine; Johns Hopkins University	Bochner, BS (corresponding author), 240 E Huron St,Rm M-306, Chicago, IL 60611 USA.	bruce.bochner@northwestern.edu		Bochner, Bruce S./0000-0002-9411-6009; O'Sullivan, Jeremy/0000-0002-3862-202X	National Heart, Lung, and Blood Institute [P01HL107151]; National Institute of Allergy and Infectious Diseases [AI072265, T32AI083216]; National Cancer Institute [NCI CA060553]; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI083216, U19AI136443, R01AI072265] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Heart, Lung, and Blood Institute (grant no. P01HL107151 to B.S.B.), the National Institute of Allergy and Infectious Diseases (grant no. AI072265 to B.S.B. and grant no. T32AI083216 to J.A.O.), and the National Cancer Institute (Cancer Center Support grant no. NCI CA060553 to the Center for Advanced Microscopy at Northwestern University).	Aizawa H, 2002, J ALLERGY CLIN IMMUN, V109, P176, DOI 10.1067/mai.2002.120550; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Barrow AD, 2006, EUR J IMMUNOL, V36, P1646, DOI 10.1002/eji.200636195; Bergamaschi G, 1996, BRIT J HAEMATOL, V93, P789, DOI 10.1046/j.1365-2141.1996.d01-1730.x; Biedermann B, 2007, LEUKEMIA RES, V31, P211, DOI 10.1016/j.leukres.2006.05.026; Bochner BS, 2016, GLYCOBIOLOGY, V26, P546, DOI 10.1093/glycob/cww024; Bolognesi A, 1996, INT J CANCER, V68, P349, DOI 10.1002/(SICI)1097-0215(19961104)68:3<349::AID-IJC13>3.0.CO;2-3; Borate U, 2016, LEUKEMIA RES, V44, P25, DOI 10.1016/j.leukres.2016.02.010; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; Collins BE, 2006, J IMMUNOL, V177, P2994, DOI 10.4049/jimmunol.177.5.2994; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; de Virgilio M, 2010, TOXINS, V2, P2699, DOI 10.3390/toxins2112699; Eckels PC, 2009, AM J PHYSIOL-CELL PH, V297, pC886, DOI 10.1152/ajpcell.00416.2008; Foussias G, 2000, BIOCHEM BIOPH RES CO, V278, P775, DOI 10.1006/bbrc.2000.3866; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Gerbe F, 2016, NATURE, V529, P226, DOI 10.1038/nature16527; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hudson SA, 2011, J CLIN IMMUNOL, V31, P1045, DOI 10.1007/s10875-011-9589-4; Hudson SA, 2009, J PHARMACOL EXP THER, V330, P608, DOI 10.1124/jpet.109.152439; Inal J, 2005, EXP CELL RES, V310, P54, DOI 10.1016/j.yexcr.2005.07.003; Ivanov Andrei I., 2008, V440, P15, DOI 10.1007/978-1-59745-178-9_2; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; Kirchhausen T, 2008, METHOD ENZYMOL, V438, P77, DOI 10.1016/S0076-6879(07)38006-3; Kiwamoto T, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Kiwamoto T, 2015, J ALLERGY CLIN IMMUN, V135, P1329, DOI 10.1016/j.jaci.2014.10.027; Klion AD, 2011, HEMATOL-AM SOC HEMAT, P257, DOI 10.1182/asheducation-2011.1.257; Laidlaw TM, 2011, J ALLERGY CLIN IMMUN, V127, P815, DOI 10.1016/j.jaci.2010.12.1101; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Mao H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068143; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Na HJ, 2012, J IMMUNOL METHODS, V383, P39, DOI 10.1016/j.jim.2012.05.017; Na HJ, 2012, CYTOKINE, V57, P169, DOI 10.1016/j.cyto.2011.10.007; North SJ, 2012, GLYCOBIOLOGY, V22, P12, DOI 10.1093/glycob/cwr089; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; O'Reilly MK, 2011, J IMMUNOL, V186, P1554, DOI 10.4049/jimmunol.1003005; Perry DG, 1999, J IMMUNOL, V162, P380; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; Polito L, 2013, TOXINS, V5, P1698, DOI 10.3390/toxins5101698; Polo S, 2006, CELL, V124, P897, DOI 10.1016/j.cell.2006.02.025; Propster JM, 2016, P NATL ACAD SCI USA, V113, pE4170, DOI 10.1073/pnas.1602214113; Razi N, 1998, P NATL ACAD SCI USA, V95, P7469, DOI 10.1073/pnas.95.13.7469; Razi N, 1999, GLYCOBIOLOGY, V9, P1225, DOI 10.1093/glycob/9.11.1225; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; SCHLEGEL R, 1982, P NATL ACAD SCI-BIOL, V79, P2291, DOI 10.1073/pnas.79.7.2291; Tateno H, 2005, GLYCOBIOLOGY, V15, P1125, DOI 10.1093/glycob/cwi097; Tateno H, 2007, MOL CELL BIOL, V27, P5699, DOI 10.1128/MCB.00383-07; Theoharides TC, 2015, NEW ENGL J MED, V373, P163, DOI 10.1056/NEJMra1409760; Walter RB, 2005, BLOOD, V105, P1295, DOI 10.1182/blood-2004-07-2784; Walter RB, 2008, J LEUKOCYTE BIOL, V83, P200, DOI 10.1189/jlb.0607388; Yokoi H, 2008, J ALLERGY CLIN IMMUN, V121, P499, DOI 10.1016/j.jaci.2007.10.004; Yu HF, 2017, GLYCOBIOLOGY, V27, P657, DOI 10.1093/glycob/cwx026; Zhang JQQ, 2004, EUR J IMMUNOL, V34, P1175, DOI 10.1002/eji.200324723; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255; Zimmermann N, 2008, ALLERGY, V63, P1156, DOI 10.1111/j.1398-9995.2008.01709.x	59	29	29	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1774	+		10.1016/j.jaci.2017.06.028	http://dx.doi.org/10.1016/j.jaci.2017.06.028			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28734845	Green Accepted, Bronze			2022-12-18	WOS:000432148200024
J	Nugraha, R; Kamath, SD; Johnston, E; Zenger, KR; Rolland, JM; O'Hehir, RE; Lopata, AL				Nugraha, Roni; Kamath, Sandip D.; Johnston, Elecia; Zenger, Kyall R.; Rolland, Jennifer M.; O'Hehir, Robyn E.; Lopata, Andreas L.			Rapid and comprehensive discovery of unreported shellfish allergens using large-scale transcriptomic and proteomic resources	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							STATISTICAL-MODEL; DATABASE; REACTIVITY; PROTEINS; UPDATE; GENOME		[Nugraha, Roni; Kamath, Sandip D.; Johnston, Elecia; Lopata, Andreas L.] James Cook Univ, Ctr Biodiscovery & Mol Dev Therapeut, Townsville, Qld, Australia; [Nugraha, Roni; Kamath, Sandip D.; Johnston, Elecia; Lopata, Andreas L.] James Cook Univ, Australian Inst Trop Hlth & Med, Townsville, Qld, Australia; [Nugraha, Roni; Kamath, Sandip D.; Johnston, Elecia; Lopata, Andreas L.] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, Australia; [Nugraha, Roni] Bogor Agr Univ, Dept Aquat Prod Technol, Bogor, Indonesia; [Zenger, Kyall R.] James Cook Univ, Coll Marine & Environm Sci, Ctr Sustainable Trop Fisheries & Aquaculture, Townsville, Qld, Australia; [Rolland, Jennifer M.; O'Hehir, Robyn E.] Monash Univ, Dept Immunol & Pathol, Melbourne, Vic, Australia; [Rolland, Jennifer M.; O'Hehir, Robyn E.] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [Rolland, Jennifer M.; O'Hehir, Robyn E.] Monash Univ, Melbourne, Vic, Australia	James Cook University; James Cook University; James Cook University; Bogor Agricultural University; James Cook University; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University	Lopata, AL (corresponding author), James Cook Univ, Ctr Biodiscovery & Mol Dev Therapeut, Townsville, Qld, Australia.; Lopata, AL (corresponding author), James Cook Univ, Australian Inst Trop Hlth & Med, Townsville, Qld, Australia.; Lopata, AL (corresponding author), James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, Australia.	andreas.lopata@jcu.edu.au	Zenger, Kyall R/ABD-2101-2020; Kamath, Sandip/H-9741-2012; Lopata, Andreas L/O-2143-2017; Nugraha, Roni/ABV-0246-2022; O'Hehir, Robyn E/H-3627-2011; Johnston, Elecia/H-7295-2016	Zenger, Kyall R/0000-0001-6817-8786; Kamath, Sandip/0000-0002-5956-8552; Lopata, Andreas L/0000-0002-2940-9235; Nugraha, Roni/0000-0001-5935-5867; O'Hehir, Robyn E/0000-0002-3489-7595; Johnston, Elecia/0000-0003-0927-6524	James Cook University Postgraduate Research Scholarship; National Health and Medical Research Council (NHMRC) Peter Doherty Fellowship; Allergy and Immunology Foundation of Australasia; Australian Research Council	James Cook University Postgraduate Research Scholarship; National Health and Medical Research Council (NHMRC) Peter Doherty Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Allergy and Immunology Foundation of Australasia; Australian Research Council(Australian Research Council)	R.N. received a James Cook University Postgraduate Research Scholarship. S.D.K is holder of the National Health and Medical Research Council (NHMRC) Peter Doherty Fellowship and supported by the Allergy and Immunology Foundation of Australasia. A.L.L. received financial support from the Australian Research Council.	Chan TF, 2015, J ALLERGY CLIN IMMUN, V135, P539, DOI 10.1016/j.jaci.2014.09.031; Eddy SR, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002195; Finn RD, 2016, NUCLEIC ACIDS RES, V44, pD279, DOI 10.1093/nar/gkv1344; Goodman RE, 2016, MOL NUTR FOOD RES, V60, P1183, DOI 10.1002/mnfr.201500769; Kamath SD, 2014, MOL NUTR FOOD RES, V58, P1144, DOI 10.1002/mnfr.201300584; Kamath SD, 2013, FOOD CHEM, V141, P4031, DOI 10.1016/j.foodchem.2013.06.105; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kuehn A, 2016, ALLERGY, V71, P1772, DOI 10.1111/all.12968; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Radauer C, 2014, ALLERGY, V69, P413, DOI 10.1111/all.12348; Tsapis M, 2013, REV FR ALLERGOL, V53, P436, DOI 10.1016/j.reval.2013.03.007; Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145; Yu W, 2016, NAT REV IMMUNOL, V16, P751, DOI 10.1038/nri.2016.111; Zhang GF, 2012, NATURE, V490, P49, DOI 10.1038/nature11413	14	29	29	3	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1501	+		10.1016/j.jaci.2017.11.028	http://dx.doi.org/10.1016/j.jaci.2017.11.028			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29258834	Bronze			2022-12-18	WOS:000429197800041
J	Chopra, R; Vakharia, PP; Sacotte, R; Patel, N; Immaneni, S; White, T; Kantor, R; Hsu, DY; Silverberg, JI				Chopra, Rishi; Vakharia, Paras P.; Sacotte, Ryan; Patel, Neha; Immaneni, Supriya; White, Takeshia; Kantor, Robert; Hsu, Derek Y.; Silverberg, Jonathan I.			Relationship between EASI and SCORAD severity assessments for atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HARMONIZING OUTCOME MEASURES; ECZEMA HOME STATEMENT; TRIALS; AREA		[Chopra, Rishi; Vakharia, Paras P.; Sacotte, Ryan; Patel, Neha; Immaneni, Supriya; White, Takeshia; Kantor, Robert; Hsu, Derek Y.; Silverberg, Jonathan I.] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Med Multidisciplinary Eczema Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Silverberg, JI (corresponding author), Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA.; Silverberg, JI (corresponding author), Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.; Silverberg, JI (corresponding author), Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA.; Silverberg, JI (corresponding author), Northwestern Med Multidisciplinary Eczema Ctr, Chicago, IL 60611 USA.	JonathanISilverberg@gmail.com	silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805; Chopra, Rishi/0000-0002-8150-6358	Agency for Healthcare Research and Quality [K12 HS023011]; Dermatology Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS023011] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Dermatology Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This publication was made possible with support from the Agency for Healthcare Research and Quality (grant no. K12 HS023011), and the Dermatology Foundation.	Charman CR, 2005, ARCH DERMATOL, V141, P1146, DOI 10.1001/archderm.141.9.1146; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Leshem YA, 2015, BRIT J DERMATOL, V172, P1353, DOI 10.1111/bjd.13662; Schmitt J, 2014, J ALLERGY CLIN IMMUN, V134, P800, DOI 10.1016/j.jaci.2014.07.043; Spuls PI, 2017, BRIT J DERMATOL, V176, P979, DOI 10.1111/bjd.15179	7	29	29	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1708	+		10.1016/j.jaci.2017.04.052	http://dx.doi.org/10.1016/j.jaci.2017.04.052			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28625808	Bronze, Green Accepted			2022-12-18	WOS:000417206000028
J	Hoch, HE; Calatroni, A; West, JB; Liu, AH; Gergen, PJ; Gruchalla, RS; Hershey, GKK; Kercsmar, CM; Kim, H; Lamm, CI; Makhija, MM; Mitchell, HE; Teach, SJ; Wildfire, JJ; Busse, WW; Szefler, SJ				Hoch, Heather E.; Calatroni, Agustin; West, Joseph B.; Liu, Andrew H.; Gergen, Peter J.; Gruchalla, Rebecca S.; Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.; Kim, Haejin; Lamm, Carin I.; Makhija, Melanie M.; Mitchell, Herman E.; Teach, Stephen J.; Wildfire, Jeremy J.; Busse, William W.; Szefler, Stanley J.			Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fall asthma exacerbation; omalizumab; guidelinesbased therapy; asthma exacerbation predictors; Seasonal Asthma Exacerbation Predictive Index (saEPI)	INNER-CITY CHILDREN; TO-TREAT ASTHMA; EMERGENCY-DEPARTMENT VISITS; FUTURE EXACERBATIONS; PRESCHOOL-CHILDREN; RISK; ADOLESCENTS; TRIAL; OMALIZUMAB; PATTERNS	Background: A Seasonal Asthma Exacerbation Predictive Index (saEPI) was previously reported based on 2 prior National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium trials. Objective: This study sought to validate the saEPI in a separate trial designed to prevent fall exacerbations with omalizumab therapy. Methods: The saEPI and its components were analyzed to characterize those who had an asthma exacerbation during the Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations (PROSE) study. We characterized those inner-city children with and without asthma exacerbations in the fall period treated with guidelines-based therapy (GBT) in the absence and presence of omalizumab. Results: A higher saEPI was associated with anexacerbation in both the GBT alone (P < .001; area under the curve, 0.76) and the GBT1 omalizumab group (P < .01; area under the curve, 0.65). In the GBT group, younger age at recruitment, higher total IgE, higher blood eosinophil percentage and number, and higher treatment step were associated with thosewho had an exacerbation compared with those who did not. In the GBT + omalizumab group, younger age at recruitment, increased eosinophil number, recent exacerbation, and higher treatment step were also associated with those who had an exacerbation. The saEPI was associated with a high negative predictive value in both groups. Conclusions: An exacerbation in children treated with GBT with or without omalizumab was associated with a higher saEPI along with higher markers of allergic inflammation, treatment step, and a recent exacerbation. Those that exacerbated on omalizumab had similar features with the exception of some markers of allergic sensitization, indicating a need to develop better markers to predict poor response to omalizumab therapy and alternative treatment strategies for children with these risk factors. The saEPI was able to reliably predict those children unlikely to have an asthma exacerbation in both groups.	[Hoch, Heather E.; Liu, Andrew H.; Szefler, Stanley J.] Childrens Hosp Colorado, Aurora, CO USA; [Hoch, Heather E.; Liu, Andrew H.; Szefler, Stanley J.] Univ Colorado, Sch Med, Aurora, CO USA; [Calatroni, Agustin; Mitchell, Herman E.; Wildfire, Jeremy J.] Rho Fed Syst Div, Chapel Hill, NC USA; [West, Joseph B.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Gergen, Peter J.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Gruchalla, Rebecca S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Cincinnati, OH USA; [Kim, Haejin] Henry Ford Hlth Syst, Detroit, MI USA; [Lamm, Carin I.] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Makhija, Melanie M.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Teach, Stephen J.] Childrens Natl Hlth Syst, Washington, DC USA; [Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Southwestern Medical Center Dallas; Cincinnati Children's Hospital Medical Center; Henry Ford Health System; Henry Ford Hospital; Columbia University; Ann & Robert H. Lurie Children's Hospital of Chicago; Children's National Health System; University of Wisconsin System; University of Wisconsin Madison	Hoch, HE (corresponding author), 13123 East 16th Ave, Aurora, CO 80045 USA.	Heather.hoch@childrenscolorado.org		Szefler, Stanley/0000-0002-6911-3199	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, UM2AI117870]; National Center for Research Resources, National Center for Advancing Translational Sciences, and National Institutes of Health [NCRR/NIH UL1TR000451, 1UL1RR025780, UL1TR000075]; NCATS/NIH [UL1 TR000154, UL1TR001082, UL1 TR000077-04, NCATS/NIH UL1TR000040, UL1TR000150]; NIH NIAID [UL1TR001105, 5R01AI098077];  [UM1AI109565]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000154, UL1TR001105, UL1TR000150, UL1TR000040, UL1TR000451, UL1TR000077, UL1TR001082, UL1TR000075, UL1TR001422] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM2AI117870, R01AI098077, UM1AI109565, UM1AI114271] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Center for Advancing Translational Sciences, and National Institutes of Health; NCATS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract numbers HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, and UM2AI117870. Additional support was provided by the National Center for Research Resources, National Center for Advancing Translational Sciences, and National Institutes of Health under grants NCRR/NIH UL1TR000451, 1UL1RR025780, UL1TR000075; NCATS/NIH UL1 TR000154, UL1TR001082, UL1 TR000077-04, NCATS/NIH UL1TR000040, UL1TR000150; UL1TR001105, NIH NIAID 5R01AI098077; and UM1AI109565. The following were donated: omalizumab and matching placebo by Novartis, and fluticasone and matching placebo by Glaxo Smith Kline, under a clinical trial agreement with the University of Wisconsin-Madison; EpiPens by Mylan; and Ayr nasal rinse by B. F. Ascher and Company, Inc. None of these companies had a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit for publication.	Bloom Barbara, 2012, Vital Health Stat 10, P1; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Chang TS, 2013, J ALLER CL IMM-PRACT, V1, P152, DOI 10.1016/j.jaip.2012.10.008; Chen H, 2007, J ALLERGY CLIN IMMUN, V120, P396, DOI 10.1016/j.jaci.2007.04.040; CHEVAN A, 1991, AM STAT, V45, P90, DOI 10.2307/2684366; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; Chipps BE, 2012, CURR PULMONOL REP, V1, P259, DOI 10.1007/s13665-012-0025-x; Chipps BE, 2012, J ALLERGY CLIN IMMUN, V130, P332, DOI 10.1016/j.jaci.2012.04.014; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Fuhlbrigge AL, 2011, J ALLERGY CLIN IMMUN, V127, P1503, DOI 10.1016/j.jaci.2011.04.023; Gergen PJ, 2015, IMMUNOL ALLERGY CLIN, V35, P101, DOI 10.1016/j.iac.2014.09.006; Gergen PJ, 2002, J PEDIATR-US, V141, P631, DOI 10.1067/mpd.2002.127510; Global Initiative for Asthma, 2016, J ALLERGY CLIN IMMUN; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, pe1, DOI DOI 10.1016/J.JACI.2009.07.035.PUBMED; Haselkorn T, 2010, PEDIAT ALLERG IMM-UK, V21, P1157, DOI 10.1111/j.1399-3038.2010.01065.x; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P921, DOI 10.1016/j.jaci.2009.09.006; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P895, DOI 10.1016/j.jaci.2009.07.035; Ivanova JI, 2012, J ALLERGY CLIN IMMUN, V129, P1229, DOI 10.1016/j.jaci.2012.01.039; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Lindeman R., 1980, INTRO BIVARIATE MULT; Lopez-Raton M, 2014, J STAT SOFTW, V61, P1; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Pescatore AM, 2014, J ALLERGY CLIN IMMUN, V133, P111, DOI 10.1016/j.jaci.2013.06.002; Reeves MJ, 2006, PEDIATRICS, V117, pS106, DOI 10.1542/peds.2005-2000H; Schatz M, 2014, J ALLERGY CLIN IMMUN, V133, P1549, DOI 10.1016/j.jaci.2013.10.006; Silverman RA, 2005, ARCH PEDIAT ADOL MED, V159, P818, DOI 10.1001/archpedi.159.9.818; Silverman RA, 2003, ANN EMERG MED, V42, P577, DOI 10.1067/S0196-0644(03)00410-4; Sullivan SD, 2007, ALLERGY, V62, P655, DOI 10.1111/j.1398-9995.2007.01383.x; Swern AS, 2008, ANN ALLERG ASTHMA IM, V101, P626, DOI 10.1016/S1081-1206(10)60226-8; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; Team RC, 2015, R LANG ENV STAT COMP; WALSH C., 2013, HIER PART HIERARCHIC; Wu AC, 2011, CHEST, V140, P100, DOI 10.1378/chest.10-2794	38	29	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1130	+		10.1016/j.jaci.2017.01.026	http://dx.doi.org/10.1016/j.jaci.2017.01.026			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28238748	Bronze, Green Accepted			2022-12-18	WOS:000412172900024
J	Melo, FR; Wallerman, O; Paivandy, A; Calounova, G; Gustafson, AM; Sabari, BR; Zabucchi, G; Allis, CD; Pejler, G				Melo, Fabio R.; Wallerman, Ola; Paivandy, Aida; Calounova, Gabriela; Gustafson, Ann-Marie; Sabari, Benjamin R.; Zabucchi, Giuliano; Allis, C. David; Pejler, Gunnar			Tryptase-catalyzed core histone truncation: A novel epigenetic regulatory mechanism in mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; epigenetics; core histones; histone acetylation; tryptase; mMCP6; secretory granules; serglycin; serglycin proteoglycan; H2B; H2BK5ac	SECRETORY GRANULE; SERGLYCIN PROTEOGLYCAN; STERILE-20 KINASE; H2B; PROTEASES; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; SERINE-10; IMMUNITY	Background: Mast cells are key effector cells in allergic reactions. When activated to degranulate, they release a plethora of bioactive compounds from their secretory granules, including mast cell-restricted proteases such as tryptase. In a previous study, we showed that tryptase, in addition to its intragranular location, can be found within the nuclei of mast cells where it truncates core histones at their N-terminal ends. Objective: Considering that the N-terminal portions of the core histones constitute sites for posttranslational modifications of major epigenetic impact, we evaluated whether histone truncation by tryptase could have an impact on epigenetic events in mast cells. Methods: Mast cells were cultured from wild-type and tryptase null mice, followed by an assessment of their profile of epigenetic histone modifications and their phenotypic characteristics. Results: We show that tryptase truncates nucleosomal histone 3 and histone 2B (H2B) and that its absence results in accumulation of the epigenetic mark, lysine 5-acetylated H2B. Intriguingly, the accumulation of lysine 5-acetylated H2B was cell age-dependent and was associated with a profound upregulation of markers of non-mast cell lineages, loss of proliferative control, chromatin remodeling as well as extensive morphological alterations. Conclusions: These findings introduce tryptase-catalyzed histone clipping as a novel epigenetic regulatory mechanism, which in the mast cell context may be crucial for maintaining cellular identity.	[Melo, Fabio R.; Wallerman, Ola; Paivandy, Aida; Gustafson, Ann-Marie; Pejler, Gunnar] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Sabari, Benjamin R.; Allis, C. David] Rockefeller Univ, Lab Chromatin Biol & Epigenet, 1230 York Ave, New York, NY 10021 USA; [Zabucchi, Giuliano] Univ Trieste, Dept Life Sci, Trieste, Italy; [Calounova, Gabriela; Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden	Uppsala University; Rockefeller University; University of Trieste; Swedish University of Agricultural Sciences	Melo, FR (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.; Pejler, G (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, BMC, Box 582, S-75123 Uppsala, Sweden.	Fabio.Melo@imbim.uu.sc; Gunnar.Pejler@imbim.uu.se	Melo, Fabio Rabelo/GQP-0844-2022; Paivandy, Aida/GXA-3575-2022		Swedish Research Council [K2014-68X-0913-23-4]; Swedish Cancer Foundation [CAN 2013/423]; Spiber Award; Swedish Heart and Lung Foundation [20150290]; Formas [221-2012-1098]; Torsten Soderberg Foundation [M80/14]; National Institutes of Health [R01-GM40922]; Rockefeller University	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Foundation; Spiber Award; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Formas(Swedish Research Council Formas); Torsten Soderberg Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rockefeller University	Supported by grants from the Swedish Research Council (K2014-68X-0913-23-4), the Swedish Cancer Foundation (CAN 2013/423), the Spiber Award, the Swedish Heart and Lung Foundation (20150290), Formas (221-2012-1098), the Torsten Soderberg Foundation (M80/14), the National Institutes of Health (R01-GM40922), and The Rockefeller University.	Abell AN, 2011, CELL STEM CELL, V8, P525, DOI 10.1016/j.stem.2011.03.008; Abrink M, 2004, J BIOL CHEM, V279, P40897, DOI 10.1074/jbc.M405856200; Ahn SH, 2005, CELL, V120, P25, DOI 10.1016/j.cell.2004.11.016; Ahn SH, 2006, MOL CELL, V24, P211, DOI 10.1016/j.molcel.2006.09.008; Azad GK, 2014, MOL BIOL REP, V41, P2717, DOI 10.1007/s11033-014-3181-y; Braga T, 2007, BIOCHEM J, V403, P49, DOI 10.1042/BJ20061257; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Dhaenens M, 2015, BIOESSAYS, V37, P70, DOI 10.1002/bies.201400118; Duncan EM, 2008, CELL, V135, P284, DOI 10.1016/j.cell.2008.09.055; Fang J, 2004, METHOD ENZYMOL, V377, P213; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Henningsson F, 2006, FEBS J, V273, P4901, DOI 10.1111/j.1742-4658.2006.05489.x; HUANG R, 1993, SCAND J IMMUNOL, V38, P359, DOI 10.1111/j.1365-3083.1993.tb01738.x; Jogie-Brahim S, 2004, J ALLERGY CLIN IMMUN, V113, P1086, DOI 10.1016/j.jaci.2004.02.032; Kolset SO, 2011, J IMMUNOL, V187, P4927, DOI 10.4049/jimmunol.1100806; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Li LX, 1998, J IMMUNOL, V161, P5079; Melo FR, 2014, J BIOL CHEM, V289, P7682, DOI 10.1074/jbc.M113.546895; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Pejler G, 2010, BLOOD, V115, P4981, DOI 10.1182/blood-2010-01-257287; Ronnberg E, 2012, J HISTOCHEM CYTOCHEM, V60, P950, DOI 10.1369/0022155412458927; Sabari BR, 2015, MOL CELL, V58, P203, DOI 10.1016/j.molcel.2015.02.029; Shin K, 2008, J IMMUNOL, V180, P4885, DOI 10.4049/jimmunol.180.7.4885; Shin K, 2009, J IMMUNOL, V182, P647, DOI 10.4049/jimmunol.182.1.647; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Weidner CI, 2014, BIOL CHEM, V395, P1307, DOI 10.1515/hsz-2014-0180; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690	29	29	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					474	485		10.1016/j.jaci.2016.11.044	http://dx.doi.org/10.1016/j.jaci.2016.11.044			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28108335	hybrid, Green Submitted			2022-12-18	WOS:000406855500020
